ss_d,tss_d,crtd_b,ss_tss,td,dscrptn,chmbl_d,rltnshp_tp,cnfdnc_scr,cll_d,ss_cll_tp,ss_strn,ss_sbclllr_frctn,src_d,src_ss_d,b_frmt,vrnt_d
1,,Autocuration,,12052,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,CHEMBL615117,H,8,,,,,1,,BAO_0000019,
2,,Autocuration,,22226,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,CHEMBL615118,U,0,,,,,1,,BAO_0000219,
3,,Autocuration,,22226,,CHEMBL615119,U,0,,,,,1,,BAO_0000019,
4,,Autocuration,,104729,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,CHEMBL615120,H,4,,,,,1,,BAO_0000249,
5,,Intermediate,,80001,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),CHEMBL615121,N,1,163.0,143B,,,1,,BAO_0000219,
6,,Intermediate,,80001,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),CHEMBL615122,N,1,163.0,143B,,,1,,BAO_0000219,
7,,Intermediate,,80001,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,CHEMBL615123,N,1,163.0,143B,,,1,,BAO_0000219,
8,,Expert,,80001,In vitro cell cytotoxicity was determined against 143B cell line,CHEMBL615124,N,1,163.0,143B,,,1,,BAO_0000219,
9,,Intermediate,,80001,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,CHEMBL615125,N,1,163.0,143B,,,1,,BAO_0000219,
10,,Intermediate,,80001,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,CHEMBL615126,N,1,163.0,143B,,,1,,BAO_0000219,
11,,Intermediate,,80001,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,CHEMBL615127,N,1,163.0,143B,,,1,,BAO_0000219,
12,,Expert,,80001,In vitro cell cytotoxicity was determined against 143B-LTK cell line,CHEMBL615128,N,1,163.0,143B,,,1,,BAO_0000219,
13,,Intermediate,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL857900,N,1,,,,,1,,BAO_0000218,
14,,Intermediate,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL615129,N,1,,,,,1,,BAO_0000218,
15,,Intermediate,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL615130,N,1,,,,,1,,BAO_0000218,
16,,Intermediate,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL615131,N,1,,,,,1,,BAO_0000218,
17,,Expert,,100122,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,CHEMBL884521,D,9,,,,,1,,BAO_0000357,
18,,Autocuration,,12054,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615132,H,8,,,,,1,,BAO_0000357,
19,,Autocuration,,12054,Inhibition of partially purified 15-lipoxygenase from human leukocytes,CHEMBL615133,H,8,,,,,1,,BAO_0000019,
20,,Autocuration,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615134,H,8,,,,,1,,BAO_0000357,
21,,Autocuration,,12054,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615135,H,8,,,,,1,,BAO_0000357,
22,,Autocuration,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615136,H,8,,,,,1,,BAO_0000357,
23,,Autocuration,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,CHEMBL615137,H,8,,,,,1,,BAO_0000357,
24,,Autocuration,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,CHEMBL615138,H,8,,,,,1,,BAO_0000357,
25,,Autocuration,,22226,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",CHEMBL836324,U,0,,,,,1,,BAO_0000219,
26,,Autocuration,,12054,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,CHEMBL615139,H,8,,,,,1,,BAO_0000357,
27,,Autocuration,,12054,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),CHEMBL615140,H,8,,,,,1,,BAO_0000357,
28,,Autocuration,,12426,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,CHEMBL615141,H,8,,,,,1,,BAO_0000219,
29,,Autocuration,,12054,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,CHEMBL615142,H,8,,,,,1,,BAO_0000357,
30,,Autocuration,,12054,Inhibitory activity against soybean 15-lipoxygenase was evaluated,CHEMBL615143,H,8,,,,,1,,BAO_0000357,
31,,Autocuration,,12054,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,CHEMBL615144,H,8,,,,,1,,BAO_0000357,
32,,Autocuration,,12054,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,CHEMBL872867,H,8,,,,,1,,BAO_0000357,
33,,Autocuration,,12054,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,CHEMBL615145,H,8,,,,,1,,BAO_0000357,
34,,Autocuration,,12054,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,CHEMBL615146,H,8,,,,,1,,BAO_0000357,
35,,Autocuration,,12054,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,CHEMBL615147,H,8,,,,,1,,BAO_0000357,
36,,Autocuration,,22226,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,CHEMBL615148,U,0,,,,,1,,BAO_0000019,
37,,Autocuration,,22226,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,CHEMBL615149,U,0,,,,,1,,BAO_0000019,
38,,Autocuration,,22226,Dissociation constant with dimeric 16S rRNA RNA construct B,CHEMBL615150,U,0,,,,,1,,BAO_0000019,
39,,Intermediate,,22222,Dissociation constant towards 16S rRNA construct A,CHEMBL615151,M,3,,,,,1,,BAO_0000225,
40,,Intermediate,,22222,Dissociation constant towards 16S rRNA construct B,CHEMBL615152,M,3,,,,,1,,BAO_0000225,
41,,Expert,,100263,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,CHEMBL615153,M,3,,,,,1,,BAO_0000225,
42,,Expert,,100263,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,CHEMBL615154,M,3,,,,,1,,BAO_0000225,
43,,Autocuration,,13053,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),CHEMBL615155,H,8,,,,,1,,BAO_0000019,
44,,Autocuration,,13053,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),CHEMBL615156,H,8,,,,,1,,BAO_0000019,
45,,Autocuration,,20001,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,CHEMBL615157,H,8,,,,,1,,BAO_0000019,
46,,Autocuration,,20001,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,CHEMBL615158,H,8,,,,,1,,BAO_0000019,
47,,Expert,,12971,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",CHEMBL615159,D,9,,,,,1,,BAO_0000019,
48,,Expert,,12971,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",CHEMBL615172,D,9,,,,,1,,BAO_0000019,
49,,Expert,,12971,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",CHEMBL615173,D,9,,,,,1,,BAO_0000019,
50,,Expert,,12971,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",CHEMBL615174,D,9,,,,,1,,BAO_0000019,
51,,Autocuration,,13053,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),CHEMBL884518,H,8,,,,,1,,BAO_0000019,
52,,Autocuration,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),CHEMBL615175,H,8,,,,,1,,BAO_0000357,
53,,Autocuration,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,CHEMBL615176,H,8,,,,,1,,BAO_0000357,
54,,Autocuration,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,CHEMBL615177,H,8,,,,,1,,BAO_0000357,
55,,Autocuration,,104740,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,CHEMBL615178,D,5,,,,Membranes,1,,BAO_0000249,
56,,Intermediate,,80002,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,CHEMBL615179,N,1,506.0,1A9,,,1,,BAO_0000219,
57,,Autocuration,,104835,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,CHEMBL615180,D,7,,Oocytes,,,1,,BAO_0000219,
58,,Autocuration,,104821,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,CHEMBL615181,D,7,,Oocytes,,,1,,BAO_0000219,
59,,Autocuration,,104848,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,CHEMBL615182,D,7,,Oocytes,,,1,,BAO_0000219,
60,,Expert,,80002,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,CHEMBL615183,N,1,506.0,1A9,,,1,,BAO_0000219,
61,,Intermediate,,80002,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,CHEMBL615184,N,1,506.0,1A9,,,1,,BAO_0000219,
62,,Intermediate,,80002,Cytotoxic activity against human ovarian cancer (1A9) cell line,CHEMBL615185,N,1,506.0,1A9,,,1,,BAO_0000219,
63,,Intermediate,,80002,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,CHEMBL615186,N,1,506.0,1A9,,,1,,BAO_0000219,
64,,Intermediate,,80002,Effective dose of compound against replication of 1A9 cell line was evaluated,CHEMBL615187,N,1,506.0,1A9,,,1,,BAO_0000219,
65,,Expert,,80002,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,CHEMBL885343,N,1,506.0,1A9,,,1,,BAO_0000219,
66,,Intermediate,,80002,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),CHEMBL615188,N,1,506.0,1A9,,,1,,BAO_0000219,
67,,Intermediate,,80002,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,CHEMBL615189,N,1,506.0,1A9,,,1,,BAO_0000219,
68,,Intermediate,,80002,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,CHEMBL615190,N,1,506.0,1A9,,,1,,BAO_0000219,
69,,Intermediate,,80002,Inhibitory activity against Taxol resistant 1A9 cell lines,CHEMBL615191,N,1,506.0,1A9,,,1,,BAO_0000219,
70,,Expert,,80002,Cytotoxicity against human ovarian cancer (1A9) cell lines.,CHEMBL615192,N,1,506.0,1A9,,,1,,BAO_0000219,
71,,Expert,,80002,Percentage inhibition of human ovarian cancer (1A9) cell lines.,CHEMBL827083,N,1,506.0,1A9,,,1,,BAO_0000219,
72,,Expert,,80002,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,CHEMBL615193,N,1,506.0,1A9,,,1,,BAO_0000219,
73,,Intermediate,,80002,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,CHEMBL615194,N,1,506.0,1A9,,,1,,BAO_0000219,
74,,Intermediate,,80002,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,CHEMBL615195,N,1,506.0,1A9,,,1,,BAO_0000219,
75,,Intermediate,,80002,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,CHEMBL615196,N,1,506.0,1A9,,,1,,BAO_0000219,
76,,Intermediate,,81072,Inhibitory concentration against Jurkat cells,CHEMBL615197,N,1,503.0,Jurkat,,,1,,BAO_0000219,
77,,Intermediate,,22226,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,CHEMBL615198,U,0,,,,,1,,BAO_0000019,
78,,Expert,,100121,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,CHEMBL615199,D,9,,,,,1,,BAO_0000357,
79,,Expert,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",CHEMBL615200,H,8,,,,,1,,BAO_0000357,
80,,Expert,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",CHEMBL615201,H,8,,,,,1,,BAO_0000357,
81,,Expert,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",CHEMBL615202,H,8,,,,,1,,BAO_0000357,
82,,Autocuration,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",CHEMBL615203,H,8,,,,Microsomes,1,,BAO_0000251,
83,,Autocuration,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",CHEMBL615204,H,8,,,,Microsomes,1,,BAO_0000251,
84,,Autocuration,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",CHEMBL615205,H,8,,,,Microsomes,1,,BAO_0000251,
85,,Autocuration,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",CHEMBL615206,H,8,,,,Microsomes,1,,BAO_0000251,
86,2107.0,Autocuration,Liver,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",CHEMBL615207,H,8,,,,Microsomes,1,,BAO_0000251,
87,,Autocuration,,11231,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",CHEMBL827084,H,8,,,,,1,,BAO_0000019,
88,,Autocuration,,11231,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",CHEMBL615208,H,8,,,,,1,,BAO_0000019,
89,,Autocuration,,11231,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",CHEMBL615209,H,8,,,,,1,,BAO_0000019,
90,2107.0,Autocuration,Liver,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",CHEMBL615210,D,9,,,,Microsomes,1,,BAO_0000251,
91,2107.0,Autocuration,Liver,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",CHEMBL615211,D,9,,,,Microsomes,1,,BAO_0000251,
92,2107.0,Autocuration,Liver,12083,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",CHEMBL615212,D,9,,,,Microsomes,1,,BAO_0000251,
93,,Expert,,11377,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),CHEMBL615213,H,8,,,,,1,,BAO_0000357,
94,,Expert,,11377,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,CHEMBL615273,H,8,,,,,1,,BAO_0000357,
95,,Expert,,81020,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,CHEMBL615274,N,1,726.0,HepG2,,,1,,BAO_0000219,
96,,Intermediate,,81020,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,CHEMBL615275,N,1,726.0,HepG2,,,1,,BAO_0000219,
97,,Intermediate,,81020,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,CHEMBL615276,N,1,726.0,HepG2,,,1,,BAO_0000219,
98,,Intermediate,,81020,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,CHEMBL615277,N,1,726.0,HepG2,,,1,,BAO_0000219,
99,,Intermediate,,81020,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,CHEMBL615326,N,1,726.0,HepG2,,,1,,BAO_0000219,
100,,Expert,,50606,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,CHEMBL883130,N,1,,,,,1,,BAO_0000218,
101,,Intermediate,,81020,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,CHEMBL884519,N,1,726.0,HepG2,,,1,,BAO_0000219,
102,,Intermediate,,81020,Concentration required to inhibit 50% of 2.2.15 cell line,CHEMBL615327,N,1,726.0,HepG2,,,1,,BAO_0000219,
103,,Intermediate,,81020,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,CHEMBL615328,N,1,726.0,HepG2,,,1,,BAO_0000219,
104,,Intermediate,,50587,Cytotoxic activity of compound against uninfected 2.2.15 cells.,CHEMBL615329,N,1,,2.2.15,,,1,,BAO_0000218,
105,,Intermediate,,50587,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,CHEMBL615330,N,1,,2.2.15,,,1,,BAO_0000218,
106,,Expert,,50606,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",CHEMBL615331,N,1,,2.2.15,,,1,,BAO_0000218,
107,,Intermediate,,50587,In vitro anti-HBV activity in 2.2.15 cells,CHEMBL615332,N,1,,2.2.15,,,1,,BAO_0000218,
108,,Intermediate,,50587,In vitro anti-HBV activity in 2.2.15 cells; Not determined,CHEMBL615333,N,1,,2.2.15,,,1,,BAO_0000218,
109,,Intermediate,,50587,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,CHEMBL615334,N,1,,2.2.15,,,1,,BAO_0000218,
110,,Intermediate,,50587,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,CHEMBL615335,N,1,,2.2.15,,,1,,BAO_0000218,
111,,Intermediate,,50587,Cytotoxicity in 2.2.15 cells,CHEMBL615336,N,1,,2.2.15,,,1,,BAO_0000218,
112,,Intermediate,,50587,Cytotoxicity in 2.2.15 cells; Not determined,CHEMBL615337,N,1,,2.2.15,,,1,,BAO_0000218,
113,,Intermediate,,50587,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,CHEMBL615338,N,1,,2.2.15,,,1,,BAO_0000218,
114,,Intermediate,,50587,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,CHEMBL615339,N,1,,2.2.15,,,1,,BAO_0000218,
115,,Intermediate,,50587,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,CHEMBL615340,N,1,,2.2.15,,,1,,BAO_0000218,
116,,Intermediate,,81020,Antiviral activity against HBV was determined in 2.215 cell line,CHEMBL615341,N,1,726.0,HepG2,,,1,,BAO_0000219,
117,,Autocuration,,22226,Inhibition of 20-HETE synthesis in human renal microsomes,CHEMBL615342,U,0,,,,Microsomes,1,,BAO_0000251,
118,,Autocuration,,22226,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,CHEMBL615343,U,0,,,,,1,,BAO_0000019,
119,,Intermediate,,80612,Inhibitory concentration against 2008 (ovarian) cells,CHEMBL615344,N,1,388.0,2008,,,1,,BAO_0000219,
120,,Intermediate,,80612,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,CHEMBL615345,N,1,388.0,2008,,,1,,BAO_0000219,
121,,Intermediate,,80612,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),CHEMBL615346,N,1,388.0,2008,,,1,,BAO_0000219,
122,,Intermediate,,80612,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,CHEMBL615347,N,1,388.0,2008,,,1,,BAO_0000219,
123,,Intermediate,,80612,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,CHEMBL615348,N,1,388.0,2008,,,1,,BAO_0000219,
124,,Intermediate,,80613,In vitro inhibition of 2008/R ovarian cancer cell line,CHEMBL827085,N,1,561.0,2008/R,,,1,,BAO_0000219,
125,,Intermediate,,80613,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,CHEMBL615349,N,1,561.0,2008/R,,,1,,BAO_0000219,
126,,Intermediate,,80614,In vitro inhibition of 2008/S ovarian cancer cell line,CHEMBL615350,N,1,389.0,2008/S,,,1,,BAO_0000219,
127,,Intermediate,,80614,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,CHEMBL615351,N,1,389.0,2008/S,,,1,,BAO_0000219,
128,,Expert,,100256,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,CHEMBL615352,S,2,,,,,1,,BAO_0000220,
129,,Intermediate,,100256,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,CHEMBL615353,S,2,,,,,1,,BAO_0000220,
130,,Expert,,100256,Inhibition of chymotrypsin-like activity of 20S proteasome,CHEMBL615354,S,2,,,,,1,,BAO_0000220,
131,,Expert,,100256,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,CHEMBL615355,S,2,,,,,1,,BAO_0000220,
132,,Intermediate,,100256,Inhibitory activity against 20S proteosome,CHEMBL615356,S,2,,,,,1,,BAO_0000220,
133,,Autocuration,,22226,Compound was tested for inhibitory activity against tryptase,CHEMBL615357,U,0,,,,,1,,BAO_0000019,
134,,Intermediate,,81020,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,CHEMBL615358,N,1,726.0,HepG2,,,1,,BAO_0000219,
135,,Intermediate,,81020,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,CHEMBL827086,N,1,726.0,HepG2,,,1,,BAO_0000219,
136,,Autocuration,,22226,Compound was tested for the inhibition of Alpha-glucosidase,CHEMBL615359,U,0,,,,,1,,BAO_0000019,
137,,Autocuration,,235,Inhibitory concentration against human neutrophil elastase (HNE),CHEMBL615360,H,8,,,,,1,,BAO_0000357,
138,948.0,Autocuration,Heart,22226,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,CHEMBL615361,U,0,,,,,1,,BAO_0000218,
139,,Autocuration,,19640,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615362,H,8,,,,,1,,BAO_0000019,
140,,Expert,,19640,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615363,H,8,,,,,1,,BAO_0000019,
141,,Autocuration,,19640,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615364,H,8,,,,,1,,BAO_0000357,
142,,Expert,,19640,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615365,H,8,,,,,1,,BAO_0000019,
143,,Intermediate,,80360,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,CHEMBL615366,N,1,524.0,P338,,,1,,BAO_0000219,
144,,Intermediate,,80360,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,CHEMBL615367,N,1,524.0,P338,,,1,,BAO_0000219,
145,,Intermediate,,80384,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,CHEMBL615368,N,1,554.0,PBL,,,1,,BAO_0000219,
146,,Autocuration,,22226,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,CHEMBL615369,U,0,,,,,1,,BAO_0000019,
147,,Autocuration,,22226,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,CHEMBL615370,U,0,,,,,1,,BAO_0000019,
148,,Autocuration,,191,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),CHEMBL615673,H,8,,,,,1,,BAO_0000357,
149,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,CHEMBL615674,U,0,,,,,1,,BAO_0000019,
150,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,CHEMBL615675,U,0,,,,,1,,BAO_0000019,
151,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,CHEMBL615676,U,0,635.0,CCRF-CEM,,,1,,BAO_0000219,
152,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,CHEMBL615677,U,0,635.0,CCRF-CEM,,,1,,BAO_0000219,
153,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,CHEMBL615678,U,0,635.0,CCRF-CEM,,,1,,BAO_0000219,
154,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,CHEMBL615679,U,0,635.0,CCRF-CEM,,,1,,BAO_0000219,
155,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,CHEMBL615680,U,0,,,,,1,,BAO_0000019,
156,,Autocuration,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,CHEMBL615681,U,0,,,,,1,,BAO_0000019,
157,,Autocuration,,104290,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,CHEMBL857972,H,6,,,,,1,,BAO_0000249,
158,,Intermediate,,50264,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,CHEMBL857899,N,1,,,,,1,,BAO_0000218,
159,,Intermediate,,50527,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),CHEMBL615371,N,1,,,,,1,,BAO_0000218,
160,,Expert,,50527,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,CHEMBL615372,N,1,468.0,HEL,,,1,,BAO_0000218,
161,,Intermediate,,50527,Antiviral activity against 07/1 strain of VZV; ND: No data,CHEMBL615373,N,1,,,,,1,,BAO_0000218,
162,,Intermediate,,50527,Antiviral activity against 07/1 strain of VZV; ND=No data,CHEMBL615374,N,1,,,,,1,,BAO_0000218,
163,,Intermediate,,50145,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",CHEMBL615375,N,1,,,,,1,,BAO_0000218,
164,,Autocuration,,22226,Ratio of Ki at A2 to Ki at A1 receptors,CHEMBL615376,U,0,,,,,1,,BAO_0000019,
165,,Expert,,11143,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",CHEMBL615377,H,8,,,,,1,,BAO_0000249,
166,,Expert,,18077,"Inhibition of 1,3-beta-glucan synthase",CHEMBL615378,H,8,,,,,1,,BAO_0000357,
167,,Intermediate,,80609,Inhibition of growth of 1-87 human tumor cell line,CHEMBL615379,N,1,832.0,1-87 tumor cell line,,,1,,BAO_0000219,
168,,Expert,,12166,Inhibition of 1-lipoxygenase (LOX)in RBL cells,CHEMBL615380,D,9,,,,,1,,BAO_0000219,
169,,Autocuration,,100171,Inhibitory activity against soybean 1-lipoxygenase (SLO),CHEMBL615381,D,9,,,,,1,,BAO_0000357,
170,,Autocuration,,100171,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,CHEMBL615382,D,9,,,,,1,,BAO_0000357,
171,,Autocuration,,100171,% inhibition against soybean 1-lipoxygenase (SLO),CHEMBL615383,D,9,,,,,1,,BAO_0000357,
172,,Autocuration,,100171,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,CHEMBL615384,D,9,,,,,1,,BAO_0000357,
173,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,CHEMBL615385,D,9,,,,,1,,BAO_0000357,
174,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,CHEMBL615386,D,9,,,,,1,,BAO_0000357,
175,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,CHEMBL615387,D,9,,,,,1,,BAO_0000357,
176,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,CHEMBL615388,D,9,,,,,1,,BAO_0000357,
177,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,CHEMBL615214,D,9,,,,,1,,BAO_0000357,
178,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,CHEMBL827087,D,9,,,,,1,,BAO_0000357,
179,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,CHEMBL615215,D,9,,,,,1,,BAO_0000357,
180,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,CHEMBL615216,D,9,,,,,1,,BAO_0000357,
181,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,CHEMBL615217,D,9,,,,,1,,BAO_0000357,
182,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,CHEMBL615218,D,9,,,,,1,,BAO_0000357,
183,,Autocuration,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,CHEMBL615219,D,9,,,,,1,,BAO_0000357,
184,,Autocuration,,22226,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,CHEMBL615220,U,0,,,,,1,,BAO_0000019,
185,,Intermediate,,80049,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),CHEMBL615221,N,1,294.0,C3H 10T1/2,,,1,,BAO_0000219,
186,,Intermediate,,22226,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,CHEMBL615222,U,0,,,,,1,,BAO_0000019,
187,,Autocuration,,11489,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),CHEMBL615223,H,8,,,,,1,,BAO_0000357,
188,,Autocuration,,11862,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),CHEMBL615224,H,8,,,,,1,,BAO_0000357,
189,,Autocuration,,11862,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,CHEMBL615225,H,8,,,,,1,,BAO_0000357,
190,,Autocuration,,11489,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,CHEMBL615226,H,8,,,,,1,,BAO_0000357,
191,,Autocuration,,11862,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,CHEMBL615227,H,8,,,,,1,,BAO_0000357,
192,,Expert,,12347,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,CHEMBL615228,D,9,,,,,1,,BAO_0000019,
193,,Expert,,100120,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,CHEMBL615229,D,9,,,,,1,,BAO_0000357,
194,2369.0,Expert,Adrenal gland,100120,Inhibition of 11 beta-hydroxylase from rat adrenal gland,CHEMBL615230,D,9,,,,,1,,BAO_0000357,
195,,Expert,,100120,Inhibition of rat adrenal 11-beta-hydroxylase,CHEMBL615231,D,9,,,,,1,,BAO_0000357,
196,,Expert,,100120,Inhibition of rat adrenal 11-beta-hydroxylase,CHEMBL884520,D,9,,,,,1,,BAO_0000357,
197,,Expert,,100120,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,CHEMBL615232,D,9,,,,,1,,BAO_0000357,
198,,Autocuration,,10328,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,CHEMBL615233,H,8,,,,,1,,BAO_0000019,
199,,Autocuration,,11490,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,CHEMBL827088,H,8,,,,,1,,BAO_0000357,
200,,Autocuration,,11490,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,CHEMBL615234,H,8,,,,,1,,BAO_0000357,
201,,Autocuration,,11134,Compound was tested for the percent of inhibition against 12-LO at 10 uM,CHEMBL615235,H,8,,,,,1,,BAO_0000019,
202,,Autocuration,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,CHEMBL615236,H,8,,,,,1,,BAO_0000019,
203,,Autocuration,,11134,Compound was tested in vitro for inhibition of 12-LO human platelet,CHEMBL615237,H,8,,,,,1,,BAO_0000019,
204,,Autocuration,,11134,Inhibitory concentration against human platelet 12-lipoxygenase,CHEMBL615238,H,8,,,,,1,,BAO_0000019,
205,,Autocuration,,11134,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,CHEMBL615239,H,8,,,,,1,,BAO_0000019,
206,,Autocuration,,11134,Inhibitory concentration against human platelet 12-lipoxygenase,CHEMBL615240,D,9,,,,,1,,BAO_0000019,
207,,Expert,,11835,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,CHEMBL615241,H,8,,,,,1,,BAO_0000019,
208,,Expert,,11601,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,CHEMBL615242,H,8,,,,,1,,BAO_0000357,
209,,Autocuration,,11134,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),CHEMBL615243,H,8,,,,,1,,BAO_0000019,
210,,Autocuration,,11134,Inhibitory activity against human platelet 12-lipoxygenase,CHEMBL615244,H,8,,,,,1,,BAO_0000019,
211,,Autocuration,,11134,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,CHEMBL615245,H,8,,,,,1,,BAO_0000019,
212,,Autocuration,,11134,% inhibition against human platelet 12-lipoxygenase (12-HLO),CHEMBL615246,H,8,,,,,1,,BAO_0000019,
213,,Autocuration,,11134,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,CHEMBL615247,H,8,,,,,1,,BAO_0000019,
214,,Autocuration,,11134,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,CHEMBL615248,H,8,,,,,1,,BAO_0000019,
215,,Autocuration,,11601,Inhibitory activity towards porcine 12-lipoxygenase,CHEMBL615249,H,8,,,,,1,,BAO_0000357,
216,,Autocuration,,11601,Tested for inhibition against porcine 12-LO,CHEMBL615250,H,8,,,,,1,,BAO_0000357,
217,,Autocuration,,12052,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,CHEMBL615251,H,8,,,,,1,,BAO_0000019,
218,,Autocuration,,12052,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,CHEMBL615252,H,8,,,,,1,,BAO_0000019,
219,,Expert,,12052,In vitro inhibition of rat platelet 12-lipoxygenase,CHEMBL828340,H,8,,,,,1,,BAO_0000019,
220,,Autocuration,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,CHEMBL615253,H,8,,,,,1,,BAO_0000019,
221,,Autocuration,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,CHEMBL615254,H,8,,,,,1,,BAO_0000019,
222,,Autocuration,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,CHEMBL615255,H,8,,,,,1,,BAO_0000019,
223,,Autocuration,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,CHEMBL615256,H,8,,,,,1,,BAO_0000019,
224,,Autocuration,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase,CHEMBL615257,H,8,,,,,1,,BAO_0000019,
225,,Autocuration,,12052,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,CHEMBL615258,H,8,,,,,1,,BAO_0000019,
226,,Intermediate,,80007,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,CHEMBL615259,N,1,621.0,41M,,,1,,BAO_0000219,
227,,Expert,,80007,In vitro antitumor activity against 41M cell line.,CHEMBL615260,N,1,621.0,41M,,,1,,BAO_0000219,
228,,Intermediate,,80007,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,CHEMBL615261,N,1,621.0,41M,,,1,,BAO_0000219,
229,,Intermediate,,80007,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,CHEMBL615262,N,1,621.0,41M,,,1,,BAO_0000219,
230,,Expert,,80007,In vitro antitumor activity against 41McisR cell line.,CHEMBL615263,N,1,621.0,41M,,,1,,BAO_0000219,
231,,Expert,,80007,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,CHEMBL838393,N,1,621.0,41M,,,1,,BAO_0000219,
232,,Intermediate,,80007,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,CHEMBL615264,N,1,621.0,41M,,,1,,BAO_0000219,
233,,Expert,,84,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),CHEMBL615265,D,9,,,,,1,,BAO_0000357,
234,,Expert,,68,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),CHEMBL615266,D,9,,,,,1,,BAO_0000357,
235,,Expert,,68,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),CHEMBL615267,H,8,,,,,1,,BAO_0000357,
236,,Expert,,10201,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,CHEMBL615268,H,8,,,,,1,,BAO_0000357,
237,,Expert,,10201,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,CHEMBL615269,H,8,,,,,1,,BAO_0000357,
238,,Expert,,10201,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,CHEMBL615270,H,8,,,,,1,,BAO_0000357,
239,,Autocuration,,12220,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",CHEMBL615271,H,8,,,,,1,,BAO_0000357,
240,,Autocuration,,11303,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",CHEMBL615272,H,8,,,,,1,,BAO_0000357,
241,,Autocuration,,11303,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",CHEMBL615103,H,8,,,,,1,,BAO_0000357,
242,,Autocuration,,11303,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",CHEMBL615104,H,8,,,,,1,,BAO_0000357,
243,,Autocuration,,12220,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",CHEMBL615105,H,8,,,,,1,,BAO_0000357,
244,,Autocuration,,12220,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",CHEMBL872866,H,8,,,,,1,,BAO_0000357,
245,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",CHEMBL615106,H,8,,,,,1,,BAO_0000357,
246,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",CHEMBL615107,H,8,,,,,1,,BAO_0000019,
247,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",CHEMBL615108,H,8,,,,,1,,BAO_0000357,
248,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",CHEMBL615109,H,8,,,,,1,,BAO_0000357,
249,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",CHEMBL615110,H,8,,,,,1,,BAO_0000357,
250,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",CHEMBL840105,H,8,,,,,1,,BAO_0000019,
251,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",CHEMBL615111,H,8,,,,,1,,BAO_0000019,
252,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",CHEMBL615112,H,8,,,,,1,,BAO_0000019,
253,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",CHEMBL615113,H,8,,,,,1,,BAO_0000019,
254,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",CHEMBL615114,H,8,,,,,1,,BAO_0000019,
255,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",CHEMBL615115,H,8,,,,,1,,BAO_0000357,
256,,Autocuration,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",CHEMBL615116,H,8,,,,,1,,BAO_0000019,
257,,Autocuration,,11303,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",CHEMBL615698,H,8,,,,,1,,BAO_0000357,
258,,Autocuration,,22226,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",CHEMBL615699,U,0,,,,,1,,BAO_0000019,
259,,Autocuration,,22226,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",CHEMBL615700,U,0,,,,,1,,BAO_0000019,
260,,Expert,,100249,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,CHEMBL615701,H,8,,,,,1,,BAO_0000357,
261,,Autocuration,,22226,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,CHEMBL615702,U,0,,,,,1,,BAO_0000019,
262,,Autocuration,,22226,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,CHEMBL615703,U,0,,,,,1,,BAO_0000019,
263,,Autocuration,,22226,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",CHEMBL615704,U,0,,,,,1,,BAO_0000019,
264,,Autocuration,,104698,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",CHEMBL615705,H,6,,,,,1,,BAO_0000019,
265,,Autocuration,,104698,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",CHEMBL615706,H,6,,,,,1,,BAO_0000019,
266,2116.0,Intermediate,Ileum,20033,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,CHEMBL615707,D,9,,,,,1,,BAO_0000221,
267,,Expert,,10623,Stimulatory activity of intragastric pressure was tested in the rat,CHEMBL615708,H,8,,,,,1,,BAO_0000019,
268,,Autocuration,,121,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,CHEMBL615709,H,8,,,,,1,,BAO_0000357,
269,,Autocuration,,22226,Dose to reduce neuronal firing against 5-HT cells in rats (iv),CHEMBL615710,U,0,,,,,1,,BAO_0000218,
270,,Autocuration,,12688,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,CHEMBL615711,H,8,,,,,1,,BAO_0000019,
271,,Expert,,121,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,CHEMBL615712,D,9,,,,,1,,BAO_0000357,
272,,Expert,,121,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,CHEMBL836325,D,9,,,,,1,,BAO_0000357,
273,,Autocuration,,12198,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,CHEMBL615713,H,8,,,,,1,,BAO_0000019,
274,,Autocuration,,12198,Inhibition constant of high-affinity 5-HT uptake,CHEMBL615714,H,8,,,,,1,,BAO_0000357,
275,,Autocuration,,12198,Michaelis-Menten constant was reported for high affinity transport of 5-HT,CHEMBL615715,H,8,,,,,1,,BAO_0000019,
276,,Autocuration,,12198,Maximum rate was determined for high affinity transport of 5-HT,CHEMBL615716,H,8,,,,,1,,BAO_0000019,
277,,Autocuration,,104714,Compound was tested for agonistic activity against 5-HT uptake,CHEMBL615717,H,4,,,,,1,,BAO_0000019,
278,,Expert,,10577,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,CHEMBL881818,H,8,,,,,1,,BAO_0000019,
279,,Expert,,105,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,CHEMBL884540,H,8,,,,,1,,BAO_0000357,
280,,Autocuration,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,CHEMBL615718,D,5,,,,,1,,BAO_0000224,
281,,Autocuration,,104744,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,CHEMBL615719,H,4,,,,,1,,BAO_0000224,
282,,Autocuration,,104744,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,CHEMBL615720,H,4,,,,Membranes,1,,BAO_0000249,
283,,Autocuration,,104744,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,CHEMBL615721,H,4,,,,Membranes,1,,BAO_0000249,
284,,Autocuration,,104744,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL615722,H,4,,,,,1,,BAO_0000019,
285,,Autocuration,,51,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,CHEMBL615723,H,8,,,,,1,,BAO_0000019,
286,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615724,H,8,,,,,1,,BAO_0000221,
287,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615725,H,8,,,,,1,,BAO_0000221,
288,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615726,H,8,,,,,1,,BAO_0000221,
289,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),CHEMBL615727,H,8,,,,,1,,BAO_0000218,
290,,Intermediate,,105570,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,CHEMBL615728,D,9,,,,,1,,BAO_0000019,
291,,Autocuration,,279,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL857971,H,8,449.0,CHO,,,1,,BAO_0000219,
292,,Autocuration,,107,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,CHEMBL615729,H,8,,,,,1,,BAO_0000357,
293,,Expert,,12687,Efficacy against 5-hydroxytryptamine 2A receptor,CHEMBL615730,D,9,,,,,1,,BAO_0000019,
294,,Expert,,12687,Intrinsic activity towards 5-HT2A receptor of rat tail artery,CHEMBL615731,H,8,,,,,1,,BAO_0000019,
295,,Expert,,12687,Relative potency towards 5-HT2A receptor of rat tail artery,CHEMBL615732,H,8,,,,,1,,BAO_0000019,
296,,Expert,,12687,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,CHEMBL615733,H,8,,,,,1,,BAO_0000019,
297,,Expert,,12687,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,CHEMBL615734,H,8,,,,,1,,BAO_0000019,
298,,Autocuration,,12687,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,CHEMBL615735,H,8,,,,,1,,BAO_0000019,
299,,Expert,,12687,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,CHEMBL615736,H,8,,,,,1,,BAO_0000019,
300,2116.0,Intermediate,Ileum,20033,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL615737,D,9,,,,,1,,BAO_0000221,
301,2116.0,Intermediate,Ileum,20033,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),CHEMBL615738,D,9,,,,,1,,BAO_0000221,
302,2116.0,Intermediate,Ileum,20033,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL615739,D,9,,,,,1,,BAO_0000221,
303,,Autocuration,,10623,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,CHEMBL615278,H,8,,,,,1,,BAO_0000357,
304,,Expert,,10623,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,CHEMBL615279,D,9,,,,,1,,BAO_0000019,
305,,Expert,,168,Binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL615280,H,8,,,,,1,,BAO_0000357,
306,,Autocuration,,22226,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,CHEMBL615281,U,0,,,,,1,,BAO_0000019,
307,,Autocuration,,22226,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,CHEMBL615282,U,0,,,,,1,,BAO_0000019,
308,,Autocuration,,22226,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,CHEMBL615283,U,0,,,,,1,,BAO_0000019,
309,,Autocuration,,80156,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,CHEMBL615284,N,1,649.0,HL-60,,,1,,BAO_0000219,
310,,Autocuration,,22226,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,CHEMBL615285,U,0,,,,,1,,BAO_0000019,
311,,Autocuration,,22226,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,CHEMBL615286,U,0,,,,,1,,BAO_0000019,
312,,Autocuration,,104703,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,CHEMBL615287,D,7,,Oocytes,,,1,,BAO_0000219,
313,,Intermediate,,100256,Chymotryptic inhibitory activity against 26S proteasome,CHEMBL615288,S,2,,,,,1,,BAO_0000220,
314,,Intermediate,,100256,Inhibitory activity against 26S proteasome degradation of IkB,CHEMBL615289,S,2,,,,,1,,BAO_0000220,
315,,Intermediate,,81034,In vitro inhibition of 2780/DOX ovarian cancer cell line,CHEMBL615290,N,1,478.0,A2780,,,1,,BAO_0000219,
316,,Intermediate,,81034,In vitro inhibition of 2780/S ovarian cancer cell line,CHEMBL884522,N,1,478.0,A2780,,,1,,BAO_0000219,
317,,Autocuration,,22226,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,CHEMBL615291,U,0,,,,,1,,BAO_0000019,
318,,Intermediate,,22222,Association constant for binding to AATT 28-mer AATT hairpin,CHEMBL615292,M,3,,,,,1,,BAO_0000225,
319,,Intermediate,,22222,Kinetically Defined Association Constant for 28-mer AATT hairpin.,CHEMBL615293,M,3,,,,,1,,BAO_0000225,
320,,Intermediate,,22222,Reaction Rate Parameter for 28-mer AATT hairpin,CHEMBL615294,M,3,,,,,1,,BAO_0000225,
321,,Intermediate,,22222,Reaction Rate Parameter for 28-mer AATT hairpin,CHEMBL615295,M,3,,,,,1,,BAO_0000225,
322,,Autocuration,,22226,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),CHEMBL825021,U,0,,,,,1,,BAO_0000019,
323,,Autocuration,,22226,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),CHEMBL615296,U,0,,,,,1,,BAO_0000019,
324,,Autocuration,,22226,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,CHEMBL615297,U,0,,,,,1,,BAO_0000019,
325,,Autocuration,,22226,Cytotoxicity against cell line 2SC/20 determined by MTT test,CHEMBL615298,U,0,,,,,1,,BAO_0000019,
326,,Autocuration,,22226,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,CHEMBL615299,U,0,,,,,1,,BAO_0000019,
327,,Autocuration,,22226,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,CHEMBL615300,U,0,,,,,1,,BAO_0000019,
328,,Autocuration,,241,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,CHEMBL615301,H,8,,,,,1,,BAO_0000357,
329,,Expert,,241,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,CHEMBL615302,D,9,,,,,1,,BAO_0000357,
330,,Autocuration,,22226,Selectivity ratio of ID50 in liver and heart,CHEMBL615303,U,0,,,,,1,,BAO_0000019,
331,,Autocuration,,12132,"Selectivity, ratio of relative ID50 in liver and heart",CHEMBL615304,H,8,,,,,1,,BAO_0000019,
332,,Autocuration,,12132,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,CHEMBL615305,H,8,,,,,1,,BAO_0000019,
333,,Autocuration,,12132,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615306,H,8,,,,,1,,BAO_0000218,
334,,Autocuration,,12132,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615307,H,8,,,,,1,,BAO_0000218,
335,,Autocuration,,12132,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615308,H,8,,,,,1,,BAO_0000218,
336,,Autocuration,,12132,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615309,H,8,,,,,1,,BAO_0000218,
337,,Autocuration,,22226,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",CHEMBL615310,U,0,,,,,1,,BAO_0000019,
338,,Autocuration,,12132,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,CHEMBL615311,H,8,,,,,1,,BAO_0000019,
339,,Autocuration,,22226,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",CHEMBL615312,U,0,,,,,1,,BAO_0000019,
340,,Autocuration,,12132,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,CHEMBL615313,H,8,,,,,1,,BAO_0000019,
341,,Autocuration,,12132,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,CHEMBL615314,H,8,,,,,1,,BAO_0000019,
342,,Autocuration,,12132,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",CHEMBL615315,H,8,,,,,1,,BAO_0000019,
343,,Autocuration,,22226,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",CHEMBL615316,U,0,,,,,1,,BAO_0000218,
344,,Autocuration,,12132,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,CHEMBL615317,H,8,,,,,1,,BAO_0000218,
345,,Autocuration,,12132,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615318,H,8,,,,,1,,BAO_0000218,
346,,Autocuration,,22226,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",CHEMBL615319,U,0,,,,,1,,BAO_0000218,
347,,Autocuration,,12132,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",CHEMBL615320,H,8,,,,,1,,BAO_0000019,
348,,Autocuration,,12132,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",CHEMBL615321,H,8,,,,,1,,BAO_0000019,
349,,Autocuration,,22226,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",CHEMBL615322,U,0,,,,,1,,BAO_0000019,
350,,Autocuration,,19690,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,CHEMBL615323,H,8,,,,,1,,BAO_0000357,
351,,Autocuration,,19690,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,CHEMBL615407,H,8,,,,,1,,BAO_0000357,
352,,Autocuration,,19690,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,CHEMBL857267,H,8,,,,,1,,BAO_0000357,
353,,Autocuration,,19690,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,CHEMBL615408,H,8,,,,,1,,BAO_0000357,
354,,Autocuration,,19690,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,CHEMBL615409,H,8,,,,,1,,BAO_0000357,
355,,Autocuration,,19690,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,CHEMBL615410,H,8,,,,,1,,BAO_0000357,
356,,Autocuration,,19690,Inhibition constant against 3-dehydroquinate synthase,CHEMBL615411,H,8,,,,,1,,BAO_0000357,
357,,Autocuration,,19690,Association rate constant against 3-dehydroquinate synthase,CHEMBL615412,H,8,,,,,1,,BAO_0000357,
358,,Autocuration,,19690,Rate constant against 3-dehydroquinate synthase,CHEMBL615413,H,8,,,,,1,,BAO_0000357,
359,,Autocuration,,22226,Inhibitory activity against fuc-TVII,CHEMBL615414,U,0,,,,,1,,BAO_0000019,
360,2107.0,Autocuration,Liver,12236,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615415,D,9,,,,Microsomes,1,,BAO_0000251,
361,2107.0,Autocuration,Liver,12236,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615416,D,9,,,,Microsomes,1,,BAO_0000251,
362,2107.0,Autocuration,Liver,12236,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615417,D,9,,,,Microsomes,1,,BAO_0000251,
363,2107.0,Autocuration,Liver,12236,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615418,D,9,,,,Microsomes,1,,BAO_0000251,
364,2107.0,Autocuration,Liver,12236,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615419,D,9,,,,Microsomes,1,,BAO_0000251,
365,2107.0,Autocuration,Liver,12236,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,CHEMBL615420,D,9,,,,Microsomes,1,,BAO_0000251,
366,2107.0,Autocuration,Liver,12236,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,CHEMBL615421,D,9,,,,Microsomes,1,,BAO_0000251,
367,2107.0,Autocuration,Liver,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,CHEMBL615422,D,9,,,,Microsomes,1,,BAO_0000251,
368,2107.0,Autocuration,Liver,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,CHEMBL615423,D,9,,,,Microsomes,1,,BAO_0000251,
369,2107.0,Autocuration,Liver,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,CHEMBL872868,D,9,,,,Microsomes,1,,BAO_0000251,
370,2107.0,Autocuration,Liver,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,CHEMBL615424,D,9,,,,Microsomes,1,,BAO_0000251,
371,,Autocuration,,104832,Inhibitory activity against 3-phosphoglycerate kinase.,CHEMBL825022,H,4,,,,,1,,BAO_0000224,
372,,Autocuration,,104832,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,CHEMBL615425,H,4,,,,,1,,BAO_0000224,
373,,Autocuration,,104832,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",CHEMBL615426,H,4,,,,,1,,BAO_0000224,
374,,Expert,,10612,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,CHEMBL615427,D,9,,,,,1,,BAO_0000357,
375,,Intermediate,,80616,Cytotoxicity on 3677 melanoma cells,CHEMBL615428,N,1,844.0,3677 melanoma cell line,,,1,,BAO_0000219,
376,,Intermediate,,80616,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,CHEMBL615429,N,1,844.0,3677 melanoma cell line,,,1,,BAO_0000219,
377,,Intermediate,,80617,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,CHEMBL615430,N,1,700.0,MC-38,,,1,,BAO_0000219,
378,,Intermediate,,22226,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,CHEMBL615431,U,0,,,,,1,,BAO_0000019,
379,,Autocuration,,22226,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,CHEMBL615432,U,0,798.0,B16,,,1,,BAO_0000218,
380,,Autocuration,,22226,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,CHEMBL615433,U,0,798.0,B16,,,1,,BAO_0000218,
381,,Expert,,12464,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,CHEMBL615434,D,9,,,,,1,,BAO_0000019,
382,,Intermediate,,50085,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,CHEMBL615435,N,1,,,,,1,,BAO_0000218,
383,,Intermediate,,50679,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,CHEMBL615436,N,1,,,,,1,,BAO_0000218,
384,,Intermediate,,50679,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,CHEMBL615437,N,1,,,,,1,,BAO_0000218,
385,,Expert,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,CHEMBL615438,D,9,,,,,1,,BAO_0000019,
386,,Expert,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,CHEMBL615439,D,9,,,,,1,,BAO_0000019,
387,,Expert,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,CHEMBL615440,D,9,,,,,1,,BAO_0000019,
388,,Expert,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,CHEMBL615441,D,9,,,,,1,,BAO_0000019,
389,,Intermediate,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,CHEMBL615641,N,1,,,,,1,,BAO_0000218,
390,,Intermediate,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,CHEMBL872065,N,1,,,,,1,,BAO_0000218,
391,,Intermediate,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,CHEMBL825023,N,1,,,,,1,,BAO_0000218,
392,,Intermediate,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,CHEMBL615642,N,1,,,,,1,,BAO_0000218,
393,,Expert,,12464,Inhibition of human rhinovirus 3C protease,CHEMBL615643,H,8,,,,,1,,BAO_0000357,
394,,Autocuration,,22226,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,CHEMBL615644,U,0,,,,,1,,BAO_0000019,
395,,Intermediate,,80619,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),CHEMBL615645,N,1,833.0,3EM 37,,,1,,BAO_0000218,
396,,Intermediate,,80619,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),CHEMBL615646,N,1,833.0,3EM 37,,,1,,BAO_0000218,
397,,Intermediate,,80619,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),CHEMBL615647,N,1,833.0,3EM 37,,,1,,BAO_0000218,
398,,Intermediate,,80619,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),CHEMBL615648,N,1,833.0,3EM 37,,,1,,BAO_0000218,
399,,Intermediate,,80619,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,CHEMBL615649,N,1,833.0,3EM 37,,,1,,BAO_0000218,
400,,Intermediate,,80619,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,CHEMBL615650,N,1,833.0,3EM 37,,,1,,BAO_0000218,
401,,Intermediate,,80620,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,CHEMBL615651,N,1,847.0,3LL cell line,,,1,,BAO_0000218,
402,,Intermediate,,80620,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,CHEMBL615652,N,1,847.0,3LL cell line,,,1,,BAO_0000218,
403,,Expert,,80620,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,CHEMBL615653,N,1,847.0,3LL cell line,,,1,,BAO_0000218,
404,,Intermediate,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,CHEMBL615654,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
405,,Intermediate,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,CHEMBL615655,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
406,,Intermediate,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,CHEMBL825024,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
407,,Intermediate,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,CHEMBL615656,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
408,,Intermediate,,80620,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,CHEMBL615657,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
409,,Intermediate,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,CHEMBL615658,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
410,,Intermediate,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,CHEMBL615659,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
411,,Intermediate,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,CHEMBL615660,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
412,,Intermediate,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,CHEMBL615661,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
413,,Intermediate,,80620,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,CHEMBL615662,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
414,,Intermediate,,80620,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,CHEMBL615663,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
415,,Intermediate,,80620,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,CHEMBL615664,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
416,,Intermediate,,80620,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,CHEMBL615665,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
417,,Intermediate,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,CHEMBL615666,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
418,,Intermediate,,80620,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,CHEMBL615667,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
419,,Intermediate,,80620,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,CHEMBL615668,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
420,,Intermediate,,80620,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,CHEMBL615669,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
421,,Intermediate,,80620,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,CHEMBL615670,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
422,,Intermediate,,80620,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,CHEMBL836739,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
423,,Intermediate,,80620,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,CHEMBL615671,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
424,,Intermediate,,80620,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,CHEMBL615672,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
425,,Intermediate,,80620,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,CHEMBL615791,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
426,,Intermediate,,80620,spermine levels in 3LL cells after the treatment of 1 uM of Compound,CHEMBL615792,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
427,,Intermediate,,80620,spermine levels in 3LL cells after the treatment of 10 uM of Compound,CHEMBL615793,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
428,,Intermediate,,80620,spermine levels in 3LL cells after the treatment of 250 uM of Compound,CHEMBL615794,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
429,,Intermediate,,80620,spermine levels in 3LL cells after the treatment of 50 uM of Compound,CHEMBL615795,N,1,847.0,3LL cell line,,,1,,BAO_0000219,
430,,Intermediate,,80621,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,CHEMBL615590,N,1,971.0,3LLD122,,,1,,BAO_0000219,
431,,Autocuration,,22226,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,CHEMBL615591,U,0,,,,,1,,BAO_0000218,
432,,Autocuration,,22226,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,CHEMBL615592,U,0,,,,,1,,BAO_0000218,
433,,Autocuration,,22226,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,CHEMBL615593,U,0,,,,,1,,BAO_0000218,
434,,Autocuration,,22226,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,CHEMBL615594,U,0,,,,,1,,BAO_0000218,
435,,Intermediate,,80951,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,CHEMBL615595,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
436,,Intermediate,,80951,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,CHEMBL615596,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
437,,Expert,,11169,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,CHEMBL615597,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
438,,Intermediate,,80951,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,CHEMBL615598,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
439,,Intermediate,,80951,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,CHEMBL615599,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
440,,Expert,,80951,Effective dose against murine 3T3 fibroblasts cells,CHEMBL615600,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
441,,Expert,,80951,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,CHEMBL615601,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
442,,Expert,,80951,Cytotoxic effect on 3T3 cells,CHEMBL615602,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
443,,Expert,,80951,Cytotoxic effect on 3T3 cells,CHEMBL615603,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
444,,Intermediate,,80951,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,CHEMBL615604,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
445,,Intermediate,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,CHEMBL615605,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
446,,Intermediate,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,CHEMBL615606,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
447,,Expert,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,CHEMBL884526,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
448,,Expert,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,CHEMBL615607,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
449,,Intermediate,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,CHEMBL615608,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
450,,Expert,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,CHEMBL615609,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
451,,Expert,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,CHEMBL615682,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
452,,Intermediate,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,CHEMBL615683,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
453,,Expert,,80951,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,CHEMBL615684,N,1,723.0,NIH3T3,,,1,,BAO_0000218,
454,,Autocuration,,104860,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,CHEMBL615685,D,7,,,,,1,,BAO_0000219,
455,,Expert,,80951,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,CHEMBL615686,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
456,,Intermediate,,80951,Inhibitory activity against 3T3 cell line,CHEMBL615687,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
457,,Intermediate,,80951,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,CHEMBL884523,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
458,,Expert,,11169,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,CHEMBL615688,H,8,,,,,1,,BAO_0000019,
459,,Intermediate,,80951,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,CHEMBL615689,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
460,,Intermediate,,80951,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,CHEMBL615690,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
461,,Expert,,11169,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,CHEMBL615691,H,8,,,,,1,,BAO_0000019,
462,,Expert,,11169,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,CHEMBL615692,H,8,,,,,1,,BAO_0000019,
463,,Intermediate,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,CHEMBL615693,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
464,,Expert,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,CHEMBL615324,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
465,,Expert,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,CHEMBL615325,D,9,723.0,NIH3T3,,,1,,BAO_0000219,
466,,Expert,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),CHEMBL615490,D,9,723.0,NIH3T3,,,1,,BAO_0000219,
467,,Expert,,188,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,CHEMBL615491,D,9,723.0,NIH3T3,,,1,,BAO_0000219,
468,,Expert,,188,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),CHEMBL615492,D,9,723.0,NIH3T3,,,1,,BAO_0000219,
469,,Intermediate,,80951,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,CHEMBL615493,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
470,,Intermediate,,80951,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,CHEMBL615494,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
471,,Intermediate,,80951,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,CHEMBL615495,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
472,,Intermediate,,80951,Inhibitory concentration was calculated on 3T3 cells by using growth assay,CHEMBL615496,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
473,,Intermediate,,80951,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,CHEMBL615497,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
474,,Expert,,80951,Inhibition of Swiss 3T3 mouse fibroblast proliferation,CHEMBL615498,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
475,,Intermediate,,80951,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,CHEMBL615499,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
476,,Expert,,80951,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,CHEMBL835522,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
477,,Intermediate,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,CHEMBL615500,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
478,,Intermediate,,80951,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615501,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
479,,Intermediate,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615502,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
480,,Intermediate,,80951,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615503,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
481,,Intermediate,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615504,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
482,,Intermediate,,80951,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615505,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
483,,Expert,,80951,Inhibition of swiss 3T3 mouse fibroblast proliferation,CHEMBL615506,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
484,,Intermediate,,80951,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,CHEMBL615507,N,1,723.0,NIH3T3,,,1,,BAO_0000219,
485,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,CHEMBL615508,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
486,,Intermediate,,80006,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,CHEMBL615509,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
487,,Intermediate,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,CHEMBL615510,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
488,,Intermediate,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,CHEMBL615511,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
489,,Intermediate,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,CHEMBL615512,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
490,,Intermediate,,80006,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",CHEMBL615513,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
491,,Intermediate,,80006,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",CHEMBL615514,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
492,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,CHEMBL615515,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
493,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,CHEMBL615516,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
494,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,CHEMBL615517,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
495,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,CHEMBL615518,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
496,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,CHEMBL615519,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
497,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,CHEMBL615520,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
498,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,CHEMBL615521,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
499,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,CHEMBL615522,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
500,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,CHEMBL615523,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
501,,Expert,,80006,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,CHEMBL615524,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
502,,Expert,,80006,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,CHEMBL615525,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
503,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,CHEMBL615526,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
504,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,CHEMBL615527,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
505,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,CHEMBL615528,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
506,,Expert,,80006,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,CHEMBL615529,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
507,,Expert,,80006,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,CHEMBL615530,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
508,,Expert,,80006,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,CHEMBL615531,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
509,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,CHEMBL615532,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
510,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,CHEMBL615533,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
511,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,CHEMBL615534,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
512,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,CHEMBL615535,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
513,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,CHEMBL615536,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
514,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,CHEMBL615537,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
515,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,CHEMBL615538,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
516,,Intermediate,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,CHEMBL836166,N,1,620.0,3T3-L1,,,1,,BAO_0000218,
517,,Expert,,11214,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,CHEMBL615539,H,8,620.0,3T3-L1,,,1,,BAO_0000219,
518,,Intermediate,,80006,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,CHEMBL615540,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
519,,Expert,,11214,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,CHEMBL615541,H,8,620.0,3T3-L1,,,1,,BAO_0000219,
520,,Expert,,80006,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,CHEMBL615542,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
521,,Intermediate,,80006,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,CHEMBL615543,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
522,,Expert,,80006,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,CHEMBL615544,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
523,,Expert,,80006,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,CHEMBL615545,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
524,,Expert,,80006,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,CHEMBL615546,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
525,,Expert,,80006,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,CHEMBL615547,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
526,,Expert,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,CHEMBL615548,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
527,,Expert,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,CHEMBL615549,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
528,,Expert,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,CHEMBL615550,N,1,620.0,3T3-L1,,,1,,BAO_0000219,
529,,Intermediate,,80622,Inhibitory activity against rat fibroblast (3Y1) cell line,CHEMBL615551,N,1,1118.0,3Y1 cell line,,,1,,BAO_0000219,
530,,Expert,,80622,Mean concentration causing inhibition of cell growth in 3Y1 cells.,CHEMBL615552,N,1,1118.0,3Y1 cell line,,,1,,BAO_0000219,
531,,Expert,,80622,Cytotoxicity in 3Y1 cells.,CHEMBL615553,N,1,1118.0,3Y1 cell line,,,1,,BAO_0000219,
532,,Expert,,80622,Cytostatic effect in 3Y1 cells.,CHEMBL615554,N,1,1118.0,3Y1 cell line,,,1,,BAO_0000219,
533,,Intermediate,,80622,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",CHEMBL615555,N,1,1118.0,3Y1 cell line,,,1,,BAO_0000219,
534,,Expert,,80622,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,CHEMBL615556,N,1,1118.0,3Y1 cell line,,,1,,BAO_0000219,
535,,Autocuration,,22226,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,CHEMBL615557,U,0,,,,,1,,BAO_0000019,
536,,Autocuration,,22226,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,CHEMBL615558,U,0,,,,,1,,BAO_0000019,
537,,Autocuration,,22226,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,CHEMBL872066,U,0,,,,,1,,BAO_0000019,
538,,Expert,,11607,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,CHEMBL615559,D,9,,,,,1,,BAO_0000019,
539,,Autocuration,,11607,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,CHEMBL615560,H,8,,,,,1,,BAO_0000019,
540,,Autocuration,,11607,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,CHEMBL615561,H,8,,,,,1,,BAO_0000019,
541,,Expert,,11607,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,CHEMBL857062,H,8,,,,,1,,BAO_0000019,
542,,Expert,,11607,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),CHEMBL615562,H,8,,,,,1,,BAO_0000019,
543,,Autocuration,,11607,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,CHEMBL615563,H,8,,,,,1,,BAO_0000019,
544,,Autocuration,,11607,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),CHEMBL615564,H,8,,,,,1,,BAO_0000357,
545,,Autocuration,,11607,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,CHEMBL615565,H,8,,,,,1,,BAO_0000019,
546,,Autocuration,,11607,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,CHEMBL615566,H,8,,,,,1,,BAO_0000019,
547,,Expert,,11607,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,CHEMBL615567,D,9,,,,,1,,BAO_0000019,
548,,Autocuration,,11607,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,CHEMBL615568,H,8,,,,,1,,BAO_0000019,
549,,Autocuration,,11607,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),CHEMBL615569,H,8,,,,,1,,BAO_0000357,
550,,Autocuration,,11607,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,CHEMBL615570,H,8,,,,,1,,BAO_0000019,
551,,Autocuration,,11607,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),CHEMBL615571,H,8,,,,,1,,BAO_0000019,
552,,Autocuration,,104733,Binding affinity against melatonin (MT1) receptor (pC1),CHEMBL615572,H,4,,,,,1,,BAO_0000224,
553,,Autocuration,,22226,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,CHEMBL615573,U,0,,,,,1,,BAO_0000019,
554,,Autocuration,,22226,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,CHEMBL615574,U,0,,,,,1,,BAO_0000019,
555,,Autocuration,,22226,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,CHEMBL615575,U,0,,,,,1,,BAO_0000019,
556,,Autocuration,,10619,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,CHEMBL615576,H,8,,,,,1,,BAO_0000357,
557,,Autocuration,,10619,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,CHEMBL615577,H,8,,,,,1,,BAO_0000357,
558,10000000.0,Autocuration,Hippocampus,51,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,CHEMBL615578,H,8,,,,,1,,BAO_0000221,
559,,Expert,,51,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,CHEMBL615579,H,8,,,,,1,,BAO_0000357,
560,,Expert,,51,Binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL615580,H,8,,,,,1,,BAO_0000357,
561,,Expert,,51,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,CHEMBL615581,H,8,,,,,1,,BAO_0000019,
562,10000000.0,Autocuration,Hippocampus,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615582,H,8,,,,,1,,BAO_0000221,
563,10000000.0,Autocuration,Hippocampus,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615583,H,8,,,,,1,,BAO_0000221,
564,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615584,H,8,,,,,1,,BAO_0000221,
565,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL833691,H,8,,,,,1,,BAO_0000221,
566,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615585,H,8,,,,,1,,BAO_0000221,
567,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615586,H,8,,,,,1,,BAO_0000221,
568,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL884524,H,8,,,,,1,,BAO_0000221,
569,10000000.0,Autocuration,Hippocampus,51,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615587,H,8,,,,,1,,BAO_0000221,
570,10000000.0,Autocuration,Hippocampus,51,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",CHEMBL615588,H,8,,,,,1,,BAO_0000221,
571,,Expert,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,CHEMBL615589,D,9,,,,Membranes,1,,BAO_0000249,
572,10000000.0,Expert,Hippocampus,51,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,CHEMBL615442,H,8,,,,,1,,BAO_0000221,
573,10000000.0,Autocuration,Hippocampus,51,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,CHEMBL615443,H,8,,,,,1,,BAO_0000221,
574,10000000.0,Autocuration,Hippocampus,51,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,CHEMBL615444,H,8,,,,,1,,BAO_0000221,
575,10000000.0,Expert,Hippocampus,51,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,CHEMBL615445,H,8,,,,,1,,BAO_0000221,
576,10000000.0,Autocuration,Hippocampus,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,CHEMBL615446,H,8,,,,,1,,BAO_0000221,
577,,Autocuration,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,CHEMBL615447,H,8,449.0,CHO,,,1,,BAO_0000219,
578,10000000.0,Expert,Hippocampus,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615448,H,8,,,,,1,,BAO_0000221,
579,10000000.0,Expert,Hippocampus,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615449,H,8,,,,,1,,BAO_0000221,
580,,Autocuration,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL615450,H,8,449.0,CHO,,,1,,BAO_0000219,
581,10000000.0,Expert,Hippocampus,51,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",CHEMBL615451,H,8,,,,,1,,BAO_0000221,
582,,Autocuration,,51,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,CHEMBL615452,H,8,,,,,1,,BAO_0000357,
583,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615453,H,8,,,,,1,,BAO_0000221,
584,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615454,H,8,,,,,1,,BAO_0000221,
585,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615455,H,8,,,,,1,,BAO_0000221,
586,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615456,H,8,,,,,1,,BAO_0000221,
587,10000000.0,Autocuration,Hippocampus,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615457,H,8,,,,,1,,BAO_0000221,
588,10000000.0,Expert,Hippocampus,51,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,CHEMBL615458,H,8,,,,,1,,BAO_0000218,
589,10000000.0,Expert,Hippocampus,51,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615459,H,8,,,,,1,,BAO_0000221,
590,,Expert,,51,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",CHEMBL615460,D,9,449.0,CHO,,,1,,BAO_0000219,
591,,Autocuration,,51,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,CHEMBL615461,H,8,,,,,1,,BAO_0000019,
592,,Autocuration,,51,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,CHEMBL615462,H,8,,,,,1,,BAO_0000019,
593,10000000.0,Autocuration,Hippocampus,51,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,CHEMBL615463,H,8,,,,,1,,BAO_0000221,
594,2116.0,Autocuration,Ileum,51,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,CHEMBL615464,H,8,,,,,1,,BAO_0000221,
595,2116.0,Autocuration,Ileum,51,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,CHEMBL615465,H,8,,,,,1,,BAO_0000221,
596,2116.0,Autocuration,Ileum,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,CHEMBL615466,H,8,,,,,1,,BAO_0000221,
597,2116.0,Autocuration,Ileum,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,CHEMBL615467,H,8,,,,,1,,BAO_0000221,
598,2116.0,Autocuration,Ileum,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,CHEMBL615468,H,8,,,,,1,,BAO_0000221,
599,2116.0,Autocuration,Ileum,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,CHEMBL615469,H,8,,,,,1,,BAO_0000221,
600,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615470,H,8,,,,,1,,BAO_0000357,
601,,Autocuration,,51,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615471,H,8,,,,,1,,BAO_0000357,
602,,Autocuration,,51,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,CHEMBL615472,H,8,,,,,1,,BAO_0000357,
603,10000000.0,Autocuration,Hippocampus,106,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,CHEMBL883242,H,8,,,,,1,,BAO_0000221,
604,10000000.0,Autocuration,Hippocampus,106,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,CHEMBL615473,H,8,,,,,1,,BAO_0000221,
605,,Autocuration,,11863,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),CHEMBL615474,H,8,449.0,CHO,,,1,,BAO_0000218,
606,,Autocuration,,51,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,CHEMBL615475,H,8,,,,,1,,BAO_0000357,
607,,Autocuration,,51,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,CHEMBL615476,H,8,308.0,HeLa,,,1,,BAO_0000219,
608,,Autocuration,,51,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,CHEMBL615477,H,8,308.0,HeLa,,,1,,BAO_0000219,
609,,Autocuration,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,CHEMBL615478,H,8,,,,,1,,BAO_0000019,
610,,Autocuration,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,CHEMBL615160,H,8,449.0,CHO,,,1,,BAO_0000219,
611,,Expert,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,CHEMBL615161,H,8,449.0,CHO,,,1,,BAO_0000219,
612,,Autocuration,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,CHEMBL615162,H,8,449.0,CHO,,,1,,BAO_0000219,
613,,Autocuration,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,CHEMBL615163,H,8,449.0,CHO,,,1,,BAO_0000219,
614,,Expert,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL615164,H,8,449.0,CHO,,,1,,BAO_0000219,
615,,Expert,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL615165,H,8,449.0,CHO,,,1,,BAO_0000219,
616,,Autocuration,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,CHEMBL615166,H,8,449.0,CHO,,,1,,BAO_0000219,
617,,Autocuration,,51,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,CHEMBL615167,H,8,,,,,1,,BAO_0000219,
618,,Expert,,51,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,CHEMBL615168,D,9,308.0,HeLa,,,1,,BAO_0000219,
619,,Expert,,51,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,CHEMBL615169,D,9,308.0,HeLa,,,1,,BAO_0000219,
620,,Expert,,51,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,CHEMBL615170,D,9,449.0,CHO,,,1,,BAO_0000219,
621,,Expert,,51,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,CHEMBL615171,D,9,449.0,CHO,,,1,,BAO_0000219,
622,,Autocuration,,51,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,CHEMBL615694,H,8,,,,,1,,BAO_0000019,
623,,Autocuration,,51,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,CHEMBL615695,H,8,,,,,1,,BAO_0000019,
624,,Autocuration,,51,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",CHEMBL615696,H,8,,,,,1,,BAO_0000019,
625,,Autocuration,,51,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHEMBL615697,H,8,449.0,CHO,,,1,,BAO_0000219,
626,,Expert,,51,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),CHEMBL859410,D,9,449.0,CHO,,,1,,BAO_0000219,
627,,Autocuration,,51,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),CHEMBL615841,H,8,449.0,CHO,,,1,,BAO_0000219,
628,,Expert,,51,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),CHEMBL615842,D,9,449.0,CHO,,,1,,BAO_0000219,
629,,Autocuration,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHEMBL835003,H,8,449.0,CHO,,,1,,BAO_0000219,
630,,Autocuration,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),CHEMBL615843,H,8,449.0,CHO,,,1,,BAO_0000219,
631,,Expert,,51,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),CHEMBL615979,D,9,449.0,CHO,,,1,,BAO_0000219,
632,,Autocuration,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),CHEMBL615980,H,8,449.0,CHO,,,1,,BAO_0000219,
633,,Expert,,51,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),CHEMBL615981,D,9,449.0,CHO,,,1,,BAO_0000219,
634,,Expert,,51,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,CHEMBL615982,D,9,,,,,1,,BAO_0000019,
635,,Expert,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",CHEMBL615983,D,9,,,,,1,,BAO_0000019,
636,,Expert,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",CHEMBL615984,D,9,,,,,1,,BAO_0000019,
637,,Expert,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",CHEMBL615985,D,9,,,,,1,,BAO_0000019,
638,,Autocuration,,51,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHEMBL615986,H,8,449.0,CHO,,,1,,BAO_0000219,
639,,Autocuration,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHEMBL615987,H,8,449.0,CHO,,,1,,BAO_0000219,
640,,Autocuration,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,CHEMBL615988,H,8,449.0,CHO,,,1,,BAO_0000219,
641,,Expert,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHEMBL615989,H,8,449.0,CHO,,,1,,BAO_0000219,
642,,Autocuration,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,CHEMBL615990,H,8,449.0,CHO,,,1,,BAO_0000219,
643,,Autocuration,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,CHEMBL615991,H,8,449.0,CHO,,,1,,BAO_0000219,
644,,Autocuration,,51,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHEMBL615992,H,8,449.0,CHO,,,1,,BAO_0000219,
645,,Autocuration,,51,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,CHEMBL615993,H,8,449.0,CHO,,,1,,BAO_0000219,
646,,Expert,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHEMBL615994,H,8,449.0,CHO,,,1,,BAO_0000219,
647,,Autocuration,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,CHEMBL615995,H,8,449.0,CHO,,,1,,BAO_0000219,
648,,Autocuration,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHEMBL615996,H,8,449.0,CHO,,,1,,BAO_0000219,
649,,Autocuration,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,CHEMBL615997,H,8,449.0,CHO,,,1,,BAO_0000219,
650,,Autocuration,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615998,H,8,,,,,1,,BAO_0000019,
651,,Autocuration,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615999,H,8,,,,,1,,BAO_0000019,
652,,Autocuration,,51,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,CHEMBL616000,H,8,,,,,1,,BAO_0000019,
653,,Autocuration,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL616001,H,8,722.0,HEK293,,,1,,BAO_0000219,
654,,Expert,,51,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",CHEMBL616002,D,9,,,,,1,,BAO_0000019,
655,,Expert,,51,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",CHEMBL616003,H,8,,,,,1,,BAO_0000019,
656,,Expert,,51,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,CHEMBL616004,D,9,,,,,1,,BAO_0000019,
657,,Expert,,51,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,CHEMBL616005,D,9,,,,,1,,BAO_0000019,
658,,Autocuration,,51,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",CHEMBL616006,H,8,,,,,1,,BAO_0000019,
659,,Expert,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",CHEMBL616007,H,8,,,,,1,,BAO_0000019,
660,,Autocuration,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",CHEMBL616008,H,8,,,,,1,,BAO_0000019,
661,,Autocuration,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",CHEMBL616009,H,8,,,,,1,,BAO_0000019,
662,,Expert,,51,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",CHEMBL616010,H,8,,,,,1,,BAO_0000019,
663,,Expert,,51,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",CHEMBL616011,D,9,,,,,1,,BAO_0000019,
664,,Expert,,51,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",CHEMBL615740,D,9,,,,,1,,BAO_0000019,
665,,Autocuration,,51,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",CHEMBL615741,H,8,,,,,1,,BAO_0000019,
666,,Expert,,51,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",CHEMBL615742,H,8,,,,,1,,BAO_0000019,
667,,Autocuration,,51,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",CHEMBL615743,H,8,,,,,1,,BAO_0000019,
668,,Autocuration,,51,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,CHEMBL615744,H,8,449.0,CHO,,,1,,BAO_0000219,
669,,Expert,,51,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,CHEMBL615745,H,8,449.0,CHO,,,1,,BAO_0000219,
670,,Autocuration,,51,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,CHEMBL615746,H,8,,,,,1,,BAO_0000357,
671,,Autocuration,,51,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,CHEMBL615747,H,8,,,,,1,,BAO_0000357,
672,,Autocuration,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615748,H,8,,,,,1,,BAO_0000019,
673,,Autocuration,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",CHEMBL615749,H,8,,,,,1,,BAO_0000019,
674,,Autocuration,,51,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,CHEMBL615750,H,8,,,,,1,,BAO_0000019,
675,,Expert,,51,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,CHEMBL616259,D,9,,,,,1,,BAO_0000019,
676,,Autocuration,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL616260,H,8,,,,,1,,BAO_0000019,
677,,Expert,,51,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,CHEMBL616261,D,9,,,,,1,,BAO_0000019,
678,,Expert,,51,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",CHEMBL616262,D,9,,,,,1,,BAO_0000019,
679,,Expert,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",CHEMBL616263,D,9,,,,,1,,BAO_0000019,
680,,Expert,,51,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,CHEMBL616264,D,9,,,,,1,,BAO_0000019,
681,,Expert,,51,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,CHEMBL616265,D,9,,,,,1,,BAO_0000019,
682,,Expert,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",CHEMBL616266,D,9,,,,,1,,BAO_0000019,
683,,Expert,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",CHEMBL616267,D,9,,,,,1,,BAO_0000019,
684,,Expert,,51,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,CHEMBL616268,D,9,,,,,1,,BAO_0000019,
685,,Expert,,51,Inhibition of human 5-hydroxytryptamine 1A receptor,CHEMBL616269,D,9,,,,,1,,BAO_0000357,
686,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL884528,H,8,449.0,CHO,,,1,,BAO_0000219,
687,,Expert,,105,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,CHEMBL616270,D,9,722.0,HEK293,,,1,,BAO_0000219,
688,,Autocuration,,51,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,CHEMBL616271,H,8,449.0,CHO,,,1,,BAO_0000219,
689,,Autocuration,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHEMBL616272,H,8,449.0,CHO,,,1,,BAO_0000219,
690,,Expert,,51,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,CHEMBL616273,H,8,,,,,1,,BAO_0000357,
691,,Expert,,51,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616274,D,9,,,,,1,,BAO_0000357,
692,,Autocuration,,51,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,CHEMBL616275,H,8,449.0,CHO,,,1,,BAO_0000219,
693,,Autocuration,,51,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL616276,H,8,449.0,CHO,,,1,,BAO_0000219,
694,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,CHEMBL616277,U,0,,,,,1,,BAO_0000218,
695,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,CHEMBL616278,U,0,,,,,1,,BAO_0000218,
696,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,CHEMBL616279,U,0,,,,,1,,BAO_0000218,
697,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,CHEMBL616280,U,0,,,,,1,,BAO_0000218,
698,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,CHEMBL616281,U,0,,,,,1,,BAO_0000218,
699,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,CHEMBL616282,U,0,,,,,1,,BAO_0000218,
700,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,CHEMBL616283,U,0,,,,,1,,BAO_0000218,
701,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,CHEMBL616284,U,0,,,,,1,,BAO_0000218,
702,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,CHEMBL616285,U,0,,,,,1,,BAO_0000218,
703,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,CHEMBL616286,U,0,,,,,1,,BAO_0000218,
704,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,CHEMBL616287,U,0,,,,,1,,BAO_0000218,
705,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,CHEMBL616288,U,0,,,,,1,,BAO_0000218,
706,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,CHEMBL616289,U,0,,,,,1,,BAO_0000218,
707,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,CHEMBL615610,U,0,,,,,1,,BAO_0000218,
708,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,CHEMBL615611,U,0,,,,,1,,BAO_0000218,
709,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,CHEMBL615612,U,0,,,,,1,,BAO_0000218,
710,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,CHEMBL615613,U,0,,,,,1,,BAO_0000218,
711,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,CHEMBL615614,U,0,,,,,1,,BAO_0000218,
712,,Autocuration,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,CHEMBL615615,U,0,,,,,1,,BAO_0000218,
713,,Autocuration,,105093,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,CHEMBL615616,H,4,,,,,1,,BAO_0000019,
714,1898.0,Autocuration,Hypothalamus,11923,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,CHEMBL615617,H,8,,,,,1,,BAO_0000249,
715,,Autocuration,,10577,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,CHEMBL615618,H,8,,,,,1,,BAO_0000019,
716,,Autocuration,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,CHEMBL615619,H,8,,,,,1,,BAO_0000019,
717,,Expert,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,CHEMBL615620,H,8,,,,,1,,BAO_0000019,
718,,Autocuration,,55,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",CHEMBL615621,H,8,,,,,1,,BAO_0000357,
719,,Autocuration,,55,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",CHEMBL615622,H,8,,,,,1,,BAO_0000357,
720,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),CHEMBL615623,H,8,,,,,1,,BAO_0000019,
721,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,CHEMBL615624,H,8,,,,,1,,BAO_0000019,
722,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,CHEMBL615625,H,8,,,,,1,,BAO_0000019,
723,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,CHEMBL767045,H,8,,,,,1,,BAO_0000019,
724,,Autocuration,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,CHEMBL615626,H,8,,,,,1,,BAO_0000019,
725,,Autocuration,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,CHEMBL615627,H,8,,,,,1,,BAO_0000019,
726,,Autocuration,,55,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,CHEMBL615628,H,8,,,,,1,,BAO_0000019,
727,,Autocuration,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,CHEMBL615629,H,8,,,,,1,,BAO_0000357,
728,,Expert,,55,Inhibitory concentration against 5-lipoxygenase from human whole blood,CHEMBL615630,D,9,,,,,1,,BAO_0000357,
729,,Autocuration,,55,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],CHEMBL615631,H,8,,,,,1,,BAO_0000219,
730,,Autocuration,,17087,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,CHEMBL615632,H,8,,,,,1,,BAO_0000218,
731,,Autocuration,,17087,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,CHEMBL615633,H,8,,,,,1,,BAO_0000357,
732,,Autocuration,,17087,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,CHEMBL615634,H,8,,,,,1,,BAO_0000218,
733,,Expert,,55,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,CHEMBL615635,H,8,,,,,1,,BAO_0000019,
734,,Expert,,12166,In vitro inhibition of rat 5-Lipoxygenase,CHEMBL615636,H,8,,,,,1,,BAO_0000357,
735,,Expert,,12166,Inhibitory activity against 5-Lipoxygenase,CHEMBL615637,D,9,,,,,1,,BAO_0000357,
736,,Expert,,12166,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,CHEMBL615638,H,8,702.0,RBL-1,,,1,,BAO_0000219,
737,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),CHEMBL615639,H,8,702.0,RBL-1,,,1,,BAO_0000219,
738,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,CHEMBL615640,H,8,702.0,RBL-1,,,1,,BAO_0000219,
739,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,CHEMBL615796,H,8,,,,,1,,BAO_0000019,
740,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],CHEMBL615845,H,8,,,,,1,,BAO_0000219,
741,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,CHEMBL615846,H,8,,,,,1,,BAO_0000357,
742,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,CHEMBL615847,H,8,702.0,RBL-1,,,1,,BAO_0000219,
743,,Autocuration,,12166,The compound was tested for inhibition of isolated 5-Lipoxygenase,CHEMBL615848,H,8,,,,,1,,BAO_0000357,
744,,Autocuration,,22226,Ratio of IC50 against 5-LO and COX,CHEMBL615849,U,0,,,,,1,,BAO_0000019,
745,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,CHEMBL615850,H,8,,,,,1,,BAO_0000357,
746,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,CHEMBL615851,H,8,,,,,1,,BAO_0000357,
747,,Autocuration,,12166,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,CHEMBL615852,H,8,,,,,1,,BAO_0000219,
748,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,CHEMBL615853,H,8,,,,,1,,BAO_0000019,
749,2367.0,Autocuration,Prostate gland,120,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,CHEMBL884527,H,8,,,,,1,,BAO_0000357,
750,,Autocuration,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,CHEMBL872871,U,0,,,,,1,,BAO_0000019,
751,,Autocuration,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,CHEMBL615854,U,0,,,,,1,,BAO_0000019,
752,,Autocuration,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,CHEMBL767046,U,0,,,,,1,,BAO_0000019,
753,,Autocuration,,10732,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,CHEMBL615855,H,8,,,,,1,,BAO_0000357,
754,,Expert,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,CHEMBL615856,D,9,,,,,1,,BAO_0000019,
755,,Expert,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),CHEMBL615857,D,9,,,,,1,,BAO_0000019,
756,,Expert,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),CHEMBL615858,D,9,,,,,1,,BAO_0000019,
757,10000000.0,Expert,Hippocampus,10576,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,CHEMBL615859,H,8,,,,,1,,BAO_0000221,
758,,Autocuration,,51,Binding affinity towards human 5-hydroxytryptamine 1 receptor,CHEMBL615860,H,8,,,,,1,,BAO_0000357,
759,,Autocuration,,22226,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,CHEMBL615861,U,0,,,,,1,,BAO_0000019,
760,,Autocuration,,22226,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,CHEMBL615862,U,0,,,,,1,,BAO_0000019,
761,,Autocuration,,22226,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,CHEMBL615863,U,0,,,,,1,,BAO_0000019,
762,,Autocuration,,22226,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,CHEMBL615864,U,0,,,,,1,,BAO_0000019,
763,10000000.0,Autocuration,Hippocampus,104744,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,CHEMBL615865,H,4,,,,,1,,BAO_0000221,
764,10000000.0,Autocuration,Hippocampus,104744,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,CHEMBL615866,H,4,,,,,1,,BAO_0000221,
765,10000000.0,Autocuration,Hippocampus,104744,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,CHEMBL615867,H,4,,,,,1,,BAO_0000221,
766,,Autocuration,,104744,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,CHEMBL615868,H,4,,,,Membranes,1,,BAO_0000249,
767,,Autocuration,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,CHEMBL615869,D,5,,,,,1,,BAO_0000249,
768,,Autocuration,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,CHEMBL615870,D,5,,,,,1,,BAO_0000019,
769,,Autocuration,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,CHEMBL615871,D,5,,,,,1,,BAO_0000019,
770,,Autocuration,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,CHEMBL615872,H,4,,,,,1,,BAO_0000224,
771,10000000.0,Autocuration,Hippocampus,104744,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,CHEMBL833492,H,4,,,,,1,,BAO_0000221,
772,10000000.0,Autocuration,Hippocampus,104744,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,CHEMBL615873,H,4,,,,,1,,BAO_0000221,
773,,Autocuration,,104744,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,CHEMBL615479,H,4,,,,,1,,BAO_0000224,
774,,Autocuration,,104744,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,CHEMBL615480,H,4,,,,,1,,BAO_0000019,
775,,Autocuration,,104744,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,CHEMBL615481,D,5,,,,,1,,BAO_0000249,
776,,Autocuration,,104744,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL872869,H,4,,,,,1,,BAO_0000019,
777,,Autocuration,,104744,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL615482,H,4,,,,,1,,BAO_0000019,
778,955.0,Autocuration,Brain,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,CHEMBL615483,H,4,,,,,1,,BAO_0000221,
779,955.0,Autocuration,Brain,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,CHEMBL615484,H,4,,,,,1,,BAO_0000221,
780,,Autocuration,,104744,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,CHEMBL615485,H,4,,,,,1,,BAO_0000019,
781,,Autocuration,,104744,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,CHEMBL615486,D,5,,,,,1,,BAO_0000224,
782,,Autocuration,,104744,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,CHEMBL615487,H,4,,,,,1,,BAO_0000224,
783,,Autocuration,,104744,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,CHEMBL615488,H,4,,,,,1,,BAO_0000224,
784,,Autocuration,,104744,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,CHEMBL615489,H,4,,,,,1,,BAO_0000224,
785,,Autocuration,,104744,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,CHEMBL615389,H,4,,,,,1,,BAO_0000224,
786,,Autocuration,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,CHEMBL615390,H,4,,,,,1,,BAO_0000019,
787,,Autocuration,,104744,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,CHEMBL615391,H,4,,,,,1,,BAO_0000019,
788,,Autocuration,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,CHEMBL615392,H,4,,,,,1,,BAO_0000224,
789,,Autocuration,,22226,Affinity for 5-hydroxytryptamine 1 receptor,CHEMBL615393,U,0,,,,,1,,BAO_0000019,
790,955.0,Autocuration,Brain,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,CHEMBL615394,H,4,,,,,1,,BAO_0000221,
791,955.0,Autocuration,Brain,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,CHEMBL615395,H,4,,,,,1,,BAO_0000221,
792,,Autocuration,,104744,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,CHEMBL615396,H,4,,,,,1,,BAO_0000224,
793,955.0,Autocuration,Brain,104744,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,CHEMBL615397,H,4,,,,,1,,BAO_0000221,
794,,Autocuration,,104744,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL615398,H,4,,,,,1,,BAO_0000019,
795,,Autocuration,,22226,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,CHEMBL615399,U,0,,,,,1,,BAO_0000019,
796,,Autocuration,,104744,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,CHEMBL615400,H,4,,,,,1,,BAO_0000019,
797,,Autocuration,,104744,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,CHEMBL615401,D,5,,,,,1,,BAO_0000019,
798,,Autocuration,,22226,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,CHEMBL615402,U,0,,,,,1,,BAO_0000019,
799,,Autocuration,,104744,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,CHEMBL615403,H,4,,,,,1,,BAO_0000019,
800,955.0,Autocuration,Brain,104744,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,CHEMBL615404,H,4,,,,,1,,BAO_0000221,
801,,Autocuration,,104744,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,CHEMBL615781,H,4,,,,,1,,BAO_0000019,
802,955.0,Autocuration,Brain,104744,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,CHEMBL615782,H,4,,,,,1,,BAO_0000220,
803,955.0,Autocuration,Brain,104744,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,CHEMBL615783,H,4,,,,,1,,BAO_0000221,
804,,Autocuration,,22226,Compound was tested for binding affinity against 5-HT1 receptor,CHEMBL873481,U,0,,,,,1,,BAO_0000019,
805,,Autocuration,,22226,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,CHEMBL615784,U,0,,,,,1,,BAO_0000019,
806,,Expert,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,CHEMBL615785,H,8,,,,,1,,BAO_0000357,
807,,Autocuration,,10576,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",CHEMBL615786,H,8,,,,,1,,BAO_0000249,
808,,Autocuration,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,CHEMBL615787,H,8,,,,,1,,BAO_0000218,
809,,Autocuration,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,CHEMBL615788,H,8,,,,,1,,BAO_0000218,
810,,Autocuration,,10576,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,CHEMBL767044,H,8,,,,,1,,BAO_0000019,
811,,Autocuration,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,CHEMBL615789,H,8,,,,,1,,BAO_0000218,
812,,Autocuration,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,CHEMBL615790,H,8,,,,,1,,BAO_0000218,
813,,Autocuration,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,CHEMBL615813,H,8,,,,,1,,BAO_0000019,
814,,Autocuration,,10576,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,CHEMBL615814,H,8,,,,,1,,BAO_0000219,
815,,Expert,,51,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,CHEMBL615815,H,8,,,,,1,,BAO_0000219,
816,,Autocuration,,10576,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,CHEMBL615816,H,8,,,,,1,,BAO_0000219,
817,,Expert,,10576,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,CHEMBL615817,H,8,,,,,1,,BAO_0000249,
818,10000000.0,Autocuration,Hippocampus,10576,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,CHEMBL615818,H,8,,,,,1,,BAO_0000221,
819,10000000.0,Autocuration,Hippocampus,10576,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,CHEMBL615819,H,8,,,,,1,,BAO_0000221,
820,,Expert,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,CHEMBL615820,H,8,,,,Membranes,1,,BAO_0000249,
821,10000000.0,Expert,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,CHEMBL615821,D,9,,,,,1,,BAO_0000221,
822,10000000.0,Expert,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,CHEMBL615822,D,9,,,,,1,,BAO_0000221,
823,10000000.0,Expert,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,CHEMBL615823,H,8,,,,,1,,BAO_0000221,
824,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,CHEMBL615824,D,9,,,,,1,,BAO_0000221,
825,10000000.0,Expert,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,CHEMBL615825,D,9,,,,,1,,BAO_0000221,
826,,Expert,,10576,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,CHEMBL615826,H,8,,,,,1,,BAO_0000357,
827,,Expert,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,CHEMBL615827,H,8,,,,,1,,BAO_0000249,
828,10000000.0,Expert,Hippocampus,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,CHEMBL615828,H,8,,,,,1,,BAO_0000249,
829,10000000.0,Expert,Hippocampus,10576,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615829,H,8,,,,,1,,BAO_0000221,
830,10000000.0,Autocuration,Hippocampus,10576,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,CHEMBL615830,H,8,,,,,1,,BAO_0000221,
831,10000000.0,Expert,Hippocampus,10576,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,CHEMBL615831,H,8,,,,,1,,BAO_0000221,
832,,Autocuration,,10576,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,CHEMBL615832,H,8,,,,,1,,BAO_0000357,
833,,Autocuration,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,CHEMBL615833,H,8,,,,,1,,BAO_0000019,
834,10000000.0,Autocuration,Hippocampus,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,CHEMBL615834,H,8,,,,,1,,BAO_0000221,
835,,Intermediate,,10576,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,CHEMBL615835,H,8,,,,,1,,BAO_0000249,
836,10000000.0,Autocuration,Hippocampus,10576,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,CHEMBL615836,H,8,,,,,1,,BAO_0000249,
837,,Expert,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,CHEMBL615837,D,9,,,,,1,,BAO_0000019,
838,,Expert,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,CHEMBL615838,D,9,,,,,1,,BAO_0000019,
839,,Expert,,10576,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",CHEMBL615839,H,8,,,,,1,,BAO_0000249,
840,,Autocuration,,10576,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,CHEMBL884525,H,8,,,,,1,,BAO_0000019,
841,,Autocuration,,10576,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,CHEMBL615840,H,8,,,,,1,,BAO_0000249,
842,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615405,H,8,,,,,1,,BAO_0000221,
843,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,CHEMBL615406,H,8,,,,,1,,BAO_0000019,
844,10000000.0,Expert,Hippocampus,10576,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,CHEMBL615900,H,8,,,,,1,,BAO_0000221,
845,10000000.0,Expert,Hippocampus,10576,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,CHEMBL615901,H,8,,,,,1,,BAO_0000221,
846,,Expert,,10576,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,CHEMBL615902,H,8,,,,,1,,BAO_0000357,
847,10000000.0,Autocuration,Hippocampus,10576,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,CHEMBL615903,H,8,,,,,1,,BAO_0000221,
848,,Autocuration,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,CHEMBL615904,H,8,,,,,1,,BAO_0000357,
849,,Expert,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,CHEMBL615905,H,8,,,,,1,,BAO_0000357,
850,,Autocuration,,10576,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,CHEMBL615906,H,8,,,,,1,,BAO_0000019,
851,,Autocuration,,10576,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,CHEMBL615907,H,8,,,,,1,,BAO_0000019,
852,,Expert,,10576,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,CHEMBL615908,H,8,,,,,1,,BAO_0000019,
853,10000000.0,Autocuration,Hippocampus,10576,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,CHEMBL615909,H,8,,,,,1,,BAO_0000221,
854,,Autocuration,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",CHEMBL615910,H,8,,,,,1,,BAO_0000019,
855,,Autocuration,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",CHEMBL615911,H,8,,,,,1,,BAO_0000019,
856,,Autocuration,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",CHEMBL615912,H,8,,,,,1,,BAO_0000019,
857,,Expert,,10576,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,CHEMBL615913,H,8,,,,,1,,BAO_0000019,
858,,Expert,,10576,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,CHEMBL615914,H,8,,,,,1,,BAO_0000357,
859,10000000.0,Autocuration,Hippocampus,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,CHEMBL615915,H,8,,,,,1,,BAO_0000221,
860,,Autocuration,,10576,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,CHEMBL615916,H,8,,,,,1,,BAO_0000357,
861,,Expert,,10576,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,CHEMBL615917,H,8,,,,,1,,BAO_0000357,
862,,Expert,,10576,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,CHEMBL615918,H,8,,,,,1,,BAO_0000357,
863,10000000.0,Expert,Hippocampus,10576,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,CHEMBL615919,H,8,,,,,1,,BAO_0000249,
864,10000000.0,Expert,Hippocampus,10576,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,CHEMBL615920,D,9,,,,,1,,BAO_0000221,
865,,Autocuration,,10576,Inhibition concentration against 5-hydroxytryptamine 1A receptor,CHEMBL615921,H,8,,,,,1,,BAO_0000357,
866,,Expert,,10576,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),CHEMBL615922,H,8,,,,,1,,BAO_0000357,
867,,Expert,,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",CHEMBL881290,D,9,,,,,1,,BAO_0000249,
868,10000000.0,Autocuration,Hippocampus,10576,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",CHEMBL615923,H,8,,,,,1,,BAO_0000221,
869,10000000.0,Autocuration,Hippocampus,10576,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615924,H,8,,,,,1,,BAO_0000221,
870,10000000.0,Autocuration,Hippocampus,10576,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615925,H,8,,,,,1,,BAO_0000221,
871,,Expert,,10576,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,CHEMBL615926,D,9,,,,,1,,BAO_0000357,
872,,Expert,,10576,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,CHEMBL615927,D,9,,,,,1,,BAO_0000019,
873,10000000.0,Autocuration,Hippocampus,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL615928,H,8,,,,,1,,BAO_0000221,
874,,Expert,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,CHEMBL615929,D,9,,,,,1,,BAO_0000357,
875,10000000.0,Autocuration,Hippocampus,10576,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,CHEMBL615930,H,8,,,,,1,,BAO_0000221,
876,,Autocuration,,51,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL615931,H,8,449.0,CHO,,,1,,BAO_0000219,
877,,Autocuration,,51,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHEMBL615932,H,8,449.0,CHO,,,1,,BAO_0000219,
878,,Autocuration,,51,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHEMBL615933,H,8,449.0,CHO,,,1,,BAO_0000219,
879,,Autocuration,,51,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,CHEMBL615934,H,8,,,,,1,,BAO_0000357,
880,,Autocuration,,51,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,CHEMBL615935,H,8,,,,,1,,BAO_0000357,
881,,Autocuration,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615936,H,8,,,,,1,,BAO_0000019,
882,,Autocuration,,51,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,CHEMBL615937,H,8,449.0,CHO,,,1,,BAO_0000219,
883,,Autocuration,,51,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,CHEMBL615938,H,8,,,,,1,,BAO_0000357,
884,,Autocuration,,51,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),CHEMBL615797,H,8,,,,,1,,BAO_0000357,
885,,Autocuration,,51,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615798,H,8,,,,,1,,BAO_0000357,
886,,Autocuration,,51,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,CHEMBL872870,H,8,,,,,1,,BAO_0000357,
887,,Autocuration,,51,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,CHEMBL615799,H,8,,,,,1,,BAO_0000357,
888,,Autocuration,,51,Percent binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615800,H,8,,,,,1,,BAO_0000357,
889,,Autocuration,,51,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL615801,H,8,722.0,HEK293,,,1,,BAO_0000219,
890,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,CHEMBL615802,H,8,,,,,1,,BAO_0000019,
891,,Autocuration,,51,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,CHEMBL615803,H,8,,,,,1,,BAO_0000357,
892,,Expert,,51,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",CHEMBL835002,H,8,,,,,1,,BAO_0000019,
893,,Autocuration,,51,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",CHEMBL615804,H,8,,,,,1,,BAO_0000019,
894,,Expert,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,CHEMBL615805,H,8,308.0,HeLa,,,1,,BAO_0000219,
895,,Autocuration,,51,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,CHEMBL615806,H,8,449.0,CHO,,,1,,BAO_0000219,
896,,Expert,,51,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,CHEMBL615807,D,9,,,,,1,,BAO_0000357,
897,,Autocuration,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,CHEMBL615808,H,8,,,,,1,,BAO_0000357,
898,,Expert,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615809,D,9,,,,,1,,BAO_0000357,
899,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,CHEMBL615810,H,8,308.0,HeLa,,,1,,BAO_0000219,
900,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615811,H,8,,,,,1,,BAO_0000357,
901,,Autocuration,,51,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,CHEMBL615812,H,8,449.0,CHO,,,1,,BAO_0000219,
902,,Autocuration,,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL615751,H,8,449.0,CHO,,,1,,BAO_0000219,
903,,Autocuration,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor,CHEMBL615752,H,8,,,,,1,,BAO_0000357,
904,,Expert,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,CHEMBL615753,H,8,449.0,CHO,,,1,,BAO_0000219,
905,,Autocuration,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,CHEMBL615754,H,8,449.0,CHO,,,1,,BAO_0000219,
906,,Autocuration,,51,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,CHEMBL615755,H,8,,,,,1,,BAO_0000357,
907,,Expert,,51,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHEMBL615756,D,9,449.0,CHO,,,1,,BAO_0000219,
908,,Autocuration,,51,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,CHEMBL615757,H,8,,,,,1,,BAO_0000019,
909,,Autocuration,,51,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,CHEMBL615758,H,8,,,,,1,,BAO_0000357,
910,,Expert,,51,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,CHEMBL615759,H,8,,,,,1,,BAO_0000357,
911,,Autocuration,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor,CHEMBL615760,H,8,,,,,1,,BAO_0000357,
912,,Expert,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,CHEMBL615761,H,8,308.0,HeLa,,,1,,BAO_0000219,
913,,Autocuration,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,CHEMBL872104,H,8,,,,,1,,BAO_0000357,
914,,Autocuration,,51,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL615762,H,8,,,,,1,,BAO_0000357,
915,,Autocuration,,51,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL615763,H,8,,,,,1,,BAO_0000357,
916,,Autocuration,,51,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,CHEMBL615764,H,8,,,,,1,,BAO_0000357,
917,,Autocuration,,51,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),CHEMBL615765,H,8,1167.0,Cell line,,,1,,BAO_0000219,
918,,Autocuration,,51,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),CHEMBL615766,H,8,,,,,1,,BAO_0000019,
919,,Autocuration,,51,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615767,H,8,,,,,1,,BAO_0000357,
920,,Expert,,51,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615768,H,8,,,,,1,,BAO_0000357,
921,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615769,H,8,,,,,1,,BAO_0000357,
922,,Expert,,51,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,CHEMBL615770,H,8,,,,,1,,BAO_0000357,
923,,Autocuration,,51,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615771,H,8,,,,,1,,BAO_0000357,
924,,Expert,,51,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,CHEMBL615772,H,8,,,,,1,,BAO_0000357,
925,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL615773,H,8,,,,,1,,BAO_0000357,
926,,Expert,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,CHEMBL615774,H,8,,,,,1,,BAO_0000357,
927,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615775,H,8,,,,,1,,BAO_0000357,
928,,Autocuration,,51,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,CHEMBL615776,H,8,,,,,1,,BAO_0000357,
929,,Expert,,51,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615777,H,8,,,,,1,,BAO_0000357,
930,,Autocuration,,51,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,CHEMBL615778,H,8,,,,,1,,BAO_0000219,
931,,Expert,,51,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,CHEMBL615779,D,9,,,,,1,,BAO_0000357,
932,,Autocuration,,51,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,CHEMBL615780,H,8,,,,,1,,BAO_0000357,
933,,Autocuration,,51,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,CHEMBL616298,H,8,,,,,1,,BAO_0000357,
934,,Autocuration,,51,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,CHEMBL616299,H,8,,,,,1,,BAO_0000357,
935,,Autocuration,,51,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,CHEMBL616300,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
936,,Expert,,51,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,CHEMBL616301,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
937,,Autocuration,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,CHEMBL616302,H,8,,,,,1,,BAO_0000019,
938,,Autocuration,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),CHEMBL616117,H,8,,,,,1,,BAO_0000019,
939,,Autocuration,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),CHEMBL616118,H,8,,,,,1,,BAO_0000019,
940,,Autocuration,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,CHEMBL616119,H,8,,,,,1,,BAO_0000019,
941,,Expert,,51,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,CHEMBL616120,D,9,308.0,HeLa,,,1,,BAO_0000219,
942,,Autocuration,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,CHEMBL616121,H,8,,,,,1,,BAO_0000357,
943,,Autocuration,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,CHEMBL616122,H,8,,,,,1,,BAO_0000357,
944,,Autocuration,,51,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,CHEMBL616123,H,8,,,,,1,,BAO_0000357,
945,,Expert,,51,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,CHEMBL616124,D,9,,,,,1,,BAO_0000357,
946,,Expert,,51,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,CHEMBL616125,H,8,,,,,1,,BAO_0000357,
947,,Expert,,51,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,CHEMBL616126,H,8,,,,,1,,BAO_0000357,
948,,Autocuration,,51,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,CHEMBL616127,H,8,449.0,CHO,,,1,,BAO_0000219,
949,,Expert,,51,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,CHEMBL616128,H,8,,,,,1,,BAO_0000019,
950,,Autocuration,,51,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,CHEMBL616129,H,8,,,,,1,,BAO_0000357,
951,,Expert,,51,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616130,H,8,,,,,1,,BAO_0000357,
952,,Autocuration,,51,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,CHEMBL616131,H,8,,,,,1,,BAO_0000357,
953,,Autocuration,,51,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,CHEMBL616132,H,8,308.0,HeLa,,,1,,BAO_0000219,
954,,Expert,,51,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,CHEMBL616133,D,9,308.0,HeLa,,,1,,BAO_0000219,
955,,Autocuration,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616134,H,8,,,,,1,,BAO_0000357,
956,,Autocuration,,51,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,CHEMBL616135,H,8,,,,,1,,BAO_0000357,
957,,Expert,,51,Affinity for 5-hydroxytryptamine 1A receptor subtype,CHEMBL616136,D,9,,,,,1,,BAO_0000357,
958,,Autocuration,,51,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,CHEMBL616137,H,8,,,,,1,,BAO_0000019,
959,,Autocuration,,51,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,CHEMBL872105,H,8,,,,,1,,BAO_0000019,
960,,Autocuration,,51,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,CHEMBL616138,H,8,,,,,1,,BAO_0000357,
961,,Expert,,51,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616139,D,9,,,,,1,,BAO_0000357,
962,,Autocuration,,51,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",CHEMBL616140,H,8,,,,,1,,BAO_0000019,
963,,Expert,,51,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,CHEMBL616141,H,8,,,,,1,,BAO_0000019,
964,,Autocuration,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616142,H,8,,,,,1,,BAO_0000357,
965,,Autocuration,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,CHEMBL616143,H,8,,,,,1,,BAO_0000357,
966,,Autocuration,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,CHEMBL616144,H,8,308.0,HeLa,,,1,,BAO_0000219,
967,,Autocuration,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,CHEMBL616145,H,8,308.0,HeLa,,,1,,BAO_0000219,
968,,Autocuration,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,CHEMBL616012,H,8,308.0,HeLa,,,1,,BAO_0000219,
969,,Autocuration,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,CHEMBL616013,H,8,308.0,HeLa,,,1,,BAO_0000219,
970,,Autocuration,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",CHEMBL616014,H,8,,,,,1,,BAO_0000019,
971,,Autocuration,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",CHEMBL616015,H,8,,,,,1,,BAO_0000019,
972,,Autocuration,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",CHEMBL616016,H,8,,,,,1,,BAO_0000019,
973,,Autocuration,,51,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,CHEMBL616017,H,8,,,,,1,,BAO_0000218,
974,,Autocuration,,51,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,CHEMBL616018,H,8,,,,,1,,BAO_0000019,
975,,Autocuration,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,CHEMBL616019,H,8,,,,,1,,BAO_0000019,
976,,Autocuration,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,CHEMBL616020,H,8,,,,,1,,BAO_0000019,
977,,Autocuration,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,CHEMBL858018,H,8,,,,,1,,BAO_0000357,
978,,Autocuration,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL616021,H,8,722.0,HEK293,,,1,,BAO_0000219,
979,,Expert,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",CHEMBL616022,H,8,,,,,1,,BAO_0000019,
980,,Autocuration,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",CHEMBL616023,H,8,,,,,1,,BAO_0000019,
981,,Autocuration,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",CHEMBL616024,H,8,,,,,1,,BAO_0000019,
982,,Autocuration,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",CHEMBL616025,H,8,,,,,1,,BAO_0000019,
983,,Autocuration,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHEMBL616026,H,8,449.0,CHO,,,1,,BAO_0000219,
984,,Autocuration,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",CHEMBL616027,H,8,,,,,1,,BAO_0000019,
985,,Expert,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",CHEMBL616028,D,9,,,,,1,,BAO_0000019,
986,,Expert,,51,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,CHEMBL616029,D,9,,,,,1,,BAO_0000019,
987,,Expert,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,CHEMBL616030,H,8,449.0,CHO,,,1,,BAO_0000219,
988,,Expert,,51,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,CHEMBL616031,H,8,,,,,1,,BAO_0000019,
989,,Expert,,51,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,CHEMBL616032,D,9,,,,,1,,BAO_0000019,
990,,Expert,,51,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,CHEMBL616033,D,9,,,,,1,,BAO_0000019,
991,,Autocuration,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616034,H,8,,,,,1,,BAO_0000019,
992,,Autocuration,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616035,H,8,,,,,1,,BAO_0000019,
993,,Autocuration,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616036,H,8,,,,,1,,BAO_0000019,
994,,Autocuration,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616037,H,8,,,,,1,,BAO_0000019,
995,,Autocuration,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616038,H,8,,,,,1,,BAO_0000019,
996,,Autocuration,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616039,H,8,,,,,1,,BAO_0000019,
997,,Autocuration,,51,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616040,H,8,,,,,1,,BAO_0000019,
998,,Expert,,51,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,CHEMBL616041,D,9,308.0,HeLa,,,1,,BAO_0000219,
999,,Expert,,51,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,CHEMBL616042,D,9,308.0,HeLa,,,1,,BAO_0000219,
1000,,Expert,,51,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,CHEMBL616043,D,9,308.0,HeLa,,,1,,BAO_0000219,
1001,,Autocuration,,51,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",CHEMBL616044,H,8,,,,,1,,BAO_0000019,
1002,,Autocuration,,51,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",CHEMBL616045,H,8,,,,,1,,BAO_0000019,
1003,,Autocuration,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL616046,H,8,722.0,HEK293,,,1,,BAO_0000219,
1004,,Autocuration,,51,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),CHEMBL616047,H,8,449.0,CHO,,,1,,BAO_0000219,
1005,,Autocuration,,51,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHEMBL616048,H,8,449.0,CHO,,,1,,BAO_0000219,
1006,,Expert,,51,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),CHEMBL616049,D,9,449.0,CHO,,,1,,BAO_0000219,
1007,,Autocuration,,51,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),CHEMBL616050,H,8,449.0,CHO,,,1,,BAO_0000219,
1008,,Expert,,51,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,CHEMBL616051,H,8,,,,,1,,BAO_0000219,
1009,,Autocuration,,51,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,CHEMBL616212,H,8,,,,,1,,BAO_0000219,
1010,,Autocuration,,51,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",CHEMBL616213,H,8,,,,,1,,BAO_0000019,
1011,,Expert,,51,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,CHEMBL616214,H,8,,,,,1,,BAO_0000219,
1012,,Expert,,51,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,CHEMBL616215,H,8,,,,,1,,BAO_0000219,
1013,,Autocuration,,51,Binding activity radioligand.,CHEMBL616216,H,8,,,,,1,,BAO_0000357,
1014,,Autocuration,,51,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL616217,H,8,,,,,1,,BAO_0000019,
1015,,Autocuration,,51,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,CHEMBL616218,H,8,,,,,1,,BAO_0000357,
1016,,Autocuration,,51,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,CHEMBL616219,H,8,,,,,1,,BAO_0000357,
1017,,Autocuration,,51,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,CHEMBL616220,H,8,,,,,1,,BAO_0000357,
1018,,Expert,,51,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,CHEMBL833493,D,9,,,,,1,,BAO_0000357,
1019,,Autocuration,,51,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,CHEMBL616221,H,8,,,,,1,,BAO_0000357,
1020,,Expert,,51,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,CHEMBL616222,D,9,449.0,CHO,,,1,,BAO_0000219,
1021,,Autocuration,,51,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616223,H,8,,,,,1,,BAO_0000019,
1022,,Autocuration,,51,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,CHEMBL616224,H,8,,,,,1,,BAO_0000019,
1023,,Expert,,51,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,CHEMBL616225,H,8,,,,,1,,BAO_0000019,
1024,,Expert,,51,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,CHEMBL616226,D,9,722.0,HEK293,,,1,,BAO_0000219,
1025,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,CHEMBL616227,H,8,722.0,HEK293,,,1,,BAO_0000219,
1026,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,CHEMBL616228,H,8,722.0,HEK293,,,1,,BAO_0000219,
1027,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,CHEMBL616229,H,8,722.0,HEK293,,,1,,BAO_0000219,
1028,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,CHEMBL616230,H,8,722.0,HEK293,,,1,,BAO_0000219,
1029,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,CHEMBL616231,H,8,722.0,HEK293,,,1,,BAO_0000219,
1030,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,CHEMBL616232,H,8,,,,,1,,BAO_0000357,
1031,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,CHEMBL616233,H,8,722.0,HEK293,,,1,,BAO_0000219,
1032,,Autocuration,,51,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,CHEMBL857973,H,8,722.0,HEK293,,,1,,BAO_0000219,
1033,,Autocuration,,51,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,CHEMBL616234,H,8,,,,,1,,BAO_0000219,
1034,,Autocuration,,51,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,CHEMBL616235,H,8,,,,,1,,BAO_0000357,
1035,,Expert,,51,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,CHEMBL616236,H,8,308.0,HeLa,,,1,,BAO_0000219,
1036,,Expert,,51,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,CHEMBL616237,H,8,,,,,1,,BAO_0000019,
1037,,Autocuration,,51,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,CHEMBL616238,H,8,722.0,HEK293,,,1,,BAO_0000219,
1038,,Autocuration,,51,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,CHEMBL616239,H,8,722.0,HEK293,,,1,,BAO_0000219,
1039,,Autocuration,,51,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,CHEMBL616240,H,8,,,,,1,,BAO_0000219,
1040,,Expert,,51,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,CHEMBL616241,D,9,308.0,HeLa,,,1,,BAO_0000219,
1041,,Autocuration,,51,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,CHEMBL616242,H,8,722.0,HEK293,,,1,,BAO_0000219,
1042,,Autocuration,,51,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",CHEMBL616243,H,8,722.0,HEK293,,,1,,BAO_0000219,
1043,,Expert,,51,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616244,D,9,,,,,1,,BAO_0000357,
1044,,Autocuration,,51,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616245,D,9,,,,,1,,BAO_0000357,
1045,,Autocuration,,106,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,CHEMBL616246,H,8,,,,,1,,BAO_0000357,
1046,,Autocuration,,105,Binding affinity against 5-HT1D receptor,CHEMBL616247,H,8,,,,,1,,BAO_0000357,
1047,,Autocuration,,105,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616248,H,8,,,,,1,,BAO_0000357,
1048,,Autocuration,,107,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,CHEMBL616249,H,8,,,,,1,,BAO_0000357,
1049,,Autocuration,,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,CHEMBL616250,H,8,,,,,1,,BAO_0000357,
1050,,Autocuration,,51,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,CHEMBL616251,H,8,,,,,1,,BAO_0000357,
1051,,Autocuration,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,CHEMBL616252,H,8,,,,,1,,BAO_0000218,
1052,,Autocuration,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,CHEMBL616253,H,8,,,,,1,,BAO_0000218,
1053,,Autocuration,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,CHEMBL616254,H,8,,,,,1,,BAO_0000218,
1054,,Expert,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,CHEMBL616255,D,9,,,,,1,,BAO_0000218,
1055,,Expert,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,CHEMBL832872,D,9,,,,,1,,BAO_0000218,
1056,,Expert,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,CHEMBL616256,D,9,,,,,1,,BAO_0000218,
1057,,Expert,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,CHEMBL616257,D,9,,,,,1,,BAO_0000218,
1058,,Expert,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,CHEMBL616258,D,9,,,,,1,,BAO_0000218,
1059,,Expert,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,CHEMBL616384,D,9,,,,,1,,BAO_0000218,
1060,10000000.0,Autocuration,Hippocampus,11863,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,CHEMBL616385,H,8,,,,,1,,BAO_0000221,
1061,,Expert,,11863,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,CHEMBL616386,H,8,,,,,1,,BAO_0000357,
1062,10000000.0,Expert,Hippocampus,11863,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,CHEMBL616387,D,9,,,,,1,,BAO_0000221,
1063,10000000.0,Autocuration,Hippocampus,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,CHEMBL616388,H,8,,,,,1,,BAO_0000221,
1064,10000000.0,Expert,Hippocampus,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,CHEMBL616389,D,9,,,,,1,,BAO_0000221,
1065,10000000.0,Autocuration,Hippocampus,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,CHEMBL616390,H,8,,,,,1,,BAO_0000221,
1066,,Autocuration,,11863,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,CHEMBL616391,H,8,,,,,1,,BAO_0000357,
1067,10000000.0,Expert,Hippocampus,11863,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,CHEMBL616392,D,9,,,,,1,,BAO_0000221,
1068,,Autocuration,,51,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,CHEMBL616393,H,8,,,,,1,,BAO_0000357,
1069,,Autocuration,,51,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,CHEMBL616394,H,8,,,,,1,,BAO_0000357,
1070,,Autocuration,,51,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,CHEMBL616395,H,8,,,,,1,,BAO_0000019,
1071,,Autocuration,,51,Compound was evaluated for the binding affinity at 5- HT1A receptor,CHEMBL616396,H,8,,,,,1,,BAO_0000357,
1072,,Autocuration,,51,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,CHEMBL872907,H,8,,,,,1,,BAO_0000019,
1073,,Autocuration,,51,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,CHEMBL616397,H,8,,,,,1,,BAO_0000019,
1074,,Autocuration,,51,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,CHEMBL616398,H,8,,,,,1,,BAO_0000019,
1075,,Expert,,51,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,CHEMBL616399,H,8,,,,,1,,BAO_0000357,
1076,,Autocuration,,51,Binding activity radioligand.,CHEMBL857065,H,8,,,,,1,,BAO_0000357,
1077,,Expert,,51,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,CHEMBL616400,H,8,,,,,1,,BAO_0000019,
1078,,Autocuration,,51,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,CHEMBL616401,H,8,,,,,1,,BAO_0000019,
1079,,Expert,,10624,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,CHEMBL616402,H,8,,,,,1,,BAO_0000019,
1080,,Expert,,51,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,CHEMBL616403,H,8,,,,,1,,BAO_0000019,
1081,10000000.0,Autocuration,Hippocampus,51,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,CHEMBL616404,H,8,,,,,1,,BAO_0000221,
1082,,Autocuration,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,CHEMBL616405,H,8,,,,,1,,BAO_0000249,
1083,,Autocuration,,51,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,CHEMBL616406,H,8,,,,,1,,BAO_0000019,
1084,,Expert,,51,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,CHEMBL616407,H,8,,,,,1,,BAO_0000019,
1085,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,CHEMBL616408,H,8,,,,,1,,BAO_0000019,
1086,,Expert,,10576,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,CHEMBL616409,D,9,,,,,1,,BAO_0000249,
1087,10000000.0,Expert,Hippocampus,10576,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",CHEMBL616410,D,9,,,,,1,,BAO_0000221,
1088,,Autocuration,,10576,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,CHEMBL616411,H,8,,,,,1,,BAO_0000357,
1089,,Expert,,10576,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",CHEMBL616412,D,9,,,,Membranes,1,,BAO_0000249,
1090,10000000.0,Expert,Hippocampus,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",CHEMBL616413,D,9,,,,Membranes,1,,BAO_0000249,
1091,10000000.0,Autocuration,Hippocampus,10576,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL616414,H,8,,,,,1,,BAO_0000221,
1092,10000000.0,Expert,Hippocampus,10576,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,CHEMBL616415,D,9,,,,,1,,BAO_0000221,
1093,,Autocuration,,10576,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,CHEMBL616416,H,8,,,,,1,,BAO_0000019,
1094,,Expert,,10576,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,CHEMBL616417,H,8,,,,,1,,BAO_0000357,
1095,,Autocuration,,10576,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,CHEMBL616418,H,8,,,,,1,,BAO_0000357,
1096,,Autocuration,,10576,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,CHEMBL616419,H,8,,,,,1,,BAO_0000219,
1097,,Autocuration,,10576,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,CHEMBL616420,H,8,,,,,1,,BAO_0000357,
1098,,Autocuration,,10576,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,CHEMBL616421,H,8,,,,Membranes,1,,BAO_0000249,
1099,,Autocuration,,10576,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,CHEMBL616422,H,8,,,,Membranes,1,,BAO_0000249,
1100,,Expert,,10576,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,CHEMBL616423,H,8,,,,Membranes,1,,BAO_0000249,
1101,,Expert,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,CHEMBL616424,D,9,,,,,1,,BAO_0000357,
1102,,Expert,,10576,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,CHEMBL616425,H,8,,,,,1,,BAO_0000357,
1103,,Expert,,10576,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,CHEMBL616426,H,8,,,,,1,,BAO_0000357,
1104,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,CHEMBL616427,H,8,,,,,1,,BAO_0000221,
1105,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,CHEMBL616428,H,8,,,,,1,,BAO_0000221,
1106,10000000.0,Autocuration,Hippocampus,10576,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616290,H,8,,,,,1,,BAO_0000221,
1107,,Expert,,10576,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,CHEMBL616052,D,9,,,,,1,,BAO_0000357,
1108,,Autocuration,,10576,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,CHEMBL616053,H,8,,,,,1,,BAO_0000357,
1109,,Autocuration,,10576,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,CHEMBL616054,H,8,,,,,1,,BAO_0000249,
1110,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616055,H,8,,,,,1,,BAO_0000357,
1111,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,CHEMBL616056,H,8,,,,,1,,BAO_0000357,
1112,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,CHEMBL616057,H,8,,,,,1,,BAO_0000019,
1113,955.0,Expert,Brain,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,CHEMBL616058,D,9,,,,,1,,BAO_0000221,
1114,955.0,Autocuration,Brain,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,CHEMBL616059,H,8,,,,,1,,BAO_0000221,
1115,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,CHEMBL616060,H,8,,,,,1,,BAO_0000249,
1116,10000000.0,Expert,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,CHEMBL616061,D,9,,,,,1,,BAO_0000221,
1117,10000000.0,Expert,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,CHEMBL616062,H,8,,,,,1,,BAO_0000221,
1118,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,CHEMBL616063,H,8,,,,,1,,BAO_0000249,
1119,2435.0,Autocuration,Striatum,10576,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",CHEMBL616064,H,8,,,,,1,,BAO_0000249,
1120,,Expert,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,CHEMBL616065,D,9,,,,Membranes,1,,BAO_0000249,
1121,,Expert,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,CHEMBL616066,D,9,,,,Membranes,1,,BAO_0000249,
1122,10000000.0,Autocuration,Hippocampus,10576,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616067,H,8,,,,,1,,BAO_0000221,
1123,10000000.0,Autocuration,Hippocampus,10576,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,CHEMBL616068,H,8,,,,,1,,BAO_0000221,
1124,10000000.0,Intermediate,Hippocampus,10576,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,CHEMBL616069,H,8,,,,,1,,BAO_0000221,
1125,,Expert,,10576,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,CHEMBL616070,H,8,,,,,1,,BAO_0000249,
1126,10000000.0,Autocuration,Hippocampus,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616071,H,8,,,,,1,,BAO_0000221,
1127,10000000.0,Expert,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,CHEMBL616072,H,8,,,,,1,,BAO_0000221,
1128,10000000.0,Autocuration,Hippocampus,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,CHEMBL616073,H,8,,,,,1,,BAO_0000221,
1129,10000000.0,Autocuration,Hippocampus,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,CHEMBL616074,H,8,,,,,1,,BAO_0000221,
1130,,Expert,,10576,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,CHEMBL616075,H,8,,,,,1,,BAO_0000019,
1131,,Autocuration,,10576,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,CHEMBL616076,H,8,,,,,1,,BAO_0000357,
1132,,Expert,,10576,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,CHEMBL616077,D,9,,,,,1,,BAO_0000019,
1133,,Expert,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,CHEMBL616078,D,9,,,,,1,,BAO_0000019,
1134,,Expert,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,CHEMBL616079,D,9,,,,,1,,BAO_0000019,
1135,,Expert,,10576,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,CHEMBL616080,D,9,485.0,CHO-K1,,,1,,BAO_0000219,
1136,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616081,H,8,,,,,1,,BAO_0000357,
1137,10000000.0,Expert,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,CHEMBL616082,D,9,,,,,1,,BAO_0000221,
1138,10000000.0,Autocuration,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,CHEMBL616083,H,8,,,,,1,,BAO_0000221,
1139,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,CHEMBL616084,H,8,,,,,1,,BAO_0000019,
1140,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,CHEMBL616085,H,8,,,,,1,,BAO_0000019,
1141,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,CHEMBL616086,H,8,,,,,1,,BAO_0000019,
1142,10000000.0,Autocuration,Hippocampus,10576,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",CHEMBL616087,H,8,,,,,1,,BAO_0000221,
1143,,Expert,,10576,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,CHEMBL616088,H,8,,,,,1,,BAO_0000357,
1144,,Autocuration,,10576,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,CHEMBL616089,H,8,,,,,1,,BAO_0000019,
1145,,Expert,,10576,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,CHEMBL616090,D,9,,,,,1,,BAO_0000357,
1146,,Autocuration,,10576,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,CHEMBL616091,H,8,,,,,1,,BAO_0000357,
1147,2435.0,Autocuration,Striatum,10576,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",CHEMBL616092,H,8,,,,Membranes,1,,BAO_0000249,
1148,,Autocuration,,10576,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),CHEMBL616093,H,8,,,,,1,,BAO_0000357,
1149,,Autocuration,,10576,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),CHEMBL616094,H,8,,,,,1,,BAO_0000218,
1150,955.0,Autocuration,Brain,10576,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,CHEMBL616095,H,8,,,,,1,,BAO_0000221,
1151,,Expert,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,CHEMBL616096,D,9,,,,,1,,BAO_0000357,
1152,,Expert,,10576,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,CHEMBL616097,H,8,,,,,1,,BAO_0000249,
1153,,Expert,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,CHEMBL616098,D,9,,,,Membranes,1,,BAO_0000249,
1154,10000000.0,Autocuration,Hippocampus,10576,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616099,H,8,,,,,1,,BAO_0000221,
1155,10000000.0,Autocuration,Hippocampus,10576,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616100,H,8,,,,,1,,BAO_0000221,
1156,,Expert,,10576,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,CHEMBL616101,H,8,,,,,1,,BAO_0000357,
1157,,Expert,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,CHEMBL616102,H,8,,,,,1,,BAO_0000249,
1158,,Autocuration,,10576,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,CHEMBL616103,H,8,,,,,1,,BAO_0000357,
1159,,Expert,,10576,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,CHEMBL616104,H,8,,,,,1,,BAO_0000019,
1160,,Expert,,10576,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",CHEMBL616105,H,8,,,,,1,,BAO_0000019,
1161,,Expert,,10576,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,CHEMBL616106,D,9,,,,,1,,BAO_0000019,
1162,,Autocuration,,10576,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,CHEMBL616107,H,8,,,,,1,,BAO_0000019,
1163,,Expert,,10576,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,CHEMBL616108,H,8,,,,,1,,BAO_0000357,
1164,10000000.0,Expert,Hippocampus,10576,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,CHEMBL616109,H,8,,,,,1,,BAO_0000221,
1165,,Autocuration,,10576,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,CHEMBL616110,H,8,,,,,1,,BAO_0000357,
1166,,Expert,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,CHEMBL616111,H,8,449.0,CHO,,,1,,BAO_0000219,
1167,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,CHEMBL616112,H,8,,,,,1,,BAO_0000019,
1168,10000000.0,Autocuration,Hippocampus,10576,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,CHEMBL616113,H,8,,,,,1,,BAO_0000221,
1169,,Autocuration,,10576,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,CHEMBL616114,H,8,,,,,1,,BAO_0000019,
1170,,Autocuration,,10576,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,CHEMBL616115,H,8,,,,,1,,BAO_0000019,
1171,,Autocuration,,10576,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL616116,H,8,,,,,1,,BAO_0000357,
1172,955.0,Expert,Brain,10576,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,CHEMBL615844,H,8,,,,,1,,BAO_0000221,
1173,10000000.0,Expert,Hippocampus,10576,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL615939,H,8,,,,,1,,BAO_0000221,
1174,,Expert,,10576,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,CHEMBL615940,H,8,,,,,1,,BAO_0000019,
1175,10000000.0,Expert,Hippocampus,10576,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,CHEMBL615941,H,8,,,,,1,,BAO_0000221,
1176,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,CHEMBL615942,H,8,,,,,1,,BAO_0000221,
1177,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,CHEMBL615943,H,8,,,,,1,,BAO_0000221,
1178,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,CHEMBL615944,H,8,,,,,1,,BAO_0000221,
1179,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,CHEMBL615945,H,8,,,,,1,,BAO_0000221,
1180,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,CHEMBL615946,H,8,,,,,1,,BAO_0000221,
1181,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,CHEMBL615947,H,8,,,,,1,,BAO_0000221,
1182,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,CHEMBL615948,H,8,,,,,1,,BAO_0000221,
1183,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,CHEMBL615949,H,8,,,,,1,,BAO_0000221,
1184,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,CHEMBL615950,H,8,,,,,1,,BAO_0000221,
1185,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,CHEMBL615951,H,8,,,,,1,,BAO_0000221,
1186,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,CHEMBL615952,H,8,,,,,1,,BAO_0000221,
1187,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,CHEMBL615953,H,8,,,,,1,,BAO_0000221,
1188,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,CHEMBL615954,H,8,,,,,1,,BAO_0000221,
1189,10000000.0,Expert,Hippocampus,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,CHEMBL615955,D,9,,,,,1,,BAO_0000221,
1190,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,CHEMBL615956,H,8,,,,,1,,BAO_0000221,
1191,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,CHEMBL615957,H,8,,,,,1,,BAO_0000221,
1192,,Expert,,10576,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,CHEMBL615958,H,8,,,,,1,,BAO_0000019,
1193,,Expert,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,CHEMBL615959,H,8,,,,,1,,BAO_0000019,
1194,,Autocuration,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),CHEMBL615960,H,8,,,,,1,,BAO_0000019,
1195,,Autocuration,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),CHEMBL615961,H,8,,,,,1,,BAO_0000019,
1196,955.0,Expert,Brain,10576,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,CHEMBL615962,H,8,,,,,1,,BAO_0000221,
1197,,Expert,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,CHEMBL615963,H,8,,,,,1,,BAO_0000019,
1198,,Autocuration,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,CHEMBL615964,H,8,,,,,1,,BAO_0000019,
1199,,Autocuration,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,CHEMBL615965,H,8,,,,,1,,BAO_0000019,
1200,,Expert,,10576,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,CHEMBL615966,H,8,449.0,CHO,,,1,,BAO_0000219,
1201,,Expert,,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,CHEMBL615967,H,8,,,,,1,,BAO_0000249,
1202,,Expert,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,CHEMBL615968,H,8,,,,,1,,BAO_0000019,
1203,,Autocuration,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),CHEMBL615969,H,8,449.0,CHO,,,1,,BAO_0000218,
1204,,Autocuration,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),CHEMBL615970,H,8,,,,,1,,BAO_0000218,
1205,,Expert,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,CHEMBL615971,D,9,,,,,1,,BAO_0000357,
1206,,Expert,,10576,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,CHEMBL615972,H,8,,,,Membranes,1,,BAO_0000249,
1207,,Autocuration,,10576,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,CHEMBL615973,H,8,,,,,1,,BAO_0000249,
1208,,Autocuration,,10576,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,CHEMBL615974,H,8,,,,,1,,BAO_0000249,
1209,,Expert,,51,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHEMBL615975,D,9,449.0,CHO,,,1,,BAO_0000219,
1210,,Expert,,10576,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,CHEMBL615976,H,8,,,,,1,,BAO_0000249,
1211,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,CHEMBL872106,D,9,,,,,1,,BAO_0000221,
1212,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL615977,H,8,,,,,1,,BAO_0000357,
1213,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,CHEMBL615978,H,8,,,,,1,,BAO_0000357,
1214,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,CHEMBL616166,H,8,,,,,1,,BAO_0000357,
1215,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,CHEMBL616167,H,8,,,,,1,,BAO_0000357,
1216,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,CHEMBL616168,H,8,,,,,1,,BAO_0000357,
1217,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,CHEMBL616169,H,8,,,,,1,,BAO_0000357,
1218,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,CHEMBL616170,H,8,,,,,1,,BAO_0000357,
1219,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,CHEMBL616171,H,8,,,,,1,,BAO_0000357,
1220,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,CHEMBL616172,H,8,,,,,1,,BAO_0000357,
1221,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,CHEMBL616173,H,8,,,,,1,,BAO_0000357,
1222,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,CHEMBL616174,H,8,,,,,1,,BAO_0000357,
1223,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,CHEMBL616175,H,8,,,,,1,,BAO_0000357,
1224,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,CHEMBL616176,H,8,,,,,1,,BAO_0000357,
1225,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,CHEMBL616177,H,8,,,,,1,,BAO_0000357,
1226,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,CHEMBL616178,H,8,,,,,1,,BAO_0000357,
1227,,Autocuration,,10576,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,CHEMBL616179,H,8,,,,,1,,BAO_0000019,
1228,,Autocuration,,10576,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,CHEMBL616180,H,8,,,,,1,,BAO_0000357,
1229,,Autocuration,,10576,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,CHEMBL616181,H,8,,,,,1,,BAO_0000357,
1230,,Autocuration,,10576,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,CHEMBL616182,H,8,,,,,1,,BAO_0000019,
1231,10000000.0,Autocuration,Hippocampus,10576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616183,H,8,,,,,1,,BAO_0000221,
1232,,Expert,,10576,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,CHEMBL615874,H,8,,,,,1,,BAO_0000019,
1233,,Expert,,10576,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,CHEMBL615875,D,9,485.0,CHO-K1,,,1,,BAO_0000219,
1234,,Autocuration,,10576,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,CHEMBL615876,H,8,,,,,1,,BAO_0000019,
1235,,Autocuration,,10576,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,CHEMBL615877,H,8,,,,,1,,BAO_0000019,
1236,,Autocuration,,10576,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),CHEMBL615878,H,8,,,,,1,,BAO_0000357,
1237,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,CHEMBL615879,H,8,,,,,1,,BAO_0000357,
1238,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,CHEMBL615880,H,8,,,,,1,,BAO_0000357,
1239,,Autocuration,,10576,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",CHEMBL615881,H,8,,,,,1,,BAO_0000019,
1240,,Expert,,10576,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",CHEMBL615882,D,9,,,,,1,,BAO_0000019,
1241,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,CHEMBL615883,H,8,,,,,1,,BAO_0000218,
1242,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),CHEMBL615884,H,8,,,,,1,,BAO_0000218,
1243,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),CHEMBL615885,H,8,,,,,1,,BAO_0000218,
1244,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),CHEMBL615886,H,8,,,,,1,,BAO_0000218,
1245,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),CHEMBL615887,H,8,,,,,1,,BAO_0000218,
1246,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),CHEMBL615888,H,8,,,,,1,,BAO_0000218,
1247,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),CHEMBL615889,H,8,,,,,1,,BAO_0000218,
1248,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),CHEMBL615890,H,8,,,,,1,,BAO_0000218,
1249,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),CHEMBL615891,H,8,,,,,1,,BAO_0000218,
1250,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),CHEMBL615892,H,8,,,,,1,,BAO_0000218,
1251,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),CHEMBL615893,H,8,,,,,1,,BAO_0000218,
1252,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),CHEMBL615894,H,8,,,,,1,,BAO_0000218,
1253,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),CHEMBL615895,H,8,,,,,1,,BAO_0000218,
1254,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),CHEMBL615896,H,8,,,,,1,,BAO_0000218,
1255,,Autocuration,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,CHEMBL615897,H,8,,,,,1,,BAO_0000218,
1256,,Expert,,10576,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",CHEMBL615898,D,9,,,,Membranes,1,,BAO_0000249,
1257,,Autocuration,,10576,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,CHEMBL615899,H,8,,,,,1,,BAO_0000019,
1258,,Autocuration,,10576,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,CHEMBL616291,H,8,,,,,1,,BAO_0000019,
1259,,Autocuration,,10576,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,CHEMBL616292,H,8,,,,,1,,BAO_0000357,
1260,,Autocuration,,10576,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",CHEMBL616293,H,8,,,,,1,,BAO_0000249,
1261,10000000.0,Expert,Hippocampus,10576,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616294,H,8,,,,,1,,BAO_0000221,
1262,10000000.0,Autocuration,Hippocampus,10576,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,CHEMBL616295,H,8,,,,,1,,BAO_0000249,
1263,955.0,Autocuration,Brain,10576,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,CHEMBL616296,H,8,,,,,1,,BAO_0000221,
1264,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,CHEMBL616297,H,8,,,,,1,,BAO_0000019,
1265,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,CHEMBL616605,H,8,,,,,1,,BAO_0000019,
1266,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,CHEMBL616606,H,8,,,,,1,,BAO_0000019,
1267,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,CHEMBL616607,H,8,,,,,1,,BAO_0000019,
1268,,Expert,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,CHEMBL616608,H,8,,,,,1,,BAO_0000019,
1269,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,CHEMBL616609,H,8,,,,,1,,BAO_0000019,
1270,,Expert,,10576,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,CHEMBL616610,D,9,,,,,1,,BAO_0000019,
1271,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,CHEMBL616611,H,8,,,,,1,,BAO_0000019,
1272,,Expert,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,CHEMBL616612,H,8,,,,,1,,BAO_0000019,
1273,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,CHEMBL616613,H,8,,,,,1,,BAO_0000019,
1274,,Expert,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,CHEMBL616614,H,8,,,,,1,,BAO_0000019,
1275,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,CHEMBL616615,H,8,,,,,1,,BAO_0000019,
1276,,Expert,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,CHEMBL616616,H,8,,,,,1,,BAO_0000019,
1277,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,CHEMBL616617,H,8,,,,,1,,BAO_0000019,
1278,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,CHEMBL616618,H,8,,,,,1,,BAO_0000019,
1279,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,CHEMBL616619,H,8,,,,,1,,BAO_0000019,
1280,,Expert,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,CHEMBL616620,H,8,,,,,1,,BAO_0000019,
1281,,Expert,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,CHEMBL616621,H,8,,,,,1,,BAO_0000019,
1282,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,CHEMBL616622,H,8,,,,,1,,BAO_0000019,
1283,,Expert,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,CHEMBL616146,H,8,,,,,1,,BAO_0000019,
1284,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,CHEMBL832873,H,8,,,,,1,,BAO_0000019,
1285,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,CHEMBL616147,H,8,,,,,1,,BAO_0000019,
1286,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,CHEMBL872872,H,8,,,,,1,,BAO_0000019,
1287,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,CHEMBL616148,H,8,,,,,1,,BAO_0000019,
1288,10000000.0,Autocuration,Hippocampus,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,CHEMBL616149,H,8,,,,,1,,BAO_0000221,
1289,10000000.0,Expert,Hippocampus,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,CHEMBL616150,H,8,,,,,1,,BAO_0000221,
1290,,Expert,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,CHEMBL616151,D,9,,,,Membranes,1,,BAO_0000249,
1291,10000000.0,Expert,Hippocampus,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,CHEMBL872873,H,8,,,,,1,,BAO_0000221,
1292,10000000.0,Autocuration,Hippocampus,10576,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,CHEMBL616670,H,8,,,,,1,,BAO_0000221,
1293,10000000.0,Autocuration,Hippocampus,10576,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,CHEMBL616671,H,8,,,,,1,,BAO_0000221,
1294,,Expert,,10576,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",CHEMBL884861,D,9,,,,,1,,BAO_0000249,
1295,,Autocuration,,10576,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,CHEMBL616672,H,8,,,,,1,,BAO_0000357,
1296,,Autocuration,,10576,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,CHEMBL616673,H,8,,,,,1,,BAO_0000019,
1297,,Expert,,10576,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,CHEMBL616674,H,8,,,,,1,,BAO_0000019,
1298,,Autocuration,,10576,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,CHEMBL616675,H,8,,,,,1,,BAO_0000357,
1299,10000000.0,Autocuration,Hippocampus,10576,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,CHEMBL616676,H,8,,,,,1,,BAO_0000221,
1300,10000000.0,Autocuration,Hippocampus,10576,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL616677,H,8,,,,,1,,BAO_0000221,
1301,10000000.0,Autocuration,Hippocampus,10576,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL616678,H,8,,,,,1,,BAO_0000221,
1302,,Expert,,10576,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,CHEMBL616679,D,9,,,,,1,,BAO_0000357,
1303,10000000.0,Expert,Hippocampus,10576,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,CHEMBL616680,H,8,,,,,1,,BAO_0000221,
1304,10000000.0,Autocuration,Hippocampus,10576,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616681,H,8,,,,,1,,BAO_0000221,
1305,10000000.0,Autocuration,Hippocampus,10576,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616682,H,8,,,,,1,,BAO_0000221,
1306,10000000.0,Autocuration,Hippocampus,10576,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616683,H,8,,,,,1,,BAO_0000221,
1307,10000000.0,Autocuration,Hippocampus,10576,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,CHEMBL616684,H,8,,,,,1,,BAO_0000221,
1308,10000000.0,Autocuration,Hippocampus,10576,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,CHEMBL616685,H,8,,,,,1,,BAO_0000221,
1309,955.0,Autocuration,Brain,10576,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,CHEMBL616686,H,8,,,,,1,,BAO_0000221,
1310,,Autocuration,,10576,Affinity for 5-hydroxytryptamine 1A receptor site,CHEMBL616687,H,8,,,,,1,,BAO_0000357,
1311,,Autocuration,,10576,Affinity for 5-hydroxytryptamine 1A receptor site,CHEMBL616688,H,8,,,,,1,,BAO_0000357,
1312,10000000.0,Autocuration,Hippocampus,10576,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,CHEMBL616689,H,8,,,,,1,,BAO_0000221,
1313,,Autocuration,,10576,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,CHEMBL616690,H,8,,,,,1,,BAO_0000357,
1314,,Expert,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,CHEMBL616691,H,8,,,,,1,,BAO_0000357,
1315,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,CHEMBL616692,D,9,,,,,1,,BAO_0000221,
1316,,Expert,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,CHEMBL616693,H,8,,,,,1,,BAO_0000249,
1317,,Expert,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",CHEMBL616694,D,9,,,,,1,,BAO_0000019,
1318,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,CHEMBL616695,H,8,,,,,1,,BAO_0000221,
1319,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,CHEMBL616696,H,8,,,,,1,,BAO_0000357,
1320,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,CHEMBL616697,H,8,,,,,1,,BAO_0000357,
1321,,Autocuration,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor,CHEMBL616698,H,8,,,,,1,,BAO_0000357,
1322,,Expert,,10576,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,CHEMBL616949,D,9,,,,,1,,BAO_0000019,
1323,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,CHEMBL616950,H,8,,,,,1,,BAO_0000221,
1324,,Autocuration,,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,CHEMBL832875,H,8,,,,,1,,BAO_0000357,
1325,955.0,Expert,Brain,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,CHEMBL616951,H,8,,,,,1,,BAO_0000221,
1326,955.0,Expert,Brain,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,CHEMBL616952,H,8,,,,,1,,BAO_0000221,
1327,,Expert,,10576,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,CHEMBL616953,H,8,,,,,1,,BAO_0000357,
1328,,Autocuration,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,CHEMBL616954,H,8,,,,,1,,BAO_0000357,
1329,,Autocuration,,106,GTPgammaS radioligand binding assay,CHEMBL616955,H,8,,,,,1,,BAO_0000357,
1330,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,CHEMBL616956,H,8,,,,,1,,BAO_0000357,
1331,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,CHEMBL616957,H,8,,,,,1,,BAO_0000019,
1332,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,CHEMBL616958,H,8,,,,,1,,BAO_0000019,
1333,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,CHEMBL616959,H,8,,,,,1,,BAO_0000357,
1334,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,CHEMBL616960,H,8,,,,,1,,BAO_0000357,
1335,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,CHEMBL616961,H,8,,,,,1,,BAO_0000019,
1336,,Expert,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,CHEMBL616962,H,8,308.0,HeLa,,,1,,BAO_0000219,
1337,,Autocuration,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,CHEMBL616963,H,8,308.0,HeLa,,,1,,BAO_0000219,
1338,,Expert,,106,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,CHEMBL616524,D,9,,,,,1,,BAO_0000357,
1339,,Autocuration,,106,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616525,H,8,449.0,CHO,,,1,,BAO_0000219,
1340,,Autocuration,,106,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,CHEMBL872908,H,8,,,,,1,,BAO_0000019,
1341,,Autocuration,,106,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,CHEMBL616526,H,8,,,,,1,,BAO_0000019,
1342,,Expert,,106,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616527,D,9,,,,,1,,BAO_0000357,
1343,,Expert,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,CHEMBL616528,H,8,,,,,1,,BAO_0000219,
1344,,Autocuration,,106,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,CHEMBL616529,H,8,,,,,1,,BAO_0000357,
1345,,Autocuration,,106,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,CHEMBL616530,H,8,,,,,1,,BAO_0000357,
1346,,Expert,,106,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616531,H,8,,,,,1,,BAO_0000357,
1347,,Autocuration,,106,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616532,H,8,,,,,1,,BAO_0000357,
1348,,Autocuration,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor,CHEMBL616533,H,8,,,,,1,,BAO_0000357,
1349,,Expert,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616534,H,8,,,,,1,,BAO_0000357,
1350,,Expert,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,CHEMBL616535,H,8,,,,,1,,BAO_0000357,
1351,,Autocuration,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,CHEMBL616536,H,8,,,,,1,,BAO_0000357,
1352,,Autocuration,,106,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,CHEMBL616537,H,8,,,,,1,,BAO_0000357,
1353,,Expert,,106,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,CHEMBL616538,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1354,,Expert,,106,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,CHEMBL616539,H,8,,,,,1,,BAO_0000019,
1355,,Expert,,106,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,CHEMBL616540,H,8,,,,,1,,BAO_0000019,
1356,,Autocuration,,106,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,CHEMBL616429,H,8,,,,,1,,BAO_0000357,
1357,,Expert,,106,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616430,H,8,,,,,1,,BAO_0000357,
1358,,Expert,,106,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,CHEMBL616431,D,9,,,,,1,,BAO_0000219,
1359,,Expert,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616432,D,9,,,,,1,,BAO_0000357,
1360,,Expert,,106,Affinity for 5-hydroxytryptamine 1B receptor subtype,CHEMBL616433,D,9,,,,,1,,BAO_0000357,
1361,,Expert,,106,Binding affinity for human 5-hydroxytryptamine 1B receptor,CHEMBL616434,D,9,,,,,1,,BAO_0000357,
1362,,Autocuration,,106,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,CHEMBL616435,H,8,449.0,CHO,,,1,,BAO_0000219,
1363,,Expert,,106,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,CHEMBL616436,H,8,,,,,1,,BAO_0000019,
1364,,Autocuration,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,CHEMBL616437,H,8,308.0,HeLa,,,1,,BAO_0000219,
1365,,Autocuration,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,CHEMBL616438,H,8,308.0,HeLa,,,1,,BAO_0000219,
1366,,Autocuration,,106,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,CHEMBL616439,H,8,308.0,HeLa,,,1,,BAO_0000219,
1367,,Expert,,106,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,CHEMBL616440,D,9,,,,,1,,BAO_0000357,
1368,,Autocuration,,106,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,CHEMBL616441,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1369,,Expert,,106,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,CHEMBL616442,H,8,,,,,1,,BAO_0000357,
1370,,Autocuration,,106,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,CHEMBL616443,H,8,,,,,1,,BAO_0000357,
1371,,Expert,,106,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,CHEMBL616444,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1372,,Expert,,106,Binding activity against human 5-hydroxytryptamine 1B receptor,CHEMBL616445,D,9,,,,,1,,BAO_0000357,
1373,,Expert,,106,Binding activity against human 5-hydroxytryptamine 1B receptor,CHEMBL616446,D,9,,,,,1,,BAO_0000357,
1374,,Expert,,106,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616447,D,9,449.0,CHO,,,1,,BAO_0000219,
1375,,Autocuration,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,CHEMBL616448,H,8,,,,,1,,BAO_0000357,
1376,,Autocuration,,106,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,CHEMBL616449,H,8,449.0,CHO,,,1,,BAO_0000219,
1377,,Autocuration,,106,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,CHEMBL616450,H,8,449.0,CHO,,,1,,BAO_0000219,
1378,,Autocuration,,106,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,CHEMBL857974,H,8,449.0,CHO,,,1,,BAO_0000219,
1379,,Autocuration,,106,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHEMBL616451,H,8,449.0,CHO,,,1,,BAO_0000219,
1380,,Autocuration,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHEMBL616452,H,8,449.0,CHO,,,1,,BAO_0000219,
1381,,Autocuration,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,CHEMBL616453,H,8,449.0,CHO,,,1,,BAO_0000219,
1382,,Autocuration,,106,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,CHEMBL616454,H,8,449.0,CHO,,,1,,BAO_0000219,
1383,,Expert,,106,Binding affinity for human 5-hydroxytryptamine 1B receptor,CHEMBL616455,D,9,,,,,1,,BAO_0000357,
1384,,Autocuration,,106,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,CHEMBL616456,H,8,449.0,CHO,,,1,,BAO_0000219,
1385,,Autocuration,,106,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,CHEMBL616457,H,8,,,,,1,,BAO_0000357,
1386,,Autocuration,,106,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,CHEMBL616458,H,8,449.0,CHO,,,1,,BAO_0000219,
1387,,Autocuration,,106,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL616459,H,8,449.0,CHO,,,1,,BAO_0000219,
1388,,Expert,,106,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,CHEMBL616460,H,8,,,,,1,,BAO_0000019,
1389,,Expert,,106,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,CHEMBL616461,H,8,,,,,1,,BAO_0000019,
1390,,Autocuration,,106,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",CHEMBL616462,H,8,449.0,CHO,,,1,,BAO_0000219,
1391,,Autocuration,,106,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",CHEMBL616463,H,8,449.0,CHO,,,1,,BAO_0000219,
1392,,Autocuration,,105,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",CHEMBL616464,H,8,,,,,1,,BAO_0000019,
1393,,Autocuration,,105,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,CHEMBL616465,H,8,449.0,CHO,,,1,,BAO_0000219,
1394,,Autocuration,,17105,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL832874,H,8,,,,,1,,BAO_0000357,
1395,,Autocuration,,106,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,CHEMBL616184,H,8,,,,,1,,BAO_0000019,
1396,,Autocuration,,106,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,CHEMBL616185,H,8,,,,,1,,BAO_0000019,
1397,,Intermediate,,106,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",CHEMBL616186,H,8,,,,,1,,BAO_0000019,
1398,,Autocuration,,106,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,CHEMBL616187,H,8,,,,,1,,BAO_0000019,
1399,,Expert,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,CHEMBL616188,H,8,,,,,1,,BAO_0000357,
1400,,Intermediate,,10577,Binding affinity for 5-hydroxytryptamine 1B receptor,CHEMBL873475,D,9,,,,,1,,BAO_0000357,
1401,2435.0,Expert,Striatum,10577,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,CHEMBL616189,D,9,,,,,1,,BAO_0000019,
1402,,Expert,,10577,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,CHEMBL616190,H,8,,,,,1,,BAO_0000357,
1403,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,CHEMBL616191,H,8,,,,,1,,BAO_0000357,
1404,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,CHEMBL616192,H,8,,,,,1,,BAO_0000357,
1405,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,CHEMBL616193,H,8,,,,,1,,BAO_0000357,
1406,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,CHEMBL616194,H,8,,,,,1,,BAO_0000357,
1407,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,CHEMBL616195,H,8,,,,,1,,BAO_0000357,
1408,,Autocuration,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,CHEMBL616196,H,8,,,,,1,,BAO_0000357,
1409,10000000.0,Autocuration,Hippocampus,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,CHEMBL616197,H,8,,,,,1,,BAO_0000249,
1410,,Intermediate,,10576,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,CHEMBL616198,H,8,,,,,1,,BAO_0000019,
1411,10000000.0,Autocuration,Hippocampus,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,CHEMBL616199,H,8,,,,,1,,BAO_0000221,
1412,10000000.0,Expert,Hippocampus,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,CHEMBL616200,H,8,,,,,1,,BAO_0000221,
1413,10000000.0,Expert,Hippocampus,10576,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL616201,H,8,,,,,1,,BAO_0000221,
1414,10000000.0,Expert,Hippocampus,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,CHEMBL616202,H,8,,,,,1,,BAO_0000221,
1415,10000000.0,Expert,Hippocampus,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,CHEMBL616203,H,8,,,,,1,,BAO_0000221,
1416,10000000.0,Expert,Hippocampus,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,CHEMBL616204,H,8,,,,,1,,BAO_0000221,
1417,10000000.0,Expert,Hippocampus,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,CHEMBL616205,H,8,,,,,1,,BAO_0000221,
1418,10000000.0,Expert,Hippocampus,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,CHEMBL616206,H,8,,,,,1,,BAO_0000221,
1419,,Expert,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,CHEMBL616207,H,8,,,,,1,,BAO_0000249,
1420,,Autocuration,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,CHEMBL616208,H,8,,,,,1,,BAO_0000249,
1421,,Autocuration,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,CHEMBL616209,H,8,,,,,1,,BAO_0000249,
1422,,Expert,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,CHEMBL616210,H,8,,,,,1,,BAO_0000357,
1423,10000000.0,Expert,Hippocampus,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,CHEMBL616211,H,8,,,,,1,,BAO_0000221,
1424,10000000.0,Autocuration,Hippocampus,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,CHEMBL616504,H,8,,,,,1,,BAO_0000221,
1425,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616505,D,9,,,,,1,,BAO_0000221,
1426,,Autocuration,,10576,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,CHEMBL616506,H,8,,,,,1,,BAO_0000019,
1427,10000000.0,Autocuration,Hippocampus,10576,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL872107,H,8,,,,,1,,BAO_0000221,
1428,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,CHEMBL616507,D,9,,,,,1,,BAO_0000221,
1429,,Autocuration,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,CHEMBL616303,H,8,,,,,1,,BAO_0000249,
1430,10000000.0,Autocuration,Hippocampus,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,CHEMBL616304,H,8,,,,,1,,BAO_0000221,
1431,10000000.0,Expert,Hippocampus,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,CHEMBL616305,H,8,,,,,1,,BAO_0000221,
1432,10000000.0,Intermediate,Hippocampus,10576,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,CHEMBL616306,H,8,,,,,1,,BAO_0000221,
1433,,Autocuration,,10576,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,CHEMBL616307,H,8,,,,,1,,BAO_0000357,
1434,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,CHEMBL881829,D,9,,,,,1,,BAO_0000221,
1435,,Expert,,10576,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,CHEMBL616308,H,8,,,,,1,,BAO_0000357,
1436,,Autocuration,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,CHEMBL616309,H,8,,,,,1,,BAO_0000019,
1437,,Expert,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,CHEMBL616310,H,8,,,,,1,,BAO_0000019,
1438,,Autocuration,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,CHEMBL616311,H,8,449.0,CHO,,,1,,BAO_0000219,
1439,,Expert,,10576,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,CHEMBL616312,H,8,,,,,1,,BAO_0000357,
1440,,Autocuration,,10576,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,CHEMBL616313,H,8,,,,,1,,BAO_0000357,
1441,10000000.0,Expert,Hippocampus,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616314,D,9,,,,,1,,BAO_0000221,
1442,10000000.0,Autocuration,Hippocampus,10576,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616315,H,8,,,,,1,,BAO_0000221,
1443,10000000.0,Autocuration,Hippocampus,10576,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,CHEMBL616567,H,8,,,,,1,,BAO_0000221,
1444,10000000.0,Autocuration,Hippocampus,10576,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,CHEMBL616568,H,8,,,,,1,,BAO_0000221,
1445,,Intermediate,,10576,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,CHEMBL616569,H,8,,,,,1,,BAO_0000019,
1446,,Expert,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,CHEMBL616570,H,8,,,,,1,,BAO_0000357,
1447,,Autocuration,,10576,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,CHEMBL616571,H,8,,,,,1,,BAO_0000357,
1448,10000000.0,Autocuration,Hippocampus,10576,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,CHEMBL616572,H,8,,,,,1,,BAO_0000221,
1449,,Expert,,10576,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,CHEMBL616573,H,8,,,,,1,,BAO_0000249,
1450,,Expert,,10576,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,CHEMBL616574,D,9,,,,,1,,BAO_0000357,
1451,10000000.0,Expert,Hippocampus,10576,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,CHEMBL616575,H,8,,,,,1,,BAO_0000221,
1452,10000000.0,Autocuration,Hippocampus,10576,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,CHEMBL872108,H,8,,,,,1,,BAO_0000221,
1453,,Autocuration,,10576,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,CHEMBL616576,H,8,,,,,1,,BAO_0000357,
1454,,Autocuration,,10576,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,CHEMBL616577,H,8,,,,,1,,BAO_0000249,
1455,,Autocuration,,10576,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,CHEMBL616578,H,8,,,,,1,,BAO_0000249,
1456,,Expert,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,CHEMBL616579,H,8,,,,,1,,BAO_0000357,
1457,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,CHEMBL616580,D,9,,,,,1,,BAO_0000019,
1458,,Autocuration,,10576,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,CHEMBL616581,H,8,,,,,1,,BAO_0000019,
1459,10000000.0,Autocuration,Hippocampus,10576,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616582,H,8,,,,,1,,BAO_0000221,
1460,10000000.0,Expert,Hippocampus,10576,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616583,H,8,,,,,1,,BAO_0000221,
1461,10000000.0,Expert,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,CHEMBL616584,D,9,,,,,1,,BAO_0000221,
1462,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616585,H,8,,,,,1,,BAO_0000357,
1463,10000000.0,Expert,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,CHEMBL616586,D,9,,,,,1,,BAO_0000221,
1464,10000000.0,Autocuration,Hippocampus,10576,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,CHEMBL616587,H,8,,,,,1,,BAO_0000221,
1465,10000000.0,Autocuration,Hippocampus,10576,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,CHEMBL616588,H,8,,,,,1,,BAO_0000221,
1466,10000000.0,Autocuration,Hippocampus,10576,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,CHEMBL616589,H,8,,,,,1,,BAO_0000221,
1467,10000000.0,Expert,Hippocampus,10576,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616590,H,8,,,,,1,,BAO_0000221,
1468,,Expert,,10576,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",CHEMBL616591,H,8,449.0,CHO,,,1,,BAO_0000219,
1469,,Expert,,10576,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,CHEMBL616592,H,8,,,,,1,,BAO_0000357,
1470,,Autocuration,,10576,The inhibition activity of 5-HT1A at 1 uM,CHEMBL616593,H,8,,,,,1,,BAO_0000357,
1471,,Expert,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",CHEMBL616594,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1472,,Expert,,10576,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,CHEMBL616595,H,8,,,,,1,,BAO_0000249,
1473,,Autocuration,,10576,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,CHEMBL616596,H,8,,,,,1,,BAO_0000357,
1474,10000000.0,Autocuration,Hippocampus,10576,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,CHEMBL616597,H,8,,,,,1,,BAO_0000221,
1475,10000000.0,Expert,Hippocampus,10576,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,CHEMBL616598,H,8,,,,,1,,BAO_0000221,
1476,,Expert,,10576,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,CHEMBL616599,D,9,,,,Membranes,1,,BAO_0000249,
1477,10000000.0,Expert,Hippocampus,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",CHEMBL616600,D,9,,,,Membranes,1,,BAO_0000249,
1478,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,CHEMBL616601,H,8,,,,,1,,BAO_0000019,
1479,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,CHEMBL616602,H,8,,,,,1,,BAO_0000019,
1480,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,CHEMBL616603,H,8,,,,,1,,BAO_0000019,
1481,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,CHEMBL616604,H,8,,,,,1,,BAO_0000019,
1482,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,CHEMBL616316,H,8,,,,,1,,BAO_0000249,
1483,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,CHEMBL616317,H,8,,,,,1,,BAO_0000249,
1484,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,CHEMBL616318,D,9,,,,,1,,BAO_0000019,
1485,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,CHEMBL616319,H,8,,,,,1,,BAO_0000221,
1486,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,CHEMBL616320,H,8,,,,,1,,BAO_0000221,
1487,10000000.0,Expert,Hippocampus,10576,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,CHEMBL616321,D,9,,,,,1,,BAO_0000221,
1488,,Autocuration,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,CHEMBL616322,H,8,,,,,1,,BAO_0000019,
1489,,Autocuration,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,CHEMBL616323,H,8,,,,,1,,BAO_0000019,
1490,,Autocuration,,10576,Ratio of binding affinity to 5-HT 1A and D2 receptor,CHEMBL616324,H,8,,,,,1,,BAO_0000357,
1491,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,CHEMBL616325,H,8,,,,,1,,BAO_0000221,
1492,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,CHEMBL616326,H,8,,,,,1,,BAO_0000221,
1493,10000000.0,Autocuration,Hippocampus,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,CHEMBL616327,H,8,,,,,1,,BAO_0000221,
1494,,Autocuration,,10576,Percentage inhibition against 5-hydroxytryptamine 1A receptor,CHEMBL616328,H,8,,,,,1,,BAO_0000357,
1495,,Autocuration,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),CHEMBL858110,H,8,,,,,1,,BAO_0000249,
1496,,Autocuration,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),CHEMBL616329,H,8,,,,,1,,BAO_0000249,
1497,,Autocuration,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),CHEMBL616330,H,8,,,,,1,,BAO_0000249,
1498,,Autocuration,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),CHEMBL616331,H,8,,,,,1,,BAO_0000249,
1499,,Autocuration,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,CHEMBL616332,H,8,,,,,1,,BAO_0000249,
1500,955.0,Autocuration,Brain,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL857063,H,8,,,,,1,,BAO_0000249,
1501,,Autocuration,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,CHEMBL616333,H,8,,,,,1,,BAO_0000019,
1502,,Expert,,10576,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,CHEMBL616334,H,8,,,,,1,,BAO_0000019,
1503,10000000.0,Autocuration,Hippocampus,10576,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,CHEMBL616335,H,8,,,,,1,,BAO_0000221,
1504,,Autocuration,,10576,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,CHEMBL616336,H,8,,,,,1,,BAO_0000019,
1505,,Expert,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,CHEMBL616337,H,8,,,,,1,,BAO_0000249,
1506,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,CHEMBL616338,H,8,,,,,1,,BAO_0000019,
1507,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,CHEMBL616339,H,8,,,,,1,,BAO_0000221,
1508,10000000.0,Autocuration,Hippocampus,10576,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,CHEMBL616340,H,8,,,,,1,,BAO_0000221,
1509,,Autocuration,,10576,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,CHEMBL616341,H,8,,,,,1,,BAO_0000357,
1510,,Expert,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor,CHEMBL616342,D,9,,,,,1,,BAO_0000357,
1511,,Expert,,10576,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,CHEMBL616343,D,9,,,,,1,,BAO_0000019,
1512,,Expert,,10576,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,CHEMBL616344,H,8,,,,,1,,BAO_0000019,
1513,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,CHEMBL616345,H,8,,,,,1,,BAO_0000357,
1514,,Expert,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,CHEMBL616346,H,8,,,,,1,,BAO_0000019,
1515,10000000.0,Autocuration,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,CHEMBL616347,H,8,,,,,1,,BAO_0000221,
1516,,Expert,,10576,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,CHEMBL616348,H,8,,,,,1,,BAO_0000019,
1517,,Expert,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor,CHEMBL616349,H,8,,,,,1,,BAO_0000357,
1518,,Expert,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,CHEMBL616152,D,9,,,,Membranes,1,,BAO_0000249,
1519,,Autocuration,,10576,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,CHEMBL616153,H,8,,,,,1,,BAO_0000249,
1520,,Expert,,10576,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",CHEMBL616154,H,8,,,,,1,,BAO_0000019,
1521,,Autocuration,,10576,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,CHEMBL616155,H,8,,,,,1,,BAO_0000019,
1522,10000000.0,Expert,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,CHEMBL616156,D,9,,,,,1,,BAO_0000221,
1523,10000000.0,Expert,Hippocampus,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,CHEMBL616157,D,9,,,,,1,,BAO_0000221,
1524,10000000.0,Autocuration,Hippocampus,10576,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,CHEMBL616158,H,8,,,,,1,,BAO_0000221,
1525,,Autocuration,,10576,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,CHEMBL616159,H,8,,,,,1,,BAO_0000357,
1526,,Expert,,10576,pKi value against rat 5-hydroxytryptamine 1A receptor.,CHEMBL616160,H,8,,,,,1,,BAO_0000357,
1527,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,CHEMBL616161,H,8,,,,,1,,BAO_0000019,
1528,,Autocuration,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,CHEMBL616162,H,8,,,,,1,,BAO_0000019,
1529,,Expert,,12687,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,CHEMBL616163,D,9,,,,,1,,BAO_0000357,
1530,,Expert,,10626,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,CHEMBL616164,H,8,,,,Membranes,1,,BAO_0000249,
1531,955.0,Autocuration,Brain,10576,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,CHEMBL616165,H,8,,,,,1,,BAO_0000221,
1532,,Autocuration,,51,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,CHEMBL616355,H,8,,,,,1,,BAO_0000019,
1533,,Autocuration,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,CHEMBL616356,H,8,,,,,1,,BAO_0000019,
1534,955.0,Autocuration,Brain,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,CHEMBL616357,H,8,,,,,1,,BAO_0000221,
1535,,Autocuration,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",CHEMBL616358,H,8,,,,,1,,BAO_0000019,
1536,,Autocuration,,51,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616359,H,8,,,,,1,,BAO_0000357,
1537,,Expert,,51,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,CHEMBL616360,H,8,,,,,1,,BAO_0000357,
1538,,Expert,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616361,H,8,,,,,1,,BAO_0000357,
1539,,Autocuration,,51,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL616362,H,8,,,,,1,,BAO_0000357,
1540,,Autocuration,,51,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,CHEMBL616363,H,8,,,,Brain membranes,1,,BAO_0000249,
1541,,Autocuration,,51,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,CHEMBL616364,H,8,,,,,1,,BAO_0000357,
1542,,Autocuration,,51,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,CHEMBL616365,H,8,,,,,1,,BAO_0000357,
1543,,Expert,,51,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,CHEMBL616366,H,8,,,,,1,,BAO_0000357,
1544,,Expert,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL872906,H,8,,,,,1,,BAO_0000357,
1545,,Autocuration,,51,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,CHEMBL616367,H,8,,,,,1,,BAO_0000357,
1546,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616368,H,8,,,,,1,,BAO_0000357,
1547,,Autocuration,,51,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,CHEMBL616369,H,8,,,,,1,,BAO_0000357,
1548,,Expert,,51,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,CHEMBL616370,D,9,,,,,1,,BAO_0000357,
1549,,Expert,,51,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,CHEMBL616371,D,9,,,,,1,,BAO_0000357,
1550,,Autocuration,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL616372,H,8,449.0,CHO,,,1,,BAO_0000219,
1551,,Expert,,51,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,CHEMBL616373,H,8,,,,,1,,BAO_0000219,
1552,,Autocuration,,51,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616374,H,8,,,,,1,,BAO_0000218,
1553,10000000.0,Autocuration,Hippocampus,51,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL616375,H,8,,,,,1,,BAO_0000221,
1554,,Autocuration,,51,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,CHEMBL616376,H,8,,,,,1,,BAO_0000357,
1555,,Expert,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,CHEMBL857064,H,8,,,,,1,,BAO_0000357,
1556,,Autocuration,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,CHEMBL616377,H,8,,,,,1,,BAO_0000357,
1557,,Autocuration,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,CHEMBL616378,H,8,,,,,1,,BAO_0000357,
1558,,Autocuration,,51,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,CHEMBL616379,H,8,,,,,1,,BAO_0000357,
1559,,Autocuration,,11863,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,CHEMBL616380,H,8,,,,,1,,BAO_0000357,
1560,,Autocuration,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,CHEMBL616381,H,8,,,,,1,,BAO_0000357,
1561,,Autocuration,,11863,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,CHEMBL616382,H,8,,,,,1,,BAO_0000357,
1562,,Autocuration,,11863,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,CHEMBL616383,H,8,,,,,1,,BAO_0000357,
1563,,Expert,,11863,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,CHEMBL616350,D,9,449.0,CHO,,,1,,BAO_0000219,
1564,,Autocuration,,11863,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,CHEMBL616351,H,8,,,,,1,,BAO_0000357,
1565,,Autocuration,,11863,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,CHEMBL616352,H,8,,,,,1,,BAO_0000357,
1566,,Autocuration,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616353,H,8,,,,,1,,BAO_0000357,
1567,,Autocuration,,11863,Binding affinity against serotonergic 5-HT1a receptor,CHEMBL616354,H,8,,,,,1,,BAO_0000357,
1568,,Autocuration,,11863,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,CHEMBL616508,H,8,,,,,1,,BAO_0000357,
1569,,Expert,,11863,Binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL616559,D,9,,,,,1,,BAO_0000357,
1570,,Autocuration,,11863,Binding affinity at 5-hydroxytryptamine 1A receptor,CHEMBL616560,H,8,,,,,1,,BAO_0000357,
1571,,Autocuration,,11863,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",CHEMBL616561,H,8,,,,,1,,BAO_0000357,
1572,,Autocuration,,11863,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL616562,H,8,449.0,CHO,,,1,,BAO_0000219,
1573,,Autocuration,,11863,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL616563,H,8,449.0,CHO,,,1,,BAO_0000219,
1574,,Autocuration,,11863,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,CHEMBL616564,H,8,,,,,1,,BAO_0000357,
1575,,Autocuration,,11863,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,CHEMBL616565,H,8,,,,,1,,BAO_0000357,
1576,,Autocuration,,11863,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,CHEMBL616566,H,8,,,,,1,,BAO_0000218,
1577,,Autocuration,,11863,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,CHEMBL616989,H,8,,,,,1,,BAO_0000357,
1578,,Autocuration,,11863,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,CHEMBL857975,H,8,,,,,1,,BAO_0000357,
1579,,Expert,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616990,D,9,,,,,1,,BAO_0000357,
1580,,Autocuration,,11863,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,CHEMBL616991,H,8,,,,,1,,BAO_0000357,
1581,,Autocuration,,11863,Tested against 5-hydroxytryptamine 1A receptor,CHEMBL616992,H,8,,,,,1,,BAO_0000357,
1582,,Autocuration,,11863,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616993,H,8,,,,,1,,BAO_0000357,
1583,,Expert,,106,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,CHEMBL616994,H,8,,,,,1,,BAO_0000019,
1584,,Autocuration,,106,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,CHEMBL616995,H,8,,,,,1,,BAO_0000019,
1585,,Intermediate,,105571,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,CHEMBL616996,D,9,722.0,HEK293,,,1,,BAO_0000219,
1586,,Autocuration,,106,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,CHEMBL616997,H,8,,,,,1,,BAO_0000218,
1587,,Autocuration,,106,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,CHEMBL616998,H,8,,,,,1,,BAO_0000218,
1588,,Autocuration,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,CHEMBL616999,H,8,,,,,1,,BAO_0000019,
1589,,Autocuration,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,CHEMBL617000,H,8,,,,,1,,BAO_0000019,
1590,,Autocuration,,106,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,CHEMBL617001,H,8,,,,,1,,BAO_0000019,
1591,,Autocuration,,106,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,CHEMBL858111,H,8,,,,,1,,BAO_0000019,
1592,,Autocuration,,106,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,CHEMBL617002,H,8,,,,,1,,BAO_0000019,
1593,,Autocuration,,106,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),CHEMBL617003,H,8,,,,,1,,BAO_0000019,
1594,,Autocuration,,106,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),CHEMBL617004,H,8,,,,,1,,BAO_0000019,
1595,,Expert,,106,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,CHEMBL617005,D,9,,,,,1,,BAO_0000019,
1596,,Expert,,106,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,CHEMBL616623,D,9,485.0,CHO-K1,,,1,,BAO_0000219,
1597,,Autocuration,,106,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,CHEMBL616624,H,8,449.0,CHO,,,1,,BAO_0000219,
1598,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,CHEMBL883243,H,8,,,,,1,,BAO_0000357,
1599,,Autocuration,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,CHEMBL616625,H,8,,,,,1,,BAO_0000019,
1600,,Expert,,106,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",CHEMBL616626,H,8,449.0,CHO,,,1,,BAO_0000219,
1601,,Autocuration,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,CHEMBL616627,H,8,449.0,CHO,,,1,,BAO_0000219,
1602,,Autocuration,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,CHEMBL616628,H,8,449.0,CHO,,,1,,BAO_0000219,
1603,,Autocuration,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,CHEMBL616629,H,8,449.0,CHO,,,1,,BAO_0000219,
1604,,Autocuration,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,CHEMBL616630,H,8,449.0,CHO,,,1,,BAO_0000219,
1605,,Expert,,106,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",CHEMBL616631,H,8,,,,,1,,BAO_0000019,
1606,,Autocuration,,106,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",CHEMBL616632,H,8,,,,,1,,BAO_0000019,
1607,,Expert,,106,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,CHEMBL616633,D,9,,,,,1,,BAO_0000357,
1608,,Expert,,106,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,CHEMBL616634,H,8,449.0,CHO,,,1,,BAO_0000219,
1609,,Autocuration,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,CHEMBL616635,H,8,,,,,1,,BAO_0000357,
1610,,Expert,,106,Binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL885358,D,9,,,,,1,,BAO_0000357,
1611,,Expert,,106,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,CHEMBL616636,D,9,449.0,CHO,,,1,,BAO_0000219,
1612,,Expert,,106,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,CHEMBL616637,H,8,449.0,CHO,,,1,,BAO_0000219,
1613,,Autocuration,,106,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,CHEMBL616638,H,8,,,,,1,,BAO_0000357,
1614,,Expert,,106,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,CHEMBL616639,H,8,449.0,CHO,,,1,,BAO_0000219,
1615,,Expert,,106,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,CHEMBL616640,H,8,449.0,CHO,,,1,,BAO_0000219,
1616,,Expert,,106,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,CHEMBL616641,H,8,449.0,CHO,,,1,,BAO_0000219,
1617,,Expert,,106,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,CHEMBL616642,H,8,449.0,CHO,,,1,,BAO_0000219,
1618,,Expert,,106,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,CHEMBL616643,H,8,449.0,CHO,,,1,,BAO_0000219,
1619,,Autocuration,,106,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),CHEMBL616644,H,8,,,,,1,,BAO_0000357,
1620,,Autocuration,,106,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,CHEMBL616645,H,8,,,,,1,,BAO_0000357,
1621,,Autocuration,,105,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),CHEMBL616646,H,8,,,,,1,,BAO_0000019,
1622,,Expert,,105,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),CHEMBL616647,H,8,,,,,1,,BAO_0000019,
1623,,Autocuration,,105,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),CHEMBL616509,H,8,,,,,1,,BAO_0000357,
1624,,Autocuration,,105,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),CHEMBL616510,H,8,,,,,1,,BAO_0000357,
1625,,Autocuration,,105,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,CHEMBL616511,H,8,,,,,1,,BAO_0000357,
1626,,Expert,,105,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,CHEMBL616512,H,8,,,,,1,,BAO_0000357,
1627,,Autocuration,,105,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,CHEMBL616513,H,8,,,,,1,,BAO_0000357,
1628,2435.0,Autocuration,Striatum,105,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,CHEMBL616514,H,8,,,,,1,,BAO_0000019,
1629,,Expert,,105,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,CHEMBL616515,H,8,,,,,1,,BAO_0000357,
1630,,Autocuration,,105,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,CHEMBL616516,H,8,,,,,1,,BAO_0000019,
1631,,Autocuration,,105,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,CHEMBL616517,H,8,,,,,1,,BAO_0000357,
1632,,Autocuration,,105,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,CHEMBL616518,H,8,,,,,1,,BAO_0000357,
1633,,Autocuration,,105,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,CHEMBL616519,H,8,,,,,1,,BAO_0000357,
1634,,Autocuration,,105,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,CHEMBL616520,H,8,,,,,1,,BAO_0000357,
1635,,Autocuration,,105,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,CHEMBL616521,H,8,,,,,1,,BAO_0000357,
1636,,Autocuration,,105,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,CHEMBL616522,H,8,,,,,1,,BAO_0000357,
1637,,Autocuration,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,CHEMBL884531,H,8,,,,,1,,BAO_0000357,
1638,,Autocuration,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,CHEMBL616523,H,8,,,,,1,,BAO_0000357,
1639,2435.0,Autocuration,Striatum,105,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,CHEMBL616731,H,8,,,,,1,,BAO_0000019,
1640,,Autocuration,,105,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,CHEMBL616732,H,8,,,,,1,,BAO_0000019,
1641,,Autocuration,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,CHEMBL616733,H,8,,,,,1,,BAO_0000357,
1642,,Autocuration,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,CHEMBL616734,H,8,,,,,1,,BAO_0000357,
1643,,Autocuration,,105,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,CHEMBL616735,H,8,,,,,1,,BAO_0000249,
1644,,Autocuration,,105,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,CHEMBL616736,H,8,,,,,1,,BAO_0000249,
1645,,Expert,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616737,H,8,,,,,1,,BAO_0000019,
1646,,Autocuration,,105,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,CHEMBL616738,H,8,,,,,1,,BAO_0000019,
1647,,Expert,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616739,H,8,,,,,1,,BAO_0000019,
1648,,Expert,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616740,H,8,,,,,1,,BAO_0000019,
1649,,Expert,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616741,H,8,,,,,1,,BAO_0000019,
1650,,Autocuration,,105,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,CHEMBL616742,H,8,722.0,HEK293,,,1,,BAO_0000219,
1651,,Intermediate,,105570,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,CHEMBL616743,D,9,,,,,1,,BAO_0000019,
1652,,Intermediate,,105570,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,CHEMBL616744,D,9,,,,,1,,BAO_0000019,
1653,,Intermediate,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,CHEMBL616745,D,9,,,,,1,,BAO_0000019,
1654,,Intermediate,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616746,D,9,,,,,1,,BAO_0000019,
1655,,Intermediate,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,CHEMBL616747,D,9,,,,,1,,BAO_0000019,
1656,,Intermediate,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,CHEMBL616748,D,9,,,,,1,,BAO_0000019,
1657,,Intermediate,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,CHEMBL616648,D,9,,,,,1,,BAO_0000019,
1658,,Intermediate,,105570,Binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL616649,D,9,,,,,1,,BAO_0000357,
1659,,Intermediate,,105570,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,CHEMBL616650,D,9,,,,,1,,BAO_0000357,
1660,,Intermediate,,105570,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616651,D,9,,,,,1,,BAO_0000218,
1661,,Intermediate,,105570,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616652,D,9,,,,,1,,BAO_0000218,
1662,,Intermediate,,105570,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616653,D,9,,,,,1,,BAO_0000218,
1663,,Intermediate,,105570,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,CHEMBL616654,D,9,,,,,1,,BAO_0000218,
1664,,Intermediate,,105570,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,CHEMBL616655,D,9,,,,,1,,BAO_0000019,
1665,,Intermediate,,105570,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,CHEMBL616656,D,9,,,,,1,,BAO_0000357,
1666,,Autocuration,,105,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,CHEMBL616657,H,8,,,,,1,,BAO_0000019,
1667,2435.0,Intermediate,Striatum,105570,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,CHEMBL616658,D,9,,,,,1,,BAO_0000357,
1668,,Intermediate,,105570,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,CHEMBL616659,D,9,,,,,1,,BAO_0000357,
1669,,Autocuration,,51,Binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL616660,H,8,,,,,1,,BAO_0000357,
1670,,Autocuration,,106,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,CHEMBL616661,H,8,,,,,1,,BAO_0000357,
1671,,Expert,,105,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,CHEMBL616662,H,8,,,,,1,,BAO_0000019,
1672,,Autocuration,,105,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616663,H,8,,,,,1,,BAO_0000019,
1673,,Autocuration,,105,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616664,H,8,,,,,1,,BAO_0000019,
1674,,Expert,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",CHEMBL881820,D,9,449.0,CHO,,,1,,BAO_0000219,
1675,,Autocuration,,105,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",CHEMBL616665,H,8,449.0,CHO,,,1,,BAO_0000219,
1676,,Expert,,105,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,CHEMBL616666,H,8,449.0,CHO,,,1,,BAO_0000219,
1677,,Autocuration,,105,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,CHEMBL616667,H,8,449.0,CHO,,,1,,BAO_0000219,
1678,,Expert,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",CHEMBL616668,H,8,449.0,CHO,,,1,,BAO_0000219,
1679,,Expert,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",CHEMBL616669,D,9,449.0,CHO,,,1,,BAO_0000219,
1680,,Expert,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",CHEMBL617040,H,8,449.0,CHO,,,1,,BAO_0000219,
1681,,Autocuration,,105,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",CHEMBL617041,H,8,449.0,CHO,,,1,,BAO_0000219,
1682,,Expert,,105,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",CHEMBL617042,H,8,449.0,CHO,,,1,,BAO_0000219,
1683,,Expert,,105,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",CHEMBL617043,H,8,449.0,CHO,,,1,,BAO_0000219,
1684,,Autocuration,,105,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,CHEMBL617044,H,8,,,,,1,,BAO_0000019,
1685,,Expert,,105,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,CHEMBL617045,H,8,449.0,CHO,,,1,,BAO_0000219,
1686,,Expert,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",CHEMBL617046,D,9,449.0,CHO,,,1,,BAO_0000219,
1687,,Expert,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",CHEMBL617047,D,9,449.0,CHO,,,1,,BAO_0000219,
1688,,Expert,,105,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",CHEMBL617048,H,8,,,,,1,,BAO_0000019,
1689,,Autocuration,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",CHEMBL616897,H,8,,,,,1,,BAO_0000019,
1690,,Expert,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",CHEMBL616898,D,9,,,,,1,,BAO_0000019,
1691,,Expert,,105,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,CHEMBL858201,D,9,449.0,CHO,,,1,,BAO_0000219,
1692,,Autocuration,,105,Intrinsic activity for 5-hydroxytryptamine 1D receptor,CHEMBL616899,H,8,,,,,1,,BAO_0000019,
1693,,Autocuration,,105,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),CHEMBL616900,H,8,,,,,1,,BAO_0000219,
1694,,Expert,,105,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,CHEMBL616901,H,8,449.0,CHO,,,1,,BAO_0000219,
1695,,Autocuration,,105,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,CHEMBL616902,H,8,,,,,1,,BAO_0000357,
1696,,Expert,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616903,D,9,449.0,CHO,,,1,,BAO_0000219,
1697,,Expert,,105,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,CHEMBL616904,H,8,449.0,CHO,,,1,,BAO_0000219,
1698,,Autocuration,,105,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,CHEMBL616905,H,8,,,,,1,,BAO_0000357,
1699,,Expert,,105,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,CHEMBL616906,H,8,449.0,CHO,,,1,,BAO_0000219,
1700,,Expert,,105,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHEMBL616907,H,8,449.0,CHO,,,1,,BAO_0000219,
1701,,Expert,,105,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHEMBL616908,H,8,449.0,CHO,,,1,,BAO_0000219,
1702,,Expert,,105,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616909,D,9,449.0,CHO,,,1,,BAO_0000219,
1703,,Expert,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616910,D,9,449.0,CHO,,,1,,BAO_0000219,
1704,,Expert,,105,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHEMBL616911,H,8,449.0,CHO,,,1,,BAO_0000219,
1705,,Expert,,105,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616912,H,8,449.0,CHO,,,1,,BAO_0000219,
1706,,Autocuration,,105,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),CHEMBL616913,H,8,,,,,1,,BAO_0000357,
1707,,Expert,,105,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,CHEMBL616914,D,9,449.0,CHO,,,1,,BAO_0000219,
1708,,Autocuration,,105,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616915,H,8,449.0,CHO,,,1,,BAO_0000219,
1709,,Autocuration,,105,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,CHEMBL616916,H,8,,,,,1,,BAO_0000019,
1710,,Expert,,105,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616917,D,9,,,,,1,,BAO_0000357,
1711,,Autocuration,,105,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",CHEMBL616918,H,8,,,,,1,,BAO_0000357,
1712,,Expert,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,CHEMBL616919,H,8,,,,,1,,BAO_0000219,
1713,,Autocuration,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,CHEMBL616920,H,8,,,,,1,,BAO_0000357,
1714,,Autocuration,,105,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,CHEMBL872914,H,8,,,,,1,,BAO_0000357,
1715,,Autocuration,,105,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,CHEMBL616921,H,8,,,,,1,,BAO_0000357,
1716,,Expert,,105,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616922,H,8,,,,,1,,BAO_0000357,
1717,,Autocuration,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor,CHEMBL616923,H,8,,,,,1,,BAO_0000357,
1718,,Expert,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616924,H,8,,,,,1,,BAO_0000357,
1719,,Expert,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,CHEMBL875909,H,8,,,,,1,,BAO_0000357,
1720,,Autocuration,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,CHEMBL616925,H,8,,,,,1,,BAO_0000357,
1721,,Autocuration,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,CHEMBL616926,H,8,,,,,1,,BAO_0000357,
1722,,Autocuration,,105,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,CHEMBL616927,H,8,,,,,1,,BAO_0000357,
1723,,Expert,,105,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,CHEMBL616928,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1724,,Expert,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),CHEMBL616929,D,9,,,,,1,,BAO_0000219,
1725,,Expert,,105,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,CHEMBL616930,D,9,,,,,1,,BAO_0000357,
1726,,Expert,,105,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616931,H,8,,,,,1,,BAO_0000019,
1727,,Autocuration,,105,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,CHEMBL616932,H,8,,,,,1,,BAO_0000357,
1728,,Expert,,105,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616933,H,8,,,,,1,,BAO_0000357,
1729,,Expert,,105,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,CHEMBL616934,D,9,,,,,1,,BAO_0000219,
1730,,Expert,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,CHEMBL616935,D,9,,,,,1,,BAO_0000357,
1731,,Autocuration,,105,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,CHEMBL616936,H,8,,,,,1,,BAO_0000357,
1732,,Expert,,105,Affinity for 5-hydroxytryptamine 1D receptor subtype,CHEMBL616937,D,9,,,,,1,,BAO_0000357,
1733,,Expert,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,CHEMBL616938,D,9,,,,,1,,BAO_0000357,
1734,,Autocuration,,105,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616939,H,8,,,,,1,,BAO_0000019,
1735,,Expert,,105,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,CHEMBL616940,H,8,,,,,1,,BAO_0000019,
1736,,Expert,,105,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,CHEMBL616941,D,9,,,,,1,,BAO_0000357,
1737,,Autocuration,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,CHEMBL616942,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1738,,Autocuration,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,CHEMBL616943,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1739,,Autocuration,,104802,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,CHEMBL616944,H,4,449.0,CHO,,,1,,BAO_0000219,
1740,,Autocuration,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",CHEMBL616945,H,8,,,,,1,,BAO_0000019,
1741,,Autocuration,,105,Binding activity radioligand.,CHEMBL616946,H,8,,,,,1,,BAO_0000357,
1742,,Autocuration,,105,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL616947,H,8,,,,,1,,BAO_0000019,
1743,,Expert,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,CHEMBL616948,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1744,,Autocuration,,105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,CHEMBL616851,H,8,,,,,1,,BAO_0000357,
1745,,Autocuration,,105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,CHEMBL616852,H,8,,,,,1,,BAO_0000357,
1746,,Autocuration,,105,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,CHEMBL616853,H,8,,,,,1,,BAO_0000357,
1747,,Expert,,105,Binding activity against human 5-hydroxytryptamine 1D receptor,CHEMBL616854,D,9,,,,,1,,BAO_0000357,
1748,,Expert,,105,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616855,D,9,449.0,CHO,,,1,,BAO_0000219,
1749,,Autocuration,,105,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,CHEMBL616856,H,8,449.0,CHO,,,1,,BAO_0000219,
1750,,Autocuration,,105,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL616857,H,8,449.0,CHO,,,1,,BAO_0000219,
1751,,Autocuration,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616858,H,8,,,,,1,,BAO_0000357,
1752,,Autocuration,,105,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,CHEMBL616859,H,8,449.0,CHO,,,1,,BAO_0000219,
1753,,Autocuration,,105,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,CHEMBL616860,H,8,449.0,CHO,,,1,,BAO_0000219,
1754,,Autocuration,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,CHEMBL616861,H,8,722.0,HEK293,,,1,,BAO_0000219,
1755,,Autocuration,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,CHEMBL616541,H,8,722.0,HEK293,,,1,,BAO_0000219,
1756,,Autocuration,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,CHEMBL616542,H,8,722.0,HEK293,,,1,,BAO_0000219,
1757,,Autocuration,,105,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,CHEMBL616543,H,8,449.0,CHO,,,1,,BAO_0000219,
1758,,Expert,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,CHEMBL616544,D,9,,,,,1,,BAO_0000357,
1759,,Autocuration,,105,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,CHEMBL616545,H,8,449.0,CHO,,,1,,BAO_0000219,
1760,,Autocuration,,105,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,CHEMBL616546,H,8,,,,,1,,BAO_0000357,
1761,,Autocuration,,105,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,CHEMBL616547,H,8,449.0,CHO,,,1,,BAO_0000219,
1762,,Autocuration,,105,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL616548,H,8,449.0,CHO,,,1,,BAO_0000219,
1763,,Expert,,105,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,CHEMBL616549,H,8,,,,,1,,BAO_0000019,
1764,,Expert,,105,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,CHEMBL616550,H,8,,,,,1,,BAO_0000019,
1765,,Autocuration,,108,Binding affinity against 5-HT2C receptor,CHEMBL857066,H,8,,,,,1,,BAO_0000357,
1766,,Autocuration,,108,Binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL616551,H,8,,,,,1,,BAO_0000357,
1767,,Autocuration,,10577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,CHEMBL616552,H,8,,,,,1,,BAO_0000357,
1768,,Autocuration,,10577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,CHEMBL832876,H,8,,,,,1,,BAO_0000019,
1769,,Expert,,10577,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",CHEMBL616553,H,8,,,,,1,,BAO_0000019,
1770,,Autocuration,,10577,Binding affinity towards 5-HT1B was determined,CHEMBL616554,H,8,,,,,1,,BAO_0000357,
1771,,Expert,,10577,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,CHEMBL616555,H,8,,,,,1,,BAO_0000019,
1772,,Expert,,10577,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",CHEMBL616556,H,8,,,,,1,,BAO_0000019,
1773,,Autocuration,,10577,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",CHEMBL616557,H,8,,,,,1,,BAO_0000019,
1774,,Expert,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,CHEMBL616558,H,8,,,,,1,,BAO_0000019,
1775,,Expert,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,CHEMBL616749,D,9,,,,,1,,BAO_0000019,
1776,,Autocuration,,10577,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,CHEMBL616750,H,8,,,,,1,,BAO_0000357,
1777,,Autocuration,,10577,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",CHEMBL616751,H,8,,,,,1,,BAO_0000357,
1778,,Autocuration,,10577,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,CHEMBL616752,H,8,,,,,1,,BAO_0000249,
1779,2435.0,Autocuration,Striatum,10577,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,CHEMBL616753,H,8,,,,,1,,BAO_0000019,
1780,,Expert,,10577,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,CHEMBL616754,D,9,,,,,1,,BAO_0000357,
1781,,Autocuration,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,CHEMBL616755,H,8,,,,,1,,BAO_0000019,
1782,2435.0,Autocuration,Striatum,10577,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,CHEMBL616756,H,8,,,,,1,,BAO_0000019,
1783,2435.0,Autocuration,Striatum,10577,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,CHEMBL616757,H,8,,,,,1,,BAO_0000019,
1784,2435.0,Autocuration,Striatum,10577,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,CHEMBL616758,H,8,,,,,1,,BAO_0000357,
1785,,Autocuration,,10577,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,CHEMBL616759,H,8,,,,,1,,BAO_0000249,
1786,,Autocuration,,10577,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,CHEMBL616760,H,8,,,,,1,,BAO_0000357,
1787,2435.0,Autocuration,Striatum,10577,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,CHEMBL616761,H,8,,,,,1,,BAO_0000019,
1788,2435.0,Autocuration,Striatum,10577,Binding affinity against 5-HT1B serotonin receptor in rat striatum,CHEMBL616762,H,8,,,,,1,,BAO_0000019,
1789,,Autocuration,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,CHEMBL616763,H,8,,,,,1,,BAO_0000019,
1790,,Expert,,10577,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,CHEMBL872909,H,8,,,,,1,,BAO_0000357,
1791,,Autocuration,,10577,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,CHEMBL616764,H,8,,,,,1,,BAO_0000357,
1792,,Expert,,10577,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,CHEMBL616765,D,9,,,,,1,,BAO_0000357,
1793,2435.0,Autocuration,Striatum,10577,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,CHEMBL616766,H,8,,,,,1,,BAO_0000357,
1794,2435.0,Autocuration,Striatum,10577,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,CHEMBL616767,H,8,,,,,1,,BAO_0000357,
1795,,Autocuration,,10577,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,CHEMBL616768,H,8,,,,,1,,BAO_0000357,
1796,,Autocuration,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,CHEMBL616769,H,8,,,,,1,,BAO_0000357,
1797,,Autocuration,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,CHEMBL616770,H,8,,,,,1,,BAO_0000019,
1798,,Autocuration,,10577,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,CHEMBL616771,H,8,,,,,1,,BAO_0000019,
1799,2435.0,Autocuration,Striatum,10577,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,CHEMBL616772,H,8,,,,,1,,BAO_0000019,
1800,,Expert,,10577,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,CHEMBL616773,H,8,,,,,1,,BAO_0000019,
1801,,Autocuration,,10577,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,CHEMBL616774,H,8,,,,,1,,BAO_0000019,
1802,,Autocuration,,10577,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,CHEMBL616775,H,8,,,,,1,,BAO_0000357,
1803,,Autocuration,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,CHEMBL616776,H,8,,,,,1,,BAO_0000249,
1804,,Autocuration,,10577,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,CHEMBL616777,H,8,,,,,1,,BAO_0000357,
1805,,Autocuration,,10577,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,CHEMBL616778,H,8,,,,,1,,BAO_0000357,
1806,,Expert,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,CHEMBL616779,D,9,,,,,1,,BAO_0000249,
1807,,Expert,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor,CHEMBL616780,D,9,,,,,1,,BAO_0000357,
1808,,Autocuration,,10577,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,CHEMBL616781,H,8,,,,,1,,BAO_0000019,
1809,,Autocuration,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,CHEMBL616782,H,8,,,,,1,,BAO_0000357,
1810,,Autocuration,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,CHEMBL616783,H,8,,,,,1,,BAO_0000357,
1811,2435.0,Expert,Striatum,10577,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,CHEMBL616784,H,8,,,,,1,,BAO_0000019,
1812,,Autocuration,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,CHEMBL616785,H,8,,,,,1,,BAO_0000357,
1813,955.0,Autocuration,Brain,10577,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL857067,H,8,,,,,1,,BAO_0000249,
1814,,Autocuration,,10577,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,CHEMBL616786,H,8,,,,,1,,BAO_0000019,
1815,955.0,Autocuration,Brain,10577,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL616787,H,8,,,,,1,,BAO_0000249,
1816,,Autocuration,,10577,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,CHEMBL616788,H,8,,,,,1,,BAO_0000357,
1817,,Autocuration,,10577,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,CHEMBL616789,H,8,,,,,1,,BAO_0000357,
1818,,Expert,,10577,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,CHEMBL616790,D,9,,,,,1,,BAO_0000019,
1819,,Expert,,10577,Binding affinity at 5-hydroxytryptamine 1B receptor,CHEMBL616791,H,8,,,,,1,,BAO_0000357,
1820,,Autocuration,,10577,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,CHEMBL616792,H,8,,,,,1,,BAO_0000019,
1821,,Expert,,10577,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,CHEMBL616793,D,9,,,,,1,,BAO_0000249,
1822,,Autocuration,,10577,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,CHEMBL616794,H,8,,,,,1,,BAO_0000357,
1823,,Autocuration,,10577,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,CHEMBL616795,H,8,,,,,1,,BAO_0000357,
1824,,Autocuration,,104686,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,CHEMBL616796,H,4,,,,,1,,BAO_0000019,
1825,,Autocuration,,106,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL616797,H,8,,,,,1,,BAO_0000357,
1826,,Autocuration,,106,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,CHEMBL616798,H,8,,,,Brain membranes,1,,BAO_0000249,
1827,,Autocuration,,106,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,CHEMBL616799,H,8,,,,,1,,BAO_0000357,
1828,,Autocuration,,106,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,CHEMBL616800,H,8,,,,,1,,BAO_0000357,
1829,,Autocuration,,106,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,CHEMBL616801,H,8,,,,,1,,BAO_0000357,
1830,,Autocuration,,106,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,CHEMBL616802,H,8,,,,,1,,BAO_0000357,
1831,,Autocuration,,106,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,CHEMBL616803,H,8,,,,,1,,BAO_0000357,
1832,,Expert,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,CHEMBL857068,H,8,,,,,1,,BAO_0000357,
1833,,Autocuration,,106,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,CHEMBL616804,H,8,,,,,1,,BAO_0000357,
1834,,Autocuration,,106,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,CHEMBL616805,H,8,,,,,1,,BAO_0000357,
1835,,Autocuration,,106,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,CHEMBL616806,H,8,,,,,1,,BAO_0000357,
1836,,Autocuration,,106,Binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL616807,H,8,,,,,1,,BAO_0000357,
1837,,Autocuration,,106,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,CHEMBL616808,H,8,,,,,1,,BAO_0000357,
1838,,Autocuration,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,CHEMBL616809,H,8,,,,,1,,BAO_0000357,
1839,,Autocuration,,106,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,CHEMBL616810,H,8,,,,,1,,BAO_0000357,
1840,,Autocuration,,104802,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,CHEMBL616811,H,4,,,,,1,,BAO_0000224,
1841,,Autocuration,,108,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,CHEMBL616812,H,8,,,,,1,,BAO_0000357,
1842,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,CHEMBL616813,H,8,,,,,1,,BAO_0000357,
1843,,Autocuration,,108,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,CHEMBL616814,H,8,,,,,1,,BAO_0000357,
1844,,Autocuration,,108,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,CHEMBL616815,H,8,,,,,1,,BAO_0000357,
1845,,Autocuration,,108,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,CHEMBL616816,H,8,,,,,1,,BAO_0000357,
1846,,Autocuration,,108,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,CHEMBL616817,H,8,,,,,1,,BAO_0000357,
1847,,Autocuration,,108,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,CHEMBL616818,H,8,,,,,1,,BAO_0000357,
1848,,Expert,,108,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,CHEMBL616819,H,8,,,,,1,,BAO_0000357,
1849,,Expert,,108,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,CHEMBL616820,H,8,,,,,1,,BAO_0000357,
1850,,Expert,,108,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,CHEMBL616821,H,8,,,,,1,,BAO_0000019,
1851,,Autocuration,,108,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,CHEMBL616822,H,8,,,,,1,,BAO_0000357,
1852,,Autocuration,,108,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,CHEMBL616823,H,8,,,,,1,,BAO_0000019,
1853,,Autocuration,,12689,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,CHEMBL616824,D,9,,,,,1,,BAO_0000357,
1854,,Autocuration,,12689,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,CHEMBL616825,D,9,,,,,1,,BAO_0000357,
1855,,Autocuration,,12689,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,CHEMBL616826,D,9,,,,,1,,BAO_0000357,
1856,,Expert,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,CHEMBL616827,D,9,,,,,1,,BAO_0000019,
1857,,Autocuration,,12689,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,CHEMBL616828,D,9,,,,,1,,BAO_0000357,
1858,,Autocuration,,12689,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,CHEMBL616829,D,9,,,,,1,,BAO_0000357,
1859,,Autocuration,,12689,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,CHEMBL616830,D,9,,,,,1,,BAO_0000019,
1860,,Expert,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,CHEMBL616831,D,9,,,,,1,,BAO_0000357,
1861,,Autocuration,,12689,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL616832,D,9,,,,,1,,BAO_0000019,
1862,,Autocuration,,12689,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL616833,D,9,,,,,1,,BAO_0000019,
1863,,Expert,,12689,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL616834,D,9,,,,,1,,BAO_0000019,
1864,,Autocuration,,12689,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL829595,D,9,,,,,1,,BAO_0000019,
1865,,Autocuration,,12689,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,CHEMBL616835,D,9,,,,,1,,BAO_0000357,
1866,,Autocuration,,12689,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,CHEMBL872910,D,9,,,,,1,,BAO_0000249,
1867,,Expert,,12689,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,CHEMBL616836,H,8,,,,,1,,BAO_0000357,
1868,,Autocuration,,12689,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,CHEMBL616837,D,9,,,,,1,,BAO_0000357,
1869,,Autocuration,,12689,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,CHEMBL616466,D,9,,,,,1,,BAO_0000019,
1870,,Autocuration,,12689,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,CHEMBL616467,D,9,722.0,HEK293,,,1,,BAO_0000219,
1871,,Autocuration,,108,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,CHEMBL616468,H,8,,,,,1,,BAO_0000357,
1872,,Autocuration,,108,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,CHEMBL616469,H,8,,,,,1,,BAO_0000357,
1873,,Autocuration,,108,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,CHEMBL616470,H,8,,,,,1,,BAO_0000357,
1874,,Autocuration,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,CHEMBL616471,H,8,,,,,1,,BAO_0000357,
1875,,Autocuration,,12689,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,CHEMBL616472,H,8,,,,,1,,BAO_0000357,
1876,,Autocuration,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,CHEMBL616473,H,8,,,,,1,,BAO_0000357,
1877,,Autocuration,,12689,Binding affinity against serotonergic 5-HT1c receptor,CHEMBL616474,H,8,,,,,1,,BAO_0000357,
1878,,Autocuration,,12689,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,CHEMBL616475,H,8,,,,,1,,BAO_0000357,
1879,,Autocuration,,12689,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,CHEMBL616476,H,8,,,,,1,,BAO_0000357,
1880,,Autocuration,,105,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),CHEMBL616477,H,8,,,,,1,,BAO_0000019,
1881,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,CHEMBL616478,H,4,,,,,1,,BAO_0000224,
1882,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,CHEMBL616479,H,4,,,,,1,,BAO_0000224,
1883,,Autocuration,,104686,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,CHEMBL616480,H,4,,,,,1,,BAO_0000019,
1884,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,CHEMBL616481,D,5,,,,,1,,BAO_0000019,
1885,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,CHEMBL616482,D,5,,,,,1,,BAO_0000249,
1886,955.0,Autocuration,Brain,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,CHEMBL884713,D,5,,,,,1,,BAO_0000221,
1887,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,CHEMBL616483,H,4,,,,,1,,BAO_0000224,
1888,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,CHEMBL616484,H,4,,,,,1,,BAO_0000224,
1889,,Autocuration,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,CHEMBL616485,H,4,,,,,1,,BAO_0000019,
1890,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,CHEMBL616486,H,4,,,,,1,,BAO_0000224,
1891,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,CHEMBL616487,H,4,,,,,1,,BAO_0000224,
1892,,Autocuration,,104686,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,CHEMBL616488,H,4,,,,,1,,BAO_0000224,
1893,,Autocuration,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616489,H,4,,,,,1,,BAO_0000019,
1894,,Autocuration,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616490,H,4,,,,,1,,BAO_0000019,
1895,,Autocuration,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,CHEMBL616491,H,4,,,,,1,,BAO_0000019,
1896,,Autocuration,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,CHEMBL616492,H,4,,,,,1,,BAO_0000019,
1897,,Autocuration,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616493,H,4,,,,,1,,BAO_0000019,
1898,,Autocuration,,104686,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,CHEMBL616494,H,4,,,,,1,,BAO_0000019,
1899,,Autocuration,,104686,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,CHEMBL616495,H,4,,,,,1,,BAO_0000019,
1900,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,CHEMBL616496,H,4,,,,,1,,BAO_0000019,
1901,,Autocuration,,104686,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616497,H,4,,,,,1,,BAO_0000019,
1902,,Autocuration,,104686,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616498,H,4,,,,,1,,BAO_0000019,
1903,,Autocuration,,104686,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,CHEMBL616499,H,4,,,,,1,,BAO_0000019,
1904,,Autocuration,,104686,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,CHEMBL616500,H,4,,,,,1,,BAO_0000019,
1905,955.0,Autocuration,Brain,104686,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,CHEMBL616501,D,5,,,,,1,,BAO_0000221,
1906,955.0,Autocuration,Brain,104686,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,CHEMBL616502,H,4,,,,,1,,BAO_0000221,
1907,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,CHEMBL884529,H,4,,,,Membranes,1,,BAO_0000249,
1908,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,CHEMBL616503,H,4,,,,Membranes,1,,BAO_0000249,
1909,,Autocuration,,104686,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,CHEMBL616964,H,4,,,,,1,,BAO_0000224,
1910,,Autocuration,,104686,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,CHEMBL616965,H,4,,,,Membranes,1,,BAO_0000249,
1911,,Autocuration,,104686,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,CHEMBL616966,H,4,,,,,1,,BAO_0000224,
1912,,Autocuration,,104686,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,CHEMBL616967,H,4,,,,,1,,BAO_0000224,
1913,,Autocuration,,104686,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,CHEMBL616968,D,5,,,,,1,,BAO_0000224,
1914,,Autocuration,,104686,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,CHEMBL616969,H,4,,,,,1,,BAO_0000224,
1915,,Autocuration,,104686,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,CHEMBL884530,H,4,,,,,1,,BAO_0000019,
1916,,Autocuration,,104686,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,CHEMBL616970,H,4,,,,,1,,BAO_0000224,
1917,,Autocuration,,104686,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,CHEMBL616971,H,4,,,,,1,,BAO_0000224,
1918,,Autocuration,,104686,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",CHEMBL616972,H,4,,,,,1,,BAO_0000224,
1919,,Autocuration,,104686,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,CHEMBL616973,H,4,,,,,1,,BAO_0000224,
1920,,Autocuration,,104686,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,CHEMBL616974,H,4,,,,,1,,BAO_0000224,
1921,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,CHEMBL616975,H,4,,,,,1,,BAO_0000019,
1922,,Autocuration,,104686,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,CHEMBL616976,H,4,,,,,1,,BAO_0000019,
1923,,Autocuration,,104686,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,CHEMBL616977,H,4,,,,,1,,BAO_0000224,
1924,,Autocuration,,104686,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,CHEMBL616978,H,4,,,,,1,,BAO_0000224,
1925,,Autocuration,,104686,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,CHEMBL616979,H,4,,,,,1,,BAO_0000224,
1926,,Autocuration,,104686,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,CHEMBL616980,H,4,,,,,1,,BAO_0000224,
1927,,Autocuration,,104686,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,CHEMBL616981,H,4,,,,Membranes,1,,BAO_0000249,
1928,,Autocuration,,104686,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,CHEMBL616982,H,4,,,,Membranes,1,,BAO_0000249,
1929,,Autocuration,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,CHEMBL616983,H,4,,,,,1,,BAO_0000224,
1930,,Autocuration,,104686,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,CHEMBL616984,H,4,,,,,1,,BAO_0000019,
1931,,Autocuration,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor,CHEMBL616985,D,5,,,,,1,,BAO_0000224,
1932,,Autocuration,,104686,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,CHEMBL616986,H,4,,,,,1,,BAO_0000224,
1933,,Autocuration,,104686,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,CHEMBL616987,H,4,,,,,1,,BAO_0000224,
1934,,Autocuration,,104686,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,CHEMBL616988,H,4,,,,,1,,BAO_0000019,
1935,,Autocuration,,104686,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,CHEMBL617243,H,4,,,,,1,,BAO_0000019,
1936,,Autocuration,,104686,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,CHEMBL617244,H,4,,,,,1,,BAO_0000019,
1937,,Autocuration,,104686,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHEMBL617245,D,5,485.0,CHO-K1,,,1,,BAO_0000219,
1938,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,CHEMBL617246,H,4,,,,Membranes,1,,BAO_0000249,
1939,,Autocuration,,104686,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),CHEMBL617546,H,4,,,,,1,,BAO_0000224,
1940,,Autocuration,,104686,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),CHEMBL617547,H,4,,,,Brain membranes,1,,BAO_0000249,
1941,,Autocuration,,104686,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,CHEMBL617548,H,4,,,,,1,,BAO_0000219,
1942,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617549,H,4,,,,,1,,BAO_0000224,
1943,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,CHEMBL617550,H,4,,,,,1,,BAO_0000224,
1944,,Autocuration,,104686,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,CHEMBL617551,H,4,,,,,1,,BAO_0000224,
1945,,Autocuration,,104686,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,CHEMBL617552,H,4,,,,Membranes,1,,BAO_0000249,
1946,,Autocuration,,104686,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,CHEMBL617553,H,4,,,,Membranes,1,,BAO_0000249,
1947,1515.0,Autocuration,Thoracic aorta,104686,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,CHEMBL617554,H,4,,,,,1,,BAO_0000019,
1948,,Autocuration,,104686,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,CHEMBL617555,H,4,,,,,1,,BAO_0000019,
1949,,Autocuration,,104686,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,CHEMBL617556,H,4,,,,,1,,BAO_0000224,
1950,,Autocuration,,10624,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,CHEMBL617557,H,8,,,,,1,,BAO_0000357,
1951,,Autocuration,,10624,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,CHEMBL617558,H,8,,,,,1,,BAO_0000357,
1952,,Expert,,17106,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,CHEMBL617559,H,8,,,,,1,,BAO_0000357,
1953,,Expert,,17106,Binding affinity for 5-hydroxytryptamine 1D receptor,CHEMBL617560,D,9,,,,,1,,BAO_0000357,
1954,,Autocuration,,17106,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,CHEMBL617561,H,8,,,,,1,,BAO_0000249,
1955,,Autocuration,,17106,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,CHEMBL617562,H,8,,,,,1,,BAO_0000249,
1956,2435.0,Autocuration,Striatum,17106,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,CHEMBL617563,H,8,,,,,1,,BAO_0000357,
1957,,Autocuration,,17106,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,CHEMBL617564,H,8,,,,,1,,BAO_0000019,
1958,,Expert,,17106,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,CHEMBL617565,H,8,,,,,1,,BAO_0000019,
1959,,Autocuration,,17106,Binding activity radioligand.,CHEMBL856076,H,8,,,,,1,,BAO_0000357,
1960,,Autocuration,,17106,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,CHEMBL617566,H,8,,,,,1,,BAO_0000019,
1961,,Expert,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL875911,H,8,,,,,1,,BAO_0000019,
1962,,Autocuration,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,CHEMBL617567,H,8,,,,,1,,BAO_0000019,
1963,,Autocuration,,17106,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,CHEMBL617568,H,8,,,,,1,,BAO_0000249,
1964,,Expert,,17106,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,CHEMBL617569,H,8,,,,,1,,BAO_0000019,
1965,,Expert,,17106,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,CHEMBL617570,H,8,,,,,1,,BAO_0000249,
1966,,Autocuration,,17106,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,CHEMBL617571,H,8,,,,,1,,BAO_0000357,
1967,,Autocuration,,105,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,CHEMBL617572,H,8,,,,,1,,BAO_0000357,
1968,,Expert,,105,The compound was tested for intrinsic activity against 5-HT1D receptor,CHEMBL617573,H,8,,,,,1,,BAO_0000357,
1969,,Autocuration,,105,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,CHEMBL617574,H,8,,,,,1,,BAO_0000019,
1970,,Expert,,105,The compound was tested for binding affinity against 5-HT1D receptor,CHEMBL617575,H,8,,,,,1,,BAO_0000357,
1971,,Autocuration,,10578,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,CHEMBL617576,H,8,,,,,1,,BAO_0000357,
1972,,Autocuration,,10578,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,CHEMBL617577,H,8,,,,,1,,BAO_0000019,
1973,,Autocuration,,10578,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,CHEMBL617578,H,8,,,,,1,,BAO_0000019,
1974,,Autocuration,,10578,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,CHEMBL617579,H,8,,,,,1,,BAO_0000357,
1975,,Expert,,10578,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,CHEMBL617580,H,8,,,,,1,,BAO_0000019,
1976,,Autocuration,,10578,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,CHEMBL617581,H,8,,,,,1,,BAO_0000249,
1977,,Autocuration,,10578,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,CHEMBL617582,H,8,,,,,1,,BAO_0000357,
1978,,Expert,,10578,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,CHEMBL617583,H,8,,,,,1,,BAO_0000019,
1979,,Autocuration,,105,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,CHEMBL617584,H,8,,,,,1,,BAO_0000357,
1980,,Autocuration,,105,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL617585,H,8,,,,,1,,BAO_0000357,
1981,,Autocuration,,105,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,CHEMBL875912,H,8,,,,,1,,BAO_0000357,
1982,,Autocuration,,105,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,CHEMBL617586,H,8,,,,,1,,BAO_0000357,
1983,,Autocuration,,105,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,CHEMBL617587,H,8,,,,,1,,BAO_0000357,
1984,,Autocuration,,105,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,CHEMBL617588,H,8,,,,,1,,BAO_0000357,
1985,,Autocuration,,105,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL857980,H,8,,,,,1,,BAO_0000357,
1986,,Autocuration,,105,Tested against 5-hydroxytryptamine 1D receptor,CHEMBL617589,H,8,,,,,1,,BAO_0000357,
1987,,Autocuration,,105,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,CHEMBL617590,H,8,,,,,1,,BAO_0000357,
1988,,Autocuration,,105,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,CHEMBL617591,H,8,722.0,HEK293,,,1,,BAO_0000219,
1989,,Expert,,105,Binding affinity against 5-Hydroxytryptamine 1D receptor,CHEMBL617592,D,9,,,,,1,,BAO_0000357,
1990,,Autocuration,,105,,CHEMBL617593,H,8,,,,,1,,BAO_0000357,
1991,,Autocuration,,106,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHEMBL617594,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1992,,Autocuration,,105,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHEMBL617595,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
1993,,Autocuration,,105,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,CHEMBL617596,H,8,722.0,HEK293,,,1,,BAO_0000219,
1994,,Autocuration,,105,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,CHEMBL617597,H,8,722.0,HEK293,,,1,,BAO_0000219,
1995,,Autocuration,,105,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,CHEMBL617598,H,8,,,,,1,,BAO_0000019,
1996,,Autocuration,,105,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,CHEMBL872916,H,8,,,,,1,,BAO_0000357,
1997,,Expert,,105,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,CHEMBL617599,H,8,,,,,1,,BAO_0000357,
1998,,Autocuration,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,CHEMBL617091,H,8,,,,,1,,BAO_0000357,
1999,,Expert,,105,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",CHEMBL617092,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2000,,Autocuration,,105,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHEMBL617093,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2001,,Autocuration,,105,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,CHEMBL617094,H,8,,,,,1,,BAO_0000019,
2002,,Autocuration,,105,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,CHEMBL617095,H,8,,,,,1,,BAO_0000019,
2003,,Autocuration,,105,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,CHEMBL617096,H,8,,,,,1,,BAO_0000019,
2004,,Autocuration,,105,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,CHEMBL617097,H,8,,,,,1,,BAO_0000019,
2005,,Autocuration,,105,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,CHEMBL617098,H,8,,,,,1,,BAO_0000019,
2006,,Autocuration,,105,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,CHEMBL617301,H,8,,,,,1,,BAO_0000357,
2007,,Autocuration,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,CHEMBL617302,H,8,,,,,1,,BAO_0000357,
2008,,Autocuration,,105,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,CHEMBL617303,H,8,,,,,1,,BAO_0000357,
2009,,Expert,,105,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,CHEMBL617304,H,8,,,,,1,,BAO_0000357,
2010,,Expert,,105,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",CHEMBL617305,H,8,449.0,CHO,,,1,,BAO_0000219,
2011,,Autocuration,,105,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,CHEMBL617306,D,9,,,,,1,,BAO_0000219,
2012,,Autocuration,,17106,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,CHEMBL617307,H,8,,,,,1,,BAO_0000357,
2013,,Autocuration,,105,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,CHEMBL617308,H,8,,,,,1,,BAO_0000019,
2014,,Autocuration,,105,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,CHEMBL617309,H,8,,,,,1,,BAO_0000357,
2015,,Autocuration,,105,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,CHEMBL617310,H,8,,,,,1,,BAO_0000357,
2016,,Autocuration,,105,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,CHEMBL617311,H,8,,,,,1,,BAO_0000357,
2017,,Autocuration,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,CHEMBL617312,H,8,,,,,1,,BAO_0000357,
2018,,Autocuration,,105,Affinity against 5-hydroxytryptamine 1D receptor alpha,CHEMBL617313,H,8,,,,,1,,BAO_0000357,
2019,,Expert,,105,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,CHEMBL617314,H,8,,,,,1,,BAO_0000357,
2020,,Autocuration,,106,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,CHEMBL617315,H,8,,,,,1,,BAO_0000019,
2021,,Autocuration,,106,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,CHEMBL617316,H,8,722.0,HEK293,,,1,,BAO_0000219,
2022,,Autocuration,,106,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,CHEMBL617317,H,8,722.0,HEK293,,,1,,BAO_0000219,
2023,,Autocuration,,106,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",CHEMBL617318,H,8,449.0,CHO,,,1,,BAO_0000219,
2024,,Autocuration,,106,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,CHEMBL617319,H,8,,,,,1,,BAO_0000019,
2025,,Expert,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,CHEMBL617320,D,9,,,,,1,,BAO_0000357,
2026,,Expert,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,CHEMBL617321,D,9,,,,,1,,BAO_0000357,
2027,,Expert,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,CHEMBL617322,D,9,,,,,1,,BAO_0000357,
2028,,Autocuration,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,CHEMBL616862,H,8,,,,,1,,BAO_0000357,
2029,,Autocuration,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL616863,H,8,,,,,1,,BAO_0000357,
2030,,Autocuration,,106,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,CHEMBL616864,H,8,449.0,CHO,,,1,,BAO_0000219,
2031,,Autocuration,,106,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,CHEMBL616865,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2032,,Autocuration,,106,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,CHEMBL616866,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2033,,Autocuration,,106,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,CHEMBL616867,H,8,,,,,1,,BAO_0000019,
2034,,Expert,,106,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",CHEMBL616868,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2035,,Expert,,105,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,CHEMBL616869,H,8,,,,,1,,BAO_0000357,
2036,,Expert,,106,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",CHEMBL616870,H,8,449.0,CHO,,,1,,BAO_0000219,
2037,,Autocuration,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,CHEMBL616871,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2038,,Autocuration,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,CHEMBL616872,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2039,,Autocuration,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,CHEMBL616873,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2040,,Autocuration,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,CHEMBL616838,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2041,,Autocuration,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,CHEMBL616839,H,8,,,,,1,,BAO_0000357,
2042,,Autocuration,,106,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,CHEMBL616840,H,8,,,,,1,,BAO_0000019,
2043,,Autocuration,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,CHEMBL616841,H,8,,,,,1,,BAO_0000357,
2044,,Autocuration,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,CHEMBL616842,H,8,,,,,1,,BAO_0000357,
2045,,Expert,,105,Binding affinity against 5-hydroxytryptamine 1D receptor beta,CHEMBL857976,H,8,,,,,1,,BAO_0000357,
2046,,Autocuration,,10618,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,CHEMBL616843,H,8,449.0,CHO,,,1,,BAO_0000219,
2047,,Expert,,10618,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,CHEMBL616844,D,9,,,,,1,,BAO_0000357,
2048,,Autocuration,,10618,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,CHEMBL616845,H,8,,,,,1,,BAO_0000357,
2049,,Expert,,10618,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,CHEMBL616846,D,9,,,,,1,,BAO_0000357,
2050,,Autocuration,,10618,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,CHEMBL616847,H,8,,,,,1,,BAO_0000357,
2051,,Autocuration,,10618,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,CHEMBL616848,H,8,,,,,1,,BAO_0000019,
2052,,Autocuration,,10618,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,CHEMBL616849,H,8,,,,,1,,BAO_0000357,
2053,,Autocuration,,10618,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,CHEMBL872911,H,8,,,,,1,,BAO_0000357,
2054,,Autocuration,,10618,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,CHEMBL616850,H,8,,,,,1,,BAO_0000019,
2055,,Expert,,10618,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,CHEMBL616699,D,9,449.0,CHO,,,1,,BAO_0000219,
2056,,Autocuration,,10618,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,CHEMBL616700,H,8,,,,,1,,BAO_0000357,
2057,,Autocuration,,10618,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL616701,H,8,449.0,CHO,,,1,,BAO_0000219,
2058,,Autocuration,,10618,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,CHEMBL616702,H,8,449.0,CHO,,,1,,BAO_0000219,
2059,,Autocuration,,10618,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,CHEMBL616703,H,8,449.0,CHO,,,1,,BAO_0000219,
2060,,Autocuration,,10618,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,CHEMBL616704,H,8,,,,,1,,BAO_0000357,
2061,,Autocuration,,10618,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,CHEMBL616705,H,8,449.0,CHO,,,1,,BAO_0000219,
2062,,Autocuration,,10618,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,CHEMBL616706,H,8,,,,,1,,BAO_0000357,
2063,,Autocuration,,10618,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,CHEMBL616707,H,8,449.0,CHO,,,1,,BAO_0000219,
2064,,Autocuration,,10618,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,CHEMBL616708,H,8,,,,,1,,BAO_0000357,
2065,,Autocuration,,10618,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,CHEMBL616709,H,8,,,,,1,,BAO_0000357,
2066,,Autocuration,,10618,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,CHEMBL616710,H,8,449.0,CHO,,,1,,BAO_0000219,
2067,,Autocuration,,10618,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,CHEMBL616711,H,8,449.0,CHO,,,1,,BAO_0000219,
2068,,Autocuration,,10618,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL616712,H,8,449.0,CHO,,,1,,BAO_0000219,
2069,,Autocuration,,10618,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,CHEMBL616713,H,8,,,,,1,,BAO_0000357,
2070,,Autocuration,,10618,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,CHEMBL616714,H,8,,,,,1,,BAO_0000357,
2071,,Autocuration,,10618,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,CHEMBL616715,H,8,,,,,1,,BAO_0000357,
2072,,Autocuration,,10618,Binding affinity towards 5-hydroxytryptamine 1E receptor,CHEMBL616716,H,8,,,,,1,,BAO_0000357,
2073,,Autocuration,,279,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",CHEMBL616717,H,8,,,,,1,,BAO_0000019,
2074,,Expert,,279,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",CHEMBL616718,H,8,,,,,1,,BAO_0000019,
2075,,Autocuration,,279,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,CHEMBL875905,H,8,,,,,1,,BAO_0000019,
2076,,Autocuration,,279,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,CHEMBL616719,H,8,,,,,1,,BAO_0000019,
2077,,Expert,,279,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",CHEMBL616720,H,8,,,,,1,,BAO_0000019,
2078,,Autocuration,,279,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,CHEMBL616721,H,8,,,,,1,,BAO_0000357,
2079,,Autocuration,,279,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,CHEMBL616722,H,8,449.0,CHO,,,1,,BAO_0000219,
2080,,Autocuration,,279,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),CHEMBL616723,H,8,,,,,1,,BAO_0000357,
2081,,Autocuration,,279,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,CHEMBL616724,H,8,449.0,CHO,,,1,,BAO_0000219,
2082,,Autocuration,,279,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,CHEMBL616725,H,8,,,,,1,,BAO_0000357,
2083,,Autocuration,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor,CHEMBL616726,H,8,,,,,1,,BAO_0000357,
2084,,Autocuration,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,CHEMBL616727,H,8,,,,,1,,BAO_0000357,
2085,,Autocuration,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,CHEMBL616728,H,8,,,,,1,,BAO_0000357,
2086,,Autocuration,,279,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,CHEMBL616729,H,8,,,,,1,,BAO_0000357,
2087,,Expert,,279,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,CHEMBL616730,H,8,,,,,1,,BAO_0000019,
2088,,Autocuration,,279,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,CHEMBL617125,H,8,,,,,1,,BAO_0000357,
2089,,Autocuration,,279,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,CHEMBL857977,H,8,,,,,1,,BAO_0000357,
2090,,Autocuration,,279,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL617126,H,8,449.0,CHO,,,1,,BAO_0000219,
2091,,Autocuration,,279,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,CHEMBL617127,H,8,449.0,CHO,,,1,,BAO_0000219,
2092,,Autocuration,,279,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,CHEMBL617128,H,8,,,,,1,,BAO_0000357,
2093,,Autocuration,,279,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,CHEMBL617129,H,8,449.0,CHO,,,1,,BAO_0000219,
2094,,Autocuration,,279,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,CHEMBL617130,H,8,,,,,1,,BAO_0000357,
2095,,Autocuration,,279,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,CHEMBL617131,H,8,449.0,CHO,,,1,,BAO_0000219,
2096,,Autocuration,,279,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL617132,H,8,449.0,CHO,,,1,,BAO_0000219,
2097,,Autocuration,,279,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL617133,H,8,449.0,CHO,,,1,,BAO_0000219,
2098,,Autocuration,,279,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,CHEMBL617134,H,8,,,,,1,,BAO_0000357,
2099,,Autocuration,,279,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,CHEMBL617135,H,8,,,,,1,,BAO_0000357,
2100,,Autocuration,,279,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,CHEMBL617136,H,8,,,,,1,,BAO_0000357,
2101,,Autocuration,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",CHEMBL617137,H,4,,,,,1,,BAO_0000019,
2102,,Autocuration,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",CHEMBL617138,H,4,,,,,1,,BAO_0000019,
2103,,Autocuration,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",CHEMBL617139,H,4,,,,,1,,BAO_0000019,
2104,,Autocuration,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,CHEMBL617140,H,8,,,,,1,,BAO_0000019,
2105,,Autocuration,,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",CHEMBL617141,H,4,,,,,1,,BAO_0000218,
2106,,Autocuration,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL858112,H,4,,,,,1,,BAO_0000019,
2107,,Intermediate,,17005,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,CHEMBL617142,H,8,,,,,1,,BAO_0000019,
2108,,Autocuration,,22226,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",CHEMBL617143,U,0,,,,,1,,BAO_0000019,
2109,,Autocuration,,22226,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,CHEMBL617144,U,0,,,,,1,,BAO_0000019,
2110,,Autocuration,,22226,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,CHEMBL617145,U,0,,,,,1,,BAO_0000019,
2111,,Autocuration,,22226,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,CHEMBL617146,U,0,,,,,1,,BAO_0000019,
2112,,Autocuration,,104784,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,CHEMBL617147,H,4,,,,,1,,BAO_0000019,
2113,,Autocuration,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,CHEMBL617148,H,4,,,,,1,,BAO_0000019,
2114,,Autocuration,,104784,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,CHEMBL617149,H,4,,,,,1,,BAO_0000019,
2115,,Autocuration,,104784,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,CHEMBL617150,H,4,,,,,1,,BAO_0000224,
2116,,Autocuration,,104784,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,CHEMBL617151,H,4,,,,,1,,BAO_0000224,
2117,,Autocuration,,104784,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,CHEMBL617201,H,4,,,,,1,,BAO_0000224,
2118,,Autocuration,,10209,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,CHEMBL617202,H,8,,,,,1,,BAO_0000357,
2119,,Autocuration,,104826,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,CHEMBL617203,H,4,,,,,1,,BAO_0000218,
2120,,Autocuration,,104826,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,CHEMBL617204,H,4,,,,,1,,BAO_0000019,
2121,,Autocuration,,104826,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,CHEMBL617205,H,4,,,,,1,,BAO_0000224,
2122,,Autocuration,,104826,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,CHEMBL617206,D,5,,,,,1,,BAO_0000019,
2123,,Autocuration,,104826,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,CHEMBL617207,H,4,,,,,1,,BAO_0000218,
2124,,Autocuration,,104826,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,CHEMBL617208,D,5,,,,,1,,BAO_0000019,
2125,,Autocuration,,104826,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617209,H,4,,,,,1,,BAO_0000224,
2126,,Autocuration,,104826,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,CHEMBL617210,H,4,,,,,1,,BAO_0000224,
2127,,Autocuration,,104826,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,CHEMBL617211,H,4,,,,,1,,BAO_0000224,
2128,,Autocuration,,104826,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,CHEMBL617212,D,5,,,,,1,,BAO_0000019,
2129,,Autocuration,,104784,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,CHEMBL617213,H,4,,,,,1,,BAO_0000224,
2130,,Autocuration,,104784,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,CHEMBL617214,H,4,,,,,1,,BAO_0000224,
2131,,Autocuration,,22226,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,CHEMBL617215,U,0,,,,,1,,BAO_0000221,
2132,,Autocuration,,22226,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,CHEMBL617216,U,0,,,,,1,,BAO_0000221,
2133,,Autocuration,,17005,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,CHEMBL617217,H,8,,,,,1,,BAO_0000357,
2134,,Autocuration,,104686,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,CHEMBL617218,H,4,,,,,1,,BAO_0000019,
2135,,Autocuration,,104686,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,CHEMBL872913,H,4,,,,,1,,BAO_0000019,
2136,,Autocuration,,104826,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,CHEMBL617219,H,4,,,,,1,,BAO_0000019,
2137,,Autocuration,,104686,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,CHEMBL873482,H,4,,,,,1,,BAO_0000224,
2138,,Autocuration,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,CHEMBL617220,D,5,,,,,1,,BAO_0000019,
2139,,Autocuration,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,CHEMBL617221,H,4,,,,,1,,BAO_0000019,
2140,,Autocuration,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,CHEMBL617222,H,4,,,,,1,,BAO_0000019,
2141,,Autocuration,,104686,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,CHEMBL875906,H,4,,,,,1,,BAO_0000019,
2142,,Autocuration,,104686,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,CHEMBL617223,H,4,,,,,1,,BAO_0000019,
2143,,Autocuration,,104686,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,CHEMBL617224,H,4,,,,,1,,BAO_0000224,
2144,,Autocuration,,104686,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,CHEMBL617225,D,5,,,,,1,,BAO_0000224,
2145,,Autocuration,,104686,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,CHEMBL617226,H,4,,,,,1,,BAO_0000224,
2146,,Autocuration,,104686,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,CHEMBL617227,H,4,,,,,1,,BAO_0000224,
2147,,Autocuration,,104686,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,CHEMBL617228,H,4,,,,,1,,BAO_0000224,
2148,,Autocuration,,104686,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,CHEMBL617229,H,4,,,,,1,,BAO_0000224,
2149,,Autocuration,,104686,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,CHEMBL617230,H,4,,,,,1,,BAO_0000224,
2150,,Autocuration,,104686,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",CHEMBL617231,H,4,,,,,1,,BAO_0000224,
2151,,Autocuration,,104686,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,CHEMBL617232,H,4,,,,,1,,BAO_0000224,
2152,,Autocuration,,104686,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,CHEMBL617233,H,4,,,,,1,,BAO_0000224,
2153,,Autocuration,,104686,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,CHEMBL617234,H,4,,,,,1,,BAO_0000224,
2154,,Autocuration,,104686,Compound was tested for the inhibition of quipazine induced head twitches in rats,CHEMBL617235,H,4,,,,,1,,BAO_0000019,
2155,,Autocuration,,104686,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,CHEMBL617236,H,4,,,,,1,,BAO_0000019,
2156,10000000.0,Autocuration,Hippocampus,104686,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,CHEMBL617237,H,4,,,,,1,,BAO_0000221,
2157,10000000.0,Autocuration,Hippocampus,104686,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,CHEMBL617238,H,4,,,,,1,,BAO_0000221,
2158,955.0,Autocuration,Brain,104686,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,CHEMBL617239,D,5,,,,,1,,BAO_0000221,
2159,,Autocuration,,104686,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,CHEMBL617240,H,4,,,,,1,,BAO_0000019,
2160,,Autocuration,,104686,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,CHEMBL617241,H,4,,,,Membranes,1,,BAO_0000249,
2161,,Autocuration,,104686,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,CHEMBL875907,H,4,,,,Membranes,1,,BAO_0000249,
2162,,Autocuration,,104686,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,CHEMBL617242,H,4,,,,,1,,BAO_0000019,
2163,,Autocuration,,104686,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,CHEMBL617152,H,4,,,,,1,,BAO_0000019,
2164,955.0,Autocuration,Brain,104686,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,CHEMBL617153,D,5,,,,,1,,BAO_0000221,
2165,,Autocuration,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,CHEMBL617154,D,5,,,,Membranes,1,,BAO_0000249,
2166,955.0,Autocuration,Brain,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,CHEMBL617155,H,4,,,,,1,,BAO_0000221,
2167,,Autocuration,,104686,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,CHEMBL617156,H,4,,,,,1,,BAO_0000019,
2168,,Autocuration,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,CHEMBL617157,H,4,,,,,1,,BAO_0000019,
2169,,Autocuration,,104686,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL617158,H,4,,,,,1,,BAO_0000019,
2170,,Autocuration,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,CHEMBL617159,H,4,,,,,1,,BAO_0000019,
2171,,Autocuration,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,CHEMBL617160,H,4,,,,,1,,BAO_0000019,
2172,,Autocuration,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL858113,H,4,,,,,1,,BAO_0000019,
2173,955.0,Autocuration,Brain,104686,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,CHEMBL617247,H,4,,,,,1,,BAO_0000220,
2174,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,CHEMBL617248,H,4,,,,,1,,BAO_0000019,
2175,955.0,Autocuration,Brain,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL617249,H,4,,,,,1,,BAO_0000249,
2176,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,CHEMBL617250,H,4,,,,,1,,BAO_0000019,
2177,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,CHEMBL617251,H,4,,,,,1,,BAO_0000019,
2178,,Autocuration,,104686,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,CHEMBL617252,D,5,,,,,1,,BAO_0000019,
2179,,Autocuration,,104686,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,CHEMBL617006,H,4,,,,,1,,BAO_0000019,
2180,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,CHEMBL617007,H,4,,,,,1,,BAO_0000019,
2181,,Autocuration,,104686,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",CHEMBL617008,H,4,,,,,1,,BAO_0000019,
2182,,Autocuration,,104686,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,CHEMBL617009,H,4,,,,,1,,BAO_0000019,
2183,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,CHEMBL617010,D,5,,,,,1,,BAO_0000224,
2184,,Autocuration,,104686,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,CHEMBL857978,D,5,,,,,1,,BAO_0000019,
2185,,Autocuration,,104686,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,CHEMBL617011,D,5,,,,,1,,BAO_0000019,
2186,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,CHEMBL617012,D,5,,,,,1,,BAO_0000019,
2187,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,CHEMBL617013,H,4,,,,,1,,BAO_0000224,
2188,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,CHEMBL617014,H,4,,,,,1,,BAO_0000249,
2189,,Autocuration,,104686,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,CHEMBL617015,H,4,,,,,1,,BAO_0000019,
2190,,Autocuration,,104686,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,CHEMBL617016,H,4,,,,,1,,BAO_0000019,
2191,,Autocuration,,104686,pKi value for 5-hydroxytryptamine 2 receptor binding site,CHEMBL617017,H,4,,,,,1,,BAO_0000224,
2192,955.0,Autocuration,Brain,104686,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,CHEMBL617018,H,4,,,,,1,,BAO_0000221,
2193,,Autocuration,,104686,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,CHEMBL617019,H,4,,,,,1,,BAO_0000019,
2194,,Autocuration,,105075,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617020,H,4,,,,,1,,BAO_0000019,
2195,,Autocuration,,105075,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617021,H,4,,,,,1,,BAO_0000019,
2196,,Autocuration,,105075,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617022,H,4,,,,,1,,BAO_0000019,
2197,,Autocuration,,105075,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617023,H,4,,,,,1,,BAO_0000019,
2198,,Autocuration,,105075,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617024,H,4,,,,,1,,BAO_0000019,
2199,,Autocuration,,105075,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617025,H,4,,,,,1,,BAO_0000019,
2200,,Autocuration,,105075,Hill coefficient of compound was determined,CHEMBL617026,H,4,,,,,1,,BAO_0000224,
2201,,Autocuration,,22226,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,CHEMBL617027,U,0,,,,,1,,BAO_0000019,
2202,,Autocuration,,104686,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,CHEMBL617028,D,5,,,,,1,,BAO_0000019,
2203,,Expert,,12687,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,CHEMBL617029,H,8,,,,,1,,BAO_0000019,
2204,,Expert,,12687,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,CHEMBL875908,H,8,,,,,1,,BAO_0000019,
2205,,Autocuration,,12687,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),CHEMBL617030,H,8,,,,,1,,BAO_0000357,
2206,,Autocuration,,12687,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),CHEMBL617031,H,8,,,,,1,,BAO_0000019,
2207,,Autocuration,,12687,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,CHEMBL617032,H,8,,,,,1,,BAO_0000019,
2208,,Autocuration,,104686,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,CHEMBL617033,D,5,,,,,1,,BAO_0000224,
2209,,Autocuration,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",CHEMBL617034,H,4,,,,,1,,BAO_0000224,
2210,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,CHEMBL617035,H,4,,,,,1,,BAO_0000224,
2211,,Autocuration,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",CHEMBL617036,H,4,,,,,1,,BAO_0000019,
2212,,Autocuration,,104784,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,CHEMBL617037,H,4,,,,,1,,BAO_0000224,
2213,,Autocuration,,22226,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,CHEMBL617038,U,0,,,,,1,,BAO_0000219,
2214,,Autocuration,,104784,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",CHEMBL617039,H,4,,,,,1,,BAO_0000219,
2215,,Autocuration,,104784,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,CHEMBL617161,H,4,,,,,1,,BAO_0000224,
2216,,Autocuration,,104784,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,CHEMBL617162,H,4,,,,,1,,BAO_0000224,
2217,,Autocuration,,104784,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617163,H,4,,,,,1,,BAO_0000224,
2218,,Autocuration,,104784,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617164,H,4,,,,,1,,BAO_0000224,
2219,,Autocuration,,104784,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,CHEMBL617165,H,4,,,,Brain membranes,1,,BAO_0000249,
2220,,Autocuration,,104784,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,CHEMBL617166,H,4,,,,,1,,BAO_0000224,
2221,,Autocuration,,104784,Binding affinity towards 5-HT2 receptor,CHEMBL617167,H,4,,,,,1,,BAO_0000224,
2222,,Autocuration,,104784,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL872912,H,4,,,,,1,,BAO_0000224,
2223,,Autocuration,,104784,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,CHEMBL617168,H,4,,,,,1,,BAO_0000224,
2224,,Autocuration,,104686,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,CHEMBL617169,H,4,,,,,1,,BAO_0000224,
2225,,Autocuration,,104784,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617170,H,4,,,,,1,,BAO_0000224,
2226,,Autocuration,,104784,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,CHEMBL617171,H,4,,,,,1,,BAO_0000224,
2227,,Autocuration,,104784,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,CHEMBL617172,H,4,,,,,1,,BAO_0000224,
2228,,Autocuration,,104784,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617173,H,4,,,,,1,,BAO_0000224,
2229,,Autocuration,,22226,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617174,U,0,,,,,1,,BAO_0000019,
2230,,Autocuration,,104784,5-hydroxytryptamine 2 receptor binding affinity,CHEMBL617175,H,4,,,,,1,,BAO_0000224,
2231,,Autocuration,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,CHEMBL617176,H,8,,,,,1,,BAO_0000357,
2232,,Autocuration,,17005,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,CHEMBL617177,H,8,,,,,1,,BAO_0000357,
2233,,Autocuration,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,CHEMBL617178,H,4,,,,,1,,BAO_0000224,
2234,,Autocuration,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,CHEMBL617179,H,4,,,,,1,,BAO_0000224,
2235,,Autocuration,,104784,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,CHEMBL617180,H,4,,,,,1,,BAO_0000224,
2236,,Autocuration,,17005,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,CHEMBL617181,H,8,,,,,1,,BAO_0000357,
2237,,Autocuration,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor,CHEMBL617182,H,8,,,,,1,,BAO_0000357,
2238,,Autocuration,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor,CHEMBL617183,H,8,,,,,1,,BAO_0000357,
2239,,Autocuration,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,CHEMBL617184,H,8,,,,,1,,BAO_0000357,
2240,,Autocuration,,17005,Binding affinity against serotonergic 5-HT2 receptor,CHEMBL617185,H,8,,,,,1,,BAO_0000357,
2241,,Autocuration,,17005,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,CHEMBL617186,H,8,,,,,1,,BAO_0000357,
2242,,Autocuration,,17005,Compound was evaluated for the binding affinity at 5- HT2 receptor,CHEMBL617187,H,8,,,,,1,,BAO_0000357,
2243,,Autocuration,,17005,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,CHEMBL617188,H,8,,,,,1,,BAO_0000357,
2244,,Autocuration,,17005,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,CHEMBL617189,H,8,,,,,1,,BAO_0000218,
2245,,Autocuration,,104784,Inhibitory activity against cloned human 5-HT2 receptor,CHEMBL617190,D,5,,,,,1,,BAO_0000224,
2246,,Autocuration,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",CHEMBL617191,D,5,449.0,CHO,,,1,,BAO_0000219,
2247,,Autocuration,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",CHEMBL617192,D,5,449.0,CHO,,,1,,BAO_0000219,
2248,,Autocuration,,104784,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",CHEMBL617193,D,5,449.0,CHO,,,1,,BAO_0000219,
2249,,Autocuration,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",CHEMBL617194,D,5,449.0,CHO,,,1,,BAO_0000219,
2250,,Autocuration,,104784,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617195,H,4,,,,,1,,BAO_0000224,
2251,,Autocuration,,104784,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,CHEMBL881830,H,4,,,,,1,,BAO_0000224,
2252,,Autocuration,,17005,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617196,H,8,,,,,1,,BAO_0000357,
2253,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,CHEMBL617197,H,4,,,,,1,,BAO_0000224,
2254,,Expert,,17005,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,CHEMBL617198,H,8,,,,,1,,BAO_0000357,
2255,,Expert,,17005,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL873476,H,8,,,,,1,,BAO_0000357,
2256,,Expert,,17005,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,CHEMBL617199,H,8,,,,,1,,BAO_0000019,
2257,,Autocuration,,107,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,CHEMBL617200,H,8,,,,,1,,BAO_0000357,
2258,,Autocuration,,51,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617484,H,8,,,,,1,,BAO_0000357,
2259,,Autocuration,,107,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617485,H,8,,,,,1,,BAO_0000357,
2260,,Autocuration,,51,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617486,H,8,,,,,1,,BAO_0000357,
2261,,Autocuration,,107,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,CHEMBL858022,H,8,,,,,1,,BAO_0000357,
2262,,Autocuration,,107,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,CHEMBL617049,H,8,449.0,CHO,,,1,,BAO_0000219,
2263,,Expert,,107,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,CHEMBL617050,D,9,449.0,CHO,,,1,,BAO_0000219,
2264,,Autocuration,,107,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,CHEMBL617051,H,8,,,,,1,,BAO_0000219,
2265,,Autocuration,,107,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,CHEMBL617052,H,8,,,,,1,,BAO_0000219,
2266,,Autocuration,,107,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,CHEMBL617053,H,8,,,,,1,,BAO_0000219,
2267,,Autocuration,,107,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",CHEMBL617054,H,8,449.0,CHO,,,1,,BAO_0000219,
2268,,Autocuration,,107,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",CHEMBL617055,H,8,449.0,CHO,,,1,,BAO_0000219,
2269,,Autocuration,,107,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,CHEMBL882924,H,8,,,,,1,,BAO_0000357,
2270,,Expert,,107,Inhibition of human 5-hydroxytryptamine 2A receptor,CHEMBL617056,D,9,,,,,1,,BAO_0000357,
2271,,Autocuration,,107,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL617057,H,8,449.0,CHO,,,1,,BAO_0000219,
2272,,Expert,,107,Inhibitory concentration against human 5-HT2A receptor in BEK cells,CHEMBL617058,H,8,,,,,1,,BAO_0000219,
2273,,Autocuration,,107,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),CHEMBL617059,H,8,,,,,1,,BAO_0000357,
2274,,Autocuration,,107,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,CHEMBL617060,H,8,449.0,CHO,,,1,,BAO_0000219,
2275,,Expert,,107,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,CHEMBL617061,H,8,449.0,CHO,,,1,,BAO_0000219,
2276,,Expert,,107,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,CHEMBL617062,H,8,307.0,L929,,,1,,BAO_0000219,
2277,,Expert,,107,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL617063,H,8,449.0,CHO,,,1,,BAO_0000219,
2278,,Autocuration,,107,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,CHEMBL617064,H,8,,,,,1,,BAO_0000019,
2279,,Autocuration,,107,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL617065,H,8,,,,,1,,BAO_0000019,
2280,,Autocuration,,107,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,CHEMBL617066,H,8,449.0,CHO,,,1,,BAO_0000219,
2281,,Autocuration,,107,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,CHEMBL617067,H,8,449.0,CHO,,,1,,BAO_0000219,
2282,,Autocuration,,107,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,CHEMBL617068,H,8,,,,,1,,BAO_0000019,
2283,,Autocuration,,107,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,CHEMBL617069,H,8,,,,,1,,BAO_0000019,
2284,,Autocuration,,107,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL617070,H,8,,,,,1,,BAO_0000019,
2285,,Autocuration,,107,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,CHEMBL617071,H,8,,,,,1,,BAO_0000357,
2286,,Autocuration,,107,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL872915,H,8,,,,,1,,BAO_0000357,
2287,,Autocuration,,107,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,CHEMBL617072,H,8,,,,,1,,BAO_0000357,
2288,,Autocuration,,107,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,CHEMBL617073,H,8,,,,,1,,BAO_0000357,
2289,,Autocuration,,107,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,CHEMBL617074,H,8,,,,,1,,BAO_0000357,
2290,,Expert,,107,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL617075,H,8,449.0,CHO,,,1,,BAO_0000219,
2291,,Autocuration,,107,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,CHEMBL617076,H,8,,,,,1,,BAO_0000357,
2292,,Expert,,107,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,CHEMBL617077,D,9,,,,,1,,BAO_0000019,
2293,,Expert,,107,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,CHEMBL617078,H,8,,,,,1,,BAO_0000357,
2294,,Expert,,107,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,CHEMBL617079,D,9,,,,,1,,BAO_0000357,
2295,,Autocuration,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,CHEMBL617080,H,8,,,,,1,,BAO_0000357,
2296,,Expert,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,CHEMBL617081,H,8,449.0,CHO,,,1,,BAO_0000219,
2297,,Expert,,107,Binding affinity towards human 5-HT2A receptor in BEK cells,CHEMBL617082,H,8,,,,,1,,BAO_0000219,
2298,,Autocuration,,107,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617083,H,8,,,,,1,,BAO_0000357,
2299,,Autocuration,,107,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,CHEMBL617084,H,8,,,,,1,,BAO_0000357,
2300,,Expert,,107,Binding affinity for human 5-hydroxytryptamine 2A receptor,CHEMBL617085,D,9,,,,,1,,BAO_0000357,
2301,,Autocuration,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL617086,H,8,,,,,1,,BAO_0000357,
2302,,Autocuration,,107,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,CHEMBL617087,H,8,,,,,1,,BAO_0000219,
2303,,Autocuration,,107,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,CHEMBL617088,H,8,,,,,1,,BAO_0000357,
2304,,Autocuration,,107,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,CHEMBL617089,H,8,,,,,1,,BAO_0000357,
2305,,Expert,,107,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",CHEMBL617090,H,8,,,,,1,,BAO_0000019,
2306,,Autocuration,,107,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,CHEMBL617513,H,8,,,,,1,,BAO_0000357,
2307,,Autocuration,,107,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,CHEMBL617514,H,8,722.0,HEK293,,,1,,BAO_0000219,
2308,,Autocuration,,107,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,CHEMBL617515,H,8,,,,,1,,BAO_0000019,
2309,,Autocuration,,107,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617516,H,8,,,,,1,,BAO_0000357,
2310,,Expert,,107,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617517,D,9,,,,,1,,BAO_0000357,
2311,,Expert,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,CHEMBL617518,D,9,449.0,CHO,,,1,,BAO_0000219,
2312,,Autocuration,,107,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617519,H,8,,,,,1,,BAO_0000357,
2313,,Expert,,107,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,CHEMBL617520,D,9,,,,,1,,BAO_0000357,
2314,,Autocuration,,107,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,CHEMBL617521,H,8,,,,,1,,BAO_0000357,
2315,,Expert,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,CHEMBL617522,D,9,,,,,1,,BAO_0000357,
2316,,Autocuration,,107,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,CHEMBL617523,H,8,,,,,1,,BAO_0000357,
2317,,Autocuration,,107,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL617524,H,8,,,,,1,,BAO_0000357,
2318,,Autocuration,,104686,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,CHEMBL617525,H,4,,,,,1,,BAO_0000019,
2319,,Autocuration,,104686,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,CHEMBL617526,D,5,,,,,1,,BAO_0000019,
2320,,Autocuration,,104686,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,CHEMBL617527,H,4,,,,,1,,BAO_0000224,
2321,,Autocuration,,104686,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,CHEMBL617528,H,4,,,,,1,,BAO_0000019,
2322,,Autocuration,,104686,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,CHEMBL617529,H,4,,,,,1,,BAO_0000019,
2323,,Autocuration,,104686,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,CHEMBL617530,H,4,,,,,1,,BAO_0000224,
2324,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,CHEMBL617531,H,4,,,,,1,,BAO_0000019,
2325,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,CHEMBL617532,H,4,,,,,1,,BAO_0000019,
2326,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,CHEMBL617533,H,4,,,,,1,,BAO_0000019,
2327,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,CHEMBL617534,H,4,,,,,1,,BAO_0000019,
2328,,Autocuration,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,CHEMBL617535,H,4,,,,,1,,BAO_0000224,
2329,,Autocuration,,104686,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,CHEMBL617536,H,4,,,,,1,,BAO_0000224,
2330,,Autocuration,,104686,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,CHEMBL617537,H,4,,,,,1,,BAO_0000224,
2331,,Autocuration,,104686,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,CHEMBL617538,H,4,,,,,1,,BAO_0000224,
2332,,Autocuration,,104686,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,CHEMBL617539,H,4,,,,,1,,BAO_0000219,
2333,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL617540,D,5,,,,,1,,BAO_0000224,
2334,,Autocuration,,104686,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,CHEMBL617541,D,5,,,,,1,,BAO_0000224,
2335,,Autocuration,,104686,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,CHEMBL617542,H,4,,,,,1,,BAO_0000224,
2336,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,CHEMBL617543,H,4,,,,,1,,BAO_0000224,
2337,,Autocuration,,104686,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHEMBL617544,D,5,485.0,CHO-K1,,,1,,BAO_0000219,
2338,,Autocuration,,104686,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHEMBL617545,D,5,485.0,CHO-K1,,,1,,BAO_0000219,
2339,,Autocuration,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,CHEMBL617413,D,5,,,,,1,,BAO_0000019,
2340,,Autocuration,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,CHEMBL617414,H,4,,,,,1,,BAO_0000019,
2341,,Autocuration,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,CHEMBL617415,D,5,,,,,1,,BAO_0000019,
2342,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617416,H,4,,,,,1,,BAO_0000224,
2343,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,CHEMBL617417,H,4,,,,,1,,BAO_0000224,
2344,,Autocuration,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",CHEMBL617418,H,4,,,,,1,,BAO_0000019,
2345,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,CHEMBL617419,H,4,,,,,1,,BAO_0000019,
2346,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,CHEMBL617420,H,4,,,,,1,,BAO_0000224,
2347,,Autocuration,,104686,Affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617421,D,5,,,,,1,,BAO_0000224,
2348,,Autocuration,,104686,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,CHEMBL617422,H,4,,,,,1,,BAO_0000224,
2349,,Autocuration,,104686,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,CHEMBL617423,H,4,,,,,1,,BAO_0000019,
2350,,Autocuration,,104686,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,CHEMBL617424,H,4,,,,,1,,BAO_0000019,
2351,,Autocuration,,104686,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,CHEMBL617425,H,4,,,,,1,,BAO_0000019,
2352,,Autocuration,,104686,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),CHEMBL617426,H,4,,,,,1,,BAO_0000224,
2353,,Autocuration,,104686,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),CHEMBL617427,H,4,,,,,1,,BAO_0000218,
2354,955.0,Autocuration,Brain,104686,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,CHEMBL617428,H,4,,,,,1,,BAO_0000221,
2355,,Autocuration,,104686,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,CHEMBL617429,H,4,,,,,1,,BAO_0000224,
2356,,Autocuration,,104686,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,CHEMBL617430,H,4,,,,,1,,BAO_0000019,
2357,,Autocuration,,104686,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,CHEMBL617431,H,4,,,,,1,,BAO_0000019,
2358,1870.0,Autocuration,Frontal cortex,104686,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,CHEMBL617432,H,4,,,,,1,,BAO_0000019,
2359,,Autocuration,,104686,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,CHEMBL617433,H,4,,,,,1,,BAO_0000224,
2360,,Autocuration,,104686,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,CHEMBL617434,H,4,,,,,1,,BAO_0000224,
2361,,Autocuration,,104686,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,CHEMBL617435,D,5,,,,,1,,BAO_0000224,
2362,,Autocuration,,104686,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,CHEMBL617436,H,4,,,,,1,,BAO_0000019,
2363,2435.0,Autocuration,Striatum,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,CHEMBL617437,D,5,,,,,1,,BAO_0000019,
2364,,Autocuration,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",CHEMBL617438,H,4,,,,,1,,BAO_0000019,
2365,,Autocuration,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",CHEMBL617439,H,4,,,,,1,,BAO_0000019,
2366,,Autocuration,,104686,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617440,H,4,,,,,1,,BAO_0000224,
2367,,Autocuration,,104686,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,CHEMBL617441,H,4,,,,,1,,BAO_0000224,
2368,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,CHEMBL872918,D,5,,,,,1,,BAO_0000019,
2369,,Autocuration,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,CHEMBL617442,D,5,,,,,1,,BAO_0000019,
2370,,Autocuration,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,CHEMBL617443,H,4,,,,,1,,BAO_0000019,
2371,,Autocuration,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,CHEMBL617444,H,4,,,,,1,,BAO_0000019,
2372,,Autocuration,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,CHEMBL617445,H,4,,,,,1,,BAO_0000019,
2373,,Autocuration,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,CHEMBL617446,H,4,,,,,1,,BAO_0000019,
2374,,Autocuration,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,CHEMBL617447,H,4,,,,,1,,BAO_0000249,
2375,,Autocuration,,104686,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,CHEMBL617448,H,4,,,,,1,,BAO_0000019,
2376,,Autocuration,,104686,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,CHEMBL617449,H,4,,,,,1,,BAO_0000019,
2377,,Autocuration,,104686,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,CHEMBL617450,H,4,,,,,1,,BAO_0000019,
2378,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,CHEMBL617451,H,4,,,,,1,,BAO_0000019,
2379,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,CHEMBL617452,H,4,,,,,1,,BAO_0000019,
2380,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,CHEMBL617453,H,4,,,,,1,,BAO_0000019,
2381,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,CHEMBL617660,H,4,,,,,1,,BAO_0000019,
2382,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,CHEMBL617661,H,4,,,,,1,,BAO_0000019,
2383,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,CHEMBL617662,H,4,,,,,1,,BAO_0000019,
2384,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,CHEMBL872919,H,4,,,,,1,,BAO_0000019,
2385,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,CHEMBL617663,H,4,,,,,1,,BAO_0000019,
2386,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,CHEMBL617664,H,4,,,,,1,,BAO_0000019,
2387,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,CHEMBL617665,H,4,,,,,1,,BAO_0000019,
2388,,Autocuration,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,CHEMBL617666,H,4,,,,,1,,BAO_0000019,
2389,,Autocuration,,104686,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,CHEMBL617667,H,4,,,,,1,,BAO_0000019,
2390,,Autocuration,,104686,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,CHEMBL617668,H,4,,,,,1,,BAO_0000249,
2391,,Autocuration,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,CHEMBL617669,H,4,,,,,1,,BAO_0000249,
2392,,Autocuration,,104686,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,CHEMBL617670,H,4,,,,,1,,BAO_0000224,
2393,,Autocuration,,104686,Inhibitory constant against 5-hydroxytryptamine 2 receptor,CHEMBL617671,D,5,,,,,1,,BAO_0000224,
2394,,Autocuration,,104686,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL617672,H,4,,,,,1,,BAO_0000224,
2395,,Autocuration,,104686,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,CHEMBL617673,H,4,,,,,1,,BAO_0000019,
2396,,Autocuration,,104686,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,CHEMBL617674,H,4,,,,,1,,BAO_0000224,
2397,,Autocuration,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,CHEMBL617675,H,4,,,,,1,,BAO_0000019,
2398,,Autocuration,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,CHEMBL617676,H,4,,,,,1,,BAO_0000019,
2399,,Autocuration,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,CHEMBL617677,H,4,,,,,1,,BAO_0000019,
2400,,Autocuration,,104686,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,CHEMBL617678,D,5,,,,,1,,BAO_0000019,
2401,,Autocuration,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,CHEMBL617679,H,4,,,,,1,,BAO_0000224,
2402,,Autocuration,,104686,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,CHEMBL617680,H,4,,,,,1,,BAO_0000224,
2403,,Autocuration,,104686,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,CHEMBL617681,H,4,,,,,1,,BAO_0000019,
2404,955.0,Autocuration,Brain,104686,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,CHEMBL617682,H,4,,,,,1,,BAO_0000221,
2405,,Autocuration,,104686,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,CHEMBL617683,H,4,,,,,1,,BAO_0000224,
2406,,Autocuration,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,CHEMBL617684,H,4,,,,,1,,BAO_0000224,
2407,,Autocuration,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617685,D,5,,,,,1,,BAO_0000224,
2408,,Autocuration,,104686,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,CHEMBL617686,H,4,,,,,1,,BAO_0000019,
2409,,Autocuration,,104686,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,CHEMBL617687,H,4,,,,,1,,BAO_0000224,
2410,,Autocuration,,104686,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL617688,H,4,,,,,1,,BAO_0000224,
2411,,Autocuration,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL617689,H,4,,,,,1,,BAO_0000019,
2412,,Autocuration,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL617690,H,4,,,,,1,,BAO_0000019,
2413,,Autocuration,,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",CHEMBL617691,H,4,,,,,1,,BAO_0000218,
2414,,Autocuration,,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",CHEMBL617692,H,4,,,,,1,,BAO_0000218,
2415,,Autocuration,,104686,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",CHEMBL617693,H,4,,,,,1,,BAO_0000218,
2416,,Autocuration,,104686,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",CHEMBL617694,H,4,,,,,1,,BAO_0000218,
2417,955.0,Expert,Brain,12687,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,CHEMBL857985,H,8,,,,,1,,BAO_0000221,
2418,,Expert,,12687,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,CHEMBL617695,D,9,,,,,1,,BAO_0000019,
2419,,Autocuration,,12687,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,CHEMBL617696,H,8,,,,,1,,BAO_0000019,
2420,,Autocuration,,12687,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,CHEMBL617697,H,8,,,,,1,,BAO_0000357,
2421,,Expert,,12687,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,CHEMBL617257,D,9,,,,,1,,BAO_0000019,
2422,,Expert,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,CHEMBL617258,D,9,,,,,1,,BAO_0000357,
2423,,Expert,,12687,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,CHEMBL617259,H,8,,,,,1,,BAO_0000019,
2424,,Autocuration,,12687,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,CHEMBL617260,H,8,,,,,1,,BAO_0000357,
2425,,Expert,,12687,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617261,D,9,,,,,1,,BAO_0000357,
2426,,Autocuration,,12687,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,CHEMBL617262,H,8,,,,,1,,BAO_0000019,
2427,,Expert,,12687,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,CHEMBL617263,H,8,,,,,1,,BAO_0000019,
2428,,Autocuration,,12687,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,CHEMBL617264,H,8,,,,,1,,BAO_0000019,
2429,,Expert,,12687,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,CHEMBL617265,D,9,,,,,1,,BAO_0000019,
2430,,Autocuration,,12687,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,CHEMBL617266,H,8,,,,Membranes,1,,BAO_0000249,
2431,,Autocuration,,12687,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,CHEMBL617267,H,8,,,,,1,,BAO_0000019,
2432,,Expert,,12687,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,CHEMBL617268,H,8,,,,,1,,BAO_0000019,
2433,,Autocuration,,12687,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,CHEMBL617269,H,8,449.0,CHO,,,1,,BAO_0000219,
2434,,Expert,,12687,Kinetic inhibition constant evaluated by measuring serotonergic activity,CHEMBL617323,H,8,,,,,1,,BAO_0000357,
2435,,Autocuration,,12687,Serotonergic activity of the compound.,CHEMBL617324,H,8,,,,,1,,BAO_0000357,
2436,,Autocuration,,12687,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,CHEMBL617325,H,8,,,,,1,,BAO_0000249,
2437,,Expert,,12687,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,CHEMBL617326,D,9,,,,,1,,BAO_0000019,
2438,,Expert,,12687,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,CHEMBL617327,H,8,,,,,1,,BAO_0000249,
2439,,Expert,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617328,D,9,,,,,1,,BAO_0000019,
2440,,Expert,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617329,D,9,,,,,1,,BAO_0000019,
2441,,Expert,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617330,D,9,,,,,1,,BAO_0000019,
2442,,Autocuration,,12687,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL617331,H,8,,,,,1,,BAO_0000357,
2443,,Autocuration,,12687,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,CHEMBL617332,H,8,,,,,1,,BAO_0000357,
2444,,Expert,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617333,H,8,,,,,1,,BAO_0000357,
2445,,Autocuration,,107,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,CHEMBL617334,H,8,,,,,1,,BAO_0000357,
2446,,Autocuration,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,CHEMBL617335,H,8,,,,,1,,BAO_0000357,
2447,,Autocuration,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,CHEMBL617336,H,8,,,,,1,,BAO_0000357,
2448,,Autocuration,,107,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,CHEMBL617337,H,8,,,,,1,,BAO_0000357,
2449,,Expert,,107,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,CHEMBL617338,D,9,,,,,1,,BAO_0000357,
2450,,Autocuration,,107,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,CHEMBL617339,H,8,,,,,1,,BAO_0000357,
2451,,Expert,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617340,H,8,,,,,1,,BAO_0000357,
2452,,Autocuration,,107,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,CHEMBL617341,H,8,,,,,1,,BAO_0000357,
2453,,Expert,,107,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617342,H,8,,,,,1,,BAO_0000357,
2454,,Expert,,107,Affinity for 5-hydroxytryptamine 2A receptor,CHEMBL617343,H,8,,,,,1,,BAO_0000357,
2455,,Expert,,107,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,CHEMBL617344,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2456,,Expert,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,CHEMBL617345,H,8,,,,,1,,BAO_0000357,
2457,,Expert,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,CHEMBL617346,H,8,,,,,1,,BAO_0000357,
2458,,Autocuration,,107,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,CHEMBL617347,H,8,,,,,1,,BAO_0000357,
2459,,Autocuration,,107,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,CHEMBL617348,H,8,,,,,1,,BAO_0000357,
2460,,Autocuration,,107,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,CHEMBL617349,H,8,,,,,1,,BAO_0000357,
2461,,Autocuration,,107,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,CHEMBL617350,H,8,,,,,1,,BAO_0000019,
2462,,Expert,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,CHEMBL872339,H,8,,,,,1,,BAO_0000357,
2463,,Autocuration,,107,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,CHEMBL617351,H,8,,,,,1,,BAO_0000357,
2464,,Expert,,107,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617352,H,8,,,,,1,,BAO_0000357,
2465,,Autocuration,,107,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617353,H,8,,,,,1,,BAO_0000357,
2466,,Autocuration,,107,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,CHEMBL617354,H,8,,,,,1,,BAO_0000357,
2467,,Autocuration,,107,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,CHEMBL617355,H,8,,,,,1,,BAO_0000357,
2468,,Expert,,107,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,CHEMBL617356,H,8,449.0,CHO,,,1,,BAO_0000219,
2469,,Autocuration,,107,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,CHEMBL617357,H,8,,,,,1,,BAO_0000357,
2470,,Autocuration,,107,Binding affinity at 5-hydroxytryptamine 2A receptor,CHEMBL617358,H,8,,,,,1,,BAO_0000357,
2471,,Expert,,107,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617359,H,8,,,,,1,,BAO_0000357,
2472,,Autocuration,,107,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,CHEMBL617360,H,8,,,,,1,,BAO_0000357,
2473,,Autocuration,,107,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,CHEMBL875913,H,8,,,,,1,,BAO_0000357,
2474,,Autocuration,,107,Affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617361,H,8,,,,,1,,BAO_0000357,
2475,,Expert,,107,Binding affinity against 5-Hydroxytryptamine 2A receptor,CHEMBL617362,D,9,,,,,1,,BAO_0000357,
2476,,Autocuration,,107,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,CHEMBL617363,H,8,,,,,1,,BAO_0000357,
2477,,Autocuration,,107,Tested against 5-hydroxytryptamine 2A receptor,CHEMBL617364,H,8,,,,,1,,BAO_0000357,
2478,,Autocuration,,105075,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,CHEMBL617365,H,4,,,,,1,,BAO_0000224,
2479,,Autocuration,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,CHEMBL617366,H,4,,,,,1,,BAO_0000224,
2480,,Autocuration,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,CHEMBL617367,H,4,,,,,1,,BAO_0000224,
2481,,Autocuration,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,CHEMBL617368,H,4,,,,,1,,BAO_0000224,
2482,,Autocuration,,107,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),CHEMBL617369,H,8,,,,,1,,BAO_0000357,
2483,,Expert,,227,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,CHEMBL617370,D,9,722.0,HEK293,,,1,,BAO_0000219,
2484,,Expert,,227,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,CHEMBL617371,D,9,449.0,CHO,,,1,,BAO_0000219,
2485,,Autocuration,,227,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),CHEMBL617372,H,8,,,,,1,,BAO_0000357,
2486,,Expert,,227,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,CHEMBL617373,D,9,,,,,1,,BAO_0000357,
2487,,Autocuration,,227,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,CHEMBL617374,H,8,,,,,1,,BAO_0000019,
2488,,Autocuration,,227,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,CHEMBL617375,H,8,,,,,1,,BAO_0000019,
2489,,Autocuration,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,CHEMBL617376,H,8,,,,,1,,BAO_0000019,
2490,,Autocuration,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,CHEMBL617377,H,8,,,,,1,,BAO_0000019,
2491,,Autocuration,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,CHEMBL617378,H,8,,,,,1,,BAO_0000019,
2492,,Autocuration,,227,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,CHEMBL617379,H,8,,,,,1,,BAO_0000019,
2493,,Autocuration,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,CHEMBL617380,H,8,,,,,1,,BAO_0000357,
2494,,Autocuration,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,CHEMBL617381,H,8,,,,,1,,BAO_0000357,
2495,,Autocuration,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,CHEMBL617382,H,8,,,,,1,,BAO_0000357,
2496,,Autocuration,,107,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617383,H,8,,,,,1,,BAO_0000357,
2497,,Expert,,107,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,CHEMBL617384,H,8,,,,,1,,BAO_0000357,
2498,,Expert,,107,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,CHEMBL617385,H,8,,,,,1,,BAO_0000357,
2499,,Autocuration,,107,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,CHEMBL617386,H,8,,,,,1,,BAO_0000019,
2500,,Autocuration,,107,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,CHEMBL617387,H,8,,,,,1,,BAO_0000019,
2501,,Autocuration,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL617388,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2502,,Autocuration,,107,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617389,H,8,449.0,CHO,,,1,,BAO_0000219,
2503,,Expert,,107,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617390,D,9,449.0,CHO,,,1,,BAO_0000219,
2504,,Autocuration,,104817,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,CHEMBL617391,H,4,,,,,1,,BAO_0000224,
2505,,Autocuration,,107,Binding activity radioligand.,CHEMBL617392,H,8,,,,,1,,BAO_0000357,
2506,,Autocuration,,107,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,CHEMBL617393,H,8,,,,,1,,BAO_0000019,
2507,,Autocuration,,107,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,CHEMBL617394,H,8,307.0,L929,,,1,,BAO_0000219,
2508,,Expert,,107,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,CHEMBL617395,H,8,307.0,L929,,,1,,BAO_0000219,
2509,,Expert,,107,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,CHEMBL617396,H,8,307.0,L929,,,1,,BAO_0000219,
2510,,Autocuration,,107,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,CHEMBL617397,H,8,307.0,L929,,,1,,BAO_0000219,
2511,,Autocuration,,107,Binding affinity against 5-HT2A receptor,CHEMBL617398,H,8,,,,,1,,BAO_0000357,
2512,,Autocuration,,107,Binding affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617399,H,8,,,,,1,,BAO_0000357,
2513,,Autocuration,,107,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,CHEMBL617400,H,8,722.0,HEK293,,,1,,BAO_0000219,
2514,,Autocuration,,107,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,CHEMBL617401,H,8,722.0,HEK293,,,1,,BAO_0000219,
2515,,Expert,,107,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,CHEMBL617402,D,9,722.0,HEK293,,,1,,BAO_0000219,
2516,,Expert,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL617403,D,9,722.0,HEK293,,,1,,BAO_0000219,
2517,,Expert,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,CHEMBL617404,H,8,,,,,1,,BAO_0000357,
2518,,Expert,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL857981,D,9,722.0,HEK293,,,1,,BAO_0000219,
2519,,Expert,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL617405,D,9,722.0,HEK293,,,1,,BAO_0000219,
2520,,Expert,,107,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,CHEMBL617253,D,9,722.0,HEK293,,,1,,BAO_0000219,
2521,,Expert,,107,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,CHEMBL617254,H,8,,,,,1,,BAO_0000357,
2522,,Autocuration,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL617255,H,8,722.0,HEK293,,,1,,BAO_0000219,
2523,,Autocuration,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL617256,H,8,722.0,HEK293,,,1,,BAO_0000219,
2524,,Autocuration,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL616874,H,8,722.0,HEK293,,,1,,BAO_0000219,
2525,,Expert,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,CHEMBL616875,D,9,722.0,HEK293,,,1,,BAO_0000219,
2526,,Expert,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL616876,H,8,722.0,HEK293,,,1,,BAO_0000219,
2527,,Expert,,107,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",CHEMBL616877,H,8,722.0,HEK293,,,1,,BAO_0000219,
2528,,Expert,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,CHEMBL616878,D,9,722.0,HEK293,,,1,,BAO_0000219,
2529,,Expert,,107,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,CHEMBL616879,H,8,722.0,HEK293,,,1,,BAO_0000219,
2530,,Expert,,107,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,CHEMBL616880,H,8,722.0,HEK293,,,1,,BAO_0000219,
2531,,Expert,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL616881,D,9,722.0,HEK293,,,1,,BAO_0000219,
2532,,Autocuration,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,CHEMBL616882,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2533,,Autocuration,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL616883,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2534,,Autocuration,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL616884,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2535,,Autocuration,,107,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,CHEMBL616885,H,8,722.0,HEK293,,,1,,BAO_0000219,
2536,,Autocuration,,107,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,CHEMBL616886,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2537,,Expert,,107,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,CHEMBL616887,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2538,,Expert,,107,Binding affinity for human 5-hydroxytryptamine 2A receptor,CHEMBL616888,D,9,,,,,1,,BAO_0000357,
2539,,Autocuration,,107,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,CHEMBL616889,H,8,722.0,HEK293,,,1,,BAO_0000219,
2540,,Autocuration,,107,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,CHEMBL616890,H,8,722.0,HEK293,,,1,,BAO_0000219,
2541,,Expert,,107,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,CHEMBL616891,D,9,449.0,CHO,,,1,,BAO_0000219,
2542,,Autocuration,,107,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,CHEMBL616892,H,8,722.0,HEK293,,,1,,BAO_0000219,
2543,,Autocuration,,107,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",CHEMBL616893,H,8,722.0,HEK293,,,1,,BAO_0000219,
2544,,Autocuration,,10620,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,CHEMBL616894,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2545,,Expert,,107,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,CHEMBL616895,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2546,,Autocuration,,10620,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,CHEMBL616896,H,8,,,,,1,,BAO_0000019,
2547,,Autocuration,,10621,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,CHEMBL617099,H,8,,,,,1,,BAO_0000357,
2548,,Autocuration,,10621,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,CHEMBL617100,H,8,,,,,1,,BAO_0000357,
2549,,Autocuration,,107,Binding affinity against rabbit aorta 5-HT2A receptor,CHEMBL884532,H,8,,,,,1,,BAO_0000357,
2550,,Expert,,107,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,CHEMBL617101,H,8,,,,,1,,BAO_0000357,
2551,,Expert,,107,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,CHEMBL617102,H,8,,,,,1,,BAO_0000357,
2552,,Autocuration,,107,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,CHEMBL617103,H,8,,,,,1,,BAO_0000019,
2553,,Expert,,107,The compound was tested for binding affinity against 5-HT2A receptor,CHEMBL617104,H,8,,,,,1,,BAO_0000357,
2554,,Autocuration,,10576,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,CHEMBL857979,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2555,,Autocuration,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein,CHEMBL857502,H,8,,,,,1,,BAO_0000019,
2556,,Autocuration,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,CHEMBL617105,H,8,,,,,1,,BAO_0000019,
2557,945.0,Autocuration,Stomach,12687,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,CHEMBL858021,H,8,,,,,1,,BAO_0000019,
2558,945.0,Expert,Stomach,12687,Binding affinity for 5-HT 2A in rat stomach fundus,CHEMBL875910,D,9,,,,,1,,BAO_0000019,
2559,,Autocuration,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,CHEMBL617106,H,8,,,,,1,,BAO_0000019,
2560,,Expert,,12687,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,CHEMBL617107,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2561,,Autocuration,,12687,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,CHEMBL617108,H,8,,,,,1,,BAO_0000019,
2562,,Autocuration,,12687,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,CHEMBL617109,H,8,,,,,1,,BAO_0000019,
2563,,Autocuration,,12687,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,CHEMBL617110,H,8,,,,,1,,BAO_0000357,
2564,,Autocuration,,12687,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,CHEMBL617111,H,8,,,,,1,,BAO_0000357,
2565,,Expert,,12687,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,CHEMBL617112,D,9,,,,,1,,BAO_0000019,
2566,,Autocuration,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617113,H,8,,,,,1,,BAO_0000357,
2567,,Autocuration,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617114,H,8,,,,,1,,BAO_0000357,
2568,,Autocuration,,12687,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617115,H,8,,,,,1,,BAO_0000357,
2569,,Autocuration,,12687,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,CHEMBL617116,H,8,,,,,1,,BAO_0000219,
2570,,Autocuration,,12687,Efficacy at 5-hydroxytryptamine 2A receptor,CHEMBL617117,H,8,,,,,1,,BAO_0000019,
2571,,Autocuration,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),CHEMBL617118,H,8,,,,,1,,BAO_0000357,
2572,,Expert,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),CHEMBL617119,D,9,,,,,1,,BAO_0000357,
2573,,Expert,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),CHEMBL617120,D,9,,,,,1,,BAO_0000357,
2574,,Expert,,12687,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,CHEMBL617121,D,9,,,,,1,,BAO_0000219,
2575,,Autocuration,,12687,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,CHEMBL617122,H,8,,,,,1,,BAO_0000219,
2576,,Autocuration,,12687,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,CHEMBL617123,H,8,,,,,1,,BAO_0000019,
2577,,Expert,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,CHEMBL617124,H,8,,,,,1,,BAO_0000019,
2578,,Expert,,12687,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,CHEMBL617600,H,8,,,,,1,,BAO_0000249,
2579,,Expert,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,CHEMBL617601,H,8,,,,,1,,BAO_0000357,
2580,,Expert,,12687,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,CHEMBL882923,H,8,,,,,1,,BAO_0000019,
2581,,Autocuration,,12687,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617602,H,8,,,,,1,,BAO_0000357,
2582,,Autocuration,,12687,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,CHEMBL617603,H,8,,,,,1,,BAO_0000019,
2583,,Autocuration,,12687,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,CHEMBL617604,H,8,,,,,1,,BAO_0000357,
2584,,Expert,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,CHEMBL617605,H,8,,,,,1,,BAO_0000019,
2585,,Expert,,12687,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,CHEMBL617606,H,8,,,,,1,,BAO_0000019,
2586,,Expert,,12687,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,CHEMBL617607,D,9,,,,,1,,BAO_0000019,
2587,,Autocuration,,12687,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617455,H,8,,,,,1,,BAO_0000249,
2588,,Expert,,12687,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,CHEMBL617456,D,9,,,,,1,,BAO_0000019,
2589,,Expert,,12687,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),CHEMBL617457,H,8,,,,,1,,BAO_0000357,
2590,,Expert,,12687,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,CHEMBL617458,D,9,,,,,1,,BAO_0000357,
2591,,Expert,,12687,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,CHEMBL617459,D,9,,,,,1,,BAO_0000019,
2592,,Expert,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,CHEMBL617460,H,8,,,,,1,,BAO_0000357,
2593,,Expert,,12687,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",CHEMBL617461,H,8,,,,,1,,BAO_0000357,
2594,,Expert,,12687,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,CHEMBL617462,D,9,,,,,1,,BAO_0000019,
2595,,Autocuration,,12687,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,CHEMBL617463,H,8,,,,,1,,BAO_0000357,
2596,,Autocuration,,12687,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",CHEMBL617464,H,8,,,,,1,,BAO_0000019,
2597,,Autocuration,,12687,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",CHEMBL617465,H,8,,,,,1,,BAO_0000019,
2598,,Expert,,12687,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,CHEMBL617466,H,8,,,,,1,,BAO_0000019,
2599,,Autocuration,,12687,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,CHEMBL617467,H,8,,,,,1,,BAO_0000019,
2600,,Expert,,12687,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,CHEMBL617468,H,8,,,,,1,,BAO_0000019,
2601,,Autocuration,,12687,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,CHEMBL617469,H,8,,,,,1,,BAO_0000019,
2602,,Autocuration,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,CHEMBL617470,H,8,,,,,1,,BAO_0000019,
2603,,Autocuration,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,CHEMBL617471,H,8,,,,,1,,BAO_0000019,
2604,,Expert,,12687,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,CHEMBL617472,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2605,,Expert,,12687,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,CHEMBL617473,H,8,,,,,1,,BAO_0000357,
2606,,Expert,,12687,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,CHEMBL617474,D,9,,,,,1,,BAO_0000019,
2607,,Expert,,12687,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,CHEMBL617475,D,9,,,,,1,,BAO_0000019,
2608,955.0,Autocuration,Brain,12687,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,CHEMBL617476,H,8,,,,,1,,BAO_0000221,
2609,,Expert,,12687,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617477,H,8,,,,,1,,BAO_0000357,
2610,,Expert,,12687,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617478,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2611,,Autocuration,,12687,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",CHEMBL617479,H,8,,,,,1,,BAO_0000221,
2612,,Autocuration,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,CHEMBL617480,H,8,,,,,1,,BAO_0000357,
2613,,Expert,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617481,H,8,,,,,1,,BAO_0000357,
2614,,Expert,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,CHEMBL617482,H,8,,,,,1,,BAO_0000019,
2615,,Autocuration,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,CHEMBL617483,H,8,,,,,1,,BAO_0000019,
2616,,Autocuration,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL621528,H,8,,,,,1,,BAO_0000357,
2617,,Expert,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,CHEMBL621529,D,9,723.0,NIH3T3,,,1,,BAO_0000219,
2618,,Expert,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL621530,H,8,,,,,1,,BAO_0000357,
2619,,Expert,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL621531,H,8,,,,,1,,BAO_0000357,
2620,,Expert,,12687,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,CHEMBL621532,D,9,,,,,1,,BAO_0000019,
2621,,Expert,,12687,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL621533,H,8,,,,,1,,BAO_0000357,
2622,,Expert,,12687,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL621534,H,8,449.0,CHO,,,1,,BAO_0000219,
2623,,Autocuration,,12687,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,CHEMBL621535,H,8,,,,,1,,BAO_0000019,
2624,,Autocuration,,12687,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,CHEMBL621536,H,8,,,,,1,,BAO_0000357,
2625,,Autocuration,,12687,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,CHEMBL621537,H,8,,,,,1,,BAO_0000357,
2626,,Expert,,12687,Binding affinity for 5-hydroxytryptamine 2A receptor,CHEMBL621538,D,9,,,,,1,,BAO_0000357,
2627,,Autocuration,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,CHEMBL621539,H,8,,,,,1,,BAO_0000019,
2628,,Autocuration,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,CHEMBL621540,H,8,,,,,1,,BAO_0000019,
2629,,Autocuration,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,CHEMBL621541,H,8,,,,,1,,BAO_0000019,
2630,,Autocuration,,12687,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,CHEMBL621542,H,8,,,,,1,,BAO_0000019,
2631,,Expert,,12687,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,CHEMBL621543,H,8,,,,,1,,BAO_0000357,
2632,,Expert,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,CHEMBL621544,H,8,,,,,1,,BAO_0000357,
2633,,Expert,,12687,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,CHEMBL621545,D,9,,,,,1,,BAO_0000357,
2634,,Autocuration,,12687,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL621546,H,8,,,,,1,,BAO_0000357,
2635,,Autocuration,,12687,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,CHEMBL621547,H,8,,,,,1,,BAO_0000357,
2636,,Expert,,12687,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,CHEMBL618692,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2637,,Autocuration,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL618693,H,8,,,,,1,,BAO_0000357,
2638,,Autocuration,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL872922,H,8,,,,,1,,BAO_0000357,
2639,,Autocuration,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,CHEMBL618694,H,8,,,,,1,,BAO_0000357,
2640,,Expert,,12687,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,CHEMBL618695,D,9,,,,,1,,BAO_0000357,
2641,,Autocuration,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,CHEMBL618696,H,8,,,,,1,,BAO_0000357,
2642,,Expert,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,CHEMBL618697,H,8,,,,,1,,BAO_0000357,
2643,,Autocuration,,12687,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,CHEMBL618892,H,8,,,,,1,,BAO_0000357,
2644,,Autocuration,,12687,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,CHEMBL618893,H,8,,,,,1,,BAO_0000357,
2645,,Autocuration,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,CHEMBL618894,H,8,,,,,1,,BAO_0000357,
2646,,Expert,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,CHEMBL618895,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2647,,Expert,,12687,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,CHEMBL618896,D,9,,,,,1,,BAO_0000357,
2648,5383.0,Autocuration,Caudate-putamen,12687,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,CHEMBL618897,H,8,,,,,1,,BAO_0000019,
2649,,Autocuration,,12687,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,CHEMBL618898,H,8,,,,,1,,BAO_0000357,
2650,,Autocuration,,12687,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,CHEMBL618899,H,8,,,,,1,,BAO_0000357,
2651,,Autocuration,,12687,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,CHEMBL618900,H,8,,,,,1,,BAO_0000357,
2652,,Autocuration,,12687,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,CHEMBL618901,H,8,,,,,1,,BAO_0000019,
2653,,Autocuration,,12687,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,CHEMBL618902,H,8,,,,,1,,BAO_0000357,
2654,10000000.0,Expert,Hippocampus,12687,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,CHEMBL618903,D,9,,,,,1,,BAO_0000221,
2655,,Autocuration,,12687,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,CHEMBL618904,H,8,,,,,1,,BAO_0000357,
2656,,Autocuration,,12687,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,CHEMBL618905,H,8,,,,,1,,BAO_0000357,
2657,,Autocuration,,12687,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,CHEMBL618906,H,8,,,,,1,,BAO_0000357,
2658,,Expert,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,CHEMBL618907,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2659,,Autocuration,,12687,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,CHEMBL618908,H,8,,,,,1,,BAO_0000019,
2660,,Autocuration,,12687,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,CHEMBL617909,H,8,,,,,1,,BAO_0000357,
2661,,Expert,,12687,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,CHEMBL617910,H,8,,,,,1,,BAO_0000019,
2662,955.0,Autocuration,Brain,12687,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,CHEMBL617911,H,8,,,,,1,,BAO_0000221,
2663,,Autocuration,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL872923,H,8,,,,,1,,BAO_0000249,
2664,,Autocuration,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617912,H,8,,,,,1,,BAO_0000249,
2665,,Expert,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,CHEMBL617913,D,9,,,,,1,,BAO_0000019,
2666,,Expert,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617914,H,8,,,,,1,,BAO_0000249,
2667,,Autocuration,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617915,H,8,,,,,1,,BAO_0000249,
2668,,Autocuration,,12687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617916,H,8,,,,,1,,BAO_0000249,
2669,,Expert,,12687,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,CHEMBL617917,D,9,,,,,1,,BAO_0000019,
2670,,Expert,,12687,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,CHEMBL617918,H,8,,,,,1,,BAO_0000019,
2671,,Autocuration,,12687,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,CHEMBL617919,H,8,,,,,1,,BAO_0000019,
2672,,Expert,,12687,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,CHEMBL617920,D,9,,,,,1,,BAO_0000019,
2673,,Expert,,12687,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,CHEMBL617921,D,9,,,,,1,,BAO_0000019,
2674,,Expert,,105102,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",CHEMBL617922,D,5,,,,,1,,BAO_0000224,
2675,,Autocuration,,12687,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL617923,H,8,,,,,1,,BAO_0000357,
2676,,Autocuration,,12687,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL617924,H,8,,,,,1,,BAO_0000357,
2677,,Autocuration,,12687,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,CHEMBL617925,H,8,,,,,1,,BAO_0000357,
2678,,Expert,,12687,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,CHEMBL617926,D,9,,,,,1,,BAO_0000357,
2679,,Autocuration,,12687,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,CHEMBL617927,H,8,,,,,1,,BAO_0000357,
2680,,Autocuration,,12687,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617928,H,8,,,,,1,,BAO_0000357,
2681,,Expert,,12687,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617929,D,9,,,,,1,,BAO_0000019,
2682,,Expert,,12687,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,CHEMBL617930,H,8,,,,,1,,BAO_0000019,
2683,,Autocuration,,12687,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,CHEMBL617931,H,8,,,,,1,,BAO_0000019,
2684,,Autocuration,,12687,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,CHEMBL617932,H,8,,,,,1,,BAO_0000019,
2685,,Autocuration,,12687,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,CHEMBL617933,H,8,449.0,CHO,,,1,,BAO_0000219,
2686,,Autocuration,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,CHEMBL617934,H,8,,,,,1,,BAO_0000019,
2687,,Autocuration,,12687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,CHEMBL617935,H,8,,,,,1,,BAO_0000019,
2688,,Autocuration,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,CHEMBL617936,H,8,,,,,1,,BAO_0000357,
2689,,Autocuration,,12687,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,CHEMBL617937,H,8,,,,,1,,BAO_0000019,
2690,,Autocuration,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,CHEMBL617938,H,8,,,,,1,,BAO_0000019,
2691,,Autocuration,,12687,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,CHEMBL617939,H,8,,,,,1,,BAO_0000218,
2692,,Autocuration,,12687,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,CHEMBL617940,H,8,,,,,1,,BAO_0000218,
2693,,Autocuration,,12687,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,CHEMBL617941,H,8,,,,,1,,BAO_0000218,
2694,,Expert,,12687,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,CHEMBL617942,H,8,,,,,1,,BAO_0000357,
2695,,Expert,,12687,Ratio of pKi of 5-HT2A to that of D2 receptor,CHEMBL617943,H,8,,,,,1,,BAO_0000357,
2696,,Expert,,105093,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,CHEMBL617944,H,4,,,,,1,,BAO_0000224,
2697,,Expert,,105093,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,CHEMBL617945,H,4,,,,,1,,BAO_0000224,
2698,,Expert,,105075,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,CHEMBL617946,H,4,,,,,1,,BAO_0000224,
2699,,Autocuration,,12687,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,CHEMBL617947,H,8,,,,,1,,BAO_0000357,
2700,,Expert,,12687,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,CHEMBL617948,H,8,,,,,1,,BAO_0000357,
2701,,Autocuration,,12687,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,CHEMBL858116,H,8,,,,,1,,BAO_0000019,
2702,,Autocuration,,12687,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,CHEMBL617949,H,8,,,,,1,,BAO_0000019,
2703,,Autocuration,,12687,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,CHEMBL617950,H,8,,,,,1,,BAO_0000019,
2704,1515.0,Expert,Thoracic aorta,12687,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,CHEMBL617951,H,8,,,,,1,,BAO_0000019,
2705,1515.0,Expert,Thoracic aorta,12687,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,CHEMBL617952,H,8,,,,,1,,BAO_0000019,
2706,1515.0,Autocuration,Thoracic aorta,12687,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,CHEMBL617953,H,8,,,,,1,,BAO_0000019,
2707,,Autocuration,,12687,Binding activity radioligand.,CHEMBL617954,H,8,,,,,1,,BAO_0000357,
2708,,Expert,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,CHEMBL617955,H,8,,,,,1,,BAO_0000019,
2709,,Autocuration,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,CHEMBL857071,H,8,,,,,1,,BAO_0000019,
2710,,Expert,,12687,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,CHEMBL617270,H,8,,,,,1,,BAO_0000019,
2711,,Autocuration,,12687,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,CHEMBL617271,H,8,339.0,N1E-115,,,1,,BAO_0000219,
2712,,Autocuration,,12687,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,CHEMBL617272,H,8,339.0,N1E-115,,,1,,BAO_0000219,
2713,,Autocuration,,12687,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,CHEMBL617273,H,8,,,,,1,,BAO_0000019,
2714,,Expert,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,CHEMBL617274,D,9,,,,,1,,BAO_0000019,
2715,,Autocuration,,108,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,CHEMBL617275,H,8,,,,,1,,BAO_0000357,
2716,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617276,H,8,,,,,1,,BAO_0000357,
2717,,Autocuration,,108,Binding affinity towards human 5-hydroxytryptamine 2C receptor,CHEMBL617277,H,8,,,,,1,,BAO_0000357,
2718,,Expert,,108,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,CHEMBL617278,H,8,,,,,1,,BAO_0000019,
2719,,Expert,,108,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,CHEMBL617279,H,8,,,,,1,,BAO_0000019,
2720,,Expert,,108,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,CHEMBL617280,H,8,,,,,1,,BAO_0000019,
2721,,Autocuration,,108,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,CHEMBL617281,H,8,,,,,1,,BAO_0000357,
2722,,Autocuration,,108,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,CHEMBL617282,H,8,,,,,1,,BAO_0000357,
2723,,Expert,,108,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,CHEMBL617283,H,8,,,,,1,,BAO_0000019,
2724,,Expert,,108,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,CHEMBL617284,H,8,,,,,1,,BAO_0000019,
2725,,Autocuration,,108,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,CHEMBL617285,H,8,722.0,HEK293,,,1,,BAO_0000219,
2726,,Autocuration,,108,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,CHEMBL617286,H,8,,,,,1,,BAO_0000019,
2727,,Expert,,108,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,CHEMBL617287,D,9,,,,,1,,BAO_0000357,
2728,,Expert,,108,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,CHEMBL617288,H,8,,,,,1,,BAO_0000357,
2729,,Autocuration,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,CHEMBL617289,H,8,,,,,1,,BAO_0000357,
2730,,Autocuration,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL872917,H,8,,,,,1,,BAO_0000357,
2731,,Autocuration,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,CHEMBL617290,H,8,,,,,1,,BAO_0000357,
2732,,Autocuration,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHEMBL617291,H,8,449.0,CHO,,,1,,BAO_0000219,
2733,,Autocuration,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,CHEMBL617292,H,8,449.0,CHO,,,1,,BAO_0000219,
2734,,Autocuration,,108,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL617293,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2735,,Expert,,108,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617294,D,9,449.0,CHO,,,1,,BAO_0000219,
2736,,Expert,,108,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,CHEMBL617295,H,8,,,,,1,,BAO_0000019,
2737,,Autocuration,,108,Binding activity radioligand.,CHEMBL617296,H,8,,,,,1,,BAO_0000357,
2738,,Autocuration,,108,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,CHEMBL617297,H,8,,,,,1,,BAO_0000019,
2739,,Expert,,108,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,CHEMBL617298,H,8,449.0,CHO,,,1,,BAO_0000219,
2740,,Expert,,108,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,CHEMBL617299,H,8,449.0,CHO,,,1,,BAO_0000219,
2741,,Autocuration,,108,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,CHEMBL617300,H,8,449.0,CHO,,,1,,BAO_0000219,
2742,,Autocuration,,108,Binding affinity against 5-HT2C receptor,CHEMBL617454,H,8,,,,,1,,BAO_0000357,
2743,,Autocuration,,108,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,CHEMBL617505,H,8,722.0,HEK293,,,1,,BAO_0000219,
2744,,Expert,,108,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,CHEMBL617506,D,9,722.0,HEK293,,,1,,BAO_0000219,
2745,,Expert,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,CHEMBL617507,D,9,722.0,HEK293,,,1,,BAO_0000219,
2746,,Expert,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,CHEMBL617508,H,8,,,,,1,,BAO_0000357,
2747,,Expert,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,CHEMBL857982,D,9,722.0,HEK293,,,1,,BAO_0000219,
2748,,Expert,,108,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,CHEMBL617509,D,9,722.0,HEK293,,,1,,BAO_0000219,
2749,,Expert,,108,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,CHEMBL617510,D,9,722.0,HEK293,,,1,,BAO_0000219,
2750,,Autocuration,,108,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,CHEMBL617511,H,8,,,,,1,,BAO_0000357,
2751,,Autocuration,,108,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,CHEMBL617512,H,8,722.0,HEK293,,,1,,BAO_0000219,
2752,,Autocuration,,108,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,CHEMBL617749,H,8,722.0,HEK293,,,1,,BAO_0000219,
2753,,Autocuration,,108,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL617750,H,8,722.0,HEK293,,,1,,BAO_0000219,
2754,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL617751,H,8,722.0,HEK293,,,1,,BAO_0000219,
2755,,Expert,,108,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,CHEMBL617752,H,8,722.0,HEK293,,,1,,BAO_0000219,
2756,,Autocuration,,108,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",CHEMBL617753,H,8,722.0,HEK293,,,1,,BAO_0000219,
2757,,Expert,,108,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",CHEMBL617754,H,8,722.0,HEK293,,,1,,BAO_0000219,
2758,,Expert,,108,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,CHEMBL617755,D,9,722.0,HEK293,,,1,,BAO_0000219,
2759,,Autocuration,,108,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",CHEMBL617756,H,8,722.0,HEK293,,,1,,BAO_0000219,
2760,,Expert,,108,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,CHEMBL617757,H,8,722.0,HEK293,,,1,,BAO_0000219,
2761,,Expert,,108,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,CHEMBL617758,H,8,722.0,HEK293,,,1,,BAO_0000219,
2762,,Autocuration,,108,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,CHEMBL617759,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2763,,Autocuration,,108,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,CHEMBL617760,H,8,722.0,HEK293,,,1,,BAO_0000219,
2764,,Expert,,108,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,CHEMBL617761,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2765,,Expert,,108,Binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617762,D,9,,,,,1,,BAO_0000357,
2766,,Autocuration,,108,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,CHEMBL617763,H,8,,,,,1,,BAO_0000357,
2767,,Autocuration,,108,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,CHEMBL857983,H,8,722.0,HEK293,,,1,,BAO_0000219,
2768,,Autocuration,,108,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,CHEMBL617764,H,8,722.0,HEK293,,,1,,BAO_0000219,
2769,,Autocuration,,108,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,CHEMBL617765,H,8,308.0,HeLa,,,1,,BAO_0000219,
2770,,Autocuration,,108,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,CHEMBL617766,H,8,,,,,1,,BAO_0000019,
2771,10000000.0,Autocuration,Hippocampus,108,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,CHEMBL617767,H,8,,,,,1,,BAO_0000221,
2772,,Autocuration,,108,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,CHEMBL617768,H,8,722.0,HEK293,,,1,,BAO_0000219,
2773,,Autocuration,,108,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",CHEMBL617769,H,8,722.0,HEK293,,,1,,BAO_0000219,
2774,,Autocuration,,11864,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,CHEMBL858023,H,8,,,,,1,,BAO_0000357,
2775,945.0,Autocuration,Stomach,11864,Binding affinity analysed on 5-HT 2C in rat stomach fundus,CHEMBL617770,H,8,,,,,1,,BAO_0000019,
2776,945.0,Autocuration,Stomach,11864,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,CHEMBL617771,H,8,,,,,1,,BAO_0000019,
2777,,Autocuration,,11864,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,CHEMBL617772,H,8,625.0,A9,,,1,,BAO_0000219,
2778,,Autocuration,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,CHEMBL617773,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2779,,Autocuration,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,CHEMBL617850,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2780,,Autocuration,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,CHEMBL617851,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2781,,Autocuration,,11864,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,CHEMBL617852,H,8,,,,,1,,BAO_0000019,
2782,945.0,Autocuration,Stomach,12689,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,CHEMBL858024,H,8,,,,,1,,BAO_0000019,
2783,945.0,Expert,Stomach,12689,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,CHEMBL617853,D,9,,,,,1,,BAO_0000019,
2784,,Expert,,108,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,CHEMBL617854,H,8,,,,,1,,BAO_0000357,
2785,,Expert,,108,Binding affinity for 5-hydroxytryptamine 2C receptor,CHEMBL873477,H,8,,,,,1,,BAO_0000357,
2786,,Expert,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617855,H,8,,,,,1,,BAO_0000357,
2787,,Expert,,108,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,CHEMBL617856,H,8,,,,,1,,BAO_0000019,
2788,,Autocuration,,108,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,CHEMBL617857,H,8,,,,,1,,BAO_0000019,
2789,,Autocuration,,108,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,CHEMBL617858,H,8,,,,,1,,BAO_0000249,
2790,,Autocuration,,108,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,CHEMBL617859,H,8,,,,,1,,BAO_0000357,
2791,,Autocuration,,108,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617860,H,8,,,,,1,,BAO_0000357,
2792,,Autocuration,,108,Binding activity radioligand.,CHEMBL617861,H,8,,,,,1,,BAO_0000357,
2793,,Expert,,108,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,CHEMBL617862,H,8,,,,,1,,BAO_0000019,
2794,,Autocuration,,108,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,CHEMBL617863,H,8,,,,,1,,BAO_0000019,
2795,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,CHEMBL617864,H,8,,,,,1,,BAO_0000249,
2796,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,CHEMBL617649,H,8,,,,,1,,BAO_0000249,
2797,,Expert,,108,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,CHEMBL617650,H,8,,,,,1,,BAO_0000019,
2798,,Expert,,108,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,CHEMBL617651,H,8,,,,,1,,BAO_0000019,
2799,,Autocuration,,108,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,CHEMBL617652,H,8,,,,,1,,BAO_0000357,
2800,,Autocuration,,108,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,CHEMBL857072,H,8,,,,,1,,BAO_0000019,
2801,,Autocuration,,108,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,CHEMBL617653,H,8,,,,,1,,BAO_0000357,
2802,,Autocuration,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,CHEMBL617654,H,8,,,,,1,,BAO_0000019,
2803,,Autocuration,,12689,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,CHEMBL617655,H,8,,,,,1,,BAO_0000019,
2804,,Expert,,12689,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,CHEMBL617656,H,8,,,,,1,,BAO_0000357,
2805,,Autocuration,,12689,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,CHEMBL617657,H,8,,,,,1,,BAO_0000357,
2806,,Autocuration,,12689,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,CHEMBL617658,H,8,,,,,1,,BAO_0000357,
2807,,Expert,,12689,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,CHEMBL617659,D,9,,,,,1,,BAO_0000357,
2808,,Expert,,12689,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,CHEMBL617838,D,9,,,,,1,,BAO_0000357,
2809,,Expert,,12689,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,CHEMBL617839,D,9,,,,Brain membranes,1,,BAO_0000249,
2810,,Autocuration,,12689,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,CHEMBL617840,H,8,,,,,1,,BAO_0000357,
2811,,Autocuration,,12689,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,CHEMBL617841,H,8,,,,,1,,BAO_0000019,
2812,,Autocuration,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,CHEMBL875915,H,8,,,,,1,,BAO_0000019,
2813,,Expert,,12689,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,CHEMBL617842,H,8,,,,,1,,BAO_0000219,
2814,,Expert,,12689,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,CHEMBL617843,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2815,,Expert,,12689,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,CHEMBL617844,H,8,,,,,1,,BAO_0000357,
2816,,Expert,,12689,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,CHEMBL617845,H,8,,,,,1,,BAO_0000357,
2817,,Expert,,12689,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,CHEMBL617846,H,8,723.0,NIH3T3,,,1,,BAO_0000219,
2818,,Autocuration,,12689,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,CHEMBL617847,H,8,,,,,1,,BAO_0000357,
2819,,Expert,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617848,H,8,,,,,1,,BAO_0000357,
2820,,Autocuration,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,CHEMBL617849,H,8,,,,,1,,BAO_0000357,
2821,,Expert,,12689,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL621507,H,8,,,,,1,,BAO_0000357,
2822,,Expert,,12689,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,CHEMBL621508,H,8,,,,,1,,BAO_0000357,
2823,,Autocuration,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,CHEMBL621509,H,8,,,,,1,,BAO_0000019,
2824,,Autocuration,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,CHEMBL621510,H,8,,,,,1,,BAO_0000019,
2825,,Autocuration,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,CHEMBL621511,H,8,,,,,1,,BAO_0000019,
2826,,Expert,,12689,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,CHEMBL621512,H,8,625.0,A9,,,1,,BAO_0000219,
2827,,Autocuration,,12689,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,CHEMBL621513,H,8,,,,,1,,BAO_0000357,
2828,,Expert,,12689,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,CHEMBL621514,H,8,,,,,1,,BAO_0000357,
2829,,Expert,,12689,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,CHEMBL621515,H,8,,,,,1,,BAO_0000219,
2830,,Autocuration,,12689,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,CHEMBL621516,H,8,,,,,1,,BAO_0000219,
2831,5383.0,Autocuration,Caudate-putamen,12689,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,CHEMBL621517,H,8,,,,,1,,BAO_0000019,
2832,,Autocuration,,12689,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,CHEMBL621518,H,8,,,,,1,,BAO_0000357,
2833,,Autocuration,,12689,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,CHEMBL621519,H,8,,,,,1,,BAO_0000019,
2834,,Autocuration,,12689,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,CHEMBL621520,H,8,,,,,1,,BAO_0000357,
2835,,Autocuration,,12689,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,CHEMBL621521,H,8,,,,,1,,BAO_0000357,
2836,,Autocuration,,12689,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,CHEMBL621522,H,8,,,,,1,,BAO_0000357,
2837,,Expert,,12689,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,CHEMBL621523,H,8,,,,,1,,BAO_0000219,
2838,,Autocuration,,12689,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,CHEMBL621524,H,8,,,,,1,,BAO_0000357,
2839,,Expert,,12689,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,CHEMBL621525,D,9,,,,,1,,BAO_0000357,
2840,,Autocuration,,12689,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,CHEMBL872921,H,8,,,,,1,,BAO_0000357,
2841,,Autocuration,,12689,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,CHEMBL621526,H,8,,,,,1,,BAO_0000357,
2842,,Expert,,12689,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,CHEMBL621527,H,8,,,,,1,,BAO_0000219,
2843,,Expert,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,CHEMBL617865,D,9,,,,,1,,BAO_0000019,
2844,,Autocuration,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617866,H,8,,,,,1,,BAO_0000357,
2845,,Autocuration,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,CHEMBL617867,H,8,,,,,1,,BAO_0000019,
2846,,Autocuration,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,CHEMBL617487,H,8,,,,,1,,BAO_0000357,
2847,,Expert,,12689,Binding affinity for 5-hydroxytryptamine 2C receptor,CHEMBL617488,H,8,,,,,1,,BAO_0000357,
2848,,Autocuration,,12689,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,CHEMBL617489,H,8,,,,,1,,BAO_0000357,
2849,,Autocuration,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,CHEMBL617490,H,8,,,,,1,,BAO_0000019,
2850,,Autocuration,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,CHEMBL617491,H,8,,,,,1,,BAO_0000019,
2851,,Autocuration,,12689,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,CHEMBL617492,H,8,,,,,1,,BAO_0000019,
2852,,Autocuration,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,CHEMBL617493,H,8,,,,,1,,BAO_0000019,
2853,,Autocuration,,12689,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,CHEMBL617494,H,8,,,,,1,,BAO_0000357,
2854,,Expert,,12689,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,CHEMBL617495,D,9,,,,,1,,BAO_0000019,
2855,,Autocuration,,12689,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,CHEMBL617496,H,8,,,,,1,,BAO_0000357,
2856,,Autocuration,,12689,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,CHEMBL617497,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2857,,Autocuration,,12689,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL617498,H,8,,,,,1,,BAO_0000357,
2858,,Autocuration,,12689,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,CHEMBL617499,H,8,,,,,1,,BAO_0000357,
2859,,Autocuration,,12689,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,CHEMBL617500,H,8,,,,,1,,BAO_0000019,
2860,,Autocuration,,108,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617501,H,8,,,,,1,,BAO_0000357,
2861,,Expert,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617502,H,8,,,,,1,,BAO_0000357,
2862,,Autocuration,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,CHEMBL617503,H,8,,,,,1,,BAO_0000357,
2863,,Autocuration,,227,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,CHEMBL617504,H,8,,,,,1,,BAO_0000357,
2864,,Autocuration,,227,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,CHEMBL617406,H,8,,,,,1,,BAO_0000357,
2865,,Expert,,227,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,CHEMBL617407,D,9,,,,,1,,BAO_0000019,
2866,,Autocuration,,227,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,CHEMBL617408,H,8,,,,,1,,BAO_0000357,
2867,,Autocuration,,227,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,CHEMBL617409,H,8,,,,,1,,BAO_0000357,
2868,,Autocuration,,227,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,CHEMBL617410,H,8,,,,,1,,BAO_0000357,
2869,,Autocuration,,227,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,CHEMBL617411,H,8,,,,,1,,BAO_0000357,
2870,,Autocuration,,227,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,CHEMBL617412,H,8,,,,,1,,BAO_0000019,
2871,,Expert,,227,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,CHEMBL617774,D,9,,,,,1,,BAO_0000357,
2872,,Expert,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,CHEMBL617775,D,9,722.0,HEK293,,,1,,BAO_0000219,
2873,,Expert,,227,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,CHEMBL617776,D,9,722.0,HEK293,,,1,,BAO_0000219,
2874,,Expert,,227,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617777,D,9,449.0,CHO,,,1,,BAO_0000219,
2875,,Expert,,227,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617778,D,9,449.0,CHO,,,1,,BAO_0000219,
2876,,Autocuration,,227,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",CHEMBL617779,H,8,722.0,HEK293,,,1,,BAO_0000219,
2877,,Expert,,227,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,CHEMBL617780,H,8,722.0,HEK293,,,1,,BAO_0000219,
2878,,Autocuration,,227,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",CHEMBL617781,H,8,722.0,HEK293,,,1,,BAO_0000219,
2879,,Expert,,227,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,CHEMBL617782,D,9,722.0,HEK293,,,1,,BAO_0000219,
2880,,Expert,,227,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,CHEMBL617783,D,9,722.0,HEK293,,,1,,BAO_0000219,
2881,,Autocuration,,227,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,CHEMBL617784,H,8,,,,,1,,BAO_0000357,
2882,,Autocuration,,227,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,CHEMBL617785,H,8,722.0,HEK293,,,1,,BAO_0000219,
2883,,Expert,,227,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,CHEMBL857984,H,8,722.0,HEK293,,,1,,BAO_0000219,
2884,,Expert,,227,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,CHEMBL617786,H,8,722.0,HEK293,,,1,,BAO_0000219,
2885,,Expert,,227,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,CHEMBL617787,H,8,722.0,HEK293,,,1,,BAO_0000219,
2886,,Expert,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,CHEMBL617788,D,9,722.0,HEK293,,,1,,BAO_0000219,
2887,,Expert,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,CHEMBL617789,D,9,722.0,HEK293,,,1,,BAO_0000219,
2888,,Autocuration,,227,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,CHEMBL617790,H,8,722.0,HEK293,,,1,,BAO_0000219,
2889,,Expert,,227,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,CHEMBL617791,H,8,485.0,CHO-K1,,,1,,BAO_0000219,
2890,,Expert,,227,Binding affinity against 5-hydroxytryptamine 2B receptor,CHEMBL617608,H,8,,,,,1,,BAO_0000357,
2891,,Autocuration,,227,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,CHEMBL617609,H,8,722.0,HEK293,,,1,,BAO_0000219,
2892,,Autocuration,,227,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,CHEMBL617610,H,8,722.0,HEK293,,,1,,BAO_0000219,
2893,,Autocuration,,227,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,CHEMBL617611,H,8,722.0,HEK293,,,1,,BAO_0000219,
2894,,Autocuration,,227,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",CHEMBL617612,H,8,722.0,HEK293,,,1,,BAO_0000219,
2895,,Autocuration,,227,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",CHEMBL617613,H,8,722.0,HEK293,,,1,,BAO_0000219,
2896,,Autocuration,,227,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,CHEMBL617614,H,8,,,,,1,,BAO_0000019,
2897,945.0,Expert,Stomach,12688,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,CHEMBL617615,H,8,,,,,1,,BAO_0000019,
2898,945.0,Expert,Stomach,12688,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,CHEMBL858114,H,8,,,,,1,,BAO_0000357,
2899,945.0,Autocuration,Stomach,12688,Affinity against serotonergic receptor in the isolated rat stomach fundus,CHEMBL617616,H,8,,,,,1,,BAO_0000357,
2900,945.0,Expert,Stomach,12688,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,CHEMBL617617,D,9,,,,,1,,BAO_0000019,
2901,,Expert,,12688,Antagonistic against 5-hydroxytryptamine 2B receptor,CHEMBL875914,D,9,,,,,1,,BAO_0000019,
2902,945.0,Autocuration,Stomach,12688,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,CHEMBL617618,H,8,,,,,1,,BAO_0000019,
2903,945.0,Expert,Stomach,12688,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,CHEMBL617619,D,9,,,,,1,,BAO_0000357,
2904,,Autocuration,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,CHEMBL617620,H,8,,,,,1,,BAO_0000019,
2905,,Autocuration,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,CHEMBL617621,H,8,,,,,1,,BAO_0000019,
2906,,Autocuration,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,CHEMBL617622,H,8,,,,,1,,BAO_0000019,
2907,945.0,Expert,Stomach,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617623,D,9,,,,,1,,BAO_0000357,
2908,945.0,Expert,Stomach,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617624,D,9,,,,,1,,BAO_0000357,
2909,945.0,Expert,Stomach,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617625,D,9,,,,,1,,BAO_0000357,
2910,945.0,Expert,Stomach,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617626,D,9,,,,,1,,BAO_0000357,
2911,945.0,Autocuration,Stomach,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,CHEMBL617627,H,8,,,,,1,,BAO_0000019,
2912,945.0,Expert,Stomach,12688,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,CHEMBL617628,H,8,,,,,1,,BAO_0000019,
2913,945.0,Autocuration,Stomach,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,CHEMBL617629,H,8,,,,,1,,BAO_0000019,
2914,945.0,Autocuration,Stomach,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,CHEMBL858115,H,8,,,,,1,,BAO_0000019,
2915,945.0,Expert,Stomach,12688,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,CHEMBL617630,D,9,,,,,1,,BAO_0000019,
2916,1515.0,Autocuration,Thoracic aorta,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,CHEMBL617631,H,8,,,,,1,,BAO_0000019,
2917,,Autocuration,,12688,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,CHEMBL617632,H,8,,,,,1,,BAO_0000357,
2918,,Expert,,12688,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,CHEMBL617633,H,8,,,,,1,,BAO_0000357,
2919,,Autocuration,,12688,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,CHEMBL617634,H,8,,,,,1,,BAO_0000357,
2920,,Autocuration,,12688,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,CHEMBL617635,H,8,,,,,1,,BAO_0000357,
2922,945.0,Autocuration,Stomach,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,CHEMBL617637,D,9,,,,,1,,BAO_0000019,
2923,,Autocuration,,227,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL617638,H,8,,,,,1,,BAO_0000357,
2924,,Autocuration,,227,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,CHEMBL617639,H,8,,,,,1,,BAO_0000357,
2925,,Autocuration,,227,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,CHEMBL617640,H,8,,,,,1,,BAO_0000357,
2926,,Autocuration,,227,Evaluated for the binding affinity to 5-HT 2B receptor,CHEMBL617641,H,8,,,,,1,,BAO_0000357,
2927,,Autocuration,,227,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,CHEMBL617642,H,8,,,,,1,,BAO_0000357,
2928,,Autocuration,,227,Binding affinities against 5-hydroxytryptamine 2B receptor,CHEMBL617643,H,8,,,,,1,,BAO_0000357,
2929,,Autocuration,,227,Binding affinities towards 5-hydroxytryptamine 2B receptor,CHEMBL617644,H,8,,,,,1,,BAO_0000357,
2930,,Autocuration,,227,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,CHEMBL617645,H,8,,,,,1,,BAO_0000357,
2931,,Expert,,108,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,CHEMBL617646,H,8,,,,,1,,BAO_0000357,
2932,,Autocuration,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,CHEMBL617647,H,8,,,,,1,,BAO_0000357,
2933,,Autocuration,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,CHEMBL617648,H,8,,,,,1,,BAO_0000357,
2934,,Autocuration,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,CHEMBL617875,H,8,,,,,1,,BAO_0000357,
2935,,Autocuration,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,CHEMBL617876,H,8,,,,,1,,BAO_0000357,
2936,,Expert,,108,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,CHEMBL617877,H,8,,,,,1,,BAO_0000357,
2937,,Expert,,108,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,CHEMBL617878,H,8,,,,,1,,BAO_0000357,
2938,,Autocuration,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,CHEMBL617879,H,8,,,,,1,,BAO_0000357,
2939,,Autocuration,,108,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,CHEMBL617880,H,8,,,,,1,,BAO_0000019,
2940,2435.0,Intermediate,Striatum,20033,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,CHEMBL617881,D,9,,,,,1,,BAO_0000357,
2941,,Autocuration,,51,Binding affinity against 5-HT1A receptor,CHEMBL857073,H,8,,,,,1,,BAO_0000357,
2942,,Expert,,108,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,CHEMBL617882,H,8,449.0,CHO,,,1,,BAO_0000219,
2943,,Expert,,108,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,CHEMBL617883,D,9,449.0,CHO,,,1,,BAO_0000219,
2944,,Autocuration,,108,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,CHEMBL617884,H,8,,,,,1,,BAO_0000219,
2945,,Autocuration,,108,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,CHEMBL617885,H,8,449.0,CHO,,,1,,BAO_0000219,
2946,,Autocuration,,108,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",CHEMBL617886,H,8,449.0,CHO,,,1,,BAO_0000219,
2947,,Expert,,108,Inhibition of human 5-hydroxytryptamine 2C receptor,CHEMBL617887,D,9,,,,,1,,BAO_0000357,
2948,,Autocuration,,108,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),CHEMBL617888,H,8,,,,,1,,BAO_0000357,
2949,,Autocuration,,108,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,CHEMBL617889,H,8,,,,,1,,BAO_0000019,
2950,,Autocuration,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,CHEMBL617890,H,8,,,,,1,,BAO_0000357,
2951,,Autocuration,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,CHEMBL617891,H,8,,,,,1,,BAO_0000357,
2952,,Autocuration,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,CHEMBL617892,H,8,,,,,1,,BAO_0000357,
2953,,Expert,,108,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,CHEMBL617893,H,8,449.0,CHO,,,1,,BAO_0000219,
2954,,Expert,,108,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,CHEMBL617894,H,8,449.0,CHO,,,1,,BAO_0000219,
2955,,Expert,,108,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHEMBL617895,H,8,449.0,CHO,,,1,,BAO_0000219,
2956,,Autocuration,,108,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,CHEMBL617896,H,8,449.0,CHO,,,1,,BAO_0000219,
2957,,Expert,,108,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,CHEMBL617897,D,9,,,,,1,,BAO_0000357,
2958,,Autocuration,,108,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,CHEMBL617898,H,8,,,,,1,,BAO_0000019,
2959,,Autocuration,,108,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,CHEMBL617899,H,8,,,,,1,,BAO_0000019,
2960,,Expert,,108,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,CHEMBL617900,H,8,449.0,CHO,,,1,,BAO_0000219,
2961,,Autocuration,,108,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,CHEMBL617901,H,8,,,,,1,,BAO_0000019,
2962,,Autocuration,,108,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,CHEMBL617902,H,8,,,,,1,,BAO_0000019,
2963,,Autocuration,,108,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL617903,H,8,,,,,1,,BAO_0000019,
2964,,Autocuration,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,CHEMBL617904,H,8,,,,,1,,BAO_0000357,
2965,,Autocuration,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,CHEMBL617905,H,8,,,,,1,,BAO_0000357,
2966,,Autocuration,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,CHEMBL617906,H,8,,,,,1,,BAO_0000357,
2967,,Autocuration,,108,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,CHEMBL617907,H,8,,,,,1,,BAO_0000357,
2968,,Autocuration,,108,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,CHEMBL617908,H,8,,,,,1,,BAO_0000357,
2969,,Expert,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHEMBL620617,H,8,449.0,CHO,,,1,,BAO_0000219,
2970,,Expert,,108,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,CHEMBL620618,D,9,,,,,1,,BAO_0000019,
2971,,Expert,,108,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,CHEMBL620619,H,8,,,,,1,,BAO_0000357,
2972,,Expert,,108,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,CHEMBL620620,D,9,,,,,1,,BAO_0000357,
2973,,Autocuration,,108,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,CHEMBL620621,H,8,,,,,1,,BAO_0000357,
2974,,Autocuration,,104698,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,CHEMBL872920,D,7,,,,Membranes,1,,BAO_0000249,
2975,,Autocuration,,104698,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,CHEMBL620622,H,6,,,,,1,,BAO_0000223,
2976,,Autocuration,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,CHEMBL620623,D,7,,,,,1,,BAO_0000019,
2977,,Autocuration,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,CHEMBL620624,H,6,,,,,1,,BAO_0000019,
2978,,Autocuration,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,CHEMBL620625,H,6,,,,,1,,BAO_0000019,
2979,,Autocuration,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,CHEMBL620626,H,6,,,,,1,,BAO_0000219,
2980,,Autocuration,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,CHEMBL621307,H,6,,,,,1,,BAO_0000019,
2981,,Autocuration,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,CHEMBL621308,H,6,,,,,1,,BAO_0000019,
2982,,Autocuration,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,CHEMBL621309,H,6,,,,,1,,BAO_0000223,
2983,,Autocuration,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,CHEMBL621310,H,6,,,,,1,,BAO_0000223,
2984,,Autocuration,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,CHEMBL621311,H,6,,,,,1,,BAO_0000223,
2985,,Autocuration,,104698,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",CHEMBL621502,H,6,,,,,1,,BAO_0000249,
2986,,Autocuration,,104698,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",CHEMBL621503,H,6,,,,,1,,BAO_0000249,
2987,,Autocuration,,104698,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,CHEMBL621504,H,6,,,,Membranes,1,,BAO_0000249,
2988,,Autocuration,,104698,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,CHEMBL621505,H,6,,,,,1,,BAO_0000223,
2989,,Autocuration,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,CHEMBL621506,H,6,,,,,1,,BAO_0000019,
2990,,Autocuration,,104698,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,CHEMBL619781,H,6,,,,,1,,BAO_0000223,
2991,,Autocuration,,104698,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,CHEMBL619782,H,6,,,,,1,,BAO_0000223,
2992,,Autocuration,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,CHEMBL619783,H,6,,,,,1,,BAO_0000019,
2993,,Autocuration,,104698,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,CHEMBL619784,D,7,,,,,1,,BAO_0000019,
2994,,Autocuration,,104698,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,CHEMBL619785,H,6,,,,,1,,BAO_0000249,
2995,,Autocuration,,104698,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,CHEMBL619786,H,6,,,,,1,,BAO_0000223,
2996,,Autocuration,,104698,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,CHEMBL619787,H,6,,,,,1,,BAO_0000019,
2997,,Autocuration,,104698,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,CHEMBL872925,H,6,,,,,1,,BAO_0000019,
2998,,Autocuration,,104698,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,CHEMBL619788,H,6,,,,,1,,BAO_0000019,
2999,,Autocuration,,104698,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,CHEMBL619789,H,6,,,,,1,,BAO_0000249,
3000,,Autocuration,,104698,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,CHEMBL619790,H,6,,,,,1,,BAO_0000249,
3001,,Autocuration,,104698,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,CHEMBL619791,H,6,,,,,1,,BAO_0000019,
3002,,Autocuration,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,CHEMBL619792,H,6,,,,,1,,BAO_0000019,
3003,,Autocuration,,104698,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,CHEMBL619793,H,6,,,,Membranes,1,,BAO_0000249,
3004,,Autocuration,,104698,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,CHEMBL619794,D,7,,,,,1,,BAO_0000223,
3005,955.0,Autocuration,Brain,104698,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,CHEMBL619795,H,6,,,,,1,,BAO_0000221,
3006,,Autocuration,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,CHEMBL619796,H,6,,,,,1,,BAO_0000019,
3007,,Autocuration,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,CHEMBL620448,H,6,,,,,1,,BAO_0000223,
3008,,Autocuration,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,CHEMBL620449,H,6,,,,,1,,BAO_0000223,
3009,,Autocuration,,104698,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,CHEMBL620450,H,6,,,,,1,,BAO_0000223,
3010,,Autocuration,,104698,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,CHEMBL620451,H,6,,,,,1,,BAO_0000223,
3011,,Autocuration,,104698,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,CHEMBL620631,H,6,,,,,1,,BAO_0000223,
3012,,Autocuration,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,CHEMBL620632,H,6,,,,,1,,BAO_0000019,
3013,,Autocuration,,104698,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,CHEMBL620633,H,6,,,,,1,,BAO_0000019,
3014,,Autocuration,,104698,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,CHEMBL620634,H,6,,,,,1,,BAO_0000223,
3015,,Autocuration,,104698,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,CHEMBL620635,H,6,,,,,1,,BAO_0000019,
3016,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620636,H,6,,,,,1,,BAO_0000218,
3017,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620637,H,6,,,,,1,,BAO_0000218,
3018,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620638,H,6,,,,,1,,BAO_0000218,
3019,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,CHEMBL620639,H,6,,,,,1,,BAO_0000218,
3020,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620640,H,6,,,,,1,,BAO_0000218,
3021,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620641,H,6,,,,,1,,BAO_0000218,
3022,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,CHEMBL620642,H,6,,,,,1,,BAO_0000218,
3023,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620643,H,6,,,,,1,,BAO_0000218,
3024,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,CHEMBL620644,H,6,,,,,1,,BAO_0000218,
3025,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620645,H,6,,,,,1,,BAO_0000218,
3026,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620646,H,6,,,,,1,,BAO_0000218,
3027,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620647,H,6,,,,,1,,BAO_0000218,
3028,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,CHEMBL620648,H,6,,,,,1,,BAO_0000218,
3029,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620649,H,6,,,,,1,,BAO_0000218,
3030,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620650,H,6,,,,,1,,BAO_0000218,
3031,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620651,H,6,,,,,1,,BAO_0000218,
3032,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL872875,H,6,,,,,1,,BAO_0000218,
3033,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620652,H,6,,,,,1,,BAO_0000218,
3034,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,CHEMBL620653,H,6,,,,,1,,BAO_0000019,
3035,,Autocuration,,104698,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,CHEMBL857076,H,6,,,,,1,,BAO_0000019,
3036,,Autocuration,,104698,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,CHEMBL620654,D,7,,,,,1,,BAO_0000019,
3037,,Autocuration,,104698,Binding activity radioligand.,CHEMBL620655,H,6,,,,,1,,BAO_0000223,
3038,,Autocuration,,104698,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,CHEMBL620656,H,6,,,,Brain membranes,1,,BAO_0000249,
3039,,Autocuration,,104698,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,CHEMBL620657,H,6,,,,Brain membranes,1,,BAO_0000249,
3040,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,CHEMBL620658,H,8,,,,,1,,BAO_0000357,
3041,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,CHEMBL620659,H,8,,,,,1,,BAO_0000357,
3042,,Autocuration,,108,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,CHEMBL620660,H,8,,,,,1,,BAO_0000357,
3043,,Autocuration,,108,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,CHEMBL620661,H,8,,,,,1,,BAO_0000357,
3044,,Autocuration,,108,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,CHEMBL620662,H,8,,,,,1,,BAO_0000357,
3045,,Expert,,108,Affinity for 5-hydroxytryptamine 2C receptor,CHEMBL620663,H,8,,,,,1,,BAO_0000357,
3046,,Autocuration,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL620664,H,8,,,,,1,,BAO_0000357,
3047,,Expert,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,CHEMBL620665,H,8,,,,,1,,BAO_0000357,
3048,,Autocuration,,108,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,CHEMBL620666,H,8,,,,,1,,BAO_0000357,
3049,,Autocuration,,108,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,CHEMBL620667,H,8,,,,,1,,BAO_0000357,
3050,,Expert,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,CHEMBL620668,H,8,,,,,1,,BAO_0000357,
3051,,Autocuration,,108,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,CHEMBL620669,H,8,,,,,1,,BAO_0000357,
3052,,Expert,,108,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,CHEMBL620670,H,8,,,,,1,,BAO_0000357,
3053,,Autocuration,,108,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,CHEMBL620671,H,8,,,,,1,,BAO_0000357,
3054,,Autocuration,,108,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,CHEMBL620672,H,8,,,,,1,,BAO_0000357,
3055,,Autocuration,,108,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,CHEMBL620673,H,8,,,,,1,,BAO_0000357,
3056,,Autocuration,,108,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,CHEMBL620674,H,8,,,,,1,,BAO_0000357,
3057,,Autocuration,,108,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,CHEMBL620675,H,8,,,,,1,,BAO_0000357,
3058,,Autocuration,,108,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,CHEMBL620676,H,8,,,,,1,,BAO_0000357,
3059,,Autocuration,,108,Affinity against 5-hydroxytryptamine 2C receptor,CHEMBL621382,H,8,,,,,1,,BAO_0000357,
3060,,Expert,,108,Binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL621383,D,9,,,,,1,,BAO_0000357,
3061,,Autocuration,,108,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,CHEMBL621384,H,8,,,,,1,,BAO_0000357,
3062,,Autocuration,,144,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,CHEMBL621385,H,8,,,,,1,,BAO_0000357,
3063,,Autocuration,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,CHEMBL617989,H,8,,,,,1,,BAO_0000357,
3064,,Expert,,104714,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,CHEMBL617990,H,4,,,,,1,,BAO_0000019,
3065,2116.0,Autocuration,Ileum,104714,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,CHEMBL875085,H,4,,,,,1,,BAO_0000221,
3066,,Autocuration,,104714,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,CHEMBL617991,H,4,,,,,1,,BAO_0000019,
3067,,Autocuration,,104714,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,CHEMBL617992,H,4,,,,,1,,BAO_0000019,
3068,2116.0,Autocuration,Ileum,104714,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,CHEMBL617993,H,4,,,,,1,,BAO_0000221,
3069,2116.0,Autocuration,Ileum,104714,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,CHEMBL617994,H,4,,,,,1,,BAO_0000221,
3070,,Autocuration,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,CHEMBL617995,H,4,,,,,1,,BAO_0000019,
3071,,Autocuration,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,CHEMBL617996,H,4,,,,,1,,BAO_0000019,
3072,,Autocuration,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,CHEMBL617997,H,4,,,,,1,,BAO_0000019,
3073,,Autocuration,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,CHEMBL617998,H,4,,,,,1,,BAO_0000019,
3074,,Autocuration,,104714,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,CHEMBL617999,H,4,,,,,1,,BAO_0000019,
3075,,Autocuration,,104714,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,CHEMBL618000,H,4,,,,,1,,BAO_0000019,
3076,2116.0,Autocuration,Ileum,104714,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",CHEMBL617815,H,4,,,,,1,,BAO_0000221,
3077,2116.0,Autocuration,Ileum,104714,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",CHEMBL617816,H,4,,,,,1,,BAO_0000221,
3078,2116.0,Autocuration,Ileum,104714,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,CHEMBL617817,H,4,,,,,1,,BAO_0000221,
3079,2116.0,Autocuration,Ileum,104714,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,CHEMBL617818,H,4,,,,,1,,BAO_0000221,
3080,2116.0,Autocuration,Ileum,104714,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,CHEMBL617819,H,4,,,,,1,,BAO_0000221,
3081,,Autocuration,,104714,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,CHEMBL617820,H,4,,,,,1,,BAO_0000223,
3082,2116.0,Autocuration,Ileum,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,CHEMBL617821,H,4,,,,,1,,BAO_0000221,
3083,2116.0,Autocuration,Ileum,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),CHEMBL617822,H,4,,,,,1,,BAO_0000221,
3084,2116.0,Autocuration,Ileum,104714,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),CHEMBL617823,H,4,,,,,1,,BAO_0000221,
3085,2116.0,Autocuration,Ileum,104714,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,CHEMBL617824,H,4,,,,,1,,BAO_0000221,
3086,2116.0,Autocuration,Ileum,104714,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,CHEMBL617825,H,4,,,,,1,,BAO_0000221,
3087,2116.0,Autocuration,Ileum,104714,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,CHEMBL617826,H,4,,,,,1,,BAO_0000221,
3088,2116.0,Autocuration,Ileum,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,CHEMBL617827,H,4,,,,,1,,BAO_0000221,
3089,2116.0,Autocuration,Ileum,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),CHEMBL617828,H,4,,,,,1,,BAO_0000221,
3090,2116.0,Autocuration,Ileum,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,CHEMBL617829,H,4,,,,,1,,BAO_0000221,
3091,2116.0,Autocuration,Ileum,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,CHEMBL617830,H,4,,,,,1,,BAO_0000221,
3092,2116.0,Autocuration,Ileum,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,CHEMBL617831,H,4,,,,,1,,BAO_0000221,
3093,2116.0,Autocuration,Ileum,104714,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,CHEMBL617832,H,4,,,,,1,,BAO_0000221,
3094,,Autocuration,,22226,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,CHEMBL617833,U,0,,,,,1,,BAO_0000019,
3095,,Autocuration,,51,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,CHEMBL617834,H,8,,,,,1,,BAO_0000357,
3096,,Expert,,104714,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,CHEMBL617835,D,5,,,,,1,,BAO_0000223,
3097,,Autocuration,,104714,Binding affinity towards 5-HT3 receptor,CHEMBL617836,H,4,,,,,1,,BAO_0000223,
3098,,Autocuration,,104714,Binding activity radioligand.,CHEMBL617837,H,4,,,,,1,,BAO_0000223,
3099,,Autocuration,,104714,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,CHEMBL620392,H,4,,,,,1,,BAO_0000019,
3100,,Autocuration,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,CHEMBL620393,H,4,,,,,1,,BAO_0000223,
3101,,Autocuration,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,CHEMBL620394,H,4,,,,,1,,BAO_0000223,
3102,,Autocuration,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,CHEMBL620395,H,4,,,,,1,,BAO_0000223,
3103,,Autocuration,,22226,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,CHEMBL620396,U,0,,,,,1,,BAO_0000019,
3104,,Expert,,105030,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,CHEMBL620582,H,4,433.0,NG108-15,,,1,,BAO_0000219,
3105,,Autocuration,,105030,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",CHEMBL620583,H,4,,,,,1,,BAO_0000218,
3106,,Autocuration,,105030,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),CHEMBL620584,H,4,,,,,1,,BAO_0000019,
3107,,Autocuration,,105030,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,CHEMBL620585,H,4,,,,,1,,BAO_0000224,
3108,,Autocuration,,105030,Compound was evaluated for the binding affinity at 5- HT3 receptor,CHEMBL620586,H,4,,,,,1,,BAO_0000224,
3109,,Autocuration,,105030,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),CHEMBL620587,H,4,,,,,1,,BAO_0000019,
3110,,Autocuration,,105030,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,CHEMBL620588,H,4,,,,,1,,BAO_0000019,
3111,,Autocuration,,105030,5-hydroxytryptamine 3 receptor agonism in mouse,CHEMBL620589,H,4,,,,,1,,BAO_0000218,
3112,,Autocuration,,105030,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,CHEMBL620590,H,4,,,,,1,,BAO_0000219,
3113,,Autocuration,,105030,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,CHEMBL617956,H,4,,,,,1,,BAO_0000019,
3114,,Autocuration,,105030,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,CHEMBL617957,H,4,,,,,1,,BAO_0000019,
3115,,Autocuration,,105030,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,CHEMBL617958,H,4,,,,,1,,BAO_0000224,
3116,,Autocuration,,105030,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,CHEMBL617959,H,4,,,,,1,,BAO_0000219,
3117,,Autocuration,,105030,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,CHEMBL617960,H,4,,,,,1,,BAO_0000219,
3118,,Autocuration,,105030,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,CHEMBL617961,H,4,,,,,1,,BAO_0000224,
3119,,Autocuration,,105030,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,CHEMBL617962,H,4,,,,,1,,BAO_0000219,
3120,,Autocuration,,105030,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,CHEMBL617963,H,4,339.0,N1E-115,,,1,,BAO_0000219,
3121,,Autocuration,,11765,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL617964,H,8,,,,,1,,BAO_0000019,
3122,,Autocuration,,11765,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,CHEMBL617965,H,8,,,,,1,,BAO_0000219,
3123,,Autocuration,,10630,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,CHEMBL617966,D,9,,,,,1,,BAO_0000357,
3124,,Autocuration,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL857074,H,8,,,,,1,,BAO_0000019,
3125,,Autocuration,,144,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,CHEMBL617967,H,8,,,,,1,,BAO_0000357,
3126,,Autocuration,,144,Binding activity radioligand.,CHEMBL617968,H,8,,,,,1,,BAO_0000357,
3127,,Autocuration,,104714,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,CHEMBL617969,H,4,,,,,1,,BAO_0000223,
3128,,Autocuration,,104714,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,CHEMBL617970,H,4,,,,,1,,BAO_0000223,
3129,,Autocuration,,104714,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,CHEMBL617971,H,4,,,,,1,,BAO_0000223,
3130,,Autocuration,,104714,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,CHEMBL617972,H,4,,,,,1,,BAO_0000019,
3131,,Autocuration,,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),CHEMBL617973,H,4,,,,,1,,BAO_0000019,
3132,,Autocuration,,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),CHEMBL617974,H,4,,,,,1,,BAO_0000019,
3133,2116.0,Autocuration,Ileum,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),CHEMBL617975,H,4,,,,,1,,BAO_0000221,
3134,,Autocuration,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),CHEMBL617976,H,4,,,,,1,,BAO_0000019,
3135,,Autocuration,,104714,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),CHEMBL617977,H,4,,,,,1,,BAO_0000019,
3136,,Autocuration,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),CHEMBL617978,H,4,,,,,1,,BAO_0000019,
3137,,Autocuration,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),CHEMBL617979,H,4,,,,,1,,BAO_0000019,
3138,,Autocuration,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL617980,H,4,449.0,CHO,,,1,,BAO_0000219,
3139,,Autocuration,,104698,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,CHEMBL617981,D,7,,,,,1,,BAO_0000019,
3140,,Autocuration,,12020,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),CHEMBL617982,H,8,,,,,1,,BAO_0000019,
3141,,Autocuration,,12020,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),CHEMBL617983,H,8,,,,,1,,BAO_0000357,
3142,,Autocuration,,104698,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,CHEMBL617984,D,7,,,,,1,,BAO_0000019,
3143,,Autocuration,,104698,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",CHEMBL617985,H,6,,,,,1,,BAO_0000019,
3144,948.0,Autocuration,Heart,104698,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",CHEMBL617986,H,6,,,,,1,,BAO_0000218,
3145,948.0,Autocuration,Heart,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",CHEMBL617987,H,6,,,,,1,,BAO_0000019,
3146,948.0,Autocuration,Heart,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",CHEMBL617988,H,6,,,,,1,,BAO_0000019,
3147,948.0,Autocuration,Heart,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",CHEMBL617792,H,6,,,,,1,,BAO_0000019,
3148,948.0,Autocuration,Heart,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",CHEMBL617793,H,6,,,,,1,,BAO_0000019,
3149,,Autocuration,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617794,H,6,,,,,1,,BAO_0000019,
3150,,Autocuration,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617795,H,6,,,,,1,,BAO_0000019,
3151,,Autocuration,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617796,H,6,,,,,1,,BAO_0000019,
3152,,Autocuration,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617797,H,6,,,,,1,,BAO_0000019,
3153,,Autocuration,,104698,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),CHEMBL617798,D,7,,,,,1,,BAO_0000218,
3154,,Autocuration,,104698,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),CHEMBL617799,H,6,,,,,1,,BAO_0000218,
3155,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617800,D,7,,,,,1,,BAO_0000218,
3156,,Autocuration,,104698,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,CHEMBL617801,D,7,,,,,1,,BAO_0000019,
3157,,Autocuration,,104698,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,CHEMBL617802,D,7,,,,,1,,BAO_0000218,
3158,,Autocuration,,104698,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),CHEMBL617803,D,7,,,,,1,,BAO_0000019,
3159,,Autocuration,,104698,Binding affinity towards 5-HT3 receptor in rat was evaluated,CHEMBL617804,H,6,,,,,1,,BAO_0000019,
3160,,Autocuration,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,CHEMBL617805,D,7,,,,,1,,BAO_0000019,
3161,,Autocuration,,104698,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,CHEMBL617806,H,6,,,,,1,,BAO_0000223,
3162,,Autocuration,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,CHEMBL617807,H,6,,,,,1,,BAO_0000019,
3163,,Autocuration,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,CHEMBL617808,H,6,,,,,1,,BAO_0000019,
3164,,Autocuration,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,CHEMBL617809,H,6,,,,,1,,BAO_0000249,
3165,,Autocuration,,104698,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,CHEMBL617810,H,6,,,,,1,,BAO_0000019,
3166,955.0,Autocuration,Brain,104698,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,CHEMBL617811,H,6,,,,,1,,BAO_0000249,
3167,955.0,Autocuration,Brain,104698,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,CHEMBL617812,H,6,,,,,1,,BAO_0000221,
3168,,Autocuration,,104698,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,CHEMBL617813,H,6,,,,,1,,BAO_0000249,
3169,,Autocuration,,104698,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,CHEMBL617814,H,6,,,,,1,,BAO_0000249,
3170,,Autocuration,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,CHEMBL617698,H,6,,,,,1,,BAO_0000019,
3171,,Autocuration,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,CHEMBL617699,D,7,,,,,1,,BAO_0000019,
3172,,Autocuration,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,CHEMBL617700,D,7,,,,,1,,BAO_0000019,
3173,,Autocuration,,104698,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,CHEMBL617701,D,7,,,,,1,,BAO_0000223,
3174,,Autocuration,,104698,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,CHEMBL617702,H,6,,,,,1,,BAO_0000019,
3175,,Autocuration,,104698,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",CHEMBL617703,H,6,,,,Membranes,1,,BAO_0000249,
3176,,Autocuration,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,CHEMBL617704,D,7,,,,,1,,BAO_0000019,
3177,,Autocuration,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,CHEMBL617705,H,6,,,,,1,,BAO_0000223,
3178,,Autocuration,,104698,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,CHEMBL617706,D,7,,,,,1,,BAO_0000223,
3179,,Autocuration,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),CHEMBL617707,H,6,433.0,NG108-15,,,1,,BAO_0000219,
3180,,Autocuration,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,CHEMBL617708,H,6,433.0,NG108-15,,,1,,BAO_0000219,
3181,,Autocuration,,104698,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,CHEMBL617709,H,6,,,,,1,,BAO_0000019,
3182,,Autocuration,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,CHEMBL617710,H,6,,,,,1,,BAO_0000019,
3183,,Autocuration,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,CHEMBL882925,H,6,,,,,1,,BAO_0000019,
3184,,Autocuration,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,CHEMBL617711,H,6,,,,,1,,BAO_0000019,
3185,,Autocuration,,104698,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,CHEMBL617712,H,6,,,,,1,,BAO_0000019,
3186,,Autocuration,,104698,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,CHEMBL617713,D,7,,,,,1,,BAO_0000019,
3187,,Autocuration,,104698,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",CHEMBL617714,H,6,,,,,1,,BAO_0000019,
3188,,Autocuration,,104698,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,CHEMBL617715,H,6,,,,,1,,BAO_0000218,
3189,,Autocuration,,104698,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,CHEMBL617716,H,6,,,,,1,,BAO_0000218,
3190,,Autocuration,,104698,Inhibition of 5-HT evoked reflex bradycardia in rat.,CHEMBL617717,H,6,,,,,1,,BAO_0000218,
3191,,Autocuration,,104698,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617718,H,6,,,,,1,,BAO_0000218,
3192,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,CHEMBL617719,H,6,,,,,1,,BAO_0000218,
3193,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),CHEMBL617720,H,6,,,,,1,,BAO_0000218,
3194,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,CHEMBL617721,D,7,,,,,1,,BAO_0000218,
3195,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617722,H,6,,,,,1,,BAO_0000218,
3196,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,CHEMBL617723,H,6,,,,,1,,BAO_0000218,
3197,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,CHEMBL617724,H,6,,,,,1,,BAO_0000218,
3198,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,CHEMBL617725,H,6,,,,,1,,BAO_0000218,
3199,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,CHEMBL617726,H,6,,,,,1,,BAO_0000218,
3200,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617727,H,6,,,,,1,,BAO_0000218,
3201,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,CHEMBL617728,H,6,,,,,1,,BAO_0000218,
3202,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,CHEMBL617729,H,6,,,,,1,,BAO_0000218,
3203,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,CHEMBL617730,H,6,,,,,1,,BAO_0000218,
3204,,Autocuration,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617731,H,6,,,,,1,,BAO_0000218,
3205,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,CHEMBL617732,H,6,,,,,1,,BAO_0000218,
3206,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,CHEMBL617733,H,6,,,,,1,,BAO_0000218,
3207,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,CHEMBL617734,H,6,,,,,1,,BAO_0000218,
3208,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,CHEMBL872874,H,6,,,,,1,,BAO_0000218,
3209,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,CHEMBL617735,H,6,,,,,1,,BAO_0000218,
3210,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,CHEMBL617736,H,6,,,,,1,,BAO_0000218,
3211,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,CHEMBL617737,H,6,,,,,1,,BAO_0000218,
3212,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,CHEMBL617738,H,6,,,,,1,,BAO_0000218,
3213,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,CHEMBL617739,H,6,,,,,1,,BAO_0000218,
3214,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,CHEMBL617740,H,6,,,,,1,,BAO_0000218,
3215,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617741,H,6,,,,,1,,BAO_0000218,
3216,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,CHEMBL617742,H,6,,,,,1,,BAO_0000218,
3217,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,CHEMBL617743,H,6,,,,,1,,BAO_0000218,
3218,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,CHEMBL617744,H,6,,,,,1,,BAO_0000218,
3219,,Autocuration,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,CHEMBL617745,H,6,,,,,1,,BAO_0000218,
3220,,Autocuration,,104698,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",CHEMBL617746,H,6,,,,,1,,BAO_0000218,
3221,,Autocuration,,104698,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",CHEMBL617747,H,6,,,,,1,,BAO_0000218,
3222,,Autocuration,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,CHEMBL617748,H,6,,,,,1,,BAO_0000218,
3223,,Autocuration,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,CHEMBL618909,H,6,,,,,1,,BAO_0000218,
3224,,Autocuration,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,CHEMBL618910,H,6,,,,,1,,BAO_0000218,
3225,,Autocuration,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,CHEMBL618911,H,6,,,,,1,,BAO_0000218,
3226,,Autocuration,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,CHEMBL618912,H,6,,,,,1,,BAO_0000218,
3227,,Autocuration,,104698,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),CHEMBL618913,H,6,,,,,1,,BAO_0000218,
3228,,Autocuration,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,CHEMBL618914,H,6,,,,,1,,BAO_0000019,
3229,,Autocuration,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,CHEMBL618915,H,6,,,,,1,,BAO_0000019,
3230,,Autocuration,,104698,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,CHEMBL618916,D,7,,,,,1,,BAO_0000223,
3231,,Autocuration,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,CHEMBL618917,H,6,,,,,1,,BAO_0000019,
3232,10000000.0,Intermediate,Hippocampus,104698,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,CHEMBL618918,D,7,,,,,1,,BAO_0000221,
3233,,Autocuration,,104698,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,CHEMBL618919,D,7,,,,,1,,BAO_0000019,
3234,,Autocuration,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,CHEMBL618920,D,7,,,,,1,,BAO_0000019,
3235,,Autocuration,,104698,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,CHEMBL618921,H,6,,,,,1,,BAO_0000223,
3236,,Autocuration,,104698,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,CHEMBL618922,H,6,,,,,1,,BAO_0000019,
3237,,Autocuration,,104698,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,CHEMBL618923,H,6,,,,,1,,BAO_0000019,
3238,,Autocuration,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,CHEMBL618924,H,6,,,,,1,,BAO_0000019,
3239,,Autocuration,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,CHEMBL618925,H,6,,,,,1,,BAO_0000019,
3240,,Autocuration,,104698,Binding affinity towards 5-HT3 receptor in rat was evaluated,CHEMBL618926,H,6,,,,,1,,BAO_0000019,
3241,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,CHEMBL618927,D,9,,,,,1,,BAO_0000221,
3242,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,CHEMBL618928,D,9,,,,,1,,BAO_0000221,
3243,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",CHEMBL618929,D,9,,,,,1,,BAO_0000221,
3244,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",CHEMBL618930,D,9,,,,,1,,BAO_0000221,
3245,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",CHEMBL618931,D,9,,,,,1,,BAO_0000221,
3246,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",CHEMBL619594,D,9,,,,,1,,BAO_0000221,
3247,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",CHEMBL619595,D,9,,,,,1,,BAO_0000221,
3248,2116.0,Intermediate,Ileum,20033,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,CHEMBL619596,D,9,,,,,1,,BAO_0000221,
3249,2116.0,Intermediate,Ileum,20033,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,CHEMBL619755,D,9,,,,,1,,BAO_0000221,
3250,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,CHEMBL619756,D,9,,,,,1,,BAO_0000221,
3251,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,CHEMBL619757,D,9,,,,,1,,BAO_0000221,
3252,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,CHEMBL619758,D,9,,,,,1,,BAO_0000221,
3253,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",CHEMBL619759,D,9,,,,,1,,BAO_0000221,
3254,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",CHEMBL619760,D,9,,,,,1,,BAO_0000221,
3255,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",CHEMBL619761,D,9,,,,,1,,BAO_0000221,
3256,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,CHEMBL619762,D,9,,,,,1,,BAO_0000221,
3257,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",CHEMBL619763,D,9,,,,,1,,BAO_0000221,
3258,2116.0,Intermediate,Ileum,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",CHEMBL617868,D,9,,,,,1,,BAO_0000221,
3259,,Intermediate,,20033,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,CHEMBL617869,D,9,,,,,1,,BAO_0000357,
3260,2435.0,Intermediate,Striatum,20033,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL882926,D,9,,,,,1,,BAO_0000249,
3261,2435.0,Intermediate,Striatum,20033,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL617870,D,9,,,,,1,,BAO_0000249,
3262,2435.0,Intermediate,Striatum,20033,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,CHEMBL617871,D,9,,,,,1,,BAO_0000357,
3263,2435.0,Intermediate,Striatum,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,CHEMBL617872,D,9,,,,,1,,BAO_0000357,
3264,2435.0,Intermediate,Striatum,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,CHEMBL617873,D,9,,,,,1,,BAO_0000357,
3265,2435.0,Intermediate,Striatum,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,CHEMBL617874,D,9,,,,,1,,BAO_0000357,
3266,2116.0,Intermediate,Ileum,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,CHEMBL619067,D,9,,,,,1,,BAO_0000221,
3267,2116.0,Intermediate,Ileum,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,CHEMBL619068,D,9,,,,,1,,BAO_0000221,
3268,2116.0,Intermediate,Ileum,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,CHEMBL619069,D,9,,,,,1,,BAO_0000221,
3269,,Intermediate,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,CHEMBL619070,D,9,,,,,1,,BAO_0000357,
3270,,Intermediate,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,CHEMBL619071,D,9,,,,,1,,BAO_0000357,
3271,,Intermediate,,20033,Agonistic activity against 5-hydroxytryptamine 4 receptor,CHEMBL619072,D,9,,,,,1,,BAO_0000019,
3272,,Intermediate,,20033,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,CHEMBL619073,D,9,,,,,1,,BAO_0000019,
3273,,Intermediate,,20033,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,CHEMBL619074,D,9,,,,,1,,BAO_0000019,
3274,,Intermediate,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,CHEMBL619075,D,9,,,,,1,,BAO_0000357,
3275,2435.0,Intermediate,Striatum,20033,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,CHEMBL619076,D,9,,,,,1,,BAO_0000357,
3276,2435.0,Intermediate,Striatum,20033,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,CHEMBL619077,D,9,,,,,1,,BAO_0000357,
3277,2435.0,Intermediate,Striatum,20033,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL619078,D,9,,,,,1,,BAO_0000249,
3278,2435.0,Intermediate,Striatum,20033,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL619079,D,9,,,,,1,,BAO_0000249,
3279,2116.0,Intermediate,Ileum,20033,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,CHEMBL619080,D,9,,,,,1,,BAO_0000221,
3280,,Expert,,20033,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,CHEMBL619081,D,9,,,,,1,,BAO_0000357,
3281,,Intermediate,,20033,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,CHEMBL619082,D,9,,,,,1,,BAO_0000357,
3282,,Intermediate,,20033,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,CHEMBL619083,D,9,,,,,1,,BAO_0000357,
3283,,Intermediate,,20033,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,CHEMBL619084,D,9,,,,,1,,BAO_0000357,
3284,2116.0,Intermediate,Ileum,20033,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL859397,D,9,,,,,1,,BAO_0000221,
3285,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,CHEMBL619085,D,9,,,,,1,,BAO_0000221,
3286,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,CHEMBL619086,D,9,,,,,1,,BAO_0000221,
3287,2116.0,Intermediate,Ileum,20033,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,CHEMBL619087,D,9,,,,,1,,BAO_0000221,
3288,2116.0,Intermediate,Ileum,20033,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL619088,D,9,,,,,1,,BAO_0000221,
3289,,Intermediate,,20033,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,CHEMBL619089,D,9,,,,,1,,BAO_0000357,
3290,,Autocuration,,168,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,CHEMBL619090,H,8,,,,,1,,BAO_0000357,
3291,,Intermediate,,20033,Antagonistic activity against 5-hydroxytryptamine 4 receptor,CHEMBL619091,D,9,,,,,1,,BAO_0000019,
3292,,Intermediate,,20033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,CHEMBL619092,D,9,,,,,1,,BAO_0000357,
3293,,Intermediate,,20033,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,CHEMBL619093,D,9,,,,,1,,BAO_0000019,
3294,,Autocuration,,168,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,CHEMBL619094,H,8,722.0,HEK293,,,1,,BAO_0000219,
3295,,Intermediate,,20033,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,CHEMBL619095,D,9,,,,,1,,BAO_0000019,
3296,,Intermediate,,20033,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,CHEMBL857988,D,9,,,,,1,,BAO_0000357,
3297,,Intermediate,,20033,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,CHEMBL619096,D,9,,,,,1,,BAO_0000357,
3298,2435.0,Intermediate,Striatum,20033,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,CHEMBL619097,D,9,,,,,1,,BAO_0000357,
3299,10000000.0,Intermediate,Hippocampus,20033,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,CHEMBL619098,D,9,,,,,1,,BAO_0000221,
3300,,Intermediate,,20033,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,CHEMBL619751,D,9,,,,,1,,BAO_0000357,
3301,,Intermediate,,20033,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,CHEMBL619752,D,9,,,,,1,,BAO_0000357,
3302,2116.0,Intermediate,Ileum,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,CHEMBL875096,D,9,,,,,1,,BAO_0000221,
3303,,Autocuration,,108,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,CHEMBL619004,H,8,,,,,1,,BAO_0000357,
3304,,Autocuration,,168,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,CHEMBL619005,H,8,,,,,1,,BAO_0000357,
3305,,Autocuration,,168,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,CHEMBL619006,H,8,,,,,1,,BAO_0000019,
3306,,Autocuration,,168,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,CHEMBL619007,H,8,308.0,HeLa,,,1,,BAO_0000219,
3307,,Autocuration,,168,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL619008,H,8,,,,,1,,BAO_0000357,
3308,,Autocuration,,168,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,CHEMBL619009,H,8,,,,,1,,BAO_0000357,
3309,,Autocuration,,168,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",CHEMBL619010,H,8,308.0,HeLa,,,1,,BAO_0000219,
3310,,Autocuration,,10622,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,CHEMBL619011,H,8,,,,,1,,BAO_0000357,
3311,,Autocuration,,10622,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,CHEMBL619012,H,8,,,,,1,,BAO_0000357,
3312,,Autocuration,,10622,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,CHEMBL619013,H,8,,,,,1,,BAO_0000219,
3313,,Autocuration,,10622,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,CHEMBL619014,H,8,,,,,1,,BAO_0000357,
3314,2081.0,Autocuration,Cardiac atrium,11249,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,CHEMBL857503,H,8,,,,,1,,BAO_0000019,
3315,2081.0,Autocuration,Cardiac atrium,11249,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,CHEMBL619015,H,8,,,,,1,,BAO_0000019,
3316,,Autocuration,,11249,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL619016,H,8,,,,,1,,BAO_0000357,
3317,10000000.0,Autocuration,Hippocampus,11249,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,CHEMBL619017,H,8,,,,,1,,BAO_0000221,
3318,10000000.0,Autocuration,Hippocampus,168,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,CHEMBL619018,H,8,,,,,1,,BAO_0000221,
3319,,Autocuration,,168,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,CHEMBL619019,H,8,,,,,1,,BAO_0000019,
3320,,Expert,,10623,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,CHEMBL619020,D,9,,,,,1,,BAO_0000357,
3321,,Autocuration,,10623,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,CHEMBL619021,H,8,,,,,1,,BAO_0000019,
3322,,Autocuration,,10623,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,CHEMBL619022,H,8,,,,,1,,BAO_0000357,
3323,,Autocuration,,10623,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,CHEMBL619023,H,8,,,,,1,,BAO_0000357,
3324,,Autocuration,,10623,lntrinsic activity relative to 5-HT receptor,CHEMBL619024,H,8,,,,,1,,BAO_0000019,
3325,,Autocuration,,10623,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,CHEMBL619025,H,8,,,,,1,,BAO_0000019,
3326,,Expert,,10623,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,CHEMBL619026,H,8,,,,,1,,BAO_0000019,
3327,,Autocuration,,10623,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,CHEMBL619027,H,8,,,,,1,,BAO_0000019,
3328,,Autocuration,,10623,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,CHEMBL619028,H,8,,,,,1,,BAO_0000019,
3329,,Autocuration,,10623,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,CHEMBL619029,H,8,,,,,1,,BAO_0000019,
3330,,Autocuration,,10623,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,CHEMBL619030,H,8,,,,,1,,BAO_0000019,
3331,,Expert,,10623,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,CHEMBL619031,H,8,,,,,1,,BAO_0000357,
3332,,Autocuration,,10623,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,CHEMBL619032,H,8,,,,,1,,BAO_0000019,
3333,,Expert,,10623,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,CHEMBL619033,D,9,,,,,1,,BAO_0000357,
3334,,Autocuration,,10623,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,CHEMBL619034,H,8,,,,,1,,BAO_0000357,
3335,,Autocuration,,10623,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,CHEMBL619035,H,8,,,,,1,,BAO_0000357,
3336,,Autocuration,,10623,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,CHEMBL619036,H,8,,,,,1,,BAO_0000357,
3337,,Expert,,10623,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,CHEMBL619037,D,9,,,,,1,,BAO_0000019,
3338,2435.0,Autocuration,Striatum,10623,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,CHEMBL619038,H,8,,,,,1,,BAO_0000249,
3339,,Autocuration,,10623,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,CHEMBL619039,H,8,,,,,1,,BAO_0000249,
3340,,Expert,,10623,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,CHEMBL619040,H,8,,,,,1,,BAO_0000249,
3341,2435.0,Expert,Striatum,10623,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,CHEMBL619041,D,9,,,,,1,,BAO_0000019,
3342,2435.0,Autocuration,Striatum,10623,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,CHEMBL619042,H,8,,,,,1,,BAO_0000019,
3343,2435.0,Expert,Striatum,10623,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,CHEMBL619043,H,8,,,,,1,,BAO_0000249,
3344,2435.0,Expert,Striatum,10623,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,CHEMBL619044,H,8,,,,,1,,BAO_0000019,
3345,2435.0,Expert,Striatum,10623,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,CHEMBL619045,H,8,,,,,1,,BAO_0000249,
3346,2435.0,Expert,Striatum,10623,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,CHEMBL619046,H,8,,,,,1,,BAO_0000249,
3347,,Expert,,10623,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,CHEMBL619047,H,8,,,,,1,,BAO_0000249,
3348,955.0,Autocuration,Brain,10623,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,CHEMBL619048,H,8,,,,,1,,BAO_0000221,
3349,,Autocuration,,10623,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,CHEMBL859398,H,8,,,,,1,,BAO_0000019,
3350,,Autocuration,,10623,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,CHEMBL619049,H,8,,,,,1,,BAO_0000019,
3351,,Autocuration,,10623,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,CHEMBL857886,H,8,,,,,1,,BAO_0000019,
3352,,Autocuration,,10623,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,CHEMBL619050,H,8,,,,,1,,BAO_0000019,
3353,,Autocuration,,10623,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,CHEMBL620591,H,8,,,,,1,,BAO_0000019,
3354,,Expert,,10623,Binding affinity against rat 5-hydroxytryptamine 4 receptor,CHEMBL620592,D,9,,,,,1,,BAO_0000357,
3355,2435.0,Expert,Striatum,10623,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,CHEMBL620593,H,8,,,,,1,,BAO_0000249,
3356,,Expert,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,CHEMBL620594,D,9,,,,,1,,BAO_0000019,
3357,,Expert,,10623,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,CHEMBL875079,H,8,,,,,1,,BAO_0000019,
3358,,Expert,,10623,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,CHEMBL620595,H,8,,,,,1,,BAO_0000019,
3359,,Expert,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,CHEMBL620596,D,9,,,,,1,,BAO_0000019,
3360,,Autocuration,,10623,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,CHEMBL620597,H,8,,,,,1,,BAO_0000019,
3361,,Expert,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,CHEMBL620598,H,8,,,,,1,,BAO_0000019,
3362,,Expert,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),CHEMBL620599,H,8,,,,,1,,BAO_0000218,
3363,,Autocuration,,10623,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,CHEMBL620600,H,8,,,,,1,,BAO_0000019,
3364,,Autocuration,,168,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,CHEMBL620601,H,8,,,,,1,,BAO_0000019,
3365,,Autocuration,,168,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,CHEMBL620602,H,8,,,,,1,,BAO_0000019,
3366,,Autocuration,,168,Tested for affinity towards 5-hydroxytryptamine 4 receptor,CHEMBL620603,H,8,,,,,1,,BAO_0000357,
3367,,Autocuration,,168,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,CHEMBL620604,H,8,,,,,1,,BAO_0000357,
3368,,Autocuration,,168,Compound was tested for 5-hydroxytryptamine 4 binding affinity,CHEMBL620605,H,8,,,,,1,,BAO_0000357,
3369,,Autocuration,,168,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,CHEMBL620606,H,8,,,,,1,,BAO_0000357,
3370,,Autocuration,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,CHEMBL620607,H,8,,,,,1,,BAO_0000019,
3371,,Autocuration,,168,In vitro binding affinity towards 5-HT4 receptor was determined,CHEMBL620608,H,8,,,,,1,,BAO_0000357,
3372,,Autocuration,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,CHEMBL620609,H,8,,,,,1,,BAO_0000019,
3373,,Autocuration,,168,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,CHEMBL620610,H,8,,,,,1,,BAO_0000019,
3374,,Autocuration,,168,Tested for selectivity for 5-hydroxytryptamine 4 receptor,CHEMBL620611,H,8,,,,,1,,BAO_0000357,
3375,,Autocuration,,168,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,CHEMBL620612,H,8,,,,,1,,BAO_0000357,
3376,,Autocuration,,168,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,CHEMBL620613,H,8,,,,,1,,BAO_0000357,
3377,,Autocuration,,168,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,CHEMBL620614,H,8,,,,,1,,BAO_0000357,
3378,,Expert,,168,Binding affinity against 5-Hydroxytryptamine 4 receptor,CHEMBL620615,H,8,,,,,1,,BAO_0000357,
3379,,Autocuration,,104698,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,CHEMBL857075,H,6,,,,Brain membranes,1,,BAO_0000249,
3380,,Autocuration,,104698,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,CHEMBL620616,H,6,,,,Brain membranes,1,,BAO_0000249,
3381,,Autocuration,,104698,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,CHEMBL619411,H,6,,,,Brain membranes,1,,BAO_0000249,
3382,,Autocuration,,104698,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,CHEMBL619412,H,6,,,,,1,,BAO_0000019,
3383,,Autocuration,,104698,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,CHEMBL619413,D,7,,,,,1,,BAO_0000019,
3384,10000000.0,Autocuration,Hippocampus,104698,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,CHEMBL619414,H,6,,,,,1,,BAO_0000221,
3385,,Autocuration,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,CHEMBL619415,H,6,,,,,1,,BAO_0000019,
3386,,Autocuration,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,CHEMBL619416,H,6,,,,,1,,BAO_0000019,
3387,,Autocuration,,104698,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,CHEMBL619417,H,6,,,,,1,,BAO_0000019,
3388,,Autocuration,,104698,Binding affinity against rat 5-hydroxytryptamine 3 receptor,CHEMBL619418,D,7,,,,,1,,BAO_0000223,
3389,,Autocuration,,104698,Binding affinity against 5-Hydroxytryptamine 3 receptor,CHEMBL619419,D,7,,,,,1,,BAO_0000223,
3390,,Autocuration,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,CHEMBL619420,H,6,,,,,1,,BAO_0000019,
3391,,Autocuration,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,CHEMBL619421,H,6,,,,,1,,BAO_0000249,
3392,,Autocuration,,104698,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,CHEMBL619422,D,7,,,,,1,,BAO_0000019,
3393,,Autocuration,,104698,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,CHEMBL619423,H,6,,,,,1,,BAO_0000019,
3394,,Autocuration,,104698,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,CHEMBL875080,H,6,,,,,1,,BAO_0000019,
3395,,Autocuration,,104698,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,CHEMBL619424,H,6,,,,,1,,BAO_0000019,
3396,,Autocuration,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,CHEMBL619425,H,6,,,,,1,,BAO_0000249,
3397,,Autocuration,,104698,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,CHEMBL619426,H,6,,,,,1,,BAO_0000223,
3398,,Autocuration,,104698,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,CHEMBL619427,H,6,,,,,1,,BAO_0000223,
3399,,Autocuration,,104698,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,CHEMBL619645,D,7,,,,,1,,BAO_0000223,
3400,,Expert,,10576,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",CHEMBL619646,D,9,,,,,1,,BAO_0000249,
3401,955.0,Autocuration,Brain,12020,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,CHEMBL619647,H,8,,,,,1,,BAO_0000221,
3402,,Autocuration,,12020,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,CHEMBL619648,H,8,,,,,1,,BAO_0000019,
3403,,Autocuration,,12020,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,CHEMBL619165,H,8,,,,,1,,BAO_0000019,
3404,,Autocuration,,12020,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,CHEMBL620719,H,8,,,,,1,,BAO_0000218,
3405,,Autocuration,,12020,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,CHEMBL872924,H,8,,,,,1,,BAO_0000019,
3406,,Autocuration,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620720,H,8,,,,,1,,BAO_0000357,
3407,,Autocuration,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,CHEMBL620721,H,8,,,,,1,,BAO_0000019,
3408,,Autocuration,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,CHEMBL620722,H,8,,,,,1,,BAO_0000019,
3409,,Autocuration,,104698,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",CHEMBL620723,H,6,,,,,1,,BAO_0000019,
3410,,Autocuration,,12020,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,CHEMBL620724,H,8,,,,,1,,BAO_0000019,
3411,,Autocuration,,104698,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,CHEMBL620725,H,6,,,,,1,,BAO_0000249,
3412,,Autocuration,,12020,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,CHEMBL620726,D,9,,,,,1,,BAO_0000019,
3413,,Expert,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620727,H,8,,,,,1,,BAO_0000357,
3414,,Autocuration,,104714,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,CHEMBL620728,H,4,,,,,1,,BAO_0000223,
3415,,Autocuration,,22226,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL620729,U,0,,,,,1,,BAO_0000019,
3416,,Autocuration,,104714,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,CHEMBL858288,H,4,,,,,1,,BAO_0000019,
3417,,Autocuration,,104714,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620730,H,4,,,,,1,,BAO_0000223,
3418,,Autocuration,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620731,H,4,,,,,1,,BAO_0000223,
3419,,Autocuration,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,CHEMBL620732,H,4,,,,,1,,BAO_0000019,
3420,,Autocuration,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,CHEMBL618042,H,4,,,,,1,,BAO_0000019,
3421,,Autocuration,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,CHEMBL618043,H,4,,,,,1,,BAO_0000019,
3422,,Autocuration,,104714,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618044,H,4,,,,,1,,BAO_0000223,
3423,,Autocuration,,104714,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,CHEMBL618045,H,4,,,,,1,,BAO_0000019,
3424,,Autocuration,,104714,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,CHEMBL618046,H,4,,,,,1,,BAO_0000223,
3425,,Autocuration,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,CHEMBL618047,H,4,,,,,1,,BAO_0000019,
3426,,Autocuration,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,CHEMBL875084,H,4,,,,,1,,BAO_0000019,
3427,,Autocuration,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,CHEMBL618048,H,4,,,,,1,,BAO_0000019,
3428,,Autocuration,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,CHEMBL618049,H,4,,,,,1,,BAO_0000223,
3429,,Autocuration,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,CHEMBL619764,H,4,,,,,1,,BAO_0000019,
3430,,Autocuration,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,CHEMBL619765,H,4,,,,,1,,BAO_0000019,
3431,,Autocuration,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,CHEMBL619766,H,4,,,,,1,,BAO_0000019,
3432,,Autocuration,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,CHEMBL619767,H,4,,,,,1,,BAO_0000223,
3433,,Autocuration,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,CHEMBL619768,H,4,,,,,1,,BAO_0000223,
3434,,Autocuration,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,CHEMBL619769,H,4,,,,,1,,BAO_0000019,
3435,,Autocuration,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,CHEMBL619770,H,4,,,,,1,,BAO_0000223,
3436,,Autocuration,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL619771,H,4,,,,,1,,BAO_0000223,
3437,,Autocuration,,104714,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,CHEMBL619772,H,4,,,,,1,,BAO_0000219,
3438,,Autocuration,,104714,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,CHEMBL619773,H,4,,,,,1,,BAO_0000223,
3439,,Autocuration,,104714,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,CHEMBL619774,H,4,433.0,NG108-15,,,1,,BAO_0000219,
3440,,Autocuration,,104714,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,CHEMBL875083,H,4,,,,,1,,BAO_0000019,
3441,,Autocuration,,104714,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,CHEMBL620718,H,4,433.0,NG108-15,,,1,,BAO_0000219,
3442,,Autocuration,,104714,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,CHEMBL618127,H,4,,,,,1,,BAO_0000223,
3443,,Autocuration,,104714,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,CHEMBL618128,H,4,,,,,1,,BAO_0000223,
3444,,Autocuration,,104714,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,CHEMBL618129,H,4,,,,,1,,BAO_0000219,
3445,,Autocuration,,104714,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,CHEMBL618130,H,4,,,,,1,,BAO_0000223,
3446,,Autocuration,,104714,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,CHEMBL618131,H,4,,,,,1,,BAO_0000019,
3447,,Autocuration,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,CHEMBL618132,H,4,,,,,1,,BAO_0000019,
3448,,Autocuration,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,CHEMBL618133,H,4,,,,,1,,BAO_0000019,
3449,,Autocuration,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,CHEMBL618134,H,4,,,,,1,,BAO_0000019,
3450,,Autocuration,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,CHEMBL618135,H,4,,,,,1,,BAO_0000019,
3451,,Autocuration,,104714,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,CHEMBL618136,H,4,,,,,1,,BAO_0000223,
3452,,Autocuration,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618137,H,4,,,,,1,,BAO_0000223,
3453,,Autocuration,,104714,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,CHEMBL618138,H,4,,,,,1,,BAO_0000223,
3454,,Autocuration,,104714,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,CHEMBL618139,H,4,,,,,1,,BAO_0000223,
3455,,Autocuration,,104714,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,CHEMBL618140,H,4,,,,,1,,BAO_0000223,
3456,,Autocuration,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,CHEMBL618141,H,4,,,,,1,,BAO_0000223,
3457,,Expert,,108,Binding affinity for 5-hydroxytryptamine 2C receptor,CHEMBL873478,H,8,,,,,1,,BAO_0000357,
3458,,Autocuration,,104698,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618142,H,6,,,,,1,,BAO_0000223,
3459,,Autocuration,,144,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,CHEMBL618143,H,8,,,,,1,,BAO_0000357,
3460,,Autocuration,,144,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618144,H,8,,,,,1,,BAO_0000357,
3461,,Autocuration,,144,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,CHEMBL618145,H,8,,,,,1,,BAO_0000357,
3462,,Autocuration,,104714,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,CHEMBL618146,H,4,,,,,1,,BAO_0000223,
3463,,Autocuration,,104714,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,CHEMBL618147,H,4,,,,,1,,BAO_0000223,
3464,,Autocuration,,104714,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,CHEMBL618148,H,4,,,,,1,,BAO_0000223,
3465,,Autocuration,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL618149,H,8,,,,,1,,BAO_0000019,
3466,,Autocuration,,144,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL872927,H,8,,,,,1,,BAO_0000357,
3467,,Autocuration,,144,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618150,H,8,,,,,1,,BAO_0000357,
3468,,Autocuration,,144,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,CHEMBL618151,H,8,,,,,1,,BAO_0000357,
3469,,Autocuration,,144,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,CHEMBL875094,H,8,,,,,1,,BAO_0000357,
3470,,Autocuration,,144,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL618152,H,8,,,,,1,,BAO_0000019,
3471,,Autocuration,,144,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,CHEMBL618153,H,8,,,,,1,,BAO_0000357,
3472,,Autocuration,,144,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,CHEMBL618888,H,8,,,,,1,,BAO_0000357,
3473,,Autocuration,,144,Tested for 5-hydroxytryptamine 3 receptor agonist activity,CHEMBL618889,H,8,,,,,1,,BAO_0000019,
3474,,Autocuration,,144,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,CHEMBL618890,H,8,,,,,1,,BAO_0000357,
3475,,Autocuration,,144,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,CHEMBL618891,H,8,,,,,1,,BAO_0000019,
3476,,Autocuration,,144,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,CHEMBL619054,H,8,,,,,1,,BAO_0000019,
3477,,Autocuration,,104714,Binding affinity against the 5-hydroxytryptamine 3 receptor,CHEMBL619055,H,4,,,,,1,,BAO_0000223,
3478,,Autocuration,,144,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL619056,H,8,,,,,1,,BAO_0000357,
3479,,Autocuration,,144,Percent efficacy against 5-hydroxytryptamine 3A receptor,CHEMBL619057,H,8,,,,,1,,BAO_0000019,
3480,,Autocuration,,144,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL619058,H,8,,,,,1,,BAO_0000357,
3481,,Expert,,12020,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,CHEMBL619059,D,9,,Oocytes,,,1,,BAO_0000219,
3482,,Expert,,12020,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,CHEMBL619060,D,9,,Oocytes,,,1,,BAO_0000219,
3483,,Expert,,12020,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,CHEMBL875095,D,9,,Oocytes,,,1,,BAO_0000219,
3484,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,CHEMBL619061,D,9,,,,,1,,BAO_0000221,
3485,2116.0,Intermediate,Ileum,20033,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,CHEMBL619062,D,9,,,,,1,,BAO_0000221,
3486,,Intermediate,,20033,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,CHEMBL619063,D,9,,,,,1,,BAO_0000019,
3487,2116.0,Intermediate,Ileum,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,CHEMBL619064,D,9,,,,,1,,BAO_0000221,
3488,,Intermediate,,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,CHEMBL619065,D,9,,,,,1,,BAO_0000357,
3489,2116.0,Intermediate,Ileum,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,CHEMBL619066,D,9,,,,,1,,BAO_0000221,
3490,2116.0,Autocuration,Ileum,10209,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,CHEMBL619775,H,8,,,,,1,,BAO_0000221,
3491,,Autocuration,,10209,Affinity against 5-hydroxytryptamine 7 receptor,CHEMBL619776,H,8,,,,,1,,BAO_0000357,
3492,,Autocuration,,104841,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,CHEMBL619777,H,4,,,,,1,,BAO_0000224,
3493,,Autocuration,,104841,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,CHEMBL619778,H,4,,,,,1,,BAO_0000224,
3494,2116.0,Autocuration,Ileum,104841,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,CHEMBL619779,H,4,,,,,1,,BAO_0000221,
3495,,Autocuration,,104841,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",CHEMBL619780,H,4,,,,,1,,BAO_0000224,
3496,,Autocuration,,104841,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",CHEMBL619166,H,4,,,,,1,,BAO_0000224,
3497,,Autocuration,,104841,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,CHEMBL619167,H,4,,,,,1,,BAO_0000019,
3498,,Autocuration,,104841,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,CHEMBL619168,H,4,,,,,1,,BAO_0000019,
3499,2081.0,Expert,Cardiac atrium,168,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,CHEMBL619169,D,9,,,,,1,,BAO_0000219,
3500,2081.0,Expert,Cardiac atrium,168,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,CHEMBL619170,D,9,,,,,1,,BAO_0000219,
3501,,Autocuration,,104841,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",CHEMBL619171,D,5,,,,,1,,BAO_0000019,
3502,2081.0,Expert,Cardiac atrium,168,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",CHEMBL619172,D,9,,,,,1,,BAO_0000219,
3503,,Autocuration,,22226,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,CHEMBL619173,U,0,,,,,1,,BAO_0000019,
3504,,Autocuration,,22226,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,CHEMBL619174,U,0,,,,,1,,BAO_0000019,
3505,,Autocuration,,104705,5-hydroxytryptamine receptor binding affinity was determined in rats,CHEMBL619175,H,4,,,,,1,,BAO_0000019,
3506,,Autocuration,,104705,Binding affinity at rat 5-hydroxytryptamine receptor.,CHEMBL619176,H,4,,,,,1,,BAO_0000224,
3507,,Autocuration,,104705,Affinity against 5-hydroxytryptamine receptors in rat fundus model,CHEMBL619177,H,4,,,,,1,,BAO_0000019,
3508,,Autocuration,,104705,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,CHEMBL619178,H,4,,,,,1,,BAO_0000224,
3509,,Autocuration,,104705,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,CHEMBL619179,H,4,,,,,1,,BAO_0000224,
3510,945.0,Autocuration,Stomach,104705,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,CHEMBL619180,H,4,,,,,1,,BAO_0000019,
3511,945.0,Autocuration,Stomach,104705,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,CHEMBL619181,H,4,,,,,1,,BAO_0000019,
3512,,Autocuration,,104705,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,CHEMBL619182,H,4,,,,,1,,BAO_0000019,
3513,,Autocuration,,104705,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,CHEMBL619183,H,4,,,,,1,,BAO_0000224,
3514,,Autocuration,,104705,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",CHEMBL619184,H,4,,,,,1,,BAO_0000224,
3515,10000000.0,Autocuration,Hippocampus,10576,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,CHEMBL619185,H,8,,,,,1,,BAO_0000221,
3516,,Expert,,12198,Binding affinity for rat 5-hydroxytryptamine transporter.,CHEMBL619186,H,8,,,,,1,,BAO_0000357,
3517,,Autocuration,,104705,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,CHEMBL619187,H,4,,,,,1,,BAO_0000019,
3518,,Autocuration,,104705,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,CHEMBL619188,D,5,,,,,1,,BAO_0000019,
3519,,Autocuration,,104705,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,CHEMBL619189,D,5,,,,,1,,BAO_0000224,
3520,955.0,Expert,Brain,12198,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,CHEMBL619190,D,9,,,,,1,,BAO_0000019,
3521,2037.0,Expert,Cerebellum,12198,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,CHEMBL619191,D,9,,,,,1,,BAO_0000221,
3522,,Autocuration,,104705,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,CHEMBL619192,D,5,,,,,1,,BAO_0000019,
3523,,Autocuration,,104705,Percent binding affinity against 5-hydroxytryptamine receptor,CHEMBL619193,D,5,,,,,1,,BAO_0000224,
3524,,Autocuration,,22226,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,CHEMBL619194,U,0,,,,,1,,BAO_0000019,
3525,,Autocuration,,104705,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,CHEMBL619195,D,5,,,,,1,,BAO_0000224,
3526,,Autocuration,,104705,Affinity against 5-hydroxytryptamine receptor was determined,CHEMBL619196,D,5,,,,,1,,BAO_0000224,
3527,945.0,Autocuration,Stomach,104705,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,CHEMBL619197,D,5,,,,,1,,BAO_0000019,
3528,,Expert,,121,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,CHEMBL619198,D,9,,,,,1,,BAO_0000219,
3529,,Expert,,121,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,CHEMBL875081,D,9,,,,,1,,BAO_0000219,
3530,,Autocuration,,18065,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,CHEMBL884712,H,8,,,,,1,,BAO_0000357,
3531,,Expert,,121,Inhibition of 5-hydroxytryptamine reuptake,CHEMBL884710,H,8,,,,,1,,BAO_0000357,
3532,,Autocuration,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",CHEMBL619199,H,8,,,,,1,,BAO_0000019,
3533,,Autocuration,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",CHEMBL619200,H,8,,,,,1,,BAO_0000019,
3534,,Autocuration,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",CHEMBL619201,H,8,,,,,1,,BAO_0000019,
3535,,Autocuration,,18065,Tested for 5-hydroxytryptamine receptor uptake,CHEMBL619202,H,8,,,,,1,,BAO_0000019,
3536,,Expert,,51,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,CHEMBL619203,D,9,449.0,CHO,,,1,,BAO_0000219,
3537,,Expert,,51,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,CHEMBL619204,D,9,,,,,1,,BAO_0000019,
3538,,Autocuration,,10576,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,CHEMBL619205,H,8,,,,,1,,BAO_0000249,
3539,,Autocuration,,10576,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,CHEMBL619206,H,8,,,,,1,,BAO_0000357,
3540,,Expert,,10576,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,CHEMBL619207,H,8,,,,,1,,BAO_0000249,
3541,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,CHEMBL619208,H,8,,,,,1,,BAO_0000019,
3542,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,CHEMBL619209,H,8,,,,,1,,BAO_0000019,
3543,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,CHEMBL619210,H,8,,,,,1,,BAO_0000019,
3544,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,CHEMBL619211,H,8,,,,,1,,BAO_0000019,
3545,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,CHEMBL619212,H,8,,,,,1,,BAO_0000019,
3546,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,CHEMBL620681,H,8,,,,,1,,BAO_0000019,
3547,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,CHEMBL620682,H,8,,,,,1,,BAO_0000019,
3548,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,CHEMBL620683,H,8,,,,,1,,BAO_0000019,
3549,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,CHEMBL620684,H,8,,,,,1,,BAO_0000019,
3550,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,CHEMBL620685,H,8,,,,,1,,BAO_0000019,
3551,2435.0,Autocuration,Striatum,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,CHEMBL620686,H,8,,,,,1,,BAO_0000019,
3552,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,CHEMBL620687,H,8,,,,,1,,BAO_0000019,
3553,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,CHEMBL620688,H,8,,,,,1,,BAO_0000019,
3554,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,CHEMBL620689,H,8,,,,,1,,BAO_0000019,
3555,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,CHEMBL620690,H,8,,,,,1,,BAO_0000019,
3556,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,CHEMBL620691,H,8,,,,,1,,BAO_0000019,
3557,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,CHEMBL620692,H,8,,,,,1,,BAO_0000019,
3558,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,CHEMBL620693,H,8,,,,,1,,BAO_0000019,
3559,,Expert,,168,Binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL620694,H,8,,,,,1,,BAO_0000357,
3560,,Autocuration,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,CHEMBL857986,H,8,,,,,1,,BAO_0000019,
3561,,Autocuration,,168,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,CHEMBL620695,H,8,,,,,1,,BAO_0000357,
3562,,Expert,,168,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,CHEMBL620696,H,8,,,,,1,,BAO_0000357,
3563,,Autocuration,,168,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,CHEMBL620697,H,8,,,,,1,,BAO_0000357,
3564,,Autocuration,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor,CHEMBL620698,H,8,,,,,1,,BAO_0000357,
3565,,Autocuration,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,CHEMBL620699,H,8,,,,,1,,BAO_0000357,
3566,,Autocuration,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,CHEMBL620700,H,8,,,,,1,,BAO_0000357,
3567,,Autocuration,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,CHEMBL620701,H,8,643.0,COS-7,,,1,,BAO_0000219,
3568,,Autocuration,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,CHEMBL875082,H,8,643.0,COS-7,,,1,,BAO_0000219,
3569,,Autocuration,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,CHEMBL620702,H,8,643.0,COS-7,,,1,,BAO_0000219,
3570,,Autocuration,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,CHEMBL620703,H,8,643.0,COS-7,,,1,,BAO_0000219,
3571,,Autocuration,,168,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,CHEMBL620704,H,8,673.0,C6,,,1,,BAO_0000219,
3572,,Expert,,168,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,CHEMBL620705,H,8,673.0,C6,,,1,,BAO_0000219,
3573,,Expert,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,CHEMBL620706,H,8,673.0,C6,,,1,,BAO_0000219,
3574,,Expert,,168,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,CHEMBL620707,H,8,673.0,C6,,,1,,BAO_0000219,
3575,,Expert,,10624,Binding affinity towards 5-hydroxytryptamine 5 receptor,CHEMBL620708,H,8,,,,,1,,BAO_0000357,
3576,,Autocuration,,105,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,CHEMBL620709,H,8,,,,,1,,BAO_0000357,
3577,,Expert,,10624,Binding affinity against 5-hydroxytryptamine 5A receptor,CHEMBL620710,D,9,,,,,1,,BAO_0000357,
3578,,Autocuration,,10624,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,CHEMBL620711,H,8,449.0,CHO,,,1,,BAO_0000219,
3579,,Expert,,10624,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,CHEMBL620712,D,9,,,,,1,,BAO_0000357,
3580,,Expert,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor,CHEMBL620713,D,9,,,,,1,,BAO_0000357,
3581,,Expert,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,CHEMBL620714,D,9,,,,,1,,BAO_0000357,
3582,,Expert,,10624,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,CHEMBL620715,D,9,,,,,1,,BAO_0000357,
3583,,Autocuration,,10624,Binding affinity towards 5-HT5A receptor,CHEMBL620716,H,8,,,,,1,,BAO_0000357,
3584,,Expert,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,CHEMBL620717,H,8,,,,,1,,BAO_0000357,
3585,,Autocuration,,10624,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,CHEMBL618072,H,8,,,,,1,,BAO_0000357,
3586,,Autocuration,,10624,Binding affinity towards cloned human 5-HT5A receptor was determined,CHEMBL857987,H,8,,,,,1,,BAO_0000357,
3587,,Autocuration,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL618073,H,8,722.0,HEK293,,,1,,BAO_0000219,
3588,,Autocuration,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,CHEMBL618074,H,8,722.0,HEK293,,,1,,BAO_0000219,
3589,,Autocuration,,10624,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),CHEMBL618075,H,8,722.0,HEK293,,,1,,BAO_0000219,
3590,,Expert,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,CHEMBL618076,D,9,,,,,1,,BAO_0000357,
3591,,Expert,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,CHEMBL618077,D,9,,,,,1,,BAO_0000357,
3592,,Expert,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,CHEMBL618078,D,9,,,,,1,,BAO_0000357,
3593,,Expert,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,CHEMBL881821,D,9,,,,,1,,BAO_0000357,
3594,,Expert,,10625,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,CHEMBL618079,D,9,,,,,1,,BAO_0000357,
3595,,Expert,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,CHEMBL618080,H,8,,,,,1,,BAO_0000357,
3596,,Autocuration,,10576,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,CHEMBL618081,H,8,722.0,HEK293,,,1,,BAO_0000219,
3597,,Autocuration,,10626,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,CHEMBL618082,H,8,722.0,HEK293,,,1,,BAO_0000219,
3598,,Expert,,10624,Binding affinity towards 5-HT5a receptor,CHEMBL618083,H,8,,,,,1,,BAO_0000357,
3599,,Expert,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor,CHEMBL618084,D,9,,,,,1,,BAO_0000357,
3600,,Expert,,10624,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,CHEMBL618085,H,8,,,,,1,,BAO_0000357,
3601,,Expert,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,CHEMBL618086,H,8,,,,,1,,BAO_0000357,
3602,,Autocuration,,10624,Binding affinities against 5-hydroxytryptamine 5A receptor,CHEMBL875092,H,8,,,,,1,,BAO_0000357,
3603,,Autocuration,,10624,Binding affinities towards 5-hydroxytryptamine 5A receptor,CHEMBL618087,H,8,,,,,1,,BAO_0000357,
3604,,Autocuration,,10624,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,CHEMBL872926,H,8,,,,,1,,BAO_0000357,
3605,,Autocuration,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,CHEMBL618088,H,4,,,,,1,,BAO_0000019,
3606,,Autocuration,,104714,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,CHEMBL618089,H,4,,,,,1,,BAO_0000223,
3607,,Expert,,10627,Inhibition of human 5-hydroxytryptamine 6 receptor,CHEMBL618090,D,9,,,,,1,,BAO_0000357,
3608,,Expert,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,CHEMBL618091,D,9,,,,,1,,BAO_0000357,
3609,,Autocuration,,10627,Inhibition against human 5-hydroxytryptamine 6 receptor,CHEMBL618092,H,8,,,,,1,,BAO_0000357,
3610,,Expert,,10627,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,CHEMBL618093,D,9,,,,,1,,BAO_0000357,
3611,,Expert,,10627,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,CHEMBL618094,H,8,308.0,HeLa,,,1,,BAO_0000219,
3612,,Expert,,10627,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,CHEMBL618095,D,9,,,,,1,,BAO_0000357,
3613,,Expert,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL875093,D,9,,,,,1,,BAO_0000357,
3614,,Expert,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,CHEMBL618096,D,9,,,,,1,,BAO_0000357,
3615,,Expert,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,CHEMBL618118,D,9,,,,,1,,BAO_0000357,
3616,,Expert,,10627,Binding affinity against 5-hydroxytryptamine 6 receptor,CHEMBL618119,D,9,,,,,1,,BAO_0000357,
3617,,Expert,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL618120,H,8,,,,,1,,BAO_0000357,
3618,,Autocuration,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL618121,H,8,,,,,1,,BAO_0000357,
3619,,Expert,,10627,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",CHEMBL618122,H,8,722.0,HEK293,,,1,,BAO_0000219,
3620,,Autocuration,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,CHEMBL618123,H,8,,,,,1,,BAO_0000357,
3621,,Expert,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,CHEMBL618124,H,8,722.0,HEK293,,,1,,BAO_0000219,
3622,,Autocuration,,10627,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL618125,H,8,,,,,1,,BAO_0000357,
3623,,Expert,,10627,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,CHEMBL618126,D,9,722.0,HEK293,,,1,,BAO_0000219,
3624,,Expert,,10627,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,CHEMBL618236,H,8,,,,,1,,BAO_0000019,
3625,,Expert,,10627,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,CHEMBL618237,H,8,,,,,1,,BAO_0000019,
3626,,Expert,,10627,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,CHEMBL618238,H,8,643.0,COS-7,,,1,,BAO_0000219,
3627,,Expert,,10627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,CHEMBL618239,D,9,,,,,1,,BAO_0000357,
3628,,Autocuration,,10627,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,CHEMBL618240,H,8,,,,,1,,BAO_0000019,
3629,,Autocuration,,10627,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,CHEMBL618241,H,8,,,,,1,,BAO_0000357,
3630,,Autocuration,,10627,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,CHEMBL859399,H,8,722.0,HEK293,,,1,,BAO_0000219,
3631,,Autocuration,,10627,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,CHEMBL618242,H,8,,,,,1,,BAO_0000019,
3632,,Autocuration,,10627,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,CHEMBL857991,H,8,,,,,1,,BAO_0000357,
3633,,Expert,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor,CHEMBL619951,H,8,,,,,1,,BAO_0000357,
3634,,Expert,,10627,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,CHEMBL619952,D,9,308.0,HeLa,,,1,,BAO_0000219,
3635,,Expert,,10627,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,CHEMBL619953,D,9,308.0,HeLa,,,1,,BAO_0000219,
3636,,Autocuration,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,CHEMBL619954,H,8,308.0,HeLa,,,1,,BAO_0000219,
3637,,Autocuration,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,CHEMBL619955,H,8,308.0,HeLa,,,1,,BAO_0000219,
3638,,Autocuration,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,CHEMBL619956,H,8,308.0,HeLa,,,1,,BAO_0000219,
3639,,Autocuration,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHEMBL619957,H,8,449.0,CHO,,,1,,BAO_0000219,
3640,,Autocuration,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL619958,H,8,722.0,HEK293,,,1,,BAO_0000219,
3641,,Autocuration,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,CHEMBL620627,H,8,722.0,HEK293,,,1,,BAO_0000219,
3642,,Autocuration,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,CHEMBL620628,H,8,722.0,HEK293,,,1,,BAO_0000219,
3643,,Autocuration,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,CHEMBL620629,H,8,308.0,HeLa,,,1,,BAO_0000219,
3644,,Autocuration,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL620630,H,8,,,,,1,,BAO_0000357,
3645,,Autocuration,,10627,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,CHEMBL620782,H,8,308.0,HeLa,,,1,,BAO_0000219,
3646,,Autocuration,,10627,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,CHEMBL620783,H,8,,,,,1,,BAO_0000357,
3647,,Expert,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor,CHEMBL620784,H,8,,,,,1,,BAO_0000357,
3648,,Expert,,10627,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,CHEMBL620785,H,8,308.0,HeLa,,,1,,BAO_0000219,
3649,,Autocuration,,10627,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),CHEMBL857992,H,8,,,,,1,,BAO_0000357,
3650,,Autocuration,,10627,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,CHEMBL620786,H,8,,,,,1,,BAO_0000219,
3651,,Autocuration,,10627,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,CHEMBL620787,H,8,308.0,HeLa,,,1,,BAO_0000219,
3652,,Autocuration,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",CHEMBL620788,H,8,308.0,HeLa,,,1,,BAO_0000219,
3653,,Autocuration,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",CHEMBL620789,H,8,308.0,HeLa,,,1,,BAO_0000219,
3654,,Autocuration,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",CHEMBL620790,H,8,308.0,HeLa,,,1,,BAO_0000219,
3655,,Autocuration,,10628,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,CHEMBL620791,H,8,449.0,CHO,,,1,,BAO_0000219,
3656,,Autocuration,,10628,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,CHEMBL620792,H,8,,,,,1,,BAO_0000019,
3657,,Autocuration,,10628,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,CHEMBL620793,H,8,,,,,1,,BAO_0000357,
3658,,Autocuration,,10628,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,CHEMBL620794,H,8,,,,,1,,BAO_0000357,
3659,,Autocuration,,10627,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,CHEMBL620795,D,9,308.0,HeLa,,,1,,BAO_0000219,
3660,,Expert,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL620796,H,8,,,,,1,,BAO_0000357,
3661,,Autocuration,,10627,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,CHEMBL620797,H,8,,,,,1,,BAO_0000357,
3662,,Expert,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,CHEMBL620798,D,9,,,,,1,,BAO_0000019,
3663,,Autocuration,,10627,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,CHEMBL620799,H,8,,,,,1,,BAO_0000357,
3664,,Expert,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL620800,H,8,,,,,1,,BAO_0000357,
3665,,Autocuration,,10627,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,CHEMBL620801,H,8,,,,,1,,BAO_0000357,
3666,,Autocuration,,10627,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,CHEMBL875100,H,8,,,,,1,,BAO_0000357,
3667,,Autocuration,,10627,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,CHEMBL620802,H,8,,,,,1,,BAO_0000357,
3668,,Expert,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,CHEMBL620803,H,8,,,,,1,,BAO_0000019,
3669,,Expert,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,CHEMBL620804,H,8,,,,,1,,BAO_0000019,
3670,,Autocuration,,10627,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,CHEMBL620805,H,8,,,,,1,,BAO_0000357,
3671,,Autocuration,,10627,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,CHEMBL620806,H,8,,,,,1,,BAO_0000357,
3672,,Autocuration,,10627,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,CHEMBL620807,H,8,,,,,1,,BAO_0000357,
3673,,Autocuration,,10627,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,CHEMBL620808,H,8,,,,,1,,BAO_0000357,
3674,,Autocuration,,10627,Binding affinities against 5-hydroxytryptamine 6 receptor,CHEMBL620809,H,8,,,,,1,,BAO_0000357,
3675,,Autocuration,,10627,Binding affinities towards 5-hydroxytryptamine 6 receptor,CHEMBL620810,H,8,,,,,1,,BAO_0000357,
3676,,Expert,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor,CHEMBL620811,D,9,,,,,1,,BAO_0000357,
3677,,Autocuration,,10627,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,CHEMBL620812,H,8,,,,,1,,BAO_0000357,
3678,,Autocuration,,10627,Affinity against 5-hydroxytryptamine 6 receptor,CHEMBL620813,H,8,,,,,1,,BAO_0000357,
3679,,Autocuration,,10627,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],CHEMBL620814,H,8,,,,,1,,BAO_0000357,
3680,,Expert,,10209,Inhibition of human 5-hydroxytryptamine 7 receptor,CHEMBL620815,D,9,,,,,1,,BAO_0000357,
3681,,Autocuration,,10209,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,CHEMBL620816,H,8,722.0,HEK293,,,1,,BAO_0000219,
3682,,Autocuration,,10209,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,CHEMBL620817,H,8,,,,,1,,BAO_0000357,
3683,,Autocuration,,10209,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),CHEMBL620818,H,8,,,,,1,,BAO_0000357,
3684,,Expert,,10209,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,CHEMBL620819,H,8,722.0,HEK293,,,1,,BAO_0000219,
3685,,Expert,,10209,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,CHEMBL620820,D,9,,,,,1,,BAO_0000357,
3686,,Autocuration,,10209,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,CHEMBL620821,H,8,449.0,CHO,,,1,,BAO_0000219,
3687,,Expert,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor,CHEMBL620822,D,9,,,,,1,,BAO_0000357,
3688,,Expert,,10209,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,CHEMBL620823,D,9,,,,,1,,BAO_0000357,
3689,,Expert,,10209,Binding affinity against 5-hydroxytryptamine 7 receptor,CHEMBL620824,D,9,,,,,1,,BAO_0000357,
3690,,Expert,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,CHEMBL620825,H,8,449.0,CHO,,,1,,BAO_0000219,
3691,,Autocuration,,10209,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,CHEMBL872930,H,8,,,,,1,,BAO_0000357,
3692,,Autocuration,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor,CHEMBL620826,H,8,,,,,1,,BAO_0000357,
3693,,Autocuration,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,CHEMBL620827,H,8,,,,,1,,BAO_0000357,
3694,,Autocuration,,10209,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,CHEMBL620828,H,8,,,,,1,,BAO_0000357,
3695,,Autocuration,,10209,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,CHEMBL620829,H,8,,,,,1,,BAO_0000357,
3696,,Expert,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,CHEMBL620830,H,8,722.0,HEK293,,,1,,BAO_0000219,
3697,,Expert,,10209,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,CHEMBL620831,H,8,,,,,1,,BAO_0000019,
3698,,Expert,,10209,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,CHEMBL620832,H,8,,,,,1,,BAO_0000019,
3699,,Expert,,10209,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,CHEMBL621548,D,9,,,,,1,,BAO_0000357,
3700,,Autocuration,,10209,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,CHEMBL621549,H,8,,,,,1,,BAO_0000019,
3701,,Autocuration,,10209,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,CHEMBL621550,H,8,,,,,1,,BAO_0000357,
3702,,Autocuration,,10209,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,CHEMBL621551,H,8,449.0,CHO,,,1,,BAO_0000219,
3703,,Autocuration,,10209,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,CHEMBL621552,H,8,,,,,1,,BAO_0000019,
3704,,Autocuration,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,CHEMBL857077,H,8,,,,,1,,BAO_0000357,
3705,,Autocuration,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,CHEMBL618158,H,8,,,,,1,,BAO_0000357,
3706,,Expert,,10209,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,CHEMBL618159,D,9,643.0,COS-7,,,1,,BAO_0000219,
3707,,Autocuration,,10209,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,CHEMBL875101,H,8,643.0,COS-7,,,1,,BAO_0000219,
3708,,Expert,,10209,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,CHEMBL618160,D,9,722.0,HEK293,,,1,,BAO_0000219,
3709,,Expert,,10209,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,CHEMBL618161,H,8,,,,,1,,BAO_0000357,
3710,,Expert,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,CHEMBL618162,H,8,722.0,HEK293,,,1,,BAO_0000219,
3711,,Expert,,10209,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,CHEMBL618163,H,8,,,,,1,,BAO_0000357,
3712,,Autocuration,,10209,Binding affinity against 5-hydroxytryptamine 7 human receptors,CHEMBL618164,H,8,,,,,1,,BAO_0000357,
3713,,Expert,,10209,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,CHEMBL618165,H,8,,,,,1,,BAO_0000219,
3714,,Autocuration,,10209,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,CHEMBL618166,H,8,722.0,HEK293,,,1,,BAO_0000219,
3715,,Autocuration,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL857989,H,8,722.0,HEK293,,,1,,BAO_0000219,
3716,,Autocuration,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL619888,H,8,722.0,HEK293,,,1,,BAO_0000219,
3717,,Autocuration,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL619889,H,8,722.0,HEK293,,,1,,BAO_0000219,
3718,,Autocuration,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL619890,H,8,722.0,HEK293,,,1,,BAO_0000219,
3719,,Autocuration,,10209,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,CHEMBL619891,H,8,449.0,CHO,,,1,,BAO_0000219,
3720,,Autocuration,,10209,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),CHEMBL619892,H,8,722.0,HEK293,,,1,,BAO_0000219,
3721,,Expert,,10209,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,CHEMBL619893,D,9,722.0,HEK293,,,1,,BAO_0000219,
3722,,Autocuration,,10209,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),CHEMBL619894,H,8,722.0,HEK293,,,1,,BAO_0000219,
3723,,Intermediate,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,CHEMBL619895,D,9,722.0,HEK293,,,1,,BAO_0000219,
3724,,Intermediate,,10209,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,CHEMBL619896,D,9,,,,,1,,BAO_0000357,
3725,,Autocuration,,10209,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,CHEMBL619897,H,8,643.0,COS-7,,,1,,BAO_0000219,
3726,,Autocuration,,10209,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,CHEMBL619898,H,8,722.0,HEK293,,,1,,BAO_0000219,
3727,,Expert,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,CHEMBL619899,H,8,722.0,HEK293,,,1,,BAO_0000219,
3728,,Autocuration,,10209,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),CHEMBL619900,H,8,722.0,HEK293,,,1,,BAO_0000219,
3729,,Expert,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,CHEMBL619901,D,9,722.0,HEK293,,,1,,BAO_0000219,
3730,,Autocuration,,10209,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,CHEMBL620580,H,8,722.0,HEK293,,,1,,BAO_0000219,
3731,,Autocuration,,10209,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,CHEMBL620581,H,8,722.0,HEK293,,,1,,BAO_0000219,
3732,,Autocuration,,10209,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",CHEMBL620733,H,8,722.0,HEK293,,,1,,BAO_0000219,
3733,,Autocuration,,10209,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,CHEMBL620734,D,9,,,,,1,,BAO_0000357,
3734,,Expert,,10022,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,CHEMBL620735,D,9,,,,,1,,BAO_0000357,
3735,,Autocuration,,10209,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,CHEMBL620736,H,8,,,,,1,,BAO_0000019,
3736,,Autocuration,,11923,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,CHEMBL620737,H,8,449.0,CHO,,,1,,BAO_0000219,
3737,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,CHEMBL620738,H,8,449.0,CHO,,,1,,BAO_0000219,
3738,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,CHEMBL620739,H,8,449.0,CHO,,,1,,BAO_0000219,
3739,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,CHEMBL620740,H,8,449.0,CHO,,,1,,BAO_0000219,
3740,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,CHEMBL620741,H,8,449.0,CHO,,,1,,BAO_0000219,
3741,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,CHEMBL620742,H,8,449.0,CHO,,,1,,BAO_0000219,
3742,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,CHEMBL620743,H,8,449.0,CHO,,,1,,BAO_0000219,
3743,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,CHEMBL620744,H,8,449.0,CHO,,,1,,BAO_0000219,
3744,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,CHEMBL620745,H,8,449.0,CHO,,,1,,BAO_0000219,
3745,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,CHEMBL620746,H,8,449.0,CHO,,,1,,BAO_0000219,
3746,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,CHEMBL620747,H,8,449.0,CHO,,,1,,BAO_0000219,
3747,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,CHEMBL620748,H,8,449.0,CHO,,,1,,BAO_0000219,
3748,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,CHEMBL620749,H,8,449.0,CHO,,,1,,BAO_0000219,
3749,,Expert,,11923,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,CHEMBL620750,H,8,,,,,1,,BAO_0000357,
3750,,Expert,,11923,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,CHEMBL620751,D,9,,,,,1,,BAO_0000357,
3751,,Expert,,11923,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,CHEMBL620752,H,8,,,,,1,,BAO_0000357,
3752,,Autocuration,,11923,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,CHEMBL872929,H,8,,,,,1,,BAO_0000019,
3753,,Expert,,11923,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,CHEMBL620753,D,9,,,,,1,,BAO_0000357,
3754,,Expert,,11923,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,CHEMBL620754,D,9,,,,,1,,BAO_0000357,
3755,,Expert,,11923,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,CHEMBL620755,D,9,449.0,CHO,,,1,,BAO_0000219,
3756,,Autocuration,,11923,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,CHEMBL620756,H,8,,,,,1,,BAO_0000357,
3757,,Autocuration,,11923,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,CHEMBL620757,H,8,,,,,1,,BAO_0000357,
3758,,Autocuration,,11923,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",CHEMBL620758,H,8,449.0,CHO,,,1,,BAO_0000219,
3759,,Autocuration,,11923,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",CHEMBL620759,H,8,449.0,CHO,,,1,,BAO_0000219,
3760,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,CHEMBL620760,H,8,449.0,CHO,,,1,,BAO_0000219,
3761,,Autocuration,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,CHEMBL620761,H,8,449.0,CHO,,,1,,BAO_0000219,
3762,2116.0,Autocuration,Ileum,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,CHEMBL620762,H,8,,,,,1,,BAO_0000221,
3763,2116.0,Autocuration,Ileum,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,CHEMBL620763,H,8,,,,,1,,BAO_0000221,
3764,2116.0,Autocuration,Ileum,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,CHEMBL620764,H,8,,,,,1,,BAO_0000221,
3765,,Expert,,11923,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,CHEMBL857990,D,9,,,,Membranes,1,,BAO_0000249,
3766,,Autocuration,,11923,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,CHEMBL620765,H,8,,,,,1,,BAO_0000357,
3767,,Expert,,11923,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,CHEMBL620766,H,8,,,,,1,,BAO_0000357,
3768,1898.0,Expert,Hypothalamus,11923,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,CHEMBL620767,H,8,,,,,1,,BAO_0000019,
3769,,Autocuration,,11923,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,CHEMBL620768,H,8,,,,,1,,BAO_0000357,
3770,1898.0,Expert,Hypothalamus,11923,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,CHEMBL619051,H,8,,,,,1,,BAO_0000249,
3771,,Expert,,11923,Binding affinity towards 5-hydroxytryptamine 7 receptor,CHEMBL619052,H,8,,,,,1,,BAO_0000357,
3772,,Expert,,11923,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,CHEMBL619053,D,9,722.0,HEK293,,,1,,BAO_0000219,
3773,,Expert,,11923,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,CHEMBL619703,D,9,722.0,HEK293,,,1,,BAO_0000219,
3774,,Autocuration,,11923,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,CHEMBL619704,D,9,722.0,HEK293,,,1,,BAO_0000219,
3775,,Expert,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor,CHEMBL619851,H,8,,,,,1,,BAO_0000357,
3776,,Autocuration,,10209,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,CHEMBL619852,H,8,,,,,1,,BAO_0000357,
3777,,Autocuration,,10209,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,CHEMBL619853,H,8,,,,,1,,BAO_0000357,
3778,,Expert,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor,CHEMBL619854,D,9,,,,,1,,BAO_0000357,
3779,,Expert,,10209,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,CHEMBL619855,H,8,,,,,1,,BAO_0000357,
3780,,Autocuration,,10209,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,CHEMBL619856,H,8,,,,,1,,BAO_0000357,
3781,,Autocuration,,10209,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,CHEMBL619857,H,8,,,,,1,,BAO_0000357,
3782,,Expert,,10209,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,CHEMBL619858,H,8,,,,,1,,BAO_0000019,
3783,,Autocuration,,10209,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,CHEMBL619859,H,8,,,,,1,,BAO_0000357,
3784,,Autocuration,,10209,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,CHEMBL619860,H,8,,,,,1,,BAO_0000357,
3785,,Autocuration,,10209,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,CHEMBL619861,H,8,,,,,1,,BAO_0000357,
3786,,Expert,,10209,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,CHEMBL619862,H,8,,,,,1,,BAO_0000357,
3787,,Autocuration,,10209,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,CHEMBL619863,H,8,,,,,1,,BAO_0000357,
3788,,Autocuration,,10209,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,CHEMBL619864,H,8,,,,,1,,BAO_0000357,
3789,,Autocuration,,10209,Binding affinities against 5-hydroxytryptamine 7 receptor,CHEMBL872928,H,8,,,,,1,,BAO_0000357,
3790,,Autocuration,,10209,Binding affinities towards 5-hydroxytryptamine 7 receptor,CHEMBL619865,H,8,,,,,1,,BAO_0000357,
3791,,Expert,,10209,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,CHEMBL619866,H,8,,,,,1,,BAO_0000357,
3792,,Autocuration,,10209,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,CHEMBL619867,H,8,,,,,1,,BAO_0000357,
3793,2116.0,Autocuration,Ileum,10209,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,CHEMBL619868,H,8,,,,,1,,BAO_0000221,
3794,,Autocuration,,55,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,CHEMBL619869,H,8,,,,,1,,BAO_0000019,
3795,,Expert,,55,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,CHEMBL619870,D,9,,,,,1,,BAO_0000019,
3796,,Autocuration,,55,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,CHEMBL619871,H,8,,,,,1,,BAO_0000357,
3797,,Autocuration,,55,In vitro inhibition of human recombinant lipoxygenase enzyme,CHEMBL619872,H,8,,,,,1,,BAO_0000357,
3798,,Autocuration,,55,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,CHEMBL619873,H,8,,,,,1,,BAO_0000357,
3799,178.0,Expert,Blood,55,Inhibition of 5-lipoxygenase in human whole blood.,CHEMBL619874,H,8,,,,,1,,BAO_0000357,
3800,178.0,Expert,Blood,55,Inhibition of 5-lipoxygenase in human whole blood.,CHEMBL619875,H,8,,,,,1,,BAO_0000357,
3801,,Autocuration,,55,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,CHEMBL619876,H,8,,,,,1,,BAO_0000357,
3802,,Autocuration,,55,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),CHEMBL619877,H,8,,,,,1,,BAO_0000357,
3803,,Expert,,55,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,CHEMBL619878,H,8,,,,,1,,BAO_0000219,
3804,178.0,Autocuration,Blood,55,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,CHEMBL619879,H,8,,,,,1,,BAO_0000019,
3805,,Autocuration,,55,In vitro inhibition of 5-lipoxygenase from human polymorphs,CHEMBL619880,H,8,,,,,1,,BAO_0000357,
3806,,Autocuration,,55,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),CHEMBL619881,H,8,,,,,1,,BAO_0000357,
3807,,Expert,,55,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,CHEMBL619882,H,8,,,,,1,,BAO_0000357,
3808,,Autocuration,,55,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,CHEMBL619883,H,8,,,,,1,,BAO_0000357,
3809,178.0,Expert,Blood,55,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),CHEMBL619884,D,9,,,,,1,,BAO_0000357,
3810,,Autocuration,,55,In vitro potency against human 5-Lipoxygenase,CHEMBL619885,H,8,,,,,1,,BAO_0000357,
3811,,Expert,,55,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,CHEMBL619886,D,9,,,,,1,,BAO_0000019,
3812,178.0,Autocuration,Blood,55,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,CHEMBL619887,H,8,,,,,1,,BAO_0000019,
3813,,Autocuration,,55,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,CHEMBL875097,H,8,,,,,1,,BAO_0000019,
3814,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,CHEMBL618001,H,8,,,,,1,,BAO_0000219,
3815,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,CHEMBL618002,H,8,,,,,1,,BAO_0000219,
3816,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,CHEMBL618003,H,8,,,,,1,,BAO_0000219,
3817,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,CHEMBL618004,H,8,,,,,1,,BAO_0000219,
3818,,Autocuration,,55,Inhibition of human 5-lipoxygenase in human cells,CHEMBL618005,H,8,,,,,1,,BAO_0000219,
3819,,Expert,,55,Inhibition of human neutrophil 5-lipoxygenase,CHEMBL618006,H,8,,,,,1,,BAO_0000357,
3820,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,CHEMBL875086,H,8,,,,,1,,BAO_0000019,
3821,178.0,Expert,Blood,55,Inhibition of 5-lipoxygenase from human whole blood,CHEMBL618007,H,8,,,,,1,,BAO_0000357,
3822,,Autocuration,,55,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,CHEMBL618008,H,8,,,,,1,,BAO_0000357,
3823,,Autocuration,,55,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,CHEMBL618009,H,8,,,,,1,,BAO_0000219,
3824,,Expert,,55,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,CHEMBL618010,H,8,,,,,1,,BAO_0000357,
3825,,Autocuration,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,CHEMBL618011,H,8,,,,,1,,BAO_0000357,
3826,,Expert,,55,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,CHEMBL618012,H,8,,,,,1,,BAO_0000357,
3827,,Autocuration,,55,Tested against 5-lipoxygenase,CHEMBL882927,H,8,,,,,1,,BAO_0000357,
3828,,Autocuration,,55,Tested for activity against 5-Lipoxygenase (5-LO),CHEMBL618013,H,8,,,,,1,,BAO_0000357,
3829,,Autocuration,,55,Tested for activity against 5-lipoxygenase,CHEMBL618014,H,8,,,,,1,,BAO_0000357,
3830,,Autocuration,,55,Tested for inhibition of 5-HPETE production by human 5-LO,CHEMBL618015,H,8,,,,,1,,BAO_0000357,
3831,,Autocuration,,55,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,CHEMBL618016,H,8,,,,,1,,BAO_0000019,
3832,,Expert,,55,Inhibition of Human 5-lipoxygenase,CHEMBL618017,H,8,,,,,1,,BAO_0000357,
3833,,Autocuration,,55,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,CHEMBL618018,H,8,,,,,1,,BAO_0000019,
3834,,Autocuration,,55,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],CHEMBL875087,H,8,,,,,1,,BAO_0000219,
3835,,Autocuration,,55,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],CHEMBL618019,H,8,,,,,1,,BAO_0000219,
3836,,Autocuration,,55,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,CHEMBL618020,H,8,,,,,1,,BAO_0000019,
3837,,Autocuration,,55,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,CHEMBL618021,H,8,,,,,1,,BAO_0000019,
3838,178.0,Autocuration,Blood,55,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),CHEMBL618022,H,8,,,,,1,,BAO_0000357,
3839,,Autocuration,,55,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,CHEMBL618023,H,8,,,,,1,,BAO_0000357,
3840,,Autocuration,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),CHEMBL618024,H,8,,,,,1,,BAO_0000357,
3841,,Expert,,55,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,CHEMBL873950,H,8,,,,,1,,BAO_0000019,
3842,,Autocuration,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,CHEMBL618025,H,8,,,,,1,,BAO_0000357,
3843,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,CHEMBL618026,H,8,,,,,1,,BAO_0000219,
3844,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,CHEMBL618027,H,8,,,,,1,,BAO_0000219,
3845,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,CHEMBL618028,H,8,,,,,1,,BAO_0000219,
3846,,Autocuration,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,CHEMBL618029,H,8,,,,,1,,BAO_0000219,
3847,,Expert,,55,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,CHEMBL618030,H,8,,,,,1,,BAO_0000357,
3848,,Expert,,55,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,CHEMBL618031,H,8,,,,,1,,BAO_0000357,
3849,,Autocuration,,55,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,CHEMBL618032,H,8,,,,,1,,BAO_0000357,
3850,,Autocuration,,55,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,CHEMBL618033,H,8,,,,,1,,BAO_0000357,
3851,,Autocuration,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,CHEMBL618034,H,8,,,,,1,,BAO_0000357,
3852,,Autocuration,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,CHEMBL875088,H,8,,,,,1,,BAO_0000357,
3853,,Autocuration,,55,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,CHEMBL618035,H,8,,,,,1,,BAO_0000019,
3854,,Autocuration,,55,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,CHEMBL618036,H,8,,,,,1,,BAO_0000019,
3855,,Expert,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,CHEMBL618037,H,8,,,,,1,,BAO_0000357,
3856,,Expert,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,CHEMBL618038,H,8,,,,,1,,BAO_0000357,
3857,,Autocuration,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,CHEMBL618761,H,8,,,,,1,,BAO_0000019,
3858,,Expert,,55,Inhibition of lipoxygenase at the concentration of 0.1 uM,CHEMBL618762,H,8,,,,,1,,BAO_0000357,
3859,,Expert,,55,Inhibition of lipoxygenase at the concentration of 1 uM,CHEMBL618763,H,8,,,,,1,,BAO_0000357,
3860,,Autocuration,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,CHEMBL618764,H,8,,,,,1,,BAO_0000357,
3861,,Expert,,55,Inhibition of 5-Lipoxygenase (5-LOX),CHEMBL618765,D,9,,,,,1,,BAO_0000357,
3862,,Expert,,17087,Inhibition of 5-lipoxygenase in mouse macrophages.,CHEMBL618766,H,8,,,,,1,,BAO_0000357,
3863,,Expert,,17087,Inhibition of 5-lipoxygenase in mouse macrophages.,CHEMBL618767,H,8,,,,,1,,BAO_0000357,
3864,,Autocuration,,17087,Inhibitory activity against lipoxygenase-2 in mice,CHEMBL619380,H,8,,,,,1,,BAO_0000357,
3865,,Expert,,17087,Inhibitory activity against murine lipoxygenase-2.,CHEMBL619381,H,8,,,,,1,,BAO_0000357,
3866,,Expert,,17087,Inhibition of 5-lipoxygenase from mouse macrophage,CHEMBL619382,D,9,,,,,1,,BAO_0000357,
3867,,Autocuration,,17087,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,CHEMBL619383,H,8,,,,,1,,BAO_0000357,
3868,,Autocuration,,55,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,CHEMBL619384,H,8,,,,,1,,BAO_0000019,
3869,,Autocuration,,55,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,CHEMBL619385,H,8,,,,,1,,BAO_0000019,
3870,,Autocuration,,55,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,CHEMBL882928,H,8,,,,,1,,BAO_0000019,
3871,,Expert,,12166,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,CHEMBL619386,D,9,,,,,1,,BAO_0000019,
3872,,Autocuration,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",CHEMBL619387,H,8,,,,,1,,BAO_0000019,
3873,,Autocuration,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",CHEMBL619388,H,8,,,,,1,,BAO_0000019,
3874,,Autocuration,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",CHEMBL619389,H,8,,,,,1,,BAO_0000019,
3875,,Expert,,12166,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),CHEMBL619390,H,8,,,,,1,,BAO_0000019,
3876,,Expert,,12166,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",CHEMBL619391,H,8,,,,,1,,BAO_0000019,
3877,,Autocuration,,12166,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,CHEMBL619392,H,8,,,,,1,,BAO_0000019,
3878,,Autocuration,,12166,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),CHEMBL619393,H,8,,,,,1,,BAO_0000019,
3879,,Autocuration,,12166,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,CHEMBL619394,H,8,,,,,1,,BAO_0000019,
3880,,Autocuration,,12166,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",CHEMBL619395,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3881,,Autocuration,,12166,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",CHEMBL619396,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3882,,Autocuration,,12166,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),CHEMBL619397,H,8,,,,,1,,BAO_0000357,
3883,,Autocuration,,12166,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",CHEMBL619398,H,8,,,,,1,,BAO_0000357,
3884,,Autocuration,,12166,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",CHEMBL619399,H,8,,,,,1,,BAO_0000357,
3885,,Autocuration,,12166,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,CHEMBL619400,H,8,,,,,1,,BAO_0000357,
3886,,Autocuration,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",CHEMBL619401,H,8,,,,,1,,BAO_0000019,
3887,,Autocuration,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",CHEMBL619402,H,8,,,,,1,,BAO_0000019,
3888,,Expert,,12166,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,CHEMBL619403,D,9,663.0,RBL-2H3,,,1,,BAO_0000219,
3889,,Autocuration,,12166,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,CHEMBL619404,H,8,,,,,1,,BAO_0000357,
3890,,Autocuration,,12166,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,CHEMBL619405,H,8,,,,,1,,BAO_0000357,
3891,,Expert,,12166,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,CHEMBL619406,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3892,,Expert,,12166,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,CHEMBL619407,D,9,702.0,RBL-1,,,1,,BAO_0000219,
3893,,Autocuration,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),CHEMBL619408,H,8,,,,,1,,BAO_0000357,
3894,,Autocuration,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,CHEMBL619409,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3895,,Expert,,12166,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,CHEMBL619410,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3896,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,CHEMBL619753,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3897,,Autocuration,,12166,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,CHEMBL619754,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3898,,Expert,,12166,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,CHEMBL619903,H,8,,,,,1,,BAO_0000357,
3899,,Expert,,12166,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",CHEMBL619904,H,8,,,,,1,,BAO_0000357,
3900,,Expert,,12166,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,CHEMBL619905,H,8,,,,,1,,BAO_0000357,
3901,,Autocuration,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,CHEMBL619906,H,8,,,,,1,,BAO_0000019,
3902,,Autocuration,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,CHEMBL619907,H,8,,,,,1,,BAO_0000019,
3903,,Autocuration,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,CHEMBL619908,H,8,,,,,1,,BAO_0000019,
3904,,Autocuration,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,CHEMBL619909,H,8,,,,,1,,BAO_0000019,
3905,,Expert,,12166,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,CHEMBL619910,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3906,,Expert,,12166,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,CHEMBL882929,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3907,,Expert,,12166,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,CHEMBL619911,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3908,,Autocuration,,12166,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,CHEMBL619912,H,8,,,,,1,,BAO_0000019,
3909,,Expert,,12166,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,CHEMBL619913,D,9,,,,,1,,BAO_0000357,
3910,,Expert,,12166,In vitro inhibitory activity against RBL-1 5-LO,CHEMBL619914,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3911,,Autocuration,,12166,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),CHEMBL619915,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3912,,Autocuration,,12166,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),CHEMBL619916,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3913,,Autocuration,,12166,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,CHEMBL619917,H,8,,,,,1,,BAO_0000218,
3914,,Autocuration,,12166,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,CHEMBL619918,H,8,,,,,1,,BAO_0000357,
3915,,Autocuration,,12166,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,CHEMBL619919,H,8,,,,,1,,BAO_0000218,
3916,,Autocuration,,12166,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,CHEMBL883710,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3917,178.0,Autocuration,Blood,12166,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,CHEMBL619920,H,8,,,,,1,,BAO_0000019,
3918,,Expert,,12166,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,CHEMBL619921,H,8,,,,,1,,BAO_0000357,
3919,,Autocuration,,12166,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,CHEMBL619922,H,8,,,,,1,,BAO_0000019,
3920,,Autocuration,,12166,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,CHEMBL619923,H,8,,,,,1,,BAO_0000219,
3921,,Expert,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,CHEMBL619924,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3922,,Expert,,12166,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,CHEMBL619925,H,8,,,,,1,,BAO_0000357,
3923,,Expert,,12166,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,CHEMBL619926,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3924,,Autocuration,,12166,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,CHEMBL619927,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3925,,Expert,,12166,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,CHEMBL619928,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3926,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase,CHEMBL619929,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3927,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,CHEMBL875089,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3928,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,CHEMBL619930,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3929,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,CHEMBL619931,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3930,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,CHEMBL619932,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3931,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,CHEMBL619933,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3932,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,CHEMBL619934,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3933,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,CHEMBL619935,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3934,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,CHEMBL619936,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3935,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,CHEMBL619937,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3936,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,CHEMBL619938,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3937,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,CHEMBL619939,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3938,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,CHEMBL619940,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3939,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,CHEMBL875090,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3940,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,CHEMBL619941,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3941,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,CHEMBL619942,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3942,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,CHEMBL883711,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3943,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,CHEMBL619943,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3944,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,CHEMBL619944,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3945,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,CHEMBL619945,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3946,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,CHEMBL619946,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3947,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,CHEMBL619947,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3948,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,CHEMBL619948,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3949,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,CHEMBL619949,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3950,,Expert,,12166,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,CHEMBL619950,H,8,,,,,1,,BAO_0000019,
3951,,Autocuration,,12166,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,CHEMBL618050,H,8,,,,,1,,BAO_0000019,
3952,,Expert,,12166,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,CHEMBL875091,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
3953,,Expert,,12166,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,CHEMBL618051,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
3954,,Expert,,12166,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,CHEMBL618052,D,9,702.0,RBL-1,,,1,,BAO_0000219,
3955,,Autocuration,,12166,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,CHEMBL618053,H,8,,,,,1,,BAO_0000019,
3956,,Expert,,12166,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),CHEMBL618054,H,8,,,,,1,,BAO_0000019,
3957,,Expert,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,CHEMBL618055,D,9,702.0,RBL-1,,,1,,BAO_0000219,
3958,,Expert,,12166,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,CHEMBL618056,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3959,,Autocuration,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined,CHEMBL618057,H,8,,,,,1,,BAO_0000357,
3960,,Autocuration,,12166,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,CHEMBL618058,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3961,,Expert,,12166,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,CHEMBL618059,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3962,,Expert,,12166,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,CHEMBL618060,D,9,,,,,1,,BAO_0000019,
3963,,Autocuration,,12166,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,CHEMBL618061,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3964,,Autocuration,,12166,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,CHEMBL618062,H,8,,,,,1,,BAO_0000019,
3965,,Expert,,12166,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,CHEMBL618063,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3966,,Autocuration,,12166,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,CHEMBL618064,H,8,,,,,1,,BAO_0000357,
3967,,Expert,,12166,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,CHEMBL618065,D,9,702.0,RBL-1,,,1,,BAO_0000219,
3968,,Expert,,12166,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,CHEMBL618066,D,9,702.0,RBL-1,,,1,,BAO_0000219,
3969,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),CHEMBL618067,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3970,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),CHEMBL618068,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3971,,Expert,,12166,Inhibition of 5-lipoxygenase in rat RBL-1 cells,CHEMBL618069,D,9,702.0,RBL-1,,,1,,BAO_0000219,
3972,,Expert,,12166,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL618070,H,8,702.0,RBL-1,,,1,,BAO_0000219,
3973,349.0,Autocuration,Limbic system,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,CHEMBL618071,H,8,,,,,1,,BAO_0000019,
3974,349.0,Autocuration,Limbic system,10825,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,CHEMBL619247,H,8,,,,,1,,BAO_0000019,
3975,,Autocuration,,10825,Approximate dose levels for a half maximal reduction of 5-HTP levels,CHEMBL619248,H,8,,,,,1,,BAO_0000019,
3976,10000000.0,Autocuration,Hippocampus,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,CHEMBL619249,H,8,,,,,1,,BAO_0000221,
3977,10000000.0,Autocuration,Hippocampus,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,CHEMBL619250,H,8,,,,,1,,BAO_0000221,
3978,,Autocuration,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,CHEMBL619251,H,8,,,,,1,,BAO_0000019,
3979,178.0,Autocuration,Blood,55,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,CHEMBL619252,H,8,,,,,1,,BAO_0000019,
3980,178.0,Autocuration,Blood,55,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,CHEMBL619253,H,8,,,,,1,,BAO_0000019,
3981,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],CHEMBL619254,H,8,,,,,1,,BAO_0000219,
3982,,Expert,,17140,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,CHEMBL619255,H,8,,,,,1,,BAO_0000219,
3983,,Expert,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,CHEMBL619256,H,8,,,,,1,,BAO_0000219,
3984,,Autocuration,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),CHEMBL875418,H,8,,,,,1,,BAO_0000219,
3985,,Expert,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,CHEMBL619257,H,8,,,,,1,,BAO_0000219,
3986,,Autocuration,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,CHEMBL619258,H,8,,,,,1,,BAO_0000219,
3987,,Expert,,17140,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,CHEMBL619259,H,8,,,,,1,,BAO_0000357,
3988,,Expert,,17140,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,CHEMBL619260,H,8,,,,,1,,BAO_0000357,
3989,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619261,H,8,,,,,1,,BAO_0000218,
3990,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619263,H,8,,,,,1,,BAO_0000218,
3991,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619264,H,8,,,,,1,,BAO_0000218,
3992,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619265,H,8,,,,,1,,BAO_0000218,
3993,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619266,H,8,,,,,1,,BAO_0000218,
3994,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619902,H,8,,,,,1,,BAO_0000218,
3995,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620058,H,8,,,,,1,,BAO_0000218,
3996,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620059,H,8,,,,,1,,BAO_0000218,
3997,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620060,H,8,,,,,1,,BAO_0000218,
3998,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620061,H,8,,,,,1,,BAO_0000218,
3999,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620062,H,8,,,,,1,,BAO_0000218,
4000,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620063,H,8,,,,,1,,BAO_0000218,
4001,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620064,H,8,,,,,1,,BAO_0000218,
4002,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620065,H,8,,,,,1,,BAO_0000218,
4003,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620066,H,8,,,,,1,,BAO_0000218,
4004,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620067,H,8,,,,,1,,BAO_0000218,
4005,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620068,H,8,,,,,1,,BAO_0000218,
4006,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620069,H,8,,,,,1,,BAO_0000218,
4007,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620070,H,8,,,,,1,,BAO_0000218,
4008,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620071,H,8,,,,,1,,BAO_0000218,
4009,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620072,H,8,,,,,1,,BAO_0000218,
4010,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620036,H,8,,,,,1,,BAO_0000218,
4011,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL857702,H,8,,,,,1,,BAO_0000218,
4012,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620037,H,8,,,,,1,,BAO_0000218,
4013,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620038,H,8,,,,,1,,BAO_0000218,
4014,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620039,H,8,,,,,1,,BAO_0000218,
4015,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620040,H,8,,,,,1,,BAO_0000218,
4016,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620041,H,8,,,,,1,,BAO_0000218,
4017,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620042,H,8,,,,,1,,BAO_0000218,
4018,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620043,H,8,,,,,1,,BAO_0000218,
4019,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620044,H,8,,,,,1,,BAO_0000218,
4020,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620045,H,8,,,,,1,,BAO_0000218,
4021,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620046,H,8,,,,,1,,BAO_0000218,
4022,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620047,H,8,,,,,1,,BAO_0000218,
4023,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620048,H,8,,,,,1,,BAO_0000218,
4024,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL857703,H,8,,,,,1,,BAO_0000218,
4025,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620049,H,8,,,,,1,,BAO_0000218,
4026,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620050,H,8,,,,,1,,BAO_0000218,
4027,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620051,H,8,,,,,1,,BAO_0000218,
4028,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619213,H,8,,,,,1,,BAO_0000218,
4029,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619214,H,8,,,,,1,,BAO_0000218,
4030,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619804,H,8,,,,,1,,BAO_0000218,
4031,178.0,Autocuration,Blood,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL619805,H,8,,,,,1,,BAO_0000218,
4032,178.0,Autocuration,Blood,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619806,H,8,,,,,1,,BAO_0000218,
4033,178.0,Autocuration,Blood,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619807,H,8,,,,,1,,BAO_0000218,
4034,178.0,Autocuration,Blood,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619808,H,8,,,,,1,,BAO_0000218,
4035,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,CHEMBL619809,H,8,,,,,1,,BAO_0000218,
4036,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,CHEMBL619810,H,8,,,,,1,,BAO_0000218,
4037,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,CHEMBL619811,H,8,,,,,1,,BAO_0000218,
4038,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,CHEMBL620769,H,8,,,,,1,,BAO_0000218,
4039,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,CHEMBL620770,H,8,,,,,1,,BAO_0000218,
4040,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,CHEMBL620771,H,8,,,,,1,,BAO_0000218,
4041,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,CHEMBL620772,H,8,,,,,1,,BAO_0000218,
4042,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,CHEMBL620773,H,8,,,,,1,,BAO_0000218,
4043,,Autocuration,,55,Ability to inhibit 5-lipoxygenase in guinea pig,CHEMBL620774,H,8,,,,,1,,BAO_0000357,
4044,,Expert,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),CHEMBL620775,H,8,,,,,1,,BAO_0000357,
4045,,Autocuration,,55,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,CHEMBL620776,H,8,,,,,1,,BAO_0000357,
4046,178.0,Autocuration,Blood,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620777,H,8,,,,,1,,BAO_0000218,
4047,,Autocuration,,55,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,CHEMBL620778,H,8,,,,,1,,BAO_0000357,
4048,,Autocuration,,55,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,CHEMBL620779,H,8,,,,,1,,BAO_0000357,
4049,,Expert,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,CHEMBL621500,H,8,,,,,1,,BAO_0000019,
4050,,Expert,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,CHEMBL621501,H,8,,,,,1,,BAO_0000019,
4051,,Autocuration,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,CHEMBL618098,H,8,,,,,1,,BAO_0000019,
4052,,Autocuration,,55,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,CHEMBL618099,H,8,,,,,1,,BAO_0000019,
4053,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase,CHEMBL618100,H,8,,,,,1,,BAO_0000357,
4054,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,CHEMBL618101,H,8,,,,,1,,BAO_0000357,
4055,,Autocuration,,55,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,CHEMBL618102,H,8,,,,,1,,BAO_0000357,
4056,,Autocuration,,55,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,CHEMBL618103,H,8,,,,,1,,BAO_0000357,
4057,,Autocuration,,55,Inhibitory activity uM,CHEMBL618104,H,8,,,,,1,,BAO_0000357,
4058,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,CHEMBL883712,H,8,,,,,1,,BAO_0000219,
4059,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase at 10 uM,CHEMBL618105,H,8,,,,,1,,BAO_0000357,
4060,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,CHEMBL618106,H,8,,,,,1,,BAO_0000357,
4061,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,CHEMBL618107,H,8,,,,,1,,BAO_0000357,
4062,,Autocuration,,55,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,CHEMBL618108,H,8,,,,,1,,BAO_0000357,
4063,,Autocuration,,55,Inhibitory activity uM,CHEMBL618109,H,8,,,,,1,,BAO_0000357,
4064,,Autocuration,,55,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,CHEMBL618110,H,8,,,,,1,,BAO_0000357,
4065,,Expert,,55,Inhibitory activity uM,CHEMBL618111,H,8,,,,,1,,BAO_0000357,
4066,,Autocuration,,55,Inhibitory activity uM,CHEMBL618112,H,8,,,,,1,,BAO_0000019,
4067,,Autocuration,,55,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,CHEMBL618113,H,8,,,,,1,,BAO_0000019,
4068,,Autocuration,,55,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,CHEMBL618114,H,8,,,,,1,,BAO_0000357,
4069,2116.0,Expert,Ileum,55,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,CHEMBL620871,H,8,,,,,1,,BAO_0000221,
4070,,Autocuration,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),CHEMBL620872,H,8,,,,,1,,BAO_0000357,
4071,,Autocuration,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),CHEMBL620873,H,8,,,,,1,,BAO_0000357,
4072,,Autocuration,,55,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),CHEMBL620874,H,8,,,,,1,,BAO_0000357,
4073,,Expert,,55,In vitro inhibition of human 5-Lipoxygenase.,CHEMBL620875,H,8,,,,,1,,BAO_0000357,
4074,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,CHEMBL620876,U,0,,,,Microsomes,1,,BAO_0000251,
4075,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,CHEMBL620877,U,0,,,,Microsomes,1,,BAO_0000251,
4076,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,CHEMBL857854,U,0,,,,Microsomes,1,,BAO_0000251,
4077,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,CHEMBL620878,U,0,,,,Microsomes,1,,BAO_0000251,
4078,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,CHEMBL620879,U,0,,,,Microsomes,1,,BAO_0000251,
4079,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,CHEMBL620880,U,0,,,,Microsomes,1,,BAO_0000251,
4080,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,CHEMBL620881,U,0,,,,Microsomes,1,,BAO_0000251,
4081,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,CHEMBL620882,U,0,,,,Microsomes,1,,BAO_0000251,
4082,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,CHEMBL620883,U,0,,,,Microsomes,1,,BAO_0000251,
4083,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,CHEMBL620884,U,0,,,,Microsomes,1,,BAO_0000251,
4084,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,CHEMBL620885,U,0,,,,Microsomes,1,,BAO_0000251,
4085,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,CHEMBL620886,U,0,,,,Microsomes,1,,BAO_0000251,
4086,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,CHEMBL620887,U,0,,,,Microsomes,1,,BAO_0000251,
4087,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,CHEMBL618039,U,0,,,,Microsomes,1,,BAO_0000251,
4088,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,CHEMBL618040,U,0,,,,Microsomes,1,,BAO_0000251,
4089,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,CHEMBL618041,U,0,,,,Microsomes,1,,BAO_0000251,
4090,2107.0,Autocuration,Liver,22226,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",CHEMBL618216,U,0,,,,Microsomes,1,,BAO_0000251,
4091,2107.0,Autocuration,Liver,22226,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",CHEMBL618217,U,0,,,,Microsomes,1,,BAO_0000251,
4092,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,CHEMBL618218,U,0,,,,Microsomes,1,,BAO_0000251,
4093,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,CHEMBL618219,U,0,,,,Microsomes,1,,BAO_0000251,
4094,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,CHEMBL618220,U,0,,,,Microsomes,1,,BAO_0000251,
4095,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,CHEMBL618221,U,0,,,,Microsomes,1,,BAO_0000251,
4096,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,CHEMBL618222,U,0,,,,Microsomes,1,,BAO_0000251,
4097,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,CHEMBL618223,U,0,,,,Microsomes,1,,BAO_0000251,
4098,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,CHEMBL618224,U,0,,,,Microsomes,1,,BAO_0000251,
4099,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,CHEMBL618225,U,0,,,,Microsomes,1,,BAO_0000251,
4100,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,CHEMBL618226,U,0,,,,Microsomes,1,,BAO_0000251,
4101,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,CHEMBL618227,U,0,,,,Microsomes,1,,BAO_0000251,
4102,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,CHEMBL618228,U,0,,,,Microsomes,1,,BAO_0000251,
4103,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,CHEMBL618229,U,0,,,,Microsomes,1,,BAO_0000251,
4104,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,CHEMBL618230,U,0,,,,Microsomes,1,,BAO_0000251,
4105,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,CHEMBL618231,U,0,,,,Microsomes,1,,BAO_0000251,
4106,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,CHEMBL618232,U,0,,,,Microsomes,1,,BAO_0000251,
4107,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,CHEMBL618233,U,0,,,,Microsomes,1,,BAO_0000251,
4108,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,CHEMBL618234,U,0,,,,Microsomes,1,,BAO_0000251,
4109,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,CHEMBL618235,U,0,,,,Microsomes,1,,BAO_0000251,
4110,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,CHEMBL618115,U,0,,,,Microsomes,1,,BAO_0000251,
4111,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,CHEMBL618116,U,0,,,,Microsomes,1,,BAO_0000251,
4112,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,CHEMBL618117,U,0,,,,Microsomes,1,,BAO_0000251,
4113,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,CHEMBL619968,U,0,,,,Microsomes,1,,BAO_0000251,
4114,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,CHEMBL619969,U,0,,,,Microsomes,1,,BAO_0000251,
4115,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,CHEMBL619970,U,0,,,,Microsomes,1,,BAO_0000251,
4116,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,CHEMBL619971,U,0,,,,Microsomes,1,,BAO_0000251,
4117,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,CHEMBL619972,U,0,,,,Microsomes,1,,BAO_0000251,
4118,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,CHEMBL619973,U,0,,,,Microsomes,1,,BAO_0000251,
4119,2107.0,Autocuration,Liver,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,CHEMBL619974,U,0,,,,Microsomes,1,,BAO_0000251,
4120,2107.0,Autocuration,Liver,22226,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,CHEMBL619975,U,0,,,,Microsomes,1,,BAO_0000251,
4121,,Autocuration,,22226,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,CHEMBL619976,U,0,,,,Microsomes,1,,BAO_0000251,
4122,2107.0,Autocuration,Liver,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",CHEMBL619977,U,0,,,,Microsomes,1,,BAO_0000251,
4123,2107.0,Autocuration,Liver,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",CHEMBL619978,U,0,,,,Microsomes,1,,BAO_0000251,
4124,2107.0,Autocuration,Liver,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",CHEMBL619979,U,0,,,,Microsomes,1,,BAO_0000251,
4125,2107.0,Autocuration,Liver,22226,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",CHEMBL619980,U,0,,,,Microsomes,1,,BAO_0000251,
4126,2107.0,Autocuration,Liver,22226,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",CHEMBL619981,U,0,,,,Microsomes,1,,BAO_0000251,
4127,,Intermediate,,80433,In vitro inhibition of 7226/S myeloma cancer cell line,CHEMBL619982,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
4128,,Intermediate,,80698,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),CHEMBL619983,N,1,993.0,BEL-7404 tumor cell line,,,1,,BAO_0000219,
4129,,Intermediate,,80640,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,CHEMBL620031,N,1,391.0,786-0,,,1,,BAO_0000219,
4130,,Intermediate,,80640,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,CHEMBL620032,N,1,391.0,786-0,,,1,,BAO_0000219,
4131,,Expert,,81264,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,CHEMBL620033,N,1,505.0,V79,,,1,,BAO_0000219,
4132,,Expert,,81264,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,CHEMBL620034,N,1,505.0,V79,,,1,,BAO_0000219,
4133,,Intermediate,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,CHEMBL620035,N,1,1119.0,7800C1 cell line,,,1,,BAO_0000219,
4134,,Intermediate,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,CHEMBL618318,N,1,1119.0,7800C1 cell line,,,1,,BAO_0000219,
4135,,Intermediate,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,CHEMBL618319,N,1,1119.0,7800C1 cell line,,,1,,BAO_0000219,
4136,,Intermediate,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,CHEMBL618320,N,1,1119.0,7800C1 cell line,,,1,,BAO_0000219,
4137,,Intermediate,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,CHEMBL618321,N,1,1119.0,7800C1 cell line,,,1,,BAO_0000219,
4138,,Intermediate,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,CHEMBL883118,N,1,1119.0,7800C1 cell line,,,1,,BAO_0000219,
4139,,Intermediate,,80640,In vitro antitumor activity against renal 786-0 tumor cell lines,CHEMBL883795,N,1,391.0,786-0,,,1,,BAO_0000219,
4140,,Intermediate,,80640,Cytotoxic activity against 786-0 Renal cancer cell line,CHEMBL618322,N,1,391.0,786-0,,,1,,BAO_0000219,
4141,,Intermediate,,80640,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,CHEMBL618323,N,1,391.0,786-0,,,1,,BAO_0000219,
4142,,Intermediate,,80640,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,CHEMBL618324,N,1,391.0,786-0,,,1,,BAO_0000219,
4143,,Intermediate,,80640,In vitro antitumor activity against human renal 786-0 cell line,CHEMBL618325,N,1,391.0,786-0,,,1,,BAO_0000219,
4144,,Intermediate,,80640,Inhibition of Renal cancer in 786-0 cancer cell lines,CHEMBL875416,N,1,391.0,786-0,,,1,,BAO_0000219,
4145,,Intermediate,,80640,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,CHEMBL618326,N,1,391.0,786-0,,,1,,BAO_0000219,
4146,,Intermediate,,80640,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,CHEMBL618327,N,1,391.0,786-0,,,1,,BAO_0000219,
4147,,Intermediate,,80640,inhibition of the growth of renal cancer(786-0) cell line,CHEMBL619215,N,1,391.0,786-0,,,1,,BAO_0000219,
4148,,Intermediate,,80640,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),CHEMBL619216,N,1,391.0,786-0,,,1,,BAO_0000219,
4149,,Intermediate,,80640,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,CHEMBL619217,N,1,391.0,786-0,,,1,,BAO_0000219,
4150,,Intermediate,,80640,The IC50 value was measured on 786-0 cell line in ovarian tumor,CHEMBL619218,N,1,391.0,786-0,,,1,,BAO_0000219,
4151,,Intermediate,,80640,The IC50 value was measured on 786-0 cell line in ovarian tumor t,CHEMBL619219,N,1,391.0,786-0,,,1,,BAO_0000219,
4152,,Intermediate,,80640,The IC50 value was measured on 786-0 cell line in renal tumor type.,CHEMBL619220,N,1,391.0,786-0,,,1,,BAO_0000219,
4153,,Intermediate,,80640,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,CHEMBL619221,N,1,391.0,786-0,,,1,,BAO_0000219,
4154,,Intermediate,,80640,Tested for cytotoxic activity against renal cancer 786-0 cell line,CHEMBL619222,N,1,391.0,786-0,,,1,,BAO_0000219,
4155,,Intermediate,,80640,Compound was tested for growth inhibitory activity against 786-0 cell line,CHEMBL857454,N,1,391.0,786-0,,,1,,BAO_0000219,
4156,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,CHEMBL619223,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4157,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,CHEMBL619224,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4158,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,CHEMBL619225,H,8,,,,,1,,BAO_0000019,
4159,,Expert,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),CHEMBL619226,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4160,,Expert,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),CHEMBL619227,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4161,,Autocuration,,12166,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,CHEMBL619228,H,8,,,,,1,,BAO_0000357,
4162,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,CHEMBL619229,H,8,,,,,1,,BAO_0000219,
4163,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,CHEMBL619230,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4164,,Autocuration,,12166,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,CHEMBL619231,H,8,,,,,1,,BAO_0000357,
4165,,Autocuration,,12166,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",CHEMBL619232,H,8,,,,,1,,BAO_0000357,
4166,,Expert,,12166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,CHEMBL619233,H,8,,,,,1,,BAO_0000357,
4167,,Autocuration,,12166,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,CHEMBL619234,H,8,,,,,1,,BAO_0000357,
4168,,Autocuration,,12166,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),CHEMBL619235,H,8,,,,,1,,BAO_0000357,
4169,,Expert,,12166,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",CHEMBL619236,D,9,,,,,1,,BAO_0000019,
4170,,Autocuration,,12166,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,CHEMBL619237,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4171,,Autocuration,,12166,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,CHEMBL619238,H,8,,,,,1,,BAO_0000357,
4172,,Expert,,12166,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,CHEMBL619239,H,8,,,,,1,,BAO_0000357,
4173,,Autocuration,,12166,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,CHEMBL619240,H,8,,,,,1,,BAO_0000357,
4174,,Autocuration,,12166,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,CHEMBL875417,H,8,,,,,1,,BAO_0000019,
4175,,Autocuration,,12166,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),CHEMBL619241,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4176,,Expert,,12166,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,CHEMBL619242,H,8,,,,,1,,BAO_0000019,
4177,,Autocuration,,12166,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,CHEMBL883796,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4178,,Autocuration,,12166,Tested for its inhibitory activity against 5-lipoxygenase,CHEMBL619243,H,8,,,,,1,,BAO_0000357,
4179,,Autocuration,,12166,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,CHEMBL619244,H,8,,,,,1,,BAO_0000357,
4180,,Expert,,12166,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",CHEMBL619245,H,8,,,,,1,,BAO_0000019,
4181,,Expert,,12166,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,CHEMBL619246,H,8,,,,,1,,BAO_0000019,
4182,,Expert,,12166,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,CHEMBL619984,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4183,,Autocuration,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,CHEMBL619985,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4184,,Autocuration,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,CHEMBL619986,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4185,,Expert,,12166,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,CHEMBL619987,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4186,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,CHEMBL619988,H,8,,,,,1,,BAO_0000218,
4187,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,CHEMBL619989,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4188,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,CHEMBL619990,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4189,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],CHEMBL619991,H,8,,,,,1,,BAO_0000219,
4190,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),CHEMBL619992,H,8,,,,,1,,BAO_0000219,
4191,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),CHEMBL619993,H,8,,,,,1,,BAO_0000218,
4192,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,CHEMBL619994,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
4193,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,CHEMBL619995,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
4194,,Autocuration,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],CHEMBL619996,H,8,,,,,1,,BAO_0000019,
4195,,Autocuration,,12166,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,CHEMBL619997,H,8,,,,,1,,BAO_0000019,
4196,,Expert,,12166,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,CHEMBL619998,H,8,,,,,1,,BAO_0000019,
4197,,Expert,,12166,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,CHEMBL619999,H,8,,,,,1,,BAO_0000019,
4198,,Autocuration,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,CHEMBL620000,H,8,,,,,1,,BAO_0000019,
4199,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,CHEMBL620001,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4200,,Expert,,12166,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,CHEMBL620002,D,9,,,,,1,,BAO_0000357,
4201,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,CHEMBL620003,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4202,,Expert,,12166,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,CHEMBL620004,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4203,,Autocuration,,12166,Compound was evaluated for the inhibition of 5-lipoxygenase,CHEMBL874063,H,8,,,,,1,,BAO_0000357,
4204,,Autocuration,,12166,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,CHEMBL620005,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4205,,Autocuration,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,CHEMBL620006,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4206,,Autocuration,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,CHEMBL620007,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4207,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,CHEMBL620008,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4208,,Expert,,12166,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,CHEMBL620009,D,9,702.0,RBL-1,,,1,,BAO_0000219,
4209,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,CHEMBL620010,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4210,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,CHEMBL620011,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4211,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,CHEMBL620677,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4212,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,CHEMBL620678,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4213,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,CHEMBL620679,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4214,,Autocuration,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,CHEMBL620680,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4215,,Expert,,12166,Inhibitory activity against 5-lipoxygenase at 10 uM,CHEMBL620838,D,9,,,,,1,,BAO_0000357,
4216,,Autocuration,,12166,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,CHEMBL620839,H,8,,,,,1,,BAO_0000357,
4217,,Expert,,12166,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,CHEMBL620840,H,8,,,,,1,,BAO_0000357,
4218,,Expert,,12166,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,CHEMBL620841,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4219,,Autocuration,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,CHEMBL620842,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4220,,Autocuration,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,CHEMBL620843,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4221,,Autocuration,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,CHEMBL620844,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4222,,Autocuration,,12166,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,CHEMBL620845,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4223,,Autocuration,,12166,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,CHEMBL620846,H,8,,,,,1,,BAO_0000019,
4224,,Autocuration,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,CHEMBL873951,H,8,,,,,1,,BAO_0000357,
4225,,Autocuration,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,CHEMBL620847,H,8,,,,,1,,BAO_0000357,
4226,,Autocuration,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,CHEMBL620848,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4227,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,CHEMBL620849,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4228,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,CHEMBL620850,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4229,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,CHEMBL620851,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4230,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,CHEMBL620852,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4231,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL875098,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4232,,Expert,,12166,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,CHEMBL620853,D,9,702.0,RBL-1,,,1,,BAO_0000219,
4233,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,CHEMBL620854,H,8,,,,,1,,BAO_0000019,
4234,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,CHEMBL620855,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4235,,Expert,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,CHEMBL839884,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4236,,Autocuration,,12166,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL620856,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4237,,Autocuration,,12166,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL620857,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4238,,Autocuration,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,CHEMBL620858,H,8,,,,,1,,BAO_0000019,
4239,,Autocuration,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,CHEMBL620859,H,8,,,,,1,,BAO_0000019,
4240,,Autocuration,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,CHEMBL620860,H,8,,,,,1,,BAO_0000019,
4241,,Autocuration,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,CHEMBL620861,H,8,,,,,1,,BAO_0000019,
4242,,Expert,,12166,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),CHEMBL620862,H,8,,,,,1,,BAO_0000357,
4243,,Autocuration,,12166,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,CHEMBL620863,H,8,,,,,1,,BAO_0000357,
4244,,Autocuration,,12166,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,CHEMBL620864,H,8,,,,,1,,BAO_0000019,
4245,,Autocuration,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,CHEMBL620865,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4246,,Autocuration,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,CHEMBL620866,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4247,,Autocuration,,12166,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,CHEMBL620867,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
4248,,Autocuration,,12166,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,CHEMBL620868,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
4249,,Autocuration,,12166,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,CHEMBL620869,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
4250,,Autocuration,,12166,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,CHEMBL873952,H,8,,,,,1,,BAO_0000019,
4251,,Autocuration,,12166,The compound was tested for inhibition of isolated 5-lipoxygenase,CHEMBL875099,H,8,,,,,1,,BAO_0000357,
4252,,Autocuration,,12166,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,CHEMBL620870,H,8,663.0,RBL-2H3,,,1,,BAO_0000219,
4253,,Autocuration,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,CHEMBL618261,H,8,,,,,1,,BAO_0000019,
4254,,Autocuration,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,CHEMBL618262,H,8,,,,,1,,BAO_0000019,
4255,,Autocuration,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,CHEMBL619428,H,8,,,,,1,,BAO_0000019,
4256,,Autocuration,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,CHEMBL619429,H,8,,,,,1,,BAO_0000019,
4257,,Autocuration,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,CHEMBL619430,H,8,,,,,1,,BAO_0000019,
4258,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,CHEMBL620017,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4259,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,CHEMBL620018,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4260,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,CHEMBL620019,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4261,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,CHEMBL620020,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4262,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,CHEMBL620021,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4263,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,CHEMBL620022,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4264,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,CHEMBL620023,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4265,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,CHEMBL620024,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4266,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,CHEMBL620025,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4267,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,CHEMBL620026,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4268,,Autocuration,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,CHEMBL620027,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4269,,Expert,,12166,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,CHEMBL620028,D,9,,,,,1,,BAO_0000019,
4270,,Autocuration,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,CHEMBL620029,H,8,,,,,1,,BAO_0000357,
4271,,Autocuration,,12166,Compound was tested for the percent of inhibition against 5-LO at 10 uM,CHEMBL620030,H,8,,,,,1,,BAO_0000357,
4272,,Autocuration,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,CHEMBL875415,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4273,,Autocuration,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,CHEMBL618256,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4274,,Autocuration,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,CHEMBL618257,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4275,,Autocuration,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,CHEMBL618258,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4276,,Autocuration,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,CHEMBL618259,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4277,,Autocuration,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,CHEMBL618260,H,8,,,,,1,,BAO_0000019,
4278,,Autocuration,,12166,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,CHEMBL618215,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4279,,Autocuration,,12166,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,CHEMBL618390,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4280,,Autocuration,,12166,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,CHEMBL618391,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4281,,Autocuration,,12166,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,CHEMBL618392,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4282,,Autocuration,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,CHEMBL618393,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4283,,Autocuration,,12166,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,CHEMBL618394,H,8,,,,,1,,BAO_0000219,
4284,,Expert,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),CHEMBL618395,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4285,,Expert,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),CHEMBL618396,D,9,702.0,RBL-1,,,1,,BAO_0000219,
4286,,Expert,,12166,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),CHEMBL858253,D,9,702.0,RBL-1,,,1,,BAO_0000219,
4287,,Autocuration,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,CHEMBL618397,D,9,,,,,1,,BAO_0000019,
4288,,Autocuration,,12054,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),CHEMBL618398,H,8,,,,,1,,BAO_0000357,
4289,,Autocuration,,22226,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",CHEMBL618399,U,0,,,,,1,,BAO_0000019,
4290,,Expert,,55,In vitro inhibition of 5-Lipoxygenase; Inactive.,CHEMBL618400,H,8,,,,,1,,BAO_0000357,
4291,,Autocuration,,55,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,CHEMBL618401,H,8,,,,,1,,BAO_0000357,
4292,,Autocuration,,55,Inhibitory concentration against 5-lipoxygenase; No inhibition,CHEMBL618402,H,8,,,,,1,,BAO_0000357,
4293,,Autocuration,,55,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,CHEMBL876400,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4294,,Expert,,55,Inhibitory activity against 5-lipoxygenase.,CHEMBL618403,H,8,,,,,1,,BAO_0000357,
4295,,Autocuration,,55,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,CHEMBL618404,H,8,,,,,1,,BAO_0000357,
4296,,Autocuration,,55,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,CHEMBL618405,H,8,,,,,1,,BAO_0000357,
4297,,Autocuration,,55,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,CHEMBL618406,H,8,,,,,1,,BAO_0000357,
4298,,Expert,,55,Inhibitory concentration against arachidonic acid 5-lipoxygenation,CHEMBL618407,H,8,,,,,1,,BAO_0000019,
4299,,Autocuration,,55,Tested for the inhibitory activity against 5-lipoxygenase,CHEMBL618408,H,8,,,,,1,,BAO_0000357,
4300,,Autocuration,,55,Compound was tested for its inhibitory activity against 5-lipoxygenase,CHEMBL618409,H,8,,,,,1,,BAO_0000357,
4301,,Autocuration,,55,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,CHEMBL618410,H,8,,,,,1,,BAO_0000357,
4302,,Autocuration,,55,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,CHEMBL618411,H,8,,,,,1,,BAO_0000357,
4303,,Autocuration,,55,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,CHEMBL618412,H,8,,,,,1,,BAO_0000357,
4304,,Autocuration,,12166,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,CHEMBL618413,H,8,702.0,RBL-1,,,1,,BAO_0000219,
4305,,Autocuration,,12166,,CHEMBL618414,H,8,,,,,1,,BAO_0000357,
4306,,Autocuration,,10102,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),CHEMBL618415,H,8,,,,,1,,BAO_0000357,
4307,,Autocuration,,10102,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,CHEMBL618416,H,8,,,,,1,,BAO_0000019,
4308,,Autocuration,,10102,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,CHEMBL876401,H,8,,,,,1,,BAO_0000357,
4309,,Expert,,10102,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,CHEMBL618417,H,8,,,,,1,,BAO_0000357,
4310,,Autocuration,,10102,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,CHEMBL618418,H,8,,,,,1,,BAO_0000357,
4311,,Autocuration,,10102,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",CHEMBL618419,H,8,,,,,1,,BAO_0000357,
4312,,Autocuration,,10102,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",CHEMBL618420,H,8,,,,,1,,BAO_0000357,
4313,,Autocuration,,10102,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,CHEMBL618421,H,8,,,,,1,,BAO_0000357,
4314,,Autocuration,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,CHEMBL618422,H,8,,,,,1,,BAO_0000019,
4315,,Autocuration,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),CHEMBL618423,H,8,,,,,1,,BAO_0000019,
4316,,Autocuration,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),CHEMBL618424,H,8,,,,,1,,BAO_0000019,
4317,,Intermediate,,100284,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,CHEMBL618425,S,2,,,,,1,,BAO_0000220,
4318,,Autocuration,,22226,The dark toxicity against 543 human galactophore carcinoma cells,CHEMBL618426,U,0,,,,,1,,BAO_0000019,
4319,,Expert,,80623,Tested in vitro for cytotoxicity against 56 human tumor cell lines,CHEMBL618427,N,1,390.0,Panel (56 tumour cell lines),,,1,,BAO_0000219,
4320,,Expert,,80008,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,CHEMBL618428,N,1,345.0,5637,,,1,,BAO_0000219,
4321,,Intermediate,,80008,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,CHEMBL618429,N,1,345.0,5637,,,1,,BAO_0000219,
4322,,Intermediate,,80008,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",CHEMBL618430,N,1,345.0,5637,,,1,,BAO_0000219,
4323,,Expert,,80008,Growth inhibition against human 5637 cell lines,CHEMBL618431,N,1,345.0,5637,,,1,,BAO_0000219,
4324,,Expert,,80008,Antitumor activity against human bladder carcinoma 5637 cells.,CHEMBL883799,N,1,345.0,5637,,,1,,BAO_0000219,
4325,,Intermediate,,80008,Antitumor activity against human bladder carcinoma 5637 cells,CHEMBL618432,N,1,345.0,5637,,,1,,BAO_0000219,
4326,,Intermediate,,80008,Antitumor activity against human bladder carcinoma 5637 cells,CHEMBL618433,N,1,345.0,5637,,,1,,BAO_0000219,
4327,,Expert,,10443,In vitro inhibition of bovine trypsin(Trp).,CHEMBL618434,D,9,,,,,1,,BAO_0000357,
4328,,Expert,,240,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,CHEMBL618435,H,8,407.0,CV-1,,,1,,BAO_0000219,
4329,,Autocuration,,10577,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,CHEMBL876402,H,8,,,,,1,,BAO_0000357,
4330,,Autocuration,,104698,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,CHEMBL618436,H,6,,,,,1,,BAO_0000019,
4331,,Autocuration,,22226,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,CHEMBL618437,U,0,,,,,1,,BAO_0000218,
4332,,Intermediate,,20033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,CHEMBL618438,D,9,,,,,1,,BAO_0000357,
4333,,Expert,,17045,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CHEMBL883800,H,8,,,,Microsomes,1,,BAO_0000251,
4334,,Expert,,17045,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CHEMBL618439,H,8,,,,Microsomes,1,,BAO_0000251,
4335,,Intermediate,,22226,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,CHEMBL618440,U,0,,,,,1,,BAO_0000019,
4336,,Intermediate,,22226,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,CHEMBL618441,U,0,,,,,1,,BAO_0000019,
4337,,Expert,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,CHEMBL618442,H,8,,,,,1,,BAO_0000019,
4338,,Autocuration,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,CHEMBL618443,H,8,,,,,1,,BAO_0000019,
4339,,Expert,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,CHEMBL619158,H,8,,,,,1,,BAO_0000019,
4340,,Autocuration,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,CHEMBL620974,H,8,,,,,1,,BAO_0000019,
4341,,Autocuration,,11938,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,CHEMBL620975,H,8,,,,,1,,BAO_0000357,
4342,,Intermediate,,22226,Average inhibitory concentration against 60 human cell lines was reported,CHEMBL620976,U,0,,,,,1,,BAO_0000019,
4343,,Expert,,22226,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,CHEMBL620977,U,0,,,,,1,,BAO_0000019,
4344,,Intermediate,,80315,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,CHEMBL620978,N,1,542.0,Panel NCI-60 (60 carcinoma cell lines),,,1,,BAO_0000219,
4345,,Intermediate,,80315,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,CHEMBL620979,N,1,542.0,Panel NCI-60 (60 carcinoma cell lines),,,1,,BAO_0000219,
4346,,Expert,,80315,In vitro mean growth inhibitory activity against 60-cell panel,CHEMBL620980,N,1,542.0,Panel NCI-60 (60 carcinoma cell lines),,,1,,BAO_0000219,
4347,,Expert,,80315,In vitro mean growth lethal concentration against 60-cell panel,CHEMBL620981,N,1,542.0,Panel NCI-60 (60 carcinoma cell lines),,,1,,BAO_0000219,
4348,,Expert,,80315,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,CHEMBL620982,N,1,542.0,Panel NCI-60 (60 carcinoma cell lines),,,1,,BAO_0000219,
4349,,Expert,,80315,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,CHEMBL620983,N,1,542.0,Panel NCI-60 (60 carcinoma cell lines),,,1,,BAO_0000219,
4350,,Autocuration,,104775,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,CHEMBL620984,H,4,,,,,1,,BAO_0000019,
4351,,Autocuration,,104775,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,CHEMBL620985,H,4,,,,,1,,BAO_0000019,
4352,,Expert,,275,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,CHEMBL620986,H,8,,,,,1,,BAO_0000357,
4353,,Expert,,50425,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,CHEMBL620987,N,1,,,,,1,,BAO_0000218,
4354,,Expert,,50425,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,CHEMBL620988,N,1,,,,,1,,BAO_0000218,
4355,,Expert,,50425,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,CHEMBL620989,N,1,,,,,1,,BAO_0000218,
4356,,Expert,,50425,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,CHEMBL620990,N,1,,,,,1,,BAO_0000218,
4357,,Intermediate,,50425,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,CHEMBL620991,N,1,,,,,1,,BAO_0000218,
4358,,Intermediate,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,CHEMBL620992,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4359,,Intermediate,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,CHEMBL620993,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4360,,Intermediate,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,CHEMBL620994,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4361,,Intermediate,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,CHEMBL620995,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4362,,Intermediate,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,CHEMBL620996,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4363,,Intermediate,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,CHEMBL875581,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4364,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,CHEMBL620997,U,0,,,,,1,,BAO_0000218,
4365,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,CHEMBL620998,U,0,,,,,1,,BAO_0000218,
4366,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),CHEMBL620999,U,0,,,,,1,,BAO_0000218,
4367,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,CHEMBL621000,U,0,,,,,1,,BAO_0000218,
4368,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,CHEMBL621001,U,0,,,,,1,,BAO_0000218,
4369,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,CHEMBL621002,U,0,,,,,1,,BAO_0000218,
4370,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,CHEMBL621003,U,0,,,,,1,,BAO_0000218,
4371,,Autocuration,,22224,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",CHEMBL621004,U,0,,,,,1,,BAO_0000218,
4372,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),CHEMBL621005,U,0,,,,,1,,BAO_0000218,
4373,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),CHEMBL621006,U,0,,,,,1,,BAO_0000218,
4374,,Autocuration,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,CHEMBL621007,U,0,,,,,1,,BAO_0000218,
4375,,Autocuration,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,CHEMBL621008,U,0,,,,,1,,BAO_0000218,
4376,,Autocuration,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,CHEMBL621009,U,0,,,,,1,,BAO_0000218,
4377,,Autocuration,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,CHEMBL857705,U,0,,,,,1,,BAO_0000218,
4378,,Autocuration,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,CHEMBL619828,U,0,,,,,1,,BAO_0000218,
4379,,Autocuration,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,CHEMBL619829,U,0,,,,,1,,BAO_0000218,
4380,,Autocuration,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,CHEMBL619830,U,0,,,,,1,,BAO_0000218,
4381,,Autocuration,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,CHEMBL619831,U,0,,,,,1,,BAO_0000218,
4382,,Autocuration,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,CHEMBL619832,U,0,,,,,1,,BAO_0000218,
4383,,Autocuration,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,CHEMBL619833,U,0,,,,,1,,BAO_0000218,
4384,,Autocuration,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,CHEMBL619834,U,0,,,,,1,,BAO_0000218,
4385,,Autocuration,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,CHEMBL619835,U,0,,,,,1,,BAO_0000218,
4386,,Autocuration,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,CHEMBL619836,U,0,,,,,1,,BAO_0000218,
4387,,Intermediate,,80628,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",CHEMBL619837,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4388,,Autocuration,,22224,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,CHEMBL619838,U,0,,,,,1,,BAO_0000218,
4389,,Intermediate,,50594,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,CHEMBL619839,N,1,,,,,1,,BAO_0000218,
4390,,Intermediate,,80628,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,CHEMBL619840,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4391,,Intermediate,,80628,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,CHEMBL619841,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4392,,Expert,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),CHEMBL857704,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4393,,Intermediate,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),CHEMBL619842,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4394,,Expert,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),CHEMBL619843,N,1,850.0,6C3HED,,,1,,BAO_0000218,
4395,,Autocuration,,22226,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",CHEMBL619844,U,0,,,,,1,,BAO_0000019,
4396,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,CHEMBL857855,U,0,,,,Microsomes,1,,BAO_0000251,
4397,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,CHEMBL619845,U,0,,,,Microsomes,1,,BAO_0000251,
4398,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,CHEMBL619846,U,0,,,,Microsomes,1,,BAO_0000251,
4399,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,CHEMBL619847,U,0,,,,Microsomes,1,,BAO_0000251,
4400,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,CHEMBL619848,U,0,,,,Microsomes,1,,BAO_0000251,
4401,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,CHEMBL620893,U,0,,,,Microsomes,1,,BAO_0000251,
4402,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,CHEMBL620894,U,0,,,,Microsomes,1,,BAO_0000251,
4403,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,CHEMBL620895,U,0,,,,Microsomes,1,,BAO_0000251,
4404,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,CHEMBL620896,U,0,,,,Microsomes,1,,BAO_0000251,
4405,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,CHEMBL620897,U,0,,,,Microsomes,1,,BAO_0000251,
4406,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,CHEMBL620898,U,0,,,,Microsomes,1,,BAO_0000251,
4407,2107.0,Autocuration,Liver,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,CHEMBL620899,U,0,,,,Microsomes,1,,BAO_0000251,
4408,1969.0,Autocuration,Plasma,22224,The apparent total plasma clearance in monkey,CHEMBL620900,U,0,,,,,1,,BAO_0000218,
4409,,Autocuration,,22224,Compound was evaluated for Hepatic clearance in monkey,CHEMBL620901,U,0,,,,,1,,BAO_0000218,
4410,,Autocuration,,22224,Lower clearance in monkey (i.v.) at 0.5 mpk,CHEMBL620902,U,0,,,,,1,,BAO_0000218,
4411,,Autocuration,,22224,Plasma clearance in rhesus monkey,CHEMBL620903,U,0,,,,,1,,BAO_0000218,
4412,,Autocuration,,22224,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,CHEMBL620904,U,0,,,,,1,,BAO_0000218,
4413,,Autocuration,,22224,Plasma clearance of compound was determined in monkey,CHEMBL620905,U,0,,,,,1,,BAO_0000218,
4414,,Autocuration,,22224,Plasma clearance was calculated in rhesus monkey,CHEMBL620906,U,0,,,,,1,,BAO_0000218,
4415,,Autocuration,,22224,Plasma clearance in rhesus monkey,CHEMBL875420,U,0,,,,,1,,BAO_0000218,
4416,,Autocuration,,22224,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL620907,U,0,,,,,1,,BAO_0000218,
4417,,Autocuration,,22224,Plasma clearance was evaluated in rhesus,CHEMBL620908,U,0,,,,,1,,BAO_0000218,
4418,,Autocuration,,22224,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,CHEMBL620909,U,0,,,,,1,,BAO_0000218,
4419,,Autocuration,,22224,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,CHEMBL620910,U,0,,,,,1,,BAO_0000218,
4420,,Autocuration,,22224,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL620911,U,0,,,,,1,,BAO_0000218,
4421,,Autocuration,,22224,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL620912,U,0,,,,,1,,BAO_0000218,
4422,,Autocuration,,22224,Cmax 24 hr after 2 mg/kg oral administration in monkeys,CHEMBL620913,U,0,,,,,1,,BAO_0000218,
4423,,Autocuration,,22224,Cmax in monkey after administration of 1 mg/kg iv,CHEMBL620914,U,0,,,,,1,,BAO_0000218,
4424,,Autocuration,,22224,Cmax was determine after peroral administration at 10 mpk in Rhesus,CHEMBL620915,U,0,,,,,1,,BAO_0000218,
4425,,Autocuration,,22224,Cmax in cynomolgus monkey by iv administration,CHEMBL620916,U,0,,,,,1,,BAO_0000218,
4426,,Autocuration,,22224,Cmax in cynomolgus monkey by po administration,CHEMBL620917,U,0,,,,,1,,BAO_0000218,
4427,,Autocuration,,22224,Cmax value evaluated in monkey,CHEMBL620918,U,0,,,,,1,,BAO_0000218,
4428,,Autocuration,,22224,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL620919,U,0,,,,,1,,BAO_0000218,
4429,1969.0,Autocuration,Plasma,22224,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,CHEMBL620920,U,0,,,,,1,,BAO_0000218,
4430,1969.0,Autocuration,Plasma,22224,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,CHEMBL620921,U,0,,,,,1,,BAO_0000218,
4431,1969.0,Autocuration,Plasma,22224,Maximal plasma concentration in squirrel monkeys,CHEMBL620922,U,0,,,,,1,,BAO_0000218,
4432,,Autocuration,,22224,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL620923,U,0,,,,,1,,BAO_0000218,
4433,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,CHEMBL620924,U,0,,,,,1,,BAO_0000218,
4434,,Autocuration,,22224,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620925,U,0,,,,,1,,BAO_0000218,
4435,,Autocuration,,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,CHEMBL620926,U,0,,,,,1,,BAO_0000218,
4436,,Autocuration,,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,CHEMBL620927,U,0,,,,,1,,BAO_0000218,
4437,,Autocuration,,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,CHEMBL620928,U,0,,,,,1,,BAO_0000218,
4438,,Autocuration,,22224,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,CHEMBL620929,U,0,,,,,1,,BAO_0000218,
4439,1969.0,Autocuration,Plasma,22224,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,CHEMBL620930,U,0,,,,,1,,BAO_0000218,
4440,,Autocuration,,22224,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,CHEMBL620931,U,0,,,,,1,,BAO_0000218,
4441,,Autocuration,,22224,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,CHEMBL620932,U,0,,,,,1,,BAO_0000218,
4442,,Autocuration,,22224,Absolute bioavailability was evaluated in monkey,CHEMBL620933,U,0,,,,,1,,BAO_0000218,
4443,,Autocuration,,22224,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL620934,U,0,,,,,1,,BAO_0000218,
4444,,Autocuration,,22224,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,CHEMBL620935,U,0,,,,,1,,BAO_0000218,
4445,,Autocuration,,22224,Bioavailability of compound was determined in rhesus monkey,CHEMBL620936,U,0,,,,,1,,BAO_0000218,
4446,,Autocuration,,22224,Bioavailability determined after oral administration in marmoset,CHEMBL620937,U,0,,,,,1,,BAO_0000218,
4447,,Autocuration,,22224,Oral bioavailability in cynomolgus monkey,CHEMBL620938,U,0,,,,,1,,BAO_0000218,
4448,,Autocuration,,22224,Bioavailability in monkey (p.o.) at 2.0 mpk,CHEMBL620939,U,0,,,,,1,,BAO_0000218,
4449,,Autocuration,,22224,Bioavailability was evaluated after oral administration in monkey,CHEMBL620940,U,0,,,,,1,,BAO_0000218,
4450,,Autocuration,,22224,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL620941,U,0,,,,,1,,BAO_0000218,
4451,,Autocuration,,22224,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL620942,U,0,,,,,1,,BAO_0000218,
4452,,Autocuration,,22224,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL620943,U,0,,,,,1,,BAO_0000218,
4453,,Autocuration,,22224,Bioavailability of the compound was determined in monkey,CHEMBL620944,U,0,,,,,1,,BAO_0000218,
4454,,Autocuration,,22224,Bioavailability in squirrel monkey (dose 5 mg/kg),CHEMBL620945,U,0,,,,,1,,BAO_0000218,
4455,,Autocuration,,22224,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620946,U,0,,,,,1,,BAO_0000218,
4456,,Autocuration,,22224,Oral bioavailability in monkey,CHEMBL620947,U,0,,,,,1,,BAO_0000218,
4457,,Autocuration,,22224,Compound was tested for bioavailability in squirrel monkey,CHEMBL620948,U,0,,,,,1,,BAO_0000218,
4458,,Autocuration,,22224,Oral bioavailability in Rhesus monkey,CHEMBL620949,U,0,,,,,1,,BAO_0000218,
4459,,Autocuration,,22224,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),CHEMBL620950,U,0,,,,,1,,BAO_0000218,
4460,,Autocuration,,22224,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,CHEMBL620951,U,0,,,,,1,,BAO_0000218,
4461,,Autocuration,,22224,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,CHEMBL620952,U,0,,,,,1,,BAO_0000218,
4462,,Autocuration,,22224,Oral bioavailability in monkey (dose 5 mg/kg),CHEMBL875421,U,0,,,,,1,,BAO_0000218,
4463,,Autocuration,,22224,Oral bioavailability of compound at 5 mg/kg in monkey,CHEMBL620953,U,0,,,,,1,,BAO_0000218,
4464,,Intermediate,,50588,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,CHEMBL873491,N,1,,,,,1,,BAO_0000218,
4465,,Intermediate,,50588,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,CHEMBL620954,N,1,,,,,1,,BAO_0000218,
4466,1969.0,Intermediate,Plasma,50588,Plasma half life determined,CHEMBL620955,N,1,,,,,1,,BAO_0000218,
4467,1969.0,Intermediate,Plasma,50588,Plasma half life in dog,CHEMBL618097,N,1,,,,,1,,BAO_0000218,
4468,1969.0,Intermediate,Plasma,50588,Plasma half-life in Beagle dogs,CHEMBL618268,N,1,,,,,1,,BAO_0000218,
4469,1969.0,Intermediate,Plasma,50588,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),CHEMBL618269,N,1,,,,,1,,BAO_0000218,
4470,1969.0,Intermediate,Plasma,50588,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),CHEMBL618270,N,1,,,,,1,,BAO_0000218,
4471,,Intermediate,,50588,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,CHEMBL618271,N,1,,,,,1,,BAO_0000218,
4472,,Intermediate,,50588,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,CHEMBL873493,N,1,,,,,1,,BAO_0000218,
4473,,Intermediate,,50588,Tested for the half life period in dog,CHEMBL621031,N,1,,,,,1,,BAO_0000218,
4474,,Intermediate,,50588,Tested for the half life period in dog at dosage of 10 mpk,CHEMBL621032,N,1,,,,,1,,BAO_0000218,
4475,,Intermediate,,50588,The compound was tested for half life in dog,CHEMBL621033,N,1,,,,,1,,BAO_0000218,
4476,1969.0,Intermediate,Plasma,50588,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",CHEMBL621034,N,1,,,,,1,,BAO_0000218,
4477,,Intermediate,,50588,The half life was determined,CHEMBL621035,N,1,,,,,1,,BAO_0000218,
4478,1969.0,Intermediate,Plasma,50588,The plasma half-life in dogs,CHEMBL621036,N,1,,,,,1,,BAO_0000218,
4479,1969.0,Intermediate,Plasma,50588,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,CHEMBL621037,N,1,,,,,1,,BAO_0000218,
4480,,Intermediate,,50588,Half life in dog,CHEMBL619812,N,1,,,,,1,,BAO_0000218,
4481,,Intermediate,,50588,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,CHEMBL619813,N,1,,,,,1,,BAO_0000218,
4482,,Intermediate,,50588,tmax upon peroral administration of 10.0 mg/Kg dose in dog,CHEMBL873335,N,1,,,,,1,,BAO_0000218,
4483,,Intermediate,,50588,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL619814,N,1,,,,,1,,BAO_0000218,
4484,,Expert,,50506,Cmax in ferrets after 30 mg/kg oral dose,CHEMBL619815,N,1,,,,,1,,BAO_0000218,
4485,,Expert,,50506,Emesis in ferrets at 30 mg/kg oral dose,CHEMBL619816,N,1,,,,,1,,BAO_0000218,
4486,,Autocuration,,22224,Bioavailability in cynomolgus monkey,CHEMBL619817,U,0,,,,,1,,BAO_0000218,
4487,,Intermediate,,100710,Volume of distribution in cynomolgus,CHEMBL619818,N,1,,,,,1,,BAO_0000218,
4488,1969.0,Autocuration,Plasma,22224,AUC tested in guinea pig when 3 mg/kg dose was given perorally,CHEMBL619819,U,0,,,,,1,,BAO_0000218,
4489,,Autocuration,,22224,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,CHEMBL619820,U,0,,,,,1,,BAO_0000218,
4490,,Autocuration,,22224,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",CHEMBL875419,U,0,,,,,1,,BAO_0000218,
4491,1969.0,Autocuration,Plasma,22224,AUC in guinea pig after 3mg/kg oral dose,CHEMBL619821,U,0,,,,,1,,BAO_0000218,
4492,,Autocuration,,22224,Bioavailability in guinea pig was tested,CHEMBL619822,U,0,,,,,1,,BAO_0000218,
4493,,Autocuration,,22224,Tested for oral bioavailability in guinea pig at 5 mg/kg,CHEMBL619823,U,0,,,,,1,,BAO_0000218,
4494,,Autocuration,,22224,Tested for the oral bioavailability of the compound,CHEMBL619824,U,0,,,,,1,,BAO_0000218,
4495,,Autocuration,,22224,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,CHEMBL619825,U,0,,,,,1,,BAO_0000218,
4496,,Autocuration,,22224,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,CHEMBL619826,U,0,,,,,1,,BAO_0000218,
4497,2048.0,Autocuration,Lung,22224,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,CHEMBL619827,U,0,,,,,1,,BAO_0000218,
4498,,Autocuration,,22224,Cmax in guinea pig after 3mg/kg oral dose,CHEMBL618167,U,0,,,,,1,,BAO_0000218,
4499,178.0,Autocuration,Blood,22224,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618168,U,0,,,,,1,,BAO_0000019,
4500,955.0,Autocuration,Brain,22224,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618169,U,0,,,,,1,,BAO_0000019,
4501,,Autocuration,,22224,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618170,U,0,,,,,1,,BAO_0000019,
4502,160.0,Autocuration,Intestine,22224,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618171,U,0,,,,,1,,BAO_0000019,
4503,2113.0,Autocuration,Kidney,22224,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618172,U,0,,,,,1,,BAO_0000019,
4504,2107.0,Autocuration,Liver,22224,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618173,U,0,,,,,1,,BAO_0000019,
4505,,Autocuration,,22224,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618174,U,0,,,,,1,,BAO_0000019,
4506,2106.0,Autocuration,Spleen,22224,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL875408,U,0,,,,,1,,BAO_0000019,
4507,,Autocuration,,22224,Elimination T1/2 in Guinea pig (PO dose),CHEMBL839827,U,0,,,,,1,,BAO_0000218,
4508,,Autocuration,,22224,Partition coefficient was measured as -log (counts per min ),CHEMBL618175,U,0,,,,,1,,BAO_0000019,
4509,,Autocuration,,22224,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,CHEMBL618176,U,0,,,,,1,,BAO_0000218,
4510,,Autocuration,,22224,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,CHEMBL618177,U,0,,,,,1,,BAO_0000218,
4511,,Autocuration,,22224,Elimination T1/2 in Guinea pig (PO dose),CHEMBL618178,U,0,,,,,1,,BAO_0000218,
4512,,Autocuration,,22224,"Tested for the half life period of the compound, intravenously",CHEMBL618179,U,0,,,,,1,,BAO_0000218,
4513,,Autocuration,,22224,Half-life was measured,CHEMBL873489,U,0,,,,,1,,BAO_0000019,
4514,,Autocuration,,22224,The time required for onset of inotropy after addition of a single dose of delta F75,CHEMBL618180,U,0,,,,,1,,BAO_0000019,
4515,,Autocuration,,22224,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,CHEMBL618181,U,0,,,,,1,,BAO_0000218,
4516,,Autocuration,,22224,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,CHEMBL618182,U,0,,,,,1,,BAO_0000218,
4517,,Autocuration,,22224,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,CHEMBL618183,U,0,,,,,1,,BAO_0000218,
4518,,Intermediate,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL618184,N,1,,,,,1,,BAO_0000218,
4519,,Intermediate,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL618185,N,1,,,,,1,,BAO_0000218,
4520,,Intermediate,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL618186,N,1,,,,,1,,BAO_0000218,
4521,,Intermediate,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL618187,N,1,,,,,1,,BAO_0000218,
4522,,Intermediate,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,CHEMBL618188,N,1,,,,,1,,BAO_0000218,
4523,,Intermediate,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL875409,N,1,,,,,1,,BAO_0000218,
4524,,Intermediate,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL618189,N,1,,,,,1,,BAO_0000218,
4525,178.0,Intermediate,Blood,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,CHEMBL618190,N,1,,,,,1,,BAO_0000218,
4526,178.0,Intermediate,Blood,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,CHEMBL618191,N,1,,,,,1,,BAO_0000218,
4527,178.0,Intermediate,Blood,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,CHEMBL618192,N,1,,,,,1,,BAO_0000218,
4528,10000001.0,Intermediate,Bone,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,CHEMBL618193,N,1,,,,,1,,BAO_0000218,
4529,10000001.0,Intermediate,Bone,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,CHEMBL618194,N,1,,,,,1,,BAO_0000218,
4530,10000001.0,Intermediate,Bone,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,CHEMBL618195,N,1,,,,,1,,BAO_0000218,
4531,955.0,Intermediate,Brain,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,CHEMBL618196,N,1,,,,,1,,BAO_0000218,
4532,955.0,Intermediate,Brain,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,CHEMBL618197,N,1,,,,,1,,BAO_0000218,
4533,955.0,Intermediate,Brain,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,CHEMBL618198,N,1,,,,,1,,BAO_0000218,
4534,948.0,Intermediate,Heart,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,CHEMBL618199,N,1,,,,,1,,BAO_0000218,
4535,948.0,Intermediate,Heart,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,CHEMBL618200,N,1,,,,,1,,BAO_0000218,
4536,948.0,Intermediate,Heart,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,CHEMBL618201,N,1,,,,,1,,BAO_0000218,
4537,160.0,Intermediate,Intestine,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,CHEMBL618202,N,1,,,,,1,,BAO_0000218,
4538,160.0,Intermediate,Intestine,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,CHEMBL618203,N,1,,,,,1,,BAO_0000218,
4539,160.0,Intermediate,Intestine,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,CHEMBL618204,N,1,,,,,1,,BAO_0000218,
4540,2113.0,Intermediate,Kidney,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,CHEMBL618205,N,1,,,,,1,,BAO_0000218,
4541,2113.0,Intermediate,Kidney,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,CHEMBL618206,N,1,,,,,1,,BAO_0000218,
4542,2113.0,Intermediate,Kidney,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,CHEMBL618207,N,1,,,,,1,,BAO_0000218,
4543,2107.0,Intermediate,Liver,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,CHEMBL618208,N,1,,,,,1,,BAO_0000218,
4544,2107.0,Intermediate,Liver,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,CHEMBL618932,N,1,,,,,1,,BAO_0000218,
4545,2107.0,Intermediate,Liver,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,CHEMBL618933,N,1,,,,,1,,BAO_0000218,
4546,2048.0,Intermediate,Lung,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,CHEMBL618934,N,1,,,,,1,,BAO_0000218,
4547,2048.0,Intermediate,Lung,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,CHEMBL618935,N,1,,,,,1,,BAO_0000218,
4548,2048.0,Intermediate,Lung,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,CHEMBL618936,N,1,,,,,1,,BAO_0000218,
4549,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,CHEMBL618937,N,1,,,,,1,,BAO_0000218,
4550,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,CHEMBL618938,N,1,,,,,1,,BAO_0000218,
4551,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,CHEMBL619104,N,1,,,,,1,,BAO_0000218,
4552,2106.0,Intermediate,Spleen,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,CHEMBL619105,N,1,,,,,1,,BAO_0000218,
4553,2106.0,Intermediate,Spleen,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,CHEMBL619106,N,1,,,,,1,,BAO_0000218,
4554,2106.0,Intermediate,Spleen,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,CHEMBL619107,N,1,,,,,1,,BAO_0000218,
4555,945.0,Intermediate,Stomach,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,CHEMBL875410,N,1,,,,,1,,BAO_0000218,
4556,945.0,Intermediate,Stomach,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,CHEMBL619108,N,1,,,,,1,,BAO_0000218,
4557,945.0,Intermediate,Stomach,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,CHEMBL619109,N,1,,,,,1,,BAO_0000218,
4558,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,CHEMBL619110,N,1,,,,,1,,BAO_0000218,
4559,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,CHEMBL619111,N,1,,,,,1,,BAO_0000218,
4560,,Intermediate,,50594,MRT value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL619112,N,1,,,,,1,,BAO_0000218,
4561,,Intermediate,,50594,MRT value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL619113,N,1,,,,,1,,BAO_0000218,
4562,,Intermediate,,50594,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,CHEMBL619114,N,1,,,,,1,,BAO_0000218,
4563,,Intermediate,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,CHEMBL619115,N,1,,,,,1,,BAO_0000218,
4564,,Intermediate,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,CHEMBL619116,N,1,478.0,A2780,,,1,,BAO_0000219,
4565,,Intermediate,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,CHEMBL619117,N,1,478.0,A2780,,,1,,BAO_0000219,
4566,,Intermediate,,81034,Compound was evaluated for cytotoxicity against A2780 cell lines.,CHEMBL619118,N,1,478.0,A2780,,,1,,BAO_0000219,
4567,,Intermediate,,81034,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,CHEMBL619119,N,1,478.0,A2780,,,1,,BAO_0000219,
4568,,Intermediate,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,CHEMBL619120,N,1,478.0,A2780,,,1,,BAO_0000219,
4569,,Intermediate,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,CHEMBL619121,N,1,478.0,A2780,,,1,,BAO_0000219,
4570,,Intermediate,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,CHEMBL619122,N,1,478.0,A2780,,,1,,BAO_0000219,
4571,,Intermediate,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,CHEMBL619123,N,1,478.0,A2780,,,1,,BAO_0000219,
4572,,Intermediate,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,CHEMBL619124,N,1,478.0,A2780,,,1,,BAO_0000219,
4573,,Intermediate,,81034,Compound was evaluated for cytotoxicity against A2780 cell line,CHEMBL619125,N,1,478.0,A2780,,,1,,BAO_0000219,
4574,,Intermediate,,81034,In vitro inhibitory activity against human tumor cell line A2780,CHEMBL875411,N,1,478.0,A2780,,,1,,BAO_0000219,
4575,,Intermediate,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,CHEMBL619126,N,1,478.0,A2780,,,1,,BAO_0000219,
4576,,Intermediate,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,CHEMBL619127,N,1,478.0,A2780,,,1,,BAO_0000219,
4577,,Intermediate,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,CHEMBL619128,N,1,478.0,A2780,,,1,,BAO_0000219,
4578,,Intermediate,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,CHEMBL619129,N,1,478.0,A2780,,,1,,BAO_0000219,
4579,,Intermediate,,81034,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,CHEMBL619130,N,1,478.0,A2780,,,1,,BAO_0000219,
4580,,Intermediate,,81034,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,CHEMBL619131,N,1,478.0,A2780,,,1,,BAO_0000219,
4581,,Intermediate,,81034,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,CHEMBL619132,N,1,478.0,A2780,,,1,,BAO_0000219,
4582,,Expert,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,CHEMBL619133,N,1,478.0,A2780,,,1,,BAO_0000218,
4583,,Intermediate,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,CHEMBL619134,N,1,478.0,A2780,,,1,,BAO_0000219,
4584,,Intermediate,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,CHEMBL619135,N,1,478.0,A2780,,,1,,BAO_0000219,
4585,,Intermediate,,81034,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,CHEMBL619136,N,1,478.0,A2780,,,1,,BAO_0000219,
4586,,Intermediate,,81034,Relative resistance factor in A2780 cisplatin-resistant line,CHEMBL619137,N,1,478.0,A2780,,,1,,BAO_0000219,
4587,,Intermediate,,81034,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,CHEMBL883713,N,1,478.0,A2780,,,1,,BAO_0000219,
4588,,Intermediate,,81034,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,CHEMBL875412,N,1,478.0,A2780,,,1,,BAO_0000219,
4589,,Expert,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,CHEMBL619138,N,1,478.0,A2780,,,1,,BAO_0000218,
4590,,Expert,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,CHEMBL619262,N,1,478.0,A2780,,,1,,BAO_0000218,
4591,,Intermediate,,81034,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,CHEMBL619139,N,1,478.0,A2780,,,1,,BAO_0000219,
4592,,Intermediate,,81034,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,CHEMBL619140,N,1,478.0,A2780,,,1,,BAO_0000219,
4593,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,CHEMBL619141,N,1,478.0,A2780,,,1,,BAO_0000219,
4594,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,CHEMBL619142,N,1,478.0,A2780,,,1,,BAO_0000219,
4595,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,CHEMBL619143,N,1,478.0,A2780,,,1,,BAO_0000219,
4596,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,CHEMBL619144,N,1,478.0,A2780,,,1,,BAO_0000219,
4597,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,CHEMBL619145,N,1,478.0,A2780,,,1,,BAO_0000219,
4598,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,CHEMBL619146,N,1,478.0,A2780,,,1,,BAO_0000219,
4599,,Intermediate,,81034,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,CHEMBL619147,N,1,478.0,A2780,,,1,,BAO_0000219,
4600,,Intermediate,,81034,Antiproliferative effect of compound on A2780/DX cell line,CHEMBL619148,N,1,478.0,A2780,,,1,,BAO_0000219,
4601,,Intermediate,,81034,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,CHEMBL619149,N,1,478.0,A2780,,,1,,BAO_0000219,
4602,,Intermediate,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),CHEMBL619150,N,1,478.0,A2780,,,1,,BAO_0000219,
4603,,Intermediate,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),CHEMBL619151,N,1,478.0,A2780,,,1,,BAO_0000219,
4604,,Intermediate,,81034,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,CHEMBL883794,N,1,478.0,A2780,,,1,,BAO_0000219,
4605,,Intermediate,,81034,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,CHEMBL619152,N,1,478.0,A2780,,,1,,BAO_0000219,
4606,,Intermediate,,81034,In vitro cytotoxicity against A2780ADR cell line,CHEMBL619153,N,1,478.0,A2780,,,1,,BAO_0000219,
4607,,Intermediate,,81034,In vitro cytotoxicity against A2780CIS cell line,CHEMBL619154,N,1,478.0,A2780,,,1,,BAO_0000219,
4608,,Intermediate,,81034,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,CHEMBL619155,N,1,478.0,A2780,,,1,,BAO_0000219,
4609,,Intermediate,,81034,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,CHEMBL619156,N,1,478.0,A2780,,,1,,BAO_0000219,
4610,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL619157,N,1,478.0,A2780,,,1,,BAO_0000219,
4611,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL619797,N,1,478.0,A2780,,,1,,BAO_0000219,
4612,,Autocuration,,22224,Oral bioavailability of compound in rhesus macaques,CHEMBL619798,U,0,,,,,1,,BAO_0000218,
4613,,Autocuration,,22224,Oral bioavailability in monkey,CHEMBL619799,U,0,,,,,1,,BAO_0000218,
4614,,Autocuration,,22224,Oral bioavailability evaluated in monkey,CHEMBL619800,U,0,,,,,1,,BAO_0000218,
4615,,Autocuration,,22224,Oral bioavailability in monkey (dose 1 mg/kg p.o.),CHEMBL619801,U,0,,,,,1,,BAO_0000218,
4616,,Autocuration,,22224,Oral bioavailability in Rhesus monkey,CHEMBL619802,U,0,,,,,1,,BAO_0000218,
4617,,Autocuration,,22224,Oral bioavailability was calculated in rhesus monkey,CHEMBL619803,U,0,,,,,1,,BAO_0000218,
4618,,Autocuration,,22224,Oral bioavailability in cynomolgus monkey,CHEMBL619965,U,0,,,,,1,,BAO_0000218,
4619,,Autocuration,,22224,Oral bioavailability in monkey,CHEMBL619966,U,0,,,,,1,,BAO_0000218,
4620,,Autocuration,,22224,Oral bioavailability in monkey,CHEMBL619967,U,0,,,,,1,,BAO_0000218,
4621,,Autocuration,,22224,Oral bioavailability in monkey (dose 1 mg/kg),CHEMBL620073,U,0,,,,,1,,BAO_0000218,
4622,,Autocuration,,22224,Oral bioavailability in monkey (dose 5 mg/kg),CHEMBL620074,U,0,,,,,1,,BAO_0000218,
4623,,Autocuration,,22224,Oral bioavailability in monkey,CHEMBL620075,U,0,,,,,1,,BAO_0000218,
4624,,Autocuration,,22224,Oral bioavailability in monkey,CHEMBL620076,U,0,,,,,1,,BAO_0000218,
4625,,Autocuration,,22224,Oral bioavailability in rhesus monkey,CHEMBL620077,U,0,,,,,1,,BAO_0000218,
4626,,Autocuration,,22224,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,CHEMBL620078,U,0,,,,,1,,BAO_0000218,
4627,,Autocuration,,22224,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,CHEMBL620079,U,0,,,,,1,,BAO_0000218,
4628,,Autocuration,,22224,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL620080,U,0,,,,,1,,BAO_0000218,
4629,,Autocuration,,22224,Oral bioavailability in Rhesus monkey,CHEMBL620081,U,0,,,,,1,,BAO_0000218,
4630,,Autocuration,,22224,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),CHEMBL620082,U,0,,,,,1,,BAO_0000218,
4631,,Autocuration,,22224,Oral bioavailability in monkey at 10 mg/kg of the compound,CHEMBL620083,U,0,,,,,1,,BAO_0000218,
4632,,Autocuration,,22224,Bioavailability in Rhesus monkey,CHEMBL620084,U,0,,,,,1,,BAO_0000218,
4633,,Autocuration,,22224,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620085,U,0,,,,,1,,BAO_0000218,
4634,,Autocuration,,22224,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL874595,U,0,,,,,1,,BAO_0000218,
4635,,Autocuration,,22224,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,CHEMBL873352,U,0,,,,,1,,BAO_0000218,
4636,,Autocuration,,22224,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,CHEMBL620086,U,0,,,,,1,,BAO_0000218,
4637,,Autocuration,,22224,Mean residence time was determined after intravenous administration in cynomolgus monkeys,CHEMBL620087,U,0,,,,,1,,BAO_0000218,
4638,,Autocuration,,22224,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,CHEMBL620088,U,0,,,,,1,,BAO_0000218,
4639,,Autocuration,,22224,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,CHEMBL620089,U,0,,,,,1,,BAO_0000218,
4640,,Autocuration,,22224,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL620090,U,0,,,,,1,,BAO_0000218,
4641,,Autocuration,,22224,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620091,U,0,,,,,1,,BAO_0000218,
4642,,Autocuration,,22224,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),CHEMBL620092,U,0,,,,Microsomes,1,,BAO_0000251,
4643,,Autocuration,,22224,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),CHEMBL620093,U,0,,,,Microsomes,1,,BAO_0000251,
4644,,Autocuration,,22224,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),CHEMBL620094,U,0,,,,Microsomes,1,,BAO_0000251,
4645,,Autocuration,,22224,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),CHEMBL620095,U,0,,,,Microsomes,1,,BAO_0000251,
4646,,Autocuration,,22224,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620096,U,0,,,,,1,,BAO_0000218,
4647,,Autocuration,,22224,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620097,U,0,,,,,1,,BAO_0000218,
4648,,Autocuration,,22224,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,CHEMBL620098,U,0,,,,,1,,BAO_0000019,
4649,,Autocuration,,22224,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620099,U,0,,,,,1,,BAO_0000218,
4650,,Autocuration,,22224,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620100,U,0,,,,,1,,BAO_0000218,
4651,,Autocuration,,22224,Elimination Half-life of compound was determined in monkey,CHEMBL620101,U,0,,,,,1,,BAO_0000019,
4652,,Autocuration,,22224,Half life of compound was determined in rhesus monkey,CHEMBL620102,U,0,,,,,1,,BAO_0000019,
4653,1969.0,Autocuration,Plasma,22224,Half life in monkey plasma,CHEMBL620103,U,0,,,,,1,,BAO_0000366,
4654,1969.0,Autocuration,Plasma,22224,Half life in monkey plasma; Not detected,CHEMBL620104,U,0,,,,,1,,BAO_0000366,
4655,,Autocuration,,22224,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL874596,U,0,,,,,1,,BAO_0000218,
4656,,Autocuration,,22224,Half-life 24 hr after 2 mg/kg iv administration in monkeys,CHEMBL873490,U,0,,,,,1,,BAO_0000218,
4657,,Autocuration,,22224,Terminal half life of the compound.,CHEMBL620105,U,0,,,,,1,,BAO_0000019,
4658,,Autocuration,,22224,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL620780,U,0,,,,,1,,BAO_0000218,
4659,,Autocuration,,22224,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620781,U,0,,,,,1,,BAO_0000218,
4660,,Autocuration,,22224,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,CHEMBL620956,U,0,,,,,1,,BAO_0000218,
4661,1088.0,Autocuration,Urine,22224,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620957,U,0,,,,,1,,BAO_0000218,
4662,1088.0,Autocuration,Urine,22224,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620958,U,0,,,,,1,,BAO_0000218,
4663,,Autocuration,,22224,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,CHEMBL620959,U,0,,,,,1,,BAO_0000218,
4664,,Autocuration,,22224,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL620960,U,0,,,,,1,,BAO_0000218,
4665,,Autocuration,,22224,Volume of distribution was evaluated in rhesus,CHEMBL620961,U,0,,,,,1,,BAO_0000218,
4666,,Autocuration,,22224,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,CHEMBL620962,U,0,,,,,1,,BAO_0000218,
4667,,Autocuration,,22224,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,CHEMBL620963,U,0,,,,,1,,BAO_0000218,
4668,,Autocuration,,22224,Bioavailability in hamster was determined,CHEMBL620964,U,0,,,,,1,,BAO_0000218,
4669,,Autocuration,,22224,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,CHEMBL620965,U,0,,,,,1,,BAO_0000218,
4670,,Autocuration,,22224,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,CHEMBL620966,U,0,,,,,1,,BAO_0000218,
4671,178.0,Autocuration,Blood,22224,Half life of compound was determined in hamster blood,CHEMBL620967,U,0,,,,,1,,BAO_0000221,
4672,,Autocuration,,22224,Michaelis-Menten constant of the compound.,CHEMBL620968,U,0,,,,,1,,BAO_0000019,
4673,,Autocuration,,22224,Vmax value was measured at 0 uM concentration of silyl ether.,CHEMBL874597,U,0,,,,,1,,BAO_0000019,
4674,,Autocuration,,22224,Vmax value was measured at 10 uM concentration of silyl ether.,CHEMBL620969,U,0,,,,,1,,BAO_0000019,
4675,,Autocuration,,22224,Vmax value was measured at 5 uM concentration of silyl ether.,CHEMBL620970,U,0,,,,,1,,BAO_0000019,
4676,,Expert,,235,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,CHEMBL620971,D,9,,,,,1,,BAO_0000357,
4677,,Autocuration,,22224,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL620972,U,0,,,,,1,,BAO_0000218,
4678,,Autocuration,,22224,Compound was evaluated for area under the curve expressed as (h*ug/ml),CHEMBL620973,U,0,,,,,1,,BAO_0000019,
4679,,Autocuration,,22224,Active metabolite of ifosfamide determined in humans; A-Active,CHEMBL618243,U,0,,,,,1,,BAO_0000019,
4680,,Autocuration,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,CHEMBL618244,U,0,,,,,1,,BAO_0000019,
4681,,Autocuration,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,CHEMBL618245,U,0,,,,,1,,BAO_0000019,
4682,,Autocuration,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,CHEMBL618246,U,0,,,,,1,,BAO_0000019,
4683,,Autocuration,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,CHEMBL618247,U,0,,,,,1,,BAO_0000019,
4684,,Autocuration,,22224,Compound was evaluated for oral bioavailability in human,CHEMBL618248,U,0,,,,,1,,BAO_0000218,
4685,1088.0,Autocuration,Urine,22224,Metabolite of ifosfamide determined in urine; NF-Not found,CHEMBL618249,U,0,,,,,1,,BAO_0000019,
4686,,Autocuration,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),CHEMBL618250,U,0,,,,,1,,BAO_0000019,
4687,,Autocuration,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,CHEMBL874598,U,0,,,,,1,,BAO_0000019,
4688,,Autocuration,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,CHEMBL618251,U,0,,,,,1,,BAO_0000019,
4689,,Autocuration,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,CHEMBL618252,U,0,,,,,1,,BAO_0000019,
4690,,Autocuration,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,CHEMBL618253,U,0,,,,,1,,BAO_0000019,
4691,,Autocuration,,22224,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),CHEMBL618254,U,0,,,,,1,,BAO_0000019,
4692,,Autocuration,,22224,Percent of compound in healthy individuals (Group D),CHEMBL618255,U,0,,,,,1,,BAO_0000019,
4693,2107.0,Autocuration,Liver,22224,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,CHEMBL618983,U,0,,,,Microsomes,1,,BAO_0000251,
4694,,Autocuration,,22224,Binding towards human plasma protein at 10 uM,CHEMBL618984,U,0,,,,,1,,BAO_0000019,
4695,,Autocuration,,22224,Binding towards human plasma protein at 100 uM,CHEMBL618985,U,0,,,,,1,,BAO_0000019,
4696,,Autocuration,,22224,Human plasma protein binding activity was determined,CHEMBL618986,U,0,,,,,1,,BAO_0000019,
4697,,Autocuration,,22224,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),CHEMBL618987,U,0,,,,,1,,BAO_0000019,
4698,,Autocuration,,22224,Percent binding of compound towards human plasma protein was determined,CHEMBL618988,U,0,,,,,1,,BAO_0000019,
4699,2107.0,Autocuration,Liver,22224,Plasma clearance in human liver microsomes,CHEMBL618989,U,0,,,,Microsomes,1,,BAO_0000251,
4700,2107.0,Autocuration,Liver,22224,In vitro intrinsic clearance in human liver microsome,CHEMBL618990,U,0,,,,Microsomes,1,,BAO_0000251,
4701,2107.0,Autocuration,Liver,22224,In vitro intrinsic clearance in human liver microsome,CHEMBL618991,U,0,,,,Microsomes,1,,BAO_0000251,
4702,,Autocuration,,22224,In vitro microsome metabolism clearance in human was determined,CHEMBL876725,U,0,,,,Microsomes,1,,BAO_0000251,
4703,,Autocuration,,22224,In vitro microsome metabolism clearance in human was determined; High,CHEMBL618992,U,0,,,,Microsomes,1,,BAO_0000251,
4704,,Autocuration,,22224,In vitro microsome metabolism clearance in human was determined; ND denotes no data,CHEMBL618993,U,0,,,,Microsomes,1,,BAO_0000251,
4705,2107.0,Autocuration,Liver,22224,Pharmacokinetic property (clearance) in human liver microsome,CHEMBL618994,U,0,,,,Microsomes,1,,BAO_0000251,
4706,2107.0,Autocuration,Liver,22224,Plasma clearance in human liver microsomes,CHEMBL618995,U,0,,,,Microsomes,1,,BAO_0000251,
4707,2107.0,Autocuration,Liver,22224,In vitro clearance in human liver microsomes,CHEMBL618996,U,0,,,,Microsomes,1,,BAO_0000251,
4708,2107.0,Autocuration,Liver,22224,Intrinsic clearance in human liver microsomes was determined,CHEMBL618997,U,0,,,,Microsomes,1,,BAO_0000251,
4709,2107.0,Autocuration,Liver,22224,Intrinsic clearance in human liver microsomes was determined,CHEMBL618998,U,0,,,,Microsomes,1,,BAO_0000251,
4710,,Autocuration,,22224,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,CHEMBL618999,U,0,,,,,1,,BAO_0000218,
4711,,Autocuration,,22224,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL620223,U,0,,,,,1,,BAO_0000218,
4712,,Autocuration,,22224,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,CHEMBL620224,U,0,,,,,1,,BAO_0000218,
4713,,Autocuration,,22224,Stability in human plasma 2 hr after incubation expressed as percent concentration,CHEMBL620225,U,0,,,,,1,,BAO_0000019,
4714,,Autocuration,,22224,Stability in human plasma 4 hr after incubation expressed as percent concentration,CHEMBL620226,U,0,,,,,1,,BAO_0000019,
4715,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL620227,U,0,,,,,1,,BAO_0000019,
4716,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL876726,U,0,,,,,1,,BAO_0000019,
4717,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL620228,U,0,,,,,1,,BAO_0000019,
4718,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL620229,U,0,,,,,1,,BAO_0000019,
4719,,Intermediate,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,CHEMBL620230,N,1,,,,,1,,BAO_0000218,
4720,,Intermediate,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,CHEMBL620231,N,1,,,,,1,,BAO_0000218,
4721,,Intermediate,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,CHEMBL620232,N,1,,,,,1,,BAO_0000218,
4722,,Intermediate,,50594,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,CHEMBL620233,N,1,,,,,1,,BAO_0000218,
4723,,Intermediate,,50594,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),CHEMBL620234,N,1,,,,,1,,BAO_0000218,
4724,,Intermediate,,50594,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),CHEMBL620235,N,1,,,,,1,,BAO_0000218,
4725,,Intermediate,,50594,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),CHEMBL620236,N,1,,,,,1,,BAO_0000218,
4726,2107.0,Intermediate,Liver,50594,In vitro metabolic potential in mouse liver microsomes,CHEMBL620237,N,1,,,,,1,,BAO_0000218,
4727,,Intermediate,,50594,Ability of compound to bind to plasma protein was evaluated in HSA cells,CHEMBL620238,N,1,,,,,1,,BAO_0000218,
4728,2369.0,Intermediate,Adrenal gland,50594,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),CHEMBL620239,N,1,,,,,1,,BAO_0000218,
4729,955.0,Intermediate,Brain,50594,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,CHEMBL620240,N,1,,,,,1,,BAO_0000218,
4730,955.0,Intermediate,Brain,50594,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,CHEMBL620241,N,1,,,,,1,,BAO_0000218,
4731,,Intermediate,,50594,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),CHEMBL876727,N,1,,,,,1,,BAO_0000218,
4732,2113.0,Intermediate,Kidney,50594,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),CHEMBL620242,N,1,,,,,1,,BAO_0000218,
4733,,Intermediate,,50594,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),CHEMBL620243,N,1,,,,,1,,BAO_0000218,
4734,,Intermediate,,50594,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,CHEMBL620244,N,1,,,,,1,,BAO_0000218,
4735,1977.0,Intermediate,Serum,50594,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,CHEMBL620245,N,1,,,,,1,,BAO_0000218,
4736,1977.0,Intermediate,Serum,50594,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,CHEMBL620246,N,1,,,,,1,,BAO_0000218,
4737,1977.0,Intermediate,Serum,50594,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,CHEMBL620247,N,1,,,,,1,,BAO_0000218,
4738,1969.0,Intermediate,Plasma,50594,Half life of compound was determined in plasma of mice at 24 mg/Kg,CHEMBL620248,N,1,,,,,1,,BAO_0000218,
4739,1969.0,Intermediate,Plasma,50594,Half life of compound was determined in plasma of mice at 40 mg/Kg,CHEMBL873497,N,1,,,,,1,,BAO_0000218,
4740,1969.0,Intermediate,Plasma,50594,Half life of compound was determined in plasma of mice at 5 mg/Kg,CHEMBL620249,N,1,,,,,1,,BAO_0000218,
4741,,Intermediate,,50594,Half life after intraperitoneal administration in mice at 18 uM/kg,CHEMBL620250,N,1,,,,,1,,BAO_0000218,
4742,,Intermediate,,50594,Half life after intraperitoneal administration in mice at 23 uM/kg,CHEMBL620251,N,1,,,,,1,,BAO_0000218,
4743,,Intermediate,,50594,Half life after intraperitoneal administration in mice at 25 uM/kg,CHEMBL620252,N,1,,,,,1,,BAO_0000218,
4744,,Intermediate,,50594,Half life after intraperitoneal administration in mice at 26 uM/kg,CHEMBL620253,N,1,,,,,1,,BAO_0000218,
4745,,Intermediate,,50594,Half life after intravenous administration in mice at 23 uM/kg,CHEMBL620254,N,1,,,,,1,,BAO_0000218,
4746,,Intermediate,,50594,Half life after intravenous administration in mice at 24 uM/kg,CHEMBL620255,N,1,,,,,1,,BAO_0000218,
4747,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,CHEMBL620256,N,1,,,,,1,,BAO_0000218,
4748,,Intermediate,,50594,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,CHEMBL876728,N,1,,,,,1,,BAO_0000218,
4749,,Intermediate,,50594,Maximum time required to reach Cp max was evaluated in mice after oral administration,CHEMBL620257,N,1,,,,,1,,BAO_0000218,
4750,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),CHEMBL620258,N,1,,,,,1,,BAO_0000218,
4751,,Intermediate,,50594,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",CHEMBL620259,N,1,,,,,1,,BAO_0000218,
4752,,Intermediate,,50594,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,CHEMBL620260,N,1,,,,,1,,BAO_0000218,
4753,178.0,Intermediate,Blood,50594,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,CHEMBL620261,N,1,,,,,1,,BAO_0000218,
4754,,Intermediate,,50594,Half life at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL620262,N,1,,,,,1,,BAO_0000218,
4755,,Intermediate,,50594,Half life at a dose of 10 mg/kg peroral administration in mice.,CHEMBL620263,N,1,,,,,1,,BAO_0000218,
4756,,Intermediate,,50594,Half life in ob/ob mice,CHEMBL620264,N,1,,,,,1,,BAO_0000218,
4757,,Intermediate,,50594,Half-life at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL620265,N,1,,,,,1,,BAO_0000218,
4758,,Intermediate,,50594,Half-life was measured in mouse,CHEMBL620266,N,1,,,,,1,,BAO_0000218,
4759,,Intermediate,,50594,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,CHEMBL620267,N,1,,,,,1,,BAO_0000218,
4760,,Intermediate,,50594,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,CHEMBL619364,N,1,,,,,1,,BAO_0000218,
4761,,Intermediate,,50594,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,CHEMBL619365,N,1,,,,,1,,BAO_0000218,
4762,955.0,Intermediate,Brain,50594,T2 in brain of mice at the oral dose of 50 mg/kg,CHEMBL619366,N,1,,,,,1,,BAO_0000218,
4763,2113.0,Intermediate,Kidney,50594,T2 in kidney of mice at the oral dose of 50 mg/kg,CHEMBL619367,N,1,,,,,1,,BAO_0000218,
4764,2107.0,Intermediate,Liver,50594,T2 in liver of mice at the oral dose of 50 mg/kg,CHEMBL619368,N,1,,,,,1,,BAO_0000218,
4765,2048.0,Intermediate,Lung,50594,T2 in lungs of mice at the oral dose of 50 mg/kg,CHEMBL619369,N,1,,,,,1,,BAO_0000218,
4766,2106.0,Intermediate,Spleen,50594,T2 in spleen of mice at the oral dose of 50 mg/kg,CHEMBL876729,N,1,,,,,1,,BAO_0000218,
4767,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,CHEMBL619370,N,1,,,,,1,,BAO_0000218,
4768,,Intermediate,,50594,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",CHEMBL619371,N,1,,,,,1,,BAO_0000218,
4769,,Intermediate,,50594,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,CHEMBL619372,N,1,,,,,1,,BAO_0000218,
4770,,Intermediate,,50594,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,CHEMBL620012,N,1,,,,,1,,BAO_0000218,
4771,,Intermediate,,50594,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,CHEMBL620013,N,1,,,,,1,,BAO_0000218,
4772,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL620014,N,1,478.0,A2780,,,1,,BAO_0000219,
4773,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL620015,N,1,478.0,A2780,,,1,,BAO_0000219,
4774,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621010,N,1,478.0,A2780,,,1,,BAO_0000219,
4775,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621011,N,1,478.0,A2780,,,1,,BAO_0000219,
4776,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621012,N,1,478.0,A2780,,,1,,BAO_0000219,
4777,,Intermediate,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621013,N,1,478.0,A2780,,,1,,BAO_0000219,
4778,,Intermediate,,81034,In vitro cytotoxicity against A2780TAX cell line,CHEMBL621014,N,1,478.0,A2780,,,1,,BAO_0000219,
4779,,Intermediate,,80017,In vitro inhibitory activity against human tumor cell line A2780cis,CHEMBL618154,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
4780,,Expert,,81034,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,CHEMBL618155,N,1,478.0,A2780,,,1,,BAO_0000219,
4781,,Intermediate,,80017,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,CHEMBL618156,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
4782,,Intermediate,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),CHEMBL618157,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
4783,,Intermediate,,81034,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,CHEMBL618328,N,1,478.0,A2780,,,1,,BAO_0000219,
4784,,Intermediate,,81034,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,CHEMBL618329,N,1,478.0,A2780,,,1,,BAO_0000219,
4785,,Intermediate,,81034,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,CHEMBL618330,N,1,478.0,A2780,,,1,,BAO_0000219,
4786,,Expert,,81034,In vitro antitumor activity against A2780cisR cell line.,CHEMBL618331,N,1,478.0,A2780,,,1,,BAO_0000219,
4787,,Intermediate,,81034,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),CHEMBL618332,N,1,478.0,A2780,,,1,,BAO_0000219,
4788,,Expert,,81034,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,CHEMBL618333,N,1,478.0,A2780,,,1,,BAO_0000219,
4789,,Intermediate,,80017,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,CHEMBL618334,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
4790,,Expert,,81034,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,CHEMBL618335,N,1,478.0,A2780,,,1,,BAO_0000219,
4791,,Expert,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,CHEMBL618336,D,9,,,,,1,,BAO_0000019,
4792,,Expert,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),CHEMBL618337,H,8,,,,,1,,BAO_0000019,
4793,,Expert,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),CHEMBL618338,D,9,,,,,1,,BAO_0000019,
4794,,Expert,,278,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,CHEMBL618339,D,9,722.0,HEK293,,,1,,BAO_0000219,
4795,,Expert,,278,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,CHEMBL618340,D,9,722.0,HEK293,,,1,,BAO_0000219,
4796,,Expert,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,CHEMBL618341,D,9,,,,,1,,BAO_0000019,
4797,,Expert,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),CHEMBL618342,H,8,,,,,1,,BAO_0000019,
4798,,Expert,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),CHEMBL618343,D,9,,,,,1,,BAO_0000019,
4799,,Expert,,280,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,CHEMBL621038,H,8,,,,,1,,BAO_0000357,
4800,,Autocuration,,22226,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),CHEMBL621039,U,0,574.0,T-cells,,,1,,BAO_0000219,
4801,,Autocuration,,22226,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,CHEMBL621040,U,0,574.0,T-cells,,,1,,BAO_0000219,
4802,,Intermediate,,80018,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,CHEMBL621041,N,1,455.0,A-375,,,1,,BAO_0000219,
4803,,Intermediate,,80018,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,CHEMBL621042,N,1,455.0,A-375,,,1,,BAO_0000219,
4804,,Intermediate,,80018,In vitro antitumor activity against A375cell line extracted form melanoma,CHEMBL621043,N,1,455.0,A-375,,,1,,BAO_0000219,
4805,,Expert,,80018,Inhibition of cell growth in (A375) melan cell line,CHEMBL621044,N,1,455.0,A-375,,,1,,BAO_0000219,
4806,,Intermediate,,80018,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,CHEMBL621045,N,1,455.0,A-375,,,1,,BAO_0000219,
4807,,Intermediate,,80018,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,CHEMBL621046,N,1,455.0,A-375,,,1,,BAO_0000219,
4808,,Intermediate,,80018,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,CHEMBL621047,N,1,455.0,A-375,,,1,,BAO_0000219,
4809,,Intermediate,,80019,Antiproliferative activity measured against A427 human lung carcinoma,CHEMBL621048,N,1,797.0,A-427,,,1,,BAO_0000219,
4810,,Intermediate,,80019,Antiproliferative activity measured against A427 human lung carcinoma,CHEMBL883798,N,1,797.0,A-427,,,1,,BAO_0000219,
4811,,Intermediate,,80019,Cytotoxicity against lung carcinoma A427 tumor cell lines,CHEMBL621049,N,1,797.0,A-427,,,1,,BAO_0000219,
4812,,Intermediate,,80019,Inhibition of large cell lung carcinoma (A427),CHEMBL621050,N,1,797.0,A-427,,,1,,BAO_0000219,
4813,,Intermediate,,80019,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,CHEMBL621051,N,1,797.0,A-427,,,1,,BAO_0000219,
4814,,Intermediate,,80019,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,CHEMBL621052,N,1,797.0,A-427,,,1,,BAO_0000219,
4815,,Intermediate,,80019,Inhibitory concentration in human lung carcinoma A427 cell line,CHEMBL621053,N,1,797.0,A-427,,,1,,BAO_0000219,
4816,,Intermediate,,80019,Inhibitory concentration in human lung carcinoma A427/VCR cell line,CHEMBL621054,N,1,797.0,A-427,,,1,,BAO_0000219,
4817,,Autocuration,,22224,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,CHEMBL621055,U,0,,,,,1,,BAO_0000218,
4818,,Autocuration,,22224,Tested for volume of distribution upon iv administration to african green monkey,CHEMBL876398,U,0,,,,,1,,BAO_0000218,
4819,,Autocuration,,22224,Volume of distribution in monkey,CHEMBL621056,U,0,,,,,1,,BAO_0000218,
4820,,Autocuration,,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL621057,U,0,,,,,1,,BAO_0000218,
4821,,Autocuration,,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,CHEMBL621058,U,0,,,,,1,,BAO_0000218,
4822,,Autocuration,,22224,Pharmacokinetic property(Vdss) in cynomolgus monkey,CHEMBL621059,U,0,,,,,1,,BAO_0000218,
4823,,Autocuration,,22224,The distribution volume after intravenous administration in cynomolgus monkeys,CHEMBL621060,U,0,,,,,1,,BAO_0000218,
4824,,Autocuration,,22224,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,CHEMBL621061,U,0,,,,,1,,BAO_0000218,
4825,,Autocuration,,22224,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,CHEMBL621062,U,0,,,,,1,,BAO_0000218,
4826,,Autocuration,,22224,Volume displacement was calculated in rhesus monkey,CHEMBL621063,U,0,,,,,1,,BAO_0000218,
4827,,Autocuration,,22224,Volume of distribution in steady state was determined in rhesus monkey,CHEMBL621064,U,0,,,,,1,,BAO_0000218,
4828,,Autocuration,,22224,Volume of distribution of compound was determined in monkey,CHEMBL621065,U,0,,,,,1,,BAO_0000218,
4829,,Autocuration,,22224,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL621066,U,0,,,,,1,,BAO_0000218,
4830,,Autocuration,,22224,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL621067,U,0,,,,,1,,BAO_0000218,
4831,,Autocuration,,22224,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL621068,U,0,,,,,1,,BAO_0000218,
4832,,Autocuration,,22224,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL876399,U,0,,,,,1,,BAO_0000218,
4833,,Autocuration,,22224,Volume distribution in monkey after administration of 1 mg/kg iv,CHEMBL621069,U,0,,,,,1,,BAO_0000218,
4834,,Autocuration,,22224,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL621070,U,0,,,,,1,,BAO_0000218,
4835,,Autocuration,,22224,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,CHEMBL621071,U,0,,,,,1,,BAO_0000218,
4836,,Autocuration,,22224,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL621072,U,0,,,,,1,,BAO_0000218,
4837,,Autocuration,,22224,Oral systemic bioavailability upon iv administration to african green monkey,CHEMBL618209,U,0,,,,,1,,BAO_0000218,
4838,,Autocuration,,22224,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL618210,U,0,,,,,1,,BAO_0000218,
4839,,Autocuration,,22224,Baboon plasma free fraction. ,CHEMBL618211,U,0,,,,,1,,BAO_0000019,
4840,,Autocuration,,22224,Area under the curve was calculated in rhesus monkey after iv administration,CHEMBL618212,U,0,,,,,1,,BAO_0000218,
4841,,Autocuration,,22224,Area under the curve was calculated in rhesus monkey after peroral administration,CHEMBL618213,U,0,,,,,1,,BAO_0000019,
4842,,Autocuration,,22224,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,CHEMBL618214,U,0,,,,,1,,BAO_0000019,
4843,,Autocuration,,22224,Half life period in monkey after 5 mg/kg dose,CHEMBL873492,U,0,,,,,1,,BAO_0000218,
4844,,Autocuration,,22224,Half-life was determined in monkey after 3 mg/kg of i.v. dose,CHEMBL618272,U,0,,,,,1,,BAO_0000218,
4845,,Autocuration,,22224,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,CHEMBL618273,U,0,,,,,1,,BAO_0000218,
4846,1969.0,Autocuration,Plasma,22224,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,CHEMBL618274,U,0,,,,,1,,BAO_0000218,
4847,,Autocuration,,22224,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,CHEMBL618275,U,0,,,,,1,,BAO_0000218,
4848,,Autocuration,,22224,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL618276,U,0,,,,,1,,BAO_0000218,
4849,,Autocuration,,22224,Compound was evaluated for terminal half life in monkey,CHEMBL618277,U,0,,,,,1,,BAO_0000019,
4850,,Autocuration,,22224,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,CHEMBL618278,U,0,,,,,1,,BAO_0000218,
4851,1969.0,Autocuration,Plasma,22224,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL618279,U,0,,,,,1,,BAO_0000218,
4852,,Autocuration,,22224,Half life of compound was determined in squirrel monkey,CHEMBL618280,U,0,,,,,1,,BAO_0000019,
4853,,Autocuration,,22224,Half life after iv administration in cynomolgus monkey,CHEMBL618281,U,0,,,,,1,,BAO_0000218,
4854,1969.0,Autocuration,Plasma,22224,Half life in monkey plasma after administration of 1 mg/kg iv,CHEMBL618282,U,0,,,,,1,,BAO_0000218,
4855,,Autocuration,,22224,Half life was calculated in rhesus monkey,CHEMBL618283,U,0,,,,,1,,BAO_0000019,
4856,,Autocuration,,22224,Half life in monkey,CHEMBL618284,U,0,,,,,1,,BAO_0000019,
4857,,Autocuration,,22224,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL618285,U,0,,,,,1,,BAO_0000218,
4858,,Autocuration,,22224,Half life was evaluated in rhesus,CHEMBL618286,U,0,,,,,1,,BAO_0000019,
4859,,Autocuration,,22224,Half life period after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL618287,U,0,,,,,1,,BAO_0000218,
4860,,Autocuration,,22224,Half life period was determine after peroral administration at 10 mpk in Rhesus,CHEMBL618288,U,0,,,,,1,,BAO_0000218,
4861,,Autocuration,,22224,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL876393,U,0,,,,,1,,BAO_0000218,
4862,,Autocuration,,22224,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,CHEMBL618289,U,0,,,,,1,,BAO_0000218,
4863,,Autocuration,,22224,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,CHEMBL618290,U,0,,,,,1,,BAO_0000218,
4864,,Autocuration,,22224,Half-life was calculated in monkey,CHEMBL618291,U,0,,,,,1,,BAO_0000019,
4865,,Autocuration,,22224,Half-life in Squirrel monkey,CHEMBL618292,U,0,,,,,1,,BAO_0000019,
4866,,Autocuration,,22224,Half-life in rhesus monkey,CHEMBL618293,U,0,,,,,1,,BAO_0000019,
4867,,Autocuration,,22224,Half-life was measured in monkey after an iv dose of 1 mg/kg,CHEMBL618294,U,0,,,,,1,,BAO_0000218,
4868,,Autocuration,,22224,Half-life period after intravenous administration in cynomolgus monkeys,CHEMBL618295,U,0,,,,,1,,BAO_0000218,
4869,,Autocuration,,22224,Half-life period after oral administration in cynomolgus monkeys,CHEMBL618296,U,0,,,,,1,,BAO_0000218,
4870,,Autocuration,,22224,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,CHEMBL618297,U,0,,,,,1,,BAO_0000218,
4871,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618298,U,0,,,,,1,,BAO_0000019,
4872,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618299,U,0,,,,,1,,BAO_0000019,
4873,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618300,U,0,,,,,1,,BAO_0000019,
4874,1088.0,Autocuration,Urine,22224,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618301,U,0,,,,,1,,BAO_0000019,
4875,1088.0,Autocuration,Urine,22224,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,CHEMBL618302,U,0,,,,,1,,BAO_0000019,
4876,1088.0,Autocuration,Urine,22224,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,CHEMBL876394,U,0,,,,,1,,BAO_0000019,
4877,1088.0,Autocuration,Urine,22224,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,CHEMBL618303,U,0,,,,,1,,BAO_0000019,
4878,1088.0,Autocuration,Urine,22224,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,CHEMBL618304,U,0,,,,,1,,BAO_0000019,
4879,,Autocuration,,22224,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,CHEMBL618305,U,0,,,,,1,,BAO_0000218,
4880,,Autocuration,,22224,Oral bioavailability in human,CHEMBL618306,U,0,,,,,1,,BAO_0000218,
4881,,Autocuration,,22224,Compound was tested for human plasma protein binding,CHEMBL618307,U,0,,,,,1,,BAO_0000019,
4882,,Autocuration,,22224,Compound was tested for human plasma protein binding; Not determined,CHEMBL618308,U,0,,,,,1,,BAO_0000019,
4883,,Autocuration,,22224,Protein binding activity of compound in human plasma; % Free,CHEMBL618309,U,0,,,,,1,,BAO_0000019,
4884,,Autocuration,,22224,Unbound fraction (plasma),CHEMBL618310,U,0,,,,,1,,BAO_0000019,
4885,1969.0,Autocuration,Plasma,22224,Half life for the hydrolysis of compound in human blood serum,CHEMBL873353,U,0,,,,,1,,BAO_0000366,
4886,1969.0,Autocuration,Plasma,22224,Half life period in human plasma using phosphate buffer (0.08 M),CHEMBL618311,U,0,,,,,1,,BAO_0000366,
4887,1969.0,Autocuration,Plasma,22224,Half life period in human plasma using phosphate buffer (0.1 M),CHEMBL618312,U,0,,,,,1,,BAO_0000366,
4888,1969.0,Autocuration,Plasma,22224,Half-life in human plasma was determined,CHEMBL618313,U,0,,,,,1,,BAO_0000366,
4889,,Autocuration,,22224,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,CHEMBL618314,U,0,,,,,1,,BAO_0000019,
4890,,Autocuration,,22224,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),CHEMBL618315,U,0,,,,,1,,BAO_0000019,
4891,,Autocuration,,22224,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",CHEMBL618316,U,0,,,,,1,,BAO_0000019,
4892,,Autocuration,,22224,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",CHEMBL618317,U,0,,,,,1,,BAO_0000019,
4893,,Autocuration,,22224,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",CHEMBL620138,U,0,,,,,1,,BAO_0000019,
4894,,Autocuration,,22224,Partition coefficient (logP),CHEMBL858280,U,0,,,,,1,,BAO_0000019,
4895,,Autocuration,,22224,In vitro metabolic stability in human was measured as pmol/min/mg/protein,CHEMBL620139,U,0,,,,,1,,BAO_0000019,
4896,,Autocuration,,22224,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,CHEMBL620140,U,0,,,,Microsomes,1,,BAO_0000251,
4897,,Autocuration,,22224,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),CHEMBL620141,U,0,,,,,1,,BAO_0000019,
4898,,Autocuration,,22224,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),CHEMBL620142,U,0,,,,,1,,BAO_0000019,
4899,,Autocuration,,22224,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),CHEMBL620143,U,0,,,,,1,,BAO_0000019,
4900,,Autocuration,,22224,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),CHEMBL620144,U,0,,,,Microsomes,1,,BAO_0000251,
4901,,Autocuration,,22224,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),CHEMBL620145,U,0,,,,Microsomes,1,,BAO_0000251,
4902,,Autocuration,,22224,Metabolism of compound in human microsomes; Trace,CHEMBL620146,U,0,,,,Microsomes,1,,BAO_0000251,
4903,2107.0,Autocuration,Liver,22224,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,CHEMBL620147,U,0,,,,Microsomes,1,,BAO_0000251,
4904,,Autocuration,,22224,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,CHEMBL620148,U,0,,,,Microsomes,1,,BAO_0000251,
4905,2107.0,Autocuration,Liver,22224,In vitro metabolic potential in human liver microsomes,CHEMBL620149,U,0,,,,Microsomes,1,,BAO_0000251,
4906,,Autocuration,,22224,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,CHEMBL876412,U,0,,,,,1,,BAO_0000019,
4907,,Autocuration,,22224,Tested for human plasma protein binding of the compound; Not tested,CHEMBL619352,U,0,,,,,1,,BAO_0000019,
4908,,Autocuration,,22224,Compound was tested for percent protein binding (PB) in human,CHEMBL619353,U,0,,,,,1,,BAO_0000019,
4909,1969.0,Autocuration,Plasma,22224,Protein binding in human plasma,CHEMBL619354,U,0,,,,,1,,BAO_0000019,
4910,,Autocuration,,22224,Permeability coefficient (B to A) in Caco-2 cell,CHEMBL619355,U,0,,,,,1,,BAO_0000019,
4911,,Autocuration,,22224,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,CHEMBL619356,U,0,,,,,1,,BAO_0000019,
4912,,Autocuration,,22224,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),CHEMBL619357,U,0,,,,,1,,BAO_0000019,
4913,,Autocuration,,22224,In vitro rate of absorption observed as Caco-2 permeability in humans,CHEMBL619358,U,0,,,,,1,,BAO_0000019,
4914,,Autocuration,,22224,Cellular permeability of compound was determined in Caco-2 cells; High,CHEMBL619359,U,0,495.0,Caco-2,,,1,,BAO_0000219,
4915,,Autocuration,,22224,Permeability in Caco-2 cells of compound,CHEMBL619360,U,0,495.0,Caco-2,,,1,,BAO_0000219,
4916,,Autocuration,,22224,Permeability coefficient (A to B) in Caco-2 cell,CHEMBL619361,U,0,,,,,1,,BAO_0000019,
4917,,Autocuration,,22224,Permeability coefficient (B to A) in Caco-2 cell,CHEMBL619362,U,0,,,,,1,,BAO_0000019,
4918,,Autocuration,,22224,Permeability coefficient (Papp) (Caco-2 cell monolayer),CHEMBL619363,U,0,,,,,1,,BAO_0000019,
4919,,Autocuration,,22224,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,CHEMBL618942,U,0,,,,,1,,BAO_0000019,
4920,,Autocuration,,22224,Compound was tested for protein binding in human plasma,CHEMBL618943,U,0,,,,,1,,BAO_0000019,
4921,,Autocuration,,22224,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,CHEMBL618944,U,0,,,,,1,,BAO_0000019,
4922,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,CHEMBL618945,U,0,,,,,1,,BAO_0000019,
4923,,Intermediate,,50594,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,CHEMBL618946,N,1,,,,,1,,BAO_0000218,
4924,,Intermediate,,50594,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),CHEMBL876413,N,1,,,,,1,,BAO_0000218,
4925,,Intermediate,,50594,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,CHEMBL618947,N,1,,,,,1,,BAO_0000218,
4926,1969.0,Intermediate,Plasma,50594,Time taken to reach maximum concentration in plasma upon oral administration in mouse,CHEMBL618948,N,1,,,,,1,,BAO_0000218,
4927,1969.0,Intermediate,Plasma,50594,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL618949,N,1,,,,,1,,BAO_0000218,
4928,,Intermediate,,50594,Tmax after intraperitoneal administration in mice at 23 uM/kg,CHEMBL618950,N,1,,,,,1,,BAO_0000218,
4929,,Intermediate,,50594,Tmax after oral administration at 30 mg/kg in ICR mouse,CHEMBL618951,N,1,,,,,1,,BAO_0000218,
4930,,Intermediate,,50594,Tmax after peroral administration in mice at 2.4 uM/kg,CHEMBL618952,N,1,,,,,1,,BAO_0000218,
4931,,Intermediate,,50594,Tmax at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL618953,N,1,,,,,1,,BAO_0000218,
4932,955.0,Intermediate,Brain,50594,Tmax in brain of mice at the oral dose of 50 mg/kg,CHEMBL618954,N,1,,,,,1,,BAO_0000218,
4933,2113.0,Intermediate,Kidney,50594,Tmax in kidney of mice at the oral dose of 50 mg/kg,CHEMBL618955,N,1,,,,,1,,BAO_0000218,
4934,2107.0,Intermediate,Liver,50594,Tmax in liver of mice at the oral dose of 50 mg/kg,CHEMBL618956,N,1,,,,,1,,BAO_0000218,
4935,2048.0,Intermediate,Lung,50594,Tmax in lungs of mice at the oral dose of 50 mg/kg,CHEMBL618957,N,1,,,,,1,,BAO_0000218,
4936,,Intermediate,,50594,Tmax in mice at 18 uM/kg i.p. administration,CHEMBL618958,N,1,,,,,1,,BAO_0000218,
4937,,Intermediate,,50594,Tmax in mice at 23 uM/kg i.v. administration,CHEMBL618959,N,1,,,,,1,,BAO_0000218,
4938,,Intermediate,,50594,Tmax in mice at 25 uM/kg i.p. administration,CHEMBL618960,N,1,,,,,1,,BAO_0000218,
4939,,Intermediate,,50594,Tmax in mice at 26 uM/kg i.p. administration,CHEMBL876723,N,1,,,,,1,,BAO_0000218,
4940,2106.0,Intermediate,Spleen,50594,Tmax in spleen of mice at the oral dose of 50 mg/kg,CHEMBL618961,N,1,,,,,1,,BAO_0000218,
4941,,Intermediate,,50594,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL618962,N,1,,,,,1,,BAO_0000218,
4942,,Intermediate,,50594,Tmax value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL618963,N,1,,,,,1,,BAO_0000218,
4943,,Intermediate,,50594,Tmax value in IRC mice,CHEMBL618964,N,1,,,,,1,,BAO_0000218,
4944,,Intermediate,,50594,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,CHEMBL618965,N,1,,,,,1,,BAO_0000218,
4945,,Intermediate,,50594,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,CHEMBL618966,N,1,,,,,1,,BAO_0000218,
4946,1088.0,Intermediate,Urine,50594,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),CHEMBL618967,N,1,,,,,1,,BAO_0000218,
4947,1088.0,Intermediate,Urine,50594,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),CHEMBL618968,N,1,,,,,1,,BAO_0000218,
4948,1088.0,Intermediate,Urine,50594,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),CHEMBL618969,N,1,,,,,1,,BAO_0000218,
4949,,Intermediate,,50594,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,CHEMBL618970,N,1,,,,,1,,BAO_0000218,
4950,,Intermediate,,50594,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,CHEMBL618971,N,1,,,,,1,,BAO_0000218,
4951,,Intermediate,,50594,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,CHEMBL618972,N,1,,,,,1,,BAO_0000218,
4952,,Intermediate,,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,CHEMBL618973,N,1,,,,,1,,BAO_0000218,
4953,,Intermediate,,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,CHEMBL618974,N,1,,,,,1,,BAO_0000218,
4954,,Intermediate,,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,CHEMBL618975,N,1,,,,,1,,BAO_0000218,
4955,,Intermediate,,50594,Vd in mice,CHEMBL618976,N,1,,,,,1,,BAO_0000218,
4956,,Intermediate,,50594,Volume of distribution in mouse,CHEMBL618977,N,1,,,,,1,,BAO_0000218,
4957,,Intermediate,,50594,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL876724,N,1,,,,,1,,BAO_0000218,
4958,,Intermediate,,50594,Volume of distribution of compound in plasma was determined at 24 mg/Kg,CHEMBL618978,N,1,,,,,1,,BAO_0000218,
4959,,Intermediate,,50594,Volume of distribution of compound in plasma was determined at 40 mg/Kg,CHEMBL618979,N,1,,,,,1,,BAO_0000218,
4960,,Intermediate,,50594,Volume of distribution of compound in plasma was determined at 5 mg/Kg,CHEMBL618980,N,1,,,,,1,,BAO_0000218,
4961,,Intermediate,,50594,Pharmacokinetic property (vdss) was measured in mouse,CHEMBL618981,N,1,,,,,1,,BAO_0000218,
4962,,Intermediate,,50594,Value distribution upon iv administration in mouse,CHEMBL618982,N,1,,,,,1,,BAO_0000218,
4963,,Intermediate,,50594,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,CHEMBL620150,N,1,,,,,1,,BAO_0000218,
4964,,Intermediate,,50594,Volume of distribution was evaluated in mice after intravenous administration,CHEMBL620151,N,1,,,,,1,,BAO_0000218,
4965,,Intermediate,,50594,Volume of distribution was evaluated in mice after oral administration,CHEMBL620152,N,1,,,,,1,,BAO_0000218,
4966,,Intermediate,,50594,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,CHEMBL620153,N,1,,,,,1,,BAO_0000218,
4967,,Intermediate,,50594,Steady state volume of distribution was determined in mice,CHEMBL876395,N,1,,,,,1,,BAO_0000218,
4968,,Intermediate,,50594,Volume distribution (steady state) of compound was determined in mouse,CHEMBL620154,N,1,,,,,1,,BAO_0000218,
4969,,Intermediate,,50594,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,CHEMBL620155,N,1,,,,,1,,BAO_0000218,
4970,,Intermediate,,50594,Vss value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL620156,N,1,,,,,1,,BAO_0000218,
4971,,Intermediate,,50594,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,CHEMBL620157,N,1,,,,,1,,BAO_0000218,
4972,2113.0,Intermediate,Kidney,50594,Biodistribution of compound (oxidized form) in in kidney tissue,CHEMBL620158,N,1,,,,,1,,BAO_0000218,
4973,178.0,Intermediate,Blood,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,CHEMBL620159,N,1,,,,,1,,BAO_0000218,
4974,178.0,Intermediate,Blood,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",CHEMBL620160,N,1,,,,,1,,BAO_0000218,
4975,178.0,Intermediate,Blood,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL620161,N,1,,,,,1,,BAO_0000218,
4976,,Intermediate,,80019,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,CHEMBL620162,N,1,797.0,A-427,,,1,,BAO_0000219,
4977,,Expert,,80852,Inhibition of A431 human squamous cell carcinoma cell proliferation,CHEMBL620163,N,1,500.0,A-431,,,1,,BAO_0000219,
4978,,Expert,,80852,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,CHEMBL620833,N,1,500.0,A-431,,,1,,BAO_0000219,
4979,,Expert,,80852,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,CHEMBL876396,N,1,500.0,A-431,,,1,,BAO_0000219,
4980,,Expert,,80852,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,CHEMBL620834,N,1,500.0,A-431,,,1,,BAO_0000219,
4981,,Expert,,80852,Inhibition of A431 human carcinoma cell proliferation,CHEMBL620835,N,1,500.0,A-431,,,1,,BAO_0000219,
4982,,Expert,,80852,In vitro inhibition of A431 (human carcinoma) cell basal growth.,CHEMBL620836,N,1,500.0,A-431,,,1,,BAO_0000219,
4983,,Intermediate,,80852,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,CHEMBL620837,N,1,500.0,A-431,,,1,,BAO_0000219,
4984,,Intermediate,,80852,In vitro cytotoxicity against epidermoid carcinoma cell line,CHEMBL621017,N,1,500.0,A-431,,,1,,BAO_0000219,
4985,,Expert,,9,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",CHEMBL621018,D,9,500.0,A-431,,,1,,BAO_0000218,
4986,,Intermediate,,80852,Antiproliferative activity of compound was measured on human tumor cell line A431.,CHEMBL621019,N,1,500.0,A-431,,,1,,BAO_0000219,
4987,,Intermediate,,80852,Antiproliferative effect of compound on A431 cell line expressing mutant p53,CHEMBL621020,N,1,500.0,A-431,,,1,,BAO_0000219,
4988,,Intermediate,,80852,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,CHEMBL621021,N,1,500.0,A-431,,,1,,BAO_0000219,
4989,,Expert,,9,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,CHEMBL621022,H,8,500.0,A-431,,,1,,BAO_0000219,
4990,,Expert,,80852,Tested for antiproliferative activity against human A431 cells,CHEMBL621023,N,1,500.0,A-431,,,1,,BAO_0000219,
4991,,Expert,,9,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,CHEMBL621024,D,9,500.0,A-431,,,1,,BAO_0000219,
4992,,Expert,,80852,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,CHEMBL621025,N,1,500.0,A-431,,,1,,BAO_0000219,
4993,,Expert,,80852,Inhibition of A431 cell proliferation,CHEMBL621026,N,1,500.0,A-431,,,1,,BAO_0000219,
4994,,Expert,,80852,Cytotoxic effect on A431 human epidermoid carcinoma cells,CHEMBL621027,N,1,500.0,A-431,,,1,,BAO_0000219,
4995,,Expert,,80852,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),CHEMBL876397,N,1,500.0,A-431,,,1,,BAO_0000219,
4996,,Intermediate,,80852,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,CHEMBL883797,N,1,500.0,A-431,,,1,,BAO_0000219,
4997,,Intermediate,,80852,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,CHEMBL621028,N,1,500.0,A-431,,,1,,BAO_0000219,
4998,,Intermediate,,80852,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,CHEMBL621029,N,1,500.0,A-431,,,1,,BAO_0000219,
4999,,Intermediate,,80852,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,CHEMBL621030,N,1,500.0,A-431,,,1,,BAO_0000219,
5000,,Expert,,9,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,CHEMBL621147,H,8,500.0,A-431,,,1,,BAO_0000219,
5001,,Intermediate,,80852,In vivo antiproliferative activity against A431 cell line,CHEMBL621148,N,1,500.0,A-431,,,1,,BAO_0000218,
5002,,Expert,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,CHEMBL621149,D,9,500.0,A-431,,,1,,BAO_0000219,
5003,,Expert,,80852,Inhibition of A431 human epidermoid carcinoma cell proliferation,CHEMBL621150,N,1,500.0,A-431,,,1,,BAO_0000219,
5004,,Expert,,9,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,CHEMBL621151,D,9,500.0,A-431,,,1,,BAO_0000219,
5005,,Intermediate,,80852,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),CHEMBL621152,N,1,500.0,A-431,,,1,,BAO_0000219,
5006,,Intermediate,,80852,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),CHEMBL621153,N,1,500.0,A-431,,,1,,BAO_0000219,
5007,,Intermediate,,80852,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),CHEMBL884000,N,1,500.0,A-431,,,1,,BAO_0000219,
5008,,Expert,,9,Inhibition of EGFR overexpressing A431 cell proliferation,CHEMBL621154,D,9,,,,,1,,BAO_0000019,
5009,,Expert,,80852,Inhibition of A431 cell proliferation,CHEMBL621155,N,1,500.0,A-431,,,1,,BAO_0000219,
5010,,Expert,,9,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,CHEMBL621156,D,9,500.0,A-431,,,1,,BAO_0000219,
5011,,Expert,,9,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",CHEMBL621157,D,9,500.0,A-431,,,1,,BAO_0000219,
5012,,Expert,,9,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),CHEMBL621158,H,8,500.0,A-431,,,1,,BAO_0000219,
5013,,Intermediate,,80852,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,CHEMBL621159,N,1,500.0,A-431,,,1,,BAO_0000219,
5014,,Intermediate,,80852,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,CHEMBL621160,N,1,500.0,A-431,,,1,,BAO_0000219,
5015,,Intermediate,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,CHEMBL621161,N,1,500.0,A-431,,,1,,BAO_0000219,
5016,,Intermediate,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,CHEMBL621162,N,1,500.0,A-431,,,1,,BAO_0000219,
5017,,Intermediate,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,CHEMBL621163,N,1,500.0,A-431,,,1,,BAO_0000219,
5018,,Intermediate,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,CHEMBL621164,N,1,500.0,A-431,,,1,,BAO_0000219,
5019,,Intermediate,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,CHEMBL621165,N,1,500.0,A-431,,,1,,BAO_0000219,
5020,,Autocuration,,22224,Half-life period in cynomolgus monkey,CHEMBL619159,U,0,,,,,1,,BAO_0000019,
5021,1969.0,Autocuration,Plasma,22224,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",CHEMBL619160,U,0,,,,,1,,BAO_0000366,
5022,,Autocuration,,22224,Longer half-life in monkey (i.v.) at 0.5 mpk,CHEMBL619161,U,0,,,,,1,,BAO_0000218,
5023,1969.0,Autocuration,Plasma,22224,Plasma half life in monkey,CHEMBL619162,U,0,,,,,1,,BAO_0000366,
5024,1969.0,Autocuration,Plasma,22224,Plasma half-life in rhesus monkey,CHEMBL619163,U,0,,,,,1,,BAO_0000366,
5025,1969.0,Autocuration,Plasma,22224,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL619164,U,0,,,,,1,,BAO_0000218,
5026,1969.0,Autocuration,Plasma,22224,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL619320,U,0,,,,,1,,BAO_0000218,
5027,,Autocuration,,22224,Tested for half life upon iv administration to african green monkey,CHEMBL619321,U,0,,,,,1,,BAO_0000218,
5028,,Autocuration,,22224,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL873336,U,0,,,,,1,,BAO_0000218,
5029,,Autocuration,,22224,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,CHEMBL619322,U,0,,,,,1,,BAO_0000218,
5030,,Autocuration,,22224,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,CHEMBL619323,U,0,,,,,1,,BAO_0000218,
5031,,Autocuration,,22224,The time for peak concentration value after oral administration in cynomolgus monkeys,CHEMBL619324,U,0,,,,,1,,BAO_0000218,
5032,,Autocuration,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,CHEMBL619325,U,0,,,,,1,,BAO_0000019,
5033,,Autocuration,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,CHEMBL876411,U,0,,,,,1,,BAO_0000019,
5034,,Autocuration,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,CHEMBL619326,U,0,,,,,1,,BAO_0000019,
5035,,Autocuration,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,CHEMBL619327,U,0,,,,,1,,BAO_0000019,
5036,,Autocuration,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,CHEMBL619328,U,0,,,,,1,,BAO_0000019,
5037,,Autocuration,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,CHEMBL619329,U,0,,,,,1,,BAO_0000019,
5038,,Autocuration,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,CHEMBL619330,U,0,,,,,1,,BAO_0000019,
5039,,Autocuration,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,CHEMBL619331,U,0,,,,,1,,BAO_0000019,
5040,,Autocuration,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,CHEMBL619332,U,0,,,,,1,,BAO_0000019,
5041,,Autocuration,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,CHEMBL619333,U,0,,,,,1,,BAO_0000019,
5042,,Autocuration,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,CHEMBL619334,U,0,,,,,1,,BAO_0000019,
5043,,Autocuration,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,CHEMBL619335,U,0,,,,,1,,BAO_0000019,
5044,,Autocuration,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,CHEMBL619336,U,0,,,,,1,,BAO_0000019,
5045,,Autocuration,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,CHEMBL619337,U,0,,,,,1,,BAO_0000019,
5046,,Autocuration,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,CHEMBL619338,U,0,,,,,1,,BAO_0000019,
5047,,Autocuration,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,CHEMBL619339,U,0,,,,,1,,BAO_0000019,
5048,,Intermediate,,50597,Bioavailability in rat (cannulated) (dose 2 mg/kg),CHEMBL619340,N,1,,,,,1,,BAO_0000218,
5049,1969.0,Intermediate,Plasma,50597,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL873496,N,1,,,,,1,,BAO_0000218,
5050,1969.0,Intermediate,Plasma,50597,AUC value in rat after IV administration at a dose of 10 mg/kg,CHEMBL619341,N,1,,,,,1,,BAO_0000218,
5051,1969.0,Intermediate,Plasma,50597,AUC value in rat after oral administration at a dose of 10 mg/kg,CHEMBL619342,N,1,,,,,1,,BAO_0000218,
5052,,Intermediate,,50597,Cmax value in rat after oral administration at a dose of 10 mg/kg,CHEMBL619343,N,1,,,,,1,,BAO_0000218,
5053,,Intermediate,,50597,Bioavailability in rat after oral administration at a dose of 10 mg/kg,CHEMBL619344,N,1,,,,,1,,BAO_0000218,
5054,,Intermediate,,50597,Tmax value in rat after oral administration at a dose of 10 mg/kg,CHEMBL619345,N,1,,,,,1,,BAO_0000218,
5055,,Intermediate,,50597,Vc value in rat after IV administration at a dose of 10 mg/kg,CHEMBL619346,N,1,,,,,1,,BAO_0000218,
5056,,Intermediate,,50597,Half life period in rat after IV administration at a dose of 10 mg/kg,CHEMBL619347,N,1,,,,,1,,BAO_0000218,
5057,,Autocuration,,22224,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,CHEMBL619348,U,0,,,,,1,,BAO_0000019,
5058,,Autocuration,,22224,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),CHEMBL619349,U,0,,,,,1,,BAO_0000019,
5059,,Autocuration,,22224,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),CHEMBL619350,U,0,,,,,1,,BAO_0000019,
5060,,Autocuration,,22224,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,CHEMBL619351,U,0,,,,,1,,BAO_0000019,
5061,,Autocuration,,22224,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,CHEMBL875953,U,0,,,,,1,,BAO_0000019,
5062,,Autocuration,,22224,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,CHEMBL621716,U,0,,,,,1,,BAO_0000019,
5063,,Autocuration,,22224,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,CHEMBL621717,U,0,,,,,1,,BAO_0000019,
5064,,Autocuration,,22224,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,CHEMBL621718,U,0,,,,,1,,BAO_0000019,
5065,,Autocuration,,22224,Area under curve after 1 mpk peroral administration to beagles,CHEMBL621719,U,0,,,,,1,,BAO_0000019,
5066,,Autocuration,,22224,Area under curve after 2 mpk peroral administration to beagles,CHEMBL621720,U,0,,,,,1,,BAO_0000019,
5067,,Autocuration,,22224,Cmax value after 1 mpk peroral administration to beagles,CHEMBL621721,U,0,,,,,1,,BAO_0000218,
5068,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,CHEMBL621722,U,0,,,,,1,,BAO_0000019,
5069,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,CHEMBL621723,U,0,,,,,1,,BAO_0000019,
5070,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,CHEMBL621724,U,0,,,,,1,,BAO_0000019,
5071,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,CHEMBL623443,U,0,,,,,1,,BAO_0000019,
5072,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,CHEMBL623444,U,0,,,,,1,,BAO_0000019,
5073,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,CHEMBL623445,U,0,,,,,1,,BAO_0000019,
5074,1088.0,Autocuration,Urine,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,CHEMBL623446,U,0,,,,,1,,BAO_0000019,
5075,2107.0,Autocuration,Liver,22224,Metabolic stability observed at 30 min after administration in human liver microsomes,CHEMBL623447,U,0,,,,Microsomes,1,,BAO_0000251,
5076,,Autocuration,,22224,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,CHEMBL623448,U,0,,,,,1,,BAO_0000019,
5077,,Autocuration,,22224,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,CHEMBL623449,U,0,,,,,1,,BAO_0000019,
5078,,Autocuration,,22224,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,CHEMBL623450,U,0,,,,,1,,BAO_0000019,
5079,2107.0,Autocuration,Liver,22224,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",CHEMBL623451,U,0,,,,Microsomes,1,,BAO_0000251,
5080,,Autocuration,,22224,Metabolic stability (% remaining at 30 mins) in human S9.,CHEMBL623452,U,0,,,,,1,,BAO_0000019,
5081,,Autocuration,,22224,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,CHEMBL623453,U,0,,,,,1,,BAO_0000019,
5082,2107.0,Autocuration,Liver,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes,CHEMBL623454,U,0,,,,Microsomes,1,,BAO_0000251,
5083,2107.0,Autocuration,Liver,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,CHEMBL623455,U,0,,,,Microsomes,1,,BAO_0000251,
5084,2107.0,Autocuration,Liver,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,CHEMBL624371,U,0,,,,Microsomes,1,,BAO_0000251,
5085,,Autocuration,,22224,First pass metabolism and metabolic bioavailability using human hepatic microsomes,CHEMBL624372,U,0,,,,,1,,BAO_0000218,
5086,,Autocuration,,22224,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,CHEMBL624373,U,0,,,,,1,,BAO_0000019,
5087,,Autocuration,,22224,Percent remaining in human plasma after incubation for 60 min at 37 C.,CHEMBL624374,U,0,,,,,1,,BAO_0000019,
5088,,Autocuration,,22224,The percent remaining in human plasma after 30 min was determined,CHEMBL624556,U,0,,,,,1,,BAO_0000019,
5089,1969.0,Autocuration,Plasma,22224,Conversion rate of the prodrug in human plasma,CHEMBL624557,U,0,,,,,1,,BAO_0000366,
5090,1969.0,Autocuration,Plasma,22224,Conversion rate of the prodrug in human plasma; ND means no data,CHEMBL624558,U,0,,,,,1,,BAO_0000366,
5091,178.0,Autocuration,Blood,22224,Half life of compound was determined in human blood,CHEMBL624559,U,0,,,,,1,,BAO_0000221,
5092,,Autocuration,,22224,Half life of compound was determined in man with once daily dosing,CHEMBL624560,U,0,,,,,1,,BAO_0000019,
5093,,Autocuration,,22224,Half life in human microsomes,CHEMBL624561,U,0,,,,Microsomes,1,,BAO_0000251,
5094,1969.0,Autocuration,Plasma,22224,Half life in human plasma,CHEMBL624562,U,0,,,,,1,,BAO_0000366,
5095,1969.0,Autocuration,Plasma,22224,Half life in human plasma; Not detected,CHEMBL624563,U,0,,,,,1,,BAO_0000366,
5096,,Autocuration,,22224,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL624564,U,0,,,,,1,,BAO_0000218,
5097,2107.0,Autocuration,Liver,22224,Half-life for oxidative metabolic stability was determined using rat liver microsomes,CHEMBL624565,U,0,,,,Microsomes,1,,BAO_0000251,
5098,1969.0,Autocuration,Plasma,22224,Half-life in human plasma,CHEMBL875152,U,0,,,,,1,,BAO_0000366,
5099,1969.0,Autocuration,Plasma,22224,Half-life of the parent prodrug in plasma,CHEMBL624566,U,0,,,,,1,,BAO_0000366,
5100,1969.0,Autocuration,Plasma,22224,In vitro half life in human plasma was determined,CHEMBL873805,U,0,,,,,1,,BAO_0000366,
5101,2107.0,Autocuration,Liver,22224,The compound was tested In Vitro for half life in human liver microsomes.,CHEMBL624567,U,0,,,,Microsomes,1,,BAO_0000251,
5102,,Autocuration,,22224,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL624568,U,0,,,,,1,,BAO_0000218,
5103,,Autocuration,,22224,Observed volume of distribution,CHEMBL624569,U,0,,,,,1,,BAO_0000218,
5104,,Autocuration,,22224,Oral bioavailability in human,CHEMBL624570,U,0,,,,,1,,BAO_0000218,
5105,,Autocuration,,22224,Tested for human plasma protein binding of the compound,CHEMBL624571,U,0,,,,,1,,BAO_0000019,
5106,,Autocuration,,22224,"First order rate constant, k was determined in human plasma",CHEMBL624572,U,0,,,,,1,,BAO_0000019,
5107,,Autocuration,,22224,Observed rate constant in 80% human plasma at 37 degree Centigrade,CHEMBL624573,U,0,,,,,1,,BAO_0000019,
5108,,Autocuration,,22224,Observed rate constant in 80% human plasma at 37 degree Centigrade,CHEMBL875153,U,0,,,,,1,,BAO_0000019,
5109,2107.0,Autocuration,Liver,22224,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,CHEMBL624574,U,0,,,,Microsomes,1,,BAO_0000251,
5110,,Autocuration,,22224,The compound was tested for the plasma binding in human,CHEMBL624575,U,0,,,,,1,,BAO_0000019,
5111,,Autocuration,,22224,Plasma protein binding (human),CHEMBL624576,U,0,,,,,1,,BAO_0000019,
5112,2107.0,Autocuration,Liver,22224,Compound was evaluated for half-life in human liver microsomes,CHEMBL624577,U,0,,,,Microsomes,1,,BAO_0000251,
5113,178.0,Autocuration,Blood,22224,Half life measured in vitro for its stability in human blood,CHEMBL624578,U,0,,,,,1,,BAO_0000221,
5114,1977.0,Autocuration,Serum,22224,Half life in human serum,CHEMBL622796,U,0,,,,,1,,BAO_0000019,
5115,1977.0,Autocuration,Serum,22224,Half life in human serum; ND=not determined,CHEMBL622797,U,0,,,,,1,,BAO_0000019,
5116,,Autocuration,,22224,Half life were determined in CEM-SS cell extract in decomposition step 1,CHEMBL622798,U,0,,,,,1,,BAO_0000019,
5117,,Autocuration,,22224,Half life were determined in CEM-SS cell extract in decomposition step 2,CHEMBL622799,U,0,,,,,1,,BAO_0000019,
5118,1969.0,Autocuration,Plasma,22224,Half life of the in human plasma,CHEMBL622800,U,0,,,,,1,,BAO_0000366,
5119,,Autocuration,,22224,Half life period in human hepatic S9 fraction was determined,CHEMBL622801,U,0,,,,S9,1,,BAO_0000220,
5120,2107.0,Autocuration,Liver,22224,Half life period in human liver microsome was determined,CHEMBL622802,U,0,,,,Microsomes,1,,BAO_0000251,
5121,,Autocuration,,22224,Half life period was determined; 6-7,CHEMBL622803,U,0,,,,,1,,BAO_0000019,
5122,,Autocuration,,22224,Half life period was evaluated in human,CHEMBL875154,U,0,,,,,1,,BAO_0000019,
5123,1969.0,Autocuration,Plasma,22224,Half life time in human plasma,CHEMBL622804,U,0,,,,,1,,BAO_0000366,
5124,955.0,Intermediate,Brain,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622805,N,1,,,,,1,,BAO_0000218,
5125,948.0,Intermediate,Heart,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622611,N,1,,,,,1,,BAO_0000218,
5126,948.0,Intermediate,Heart,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622612,N,1,,,,,1,,BAO_0000218,
5127,2113.0,Intermediate,Kidney,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL875160,N,1,,,,,1,,BAO_0000218,
5128,2113.0,Intermediate,Kidney,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",CHEMBL622613,N,1,,,,,1,,BAO_0000218,
5129,2113.0,Intermediate,Kidney,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622614,N,1,,,,,1,,BAO_0000218,
5130,2107.0,Intermediate,Liver,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622615,N,1,,,,,1,,BAO_0000218,
5131,2107.0,Intermediate,Liver,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,CHEMBL622616,N,1,,,,,1,,BAO_0000218,
5132,2107.0,Intermediate,Liver,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622617,N,1,,,,,1,,BAO_0000218,
5133,2106.0,Intermediate,Spleen,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,CHEMBL622618,N,1,,,,,1,,BAO_0000218,
5134,2106.0,Intermediate,Spleen,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",CHEMBL622619,N,1,,,,,1,,BAO_0000218,
5135,2106.0,Intermediate,Spleen,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622620,N,1,,,,,1,,BAO_0000218,
5136,955.0,Intermediate,Brain,50594,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622621,N,1,,,,,1,,BAO_0000218,
5137,178.0,Intermediate,Blood,50594,Biodistribution of compound (oxidized form) in blood tissue,CHEMBL622622,N,1,,,,,1,,BAO_0000218,
5138,178.0,Intermediate,Blood,50594,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622623,N,1,,,,,1,,BAO_0000218,
5139,178.0,Intermediate,Blood,50594,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",CHEMBL622624,N,1,,,,,1,,BAO_0000218,
5140,178.0,Intermediate,Blood,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622625,N,1,,,,,1,,BAO_0000218,
5141,178.0,Intermediate,Blood,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622626,N,1,,,,,1,,BAO_0000218,
5142,178.0,Intermediate,Blood,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL622627,N,1,,,,,1,,BAO_0000218,
5143,955.0,Intermediate,Brain,50594,Biodistribution of compound (oxidized form) in brain tissue of mice,CHEMBL622628,N,1,,,,,1,,BAO_0000218,
5144,955.0,Intermediate,Brain,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622629,N,1,,,,,1,,BAO_0000218,
5145,955.0,Intermediate,Brain,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622630,N,1,,,,,1,,BAO_0000218,
5146,955.0,Intermediate,Brain,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622631,N,1,,,,,1,,BAO_0000218,
5147,955.0,Intermediate,Brain,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL622632,N,1,,,,,1,,BAO_0000218,
5148,955.0,Intermediate,Brain,50594,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",CHEMBL622633,N,1,,,,,1,,BAO_0000218,
5149,948.0,Intermediate,Heart,50594,Biodistribution of compound (oxidized form) in heart tissue of mice,CHEMBL622634,N,1,,,,,1,,BAO_0000218,
5150,948.0,Intermediate,Heart,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622635,N,1,,,,,1,,BAO_0000218,
5151,948.0,Intermediate,Heart,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL875161,N,1,,,,,1,,BAO_0000218,
5152,948.0,Intermediate,Heart,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622636,N,1,,,,,1,,BAO_0000218,
5153,948.0,Intermediate,Heart,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL623335,N,1,,,,,1,,BAO_0000218,
5154,948.0,Intermediate,Heart,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL623336,N,1,,,,,1,,BAO_0000218,
5155,2113.0,Intermediate,Kidney,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL623337,N,1,,,,,1,,BAO_0000218,
5156,2113.0,Intermediate,Kidney,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",CHEMBL623338,N,1,,,,,1,,BAO_0000218,
5157,2113.0,Intermediate,Kidney,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL623339,N,1,,,,,1,,BAO_0000218,
5158,2113.0,Intermediate,Kidney,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL623524,N,1,,,,,1,,BAO_0000218,
5159,2113.0,Intermediate,Kidney,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL623525,N,1,,,,,1,,BAO_0000218,
5160,2107.0,Intermediate,Liver,50594,Biodistribution of compound (oxidized form) in liver tissue,CHEMBL623526,N,1,,,,,1,,BAO_0000218,
5161,2107.0,Intermediate,Liver,50594,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL623527,N,1,,,,,1,,BAO_0000218,
5162,2107.0,Intermediate,Liver,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL623528,N,1,,,,,1,,BAO_0000218,
5163,,Intermediate,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,CHEMBL624615,N,1,500.0,A-431,,,1,,BAO_0000219,
5164,,Intermediate,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,CHEMBL621672,N,1,500.0,A-431,,,1,,BAO_0000219,
5165,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",CHEMBL621673,N,1,500.0,A-431,,,1,,BAO_0000218,
5166,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",CHEMBL621674,N,1,500.0,A-431,,,1,,BAO_0000218,
5167,,Expert,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,CHEMBL884002,D,9,500.0,A-431,,,1,,BAO_0000219,
5168,,Intermediate,,80852,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",CHEMBL621850,N,1,500.0,A-431,,,1,,BAO_0000219,
5169,,Intermediate,,80852,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,CHEMBL621851,N,1,500.0,A-431,,,1,,BAO_0000219,
5170,,Expert,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,CHEMBL621852,D,9,500.0,A-431,,,1,,BAO_0000219,
5171,,Expert,,9,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CHEMBL621853,D,9,500.0,A-431,,,1,,BAO_0000219,
5172,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",CHEMBL621854,N,1,500.0,A-431,,,1,,BAO_0000218,
5173,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",CHEMBL621855,N,1,500.0,A-431,,,1,,BAO_0000218,
5174,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",CHEMBL623724,N,1,500.0,A-431,,,1,,BAO_0000218,
5175,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",CHEMBL623725,N,1,500.0,A-431,,,1,,BAO_0000218,
5176,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",CHEMBL623726,N,1,500.0,A-431,,,1,,BAO_0000218,
5177,,Expert,,9,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",CHEMBL623727,D,9,500.0,A-431,,,1,,BAO_0000219,
5178,,Expert,,9,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,CHEMBL623728,H,8,500.0,A-431,,,1,,BAO_0000219,
5179,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",CHEMBL623729,N,1,500.0,A-431,,,1,,BAO_0000218,
5180,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",CHEMBL623730,N,1,500.0,A-431,,,1,,BAO_0000218,
5181,,Expert,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",CHEMBL623731,N,1,500.0,A-431,,,1,,BAO_0000218,
5182,,Expert,,80852,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623732,N,1,500.0,A-431,,,1,,BAO_0000218,
5183,,Expert,,80852,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623733,N,1,500.0,A-431,,,1,,BAO_0000218,
5184,,Expert,,80852,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623734,N,1,500.0,A-431,,,1,,BAO_0000218,
5185,,Expert,,80852,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623735,N,1,500.0,A-431,,,1,,BAO_0000218,
5186,,Expert,,80852,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,CHEMBL623736,N,1,500.0,A-431,,,1,,BAO_0000219,
5187,,Intermediate,,80852,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,CHEMBL623737,N,1,500.0,A-431,,,1,,BAO_0000219,
5188,,Intermediate,,80852,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,CHEMBL623738,N,1,500.0,A-431,,,1,,BAO_0000219,
5189,,Intermediate,,80852,Dose giving a 50% decrease in the living cell number (A437 cells),CHEMBL875168,N,1,500.0,A-431,,,1,,BAO_0000219,
5190,,Expert,,80682,In vitro inhibitory concentration against proliferation of A459 cell line.,CHEMBL623739,N,1,646.0,A549,,,1,,BAO_0000219,
5191,,Intermediate,,80682,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,CHEMBL623740,N,1,646.0,A549,,,1,,BAO_0000219,
5192,,Intermediate,,80682,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,CHEMBL624424,N,1,646.0,A549,,,1,,BAO_0000219,
5193,,Intermediate,,80021,In vitro antitumor activity against renal A498 tumor cell lines,CHEMBL624425,N,1,624.0,A498,,,1,,BAO_0000219,
5194,,Intermediate,,80021,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",CHEMBL624426,N,1,624.0,A498,,,1,,BAO_0000219,
5195,,Intermediate,,80021,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",CHEMBL624427,N,1,624.0,A498,,,1,,BAO_0000219,
5196,,Intermediate,,80021,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,CHEMBL624428,N,1,624.0,A498,,,1,,BAO_0000219,
5197,,Intermediate,,80021,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,CHEMBL624429,N,1,624.0,A498,,,1,,BAO_0000219,
5198,,Intermediate,,80021,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,CHEMBL624620,N,1,624.0,A498,,,1,,BAO_0000219,
5199,,Intermediate,,80021,Cytotoxicity on kidney carcinoma (A-498) cell line,CHEMBL624621,N,1,624.0,A498,,,1,,BAO_0000219,
5200,,Intermediate,,80021,Compound was evaluated against Human cell line renal A498,CHEMBL624622,N,1,624.0,A498,,,1,,BAO_0000219,
5201,,Intermediate,,80021,Compound was tested for inhibition of A498 human renal cancer cell line,CHEMBL624623,N,1,624.0,A498,,,1,,BAO_0000219,
5202,,Intermediate,,80021,Growth inhibitory activity against A498 human cancer cell line,CHEMBL874365,N,1,624.0,A498,,,1,,BAO_0000219,
5203,,Intermediate,,80021,In vitro antitumor activity against human renal A498 cell line,CHEMBL624624,N,1,624.0,A498,,,1,,BAO_0000219,
5204,,Intermediate,,80021,In vitro cytotoxic activity against renal (A498) cell line,CHEMBL624625,N,1,624.0,A498,,,1,,BAO_0000219,
5205,,Intermediate,,80021,In vitro cytotoxic activity against human renal cancer (A498) cell line,CHEMBL624626,N,1,624.0,A498,,,1,,BAO_0000219,
5206,,Intermediate,,80021,Tested for cytostatic activity against renal A498 cell line,CHEMBL624627,N,1,624.0,A498,,,1,,BAO_0000219,
5207,,Intermediate,,80021,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,CHEMBL883157,N,1,624.0,A498,,,1,,BAO_0000219,
5208,,Expert,,80021,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,CHEMBL624628,N,1,624.0,A498,,,1,,BAO_0000219,
5209,,Autocuration,,22224,Cmax value after 2 mpk peroral administration to beagles,CHEMBL624629,U,0,,,,,1,,BAO_0000218,
5210,,Autocuration,,22224,Bioavailability,CHEMBL623551,U,0,,,beagle,,1,,BAO_0000218,
5211,,Autocuration,,22224,Bioavailability after 1 mpk peroral administration to beagles,CHEMBL623552,U,0,,,beagle,,1,,BAO_0000218,
5212,,Autocuration,,22224,Bioavailability after 2 mpk peroral administration to beagles,CHEMBL623553,U,0,,,beagle,,1,,BAO_0000218,
5213,,Autocuration,,22224,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,CHEMBL623554,U,0,,,,,1,,BAO_0000019,
5214,,Autocuration,,22224,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,CHEMBL623555,U,0,,,,,1,,BAO_0000019,
5215,,Autocuration,,22224,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,CHEMBL623556,U,0,,,,,1,,BAO_0000019,
5216,,Autocuration,,22224,Solubility against bovine alpha-chymotrypsin,CHEMBL623557,U,0,,,,,1,,BAO_0000019,
5217,,Autocuration,,22224,Rate constant of the bovine serum albumin catalyzed reaction of the compound,CHEMBL623558,U,0,,,,,1,,BAO_0000019,
5218,,Autocuration,,22224,Rate constant of the bovine serum albumin catalyzed reaction of the compound,CHEMBL623559,U,0,,,,,1,,BAO_0000019,
5219,2106.0,Autocuration,Spleen,22224,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,CHEMBL623560,U,0,,,,,1,,BAO_0000221,
5220,,Autocuration,,22224,Half life in culture medium containing 10% of heat inactivated foetal calf serum,CHEMBL623561,U,0,,,,,1,,BAO_0000019,
5221,,Autocuration,,22224,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,CHEMBL623562,U,0,,,,,1,,BAO_0000019,
5222,,Autocuration,,22224,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,CHEMBL623563,U,0,,,,,1,,BAO_0000019,
5223,2106.0,Autocuration,Spleen,22224,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,CHEMBL623564,U,0,,,,,1,,BAO_0000221,
5224,,Autocuration,,22224,Half life in presence of 2 mg/mL BSA at pH 8.8,CHEMBL873806,U,0,,,,,1,,BAO_0000019,
5225,,Autocuration,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,CHEMBL623565,U,0,,,,,1,,BAO_0000019,
5226,,Autocuration,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,CHEMBL623566,U,0,,,,,1,,BAO_0000019,
5227,,Autocuration,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,CHEMBL623567,U,0,,,,,1,,BAO_0000019,
5228,,Autocuration,,22224,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),CHEMBL623568,U,0,,,,,1,,BAO_0000019,
5229,1969.0,Intermediate,Plasma,50588,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,CHEMBL623569,N,1,,,,,1,,BAO_0000218,
5230,1969.0,Intermediate,Plasma,50588,AUC after administration at 100 mg/kg/day in dogs,CHEMBL623570,N,1,,,,,1,,BAO_0000218,
5231,1969.0,Intermediate,Plasma,50588,AUC in dog at 0-24 hr by peroral administration at 3 mpk,CHEMBL624254,N,1,,,,,1,,BAO_0000218,
5232,1969.0,Intermediate,Plasma,50588,AUC value after 15 mg/kg iv dose in Dogs,CHEMBL624255,N,1,,,,,1,,BAO_0000218,
5233,1969.0,Intermediate,Plasma,50588,AUC value after 30 mg/kg po dose in Dogs,CHEMBL624256,N,1,,,,,1,,BAO_0000218,
5234,1969.0,Intermediate,Plasma,50588,AUC value after administration of 4 mg/Kg oral dose in dog,CHEMBL624257,N,1,,,,,1,,BAO_0000218,
5235,1969.0,Intermediate,Plasma,50588,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,CHEMBL624258,N,1,,,,,1,,BAO_0000218,
5236,,Intermediate,,50588,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,CHEMBL875277,N,1,,,,,1,,BAO_0000218,
5237,,Intermediate,,50588,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,CHEMBL622667,N,1,,,,,1,,BAO_0000218,
5238,,Intermediate,,50588,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,CHEMBL622668,N,1,,,,,1,,BAO_0000218,
5239,,Intermediate,,50588,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL622669,N,1,,,,,1,,BAO_0000218,
5240,,Intermediate,,50588,Area under curve determined in dogs after intravenous administration of 3 mg/kg,CHEMBL622670,N,1,,,,,1,,BAO_0000218,
5241,,Intermediate,,50588,Area under curve determined in dogs after oral administration of 10 mg/kg,CHEMBL622671,N,1,,,,,1,,BAO_0000218,
5242,,Intermediate,,50588,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL622672,N,1,,,,,1,,BAO_0000218,
5243,,Expert,,50588,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL622673,N,1,,,,,1,,BAO_0000218,
5244,,Expert,,50588,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL622674,N,1,,,,,1,,BAO_0000218,
5245,,Intermediate,,50588,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL622675,N,1,,,,,1,,BAO_0000218,
5246,,Intermediate,,50588,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,CHEMBL622676,N,1,,,,,1,,BAO_0000218,
5247,,Intermediate,,50588,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL622677,N,1,,,,,1,,BAO_0000218,
5248,,Intermediate,,50588,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,CHEMBL622678,N,1,,,,,1,,BAO_0000218,
5249,,Intermediate,,50588,Area under curve in dog after administration of 20 mg/kg dose through peroral route,CHEMBL622679,N,1,,,,,1,,BAO_0000218,
5250,,Intermediate,,50588,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL622680,N,1,,,,,1,,BAO_0000218,
5251,,Intermediate,,50588,Area under curve was determine after peroral administration at 10 mpk in dog,CHEMBL622681,N,1,,,,,1,,BAO_0000218,
5252,,Intermediate,,50588,Area under curve was determine after peroral administration at 5 mpk in dog,CHEMBL875278,N,1,,,,,1,,BAO_0000218,
5253,,Intermediate,,50588,Area under curve was determined,CHEMBL622682,N,1,,,,,1,,BAO_0000218,
5254,,Intermediate,,50588,Area under curve in dogs,CHEMBL622683,N,1,,,,,1,,BAO_0000218,
5255,,Intermediate,,50588,Area under curve in dogs at 10 mg/kg dose fo oral administration,CHEMBL622684,N,1,,,,,1,,BAO_0000218,
5256,,Intermediate,,50588,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),CHEMBL622685,N,1,,,,,1,,BAO_0000218,
5257,,Intermediate,,50588,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,CHEMBL622686,N,1,,,,,1,,BAO_0000218,
5258,,Intermediate,,50588,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL618344,N,1,,,,,1,,BAO_0000218,
5259,,Intermediate,,50588,Area under curve value in dog at a dose of 5 mg/kg,CHEMBL875582,N,1,,,,,1,,BAO_0000218,
5260,,Intermediate,,50588,Area under curve was determined after 0.1 mg/kg iv administration in dog,CHEMBL618345,N,1,,,,,1,,BAO_0000218,
5261,,Intermediate,,50588,Area under curve was determined after 0.3 mg/kg po administration in dog,CHEMBL618346,N,1,,,,,1,,BAO_0000218,
5262,,Intermediate,,50588,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,CHEMBL618347,N,1,,,,,1,,BAO_0000218,
5263,,Intermediate,,50588,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,CHEMBL618348,N,1,,,,,1,,BAO_0000218,
5264,,Autocuration,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,CHEMBL618349,U,0,,,,,1,,BAO_0000019,
5265,,Autocuration,,22224,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,CHEMBL618350,U,0,,,,,1,,BAO_0000019,
5266,,Autocuration,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,CHEMBL618351,U,0,,,,,1,,BAO_0000019,
5267,,Autocuration,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,CHEMBL618352,U,0,,,,,1,,BAO_0000019,
5268,178.0,Autocuration,Blood,22224,Time taken to reduce 50% of the concentration of compound in blood plasma,CHEMBL873494,U,0,,,,,1,,BAO_0000221,
5269,1969.0,Autocuration,Plasma,22224,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",CHEMBL618353,U,0,,,,,1,,BAO_0000366,
5270,1969.0,Autocuration,Plasma,22224,Half life in human plasma,CHEMBL618354,U,0,,,,,1,,BAO_0000366,
5271,1969.0,Autocuration,Plasma,22224,Half life in human plasma was reported,CHEMBL875583,U,0,,,,,1,,BAO_0000366,
5272,1977.0,Autocuration,Serum,22224,Half life in human serum,CHEMBL618355,U,0,,,,,1,,BAO_0000019,
5273,1969.0,Autocuration,Plasma,22224,Half life upon exposure to human plasma,CHEMBL618356,U,0,,,,,1,,BAO_0000366,
5274,,Autocuration,,22224,t1/2 in human microsomes,CHEMBL618357,U,0,,,,Microsomes,1,,BAO_0000251,
5275,1969.0,Autocuration,Plasma,22224,Half life period in 80% human plasma at 37 degree Centigrade,CHEMBL618358,U,0,,,,,1,,BAO_0000366,
5276,14.0,Autocuration,Zone of skin,22224,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),CHEMBL618359,U,0,,,,,1,,BAO_0000221,
5277,1969.0,Autocuration,Plasma,22224,Half-life measured in in vitro Cathepsin B assay in human plasma,CHEMBL618360,U,0,,,,,1,,BAO_0000366,
5278,,Autocuration,,22224,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,CHEMBL618361,U,0,,,,,1,,BAO_0000019,
5279,2107.0,Autocuration,Liver,22224,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,CHEMBL618362,U,0,,,,Microsomes,1,,BAO_0000251,
5280,1969.0,Autocuration,Plasma,22224,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",CHEMBL618363,U,0,,,,,1,,BAO_0000366,
5281,1969.0,Autocuration,Plasma,22224,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",CHEMBL618364,U,0,,,,,1,,BAO_0000366,
5282,1969.0,Autocuration,Plasma,22224,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",CHEMBL875584,U,0,,,,,1,,BAO_0000366,
5283,,Autocuration,,22224,Half-life in the CEM cell extracts,CHEMBL618365,U,0,,,,,1,,BAO_0000019,
5284,1969.0,Autocuration,Plasma,22224,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,CHEMBL873495,U,0,,,,,1,,BAO_0000366,
5285,1969.0,Autocuration,Plasma,22224,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,CHEMBL618366,U,0,,,,,1,,BAO_0000366,
5286,,Autocuration,,22224,Half-life was determined,CHEMBL618367,U,0,,,,,1,,BAO_0000019,
5287,178.0,Autocuration,Blood,22224,Half-life (human blood stability),CHEMBL618368,U,0,,,,,1,,BAO_0000221,
5288,178.0,Autocuration,Blood,22224,Half-life (human blood stability); no data,CHEMBL618369,U,0,,,,,1,,BAO_0000221,
5289,1969.0,Autocuration,Plasma,22224,Half-life in human plasma,CHEMBL618370,U,0,,,,,1,,BAO_0000366,
5290,,Autocuration,,22224,CYP3A4 metabolism half-life (t1/2),CHEMBL618371,U,0,,,,,1,,BAO_0000019,
5291,178.0,Autocuration,Blood,22224,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),CHEMBL618372,U,0,,,,,1,,BAO_0000221,
5292,1969.0,Autocuration,Plasma,22224,In vitro half life in human plasma,CHEMBL618373,U,0,,,,,1,,BAO_0000366,
5293,1969.0,Autocuration,Plasma,22224,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",CHEMBL618374,U,0,,,,,1,,BAO_0000366,
5294,1969.0,Autocuration,Plasma,22224,In vitro hydrolysis in human plasma,CHEMBL618375,U,0,,,,,1,,BAO_0000366,
5295,1969.0,Autocuration,Plasma,22224,In vitro hydrolysis in human plasma; no data,CHEMBL618376,U,0,,,,,1,,BAO_0000366,
5296,2107.0,Autocuration,Liver,22224,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,CHEMBL618377,U,0,,,,Microsomes,1,,BAO_0000251,
5297,1969.0,Autocuration,Plasma,22224,Plasma half life in human,CHEMBL618378,U,0,,,,,1,,BAO_0000366,
5298,1969.0,Autocuration,Plasma,22224,Stability after incubation with human plasma (at 37 degree C),CHEMBL618379,U,0,,,,,1,,BAO_0000366,
5299,1969.0,Autocuration,Plasma,22224,T1/2 was evaluated in human plasma,CHEMBL618380,U,0,,,,,1,,BAO_0000366,
5300,1969.0,Autocuration,Plasma,22224,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",CHEMBL618381,U,0,,,,,1,,BAO_0000366,
5301,1969.0,Autocuration,Plasma,22224,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",CHEMBL618382,U,0,,,,,1,,BAO_0000366,
5302,,Autocuration,,22224,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,CHEMBL618383,U,0,,,,,1,,BAO_0000019,
5303,,Autocuration,,22224,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,CHEMBL618384,U,0,,,,,1,,BAO_0000019,
5304,,Autocuration,,22224,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,CHEMBL618385,U,0,,,,,1,,BAO_0000019,
5305,1969.0,Autocuration,Plasma,22224,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,CHEMBL619099,U,0,,,,,1,,BAO_0000366,
5306,1969.0,Autocuration,Plasma,22224,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,CHEMBL619100,U,0,,,,,1,,BAO_0000366,
5307,,Autocuration,,22224,Time taken for 50% to be consumed by serum PON1 was determined,CHEMBL619101,U,0,,,,,1,,BAO_0000019,
5308,,Autocuration,,22224,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,CHEMBL619102,U,0,,,,,1,,BAO_0000019,
5309,2107.0,Autocuration,Liver,22224,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,CHEMBL619103,U,0,,,,Microsomes,1,,BAO_0000251,
5310,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL619268,U,0,,,,,1,,BAO_0000218,
5311,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL619269,U,0,,,,,1,,BAO_0000218,
5312,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL619270,U,0,,,,,1,,BAO_0000218,
5313,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL619271,U,0,,,,,1,,BAO_0000218,
5314,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL875585,U,0,,,,,1,,BAO_0000218,
5315,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL619272,U,0,,,,,1,,BAO_0000218,
5316,,Intermediate,,80640,Compound tested for growth inhibition of renal cancer cell line 786-0,CHEMBL619273,N,1,391.0,786-0,,,1,,BAO_0000219,
5317,,Intermediate,,80640,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,CHEMBL619274,N,1,391.0,786-0,,,1,,BAO_0000219,
5318,,Expert,,80640,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,CHEMBL619275,N,1,391.0,786-0,,,1,,BAO_0000219,
5319,,Intermediate,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",CHEMBL619276,N,1,391.0,786-0,,,1,,BAO_0000219,
5320,,Intermediate,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",CHEMBL619277,N,1,391.0,786-0,,,1,,BAO_0000219,
5321,,Intermediate,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",CHEMBL619278,N,1,391.0,786-0,,,1,,BAO_0000219,
5322,,Intermediate,,80640,Tested for cytotoxicity against 786-0 cell lines in renal cancer,CHEMBL619279,N,1,391.0,786-0,,,1,,BAO_0000219,
5323,,Intermediate,,80640,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,CHEMBL858458,N,1,391.0,786-0,,,1,,BAO_0000219,
5324,,Expert,,80640,Cytotoxic effect on renal cancer line 786-0,CHEMBL619280,N,1,391.0,786-0,,,1,,BAO_0000219,
5325,,Intermediate,,80640,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,CHEMBL619281,N,1,391.0,786-0,,,1,,BAO_0000219,
5326,,Intermediate,,80640,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),CHEMBL619282,N,1,391.0,786-0,,,1,,BAO_0000219,
5327,,Intermediate,,80640,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",CHEMBL619283,N,1,391.0,786-0,,,1,,BAO_0000219,
5328,,Intermediate,,80640,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,CHEMBL619284,N,1,391.0,786-0,,,1,,BAO_0000219,
5329,,Intermediate,,80640,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,CHEMBL619285,N,1,391.0,786-0,,,1,,BAO_0000219,
5330,,Intermediate,,80640,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),CHEMBL619286,N,1,391.0,786-0,,,1,,BAO_0000219,
5331,,Intermediate,,80640,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,CHEMBL619287,N,1,391.0,786-0,,,1,,BAO_0000219,
5332,,Intermediate,,80640,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,CHEMBL857455,N,1,391.0,786-0,,,1,,BAO_0000219,
5333,,Intermediate,,80640,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),CHEMBL883801,N,1,391.0,786-0,,,1,,BAO_0000219,
5334,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,CHEMBL619288,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5335,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),CHEMBL619289,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5336,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,CHEMBL619290,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5337,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),CHEMBL619291,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5338,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),CHEMBL619292,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5339,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,CHEMBL619293,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5340,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),CHEMBL619294,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5341,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),CHEMBL619295,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5342,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),CHEMBL619296,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5343,,Intermediate,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,CHEMBL619297,N,1,972.0,791T cell line,,,1,,BAO_0000219,
5344,,Intermediate,,80640,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,CHEMBL619298,N,1,391.0,786-0,,,1,,BAO_0000219,
5345,,Intermediate,,22226,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,CHEMBL619299,U,0,,,,,1,,BAO_0000019,
5346,,Expert,,80433,Inhibition of cell growth in drug resistant 8226 myeloma cell line,CHEMBL619300,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5347,,Expert,,80433,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,CHEMBL619301,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5348,,Intermediate,,80433,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,CHEMBL619302,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5349,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,CHEMBL619303,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5350,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,CHEMBL619304,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5351,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),CHEMBL857706,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5352,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),CHEMBL619305,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5353,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),CHEMBL619306,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5354,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL619307,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5355,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL619308,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5356,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),CHEMBL619309,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5357,,Intermediate,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),CHEMBL619310,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5358,,Intermediate,,80021,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),CHEMBL619311,N,1,624.0,A498,,,1,,BAO_0000219,
5359,,Intermediate,,80021,Compound was tested for the growth inhibition of A498 renal tumor cell line,CHEMBL619312,N,1,624.0,A498,,,1,,BAO_0000219,
5360,,Intermediate,,80021,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),CHEMBL619313,N,1,624.0,A498,,,1,,BAO_0000219,
5361,,Intermediate,,80021,In vitro inhibitory concentration against renal cancer cell line A498,CHEMBL619314,N,1,624.0,A498,,,1,,BAO_0000219,
5362,,Intermediate,,80021,Cytotoxicity against A 498 tumor cell line,CHEMBL619959,N,1,624.0,A498,,,1,,BAO_0000219,
5363,,Intermediate,,80021,In vitro antitumor activity against A498 human cancer cell line,CHEMBL619960,N,1,624.0,A498,,,1,,BAO_0000219,
5364,,Intermediate,,80021,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),CHEMBL619961,N,1,624.0,A498,,,1,,BAO_0000219,
5365,,Intermediate,,80021,Inhibitory dose required against A498 human tumor cell lines,CHEMBL619962,N,1,624.0,A498,,,1,,BAO_0000219,
5366,,Intermediate,,80021,Anticancer activity against one renal cancer (A498 cell line),CHEMBL875586,N,1,624.0,A498,,,1,,BAO_0000219,
5367,,Intermediate,,80021,In vitro cytotoxicity against melanoma A498 cell line,CHEMBL619963,N,1,624.0,A498,,,1,,BAO_0000219,
5368,,Intermediate,,80021,Compound was tested for growth inhibitory activity against A498 cell line,CHEMBL619964,N,1,624.0,A498,,,1,,BAO_0000219,
5369,,Intermediate,,80021,Compound tested for growth inhibition of renal cancer cell line A498,CHEMBL620108,N,1,624.0,A498,,,1,,BAO_0000219,
5370,,Intermediate,,80021,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,CHEMBL620109,N,1,624.0,A498,,,1,,BAO_0000219,
5371,,Intermediate,,80021,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,CHEMBL620110,N,1,624.0,A498,,,1,,BAO_0000219,
5372,,Intermediate,,80021,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,CHEMBL620111,N,1,624.0,A498,,,1,,BAO_0000219,
5373,,Intermediate,,80021,Tested for cytotoxicity against A498 cell lines in renal cancer,CHEMBL620112,N,1,624.0,A498,,,1,,BAO_0000219,
5374,,Intermediate,,80021,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,CHEMBL620113,N,1,624.0,A498,,,1,,BAO_0000219,
5375,,Expert,,80021,Cytotoxic effect on renal cancer lines A498,CHEMBL620114,N,1,624.0,A498,,,1,,BAO_0000219,
5376,,Intermediate,,80021,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,CHEMBL620115,N,1,624.0,A498,,,1,,BAO_0000219,
5377,,Intermediate,,80021,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),CHEMBL620116,N,1,624.0,A498,,,1,,BAO_0000219,
5378,,Intermediate,,80021,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,CHEMBL620117,N,1,624.0,A498,,,1,,BAO_0000219,
5379,,Intermediate,,80021,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,CHEMBL620118,N,1,624.0,A498,,,1,,BAO_0000219,
5380,,Intermediate,,80021,Cytotoxicity against human kidney carcinoma cell lines A4982LM,CHEMBL620119,N,1,624.0,A498,,,1,,BAO_0000219,
5381,,Intermediate,,80021,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,CHEMBL620120,N,1,624.0,A498,,,1,,BAO_0000219,
5382,,Expert,,80682,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,CHEMBL620121,N,1,646.0,A549,,,1,,BAO_0000219,
5383,,Intermediate,,80682,Antitumor activity against A549 human lung carcinoma cell line,CHEMBL620122,N,1,646.0,A549,,,1,,BAO_0000219,
5384,,Intermediate,,80682,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,CHEMBL620123,N,1,646.0,A549,,,1,,BAO_0000219,
5385,,Intermediate,,80682,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,CHEMBL620124,N,1,646.0,A549,,,1,,BAO_0000219,
5386,,Intermediate,,80682,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",CHEMBL620125,N,1,646.0,A549,,,1,,BAO_0000219,
5387,,Expert,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,CHEMBL620126,N,1,646.0,A549,,,1,,BAO_0000219,
5388,,Intermediate,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL883027,N,1,646.0,A549,,,1,,BAO_0000219,
5389,,Expert,,80682,In vitro cytotoxic activity against human lung A549 cell line,CHEMBL620127,N,1,646.0,A549,,,1,,BAO_0000219,
5390,,Intermediate,,80682,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),CHEMBL620128,N,1,646.0,A549,,,1,,BAO_0000219,
5391,,Intermediate,,80682,In vitro cytotoxic activity against human lung A549 cell line),CHEMBL620129,N,1,646.0,A549,,,1,,BAO_0000219,
5392,,Intermediate,,80682,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,CHEMBL620130,N,1,646.0,A549,,,1,,BAO_0000219,
5393,,Expert,,80682,In vitro cytotoxicity against human non small-cell-lung cell line A549.,CHEMBL620131,N,1,646.0,A549,,,1,,BAO_0000219,
5394,,Intermediate,,80682,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",CHEMBL620132,N,1,646.0,A549,,,1,,BAO_0000219,
5395,,Intermediate,,80682,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",CHEMBL620133,N,1,646.0,A549,,,1,,BAO_0000219,
5396,,Expert,,80682,Inhibition of A549 human lung carcinoma cell proliferation,CHEMBL620134,N,1,646.0,A549,,,1,,BAO_0000219,
5397,,Intermediate,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line,CHEMBL620135,N,1,646.0,A549,,,1,,BAO_0000219,
5398,,Intermediate,,80682,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,CHEMBL620136,N,1,646.0,A549,,,1,,BAO_0000219,
5399,,Intermediate,,80682,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,CHEMBL620137,N,1,646.0,A549,,,1,,BAO_0000219,
5400,,Intermediate,,80682,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,CHEMBL620268,N,1,646.0,A549,,,1,,BAO_0000219,
5401,,Intermediate,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL620269,N,1,646.0,A549,,,1,,BAO_0000219,
5402,,Intermediate,,80682,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,CHEMBL620270,N,1,646.0,A549,,,1,,BAO_0000219,
5403,,Intermediate,,80682,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,CHEMBL620271,N,1,646.0,A549,,,1,,BAO_0000219,
5404,,Expert,,80682,Inhibition of A549 cancer cell proliferation,CHEMBL620272,N,1,646.0,A549,,,1,,BAO_0000219,
5405,,Expert,,80682,Inhibition of A549 cancer cell proliferation (Not tested),CHEMBL620273,N,1,646.0,A549,,,1,,BAO_0000219,
5406,,Intermediate,,80682,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,CHEMBL620274,N,1,646.0,A549,,,1,,BAO_0000219,
5407,,Intermediate,,80682,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,CHEMBL620275,N,1,646.0,A549,,,1,,BAO_0000219,
5408,,Intermediate,,80682,Antiproliferative potency determined as inhibitory concentration against A549 cells,CHEMBL620276,N,1,646.0,A549,,,1,,BAO_0000219,
5409,,Intermediate,,80682,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,CHEMBL620277,N,1,646.0,A549,,,1,,BAO_0000219,
5410,,Intermediate,,80682,Cytotoxicity against Renal cell lines A549 was determined,CHEMBL620278,N,1,646.0,A549,,,1,,BAO_0000219,
5411,,Intermediate,,50588,Area under curve was determined in dog after a 3 mg/kg of oral dose,CHEMBL620279,N,1,,,,,1,,BAO_0000218,
5412,,Intermediate,,50588,Area under curve was determined in dog after oral administration at 1 mg/kg,CHEMBL620280,N,1,,,,,1,,BAO_0000218,
5413,,Intermediate,,50588,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL620281,N,1,,,,,1,,BAO_0000218,
5414,,Intermediate,,50588,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL620282,N,1,,,,,1,,BAO_0000218,
5415,,Intermediate,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),CHEMBL621134,N,1,,,,,1,,BAO_0000218,
5416,,Intermediate,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),CHEMBL621135,N,1,,,,,1,,BAO_0000218,
5417,,Intermediate,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),CHEMBL621136,N,1,,,,,1,,BAO_0000218,
5418,,Intermediate,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),CHEMBL621137,N,1,,,,,1,,BAO_0000218,
5419,1969.0,Intermediate,Plasma,50588,Area under plasma concentration time curve in dog upon oral administration,CHEMBL621138,N,1,,,,,1,,BAO_0000218,
5420,1969.0,Intermediate,Plasma,50588,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,CHEMBL875587,N,1,,,,,1,,BAO_0000218,
5421,,Intermediate,,50588,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,CHEMBL621139,N,1,,,,,1,,BAO_0000218,
5422,,Intermediate,,50588,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,CHEMBL621140,N,1,,,,,1,,BAO_0000218,
5423,,Intermediate,,50588,Area under the curve for the compound was obtained when tested in dog,CHEMBL621141,N,1,,,,,1,,BAO_0000218,
5424,,Intermediate,,50588,Area under the curve at a dose of 1 mg/kg,CHEMBL621142,N,1,,,,,1,,BAO_0000218,
5425,,Intermediate,,50588,Area under the curve at a dose of 1 mg/kg (oral),CHEMBL621143,N,1,,,,,1,,BAO_0000218,
5426,,Intermediate,,50588,Area under the curve at i.v. dose of 0.2 mg/kg,CHEMBL621144,N,1,,,,,1,,BAO_0000218,
5427,,Intermediate,,50588,Area under the curve was measured in dog after an iv dose of 1 mg/kg,CHEMBL621145,N,1,,,,,1,,BAO_0000218,
5428,,Intermediate,,50588,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,CHEMBL621146,N,1,,,,,1,,BAO_0000218,
5429,,Intermediate,,50588,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,CHEMBL622567,N,1,,,,,1,,BAO_0000218,
5430,,Intermediate,,50588,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,CHEMBL622568,N,1,,,,,1,,BAO_0000218,
5431,,Intermediate,,50588,Compound was evaluated for area under the curve in dog blood.,CHEMBL622569,N,1,,,,,1,,BAO_0000218,
5432,,Intermediate,,50588,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,CHEMBL622570,N,1,,,,,1,,BAO_0000218,
5433,1969.0,Intermediate,Plasma,50588,AUC in dog after oral dose (1 mg/kg),CHEMBL622571,N,1,,,,,1,,BAO_0000218,
5434,,Intermediate,,50588,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,CHEMBL622572,N,1,,,,,1,,BAO_0000218,
5435,,Intermediate,,50588,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",CHEMBL622573,N,1,,,,,1,,BAO_0000218,
5436,,Intermediate,,50588,Pharmacokinetic parameter AUC after intravenous administration to dogs,CHEMBL622574,N,1,,,,,1,,BAO_0000218,
5437,,Intermediate,,50588,Pharmacokinetic parameter AUC after oral administration to dogs,CHEMBL622575,N,1,,,,,1,,BAO_0000218,
5438,,Intermediate,,50588,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,CHEMBL622576,N,1,,,,,1,,BAO_0000218,
5439,,Intermediate,,50588,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,CHEMBL622577,N,1,,,,,1,,BAO_0000218,
5440,,Intermediate,,50588,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,CHEMBL622578,N,1,,,,,1,,BAO_0000218,
5441,,Intermediate,,50588,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,CHEMBL622579,N,1,,,,,1,,BAO_0000218,
5442,,Intermediate,,50588,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",CHEMBL622580,N,1,,,,,1,,BAO_0000218,
5443,,Intermediate,,50588,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",CHEMBL622581,N,1,,,,,1,,BAO_0000218,
5444,,Intermediate,,50588,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL622582,N,1,,,,,1,,BAO_0000218,
5445,,Intermediate,,50588,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL622583,N,1,,,,,1,,BAO_0000218,
5446,,Intermediate,,50588,Oral AUCN in dog (dosed at 0.5 mpk iv ),CHEMBL622584,N,1,,,,,1,,BAO_0000218,
5447,,Intermediate,,50588,Oral AUCN in dog (dosed at 0.5 mpk iv ),CHEMBL622585,N,1,,,,,1,,BAO_0000218,
5448,,Intermediate,,50588,Compound was evaluated for oral bioavailability in dog; 90-100,CHEMBL622586,N,1,,,,,1,,BAO_0000218,
5449,,Intermediate,,50588,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,CHEMBL623281,N,1,,,,,1,,BAO_0000218,
5450,,Intermediate,,50588,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,CHEMBL623282,N,1,,,,,1,,BAO_0000218,
5451,,Intermediate,,50588,PAPP (membrane permeability) in dog kidney cell monolayer assay,CHEMBL623283,N,1,,,,,1,,BAO_0000218,
5452,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623284,N,1,,,,,1,,BAO_0000218,
5453,,Intermediate,,50588,Bioavailability administered orally at a dose of 10 mg/kg to dogs,CHEMBL623285,N,1,,,,,1,,BAO_0000218,
5454,1969.0,Intermediate,Plasma,50588,Plasma protein binding towards dog plasma at 10 uM,CHEMBL623463,N,1,,,,,1,,BAO_0000218,
5455,1969.0,Intermediate,Plasma,50588,Plasma protein binding towards dog plasma at 100 uM,CHEMBL875952,N,1,,,,,1,,BAO_0000218,
5456,,Intermediate,,50588,Bioavailability in dog (dose 4 mg/kg p.o.),CHEMBL621705,N,1,,,,,1,,BAO_0000218,
5457,,Intermediate,,50588,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,CHEMBL621706,N,1,,,,,1,,BAO_0000218,
5458,,Intermediate,,50588,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL621707,N,1,,,,,1,,BAO_0000218,
5459,,Intermediate,,50588,Bioavailability in dogs,CHEMBL621708,N,1,,,,,1,,BAO_0000218,
5460,,Intermediate,,50588,Bioavailability,CHEMBL621709,N,1,,,,,1,,BAO_0000218,
5461,,Intermediate,,50588,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621710,N,1,,,,,1,,BAO_0000218,
5462,,Intermediate,,50588,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,CHEMBL621711,N,1,,,,,1,,BAO_0000218,
5463,,Intermediate,,50588,Bioavailability in dog (dose 10.0 mg/kg p.o.),CHEMBL621712,N,1,,,,,1,,BAO_0000218,
5464,,Intermediate,,50588,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,CHEMBL621713,N,1,,,,,1,,BAO_0000218,
5465,,Intermediate,,50588,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,CHEMBL621714,N,1,,,,,1,,BAO_0000218,
5466,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL621715,U,0,,,,,1,,BAO_0000218,
5467,2107.0,Autocuration,Liver,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL623717,U,0,,,,,1,,BAO_0000218,
5468,2107.0,Autocuration,Liver,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL623718,U,0,,,,,1,,BAO_0000218,
5469,2107.0,Autocuration,Liver,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL623719,U,0,,,,,1,,BAO_0000218,
5470,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL623720,U,0,,,,,1,,BAO_0000218,
5471,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL623721,U,0,,,,,1,,BAO_0000218,
5472,2385.0,Autocuration,Muscle tissue,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL623722,U,0,,,,,1,,BAO_0000218,
5473,2385.0,Autocuration,Muscle tissue,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL623723,U,0,,,,,1,,BAO_0000218,
5474,2385.0,Autocuration,Muscle tissue,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL618543,U,0,,,,,1,,BAO_0000218,
5475,2106.0,Autocuration,Spleen,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL618544,U,0,,,,,1,,BAO_0000218,
5476,2106.0,Autocuration,Spleen,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL875155,U,0,,,,,1,,BAO_0000218,
5477,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL618545,U,0,,,,,1,,BAO_0000218,
5478,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL618546,U,0,,,,,1,,BAO_0000218,
5479,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL623529,U,0,,,,,1,,BAO_0000218,
5480,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL623530,U,0,,,,,1,,BAO_0000218,
5481,,Autocuration,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL621764,U,0,,,,,1,,BAO_0000218,
5482,,Autocuration,,22224,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),CHEMBL621765,U,0,,,,,1,,BAO_0000019,
5483,2037.0,Autocuration,Cerebellum,22224,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),CHEMBL621766,U,0,,,,,1,,BAO_0000019,
5484,1870.0,Autocuration,Frontal cortex,22224,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),CHEMBL621767,U,0,,,,,1,,BAO_0000019,
5485,,Autocuration,,22224,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),CHEMBL621768,U,0,,,,,1,,BAO_0000019,
5486,2435.0,Autocuration,Striatum,22224,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),CHEMBL621769,U,0,,,,,1,,BAO_0000019,
5487,,Autocuration,,22224,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),CHEMBL621770,U,0,,,,,1,,BAO_0000019,
5488,2037.0,Autocuration,Cerebellum,22224,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),CHEMBL621771,U,0,,,,,1,,BAO_0000019,
5489,1870.0,Autocuration,Frontal cortex,22224,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),CHEMBL621772,U,0,,,,,1,,BAO_0000019,
5490,,Autocuration,,22224,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),CHEMBL621773,U,0,,,,,1,,BAO_0000019,
5491,2435.0,Autocuration,Striatum,22224,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),CHEMBL621774,U,0,,,,,1,,BAO_0000019,
5492,,Autocuration,,22224,Compound was evaluated for oral bioavailability in rats,CHEMBL621775,U,0,,,,,1,,BAO_0000218,
5493,1969.0,Autocuration,Plasma,22224,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,CHEMBL621776,U,0,,,,,1,,BAO_0000218,
5494,,Autocuration,,22224,Half life period was evaluated in monkey,CHEMBL621777,U,0,,,,,1,,BAO_0000019,
5495,,Autocuration,,22224,Half-life in rhesus monkeys by intravenous administration of dose,CHEMBL875162,U,0,,,,,1,,BAO_0000218,
5496,1969.0,Intermediate,Plasma,50594,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,CHEMBL621778,N,1,,,,,1,,BAO_0000218,
5497,1969.0,Intermediate,Plasma,50594,AUC after intraperitoneal administration of 100 mg/kg in mice,CHEMBL621779,N,1,,,,,1,,BAO_0000218,
5498,1969.0,Intermediate,Plasma,50594,AUC value was determined after oral administration,CHEMBL622479,N,1,,,,,1,,BAO_0000218,
5499,,Intermediate,,50594,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,CHEMBL622480,N,1,,,,,1,,BAO_0000218,
5500,,Intermediate,,50594,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),CHEMBL622481,N,1,,,,,1,,BAO_0000218,
5501,,Intermediate,,50594,Area under curve by ioral administration in mouse,CHEMBL622482,N,1,,,,,1,,BAO_0000218,
5502,,Intermediate,,50594,Area under curve by iv administration in mouse,CHEMBL622483,N,1,,,,,1,,BAO_0000218,
5503,,Intermediate,,50594,Area under curve at 0-8 hr in IRC mice after peroral administration,CHEMBL622484,N,1,,,,,1,,BAO_0000218,
5504,,Intermediate,,50594,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,CHEMBL622641,N,1,,,,,1,,BAO_0000218,
5505,,Intermediate,,50594,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,CHEMBL622642,N,1,,,,,1,,BAO_0000218,
5506,,Intermediate,,50594,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,CHEMBL622643,N,1,,,,,1,,BAO_0000218,
5507,,Intermediate,,50594,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,CHEMBL622644,N,1,,,,,1,,BAO_0000218,
5508,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,CHEMBL622645,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5509,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,CHEMBL622646,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5510,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),CHEMBL621238,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5511,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),CHEMBL621239,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5512,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),CHEMBL621240,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5513,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL621241,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5514,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),CHEMBL621242,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5515,,Intermediate,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),CHEMBL620350,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5516,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,CHEMBL620351,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5517,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,CHEMBL620352,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5518,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),CHEMBL620353,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5519,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),CHEMBL620354,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5520,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),CHEMBL620355,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5521,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL620356,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5522,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),CHEMBL620357,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5523,,Intermediate,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),CHEMBL620358,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5524,,Expert,,80433,In vitro inhibition of human 8226 myeloma tumor cell line growth.,CHEMBL620359,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5525,,Intermediate,,80433,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,CHEMBL620360,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5526,,Intermediate,,80433,Cytotoxicity of compound against 8226/DOX1V cells,CHEMBL620361,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5527,,Intermediate,,80433,Cytotoxicity of compound against 8226/S cells,CHEMBL620362,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5528,,Intermediate,,80433,Inhibitory concentration against 8226 myeloma cancer cell line,CHEMBL620363,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5529,,Intermediate,,80433,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,CHEMBL620364,N,1,741.0,RPMI-8226,,,1,,BAO_0000219,
5530,,Intermediate,,80647,Inhibition of cell growth was studied in human teratocarcinoma (833K).,CHEMBL620365,N,1,854.0,833K,,,1,,BAO_0000219,
5531,,Intermediate,,80647,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',CHEMBL620366,N,1,854.0,833K,,,1,,BAO_0000219,
5532,,Expert,,80647,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,CHEMBL620367,N,1,854.0,833K,,,1,,BAO_0000219,
5533,,Intermediate,,80647,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,CHEMBL620368,N,1,854.0,833K,,,1,,BAO_0000219,
5534,,Autocuration,,22226,Inhibitory activity against caspase-1,CHEMBL620369,U,0,,,,,1,,BAO_0000019,
5535,,Autocuration,,45,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,CHEMBL620370,H,8,,,,,1,,BAO_0000357,
5536,,Intermediate,,80648,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,CHEMBL620371,N,1,705.0,8701-BC,,,1,,BAO_0000219,
5537,,Intermediate,,80648,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,CHEMBL620372,N,1,705.0,8701-BC,,,1,,BAO_0000219,
5538,,Intermediate,,22226,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,CHEMBL876492,U,0,,,,,1,,BAO_0000019,
5539,,Intermediate,,22226,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,CHEMBL620373,U,0,,,,,1,,BAO_0000019,
5540,,Intermediate,,22226,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,CHEMBL620374,U,0,,,,,1,,BAO_0000019,
5541,,Autocuration,,22226,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,CHEMBL620375,U,0,,,,,1,,BAO_0000019,
5542,,Autocuration,,22226,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,CHEMBL857902,U,0,,,,,1,,BAO_0000019,
5543,,Autocuration,,22226,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,CHEMBL620376,U,0,,,,,1,,BAO_0000019,
5544,,Autocuration,,11922,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,CHEMBL620377,H,8,,,,,1,,BAO_0000357,
5545,,Intermediate,,81115,Tested for in vitro cytotoxic potency of compound in 9KB assay,CHEMBL620378,N,1,324.0,KB ,,,1,,BAO_0000219,
5546,,Intermediate,,81115,Tested for in vitro cytotoxic potency of compound in 9KB assay,CHEMBL620379,N,1,324.0,KB ,,,1,,BAO_0000219,
5547,,Autocuration,,22226,In vitro cytotoxicity of compound was tested against 9KB cells.,CHEMBL620380,U,0,,,,,1,,BAO_0000219,
5548,,Intermediate,,80653,Cytotoxic concentration against 9L cells was determined on day 3,CHEMBL884006,N,1,392.0,9L,,,1,,BAO_0000219,
5549,,Expert,,80653,Tested in vitro for anticancer activity against 9L cells,CHEMBL620381,N,1,392.0,9L,,,1,,BAO_0000219,
5550,,Expert,,80653,Tested in vitro for anticancer activity against 9L cells; Not determined,CHEMBL620382,N,1,392.0,9L,,,1,,BAO_0000219,
5551,,Intermediate,,80682,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,CHEMBL620383,N,1,646.0,A549,,,1,,BAO_0000219,
5552,,Intermediate,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,CHEMBL876493,N,1,646.0,A549,,,1,,BAO_0000219,
5553,,Intermediate,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,CHEMBL620384,N,1,646.0,A549,,,1,,BAO_0000219,
5554,,Intermediate,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,CHEMBL620385,N,1,646.0,A549,,,1,,BAO_0000219,
5555,,Expert,,80682,Cytotoxicity against human lung carcinoma A549 cell line,CHEMBL620386,N,1,646.0,A549,,,1,,BAO_0000219,
5556,,Expert,,25,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,CHEMBL620387,D,9,646.0,A549,,,1,,BAO_0000219,
5557,,Expert,,25,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",CHEMBL621404,D,9,646.0,A549,,,1,,BAO_0000219,
5558,,Intermediate,,80682,"In vitro growth inhibition of A549, lung carcinoma",CHEMBL621405,N,1,646.0,A549,,,1,,BAO_0000219,
5559,,Intermediate,,80682,"In vitro growth inhibition of A549, lung carcinoma.",CHEMBL621406,N,1,646.0,A549,,,1,,BAO_0000219,
5560,,Expert,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,CHEMBL621407,N,1,646.0,A549,,,1,,BAO_0000219,
5561,,Intermediate,,80682,Cytotoxic activity against human lung cancer A549 cell line was determined,CHEMBL621408,N,1,646.0,A549,,,1,,BAO_0000219,
5562,,Expert,,80682,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,CHEMBL885345,N,1,646.0,A549,,,1,,BAO_0000219,
5563,,Intermediate,,80682,Cytotoxicity concentration against human lung carcinoma A-549 cell line,CHEMBL621409,N,1,646.0,A549,,,1,,BAO_0000219,
5564,,Expert,,80682,Cytotoxicity in A549 (human carcinoma) cell line.,CHEMBL876034,N,1,646.0,A549,,,1,,BAO_0000219,
5565,,Intermediate,,80682,Cytotoxicity on lung carcinoma (A-549) cell line,CHEMBL621410,N,1,646.0,A549,,,1,,BAO_0000219,
5566,,Expert,,80682,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,CHEMBL621411,N,1,646.0,A549,,,1,,BAO_0000219,
5567,,Intermediate,,80682,Effective dose of compound against replication of A549 cell line was evaluated,CHEMBL621412,N,1,646.0,A549,,,1,,BAO_0000219,
5568,,Expert,,80682,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,CHEMBL621413,N,1,646.0,A549,,,1,,BAO_0000219,
5569,,Intermediate,,80682,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),CHEMBL621414,N,1,646.0,A549,,,1,,BAO_0000219,
5570,,Intermediate,,80682,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,CHEMBL621415,N,1,646.0,A549,,,1,,BAO_0000219,
5571,,Intermediate,,80682,The compound was evaluated for antiproliferative activity against A549 cell line,CHEMBL621416,N,1,646.0,A549,,,1,,BAO_0000219,
5572,,Intermediate,,80682,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,CHEMBL621417,N,1,646.0,A549,,,1,,BAO_0000219,
5573,,Intermediate,,80682,Concentration required for growth inhibition of human lung carcinoma cell line A549,CHEMBL621418,N,1,646.0,A549,,,1,,BAO_0000219,
5574,,Intermediate,,80682,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,CHEMBL621419,N,1,646.0,A549,,,1,,BAO_0000219,
5575,,Intermediate,,80682,Growth inhibition against A549 cell line was evaluated,CHEMBL621420,N,1,646.0,A549,,,1,,BAO_0000219,
5576,,Intermediate,,80682,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,CHEMBL875823,N,1,646.0,A549,,,1,,BAO_0000219,
5577,,Expert,,80682,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,CHEMBL621421,N,1,646.0,A549,,,1,,BAO_0000219,
5578,,Intermediate,,80682,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,CHEMBL621422,N,1,646.0,A549,,,1,,BAO_0000219,
5579,,Expert,,80682,Chemosensitivity against DT-diaphorase rich A549 cell lines,CHEMBL884014,N,1,646.0,A549,,,1,,BAO_0000219,
5580,,Intermediate,,80682,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,CHEMBL621423,N,1,646.0,A549,,,1,,BAO_0000219,
5581,,Expert,,80682,In vitro cytotoxicity against human A549 (lung cancer) cell line.,CHEMBL621424,N,1,646.0,A549,,,1,,BAO_0000219,
5582,,Intermediate,,80682,In vitro antitumor activity against A549 (lung) human tumor cell lines.,CHEMBL621425,N,1,646.0,A549,,,1,,BAO_0000219,
5583,,Expert,,80682,In vitro cytotoxic activity against human lung carcinoma A549 cell line,CHEMBL621426,N,1,646.0,A549,,,1,,BAO_0000219,
5584,,Intermediate,,80682,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,CHEMBL621427,N,1,646.0,A549,,,1,,BAO_0000219,
5585,,Intermediate,,80682,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,CHEMBL621428,N,1,646.0,A549,,,1,,BAO_0000219,
5586,,Expert,,80682,Tested against A549 lung carcinoma in the sulforhodamine B assay.,CHEMBL621429,N,1,646.0,A549,,,1,,BAO_0000219,
5587,,Intermediate,,80682,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),CHEMBL621430,N,1,646.0,A549,,,1,,BAO_0000219,
5588,,Intermediate,,80682,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,CHEMBL621431,N,1,646.0,A549,,,1,,BAO_0000219,
5589,,Intermediate,,80682,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,CHEMBL621432,N,1,646.0,A549,,,1,,BAO_0000219,
5590,,Expert,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,CHEMBL621433,N,1,646.0,A549,,,1,,BAO_0000219,
5591,,Intermediate,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,CHEMBL875824,N,1,646.0,A549,,,1,,BAO_0000219,
5592,,Intermediate,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,CHEMBL621434,N,1,646.0,A549,,,1,,BAO_0000219,
5593,,Intermediate,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,CHEMBL621435,N,1,646.0,A549,,,1,,BAO_0000219,
5594,,Intermediate,,80682,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,CHEMBL621436,N,1,646.0,A549,,,1,,BAO_0000219,
5595,,Intermediate,,80682,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,CHEMBL621437,N,1,646.0,A549,,,1,,BAO_0000219,
5596,,Intermediate,,80682,Compound was tested for the growth inhibition of A549 lung tumor cell line,CHEMBL621438,N,1,646.0,A549,,,1,,BAO_0000219,
5597,,Expert,,80682,Growth inhibition of human non-small-lung carcinoma (A549) cell line,CHEMBL621439,N,1,646.0,A549,,,1,,BAO_0000219,
5598,,Intermediate,,80682,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,CHEMBL621440,N,1,646.0,A549,,,1,,BAO_0000219,
5599,,Intermediate,,50588,Oral bioavailability in dog (conscious),CHEMBL621441,N,1,,,,,1,,BAO_0000218,
5600,,Intermediate,,50588,Compound was evaluated for the oral bioavailability after oral administration in dog.,CHEMBL621442,N,1,,,,,1,,BAO_0000218,
5601,,Intermediate,,50588,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,CHEMBL621443,N,1,,,,,1,,BAO_0000218,
5602,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621444,N,1,,,,,1,,BAO_0000218,
5603,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL625133,N,1,,,,,1,,BAO_0000218,
5604,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL625134,N,1,,,,,1,,BAO_0000218,
5605,,Intermediate,,50588,Oral bioavailability in dog (fasted),CHEMBL625135,N,1,,,,,1,,BAO_0000218,
5606,,Intermediate,,50588,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,CHEMBL625136,N,1,,,,,1,,BAO_0000218,
5607,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL625137,N,1,,,,,1,,BAO_0000218,
5608,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL625138,N,1,,,,,1,,BAO_0000218,
5609,,Intermediate,,50588,Percent bioavailability in dog,CHEMBL625139,N,1,,,,,1,,BAO_0000218,
5610,,Intermediate,,50588,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,CHEMBL872264,N,1,,,,,1,,BAO_0000218,
5611,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL625140,N,1,,,,,1,,BAO_0000218,
5612,,Intermediate,,50588,The compound was evaluated for bioavailability in dogs; 34-44,CHEMBL624436,N,1,,,,,1,,BAO_0000218,
5613,,Intermediate,,50588,Bioavailability in dog (dose 4 mg/kg p.o.),CHEMBL624437,N,1,,,,,1,,BAO_0000218,
5614,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL872261,N,1,,,,,1,,BAO_0000218,
5615,,Intermediate,,50588,8 hour trough Blood level in dog was measured after administration of compound,CHEMBL624438,N,1,,,,,1,,BAO_0000218,
5616,1969.0,Intermediate,Plasma,50588,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,CHEMBL624439,N,1,,,,,1,,BAO_0000218,
5617,,Intermediate,,50588,C24 after oral administration at 5 mg/kg,CHEMBL624440,N,1,,,,,1,,BAO_0000218,
5618,,Intermediate,,50588,Clearance after oral and iv dosing in dogs,CHEMBL624441,N,1,,,,,1,,BAO_0000218,
5619,1969.0,Intermediate,Plasma,50588,Clearance of the drug was measured in the plasma of dog,CHEMBL624442,N,1,,,,,1,,BAO_0000218,
5620,,Intermediate,,50588,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,CHEMBL624443,N,1,,,,,1,,BAO_0000218,
5621,,Intermediate,,50588,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,CHEMBL624444,N,1,,,,,1,,BAO_0000218,
5622,,Intermediate,,50588,Clearance of compound was determined in dogs,CHEMBL624445,N,1,,,,,1,,BAO_0000218,
5623,,Intermediate,,50588,Clearance on i.v. administration of 2 mg/kg was measured in dog,CHEMBL624446,N,1,,,,,1,,BAO_0000218,
5624,,Intermediate,,50588,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL624447,N,1,,,,,1,,BAO_0000218,
5625,,Intermediate,,50588,Plasma clearance in dog was determined,CHEMBL624448,N,1,,,,,1,,BAO_0000218,
5626,,Intermediate,,50588,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL624449,N,1,,,,,1,,BAO_0000218,
5627,,Intermediate,,50588,Plasma clearance in dog after administration of 0.25 mg/kg iv,CHEMBL624450,N,1,,,,,1,,BAO_0000218,
5628,,Intermediate,,50588,Plasma clearance in dog after administration of 1 mg/kg iv,CHEMBL875942,N,1,,,,,1,,BAO_0000218,
5629,,Intermediate,,50588,Plasma clearance in dogs,CHEMBL624451,N,1,,,,,1,,BAO_0000218,
5630,,Intermediate,,50588,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,CHEMBL624452,N,1,,,,,1,,BAO_0000218,
5631,,Intermediate,,50588,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,CHEMBL624453,N,1,,,,,1,,BAO_0000218,
5632,,Intermediate,,50588,Plasma clearance after 15 mg/kg iv dose in Dogs,CHEMBL624454,N,1,,,,,1,,BAO_0000218,
5633,,Intermediate,,50588,Plasma clearance after 30 mg/kg po dose in Dogs,CHEMBL624455,N,1,,,,,1,,BAO_0000218,
5634,,Intermediate,,50588,Plasma administration to dogs,CHEMBL624456,N,1,,,,,1,,BAO_0000218,
5635,,Intermediate,,50588,Plasma clearance was determined,CHEMBL624457,N,1,,,,,1,,BAO_0000218,
5636,,Intermediate,,50588,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,CHEMBL624458,N,1,,,,,1,,BAO_0000218,
5637,,Intermediate,,50588,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,CHEMBL624459,N,1,,,,,1,,BAO_0000218,
5638,2107.0,Intermediate,Liver,102164,Intrinsic clearance in human liver microsomes,CHEMBL624460,S,2,,,,Microsomes,1,,BAO_0000251,
5639,2107.0,Intermediate,Liver,102164,Intrinsic clearance in human liver microsomes,CHEMBL624461,S,2,,,,Microsomes,1,,BAO_0000251,
5640,,Intermediate,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,CHEMBL875943,N,1,,,,,1,,BAO_0000218,
5641,,Intermediate,,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,CHEMBL624462,N,1,,,,,1,,BAO_0000218,
5642,,Intermediate,,50588,Clearance in dog (dose 1 mg/kg i.v.),CHEMBL624463,N,1,,,,,1,,BAO_0000218,
5643,,Intermediate,,50588,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,CHEMBL624464,N,1,,,,,1,,BAO_0000218,
5644,,Intermediate,,50588,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL624465,N,1,,,,,1,,BAO_0000218,
5645,,Intermediate,,50588,Plasma clearance after peroral administration at 10 mpk in dog,CHEMBL624466,N,1,,,,,1,,BAO_0000218,
5646,,Intermediate,,50588,Plasma clearance after peroral administration at 5 mpk in dog,CHEMBL624467,N,1,,,,,1,,BAO_0000218,
5647,,Intermediate,,50588,Plasma clearance after peroral administration at 5 mg/kg in dog,CHEMBL624468,N,1,,,,,1,,BAO_0000218,
5648,,Intermediate,,50588,Plasma clearance was measured in dog,CHEMBL624469,N,1,,,,,1,,BAO_0000218,
5649,,Intermediate,,50588,Plasma clearance was measured in dog,CHEMBL624470,N,1,,,,,1,,BAO_0000218,
5650,,Intermediate,,50588,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,CHEMBL624471,N,1,,,,,1,,BAO_0000218,
5651,,Intermediate,,50588,Total clearance was determined after 0.1 mg/kg iv administration in dog,CHEMBL624472,N,1,,,,,1,,BAO_0000218,
5652,,Intermediate,,50588,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,CHEMBL622775,N,1,,,,,1,,BAO_0000218,
5653,,Intermediate,,50588,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,CHEMBL622776,N,1,,,,,1,,BAO_0000218,
5654,,Intermediate,,50588,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,CHEMBL622777,N,1,,,,,1,,BAO_0000218,
5655,,Intermediate,,50588,Clearance after peroral administration of 0.2 mg/kg in dog was determined,CHEMBL622778,N,1,,,,,1,,BAO_0000218,
5656,,Intermediate,,50588,Clearance by intravenous administration of 1.2 mg/kg in dog,CHEMBL622779,N,1,,,,,1,,BAO_0000218,
5657,,Intermediate,,50588,Clearance by iv administration in dogs at a dose of 1 mg/kg,CHEMBL622780,N,1,,,,,1,,BAO_0000218,
5658,1969.0,Intermediate,Plasma,50588,Clearance value was evaluated in dog plasma,CHEMBL622781,N,1,,,,,1,,BAO_0000218,
5659,,Intermediate,,50588,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,CHEMBL622782,N,1,,,,,1,,BAO_0000218,
5660,1969.0,Intermediate,Plasma,50588,Compound was tested for plasma clearance in dog,CHEMBL622783,N,1,,,,,1,,BAO_0000218,
5661,,Intermediate,,50588,Pharmacokinetic property (Plasma clearance) was measured in dog,CHEMBL622784,N,1,,,,,1,,BAO_0000218,
5662,,Intermediate,,50594,Area under curve when injected perorally in mice at a dose of 50 mg/kg,CHEMBL622785,N,1,,,,,1,,BAO_0000218,
5663,,Intermediate,,50594,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,CHEMBL622786,N,1,,,,,1,,BAO_0000218,
5664,,Intermediate,,50594,Area under curve value in mouse at a dose of 10 mg/kg,CHEMBL622787,N,1,,,,,1,,BAO_0000218,
5665,,Intermediate,,50594,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,CHEMBL875949,N,1,,,,,1,,BAO_0000218,
5666,,Intermediate,,50594,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,CHEMBL622788,N,1,,,,,1,,BAO_0000218,
5667,,Intermediate,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,CHEMBL622789,N,1,,,,,1,,BAO_0000218,
5668,,Intermediate,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,CHEMBL622790,N,1,,,,,1,,BAO_0000218,
5669,,Intermediate,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,CHEMBL622791,N,1,,,,,1,,BAO_0000218,
5670,,Intermediate,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,CHEMBL622792,N,1,,,,,1,,BAO_0000218,
5671,,Intermediate,,50594,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,CHEMBL622793,N,1,,,,,1,,BAO_0000218,
5672,,Intermediate,,50594,Area under curve was determined for the compound at 24 mg/Kg,CHEMBL622794,N,1,,,,,1,,BAO_0000218,
5673,,Intermediate,,50594,Area under curve was determined for the compound at 40 mg/Kg,CHEMBL622795,N,1,,,,,1,,BAO_0000218,
5674,,Intermediate,,50594,Area under curve was determined for the compound at 5 mg/Kg,CHEMBL621803,N,1,,,,,1,,BAO_0000218,
5675,,Intermediate,,50594,Area under the curve for the compound is obtained at dose 25 mg/kg,CHEMBL621804,N,1,,,,,1,,BAO_0000218,
5676,,Intermediate,,50594,Area under the curve for the compound was obtained when tested in mouse,CHEMBL621805,N,1,,,,,1,,BAO_0000218,
5677,,Intermediate,,50594,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,CHEMBL621806,N,1,,,,,1,,BAO_0000218,
5678,,Intermediate,,50594,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,CHEMBL621807,N,1,,,,,1,,BAO_0000218,
5679,,Intermediate,,50594,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,CHEMBL621808,N,1,,,,,1,,BAO_0000218,
5680,,Intermediate,,50594,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL621809,N,1,,,,,1,,BAO_0000218,
5681,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),CHEMBL621810,N,1,,,,,1,,BAO_0000218,
5682,,Intermediate,,50594,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,CHEMBL875164,N,1,,,,,1,,BAO_0000218,
5683,,Intermediate,,50594,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,CHEMBL621811,N,1,,,,,1,,BAO_0000218,
5684,,Intermediate,,50594,"Compound was evaluated for the pharmacokinetic parameter, area under curve",CHEMBL621812,N,1,,,,,1,,BAO_0000218,
5685,,Intermediate,,50594,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),CHEMBL621813,N,1,,,,,1,,BAO_0000218,
5686,,Intermediate,,50594,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),CHEMBL621814,N,1,,,,,1,,BAO_0000218,
5687,,Intermediate,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,CHEMBL621815,N,1,,,,,1,,BAO_0000218,
5688,,Intermediate,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,CHEMBL621816,N,1,,,,,1,,BAO_0000218,
5689,,Intermediate,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,CHEMBL621817,N,1,,,,,1,,BAO_0000218,
5690,,Intermediate,,50594,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,CHEMBL621818,N,1,,,,,1,,BAO_0000218,
5691,,Intermediate,,50594,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,CHEMBL621819,N,1,,,,,1,,BAO_0000218,
5692,,Intermediate,,50594,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,CHEMBL621820,N,1,,,,,1,,BAO_0000218,
5693,,Intermediate,,50594,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,CHEMBL621821,N,1,,,,,1,,BAO_0000218,
5694,,Intermediate,,50594,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,CHEMBL621822,N,1,,,,,1,,BAO_0000218,
5695,,Intermediate,,50594,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,CHEMBL619474,N,1,,,,,1,,BAO_0000218,
5696,,Intermediate,,50594,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",CHEMBL619475,N,1,,,,,1,,BAO_0000218,
5697,,Intermediate,,50594,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",CHEMBL619476,N,1,,,,,1,,BAO_0000218,
5698,,Intermediate,,50594,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",CHEMBL619477,N,1,,,,,1,,BAO_0000218,
5699,,Intermediate,,50594,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",CHEMBL619478,N,1,,,,,1,,BAO_0000218,
5700,,Intermediate,,50594,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",CHEMBL619479,N,1,,,,,1,,BAO_0000218,
5701,,Intermediate,,50594,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",CHEMBL619480,N,1,,,,,1,,BAO_0000218,
5702,,Intermediate,,50594,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,CHEMBL619481,N,1,,,,,1,,BAO_0000218,
5703,,Intermediate,,50594,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,CHEMBL619482,N,1,,,,,1,,BAO_0000218,
5704,,Intermediate,,50594,Area under the curve was evaluated in mice after intravenous administration,CHEMBL619483,N,1,,,,,1,,BAO_0000218,
5705,,Intermediate,,50594,Area under the curve was evaluated in mice after oral administration,CHEMBL619484,N,1,,,,,1,,BAO_0000218,
5706,1969.0,Intermediate,Plasma,50594,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL619485,N,1,,,,,1,,BAO_0000218,
5707,1969.0,Intermediate,Plasma,50594,AUC total value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL619486,N,1,,,,,1,,BAO_0000218,
5708,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),CHEMBL619487,N,1,,,,,1,,BAO_0000218,
5709,,Intermediate,,50594,AUMC after intraperitoneal administration of 100 mg/kg in mice,CHEMBL619488,N,1,,,,,1,,BAO_0000218,
5710,178.0,Intermediate,Blood,50594,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,CHEMBL620106,N,1,,,,,1,,BAO_0000218,
5711,,Intermediate,,80653,The compound was tested in vitro for anticancer activity against 9L cells,CHEMBL620107,N,1,392.0,9L,,,1,,BAO_0000219,
5712,,Autocuration,,22226,Anti proliferation activity determined; Weak effect,CHEMBL620283,U,0,,,,,1,,BAO_0000019,
5713,,Autocuration,,22226,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,CHEMBL875176,U,0,,,,,1,,BAO_0000219,
5714,,Autocuration,,22226,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,CHEMBL620284,U,0,,,,,1,,BAO_0000219,
5715,,Autocuration,,22226,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,CHEMBL623515,U,0,,,,,1,,BAO_0000219,
5716,,Autocuration,,22226,The cytotoxic activity was in vitro tested by 9PS assay method,CHEMBL623516,U,0,,,,,1,,BAO_0000019,
5717,,Autocuration,,22226,The cytotoxic activity was in vitro tested by 9PS assay method.,CHEMBL623517,U,0,,,,,1,,BAO_0000019,
5718,,Autocuration,,22224,Partition coefficient (logD6.5),CHEMBL857878,U,0,,,,,1,,BAO_0000019,
5719,,Expert,,81034,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,CHEMBL623518,N,1,478.0,A2780,,,1,,BAO_0000219,
5720,,Intermediate,,80018,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),CHEMBL624195,N,1,455.0,A-375,,,1,,BAO_0000219,
5721,,Expert,,80852,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,CHEMBL624196,N,1,500.0,A-431,,,1,,BAO_0000219,
5722,,Expert,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,CHEMBL624197,D,9,500.0,A-431,,,1,,BAO_0000219,
5723,,Intermediate,,80021,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,CHEMBL624198,N,1,624.0,A498,,,1,,BAO_0000219,
5724,,Intermediate,,80021,in vitro cytotoxicity against A 498 cancer cell line,CHEMBL621287,N,1,624.0,A498,,,1,,BAO_0000219,
5725,,Intermediate,,80021,In vitro cytotoxic activity against renal (A 498) cancer cell line.,CHEMBL621288,N,1,624.0,A498,,,1,,BAO_0000219,
5726,,Intermediate,,80021,Cytotoxic activity against A 498 renal cancer cell lines.,CHEMBL876496,N,1,624.0,A498,,,1,,BAO_0000219,
5727,,Intermediate,,80021,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,CHEMBL621289,N,1,624.0,A498,,,1,,BAO_0000219,
5728,,Autocuration,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,CHEMBL621290,U,0,,,,,1,,BAO_0000019,
5729,,Autocuration,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,CHEMBL621291,U,0,,,,,1,,BAO_0000019,
5730,,Autocuration,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,CHEMBL621292,U,0,,,,,1,,BAO_0000019,
5731,,Autocuration,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,CHEMBL621293,U,0,,,,,1,,BAO_0000019,
5732,,Intermediate,,80682,Inhibitory concentration required against A 549 lung cancer cell line,CHEMBL621294,N,1,646.0,A549,,,1,,BAO_0000219,
5733,,Intermediate,,80682,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,CHEMBL621295,N,1,646.0,A549,,,1,,BAO_0000219,
5734,,Intermediate,,80682,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,CHEMBL884007,N,1,646.0,A549,,,1,,BAO_0000219,
5735,,Intermediate,,80682,In vitro cytotoxicity against lung cancer A 549 cell lines,CHEMBL621296,N,1,646.0,A549,,,1,,BAO_0000219,
5736,,Intermediate,,80682,Compound was tested for its cytotoxicity against A 549 cell line,CHEMBL621297,N,1,646.0,A549,,,1,,BAO_0000219,
5737,,Expert,,80682,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",CHEMBL839828,N,1,646.0,A549,,,1,,BAO_0000219,
5738,,Intermediate,,80682,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",CHEMBL620397,N,1,646.0,A549,,,1,,BAO_0000219,
5739,,Expert,,80682,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,CHEMBL620398,N,1,646.0,A549,,,1,,BAO_0000219,
5740,,Intermediate,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,CHEMBL620399,N,1,646.0,A549,,,1,,BAO_0000219,
5741,,Expert,,80682,In vitro inhibition of A549 (human lung cancer) cell growth.,CHEMBL620400,N,1,646.0,A549,,,1,,BAO_0000219,
5742,,Intermediate,,80682,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,CHEMBL620401,N,1,646.0,A549,,,1,,BAO_0000219,
5743,,Expert,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,CHEMBL620402,N,1,646.0,A549,,,1,,BAO_0000219,
5744,,Expert,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),CHEMBL620403,N,1,646.0,A549,,,1,,BAO_0000219,
5745,,Autocuration,,22226,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,CHEMBL620404,U,0,,,,,1,,BAO_0000218,
5746,,Autocuration,,104694,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,CHEMBL620405,H,4,,,,,1,,BAO_0000218,
5747,,Autocuration,,104694,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,CHEMBL620406,H,4,,,,,1,,BAO_0000218,
5748,,Autocuration,,104694,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,CHEMBL620407,H,4,,,,,1,,BAO_0000218,
5749,,Autocuration,,104694,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,CHEMBL620408,H,4,,,,,1,,BAO_0000218,
5750,,Autocuration,,104694,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,CHEMBL620409,H,4,,,,,1,,BAO_0000218,
5751,,Expert,,80021,Inhibition of A-498 human Renal cell proliferation,CHEMBL620410,N,1,624.0,A498,,,1,,BAO_0000219,
5752,,Autocuration,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",CHEMBL620411,U,0,,,,,1,,BAO_0000019,
5753,,Autocuration,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",CHEMBL620412,U,0,,,,,1,,BAO_0000019,
5754,,Autocuration,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",CHEMBL876596,U,0,,,,,1,,BAO_0000019,
5755,,Expert,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,CHEMBL620413,N,1,622.0,A 172,,,1,,BAO_0000219,
5756,,Intermediate,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL620414,N,1,622.0,A 172,,,1,,BAO_0000219,
5757,,Intermediate,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL620415,N,1,622.0,A 172,,,1,,BAO_0000219,
5758,,Expert,,80682,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,CHEMBL620416,N,1,646.0,A549,,,1,,BAO_0000219,
5759,,Intermediate,,80682,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,CHEMBL620417,N,1,646.0,A549,,,1,,BAO_0000219,
5760,,Expert,,80682,Cytotoxic activity evaluated against A549 tumor cells,CHEMBL620418,N,1,646.0,A549,,,1,,BAO_0000219,
5761,,Intermediate,,80682,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,CHEMBL620419,N,1,646.0,A549,,,1,,BAO_0000219,
5762,,Intermediate,,80682,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,CHEMBL620420,N,1,646.0,A549,,,1,,BAO_0000219,
5763,,Intermediate,,80682,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,CHEMBL620421,N,1,646.0,A549,,,1,,BAO_0000219,
5764,,Intermediate,,80682,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,CHEMBL620422,N,1,646.0,A549,,,1,,BAO_0000219,
5765,,Intermediate,,80682,Cytotoxicity of compound against A549 cell line,CHEMBL620423,N,1,646.0,A549,,,1,,BAO_0000219,
5766,,Expert,,80682,Cytotoxicity against human lung cell carcinoma A549 cell line,CHEMBL620424,N,1,646.0,A549,,,1,,BAO_0000219,
5767,,Intermediate,,80682,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,CHEMBL620425,N,1,646.0,A549,,,1,,BAO_0000219,
5768,,Intermediate,,80682,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,CHEMBL620426,N,1,646.0,A549,,,1,,BAO_0000219,
5769,,Intermediate,,80682,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,CHEMBL620427,N,1,646.0,A549,,,1,,BAO_0000219,
5770,,Intermediate,,80682,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,CHEMBL620428,N,1,646.0,A549,,,1,,BAO_0000219,
5771,,Intermediate,,80682,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,CHEMBL620429,N,1,646.0,A549,,,1,,BAO_0000219,
5772,,Expert,,80682,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,CHEMBL620430,N,1,646.0,A549,,,1,,BAO_0000219,
5773,,Expert,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,CHEMBL839887,N,1,646.0,A549,,,1,,BAO_0000219,
5774,,Intermediate,,80682,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,CHEMBL620431,N,1,646.0,A549,,,1,,BAO_0000219,
5775,,Intermediate,,80682,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,CHEMBL884010,N,1,646.0,A549,,,1,,BAO_0000219,
5776,,Intermediate,,80682,In vitro cytotoxicity against A549 (human lung cancer),CHEMBL620538,N,1,646.0,A549,,,1,,BAO_0000219,
5777,,Expert,,80682,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,CHEMBL620539,N,1,646.0,A549,,,1,,BAO_0000219,
5778,,Intermediate,,80682,In vivo antiproliferative activity against A549 cell line,CHEMBL623373,N,1,646.0,A549,,,1,,BAO_0000218,
5779,,Intermediate,,80682,Inhibition of non-small-cell lung adenocarcinoma (A549),CHEMBL623374,N,1,646.0,A549,,,1,,BAO_0000219,
5780,,Intermediate,,80682,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,CHEMBL623375,N,1,646.0,A549,,,1,,BAO_0000219,
5781,,Intermediate,,80682,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,CHEMBL623376,N,1,646.0,A549,,,1,,BAO_0000219,
5782,,Intermediate,,80682,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),CHEMBL623377,N,1,646.0,A549,,,1,,BAO_0000219,
5783,,Intermediate,,80682,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,CHEMBL623378,N,1,646.0,A549,,,1,,BAO_0000219,
5784,,Intermediate,,80682,Inhibitory activity of compound against human A549 lung carcinoma cell line.,CHEMBL623379,N,1,646.0,A549,,,1,,BAO_0000219,
5785,,Intermediate,,80682,Inhibitory activity against A549 lung cancer cell line,CHEMBL623380,N,1,646.0,A549,,,1,,BAO_0000219,
5786,,Intermediate,,80682,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,CHEMBL623381,N,1,646.0,A549,,,1,,BAO_0000219,
5787,,Intermediate,,80682,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,CHEMBL623382,N,1,646.0,A549,,,1,,BAO_0000219,
5788,,Intermediate,,80682,Inhibitory concentration against A549 (lung cancer) cell line,CHEMBL623383,N,1,646.0,A549,,,1,,BAO_0000219,
5789,,Expert,,80682,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,CHEMBL623384,N,1,646.0,A549,,,1,,BAO_0000219,
5790,,Intermediate,,80682,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,CHEMBL623385,N,1,646.0,A549,,,1,,BAO_0000219,
5791,,Expert,,80682,Activity against A549 cancer cell line.,CHEMBL623386,N,1,646.0,A549,,,1,,BAO_0000219,
5792,,Intermediate,,80682,The compound was evaluated for cytotoxicity against A549 cell line,CHEMBL884105,N,1,646.0,A549,,,1,,BAO_0000219,
5793,,Intermediate,,80682,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,CHEMBL623387,N,1,646.0,A549,,,1,,BAO_0000219,
5794,,Intermediate,,80682,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,CHEMBL621568,N,1,646.0,A549,,,1,,BAO_0000219,
5795,,Intermediate,,80682,Growth inhibitory activity was measured for human A549 tumor cell line.,CHEMBL621569,N,1,646.0,A549,,,1,,BAO_0000219,
5796,,Intermediate,,80682,Inhibitory activity against A549 lung cancer cell line,CHEMBL621570,N,1,646.0,A549,,,1,,BAO_0000219,
5797,,Intermediate,,80682,Inhibitory activity against A549 cell line; inactive,CHEMBL621571,N,1,646.0,A549,,,1,,BAO_0000219,
5798,,Expert,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,CHEMBL621572,N,1,646.0,A549,,,1,,BAO_0000219,
5799,,Expert,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,CHEMBL621573,N,1,646.0,A549,,,1,,BAO_0000219,
5800,,Intermediate,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,CHEMBL621574,N,1,646.0,A549,,,1,,BAO_0000219,
5801,,Intermediate,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),CHEMBL621575,N,1,646.0,A549,,,1,,BAO_0000219,
5802,,Intermediate,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),CHEMBL621576,N,1,646.0,A549,,,1,,BAO_0000219,
5803,,Intermediate,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),CHEMBL621577,N,1,646.0,A549,,,1,,BAO_0000219,
5804,,Intermediate,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),CHEMBL621578,N,1,646.0,A549,,,1,,BAO_0000219,
5805,,Intermediate,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),CHEMBL621579,N,1,646.0,A549,,,1,,BAO_0000219,
5806,,Intermediate,,80682,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,CHEMBL621580,N,1,646.0,A549,,,1,,BAO_0000219,
5807,,Intermediate,,50588,Plasma clearance (in vivo) in mongrel dogs was determined,CHEMBL621581,N,1,,,,,1,,BAO_0000218,
5808,,Intermediate,,50588,Plasma clearance was measured in dog,CHEMBL621582,N,1,,,,,1,,BAO_0000218,
5809,,Intermediate,,50588,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,CHEMBL621583,N,1,,,,,1,,BAO_0000218,
5810,,Intermediate,,50588,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,CHEMBL621584,N,1,,,,,1,,BAO_0000218,
5811,1969.0,Intermediate,Plasma,50588,Tested for plasma clearance in dog,CHEMBL621585,N,1,,,,,1,,BAO_0000218,
5812,,Intermediate,,50588,The compound was tested for clearance in dog plasma.,CHEMBL621586,N,1,,,,,1,,BAO_0000218,
5813,,Intermediate,,50588,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",CHEMBL875835,N,1,,,,,1,,BAO_0000218,
5814,,Intermediate,,50588,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,CHEMBL621587,N,1,,,,,1,,BAO_0000218,
5815,1969.0,Intermediate,Plasma,50588,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),CHEMBL621588,N,1,,,,,1,,BAO_0000218,
5816,2107.0,Intermediate,Liver,50588,In vitro clearance in dog liver microsomes,CHEMBL621589,N,1,,,,Microsomes,1,,BAO_0000218,
5817,,Intermediate,,50588,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,CHEMBL621590,N,1,,,,,1,,BAO_0000218,
5818,,Intermediate,,50588,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,CHEMBL621591,N,1,,,,,1,,BAO_0000218,
5819,,Intermediate,,50588,Plasma clearance in dog,CHEMBL621592,N,1,,,,,1,,BAO_0000218,
5820,,Intermediate,,50588,Clearance rate in dog,CHEMBL621593,N,1,,,,,1,,BAO_0000218,
5821,1969.0,Intermediate,Plasma,50588,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,CHEMBL621594,N,1,,,,,1,,BAO_0000218,
5822,,Intermediate,,50588,Clearance in dogs,CHEMBL621595,N,1,,,,,1,,BAO_0000218,
5823,,Intermediate,,50588,Plasma clearance in dogs,CHEMBL621596,N,1,,,,,1,,BAO_0000218,
5824,,Intermediate,,50588,Plasma clearance was determined,CHEMBL621597,N,1,,,,,1,,BAO_0000218,
5825,,Intermediate,,50588,Lower clearance in dog (i.v.) at 0.5 mpk,CHEMBL621598,N,1,,,,,1,,BAO_0000218,
5826,,Intermediate,,50588,Plasma clearance in Beagle dogs,CHEMBL621599,N,1,,,,,1,,BAO_0000218,
5827,,Intermediate,,50588,Plasma clearance (Clp) in dog,CHEMBL875836,N,1,,,,,1,,BAO_0000218,
5828,,Intermediate,,50588,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,CHEMBL621600,N,1,,,,,1,,BAO_0000218,
5829,,Intermediate,,50588,Plasma clearance (pharmacokinetic parameter) in dog was determined,CHEMBL621601,N,1,,,,,1,,BAO_0000218,
5830,,Intermediate,,50588,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,CHEMBL618474,N,1,,,,,1,,BAO_0000218,
5831,,Intermediate,,50588,Plasma clearance of compound was determined in dog,CHEMBL618475,N,1,,,,,1,,BAO_0000218,
5832,,Intermediate,,50588,Plasma clearance after intravenous administration of 1 mg/kg in dog,CHEMBL624524,N,1,,,,,1,,BAO_0000218,
5833,,Intermediate,,50588,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,CHEMBL624525,N,1,,,,,1,,BAO_0000218,
5834,,Intermediate,,50588,Plasma clearance in dog was determined,CHEMBL624526,N,1,,,,,1,,BAO_0000218,
5835,,Intermediate,,50588,Plasma clearance was calculated in dog,CHEMBL624527,N,1,,,,,1,,BAO_0000218,
5836,,Intermediate,,50588,Plasma clearance at the dose of 2 mg/kg in dog,CHEMBL624528,N,1,,,,,1,,BAO_0000218,
5837,,Intermediate,,50588,Plasma clearance in dog,CHEMBL624529,N,1,,,,,1,,BAO_0000218,
5838,,Intermediate,,50588,Plasma clearance in dog,CHEMBL624530,N,1,,,,,1,,BAO_0000218,
5839,,Intermediate,,50588,Plasma clearance in dog; Unable to calculate,CHEMBL624531,N,1,,,,,1,,BAO_0000218,
5840,,Intermediate,,50588,Plasma clearance in rhesus monkey,CHEMBL624532,N,1,,,,,1,,BAO_0000218,
5841,,Intermediate,,50588,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL624533,N,1,,,,,1,,BAO_0000218,
5842,,Intermediate,,50588,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624534,N,1,,,,,1,,BAO_0000218,
5843,,Intermediate,,50588,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624535,N,1,,,,,1,,BAO_0000218,
5844,,Intermediate,,50588,Plasma clearance was evaluated in dog,CHEMBL624536,N,1,,,,,1,,BAO_0000218,
5845,,Intermediate,,50588,Plasma clearance was evaluated in dog; Not tested,CHEMBL624537,N,1,,,,,1,,BAO_0000218,
5846,,Intermediate,,50588,Plasma clearance was evaluated in rhesus,CHEMBL624538,N,1,,,,,1,,BAO_0000218,
5847,,Intermediate,,50588,Plasma clearance was evaluated in rhesus; Not tested,CHEMBL624539,N,1,,,,,1,,BAO_0000218,
5848,,Intermediate,,50588,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,CHEMBL624540,N,1,,,,,1,,BAO_0000218,
5849,,Intermediate,,50588,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL624541,N,1,,,,,1,,BAO_0000218,
5850,,Intermediate,,50588,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,CHEMBL624542,N,1,,,,,1,,BAO_0000218,
5851,,Intermediate,,50588,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL624543,N,1,,,,,1,,BAO_0000218,
5852,,Intermediate,,50588,Clearance value at a dose of 0.2 mg/kg i.v.,CHEMBL624544,N,1,,,,,1,,BAO_0000218,
5853,1969.0,Intermediate,Plasma,50588,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,CHEMBL624545,N,1,,,,,1,,BAO_0000218,
5854,,Intermediate,,50588,Cmax after oral dose of compound at 3 mg/kg in dogs,CHEMBL624546,N,1,,,,,1,,BAO_0000218,
5855,,Intermediate,,50588,Cmax after single intravenous bolus of 1 mg/kg in dogs,CHEMBL875957,N,1,,,,,1,,BAO_0000218,
5856,,Intermediate,,50588,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL624547,N,1,,,,,1,,BAO_0000218,
5857,,Intermediate,,50588,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,CHEMBL624548,N,1,,,,,1,,BAO_0000218,
5858,,Intermediate,,50588,Cmax in dog after administration of 1 mg/kg iv,CHEMBL624549,N,1,,,,,1,,BAO_0000218,
5859,1969.0,Intermediate,Plasma,50588,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,CHEMBL624550,N,1,,,,,1,,BAO_0000218,
5860,,Intermediate,,50588,Cmax on p.o. administration of 10 mg/kg was measured in dog,CHEMBL621613,N,1,,,,,1,,BAO_0000218,
5861,,Intermediate,,50588,Cmax was determine after peroral administration at 10 mpk in dog,CHEMBL621614,N,1,,,,,1,,BAO_0000218,
5862,,Intermediate,,50588,Cmax was determine after peroral administration at 5 mpk in dog,CHEMBL623431,N,1,,,,,1,,BAO_0000218,
5863,,Intermediate,,50588,Cmax was determine after peroral administration at 5 mg/kg in dog,CHEMBL623432,N,1,,,,,1,,BAO_0000218,
5864,,Intermediate,,50588,Cmax after 0.3 mg/kg po administration in dog,CHEMBL623433,N,1,,,,,1,,BAO_0000218,
5865,,Intermediate,,50588,Cmax after peroral administration in dogs at 2.4 uM/kg,CHEMBL623434,N,1,,,,,1,,BAO_0000218,
5866,,Intermediate,,50588,Cmax in dog after oral administration at 1 mg/kg,CHEMBL623435,N,1,,,,,1,,BAO_0000218,
5867,,Intermediate,,50588,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,CHEMBL623436,N,1,,,,,1,,BAO_0000218,
5868,,Intermediate,,50588,Cmax upon oral administration in male Beagle dog at 10 mg/kg,CHEMBL875958,N,1,,,,,1,,BAO_0000218,
5869,,Intermediate,,50588,Cmax value after 15 mg/kg iv dose in Dogs,CHEMBL623437,N,1,,,,,1,,BAO_0000218,
5870,178.0,Intermediate,Blood,50594,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623438,N,1,,,,,1,,BAO_0000218,
5871,178.0,Intermediate,Blood,50594,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623439,N,1,,,,,1,,BAO_0000218,
5872,10000001.0,Intermediate,Bone,50594,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623440,N,1,,,,,1,,BAO_0000218,
5873,10000001.0,Intermediate,Bone,50594,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623441,N,1,,,,,1,,BAO_0000218,
5874,10000001.0,Intermediate,Bone,50594,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623442,N,1,,,,,1,,BAO_0000218,
5875,,Intermediate,,50594,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623469,N,1,,,,,1,,BAO_0000218,
5876,,Intermediate,,50594,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623470,N,1,,,,,1,,BAO_0000218,
5877,,Intermediate,,50594,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623471,N,1,,,,,1,,BAO_0000218,
5878,948.0,Intermediate,Heart,50594,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623472,N,1,,,,,1,,BAO_0000218,
5879,948.0,Intermediate,Heart,50594,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623473,N,1,,,,,1,,BAO_0000218,
5880,948.0,Intermediate,Heart,50594,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623474,N,1,,,,,1,,BAO_0000218,
5881,2113.0,Intermediate,Kidney,50594,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623475,N,1,,,,,1,,BAO_0000218,
5882,2113.0,Intermediate,Kidney,50594,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623476,N,1,,,,,1,,BAO_0000218,
5883,2113.0,Intermediate,Kidney,50594,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623477,N,1,,,,,1,,BAO_0000218,
5884,160.0,Intermediate,Intestine,50594,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL621896,N,1,,,,,1,,BAO_0000218,
5885,160.0,Intermediate,Intestine,50594,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL621897,N,1,,,,,1,,BAO_0000218,
5886,160.0,Intermediate,Intestine,50594,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL621898,N,1,,,,,1,,BAO_0000218,
5887,2107.0,Intermediate,Liver,50594,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL621899,N,1,,,,,1,,BAO_0000218,
5888,2107.0,Intermediate,Liver,50594,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL621900,N,1,,,,,1,,BAO_0000218,
5889,2107.0,Intermediate,Liver,50594,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL621901,N,1,,,,,1,,BAO_0000218,
5890,2048.0,Intermediate,Lung,50594,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL621902,N,1,,,,,1,,BAO_0000218,
5891,2048.0,Intermediate,Lung,50594,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL621903,N,1,,,,,1,,BAO_0000218,
5892,2048.0,Intermediate,Lung,50594,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL622587,N,1,,,,,1,,BAO_0000218,
5893,2385.0,Intermediate,Muscle tissue,50594,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620285,N,1,,,,,1,,BAO_0000218,
5894,2385.0,Intermediate,Muscle tissue,50594,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL875285,N,1,,,,,1,,BAO_0000218,
5895,2385.0,Intermediate,Muscle tissue,50594,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL620286,N,1,,,,,1,,BAO_0000218,
5896,,Intermediate,,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620287,N,1,,,,,1,,BAO_0000218,
5897,,Intermediate,,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL620288,N,1,,,,,1,,BAO_0000218,
5898,,Intermediate,,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL620289,N,1,,,,,1,,BAO_0000218,
5899,160.0,Intermediate,Intestine,50594,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620290,N,1,,,,,1,,BAO_0000218,
5900,160.0,Intermediate,Intestine,50594,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL620291,N,1,,,,,1,,BAO_0000218,
5901,160.0,Intermediate,Intestine,50594,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL620292,N,1,,,,,1,,BAO_0000218,
5902,2106.0,Intermediate,Spleen,50594,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620293,N,1,,,,,1,,BAO_0000218,
5903,2106.0,Intermediate,Spleen,50594,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL620294,N,1,,,,,1,,BAO_0000218,
5904,2106.0,Intermediate,Spleen,50594,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL618614,N,1,,,,,1,,BAO_0000218,
5905,945.0,Intermediate,Stomach,50594,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL618615,N,1,,,,,1,,BAO_0000218,
5906,945.0,Intermediate,Stomach,50594,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL618616,N,1,,,,,1,,BAO_0000218,
5907,,Expert,,80012,Cytotoxicity against A-172 human tumor cell lines,CHEMBL618617,N,1,622.0,A 172,,,1,,BAO_0000219,
5908,,Intermediate,,80012,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,CHEMBL618618,N,1,622.0,A 172,,,1,,BAO_0000219,
5909,,Intermediate,,80014,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,CHEMBL618619,N,1,623.0,A204,,,1,,BAO_0000219,
5910,,Intermediate,,81034,Tested for antiproliferative activity against A-2780 tumoral cell line,CHEMBL618620,N,1,478.0,A2780,,,1,,BAO_0000219,
5911,,Intermediate,,80018,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,CHEMBL618621,N,1,455.0,A-375,,,1,,BAO_0000219,
5912,,Intermediate,,80018,Tested in vitro against A-375 cell line human melanoma,CHEMBL618622,N,1,455.0,A-375,,,1,,BAO_0000219,
5913,,Expert,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,CHEMBL618623,N,1,797.0,A-427,,,1,,BAO_0000219,
5914,,Intermediate,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL618624,N,1,797.0,A-427,,,1,,BAO_0000219,
5915,,Expert,,80019,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,CHEMBL618625,N,1,797.0,A-427,,,1,,BAO_0000219,
5916,,Intermediate,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL618626,N,1,797.0,A-427,,,1,,BAO_0000219,
5917,,Intermediate,,80019,Antitumor activity on A-427 lung carcinoma cell lines,CHEMBL618627,N,1,797.0,A-427,,,1,,BAO_0000219,
5918,,Intermediate,,80019,Cytotoxic activity against human A-427 lung tumor cell line,CHEMBL618628,N,1,797.0,A-427,,,1,,BAO_0000219,
5919,,Expert,,80019,In vitro antitumor effects against human A-427 cell lines.,CHEMBL618629,N,1,797.0,A-427,,,1,,BAO_0000219,
5920,,Expert,,80019,In vitro inhibition of A-427 (human lung cancer) cell growth.,CHEMBL618630,N,1,797.0,A-427,,,1,,BAO_0000219,
5921,,Intermediate,,80019,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,CHEMBL618631,N,1,797.0,A-427,,,1,,BAO_0000219,
5922,,Intermediate,,80019,Cytotoxic activity of compound against A-427 lung human tumor cell line,CHEMBL618632,N,1,797.0,A-427,,,1,,BAO_0000219,
5923,,Expert,,80852,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,CHEMBL618633,N,1,500.0,A-431,,,1,,BAO_0000219,
5924,,Intermediate,,80021,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,CHEMBL619315,N,1,624.0,A498,,,1,,BAO_0000219,
5925,,Expert,,80021,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,CHEMBL619316,N,1,624.0,A498,,,1,,BAO_0000219,
5926,,Intermediate,,80021,Cytotoxicity against human kidney carcinoma A-498cell lines,CHEMBL619317,N,1,624.0,A498,,,1,,BAO_0000219,
5927,,Intermediate,,80021,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,CHEMBL619318,N,1,624.0,A498,,,1,,BAO_0000219,
5928,,Intermediate,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,CHEMBL619319,N,1,624.0,A498,,,1,,BAO_0000219,
5929,,Intermediate,,80021,Antitumor cytotoxic activity against A-498 cell line was determined,CHEMBL619739,N,1,624.0,A498,,,1,,BAO_0000219,
5930,,Intermediate,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,CHEMBL619740,N,1,624.0,A498,,,1,,BAO_0000219,
5931,,Intermediate,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,CHEMBL883158,N,1,624.0,A498,,,1,,BAO_0000219,
5932,,Intermediate,,80021,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,CHEMBL884012,N,1,624.0,A498,,,1,,BAO_0000219,
5933,,Intermediate,,80021,In vitro inhibitory activity against A-498 ovarian cancer cell lines,CHEMBL619741,N,1,624.0,A498,,,1,,BAO_0000219,
5934,,Intermediate,,80021,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",CHEMBL619742,N,1,624.0,A498,,,1,,BAO_0000219,
5935,,Intermediate,,80682,Inhibition of growth lung non-small cell carcinoma A-549 cell line,CHEMBL876610,N,1,646.0,A549,,,1,,BAO_0000219,
5936,,Intermediate,,80682,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,CHEMBL619743,N,1,646.0,A549,,,1,,BAO_0000219,
5937,,Intermediate,,80682,In vitro antiproliferative activity against human A-549 NSCL cell line,CHEMBL619744,N,1,646.0,A549,,,1,,BAO_0000219,
5938,,Intermediate,,80682,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,CHEMBL619745,N,1,646.0,A549,,,1,,BAO_0000219,
5939,,Intermediate,,80682,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,CHEMBL619746,N,1,646.0,A549,,,1,,BAO_0000219,
5940,,Intermediate,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,CHEMBL619747,N,1,646.0,A549,,,1,,BAO_0000219,
5941,,Intermediate,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,CHEMBL619748,N,1,646.0,A549,,,1,,BAO_0000219,
5942,,Intermediate,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,CHEMBL619749,N,1,646.0,A549,,,1,,BAO_0000219,
5943,,Intermediate,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,CHEMBL619750,N,1,646.0,A549,,,1,,BAO_0000219,
5944,,Intermediate,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,CHEMBL624014,N,1,646.0,A549,,,1,,BAO_0000219,
5945,,Intermediate,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,CHEMBL624015,N,1,646.0,A549,,,1,,BAO_0000219,
5946,,Expert,,80682,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,CHEMBL885344,N,1,646.0,A549,,,1,,BAO_0000219,
5947,,Intermediate,,80682,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,CHEMBL623224,N,1,646.0,A549,,,1,,BAO_0000219,
5948,,Intermediate,,80682,Cytotoxic activity against A-549 cell line,CHEMBL623225,N,1,646.0,A549,,,1,,BAO_0000219,
5949,,Intermediate,,80682,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,CHEMBL622698,N,1,646.0,A549,,,1,,BAO_0000219,
5950,,Intermediate,,80682,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,CHEMBL622699,N,1,646.0,A549,,,1,,BAO_0000219,
5951,,Expert,,80682,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",CHEMBL622700,N,1,646.0,A549,,,1,,BAO_0000219,
5952,,Intermediate,,80682,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),CHEMBL622701,N,1,646.0,A549,,,1,,BAO_0000219,
5953,,Intermediate,,80682,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),CHEMBL622702,N,1,646.0,A549,,,1,,BAO_0000219,
5954,,Intermediate,,80682,Cytotoxic activity against human lung carcinoma (A-549) cell line,CHEMBL622703,N,1,646.0,A549,,,1,,BAO_0000219,
5955,,Expert,,80682,Cytotoxic activity towards A-549 cells,CHEMBL622704,N,1,646.0,A549,,,1,,BAO_0000219,
5956,,Intermediate,,80682,"In vitro percent inhibition of A549, lung carcinoma.",CHEMBL622705,N,1,646.0,A549,,,1,,BAO_0000219,
5957,,Intermediate,,80682,"In vitro percent inhibition of A549, lung carcinoma",CHEMBL622706,N,1,646.0,A549,,,1,,BAO_0000219,
5958,,Intermediate,,80682,"In vitro percent inhibition of A549, lung carcinoma.",CHEMBL622707,N,1,646.0,A549,,,1,,BAO_0000219,
5959,,Intermediate,,80682,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",CHEMBL622708,N,1,646.0,A549,,,1,,BAO_0000219,
5960,,Intermediate,,80682,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,CHEMBL622709,N,1,646.0,A549,,,1,,BAO_0000219,
5961,,Intermediate,,80682,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,CHEMBL622710,N,1,646.0,A549,,,1,,BAO_0000219,
5962,,Intermediate,,80682,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,CHEMBL622711,N,1,646.0,A549,,,1,,BAO_0000219,
5963,,Intermediate,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622712,N,1,646.0,A549,,,1,,BAO_0000218,
5964,,Intermediate,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622713,N,1,646.0,A549,,,1,,BAO_0000218,
5965,,Intermediate,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622714,N,1,646.0,A549,,,1,,BAO_0000218,
5966,,Intermediate,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622715,N,1,646.0,A549,,,1,,BAO_0000218,
5967,,Intermediate,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622716,N,1,646.0,A549,,,1,,BAO_0000218,
5968,,Intermediate,,80682,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",CHEMBL622717,N,1,646.0,A549,,,1,,BAO_0000219,
5969,,Intermediate,,80682,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),CHEMBL622718,N,1,646.0,A549,,,1,,BAO_0000218,
5970,,Expert,,80682,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,CHEMBL622719,N,1,646.0,A549,,,1,,BAO_0000219,
5971,,Intermediate,,80682,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,CHEMBL622720,N,1,646.0,A549,,,1,,BAO_0000219,
5972,,Intermediate,,80682,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,CHEMBL622721,N,1,646.0,A549,,,1,,BAO_0000219,
5973,,Intermediate,,80682,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,CHEMBL622722,N,1,646.0,A549,,,1,,BAO_0000219,
5974,,Intermediate,,80682,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,CHEMBL876030,N,1,646.0,A549,,,1,,BAO_0000219,
5975,,Intermediate,,80682,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",CHEMBL620206,N,1,646.0,A549,,,1,,BAO_0000219,
5976,,Expert,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,CHEMBL620207,N,1,646.0,A549,,,1,,BAO_0000219,
5977,,Expert,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,CHEMBL620208,N,1,646.0,A549,,,1,,BAO_0000219,
5978,,Expert,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,CHEMBL620209,N,1,646.0,A549,,,1,,BAO_0000219,
5979,,Expert,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,CHEMBL620210,N,1,646.0,A549,,,1,,BAO_0000219,
5980,,Expert,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,CHEMBL621639,N,1,646.0,A549,,,1,,BAO_0000219,
5981,,Intermediate,,80682,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,CHEMBL621640,N,1,646.0,A549,,,1,,BAO_0000219,
5982,,Expert,,80682,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,CHEMBL621641,N,1,646.0,A549,,,1,,BAO_0000219,
5983,,Expert,,80682,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,CHEMBL621642,N,1,646.0,A549,,,1,,BAO_0000219,
5984,,Intermediate,,80682,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,CHEMBL621643,N,1,646.0,A549,,,1,,BAO_0000219,
5985,,Intermediate,,80682,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,CHEMBL621644,N,1,646.0,A549,,,1,,BAO_0000219,
5986,,Intermediate,,80682,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,CHEMBL621645,N,1,646.0,A549,,,1,,BAO_0000219,
5987,,Intermediate,,80682,In vitro antiproliferative activity against A549 cell line,CHEMBL621646,N,1,646.0,A549,,,1,,BAO_0000219,
5988,,Intermediate,,80682,Synergism with indomethacin in A549 cells,CHEMBL621647,N,1,646.0,A549,,,1,,BAO_0000219,
5989,,Intermediate,,80682,Synergism with tolmetin in A549 cells,CHEMBL621648,N,1,646.0,A549,,,1,,BAO_0000219,
5990,,Intermediate,,80682,Synergism with sulindac in A549 cells,CHEMBL621649,N,1,646.0,A549,,,1,,BAO_0000219,
5991,,Intermediate,,80682,Antagonism of indomethacin in A549 cells,CHEMBL621650,N,1,646.0,A549,,,1,,BAO_0000219,
5992,,Intermediate,,80682,Antagonism of sulindac in A549 cells,CHEMBL621651,N,1,646.0,A549,,,1,,BAO_0000219,
5993,,Intermediate,,80682,Antagonism of tolmetin in A549 cells,CHEMBL621652,N,1,646.0,A549,,,1,,BAO_0000219,
5994,,Intermediate,,80682,Synergism with indomethacin in A549 cells,CHEMBL621653,N,1,646.0,A549,,,1,,BAO_0000219,
5995,,Intermediate,,80682,Synergism with sulindac in A549 cells,CHEMBL621654,N,1,646.0,A549,,,1,,BAO_0000219,
5996,,Intermediate,,80682,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,CHEMBL621655,N,1,646.0,A549,,,1,,BAO_0000219,
5997,,Intermediate,,50588,Cmax value after 30 mg/kg po dose in Dogs,CHEMBL621656,N,1,,,,,1,,BAO_0000218,
5998,,Intermediate,,50588,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL621657,N,1,,,,,1,,BAO_0000218,
5999,,Intermediate,,50588,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,CHEMBL621658,N,1,,,,,1,,BAO_0000218,
6000,,Intermediate,,50588,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL621659,N,1,,,,,1,,BAO_0000218,
6001,,Intermediate,,50588,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,CHEMBL621660,N,1,,,,,1,,BAO_0000218,
6002,,Intermediate,,50588,Cmax value after administration of 4 mg/Kg oral dose in dog,CHEMBL621661,N,1,,,,,1,,BAO_0000218,
6003,,Intermediate,,50588,Cmax value in dog,CHEMBL621662,N,1,,,,,1,,BAO_0000218,
6004,,Intermediate,,50588,Cmax value in dogs after oral administration at 1 mg/kg,CHEMBL621663,N,1,,,,,1,,BAO_0000218,
6005,,Intermediate,,50588,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,CHEMBL621664,N,1,,,,,1,,BAO_0000218,
6006,1969.0,Intermediate,Plasma,50588,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,CHEMBL621665,N,1,,,,,1,,BAO_0000218,
6007,1969.0,Intermediate,Plasma,50588,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,CHEMBL621666,N,1,,,,,1,,BAO_0000218,
6008,,Intermediate,,50588,Concentration maxima after oral dosing in dogs,CHEMBL621667,N,1,,,,,1,,BAO_0000218,
6009,,Intermediate,,50588,Concentration maxima after oral dosing in dogs; not available,CHEMBL876738,N,1,,,,,1,,BAO_0000218,
6010,,Intermediate,,50588,Concentration maxima after oral dosing in dogs; not available,CHEMBL621668,N,1,,,,,1,,BAO_0000218,
6011,,Intermediate,,50588,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,CHEMBL621669,N,1,,,,,1,,BAO_0000218,
6012,,Intermediate,,50588,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,CHEMBL621670,N,1,,,,,1,,BAO_0000218,
6013,,Intermediate,,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog,CHEMBL621671,N,1,,,,,1,,BAO_0000218,
6014,,Intermediate,,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,CHEMBL622360,N,1,,,,,1,,BAO_0000218,
6015,,Intermediate,,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,CHEMBL622361,N,1,,,,,1,,BAO_0000218,
6016,1969.0,Intermediate,Plasma,50588,Cmax in dog plasma after oral dose (1 mg/kg),CHEMBL622362,N,1,,,,,1,,BAO_0000218,
6017,1969.0,Intermediate,Plasma,50588,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,CHEMBL622363,N,1,,,,,1,,BAO_0000218,
6018,1969.0,Intermediate,Plasma,50588,Maximal plasma concentration at a dose of 1 mg/kg,CHEMBL622364,N,1,,,,,1,,BAO_0000218,
6019,1969.0,Intermediate,Plasma,50588,Maximal plasma concentration at a dose of 1 mg/kg (oral),CHEMBL622365,N,1,,,,,1,,BAO_0000218,
6020,1969.0,Intermediate,Plasma,50588,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,CHEMBL622533,N,1,,,,,1,,BAO_0000218,
6021,,Intermediate,,50588,Maximum concentration of compound in dog was evaluated.,CHEMBL622534,N,1,,,,,1,,BAO_0000218,
6022,,Intermediate,,50588,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL622535,N,1,,,,,1,,BAO_0000218,
6023,,Intermediate,,50588,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,CHEMBL876739,N,1,,,,,1,,BAO_0000218,
6024,,Intermediate,,50588,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL622536,N,1,,,,,1,,BAO_0000218,
6025,1969.0,Intermediate,Plasma,50588,Maximum concentration obtained in dog plasma was determined,CHEMBL622537,N,1,,,,,1,,BAO_0000218,
6026,,Intermediate,,50588,Maximum concentration was determined,CHEMBL622538,N,1,,,,,1,,BAO_0000218,
6027,,Intermediate,,50588,Maximum concentration at the dose of 2 mg/kg in dog,CHEMBL627867,N,1,,,,,1,,BAO_0000218,
6028,,Intermediate,,50588,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL627868,N,1,,,,,1,,BAO_0000218,
6029,1969.0,Intermediate,Plasma,50588,Maximum concentration was evaluated in dog plasma,CHEMBL627869,N,1,,,,,1,,BAO_0000218,
6030,,Intermediate,,50588,Maximum concentration was evaluated after 75 min after administration in dog,CHEMBL627870,N,1,,,,,1,,BAO_0000218,
6031,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration determined in dog after oral administration of 17b,CHEMBL627871,N,1,,,,,1,,BAO_0000218,
6032,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration determined in dog after oral administration of 2b,CHEMBL627872,N,1,,,,,1,,BAO_0000218,
6033,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration in dog,CHEMBL627873,N,1,,,,,1,,BAO_0000218,
6034,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,CHEMBL627874,N,1,,,,,1,,BAO_0000218,
6035,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,CHEMBL627875,N,1,,,,,1,,BAO_0000218,
6036,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,CHEMBL627876,N,1,,,,,1,,BAO_0000218,
6037,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,CHEMBL627877,N,1,,,,,1,,BAO_0000218,
6038,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL627878,N,1,,,,,1,,BAO_0000218,
6039,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,CHEMBL627879,N,1,,,,,1,,BAO_0000218,
6040,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL875355,N,1,,,,,1,,BAO_0000218,
6041,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL627880,N,1,,,,,1,,BAO_0000218,
6042,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,CHEMBL627881,N,1,,,,,1,,BAO_0000218,
6043,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,CHEMBL627882,N,1,,,,,1,,BAO_0000218,
6044,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,CHEMBL627883,N,1,,,,,1,,BAO_0000218,
6045,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,CHEMBL628526,N,1,,,,,1,,BAO_0000218,
6046,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,CHEMBL628527,N,1,,,,,1,,BAO_0000218,
6047,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,CHEMBL628528,N,1,,,,,1,,BAO_0000218,
6048,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,CHEMBL628529,N,1,,,,,1,,BAO_0000218,
6049,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,CHEMBL628530,N,1,,,,,1,,BAO_0000218,
6050,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,CHEMBL625243,N,1,,,,,1,,BAO_0000218,
6051,1969.0,Expert,Plasma,50588,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL625244,N,1,,,,,1,,BAO_0000218,
6052,,Intermediate,,50588,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,CHEMBL625245,N,1,,,,,1,,BAO_0000218,
6053,,Intermediate,,50588,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,CHEMBL625246,N,1,,,,,1,,BAO_0000218,
6054,945.0,Intermediate,Stomach,50594,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL625247,N,1,,,,,1,,BAO_0000218,
6055,1088.0,Intermediate,Urine,50594,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL625248,N,1,,,,,1,,BAO_0000218,
6056,1088.0,Intermediate,Urine,50594,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,CHEMBL625249,N,1,,,,,1,,BAO_0000218,
6057,1088.0,Intermediate,Urine,50594,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,CHEMBL625250,N,1,,,,,1,,BAO_0000218,
6058,,Intermediate,,50594,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,CHEMBL625251,N,1,,,,,1,,BAO_0000218,
6059,,Intermediate,,50594,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,CHEMBL875356,N,1,,,,,1,,BAO_0000218,
6060,,Intermediate,,50594,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),CHEMBL625252,N,1,,,,,1,,BAO_0000218,
6061,178.0,Intermediate,Blood,50594,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),CHEMBL625253,N,1,,,,,1,,BAO_0000218,
6062,,Intermediate,,50594,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),CHEMBL625254,N,1,,,,,1,,BAO_0000218,
6063,,Intermediate,,50594,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),CHEMBL625255,N,1,,,,,1,,BAO_0000218,
6064,,Intermediate,,50594,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),CHEMBL625256,N,1,,,,,1,,BAO_0000218,
6065,178.0,Intermediate,Blood,50594,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),CHEMBL625257,N,1,,,,,1,,BAO_0000218,
6066,178.0,Intermediate,Blood,50594,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),CHEMBL625258,N,1,,,,,1,,BAO_0000218,
6067,,Intermediate,,50594,Compound was evaluated for washout rate in mice (Radiolabeled compound),CHEMBL625259,N,1,,,,,1,,BAO_0000218,
6068,,Intermediate,,50594,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,CHEMBL625260,N,1,,,,,1,,BAO_0000218,
6069,,Intermediate,,50594,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",CHEMBL625261,N,1,,,,,1,,BAO_0000218,
6070,,Intermediate,,50594,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",CHEMBL625262,N,1,,,,,1,,BAO_0000218,
6071,,Intermediate,,50594,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",CHEMBL622639,N,1,,,,,1,,BAO_0000218,
6072,,Intermediate,,50594,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,CHEMBL622640,N,1,,,,,1,,BAO_0000218,
6073,,Intermediate,,50594,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,CHEMBL622812,N,1,,,,,1,,BAO_0000218,
6074,,Intermediate,,50594,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,CHEMBL622813,N,1,,,,,1,,BAO_0000218,
6075,,Intermediate,,50594,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,CHEMBL622814,N,1,,,,,1,,BAO_0000218,
6076,,Intermediate,,50594,Time at maximum activity in mice (Radiolabeled compound),CHEMBL622815,N,1,,,,,1,,BAO_0000218,
6077,,Intermediate,,50594,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,CHEMBL625342,N,1,,,,,1,,BAO_0000218,
6078,,Intermediate,,50594,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,CHEMBL625343,N,1,,,,,1,,BAO_0000218,
6079,,Intermediate,,50594,Binding towards mouse plasma protein at 10 uM,CHEMBL877591,N,1,,,,,1,,BAO_0000218,
6080,,Intermediate,,50594,Binding towards mouse plasma protein at 100 uM,CHEMBL625344,N,1,,,,,1,,BAO_0000218,
6081,,Intermediate,,50594,Bioavailability was evaluated in mice after intravenous administration,CHEMBL625345,N,1,,,,,1,,BAO_0000218,
6082,,Intermediate,,50594,Bioavailability was evaluated in mice after oral administration,CHEMBL625346,N,1,,,,,1,,BAO_0000218,
6083,,Intermediate,,50594,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,CHEMBL625347,N,1,,,,,1,,BAO_0000218,
6084,,Intermediate,,50594,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,CHEMBL625348,N,1,,,,,1,,BAO_0000218,
6085,,Intermediate,,50594,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,CHEMBL625349,N,1,,,,,1,,BAO_0000218,
6086,,Intermediate,,50594,Oral bioavailability in mouse,CHEMBL625350,N,1,,,,,1,,BAO_0000218,
6087,,Intermediate,,50594,Oral bioavailability after intravenous administration in mice at 24 uM/kg,CHEMBL882952,N,1,,,,,1,,BAO_0000218,
6088,955.0,Intermediate,Brain,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL625351,N,1,,,,,1,,BAO_0000218,
6089,955.0,Intermediate,Brain,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL625352,N,1,,,,,1,,BAO_0000218,
6090,955.0,Intermediate,Brain,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL877592,N,1,,,,,1,,BAO_0000218,
6091,955.0,Intermediate,Brain,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL625353,N,1,,,,,1,,BAO_0000218,
6092,955.0,Intermediate,Brain,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL625354,N,1,,,,,1,,BAO_0000218,
6093,955.0,Intermediate,Brain,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626019,N,1,,,,,1,,BAO_0000218,
6094,948.0,Intermediate,Heart,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626020,N,1,,,,,1,,BAO_0000218,
6095,948.0,Intermediate,Heart,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL626021,N,1,,,,,1,,BAO_0000218,
6096,948.0,Intermediate,Heart,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626022,N,1,,,,,1,,BAO_0000218,
6097,948.0,Intermediate,Heart,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626192,N,1,,,,,1,,BAO_0000218,
6098,,Intermediate,,80682,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),CHEMBL626193,N,1,646.0,A549,,,1,,BAO_0000219,
6099,,Expert,,80682,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,CHEMBL626194,N,1,646.0,A549,,,1,,BAO_0000219,
6100,,Intermediate,,80682,Cytotoxicity against human lung carcinoma A-549 cell lines,CHEMBL626195,N,1,646.0,A549,,,1,,BAO_0000219,
6101,,Intermediate,,80682,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,CHEMBL626196,N,1,646.0,A549,,,1,,BAO_0000219,
6102,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549,CHEMBL626197,N,1,646.0,A549,,,1,,BAO_0000219,
6103,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,CHEMBL626198,N,1,646.0,A549,,,1,,BAO_0000219,
6104,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,CHEMBL626199,N,1,646.0,A549,,,1,,BAO_0000219,
6105,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,CHEMBL626200,N,1,646.0,A549,,,1,,BAO_0000219,
6106,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,CHEMBL626201,N,1,646.0,A549,,,1,,BAO_0000219,
6107,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,CHEMBL626202,N,1,646.0,A549,,,1,,BAO_0000219,
6108,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,CHEMBL626203,N,1,646.0,A549,,,1,,BAO_0000219,
6109,,Intermediate,,80682,In vitro cytotoxicity against A-549 human lung cancer cells,CHEMBL626204,N,1,646.0,A549,,,1,,BAO_0000219,
6110,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,CHEMBL624701,N,1,646.0,A549,,,1,,BAO_0000219,
6111,,Intermediate,,80682,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,CHEMBL624702,N,1,646.0,A549,,,1,,BAO_0000219,
6112,,Expert,,80682,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,CHEMBL624703,N,1,646.0,A549,,,1,,BAO_0000219,
6113,,Intermediate,,80682,Tested in vitro for cytotoxicity against A-549 lung cancer cells,CHEMBL624704,N,1,646.0,A549,,,1,,BAO_0000219,
6114,,Intermediate,,80682,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,CHEMBL624705,N,1,646.0,A549,,,1,,BAO_0000219,
6115,,Expert,,80682,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,CHEMBL624706,N,1,646.0,A549,,,1,,BAO_0000219,
6116,,Intermediate,,80682,Antitumor cytotoxic activity against A-549 cell line was determined,CHEMBL624707,N,1,646.0,A549,,,1,,BAO_0000219,
6117,,Intermediate,,80682,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",CHEMBL624708,N,1,646.0,A549,,,1,,BAO_0000219,
6118,,Intermediate,,80682,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,CHEMBL624709,N,1,646.0,A549,,,1,,BAO_0000219,
6119,,Expert,,80682,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,CHEMBL884107,N,1,646.0,A549,,,1,,BAO_0000219,
6120,,Intermediate,,80682,Antitumoral activity was assayed against A-549 cell line,CHEMBL624710,N,1,646.0,A549,,,1,,BAO_0000219,
6121,,Intermediate,,80682,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,CHEMBL624711,N,1,646.0,A549,,,1,,BAO_0000219,
6122,,Intermediate,,80682,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,CHEMBL624712,N,1,646.0,A549,,,1,,BAO_0000219,
6123,,Expert,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,CHEMBL624713,N,1,646.0,A549,,,1,,BAO_0000219,
6124,,Intermediate,,80682,Compound was tested for inhibition of cell growth of A-549 cells,CHEMBL624714,N,1,646.0,A549,,,1,,BAO_0000219,
6125,,Intermediate,,80682,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,CHEMBL624715,N,1,646.0,A549,,,1,,BAO_0000219,
6126,,Intermediate,,80682,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,CHEMBL624716,N,1,646.0,A549,,,1,,BAO_0000219,
6127,,Expert,,80682,In vitro cytotoxicity against A549-human lung carcinoma cells.,CHEMBL619505,N,1,646.0,A549,,,1,,BAO_0000219,
6128,,Expert,,80682,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,CHEMBL619506,N,1,646.0,A549,,,1,,BAO_0000219,
6129,,Intermediate,,80682,Cytotoxic activity against A-549 cell lines.,CHEMBL619507,N,1,646.0,A549,,,1,,BAO_0000219,
6130,,Expert,,80682,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,CHEMBL619508,N,1,646.0,A549,,,1,,BAO_0000219,
6131,,Intermediate,,80682,Cytotoxicity against human A549 non small cell lung cell lines,CHEMBL619509,N,1,646.0,A549,,,1,,BAO_0000219,
6132,,Expert,,80682,Inhibition of cell growth in (A-549) lung cell line,CHEMBL619510,N,1,646.0,A549,,,1,,BAO_0000219,
6133,,Intermediate,,80682,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,CHEMBL619511,N,1,646.0,A549,,,1,,BAO_0000219,
6134,,Intermediate,,80682,In vitro antitumor activity against A-549 tumor cells.,CHEMBL619512,N,1,646.0,A549,,,1,,BAO_0000219,
6135,,Expert,,80682,In vitro antitumor effects against human A-549 cell lines.,CHEMBL619513,N,1,646.0,A549,,,1,,BAO_0000219,
6136,,Intermediate,,80682,In vitro cytotoxic activity of compound against A-549 cell line,CHEMBL619514,N,1,646.0,A549,,,1,,BAO_0000219,
6137,,Intermediate,,80682,In vitro cytotoxicity against human lung carcinoma A-549 cell line,CHEMBL619515,N,1,646.0,A549,,,1,,BAO_0000219,
6138,,Intermediate,,80682,In vitro cytotoxicity against human non-small cell lung carcinoma A549,CHEMBL619516,N,1,646.0,A549,,,1,,BAO_0000219,
6139,,Intermediate,,80682,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,CHEMBL884005,N,1,646.0,A549,,,1,,BAO_0000219,
6140,,Expert,,80682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,CHEMBL619517,N,1,646.0,A549,,,1,,BAO_0000219,
6141,,Intermediate,,80682,Inhibitory concentration of compound against A-549 cell line,CHEMBL619518,N,1,646.0,A549,,,1,,BAO_0000219,
6142,,Intermediate,,80682,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,CHEMBL619519,N,1,646.0,A549,,,1,,BAO_0000219,
6143,,Intermediate,,80682,cytotoxic activity against leukemia (A-549) cancer cell line,CHEMBL876489,N,1,646.0,A549,,,1,,BAO_0000219,
6144,,Expert,,80682,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,CHEMBL619520,N,1,646.0,A549,,,1,,BAO_0000219,
6145,,Intermediate,,80682,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,CHEMBL619521,N,1,646.0,A549,,,1,,BAO_0000219,
6146,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),CHEMBL619522,N,1,646.0,A549,,,1,,BAO_0000219,
6147,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),CHEMBL619523,N,1,646.0,A549,,,1,,BAO_0000219,
6148,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),CHEMBL619524,N,1,646.0,A549,,,1,,BAO_0000219,
6149,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),CHEMBL619525,N,1,646.0,A549,,,1,,BAO_0000219,
6150,,Intermediate,,80682,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,CHEMBL619526,N,1,646.0,A549,,,1,,BAO_0000219,
6151,,Intermediate,,80682,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,CHEMBL619527,N,1,646.0,A549,,,1,,BAO_0000219,
6152,,Intermediate,,80682,Cytotoxicity against A549 cells; No cytotoxicity,CHEMBL619528,N,1,646.0,A549,,,1,,BAO_0000219,
6153,,Expert,,80682,Cytotoxicity against human lung carcinoma (A549) cell lines,CHEMBL619529,N,1,646.0,A549,,,1,,BAO_0000219,
6154,,Expert,,80682,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,CHEMBL619530,N,1,646.0,A549,,,1,,BAO_0000219,
6155,,Intermediate,,80682,In vitro anticancer activity against human lung (A549) cell line,CHEMBL876490,N,1,646.0,A549,,,1,,BAO_0000219,
6156,,Intermediate,,80682,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,CHEMBL619531,N,1,646.0,A549,,,1,,BAO_0000219,
6157,,Intermediate,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,CHEMBL619532,N,1,646.0,A549,,,1,,BAO_0000219,
6158,,Intermediate,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,CHEMBL619533,N,1,646.0,A549,,,1,,BAO_0000219,
6159,,Intermediate,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,CHEMBL619534,N,1,646.0,A549,,,1,,BAO_0000219,
6160,,Intermediate,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,CHEMBL620164,N,1,646.0,A549,,,1,,BAO_0000219,
6161,,Intermediate,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,CHEMBL620165,N,1,646.0,A549,,,1,,BAO_0000219,
6162,,Expert,,80682,Inhibition of A549 human lung tumor cell proliferation,CHEMBL620166,N,1,646.0,A549,,,1,,BAO_0000219,
6163,,Intermediate,,80682,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",CHEMBL620167,N,1,646.0,A549,,,1,,BAO_0000219,
6164,,Expert,,80682,In vitro cytotoxicity against human tumor cell line A549,CHEMBL620168,N,1,646.0,A549,,,1,,BAO_0000219,
6165,,Intermediate,,80682,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,CHEMBL620338,N,1,646.0,A549,,,1,,BAO_0000219,
6166,,Intermediate,,80682,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,CHEMBL620339,N,1,646.0,A549,,,1,,BAO_0000219,
6167,,Intermediate,,80682,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,CHEMBL620340,N,1,646.0,A549,,,1,,BAO_0000219,
6168,,Intermediate,,80682,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,CHEMBL620341,N,1,646.0,A549,,,1,,BAO_0000219,
6169,,Intermediate,,80682,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,CHEMBL876491,N,1,646.0,A549,,,1,,BAO_0000219,
6170,,Intermediate,,80682,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,CHEMBL620342,N,1,646.0,A549,,,1,,BAO_0000219,
6171,,Intermediate,,80682,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,CHEMBL620343,N,1,646.0,A549,,,1,,BAO_0000219,
6172,,Intermediate,,80682,% inhibition against A549 cells (lung cancer) at 4 ug/mL,CHEMBL620344,N,1,646.0,A549,,,1,,BAO_0000219,
6173,,Intermediate,,80682,In vitro anticancer activity against human lung (A549) cell line,CHEMBL620345,N,1,646.0,A549,,,1,,BAO_0000219,
6174,,Intermediate,,80682,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,CHEMBL620346,N,1,646.0,A549,,,1,,BAO_0000219,
6175,,Intermediate,,80682,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,CHEMBL620347,N,1,646.0,A549,,,1,,BAO_0000219,
6176,,Intermediate,,80682,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,CHEMBL620348,N,1,646.0,A549,,,1,,BAO_0000219,
6177,,Intermediate,,80682,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,CHEMBL620349,N,1,646.0,A549,,,1,,BAO_0000219,
6178,,Intermediate,,80682,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,CHEMBL618667,N,1,646.0,A549,,,1,,BAO_0000219,
6179,,Expert,,80682,Percentage inhibition of human lung carcinoma (A549) cell lines,CHEMBL618668,N,1,646.0,A549,,,1,,BAO_0000219,
6180,,Intermediate,,80682,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,CHEMBL876031,N,1,646.0,A549,,,1,,BAO_0000219,
6181,,Intermediate,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",CHEMBL618759,N,1,646.0,A549,,,1,,BAO_0000219,
6182,,Intermediate,,80682,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,CHEMBL618760,N,1,646.0,A549,,,1,,BAO_0000219,
6183,,Intermediate,,80682,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,CHEMBL619000,N,1,646.0,A549,,,1,,BAO_0000219,
6184,,Intermediate,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",CHEMBL619001,N,1,646.0,A549,,,1,,BAO_0000219,
6185,,Intermediate,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",CHEMBL619002,N,1,646.0,A549,,,1,,BAO_0000219,
6186,,Intermediate,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",CHEMBL619003,N,1,646.0,A549,,,1,,BAO_0000219,
6187,,Intermediate,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",CHEMBL619597,N,1,646.0,A549,,,1,,BAO_0000219,
6188,,Intermediate,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",CHEMBL619598,N,1,646.0,A549,,,1,,BAO_0000219,
6189,,Intermediate,,80682,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,CHEMBL619599,N,1,646.0,A549,,,1,,BAO_0000219,
6190,,Intermediate,,80682,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,CHEMBL619600,N,1,646.0,A549,,,1,,BAO_0000219,
6191,,Intermediate,,80682,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,CHEMBL619601,N,1,646.0,A549,,,1,,BAO_0000219,
6192,,Intermediate,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,CHEMBL619602,N,1,646.0,A549,,,1,,BAO_0000219,
6193,,Intermediate,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,CHEMBL619603,N,1,646.0,A549,,,1,,BAO_0000219,
6194,,Intermediate,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,CHEMBL619604,N,1,646.0,A549,,,1,,BAO_0000219,
6195,,Intermediate,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,CHEMBL619605,N,1,646.0,A549,,,1,,BAO_0000219,
6196,,Intermediate,,50588,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,CHEMBL619606,N,1,,,,,1,,BAO_0000218,
6197,,Intermediate,,50588,Pharmacokinetic activity (Cmax) in dog,CHEMBL876032,N,1,,,,,1,,BAO_0000218,
6198,,Intermediate,,50588,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),CHEMBL619607,N,1,,,,,1,,BAO_0000218,
6199,,Intermediate,,50588,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,CHEMBL619608,N,1,,,,,1,,BAO_0000218,
6200,,Intermediate,,50588,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,CHEMBL619609,N,1,,,,,1,,BAO_0000218,
6201,1969.0,Intermediate,Plasma,50588,Cmax in dog plasma after 30mg/kg oral dose,CHEMBL619610,N,1,,,,,1,,BAO_0000218,
6202,178.0,Intermediate,Blood,50588,Tested for the peak blood level in dog,CHEMBL619611,N,1,,,,,1,,BAO_0000218,
6203,,Intermediate,,50588,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",CHEMBL619612,N,1,,,,,1,,BAO_0000218,
6204,,Intermediate,,50588,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",CHEMBL619613,N,1,,,,,1,,BAO_0000218,
6205,178.0,Intermediate,Blood,50588,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,CHEMBL619614,N,1,,,,,1,,BAO_0000218,
6206,,Intermediate,,50588,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,CHEMBL619615,N,1,,,,,1,,BAO_0000218,
6207,,Intermediate,,50588,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,CHEMBL619616,N,1,,,,,1,,BAO_0000218,
6208,1969.0,Intermediate,Plasma,50588,Final plasma concentration in dogs after oral administration at 1 mg/kg,CHEMBL619617,N,1,,,,,1,,BAO_0000218,
6209,,Intermediate,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,CHEMBL619618,N,1,,,,,1,,BAO_0000218,
6210,,Intermediate,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,CHEMBL876033,N,1,,,,,1,,BAO_0000218,
6211,,Intermediate,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,CHEMBL619619,N,1,,,,,1,,BAO_0000218,
6212,,Intermediate,,50588,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,CHEMBL619620,N,1,,,,,1,,BAO_0000218,
6213,1088.0,Intermediate,Urine,50588,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,CHEMBL619621,N,1,,,,,1,,BAO_0000218,
6214,1088.0,Intermediate,Urine,50588,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,CHEMBL619622,N,1,,,,,1,,BAO_0000218,
6215,1088.0,Intermediate,Urine,50588,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,CHEMBL618874,N,1,,,,,1,,BAO_0000218,
6216,,Intermediate,,50588,Absolute bioavailability was evaluated in dog,CHEMBL618875,N,1,,,,,1,,BAO_0000218,
6217,,Intermediate,,50588,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,CHEMBL618876,N,1,,,,,1,,BAO_0000218,
6218,,Intermediate,,50588,Bioavailability after peroral administration (1 mg/kg) was determined in dog,CHEMBL618877,N,1,,,,,1,,BAO_0000218,
6219,,Intermediate,,50588,Bioavailability in dog,CHEMBL618878,N,1,,,,,1,,BAO_0000218,
6220,,Intermediate,,50588,Bioavailability in dog,CHEMBL618879,N,1,,,,,1,,BAO_0000218,
6221,,Intermediate,,50588,Bioavailability after intravenous administration in dogs,CHEMBL618880,N,1,,,,,1,,BAO_0000218,
6222,,Intermediate,,50588,Bioavailability after peroral administration in dogs,CHEMBL618881,N,1,,,,,1,,BAO_0000218,
6223,,Intermediate,,50588,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),CHEMBL618882,N,1,,,,,1,,BAO_0000218,
6224,,Intermediate,,50588,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,CHEMBL624226,N,1,,,,,1,,BAO_0000218,
6225,1969.0,Intermediate,Plasma,50588,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,CHEMBL624227,N,1,,,,,1,,BAO_0000218,
6226,,Intermediate,,50588,Bioavailability,CHEMBL624228,N,1,,,,,1,,BAO_0000218,
6227,,Intermediate,,50588,Bioavailability,CHEMBL624229,N,1,,,,,1,,BAO_0000218,
6228,,Intermediate,,50588,Bioavailability by intravenous administration of 1.2 mg/kg in dog,CHEMBL624230,N,1,,,,,1,,BAO_0000218,
6229,,Intermediate,,50588,Bioavailability in dog,CHEMBL624231,N,1,,,,,1,,BAO_0000218,
6230,,Intermediate,,50588,Bioavailability in dog,CHEMBL624232,N,1,,,,,1,,BAO_0000218,
6231,,Intermediate,,50588,Bioavailability in dog,CHEMBL625127,N,1,,,,,1,,BAO_0000218,
6232,,Intermediate,,50588,Bioavailability in dog,CHEMBL625128,N,1,,,,,1,,BAO_0000218,
6233,,Intermediate,,50588,Bioavailability in dog,CHEMBL621675,N,1,,,,,1,,BAO_0000218,
6234,,Intermediate,,50588,Bioavailability in dog (p.o.) at 2.0 mpk,CHEMBL621676,N,1,,,,,1,,BAO_0000218,
6235,,Intermediate,,50588,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),CHEMBL621677,N,1,,,,,1,,BAO_0000218,
6236,,Intermediate,,50588,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL621678,N,1,,,,,1,,BAO_0000218,
6237,,Intermediate,,50588,Bioavailability in dog,CHEMBL621679,N,1,,,,,1,,BAO_0000218,
6238,,Intermediate,,50588,Bioavailability was evaluated after oral administration in dog,CHEMBL621680,N,1,,,,,1,,BAO_0000218,
6239,,Intermediate,,50588,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL621681,N,1,,,,,1,,BAO_0000218,
6240,,Intermediate,,50588,Bioavailability was evaluated in dog,CHEMBL876740,N,1,,,,,1,,BAO_0000218,
6241,,Intermediate,,50588,Bioavailability in dog,CHEMBL621682,N,1,,,,,1,,BAO_0000218,
6242,,Intermediate,,50588,Bioavailability in dog,CHEMBL621683,N,1,,,,,1,,BAO_0000218,
6243,,Intermediate,,50588,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),CHEMBL621684,N,1,,,,,1,,BAO_0000218,
6244,,Intermediate,,50588,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),CHEMBL621685,N,1,,,,,1,,BAO_0000218,
6245,,Intermediate,,50588,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),CHEMBL621686,N,1,,,,,1,,BAO_0000218,
6246,,Intermediate,,50588,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL621687,N,1,,,,,1,,BAO_0000218,
6247,,Intermediate,,50588,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,CHEMBL621688,N,1,,,,,1,,BAO_0000218,
6248,,Intermediate,,50588,Bioavailability of compound in dog was determined after peroral administration,CHEMBL621689,N,1,,,,,1,,BAO_0000218,
6249,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621690,N,1,,,,,1,,BAO_0000218,
6250,,Intermediate,,50588,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,CHEMBL621691,N,1,,,,,1,,BAO_0000218,
6251,,Intermediate,,50588,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,CHEMBL875941,N,1,,,,,1,,BAO_0000218,
6252,,Intermediate,,50588,Compound was evaluated for oral bioavailability in dogs; 37-38 %,CHEMBL621692,N,1,,,,,1,,BAO_0000218,
6253,,Intermediate,,50588,Bioavailability in dog,CHEMBL621693,N,1,,,,,1,,BAO_0000218,
6254,,Intermediate,,50588,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),CHEMBL621694,N,1,,,,,1,,BAO_0000218,
6255,948.0,Intermediate,Heart,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL621695,N,1,,,,,1,,BAO_0000218,
6256,948.0,Intermediate,Heart,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL621696,N,1,,,,,1,,BAO_0000218,
6257,2113.0,Intermediate,Kidney,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL621697,N,1,,,,,1,,BAO_0000218,
6258,2113.0,Intermediate,Kidney,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL621698,N,1,,,,,1,,BAO_0000218,
6259,2113.0,Intermediate,Kidney,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623420,N,1,,,,,1,,BAO_0000218,
6260,2113.0,Intermediate,Kidney,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623421,N,1,,,,,1,,BAO_0000218,
6261,2113.0,Intermediate,Kidney,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623422,N,1,,,,,1,,BAO_0000218,
6262,2113.0,Intermediate,Kidney,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623423,N,1,,,,,1,,BAO_0000218,
6263,2107.0,Intermediate,Liver,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623424,N,1,,,,,1,,BAO_0000218,
6264,2107.0,Intermediate,Liver,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623425,N,1,,,,,1,,BAO_0000218,
6265,2107.0,Intermediate,Liver,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623426,N,1,,,,,1,,BAO_0000218,
6266,2107.0,Intermediate,Liver,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623427,N,1,,,,,1,,BAO_0000218,
6267,2107.0,Intermediate,Liver,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623428,N,1,,,,,1,,BAO_0000218,
6268,2107.0,Intermediate,Liver,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL875947,N,1,,,,,1,,BAO_0000218,
6269,2048.0,Intermediate,Lung,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623429,N,1,,,,,1,,BAO_0000218,
6270,2048.0,Intermediate,Lung,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623430,N,1,,,,,1,,BAO_0000218,
6271,2048.0,Intermediate,Lung,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL622588,N,1,,,,,1,,BAO_0000218,
6272,2048.0,Intermediate,Lung,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL622589,N,1,,,,,1,,BAO_0000218,
6273,2048.0,Intermediate,Lung,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL622751,N,1,,,,,1,,BAO_0000218,
6274,2048.0,Intermediate,Lung,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL622752,N,1,,,,,1,,BAO_0000218,
6275,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,CHEMBL622753,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6276,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,CHEMBL622647,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6277,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,CHEMBL875163,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6278,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,CHEMBL622648,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6279,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,CHEMBL622649,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6280,955.0,Intermediate,Brain,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,CHEMBL622650,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6281,955.0,Intermediate,Brain,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,CHEMBL622651,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6282,955.0,Intermediate,Brain,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,CHEMBL622652,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6283,955.0,Intermediate,Brain,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,CHEMBL622653,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6284,955.0,Intermediate,Brain,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,CHEMBL622654,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6285,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,CHEMBL622655,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6286,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,CHEMBL622656,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6287,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,CHEMBL622657,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6288,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,CHEMBL622658,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6289,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,CHEMBL622659,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6290,2113.0,Intermediate,Kidney,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,CHEMBL624630,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6291,2113.0,Intermediate,Kidney,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,CHEMBL624631,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6292,2113.0,Intermediate,Kidney,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,CHEMBL624632,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6293,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,CHEMBL624633,N,1,646.0,A549,,,1,,BAO_0000219,
6294,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,CHEMBL624634,N,1,646.0,A549,,,1,,BAO_0000219,
6295,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),CHEMBL624635,N,1,646.0,A549,,,1,,BAO_0000219,
6296,,Intermediate,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),CHEMBL624636,N,1,646.0,A549,,,1,,BAO_0000219,
6297,,Expert,,80682,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,CHEMBL857055,N,1,646.0,A549,,,1,,BAO_0000219,
6298,,Expert,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,CHEMBL624637,N,1,646.0,A549,,,1,,BAO_0000219,
6299,,Expert,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,CHEMBL624638,N,1,646.0,A549,,,1,,BAO_0000219,
6300,,Expert,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,CHEMBL874366,N,1,646.0,A549,,,1,,BAO_0000219,
6301,,Expert,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,CHEMBL624639,N,1,646.0,A549,,,1,,BAO_0000219,
6302,,Expert,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,CHEMBL624640,N,1,646.0,A549,,,1,,BAO_0000219,
6303,,Intermediate,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,CHEMBL624641,N,1,646.0,A549,,,1,,BAO_0000219,
6304,,Intermediate,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,CHEMBL624642,N,1,646.0,A549,,,1,,BAO_0000219,
6305,,Intermediate,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,CHEMBL624643,N,1,646.0,A549,,,1,,BAO_0000219,
6306,,Intermediate,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,CHEMBL624644,N,1,646.0,A549,,,1,,BAO_0000219,
6307,,Intermediate,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,CHEMBL624645,N,1,646.0,A549,,,1,,BAO_0000219,
6308,,Intermediate,,80682,The compound was evaluated for its cytotoxic potency against A-549 cell line,CHEMBL619445,N,1,646.0,A549,,,1,,BAO_0000219,
6309,,Expert,,80682,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,CHEMBL839886,N,1,646.0,A549,,,1,,BAO_0000219,
6310,,Intermediate,,80682,Cytotoxic activity of compound against A-549 tumor cell line.,CHEMBL619446,N,1,646.0,A549,,,1,,BAO_0000219,
6311,,Intermediate,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,CHEMBL619447,N,1,646.0,A549,,,1,,BAO_0000219,
6312,,Intermediate,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,CHEMBL619448,N,1,646.0,A549,,,1,,BAO_0000219,
6313,,Intermediate,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,CHEMBL619449,N,1,646.0,A549,,,1,,BAO_0000219,
6314,,Intermediate,,80682,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,CHEMBL619450,N,1,646.0,A549,,,1,,BAO_0000219,
6315,,Intermediate,,80682,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),CHEMBL619451,N,1,646.0,A549,,,1,,BAO_0000219,
6316,,Expert,,80682,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,CHEMBL619452,N,1,646.0,A549,,,1,,BAO_0000219,
6317,,Intermediate,,80682,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,CHEMBL619453,N,1,646.0,A549,,,1,,BAO_0000219,
6318,,Intermediate,,80682,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,CHEMBL874367,N,1,646.0,A549,,,1,,BAO_0000219,
6319,,Intermediate,,80682,Cytotoxic concentration against A-549 tumor cells.,CHEMBL619454,N,1,646.0,A549,,,1,,BAO_0000219,
6320,,Intermediate,,80682,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,CHEMBL619455,N,1,646.0,A549,,,1,,BAO_0000219,
6321,,Intermediate,,80682,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",CHEMBL619456,N,1,646.0,A549,,,1,,BAO_0000219,
6322,,Expert,,50191,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,CHEMBL619457,N,1,,,,,1,,BAO_0000218,
6323,,Intermediate,,50192,Activity against Acinetobacter calcoaceticus (AC54),CHEMBL619458,N,1,,,,,1,,BAO_0000218,
6324,,Expert,,50274,In vitro antifungal activity against Aspergillus flavus CM74,CHEMBL619459,N,1,,,,,1,,BAO_0000218,
6325,,Expert,,50274,In vitro antifungal activity against Aspergillus flavus CM74,CHEMBL619460,N,1,,,,,1,,BAO_0000218,
6326,,Intermediate,,50416,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,CHEMBL619461,N,1,,,,,1,,BAO_0000218,
6327,,Intermediate,,50416,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),CHEMBL619462,N,1,,,,,1,,BAO_0000218,
6328,,Intermediate,,50416,Antimicrobial activity against Aspergillus fumigatus (MIC),CHEMBL620388,N,1,,,,,1,,BAO_0000218,
6329,,Intermediate,,50416,Antimicrobial activity against Aspergillus fumigatus (MIC),CHEMBL620389,N,1,,,,,1,,BAO_0000218,
6330,,Intermediate,,50416,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),CHEMBL620390,N,1,,,,,1,,BAO_0000218,
6331,,Expert,,50416,In vitro antifungal activity against Aspergillus fumigatus 48238E,CHEMBL620391,N,1,,,,,1,,BAO_0000218,
6332,,Expert,,50416,In vitro antifungal activity against Aspergillus fumigatus 48238E,CHEMBL621073,N,1,,,,,1,,BAO_0000218,
6333,,Intermediate,,50296,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,CHEMBL621074,N,1,,,,,1,,BAO_0000218,
6334,,Intermediate,,50366,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,CHEMBL621075,N,1,,,,,1,,BAO_0000218,
6335,,Intermediate,,50535,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),CHEMBL619554,N,1,,,,,1,,BAO_0000218,
6336,,Intermediate,,50535,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),CHEMBL619555,N,1,,,,,1,,BAO_0000218,
6337,,Intermediate,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,CHEMBL619556,N,1,,,,,1,,BAO_0000218,
6338,,Intermediate,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,CHEMBL619557,N,1,,,,,1,,BAO_0000218,
6339,,Intermediate,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,CHEMBL619558,N,1,,,,,1,,BAO_0000218,
6340,,Intermediate,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,CHEMBL619559,N,1,646.0,A549,,,1,,BAO_0000219,
6341,,Intermediate,,80682,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,CHEMBL619560,N,1,646.0,A549,,,1,,BAO_0000219,
6342,,Intermediate,,80682,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,CHEMBL619561,N,1,646.0,A549,,,1,,BAO_0000219,
6343,,Intermediate,,80682,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,CHEMBL619562,N,1,646.0,A549,,,1,,BAO_0000219,
6344,,Intermediate,,80682,% inhibition against A549 cells (lung cancer) at 4 ug/mL,CHEMBL619563,N,1,646.0,A549,,,1,,BAO_0000219,
6345,,Intermediate,,80682,GI values against A549 cells (lung cancer),CHEMBL857457,N,1,646.0,A549,,,1,,BAO_0000219,
6346,,Intermediate,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,CHEMBL619564,N,1,646.0,A549,,,1,,BAO_0000219,
6347,,Intermediate,,80682,Inhibitory activity against A549 human adenocarcinoma,CHEMBL619565,N,1,646.0,A549,,,1,,BAO_0000219,
6348,,Intermediate,,80682,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,CHEMBL619566,N,1,646.0,A549,,,1,,BAO_0000218,
6349,,Intermediate,,80682,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,CHEMBL619567,N,1,646.0,A549,,,1,,BAO_0000218,
6350,,Intermediate,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line,CHEMBL619568,N,1,646.0,A549,,,1,,BAO_0000219,
6351,,Intermediate,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,CHEMBL619569,N,1,646.0,A549,,,1,,BAO_0000219,
6352,,Intermediate,,80682,Cytotoxicity against human A549 lung cells,CHEMBL619570,N,1,646.0,A549,,,1,,BAO_0000219,
6353,,Intermediate,,80682,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,CHEMBL619571,N,1,646.0,A549,,,1,,BAO_0000218,
6354,,Expert,,80682,Growth inhibition of A549 (human lung carcinoma) cell line.,CHEMBL619572,N,1,646.0,A549,,,1,,BAO_0000219,
6355,,Expert,,80682,Effective dose required for inhibitory activity against A549 human tumor cell line.,CHEMBL619573,N,1,646.0,A549,,,1,,BAO_0000219,
6356,,Intermediate,,80682,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,CHEMBL619574,N,1,646.0,A549,,,1,,BAO_0000219,
6357,,Intermediate,,80682,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,CHEMBL619575,N,1,646.0,A549,,,1,,BAO_0000219,
6358,,Expert,,80682,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,CHEMBL619576,N,1,646.0,A549,,,1,,BAO_0000219,
6359,,Intermediate,,80682,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,CHEMBL619577,N,1,646.0,A549,,,1,,BAO_0000219,
6360,,Intermediate,,80682,In vitro inhibitory activity against A549 tumor cell culture,CHEMBL619578,N,1,646.0,A549,,,1,,BAO_0000219,
6361,,Intermediate,,80682,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,CHEMBL884009,N,1,646.0,A549,,,1,,BAO_0000219,
6362,,Intermediate,,80682,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),CHEMBL619579,N,1,646.0,A549,,,1,,BAO_0000219,
6363,,Intermediate,,80682,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,CHEMBL619580,N,1,646.0,A549,,,1,,BAO_0000219,
6364,,Intermediate,,80682,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,CHEMBL619581,N,1,646.0,A549,,,1,,BAO_0000219,
6365,,Intermediate,,80682,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,CHEMBL619582,N,1,646.0,A549,,,1,,BAO_0000219,
6366,,Intermediate,,80682,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,CHEMBL619583,N,1,646.0,A549,,,1,,BAO_0000219,
6367,,Intermediate,,80682,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,CHEMBL876502,N,1,646.0,A549,,,1,,BAO_0000219,
6368,,Intermediate,,80682,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,CHEMBL619584,N,1,646.0,A549,,,1,,BAO_0000219,
6369,,Intermediate,,80682,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,CHEMBL619585,N,1,646.0,A549,,,1,,BAO_0000219,
6370,,Intermediate,,80682,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,CHEMBL619586,N,1,646.0,A549,,,1,,BAO_0000219,
6371,,Intermediate,,80682,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,CHEMBL619587,N,1,646.0,A549,,,1,,BAO_0000219,
6372,,Intermediate,,80682,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,CHEMBL619588,N,1,646.0,A549,,,1,,BAO_0000219,
6373,,Intermediate,,80682,Tested in vitro for cytotoxicity in A549/ATCC cell lines,CHEMBL619589,N,1,646.0,A549,,,1,,BAO_0000219,
6374,,Intermediate,,80682,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,CHEMBL619590,N,1,646.0,A549,,,1,,BAO_0000219,
6375,,Intermediate,,80682,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),CHEMBL619591,N,1,646.0,A549,,,1,,BAO_0000219,
6376,,Intermediate,,80682,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,CHEMBL619592,N,1,646.0,A549,,,1,,BAO_0000219,
6377,,Intermediate,,80682,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,CHEMBL619593,N,1,646.0,A549,,,1,,BAO_0000219,
6378,,Intermediate,,80682,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,CHEMBL620217,N,1,646.0,A549,,,1,,BAO_0000219,
6379,,Intermediate,,80682,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,CHEMBL620218,N,1,646.0,A549,,,1,,BAO_0000219,
6380,,Intermediate,,80682,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,CHEMBL620219,N,1,646.0,A549,,,1,,BAO_0000219,
6381,,Intermediate,,80682,Antitumor activity against A549/ATCC cell line,CHEMBL620220,N,1,646.0,A549,,,1,,BAO_0000219,
6382,,Intermediate,,80682,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,CHEMBL625141,N,1,646.0,A549,,,1,,BAO_0000219,
6383,,Expert,,80682,In vitro cytotoxicity against A549/ATCC cell line.,CHEMBL625142,N,1,646.0,A549,,,1,,BAO_0000219,
6384,,Intermediate,,80682,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,CHEMBL625143,N,1,646.0,A549,,,1,,BAO_0000219,
6385,,Intermediate,,80682,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,CHEMBL625144,N,1,646.0,A549,,,1,,BAO_0000219,
6386,,Intermediate,,80682,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,CHEMBL622474,N,1,646.0,A549,,,1,,BAO_0000219,
6387,,Intermediate,,80682,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,CHEMBL884104,N,1,646.0,A549,,,1,,BAO_0000219,
6388,,Autocuration,,22226,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,CHEMBL622475,U,0,,,,,1,,BAO_0000219,
6389,,Intermediate,,22224,Compound was tested for oral bioavailability in dogs,CHEMBL622476,U,0,,,,,1,,BAO_0000218,
6390,,Intermediate,,50588,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,CHEMBL875831,N,1,,,,,1,,BAO_0000218,
6391,,Intermediate,,50588,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,CHEMBL622477,N,1,,,,,1,,BAO_0000218,
6392,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL622478,N,1,,,,,1,,BAO_0000218,
6393,,Intermediate,,50588,Compound was tested for the oral bioavailability in dog; No availability,CHEMBL623172,N,1,,,,,1,,BAO_0000218,
6394,,Intermediate,,50588,Oral bioavailability in dog (dose 5 mg/kg),CHEMBL623173,N,1,,,,,1,,BAO_0000218,
6395,,Intermediate,,50588,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,CHEMBL623174,N,1,,,,,1,,BAO_0000218,
6396,,Intermediate,,50588,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,CHEMBL623175,N,1,,,,,1,,BAO_0000218,
6397,,Intermediate,,50588,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),CHEMBL623340,N,1,,,,,1,,BAO_0000218,
6398,,Intermediate,,50588,Oral bioavailability in dog (dose 5 mg/kg),CHEMBL623341,N,1,,,,,1,,BAO_0000218,
6399,,Intermediate,,50588,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),CHEMBL623342,N,1,,,,,1,,BAO_0000218,
6400,,Intermediate,,50588,Oral bioavailability of active FTIs in dogs,CHEMBL623343,N,1,,,,,1,,BAO_0000218,
6401,,Intermediate,,50588,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),CHEMBL623344,N,1,,,,,1,,BAO_0000218,
6402,,Expert,,50588,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL623345,N,1,,,,,1,,BAO_0000218,
6403,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL875832,N,1,,,,,1,,BAO_0000218,
6404,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623346,N,1,,,,,1,,BAO_0000218,
6405,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623347,N,1,,,,,1,,BAO_0000218,
6406,,Intermediate,,50588,Oral bioavailability of compound was determined in dog; Not tested,CHEMBL623348,N,1,,,,,1,,BAO_0000218,
6407,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623349,N,1,,,,,1,,BAO_0000218,
6408,,Intermediate,,50588,Oral bioavailability (10 mg/kg) was determined in dog,CHEMBL623350,N,1,,,,,1,,BAO_0000218,
6409,,Intermediate,,50588,Oral bioavailability,CHEMBL623351,N,1,,,,,1,,BAO_0000218,
6410,,Intermediate,,50588,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),CHEMBL623352,N,1,,,,,1,,BAO_0000218,
6411,,Intermediate,,50588,Oral bioavailability administered in solution in rats,CHEMBL623353,N,1,,,,,1,,BAO_0000218,
6412,,Intermediate,,50588,Oral bioavailability after 30 mg/kg po dose in Dogs,CHEMBL875833,N,1,,,,,1,,BAO_0000218,
6413,,Intermediate,,50588,Oral bioavailability at a dose of 1 mg/kg in dogs,CHEMBL623354,N,1,,,,,1,,BAO_0000218,
6414,,Intermediate,,50588,Oral bioavailability in dog (dose 1 mg/kg p.o.),CHEMBL623355,N,1,,,,,1,,BAO_0000218,
6415,,Intermediate,,50588,Oral bioavailability in Dog; ND = not determined,CHEMBL623356,N,1,,,,,1,,BAO_0000218,
6416,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623357,N,1,,,,,1,,BAO_0000218,
6417,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623358,N,1,,,,,1,,BAO_0000218,
6418,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623359,N,1,,,,,1,,BAO_0000218,
6419,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623360,N,1,,,,,1,,BAO_0000218,
6420,,Intermediate,,50588,Oral bioavailability in dogs; No data,CHEMBL623361,N,1,,,,,1,,BAO_0000218,
6421,,Intermediate,,50588,Oral bioavailability measured in dogs,CHEMBL623362,N,1,,,,,1,,BAO_0000218,
6422,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623363,N,1,,,,,1,,BAO_0000218,
6423,,Intermediate,,50588,Oral bioavailability was calculated in dog,CHEMBL623364,N,1,,,,,1,,BAO_0000218,
6424,,Intermediate,,50588,Oral bioavailability after 0.3 mg/kg po administration in dog,CHEMBL875834,N,1,,,,,1,,BAO_0000218,
6425,,Intermediate,,50588,Oral bioavailability in dog (i.v. dosing),CHEMBL623365,N,1,,,,,1,,BAO_0000218,
6426,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623366,N,1,,,,,1,,BAO_0000218,
6427,,Intermediate,,50588,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,CHEMBL623367,N,1,,,,,1,,BAO_0000218,
6428,,Intermediate,,50588,Oral bioavailability in Beagle dogs,CHEMBL623368,N,1,,,,,1,,BAO_0000218,
6429,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623369,N,1,,,,,1,,BAO_0000218,
6430,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623370,N,1,,,,,1,,BAO_0000218,
6431,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623371,N,1,,,,,1,,BAO_0000218,
6432,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL623372,N,1,,,,,1,,BAO_0000218,
6433,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621351,N,1,,,,,1,,BAO_0000218,
6434,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621352,N,1,,,,,1,,BAO_0000218,
6435,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621353,N,1,,,,,1,,BAO_0000218,
6436,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621354,N,1,,,,,1,,BAO_0000218,
6437,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621355,N,1,,,,,1,,BAO_0000218,
6438,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621356,N,1,,,,,1,,BAO_0000218,
6439,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621357,N,1,,,,,1,,BAO_0000218,
6440,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621358,N,1,,,,,1,,BAO_0000218,
6441,,Intermediate,,50588,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),CHEMBL621359,N,1,,,,,1,,BAO_0000218,
6442,,Intermediate,,50588,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),CHEMBL621360,N,1,,,,,1,,BAO_0000218,
6443,,Intermediate,,50588,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),CHEMBL621361,N,1,,,,,1,,BAO_0000218,
6444,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621362,N,1,,,,,1,,BAO_0000218,
6445,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621363,N,1,,,,,1,,BAO_0000218,
6446,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621364,N,1,,,,,1,,BAO_0000218,
6447,,Intermediate,,50588,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),CHEMBL621166,N,1,,,,,1,,BAO_0000218,
6448,,Intermediate,,50588,Oral bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL621167,N,1,,,,,1,,BAO_0000218,
6449,,Intermediate,,50588,Oral bioavailability (F) in dogs,CHEMBL621168,N,1,,,,,1,,BAO_0000218,
6450,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL621169,N,1,,,,,1,,BAO_0000218,
6451,,Intermediate,,50588,Bioavailability in dog,CHEMBL875950,N,1,,,,,1,,BAO_0000218,
6452,,Intermediate,,50588,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621170,N,1,,,,,1,,BAO_0000218,
6453,,Intermediate,,50588,Oral bioavailability after peroral administration at 5 mpk in Dog,CHEMBL621171,N,1,,,,,1,,BAO_0000218,
6454,,Intermediate,,50588,Oral bioavailability in dog (dose 5 mg/kg),CHEMBL621172,N,1,,,,,1,,BAO_0000218,
6455,,Intermediate,,50588,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621173,N,1,,,,,1,,BAO_0000218,
6456,2113.0,Intermediate,Kidney,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,CHEMBL621174,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6457,2113.0,Intermediate,Kidney,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,CHEMBL621175,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6458,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,CHEMBL621176,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6459,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,CHEMBL621177,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6460,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,CHEMBL621178,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6461,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,CHEMBL621179,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6462,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,CHEMBL621180,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6463,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,CHEMBL875951,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6464,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,CHEMBL621181,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6465,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,CHEMBL621182,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6466,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,CHEMBL621183,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6467,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,CHEMBL621184,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6468,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,CHEMBL621185,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6469,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,CHEMBL621186,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6470,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,CHEMBL621187,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6471,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,CHEMBL621188,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6472,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,CHEMBL621189,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6473,2106.0,Intermediate,Spleen,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,CHEMBL621190,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6474,2106.0,Intermediate,Spleen,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,CHEMBL618520,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6475,2106.0,Intermediate,Spleen,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,CHEMBL621739,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6476,2106.0,Intermediate,Spleen,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,CHEMBL621740,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6477,2106.0,Intermediate,Spleen,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,CHEMBL621741,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6478,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,CHEMBL621742,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6479,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,CHEMBL621743,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6480,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,CHEMBL621744,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6481,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,CHEMBL621745,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6482,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,CHEMBL621746,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6483,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,CHEMBL621747,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6484,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,CHEMBL621748,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6485,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,CHEMBL621749,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6486,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,CHEMBL621750,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6487,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,CHEMBL621751,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6488,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,CHEMBL621752,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6489,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,CHEMBL621753,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6490,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,CHEMBL875955,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6491,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,CHEMBL621754,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6492,948.0,Intermediate,Heart,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,CHEMBL621755,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6493,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,CHEMBL621756,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6494,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,CHEMBL624199,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6495,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,CHEMBL624200,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6496,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,CHEMBL624375,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6497,2107.0,Intermediate,Liver,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,CHEMBL624376,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6498,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,CHEMBL624377,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6499,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,CHEMBL624378,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6500,,Intermediate,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL857901,N,1,,,,,1,,BAO_0000218,
6501,,Intermediate,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL875274,N,1,,,,,1,,BAO_0000218,
6502,,Intermediate,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL624379,N,1,,,,,1,,BAO_0000218,
6503,,Intermediate,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL624380,N,1,,,,,1,,BAO_0000218,
6504,,Intermediate,,50192,Activity against Acinetobacter calcoaceticus (AC54),CHEMBL624381,N,1,,,,,1,,BAO_0000218,
6505,,Intermediate,,50714,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,CHEMBL624382,N,1,,,,,1,,BAO_0000218,
6506,,Intermediate,,50714,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,CHEMBL624383,N,1,,,,,1,,BAO_0000218,
6507,,Intermediate,,50296,Chlorohexidine coefficient for Actinomyces naeslundii 631,CHEMBL624384,N,1,,,,,1,,BAO_0000218,
6508,,Intermediate,,50296,Chlorohexidine coefficient for Actinomyces naeslundii B74,CHEMBL624385,N,1,,,,,1,,BAO_0000218,
6509,,Intermediate,,50296,Chlorohexidine coefficient for Actinomyces naeslundii N/3,CHEMBL624386,N,1,,,,,1,,BAO_0000218,
6510,,Intermediate,,50296,Chlorohexidine coefficient for Actinomyces naeslundii N/9,CHEMBL624387,N,1,,,,,1,,BAO_0000218,
6511,,Intermediate,,50296,Plaque bactericidal index against Actinomyces naeslundii 631,CHEMBL624388,N,1,,,,,1,,BAO_0000218,
6512,,Intermediate,,50296,Plaque bactericidal index against Actinomyces naeslundii N/9,CHEMBL624389,N,1,,,,,1,,BAO_0000218,
6513,,Intermediate,,50296,Plaque bactericidal index against Actinomyces naeslundii B74,CHEMBL624390,N,1,,,,,1,,BAO_0000218,
6514,,Intermediate,,50296,Plaque bactericidal index against Actinomyces naeslundii N/3,CHEMBL875275,N,1,,,,,1,,BAO_0000218,
6515,,Intermediate,,50056,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,CHEMBL624391,N,1,,,,,1,,BAO_0000218,
6516,,Intermediate,,50056,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",CHEMBL623636,N,1,,,,,1,,BAO_0000218,
6517,,Intermediate,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,CHEMBL623637,N,1,,,,,1,,BAO_0000218,
6518,,Intermediate,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,CHEMBL623638,N,1,,,,,1,,BAO_0000218,
6519,,Intermediate,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,CHEMBL623639,N,1,,,,,1,,BAO_0000218,
6520,,Intermediate,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,CHEMBL623640,N,1,,,,,1,,BAO_0000218,
6521,,Intermediate,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,CHEMBL623641,N,1,,,,,1,,BAO_0000218,
6522,,Intermediate,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,CHEMBL623642,N,1,,,,,1,,BAO_0000218,
6523,,Intermediate,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,CHEMBL623643,N,1,,,,,1,,BAO_0000218,
6524,,Intermediate,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,CHEMBL623644,N,1,,,,,1,,BAO_0000218,
6525,,Intermediate,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,CHEMBL623645,N,1,,,,,1,,BAO_0000218,
6526,,Intermediate,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,CHEMBL623646,N,1,,,,,1,,BAO_0000218,
6527,,Intermediate,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,CHEMBL623647,N,1,,,,,1,,BAO_0000218,
6528,,Intermediate,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,CHEMBL623648,N,1,,,,,1,,BAO_0000218,
6529,,Intermediate,,50366,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,CHEMBL623649,N,1,,,,,1,,BAO_0000218,
6530,,Intermediate,,50366,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,CHEMBL623650,N,1,,,,,1,,BAO_0000218,
6531,,Intermediate,,50366,Chlorohexidine coefficient for Actinomyces viscosus 8A06,CHEMBL623651,N,1,,,,,1,,BAO_0000218,
6532,,Expert,,50366,Chlorohexidine coefficient for Actinomyces viscosus M-100,CHEMBL623652,N,1,,,,,1,,BAO_0000218,
6533,,Intermediate,,50366,Chlorohexidine coefficient for Actinomyces viscosus M-626,CHEMBL623653,N,1,,,,,1,,BAO_0000218,
6534,,Intermediate,,50366,Chlorohexidine coefficient for Actinomyces viscosus T14V,CHEMBL623654,N,1,,,,,1,,BAO_0000218,
6535,,Intermediate,,50366,Plaque bactericidal index against Actinomyces viscosus 8A06,CHEMBL623655,N,1,,,,,1,,BAO_0000218,
6536,,Intermediate,,50366,Plaque bactericidal index against Actinomyces viscosus M-100,CHEMBL623656,N,1,,,,,1,,BAO_0000218,
6537,,Expert,,50366,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,CHEMBL623657,N,1,,,,,1,,BAO_0000218,
6538,,Intermediate,,50366,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",CHEMBL623658,N,1,,,,,1,,BAO_0000218,
6539,,Intermediate,,50366,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",CHEMBL623659,N,1,,,,,1,,BAO_0000218,
6540,,Intermediate,,50366,Plaque bactericidal index against Actinomyces viscosus 626,CHEMBL623660,N,1,,,,,1,,BAO_0000218,
6541,,Intermediate,,50366,Plaque bactericidal index against Actinomyces viscosus T14V,CHEMBL623661,N,1,,,,,1,,BAO_0000218,
6542,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,CHEMBL875281,N,1,,,,,1,,BAO_0000218,
6543,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,CHEMBL623662,N,1,,,,,1,,BAO_0000218,
6544,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,CHEMBL623663,N,1,,,,,1,,BAO_0000218,
6545,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,CHEMBL623664,N,1,,,,,1,,BAO_0000218,
6546,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,CHEMBL623665,N,1,,,,,1,,BAO_0000218,
6547,,Intermediate,,80023,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,CHEMBL621856,N,1,165.0,A673,,,1,,BAO_0000219,
6548,,Intermediate,,80661,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,CHEMBL620432,N,1,645.0,A704,,,1,,BAO_0000219,
6549,,Autocuration,,22226,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,CHEMBL620433,U,0,,,,,1,,BAO_0000219,
6550,,Intermediate,,80024,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,CHEMBL620434,N,1,625.0,A9,,,1,,BAO_0000219,
6551,,Intermediate,,80024,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,CHEMBL620435,N,1,625.0,A9,,,1,,BAO_0000219,
6552,,Intermediate,,80024,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,CHEMBL620436,N,1,625.0,A9,,,1,,BAO_0000219,
6553,,Intermediate,,80024,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,CHEMBL876597,N,1,625.0,A9,,,1,,BAO_0000219,
6554,,Expert,,81037,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,CHEMBL620437,N,1,874.0,Human ovarian carcinoma cell line,,,1,,BAO_0000219,
6555,,Expert,,80024,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",CHEMBL620438,N,1,625.0,A9,,,1,,BAO_0000219,
6556,,Expert,,80024,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,CHEMBL620439,N,1,625.0,A9,,,1,,BAO_0000219,
6557,,Expert,,80024,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,CHEMBL619657,N,1,625.0,A9,,,1,,BAO_0000219,
6558,,Intermediate,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,CHEMBL619658,N,1,625.0,A9,,,1,,BAO_0000219,
6559,,Intermediate,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,CHEMBL619659,N,1,625.0,A9,,,1,,BAO_0000219,
6560,,Expert,,10649,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",CHEMBL619660,H,8,,,,,1,,BAO_0000019,
6561,,Intermediate,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,CHEMBL619661,N,1,625.0,A9,,,1,,BAO_0000219,
6562,,Intermediate,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,CHEMBL619662,N,1,625.0,A9,,,1,,BAO_0000219,
6563,,Intermediate,,80663,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,CHEMBL619663,N,1,975.0,AA6,,,1,,BAO_0000219,
6564,,Autocuration,,22226,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,CHEMBL619664,U,0,,,,,1,,BAO_0000219,
6565,,Autocuration,,22226,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",CHEMBL619665,U,0,,,,,1,,BAO_0000219,
6566,,Intermediate,,80662,Anti -HIV activity was measured against AA5/HIV-1(IIIB),CHEMBL883244,N,1,974.0,AA5,,,1,,BAO_0000219,
6567,,Intermediate,,80662,Cytotoxicity was measured against AA5/HIV-1(IIIB),CHEMBL884011,N,1,974.0,AA5,,,1,,BAO_0000219,
6568,,Intermediate,,80662,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,CHEMBL619666,N,1,974.0,AA5,,,1,,BAO_0000219,
6569,,Intermediate,,80566,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,CHEMBL619667,N,1,379.0,U-937,,,1,,BAO_0000219,
6570,,Intermediate,,80578,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,CHEMBL619668,N,1,274.0,UV4,,,1,,BAO_0000219,
6571,,Expert,,80089,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",CHEMBL619669,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6572,,Intermediate,,80089,Average intracellular compound concentration when the hypoxic SER=1.6,CHEMBL876608,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6573,,Intermediate,,80089,Average intracellular compound concentration when the hypoxic SER=1.6.,CHEMBL619670,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6574,,Intermediate,,80089,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,CHEMBL619671,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6575,,Intermediate,,80089,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,CHEMBL619672,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6576,,Intermediate,,80089,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,CHEMBL619673,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6577,,Intermediate,,80089,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",CHEMBL619674,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6578,,Intermediate,,80089,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",CHEMBL619675,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6579,,Intermediate,,80089,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,CHEMBL619676,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6580,,Intermediate,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,CHEMBL619677,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6581,,Intermediate,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,CHEMBL619678,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6582,,Intermediate,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,CHEMBL619679,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6583,,Expert,,80089,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,CHEMBL619680,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6584,,Intermediate,,80089,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,CHEMBL621457,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6585,,Expert,,80089,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,CHEMBL876609,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6586,,Intermediate,,80089,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,CHEMBL621458,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6587,,Expert,,80089,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,CHEMBL621459,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6588,,Expert,,80089,Aerobic growth inhibition in Chinese hamster cell line AA8,CHEMBL621460,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6589,,Expert,,80089,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,CHEMBL621461,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6590,,Expert,,80089,Inhibition of growth under aerobic conditions in AA8 cells,CHEMBL621462,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6591,,Intermediate,,50588,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621463,N,1,,,,,1,,BAO_0000218,
6592,,Intermediate,,50588,Oral bioavailability in dog at 10 mg/kg of the compound,CHEMBL621464,N,1,,,,,1,,BAO_0000218,
6593,,Intermediate,,50588,Oral bioavailability in dog (dose 5 uM/kg),CHEMBL621465,N,1,,,,,1,,BAO_0000218,
6594,,Intermediate,,50588,Oral bioavailability in dog (dose 5 uM/kg),CHEMBL621466,N,1,,,,,1,,BAO_0000218,
6595,,Intermediate,,50588,Oral bioavailability in dog (mongrel),CHEMBL621467,N,1,,,,,1,,BAO_0000218,
6596,,Intermediate,,50588,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621468,N,1,,,,,1,,BAO_0000218,
6597,,Intermediate,,50588,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL876734,N,1,,,,,1,,BAO_0000218,
6598,,Intermediate,,50588,Bioavailability in dog,CHEMBL618476,N,1,,,,,1,,BAO_0000218,
6599,,Intermediate,,50588,Bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL618477,N,1,,,,,1,,BAO_0000218,
6600,,Intermediate,,50588,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),CHEMBL618478,N,1,,,,,1,,BAO_0000218,
6601,,Intermediate,,50588,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,CHEMBL618479,N,1,,,,,1,,BAO_0000218,
6602,,Intermediate,,50588,Bioavailability in dog,CHEMBL618480,N,1,,,,,1,,BAO_0000218,
6603,,Intermediate,,50588,Bioavailability in dog (dose 3-10 mg/kg),CHEMBL618481,N,1,,,,,1,,BAO_0000218,
6604,1969.0,Intermediate,Plasma,50588,The compound was tested for bioavailability of compound in plasma of dog; Complete,CHEMBL618482,N,1,,,,,1,,BAO_0000218,
6605,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL618483,N,1,,,,,1,,BAO_0000218,
6606,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL618484,N,1,,,,,1,,BAO_0000218,
6607,,Intermediate,,50588,Bioavailability in dog,CHEMBL618485,N,1,,,,,1,,BAO_0000218,
6608,,Intermediate,,50588,oral bioavailability was measured in dogs,CHEMBL618486,N,1,,,,,1,,BAO_0000218,
6609,,Intermediate,,50588,Compound was tested for plasma protein binding in dog; Not determined,CHEMBL618487,N,1,,,,,1,,BAO_0000218,
6610,,Intermediate,,50588,Compound was tested for plasma protein binding of dog,CHEMBL618488,N,1,,,,,1,,BAO_0000218,
6611,,Intermediate,,50588,Compound was tested for plasma protein binding of dog; Not determined,CHEMBL876735,N,1,,,,,1,,BAO_0000218,
6612,,Intermediate,,50588,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,CHEMBL618489,N,1,,,,,1,,BAO_0000218,
6613,,Intermediate,,50588,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,CHEMBL618490,N,1,,,,,1,,BAO_0000218,
6614,,Intermediate,,50588,Half life was determined,CHEMBL618491,N,1,,,,,1,,BAO_0000218,
6615,,Intermediate,,50588,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,CHEMBL618492,N,1,,,,,1,,BAO_0000218,
6616,,Intermediate,,50588,Half life was evaluated in dog,CHEMBL873354,N,1,,,,,1,,BAO_0000218,
6617,,Intermediate,,50588,Half life was determined,CHEMBL618493,N,1,,,,,1,,BAO_0000218,
6618,,Intermediate,,50588,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618494,N,1,,,,,1,,BAO_0000218,
6619,948.0,Intermediate,Heart,50588,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618495,N,1,,,,,1,,BAO_0000218,
6620,2113.0,Intermediate,Kidney,50588,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618496,N,1,,,,,1,,BAO_0000218,
6621,2107.0,Intermediate,Liver,50588,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618497,N,1,,,,,1,,BAO_0000218,
6622,2048.0,Intermediate,Lung,50588,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618498,N,1,,,,,1,,BAO_0000218,
6623,2106.0,Intermediate,Spleen,50588,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618499,N,1,,,,,1,,BAO_0000218,
6624,,Intermediate,,50588,LogP in dog,CHEMBL876736,N,1,,,,,1,,BAO_0000218,
6625,,Intermediate,,50588,Partition coefficient (logP),CHEMBL618500,N,1,,,,,1,,BAO_0000218,
6626,,Intermediate,,50588,Partition coefficient in dog,CHEMBL857831,N,1,,,,,1,,BAO_0000218,
6627,,Intermediate,,50588,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,CHEMBL618501,N,1,,,,,1,,BAO_0000218,
6628,,Intermediate,,50588,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),CHEMBL618502,N,1,,,,,1,,BAO_0000218,
6629,,Intermediate,,50588,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,CHEMBL618503,N,1,,,,,1,,BAO_0000218,
6630,,Intermediate,,50588,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),CHEMBL618504,N,1,,,,,1,,BAO_0000218,
6631,,Intermediate,,50588,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),CHEMBL618505,N,1,,,,,1,,BAO_0000218,
6632,,Intermediate,,50588,Metabolism of compound in dog S9 microsomes; Trace,CHEMBL618506,N,1,,,,,1,,BAO_0000218,
6633,2107.0,Intermediate,Liver,50588,In vitro metabolic potential in dog liver microsomes,CHEMBL618507,N,1,,,,,1,,BAO_0000218,
6634,,Intermediate,,50588,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,CHEMBL876737,N,1,,,,,1,,BAO_0000218,
6635,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL618508,N,1,,,,,1,,BAO_0000218,
6636,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL618509,N,1,,,,,1,,BAO_0000218,
6637,,Intermediate,,50588,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL618510,N,1,,,,,1,,BAO_0000218,
6638,,Intermediate,,50588,The compound was tested for bioavailability in dogs,CHEMBL618511,N,1,,,,,1,,BAO_0000218,
6639,,Intermediate,,50588,The compound was tested for oral bioavailability in dogs,CHEMBL618512,N,1,,,,,1,,BAO_0000218,
6640,,Intermediate,,50588,Oral bioavailability in dog,CHEMBL618513,N,1,,,,,1,,BAO_0000218,
6641,,Intermediate,,50588,Compound was tested for percent protein binding (PB) in dog,CHEMBL618514,N,1,,,,,1,,BAO_0000218,
6642,,Intermediate,,50588,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,CHEMBL620052,N,1,,,,,1,,BAO_0000218,
6643,1969.0,Intermediate,Plasma,50588,Compound was evaluated for plasma clearance.,CHEMBL620053,N,1,,,,,1,,BAO_0000218,
6644,1969.0,Intermediate,Plasma,50588,The compound was tested for plasma clearance in dog,CHEMBL620054,N,1,,,,,1,,BAO_0000218,
6645,1969.0,Intermediate,Plasma,50588,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,CHEMBL620055,N,1,,,,,1,,BAO_0000218,
6646,,Intermediate,,50588,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,CHEMBL620056,N,1,,,,,1,,BAO_0000218,
6647,2107.0,Intermediate,Liver,50588,In vitro relative rate of metabolism was determined in dog liver microsomes,CHEMBL620057,N,1,,,,,1,,BAO_0000218,
6648,,Intermediate,,50588,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,CHEMBL618939,N,1,,,,,1,,BAO_0000218,
6649,,Intermediate,,50588,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,CHEMBL618940,N,1,,,,,1,,BAO_0000218,
6650,,Intermediate,,50588,Half life after intravenous administration in dogs at 1.2 uM/kg,CHEMBL618941,N,1,,,,,1,,BAO_0000218,
6651,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,CHEMBL624473,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6652,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,CHEMBL624474,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6653,2048.0,Intermediate,Lung,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,CHEMBL624475,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6654,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,CHEMBL624476,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6655,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,CHEMBL623478,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6656,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,CHEMBL623479,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6657,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,CHEMBL623480,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6658,,Intermediate,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,CHEMBL623481,N,1,42.0,CCRF S-180,,,1,,BAO_0000218,
6659,955.0,Intermediate,Brain,50594,C2 in brain of mice at the oral dose of 50 mg/kg,CHEMBL623482,N,1,,,,,1,,BAO_0000218,
6660,2113.0,Intermediate,Kidney,50594,C2 in kidney of mice at the oral dose of 50 mg/kg,CHEMBL623483,N,1,,,,,1,,BAO_0000218,
6661,2107.0,Intermediate,Liver,50594,C2 in liver of mice at the oral dose of 50 mg/kg,CHEMBL623484,N,1,,,,,1,,BAO_0000218,
6662,2048.0,Intermediate,Lung,50594,C2 in lungs of mice at the oral dose of 50 mg/kg,CHEMBL623485,N,1,,,,,1,,BAO_0000218,
6663,2106.0,Intermediate,Spleen,50594,C2 in spleen of mice at the oral dose of 50 mg/kg,CHEMBL623486,N,1,,,,,1,,BAO_0000218,
6664,,Intermediate,,50594,Plasma clearance in mouse,CHEMBL623487,N,1,,,,,1,,BAO_0000218,
6665,,Intermediate,,50594,Clearance of compound after intravenous administration in mice at 24 uM/kg,CHEMBL623488,N,1,,,,,1,,BAO_0000218,
6666,,Intermediate,,50594,Clearance from mouse blood following i.v. administration of 10 mg/kg,CHEMBL623489,N,1,,,,,1,,BAO_0000218,
6667,,Intermediate,,50594,Clearance was evaluated in mice after intravenous administration,CHEMBL875157,N,1,,,,,1,,BAO_0000218,
6668,,Intermediate,,50594,Clearance was evaluated in mice after oral administration,CHEMBL623490,N,1,,,,,1,,BAO_0000218,
6669,,Intermediate,,50594,Pharmacokinetic property (Plasma clearance) was measured in mouse,CHEMBL623491,N,1,,,,,1,,BAO_0000218,
6670,,Intermediate,,50594,Plasma clearance of compound was determined at 40 mg/Kg,CHEMBL623492,N,1,,,,,1,,BAO_0000218,
6671,,Intermediate,,50594,Plasma clearance of at 24 mg/Kg,CHEMBL623493,N,1,,,,,1,,BAO_0000218,
6672,,Intermediate,,50594,Plasma clearance at 24 mg/Kg,CHEMBL623494,N,1,,,,,1,,BAO_0000218,
6673,,Intermediate,,50594,Plasma clearance at 5 mg/Kg,CHEMBL623495,N,1,,,,,1,,BAO_0000218,
6674,,Intermediate,,50594,Plasma clearance in mice,CHEMBL623496,N,1,,,,,1,,BAO_0000218,
6675,,Intermediate,,50594,Plasma clearance value upon iv administration in mouse,CHEMBL623497,N,1,,,,,1,,BAO_0000218,
6676,1969.0,Intermediate,Plasma,50594,Total plasma clearance in mice,CHEMBL623498,N,1,,,,,1,,BAO_0000218,
6677,,Intermediate,,50594,Clearance in mouse,CHEMBL623499,N,1,,,,,1,,BAO_0000218,
6678,,Intermediate,,50594,Clearance value was determined,CHEMBL623500,N,1,,,,,1,,BAO_0000218,
6679,,Intermediate,,50594,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL623501,N,1,,,,,1,,BAO_0000218,
6680,,Intermediate,,22229,Calculated partition coefficient (clogP),CHEMBL875158,U,0,,,,,1,,BAO_0000100,
6681,,Intermediate,,50594,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,CHEMBL623502,N,1,,,,,1,,BAO_0000218,
6682,,Intermediate,,50594,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,CHEMBL623503,N,1,,,,,1,,BAO_0000218,
6683,,Intermediate,,50594,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL623504,N,1,,,,,1,,BAO_0000218,
6684,,Intermediate,,50594,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,CHEMBL623505,N,1,,,,,1,,BAO_0000218,
6685,,Intermediate,,50594,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,CHEMBL623506,N,1,,,,,1,,BAO_0000218,
6686,,Intermediate,,50594,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,CHEMBL623507,N,1,,,,,1,,BAO_0000218,
6687,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,CHEMBL623508,N,1,,,,,1,,BAO_0000218,
6688,,Intermediate,,50594,Cmax after oral administration at 30 mg/kg in ICR mouse,CHEMBL623509,N,1,,,,,1,,BAO_0000218,
6689,,Intermediate,,50594,Cmax after peroral administration in mice at 2.4 uM/kg,CHEMBL875159,N,1,,,,,1,,BAO_0000218,
6690,955.0,Intermediate,Brain,50594,Cmax in brain of mice at the oral dose of 50 mg/kg,CHEMBL623510,N,1,,,,,1,,BAO_0000218,
6691,2113.0,Intermediate,Kidney,50594,Cmax in kidney of mice at the oral dose of 50 mg/kg,CHEMBL623511,N,1,,,,,1,,BAO_0000218,
6692,2107.0,Intermediate,Liver,50594,Cmax in liver of mice at the oral dose of 50 mg/kg,CHEMBL623512,N,1,,,,,1,,BAO_0000218,
6693,2048.0,Intermediate,Lung,50594,Cmax in lungs of mice at the oral dose of 50 mg/kg,CHEMBL623513,N,1,,,,,1,,BAO_0000218,
6694,,Intermediate,,50594,Cmax in mice at 18 uM/kg i.p. administration,CHEMBL623514,N,1,,,,,1,,BAO_0000218,
6695,,Intermediate,,50594,Cmax in mice at 23 uM/kg i.v. administration,CHEMBL622609,N,1,,,,,1,,BAO_0000218,
6696,,Intermediate,,50594,Cmax in mice at 24 uM/kg i.p. administration,CHEMBL622610,N,1,,,,,1,,BAO_0000218,
6697,,Intermediate,,50594,Cmax in mice at 25 uM/kg i.p. administration,CHEMBL621823,N,1,,,,,1,,BAO_0000218,
6698,,Intermediate,,50594,Cmax in mice at 26 uM/kg i.p. administration,CHEMBL621824,N,1,,,,,1,,BAO_0000218,
6699,2106.0,Intermediate,Spleen,50594,Cmax in spleen of mice at the oral dose of 50 mg/kg,CHEMBL621825,N,1,,,,,1,,BAO_0000218,
6700,,Intermediate,,50594,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL621826,N,1,,,,,1,,BAO_0000218,
6701,,Intermediate,,50594,Cmax value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL621827,N,1,,,,,1,,BAO_0000218,
6702,,Intermediate,,50594,Cmax value was determined,CHEMBL621828,N,1,,,,,1,,BAO_0000218,
6703,,Intermediate,,50594,Cmax value in IRC mice,CHEMBL621829,N,1,,,,,1,,BAO_0000218,
6704,,Intermediate,,50594,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,CHEMBL621830,N,1,,,,,1,,BAO_0000218,
6705,,Intermediate,,50594,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,CHEMBL621831,N,1,,,,,1,,BAO_0000218,
6706,1969.0,Intermediate,Plasma,50594,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,CHEMBL621832,N,1,,,,,1,,BAO_0000218,
6707,1969.0,Intermediate,Plasma,50594,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",CHEMBL624579,N,1,,,,,1,,BAO_0000218,
6708,,Intermediate,,50594,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,CHEMBL624580,N,1,,,,,1,,BAO_0000218,
6709,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,CHEMBL624581,N,1,,,,,1,,BAO_0000218,
6710,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,CHEMBL624582,N,1,,,,,1,,BAO_0000218,
6711,,Intermediate,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,CHEMBL624583,N,1,,,,,1,,BAO_0000218,
6712,,Intermediate,,80018,Inhibitory activity against human tumor cell line A0375 melanoma.,CHEMBL624584,N,1,455.0,A-375,,,1,,BAO_0000219,
6713,,Expert,,12512,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,CHEMBL624585,D,9,,,,Brain membranes,1,,BAO_0000249,
6714,,Expert,,114,Forskolin-induced cAMP production at human A1 adenosine receptor,CHEMBL875165,D,9,,,,,1,,BAO_0000019,
6715,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,CHEMBL619490,H,8,449.0,CHO,,,1,,BAO_0000219,
6716,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,CHEMBL619491,H,8,449.0,CHO,,,1,,BAO_0000219,
6717,,Expert,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,CHEMBL619492,H,8,449.0,CHO,,,1,,BAO_0000219,
6718,,Expert,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,CHEMBL619493,H,8,449.0,CHO,,,1,,BAO_0000219,
6719,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,CHEMBL619494,H,8,449.0,CHO,,,1,,BAO_0000219,
6720,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,CHEMBL619495,H,8,449.0,CHO,,,1,,BAO_0000219,
6721,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,CHEMBL619496,H,8,449.0,CHO,,,1,,BAO_0000219,
6722,,Expert,,114,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,CHEMBL619497,D,9,449.0,CHO,,,1,,BAO_0000219,
6723,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,CHEMBL619498,H,8,449.0,CHO,,,1,,BAO_0000219,
6724,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,CHEMBL619499,H,8,449.0,CHO,,,1,,BAO_0000219,
6725,,Expert,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,CHEMBL619500,H,8,449.0,CHO,,,1,,BAO_0000219,
6726,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,CHEMBL619501,H,8,449.0,CHO,,,1,,BAO_0000219,
6727,,Expert,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,CHEMBL619502,H,8,449.0,CHO,,,1,,BAO_0000219,
6728,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,CHEMBL619503,H,8,449.0,CHO,,,1,,BAO_0000219,
6729,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,CHEMBL619504,H,8,449.0,CHO,,,1,,BAO_0000219,
6730,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,CHEMBL621298,H,8,449.0,CHO,,,1,,BAO_0000219,
6731,,Expert,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,CHEMBL621299,H,8,449.0,CHO,,,1,,BAO_0000219,
6732,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,CHEMBL621300,H,8,449.0,CHO,,,1,,BAO_0000219,
6733,,Autocuration,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,CHEMBL621301,H,8,449.0,CHO,,,1,,BAO_0000219,
6734,,Expert,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,CHEMBL621302,H,8,449.0,CHO,,,1,,BAO_0000219,
6735,,Intermediate,,80013,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,CHEMBL621303,N,1,164.0,A10,,,1,,BAO_0000219,
6736,,Autocuration,,22226,In vitro potassium channel opening activity in A10 (smooth muscle) cells,CHEMBL621304,U,0,164.0,A10,,,1,,BAO_0000219,
6737,,Autocuration,,22226,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,CHEMBL621305,U,0,164.0,A10,,,1,,BAO_0000219,
6738,,Intermediate,,80013,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,CHEMBL621306,N,1,164.0,A10,,,1,,BAO_0000219,
6739,,Intermediate,,80013,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,CHEMBL618444,N,1,164.0,A10,,,1,,BAO_0000219,
6740,,Intermediate,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,CHEMBL618445,N,1,164.0,A10,,,1,,BAO_0000219,
6741,,Intermediate,,80089,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,CHEMBL618446,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6742,,Intermediate,,80089,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,CHEMBL618447,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6743,,Intermediate,,80089,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,CHEMBL618448,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6744,,Intermediate,,80089,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,CHEMBL618449,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6745,,Intermediate,,80089,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,CHEMBL618637,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6746,,Intermediate,,80089,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",CHEMBL618638,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6747,,Intermediate,,80089,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),CHEMBL618639,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6748,,Expert,,80089,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",CHEMBL618640,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6749,,Expert,,80089,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,CHEMBL618641,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6750,,Intermediate,,80089,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,CHEMBL618642,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6751,,Intermediate,,80089,Inhibitory activity against aerobic growth of AA8 cells.,CHEMBL618643,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6752,,Intermediate,,80089,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHEMBL884013,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6753,,Expert,,80089,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHEMBL622723,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6754,,Intermediate,,80089,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHEMBL622724,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6755,,Expert,,80089,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,CHEMBL622725,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6756,,Expert,,80089,Cytotoxicity against AA8 cell line,CHEMBL622726,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6757,,Intermediate,,80089,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),CHEMBL622727,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6758,,Intermediate,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHEMBL622728,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6759,,Intermediate,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHEMBL622729,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6760,,Intermediate,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHEMBL622730,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6761,,Intermediate,,80089,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,CHEMBL622731,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6762,,Intermediate,,80089,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,CHEMBL622732,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6763,,Intermediate,,80089,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,CHEMBL622733,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6764,,Autocuration,,22224,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),CHEMBL622734,U,0,,,,,1,,BAO_0000218,
6765,,Expert,,80089,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,CHEMBL622735,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6766,,Autocuration,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,CHEMBL618746,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6767,,Autocuration,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,CHEMBL618747,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6768,,Autocuration,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,CHEMBL620540,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6769,,Autocuration,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,CHEMBL620541,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6770,,Autocuration,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,CHEMBL620542,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6771,,Autocuration,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,CHEMBL620543,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6772,,Autocuration,,22224,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,CHEMBL618832,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6773,,Expert,,80089,Concentration required to reduce AA8 cell survival by 10%,CHEMBL618833,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6774,,Autocuration,,22224,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",CHEMBL618834,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6775,,Autocuration,,22224,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,CHEMBL618835,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6776,,Autocuration,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,CHEMBL618836,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6777,,Autocuration,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,CHEMBL618837,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6778,,Autocuration,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,CHEMBL618838,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6779,,Autocuration,,22224,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,CHEMBL618839,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6780,,Autocuration,,22224,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,CHEMBL618840,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6781,,Autocuration,,22224,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",CHEMBL618841,U,0,,,,,1,,BAO_0000019,
6782,,Autocuration,,22224,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,CHEMBL618842,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6783,,Autocuration,,22224,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,CHEMBL618843,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6784,,Intermediate,,50588,Half life period after 15 mg/kg iv dose in Dogs,CHEMBL618844,N,1,,,,,1,,BAO_0000218,
6785,,Intermediate,,50588,Half life period after 30 mg/kg po dose in Dogs,CHEMBL618845,N,1,,,,,1,,BAO_0000218,
6786,,Intermediate,,50588,Half life was measured after oral 2b administration (tested in 6 dogs),CHEMBL618846,N,1,,,,,1,,BAO_0000218,
6787,,Intermediate,,50588,Half life was measured in dog after oral 17b administration,CHEMBL618847,N,1,,,,,1,,BAO_0000218,
6788,,Intermediate,,50588,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,CHEMBL618848,N,1,,,,,1,,BAO_0000218,
6789,,Intermediate,,50588,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,CHEMBL618849,N,1,,,,,1,,BAO_0000218,
6790,,Intermediate,,50588,Tmax value after 15 mg/kg iv dose in Dogs,CHEMBL618850,N,1,,,,,1,,BAO_0000218,
6791,,Intermediate,,50588,Tmax value after 30 mg/kg po dose in Dogs,CHEMBL618851,N,1,,,,,1,,BAO_0000218,
6792,,Intermediate,,50588,Compound was evaluated for its half life when administered intravenously in dog,CHEMBL873815,N,1,,,,,1,,BAO_0000218,
6793,1969.0,Intermediate,Plasma,50588,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),CHEMBL618852,N,1,,,,,1,,BAO_0000218,
6794,,Intermediate,,50588,Elimination Half-life of compound was determined in dog,CHEMBL618853,N,1,,,,,1,,BAO_0000218,
6795,,Intermediate,,50588,Half life of compound in dog following oral administration,CHEMBL618854,N,1,,,,,1,,BAO_0000218,
6796,,Intermediate,,50588,Half life of compound was determined in dog,CHEMBL618855,N,1,,,,,1,,BAO_0000218,
6797,178.0,Intermediate,Blood,50588,Half life of compound was determined in dog blood,CHEMBL618856,N,1,,,,,1,,BAO_0000218,
6798,,Intermediate,,50588,Half life after oral and iv dosing in dogs,CHEMBL875827,N,1,,,,,1,,BAO_0000218,
6799,,Intermediate,,50588,Half life in dogs in hours,CHEMBL618857,N,1,,,,,1,,BAO_0000218,
6800,,Intermediate,,50588,Half life on i.v. administration of 2 mg/kg was measured in dog,CHEMBL618858,N,1,,,,,1,,BAO_0000218,
6801,,Intermediate,,50588,t1/2 in dog after oral dose (1 mg/kg),CHEMBL618859,N,1,,,,,1,,BAO_0000218,
6802,,Intermediate,,50588,Half life was evaluated in dog,CHEMBL618860,N,1,,,,,1,,BAO_0000218,
6803,,Intermediate,,50588,Half life period of compound was determined after intravenous administration at 2 mg/kg,CHEMBL618861,N,1,,,,,1,,BAO_0000218,
6804,,Intermediate,,50588,Half life period of compound was determined after peroral administration at 2 mg/kg,CHEMBL622539,N,1,,,,,1,,BAO_0000218,
6805,,Intermediate,,50588,Half life period (10 mg/kg) was determined in dog,CHEMBL622540,N,1,,,,,1,,BAO_0000218,
6806,,Intermediate,,50588,Half life period (10 mg/kg) was determined in dog,CHEMBL873803,N,1,,,,,1,,BAO_0000218,
6807,,Intermediate,,50588,Half life period by iv administration in dog at a dose of 0.3 mg/kg,CHEMBL873804,N,1,,,,,1,,BAO_0000218,
6808,,Intermediate,,50588,Half life period by po administration in dog at a dose of 0.3 mg/kg,CHEMBL624311,N,1,,,,,1,,BAO_0000218,
6809,,Intermediate,,50588,Half life period in dog,CHEMBL624312,N,1,,,,,1,,BAO_0000218,
6810,,Intermediate,,50588,Half life period in dogs after oral administration at 1 mg/kg,CHEMBL624313,N,1,,,,,1,,BAO_0000218,
6811,,Intermediate,,50588,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL624314,N,1,,,,,1,,BAO_0000218,
6812,,Intermediate,,50588,Half-life of compound was determined in dogs,CHEMBL624315,N,1,,,,,1,,BAO_0000218,
6813,1969.0,Intermediate,Plasma,50588,Half-life in dog plasma,CHEMBL624316,N,1,,,,,1,,BAO_0000218,
6814,,Intermediate,,50588,Half-life in mongrel dogs was determined,CHEMBL624317,N,1,,,,,1,,BAO_0000218,
6815,,Intermediate,,50588,Half-life in dog upon oral administration,CHEMBL624318,N,1,,,,,1,,BAO_0000218,
6816,,Intermediate,,50588,Half-life in dog upon oral administration; Unable to calculate,CHEMBL624319,N,1,,,,,1,,BAO_0000218,
6817,,Intermediate,,50588,Half-life was measured in dog,CHEMBL624496,N,1,,,,,1,,BAO_0000218,
6818,,Intermediate,,50588,Half-life was measured in dog,CHEMBL624497,N,1,,,,,1,,BAO_0000218,
6819,,Intermediate,,50588,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,CHEMBL624498,N,1,,,,,1,,BAO_0000218,
6820,,Intermediate,,50588,Oral half life was determined,CHEMBL624499,N,1,,,,,1,,BAO_0000218,
6821,1969.0,Intermediate,Plasma,50588,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,CHEMBL624500,N,1,,,,,1,,BAO_0000218,
6822,1969.0,Intermediate,Plasma,50588,Plasma half life was evaluated,CHEMBL624501,N,1,,,,,1,,BAO_0000218,
6823,1969.0,Intermediate,Plasma,50588,Plasma half life was evaluated in Dog,CHEMBL623666,N,1,,,,,1,,BAO_0000218,
6824,1969.0,Intermediate,Plasma,50588,Plasma half life was evaluated in dog,CHEMBL623667,N,1,,,,,1,,BAO_0000218,
6825,,Intermediate,,50588,T1/2 (Half-life) was after oral administration at 5 mg/kg,CHEMBL623668,N,1,,,,,1,,BAO_0000218,
6826,,Intermediate,,50588,Tested for the half life value in dog,CHEMBL623669,N,1,,,,,1,,BAO_0000218,
6827,,Intermediate,,50588,Maximum time at the dose of 2 mg/kg in dog,CHEMBL623670,N,1,,,,,1,,BAO_0000218,
6828,,Intermediate,,50588,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL623671,N,1,,,,,1,,BAO_0000218,
6829,178.0,Intermediate,Blood,50588,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL875945,N,1,,,,,1,,BAO_0000218,
6830,178.0,Intermediate,Blood,50588,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL623672,N,1,,,,,1,,BAO_0000218,
6831,,Intermediate,,50588,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,CHEMBL623673,N,1,,,,,1,,BAO_0000218,
6832,,Intermediate,,50588,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),CHEMBL623674,N,1,,,,,1,,BAO_0000218,
6833,,Intermediate,,50588,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,CHEMBL623675,N,1,,,,,1,,BAO_0000218,
6834,,Intermediate,,50588,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",CHEMBL872526,N,1,,,,,1,,BAO_0000218,
6835,,Intermediate,,50588,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",CHEMBL623676,N,1,,,,,1,,BAO_0000218,
6836,1969.0,Intermediate,Plasma,50588,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,CHEMBL623677,N,1,,,,,1,,BAO_0000218,
6837,1969.0,Intermediate,Plasma,50588,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,CHEMBL623678,N,1,,,,,1,,BAO_0000218,
6838,1969.0,Intermediate,Plasma,50588,Time taken for maximum plasma concentration in dog,CHEMBL623679,N,1,,,,,1,,BAO_0000218,
6839,,Intermediate,,50588,Time to reach Cmax after oral administration to dogs,CHEMBL623680,N,1,,,,,1,,BAO_0000218,
6840,1969.0,Intermediate,Plasma,50588,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL623681,N,1,,,,,1,,BAO_0000218,
6841,,Intermediate,,50588,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,CHEMBL623682,N,1,,,,,1,,BAO_0000218,
6842,,Intermediate,,50588,Tmax after peroral administration (1 mg/kg) was determined in dog,CHEMBL623683,N,1,,,,,1,,BAO_0000218,
6843,,Expert,,50588,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL623684,N,1,,,,,1,,BAO_0000218,
6844,,Intermediate,,50588,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL622745,N,1,,,,,1,,BAO_0000218,
6845,,Intermediate,,50588,Tmax after peroral administration in dogs at 2.4 uM/kg,CHEMBL622746,N,1,,,,,1,,BAO_0000218,
6846,,Intermediate,,50594,In vivo Cmax in mice at dose of 100 mg/kg,CHEMBL622747,N,1,,,,,1,,BAO_0000218,
6847,,Intermediate,,50594,In vivo Cmax in mice at dose of 50 mg/kg,CHEMBL622748,N,1,,,,,1,,BAO_0000218,
6848,,Intermediate,,50594,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,CHEMBL622749,N,1,,,,,1,,BAO_0000218,
6849,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),CHEMBL622750,N,1,,,,,1,,BAO_0000218,
6850,1969.0,Intermediate,Plasma,50594,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,CHEMBL623411,N,1,,,,,1,,BAO_0000218,
6851,1969.0,Intermediate,Plasma,50594,Maximum concentration obtained in mouse plasma was determined,CHEMBL875946,N,1,,,,,1,,BAO_0000218,
6852,1969.0,Intermediate,Plasma,50594,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,CHEMBL623412,N,1,,,,,1,,BAO_0000218,
6853,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL623413,N,1,,,,,1,,BAO_0000218,
6854,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,CHEMBL623414,N,1,,,,,1,,BAO_0000218,
6855,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,CHEMBL623415,N,1,,,,,1,,BAO_0000218,
6856,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,CHEMBL623416,N,1,,,,,1,,BAO_0000218,
6857,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,CHEMBL623417,N,1,,,,,1,,BAO_0000218,
6858,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,CHEMBL623418,N,1,,,,,1,,BAO_0000218,
6859,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,CHEMBL623419,N,1,,,,,1,,BAO_0000218,
6860,,Intermediate,,50594,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL622816,N,1,,,,,1,,BAO_0000218,
6861,,Intermediate,,50594,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,CHEMBL623313,N,1,,,,,1,,BAO_0000218,
6862,,Intermediate,,50594,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,CHEMBL623314,N,1,,,,,1,,BAO_0000218,
6863,,Intermediate,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,CHEMBL876788,N,1,,,,,1,,BAO_0000218,
6864,,Intermediate,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,CHEMBL623315,N,1,,,,,1,,BAO_0000218,
6865,,Intermediate,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,CHEMBL623316,N,1,,,,,1,,BAO_0000218,
6866,,Intermediate,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,CHEMBL623317,N,1,,,,,1,,BAO_0000218,
6868,,Intermediate,,50594,Cmax in male mice after 2 mg/kg oral dose,CHEMBL623319,N,1,,,,,1,,BAO_0000218,
6869,,Intermediate,,50594,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,CHEMBL623320,N,1,,,,,1,,BAO_0000218,
6870,,Intermediate,,50594,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,CHEMBL623321,N,1,,,,,1,,BAO_0000218,
6871,,Intermediate,,50594,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,CHEMBL623322,N,1,,,,,1,,BAO_0000218,
6872,,Intermediate,,50594,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,CHEMBL623323,N,1,,,,,1,,BAO_0000218,
6873,,Intermediate,,50594,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,CHEMBL623324,N,1,,,,,1,,BAO_0000218,
6874,,Intermediate,,50594,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,CHEMBL623325,N,1,,,,,1,,BAO_0000218,
6875,,Intermediate,,50594,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,CHEMBL623326,N,1,,,,,1,,BAO_0000218,
6876,,Intermediate,,50594,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,CHEMBL623327,N,1,,,,,1,,BAO_0000218,
6877,1969.0,Intermediate,Plasma,50594,Maximum concentration in plasma upon oral administration in mouse,CHEMBL623328,N,1,,,,,1,,BAO_0000218,
6878,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration was evaluated in mice after oral administration,CHEMBL623329,N,1,,,,,1,,BAO_0000218,
6879,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,CHEMBL623330,N,1,,,,,1,,BAO_0000218,
6880,,Intermediate,,50594,Dose at which the compound induced fecal excretion in mice,CHEMBL876789,N,1,,,,,1,,BAO_0000218,
6893,,Expert,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,CHEMBL623333,N,1,164.0,A10,,,1,,BAO_0000219,
6894,,Expert,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,CHEMBL623334,N,1,164.0,A10,,,1,,BAO_0000219,
6895,,Expert,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,CHEMBL627536,N,1,164.0,A10,,,1,,BAO_0000219,
6896,,Expert,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,CHEMBL627537,N,1,164.0,A10,,,1,,BAO_0000219,
6897,,Intermediate,,80013,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),CHEMBL627538,N,1,164.0,A10,,,1,,BAO_0000219,
6898,,Intermediate,,80655,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,CHEMBL884106,N,1,393.0,A121,,,1,,BAO_0000219,
6899,,Intermediate,,80655,Anticancer activity against human ovarian carcinoma A121 cells,CHEMBL625294,N,1,393.0,A121,,,1,,BAO_0000219,
6900,,Intermediate,,80655,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,CHEMBL625295,N,1,393.0,A121,,,1,,BAO_0000219,
6901,,Intermediate,,80655,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,CHEMBL625296,N,1,393.0,A121,,,1,,BAO_0000219,
6902,,Expert,,80655,Growth inhibition of human ovarian carcinoma (A121) cell line,CHEMBL625297,N,1,393.0,A121,,,1,,BAO_0000219,
6903,,Expert,,80655,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,CHEMBL625298,N,1,393.0,A121,,,1,,BAO_0000219,
6904,,Intermediate,,80655,Cytotoxicity against human A121 ovarian cells,CHEMBL625960,N,1,393.0,A121,,,1,,BAO_0000219,
6905,,Intermediate,,80655,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,CHEMBL625961,N,1,393.0,A121,,,1,,BAO_0000219,
6906,,Intermediate,,80655,In vitro cytotoxicity against human ovarian carcinoma A21,CHEMBL625962,N,1,393.0,A121,,,1,,BAO_0000219,
6907,,Intermediate,,80655,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,CHEMBL624717,N,1,393.0,A121,,,1,,BAO_0000219,
6908,,Intermediate,,80655,Inhibitory activity of compound against human A121 ovarian cell line.,CHEMBL624718,N,1,393.0,A121,,,1,,BAO_0000219,
6909,,Intermediate,,80655,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,CHEMBL624719,N,1,393.0,A121,,,1,,BAO_0000219,
6910,,Intermediate,,80655,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,CHEMBL624720,N,1,393.0,A121,,,1,,BAO_0000219,
6911,,Intermediate,,80012,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,CHEMBL624721,N,1,622.0,A 172,,,1,,BAO_0000219,
6912,,Expert,,80012,In vitro cytotoxicity against A172 human tumor cell lines.,CHEMBL624722,N,1,622.0,A 172,,,1,,BAO_0000219,
6913,,Intermediate,,80012,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,CHEMBL877597,N,1,622.0,A 172,,,1,,BAO_0000219,
6914,,Intermediate,,80012,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,CHEMBL624723,N,1,622.0,A 172,,,1,,BAO_0000219,
6915,,Intermediate,,80012,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,CHEMBL624724,N,1,622.0,A 172,,,1,,BAO_0000219,
6916,,Autocuration,,104729,Association constant against A2 adenosine receptor,CHEMBL624725,H,4,,,,,1,,BAO_0000224,
6917,,Intermediate,,80656,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,CHEMBL624726,N,1,1085.0,A2,,,1,,BAO_0000219,
6918,,Autocuration,,104713,Ratio of Ki for adenosine A2 and A1 receptor binding,CHEMBL857535,D,5,,,,,1,,BAO_0000224,
6919,,Expert,,80014,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,CHEMBL624727,N,1,623.0,A204,,,1,,BAO_0000219,
6920,,Expert,,80014,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,CHEMBL624728,N,1,623.0,A204,,,1,,BAO_0000219,
6921,,Intermediate,,80015,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,CHEMBL624729,N,1,404.0,A2058,,,1,,BAO_0000219,
6922,,Intermediate,,80657,Growth inhibition against Human squamous cell line(A 253),CHEMBL624730,N,1,973.0,A253 cell line,,,1,,BAO_0000219,
6923,,Intermediate,,80657,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,CHEMBL624731,N,1,973.0,A253 cell line,,,1,,BAO_0000219,
6924,,Intermediate,,80657,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,CHEMBL624732,N,1,973.0,A253 cell line,,,1,,BAO_0000219,
6925,,Intermediate,,80657,Growth inhibition of A253 cell lines.,CHEMBL883245,N,1,973.0,A253 cell line,,,1,,BAO_0000219,
6926,,Intermediate,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),CHEMBL624733,N,1,973.0,A253 cell line,,,1,,BAO_0000219,
6927,,Intermediate,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,CHEMBL624734,N,1,973.0,A253 cell line,,,1,,BAO_0000219,
6928,,Intermediate,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,CHEMBL624735,N,1,973.0,A253 cell line,,,1,,BAO_0000219,
6929,,Intermediate,,81034,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,CHEMBL621780,N,1,478.0,A2780,,,1,,BAO_0000219,
6930,,Intermediate,,81034,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,CHEMBL877598,N,1,478.0,A2780,,,1,,BAO_0000219,
6931,,Expert,,81034,Cytotoxic activity against A2780 human ovarian carcinoma cell line,CHEMBL621781,N,1,478.0,A2780,,,1,,BAO_0000219,
6932,,Intermediate,,81034,Cytotoxicity against human cancer cell lines A2780 (ovarian),CHEMBL621782,N,1,478.0,A2780,,,1,,BAO_0000219,
6933,,Expert,,81034,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,CHEMBL621783,N,1,478.0,A2780,,,1,,BAO_0000219,
6934,,Intermediate,,81034,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,CHEMBL621784,N,1,478.0,A2780,,,1,,BAO_0000219,
6935,,Intermediate,,81034,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),CHEMBL621785,N,1,478.0,A2780,,,1,,BAO_0000219,
6936,,Expert,,81034,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,CHEMBL621968,N,1,478.0,A2780,,,1,,BAO_0000219,
6937,,Expert,,81034,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,CHEMBL621969,N,1,478.0,A2780,,,1,,BAO_0000219,
6938,,Expert,,81034,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,CHEMBL621970,N,1,478.0,A2780,,,1,,BAO_0000219,
6939,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,CHEMBL621971,N,1,478.0,A2780,,,1,,BAO_0000219,
6940,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,CHEMBL621972,N,1,478.0,A2780,,,1,,BAO_0000219,
6941,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,CHEMBL884108,N,1,478.0,A2780,,,1,,BAO_0000219,
6942,,Autocuration,,22224,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,CHEMBL623826,U,0,,,,,1,,BAO_0000019,
6943,,Autocuration,,22224,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,CHEMBL623827,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6944,,Autocuration,,22224,Evaluated for growth inhibition of AA8 cells under aerobic conditions,CHEMBL623828,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6945,,Autocuration,,22224,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,CHEMBL623829,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6946,,Autocuration,,22224,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),CHEMBL623830,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6947,,Autocuration,,22224,Growth inhibition against CHO-derived cell line AA8,CHEMBL623831,U,0,,,,,1,,BAO_0000019,
6948,,Autocuration,,22224,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],CHEMBL623832,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6949,,Expert,,80089,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,CHEMBL623833,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6950,,Expert,,80089,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,CHEMBL623834,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6951,,Autocuration,,22224,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,CHEMBL623835,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6952,,Autocuration,,22224,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,CHEMBL623836,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6953,,Autocuration,,22224,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,CHEMBL623837,U,0,185.0,CHO-AA8,,,1,,BAO_0000219,
6954,,Expert,,80089,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,CHEMBL623838,N,1,185.0,CHO-AA8,,,1,,BAO_0000219,
6955,,Autocuration,,12675,compound was evaluated for association constant (Ka) of isolated serum protein AAG,CHEMBL623839,H,8,,,,,1,,BAO_0000019,
6956,,Autocuration,,12675,Number of binding sites (n) of isolated serum protein AAG,CHEMBL623840,H,8,,,,,1,,BAO_0000019,
6957,,Intermediate,,22222,Association constant for binding to AATT duplex,CHEMBL623841,M,3,,,,,1,,BAO_0000225,
6958,,Expert,,100090,Inhibition of ABAE human fibroblast cell proliferation,CHEMBL623842,N,1,416.0,ABAE,,,1,,BAO_0000219,
6959,,Intermediate,,80668,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",CHEMBL623843,N,1,1064.0,AC755,,,1,,BAO_0000218,
6960,,Expert,,102444,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,CHEMBL618669,D,9,,,,,1,,BAO_0000218,
6961,,Expert,,102444,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,CHEMBL618670,D,9,,,,,1,,BAO_0000218,
6962,,Autocuration,,69,Inhibitory activity against angiotensin-converting enzyme (ACE).,CHEMBL618671,H,8,,,,,1,,BAO_0000357,
6963,,Autocuration,,69,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,CHEMBL618672,H,8,,,,,1,,BAO_0000357,
6964,,Intermediate,,80669,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,CHEMBL618673,N,1,978.0,ACH-2 cell line,,,1,,BAO_0000219,
6965,,Intermediate,,80669,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),CHEMBL618674,N,1,978.0,ACH-2 cell line,,,1,,BAO_0000219,
6966,,Autocuration,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,CHEMBL618675,U,0,998.0,T cell line,,,1,,BAO_0000219,
6967,,Autocuration,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),CHEMBL618676,U,0,998.0,T cell line,,,1,,BAO_0000219,
6968,,Autocuration,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),CHEMBL618677,U,0,998.0,T cell line,,,1,,BAO_0000219,
6969,,Intermediate,,80025,Inhibition of growth of renal cancer ACHN cell line,CHEMBL618678,N,1,626.0,ACHN,,,1,,BAO_0000219,
6970,,Intermediate,,80025,Inhibition of growth of ACHN renal cancer cell line,CHEMBL618679,N,1,626.0,ACHN,,,1,,BAO_0000219,
6971,,Intermediate,,80025,Inhibitory concentration required against ACHN renal cancer cell line,CHEMBL618680,N,1,626.0,ACHN,,,1,,BAO_0000219,
6972,,Expert,,80025,Concentration required to inhibit growth of human renal (ACHN) cell line,CHEMBL618681,N,1,626.0,ACHN,,,1,,BAO_0000219,
6973,,Intermediate,,80025,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,CHEMBL618682,N,1,626.0,ACHN,,,1,,BAO_0000219,
6974,,Intermediate,,80025,Cytotoxic activity against ACHN Renal cancer cell line,CHEMBL618683,N,1,626.0,ACHN,,,1,,BAO_0000219,
6975,,Intermediate,,80025,Cytotoxicity evaluation against ACHN renal cancer cells,CHEMBL618684,N,1,626.0,ACHN,,,1,,BAO_0000219,
6976,,Intermediate,,80025,In vitro antitumor activity against human renal ACHN cell line,CHEMBL618685,N,1,626.0,ACHN,,,1,,BAO_0000219,
6977,,Intermediate,,80025,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,CHEMBL876499,N,1,626.0,ACHN,,,1,,BAO_0000219,
6978,,Intermediate,,80025,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,CHEMBL618686,N,1,626.0,ACHN,,,1,,BAO_0000219,
6979,,Intermediate,,80025,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",CHEMBL618687,N,1,626.0,ACHN,,,1,,BAO_0000219,
6980,,Intermediate,,80025,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,CHEMBL618688,N,1,626.0,ACHN,,,1,,BAO_0000219,
6981,,Expert,,80025,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,CHEMBL618689,N,1,626.0,ACHN,,,1,,BAO_0000219,
6982,,Intermediate,,80025,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,CHEMBL618690,N,1,626.0,ACHN,,,1,,BAO_0000219,
6983,,Intermediate,,80025,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,CHEMBL618691,N,1,626.0,ACHN,,,1,,BAO_0000219,
6984,,Intermediate,,80025,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),CHEMBL619373,N,1,626.0,ACHN,,,1,,BAO_0000219,
6985,,Intermediate,,80025,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",CHEMBL884008,N,1,626.0,ACHN,,,1,,BAO_0000219,
6986,,Intermediate,,80025,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,CHEMBL619374,N,1,626.0,ACHN,,,1,,BAO_0000219,
6987,,Intermediate,,80025,Compound was tested for the growth inhibition of ACHN renal tumor cell line,CHEMBL619375,N,1,626.0,ACHN,,,1,,BAO_0000219,
6988,,Intermediate,,80025,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,CHEMBL619376,N,1,626.0,ACHN,,,1,,BAO_0000219,
6989,,Intermediate,,80025,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,CHEMBL619377,N,1,626.0,ACHN,,,1,,BAO_0000219,
6990,,Intermediate,,80025,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,CHEMBL619378,N,1,626.0,ACHN,,,1,,BAO_0000219,
6991,,Intermediate,,50588,Tmax value after administration of 4 mg/Kg oral dose in dog,CHEMBL872527,N,1,,,,,1,,BAO_0000218,
6992,,Intermediate,,50588,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",CHEMBL876500,N,1,,,,,1,,BAO_0000218,
6993,,Intermediate,,50588,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,CHEMBL619379,N,1,,,,,1,,BAO_0000218,
6994,,Intermediate,,50588,Volume distribution after 15 mg/kg iv dose in Dogs,CHEMBL619538,N,1,,,,,1,,BAO_0000218,
6995,,Intermediate,,50588,Volume distribution after 30 mg/kg po dose in Dogs,CHEMBL619539,N,1,,,,,1,,BAO_0000218,
6996,,Intermediate,,50588,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,CHEMBL619540,N,1,,,,,1,,BAO_0000218,
6997,,Intermediate,,50588,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,CHEMBL619541,N,1,,,,,1,,BAO_0000218,
6998,,Intermediate,,50588,Volume of distribution was evaluated in dog,CHEMBL619542,N,1,,,,,1,,BAO_0000218,
6999,,Intermediate,,50588,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,CHEMBL619543,N,1,,,,,1,,BAO_0000218,
7000,,Expert,,50588,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL619544,N,1,,,,,1,,BAO_0000218,
7001,,Intermediate,,50588,The compound was tested for volume of distribution in dog,CHEMBL619545,N,1,,,,,1,,BAO_0000218,
7002,,Intermediate,,50588,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,CHEMBL619546,N,1,,,,,1,,BAO_0000218,
7003,,Intermediate,,50588,Vd (1 mg/kg) was determined in dog (in vivo),CHEMBL619547,N,1,,,,,1,,BAO_0000218,
7004,,Intermediate,,50588,Vd in dog,CHEMBL619548,N,1,,,,,1,,BAO_0000218,
7005,,Intermediate,,50588,Volume distribution was determined,CHEMBL619549,N,1,,,,,1,,BAO_0000218,
7006,,Intermediate,,50588,Volume of distribution in dog,CHEMBL619550,N,1,,,,,1,,BAO_0000218,
7007,,Intermediate,,50588,Volume of distribution by as 4 fold increase by iv administration in dogs,CHEMBL876501,N,1,,,,,1,,BAO_0000218,
7008,,Intermediate,,50588,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,CHEMBL619551,N,1,,,,,1,,BAO_0000218,
7009,,Intermediate,,50588,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL619552,N,1,,,,,1,,BAO_0000218,
7010,,Intermediate,,50588,Volume distribution at the dose of 2 mg/kg in dog,CHEMBL619553,N,1,,,,,1,,BAO_0000218,
7011,,Intermediate,,50588,Steady state volume of distribution was determined,CHEMBL618722,N,1,,,,,1,,BAO_0000218,
7012,,Intermediate,,50588,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,CHEMBL618723,N,1,,,,,1,,BAO_0000218,
7013,,Intermediate,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,CHEMBL618724,N,1,,,,,1,,BAO_0000218,
7014,,Intermediate,,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,CHEMBL618725,N,1,,,,,1,,BAO_0000218,
7015,,Intermediate,,50588,Bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL618726,N,1,,,,,1,,BAO_0000218,
7016,,Intermediate,,50588,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),CHEMBL618727,N,1,,,,,1,,BAO_0000218,
7017,,Intermediate,,50588,Pharmacokinetic property (vdss) was measured in dog,CHEMBL624233,N,1,,,,,1,,BAO_0000218,
7018,,Intermediate,,50588,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,CHEMBL624234,N,1,,,,,1,,BAO_0000218,
7019,,Intermediate,,50588,Vdss was determined after iv 0.1 mg/kg administration in dog,CHEMBL624235,N,1,,,,,1,,BAO_0000218,
7020,,Intermediate,,50588,Volume displacement was calculated in dog,CHEMBL624236,N,1,,,,,1,,BAO_0000218,
7021,,Intermediate,,50588,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,CHEMBL624237,N,1,,,,,1,,BAO_0000218,
7022,,Intermediate,,50588,Volume distribution constant was determined,CHEMBL624238,N,1,,,,,1,,BAO_0000218,
7023,,Intermediate,,50588,Volume distribution at a dose of 1 uM/kg in dog was determined,CHEMBL624239,N,1,,,,,1,,BAO_0000218,
7024,,Intermediate,,50588,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,CHEMBL875829,N,1,,,,,1,,BAO_0000218,
7025,,Intermediate,,50588,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL624240,N,1,,,,,1,,BAO_0000218,
7026,,Intermediate,,50588,Volume distribution (Vdss) was measured in dog,CHEMBL624241,N,1,,,,,1,,BAO_0000218,
7027,,Intermediate,,50588,Volume distribution (Vdss) was measured in dog,CHEMBL624242,N,1,,,,,1,,BAO_0000218,
7028,,Intermediate,,50588,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL624243,N,1,,,,,1,,BAO_0000218,
7029,,Intermediate,,50588,Volume of distribution in steady state was determined in dog,CHEMBL624244,N,1,,,,,1,,BAO_0000218,
7030,,Intermediate,,50588,Volume of distribution of compound was determined in dog,CHEMBL624245,N,1,,,,,1,,BAO_0000218,
7031,,Intermediate,,50588,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,CHEMBL624246,N,1,,,,,1,,BAO_0000218,
7032,,Intermediate,,50588,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),CHEMBL624247,N,1,,,,,1,,BAO_0000218,
7033,,Intermediate,,50588,Volume of distribution (Vdss) was measured in dog,CHEMBL624248,N,1,,,,,1,,BAO_0000218,
7034,,Intermediate,,50588,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL624249,N,1,,,,,1,,BAO_0000218,
7035,,Intermediate,,50588,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624250,N,1,,,,,1,,BAO_0000218,
7036,,Intermediate,,50588,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624251,N,1,,,,,1,,BAO_0000218,
7037,,Intermediate,,50588,Maximum rate of depolarization of the upstroke of the action potential,CHEMBL624252,N,1,,,,,1,,BAO_0000218,
7038,,Intermediate,,50588,Steady state volume distribution in dog,CHEMBL624253,N,1,,,,,1,,BAO_0000218,
7039,,Intermediate,,50588,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,CHEMBL624950,N,1,,,,,1,,BAO_0000218,
7040,,Intermediate,,50588,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,CHEMBL624951,N,1,,,,,1,,BAO_0000218,
7041,,Intermediate,,50588,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,CHEMBL875830,N,1,,,,,1,,BAO_0000218,
7042,,Intermediate,,50588,Volume distribution in dog after administration of 1 mg/kg iv,CHEMBL624952,N,1,,,,,1,,BAO_0000218,
7043,,Intermediate,,50588,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,CHEMBL624953,N,1,,,,,1,,BAO_0000218,
7044,,Intermediate,,50588,Vss after intravenous administration (0.5 mg/kg) was determined in dog,CHEMBL624954,N,1,,,,,1,,BAO_0000218,
7045,,Intermediate,,50588,Vss on i.v. administration of 2 mg/kg was measured in dog,CHEMBL624955,N,1,,,,,1,,BAO_0000218,
7046,,Intermediate,,50588,Vss was determined,CHEMBL624956,N,1,,,,,1,,BAO_0000218,
7047,,Intermediate,,50588,Vss in dog,CHEMBL625129,N,1,,,,,1,,BAO_0000218,
7048,,Intermediate,,50588,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,CHEMBL625130,N,1,,,,,1,,BAO_0000218,
7049,,Intermediate,,50588,Volume distribution in dogs,CHEMBL625131,N,1,,,,,1,,BAO_0000218,
7050,,Intermediate,,50588,Volume of distribution in dog,CHEMBL625132,N,1,,,,,1,,BAO_0000218,
7051,,Intermediate,,50588,Tested for the oral bioavailability in dog,CHEMBL872263,N,1,,,,,1,,BAO_0000218,
7060,,Intermediate,,50594,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,CHEMBL624336,N,1,,,,,1,,BAO_0000218,
7061,,Intermediate,,50594,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,CHEMBL624337,N,1,,,,,1,,BAO_0000218,
7062,,Intermediate,,50594,Bioavailability after peroral administration of 50 mg/kg of dose in mice,CHEMBL624338,N,1,,,,,1,,BAO_0000218,
7063,,Intermediate,,50594,Bioavailability was measured in mouse,CHEMBL624339,N,1,,,,,1,,BAO_0000218,
7064,,Intermediate,,50594,Bioavailability in mouse,CHEMBL624340,N,1,,,,,1,,BAO_0000218,
7065,,Intermediate,,50594,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL624341,N,1,,,,,1,,BAO_0000218,
7066,,Intermediate,,50594,Bioavailability in mouse,CHEMBL624342,N,1,,,,,1,,BAO_0000218,
7067,,Intermediate,,50594,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,CHEMBL624343,N,1,,,,,1,,BAO_0000218,
7068,,Intermediate,,50594,Oral bioavailability in mouse,CHEMBL624344,N,1,,,,,1,,BAO_0000218,
7069,,Intermediate,,50594,Oral availability at 50 mg/kg po in male mice,CHEMBL624345,N,1,,,,,1,,BAO_0000218,
7070,,Intermediate,,50594,Oral bioavailability in mouse (dose 10 mg/kg),CHEMBL624346,N,1,,,,,1,,BAO_0000218,
7071,,Expert,,50594,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,CHEMBL624347,N,1,,,,,1,,BAO_0000218,
7072,,Intermediate,,50594,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",CHEMBL624348,N,1,,,,,1,,BAO_0000218,
7074,,Intermediate,,50594,Oral bioavailability in mouse,CHEMBL622754,N,1,,,,,1,,BAO_0000218,
7075,,Intermediate,,50594,Oral bioavailability in vivo in mice;ND=Not determined,CHEMBL622755,N,1,,,,,1,,BAO_0000218,
7076,,Intermediate,,50594,Oral bioavailability in mouse at 10 mg/kg of the compound,CHEMBL622756,N,1,,,,,1,,BAO_0000218,
7077,,Intermediate,,50594,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),CHEMBL622757,N,1,,,,,1,,BAO_0000218,
7078,,Intermediate,,50594,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),CHEMBL622758,N,1,,,,,1,,BAO_0000218,
7079,,Intermediate,,50594,Tested for bioavailability of the compound,CHEMBL622759,N,1,,,,,1,,BAO_0000218,
7080,,Intermediate,,50594,Tested for half life at the dose of 10 mg/kg when administered intravenously,CHEMBL622760,N,1,,,,,1,,BAO_0000218,
7081,1969.0,Intermediate,Plasma,50594,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,CHEMBL622761,N,1,,,,,1,,BAO_0000218,
7082,1969.0,Intermediate,Plasma,50594,The plasma half life of compound was determined on heparin prepared by human plasma. ,CHEMBL622762,N,1,,,,,1,,BAO_0000218,
7083,1969.0,Intermediate,Plasma,50594,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,CHEMBL622763,N,1,,,,,1,,BAO_0000218,
7084,1969.0,Intermediate,Plasma,50594,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,CHEMBL622764,N,1,,,,,1,,BAO_0000218,
7085,1969.0,Intermediate,Plasma,50594,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,CHEMBL622765,N,1,,,,,1,,BAO_0000218,
7086,,Intermediate,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,CHEMBL622766,N,1,,,,,1,,BAO_0000218,
7087,,Intermediate,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,CHEMBL622767,N,1,,,,,1,,BAO_0000218,
7088,,Intermediate,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,CHEMBL622768,N,1,,,,,1,,BAO_0000218,
7089,178.0,Intermediate,Blood,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL875948,N,1,,,,,1,,BAO_0000218,
7090,178.0,Intermediate,Blood,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL622769,N,1,,,,,1,,BAO_0000218,
7091,178.0,Intermediate,Blood,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL622770,N,1,,,,,1,,BAO_0000218,
7092,178.0,Intermediate,Blood,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL622771,N,1,,,,,1,,BAO_0000218,
7093,178.0,Intermediate,Blood,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL622772,N,1,,,,,1,,BAO_0000218,
7094,178.0,Intermediate,Blood,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL622773,N,1,,,,,1,,BAO_0000218,
7095,178.0,Intermediate,Blood,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL622774,N,1,,,,,1,,BAO_0000218,
7096,10000001.0,Intermediate,Bone,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL621725,N,1,,,,,1,,BAO_0000218,
7097,10000001.0,Intermediate,Bone,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL621726,N,1,,,,,1,,BAO_0000218,
7098,,Intermediate,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,CHEMBL621727,N,1,478.0,A2780,,,1,,BAO_0000219,
7099,,Expert,,81034,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,CHEMBL622413,N,1,478.0,A2780,,,1,,BAO_0000219,
7100,,Intermediate,,81034,Compound was evaluated for cytotoxicity against A2780 cell line,CHEMBL622414,N,1,478.0,A2780,,,1,,BAO_0000219,
7101,,Expert,,81034,Inhibition of A2780 cell clonogenic assay,CHEMBL622415,N,1,478.0,A2780,,,1,,BAO_0000219,
7102,,Expert,,81034,Cytotoxic effect on ovarian cancer cell line (A2780),CHEMBL884001,N,1,478.0,A2780,,,1,,BAO_0000219,
7103,,Intermediate,,81034,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,CHEMBL622416,N,1,478.0,A2780,,,1,,BAO_0000219,
7104,,Intermediate,,81034,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",CHEMBL622417,N,1,478.0,A2780,,,1,,BAO_0000219,
7105,,Expert,,81034,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,CHEMBL622590,N,1,478.0,A2780,,,1,,BAO_0000219,
7106,,Expert,,81034,Antiproliferative activity against human A2780 cells,CHEMBL622591,N,1,478.0,A2780,,,1,,BAO_0000219,
7107,,Expert,,81034,Inhibition of human A2780 cell proliferation,CHEMBL622592,N,1,478.0,A2780,,,1,,BAO_0000219,
7108,,Expert,,81034,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,CHEMBL622593,N,1,478.0,A2780,,,1,,BAO_0000219,
7109,,Expert,,81034,Inhibition of human A2780 cell proliferation (No data),CHEMBL622594,N,1,478.0,A2780,,,1,,BAO_0000219,
7110,,Intermediate,,81034,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,CHEMBL622595,N,1,478.0,A2780,,,1,,BAO_0000219,
7111,,Intermediate,,81034,Compound was evaluated against human Ovarian carcinoma cell line A2780,CHEMBL622596,N,1,478.0,A2780,,,1,,BAO_0000219,
7112,,Expert,,81034,Growth inhibition against A2780 wild-type ovarian cell lines,CHEMBL622597,N,1,478.0,A2780,,,1,,BAO_0000219,
7113,,Intermediate,,81034,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,CHEMBL622598,N,1,478.0,A2780,,,1,,BAO_0000219,
7114,,Autocuration,,104766,Inhibition of tubulin polymerization in human ovarian cancer cell lines,CHEMBL622599,D,5,,,,,1,,BAO_0000019,
7115,,Intermediate,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,CHEMBL622600,N,1,478.0,A2780,,,1,,BAO_0000219,
7116,,Intermediate,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,CHEMBL622601,N,1,478.0,A2780,,,1,,BAO_0000219,
7117,,Intermediate,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,CHEMBL622602,N,1,478.0,A2780,,,1,,BAO_0000219,
7118,,Intermediate,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,CHEMBL622603,N,1,478.0,A2780,,,1,,BAO_0000219,
7119,,Intermediate,,81034,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,CHEMBL622604,N,1,478.0,A2780,,,1,,BAO_0000219,
7120,,Intermediate,,81034,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,CHEMBL622605,N,1,478.0,A2780,,,1,,BAO_0000219,
7121,,Expert,,81034,In vitro inhibition of human ovarian cell line A2780,CHEMBL622606,N,1,478.0,A2780,,,1,,BAO_0000219,
7122,,Expert,,81034,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",CHEMBL619463,N,1,478.0,A2780,,,1,,BAO_0000219,
7123,,Intermediate,,81034,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),CHEMBL619464,N,1,478.0,A2780,,,1,,BAO_0000219,
7124,,Expert,,81034,Concentration required to inhibit A2780-cell growth by 50%,CHEMBL619465,N,1,478.0,A2780,,,1,,BAO_0000219,
7125,,Expert,,81034,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,CHEMBL619466,N,1,478.0,A2780,,,1,,BAO_0000219,
7126,,Expert,,81034,Cytotoxic effect on human ovarian (A2780) cancer cell line,CHEMBL619467,N,1,478.0,A2780,,,1,,BAO_0000219,
7127,,Intermediate,,81034,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,CHEMBL619468,N,1,478.0,A2780,,,1,,BAO_0000219,
7128,,Expert,,81034,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,CHEMBL619469,N,1,478.0,A2780,,,1,,BAO_0000219,
7129,,Expert,,81034,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,CHEMBL619470,N,1,478.0,A2780,,,1,,BAO_0000219,
7130,,Intermediate,,81034,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,CHEMBL619471,N,1,478.0,A2780,,,1,,BAO_0000219,
7131,,Intermediate,,81034,Cytotoxicity against human ovarian carcinoma A2780 cell line,CHEMBL619472,N,1,478.0,A2780,,,1,,BAO_0000219,
7132,,Intermediate,,81034,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",CHEMBL619473,N,1,478.0,A2780,,,1,,BAO_0000219,
7133,,Intermediate,,81034,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",CHEMBL874368,N,1,478.0,A2780,,,1,,BAO_0000219,
7134,,Intermediate,,81034,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",CHEMBL884003,N,1,478.0,A2780,,,1,,BAO_0000219,
7135,,Intermediate,,81034,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",CHEMBL622690,N,1,478.0,A2780,,,1,,BAO_0000219,
7136,,Intermediate,,81034,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,CHEMBL622691,N,1,478.0,A2780,,,1,,BAO_0000219,
7137,,Intermediate,,81034,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,CHEMBL622692,N,1,478.0,A2780,,,1,,BAO_0000219,
7138,,Intermediate,,81034,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,CHEMBL623406,N,1,478.0,A2780,,,1,,BAO_0000219,
7139,,Intermediate,,81034,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",CHEMBL884004,N,1,478.0,A2780,,,1,,BAO_0000219,
7140,,Intermediate,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,CHEMBL623407,N,1,478.0,A2780,,,1,,BAO_0000219,
7141,,Intermediate,,81034,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,CHEMBL623408,N,1,478.0,A2780,,,1,,BAO_0000219,
7142,,Expert,,81034,In vitro antitumor activity against A2780 cell line.,CHEMBL623409,N,1,478.0,A2780,,,1,,BAO_0000219,
7143,,Intermediate,,81034,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,CHEMBL623410,N,1,478.0,A2780,,,1,,BAO_0000219,
7144,,Expert,,81034,In vitro cytotoxicity against A2780 human ovarian cancer cell line,CHEMBL623576,N,1,478.0,A2780,,,1,,BAO_0000219,
7145,,Intermediate,,80025,Inhibitory activity against kidney A-CHN tumor cell growth in culture,CHEMBL623577,N,1,626.0,ACHN,,,1,,BAO_0000219,
7146,,Intermediate,,80025,The IC50 value was measured on ACHN cell line in renal tumor type.,CHEMBL623578,N,1,626.0,ACHN,,,1,,BAO_0000219,
7147,,Intermediate,,80025,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,CHEMBL623579,N,1,626.0,ACHN,,,1,,BAO_0000219,
7148,,Expert,,80025,In vitro lethal concentration against most sensitive ACHN cell line,CHEMBL623580,N,1,626.0,ACHN,,,1,,BAO_0000219,
7149,,Intermediate,,80025,Tested for cytotoxic activity against renal cancer ACHN cell line,CHEMBL623581,N,1,626.0,ACHN,,,1,,BAO_0000219,
7150,,Intermediate,,80025,Compound tested for growth inhibition of renal cancer cell line ACHN,CHEMBL857456,N,1,626.0,ACHN,,,1,,BAO_0000219,
7151,,Intermediate,,80025,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,CHEMBL623582,N,1,626.0,ACHN,,,1,,BAO_0000219,
7152,,Intermediate,,80025,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,CHEMBL623583,N,1,626.0,ACHN,,,1,,BAO_0000219,
7153,,Intermediate,,80025,In vitro anticancer activity against ACHN renal cancer cell line,CHEMBL623584,N,1,626.0,ACHN,,,1,,BAO_0000219,
7154,,Intermediate,,80025,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,CHEMBL623585,N,1,626.0,ACHN,,,1,,BAO_0000219,
7155,,Intermediate,,80025,Percent selectivity was evaluated in renal ACHN cell lines,CHEMBL623586,N,1,626.0,ACHN,,,1,,BAO_0000219,
7156,,Intermediate,,80025,In vitro inhibitory activity against renal ACHN cancer cell line,CHEMBL623587,N,1,626.0,ACHN,,,1,,BAO_0000219,
7157,,Intermediate,,80025,Tested for cytotoxicity against ACHN cell lines in renal cancer,CHEMBL875279,N,1,626.0,ACHN,,,1,,BAO_0000219,
7158,,Intermediate,,80025,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,CHEMBL623588,N,1,626.0,ACHN,,,1,,BAO_0000219,
7159,,Intermediate,,80025,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,CHEMBL623589,N,1,626.0,ACHN,,,1,,BAO_0000219,
7160,,Intermediate,,80025,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,CHEMBL623590,N,1,626.0,ACHN,,,1,,BAO_0000219,
7161,,Expert,,80025,Cytotoxic effect on renal cancer line ACHN,CHEMBL623591,N,1,626.0,ACHN,,,1,,BAO_0000219,
7162,,Intermediate,,80025,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,CHEMBL623592,N,1,626.0,ACHN,,,1,,BAO_0000219,
7163,,Intermediate,,80025,In vitro inhibition of Renal Cancer ACHN cell lines,CHEMBL623593,N,1,626.0,ACHN,,,1,,BAO_0000219,
7164,,Intermediate,,80025,Antitumor activity against human renal adenocarcinoma ACHN cells,CHEMBL623594,N,1,626.0,ACHN,,,1,,BAO_0000219,
7165,,Expert,,80025,Antitumor activity against human renal adenocarcinoma ACHN cells.,CHEMBL621833,N,1,626.0,ACHN,,,1,,BAO_0000219,
7166,,Intermediate,,80025,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,CHEMBL621834,N,1,626.0,ACHN,,,1,,BAO_0000219,
7167,,Intermediate,,80025,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),CHEMBL621835,N,1,626.0,ACHN,,,1,,BAO_0000219,
7168,,Intermediate,,80025,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",CHEMBL621836,N,1,626.0,ACHN,,,1,,BAO_0000219,
7169,,Intermediate,,80025,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,CHEMBL621837,N,1,626.0,ACHN,,,1,,BAO_0000219,
7170,,Intermediate,,80025,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,CHEMBL875280,N,1,626.0,ACHN,,,1,,BAO_0000219,
7171,,Intermediate,,80025,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,CHEMBL621838,N,1,626.0,ACHN,,,1,,BAO_0000219,
7172,,Intermediate,,80025,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,CHEMBL621839,N,1,626.0,ACHN,,,1,,BAO_0000219,
7173,,Autocuration,,22224,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,CHEMBL621840,U,0,,,,,1,,BAO_0000019,
7174,,Autocuration,,10647,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,CHEMBL621841,H,8,,,,,1,,BAO_0000019,
7175,,Expert,,50529,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,CHEMBL622979,N,1,468.0,HEL,,,1,,BAO_0000218,
7176,,Intermediate,,50529,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,CHEMBL876595,N,1,,,,,1,,BAO_0000218,
7177,,Autocuration,,12159,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),CHEMBL620221,H,8,,,,,1,,BAO_0000357,
7178,,Autocuration,,12159,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),CHEMBL620222,H,8,,,,,1,,BAO_0000357,
7179,,Intermediate,,80670,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,CHEMBL620506,N,1,979.0,ADDP cell line,,,1,,BAO_0000219,
7180,,Intermediate,,80671,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,CHEMBL620507,N,1,980.0,ADJ/PC6,,,1,,BAO_0000219,
7181,,Intermediate,,80671,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,CHEMBL620508,N,1,980.0,ADJ/PC6,,,1,,BAO_0000219,
7182,,Intermediate,,80671,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",CHEMBL620509,N,1,980.0,ADJ/PC6,,,1,,BAO_0000219,
7183,,Intermediate,,80671,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,CHEMBL620510,N,1,980.0,ADJ/PC6,,,1,,BAO_0000219,
7184,,Intermediate,,80671,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,CHEMBL620511,N,1,980.0,ADJ/PC6,,,1,,BAO_0000219,
7185,,Intermediate,,80671,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,CHEMBL620512,N,1,980.0,ADJ/PC6,,,1,,BAO_0000219,
7186,,Autocuration,,22224,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,CHEMBL620513,U,0,,,,,1,,BAO_0000019,
7187,,Autocuration,,22224,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,CHEMBL620514,U,0,,,,,1,,BAO_0000019,
7188,,Autocuration,,22224,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,CHEMBL620515,U,0,,,,,1,,BAO_0000019,
7189,,Autocuration,,22224,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),CHEMBL620516,U,0,,,,,1,,BAO_0000218,
7190,1969.0,Intermediate,Plasma,50588,AUC value in dog after IV administration at a dose of 5 mg/kg,CHEMBL620517,N,1,,,,,1,,BAO_0000218,
7191,1969.0,Intermediate,Plasma,50588,AUC value in dog after oral administration at a dose of 5 mg/kg,CHEMBL620518,N,1,,,,,1,,BAO_0000218,
7192,,Intermediate,,50588,Cmax value in dog after oral administration at a dose of 5 mg/kg,CHEMBL620519,N,1,,,,,1,,BAO_0000218,
7193,,Intermediate,,50588,Bioavailability in dog after oral administration at a dose of 5 mg/kg,CHEMBL621386,N,1,,,,,1,,BAO_0000218,
7194,,Intermediate,,50588,Tmax value in dog after oral administration at a dose of 5 mg/kg,CHEMBL621387,N,1,,,,,1,,BAO_0000218,
7195,,Intermediate,,50588,Compound was evaluated for its clearance when administered intravenously in dog,CHEMBL621388,N,1,,,,,1,,BAO_0000218,
7196,,Intermediate,,50588,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL621389,N,1,,,,,1,,BAO_0000218,
7197,,Intermediate,,50588,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),CHEMBL621390,N,1,,,,,1,,BAO_0000218,
7198,,Intermediate,,22229,Calculated partition coefficient (clogP),CHEMBL621391,U,0,,,,,1,,BAO_0000100,
7199,,Intermediate,,50588,Half life in dog,CHEMBL621392,N,1,,,,,1,,BAO_0000218,
7200,,Intermediate,,50588,Time taken for EC90 was determined when tested in dog,CHEMBL621393,N,1,,,,,1,,BAO_0000218,
7201,,Intermediate,,50588,Half life (iv) was determined,CHEMBL621394,N,1,,,,,1,,BAO_0000218,
7202,2107.0,Intermediate,Liver,50588,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,CHEMBL621395,N,1,,,,,1,,BAO_0000218,
7203,,Intermediate,,50588,Area under the curve was calculated in dog after iv administration,CHEMBL621396,N,1,,,,,1,,BAO_0000218,
7204,,Intermediate,,50588,Area under the curve was calculated in dog after peroral administration,CHEMBL621397,N,1,,,,,1,,BAO_0000218,
7205,,Intermediate,,50588,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,CHEMBL621398,N,1,,,,,1,,BAO_0000218,
7206,,Intermediate,,50588,pKa was evaluated in dog,CHEMBL618818,N,1,,,,,1,,BAO_0000218,
7207,,Intermediate,,50588,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,CHEMBL618819,N,1,,,,,1,,BAO_0000218,
7208,,Intermediate,,50588,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL618820,N,1,,,,,1,,BAO_0000218,
7209,,Intermediate,,50588,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL873810,N,1,,,,,1,,BAO_0000218,
7210,,Intermediate,,50588,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,CHEMBL876606,N,1,,,,,1,,BAO_0000218,
7211,,Intermediate,,50588,Compound was evaluated for the half-life (t 1/2) in hours,CHEMBL618821,N,1,,,,,1,,BAO_0000218,
7212,178.0,Intermediate,Blood,50588,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL618822,N,1,,,,,1,,BAO_0000218,
7213,178.0,Intermediate,Blood,50588,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL618823,N,1,,,,,1,,BAO_0000218,
7214,,Intermediate,,50588,Half life after intravenous administration of 1 mg/kg in dog,CHEMBL618824,N,1,,,,,1,,BAO_0000218,
7215,,Intermediate,,50588,Half life was measured in dog,CHEMBL618825,N,1,,,,,1,,BAO_0000218,
7216,,Intermediate,,50588,Half life period in dog after 5 mg/kg dose,CHEMBL618826,N,1,,,,,1,,BAO_0000218,
7217,,Intermediate,,50588,Half life period was evaluated in dog; 4-4.8,CHEMBL618827,N,1,,,,,1,,BAO_0000218,
7218,,Intermediate,,50588,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL618828,N,1,,,,,1,,BAO_0000218,
7219,,Intermediate,,50588,Half-life was determined in dog after a3 mg/kg of iv dose,CHEMBL618829,N,1,,,,,1,,BAO_0000218,
7220,,Intermediate,,50588,Half-life was determined,CHEMBL618830,N,1,,,,,1,,BAO_0000218,
7221,,Intermediate,,50588,Half life in dogs,CHEMBL618831,N,1,,,,,1,,BAO_0000218,
7222,1969.0,Intermediate,Plasma,50588,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,CHEMBL619489,N,1,,,,,1,,BAO_0000218,
7223,,Intermediate,,50588,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,CHEMBL619649,N,1,,,,,1,,BAO_0000218,
7224,,Intermediate,,50588,Compound was evaluated for the half life period after iv administration in Beagle dog.,CHEMBL876607,N,1,,,,,1,,BAO_0000218,
7225,,Intermediate,,50588,Compound was evaluated for the half life period after oral administration in conscious dog.,CHEMBL619650,N,1,,,,,1,,BAO_0000218,
7226,,Intermediate,,50588,Compound was tested for half life in dog,CHEMBL619651,N,1,,,,,1,,BAO_0000218,
7227,,Intermediate,,50588,Compound was tested for its half life in dog,CHEMBL619652,N,1,,,,,1,,BAO_0000218,
7228,,Intermediate,,50588,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL619653,N,1,,,,,1,,BAO_0000218,
7229,,Intermediate,,50588,Half life of compound in dog was determined,CHEMBL619654,N,1,,,,,1,,BAO_0000218,
7230,,Intermediate,,50588,Half life (iv) was determined,CHEMBL619655,N,1,,,,,1,,BAO_0000218,
7231,178.0,Intermediate,Blood,50588,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),CHEMBL619656,N,1,,,,,1,,BAO_0000218,
7232,1969.0,Intermediate,Plasma,50588,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,CHEMBL873812,N,1,,,,,1,,BAO_0000218,
7233,1969.0,Intermediate,Plasma,50588,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,CHEMBL621365,N,1,,,,,1,,BAO_0000218,
7234,,Intermediate,,50588,Half life in dog,CHEMBL621366,N,1,,,,,1,,BAO_0000218,
7235,1969.0,Intermediate,Plasma,50588,Half life in dog plasma,CHEMBL621367,N,1,,,,,1,,BAO_0000218,
7236,1969.0,Intermediate,Plasma,50588,Half life in dog plasma after administration of 0.25 mg/kg iv,CHEMBL621368,N,1,,,,,1,,BAO_0000218,
7237,1969.0,Intermediate,Plasma,50588,Half life in dog plasma after administration of 1 mg/kg iv,CHEMBL621369,N,1,,,,,1,,BAO_0000218,
7238,1969.0,Intermediate,Plasma,50588,Half life in dog plasma was determined at dose 10 mg/kg,CHEMBL621370,N,1,,,,,1,,BAO_0000218,
7239,,Intermediate,,50588,Half life in dog was determined,CHEMBL621371,N,1,,,,,1,,BAO_0000218,
7240,,Intermediate,,50588,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL621372,N,1,,,,,1,,BAO_0000218,
7241,1969.0,Intermediate,Plasma,50588,Half life upon exposure to human plasma,CHEMBL621373,N,1,,,,,1,,BAO_0000218,
7242,,Intermediate,,50588,Half life was calculated in dog,CHEMBL621374,N,1,,,,,1,,BAO_0000218,
7243,,Intermediate,,50588,Half life was determined,CHEMBL621375,N,1,,,,,1,,BAO_0000218,
7244,,Intermediate,,50588,Half life was determined,CHEMBL621376,N,1,,,,,1,,BAO_0000218,
7245,,Intermediate,,50588,Half life by intravenous administration of 1.2 mg/kg in dog,CHEMBL619624,N,1,,,,,1,,BAO_0000218,
7246,,Intermediate,,50588,Half life in dog,CHEMBL875840,N,1,,,,,1,,BAO_0000218,
7247,,Intermediate,,50588,Half life in dog after intra venous administration of the compound,CHEMBL619625,N,1,,,,,1,,BAO_0000218,
7248,,Intermediate,,50588,Half life in dog after intra venous administration of the compound; ND means Not determined,CHEMBL619626,N,1,,,,,1,,BAO_0000218,
7249,,Intermediate,,50588,Half life in dog after po administration of the compound,CHEMBL619627,N,1,,,,,1,,BAO_0000218,
7250,,Intermediate,,50588,Half life in dog after po administration of the compound; ND means Not determined,CHEMBL873817,N,1,,,,,1,,BAO_0000218,
7251,,Intermediate,,50588,Half life in dog at the single oral dose of 1 mg/kg,CHEMBL619628,N,1,,,,,1,,BAO_0000218,
7252,,Intermediate,,50588,Half life in dogs,CHEMBL619629,N,1,,,,,1,,BAO_0000218,
7253,,Intermediate,,50588,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,CHEMBL619630,N,1,,,,,1,,BAO_0000218,
7254,,Intermediate,,50588,Half life in rat,CHEMBL619631,N,1,,,,,1,,BAO_0000218,
7255,,Intermediate,,50588,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL619632,N,1,,,,,1,,BAO_0000218,
7256,10000001.0,Intermediate,Bone,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL619633,N,1,,,,,1,,BAO_0000218,
7257,10000001.0,Intermediate,Bone,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL875841,N,1,,,,,1,,BAO_0000218,
7258,10000001.0,Intermediate,Bone,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL619634,N,1,,,,,1,,BAO_0000218,
7259,10000001.0,Intermediate,Bone,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL619635,N,1,,,,,1,,BAO_0000218,
7260,10000001.0,Intermediate,Bone,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL619636,N,1,,,,,1,,BAO_0000218,
7261,10000004.0,Intermediate,Gut,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL619637,N,1,,,,,1,,BAO_0000218,
7262,10000004.0,Intermediate,Gut,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL619638,N,1,,,,,1,,BAO_0000218,
7263,10000004.0,Intermediate,Gut,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL619639,N,1,,,,,1,,BAO_0000218,
7264,10000004.0,Intermediate,Gut,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL619640,N,1,,,,,1,,BAO_0000218,
7265,10000004.0,Intermediate,Gut,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL619641,N,1,,,,,1,,BAO_0000218,
7266,10000004.0,Intermediate,Gut,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL619642,N,1,,,,,1,,BAO_0000218,
7267,10000004.0,Intermediate,Gut,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL619643,N,1,,,,,1,,BAO_0000218,
7268,948.0,Intermediate,Heart,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL619644,N,1,,,,,1,,BAO_0000218,
7269,948.0,Intermediate,Heart,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL621112,N,1,,,,,1,,BAO_0000218,
7270,948.0,Intermediate,Heart,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL621113,N,1,,,,,1,,BAO_0000218,
7271,948.0,Intermediate,Heart,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL621114,N,1,,,,,1,,BAO_0000218,
7272,948.0,Intermediate,Heart,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL621115,N,1,,,,,1,,BAO_0000218,
7273,948.0,Intermediate,Heart,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL621116,N,1,,,,,1,,BAO_0000218,
7274,948.0,Intermediate,Heart,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL621117,N,1,,,,,1,,BAO_0000218,
7275,2113.0,Intermediate,Kidney,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL621118,N,1,,,,,1,,BAO_0000218,
7276,2113.0,Intermediate,Kidney,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL621119,N,1,,,,,1,,BAO_0000218,
7277,2113.0,Intermediate,Kidney,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL621120,N,1,,,,,1,,BAO_0000218,
7278,2113.0,Intermediate,Kidney,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL621757,N,1,,,,,1,,BAO_0000218,
7279,2113.0,Intermediate,Kidney,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL621758,N,1,,,,,1,,BAO_0000218,
7280,2113.0,Intermediate,Kidney,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL621759,N,1,,,,,1,,BAO_0000218,
7281,2113.0,Intermediate,Kidney,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL621760,N,1,,,,,1,,BAO_0000218,
7282,2107.0,Intermediate,Liver,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL621761,N,1,,,,,1,,BAO_0000218,
7283,2107.0,Intermediate,Liver,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL621762,N,1,,,,,1,,BAO_0000218,
7284,2107.0,Intermediate,Liver,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL621763,N,1,,,,,1,,BAO_0000218,
7285,2107.0,Intermediate,Liver,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL624502,N,1,,,,,1,,BAO_0000218,
7286,2107.0,Intermediate,Liver,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL624503,N,1,,,,,1,,BAO_0000218,
7287,2107.0,Intermediate,Liver,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL624504,N,1,,,,,1,,BAO_0000218,
7288,2107.0,Intermediate,Liver,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL624505,N,1,,,,,1,,BAO_0000218,
7289,2048.0,Intermediate,Lung,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL624506,N,1,,,,,1,,BAO_0000218,
7290,,Intermediate,,81034,In vitro cytotoxicity against A2780 (human ovarian cancer),CHEMBL624507,N,1,478.0,A2780,,,1,,BAO_0000219,
7291,,Intermediate,,81034,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,CHEMBL624508,N,1,478.0,A2780,,,1,,BAO_0000219,
7292,,Intermediate,,81034,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,CHEMBL624509,N,1,478.0,A2780,,,1,,BAO_0000219,
7293,,Intermediate,,81034,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,CHEMBL624510,N,1,478.0,A2780,,,1,,BAO_0000219,
7294,,Expert,,81034,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,CHEMBL875956,N,1,478.0,A2780,,,1,,BAO_0000219,
7295,,Expert,,81034,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,CHEMBL839885,N,1,478.0,A2780,,,1,,BAO_0000219,
7296,,Expert,,81034,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,CHEMBL624511,N,1,478.0,A2780,,,1,,BAO_0000219,
7297,,Intermediate,,81034,In vitro cytotoxicity against A2780 cell line,CHEMBL624512,N,1,478.0,A2780,,,1,,BAO_0000219,
7298,,Intermediate,,81034,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,CHEMBL624513,N,1,478.0,A2780,,,1,,BAO_0000219,
7299,,Intermediate,,81034,In vitro inhibitory activity against human ovarian cancer A2780 cell line,CHEMBL624514,N,1,478.0,A2780,,,1,,BAO_0000219,
7300,,Intermediate,,81034,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,CHEMBL618547,N,1,478.0,A2780,,,1,,BAO_0000218,
7301,,Intermediate,,81034,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",CHEMBL618548,N,1,478.0,A2780,,,1,,BAO_0000219,
7302,,Intermediate,,81034,Inhibition of tubulin polymerization in analogy of ca.,CHEMBL618549,N,1,478.0,A2780,,,1,,BAO_0000219,
7303,,Intermediate,,81034,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,CHEMBL618550,N,1,478.0,A2780,,,1,,BAO_0000219,
7304,,Expert,,81034,Cytotoxic effect in ovarian cancer cell line (A2780),CHEMBL618551,N,1,478.0,A2780,,,1,,BAO_0000219,
7305,,Intermediate,,81034,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,CHEMBL618552,N,1,478.0,A2780,,,1,,BAO_0000219,
7306,,Intermediate,,81034,Tested for the cytotoxicity in A2780 ovarian cell line,CHEMBL618553,N,1,478.0,A2780,,,1,,BAO_0000219,
7307,,Intermediate,,81034,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),CHEMBL618554,N,1,478.0,A2780,,,1,,BAO_0000219,
7308,,Intermediate,,81034,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,CHEMBL618555,N,1,478.0,A2780,,,1,,BAO_0000219,
7309,,Intermediate,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,CHEMBL618556,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
7310,,Intermediate,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),CHEMBL618557,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
7311,,Intermediate,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,CHEMBL618558,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
7312,,Intermediate,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),CHEMBL618559,N,1,481.0,A2780cisR,,,1,,BAO_0000219,
7313,,Intermediate,,81034,In vivo log of cells killed after administration of compound in A2780 cell line,CHEMBL618560,N,1,478.0,A2780,,,1,,BAO_0000218,
7314,,Intermediate,,81034,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,CHEMBL618561,N,1,478.0,A2780,,,1,,BAO_0000218,
7315,,Intermediate,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,CHEMBL618562,N,1,478.0,A2780,,,1,,BAO_0000219,
7316,,Intermediate,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,CHEMBL618563,N,1,478.0,A2780,,,1,,BAO_0000219,
7317,,Intermediate,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,CHEMBL618564,N,1,478.0,A2780,,,1,,BAO_0000219,
7318,,Intermediate,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,CHEMBL618565,N,1,478.0,A2780,,,1,,BAO_0000219,
7319,,Intermediate,,81034,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),CHEMBL618566,N,1,478.0,A2780,,,1,,BAO_0000218,
7320,,Intermediate,,81034,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,CHEMBL618567,N,1,478.0,A2780,,,1,,BAO_0000219,
7321,,Expert,,81034,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,CHEMBL618568,N,1,478.0,A2780,,,1,,BAO_0000219,
7322,,Expert,,81034,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,CHEMBL618569,N,1,478.0,A2780,,,1,,BAO_0000219,
7323,,Intermediate,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,CHEMBL621857,N,1,478.0,A2780,,,1,,BAO_0000219,
7324,,Intermediate,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,CHEMBL621858,N,1,478.0,A2780,,,1,,BAO_0000219,
7325,,Intermediate,,81034,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,CHEMBL621859,N,1,478.0,A2780,,,1,,BAO_0000219,
7326,,Intermediate,,81034,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",CHEMBL621860,N,1,478.0,A2780,,,1,,BAO_0000219,
7327,,Intermediate,,81034,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),CHEMBL621861,N,1,478.0,A2780,,,1,,BAO_0000219,
7328,,Expert,,81034,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",CHEMBL621862,N,1,478.0,A2780,,,1,,BAO_0000219,
7329,,Intermediate,,81034,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),CHEMBL621863,N,1,478.0,A2780,,,1,,BAO_0000219,
7330,,Intermediate,,81034,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),CHEMBL621864,N,1,478.0,A2780,,,1,,BAO_0000219,
7331,,Intermediate,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),CHEMBL621865,N,1,478.0,A2780,,,1,,BAO_0000219,
7332,,Intermediate,,81034,In vitro antiproliferative activity against A2780 cell line,CHEMBL621866,N,1,478.0,A2780,,,1,,BAO_0000219,
7333,,Expert,,81034,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,CHEMBL621867,N,1,478.0,A2780,,,1,,BAO_0000219,
7334,,Intermediate,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,CHEMBL621868,N,1,478.0,A2780,,,1,,BAO_0000219,
7335,,Intermediate,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,CHEMBL875282,N,1,478.0,A2780,,,1,,BAO_0000219,
7336,,Intermediate,,50588,Vc value in dog after IV administration at a dose of 5 mg/kg,CHEMBL621869,N,1,,,,,1,,BAO_0000218,
7337,,Intermediate,,50588,Half life period in dog after IV administration at a dose of 5 mg/kg,CHEMBL621870,N,1,,,,,1,,BAO_0000218,
7338,,Autocuration,,22224,Area under curve was determine after peroral administration at 10 mpk in Rhesus,CHEMBL621871,U,0,,,,,1,,BAO_0000019,
7339,1969.0,Autocuration,Plasma,22224,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL621243,U,0,,,,,1,,BAO_0000218,
7340,1969.0,Autocuration,Plasma,22224,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL621244,U,0,,,,,1,,BAO_0000218,
7341,,Autocuration,,22224,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,CHEMBL621245,U,0,,,,,1,,BAO_0000218,
7342,,Autocuration,,22224,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,CHEMBL621246,U,0,,,,,1,,BAO_0000218,
7343,,Autocuration,,22224,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,CHEMBL621247,U,0,,,,,1,,BAO_0000218,
7344,,Autocuration,,22224,Oral Bioavailability in rat,CHEMBL618386,U,0,,,,,1,,BAO_0000218,
7345,,Autocuration,,22224,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL618387,U,0,,,,,1,,BAO_0000218,
7346,,Autocuration,,22224,Area under curve value in monkey at a dose of 5 mg/kg,CHEMBL618388,U,0,,,,,1,,BAO_0000218,
7347,,Autocuration,,22224,Area under curve was determined in monkey after a 3 mg/kg of oral dose,CHEMBL618389,U,0,,,,,1,,BAO_0000218,
7348,,Autocuration,,22224,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,CHEMBL618574,U,0,,,,,1,,BAO_0000019,
7349,,Autocuration,,22224,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,CHEMBL618575,U,0,,,,,1,,BAO_0000019,
7350,,Autocuration,,22224,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,CHEMBL618576,U,0,,,,,1,,BAO_0000019,
7351,,Autocuration,,22224,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,CHEMBL618577,U,0,,,,,1,,BAO_0000218,
7352,,Autocuration,,22224,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,CHEMBL876487,U,0,,,,,1,,BAO_0000218,
7353,,Autocuration,,22224,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,CHEMBL618578,U,0,,,,,1,,BAO_0000218,
7354,,Autocuration,,22224,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL618579,U,0,,,,,1,,BAO_0000218,
7355,,Autocuration,,22224,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL618580,U,0,,,,,1,,BAO_0000019,
7356,,Autocuration,,22224,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,CHEMBL618581,U,0,,,,,1,,BAO_0000218,
7357,,Autocuration,,22224,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,CHEMBL618582,U,0,,,,,1,,BAO_0000218,
7358,,Autocuration,,22224,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,CHEMBL618583,U,0,,,,,1,,BAO_0000218,
7359,,Autocuration,,22224,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,CHEMBL618584,U,0,,,,,1,,BAO_0000218,
7360,,Autocuration,,22224,Oral AUCN in monkey (dosed at 0.5 mpk iv ),CHEMBL618585,U,0,,,,,1,,BAO_0000218,
7361,,Autocuration,,22224,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),CHEMBL618586,U,0,,,,,1,,BAO_0000218,
7362,,Autocuration,,22224,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL618587,U,0,,,,,1,,BAO_0000218,
7363,,Autocuration,,22224,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL618588,U,0,,,,,1,,BAO_0000218,
7364,,Autocuration,,22224,Binding towards monkey plasma protein at 10 uM,CHEMBL618589,U,0,,,,,1,,BAO_0000019,
7365,,Autocuration,,22224,Binding towards monkey plasma protein at 100 uM,CHEMBL618590,U,0,,,,,1,,BAO_0000019,
7366,,Autocuration,,22224,Apparent bioavailability in squirrel monkey was determined,CHEMBL872262,U,0,,,,,1,,BAO_0000218,
7367,,Autocuration,,22224,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,CHEMBL618591,U,0,,,,,1,,BAO_0000218,
7368,,Autocuration,,22224,Bioavailability in monkey (dose 2 mg/kg),CHEMBL618592,U,0,,,,,1,,BAO_0000218,
7369,,Autocuration,,22224,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,CHEMBL876488,U,0,,,,,1,,BAO_0000218,
7370,,Autocuration,,22224,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL618593,U,0,,,,,1,,BAO_0000218,
7371,,Autocuration,,22224,Bioavailability in monkey (i.d. dosing),CHEMBL618594,U,0,,,,,1,,BAO_0000218,
7372,,Autocuration,,22224,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,CHEMBL618595,U,0,,,,,1,,BAO_0000218,
7373,,Autocuration,,22224,Clearance of the drug was measured in cynomolgus,CHEMBL621469,U,0,,,,,1,,BAO_0000019,
7374,,Autocuration,,22224,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,CHEMBL621470,U,0,,,,,1,,BAO_0000218,
7375,,Autocuration,,22224,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL621471,U,0,,,,,1,,BAO_0000218,
7376,1969.0,Autocuration,Plasma,22224,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL621472,U,0,,,,,1,,BAO_0000218,
7377,,Autocuration,,22224,Plasma clearance in rhesus monkey was determined,CHEMBL621473,U,0,,,,,1,,BAO_0000218,
7378,,Autocuration,,22224,Plasma clearance in monkey after administration of 1 mg/kg iv,CHEMBL621474,U,0,,,,,1,,BAO_0000218,
7379,,Autocuration,,22224,Plasma clearance in cynomolgus monkey,CHEMBL621475,U,0,,,,,1,,BAO_0000218,
7380,,Autocuration,,22224,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL621476,U,0,,,,,1,,BAO_0000218,
7381,,Autocuration,,22224,Plasma clearance after peroral administration at 10 mpk in Rhesus,CHEMBL624290,U,0,,,,,1,,BAO_0000218,
7382,,Autocuration,,22224,The total clearance was determined after intravenous administration in cynomolgus monkeys,CHEMBL624291,U,0,,,,,1,,BAO_0000218,
7383,,Autocuration,,22224,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,CHEMBL624292,U,0,,,,,1,,BAO_0000218,
7384,,Autocuration,,22224,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,CHEMBL624293,U,0,,,,,1,,BAO_0000218,
7385,,Autocuration,,22224,Tested for Clearance upon iv administration to african green monkey,CHEMBL624294,U,0,,,,,1,,BAO_0000218,
7386,,Autocuration,,22224,Clearance in monkey,CHEMBL624295,U,0,,,,,1,,BAO_0000218,
7387,,Intermediate,,50588,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624296,N,1,,,,,1,,BAO_0000218,
7388,,Intermediate,,50588,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624297,N,1,,,,,1,,BAO_0000218,
7389,,Intermediate,,50588,Half life was evaluated after intravenous administration to dogs,CHEMBL624298,N,1,,,,,1,,BAO_0000218,
7390,,Intermediate,,50588,Half life was evaluated in dog,CHEMBL624299,N,1,,,,,1,,BAO_0000218,
7391,,Intermediate,,50588,Half life was evaluated in dog,CHEMBL624300,N,1,,,,,1,,BAO_0000218,
7392,,Intermediate,,50588,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,CHEMBL624301,N,1,,,,,1,,BAO_0000218,
7393,,Intermediate,,50588,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),CHEMBL624302,N,1,,,,,1,,BAO_0000218,
7394,,Intermediate,,50588,Half life period after intravenous administration in dog,CHEMBL876026,N,1,,,,,1,,BAO_0000218,
7395,,Intermediate,,50588,Half life period after oral administration (2.5 mg/kg) in dog was determined,CHEMBL624303,N,1,,,,,1,,BAO_0000218,
7396,,Intermediate,,50588,Half life period at a dose of 1 uM/kg in dog was determined,CHEMBL624304,N,1,,,,,1,,BAO_0000218,
7397,,Intermediate,,50588,Half life period was determine after peroral administration at 10 mpk in dog,CHEMBL624305,N,1,,,,,1,,BAO_0000218,
7398,,Intermediate,,50588,Half life period was determine after peroral administration at 5 mpk in dog,CHEMBL624306,N,1,,,,,1,,BAO_0000218,
7399,,Intermediate,,50588,Half life period was determined,CHEMBL624307,N,1,,,,,1,,BAO_0000218,
7400,,Intermediate,,50588,Half life period was determined,CHEMBL624308,N,1,,,,,1,,BAO_0000218,
7401,,Intermediate,,50588,Half life period by iv administration in dog at a dose of 6 mg/kg,CHEMBL624309,N,1,,,,,1,,BAO_0000218,
7402,,Intermediate,,50588,Half life period was evaluated in dog,CHEMBL624310,N,1,,,,,1,,BAO_0000218,
7403,,Intermediate,,50588,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,CHEMBL625003,N,1,,,,,1,,BAO_0000218,
7404,,Intermediate,,50588,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),CHEMBL625004,N,1,,,,,1,,BAO_0000218,
7405,,Intermediate,,50588,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,CHEMBL625005,N,1,,,,,1,,BAO_0000218,
7406,,Intermediate,,50588,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL873813,N,1,,,,,1,,BAO_0000218,
7407,,Intermediate,,50588,Half-life after oral dose of compound at 3 mg/kg in dogs,CHEMBL625006,N,1,,,,,1,,BAO_0000218,
7408,,Intermediate,,50588,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,CHEMBL625007,N,1,,,,,1,,BAO_0000218,
7409,,Intermediate,,50588,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,CHEMBL876027,N,1,,,,,1,,BAO_0000218,
7410,,Intermediate,,50588,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,CHEMBL625008,N,1,,,,,1,,BAO_0000218,
7411,,Intermediate,,50588,Half-life of compound in dog following p.o. administration of 1 mg/kg,CHEMBL625009,N,1,,,,,1,,BAO_0000218,
7412,1969.0,Intermediate,Plasma,50588,Half-life of compound in plasma of dog was determined,CHEMBL625010,N,1,,,,,1,,BAO_0000218,
7413,,Intermediate,,50588,Half-life of compound was determined in dogs,CHEMBL625011,N,1,,,,,1,,BAO_0000218,
7414,,Intermediate,,50588,Half-life after administration of 4 mg/Kg oral dose in dog,CHEMBL621553,N,1,,,,,1,,BAO_0000218,
7415,,Intermediate,,50588,Half-life after intravenous administration of 1 mg/kg/h in dog,CHEMBL621554,N,1,,,,,1,,BAO_0000218,
7416,,Intermediate,,50588,Half-life in Dog,CHEMBL621555,N,1,,,,,1,,BAO_0000218,
7417,,Intermediate,,50588,Half-life in Dog,CHEMBL621556,N,1,,,,,1,,BAO_0000218,
7418,,Intermediate,,50588,Half-life in dog,CHEMBL621557,N,1,,,,,1,,BAO_0000218,
7419,,Intermediate,,50588,Half-life in dog after oral administration at 1 mg/kg,CHEMBL621558,N,1,,,,,1,,BAO_0000218,
7420,,Intermediate,,50588,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,CHEMBL621559,N,1,,,,,1,,BAO_0000218,
7421,,Intermediate,,50588,Half-life in dogs,CHEMBL621560,N,1,,,,,1,,BAO_0000218,
7422,,Intermediate,,50588,Half-life in dogs; ND indicates not determined,CHEMBL876028,N,1,,,,,1,,BAO_0000218,
7423,1969.0,Intermediate,Plasma,50588,Half-life in plasma of dog,CHEMBL621561,N,1,,,,,1,,BAO_0000218,
7424,1969.0,Intermediate,Plasma,50588,Half-life in plasma of dog at dose of 3-10 mgkg,CHEMBL621562,N,1,,,,,1,,BAO_0000218,
7425,,Intermediate,,50588,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,CHEMBL621563,N,1,,,,,1,,BAO_0000218,
7426,,Intermediate,,50588,Half-life was measured in dog after an iv dose of 1 mg/kg,CHEMBL621564,N,1,,,,,1,,BAO_0000218,
7427,,Intermediate,,50588,Half-life was measured in dogs after an oral dose of 10 uM/kg,CHEMBL621565,N,1,,,,,1,,BAO_0000218,
7428,,Intermediate,,50588,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,CHEMBL621566,N,1,,,,,1,,BAO_0000218,
7429,,Intermediate,,50588,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,CHEMBL621567,N,1,,,,,1,,BAO_0000218,
7430,,Intermediate,,50588,Half-life of the compound after 0.3 mg/kg po administration in dog,CHEMBL622978,N,1,,,,,1,,BAO_0000218,
7431,,Intermediate,,50588,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,CHEMBL873814,N,1,,,,,1,,BAO_0000218,
7432,,Intermediate,,50588,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,CHEMBL623219,N,1,,,,,1,,BAO_0000218,
7433,,Intermediate,,50588,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,CHEMBL624477,N,1,,,,,1,,BAO_0000218,
7434,,Intermediate,,50588,t1/2 in dog,CHEMBL624478,N,1,,,,,1,,BAO_0000218,
7435,,Intermediate,,50588,Half-life period measured in dogs,CHEMBL624479,N,1,,,,,1,,BAO_0000218,
7436,,Intermediate,,50588,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,CHEMBL624480,N,1,,,,,1,,BAO_0000218,
7437,,Intermediate,,50588,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL623595,N,1,,,,,1,,BAO_0000218,
7438,,Intermediate,,50588,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL623596,N,1,,,,,1,,BAO_0000218,
7439,1969.0,Intermediate,Plasma,50588,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",CHEMBL623597,N,1,,,,,1,,BAO_0000218,
7440,,Intermediate,,50588,In vivo half life period was calculated at 1 mg/kg in dog,CHEMBL623598,N,1,,,,,1,,BAO_0000218,
7441,,Intermediate,,50588,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,CHEMBL623599,N,1,,,,,1,,BAO_0000218,
7442,,Intermediate,,50588,Longer half-life in dog (i.v.) at 0.5 mpk,CHEMBL623600,N,1,,,,,1,,BAO_0000218,
7443,,Intermediate,,50588,Oral bioavailability in dog (dose 5 uM/kg),CHEMBL623601,N,1,,,,,1,,BAO_0000218,
7444,,Intermediate,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,CHEMBL623602,N,1,,,,,1,,BAO_0000218,
7445,,Intermediate,,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,CHEMBL623603,N,1,,,,,1,,BAO_0000218,
7446,,Intermediate,,50588,Bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL623604,N,1,,,,,1,,BAO_0000218,
7447,2048.0,Intermediate,Lung,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL623605,N,1,,,,,1,,BAO_0000218,
7448,2048.0,Intermediate,Lung,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL623606,N,1,,,,,1,,BAO_0000218,
7449,2048.0,Intermediate,Lung,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL623607,N,1,,,,,1,,BAO_0000218,
7450,2048.0,Intermediate,Lung,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL623608,N,1,,,,,1,,BAO_0000218,
7451,2048.0,Intermediate,Lung,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL623609,N,1,,,,,1,,BAO_0000218,
7452,2048.0,Intermediate,Lung,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL623610,N,1,,,,,1,,BAO_0000218,
7453,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL623611,N,1,,,,,1,,BAO_0000218,
7454,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL623612,N,1,,,,,1,,BAO_0000218,
7455,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL623613,N,1,,,,,1,,BAO_0000218,
7456,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL623614,N,1,,,,,1,,BAO_0000218,
7457,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL623615,N,1,,,,,1,,BAO_0000218,
7458,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL623616,N,1,,,,,1,,BAO_0000218,
7459,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL623617,N,1,,,,,1,,BAO_0000218,
7460,14.0,Intermediate,Zone of skin,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL875944,N,1,,,,,1,,BAO_0000218,
7461,14.0,Intermediate,Zone of skin,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL623618,N,1,,,,,1,,BAO_0000218,
7462,14.0,Intermediate,Zone of skin,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL623619,N,1,,,,,1,,BAO_0000218,
7463,14.0,Intermediate,Zone of skin,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL623620,N,1,,,,,1,,BAO_0000218,
7464,14.0,Intermediate,Zone of skin,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL623621,N,1,,,,,1,,BAO_0000218,
7465,14.0,Intermediate,Zone of skin,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL623622,N,1,,,,,1,,BAO_0000218,
7466,14.0,Intermediate,Zone of skin,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL623623,N,1,,,,,1,,BAO_0000218,
7467,2106.0,Intermediate,Spleen,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL623624,N,1,,,,,1,,BAO_0000218,
7468,2106.0,Intermediate,Spleen,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL618521,N,1,,,,,1,,BAO_0000218,
7469,2106.0,Intermediate,Spleen,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL618522,N,1,,,,,1,,BAO_0000218,
7470,2106.0,Intermediate,Spleen,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL618523,N,1,,,,,1,,BAO_0000218,
7471,2106.0,Intermediate,Spleen,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL618524,N,1,,,,,1,,BAO_0000218,
7472,2106.0,Intermediate,Spleen,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL618525,N,1,,,,,1,,BAO_0000218,
7473,2106.0,Intermediate,Spleen,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL624586,N,1,,,,,1,,BAO_0000218,
7474,945.0,Intermediate,Stomach,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL624587,N,1,,,,,1,,BAO_0000218,
7475,945.0,Intermediate,Stomach,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL624588,N,1,,,,,1,,BAO_0000218,
7476,945.0,Intermediate,Stomach,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL624589,N,1,,,,,1,,BAO_0000218,
7477,945.0,Intermediate,Stomach,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL624590,N,1,,,,,1,,BAO_0000218,
7478,945.0,Intermediate,Stomach,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL624591,N,1,,,,,1,,BAO_0000218,
7479,945.0,Intermediate,Stomach,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL624592,N,1,,,,,1,,BAO_0000218,
7480,945.0,Intermediate,Stomach,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL624593,N,1,,,,,1,,BAO_0000218,
7481,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL624594,N,1,,,,,1,,BAO_0000218,
7482,,Intermediate,,50597,Tested for the bioavailability in rat,CHEMBL624595,N,1,,,,,1,,BAO_0000218,
7483,,Intermediate,,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),CHEMBL624596,N,1,,,,,1,,BAO_0000218,
7484,,Intermediate,,50597,Bioavailability in rat,CHEMBL624597,N,1,,,,,1,,BAO_0000218,
7485,,Intermediate,,50597,Bioavailability in rat,CHEMBL624598,N,1,,,,,1,,BAO_0000218,
7486,,Intermediate,,50597,Bioavailability in rat (dose 3-10 mg/kg),CHEMBL624599,N,1,,,,,1,,BAO_0000218,
7487,,Intermediate,,50597,Bioavailability in rat,CHEMBL875166,N,1,,,,,1,,BAO_0000218,
7488,1969.0,Intermediate,Plasma,50597,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,CHEMBL624600,N,1,,,,,1,,BAO_0000218,
7489,1969.0,Intermediate,Plasma,50597,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,CHEMBL624601,N,1,,,,,1,,BAO_0000218,
7490,,Intermediate,,50597,Half life after oral administration was determined in rats at 6 mg/kg,CHEMBL624602,N,1,,,,,1,,BAO_0000218,
7491,,Intermediate,,50597,Half life was determined,CHEMBL624603,N,1,,,,,1,,BAO_0000218,
7492,,Intermediate,,50597,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,CHEMBL624604,N,1,,,,,1,,BAO_0000218,
7493,1969.0,Intermediate,Plasma,50597,Plasma half life in rat at oral dose 2.8 mg/mk body weight,CHEMBL624605,N,1,,,,,1,,BAO_0000218,
7494,,Intermediate,,50597,Half life in rats,CHEMBL624606,N,1,,,,,1,,BAO_0000218,
7495,178.0,Intermediate,Blood,50597,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,CHEMBL624607,N,1,,,,,1,,BAO_0000218,
7496,,Intermediate,,50597,Hill coefficient of the compound,CHEMBL624608,N,1,,,,,1,,BAO_0000218,
7497,178.0,Intermediate,Blood,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,CHEMBL624609,N,1,,,,,1,,BAO_0000218,
7498,178.0,Intermediate,Blood,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,CHEMBL624610,N,1,,,,,1,,BAO_0000218,
7499,178.0,Intermediate,Blood,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,CHEMBL624611,N,1,,,,,1,,BAO_0000218,
7500,178.0,Intermediate,Blood,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,CHEMBL624612,N,1,,,,,1,,BAO_0000218,
7501,178.0,Intermediate,Blood,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,CHEMBL875167,N,1,,,,,1,,BAO_0000218,
7502,178.0,Intermediate,Blood,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,CHEMBL624613,N,1,,,,,1,,BAO_0000218,
7503,178.0,Intermediate,Blood,50597,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",CHEMBL624614,N,1,,,,,1,,BAO_0000218,
7504,,Intermediate,,50597,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,CHEMBL624392,N,1,,,,,1,,BAO_0000218,
7505,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,CHEMBL624393,N,1,,,,,1,,BAO_0000218,
7506,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,CHEMBL624394,N,1,,,,,1,,BAO_0000218,
7507,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,CHEMBL624395,N,1,,,,,1,,BAO_0000218,
7508,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,CHEMBL624396,N,1,,,,,1,,BAO_0000218,
7509,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,CHEMBL624397,N,1,,,,,1,,BAO_0000218,
7510,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,CHEMBL624398,N,1,,,,,1,,BAO_0000218,
7511,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,CHEMBL624399,N,1,,,,,1,,BAO_0000218,
7512,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,CHEMBL624400,N,1,,,,,1,,BAO_0000218,
7513,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,CHEMBL624401,N,1,,,,,1,,BAO_0000218,
7514,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,CHEMBL624402,N,1,,,,,1,,BAO_0000218,
7515,178.0,Intermediate,Blood,50597,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL624403,N,1,,,,,1,,BAO_0000218,
7516,178.0,Intermediate,Blood,50597,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,CHEMBL624404,N,1,,,,,1,,BAO_0000218,
7517,178.0,Intermediate,Blood,50597,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL624405,N,1,,,,,1,,BAO_0000218,
7518,10000001.0,Intermediate,Bone,50597,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL624406,N,1,,,,,1,,BAO_0000218,
7519,10000001.0,Intermediate,Bone,50597,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,CHEMBL624407,N,1,,,,,1,,BAO_0000218,
7520,10000001.0,Intermediate,Bone,50597,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL624408,N,1,,,,,1,,BAO_0000218,
7521,948.0,Intermediate,Heart,50597,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL618644,N,1,,,,,1,,BAO_0000218,
7522,948.0,Intermediate,Heart,50597,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,CHEMBL618645,N,1,,,,,1,,BAO_0000218,
7523,948.0,Intermediate,Heart,50597,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL618646,N,1,,,,,1,,BAO_0000218,
7524,2113.0,Intermediate,Kidney,50597,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL618647,N,1,,,,,1,,BAO_0000218,
7525,2113.0,Intermediate,Kidney,50597,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,CHEMBL618648,N,1,,,,,1,,BAO_0000218,
7526,2113.0,Intermediate,Kidney,50597,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL618649,N,1,,,,,1,,BAO_0000218,
7527,2107.0,Intermediate,Liver,50597,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL618650,N,1,,,,,1,,BAO_0000218,
7528,2107.0,Intermediate,Liver,50597,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,CHEMBL618651,N,1,,,,,1,,BAO_0000218,
7529,2107.0,Intermediate,Liver,50597,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL876497,N,1,,,,,1,,BAO_0000218,
7530,2048.0,Intermediate,Lung,50597,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL618652,N,1,,,,,1,,BAO_0000218,
7531,2048.0,Intermediate,Lung,50597,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,CHEMBL618653,N,1,,,,,1,,BAO_0000218,
7532,2048.0,Intermediate,Lung,50597,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL618654,N,1,,,,,1,,BAO_0000218,
7533,,Intermediate,,50597,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,CHEMBL618655,N,1,,,,,1,,BAO_0000218,
7534,,Intermediate,,50597,Compound was tested for solubility in water,CHEMBL618656,N,1,,,,,1,,BAO_0000218,
7535,,Intermediate,,22229,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),CHEMBL618657,U,0,,,,,1,,BAO_0000100,
7536,,Intermediate,,50597,Solubility was determined,CHEMBL618658,N,1,,,,,1,,BAO_0000218,
7537,,Intermediate,,50597,solubility in water (ug/mL) at 37 degree C.,CHEMBL618659,N,1,,,,,1,,BAO_0000218,
7538,,Intermediate,,50597,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,CHEMBL618660,N,1,,,,,1,,BAO_0000218,
7539,,Intermediate,,50597,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,CHEMBL618661,N,1,,,,,1,,BAO_0000218,
7540,,Intermediate,,50597,Half life in rats,CHEMBL873807,N,1,,,,,1,,BAO_0000218,
7541,,Intermediate,,50597,Half life in Dawley rat,CHEMBL618662,N,1,,,,,1,,BAO_0000218,
7542,,Intermediate,,50597,Half life period after 3 mg/kg iv administration,CHEMBL618663,N,1,,,,,1,,BAO_0000218,
7543,,Intermediate,,50597,Half life period after 3 mg/kg iv administration in rat,CHEMBL618664,N,1,,,,,1,,BAO_0000218,
7544,,Intermediate,,50597,Half life period after 3 mg/kg iv administration in the rat,CHEMBL618665,N,1,,,,,1,,BAO_0000218,
7545,,Intermediate,,50597,Half life period in female Sprague-Dawley rats,CHEMBL876498,N,1,,,,,1,,BAO_0000218,
7546,,Intermediate,,50597,Half life period in rat,CHEMBL618666,N,1,,,,,1,,BAO_0000218,
7547,,Intermediate,,50597,Half-life in rats was determined,CHEMBL620440,N,1,,,,,1,,BAO_0000218,
7548,,Intermediate,,50597,Half-life in rats with metabolic oxidation,CHEMBL620441,N,1,,,,,1,,BAO_0000218,
7549,,Intermediate,,50597,Half-life in rats,CHEMBL620442,N,1,,,,,1,,BAO_0000218,
7550,,Intermediate,,50597,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,CHEMBL620443,N,1,,,,,1,,BAO_0000218,
7551,,Intermediate,,50597,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,CHEMBL620444,N,1,,,,,1,,BAO_0000218,
7552,,Intermediate,,50597,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,CHEMBL620445,N,1,,,,,1,,BAO_0000218,
7553,,Intermediate,,50597,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,CHEMBL620446,N,1,,,,,1,,BAO_0000218,
7554,1969.0,Intermediate,Plasma,50597,Biological half-life measured in plasma of rat,CHEMBL620447,N,1,,,,,1,,BAO_0000218,
7555,1969.0,Intermediate,Plasma,50597,Biological half-life measured in plasma of rat; 22-25,CHEMBL621129,N,1,,,,,1,,BAO_0000218,
7556,1969.0,Intermediate,Plasma,50597,Biological half-life measured in plasma of rat; 9-16,CHEMBL621130,N,1,,,,,1,,BAO_0000218,
7557,,Intermediate,,50597,Compound was evaluated for its half life when administered intravenously in rat,CHEMBL873808,N,1,,,,,1,,BAO_0000218,
7558,,Intermediate,,50597,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,CHEMBL876598,N,1,,,,,1,,BAO_0000218,
7559,,Intermediate,,50597,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,CHEMBL621131,N,1,,,,,1,,BAO_0000218,
7560,,Intermediate,,50597,Half life (T1/2) after oral administration in rat,CHEMBL621132,N,1,,,,,1,,BAO_0000218,
7561,,Intermediate,,50597,Half life of compound after iv administration of 20 mg/kg dose in rat,CHEMBL621133,N,1,,,,,1,,BAO_0000218,
7562,,Expert,,50597,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL621312,N,1,,,,,1,,BAO_0000218,
7563,,Intermediate,,50597,Half life of compound was determined in rat,CHEMBL621313,N,1,,,,,1,,BAO_0000218,
7564,178.0,Intermediate,Blood,50597,Half life of compound was determined in rat blood,CHEMBL621314,N,1,,,,,1,,BAO_0000218,
7565,,Intermediate,,50597,Half life at 1 mg/kg was determined in rat,CHEMBL621315,N,1,,,,,1,,BAO_0000218,
7566,,Intermediate,,50597,Half life at 10 mg/kg was determined in rat,CHEMBL621316,N,1,,,,,1,,BAO_0000218,
7567,,Intermediate,,50597,Half life in rats,CHEMBL621317,N,1,,,,,1,,BAO_0000218,
7568,,Intermediate,,50597,Half life in rats in hours,CHEMBL621318,N,1,,,,,1,,BAO_0000218,
7569,,Intermediate,,50597,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,CHEMBL621319,N,1,,,,,1,,BAO_0000218,
7570,,Intermediate,,50597,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,CHEMBL621377,N,1,,,,,1,,BAO_0000218,
7571,,Intermediate,,50597,Half life was determined,CHEMBL621378,N,1,,,,,1,,BAO_0000218,
7572,,Intermediate,,50597,Half life after i.v. administration,CHEMBL876599,N,1,,,,,1,,BAO_0000218,
7573,,Intermediate,,50597,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,CHEMBL621379,N,1,,,,,1,,BAO_0000218,
7574,1969.0,Intermediate,Plasma,50597,Half life in rat plasma,CHEMBL621380,N,1,,,,,1,,BAO_0000218,
7575,1969.0,Intermediate,Plasma,50597,Half life in rat plasma; Not detected,CHEMBL621381,N,1,,,,,1,,BAO_0000218,
7576,,Intermediate,,50597,Half life in rats,CHEMBL618515,N,1,,,,,1,,BAO_0000218,
7577,,Intermediate,,50597,Half life period of compound was determined after peroral administration,CHEMBL618516,N,1,,,,,1,,BAO_0000218,
7578,,Intermediate,,50597,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,CHEMBL618517,N,1,,,,,1,,BAO_0000218,
7579,,Intermediate,,50597,Half life period in rat,CHEMBL618518,N,1,,,,,1,,BAO_0000218,
7580,,Intermediate,,50597,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,CHEMBL618519,N,1,,,,,1,,BAO_0000218,
7581,,Intermediate,,50597,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,CHEMBL618698,N,1,,,,,1,,BAO_0000218,
7582,,Intermediate,,50597,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,CHEMBL618862,N,1,,,,,1,,BAO_0000218,
7583,,Intermediate,,50597,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,CHEMBL618863,N,1,,,,,1,,BAO_0000218,
7584,,Intermediate,,50597,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,CHEMBL618864,N,1,,,,,1,,BAO_0000218,
7585,,Intermediate,,50597,Half life time in rat the dose of 2 mg/kg,CHEMBL618865,N,1,,,,,1,,BAO_0000218,
7586,,Intermediate,,50597,Half-life 24 hr after 10 mg/kg iv administration in rats,CHEMBL618866,N,1,,,,,1,,BAO_0000218,
7587,,Intermediate,,50597,Half-life 24 hr after 2 mg/kg iv administration in rats,CHEMBL618867,N,1,,,,,1,,BAO_0000218,
7588,,Intermediate,,50597,Half-life consistent with the observed metabolic steady state in rats,CHEMBL875828,N,1,,,,,1,,BAO_0000218,
7589,,Intermediate,,50597,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,CHEMBL618868,N,1,,,,,1,,BAO_0000218,
7590,,Intermediate,,50597,Half-life for oxidative metabolic stability was determined using male human,CHEMBL618869,N,1,,,,,1,,BAO_0000218,
7591,,Intermediate,,50597,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",CHEMBL618870,N,1,,,,,1,,BAO_0000218,
7592,1969.0,Intermediate,Plasma,50597,Half-life in rat plasma,CHEMBL618871,N,1,,,,,1,,BAO_0000218,
7593,1969.0,Intermediate,Plasma,50597,Half-life in rat plasma was determined,CHEMBL618872,N,1,,,,,1,,BAO_0000218,
7594,,Intermediate,,50597,Half-life in rats was determined,CHEMBL873816,N,1,,,,,1,,BAO_0000218,
7595,,Autocuration,,22224,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,CHEMBL618873,U,0,,,,,1,,BAO_0000218,
7596,,Autocuration,,22224,Area under curve after oral dose of 0.1 mg//kg,CHEMBL621602,U,0,,,,,1,,BAO_0000019,
7597,,Autocuration,,22224,Area under curve after oral dose of 0.3 mg/kg,CHEMBL621603,U,0,,,,,1,,BAO_0000218,
7598,,Autocuration,,22224,Area under curve after oral dose of 1 mg/kg,CHEMBL621604,U,0,,,,,1,,BAO_0000218,
7599,,Autocuration,,22224,Area under curve after oral dose of 10 mg/kg,CHEMBL621605,U,0,,,,,1,,BAO_0000218,
7600,,Autocuration,,22224,Area under curve after oral dose of 23.4 mg/kg,CHEMBL621606,U,0,,,,,1,,BAO_0000218,
7601,,Autocuration,,22224,Area under curve after oral dose of 3 mg/kg,CHEMBL621607,U,0,,,,,1,,BAO_0000218,
7602,,Autocuration,,22224,Area under curve after oral dose of 3.87 mg/kg,CHEMBL621608,U,0,,,,,1,,BAO_0000218,
7603,,Autocuration,,22224,Area under curve was determined,CHEMBL621609,U,0,,,,,1,,BAO_0000019,
7604,,Autocuration,,22224,Area under curve at a dose of 10 mg/kg,CHEMBL621610,U,0,,,,,1,,BAO_0000218,
7605,,Intermediate,,50597,Area under curve was determined; ND=No data,CHEMBL621611,N,1,,,,,1,,BAO_0000218,
7606,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,CHEMBL621612,N,1,,,,,1,,BAO_0000218,
7607,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,CHEMBL622308,N,1,,,,,1,,BAO_0000218,
7608,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,CHEMBL622309,N,1,,,,,1,,BAO_0000218,
7609,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,CHEMBL622310,N,1,,,,,1,,BAO_0000218,
7610,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,CHEMBL622311,N,1,,,,,1,,BAO_0000218,
7611,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,CHEMBL622312,N,1,,,,,1,,BAO_0000218,
7612,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,CHEMBL622931,N,1,,,,,1,,BAO_0000218,
7613,,Intermediate,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,CHEMBL622932,N,1,,,,,1,,BAO_0000218,
7614,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,CHEMBL622736,N,1,,,,,1,,BAO_0000218,
7615,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,CHEMBL622737,N,1,,,,,1,,BAO_0000218,
7616,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,CHEMBL622738,N,1,,,,,1,,BAO_0000218,
7617,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,CHEMBL622739,N,1,,,,,1,,BAO_0000218,
7618,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,CHEMBL622740,N,1,,,,,1,,BAO_0000218,
7619,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,CHEMBL622741,N,1,,,,,1,,BAO_0000218,
7620,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,CHEMBL622742,N,1,,,,,1,,BAO_0000218,
7621,1969.0,Intermediate,Plasma,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,CHEMBL622743,N,1,,,,,1,,BAO_0000218,
7622,1969.0,Intermediate,Plasma,50594,AUC in mice,CHEMBL622744,N,1,,,,,1,,BAO_0000218,
7623,,Autocuration,,22224,Area under curve was measured from the graph obtained from concentration Vs time,CHEMBL624134,U,0,,,,,1,,BAO_0000019,
7624,,Autocuration,,22224,Area under curve value of compound per hour after oral administration,CHEMBL624135,U,0,,,,,1,,BAO_0000019,
7625,,Intermediate,,50597,Area under curve was determined after oral administration in rats,CHEMBL624136,N,1,,,,,1,,BAO_0000218,
7626,,Intermediate,,50597,Area under curve was determined after oral administration in rats; No data,CHEMBL624137,N,1,,,,,1,,BAO_0000218,
7627,,Intermediate,,50597,Area under curve was determined after oral administration in rats;No data,CHEMBL624320,N,1,,,,,1,,BAO_0000218,
7628,,Intermediate,,50588,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,CHEMBL624321,N,1,,,,,1,,BAO_0000218,
7629,,Intermediate,,50597,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,CHEMBL624322,N,1,,,,,1,,BAO_0000218,
7630,,Intermediate,,50597,Area under curve was determined for the compound after iv dose of 5.06 in rats,CHEMBL624323,N,1,,,,,1,,BAO_0000218,
7631,,Intermediate,,50597,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,CHEMBL624324,N,1,,,,,1,,BAO_0000218,
7632,,Intermediate,,50597,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,CHEMBL624325,N,1,,,,,1,,BAO_0000218,
7633,,Intermediate,,50597,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,CHEMBL624326,N,1,,,,,1,,BAO_0000218,
7634,,Intermediate,,50597,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,CHEMBL624327,N,1,,,,,1,,BAO_0000218,
7635,,Intermediate,,50597,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,CHEMBL624328,N,1,,,,,1,,BAO_0000218,
7636,,Intermediate,,50588,Area under curve was determined in Dogs after peroral administration,CHEMBL627848,N,1,,,,,1,,BAO_0000218,
7637,,Intermediate,,50597,Area under curve was determined in Rats after peroral administration,CHEMBL627849,N,1,,,,,1,,BAO_0000218,
7638,,Intermediate,,50597,Area under curve was determined in carotid blood of rat when administered intradermally,CHEMBL627850,N,1,,,,,1,,BAO_0000218,
7639,,Intermediate,,50597,Area under curve was determined in portal blood of rat when administered intradermally,CHEMBL627851,N,1,,,,,1,,BAO_0000218,
7640,,Intermediate,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,CHEMBL627852,N,1,,,,,1,,BAO_0000218,
7641,,Intermediate,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,CHEMBL627853,N,1,,,,,1,,BAO_0000218,
7642,,Intermediate,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),CHEMBL627854,N,1,,,,,1,,BAO_0000218,
7643,,Intermediate,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,CHEMBL627855,N,1,,,,,1,,BAO_0000218,
7644,,Intermediate,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),CHEMBL627856,N,1,,,,,1,,BAO_0000218,
7645,,Intermediate,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,CHEMBL875339,N,1,,,,,1,,BAO_0000218,
7646,,Intermediate,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),CHEMBL627857,N,1,,,,,1,,BAO_0000218,
7647,2106.0,Intermediate,Spleen,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,CHEMBL627858,N,1,,,,,1,,BAO_0000218,
7648,178.0,Intermediate,Blood,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,CHEMBL627859,N,1,,,,,1,,BAO_0000218,
7649,955.0,Intermediate,Brain,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,CHEMBL627860,N,1,,,,,1,,BAO_0000218,
7650,948.0,Intermediate,Heart,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,CHEMBL627019,N,1,,,,,1,,BAO_0000218,
7651,2107.0,Intermediate,Liver,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,CHEMBL627020,N,1,,,,,1,,BAO_0000218,
7652,2048.0,Intermediate,Lung,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,CHEMBL627021,N,1,,,,,1,,BAO_0000218,
7653,2385.0,Intermediate,Muscle tissue,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,CHEMBL627022,N,1,,,,,1,,BAO_0000218,
7654,,Intermediate,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,CHEMBL627023,N,1,,,,,1,,BAO_0000218,
7655,2106.0,Intermediate,Spleen,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,CHEMBL627024,N,1,,,,,1,,BAO_0000218,
7656,2046.0,Intermediate,Thyroid gland,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,CHEMBL627025,N,1,,,,,1,,BAO_0000218,
7657,2113.0,Intermediate,Kidney,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,CHEMBL627026,N,1,,,,,1,,BAO_0000218,
7658,178.0,Intermediate,Blood,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,CHEMBL627027,N,1,,,,,1,,BAO_0000218,
7659,955.0,Intermediate,Brain,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,CHEMBL627028,N,1,,,,,1,,BAO_0000218,
7660,948.0,Intermediate,Heart,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,CHEMBL627029,N,1,,,,,1,,BAO_0000218,
7661,2113.0,Intermediate,Kidney,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,CHEMBL627030,N,1,,,,,1,,BAO_0000218,
7662,2107.0,Intermediate,Liver,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,CHEMBL627031,N,1,,,,,1,,BAO_0000218,
7663,2048.0,Intermediate,Lung,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,CHEMBL627032,N,1,,,,,1,,BAO_0000218,
7664,2385.0,Intermediate,Muscle tissue,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,CHEMBL627033,N,1,,,,,1,,BAO_0000218,
7665,,Intermediate,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,CHEMBL627034,N,1,,,,,1,,BAO_0000218,
7666,2106.0,Intermediate,Spleen,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,CHEMBL627035,N,1,,,,,1,,BAO_0000218,
7667,2046.0,Intermediate,Thyroid gland,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,CHEMBL627036,N,1,,,,,1,,BAO_0000218,
7668,178.0,Intermediate,Blood,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,CHEMBL875340,N,1,,,,,1,,BAO_0000218,
7669,948.0,Intermediate,Heart,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,CHEMBL627037,N,1,,,,,1,,BAO_0000218,
7670,2113.0,Intermediate,Kidney,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,CHEMBL627038,N,1,,,,,1,,BAO_0000218,
7671,2107.0,Intermediate,Liver,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,CHEMBL627039,N,1,,,,,1,,BAO_0000218,
7672,2385.0,Intermediate,Muscle tissue,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,CHEMBL627040,N,1,,,,,1,,BAO_0000218,
7673,2106.0,Intermediate,Spleen,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,CHEMBL624663,N,1,,,,,1,,BAO_0000218,
7674,2046.0,Intermediate,Thyroid gland,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,CHEMBL625963,N,1,,,,,1,,BAO_0000218,
7675,955.0,Intermediate,Brain,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,CHEMBL876799,N,1,,,,,1,,BAO_0000218,
7676,2048.0,Intermediate,Lung,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,CHEMBL626133,N,1,,,,,1,,BAO_0000218,
7677,,Intermediate,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,CHEMBL626134,N,1,,,,,1,,BAO_0000218,
7678,,Intermediate,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,CHEMBL626135,N,1,,,,,1,,BAO_0000218,
7679,,Intermediate,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,CHEMBL626136,N,1,,,,,1,,BAO_0000218,
7680,,Intermediate,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,CHEMBL626137,N,1,,,,,1,,BAO_0000218,
7681,,Intermediate,,50597,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,CHEMBL626138,N,1,,,,,1,,BAO_0000218,
7682,,Intermediate,,50597,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,CHEMBL626139,N,1,,,,,1,,BAO_0000218,
7683,,Intermediate,,50597,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,CHEMBL626140,N,1,,,,,1,,BAO_0000218,
7684,,Intermediate,,50597,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,CHEMBL626141,N,1,,,,,1,,BAO_0000218,
7685,,Intermediate,,50597,C24h in rat p.o. at 20 mg/kg concentration,CHEMBL626142,N,1,,,,,1,,BAO_0000218,
7686,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL627930,N,1,,,,,1,,BAO_0000218,
7687,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,CHEMBL627931,N,1,,,,,1,,BAO_0000218,
7688,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL627932,N,1,,,,,1,,BAO_0000218,
7689,2106.0,Intermediate,Spleen,50597,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL627933,N,1,,,,,1,,BAO_0000218,
7690,2106.0,Intermediate,Spleen,50597,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,CHEMBL627934,N,1,,,,,1,,BAO_0000218,
7691,2106.0,Intermediate,Spleen,50597,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL627935,N,1,,,,,1,,BAO_0000218,
7692,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,CHEMBL627936,N,1,,,,,1,,BAO_0000218,
7693,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,CHEMBL627937,N,1,,,,,1,,BAO_0000218,
7694,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,CHEMBL627938,N,1,,,,,1,,BAO_0000218,
7695,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,CHEMBL627939,N,1,,,,,1,,BAO_0000218,
7696,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,CHEMBL627940,N,1,,,,,1,,BAO_0000218,
7697,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,CHEMBL627941,N,1,,,,,1,,BAO_0000218,
7698,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,CHEMBL876800,N,1,,,,,1,,BAO_0000218,
7699,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,CHEMBL627942,N,1,,,,,1,,BAO_0000218,
7700,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,CHEMBL627943,N,1,,,,,1,,BAO_0000218,
7701,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,CHEMBL627944,N,1,,,,,1,,BAO_0000218,
7702,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,CHEMBL627945,N,1,,,,,1,,BAO_0000218,
7703,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,CHEMBL628584,N,1,,,,,1,,BAO_0000218,
7704,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA at 15 min,CHEMBL628585,N,1,,,,,1,,BAO_0000218,
7705,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,CHEMBL628586,N,1,,,,,1,,BAO_0000218,
7706,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA at 30 min,CHEMBL628587,N,1,,,,,1,,BAO_0000218,
7707,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,CHEMBL628588,N,1,,,,,1,,BAO_0000218,
7708,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,CHEMBL628589,N,1,,,,,1,,BAO_0000218,
7709,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,CHEMBL625304,N,1,,,,,1,,BAO_0000218,
7710,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,CHEMBL625305,N,1,,,,,1,,BAO_0000218,
7711,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,CHEMBL625306,N,1,,,,,1,,BAO_0000218,
7712,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,CHEMBL625307,N,1,,,,,1,,BAO_0000218,
7713,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,CHEMBL625308,N,1,,,,,1,,BAO_0000218,
7714,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,CHEMBL627740,N,1,,,,,1,,BAO_0000218,
7715,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,CHEMBL627741,N,1,,,,,1,,BAO_0000218,
7716,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,CHEMBL627742,N,1,,,,,1,,BAO_0000218,
7717,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,CHEMBL627743,N,1,,,,,1,,BAO_0000218,
7718,178.0,Intermediate,Blood,50597,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,CHEMBL627744,N,1,,,,,1,,BAO_0000218,
7719,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,CHEMBL627745,N,1,,,,,1,,BAO_0000218,
7720,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,CHEMBL627746,N,1,,,,,1,,BAO_0000218,
7721,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,CHEMBL627747,N,1,,,,,1,,BAO_0000218,
7722,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,CHEMBL876810,N,1,,,,,1,,BAO_0000218,
7723,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,CHEMBL627748,N,1,,,,,1,,BAO_0000218,
7724,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,CHEMBL627749,N,1,,,,,1,,BAO_0000218,
7725,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,CHEMBL627750,N,1,,,,,1,,BAO_0000218,
7726,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,CHEMBL618728,N,1,,,,,1,,BAO_0000218,
7727,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,CHEMBL618729,N,1,,,,,1,,BAO_0000218,
7728,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA at 15 min,CHEMBL618730,N,1,,,,,1,,BAO_0000218,
7729,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,CHEMBL618731,N,1,,,,,1,,BAO_0000218,
7730,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA at 30 min,CHEMBL618732,N,1,,,,,1,,BAO_0000218,
7731,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,CHEMBL618733,N,1,,,,,1,,BAO_0000218,
7732,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,CHEMBL618734,N,1,,,,,1,,BAO_0000218,
7733,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,CHEMBL618735,N,1,,,,,1,,BAO_0000218,
7734,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,CHEMBL876602,N,1,,,,,1,,BAO_0000218,
7735,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,CHEMBL618736,N,1,,,,,1,,BAO_0000218,
7736,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,CHEMBL618737,N,1,,,,,1,,BAO_0000218,
7737,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,CHEMBL618738,N,1,,,,,1,,BAO_0000218,
7738,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,CHEMBL618739,N,1,,,,,1,,BAO_0000218,
7739,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,CHEMBL618740,N,1,,,,,1,,BAO_0000218,
7740,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,CHEMBL618741,N,1,,,,,1,,BAO_0000218,
7741,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,CHEMBL618742,N,1,,,,,1,,BAO_0000218,
7742,10000001.0,Intermediate,Bone,50597,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,CHEMBL618743,N,1,,,,,1,,BAO_0000218,
7743,1969.0,Intermediate,Plasma,50597,Half-life from rat plasma at a single oral dose of 25 mg/kg,CHEMBL618744,N,1,,,,,1,,BAO_0000218,
7744,,Intermediate,,50597,Half-life in male rat,CHEMBL618745,N,1,,,,,1,,BAO_0000218,
7745,,Intermediate,,50597,Half-life in rat after peroral administration at 10 mg/kg concentration,CHEMBL620479,N,1,,,,,1,,BAO_0000218,
7746,,Intermediate,,50597,Half-life in rat after peroral administration at 5 mg/kg concentration,CHEMBL620480,N,1,,,,,1,,BAO_0000218,
7747,,Intermediate,,50597,Half-life in rat at a dose of 3 mg/kg,CHEMBL620481,N,1,,,,,1,,BAO_0000218,
7748,,Intermediate,,50597,Half-life was evaluated in rats,CHEMBL620482,N,1,,,,,1,,BAO_0000218,
7749,,Intermediate,,50597,Half-life was measured in rat,CHEMBL876603,N,1,,,,,1,,BAO_0000218,
7750,,Intermediate,,50597,Half-life period for the compound was determined in rats at 50 mg/kg dose,CHEMBL620483,N,1,,,,,1,,BAO_0000218,
7751,,Intermediate,,50597,Half-life period in rats after intravenous administration at 5 mg/kg,CHEMBL620484,N,1,,,,,1,,BAO_0000218,
7752,,Intermediate,,50597,Half-life period in rat at 10 mg/kg,CHEMBL620485,N,1,,,,,1,,BAO_0000218,
7753,,Intermediate,,50597,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",CHEMBL620486,N,1,,,,,1,,BAO_0000218,
7754,,Intermediate,,50597,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",CHEMBL620487,N,1,,,,,1,,BAO_0000218,
7755,,Intermediate,,50597,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",CHEMBL620488,N,1,,,,,1,,BAO_0000218,
7756,,Intermediate,,50597,Half-life time in rat the dose of 2 mg/kg,CHEMBL620489,N,1,,,,,1,,BAO_0000218,
7757,,Intermediate,,50597,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,CHEMBL620490,N,1,,,,,1,,BAO_0000218,
7758,,Intermediate,,50597,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,CHEMBL620491,N,1,,,,,1,,BAO_0000218,
7759,1969.0,Intermediate,Plasma,50597,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",CHEMBL876604,N,1,,,,,1,,BAO_0000218,
7760,,Intermediate,,50597,Oral half life was determined,CHEMBL620492,N,1,,,,,1,,BAO_0000218,
7761,,Intermediate,,50597,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",CHEMBL620493,N,1,,,,,1,,BAO_0000218,
7762,,Intermediate,,50597,Pharmacokinetic property (t1/2) in rat,CHEMBL620494,N,1,,,,,1,,BAO_0000218,
7763,1969.0,Intermediate,Plasma,50597,Plasma elimination half-life was determined,CHEMBL620495,N,1,,,,,1,,BAO_0000218,
7764,1969.0,Intermediate,Plasma,50597,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,CHEMBL620496,N,1,,,,,1,,BAO_0000218,
7765,1969.0,Intermediate,Plasma,50597,Plasma half life was observed after intravenous administration in rat,CHEMBL620497,N,1,,,,,1,,BAO_0000218,
7766,1969.0,Intermediate,Plasma,50597,Plasma half-life was determined,CHEMBL620498,N,1,,,,,1,,BAO_0000218,
7767,1969.0,Intermediate,Plasma,50597,Plasma half-life following oral administration in Fisher rats,CHEMBL620499,N,1,,,,,1,,BAO_0000218,
7768,1969.0,Intermediate,Plasma,50597,Plasma half-life in rat,CHEMBL620500,N,1,,,,,1,,BAO_0000218,
7769,1969.0,Intermediate,Plasma,50597,Plasmatic Half-life after intravenous administration to rat,CHEMBL873809,N,1,,,,,1,,BAO_0000218,
7770,,Intermediate,,50597,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,CHEMBL620501,N,1,,,,,1,,BAO_0000218,
7771,,Intermediate,,50597,Terminal half life after intravenous administration (1 mg/kg) in rat,CHEMBL620502,N,1,,,,,1,,BAO_0000218,
7772,,Intermediate,,50597,Terminal half life in Rat at a oral dose of 5 mg/kg,CHEMBL620503,N,1,,,,,1,,BAO_0000218,
7773,,Intermediate,,50597,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,CHEMBL620504,N,1,,,,,1,,BAO_0000218,
7774,,Intermediate,,50597,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,CHEMBL876605,N,1,,,,,1,,BAO_0000218,
7775,,Intermediate,,50597,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,CHEMBL620505,N,1,,,,,1,,BAO_0000218,
7776,1969.0,Intermediate,Plasma,50597,plasma half life was observed after intravenous administration in rat,CHEMBL873811,N,1,,,,,1,,BAO_0000218,
7777,,Expert,,50597,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL624016,N,1,,,,,1,,BAO_0000218,
7778,,Intermediate,,50597,Half life of compound determined in rat,CHEMBL624017,N,1,,,,,1,,BAO_0000218,
7779,,Intermediate,,50597,Mean residence time determined in rat,CHEMBL624018,N,1,,,,,1,,BAO_0000218,
7780,,Intermediate,,50597,Plasma half life determined in rat,CHEMBL624019,N,1,,,,,1,,BAO_0000218,
7781,955.0,Intermediate,Brain,50597,Compound was evaluated for Tmax in brain after intravenous administration in male rats,CHEMBL624020,N,1,,,,,1,,BAO_0000218,
7782,,Intermediate,,50597,Compound was evaluated for pharmacokinetic parameter maximum time period,CHEMBL624201,N,1,,,,,1,,BAO_0000218,
7783,,Intermediate,,50597,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,CHEMBL872528,N,1,,,,,1,,BAO_0000218,
7784,,Intermediate,,50597,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,CHEMBL624202,N,1,,,,,1,,BAO_0000218,
7785,,Intermediate,,50597,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,CHEMBL624203,N,1,,,,,1,,BAO_0000218,
7786,,Intermediate,,50597,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,CHEMBL624350,N,1,,,,,1,,BAO_0000218,
7787,,Intermediate,,50597,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,CHEMBL621320,N,1,,,,,1,,BAO_0000218,
7788,,Intermediate,,50597,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,CHEMBL621321,N,1,,,,,1,,BAO_0000218,
7789,,Intermediate,,50597,Maximum time (Tmax) required to reach Cmax in rats,CHEMBL621322,N,1,,,,,1,,BAO_0000218,
7790,,Intermediate,,50597,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,CHEMBL621323,N,1,,,,,1,,BAO_0000218,
7791,,Intermediate,,50597,Maximum time of clearance of compound in rats after peroral administration,CHEMBL621324,N,1,,,,,1,,BAO_0000218,
7792,,Intermediate,,50597,Maximum time at the dose of 2 mg/kg in rat,CHEMBL621325,N,1,,,,,1,,BAO_0000218,
7793,1969.0,Intermediate,Plasma,50597,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,CHEMBL875837,N,1,,,,,1,,BAO_0000218,
7794,1969.0,Intermediate,Plasma,50597,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,CHEMBL621326,N,1,,,,,1,,BAO_0000218,
7795,,Intermediate,,50597,Tmax in Guinea pig (PO dose),CHEMBL621327,N,1,,,,,1,,BAO_0000218,
7796,,Intermediate,,50597,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",CHEMBL621328,N,1,,,,,1,,BAO_0000218,
7797,,Intermediate,,50597,Pharmacokinetic parameter (Tmax) in rat,CHEMBL621329,N,1,,,,,1,,BAO_0000218,
7798,,Intermediate,,50597,Pharmacokinetic parameter (Tmax) was estimated,CHEMBL621330,N,1,,,,,1,,BAO_0000218,
7799,,Intermediate,,50597,Pharmacokinetic property (Tmax) in rat,CHEMBL621331,N,1,,,,,1,,BAO_0000218,
7800,,Intermediate,,50597,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,CHEMBL621332,N,1,,,,,1,,BAO_0000218,
7801,,Intermediate,,50597,T max in Rat at a oral dose of 5 mg/kg,CHEMBL621333,N,1,,,,,1,,BAO_0000218,
7802,,Intermediate,,50597,T max was determined at 10 mg/kg po dose in rats,CHEMBL621334,N,1,,,,,1,,BAO_0000218,
7803,,Intermediate,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),CHEMBL621335,N,1,,,,,1,,BAO_0000218,
7804,,Intermediate,,50588,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,CHEMBL621336,N,1,,,,,1,,BAO_0000218,
7805,,Intermediate,,50597,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,CHEMBL621337,N,1,,,,,1,,BAO_0000218,
7806,,Intermediate,,50588,Area under curve was measured after i.v. administration into Beagle dog.,CHEMBL621338,N,1,,,,,1,,BAO_0000218,
7807,,Intermediate,,50588,Area under curve was measured after iv administration into Beagle dog,CHEMBL875838,N,1,,,,,1,,BAO_0000218,
7808,,Intermediate,,50588,Area under curve was measured after po administration into Beagle dog,CHEMBL621339,N,1,,,,,1,,BAO_0000218,
7809,,Intermediate,,50588,Area under curve was measured after po administration into Beagle dog.,CHEMBL621340,N,1,,,,,1,,BAO_0000218,
7810,,Autocuration,,22224,Area under curve was measured at peroral dose of 3 mg/kg,CHEMBL621341,U,0,,,,,1,,BAO_0000218,
7811,,Autocuration,,22224,Area under curve was measured by using concentration Vs time,CHEMBL621342,U,0,,,,,1,,BAO_0000019,
7812,,Autocuration,,22224,Area under curve was measured by using concentration Vs time; not tested,CHEMBL621343,U,0,,,,,1,,BAO_0000019,
7813,,Intermediate,,50594,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),CHEMBL621344,N,1,,,,,1,,BAO_0000218,
7814,,Intermediate,,50594,Area under curve(AUC) was measured in mice after oral administration.,CHEMBL621345,N,1,,,,,1,,BAO_0000218,
7815,,Autocuration,,22224,Area under curve(AUC) value of the compound,CHEMBL621346,U,0,,,,,1,,BAO_0000019,
7816,,Autocuration,,22224,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,CHEMBL621347,U,0,,,,,1,,BAO_0000218,
7817,,Intermediate,,50588,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,CHEMBL621348,N,1,,,,,1,,BAO_0000218,
7818,178.0,Autocuration,Blood,22224,Area under curve(carotid artery) was determined by the availability in blood,CHEMBL621349,U,0,,,,,1,,BAO_0000019,
7819,178.0,Autocuration,Blood,22224,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,CHEMBL621350,U,0,,,,,1,,BAO_0000019,
7820,178.0,Autocuration,Blood,22224,Area under curve(carotid artery) was determined by the availability in blood; No data,CHEMBL875839,U,0,,,,,1,,BAO_0000019,
7821,178.0,Autocuration,Blood,22224,Area under curve(portal vein) was determined by the availability in blood,CHEMBL620211,U,0,,,,,1,,BAO_0000019,
7822,178.0,Autocuration,Blood,22224,Area under curve(portal vein) was determined by the availability in blood; ND means no data,CHEMBL620212,U,0,,,,,1,,BAO_0000019,
7823,178.0,Autocuration,Blood,22224,Area under curve(portal vein) was determined by the availability in blood; No data,CHEMBL620213,U,0,,,,,1,,BAO_0000019,
7824,1969.0,Intermediate,Plasma,50797,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",CHEMBL620214,N,1,,,,,1,,BAO_0000218,
7825,1969.0,Intermediate,Plasma,50797,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",CHEMBL620215,N,1,,,,,1,,BAO_0000218,
7826,1969.0,Intermediate,Plasma,50797,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,CHEMBL620216,N,1,,,,,1,,BAO_0000218,
7827,1969.0,Intermediate,Plasma,50588,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",CHEMBL620888,N,1,,,,,1,,BAO_0000218,
7828,1969.0,Intermediate,Plasma,50588,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",CHEMBL620889,N,1,,,,,1,,BAO_0000218,
7829,1969.0,Autocuration,Plasma,22224,Area under plasma concentration vs time curve observed in rats for 0-3 h,CHEMBL620890,U,0,,,,,1,,BAO_0000019,
7830,1969.0,Intermediate,Plasma,50597,Area under plasma time curve determined in male rat,CHEMBL620891,N,1,,,,,1,,BAO_0000218,
7831,,Autocuration,,22224,Area under the MAP curve measured over 5 min.,CHEMBL620892,U,0,,,,,1,,BAO_0000019,
7832,,Intermediate,,50594,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,CHEMBL621079,N,1,,,,,1,,BAO_0000218,
7833,,Intermediate,,50594,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,CHEMBL621080,N,1,,,,,1,,BAO_0000218,
7834,,Intermediate,,50588,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,CHEMBL621081,N,1,,,,,1,,BAO_0000218,
7835,,Intermediate,,100712,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,CHEMBL621082,N,1,,,,,1,,BAO_0000218,
7836,,Intermediate,,50597,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,CHEMBL621083,N,1,,,,,1,,BAO_0000218,
7837,,Intermediate,,50588,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,CHEMBL621084,N,1,,,,,1,,BAO_0000218,
7838,,Intermediate,,50588,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,CHEMBL621085,N,1,,,,,1,,BAO_0000218,
7839,,Intermediate,,50588,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,CHEMBL621086,N,1,,,,,1,,BAO_0000218,
7840,,Intermediate,,50588,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),CHEMBL621087,N,1,,,,,1,,BAO_0000218,
7841,,Intermediate,,50588,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),CHEMBL622607,N,1,,,,,1,,BAO_0000218,
7842,,Intermediate,,50588,Serum AUC in marmosets (IV dose),CHEMBL622608,N,1,,,,,1,,BAO_0000218,
7843,,Autocuration,,22224,Area under the curve after intravenous administration at a dose of 10 umol/kg,CHEMBL624481,U,0,,,,,1,,BAO_0000019,
7844,,Autocuration,,22224,Area under the curve after intravenous administration at a dose of 2 umol/kg,CHEMBL624482,U,0,,,,,1,,BAO_0000019,
7845,,Autocuration,,22224,Area under the curve after intravenous administration at a dose of 4 umol/kg,CHEMBL624483,U,0,,,,,1,,BAO_0000019,
7846,,Autocuration,,22224,Area under the curve after intravenous administration at a dose of 40 umol/kg,CHEMBL624484,U,0,,,,,1,,BAO_0000019,
7847,,Autocuration,,22224,Area under the curve after intravenous administration at a dose of 5 umol/kg,CHEMBL624485,U,0,,,,,1,,BAO_0000019,
7848,,Intermediate,,50597,Area under the curve for fumarate salt was evaluated in F344 Rats.,CHEMBL624486,N,1,,,,,1,,BAO_0000218,
7849,,Autocuration,,22224,Area under the curve for the compound was calculated.,CHEMBL624487,U,0,,,,,1,,BAO_0000019,
7850,,Autocuration,,22224,Area under the curve in concentration/ time,CHEMBL624488,U,0,,,,,1,,BAO_0000019,
7851,,Intermediate,,50597,Area under the curve administered intraintestinal in rats.,CHEMBL624489,N,1,,,,,1,,BAO_0000218,
7852,,Intermediate,,50597,Area under the curve administered intravenously in rats.,CHEMBL625184,N,1,,,,,1,,BAO_0000218,
7853,,Autocuration,,22224,Area under the curve during intravenous administration,CHEMBL625185,U,0,,,,,1,,BAO_0000019,
7854,,Autocuration,,22224,Area under the curve during intravenous administration; Not determined,CHEMBL875954,U,0,,,,,1,,BAO_0000019,
7855,,Autocuration,,22224,Area under the curve during systemic administration,CHEMBL625186,U,0,,,,,1,,BAO_0000019,
7856,,Autocuration,,22224,Area under the curve during systemic administration; Not determined,CHEMBL625187,U,0,,,,,1,,BAO_0000019,
7857,,Autocuration,,22224,Area under the curve was calculated for the compound.,CHEMBL625188,U,0,,,,,1,,BAO_0000019,
7858,,Intermediate,,50588,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,CHEMBL625189,N,1,,,,,1,,BAO_0000218,
7859,,Intermediate,,50588,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,CHEMBL625190,N,1,,,,,1,,BAO_0000218,
7860,,Intermediate,,50597,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,CHEMBL621733,N,1,,,,,1,,BAO_0000218,
7861,,Intermediate,,50597,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,CHEMBL621734,N,1,,,,,1,,BAO_0000218,
7862,,Intermediate,,50597,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,CHEMBL621735,N,1,,,,,1,,BAO_0000218,
7863,1969.0,Intermediate,Plasma,50597,Clearance of the drug was measured in the plasma of rat; No data,CHEMBL621736,N,1,,,,,1,,BAO_0000218,
7864,1969.0,Intermediate,Plasma,50597,The pharmacokinetic parameter plasma clearance in vivo in rats,CHEMBL621737,N,1,,,,,1,,BAO_0000218,
7865,,Intermediate,,50597,Plasma clearance at the dose of 2 mg/kg in rat,CHEMBL621738,N,1,,,,,1,,BAO_0000218,
7866,,Intermediate,,50597,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,CHEMBL622806,N,1,,,,,1,,BAO_0000218,
7867,,Intermediate,,50597,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,CHEMBL623519,N,1,,,,,1,,BAO_0000218,
7868,,Intermediate,,50597,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,CHEMBL623520,N,1,,,,,1,,BAO_0000218,
7869,,Intermediate,,50597,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,CHEMBL623521,N,1,,,,,1,,BAO_0000218,
7870,,Intermediate,,50597,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,CHEMBL623522,N,1,,,,,1,,BAO_0000218,
7871,,Intermediate,,50597,Clearance rate in rat,CHEMBL623523,N,1,,,,,1,,BAO_0000218,
7872,,Intermediate,,50597,Clearance rate in rat,CHEMBL623690,N,1,,,,,1,,BAO_0000218,
7873,,Intermediate,,50597,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL623691,N,1,,,,,1,,BAO_0000218,
7874,,Intermediate,,50597,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL623692,N,1,,,,,1,,BAO_0000218,
7875,,Intermediate,,50597,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL623693,N,1,,,,,1,,BAO_0000218,
7876,,Intermediate,,50597,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL623694,N,1,,,,,1,,BAO_0000218,
7877,,Intermediate,,50597,Clearance of compound after iv administration of 20 mg/kg dose in rat,CHEMBL623695,N,1,,,,,1,,BAO_0000218,
7878,,Intermediate,,50597,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,CHEMBL623696,N,1,,,,,1,,BAO_0000218,
7879,,Intermediate,,50597,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,CHEMBL623697,N,1,,,,,1,,BAO_0000218,
7880,1969.0,Intermediate,Plasma,22224,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL623698,U,0,,,,,1,,BAO_0000218,
7881,1969.0,Intermediate,Plasma,22224,Compound was tested for its plasma clearance rate in Sprague Dawley rats,CHEMBL623699,U,0,,,,,1,,BAO_0000218,
7882,,Intermediate,,50597,Mean (%CV) PK parameters for CL(mL/min/kg).,CHEMBL623700,N,1,,,,,1,,BAO_0000218,
7883,,Intermediate,,50597,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,CHEMBL623701,N,1,,,,,1,,BAO_0000218,
7884,1969.0,Intermediate,Plasma,50597,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,CHEMBL623702,N,1,,,,,1,,BAO_0000218,
7885,,Intermediate,,50597,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,CHEMBL623703,N,1,,,,,1,,BAO_0000218,
7886,,Intermediate,,50597,Plasma clearance in rat was determined,CHEMBL623704,N,1,,,,,1,,BAO_0000218,
7887,,Intermediate,,50597,Plasma clearance in rat after administration of 2 mg/kg iv,CHEMBL623705,N,1,,,,,1,,BAO_0000218,
7888,,Intermediate,,50597,Plasma clearance in rat after administration of 2 mg/kg iv,CHEMBL623706,N,1,,,,,1,,BAO_0000218,
7889,,Intermediate,,50597,Plasma clearance was determined,CHEMBL623707,N,1,,,,,1,,BAO_0000218,
7890,,Intermediate,,50597,Plasma clearance in rat,CHEMBL623708,N,1,,,,,1,,BAO_0000218,
7891,,Intermediate,,50597,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,CHEMBL623709,N,1,,,,,1,,BAO_0000218,
7892,,Intermediate,,50597,Plasma clearance in rat by iv administration,CHEMBL623710,N,1,,,,,1,,BAO_0000218,
7893,,Intermediate,,50597,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,CHEMBL623711,N,1,,,,,1,,BAO_0000218,
7894,,Intermediate,,50597,Plasma clearance in rat p.o.,CHEMBL623712,N,1,,,,,1,,BAO_0000218,
7895,,Intermediate,,50597,Plasma clearance in rats,CHEMBL623713,N,1,,,,,1,,BAO_0000218,
7896,,Intermediate,,50597,Plasma clearance was determined; ND denotes no data,CHEMBL623714,N,1,,,,,1,,BAO_0000218,
7897,,Intermediate,,50597,Plasma clearance was determined; ND denotes not determined,CHEMBL623715,N,1,,,,,1,,BAO_0000218,
7898,,Intermediate,,50597,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,CHEMBL623716,N,1,,,,,1,,BAO_0000218,
7899,,Intermediate,,50597,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,CHEMBL622980,N,1,,,,,1,,BAO_0000218,
7900,,Intermediate,,50597,Plasma administration to rats,CHEMBL622981,N,1,,,,,1,,BAO_0000218,
7901,,Intermediate,,50597,Plasma clearance of the compound in female Sprague-Dawley rats,CHEMBL622982,N,1,,,,,1,,BAO_0000218,
7902,,Intermediate,,50597,Plasma clearance was observed after intravenous administration in rat,CHEMBL622983,N,1,,,,,1,,BAO_0000218,
7903,,Intermediate,,50597,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,CHEMBL622984,N,1,,,,,1,,BAO_0000218,
7904,,Intermediate,,50597,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,CHEMBL622985,N,1,,,,,1,,BAO_0000218,
7905,1969.0,Intermediate,Plasma,50597,plasma clearance was observed after intravenous administration in rat,CHEMBL623631,N,1,,,,,1,,BAO_0000218,
7906,,Intermediate,,50597,In vivo CL/F determined,CHEMBL623632,N,1,,,,,1,,BAO_0000218,
7907,1969.0,Intermediate,Plasma,50597,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,CHEMBL623633,N,1,,,,,1,,BAO_0000218,
7908,1969.0,Intermediate,Plasma,50597,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,CHEMBL623634,N,1,,,,,1,,BAO_0000218,
7909,,Intermediate,,50597,Compound was tested for the lower blood clearance in rat,CHEMBL623635,N,1,,,,,1,,BAO_0000218,
7910,,Intermediate,,50597,Evaluated for the low clearance in rat (in vivo),CHEMBL621195,N,1,,,,,1,,BAO_0000218,
7911,,Intermediate,,50597,Pharmacokinetic property (CLb)of the compound was determined in rat,CHEMBL621196,N,1,,,,,1,,BAO_0000218,
7912,,Intermediate,,50597,Rapid clearance after intravenous administration in rat was determined,CHEMBL875287,N,1,,,,,1,,BAO_0000218,
7913,,Intermediate,,50597,Clearance measured in rat,CHEMBL621197,N,1,,,,,1,,BAO_0000218,
7914,1969.0,Intermediate,Plasma,50597,Compound was evaluated for plasma clearance in rat,CHEMBL621198,N,1,,,,,1,,BAO_0000218,
7915,1969.0,Intermediate,Plasma,50597,Low plasma clearance was calculated in rat,CHEMBL621199,N,1,,,,,1,,BAO_0000218,
7916,,Intermediate,,50597,Pharmacokinetic property (Clp) in rat,CHEMBL621200,N,1,,,,,1,,BAO_0000218,
7917,,Intermediate,,50597,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,CHEMBL621201,N,1,,,,,1,,BAO_0000218,
7918,,Intermediate,,50597,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,CHEMBL621202,N,1,,,,,1,,BAO_0000218,
7919,,Intermediate,,50597,Plasma clearance after IV dosing at 0.5 mg/kg in rat,CHEMBL621203,N,1,,,,,1,,BAO_0000218,
7920,,Intermediate,,50597,Plasma clearance after IV dosing at 1 mg/kg in rat,CHEMBL621204,N,1,,,,,1,,BAO_0000218,
7921,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,CHEMBL621205,N,1,,,,,1,,BAO_0000218,
7922,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,CHEMBL621206,N,1,,,,,1,,BAO_0000218,
7923,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,CHEMBL621207,N,1,,,,,1,,BAO_0000218,
7924,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,CHEMBL621208,N,1,,,,,1,,BAO_0000218,
7925,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,CHEMBL621209,N,1,,,,,1,,BAO_0000218,
7926,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,CHEMBL876484,N,1,,,,,1,,BAO_0000218,
7927,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,CHEMBL621210,N,1,,,,,1,,BAO_0000218,
7928,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,CHEMBL621211,N,1,,,,,1,,BAO_0000218,
7929,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,CHEMBL621212,N,1,,,,,1,,BAO_0000218,
7930,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA at 15 min,CHEMBL621213,N,1,,,,,1,,BAO_0000218,
7931,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,CHEMBL621214,N,1,,,,,1,,BAO_0000218,
7932,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA at 30 min,CHEMBL621215,N,1,,,,,1,,BAO_0000218,
7933,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,CHEMBL621216,N,1,,,,,1,,BAO_0000218,
7934,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,CHEMBL621217,N,1,,,,,1,,BAO_0000218,
7935,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,CHEMBL621218,N,1,,,,,1,,BAO_0000218,
7936,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,CHEMBL621219,N,1,,,,,1,,BAO_0000218,
7937,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,CHEMBL621220,N,1,,,,,1,,BAO_0000218,
7938,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,CHEMBL621221,N,1,,,,,1,,BAO_0000218,
7939,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,CHEMBL621222,N,1,,,,,1,,BAO_0000218,
7940,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,CHEMBL621223,N,1,,,,,1,,BAO_0000218,
7941,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,CHEMBL876485,N,1,,,,,1,,BAO_0000218,
7942,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,CHEMBL621224,N,1,,,,,1,,BAO_0000218,
7943,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,CHEMBL621225,N,1,,,,,1,,BAO_0000218,
7944,948.0,Intermediate,Heart,50597,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,CHEMBL621226,N,1,,,,,1,,BAO_0000218,
7945,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,CHEMBL621227,N,1,,,,,1,,BAO_0000218,
7946,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,CHEMBL621228,N,1,,,,,1,,BAO_0000218,
7947,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,CHEMBL621229,N,1,,,,,1,,BAO_0000218,
7948,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,CHEMBL621230,N,1,,,,,1,,BAO_0000218,
7949,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,CHEMBL621231,N,1,,,,,1,,BAO_0000218,
7950,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,CHEMBL621232,N,1,,,,,1,,BAO_0000218,
7951,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,CHEMBL621233,N,1,,,,,1,,BAO_0000218,
7952,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,CHEMBL621234,N,1,,,,,1,,BAO_0000218,
7953,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,CHEMBL621235,N,1,,,,,1,,BAO_0000218,
7954,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,CHEMBL621236,N,1,,,,,1,,BAO_0000218,
7955,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,CHEMBL621237,N,1,,,,,1,,BAO_0000218,
7956,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,CHEMBL876486,N,1,,,,,1,,BAO_0000218,
7957,160.0,Intermediate,Intestine,50597,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,CHEMBL622436,N,1,,,,,1,,BAO_0000218,
7958,160.0,Intermediate,Intestine,50597,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,CHEMBL622437,N,1,,,,,1,,BAO_0000218,
7959,160.0,Intermediate,Intestine,50597,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,CHEMBL622438,N,1,,,,,1,,BAO_0000218,
7960,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,CHEMBL622439,N,1,,,,,1,,BAO_0000218,
7961,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,CHEMBL622440,N,1,,,,,1,,BAO_0000218,
7962,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,CHEMBL622441,N,1,,,,,1,,BAO_0000218,
7963,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,CHEMBL622442,N,1,,,,,1,,BAO_0000218,
7964,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,CHEMBL622443,N,1,,,,,1,,BAO_0000218,
7965,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,CHEMBL622444,N,1,,,,,1,,BAO_0000218,
7966,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,CHEMBL622445,N,1,,,,,1,,BAO_0000218,
7967,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,CHEMBL622446,N,1,,,,,1,,BAO_0000218,
7968,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,CHEMBL622447,N,1,,,,,1,,BAO_0000218,
7969,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,CHEMBL622448,N,1,,,,,1,,BAO_0000218,
7970,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,CHEMBL622449,N,1,,,,,1,,BAO_0000218,
7971,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,CHEMBL622450,N,1,,,,,1,,BAO_0000218,
7972,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,CHEMBL622451,N,1,,,,,1,,BAO_0000218,
7973,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA at 15 min,CHEMBL622452,N,1,,,,,1,,BAO_0000218,
7974,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,CHEMBL622453,N,1,,,,,1,,BAO_0000218,
7975,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA at 30 min,CHEMBL622454,N,1,,,,,1,,BAO_0000218,
7976,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,CHEMBL622455,N,1,,,,,1,,BAO_0000218,
7977,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,CHEMBL876024,N,1,,,,,1,,BAO_0000218,
7978,,Intermediate,,50597,T max was determined at 3 mg/kg po dose in rats,CHEMBL622456,N,1,,,,,1,,BAO_0000218,
7979,,Intermediate,,50597,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL622457,N,1,,,,,1,,BAO_0000218,
7980,,Intermediate,,50597,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",CHEMBL622458,N,1,,,,,1,,BAO_0000218,
7981,,Intermediate,,50597,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,CHEMBL622459,N,1,,,,,1,,BAO_0000218,
7982,,Intermediate,,50597,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,CHEMBL873343,N,1,,,,,1,,BAO_0000218,
7983,,Intermediate,,50597,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,CHEMBL622460,N,1,,,,,1,,BAO_0000218,
7984,1969.0,Intermediate,Plasma,50597,Time for maximum plasma concentration determined in rat,CHEMBL622461,N,1,,,,,1,,BAO_0000218,
7985,1969.0,Intermediate,Plasma,50597,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,CHEMBL622462,N,1,,,,,1,,BAO_0000218,
7986,,Intermediate,,50597,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,CHEMBL622463,N,1,,,,,1,,BAO_0000218,
7987,,Intermediate,,50597,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,CHEMBL622464,N,1,,,,,1,,BAO_0000218,
7988,,Intermediate,,50597,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,CHEMBL622465,N,1,,,,,1,,BAO_0000218,
7989,,Intermediate,,50597,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,CHEMBL622466,N,1,,,,,1,,BAO_0000218,
7990,,Intermediate,,50597,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,CHEMBL622467,N,1,,,,,1,,BAO_0000218,
7991,1969.0,Intermediate,Plasma,50597,Time of maximum plasma concentration in rat,CHEMBL622468,N,1,,,,,1,,BAO_0000218,
7992,1969.0,Intermediate,Plasma,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",CHEMBL876025,N,1,,,,,1,,BAO_0000218,
7993,1969.0,Intermediate,Plasma,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",CHEMBL622469,N,1,,,,,1,,BAO_0000218,
7994,1969.0,Intermediate,Plasma,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",CHEMBL622470,N,1,,,,,1,,BAO_0000218,
7995,,Intermediate,,50597,Time required to reach maximum concentration (Cmax) after oral administration in rat,CHEMBL622471,N,1,,,,,1,,BAO_0000218,
7996,1969.0,Intermediate,Plasma,50597,Time required to reach maximum concentration in rat plasma,CHEMBL622472,N,1,,,,,1,,BAO_0000218,
7997,1969.0,Intermediate,Plasma,50597,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,CHEMBL622473,N,1,,,,,1,,BAO_0000218,
7998,1969.0,Intermediate,Plasma,50597,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,CHEMBL624282,N,1,,,,,1,,BAO_0000218,
7999,1969.0,Intermediate,Plasma,50597,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,CHEMBL624283,N,1,,,,,1,,BAO_0000218,
8000,1969.0,Intermediate,Plasma,50597,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,CHEMBL624284,N,1,,,,,1,,BAO_0000218,
8001,1969.0,Intermediate,Plasma,50597,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,CHEMBL624285,N,1,,,,,1,,BAO_0000218,
8002,,Intermediate,,50597,Time to reach Cmax after oral administration to rats,CHEMBL624286,N,1,,,,,1,,BAO_0000218,
8003,,Intermediate,,50597,Time to reach Cmax when a dose of 1 mg/kg is administered orally,CHEMBL624287,N,1,,,,,1,,BAO_0000218,
8004,,Intermediate,,50597,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,CHEMBL624288,N,1,,,,,1,,BAO_0000218,
8005,1969.0,Intermediate,Plasma,50597,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,CHEMBL624289,N,1,,,,,1,,BAO_0000218,
8006,1969.0,Intermediate,Plasma,50597,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,CHEMBL873344,N,1,,,,,1,,BAO_0000218,
8007,,Intermediate,,50597,Tmax after peroral administration (10 mg/kg) was determined in rat,CHEMBL619623,N,1,,,,,1,,BAO_0000218,
8008,,Expert,,50597,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL621399,N,1,,,,,1,,BAO_0000218,
8009,,Intermediate,,50597,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,CHEMBL621400,N,1,,,,,1,,BAO_0000218,
8010,,Intermediate,,50597,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",CHEMBL621401,N,1,,,,,1,,BAO_0000218,
8011,,Intermediate,,50597,Tmax was determined,CHEMBL621402,N,1,,,,,1,,BAO_0000218,
8012,,Intermediate,,50597,Tmax was determined,CHEMBL621403,N,1,,,,,1,,BAO_0000218,
8013,,Intermediate,,50597,Tmax after oral administration in rat,CHEMBL621121,N,1,,,,,1,,BAO_0000218,
8014,,Intermediate,,50597,Tmax after peroral administration in rats at 2.4 uM/kg,CHEMBL872525,N,1,,,,,1,,BAO_0000218,
8015,,Intermediate,,50597,Tmax in male rat,CHEMBL621122,N,1,,,,,1,,BAO_0000218,
8016,,Intermediate,,50597,Tmax in rat at 10 mg/kg,CHEMBL621123,N,1,,,,,1,,BAO_0000218,
8017,,Intermediate,,50597,Tmax in rat by po administration at a dose of 40 mg/kg,CHEMBL621124,N,1,,,,,1,,BAO_0000218,
8018,,Intermediate,,50597,Tmax in rats,CHEMBL621125,N,1,,,,,1,,BAO_0000218,
8019,,Intermediate,,50597,Tmax was measured in rats after peroral administration at 5 mg/kg,CHEMBL621126,N,1,,,,,1,,BAO_0000218,
8020,,Intermediate,,50597,Tmax value after oral dose at a dose of 10 mg/kg in rats.,CHEMBL621127,N,1,,,,,1,,BAO_0000218,
8021,,Intermediate,,50597,Tmax value after administration of 20 mg/Kg oral dose in rat,CHEMBL621128,N,1,,,,,1,,BAO_0000218,
8022,,Intermediate,,50597,Tmax value at a dose of 10 mg/kg in male SD rats,CHEMBL618263,N,1,,,,,1,,BAO_0000218,
8023,,Intermediate,,50597,Tmax value at a dose of 100 mg/kg in male SD rats,CHEMBL618264,N,1,,,,,1,,BAO_0000218,
8024,,Intermediate,,50597,Tmax value at a dose of 50 mg/kg in male SD rats,CHEMBL618265,N,1,,,,,1,,BAO_0000218,
8025,1969.0,Intermediate,Plasma,50597,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,CHEMBL618266,N,1,,,,,1,,BAO_0000218,
8026,,Intermediate,,50597,time required to reach maximum concentration (Cmax) after oral administration in rat,CHEMBL618267,N,1,,,,,1,,BAO_0000218,
8027,1088.0,Intermediate,Urine,50597,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),CHEMBL618450,N,1,,,,,1,,BAO_0000218,
8028,1088.0,Intermediate,Urine,50597,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),CHEMBL618451,N,1,,,,,1,,BAO_0000218,
8029,,Intermediate,,50597,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,CHEMBL618452,N,1,,,,,1,,BAO_0000218,
8030,1088.0,Intermediate,Urine,50597,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,CHEMBL618453,N,1,,,,,1,,BAO_0000218,
8031,1088.0,Intermediate,Urine,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,CHEMBL618454,N,1,,,,,1,,BAO_0000218,
8032,1088.0,Intermediate,Urine,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,CHEMBL618455,N,1,,,,,1,,BAO_0000218,
8033,,Intermediate,,50597,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,CHEMBL618456,N,1,,,,,1,,BAO_0000218,
8034,,Intermediate,,50597,Compound distribution in rat tissues was determined,CHEMBL618457,N,1,,,,,1,,BAO_0000218,
8035,,Intermediate,,50597,Volume of distribution was evaluated in rat,CHEMBL618458,N,1,,,,,1,,BAO_0000218,
8036,,Intermediate,,50597,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,CHEMBL618459,N,1,,,,,1,,BAO_0000218,
8037,,Intermediate,,50597,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,CHEMBL876733,N,1,,,,,1,,BAO_0000218,
8038,,Intermediate,,50588,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,CHEMBL618460,N,1,,,,,1,,BAO_0000218,
8039,,Intermediate,,50597,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,CHEMBL618461,N,1,,,,,1,,BAO_0000218,
8040,,Autocuration,,22224,Area under the curve was determined after oral administration (300 uM/Kg),CHEMBL618462,U,0,,,,,1,,BAO_0000019,
8041,,Intermediate,,50597,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,CHEMBL618463,N,1,,,,,1,,BAO_0000218,
8042,,Intermediate,,50597,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,CHEMBL618464,N,1,,,,,1,,BAO_0000218,
8043,,Intermediate,,50597,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,CHEMBL618465,N,1,,,,,1,,BAO_0000218,
8044,,Intermediate,,50597,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,CHEMBL618466,N,1,,,,,1,,BAO_0000218,
8045,,Intermediate,,50597,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,CHEMBL618467,N,1,,,,,1,,BAO_0000218,
8046,,Intermediate,,50597,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,CHEMBL618468,N,1,,,,,1,,BAO_0000218,
8047,1969.0,Intermediate,Plasma,50588,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,CHEMBL618469,N,1,,,,,1,,BAO_0000218,
8048,1969.0,Intermediate,Plasma,50588,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,CHEMBL618470,N,1,,,,,1,,BAO_0000218,
8049,,Autocuration,,22224,Plasma drug AUC in rat (PO dose),CHEMBL618471,U,0,,,,,1,,BAO_0000218,
8050,,Intermediate,,50594,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,CHEMBL618472,N,1,,,,,1,,BAO_0000218,
8051,,Autocuration,,22224,Area under was determined at a dose of 30 mg/kg,CHEMBL618473,U,0,,,,,1,,BAO_0000218,
8052,,Intermediate,,50506,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,CHEMBL621699,N,1,,,,,1,,BAO_0000218,
8053,,Intermediate,,50597,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,CHEMBL621700,N,1,,,,,1,,BAO_0000218,
8054,,Intermediate,,50597,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,CHEMBL621701,N,1,,,,,1,,BAO_0000218,
8055,,Intermediate,,50506,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,CHEMBL621702,N,1,,,,,1,,BAO_0000218,
8056,,Intermediate,,50588,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,CHEMBL621703,N,1,,,,,1,,BAO_0000218,
8057,,Intermediate,,50588,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,CHEMBL621704,N,1,,,,,1,,BAO_0000218,
8058,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",CHEMBL624259,N,1,,,,,1,,BAO_0000218,
8059,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",CHEMBL624260,N,1,,,,,1,,BAO_0000218,
8060,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",CHEMBL624430,N,1,,,,,1,,BAO_0000218,
8061,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",CHEMBL624431,N,1,,,,,1,,BAO_0000218,
8062,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",CHEMBL624432,N,1,,,,,1,,BAO_0000218,
8063,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",CHEMBL624433,N,1,,,,,1,,BAO_0000218,
8064,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",CHEMBL624434,N,1,,,,,1,,BAO_0000218,
8065,,Intermediate,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",CHEMBL624435,N,1,,,,,1,,BAO_0000218,
8066,,Intermediate,,50594,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,CHEMBL618570,N,1,,,,,1,,BAO_0000218,
8067,,Intermediate,,50594,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),CHEMBL618571,N,1,,,,,1,,BAO_0000218,
8068,,Intermediate,,50594,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,CHEMBL618572,N,1,,,,,1,,BAO_0000218,
8069,,Intermediate,,50594,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),CHEMBL618573,N,1,,,,,1,,BAO_0000218,
8070,,Intermediate,,50594,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,CHEMBL619267,N,1,,,,,1,,BAO_0000218,
8071,,Intermediate,,50594,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),CHEMBL619431,N,1,,,,,1,,BAO_0000218,
8072,,Intermediate,,50594,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,CHEMBL619432,N,1,,,,,1,,BAO_0000218,
8073,,Intermediate,,50594,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),CHEMBL619433,N,1,,,,,1,,BAO_0000218,
8074,1969.0,Autocuration,Plasma,22224,AUC in mice after oral dose (50 mg/kg),CHEMBL619434,U,0,,,,,1,,BAO_0000218,
8075,1977.0,Intermediate,Serum,50594,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,CHEMBL619435,N,1,,,,,1,,BAO_0000218,
8076,1969.0,Autocuration,Plasma,22224,AUC (0-4 hr) ug/ml/h,CHEMBL619436,U,0,,,,,1,,BAO_0000019,
8077,,Intermediate,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,CHEMBL619437,N,1,,,,,1,,BAO_0000218,
8078,,Autocuration,,22224,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,CHEMBL619438,U,0,,,,,1,,BAO_0000218,
8079,,Intermediate,,50594,Compound was evaluated for Area under curve in mice,CHEMBL619439,N,1,,,,,1,,BAO_0000218,
8080,,Intermediate,,50597,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,CHEMBL619440,N,1,,,,,1,,BAO_0000218,
8081,,Autocuration,,22224,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,CHEMBL619441,U,0,,,,,1,,BAO_0000218,
8082,,Intermediate,,50597,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,CHEMBL619442,N,1,,,,,1,,BAO_0000218,
8083,,Autocuration,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,CHEMBL875156,U,0,,,,,1,,BAO_0000019,
8084,,Autocuration,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,CHEMBL619443,U,0,,,,,1,,BAO_0000019,
8085,,Autocuration,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,CHEMBL619444,U,0,,,,,1,,BAO_0000019,
8086,,Autocuration,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,CHEMBL623464,U,0,,,,,1,,BAO_0000019,
8087,,Intermediate,,50594,Compound was evaluated for area under curve when administered through oral route in mouse,CHEMBL623465,N,1,,,,,1,,BAO_0000218,
8088,,Intermediate,,50597,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,CHEMBL623466,N,1,,,,,1,,BAO_0000218,
8089,,Intermediate,,50597,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,CHEMBL623467,N,1,,,,,1,,BAO_0000218,
8090,,Intermediate,,50597,Plasma clearance in rat,CHEMBL623468,N,1,,,,,1,,BAO_0000218,
8091,,Intermediate,,50597,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,CHEMBL622660,N,1,,,,,1,,BAO_0000218,
8092,,Intermediate,,50597,Plasma clearance rate in Sprague-Dawley rats,CHEMBL622661,N,1,,,,,1,,BAO_0000218,
8093,,Intermediate,,50597,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL622662,N,1,,,,,1,,BAO_0000218,
8094,,Intermediate,,50597,Pharmacokinetic property (total body clearance) in rat,CHEMBL622663,N,1,,,,,1,,BAO_0000218,
8095,,Intermediate,,50597,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,CHEMBL622664,N,1,,,,,1,,BAO_0000218,
8096,,Intermediate,,50597,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,CHEMBL622665,N,1,,,,,1,,BAO_0000218,
8097,,Intermediate,,50597,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,CHEMBL622666,N,1,,,,,1,,BAO_0000218,
8098,,Intermediate,,50597,Cl in rat i.v. at 2 mg/kg concentration,CHEMBL621615,N,1,,,,,1,,BAO_0000218,
8099,,Intermediate,,50597,Clearance of compound after intravenous administration in rats at 24 uM/kg,CHEMBL621616,N,1,,,,,1,,BAO_0000218,
8100,,Intermediate,,50597,Clearance was determined,CHEMBL621617,N,1,,,,,1,,BAO_0000218,
8101,,Intermediate,,50597,Clearance by intravenous administration of 3.4 mg/kg in rat,CHEMBL621618,N,1,,,,,1,,BAO_0000218,
8102,,Intermediate,,50597,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,CHEMBL621619,N,1,,,,,1,,BAO_0000218,
8103,,Intermediate,,50597,Clearance rate after i.v. administration in rats,CHEMBL621620,N,1,,,,,1,,BAO_0000218,
8104,,Intermediate,,50597,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,CHEMBL621786,N,1,,,,,1,,BAO_0000218,
8105,,Intermediate,,50597,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,CHEMBL621787,N,1,,,,,1,,BAO_0000218,
8106,,Intermediate,,50597,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,CHEMBL621788,N,1,,,,,1,,BAO_0000218,
8107,,Intermediate,,50597,Clearance (Cl) after oral administration in rat,CHEMBL621789,N,1,,,,,1,,BAO_0000218,
8108,,Intermediate,,50597,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,CHEMBL621790,N,1,,,,,1,,BAO_0000218,
8109,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma clearance in rat,CHEMBL621791,N,1,,,,,1,,BAO_0000218,
8110,,Intermediate,,50597,In vitro microsome metabolism clearance in rat was determined,CHEMBL621792,N,1,,,,Microsomes,1,,BAO_0000218,
8111,,Intermediate,,50597,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,CHEMBL621793,N,1,,,,Microsomes,1,,BAO_0000218,
8112,,Intermediate,,50597,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,CHEMBL621794,N,1,,,,,1,,BAO_0000218,
8113,1969.0,Intermediate,Plasma,50597,In vivo plasma clearance was determined,CHEMBL621795,N,1,,,,,1,,BAO_0000218,
8114,,Intermediate,,50597,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,CHEMBL621796,N,1,,,,,1,,BAO_0000218,
8115,2107.0,Intermediate,Liver,50597,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,CHEMBL621797,N,1,401.0,Hepatocyte,,,1,,BAO_0000218,
8116,,Intermediate,,50597,Pharmacokinetic property (Plasma clearance) was measured in rat,CHEMBL621798,N,1,,,,,1,,BAO_0000218,
8117,,Intermediate,,50597,Pharmacokinetic property (clearance) in rat i.v.,CHEMBL621799,N,1,,,,,1,,BAO_0000218,
8118,,Intermediate,,50597,"Plasma Clearance was evaluated in rats, iv",CHEMBL621800,N,1,,,,,1,,BAO_0000218,
8119,,Intermediate,,50597,Plasma clearance (in vivo) in rats was determined,CHEMBL621801,N,1,,,,,1,,BAO_0000218,
8120,,Intermediate,,50597,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,CHEMBL621802,N,1,,,,,1,,BAO_0000218,
8121,,Intermediate,,50597,Plasma clearance was determined,CHEMBL618596,N,1,,,,,1,,BAO_0000218,
8122,,Intermediate,,50597,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,CHEMBL618597,N,1,,,,,1,,BAO_0000218,
8123,,Intermediate,,50597,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,CHEMBL618598,N,1,,,,,1,,BAO_0000218,
8124,,Intermediate,,50597,Plasma clearance in rats,CHEMBL618599,N,1,,,,,1,,BAO_0000218,
8125,,Intermediate,,50597,Plasma clearance rate determined in rat,CHEMBL618600,N,1,,,,,1,,BAO_0000218,
8126,,Intermediate,,50597,Plasma clearance was determined in rat,CHEMBL618601,N,1,,,,,1,,BAO_0000218,
8127,,Intermediate,,50597,Plasma clearance was determined,CHEMBL618602,N,1,,,,,1,,BAO_0000218,
8128,,Intermediate,,50597,Plasma clearance value in rat,CHEMBL618603,N,1,,,,,1,,BAO_0000218,
8129,2107.0,Intermediate,Liver,50597,Clearance rate constant using isolated perfused rat liver (IPRL) assay,CHEMBL618604,N,1,,,,,1,,BAO_0000218,
8130,,Intermediate,,50597,Clearance in rat,CHEMBL618605,N,1,,,,,1,,BAO_0000218,
8131,,Intermediate,,50597,Total body clearance in rat i.v. at 2 mg/kg concentration,CHEMBL618606,N,1,,,,,1,,BAO_0000218,
8132,,Intermediate,,50597,Clearance of compound in rats after intravenous administration,CHEMBL618607,N,1,,,,,1,,BAO_0000218,
8133,,Intermediate,,50597,Clearance after iv administration to rats,CHEMBL618608,N,1,,,,,1,,BAO_0000218,
8134,,Intermediate,,50597,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,CHEMBL618609,N,1,,,,,1,,BAO_0000218,
8135,,Intermediate,,50597,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,CHEMBL618610,N,1,,,,,1,,BAO_0000218,
8136,,Intermediate,,50597,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,CHEMBL618611,N,1,,,,,1,,BAO_0000218,
8137,,Intermediate,,50597,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,CHEMBL618612,N,1,,,,,1,,BAO_0000218,
8138,,Intermediate,,50597,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,CHEMBL618613,N,1,,,,,1,,BAO_0000218,
8139,,Intermediate,,50597,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,CHEMBL621076,N,1,,,,,1,,BAO_0000218,
8140,,Intermediate,,50597,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,CHEMBL621077,N,1,,,,,1,,BAO_0000218,
8141,,Intermediate,,50597,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",CHEMBL621078,N,1,,,,,1,,BAO_0000218,
8142,,Intermediate,,50597,Clearance in rat,CHEMBL621251,N,1,,,,,1,,BAO_0000218,
8143,,Intermediate,,50597,Clearance in rat after oral administration at 10 mg/kg,CHEMBL621252,N,1,,,,,1,,BAO_0000218,
8144,,Intermediate,,50597,Clearance in rat.,CHEMBL621253,N,1,,,,,1,,BAO_0000218,
8145,,Intermediate,,50597,Clearance rate following an oral dose of 20 mg/kg in rats,CHEMBL621254,N,1,,,,,1,,BAO_0000218,
8146,,Intermediate,,50597,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,CHEMBL621255,N,1,,,,,1,,BAO_0000218,
8147,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,CHEMBL621256,N,1,,,,,1,,BAO_0000218,
8148,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,CHEMBL621257,N,1,,,,,1,,BAO_0000218,
8149,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,CHEMBL621258,N,1,,,,,1,,BAO_0000218,
8150,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,CHEMBL621259,N,1,,,,,1,,BAO_0000218,
8151,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,CHEMBL621260,N,1,,,,,1,,BAO_0000218,
8152,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,CHEMBL876494,N,1,,,,,1,,BAO_0000218,
8153,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,CHEMBL621261,N,1,,,,,1,,BAO_0000218,
8154,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,CHEMBL621262,N,1,,,,,1,,BAO_0000218,
8155,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,CHEMBL621263,N,1,,,,,1,,BAO_0000218,
8156,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,CHEMBL621264,N,1,,,,,1,,BAO_0000218,
8157,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,CHEMBL621265,N,1,,,,,1,,BAO_0000218,
8158,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,CHEMBL621266,N,1,,,,,1,,BAO_0000218,
8159,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,CHEMBL621267,N,1,,,,,1,,BAO_0000218,
8160,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,CHEMBL621268,N,1,,,,,1,,BAO_0000218,
8161,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,CHEMBL621269,N,1,,,,,1,,BAO_0000218,
8162,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,CHEMBL621270,N,1,,,,,1,,BAO_0000218,
8163,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,CHEMBL621271,N,1,,,,,1,,BAO_0000218,
8164,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,CHEMBL621272,N,1,,,,,1,,BAO_0000218,
8165,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,CHEMBL621273,N,1,,,,,1,,BAO_0000218,
8166,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,CHEMBL621274,N,1,,,,,1,,BAO_0000218,
8167,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,CHEMBL876495,N,1,,,,,1,,BAO_0000218,
8168,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,CHEMBL621275,N,1,,,,,1,,BAO_0000218,
8169,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,CHEMBL621276,N,1,,,,,1,,BAO_0000218,
8170,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,CHEMBL621277,N,1,,,,,1,,BAO_0000218,
8171,160.0,Intermediate,Intestine,50597,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,CHEMBL621278,N,1,,,,,1,,BAO_0000218,
8172,160.0,Intermediate,Intestine,50597,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,CHEMBL621279,N,1,,,,,1,,BAO_0000218,
8173,160.0,Intermediate,Intestine,50597,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),CHEMBL621280,N,1,,,,,1,,BAO_0000218,
8174,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,CHEMBL621281,N,1,,,,,1,,BAO_0000218,
8175,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,CHEMBL621282,N,1,,,,,1,,BAO_0000218,
8176,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,CHEMBL621283,N,1,,,,,1,,BAO_0000218,
8177,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,CHEMBL621284,N,1,,,,,1,,BAO_0000218,
8178,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,CHEMBL621285,N,1,,,,,1,,BAO_0000218,
8179,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,CHEMBL621286,N,1,,,,,1,,BAO_0000218,
8180,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,CHEMBL623220,N,1,,,,,1,,BAO_0000218,
8181,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,CHEMBL623221,N,1,,,,,1,,BAO_0000218,
8182,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,CHEMBL876029,N,1,,,,,1,,BAO_0000218,
8183,945.0,Intermediate,Stomach,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,CHEMBL623222,N,1,,,,,1,,BAO_0000218,
8184,945.0,Intermediate,Stomach,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,CHEMBL623223,N,1,,,,,1,,BAO_0000218,
8185,945.0,Intermediate,Stomach,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,CHEMBL621445,N,1,,,,,1,,BAO_0000218,
8186,178.0,Intermediate,Blood,50597,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL621446,N,1,,,,,1,,BAO_0000218,
8187,178.0,Intermediate,Blood,50597,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL621447,N,1,,,,,1,,BAO_0000218,
8188,178.0,Intermediate,Blood,50597,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL619681,N,1,,,,,1,,BAO_0000218,
8189,178.0,Intermediate,Blood,50597,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL619682,N,1,,,,,1,,BAO_0000218,
8190,178.0,Intermediate,Blood,50597,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL619683,N,1,,,,,1,,BAO_0000218,
8191,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL619684,N,1,,,,,1,,BAO_0000218,
8192,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL619685,N,1,,,,,1,,BAO_0000218,
8193,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL619686,N,1,,,,,1,,BAO_0000218,
8194,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL619687,N,1,,,,,1,,BAO_0000218,
8195,955.0,Intermediate,Brain,50597,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL619688,N,1,,,,,1,,BAO_0000218,
8196,948.0,Intermediate,Heart,50597,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL619689,N,1,,,,,1,,BAO_0000218,
8197,948.0,Intermediate,Heart,50597,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL619690,N,1,,,,,1,,BAO_0000218,
8198,948.0,Intermediate,Heart,50597,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL619691,N,1,,,,,1,,BAO_0000218,
8199,,Intermediate,,50597,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,CHEMBL619692,N,1,,,,,1,,BAO_0000218,
8200,,Expert,,50597,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL619693,N,1,,,,,1,,BAO_0000218,
8201,,Intermediate,,50597,Vc value after IV dose at a dose of 5 mg/kg in rats.,CHEMBL619694,N,1,,,,,1,,BAO_0000218,
8202,,Intermediate,,50597,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,CHEMBL619695,N,1,,,,,1,,BAO_0000218,
8203,,Intermediate,,50597,Compound was evaluated for pharmacokinetic parameter volume of distribution,CHEMBL619696,N,1,,,,,1,,BAO_0000218,
8204,,Intermediate,,50597,Compound was evaluated for volume of distribution in rat,CHEMBL619697,N,1,,,,,1,,BAO_0000218,
8205,,Intermediate,,50597,Steady state volume distribution was determined; steady state(ss),CHEMBL619698,N,1,,,,,1,,BAO_0000218,
8206,,Intermediate,,50597,Steady state volume of distribution after iv administration to rats,CHEMBL619699,N,1,,,,,1,,BAO_0000218,
8207,,Intermediate,,50597,Steady state volume of distribution dosing at 3 mg/kg iv,CHEMBL619700,N,1,,,,,1,,BAO_0000218,
8208,,Intermediate,,50597,The compound was evaluated for volume of distribution in rat,CHEMBL619701,N,1,,,,,1,,BAO_0000218,
8209,,Intermediate,,50597,The compound was tested for volume of distribution in rat,CHEMBL619702,N,1,,,,,1,,BAO_0000218,
8210,,Intermediate,,50597,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,CHEMBL620335,N,1,,,,,1,,BAO_0000218,
8211,,Intermediate,,50597,Volume distribution (VD) after oral administration in rat,CHEMBL620336,N,1,,,,,1,,BAO_0000218,
8212,,Intermediate,,50597,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,CHEMBL620337,N,1,,,,,1,,BAO_0000218,
8213,,Intermediate,,50597,Volume distribution in rat,CHEMBL620520,N,1,,,,,1,,BAO_0000218,
8214,,Intermediate,,50597,Volume distribution in rat,CHEMBL620521,N,1,,,,,1,,BAO_0000218,
8215,,Intermediate,,50597,Volume distribution in rat after peroral administration at 10 mg/kg,CHEMBL875825,N,1,,,,,1,,BAO_0000218,
8216,,Intermediate,,50597,Volume distribution in rat after peroral administration at 5 mg/kg,CHEMBL620522,N,1,,,,,1,,BAO_0000218,
8217,,Intermediate,,50597,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,CHEMBL620523,N,1,,,,,1,,BAO_0000218,
8218,,Intermediate,,50597,Volume of distribution in rat.,CHEMBL620524,N,1,,,,,1,,BAO_0000218,
8219,,Intermediate,,50597,Volume of distribution in rat,CHEMBL620525,N,1,,,,,1,,BAO_0000218,
8220,,Intermediate,,50597,Volume of distribution in rat,CHEMBL620526,N,1,,,,,1,,BAO_0000218,
8221,,Intermediate,,50597,Volume of distribution in rat by iv administration,CHEMBL620527,N,1,,,,,1,,BAO_0000218,
8222,,Intermediate,,50597,Volume of distribution in rats,CHEMBL620528,N,1,,,,,1,,BAO_0000218,
8223,,Intermediate,,50597,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,CHEMBL620529,N,1,,,,,1,,BAO_0000218,
8224,,Intermediate,,50597,Volume distribution at the dose of 2 mg/kg in rat,CHEMBL620530,N,1,,,,,1,,BAO_0000218,
8225,,Intermediate,,50597,Steady state volume of distribution was determined,CHEMBL620531,N,1,,,,,1,,BAO_0000218,
8226,,Intermediate,,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL620532,U,0,,,,,1,,BAO_0000218,
8227,,Intermediate,,22224,Compound was tested for its plasma volume distribution in Sprague Dawley rats,CHEMBL620533,U,0,,,,,1,,BAO_0000218,
8228,,Intermediate,,22224,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,CHEMBL620534,U,0,,,,,1,,BAO_0000218,
8229,,Intermediate,,50597,Mean (%CV) PK parameters for Vdss(mL/kg).,CHEMBL620535,N,1,,,,,1,,BAO_0000218,
8230,,Intermediate,,50597,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,CHEMBL875826,N,1,,,,,1,,BAO_0000218,
8231,,Intermediate,,50597,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,CHEMBL620536,N,1,,,,,1,,BAO_0000218,
8232,,Intermediate,,50597,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,CHEMBL620537,N,1,,,,,1,,BAO_0000218,
8233,,Intermediate,,50597,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,CHEMBL618526,N,1,,,,,1,,BAO_0000218,
8234,,Intermediate,,50597,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,CHEMBL618527,N,1,,,,,1,,BAO_0000218,
8235,,Intermediate,,50597,Pharmacokinetic property (Vdss) in rat,CHEMBL618528,N,1,,,,,1,,BAO_0000218,
8236,,Intermediate,,50597,Pharmacokinetic property (vdss) was measured in rat,CHEMBL618529,N,1,,,,,1,,BAO_0000218,
8237,,Intermediate,,50597,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,CHEMBL618530,N,1,,,,,1,,BAO_0000218,
8238,,Intermediate,,50597,Volume of distribution in rat,CHEMBL618531,N,1,,,,,1,,BAO_0000218,
8239,,Intermediate,,50597,The pharmacokinetic parameter volume of distribution in vivo in rats,CHEMBL618532,N,1,,,,,1,,BAO_0000218,
8240,,Intermediate,,50597,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL618533,N,1,,,,,1,,BAO_0000218,
8241,,Intermediate,,50597,Vdss in rat i.v. at 2 mg/kg concentration,CHEMBL618534,N,1,,,,,1,,BAO_0000218,
8242,,Intermediate,,50597,Volume distribution after intravenous administration (1 mg/kg) in rat,CHEMBL618535,N,1,,,,,1,,BAO_0000218,
8243,,Intermediate,,50597,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,CHEMBL618536,N,1,,,,,1,,BAO_0000218,
8244,,Intermediate,,50597,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,CHEMBL618537,N,1,,,,,1,,BAO_0000218,
8245,,Intermediate,,50597,Volume distribution at a dose of 10 uM/kg in rat was determined,CHEMBL618538,N,1,,,,,1,,BAO_0000218,
8246,,Intermediate,,50597,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,CHEMBL618539,N,1,,,,,1,,BAO_0000218,
8247,,Intermediate,,50597,Volume distribution was calculated in rat,CHEMBL618540,N,1,,,,,1,,BAO_0000218,
8248,,Intermediate,,50597,Volume distribution was determined,CHEMBL618541,N,1,,,,,1,,BAO_0000218,
8249,,Intermediate,,50597,Volume of distribution after intravenous administration was evaluated in rat,CHEMBL618542,N,1,,,,,1,,BAO_0000218,
8250,,Intermediate,,50597,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL622544,N,1,,,,,1,,BAO_0000218,
8251,,Intermediate,,50597,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",CHEMBL622545,N,1,,,,,1,,BAO_0000218,
8252,,Intermediate,,50597,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",CHEMBL622546,N,1,,,,,1,,BAO_0000218,
8253,,Intermediate,,50597,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",CHEMBL622547,N,1,,,,,1,,BAO_0000218,
8254,,Intermediate,,50597,Volume of distribution in steady state was determined in rat,CHEMBL622548,N,1,,,,,1,,BAO_0000218,
8255,,Intermediate,,50597,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,CHEMBL622549,N,1,,,,,1,,BAO_0000218,
8256,,Intermediate,,50597,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,CHEMBL622550,N,1,,,,,1,,BAO_0000218,
8257,,Intermediate,,50594,Compound was evaluated for area under curve when administered through oral route to mouse,CHEMBL622551,N,1,,,,,1,,BAO_0000218,
8258,,Intermediate,,50597,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,CHEMBL622552,N,1,,,,,1,,BAO_0000218,
8259,,Intermediate,,50597,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,CHEMBL622553,N,1,,,,,1,,BAO_0000218,
8260,,Autocuration,,22224,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,CHEMBL622554,U,0,,,,,1,,BAO_0000218,
8261,,Intermediate,,50588,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,CHEMBL622555,N,1,,,,,1,,BAO_0000218,
8262,,Intermediate,,50594,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,CHEMBL622556,N,1,,,,,1,,BAO_0000218,
8263,,Intermediate,,50594,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,CHEMBL622557,N,1,,,,,1,,BAO_0000218,
8264,178.0,Intermediate,Blood,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,CHEMBL622558,N,1,,,,,1,,BAO_0000218,
8265,178.0,Intermediate,Blood,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,CHEMBL622559,N,1,,,,,1,,BAO_0000218,
8266,,Intermediate,,50588,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,CHEMBL622560,N,1,,,,,1,,BAO_0000218,
8267,,Intermediate,,50597,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,CHEMBL622561,N,1,,,,,1,,BAO_0000218,
8268,,Intermediate,,50597,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,CHEMBL622562,N,1,,,,,1,,BAO_0000218,
8269,,Intermediate,,50597,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,CHEMBL622563,N,1,,,,,1,,BAO_0000218,
8270,,Autocuration,,22224,Concentration of compound in Central nervous system,CHEMBL622564,U,0,,,,,1,,BAO_0000019,
8271,,Autocuration,,22224,Concentration of compound in Central nervous system; Not detectable,CHEMBL622565,U,0,,,,,1,,BAO_0000019,
8272,,Intermediate,,50594,"Concentration of diester in the blood, following oral administration in mice",CHEMBL622566,N,1,,,,,1,,BAO_0000218,
8273,,Intermediate,,50594,"Concentration of monoester in the blood, following oral administration in mice",CHEMBL624515,N,1,,,,,1,,BAO_0000218,
8274,,Intermediate,,50594,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,CHEMBL624516,N,1,,,,,1,,BAO_0000218,
8275,,Autocuration,,22224,Evaluated for Pharmacokinetic property: Area under the curve,CHEMBL624517,U,0,,,,,1,,BAO_0000019,
8276,,Intermediate,,50594,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,CHEMBL624518,N,1,,,,,1,,BAO_0000218,
8277,,Intermediate,,100710,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,CHEMBL624519,N,1,,,,,1,,BAO_0000218,
8278,,Intermediate,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,CHEMBL624520,N,1,,,,,1,,BAO_0000218,
8279,,Intermediate,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,CHEMBL624521,N,1,,,,,1,,BAO_0000218,
8280,,Intermediate,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,CHEMBL624522,N,1,,,,,1,,BAO_0000218,
8281,,Intermediate,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,CHEMBL624523,N,1,,,,,1,,BAO_0000218,
8282,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",CHEMBL624409,N,1,,,,,1,,BAO_0000218,
8283,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",CHEMBL624410,N,1,,,,,1,,BAO_0000218,
8284,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",CHEMBL624411,N,1,,,,,1,,BAO_0000218,
8285,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",CHEMBL623531,N,1,,,,,1,,BAO_0000218,
8286,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",CHEMBL623532,N,1,,,,,1,,BAO_0000218,
8287,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",CHEMBL623533,N,1,,,,,1,,BAO_0000218,
8288,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",CHEMBL623534,N,1,,,,,1,,BAO_0000218,
8289,,Intermediate,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,CHEMBL623535,N,1,,,,,1,,BAO_0000218,
8290,,Intermediate,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,CHEMBL623536,N,1,,,,,1,,BAO_0000218,
8291,,Intermediate,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,CHEMBL623537,N,1,,,,,1,,BAO_0000218,
8292,,Intermediate,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,CHEMBL623538,N,1,,,,,1,,BAO_0000218,
8293,,Intermediate,,50594,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,CHEMBL623539,N,1,,,,,1,,BAO_0000218,
8294,,Intermediate,,50594,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,CHEMBL623540,N,1,,,,,1,,BAO_0000218,
8295,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",CHEMBL623541,N,1,,,,,1,,BAO_0000218,
8296,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",CHEMBL623542,N,1,,,,,1,,BAO_0000218,
8297,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",CHEMBL623543,N,1,,,,,1,,BAO_0000218,
8298,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",CHEMBL623544,N,1,,,,,1,,BAO_0000218,
8299,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",CHEMBL623545,N,1,,,,,1,,BAO_0000218,
8300,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",CHEMBL623546,N,1,,,,,1,,BAO_0000218,
8301,1969.0,Intermediate,Plasma,50597,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,CHEMBL623547,N,1,,,,,1,,BAO_0000218,
8302,,Intermediate,,50597,High i.v. clearance in Dawley rats,CHEMBL623548,N,1,,,,,1,,BAO_0000218,
8303,2107.0,Intermediate,Liver,50597,In vitro clearance in rat liver microsomes,CHEMBL623549,N,1,,,,Microsomes,1,,BAO_0000218,
8304,2107.0,Intermediate,Liver,50597,Intrinsic clearance in rat liver microsomes was determined,CHEMBL623550,N,1,,,,Microsomes,1,,BAO_0000218,
8305,2107.0,Intermediate,Liver,50597,Intrinsic clearance in rat hepatocytes was determined,CHEMBL875276,N,1,401.0,Hepatocyte,,,1,,BAO_0000218,
8306,,Intermediate,,50597,Plasma Clearance was determined,CHEMBL621872,N,1,,,,,1,,BAO_0000218,
8307,,Intermediate,,50597,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,CHEMBL621873,N,1,,,,,1,,BAO_0000218,
8308,,Intermediate,,50597,Plasma clearance in rat.,CHEMBL621874,N,1,,,,,1,,BAO_0000218,
8309,,Intermediate,,50597,Plasma clearance in rats,CHEMBL621875,N,1,,,,,1,,BAO_0000218,
8310,,Intermediate,,50597,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,CHEMBL621876,N,1,,,,,1,,BAO_0000218,
8311,,Intermediate,,50597,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,CHEMBL621877,N,1,,,,,1,,BAO_0000218,
8312,,Intermediate,,50597,Plasma clearance was measured in rat,CHEMBL621878,N,1,,,,,1,,BAO_0000218,
8313,,Intermediate,,50597,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,CHEMBL621879,N,1,,,,,1,,BAO_0000218,
8314,1969.0,Intermediate,Plasma,50597,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",CHEMBL621880,N,1,,,,,1,,BAO_0000218,
8315,,Intermediate,,50597,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,CHEMBL621881,N,1,,,,,1,,BAO_0000218,
8316,,Intermediate,,50597,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,CHEMBL621882,N,1,,,,,1,,BAO_0000218,
8317,,Intermediate,,50597,Total clearance at 1 mg/kg was determined in rat,CHEMBL875283,N,1,,,,,1,,BAO_0000218,
8318,,Intermediate,,50597,Total clearance at 10 mg/kg was determined in rat,CHEMBL621883,N,1,,,,,1,,BAO_0000218,
8319,,Intermediate,,50597,Clearance in rat,CHEMBL621884,N,1,,,,,1,,BAO_0000218,
8320,,Intermediate,,50597,Plasma clearance rate determined in rats,CHEMBL621885,N,1,,,,,1,,BAO_0000218,
8321,,Intermediate,,50597,Clearance of compound in rat was evaluated,CHEMBL621886,N,1,,,,,1,,BAO_0000218,
8322,1969.0,Intermediate,Plasma,50597,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,CHEMBL621887,N,1,,,,,1,,BAO_0000218,
8323,,Intermediate,,50597,Pharmacokinetic property (blood clearance) in rat,CHEMBL621888,N,1,,,,,1,,BAO_0000218,
8324,,Intermediate,,50597,Plasma clearance in rat,CHEMBL621889,N,1,,,,,1,,BAO_0000218,
8325,,Intermediate,,50597,Plasma clearance in rats,CHEMBL621890,N,1,,,,,1,,BAO_0000218,
8326,2107.0,Intermediate,Liver,50597,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,CHEMBL621891,N,1,,,,Microsomes,1,,BAO_0000218,
8327,,Intermediate,,50597,Clearance in Dawley rat,CHEMBL621892,N,1,,,,,1,,BAO_0000218,
8328,,Intermediate,,50597,Clearance rat,CHEMBL621893,N,1,,,,,1,,BAO_0000218,
8329,,Intermediate,,50597,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),CHEMBL621894,N,1,,,,,1,,BAO_0000218,
8330,,Intermediate,,50597,Clearance rat; Not determined,CHEMBL621895,N,1,,,,,1,,BAO_0000218,
8331,,Intermediate,,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.,CHEMBL875284,N,1,,,,,1,,BAO_0000218,
8332,,Intermediate,,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,CHEMBL618699,N,1,,,,,1,,BAO_0000218,
8333,,Intermediate,,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,CHEMBL618700,N,1,,,,,1,,BAO_0000218,
8334,,Intermediate,,50597,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,CHEMBL618701,N,1,,,,,1,,BAO_0000218,
8335,1969.0,Intermediate,Plasma,50597,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",CHEMBL876600,N,1,,,,,1,,BAO_0000218,
8336,,Intermediate,,50597,Clearance of compound in rat after 1 mg/kg i.v. administration,CHEMBL618702,N,1,,,,,1,,BAO_0000218,
8337,,Intermediate,,50597,Compound was evaluated for Hepatic clearance in rat,CHEMBL618703,N,1,,,,,1,,BAO_0000218,
8338,,Intermediate,,50597,In vivo clearance after 5 mg/kg dose,CHEMBL618704,N,1,,,,,1,,BAO_0000218,
8339,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma clearance in rats,CHEMBL618705,N,1,,,,,1,,BAO_0000218,
8340,,Intermediate,,50597,Hepatic clearance after intravenous administration was evaluated in rat,CHEMBL618706,N,1,,,,,1,,BAO_0000218,
8341,,Intermediate,,50597,Lower clearance in rat (i.v.) at 0.5 mpk,CHEMBL618707,N,1,,,,,1,,BAO_0000218,
8342,1969.0,Intermediate,Plasma,50597,Pharmacokinetic parameter expressed as plasma clearance in rat,CHEMBL618708,N,1,,,,,1,,BAO_0000218,
8343,,Intermediate,,50597,Pharmacokinetic property (Clp) in rat,CHEMBL618709,N,1,,,,,1,,BAO_0000218,
8344,,Intermediate,,50597,Plasma clearance in Sprague-Dawley rats,CHEMBL618710,N,1,,,,,1,,BAO_0000218,
8345,,Intermediate,,50597,Plasma clearance (Clp) in rat,CHEMBL618711,N,1,,,,,1,,BAO_0000218,
8346,,Intermediate,,50597,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,CHEMBL618712,N,1,,,,,1,,BAO_0000218,
8347,,Intermediate,,50597,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,CHEMBL618713,N,1,,,,,1,,BAO_0000218,
8348,,Intermediate,,50597,Plasma clearance after intravenous administration of 1 mg/kg in rat,CHEMBL618714,N,1,,,,,1,,BAO_0000218,
8349,,Intermediate,,50597,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,CHEMBL618715,N,1,,,,,1,,BAO_0000218,
8350,,Intermediate,,50597,Plasma clearance in rat was determined,CHEMBL618716,N,1,,,,,1,,BAO_0000218,
8351,,Intermediate,,50597,Plasma clearance measured in rat,CHEMBL876601,N,1,,,,,1,,BAO_0000218,
8352,,Intermediate,,50597,Plasma clearance was calculated in rat,CHEMBL618717,N,1,,,,,1,,BAO_0000218,
8353,,Intermediate,,50597,Plasma clearance in rat,CHEMBL618718,N,1,,,,,1,,BAO_0000218,
8354,,Intermediate,,50597,Plasma clearance in rat,CHEMBL618719,N,1,,,,,1,,BAO_0000218,
8355,,Intermediate,,50597,Plasma clearance in rat,CHEMBL618720,N,1,,,,,1,,BAO_0000218,
8356,,Intermediate,,50597,Plasma clearance in rat,CHEMBL618721,N,1,,,,,1,,BAO_0000218,
8357,,Intermediate,,50597,Plasma clearance in rats,CHEMBL621477,N,1,,,,,1,,BAO_0000218,
8358,,Intermediate,,50597,Plasma clearance in rat,CHEMBL621478,N,1,,,,,1,,BAO_0000218,
8359,,Intermediate,,50597,Plasma clearance was evaluated in rat,CHEMBL621479,N,1,,,,,1,,BAO_0000218,
8360,,Intermediate,,50597,Plasma clearance was evaluated in rat; Not tested,CHEMBL621480,N,1,,,,,1,,BAO_0000218,
8361,,Intermediate,,50597,Plasma clearance rate was determined for the compound in rat,CHEMBL621481,N,1,,,,,1,,BAO_0000218,
8362,,Intermediate,,50597,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",CHEMBL621482,N,1,,,,,1,,BAO_0000218,
8363,,Intermediate,,50597,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",CHEMBL621483,N,1,,,,,1,,BAO_0000218,
8364,,Intermediate,,50597,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",CHEMBL621484,N,1,,,,,1,,BAO_0000218,
8365,948.0,Intermediate,Heart,50597,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL621485,N,1,,,,,1,,BAO_0000218,
8366,948.0,Intermediate,Heart,50597,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL621486,N,1,,,,,1,,BAO_0000218,
8367,160.0,Intermediate,Intestine,50597,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL621487,N,1,,,,,1,,BAO_0000218,
8368,160.0,Intermediate,Intestine,50597,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL621488,N,1,,,,,1,,BAO_0000218,
8369,160.0,Intermediate,Intestine,50597,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL621489,N,1,,,,,1,,BAO_0000218,
8370,160.0,Intermediate,Intestine,50597,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL621490,N,1,,,,,1,,BAO_0000218,
8371,160.0,Intermediate,Intestine,50597,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL621491,N,1,,,,,1,,BAO_0000218,
8372,2113.0,Intermediate,Kidney,50597,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL621492,N,1,,,,,1,,BAO_0000218,
8373,2113.0,Intermediate,Kidney,50597,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,CHEMBL621493,N,1,,,,,1,,BAO_0000218,
8374,2113.0,Intermediate,Kidney,50597,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL621494,N,1,,,,,1,,BAO_0000218,
8375,2113.0,Intermediate,Kidney,50597,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL621495,N,1,,,,,1,,BAO_0000218,
8376,2113.0,Intermediate,Kidney,50597,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL621496,N,1,,,,,1,,BAO_0000218,
8377,2107.0,Intermediate,Liver,50597,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL621497,N,1,,,,,1,,BAO_0000218,
8378,2107.0,Intermediate,Liver,50597,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL621498,N,1,,,,,1,,BAO_0000218,
8379,2107.0,Intermediate,Liver,50597,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL621499,N,1,,,,,1,,BAO_0000218,
8380,2107.0,Intermediate,Liver,50597,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,CHEMBL618634,N,1,,,,,1,,BAO_0000218,
8381,2107.0,Intermediate,Liver,50597,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL618635,N,1,,,,,1,,BAO_0000218,
8382,2048.0,Intermediate,Lung,50597,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL618636,N,1,,,,,1,,BAO_0000218,
8383,2048.0,Intermediate,Lung,50597,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL619737,N,1,,,,,1,,BAO_0000218,
8384,2048.0,Intermediate,Lung,50597,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL619738,N,1,,,,,1,,BAO_0000218,
8385,2048.0,Intermediate,Lung,50597,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL624329,N,1,,,,,1,,BAO_0000218,
8386,2048.0,Intermediate,Lung,50597,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL624330,N,1,,,,,1,,BAO_0000218,
8387,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL624331,N,1,,,,,1,,BAO_0000218,
8388,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL624332,N,1,,,,,1,,BAO_0000218,
8389,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL624333,N,1,,,,,1,,BAO_0000218,
8390,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL624334,N,1,,,,,1,,BAO_0000218,
8391,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL624335,N,1,,,,,1,,BAO_0000218,
8392,2106.0,Intermediate,Spleen,50597,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL620016,N,1,,,,,1,,BAO_0000218,
8393,2106.0,Intermediate,Spleen,50597,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,CHEMBL620169,N,1,,,,,1,,BAO_0000218,
8394,2106.0,Intermediate,Spleen,50597,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL620170,N,1,,,,,1,,BAO_0000218,
8395,2106.0,Intermediate,Spleen,50597,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,CHEMBL620171,N,1,,,,,1,,BAO_0000218,
8396,2106.0,Intermediate,Spleen,50597,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL620172,N,1,,,,,1,,BAO_0000218,
8397,945.0,Intermediate,Stomach,50597,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,CHEMBL620173,N,1,,,,,1,,BAO_0000218,
8398,945.0,Intermediate,Stomach,50597,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,CHEMBL620174,N,1,,,,,1,,BAO_0000218,
8399,945.0,Intermediate,Stomach,50597,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,CHEMBL620175,N,1,,,,,1,,BAO_0000218,
8400,945.0,Intermediate,Stomach,50597,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,CHEMBL620176,N,1,,,,,1,,BAO_0000218,
8401,945.0,Intermediate,Stomach,50597,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,CHEMBL620177,N,1,,,,,1,,BAO_0000218,
8402,2037.0,Intermediate,Cerebellum,50597,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620178,N,1,,,,,1,,BAO_0000218,
8403,2037.0,Intermediate,Cerebellum,50597,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL620179,N,1,,,,,1,,BAO_0000218,
8404,,Intermediate,,50597,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620180,N,1,,,,,1,,BAO_0000218,
8405,,Intermediate,,50597,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,CHEMBL620181,N,1,,,,,1,,BAO_0000218,
8406,,Intermediate,,50597,Volume of distribution of compound in rats after intravenous administration,CHEMBL620182,N,1,,,,,1,,BAO_0000218,
8407,,Intermediate,,50597,Volume of distribution in rat,CHEMBL620183,N,1,,,,,1,,BAO_0000218,
8408,,Intermediate,,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,CHEMBL620184,N,1,,,,,1,,BAO_0000218,
8409,,Intermediate,,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,CHEMBL620185,N,1,,,,,1,,BAO_0000218,
8410,,Intermediate,,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,CHEMBL620186,N,1,,,,,1,,BAO_0000218,
8411,,Intermediate,,50597,Volume of distribution was determined in Dawley rat,CHEMBL620187,N,1,,,,,1,,BAO_0000218,
8412,,Intermediate,,50597,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,CHEMBL620188,N,1,,,,,1,,BAO_0000218,
8413,,Intermediate,,50597,Volume of distribution was reported in Sprague-Dawley rat,CHEMBL620189,N,1,,,,,1,,BAO_0000218,
8414,,Intermediate,,50597,Volumes of distribution in rat after peroral administration,CHEMBL620190,N,1,,,,,1,,BAO_0000218,
8415,,Intermediate,,50597,Volumes of distribution in rat after po administration,CHEMBL620191,N,1,,,,,1,,BAO_0000218,
8416,,Intermediate,,50597,Volumes of distribution in rat after po administration; Not determined,CHEMBL620192,N,1,,,,,1,,BAO_0000218,
8417,,Intermediate,,50597,Pharmacokinetic property (Volume) in rat i.v.,CHEMBL620193,N,1,,,,,1,,BAO_0000218,
8418,,Intermediate,,50597,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,CHEMBL620194,N,1,,,,,1,,BAO_0000218,
8419,,Intermediate,,50597,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",CHEMBL876730,N,1,,,,,1,,BAO_0000218,
8420,,Intermediate,,50597,Volume distribution in rat after oral administration at 10 mg/kg,CHEMBL620195,N,1,,,,,1,,BAO_0000218,
8421,,Intermediate,,50597,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,CHEMBL620196,N,1,,,,,1,,BAO_0000218,
8422,,Intermediate,,50597,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,CHEMBL620197,N,1,,,,,1,,BAO_0000218,
8423,,Intermediate,,50597,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,CHEMBL620198,N,1,,,,,1,,BAO_0000218,
8424,,Intermediate,,50597,Volume of distribution in rats,CHEMBL620199,N,1,,,,,1,,BAO_0000218,
8425,,Intermediate,,50597,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,CHEMBL620200,N,1,,,,,1,,BAO_0000218,
8426,,Intermediate,,50597,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,CHEMBL620201,N,1,,,,,1,,BAO_0000218,
8427,,Intermediate,,50597,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,CHEMBL620202,N,1,,,,,1,,BAO_0000218,
8428,,Intermediate,,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,CHEMBL620203,N,1,,,,,1,,BAO_0000218,
8429,,Intermediate,,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,CHEMBL620204,N,1,,,,,1,,BAO_0000218,
8430,,Intermediate,,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,CHEMBL620205,N,1,,,,,1,,BAO_0000218,
8431,,Intermediate,,50597,Pharmacokinetic parameter (Vss) in rat,CHEMBL624664,N,1,,,,,1,,BAO_0000218,
8432,,Intermediate,,50597,Pharmacokinetic property (Volume) in rat i.v.,CHEMBL624665,N,1,,,,,1,,BAO_0000218,
8433,,Intermediate,,50597,Pharmacokinetic property (Vss) in rat,CHEMBL624666,N,1,,,,,1,,BAO_0000218,
8434,,Intermediate,,50597,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,CHEMBL624667,N,1,,,,,1,,BAO_0000218,
8435,,Intermediate,,50597,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,CHEMBL624668,N,1,,,,,1,,BAO_0000218,
8436,,Intermediate,,50597,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL624669,N,1,,,,,1,,BAO_0000218,
8437,,Intermediate,,50597,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL624670,N,1,,,,,1,,BAO_0000218,
8438,,Intermediate,,50597,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL624671,N,1,,,,,1,,BAO_0000218,
8439,,Intermediate,,50597,Steady state volume distribution in rat,CHEMBL624672,N,1,,,,,1,,BAO_0000218,
8440,1969.0,Intermediate,Plasma,50597,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",CHEMBL624673,N,1,,,,,1,,BAO_0000218,
8441,,Intermediate,,50597,Steady state volume of distribution determined in rat,CHEMBL624674,N,1,,,,,1,,BAO_0000218,
8442,,Intermediate,,50597,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,CHEMBL624675,N,1,,,,,1,,BAO_0000218,
8443,,Intermediate,,50597,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,CHEMBL621728,N,1,,,,,1,,BAO_0000218,
8444,,Intermediate,,50597,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,CHEMBL621729,N,1,,,,,1,,BAO_0000218,
8445,,Intermediate,,50597,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,CHEMBL621730,N,1,,,,,1,,BAO_0000218,
8446,,Intermediate,,50597,Volume distribution in rat after administration of 2 mg/kg iv,CHEMBL621731,N,1,,,,,1,,BAO_0000218,
8447,,Intermediate,,50597,Volume distribution in rat after administration of 2 mg/kg iv,CHEMBL621732,N,1,,,,,1,,BAO_0000218,
8448,,Intermediate,,50597,Volume in steady state distribution value was determined,CHEMBL621908,N,1,,,,,1,,BAO_0000218,
8449,,Intermediate,,50597,Volume in steady state distribution value was determined; ND denotes no data,CHEMBL875347,N,1,,,,,1,,BAO_0000218,
8450,,Intermediate,,50597,Volume in steady state distribution value was determined; ND denotes not determined,CHEMBL621909,N,1,,,,,1,,BAO_0000218,
8451,,Intermediate,,50597,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,CHEMBL621910,N,1,,,,,1,,BAO_0000218,
8452,,Intermediate,,50597,Volume of distribution at steady state was evaluated in rats,CHEMBL621911,N,1,,,,,1,,BAO_0000218,
8453,,Intermediate,,50597,Volume of distribution at steady state was observed after intravenous administration in rat,CHEMBL621912,N,1,,,,,1,,BAO_0000218,
8454,,Intermediate,,50597,Volume of distribution in steady state was determined in rat,CHEMBL621913,N,1,,,,,1,,BAO_0000218,
8455,,Intermediate,,50597,Volume of distribution in steady state was determined in rat,CHEMBL621914,N,1,,,,,1,,BAO_0000218,
8456,,Intermediate,,50597,Volume of distribution after i.v. administration,CHEMBL621915,N,1,,,,,1,,BAO_0000218,
8457,,Intermediate,,50597,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,CHEMBL621916,N,1,,,,,1,,BAO_0000218,
8458,2107.0,Intermediate,Liver,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL621917,N,1,,,,,1,,BAO_0000218,
8459,2107.0,Intermediate,Liver,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL621918,N,1,,,,,1,,BAO_0000218,
8460,2106.0,Intermediate,Spleen,50594,Biodistribution of compound (oxidized form) in spleen tissue,CHEMBL621919,N,1,,,,,1,,BAO_0000218,
8461,2106.0,Intermediate,Spleen,50594,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL621920,N,1,,,,,1,,BAO_0000218,
8462,2106.0,Intermediate,Spleen,50594,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",CHEMBL621921,N,1,,,,,1,,BAO_0000218,
8463,2106.0,Intermediate,Spleen,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622401,N,1,,,,,1,,BAO_0000218,
8464,2106.0,Intermediate,Spleen,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL875348,N,1,,,,,1,,BAO_0000218,
8465,2106.0,Intermediate,Spleen,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL622402,N,1,,,,,1,,BAO_0000218,
8466,178.0,Intermediate,Blood,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,CHEMBL622403,N,1,,,,,1,,BAO_0000218,
8467,178.0,Intermediate,Blood,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622404,N,1,,,,,1,,BAO_0000218,
8468,955.0,Intermediate,Brain,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,CHEMBL622405,N,1,,,,,1,,BAO_0000218,
8469,955.0,Intermediate,Brain,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",CHEMBL622406,N,1,,,,,1,,BAO_0000218,
8470,955.0,Intermediate,Brain,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622407,N,1,,,,,1,,BAO_0000218,
8471,948.0,Intermediate,Heart,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,CHEMBL622408,N,1,,,,,1,,BAO_0000218,
8472,948.0,Intermediate,Heart,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",CHEMBL622409,N,1,,,,,1,,BAO_0000218,
8473,948.0,Intermediate,Heart,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622410,N,1,,,,,1,,BAO_0000218,
8474,2113.0,Intermediate,Kidney,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,CHEMBL622411,N,1,,,,,1,,BAO_0000218,
8475,2113.0,Intermediate,Kidney,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",CHEMBL627864,N,1,,,,,1,,BAO_0000218,
8476,2113.0,Intermediate,Kidney,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL627865,N,1,,,,,1,,BAO_0000218,
8477,2107.0,Intermediate,Liver,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,CHEMBL627866,N,1,,,,,1,,BAO_0000218,
8478,2107.0,Intermediate,Liver,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL627751,N,1,,,,,1,,BAO_0000218,
8479,2106.0,Intermediate,Spleen,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,CHEMBL627752,N,1,,,,,1,,BAO_0000218,
8480,2106.0,Intermediate,Spleen,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",CHEMBL627753,N,1,,,,,1,,BAO_0000218,
8481,2106.0,Intermediate,Spleen,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL627754,N,1,,,,,1,,BAO_0000218,
8482,,Intermediate,,50594,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,CHEMBL627755,N,1,,,,,1,,BAO_0000218,
8483,955.0,Intermediate,Brain,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL627756,N,1,,,,,1,,BAO_0000218,
8484,955.0,Intermediate,Brain,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627757,N,1,,,,,1,,BAO_0000218,
8485,955.0,Intermediate,Brain,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL627758,N,1,,,,,1,,BAO_0000218,
8486,955.0,Intermediate,Brain,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627759,N,1,,,,,1,,BAO_0000218,
8487,955.0,Intermediate,Brain,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL627760,N,1,,,,,1,,BAO_0000218,
8488,955.0,Intermediate,Brain,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627761,N,1,,,,,1,,BAO_0000218,
8489,948.0,Intermediate,Heart,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL876811,N,1,,,,,1,,BAO_0000218,
8490,948.0,Intermediate,Heart,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627762,N,1,,,,,1,,BAO_0000218,
8491,948.0,Intermediate,Heart,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL627763,N,1,,,,,1,,BAO_0000218,
8492,948.0,Intermediate,Heart,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627764,N,1,,,,,1,,BAO_0000218,
8493,948.0,Intermediate,Heart,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL627765,N,1,,,,,1,,BAO_0000218,
8494,948.0,Intermediate,Heart,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627766,N,1,,,,,1,,BAO_0000218,
8495,2113.0,Intermediate,Kidney,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL627767,N,1,,,,,1,,BAO_0000218,
8496,2113.0,Intermediate,Kidney,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627768,N,1,,,,,1,,BAO_0000218,
8497,2113.0,Intermediate,Kidney,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL628422,N,1,,,,,1,,BAO_0000218,
8498,2113.0,Intermediate,Kidney,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL628423,N,1,,,,,1,,BAO_0000218,
8499,,Intermediate,,50597,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,CHEMBL628424,N,1,,,,,1,,BAO_0000218,
8500,,Intermediate,,50597,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,CHEMBL628425,N,1,,,,,1,,BAO_0000218,
8501,,Intermediate,,50597,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,CHEMBL628426,N,1,,,,,1,,BAO_0000218,
8502,,Intermediate,,50597,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL628427,N,1,,,,,1,,BAO_0000218,
8503,,Intermediate,,50597,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,CHEMBL626938,N,1,,,,,1,,BAO_0000218,
8504,,Intermediate,,50597,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,CHEMBL626939,N,1,,,,,1,,BAO_0000218,
8505,,Intermediate,,50597,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,CHEMBL626940,N,1,,,,,1,,BAO_0000218,
8506,,Intermediate,,50597,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,CHEMBL626941,N,1,,,,,1,,BAO_0000218,
8507,,Intermediate,,50597,Plasma clearance was reported in Sprague-Dawley rat,CHEMBL626942,N,1,,,,,1,,BAO_0000218,
8508,,Intermediate,,50597,Plasma clearance after intravenous administration (1 mg/kg) in rat,CHEMBL876812,N,1,,,,,1,,BAO_0000218,
8509,,Intermediate,,50597,Plasma clearance of compound in rats was evaluated,CHEMBL626943,N,1,,,,,1,,BAO_0000218,
8510,,Intermediate,,50597,Plasma clearance of compound in rats was evaluated; ND indicates not determined,CHEMBL626944,N,1,,,,,1,,BAO_0000218,
8511,,Intermediate,,50597,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,CHEMBL626945,N,1,,,,,1,,BAO_0000218,
8512,,Intermediate,,50597,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,CHEMBL626946,N,1,,,,,1,,BAO_0000218,
8513,,Intermediate,,50597,Plasma clearance rate in Sprague-Dawley rats,CHEMBL626856,N,1,,,,,1,,BAO_0000218,
8514,,Intermediate,,50597,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),CHEMBL626857,N,1,,,,,1,,BAO_0000218,
8515,1969.0,Intermediate,Plasma,50597,The compound was evaluated for plasma clearance in rat,CHEMBL626858,N,1,,,,,1,,BAO_0000218,
8516,1969.0,Intermediate,Plasma,50597,Total plasma clearance in rat,CHEMBL627018,N,1,,,,,1,,BAO_0000218,
8517,178.0,Intermediate,Blood,50597,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,CHEMBL625331,N,1,,,,,1,,BAO_0000218,
8518,178.0,Intermediate,Blood,50597,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,CHEMBL625332,N,1,,,,,1,,BAO_0000218,
8519,,Intermediate,,50597,C max was determined at 10 mg/kg po dose in rats,CHEMBL877590,N,1,,,,,1,,BAO_0000218,
8520,,Intermediate,,50597,C max was determined at 3 mg/kg po dose in rats,CHEMBL625333,N,1,,,,,1,,BAO_0000218,
8521,,Intermediate,,50597,Cmax after repeated oral dose of compound at 1 mg/kg in rats,CHEMBL625334,N,1,,,,,1,,BAO_0000218,
8522,,Intermediate,,50597,Cmax after single intravenous bolus of 1 mg/kg in rats,CHEMBL625335,N,1,,,,,1,,BAO_0000218,
8523,,Intermediate,,50597,Cmax of compound at 5 mg/kg after po administration was determined in rat,CHEMBL625336,N,1,,,,,1,,BAO_0000218,
8524,,Intermediate,,50597,Cmax 24 hr after 10 mg/kg oral administration in rats,CHEMBL625337,N,1,,,,,1,,BAO_0000218,
8525,,Intermediate,,50597,Cmax 24 hr after 2 mg/kg oral administration in rats,CHEMBL625338,N,1,,,,,1,,BAO_0000218,
8526,1969.0,Intermediate,Plasma,50597,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,CHEMBL625339,N,1,,,,,1,,BAO_0000218,
8527,,Intermediate,,50597,Cmax in rat after administration of 2 mg/kg iv,CHEMBL625340,N,1,,,,,1,,BAO_0000218,
8528,,Intermediate,,50597,Cmax in rat after administration of 2 mg/kg iv,CHEMBL625341,N,1,,,,,1,,BAO_0000218,
8529,,Intermediate,,50597,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,CHEMBL622687,N,1,,,,,1,,BAO_0000218,
8530,1969.0,Intermediate,Plasma,50597,Cmax wa determined in rat plasma at 30 mg/kg after po administration,CHEMBL622688,N,1,,,,,1,,BAO_0000218,
8531,178.0,Intermediate,Blood,50597,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,CHEMBL622689,N,1,,,,,1,,BAO_0000218,
8532,178.0,Intermediate,Blood,50597,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,CHEMBL620295,N,1,,,,,1,,BAO_0000218,
8533,,Intermediate,,50597,Cmax after 10 mg/kg oral administration in rat,CHEMBL620296,N,1,,,,,1,,BAO_0000218,
8534,,Intermediate,,50597,Cmax after IV dosing at 0.5 mg/kg in rat; no data,CHEMBL620297,N,1,,,,,1,,BAO_0000218,
8535,,Intermediate,,50597,Cmax after IV dosing at 1 mg/kg in rat; no data,CHEMBL620298,N,1,,,,,1,,BAO_0000218,
8536,,Intermediate,,50597,Cmax after oral administration at 20 mpk in rats,CHEMBL620299,N,1,,,,,1,,BAO_0000218,
8537,,Intermediate,,50597,Cmax after oral administration at 20 mpk in rats; Not performed.,CHEMBL620300,N,1,,,,,1,,BAO_0000218,
8538,,Intermediate,,50597,Cmax after oral administration at 20 mpk in rats d; Not performed.,CHEMBL620301,N,1,,,,,1,,BAO_0000218,
8539,,Intermediate,,50597,Cmax after oral administration in rat,CHEMBL620302,N,1,,,,,1,,BAO_0000218,
8540,,Intermediate,,50597,Cmax after oral administration at a dose of 2 mg/kg in rat,CHEMBL620303,N,1,,,,,1,,BAO_0000218,
8541,,Intermediate,,50597,Cmax after oral administration at a dose of 4 mg/kg in rat,CHEMBL620304,N,1,,,,,1,,BAO_0000218,
8542,,Intermediate,,50597,Cmax in rats after 20 mg/kg oral dose,CHEMBL620305,N,1,,,,,1,,BAO_0000218,
8543,,Intermediate,,50597,Cmax after peroral administration in rats at 2.4 uM/kg,CHEMBL620306,N,1,,,,,1,,BAO_0000218,
8544,,Intermediate,,50597,Cmax at the dose of 2 mg/Kg administered perorally in rats,CHEMBL620307,N,1,,,,,1,,BAO_0000218,
8545,,Intermediate,,50597,Cmax at the dose of 5 mg/Kg administered perorally in rats,CHEMBL620308,N,1,,,,,1,,BAO_0000218,
8546,,Intermediate,,50597,Cmax by administering at 20 mg/kg p.o. in rats,CHEMBL620309,N,1,,,,,1,,BAO_0000218,
8547,,Intermediate,,50597,Cmax in male rat,CHEMBL620310,N,1,,,,,1,,BAO_0000218,
8548,,Intermediate,,50597,Cmax in rat,CHEMBL620311,N,1,,,,,1,,BAO_0000218,
8549,,Intermediate,,50597,Cmax in rat,CHEMBL620312,N,1,,,,,1,,BAO_0000218,
8550,,Intermediate,,50597,Cmax in rat,CHEMBL620313,N,1,,,,,1,,BAO_0000218,
8551,,Intermediate,,50597,Cmax in rat at 10 mg/kg,CHEMBL620314,N,1,,,,,1,,BAO_0000218,
8552,,Intermediate,,50597,Cmax in rat at the dose of 1 mg/kg i.v.,CHEMBL620315,N,1,,,,,1,,BAO_0000218,
8553,,Intermediate,,50597,Cmax in rat by po administration at a dose of 40 mg/kg,CHEMBL620316,N,1,,,,,1,,BAO_0000218,
8554,,Intermediate,,50597,Cmax in rat p.o. at 20 mg/kg concentration,CHEMBL620317,N,1,,,,,1,,BAO_0000218,
8555,,Intermediate,,50597,Cmax in rats,CHEMBL620318,N,1,,,,,1,,BAO_0000218,
8556,,Intermediate,,50597,Cmax in rats,CHEMBL620319,N,1,,,,,1,,BAO_0000218,
8557,,Intermediate,,50597,Cmax was evaluated after 20 uM/kg of peroral administration,CHEMBL620320,N,1,,,,,1,,BAO_0000218,
8558,,Intermediate,,50597,Cmax was measured in rats after peroral administration at 3 mg/kg,CHEMBL620321,N,1,,,,,1,,BAO_0000218,
8559,,Intermediate,,50597,Cmax value after oral dose at a dose of 10 mg/kg in rats.,CHEMBL620322,N,1,,,,,1,,BAO_0000218,
8560,,Intermediate,,50597,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL620323,N,1,,,,,1,,BAO_0000218,
8561,1870.0,Intermediate,Frontal cortex,50597,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620324,N,1,,,,,1,,BAO_0000218,
8562,1870.0,Intermediate,Frontal cortex,50597,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL620325,N,1,,,,,1,,BAO_0000218,
8563,10000000.0,Intermediate,Hippocampus,50597,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620326,N,1,,,,,1,,BAO_0000218,
8564,10000000.0,Intermediate,Hippocampus,50597,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL620327,N,1,,,,,1,,BAO_0000218,
8565,,Intermediate,,50597,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620328,N,1,,,,,1,,BAO_0000218,
8566,,Intermediate,,50597,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL620329,N,1,,,,,1,,BAO_0000218,
8567,1891.0,Intermediate,Midbrain,50597,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620330,N,1,,,,,1,,BAO_0000218,
8568,1891.0,Intermediate,Midbrain,50597,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL875286,N,1,,,,,1,,BAO_0000218,
8569,,Intermediate,,50597,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620331,N,1,,,,,1,,BAO_0000218,
8570,,Intermediate,,50597,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL620332,N,1,,,,,1,,BAO_0000218,
8571,2435.0,Intermediate,Striatum,50597,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,CHEMBL620333,N,1,,,,,1,,BAO_0000218,
8572,2435.0,Intermediate,Striatum,50597,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,CHEMBL620334,N,1,,,,,1,,BAO_0000218,
8573,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL621015,N,1,,,,,1,,BAO_0000218,
8574,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL621016,N,1,,,,,1,,BAO_0000218,
8575,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL621191,N,1,,,,,1,,BAO_0000218,
8576,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL621192,N,1,,,,,1,,BAO_0000218,
8577,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL621193,N,1,,,,,1,,BAO_0000218,
8578,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL621194,N,1,,,,,1,,BAO_0000218,
8579,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL624204,N,1,,,,,1,,BAO_0000218,
8580,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL624205,N,1,,,,,1,,BAO_0000218,
8581,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL624206,N,1,,,,,1,,BAO_0000218,
8582,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL624207,N,1,,,,,1,,BAO_0000218,
8583,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL624208,N,1,,,,,1,,BAO_0000218,
8584,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL624209,N,1,,,,,1,,BAO_0000218,
8585,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL624210,N,1,,,,,1,,BAO_0000218,
8586,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL624211,N,1,,,,,1,,BAO_0000218,
8587,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL624212,N,1,,,,,1,,BAO_0000218,
8588,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL624213,N,1,,,,,1,,BAO_0000218,
8589,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL876611,N,1,,,,,1,,BAO_0000218,
8590,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL624214,N,1,,,,,1,,BAO_0000218,
8591,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL624215,N,1,,,,,1,,BAO_0000218,
8592,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL624216,N,1,,,,,1,,BAO_0000218,
8593,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL624217,N,1,,,,,1,,BAO_0000218,
8594,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL624218,N,1,,,,,1,,BAO_0000218,
8595,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL624219,N,1,,,,,1,,BAO_0000218,
8596,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL624220,N,1,,,,,1,,BAO_0000218,
8597,178.0,Intermediate,Blood,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL624221,N,1,,,,,1,,BAO_0000218,
8598,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL624222,N,1,,,,,1,,BAO_0000218,
8599,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL624223,N,1,,,,,1,,BAO_0000218,
8600,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL624224,N,1,,,,,1,,BAO_0000218,
8601,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL624225,N,1,,,,,1,,BAO_0000218,
8602,,Intermediate,,50597,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,CHEMBL622420,N,1,,,,,1,,BAO_0000218,
8603,,Intermediate,,50597,Volume of steady state distribution after i.v. administration in rats,CHEMBL622421,N,1,,,,,1,,BAO_0000218,
8604,,Intermediate,,50597,Vss after intravenous administration (5.0 mg/kg) was determined in rat,CHEMBL622422,N,1,,,,,1,,BAO_0000218,
8605,,Intermediate,,50597,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,CHEMBL622423,N,1,,,,,1,,BAO_0000218,
8606,,Intermediate,,50597,Vss was determined,CHEMBL622424,N,1,,,,,1,,BAO_0000218,
8607,,Intermediate,,50597,Vss in rat,CHEMBL622425,N,1,,,,,1,,BAO_0000218,
8608,,Intermediate,,50597,Vss was evaluated after 10 uM/kg of intra arterial administration,CHEMBL876612,N,1,,,,,1,,BAO_0000218,
8609,,Intermediate,,50597,volume of distribution at steady state was observed after intravenous administration in rat,CHEMBL622426,N,1,,,,,1,,BAO_0000218,
8610,,Intermediate,,50597,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,CHEMBL622427,N,1,,,,,1,,BAO_0000218,
8611,,Intermediate,,50597,Pharmacokinetic (PK) parameter Vz in rat,CHEMBL622428,N,1,,,,,1,,BAO_0000218,
8612,,Intermediate,,50597,Volume distribution in rats,CHEMBL622429,N,1,,,,,1,,BAO_0000218,
8613,,Intermediate,,50597,Volume of distribution in rat; No data,CHEMBL622430,N,1,,,,,1,,BAO_0000218,
8614,,Intermediate,,50597,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,CHEMBL622431,N,1,,,,,1,,BAO_0000218,
8615,2116.0,Intermediate,Ileum,50597,% absorption predicted from in vitro rat ileum transport studies,CHEMBL622432,N,1,,,,,1,,BAO_0000218,
8616,,Intermediate,,50597,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,CHEMBL622433,N,1,,,,,1,,BAO_0000218,
8617,,Intermediate,,50597,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,CHEMBL622434,N,1,,,,,1,,BAO_0000218,
8618,,Intermediate,,50597,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,CHEMBL622435,N,1,,,,,1,,BAO_0000218,
8619,,Intermediate,,50597,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),CHEMBL618748,N,1,,,,,1,,BAO_0000218,
8620,,Intermediate,,50597,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,CHEMBL618749,N,1,,,,,1,,BAO_0000218,
8621,,Intermediate,,50597,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,CHEMBL618750,N,1,,,,,1,,BAO_0000218,
8622,,Intermediate,,50597,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,CHEMBL618751,N,1,,,,,1,,BAO_0000218,
8623,,Intermediate,,50597,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,CHEMBL618752,N,1,,,,,1,,BAO_0000218,
8624,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL618753,N,1,,,,,1,,BAO_0000218,
8625,1969.0,Intermediate,Plasma,50597,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,CHEMBL618754,N,1,,,,,1,,BAO_0000218,
8626,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL618755,N,1,,,,,1,,BAO_0000218,
8627,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL618756,N,1,,,,,1,,BAO_0000218,
8628,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL618757,N,1,,,,,1,,BAO_0000218,
8629,,Intermediate,,50597,Bioavailability in rat,CHEMBL618758,N,1,,,,,1,,BAO_0000218,
8630,,Intermediate,,50597,Oral bioavailability in rat (dose 30 mg/kg),CHEMBL621088,N,1,,,,,1,,BAO_0000218,
8631,,Intermediate,,50597,Pharmacokinetic property (cLogP) in rat,CHEMBL621089,N,1,,,,,1,,BAO_0000218,
8632,178.0,Intermediate,Blood,50597,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,CHEMBL621090,N,1,,,,,1,,BAO_0000218,
8633,178.0,Intermediate,Blood,50597,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,CHEMBL621091,N,1,,,,,1,,BAO_0000218,
8634,,Intermediate,,50597,Clearance in rat.,CHEMBL876731,N,1,,,,,1,,BAO_0000218,
8635,,Intermediate,,50597,Compound was evaluated for its clearance when administered intravenously in rat,CHEMBL621092,N,1,,,,,1,,BAO_0000218,
8636,,Intermediate,,50597,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,CHEMBL621093,N,1,,,,,1,,BAO_0000218,
8637,,Intermediate,,50597,Blood: Brain distribution ratio is determined in rat,CHEMBL621094,N,1,,,,,1,,BAO_0000218,
8638,,Intermediate,,50597,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,CHEMBL621095,N,1,,,,,1,,BAO_0000218,
8639,,Intermediate,,50597,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,CHEMBL621096,N,1,,,,,1,,BAO_0000218,
8640,2113.0,Intermediate,Kidney,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL621097,N,1,,,,,1,,BAO_0000218,
8641,,Intermediate,,50597,Percent dose excreted in 0-48 hours administered ip to male rat,CHEMBL621098,N,1,,,,,1,,BAO_0000218,
8642,2037.0,Intermediate,Cerebellum,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621099,N,1,,,,,1,,BAO_0000218,
8643,2037.0,Intermediate,Cerebellum,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621100,N,1,,,,,1,,BAO_0000218,
8644,2037.0,Intermediate,Cerebellum,50597,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL621101,N,1,,,,,1,,BAO_0000218,
8645,2037.0,Intermediate,Cerebellum,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621102,N,1,,,,,1,,BAO_0000218,
8646,2037.0,Intermediate,Cerebellum,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL876732,N,1,,,,,1,,BAO_0000218,
8647,,Intermediate,,50597,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621103,N,1,,,,,1,,BAO_0000218,
8648,,Intermediate,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621104,N,1,,,,,1,,BAO_0000218,
8649,,Intermediate,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL621105,N,1,,,,,1,,BAO_0000218,
8650,,Intermediate,,50597,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621106,N,1,,,,,1,,BAO_0000218,
8651,,Intermediate,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621107,N,1,,,,,1,,BAO_0000218,
8652,,Intermediate,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621108,N,1,,,,,1,,BAO_0000218,
8653,,Intermediate,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621109,N,1,,,,,1,,BAO_0000218,
8654,2113.0,Intermediate,Kidney,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL621110,N,1,,,,,1,,BAO_0000218,
8655,2113.0,Intermediate,Kidney,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL621111,N,1,,,,,1,,BAO_0000218,
8656,2107.0,Intermediate,Liver,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL622541,N,1,,,,,1,,BAO_0000218,
8657,2107.0,Intermediate,Liver,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL622542,N,1,,,,,1,,BAO_0000218,
8658,2107.0,Intermediate,Liver,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL622543,N,1,,,,,1,,BAO_0000218,
8659,2107.0,Intermediate,Liver,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL624412,N,1,,,,,1,,BAO_0000218,
8660,2107.0,Intermediate,Liver,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL624413,N,1,,,,,1,,BAO_0000218,
8661,2107.0,Intermediate,Liver,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL624414,N,1,,,,,1,,BAO_0000218,
8662,2048.0,Intermediate,Lung,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL624415,N,1,,,,,1,,BAO_0000218,
8663,2048.0,Intermediate,Lung,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL624416,N,1,,,,,1,,BAO_0000218,
8664,2048.0,Intermediate,Lung,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL624417,N,1,,,,,1,,BAO_0000218,
8665,2048.0,Intermediate,Lung,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL624418,N,1,,,,,1,,BAO_0000218,
8666,2048.0,Intermediate,Lung,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL624419,N,1,,,,,1,,BAO_0000218,
8667,2048.0,Intermediate,Lung,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL624420,N,1,,,,,1,,BAO_0000218,
8668,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),CHEMBL624421,N,1,,,,,1,,BAO_0000218,
8669,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL624422,N,1,,,,,1,,BAO_0000218,
8670,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL624423,N,1,,,,,1,,BAO_0000218,
8671,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL625123,N,1,,,,,1,,BAO_0000218,
8672,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL625124,N,1,,,,,1,,BAO_0000218,
8673,2385.0,Intermediate,Muscle tissue,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL625125,N,1,,,,,1,,BAO_0000218,
8674,14.0,Intermediate,Zone of skin,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL625126,N,1,,,,,1,,BAO_0000218,
8675,14.0,Intermediate,Zone of skin,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626947,N,1,,,,,1,,BAO_0000218,
8676,14.0,Intermediate,Zone of skin,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL626948,N,1,,,,,1,,BAO_0000218,
8677,14.0,Intermediate,Zone of skin,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626949,N,1,,,,,1,,BAO_0000218,
8678,14.0,Intermediate,Zone of skin,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL626950,N,1,,,,,1,,BAO_0000218,
8679,14.0,Intermediate,Zone of skin,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626951,N,1,,,,,1,,BAO_0000218,
8680,2106.0,Intermediate,Spleen,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL626952,N,1,,,,,1,,BAO_0000218,
8681,2106.0,Intermediate,Spleen,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626953,N,1,,,,,1,,BAO_0000218,
8682,2106.0,Intermediate,Spleen,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL626954,N,1,,,,,1,,BAO_0000218,
8683,2106.0,Intermediate,Spleen,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626955,N,1,,,,,1,,BAO_0000218,
8684,2106.0,Intermediate,Spleen,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL626956,N,1,,,,,1,,BAO_0000218,
8685,2106.0,Intermediate,Spleen,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626957,N,1,,,,,1,,BAO_0000218,
8686,178.0,Intermediate,Blood,50594,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),CHEMBL626958,N,1,,,,,1,,BAO_0000218,
8687,178.0,Intermediate,Blood,50594,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626959,N,1,,,,,1,,BAO_0000218,
8688,178.0,Intermediate,Blood,50594,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL626960,N,1,,,,,1,,BAO_0000218,
8689,178.0,Intermediate,Blood,50594,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),CHEMBL626961,N,1,,,,,1,,BAO_0000218,
8690,178.0,Intermediate,Blood,50594,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),CHEMBL627589,N,1,,,,,1,,BAO_0000218,
8691,178.0,Intermediate,Blood,50594,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),CHEMBL627590,N,1,,,,,1,,BAO_0000218,
8692,,Intermediate,,50594,Time taken for EC90 was determined when tested in mouse,CHEMBL627591,N,1,,,,,1,,BAO_0000218,
8693,,Intermediate,,50594,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,CHEMBL627592,N,1,,,,,1,,BAO_0000218,
8694,,Intermediate,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),CHEMBL627593,N,1,,,,,1,,BAO_0000218,
8695,,Intermediate,,50594,Half life in mice,CHEMBL627594,N,1,,,,,1,,BAO_0000218,
8696,,Intermediate,,50594,Half life period in mouse after 10 mg/Kg dose,CHEMBL876813,N,1,,,,,1,,BAO_0000218,
8697,,Intermediate,,50594,Half life period in mouse after 10 mg/kg dose,CHEMBL627595,N,1,,,,,1,,BAO_0000218,
8698,,Intermediate,,50594,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL627596,N,1,,,,,1,,BAO_0000218,
8699,,Intermediate,,50597,Cmax value at 5 mg/kg po was determined in rat,CHEMBL627597,N,1,,,,,1,,BAO_0000218,
8700,,Intermediate,,50597,Cmax value evaluated in rat,CHEMBL627598,N,1,,,,,1,,BAO_0000218,
8701,955.0,Intermediate,Brain,50597,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,CHEMBL627599,N,1,,,,,1,,BAO_0000218,
8702,,Intermediate,,50597,Cmax value after administration of 20 mg/Kg oral dose in rat,CHEMBL627600,N,1,,,,,1,,BAO_0000218,
8703,,Intermediate,,50597,Cmax value at 1 mg/kg po in rat,CHEMBL627601,N,1,,,,,1,,BAO_0000218,
8704,,Intermediate,,50597,Cmax value at 5 mg/kg po in rat,CHEMBL627776,N,1,,,,,1,,BAO_0000218,
8705,,Intermediate,,50597,Cmax value at a dose of 10 mg/kg in male SD rats,CHEMBL627777,N,1,,,,,1,,BAO_0000218,
8706,,Intermediate,,50597,Cmax value at a dose of 100 mg/kg in male SD rats,CHEMBL627778,N,1,,,,,1,,BAO_0000218,
8707,,Intermediate,,50597,Cmax value at a dose of 50 mg/kg in male SD rats,CHEMBL627779,N,1,,,,,1,,BAO_0000218,
8708,,Intermediate,,50597,Cmax value in rats at 10 mg/kg,CHEMBL876814,N,1,,,,,1,,BAO_0000218,
8709,,Intermediate,,50597,Cmax value was evaluated in rats at a dose of 20 mg/kg,CHEMBL627780,N,1,,,,,1,,BAO_0000218,
8710,,Intermediate,,50597,Cmax value was determined after peroral administration of 20 mg/kg in rat,CHEMBL627781,N,1,,,,,1,,BAO_0000218,
8711,,Intermediate,,50597,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,CHEMBL627782,N,1,,,,,1,,BAO_0000218,
8712,1969.0,Intermediate,Plasma,50597,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,CHEMBL627783,N,1,,,,,1,,BAO_0000218,
8713,1969.0,Intermediate,Plasma,50597,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,CHEMBL627784,N,1,,,,,1,,BAO_0000218,
8714,,Intermediate,,50597,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,CHEMBL627785,N,1,,,,,1,,BAO_0000218,
8715,,Intermediate,,50597,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,CHEMBL627786,N,1,,,,,1,,BAO_0000218,
8716,1969.0,Intermediate,Plasma,50597,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,CHEMBL627787,N,1,,,,,1,,BAO_0000218,
8717,1969.0,Intermediate,Plasma,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,CHEMBL627788,N,1,,,,,1,,BAO_0000218,
8718,1969.0,Intermediate,Plasma,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,CHEMBL626579,N,1,,,,,1,,BAO_0000218,
8719,1969.0,Intermediate,Plasma,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,CHEMBL626580,N,1,,,,,1,,BAO_0000218,
8720,,Intermediate,,50597,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,CHEMBL876815,N,1,,,,,1,,BAO_0000218,
8721,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,CHEMBL626581,N,1,,,,,1,,BAO_0000218,
8722,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,CHEMBL626582,N,1,,,,,1,,BAO_0000218,
8723,,Intermediate,,50597,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,CHEMBL626583,N,1,,,,,1,,BAO_0000218,
8724,,Intermediate,,50597,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,CHEMBL626205,N,1,,,,,1,,BAO_0000218,
8725,,Intermediate,,50597,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,CHEMBL626206,N,1,,,,,1,,BAO_0000218,
8726,,Intermediate,,50597,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,CHEMBL626207,N,1,,,,,1,,BAO_0000218,
8727,,Intermediate,,50597,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,CHEMBL623882,N,1,,,,,1,,BAO_0000218,
8728,,Intermediate,,50597,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,CHEMBL623883,N,1,,,,,1,,BAO_0000218,
8729,,Intermediate,,50597,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,CHEMBL623884,N,1,,,,,1,,BAO_0000218,
8730,1969.0,Intermediate,Plasma,50597,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",CHEMBL623885,N,1,,,,,1,,BAO_0000218,
8731,1969.0,Intermediate,Plasma,50597,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,CHEMBL623886,N,1,,,,,1,,BAO_0000218,
8732,,Intermediate,,50597,Maximal concentration in rat was determined,CHEMBL623887,N,1,,,,,1,,BAO_0000218,
8733,,Intermediate,,50597,Maximal concentration after i.v. administration,CHEMBL623888,N,1,,,,,1,,BAO_0000218,
8734,1969.0,Intermediate,Plasma,50597,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,CHEMBL623889,N,1,,,,,1,,BAO_0000218,
8735,1969.0,Intermediate,Plasma,50597,Maximal plasma concentration in rat after oral administration at 50 mg/kg,CHEMBL623890,N,1,,,,,1,,BAO_0000218,
8736,1969.0,Intermediate,Plasma,50597,Cmax in rat plasma after oral dose (50 mg/Kg),CHEMBL623891,N,1,,,,,1,,BAO_0000218,
8737,1969.0,Intermediate,Plasma,50597,Maximal plasma concentration was determined.,CHEMBL623892,N,1,,,,,1,,BAO_0000218,
8738,1969.0,Intermediate,Plasma,50597,Maximal plasma drug concentration was determined,CHEMBL623893,N,1,,,,,1,,BAO_0000218,
8739,,Intermediate,,50597,Maximal concentration in rats after peroral administration,CHEMBL877616,N,1,,,,,1,,BAO_0000218,
8740,,Intermediate,,50597,Maximum concentration in rat after 2 mg/kg peroral administration,CHEMBL623894,N,1,,,,,1,,BAO_0000218,
8741,1969.0,Intermediate,Plasma,50597,Maximum concentration in rat plasma after 5 mg/kg oral gavage,CHEMBL623895,N,1,,,,,1,,BAO_0000218,
8742,,Intermediate,,50597,Maximum concentration of compound in rat was evaluated.,CHEMBL623896,N,1,,,,,1,,BAO_0000218,
8743,,Intermediate,,50597,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,CHEMBL623897,N,1,,,,,1,,BAO_0000218,
8744,,Intermediate,,50597,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,CHEMBL623898,N,1,,,,,1,,BAO_0000218,
8745,,Intermediate,,50597,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,CHEMBL623899,N,1,,,,,1,,BAO_0000218,
8746,,Intermediate,,50597,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,CHEMBL623900,N,1,,,,,1,,BAO_0000218,
8747,,Intermediate,,50597,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,CHEMBL623901,N,1,,,,,1,,BAO_0000218,
8748,,Intermediate,,50597,Maximum concentration was evaluated in rats,CHEMBL623902,N,1,,,,,1,,BAO_0000218,
8749,1359.0,Intermediate,Cerebrospinal fluid,50597,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,CHEMBL623903,N,1,,,,,1,,BAO_0000218,
8750,1969.0,Intermediate,Plasma,50597,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,CHEMBL623904,N,1,,,,,1,,BAO_0000218,
8751,1969.0,Intermediate,Plasma,50597,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,CHEMBL877617,N,1,,,,,1,,BAO_0000218,
8752,,Intermediate,,50597,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,CHEMBL623905,N,1,,,,,1,,BAO_0000218,
8753,,Intermediate,,50597,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,CHEMBL623906,N,1,,,,,1,,BAO_0000218,
8754,1969.0,Intermediate,Plasma,50597,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,CHEMBL623907,N,1,,,,,1,,BAO_0000218,
8755,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL623908,N,1,,,,,1,,BAO_0000218,
8756,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,CHEMBL623909,N,1,,,,,1,,BAO_0000218,
8757,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL623910,N,1,,,,,1,,BAO_0000218,
8758,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL623911,N,1,,,,,1,,BAO_0000218,
8759,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL623912,N,1,,,,,1,,BAO_0000218,
8760,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL624616,N,1,,,,,1,,BAO_0000218,
8761,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL624617,N,1,,,,,1,,BAO_0000218,
8762,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL624618,N,1,,,,,1,,BAO_0000218,
8763,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL624619,N,1,,,,,1,,BAO_0000218,
8764,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL624794,N,1,,,,,1,,BAO_0000218,
8765,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL624795,N,1,,,,,1,,BAO_0000218,
8766,,Intermediate,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL623921,N,1,,,,,1,,BAO_0000218,
8767,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL623922,N,1,,,,,1,,BAO_0000218,
8768,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL623923,N,1,,,,,1,,BAO_0000218,
8769,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL623924,N,1,,,,,1,,BAO_0000218,
8770,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL623925,N,1,,,,,1,,BAO_0000218,
8771,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL623926,N,1,,,,,1,,BAO_0000218,
8772,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL623927,N,1,,,,,1,,BAO_0000218,
8773,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL623928,N,1,,,,,1,,BAO_0000218,
8774,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL623929,N,1,,,,,1,,BAO_0000218,
8775,,Intermediate,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL623930,N,1,,,,,1,,BAO_0000218,
8776,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL623931,N,1,,,,,1,,BAO_0000218,
8777,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL622165,N,1,,,,,1,,BAO_0000218,
8778,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL621249,N,1,,,,,1,,BAO_0000218,
8779,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL621250,N,1,,,,,1,,BAO_0000218,
8780,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL621448,N,1,,,,,1,,BAO_0000218,
8781,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL621449,N,1,,,,,1,,BAO_0000218,
8782,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL621450,N,1,,,,,1,,BAO_0000218,
8783,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL621451,N,1,,,,,1,,BAO_0000218,
8784,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL621452,N,1,,,,,1,,BAO_0000218,
8785,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL621453,N,1,,,,,1,,BAO_0000218,
8786,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL621454,N,1,,,,,1,,BAO_0000218,
8787,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL621455,N,1,,,,,1,,BAO_0000218,
8788,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL621456,N,1,,,,,1,,BAO_0000218,
8789,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL625145,N,1,,,,,1,,BAO_0000218,
8790,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL875847,N,1,,,,,1,,BAO_0000218,
8791,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL625146,N,1,,,,,1,,BAO_0000218,
8792,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL625147,N,1,,,,,1,,BAO_0000218,
8793,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL625148,N,1,,,,,1,,BAO_0000218,
8794,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL625149,N,1,,,,,1,,BAO_0000218,
8795,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL625150,N,1,,,,,1,,BAO_0000218,
8796,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL625151,N,1,,,,,1,,BAO_0000218,
8797,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL625152,N,1,,,,,1,,BAO_0000218,
8798,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL625153,N,1,,,,,1,,BAO_0000218,
8799,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL625154,N,1,,,,,1,,BAO_0000218,
8800,955.0,Intermediate,Brain,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL625155,N,1,,,,,1,,BAO_0000218,
8801,,Intermediate,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL625156,N,1,,,,,1,,BAO_0000218,
8802,,Intermediate,,50597,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624354,N,1,,,,,1,,BAO_0000218,
8803,10000000.0,Intermediate,Hippocampus,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624355,N,1,,,,,1,,BAO_0000218,
8804,10000000.0,Intermediate,Hippocampus,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624356,N,1,,,,,1,,BAO_0000218,
8805,10000000.0,Intermediate,Hippocampus,50597,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624357,N,1,,,,,1,,BAO_0000218,
8806,10000000.0,Intermediate,Hippocampus,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624358,N,1,,,,,1,,BAO_0000218,
8807,2435.0,Intermediate,Striatum,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624359,N,1,,,,,1,,BAO_0000218,
8808,2435.0,Intermediate,Striatum,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624360,N,1,,,,,1,,BAO_0000218,
8809,2435.0,Intermediate,Striatum,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL624361,N,1,,,,,1,,BAO_0000218,
8810,2435.0,Intermediate,Striatum,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624362,N,1,,,,,1,,BAO_0000218,
8811,2435.0,Intermediate,Striatum,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624363,N,1,,,,,1,,BAO_0000218,
8812,178.0,Intermediate,Blood,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624364,N,1,,,,,1,,BAO_0000218,
8813,178.0,Intermediate,Blood,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624365,N,1,,,,,1,,BAO_0000218,
8814,178.0,Intermediate,Blood,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624366,N,1,,,,,1,,BAO_0000218,
8815,178.0,Intermediate,Blood,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624367,N,1,,,,,1,,BAO_0000218,
8816,955.0,Intermediate,Brain,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624368,N,1,,,,,1,,BAO_0000218,
8817,955.0,Intermediate,Brain,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL624369,N,1,,,,,1,,BAO_0000218,
8818,955.0,Intermediate,Brain,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL624370,N,1,,,,,1,,BAO_0000218,
8819,955.0,Intermediate,Brain,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625069,N,1,,,,,1,,BAO_0000218,
8820,955.0,Intermediate,Brain,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625070,N,1,,,,,1,,BAO_0000218,
8821,948.0,Intermediate,Heart,50597,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626051,N,1,,,,,1,,BAO_0000218,
8822,948.0,Intermediate,Heart,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626052,N,1,,,,,1,,BAO_0000218,
8823,948.0,Intermediate,Heart,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL626053,N,1,,,,,1,,BAO_0000218,
8824,948.0,Intermediate,Heart,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626054,N,1,,,,,1,,BAO_0000218,
8825,948.0,Intermediate,Heart,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626055,N,1,,,,,1,,BAO_0000218,
8826,2113.0,Intermediate,Kidney,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626056,N,1,,,,,1,,BAO_0000218,
8827,2113.0,Intermediate,Kidney,50597,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626057,N,1,,,,,1,,BAO_0000218,
8828,2113.0,Intermediate,Kidney,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625193,N,1,,,,,1,,BAO_0000218,
8829,2113.0,Intermediate,Kidney,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625194,N,1,,,,,1,,BAO_0000218,
8830,2107.0,Intermediate,Liver,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625195,N,1,,,,,1,,BAO_0000218,
8831,2107.0,Intermediate,Liver,50597,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625196,N,1,,,,,1,,BAO_0000218,
8832,2107.0,Intermediate,Liver,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL625197,N,1,,,,,1,,BAO_0000218,
8833,2107.0,Intermediate,Liver,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625198,N,1,,,,,1,,BAO_0000218,
8834,2107.0,Intermediate,Liver,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL627929,N,1,,,,,1,,BAO_0000218,
8835,2048.0,Intermediate,Lung,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL627074,N,1,,,,,1,,BAO_0000218,
8836,2048.0,Intermediate,Lung,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL627075,N,1,,,,,1,,BAO_0000218,
8837,2048.0,Intermediate,Lung,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL627076,N,1,,,,,1,,BAO_0000218,
8838,2048.0,Intermediate,Lung,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL627077,N,1,,,,,1,,BAO_0000218,
8839,2048.0,Intermediate,Lung,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL627078,N,1,,,,,1,,BAO_0000218,
8840,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),CHEMBL627079,N,1,,,,,1,,BAO_0000218,
8841,,Intermediate,,50594,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,CHEMBL873824,N,1,,,,,1,,BAO_0000218,
8842,1969.0,Intermediate,Plasma,50594,Half life in mouse plasma was determined at dose 25 mg/kg,CHEMBL627080,N,1,,,,,1,,BAO_0000218,
8843,,Intermediate,,50594,Half life was determined,CHEMBL627081,N,1,,,,,1,,BAO_0000218,
8844,,Intermediate,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,CHEMBL627082,N,1,,,,,1,,BAO_0000218,
8845,,Intermediate,,50594,Half-life in male mice after 1 mg/kg intravenous dose,CHEMBL627083,N,1,,,,,1,,BAO_0000218,
8847,1969.0,Intermediate,Plasma,50594,Half life in mice plasma,CHEMBL627085,N,1,,,,,1,,BAO_0000218,
8848,,Intermediate,,50594,Half life in mouse,CHEMBL627086,N,1,,,,,1,,BAO_0000218,
8849,1969.0,Intermediate,Plasma,50594,Half life in mouse plasma at dose 25 mg/kg,CHEMBL627087,N,1,,,,,1,,BAO_0000218,
8850,,Intermediate,,50594,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,CHEMBL627088,N,1,,,,,1,,BAO_0000218,
8851,,Intermediate,,50594,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,CHEMBL627089,N,1,,,,,1,,BAO_0000218,
8852,,Intermediate,,50594,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,CHEMBL627090,N,1,,,,,1,,BAO_0000218,
8853,,Intermediate,,50594,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),CHEMBL627091,N,1,,,,,1,,BAO_0000218,
8854,,Intermediate,,50594,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",CHEMBL627092,N,1,,,,,1,,BAO_0000218,
8855,,Intermediate,,50594,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",CHEMBL876785,N,1,,,,,1,,BAO_0000218,
8856,,Intermediate,,50594,Half-life by iv administration in mouse,CHEMBL627093,N,1,,,,,1,,BAO_0000218,
8857,,Intermediate,,50594,Half-life by oral administration in mouse,CHEMBL627094,N,1,,,,,1,,BAO_0000218,
8858,,Intermediate,,50594,Half-life in mice,CHEMBL627095,N,1,,,,,1,,BAO_0000218,
8859,955.0,Intermediate,Brain,50594,Half-life using mouse brain homogenate,CHEMBL627096,N,1,,,,,1,,BAO_0000218,
8860,,Intermediate,,50594,Half-life was measured in mice,CHEMBL627097,N,1,,,,,1,,BAO_0000218,
8861,,Intermediate,,50594,Half-life was measured in mouse after an iv dose of 1 mg/kg,CHEMBL627098,N,1,,,,,1,,BAO_0000218,
8862,178.0,Intermediate,Blood,50594,Half-life period was determined in mouse blood,CHEMBL627099,N,1,,,,,1,,BAO_0000218,
8863,955.0,Intermediate,Brain,50594,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",CHEMBL627100,N,1,,,,,1,,BAO_0000218,
8864,1969.0,Intermediate,Plasma,50594,Plasma half life in mouse,CHEMBL627101,N,1,,,,,1,,BAO_0000218,
8865,,Intermediate,,50594,Stability of the peptide in the presence of mouse serum,CHEMBL627102,N,1,,,,,1,,BAO_0000218,
8866,,Intermediate,,50594,Terminal half life of compound was determined in mouse,CHEMBL627103,N,1,,,,,1,,BAO_0000218,
8867,,Intermediate,,50594,Terminal half life was evaluated in mice after intravenous administration,CHEMBL627104,N,1,,,,,1,,BAO_0000218,
8868,,Intermediate,,50594,Terminal half life was evaluated in mice after oral administration,CHEMBL627105,N,1,,,,,1,,BAO_0000218,
8869,,Intermediate,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,CHEMBL876786,N,1,,,,,1,,BAO_0000218,
8870,,Intermediate,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,CHEMBL873825,N,1,,,,,1,,BAO_0000218,
8871,,Intermediate,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,CHEMBL627106,N,1,,,,,1,,BAO_0000218,
8872,,Intermediate,,50594,half life period is evaluated by administering intravenously at 25 mg/kg in mice,CHEMBL626336,N,1,,,,,1,,BAO_0000218,
8873,,Intermediate,,50594,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",CHEMBL877462,N,1,,,,,1,,BAO_0000218,
8874,,Intermediate,,50594,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",CHEMBL626337,N,1,,,,,1,,BAO_0000218,
8875,,Intermediate,,50594,Half life after intraperitoneal administration of 100 mg/kg in mice,CHEMBL626338,N,1,,,,,1,,BAO_0000218,
8876,,Intermediate,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,CHEMBL626339,N,1,,,,,1,,BAO_0000218,
8877,,Intermediate,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,CHEMBL626340,N,1,,,,,1,,BAO_0000218,
8878,,Intermediate,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,CHEMBL625377,N,1,,,,,1,,BAO_0000218,
8879,,Intermediate,,50594,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,CHEMBL625378,N,1,,,,,1,,BAO_0000218,
8880,,Intermediate,,50594,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,CHEMBL625379,N,1,,,,,1,,BAO_0000218,
8881,,Autocuration,,22224,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),CHEMBL625380,U,0,,,,Microsomes,1,,BAO_0000251,
8882,,Autocuration,,22224,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),CHEMBL625381,U,0,,,,Microsomes,1,,BAO_0000251,
8883,,Autocuration,,22224,Stability to porcine renal DHP-I,CHEMBL625382,U,0,,,,,1,,BAO_0000019,
8884,,Autocuration,,22224,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,CHEMBL873828,U,0,,,,,1,,BAO_0000218,
8885,,Autocuration,,22224,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,CHEMBL625383,U,0,,,,,1,,BAO_0000218,
8886,,Autocuration,,22224,Half-life of the parent prodrug in porcine esterase solution,CHEMBL625384,U,0,,,,,1,,BAO_0000019,
8887,,Autocuration,,22224,"First order rate constant, k was determined in in pig liver Esterase",CHEMBL625385,U,0,,,,,1,,BAO_0000019,
8888,2107.0,Autocuration,Liver,22224,Half life of the in pig liver Esterase,CHEMBL625386,U,0,,,,,1,,BAO_0000221,
8889,2107.0,Autocuration,Liver,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,CHEMBL623571,U,0,,,,,1,,BAO_0000221,
8890,2107.0,Autocuration,Liver,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,CHEMBL623572,U,0,,,,,1,,BAO_0000221,
8891,2107.0,Autocuration,Liver,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,CHEMBL623573,U,0,,,,,1,,BAO_0000221,
8892,2107.0,Autocuration,Liver,22224,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,CHEMBL623574,U,0,,,,,1,,BAO_0000221,
8893,2107.0,Autocuration,Liver,22224,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,CHEMBL623575,U,0,,,,,1,,BAO_0000221,
8894,2107.0,Autocuration,Liver,22224,Half-life in the presence of pig liver esterase(PLE) was evaluated.,CHEMBL623749,U,0,,,,,1,,BAO_0000221,
8895,2107.0,Autocuration,Liver,22224,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,CHEMBL623750,U,0,,,,,1,,BAO_0000221,
8896,2107.0,Autocuration,Liver,22224,Half-life in vitro in pig liver,CHEMBL623751,U,0,,,,,1,,BAO_0000221,
8897,2107.0,Autocuration,Liver,22224,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,CHEMBL623752,U,0,,,,,1,,BAO_0000221,
8898,1969.0,Intermediate,Plasma,50597,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,CHEMBL623753,N,1,,,,,1,,BAO_0000218,
8899,1969.0,Intermediate,Plasma,50597,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,CHEMBL623754,N,1,,,,,1,,BAO_0000218,
8900,1969.0,Intermediate,Plasma,50597,Maximum concentration in rat plasma was determined,CHEMBL623755,N,1,,,,,1,,BAO_0000218,
8901,,Intermediate,,50597,Maximum concentration in rats,CHEMBL623756,N,1,,,,,1,,BAO_0000218,
8902,,Intermediate,,50597,Maximum concentration in rats at 1-2 hours,CHEMBL623757,N,1,,,,,1,,BAO_0000218,
8903,,Intermediate,,50597,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,CHEMBL623758,N,1,,,,,1,,BAO_0000218,
8904,955.0,Intermediate,Brain,50597,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,CHEMBL623759,N,1,,,,,1,,BAO_0000218,
8905,,Intermediate,,50597,Maximum concentration at the dose of 2 mg/kg in rat,CHEMBL623760,N,1,,,,,1,,BAO_0000218,
8906,,Intermediate,,50597,Maximum concentration was evaluated in rats,CHEMBL623761,N,1,,,,,1,,BAO_0000218,
8907,1969.0,Intermediate,Plasma,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,CHEMBL623762,N,1,,,,,1,,BAO_0000218,
8908,1969.0,Intermediate,Plasma,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,CHEMBL877594,N,1,,,,,1,,BAO_0000218,
8909,1969.0,Intermediate,Plasma,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,CHEMBL623763,N,1,,,,,1,,BAO_0000218,
8910,1969.0,Intermediate,Plasma,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,CHEMBL623764,N,1,,,,,1,,BAO_0000218,
8911,1969.0,Intermediate,Plasma,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,CHEMBL623765,N,1,,,,,1,,BAO_0000218,
8912,178.0,Intermediate,Blood,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,CHEMBL623766,N,1,,,,,1,,BAO_0000218,
8913,178.0,Intermediate,Blood,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,CHEMBL623767,N,1,,,,,1,,BAO_0000218,
8914,178.0,Intermediate,Blood,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,CHEMBL623768,N,1,,,,,1,,BAO_0000218,
8915,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,CHEMBL623769,N,1,,,,,1,,BAO_0000218,
8916,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,CHEMBL623770,N,1,,,,,1,,BAO_0000218,
8917,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,CHEMBL623771,N,1,,,,,1,,BAO_0000218,
8918,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,CHEMBL623772,N,1,,,,,1,,BAO_0000218,
8919,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,CHEMBL623773,N,1,,,,,1,,BAO_0000218,
8920,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,CHEMBL623774,N,1,,,,,1,,BAO_0000218,
8921,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,CHEMBL623775,N,1,,,,,1,,BAO_0000218,
8922,,Intermediate,,50597,Cmax in rat (PO dose),CHEMBL623776,N,1,,,,,1,,BAO_0000218,
8923,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL622191,N,1,,,,,1,,BAO_0000218,
8924,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL622192,N,1,,,,,1,,BAO_0000218,
8925,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration determined in rat,CHEMBL622193,N,1,,,,,1,,BAO_0000218,
8926,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,CHEMBL622194,N,1,,,,,1,,BAO_0000218,
8927,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,CHEMBL622195,N,1,,,,,1,,BAO_0000218,
8928,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration in rat,CHEMBL622196,N,1,,,,,1,,BAO_0000218,
8929,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,CHEMBL622197,N,1,,,,,1,,BAO_0000218,
8930,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,CHEMBL622198,N,1,,,,,1,,BAO_0000218,
8931,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,CHEMBL622199,N,1,,,,,1,,BAO_0000218,
8932,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration of compound was measured in rat,CHEMBL622200,N,1,,,,,1,,BAO_0000218,
8933,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration after 20 mg/kg oral administration in rat,CHEMBL622201,N,1,,,,,1,,BAO_0000218,
8934,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration after oral administration to rats,CHEMBL623990,N,1,,,,,1,,BAO_0000218,
8935,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,CHEMBL623991,N,1,,,,,1,,BAO_0000218,
8936,1969.0,Intermediate,Plasma,50597,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",CHEMBL623992,N,1,,,,,1,,BAO_0000218,
8937,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,CHEMBL623993,N,1,,,,,1,,BAO_0000218,
8938,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,CHEMBL623994,N,1,,,,,1,,BAO_0000218,
8939,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,CHEMBL623995,N,1,,,,,1,,BAO_0000218,
8940,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL623996,N,1,,,,,1,,BAO_0000218,
8941,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,CHEMBL623997,N,1,,,,,1,,BAO_0000218,
8942,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration dosed orally in rats,CHEMBL623998,N,1,,,,,1,,BAO_0000218,
8943,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration dosed orally in rats after 6 hours,CHEMBL623999,N,1,,,,,1,,BAO_0000218,
8944,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,CHEMBL624000,N,1,,,,,1,,BAO_0000218,
8945,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,CHEMBL624001,N,1,,,,,1,,BAO_0000218,
8946,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration in rat after po administration,CHEMBL624002,N,1,,,,,1,,BAO_0000218,
8947,1969.0,Intermediate,Plasma,50597,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",CHEMBL624003,N,1,,,,,1,,BAO_0000218,
8948,1969.0,Intermediate,Plasma,50597,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",CHEMBL624004,N,1,,,,,1,,BAO_0000218,
8949,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL624005,N,1,,,,,1,,BAO_0000218,
8950,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL624006,N,1,,,,,1,,BAO_0000218,
8951,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL624007,N,1,,,,,1,,BAO_0000218,
8952,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL624008,N,1,,,,,1,,BAO_0000218,
8953,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL624009,N,1,,,,,1,,BAO_0000218,
8954,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL874387,N,1,,,,,1,,BAO_0000218,
8955,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL624010,N,1,,,,,1,,BAO_0000218,
8956,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,CHEMBL624011,N,1,,,,,1,,BAO_0000218,
8957,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL624012,N,1,,,,,1,,BAO_0000218,
8958,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL624013,N,1,,,,,1,,BAO_0000218,
8959,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL624736,N,1,,,,,1,,BAO_0000218,
8960,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL624737,N,1,,,,,1,,BAO_0000218,
8961,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL624738,N,1,,,,,1,,BAO_0000218,
8962,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL624739,N,1,,,,,1,,BAO_0000218,
8963,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL624740,N,1,,,,,1,,BAO_0000218,
8964,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL624896,N,1,,,,,1,,BAO_0000218,
8965,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL624897,N,1,,,,,1,,BAO_0000218,
8966,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL624108,N,1,,,,,1,,BAO_0000218,
8967,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL624109,N,1,,,,,1,,BAO_0000218,
8968,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL624110,N,1,,,,,1,,BAO_0000218,
8969,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL624111,N,1,,,,,1,,BAO_0000218,
8970,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL624112,N,1,,,,,1,,BAO_0000218,
8971,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL624113,N,1,,,,,1,,BAO_0000218,
8972,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL619709,N,1,,,,,1,,BAO_0000218,
8973,948.0,Intermediate,Heart,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL619710,N,1,,,,,1,,BAO_0000218,
8974,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL619711,N,1,,,,,1,,BAO_0000218,
8975,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL619712,N,1,,,,,1,,BAO_0000218,
8976,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL619713,N,1,,,,,1,,BAO_0000218,
8977,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL619714,N,1,,,,,1,,BAO_0000218,
8978,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL619715,N,1,,,,,1,,BAO_0000218,
8979,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL619716,N,1,,,,,1,,BAO_0000218,
8980,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL619717,N,1,,,,,1,,BAO_0000218,
8981,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL619718,N,1,,,,,1,,BAO_0000218,
8982,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL619719,N,1,,,,,1,,BAO_0000218,
8983,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL875329,N,1,,,,,1,,BAO_0000218,
8984,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL619720,N,1,,,,,1,,BAO_0000218,
8985,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL619721,N,1,,,,,1,,BAO_0000218,
8986,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL619722,N,1,,,,,1,,BAO_0000218,
8987,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL619723,N,1,,,,,1,,BAO_0000218,
8988,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL619724,N,1,,,,,1,,BAO_0000218,
8989,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL619725,N,1,,,,,1,,BAO_0000218,
8990,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL619726,N,1,,,,,1,,BAO_0000218,
8991,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL619727,N,1,,,,,1,,BAO_0000218,
8992,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL619728,N,1,,,,,1,,BAO_0000218,
8993,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL619729,N,1,,,,,1,,BAO_0000218,
8994,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL619730,N,1,,,,,1,,BAO_0000218,
8995,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL619731,N,1,,,,,1,,BAO_0000218,
8996,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL619732,N,1,,,,,1,,BAO_0000218,
8997,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL619733,N,1,,,,,1,,BAO_0000218,
8998,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL619734,N,1,,,,,1,,BAO_0000218,
8999,14.0,Intermediate,Zone of skin,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL619735,N,1,,,,,1,,BAO_0000218,
9000,14.0,Intermediate,Zone of skin,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL875330,N,1,,,,,1,,BAO_0000218,
9001,14.0,Intermediate,Zone of skin,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL628465,N,1,,,,,1,,BAO_0000218,
9002,14.0,Intermediate,Zone of skin,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL628466,N,1,,,,,1,,BAO_0000218,
9003,14.0,Intermediate,Zone of skin,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL628467,N,1,,,,,1,,BAO_0000218,
9004,2106.0,Intermediate,Spleen,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL628468,N,1,,,,,1,,BAO_0000218,
9005,2106.0,Intermediate,Spleen,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL628469,N,1,,,,,1,,BAO_0000218,
9006,2106.0,Intermediate,Spleen,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL628470,N,1,,,,,1,,BAO_0000218,
9007,2106.0,Intermediate,Spleen,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL628471,N,1,,,,,1,,BAO_0000218,
9008,2106.0,Intermediate,Spleen,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL628472,N,1,,,,,1,,BAO_0000218,
9009,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625191,N,1,,,,,1,,BAO_0000218,
9010,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL625192,N,1,,,,,1,,BAO_0000218,
9011,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),CHEMBL875337,N,1,,,,,1,,BAO_0000218,
9012,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626341,N,1,,,,,1,,BAO_0000218,
9013,2046.0,Intermediate,Thyroid gland,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),CHEMBL626342,N,1,,,,,1,,BAO_0000218,
9014,2107.0,Intermediate,Liver,50597,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),CHEMBL621943,N,1,,,,,1,,BAO_0000218,
9015,,Intermediate,,50597,Half life in rats,CHEMBL621944,N,1,,,,,1,,BAO_0000218,
9016,,Intermediate,,50597,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,CHEMBL621945,N,1,,,,,1,,BAO_0000218,
9017,,Intermediate,,50597,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),CHEMBL621946,N,1,,,,,1,,BAO_0000218,
9018,,Intermediate,,50597,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,CHEMBL621947,N,1,,,,,1,,BAO_0000218,
9019,,Intermediate,,50597,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),CHEMBL621948,N,1,,,,,1,,BAO_0000218,
9020,,Intermediate,,50597,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,CHEMBL621949,N,1,,,,,1,,BAO_0000218,
9021,,Intermediate,,50597,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),CHEMBL621950,N,1,,,,,1,,BAO_0000218,
9022,,Intermediate,,50597,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,CHEMBL621951,N,1,,,,,1,,BAO_0000218,
9023,178.0,Intermediate,Blood,50597,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,CHEMBL621952,N,1,,,,,1,,BAO_0000218,
9024,2107.0,Intermediate,Liver,50597,Stability (%) in rat liver microsomes,CHEMBL621953,N,1,,,,,1,,BAO_0000218,
9025,,Intermediate,,50597,Area under curve was calculated after intravenous administration,CHEMBL621954,N,1,,,,,1,,BAO_0000218,
9026,,Intermediate,,50597,Area under the curve was calculated after iv administration in rat,CHEMBL621955,N,1,,,,,1,,BAO_0000218,
9027,,Intermediate,,50597,Area under the curve was calculated in rat after peroral administration,CHEMBL621956,N,1,,,,,1,,BAO_0000218,
9028,,Intermediate,,50597,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,CHEMBL621957,N,1,,,,,1,,BAO_0000218,
9029,,Intermediate,,50597,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,CHEMBL621958,N,1,,,,,1,,BAO_0000218,
9030,,Intermediate,,50597,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,CHEMBL621959,N,1,,,,,1,,BAO_0000218,
9031,,Intermediate,,50597,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,CHEMBL621960,N,1,,,,,1,,BAO_0000218,
9032,,Intermediate,,50597,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,CHEMBL621961,N,1,,,,,1,,BAO_0000218,
9033,,Intermediate,,50597,p value of the compound,CHEMBL621962,N,1,,,,,1,,BAO_0000218,
9034,,Intermediate,,50597,p value of the compound,CHEMBL876787,N,1,,,,,1,,BAO_0000218,
9035,,Intermediate,,50597,p value of the compound,CHEMBL621963,N,1,,,,,1,,BAO_0000218,
9036,945.0,Intermediate,Stomach,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),CHEMBL622637,N,1,,,,,1,,BAO_0000218,
9037,945.0,Intermediate,Stomach,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),CHEMBL622638,N,1,,,,,1,,BAO_0000218,
9038,945.0,Intermediate,Stomach,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),CHEMBL626561,N,1,,,,,1,,BAO_0000218,
9039,,Autocuration,,22224,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),CHEMBL626562,U,0,,,,,1,,BAO_0000019,
9040,,Autocuration,,22224,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),CHEMBL626563,U,0,,,,,1,,BAO_0000218,
9041,,Autocuration,,22224,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),CHEMBL626564,U,0,,,,,1,,BAO_0000218,
9042,,Autocuration,,22224,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,CHEMBL626565,U,0,,,,,1,,BAO_0000218,
9043,,Autocuration,,22224,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,CHEMBL626566,U,0,,,,,1,,BAO_0000218,
9044,,Autocuration,,22224,Clearance rate in rabbits,CHEMBL626567,U,0,,,,,1,,BAO_0000218,
9045,,Autocuration,,22224,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,CHEMBL626568,U,0,,,,,1,,BAO_0000218,
9046,,Autocuration,,22224,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,CHEMBL626569,U,0,,,,,1,,BAO_0000218,
9047,,Autocuration,,22224,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,CHEMBL626570,U,0,,,,,1,,BAO_0000218,
9048,,Autocuration,,22224,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,CHEMBL626571,U,0,,,,,1,,BAO_0000218,
9049,,Autocuration,,22224,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,CHEMBL626572,U,0,,,,,1,,BAO_0000218,
9050,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,CHEMBL626573,U,0,,,,,1,,BAO_0000218,
9051,2107.0,Autocuration,Liver,22224,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,CHEMBL626574,U,0,,,,Microsomes,1,,BAO_0000251,
9052,2107.0,Autocuration,Liver,22224,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,CHEMBL626575,U,0,,,,Microsomes,1,,BAO_0000251,
9053,,Autocuration,,22224,Dose at which bioavailability of intravenously administered compound was tested in rabbit,CHEMBL626576,U,0,,,,,1,,BAO_0000218,
9054,,Autocuration,,22224,Dose at which bioavailability of perorally administered compound was tested in rabbit,CHEMBL626577,U,0,,,,,1,,BAO_0000218,
9055,,Autocuration,,22224,The compound was tested for its bioavailability in rabbit (by oral dosage).,CHEMBL626578,U,0,,,,,1,,BAO_0000218,
9056,,Autocuration,,22224,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,CHEMBL625263,U,0,,,,,1,,BAO_0000218,
9057,,Autocuration,,22224,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,CHEMBL625264,U,0,,,,,1,,BAO_0000218,
9058,,Autocuration,,22224,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,CHEMBL625265,U,0,,,,,1,,BAO_0000218,
9059,,Autocuration,,22224,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),CHEMBL625266,U,0,,,,Microsomes,1,,BAO_0000251,
9060,,Autocuration,,22224,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),CHEMBL876796,U,0,,,,Microsomes,1,,BAO_0000251,
9061,,Autocuration,,22224,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,CHEMBL625267,U,0,,,,,1,,BAO_0000218,
9062,1969.0,Autocuration,Plasma,22224,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,CHEMBL625268,U,0,,,,,1,,BAO_0000218,
9063,1969.0,Autocuration,Plasma,22224,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,CHEMBL625269,U,0,,,,,1,,BAO_0000218,
9064,1969.0,Autocuration,Plasma,22224,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,CHEMBL624689,U,0,,,,,1,,BAO_0000218,
9065,,Autocuration,,22224,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,CHEMBL624690,U,0,,,,,1,,BAO_0000218,
9066,1088.0,Autocuration,Urine,22224,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),CHEMBL624691,U,0,,,,,1,,BAO_0000218,
9067,1088.0,Autocuration,Urine,22224,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),CHEMBL624692,U,0,,,,,1,,BAO_0000218,
9068,,Autocuration,,22224,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,CHEMBL624693,U,0,,,,,1,,BAO_0000218,
9069,,Autocuration,,22224,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,CHEMBL624694,U,0,,,,,1,,BAO_0000218,
9070,,Autocuration,,22224,In vitro Biological half-life in crude homogenate of rabbit renal cortex,CHEMBL877596,U,0,,,,,1,,BAO_0000221,
9071,,Autocuration,,22224,Time within which only 10% of the drug was degraded,CHEMBL624695,U,0,,,,,1,,BAO_0000019,
9072,2107.0,Autocuration,Liver,22224,Half life period in rabbit liver homogenate,CHEMBL624696,U,0,,,,,1,,BAO_0000221,
9073,,Autocuration,,22224,Half life value in rabbits,CHEMBL624697,U,0,,,,,1,,BAO_0000019,
9074,178.0,Autocuration,Blood,22224,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,CHEMBL624698,U,0,,,,,1,,BAO_0000218,
9075,178.0,Autocuration,Blood,22224,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,CHEMBL624699,U,0,,,,,1,,BAO_0000218,
9076,,Autocuration,,22224,Half-life period in rabbits following intravenous administration at 2 mg/kg,CHEMBL624700,U,0,,,,,1,,BAO_0000218,
9077,1969.0,Intermediate,Plasma,50597,AUC 0-8 hr value in rats at 10 mg/kg,CHEMBL622903,N,1,,,,,1,,BAO_0000218,
9078,1969.0,Intermediate,Plasma,50597,AUC after administration at 2000 mg/kg/day in rats,CHEMBL622904,N,1,,,,,1,,BAO_0000218,
9079,1969.0,Intermediate,Plasma,50597,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,CHEMBL622905,N,1,,,,,1,,BAO_0000218,
9080,1969.0,Intermediate,Plasma,50597,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,CHEMBL622906,N,1,,,,,1,,BAO_0000218,
9081,1969.0,Intermediate,Plasma,50597,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,CHEMBL622907,N,1,,,,,1,,BAO_0000218,
9082,1969.0,Intermediate,Plasma,50597,AUC in rat after oral administration at 10.5 mg/kg dose,CHEMBL622908,N,1,,,,,1,,BAO_0000218,
9083,1969.0,Intermediate,Plasma,50597,AUC in rat after oral administration at 11.2 mg/kg dose,CHEMBL622909,N,1,,,,,1,,BAO_0000218,
9084,1969.0,Intermediate,Plasma,50597,AUC in rat after oral administration at 9.7 mg/kg dose,CHEMBL622910,N,1,,,,,1,,BAO_0000218,
9085,955.0,Intermediate,Brain,50597,AUC in rat brain after oral administration at 10 mg/kg,CHEMBL622911,N,1,,,,,1,,BAO_0000218,
9086,1969.0,Intermediate,Plasma,50597,AUC in rat p.o.,CHEMBL622912,N,1,,,,,1,,BAO_0000218,
9087,1969.0,Intermediate,Plasma,50597,AUC in rat p.o. at 20 mg/kg concentration,CHEMBL622913,N,1,,,,,1,,BAO_0000218,
9088,1969.0,Intermediate,Plasma,50597,AUC in rat plasma after oral administration at 10 mg/kg,CHEMBL622914,N,1,,,,,1,,BAO_0000218,
9089,1969.0,Intermediate,Plasma,50597,AUC in rats,CHEMBL622915,N,1,,,,,1,,BAO_0000218,
9090,1969.0,Intermediate,Plasma,50597,AUC value after IV dose at a dose of 5 mg/kg in rats.,CHEMBL622916,N,1,,,,,1,,BAO_0000218,
9091,1969.0,Intermediate,Plasma,50597,AUC value after oral dose at a dose of 10 mg/kg in rats.,CHEMBL622917,N,1,,,,,1,,BAO_0000218,
9092,1969.0,Intermediate,Plasma,50597,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",CHEMBL622918,N,1,,,,,1,,BAO_0000218,
9093,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,CHEMBL622919,N,1,,,,,1,,BAO_0000218,
9094,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration was evaluated in rat,CHEMBL622920,N,1,,,,,1,,BAO_0000218,
9095,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,CHEMBL622921,N,1,,,,,1,,BAO_0000218,
9096,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,CHEMBL622922,N,1,,,,,1,,BAO_0000218,
9097,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,CHEMBL622923,N,1,,,,,1,,BAO_0000218,
9098,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,CHEMBL877604,N,1,,,,,1,,BAO_0000218,
9099,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,CHEMBL622924,N,1,,,,,1,,BAO_0000218,
9100,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,CHEMBL622925,N,1,,,,,1,,BAO_0000218,
9101,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,CHEMBL622926,N,1,,,,,1,,BAO_0000218,
9102,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,CHEMBL623625,N,1,,,,,1,,BAO_0000218,
9103,1969.0,Expert,Plasma,50597,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL623626,N,1,,,,,1,,BAO_0000218,
9104,1969.0,Intermediate,Plasma,50597,Maximum plasma drug concentration was determined,CHEMBL623627,N,1,,,,,1,,BAO_0000218,
9105,,Intermediate,,50597,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,CHEMBL623628,N,1,,,,,1,,BAO_0000218,
9106,1969.0,Intermediate,Plasma,50597,Mean peak plasma concentration was observed after intravenous administration in rat,CHEMBL623629,N,1,,,,,1,,BAO_0000218,
9107,1969.0,Intermediate,Plasma,50597,Mean peak plasma concentration was observed after oral administration in rat,CHEMBL623630,N,1,,,,,1,,BAO_0000218,
9108,,Intermediate,,50597,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,CHEMBL623804,N,1,,,,,1,,BAO_0000218,
9109,,Intermediate,,50597,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,CHEMBL623805,N,1,,,,,1,,BAO_0000218,
9110,1969.0,Intermediate,Plasma,50597,Peak oral plasma concentration was determined in rats by oral administration,CHEMBL623806,N,1,,,,,1,,BAO_0000218,
9111,1969.0,Intermediate,Plasma,50597,Peak plasma concentration (Cmax) was determined,CHEMBL623807,N,1,,,,,1,,BAO_0000218,
9112,1969.0,Intermediate,Plasma,50597,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,CHEMBL623808,N,1,,,,,1,,BAO_0000218,
9113,1969.0,Intermediate,Plasma,50597,Peak plasma concentration (Cmax) in rats,CHEMBL623809,N,1,,,,,1,,BAO_0000218,
9114,1969.0,Intermediate,Plasma,50597,Peak plasma concentration at 1 mg/kg peroral administration,CHEMBL623810,N,1,,,,,1,,BAO_0000218,
9115,1969.0,Intermediate,Plasma,50597,Peak plasma concentration in rat,CHEMBL623811,N,1,,,,,1,,BAO_0000218,
9116,1969.0,Intermediate,Plasma,50597,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",CHEMBL623812,N,1,,,,,1,,BAO_0000218,
9117,,Intermediate,,50597,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,CHEMBL877605,N,1,,,,,1,,BAO_0000218,
9118,,Intermediate,,50597,Pharmacokinetic property (Cmax) in rat,CHEMBL623813,N,1,,,,,1,,BAO_0000218,
9119,,Intermediate,,50597,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,CHEMBL623814,N,1,,,,,1,,BAO_0000218,
9120,,Intermediate,,50597,Cmax in rat after 3mg/kg oral dose,CHEMBL623815,N,1,,,,,1,,BAO_0000218,
9121,,Intermediate,,50597,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,CHEMBL623816,N,1,,,Sprague-Dawley,,1,,BAO_0000218,
9122,,Intermediate,,50597,Cmax in rats after 20 mg/kg oral dose,CHEMBL623145,N,1,,,,,1,,BAO_0000218,
9123,1969.0,Intermediate,Plasma,50597,Cmax in rat plasma after 30mg/kg oral dose,CHEMBL623146,N,1,,,,,1,,BAO_0000218,
9124,1969.0,Intermediate,Plasma,50597,Plasma concentration after oral administration of 100 mg/kg to rats,CHEMBL623147,N,1,,,,,1,,BAO_0000218,
9125,955.0,Intermediate,Brain,50597,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,CHEMBL623042,N,1,,,,,1,,BAO_0000218,
9126,,Intermediate,,50597,Tested for the Cmax in rat at 10 mg/kg per orally,CHEMBL623043,N,1,,,,,1,,BAO_0000218,
9127,,Intermediate,,50597,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL623044,N,1,,,,,1,,BAO_0000218,
9128,,Intermediate,,50597,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",CHEMBL623045,N,1,,,,,1,,BAO_0000218,
9129,,Intermediate,,50597,Bioavailability as oral Cmax in rats at 30 mins,CHEMBL623046,N,1,,,,,1,,BAO_0000218,
9130,,Intermediate,,50597,Bioavailability as oral Cmax in rats at 6hr,CHEMBL623226,N,1,,,,,1,,BAO_0000218,
9131,,Intermediate,,50597,The maximum concentration of compound was measured at the dose of 100 umol/kg,CHEMBL623227,N,1,,,,,1,,BAO_0000218,
9132,,Intermediate,,50597,The maximum concentration of compound was measured at the dose of 300 umol/kg,CHEMBL623228,N,1,,,,,1,,BAO_0000218,
9133,,Intermediate,,50597,The maximum concentration of compound was measured at the dose of 30 umol/kg,CHEMBL623229,N,1,,,,,1,,BAO_0000218,
9134,1969.0,Intermediate,Plasma,50597,The maximum plasma levels for the compounds were determined by LC-MS.,CHEMBL623230,N,1,,,,,1,,BAO_0000218,
9135,1969.0,Intermediate,Plasma,50597,mean peak plasma concentration was observed after intravenous administration in rat,CHEMBL623231,N,1,,,,,1,,BAO_0000218,
9136,1969.0,Intermediate,Plasma,50597,mean peak plasma concentration was observed after oral administration in rat,CHEMBL623232,N,1,,,,,1,,BAO_0000218,
9137,,Intermediate,,50597,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,CHEMBL623233,N,1,,,,,1,,BAO_0000218,
9138,,Intermediate,,50597,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,CHEMBL623234,N,1,,,,,1,,BAO_0000218,
9139,,Intermediate,,50597,Concentration in plasma (portal) following oral dose in rats at 1 hr,CHEMBL623235,N,1,,,,,1,,BAO_0000218,
9140,,Intermediate,,50597,Concentration in plasma (portal) following oral dose in rats at 2 hr,CHEMBL623236,N,1,,,,,1,,BAO_0000218,
9141,,Intermediate,,50597,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,CHEMBL623237,N,1,,,,,1,,BAO_0000218,
9142,,Intermediate,,50597,Concentration in plasma (systemic) following oral dose in rats at 1 hr,CHEMBL623238,N,1,,,,,1,,BAO_0000218,
9143,,Intermediate,,50597,Concentration in plasma (systemic) following oral dose in rats at 2 hr,CHEMBL623239,N,1,,,,,1,,BAO_0000218,
9144,1969.0,Intermediate,Plasma,22224,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,CHEMBL623240,U,0,,,,,1,,BAO_0000218,
9145,1898.0,Intermediate,Hypothalamus,50597,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",CHEMBL623241,N,1,,,,,1,,BAO_0000218,
9146,1898.0,Intermediate,Hypothalamus,50597,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",CHEMBL623242,N,1,,,,,1,,BAO_0000218,
9147,,Intermediate,,50597,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",CHEMBL874394,N,1,,,,,1,,BAO_0000218,
9148,,Intermediate,,50597,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",CHEMBL623243,N,1,,,,,1,,BAO_0000218,
9149,,Intermediate,,50597,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL623244,N,1,,,,,1,,BAO_0000218,
9150,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL623245,N,1,,,,,1,,BAO_0000218,
9151,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL623246,N,1,,,,,1,,BAO_0000218,
9152,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL623247,N,1,,,,,1,,BAO_0000218,
9153,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL623248,N,1,,,,,1,,BAO_0000218,
9154,2113.0,Intermediate,Kidney,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL623249,N,1,,,,,1,,BAO_0000218,
9155,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL625072,N,1,,,,,1,,BAO_0000218,
9156,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL625073,N,1,,,,,1,,BAO_0000218,
9157,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL625074,N,1,,,,,1,,BAO_0000218,
9158,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL625075,N,1,,,,,1,,BAO_0000218,
9159,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,CHEMBL625076,N,1,,,,,1,,BAO_0000218,
9160,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL625077,N,1,,,,,1,,BAO_0000218,
9161,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL625078,N,1,,,,,1,,BAO_0000218,
9162,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL874395,N,1,,,,,1,,BAO_0000218,
9163,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL625079,N,1,,,,,1,,BAO_0000218,
9164,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL625080,N,1,,,,,1,,BAO_0000218,
9165,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL625081,N,1,,,,,1,,BAO_0000218,
9166,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL625082,N,1,,,,,1,,BAO_0000218,
9167,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL625083,N,1,,,,,1,,BAO_0000218,
9168,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL625084,N,1,,,,,1,,BAO_0000218,
9169,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL625085,N,1,,,,,1,,BAO_0000218,
9170,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL625086,N,1,,,,,1,,BAO_0000218,
9171,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL625087,N,1,,,,,1,,BAO_0000218,
9172,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL625088,N,1,,,,,1,,BAO_0000218,
9173,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL622205,N,1,,,,,1,,BAO_0000218,
9174,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL622206,N,1,,,,,1,,BAO_0000218,
9175,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL622207,N,1,,,,,1,,BAO_0000218,
9176,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL622366,N,1,,,,,1,,BAO_0000218,
9177,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL622367,N,1,,,,,1,,BAO_0000218,
9178,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL875331,N,1,,,,,1,,BAO_0000218,
9179,2107.0,Intermediate,Liver,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL622368,N,1,,,,,1,,BAO_0000218,
9180,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL622369,N,1,,,,,1,,BAO_0000218,
9181,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL622370,N,1,,,,,1,,BAO_0000218,
9182,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL622371,N,1,,,,,1,,BAO_0000218,
9183,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL622372,N,1,,,,,1,,BAO_0000218,
9184,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL622373,N,1,,,,,1,,BAO_0000218,
9185,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL622374,N,1,,,,,1,,BAO_0000218,
9186,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL622375,N,1,,,,,1,,BAO_0000218,
9187,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,CHEMBL622376,N,1,,,,,1,,BAO_0000218,
9188,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL622377,N,1,,,,,1,,BAO_0000218,
9189,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL622378,N,1,,,,,1,,BAO_0000218,
9190,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL622379,N,1,,,,,1,,BAO_0000218,
9191,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL622380,N,1,,,,,1,,BAO_0000218,
9192,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL622381,N,1,,,,,1,,BAO_0000218,
9193,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL622382,N,1,,,,,1,,BAO_0000218,
9194,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,CHEMBL622383,N,1,,,,,1,,BAO_0000218,
9195,945.0,Intermediate,Stomach,50597,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),CHEMBL875332,N,1,,,,,1,,BAO_0000218,
9196,945.0,Intermediate,Stomach,50597,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),CHEMBL622384,N,1,,,,,1,,BAO_0000218,
9197,945.0,Intermediate,Stomach,50597,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),CHEMBL622385,N,1,,,,,1,,BAO_0000218,
9198,945.0,Intermediate,Stomach,50597,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),CHEMBL622386,N,1,,,,,1,,BAO_0000218,
9199,,Intermediate,,50597,The compound was tested for the plasma binding in rat,CHEMBL622387,N,1,,,,,1,,BAO_0000218,
9200,,Intermediate,,50597,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",CHEMBL622388,N,1,,,,,1,,BAO_0000218,
9201,,Intermediate,,50597,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",CHEMBL622389,N,1,,,,,1,,BAO_0000218,
9202,,Intermediate,,50597,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",CHEMBL622390,N,1,,,,,1,,BAO_0000218,
9203,,Intermediate,,50597,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),CHEMBL622391,N,1,,,,,1,,BAO_0000218,
9204,,Intermediate,,50597,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),CHEMBL622392,N,1,,,,,1,,BAO_0000218,
9205,,Intermediate,,50597,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),CHEMBL622393,N,1,,,,,1,,BAO_0000218,
9206,,Intermediate,,50597,Plasma level at 2 hr after administration of the compound,CHEMBL622394,N,1,,,,,1,,BAO_0000218,
9207,,Intermediate,,50597,plasma level at 2 hr after administration of the compound,CHEMBL622395,N,1,,,,,1,,BAO_0000218,
9208,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 1 min,CHEMBL622396,N,1,,,,,1,,BAO_0000218,
9209,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 10 min,CHEMBL624894,N,1,,,,,1,,BAO_0000218,
9210,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 10 mins,CHEMBL624895,N,1,,,,,1,,BAO_0000218,
9211,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 2 hr,CHEMBL624058,N,1,,,,,1,,BAO_0000218,
9212,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 3 min,CHEMBL624059,N,1,,,,,1,,BAO_0000218,
9213,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 3 mins,CHEMBL624060,N,1,,,,,1,,BAO_0000218,
9214,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 5 min,CHEMBL624061,N,1,,,,,1,,BAO_0000218,
9215,1977.0,Intermediate,Serum,50597,Stability in rat serum measured as % recovery at 5 mins,CHEMBL624062,N,1,,,,,1,,BAO_0000218,
9216,,Intermediate,,50597,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,CHEMBL624063,N,1,,,,,1,,BAO_0000218,
9217,,Intermediate,,50597,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,CHEMBL624064,N,1,,,,,1,,BAO_0000218,
9218,1969.0,Intermediate,Plasma,50597,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,CHEMBL624065,N,1,,,,,1,,BAO_0000218,
9219,1969.0,Intermediate,Plasma,50597,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,CHEMBL624066,N,1,,,,,1,,BAO_0000218,
9220,,Intermediate,,50597,Half life tested in mature male rat at a dose of 30 mg/kg,CHEMBL877490,N,1,,,,,1,,BAO_0000218,
9221,,Intermediate,,50597,Half life after intravenous administration of 1 mg/kg in rat,CHEMBL874442,N,1,,,,,1,,BAO_0000218,
9222,,Intermediate,,50597,Half life period after administration (30 mg/kg) in rat,CHEMBL626890,N,1,,,,,1,,BAO_0000218,
9223,,Intermediate,,50597,Half life period in rat after 5 mg/Kg dose,CHEMBL626891,N,1,,,,,1,,BAO_0000218,
9224,,Intermediate,,50597,Half life period in rat after 5 mg/kg dose,CHEMBL626892,N,1,,,,,1,,BAO_0000218,
9225,,Intermediate,,50597,Half life period was determined,CHEMBL626893,N,1,,,,,1,,BAO_0000218,
9226,,Intermediate,,50597,Half life period was evaluated in rat,CHEMBL626894,N,1,,,,,1,,BAO_0000218,
9227,,Intermediate,,50597,Half life period was evaluated in rat; 0.5-1.0,CHEMBL626895,N,1,,,,,1,,BAO_0000218,
9228,,Intermediate,,50597,Half life period was evaluated in rat; 5.9-7.5,CHEMBL626896,N,1,,,,,1,,BAO_0000218,
9229,1969.0,Intermediate,Plasma,50597,Half-life in rat plasma,CHEMBL626897,N,1,,,,,1,,BAO_0000218,
9230,,Intermediate,,50597,Half-life time in rat was determined,CHEMBL626898,N,1,,,,,1,,BAO_0000218,
9231,,Intermediate,,50597,Terminal half-life after iv administration to rats,CHEMBL626899,N,1,,,,,1,,BAO_0000218,
9232,,Intermediate,,50597,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,CHEMBL626900,N,1,,,,,1,,BAO_0000218,
9233,,Intermediate,,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,CHEMBL626901,N,1,,,,,1,,BAO_0000218,
9234,,Intermediate,,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),CHEMBL626902,N,1,,,,,1,,BAO_0000218,
9235,,Intermediate,,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),CHEMBL626903,N,1,,,,,1,,BAO_0000218,
9236,,Intermediate,,50597,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,CHEMBL874443,N,1,,,,,1,,BAO_0000218,
9237,,Intermediate,,50597,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,CHEMBL626904,N,1,,,,,1,,BAO_0000218,
9238,,Intermediate,,50597,Half life in rats,CHEMBL626905,N,1,,,,,1,,BAO_0000218,
9239,1969.0,Intermediate,Plasma,50597,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,CHEMBL873830,N,1,,,,,1,,BAO_0000218,
9240,,Intermediate,,50597,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,CHEMBL626906,N,1,,,,,1,,BAO_0000218,
9241,1969.0,Intermediate,Plasma,50597,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,CHEMBL631076,N,1,,,,,1,,BAO_0000218,
9242,1969.0,Intermediate,Plasma,50597,Biological half-life was measured in plasma of rats,CHEMBL631077,N,1,,,,,1,,BAO_0000218,
9243,,Intermediate,,50597,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,CHEMBL631078,N,1,,,,,1,,BAO_0000218,
9244,,Intermediate,,50597,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,CHEMBL631079,N,1,,,,,1,,BAO_0000218,
9245,,Intermediate,,50597,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,CHEMBL631080,N,1,,,,,1,,BAO_0000218,
9246,,Intermediate,,50597,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,CHEMBL631081,N,1,,,,,1,,BAO_0000218,
9247,,Intermediate,,50597,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,CHEMBL631239,N,1,,,,,1,,BAO_0000218,
9248,1969.0,Intermediate,Plasma,50597,Compound was evaluated for plasma half life in rat,CHEMBL631240,N,1,,,,,1,,BAO_0000218,
9249,1969.0,Intermediate,Plasma,50597,AUC value at a dose of 5 mg/kg (p.o.) in rats,CHEMBL631241,N,1,,,,,1,,BAO_0000218,
9250,1969.0,Intermediate,Plasma,50597,AUC value after administration of 20 mg/Kg oral dose in rat,CHEMBL631242,N,1,,,,,1,,BAO_0000218,
9251,1969.0,Intermediate,Plasma,50597,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,CHEMBL631243,N,1,,,,,1,,BAO_0000218,
9252,1969.0,Intermediate,Plasma,50597,AUC0-96 after administration at 50 mg/kg,CHEMBL874444,N,1,,,,,1,,BAO_0000218,
9253,1969.0,Intermediate,Plasma,50597,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,CHEMBL631244,N,1,,,,,1,,BAO_0000218,
9254,,Intermediate,,50597,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",CHEMBL631245,N,1,,,,,1,,BAO_0000218,
9255,,Intermediate,,50597,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,CHEMBL627162,N,1,,,,,1,,BAO_0000218,
9256,,Intermediate,,50597,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,CHEMBL627163,N,1,,,,,1,,BAO_0000218,
9257,,Intermediate,,50597,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,CHEMBL627164,N,1,,,,,1,,BAO_0000218,
9258,2113.0,Intermediate,Kidney,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,CHEMBL627165,N,1,,,,,1,,BAO_0000218,
9259,,Intermediate,,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,CHEMBL627166,N,1,,,,,1,,BAO_0000218,
9260,,Intermediate,,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,CHEMBL627167,N,1,,,,,1,,BAO_0000218,
9261,,Intermediate,,50597,Area under curve (AUC) at a dose of 30 mg/kg in rats,CHEMBL627822,N,1,,,,,1,,BAO_0000218,
9262,,Intermediate,,50597,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,CHEMBL627823,N,1,,,,,1,,BAO_0000218,
9263,,Intermediate,,50597,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,CHEMBL627824,N,1,,,,,1,,BAO_0000218,
9264,,Intermediate,,50597,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,CHEMBL627825,N,1,,,,,1,,BAO_0000218,
9265,,Intermediate,,50597,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,CHEMBL627826,N,1,,,,,1,,BAO_0000218,
9266,,Intermediate,,50597,Area under curve (Pharmacokinetic property) was determined,CHEMBL627827,N,1,,,,,1,,BAO_0000218,
9267,,Intermediate,,50597,Area under curve (Pharmacokinetic property) of the compound; Not determined,CHEMBL627828,N,1,,,,,1,,BAO_0000218,
9268,,Intermediate,,50597,Area under curve after intravenous administration (1 mg/kg) in rat,CHEMBL627829,N,1,,,,,1,,BAO_0000218,
9269,,Intermediate,,50597,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,CHEMBL627830,N,1,,,,,1,,BAO_0000218,
9270,,Intermediate,,50597,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,CHEMBL627831,N,1,,,,,1,,BAO_0000218,
9271,,Intermediate,,50597,Area under curve in male SD rats was observed after oral administration in rat,CHEMBL627832,N,1,,,,,1,,BAO_0000218,
9272,,Intermediate,,50597,Area under curve of compound after iv administration of 20 mg/kg dose in rat,CHEMBL627833,N,1,,,,,1,,BAO_0000218,
9273,,Expert,,50597,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL627834,N,1,,,,,1,,BAO_0000218,
9274,,Expert,,50597,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL628004,N,1,,,,,1,,BAO_0000218,
9275,,Intermediate,,50597,Area under curve at 5 mg/kg po was determined in rat,CHEMBL628005,N,1,,,,,1,,BAO_0000218,
9276,,Intermediate,,50597,Area under curve in Rat at a oral dose of 5 mg/kg,CHEMBL628006,N,1,,,,,1,,BAO_0000218,
9277,,Intermediate,,50597,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,CHEMBL628007,N,1,,,,,1,,BAO_0000218,
9278,,Intermediate,,50597,Area under curve was determined,CHEMBL625676,N,1,,,,,1,,BAO_0000218,
9279,,Intermediate,,50597,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,CHEMBL631309,N,1,,,,,1,,BAO_0000218,
9280,,Intermediate,,50597,Area under curve after intravenous administration at 3 mg/kg,CHEMBL631310,N,1,,,,,1,,BAO_0000218,
9281,,Intermediate,,50597,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,CHEMBL631311,N,1,,,,,1,,BAO_0000218,
9282,,Intermediate,,50597,Area under curve at 4 hr in rat,CHEMBL631312,N,1,,,,,1,,BAO_0000218,
9283,,Intermediate,,50597,Area under curve at a dose of 30 mg/kg,CHEMBL631313,N,1,,,,,1,,BAO_0000218,
9284,,Intermediate,,50597,Area under curve at the dose of 2 mg/Kg administered perorally in rats,CHEMBL631314,N,1,,,,,1,,BAO_0000218,
9285,,Intermediate,,50597,Area under curve at the dose of 5 mg/Kg administered perorally in rats,CHEMBL631315,N,1,,,,,1,,BAO_0000218,
9286,,Intermediate,,50597,Area under curve for a 2-mpk po dose in SD rats,CHEMBL631316,N,1,,,,,1,,BAO_0000218,
9287,,Intermediate,,50597,Area under curve in SD rats,CHEMBL631317,N,1,,,,,1,,BAO_0000218,
9288,,Intermediate,,50597,Area under curve in rat after oral administration at 13 mg/kg dose,CHEMBL874471,N,1,,,,,1,,BAO_0000218,
9289,,Intermediate,,50597,Area under curve in rat by po administration at 0-24 hr,CHEMBL631318,N,1,,,,,1,,BAO_0000218,
9290,1969.0,Intermediate,Plasma,50597,Area under curve in rat plasma,CHEMBL631319,N,1,,,,,1,,BAO_0000218,
9291,,Intermediate,,50597,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,CHEMBL631320,N,1,,,,,1,,BAO_0000218,
9292,,Intermediate,,50597,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,CHEMBL631321,N,1,,,,,1,,BAO_0000218,
9293,,Intermediate,,50597,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,CHEMBL631322,N,1,,,,,1,,BAO_0000218,
9294,,Intermediate,,50597,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,CHEMBL631323,N,1,,,,,1,,BAO_0000218,
9295,,Intermediate,,50597,Area under curve value in rat at a dose of 5 mg/kg,CHEMBL631324,N,1,,,,,1,,BAO_0000218,
9296,,Intermediate,,50597,Area under curve was determined after oral administration in rats,CHEMBL631325,N,1,,,,,1,,BAO_0000218,
9297,,Intermediate,,50597,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,CHEMBL631326,N,1,,,,,1,,BAO_0000218,
9298,,Intermediate,,50597,Area under curve was determined after peroral administration in rat,CHEMBL631327,N,1,,,,,1,,BAO_0000218,
9299,,Intermediate,,50597,Area under curve was determined at a dose 30 mpk administered orally.,CHEMBL631328,N,1,,,,,1,,BAO_0000218,
9300,,Intermediate,,50597,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,CHEMBL631329,N,1,,,,,1,,BAO_0000218,
9301,,Intermediate,,50597,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,CHEMBL627217,N,1,,,,,1,,BAO_0000218,
9302,,Intermediate,,50597,Area under curve was determined in male rat,CHEMBL626352,N,1,,,,,1,,BAO_0000218,
9303,,Intermediate,,50597,Area under curve was determined in rat after PO administration,CHEMBL626353,N,1,,,,,1,,BAO_0000218,
9304,,Intermediate,,50597,Area under curve was determined in rat after a 3 mg/kg of oral dose,CHEMBL626354,N,1,,,,,1,,BAO_0000218,
9305,,Intermediate,,50597,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,CHEMBL626355,N,1,,,,,1,,BAO_0000218,
9306,,Intermediate,,50597,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,CHEMBL626356,N,1,,,,,1,,BAO_0000218,
9307,,Intermediate,,50597,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,CHEMBL626357,N,1,,,,,1,,BAO_0000218,
9308,,Intermediate,,50597,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL626358,N,1,,,,,1,,BAO_0000218,
9309,,Intermediate,,50597,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL626359,N,1,,,,,1,,BAO_0000218,
9310,1969.0,Intermediate,Plasma,50597,Peak plasma concentration in rat at a dose of 3 mg/kg,CHEMBL626360,N,1,,,,,1,,BAO_0000218,
9311,,Intermediate,,50597,Plasma concentration at 2 hr in rats was evaluated.,CHEMBL626361,N,1,,,,,1,,BAO_0000218,
9312,,Intermediate,,50597,Plasma concentration at 2 hr in rats was evaluated; Not available,CHEMBL626362,N,1,,,,,1,,BAO_0000218,
9313,,Intermediate,,50597,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL626363,N,1,,,,,1,,BAO_0000218,
9314,,Intermediate,,50597,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL626970,N,1,,,,,1,,BAO_0000218,
9315,,Intermediate,,50597,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL626971,N,1,,,,,1,,BAO_0000218,
9316,1969.0,Intermediate,Plasma,50597,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL626972,N,1,,,,,1,,BAO_0000218,
9317,1969.0,Intermediate,Plasma,50597,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL626973,N,1,,,,,1,,BAO_0000218,
9318,1969.0,Intermediate,Plasma,50597,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL626974,N,1,,,,,1,,BAO_0000218,
9319,1969.0,Intermediate,Plasma,50597,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL874592,N,1,,,,,1,,BAO_0000218,
9320,,Intermediate,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,CHEMBL626975,N,1,,,,,1,,BAO_0000218,
9321,,Intermediate,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,CHEMBL626976,N,1,,,,,1,,BAO_0000218,
9322,,Intermediate,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,CHEMBL626977,N,1,,,,,1,,BAO_0000218,
9323,,Intermediate,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,CHEMBL626978,N,1,,,,,1,,BAO_0000218,
9324,,Intermediate,,50597,PK study was carried to determine the relative absorption ranking in rat.,CHEMBL626979,N,1,,,,,1,,BAO_0000218,
9325,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,CHEMBL626980,N,1,,,,,1,,BAO_0000218,
9326,178.0,Intermediate,Blood,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",CHEMBL626981,N,1,,,,,1,,BAO_0000218,
9327,178.0,Intermediate,Blood,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",CHEMBL626982,N,1,,,,,1,,BAO_0000218,
9328,178.0,Intermediate,Blood,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",CHEMBL626983,N,1,,,,,1,,BAO_0000218,
9329,178.0,Intermediate,Blood,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",CHEMBL622522,N,1,,,,,1,,BAO_0000218,
9330,178.0,Intermediate,Blood,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",CHEMBL622523,N,1,,,,,1,,BAO_0000218,
9331,178.0,Intermediate,Blood,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",CHEMBL622524,N,1,,,,,1,,BAO_0000218,
9332,955.0,Intermediate,Brain,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",CHEMBL622525,N,1,,,,,1,,BAO_0000218,
9333,955.0,Intermediate,Brain,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",CHEMBL622526,N,1,,,,,1,,BAO_0000218,
9334,955.0,Intermediate,Brain,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",CHEMBL619849,N,1,,,,,1,,BAO_0000218,
9335,955.0,Intermediate,Brain,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",CHEMBL619850,N,1,,,,,1,,BAO_0000218,
9336,955.0,Intermediate,Brain,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",CHEMBL623864,N,1,,,,,1,,BAO_0000218,
9337,955.0,Intermediate,Brain,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",CHEMBL623865,N,1,,,,,1,,BAO_0000218,
9338,948.0,Intermediate,Heart,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",CHEMBL623866,N,1,,,,,1,,BAO_0000218,
9339,948.0,Intermediate,Heart,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",CHEMBL623867,N,1,,,,,1,,BAO_0000218,
9340,948.0,Intermediate,Heart,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",CHEMBL877615,N,1,,,,,1,,BAO_0000218,
9341,948.0,Intermediate,Heart,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",CHEMBL623868,N,1,,,,,1,,BAO_0000218,
9342,948.0,Intermediate,Heart,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",CHEMBL623869,N,1,,,,,1,,BAO_0000218,
9343,948.0,Intermediate,Heart,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",CHEMBL623870,N,1,,,,,1,,BAO_0000218,
9344,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,CHEMBL623871,N,1,,,,,1,,BAO_0000218,
9345,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL623872,N,1,,,,,1,,BAO_0000218,
9346,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL622129,N,1,,,,,1,,BAO_0000218,
9347,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL622130,N,1,,,,,1,,BAO_0000218,
9348,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL622131,N,1,,,,,1,,BAO_0000218,
9349,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL622132,N,1,,,,,1,,BAO_0000218,
9350,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL622133,N,1,,,,,1,,BAO_0000218,
9351,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL622134,N,1,,,,,1,,BAO_0000218,
9352,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL622135,N,1,,,,,1,,BAO_0000218,
9353,2048.0,Intermediate,Lung,50597,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL622136,N,1,,,,,1,,BAO_0000218,
9354,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL622137,N,1,,,,,1,,BAO_0000218,
9355,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL622138,N,1,,,,,1,,BAO_0000218,
9356,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL623017,N,1,,,,,1,,BAO_0000218,
9357,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL623018,N,1,,,,,1,,BAO_0000218,
9358,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL623019,N,1,,,,,1,,BAO_0000218,
9359,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL623020,N,1,,,,,1,,BAO_0000218,
9360,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,CHEMBL623021,N,1,,,,,1,,BAO_0000218,
9361,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,CHEMBL623022,N,1,,,,,1,,BAO_0000218,
9362,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL623023,N,1,,,,,1,,BAO_0000218,
9363,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL623024,N,1,,,,,1,,BAO_0000218,
9364,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL623025,N,1,,,,,1,,BAO_0000218,
9365,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL620545,N,1,,,,,1,,BAO_0000218,
9366,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL620546,N,1,,,,,1,,BAO_0000218,
9367,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL620547,N,1,,,,,1,,BAO_0000218,
9368,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL620548,N,1,,,,,1,,BAO_0000218,
9369,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL620549,N,1,,,,,1,,BAO_0000218,
9370,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL620550,N,1,,,,,1,,BAO_0000218,
9371,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,CHEMBL620551,N,1,,,,,1,,BAO_0000218,
9372,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL620552,N,1,,,,,1,,BAO_0000218,
9373,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL620553,N,1,,,,,1,,BAO_0000218,
9374,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL620554,N,1,,,,,1,,BAO_0000218,
9375,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL875845,N,1,,,,,1,,BAO_0000218,
9376,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL620555,N,1,,,,,1,,BAO_0000218,
9377,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL620556,N,1,,,,,1,,BAO_0000218,
9378,2385.0,Intermediate,Muscle tissue,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL620557,N,1,,,,,1,,BAO_0000218,
9379,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL620558,N,1,,,,,1,,BAO_0000218,
9380,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL620559,N,1,,,,,1,,BAO_0000218,
9381,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL622939,N,1,,,,,1,,BAO_0000218,
9382,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL622940,N,1,,,,,1,,BAO_0000218,
9383,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL622941,N,1,,,,,1,,BAO_0000218,
9384,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL622942,N,1,,,,,1,,BAO_0000218,
9385,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL622943,N,1,,,,,1,,BAO_0000218,
9386,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL622944,N,1,,,,,1,,BAO_0000218,
9387,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL622945,N,1,,,,,1,,BAO_0000218,
9388,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL622946,N,1,,,,,1,,BAO_0000218,
9389,,Intermediate,,50597,Compound was evaluated for terminal half life in rat,CHEMBL622947,N,1,,,,,1,,BAO_0000218,
9390,1969.0,Intermediate,Plasma,50597,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,CHEMBL622948,N,1,,,,,1,,BAO_0000218,
9391,1969.0,Intermediate,Plasma,50597,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,CHEMBL622949,N,1,,,,,1,,BAO_0000218,
9392,,Intermediate,,50597,Compound was tested for its half life in rat,CHEMBL622950,N,1,,,,,1,,BAO_0000218,
9393,1969.0,Intermediate,Plasma,22224,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,CHEMBL622951,U,0,,,,,1,,BAO_0000218,
9394,1969.0,Intermediate,Plasma,22224,Compound was tested for its plasma half life in Sprague Dawley rats,CHEMBL622952,U,0,,,,,1,,BAO_0000366,
9395,1969.0,Intermediate,Plasma,22224,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,CHEMBL622953,U,0,,,,,1,,BAO_0000366,
9396,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma half-life period in rat,CHEMBL873818,N,1,,,,,1,,BAO_0000218,
9397,,Intermediate,,50597,Elimination half life after i.v. administration of compound in rats,CHEMBL622954,N,1,,,,,1,,BAO_0000218,
9398,,Intermediate,,50597,Elimination half-life after IV dosing at 0.5 mg/kg in rat,CHEMBL622955,N,1,,,,,1,,BAO_0000218,
9399,,Intermediate,,50597,Elimination half-life after IV dosing at 1 mg/kg in rat,CHEMBL875229,N,1,,,,,1,,BAO_0000218,
9400,,Intermediate,,50597,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,CHEMBL622956,N,1,,,,,1,,BAO_0000218,
9401,,Intermediate,,50597,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,CHEMBL622957,N,1,,,,,1,,BAO_0000218,
9402,955.0,Intermediate,Brain,50597,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,CHEMBL622958,N,1,,,,,1,,BAO_0000218,
9403,1969.0,Intermediate,Plasma,50597,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,CHEMBL622959,N,1,,,,,1,,BAO_0000218,
9404,955.0,Intermediate,Brain,50597,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,CHEMBL622960,N,1,,,,,1,,BAO_0000218,
9405,1969.0,Intermediate,Plasma,50597,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,CHEMBL622961,N,1,,,,,1,,BAO_0000218,
9406,,Intermediate,,50597,Evaluated for the half life in rat (in vivo),CHEMBL622962,N,1,,,,,1,,BAO_0000218,
9407,,Intermediate,,50597,Hafl life in rat,CHEMBL622963,N,1,,,,,1,,BAO_0000218,
9408,,Intermediate,,50597,Hafl life rat,CHEMBL622964,N,1,,,,,1,,BAO_0000218,
9409,,Intermediate,,50597,Hafl life rat,CHEMBL622965,N,1,,,,,1,,BAO_0000218,
9410,,Intermediate,,50597,Hafl life rat; Not determined,CHEMBL622966,N,1,,,,,1,,BAO_0000218,
9411,,Intermediate,,50597,Hafl life rat; Not determined,CHEMBL622967,N,1,,,,,1,,BAO_0000218,
9412,2113.0,Intermediate,Kidney,50597,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL622968,N,1,,,,,1,,BAO_0000218,
9413,2107.0,Intermediate,Liver,50597,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL622969,N,1,,,,,1,,BAO_0000218,
9414,2048.0,Intermediate,Lung,50597,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL875327,N,1,,,,,1,,BAO_0000218,
9415,,Intermediate,,50597,Half life in rat after 1 mg/kg i.v. administration,CHEMBL628638,N,1,,,,,1,,BAO_0000218,
9416,,Intermediate,,50597,Half life in rat after 2 mg/kg peroral administration,CHEMBL628639,N,1,,,,,1,,BAO_0000218,
9417,,Intermediate,,50597,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL625840,N,1,,,,,1,,BAO_0000218,
9418,,Intermediate,,50597,Half life of 10 mg/kg oral dose determined in rats,CHEMBL625841,N,1,,,,,1,,BAO_0000218,
9419,,Intermediate,,50597,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL625842,N,1,,,,,1,,BAO_0000218,
9420,,Intermediate,,50597,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL625843,N,1,,,,,1,,BAO_0000218,
9421,,Intermediate,,50597,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL625844,N,1,,,,,1,,BAO_0000218,
9422,,Intermediate,,50597,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL873822,N,1,,,,,1,,BAO_0000218,
9423,,Intermediate,,50597,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL625845,N,1,,,,,1,,BAO_0000218,
9424,,Intermediate,,50597,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL627059,N,1,,,,,1,,BAO_0000218,
9425,,Intermediate,,50597,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL627060,N,1,,,,,1,,BAO_0000218,
9426,,Intermediate,,50597,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,CHEMBL627061,N,1,,,,,1,,BAO_0000218,
9427,,Intermediate,,50597,Half life of compound at 5 mg/kg after po administration was determined in rat,CHEMBL627709,N,1,,,,,1,,BAO_0000218,
9428,,Intermediate,,50597,Half life of compound determined after intravenous administration to rat,CHEMBL627710,N,1,,,,,1,,BAO_0000218,
9429,,Intermediate,,50597,Half life of compound was determined in rat,CHEMBL627711,N,1,,,,,1,,BAO_0000218,
9430,1969.0,Intermediate,Plasma,50597,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL627712,N,1,,,,,1,,BAO_0000218,
9431,,Intermediate,,50597,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL627713,N,1,,,,,1,,BAO_0000218,
9432,,Intermediate,,50597,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL627714,N,1,,,,,1,,BAO_0000218,
9433,,Intermediate,,22224,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,CHEMBL627889,U,0,,,,,1,,BAO_0000218,
9434,,Intermediate,,22224,Half life determined in rat by intravenous administration,CHEMBL627890,U,0,,,,,1,,BAO_0000218,
9435,,Intermediate,,50597,Half life determined in rats after iv administration,CHEMBL627891,N,1,,,,,1,,BAO_0000218,
9436,1969.0,Intermediate,Plasma,50597,Half life in rat plasma after administration of 2 mg/kg iv,CHEMBL627892,N,1,,,,,1,,BAO_0000218,
9437,1969.0,Intermediate,Plasma,50597,Half life in rat plasma after administration of 2 mg/kg iv,CHEMBL627893,N,1,,,,,1,,BAO_0000218,
9438,1969.0,Intermediate,Plasma,50597,Half life in rat plasma was determined,CHEMBL627894,N,1,,,,,1,,BAO_0000218,
9439,1969.0,Intermediate,Plasma,50597,Half life in rat plasma was determined; NA means not applicable,CHEMBL627895,N,1,,,,,1,,BAO_0000218,
9440,,Intermediate,,50597,Half life in rat was tested,CHEMBL627896,N,1,,,,,1,,BAO_0000218,
9441,1969.0,Intermediate,Plasma,50597,Half life measured in rat plasma,CHEMBL627897,N,1,,,,,1,,BAO_0000218,
9442,,Intermediate,,50597,Half life recorded in rats,CHEMBL627898,N,1,,,,,1,,BAO_0000218,
9443,,Intermediate,,50597,Half life was calculated,CHEMBL627899,N,1,,,,,1,,BAO_0000218,
9444,,Intermediate,,50597,Half life was calculated in rat,CHEMBL873823,N,1,,,,,1,,BAO_0000218,
9445,,Intermediate,,50597,Half life was determined,CHEMBL627900,N,1,,,,,1,,BAO_0000218,
9446,,Intermediate,,50597,Half life after 10 mg/kg oral administration in rat,CHEMBL627901,N,1,,,,,1,,BAO_0000218,
9447,,Intermediate,,50597,Half life after administering orally a dose of 10 mg/kg to a fasting rat,CHEMBL627902,N,1,,,,,1,,BAO_0000218,
9448,,Intermediate,,50597,Half life after administering orally a dose of 30 mg/kg,CHEMBL627903,N,1,,,,,1,,BAO_0000218,
9449,,Intermediate,,50597,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,CHEMBL627904,N,1,,,,,1,,BAO_0000218,
9450,,Intermediate,,50597,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,CHEMBL627905,N,1,,,,,1,,BAO_0000218,
9451,,Intermediate,,50597,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,CHEMBL627906,N,1,,,,,1,,BAO_0000218,
9452,,Intermediate,,50597,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,CHEMBL627907,N,1,,,,,1,,BAO_0000218,
9453,,Intermediate,,50597,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,CHEMBL876783,N,1,,,,,1,,BAO_0000218,
9454,,Intermediate,,50597,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,CHEMBL627908,N,1,,,,,1,,BAO_0000218,
9455,,Intermediate,,50597,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,CHEMBL627909,N,1,,,,,1,,BAO_0000218,
9456,,Intermediate,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,CHEMBL627910,N,1,,,,,1,,BAO_0000218,
9457,,Intermediate,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),CHEMBL627911,N,1,,,,,1,,BAO_0000218,
9458,,Intermediate,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),CHEMBL627912,N,1,,,,,1,,BAO_0000218,
9459,,Intermediate,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),CHEMBL627913,N,1,,,,,1,,BAO_0000218,
9460,,Intermediate,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),CHEMBL627914,N,1,,,,,1,,BAO_0000218,
9461,,Intermediate,,50597,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,CHEMBL627915,N,1,,,,,1,,BAO_0000218,
9462,,Intermediate,,50597,Area under the curve was evaluated after 20 uM/kg of peroral administration,CHEMBL627916,N,1,,,,,1,,BAO_0000218,
9463,,Intermediate,,50597,Area under the curve was measured in rat after an iv dose of 1 mg/kg,CHEMBL627917,N,1,,,,,1,,BAO_0000218,
9464,,Intermediate,,50597,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,CHEMBL627918,N,1,,,,,1,,BAO_0000218,
9465,,Intermediate,,50597,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,CHEMBL627919,N,1,,,,,1,,BAO_0000218,
9466,,Intermediate,,50597,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,CHEMBL627920,N,1,,,,,1,,BAO_0000218,
9467,,Intermediate,,50597,Area under the curve was evaluated at an oral dose of 30 mg/kg,CHEMBL627921,N,1,,,,,1,,BAO_0000218,
9468,,Intermediate,,50597,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL627922,N,1,,,,,1,,BAO_0000218,
9469,,Intermediate,,50597,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL876784,N,1,,,,,1,,BAO_0000218,
9470,,Intermediate,,50597,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL627923,N,1,,,,,1,,BAO_0000218,
9471,,Intermediate,,50597,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL626208,N,1,,,,,1,,BAO_0000218,
9472,,Intermediate,,50597,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL626209,N,1,,,,,1,,BAO_0000218,
9473,,Intermediate,,50597,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL626210,N,1,,,,,1,,BAO_0000218,
9474,1969.0,Intermediate,Plasma,50597,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,CHEMBL627994,N,1,,,,,1,,BAO_0000218,
9475,,Intermediate,,50597,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,CHEMBL627995,N,1,,,,,1,,BAO_0000218,
9476,,Intermediate,,50597,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,CHEMBL627996,N,1,,,,,1,,BAO_0000218,
9477,,Intermediate,,50597,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,CHEMBL627997,N,1,,,,,1,,BAO_0000218,
9478,,Intermediate,,50597,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,CHEMBL627998,N,1,,,,,1,,BAO_0000218,
9479,,Intermediate,,50597,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,CHEMBL628640,N,1,,,,,1,,BAO_0000218,
9480,,Intermediate,,50597,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,CHEMBL628641,N,1,,,,,1,,BAO_0000218,
9481,,Intermediate,,50597,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,CHEMBL628642,N,1,,,,,1,,BAO_0000218,
9482,,Intermediate,,50597,Compound was evaluated for area under the curve expressed as (h*ug/ml),CHEMBL628643,N,1,,,,,1,,BAO_0000218,
9483,,Intermediate,,50597,Compound was tested for area under curve in rat,CHEMBL628644,N,1,,,,,1,,BAO_0000218,
9484,,Intermediate,,50597,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,CHEMBL628645,N,1,,,,,1,,BAO_0000218,
9485,,Intermediate,,50597,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,CHEMBL628646,N,1,,,,,1,,BAO_0000218,
9486,,Intermediate,,50597,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),CHEMBL628647,N,1,,,,,1,,BAO_0000218,
9487,,Intermediate,,50597,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,CHEMBL628648,N,1,,,,,1,,BAO_0000218,
9488,,Intermediate,,50597,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,CHEMBL625358,N,1,,,,,1,,BAO_0000218,
9489,,Intermediate,,50597,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,CHEMBL625359,N,1,,,,,1,,BAO_0000218,
9490,,Intermediate,,50597,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,CHEMBL625360,N,1,,,,,1,,BAO_0000218,
9491,,Intermediate,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),CHEMBL625361,N,1,,,,,1,,BAO_0000218,
9492,,Intermediate,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),CHEMBL625362,N,1,,,,,1,,BAO_0000218,
9493,,Intermediate,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),CHEMBL625363,N,1,,,,,1,,BAO_0000218,
9494,,Intermediate,,50597,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,CHEMBL625364,N,1,,,,,1,,BAO_0000218,
9495,,Intermediate,,50597,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,CHEMBL625365,N,1,,,,,1,,BAO_0000218,
9496,,Intermediate,,50597,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,CHEMBL625366,N,1,,,,,1,,BAO_0000218,
9497,,Intermediate,,50597,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,CHEMBL625367,N,1,,,,,1,,BAO_0000218,
9498,2113.0,Intermediate,Kidney,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",CHEMBL625368,N,1,,,,,1,,BAO_0000218,
9499,2113.0,Intermediate,Kidney,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",CHEMBL625369,N,1,,,,,1,,BAO_0000218,
9500,2113.0,Intermediate,Kidney,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",CHEMBL625370,N,1,,,,,1,,BAO_0000218,
9501,2113.0,Intermediate,Kidney,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",CHEMBL625371,N,1,,,,,1,,BAO_0000218,
9502,2113.0,Intermediate,Kidney,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",CHEMBL625372,N,1,,,,,1,,BAO_0000218,
9503,2113.0,Intermediate,Kidney,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",CHEMBL625373,N,1,,,,,1,,BAO_0000218,
9504,2107.0,Intermediate,Liver,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",CHEMBL625374,N,1,,,,,1,,BAO_0000218,
9505,2107.0,Intermediate,Liver,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",CHEMBL877593,N,1,,,,,1,,BAO_0000218,
9506,2107.0,Intermediate,Liver,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",CHEMBL625375,N,1,,,,,1,,BAO_0000218,
9507,2107.0,Intermediate,Liver,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",CHEMBL625376,N,1,,,,,1,,BAO_0000218,
9508,2107.0,Intermediate,Liver,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",CHEMBL621973,N,1,,,,,1,,BAO_0000218,
9509,2107.0,Intermediate,Liver,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",CHEMBL621974,N,1,,,,,1,,BAO_0000218,
9510,2048.0,Intermediate,Lung,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",CHEMBL621975,N,1,,,,,1,,BAO_0000218,
9511,2048.0,Intermediate,Lung,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",CHEMBL622166,N,1,,,,,1,,BAO_0000218,
9512,2048.0,Intermediate,Lung,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",CHEMBL622167,N,1,,,,,1,,BAO_0000218,
9513,2048.0,Intermediate,Lung,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",CHEMBL622168,N,1,,,,,1,,BAO_0000218,
9514,2048.0,Intermediate,Lung,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",CHEMBL622169,N,1,,,,,1,,BAO_0000218,
9515,2048.0,Intermediate,Lung,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",CHEMBL622170,N,1,,,,,1,,BAO_0000218,
9516,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",CHEMBL622171,N,1,,,,,1,,BAO_0000218,
9517,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",CHEMBL622172,N,1,,,,,1,,BAO_0000218,
9518,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",CHEMBL622173,N,1,,,,,1,,BAO_0000218,
9519,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",CHEMBL622174,N,1,,,,,1,,BAO_0000218,
9520,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",CHEMBL622175,N,1,,,,,1,,BAO_0000218,
9521,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",CHEMBL622176,N,1,,,,,1,,BAO_0000218,
9522,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",CHEMBL622177,N,1,,,,,1,,BAO_0000218,
9523,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",CHEMBL622178,N,1,,,,,1,,BAO_0000218,
9524,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",CHEMBL622179,N,1,,,,,1,,BAO_0000218,
9525,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",CHEMBL622180,N,1,,,,,1,,BAO_0000218,
9526,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL622181,N,1,,,,,1,,BAO_0000218,
9527,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL622182,N,1,,,,,1,,BAO_0000218,
9528,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL622183,N,1,,,,,1,,BAO_0000218,
9529,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL622184,N,1,,,,,1,,BAO_0000218,
9530,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL622185,N,1,,,,,1,,BAO_0000218,
9531,,Intermediate,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL622186,N,1,,,,,1,,BAO_0000218,
9532,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL622187,N,1,,,,,1,,BAO_0000218,
9533,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,CHEMBL625002,N,1,,,,,1,,BAO_0000218,
9534,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,CHEMBL622090,N,1,,,,,1,,BAO_0000218,
9535,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL622091,N,1,,,,,1,,BAO_0000218,
9536,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL622092,N,1,,,,,1,,BAO_0000218,
9537,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL622093,N,1,,,,,1,,BAO_0000218,
9538,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL622094,N,1,,,,,1,,BAO_0000218,
9539,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL622095,N,1,,,,,1,,BAO_0000218,
9540,,Intermediate,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL622264,N,1,,,,,1,,BAO_0000218,
9541,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL622265,N,1,,,,,1,,BAO_0000218,
9542,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL622266,N,1,,,,,1,,BAO_0000218,
9543,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL622267,N,1,,,,,1,,BAO_0000218,
9544,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL622268,N,1,,,,,1,,BAO_0000218,
9545,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL622269,N,1,,,,,1,,BAO_0000218,
9546,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL625071,N,1,,,,,1,,BAO_0000218,
9547,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL621621,N,1,,,,,1,,BAO_0000218,
9548,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL621622,N,1,,,,,1,,BAO_0000218,
9549,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL621623,N,1,,,,,1,,BAO_0000218,
9550,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL621624,N,1,,,,,1,,BAO_0000218,
9551,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL621625,N,1,,,,,1,,BAO_0000218,
9552,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL621626,N,1,,,,,1,,BAO_0000218,
9553,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL621627,N,1,,,,,1,,BAO_0000218,
9554,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL621628,N,1,,,,,1,,BAO_0000218,
9555,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL875328,N,1,,,,,1,,BAO_0000218,
9556,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL621629,N,1,,,,,1,,BAO_0000218,
9557,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL621630,N,1,,,,,1,,BAO_0000218,
9558,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL621631,N,1,,,,,1,,BAO_0000218,
9559,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL621632,N,1,,,,,1,,BAO_0000218,
9560,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL621633,N,1,,,,,1,,BAO_0000218,
9561,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL621634,N,1,,,,,1,,BAO_0000218,
9562,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL621635,N,1,,,,,1,,BAO_0000218,
9563,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL621636,N,1,,,,,1,,BAO_0000218,
9564,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL621637,N,1,,,,,1,,BAO_0000218,
9565,2106.0,Intermediate,Spleen,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL621638,N,1,,,,,1,,BAO_0000218,
9566,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL618883,N,1,,,,,1,,BAO_0000218,
9567,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,CHEMBL618884,N,1,,,,,1,,BAO_0000218,
9568,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL628627,N,1,,,,,1,,BAO_0000218,
9569,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL628628,N,1,,,,,1,,BAO_0000218,
9570,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,CHEMBL628629,N,1,,,,,1,,BAO_0000218,
9571,,Intermediate,,50597,Half life after administering orally a dose of 3 mg/kg,CHEMBL628630,N,1,,,,,1,,BAO_0000218,
9572,,Intermediate,,50597,Half life after administering orally a dose of 3 mg/kg to a fasting rat,CHEMBL628631,N,1,,,,,1,,BAO_0000218,
9573,,Intermediate,,50597,Half life after administering intravenously a dose of 1 mg/kg,CHEMBL628632,N,1,,,,,1,,BAO_0000218,
9574,,Intermediate,,50597,Half life after oral dosing in rats,CHEMBL628633,N,1,,,,,1,,BAO_0000218,
9575,,Intermediate,,50597,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,CHEMBL628634,N,1,,,,,1,,BAO_0000218,
9576,,Intermediate,,50597,Half life by intravenous administration of 3.4 mg/kg in rat,CHEMBL627789,N,1,,,,,1,,BAO_0000218,
9577,,Intermediate,,50597,Half life in rat,CHEMBL627790,N,1,,,,,1,,BAO_0000218,
9578,,Intermediate,,50597,Half life in rat,CHEMBL627791,N,1,,,,,1,,BAO_0000218,
9579,,Intermediate,,50597,Half life in rat,CHEMBL627792,N,1,,,,,1,,BAO_0000218,
9580,,Intermediate,,50597,Half life in rat after intravenous administration of the compound,CHEMBL627793,N,1,,,,,1,,BAO_0000218,
9581,1969.0,Intermediate,Plasma,50597,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,CHEMBL627794,N,1,,,,,1,,BAO_0000218,
9582,,Intermediate,,50597,Half life in rat after po administration of the compound,CHEMBL627795,N,1,,,,,1,,BAO_0000218,
9583,,Intermediate,,50597,Half life in rat after po administration of the compound; ND means Not determined,CHEMBL627796,N,1,,,,,1,,BAO_0000218,
9584,1969.0,Intermediate,Plasma,50597,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,CHEMBL875335,N,1,,,,,1,,BAO_0000218,
9585,1969.0,Intermediate,Plasma,50597,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,CHEMBL627797,N,1,,,,,1,,BAO_0000218,
9586,,Intermediate,,50597,Half life in rat i.v.,CHEMBL627798,N,1,,,,,1,,BAO_0000218,
9587,,Intermediate,,50597,Half life in rat i.v. at 2 mg/kg concentration,CHEMBL627799,N,1,,,,,1,,BAO_0000218,
9588,,Intermediate,,50597,Half life in rats,CHEMBL627800,N,1,,,,,1,,BAO_0000218,
9589,,Intermediate,,50597,Half life in rats after intravenous administration,CHEMBL627801,N,1,,,,,1,,BAO_0000218,
9590,,Intermediate,,50597,Half life in rats at the dose of 1.0 mpk by i.v. administration,CHEMBL627802,N,1,,,,,1,,BAO_0000218,
9591,,Expert,,50597,Half life in rat,CHEMBL627803,N,1,,,,,1,,BAO_0000218,
9592,,Intermediate,,50597,Half life was evaluated after intravenous administration to rats,CHEMBL873820,N,1,,,,,1,,BAO_0000218,
9593,,Intermediate,,50597,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),CHEMBL627804,N,1,,,,,1,,BAO_0000218,
9594,,Intermediate,,50597,Half life was evaluated in rat,CHEMBL627805,N,1,,,,,1,,BAO_0000218,
9595,,Intermediate,,50597,Half life was evaluated in rat,CHEMBL627806,N,1,,,,,1,,BAO_0000218,
9596,,Intermediate,,50597,Half life was evaluated in rat; Not tested,CHEMBL627107,N,1,,,,,1,,BAO_0000218,
9597,,Intermediate,,50597,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,CHEMBL627108,N,1,,,,,1,,BAO_0000218,
9598,,Intermediate,,50597,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,CHEMBL627109,N,1,,,,,1,,BAO_0000218,
9599,178.0,Intermediate,Blood,50597,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,CHEMBL627110,N,1,,,,,1,,BAO_0000218,
9600,,Intermediate,,22224,Half life was measured in monkey at dose of 10 mg/kg by po administration,CHEMBL627111,U,0,,,,,1,,BAO_0000218,
9601,,Intermediate,,22224,Half life was measured in monkey at dose of 10 mg/kg by po administration,CHEMBL627112,U,0,,,,,1,,BAO_0000218,
9602,,Intermediate,,22224,Half life was measured in rat at dose of 30 mg/kg by iv administration,CHEMBL627113,U,0,,,,,1,,BAO_0000218,
9603,,Intermediate,,22224,Half life was measured in rat at dose of 30 mg/kg by po administration,CHEMBL627114,U,0,,,,,1,,BAO_0000218,
9604,,Intermediate,,50597,Half life (t1/2) was determined,CHEMBL627115,N,1,,,,,1,,BAO_0000218,
9605,,Intermediate,,50597,Half life period at a dose of 10 uM/kg in rat was determined,CHEMBL627116,N,1,,,,,1,,BAO_0000218,
9606,,Intermediate,,50597,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,CHEMBL627117,N,1,,,,,1,,BAO_0000218,
9607,,Intermediate,,50597,Half life period was determined,CHEMBL627118,N,1,,,,,1,,BAO_0000218,
9608,,Intermediate,,50597,Half life period after intravenous administration at 20 mpk in rats,CHEMBL627119,N,1,,,,,1,,BAO_0000218,
9609,,Intermediate,,50597,Half life period after intravenous administration at 20 mpk in rats; Not performed.,CHEMBL627120,N,1,,,,,1,,BAO_0000218,
9610,,Intermediate,,50597,Half life period after intravenous administration in rat,CHEMBL626922,N,1,,,,,1,,BAO_0000218,
9611,,Intermediate,,50597,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,CHEMBL626923,N,1,,,,,1,,BAO_0000218,
9612,,Intermediate,,50597,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,CHEMBL626924,N,1,,,,,1,,BAO_0000218,
9613,1969.0,Intermediate,Plasma,50597,Half life period in 80% rat plasma at 37 degree Centigrade,CHEMBL626925,N,1,,,,,1,,BAO_0000218,
9614,,Intermediate,,50597,Half life period in SD rats,CHEMBL626926,N,1,,,,,1,,BAO_0000218,
9615,1969.0,Intermediate,Plasma,50597,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),CHEMBL626927,N,1,,,,,1,,BAO_0000218,
9616,1969.0,Intermediate,Plasma,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),CHEMBL626928,N,1,,,,,1,,BAO_0000218,
9617,1969.0,Intermediate,Plasma,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,CHEMBL626929,N,1,,,,,1,,BAO_0000218,
9618,1969.0,Intermediate,Plasma,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,CHEMBL626930,N,1,,,,,1,,BAO_0000218,
9619,,Intermediate,,50597,Half life period in rat,CHEMBL626931,N,1,,,,,1,,BAO_0000218,
9620,,Intermediate,,50597,Half life period in rat,CHEMBL626932,N,1,,,,,1,,BAO_0000218,
9621,,Intermediate,,50597,Half life period in rat,CHEMBL626933,N,1,,,,,1,,BAO_0000218,
9622,,Intermediate,,50597,Half life period in rat after oral administration at 10.5 mg/kg dose,CHEMBL873826,N,1,,,,,1,,BAO_0000218,
9623,,Intermediate,,50597,Half life period in rat after oral administration at 11.2 mg/kg dose,CHEMBL626934,N,1,,,,,1,,BAO_0000218,
9624,,Intermediate,,50597,Half life period in rat after oral administration at 13 mg/kg dose,CHEMBL626935,N,1,,,,,1,,BAO_0000218,
9625,,Intermediate,,50597,Half life period in rat after oral administration at 9.7 mg/kg dose,CHEMBL626936,N,1,,,,,1,,BAO_0000218,
9626,,Intermediate,,50597,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,CHEMBL626937,N,1,,,,,1,,BAO_0000218,
9627,,Intermediate,,50597,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,CHEMBL625906,N,1,,,,,1,,BAO_0000218,
9628,,Intermediate,,50597,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,CHEMBL625907,N,1,,,,,1,,BAO_0000218,
9629,,Intermediate,,50597,PK study was carried to determine AUC (area under curve) value in rat,CHEMBL625908,N,1,,,,,1,,BAO_0000218,
9630,,Intermediate,,50597,Pharmacokinetic parameter AUC after intravenous administration to rats,CHEMBL625909,N,1,,,,,1,,BAO_0000218,
9631,,Intermediate,,50597,Pharmacokinetic parameter AUC after oral administration to rats,CHEMBL625910,N,1,,,,,1,,BAO_0000218,
9632,,Intermediate,,50597,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,CHEMBL625911,N,1,,,,,1,,BAO_0000218,
9633,,Intermediate,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,CHEMBL625912,N,1,,,,,1,,BAO_0000218,
9634,,Intermediate,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,CHEMBL626538,N,1,,,,,1,,BAO_0000218,
9635,,Intermediate,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,CHEMBL876794,N,1,,,,,1,,BAO_0000218,
9636,,Intermediate,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,CHEMBL626539,N,1,,,,,1,,BAO_0000218,
9637,,Intermediate,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,CHEMBL626540,N,1,,,,,1,,BAO_0000218,
9638,,Intermediate,,50597,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,CHEMBL626541,N,1,,,,,1,,BAO_0000218,
9639,,Intermediate,,50597,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,CHEMBL626542,N,1,,,,,1,,BAO_0000218,
9640,,Intermediate,,50597,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,CHEMBL626543,N,1,,,,,1,,BAO_0000218,
9641,,Intermediate,,50597,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,CHEMBL626544,N,1,,,,,1,,BAO_0000218,
9642,,Intermediate,,50597,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,CHEMBL626545,N,1,,,,,1,,BAO_0000218,
9643,,Intermediate,,50597,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,CHEMBL626546,N,1,,,,,1,,BAO_0000218,
9644,,Intermediate,,50597,Pharmacokinetic parameter area under curve was reported,CHEMBL626547,N,1,,,,,1,,BAO_0000218,
9645,,Intermediate,,50597,Pharmacokinetic property (AUC) in rat,CHEMBL626548,N,1,,,,,1,,BAO_0000218,
9646,,Intermediate,,50597,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,CHEMBL626549,N,1,,,,,1,,BAO_0000218,
9647,,Intermediate,,50597,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,CHEMBL626550,N,1,,,,,1,,BAO_0000218,
9648,,Intermediate,,50597,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,CHEMBL626551,N,1,,,,,1,,BAO_0000218,
9649,,Intermediate,,50597,Pharmacokinetic property was determined,CHEMBL623777,N,1,,,,,1,,BAO_0000218,
9650,,Intermediate,,50597,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,CHEMBL623778,N,1,,,,,1,,BAO_0000218,
9651,,Intermediate,,50597,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,CHEMBL623779,N,1,,,,,1,,BAO_0000218,
9652,1969.0,Intermediate,Plasma,50597,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,CHEMBL623780,N,1,,,,,1,,BAO_0000218,
9653,1969.0,Intermediate,Plasma,50597,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,CHEMBL622015,N,1,,,,,1,,BAO_0000218,
9654,1969.0,Intermediate,Plasma,50597,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,CHEMBL622016,N,1,,,,,1,,BAO_0000218,
9655,,Intermediate,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",CHEMBL622017,N,1,,,,,1,,BAO_0000218,
9656,,Intermediate,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",CHEMBL622018,N,1,,,,,1,,BAO_0000218,
9657,,Intermediate,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",CHEMBL622019,N,1,,,,,1,,BAO_0000218,
9658,,Intermediate,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",CHEMBL622020,N,1,,,,,1,,BAO_0000218,
9659,,Intermediate,,50597,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,CHEMBL622021,N,1,,,,,1,,BAO_0000218,
9660,,Intermediate,,50597,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,CHEMBL622022,N,1,,,,,1,,BAO_0000218,
9661,,Intermediate,,50597,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,CHEMBL622023,N,1,,,,,1,,BAO_0000218,
9662,,Intermediate,,50597,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,CHEMBL622024,N,1,,,,,1,,BAO_0000218,
9663,,Intermediate,,50597,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),CHEMBL622693,N,1,,,,,1,,BAO_0000218,
9664,,Intermediate,,50597,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),CHEMBL622694,N,1,,,,,1,,BAO_0000218,
9665,,Intermediate,,50597,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",CHEMBL622695,N,1,,,,,1,,BAO_0000218,
9666,,Intermediate,,50597,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",CHEMBL622696,N,1,,,,,1,,BAO_0000218,
9667,,Intermediate,,50597,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",CHEMBL622697,N,1,,,,,1,,BAO_0000218,
9668,,Intermediate,,50597,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",CHEMBL622874,N,1,,,,,1,,BAO_0000218,
9669,,Intermediate,,50597,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",CHEMBL622875,N,1,,,,,1,,BAO_0000218,
9670,,Intermediate,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,CHEMBL622876,N,1,,,,,1,,BAO_0000218,
9671,,Intermediate,,50597,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,CHEMBL622877,N,1,,,,,1,,BAO_0000218,
9672,,Intermediate,,50597,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,CHEMBL622878,N,1,,,,,1,,BAO_0000218,
9673,1969.0,Intermediate,Plasma,50597,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,CHEMBL622879,N,1,,,,,1,,BAO_0000218,
9674,,Intermediate,,50597,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,CHEMBL877602,N,1,,,,,1,,BAO_0000218,
9675,,Intermediate,,50597,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL622880,N,1,,,,,1,,BAO_0000218,
9676,,Intermediate,,50597,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",CHEMBL622881,N,1,,,,,1,,BAO_0000218,
9677,,Intermediate,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL622882,N,1,,,,,1,,BAO_0000218,
9678,,Intermediate,,50597,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",CHEMBL622883,N,1,,,,,1,,BAO_0000218,
9679,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",CHEMBL622884,N,1,,,,,1,,BAO_0000218,
9680,2046.0,Intermediate,Thyroid gland,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",CHEMBL622885,N,1,,,,,1,,BAO_0000218,
9681,,Intermediate,,50597,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,CHEMBL622886,N,1,,,,,1,,BAO_0000218,
9682,,Intermediate,,50597,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,CHEMBL622887,N,1,,,,,1,,BAO_0000218,
9683,1088.0,Intermediate,Urine,50597,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,CHEMBL622888,N,1,,,,,1,,BAO_0000218,
9684,178.0,Intermediate,Blood,50597,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622889,N,1,,,,,1,,BAO_0000218,
9685,178.0,Intermediate,Blood,50597,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622890,N,1,,,,,1,,BAO_0000218,
9686,178.0,Intermediate,Blood,50597,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622891,N,1,,,,,1,,BAO_0000218,
9687,178.0,Intermediate,Blood,50597,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL877603,N,1,,,,,1,,BAO_0000218,
9688,955.0,Intermediate,Brain,50597,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622892,N,1,,,,,1,,BAO_0000218,
9689,955.0,Intermediate,Brain,50597,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622893,N,1,,,,,1,,BAO_0000218,
9690,955.0,Intermediate,Brain,50597,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622894,N,1,,,,,1,,BAO_0000218,
9691,955.0,Intermediate,Brain,50597,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622895,N,1,,,,,1,,BAO_0000218,
9692,955.0,Intermediate,Brain,50597,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,CHEMBL622896,N,1,,,,,1,,BAO_0000218,
9693,948.0,Intermediate,Heart,50597,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622897,N,1,,,,,1,,BAO_0000218,
9694,948.0,Intermediate,Heart,50597,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622898,N,1,,,,,1,,BAO_0000218,
9695,948.0,Intermediate,Heart,50597,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622899,N,1,,,,,1,,BAO_0000218,
9696,2113.0,Intermediate,Kidney,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622900,N,1,,,,,1,,BAO_0000218,
9697,2113.0,Intermediate,Kidney,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624114,N,1,,,,,1,,BAO_0000218,
9698,2113.0,Intermediate,Kidney,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624115,N,1,,,,,1,,BAO_0000218,
9699,2113.0,Intermediate,Kidney,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624116,N,1,,,,,1,,BAO_0000218,
9700,2107.0,Intermediate,Liver,50597,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624117,N,1,,,,,1,,BAO_0000218,
9701,2107.0,Intermediate,Liver,50597,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624118,N,1,,,,,1,,BAO_0000218,
9702,2107.0,Intermediate,Liver,50597,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624119,N,1,,,,,1,,BAO_0000218,
9703,2107.0,Intermediate,Liver,50597,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624120,N,1,,,,,1,,BAO_0000218,
9704,2048.0,Intermediate,Lung,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624121,N,1,,,,,1,,BAO_0000218,
9705,2048.0,Intermediate,Lung,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624122,N,1,,,,,1,,BAO_0000218,
9706,2048.0,Intermediate,Lung,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624123,N,1,,,,,1,,BAO_0000218,
9707,2048.0,Intermediate,Lung,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624124,N,1,,,,,1,,BAO_0000218,
9708,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624125,N,1,,,,,1,,BAO_0000218,
9709,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624126,N,1,,,,,1,,BAO_0000218,
9710,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624127,N,1,,,,,1,,BAO_0000218,
9711,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624128,N,1,,,,,1,,BAO_0000218,
9712,14.0,Intermediate,Zone of skin,50597,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL624129,N,1,,,,,1,,BAO_0000218,
9713,14.0,Intermediate,Zone of skin,50597,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL624130,N,1,,,,,1,,BAO_0000218,
9714,14.0,Intermediate,Zone of skin,50597,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622340,N,1,,,,,1,,BAO_0000218,
9715,14.0,Intermediate,Zone of skin,50597,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622341,N,1,,,,,1,,BAO_0000218,
9716,160.0,Intermediate,Intestine,50597,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622342,N,1,,,,,1,,BAO_0000218,
9717,160.0,Intermediate,Intestine,50597,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622343,N,1,,,,,1,,BAO_0000218,
9718,160.0,Intermediate,Intestine,50597,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622344,N,1,,,,,1,,BAO_0000218,
9719,160.0,Intermediate,Intestine,50597,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622345,N,1,,,,,1,,BAO_0000218,
9720,2106.0,Intermediate,Spleen,50597,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622346,N,1,,,,,1,,BAO_0000218,
9721,2106.0,Intermediate,Spleen,50597,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622347,N,1,,,,,1,,BAO_0000218,
9722,2106.0,Intermediate,Spleen,50597,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622348,N,1,,,,,1,,BAO_0000218,
9723,2106.0,Intermediate,Spleen,50597,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622349,N,1,,,,,1,,BAO_0000218,
9724,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,CHEMBL622350,N,1,,,,,1,,BAO_0000218,
9725,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,CHEMBL622351,N,1,,,,,1,,BAO_0000218,
9726,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,CHEMBL622352,N,1,,,,,1,,BAO_0000218,
9727,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,CHEMBL622353,N,1,,,,,1,,BAO_0000218,
9728,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,CHEMBL622354,N,1,,,,,1,,BAO_0000218,
9729,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,CHEMBL622355,N,1,,,,,1,,BAO_0000218,
9730,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,CHEMBL622356,N,1,,,,,1,,BAO_0000218,
9731,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,CHEMBL622357,N,1,,,,,1,,BAO_0000218,
9732,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,CHEMBL622358,N,1,,,,,1,,BAO_0000218,
9733,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,CHEMBL622359,N,1,,,,,1,,BAO_0000218,
9734,,Intermediate,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,CHEMBL874393,N,1,,,,,1,,BAO_0000218,
9735,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL622872,N,1,,,,,1,,BAO_0000218,
9736,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL622873,N,1,,,,,1,,BAO_0000218,
9737,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL623047,N,1,,,,,1,,BAO_0000218,
9738,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL623048,N,1,,,,,1,,BAO_0000218,
9739,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL623049,N,1,,,,,1,,BAO_0000218,
9740,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL623050,N,1,,,,,1,,BAO_0000218,
9741,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL623051,N,1,,,,,1,,BAO_0000218,
9742,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL623052,N,1,,,,,1,,BAO_0000218,
9743,,Intermediate,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL626343,N,1,,,,,1,,BAO_0000218,
9744,,Intermediate,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,CHEMBL626344,N,1,,,,,1,,BAO_0000218,
9745,,Intermediate,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,CHEMBL626345,N,1,,,,,1,,BAO_0000218,
9746,,Intermediate,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,CHEMBL626346,N,1,,,,,1,,BAO_0000218,
9747,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,CHEMBL626347,N,1,,,,,1,,BAO_0000218,
9748,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,CHEMBL626348,N,1,,,,,1,,BAO_0000218,
9749,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,CHEMBL626349,N,1,,,,,1,,BAO_0000218,
9750,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,CHEMBL626350,N,1,,,,,1,,BAO_0000218,
9751,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,CHEMBL626351,N,1,,,,,1,,BAO_0000218,
9752,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,CHEMBL627650,N,1,,,,,1,,BAO_0000218,
9753,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,CHEMBL627651,N,1,,,,,1,,BAO_0000218,
9754,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,CHEMBL627652,N,1,,,,,1,,BAO_0000218,
9755,,Intermediate,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,CHEMBL627653,N,1,,,,,1,,BAO_0000218,
9756,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,CHEMBL627654,N,1,,,,,1,,BAO_0000218,
9757,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,CHEMBL627835,N,1,,,,,1,,BAO_0000218,
9758,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,CHEMBL627836,N,1,,,,,1,,BAO_0000218,
9759,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,CHEMBL627837,N,1,,,,,1,,BAO_0000218,
9760,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,CHEMBL627838,N,1,,,,,1,,BAO_0000218,
9761,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,CHEMBL875338,N,1,,,,,1,,BAO_0000218,
9762,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,CHEMBL627839,N,1,,,,,1,,BAO_0000218,
9763,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,CHEMBL627840,N,1,,,,,1,,BAO_0000218,
9764,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,CHEMBL627841,N,1,,,,,1,,BAO_0000218,
9765,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,CHEMBL627842,N,1,,,,,1,,BAO_0000218,
9766,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,CHEMBL627843,N,1,,,,,1,,BAO_0000218,
9767,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,CHEMBL627844,N,1,,,,,1,,BAO_0000218,
9768,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,CHEMBL627845,N,1,,,,,1,,BAO_0000218,
9769,,Intermediate,,50597,Half life period in rat by iv administration at a dose of 3 mg/kg,CHEMBL627846,N,1,,,,,1,,BAO_0000218,
9770,1969.0,Intermediate,Plasma,50597,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),CHEMBL627847,N,1,,,,,1,,BAO_0000218,
9771,1969.0,Intermediate,Plasma,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),CHEMBL873821,N,1,,,,,1,,BAO_0000218,
9772,1969.0,Intermediate,Plasma,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,CHEMBL626079,N,1,,,,,1,,BAO_0000218,
9773,1969.0,Intermediate,Plasma,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,CHEMBL626080,N,1,,,,,1,,BAO_0000218,
9774,1969.0,Intermediate,Plasma,50597,Half life period was evaluated in rat plasma,CHEMBL626081,N,1,,,,,1,,BAO_0000218,
9775,1969.0,Intermediate,Plasma,50597,Half life period was evaluated in rat plasma; Not tested,CHEMBL875344,N,1,,,,,1,,BAO_0000218,
9776,,Intermediate,,50597,Half life period was evaluated in rats,CHEMBL626082,N,1,,,,,1,,BAO_0000218,
9777,,Intermediate,,50597,"Half life period was evaluated in rats, iv",CHEMBL626250,N,1,,,,,1,,BAO_0000218,
9778,,Intermediate,,50597,Half life period after intravenous administration at 5 mg/kg in rat,CHEMBL626251,N,1,,,,,1,,BAO_0000218,
9779,,Intermediate,,50597,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,CHEMBL626252,N,1,,,,,1,,BAO_0000218,
9780,,Intermediate,,50597,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,CHEMBL626253,N,1,,,,,1,,BAO_0000218,
9781,1969.0,Intermediate,Plasma,50597,Half life stability of compound was evaluated in rat plasma,CHEMBL626254,N,1,,,,,1,,BAO_0000218,
9782,,Intermediate,,50597,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,CHEMBL626255,N,1,,,,,1,,BAO_0000218,
9783,,Intermediate,,50597,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,CHEMBL626256,N,1,,,,,1,,BAO_0000218,
9784,,Intermediate,,50597,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,CHEMBL626257,N,1,,,,,1,,BAO_0000218,
9785,,Intermediate,,50597,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,CHEMBL626258,N,1,,,,,1,,BAO_0000218,
9786,,Intermediate,,50597,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,CHEMBL626259,N,1,,,,,1,,BAO_0000218,
9787,,Intermediate,,50597,Half in rat i.v.,CHEMBL626260,N,1,,,,,1,,BAO_0000218,
9788,,Intermediate,,50597,Half period in rat after intravenous administration,CHEMBL875345,N,1,,,,,1,,BAO_0000218,
9789,,Intermediate,,50597,Half-life after repeated oral dose of compound at 1 mg/kg in rats,CHEMBL626261,N,1,,,,,1,,BAO_0000218,
9790,2107.0,Intermediate,Liver,50597,Half-life measured in in vitro Cathepsin B assay in rat liver,CHEMBL626262,N,1,,,,,1,,BAO_0000218,
9791,,Intermediate,,50597,Half-life of compound was determined in rats,CHEMBL626263,N,1,,,,,1,,BAO_0000218,
9792,,Intermediate,,50597,Half-life at 10 mg/kg in rat upon intravenous administration,CHEMBL625270,N,1,,,,,1,,BAO_0000218,
9793,,Intermediate,,50597,Half-life determined in rat,CHEMBL625271,N,1,,,,,1,,BAO_0000218,
9794,,Intermediate,,50597,Half-life determined in rat,CHEMBL625272,N,1,,,,,1,,BAO_0000218,
9795,955.0,Intermediate,Brain,50597,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,CHEMBL625273,N,1,,,,,1,,BAO_0000218,
9796,1969.0,Intermediate,Plasma,50597,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",CHEMBL625274,N,1,,,,,1,,BAO_0000218,
9797,,Intermediate,,50597,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,CHEMBL625275,N,1,,,,,1,,BAO_0000218,
9798,1969.0,Intermediate,Plasma,50597,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,CHEMBL625276,N,1,,,,,1,,BAO_0000218,
9799,1969.0,Intermediate,Plasma,50597,Half-life in rat plasma,CHEMBL625277,N,1,,,,,1,,BAO_0000218,
9800,1969.0,Intermediate,Plasma,50597,Half-life in rat plasma was determined,CHEMBL625278,N,1,,,,,1,,BAO_0000218,
9801,1969.0,Intermediate,Plasma,50597,Half-life in rat plasma; Not tested,CHEMBL625279,N,1,,,,,1,,BAO_0000218,
9802,1977.0,Intermediate,Serum,50597,Half-life in rat serum,CHEMBL625280,N,1,,,,,1,,BAO_0000218,
9803,1977.0,Intermediate,Serum,50597,Half-life in rat serum; na is not available,CHEMBL876797,N,1,,,,,1,,BAO_0000218,
9804,,Intermediate,,50597,Half-life was calculated in rat,CHEMBL625281,N,1,,,,,1,,BAO_0000218,
9805,1969.0,Intermediate,Plasma,50597,Half-life was calculated in rat plasma,CHEMBL873827,N,1,,,,,1,,BAO_0000218,
9806,,Intermediate,,50597,Half-life was determined,CHEMBL625282,N,1,,,,,1,,BAO_0000218,
9807,,Intermediate,,50597,Half-life was determined,CHEMBL625283,N,1,,,,,1,,BAO_0000218,
9808,,Intermediate,,50597,Half-life after administration of 20 mg/Kg oral dose in rat,CHEMBL625284,N,1,,,,,1,,BAO_0000218,
9809,,Intermediate,,50597,Half-life after administration of 3.2 mg/kg intravenously in male rat,CHEMBL625285,N,1,,,,,1,,BAO_0000218,
9810,,Intermediate,,50597,Half-life after intravenous administration in female rat,CHEMBL625286,N,1,,,,,1,,BAO_0000218,
9811,,Intermediate,,50597,Half-life after intravenous administration in male rat,CHEMBL625287,N,1,,,,,1,,BAO_0000218,
9812,,Intermediate,,50597,Half-life after intravenous dose in rat,CHEMBL625288,N,1,,,,,1,,BAO_0000218,
9813,2107.0,Intermediate,Liver,50597,Half-life in a rat liver homogenate preparation,CHEMBL625289,N,1,,,,,1,,BAO_0000218,
9814,1969.0,Intermediate,Plasma,50597,Half-life in plasma of rat,CHEMBL625290,N,1,,,,,1,,BAO_0000218,
9815,1969.0,Intermediate,Plasma,50597,Half-life in plasma of rat at dose of 3-10 mgkg,CHEMBL876798,N,1,,,,,1,,BAO_0000218,
9816,,Intermediate,,50597,Half-life in rat,CHEMBL625291,N,1,,,,,1,,BAO_0000218,
9817,,Intermediate,,50597,Half-life in rat,CHEMBL625292,N,1,,,,,1,,BAO_0000218,
9818,,Intermediate,,50597,Half-life in rat,CHEMBL625293,N,1,,,,,1,,BAO_0000218,
9819,,Intermediate,,50597,Half-life in rat,CHEMBL622832,N,1,,,,,1,,BAO_0000218,
9820,,Intermediate,,50597,Half-life in rat,CHEMBL622833,N,1,,,,,1,,BAO_0000218,
9821,,Intermediate,,50597,Half-life in rat,CHEMBL622834,N,1,,,,,1,,BAO_0000218,
9822,,Intermediate,,50597,Half-life in rat after oral administration at 10 mg/kg,CHEMBL622835,N,1,,,,,1,,BAO_0000218,
9823,,Intermediate,,50597,Half-life in rat after po administration at a dose of 10 mg/kg,CHEMBL622836,N,1,,,,,1,,BAO_0000218,
9824,,Intermediate,,50597,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,CHEMBL622837,N,1,,,,,1,,BAO_0000218,
9825,,Intermediate,,50597,Half-life in rat at 3 mg/kg dose administered intravenously,CHEMBL622838,N,1,,,,,1,,BAO_0000218,
9826,955.0,Intermediate,Brain,50597,Half-life in rat brain homogenate,CHEMBL622839,N,1,,,,,1,,BAO_0000218,
9827,1969.0,Intermediate,Plasma,50597,Half-life in rat plasma,CHEMBL622840,N,1,,,,,1,,BAO_0000218,
9828,,Intermediate,,50597,Half-life in rats,CHEMBL622841,N,1,,,,,1,,BAO_0000218,
9829,,Intermediate,,50597,Half-life in Dawley rats,CHEMBL622842,N,1,,,,,1,,BAO_0000218,
9830,1969.0,Intermediate,Plasma,50597,Half-life in vitro in rat plasma,CHEMBL622843,N,1,,,,,1,,BAO_0000218,
9831,1969.0,Intermediate,Plasma,50597,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,CHEMBL622844,N,1,,,,,1,,BAO_0000218,
9832,,Intermediate,,50597,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",CHEMBL622845,N,1,,,,,1,,BAO_0000218,
9833,,Intermediate,,50597,The area under the curve of compound was measured at the dose of 100 umol/kg,CHEMBL622846,N,1,,,,,1,,BAO_0000218,
9834,,Intermediate,,50597,The area under the curve of compound was measured at the dose of 300 umol/kg,CHEMBL622847,N,1,,,,,1,,BAO_0000218,
9835,,Intermediate,,50597,The area under the curve of compound was measured at the dose of 30 umol/kg,CHEMBL622848,N,1,,,,,1,,BAO_0000218,
9836,,Intermediate,,50597,Bioavailability as oral AUC in rats,CHEMBL622849,N,1,,,,,1,,BAO_0000218,
9837,1969.0,Intermediate,Plasma,50597,The plasma concentration versus time curve (AUC) was determined,CHEMBL622850,N,1,,,,,1,,BAO_0000218,
9838,,Intermediate,,50597,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL876807,N,1,,,,,1,,BAO_0000218,
9839,,Intermediate,,50597,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL622851,N,1,,,,,1,,BAO_0000218,
9840,,Intermediate,,50597,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL622852,N,1,,,,,1,,BAO_0000218,
9841,,Intermediate,,50597,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,CHEMBL622853,N,1,,,,,1,,BAO_0000218,
9842,,Intermediate,,50597,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,CHEMBL622854,N,1,,,,,1,,BAO_0000218,
9843,,Intermediate,,50597,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,CHEMBL622855,N,1,,,,,1,,BAO_0000218,
9844,1969.0,Intermediate,Plasma,50597,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",CHEMBL622856,N,1,,,,,1,,BAO_0000218,
9845,1969.0,Intermediate,Plasma,50597,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",CHEMBL622857,N,1,,,,,1,,BAO_0000218,
9846,1969.0,Intermediate,Plasma,50597,AUC in rat after po administration at a dose of 10 mg/kg,CHEMBL622858,N,1,,,,,1,,BAO_0000218,
9847,1969.0,Intermediate,Plasma,50597,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,CHEMBL622859,N,1,,,,,1,,BAO_0000218,
9848,,Intermediate,,50597,Area under curve value 24 hr after 10 mg/kg iv administration in rats,CHEMBL622860,N,1,,,,,1,,BAO_0000218,
9849,,Intermediate,,50597,Area under curve value 24 hr after 10 mg/kg oral administration in rats,CHEMBL622861,N,1,,,,,1,,BAO_0000218,
9850,,Intermediate,,50597,Area under curve value 24 hr after 2 mg/kg iv administration in rats,CHEMBL622862,N,1,,,,,1,,BAO_0000218,
9851,,Intermediate,,50597,Area under curve value 24 hr after 2 mg/kg oral administration in rats,CHEMBL622863,N,1,,,,,1,,BAO_0000218,
9852,,Intermediate,,50597,Area under curve value 6 hr after po administration in rat,CHEMBL623817,N,1,,,,,1,,BAO_0000218,
9853,,Intermediate,,50597,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,CHEMBL623818,N,1,,,,,1,,BAO_0000218,
9854,,Intermediate,,50597,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",CHEMBL623819,N,1,,,,,1,,BAO_0000218,
9855,,Intermediate,,50597,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,CHEMBL623820,N,1,,,,,1,,BAO_0000218,
9856,,Intermediate,,50597,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,CHEMBL623821,N,1,,,,,1,,BAO_0000218,
9857,1969.0,Intermediate,Plasma,50597,AUC normalized for dose (AUCN) in rat,CHEMBL623822,N,1,,,,,1,,BAO_0000218,
9858,,Intermediate,,50597,Area under curve in rat after p.o. administration,CHEMBL623823,N,1,,,,,1,,BAO_0000218,
9859,,Intermediate,,50597,Area under curve in rat after p.o. administration,CHEMBL623824,N,1,,,,,1,,BAO_0000218,
9860,,Intermediate,,50597,Area under curve in rat after p.o. administration; Not determined,CHEMBL623825,N,1,,,,,1,,BAO_0000218,
9861,,Intermediate,,50597,Area under curve in rat after peroral administration,CHEMBL622070,N,1,,,,,1,,BAO_0000218,
9862,,Intermediate,,50597,Area under curve (carotid artery) value of the compound,CHEMBL622071,N,1,,,,,1,,BAO_0000218,
9863,,Intermediate,,50597,Bioavailability expressed as the area under curve of rat carotid artery,CHEMBL622072,N,1,,,,,1,,BAO_0000218,
9864,,Intermediate,,50597,Area under curve in male SD rats was observed after intravenous administration in rat,CHEMBL622073,N,1,,,,,1,,BAO_0000218,
9865,,Intermediate,,50597,Area under curve of the compound was determined,CHEMBL622074,N,1,,,,,1,,BAO_0000218,
9866,,Intermediate,,50597,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,CHEMBL622075,N,1,,,,,1,,BAO_0000218,
9867,1969.0,Intermediate,Plasma,50597,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,CHEMBL622076,N,1,,,,,1,,BAO_0000218,
9868,1969.0,Intermediate,Plasma,50597,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,CHEMBL622077,N,1,,,,,1,,BAO_0000218,
9869,,Intermediate,,50597,Area under curve (portal vein) value of the compound,CHEMBL622078,N,1,,,,,1,,BAO_0000218,
9870,,Intermediate,,50597,Bioavailability expressed as the area under curve of rat portal vein,CHEMBL622079,N,1,,,,,1,,BAO_0000218,
9871,1969.0,Intermediate,Plasma,50597,Area Under plasma concentration time curve in rat upon peroral administration,CHEMBL622080,N,1,,,,,1,,BAO_0000218,
9872,,Intermediate,,50597,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,CHEMBL877612,N,1,,,,,1,,BAO_0000218,
9873,,Intermediate,,50597,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,CHEMBL622081,N,1,,,,,1,,BAO_0000218,
9874,,Intermediate,,50597,Compound was evaluated for oral bioavailability in rats,CHEMBL622082,N,1,,,,,1,,BAO_0000218,
9875,,Intermediate,,50597,Compound was evaluated for oral bioavailability in rats after iv administration,CHEMBL622083,N,1,,,,,1,,BAO_0000218,
9876,,Intermediate,,50597,Compound was evaluated for oral bioavailability in rats; 30-80,CHEMBL622084,N,1,,,,,1,,BAO_0000218,
9877,,Intermediate,,50597,Compound was evaluated for oral bioavailability in rats; 50-60,CHEMBL622085,N,1,,,,,1,,BAO_0000218,
9878,,Intermediate,,50597,Compound was evaluated for oral bioavailability in rats; no data,CHEMBL622086,N,1,,,,,1,,BAO_0000218,
9879,,Intermediate,,50597,Compound was evaluated for oral bioavailability in rats; peptide,CHEMBL622087,N,1,,,,,1,,BAO_0000218,
9880,178.0,Intermediate,Blood,50597,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",CHEMBL622088,N,1,,,,,1,,BAO_0000218,
9881,178.0,Intermediate,Blood,50597,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",CHEMBL622089,N,1,,,,,1,,BAO_0000218,
9882,178.0,Intermediate,Blood,50597,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",CHEMBL623685,N,1,,,,,1,,BAO_0000218,
9883,178.0,Intermediate,Blood,50597,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",CHEMBL623686,N,1,,,,,1,,BAO_0000218,
9884,945.0,Intermediate,Stomach,50597,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL623687,N,1,,,,,1,,BAO_0000218,
9885,945.0,Intermediate,Stomach,50597,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL623688,N,1,,,,,1,,BAO_0000218,
9886,945.0,Intermediate,Stomach,50597,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL623689,N,1,,,,,1,,BAO_0000218,
9887,945.0,Intermediate,Stomach,50597,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622485,N,1,,,,,1,,BAO_0000218,
9888,2046.0,Intermediate,Thyroid gland,50597,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622486,N,1,,,,,1,,BAO_0000218,
9889,2046.0,Intermediate,Thyroid gland,50597,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL877613,N,1,,,,,1,,BAO_0000218,
9890,2046.0,Intermediate,Thyroid gland,50597,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622487,N,1,,,,,1,,BAO_0000218,
9891,2046.0,Intermediate,Thyroid gland,50597,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622488,N,1,,,,,1,,BAO_0000218,
9892,948.0,Intermediate,Heart,50597,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",CHEMBL622489,N,1,,,,,1,,BAO_0000218,
9893,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,CHEMBL622490,N,1,,,,,1,,BAO_0000218,
9894,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,CHEMBL622491,N,1,,,,,1,,BAO_0000218,
9895,2107.0,Intermediate,Liver,50597,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,CHEMBL622492,N,1,,,,,1,,BAO_0000218,
9896,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,CHEMBL622493,N,1,,,,,1,,BAO_0000218,
9897,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,CHEMBL622494,N,1,,,,,1,,BAO_0000218,
9898,2385.0,Intermediate,Muscle tissue,50597,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",CHEMBL622495,N,1,,,,,1,,BAO_0000218,
9899,,Intermediate,,50597,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,CHEMBL622496,N,1,,,,,1,,BAO_0000218,
9900,1088.0,Intermediate,Urine,50597,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,CHEMBL622497,N,1,,,,,1,,BAO_0000218,
9901,,Intermediate,,50597,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,CHEMBL622498,N,1,,,,,1,,BAO_0000218,
9902,1088.0,Intermediate,Urine,50597,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,CHEMBL624918,N,1,,,,,1,,BAO_0000218,
9903,1088.0,Intermediate,Urine,50597,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,CHEMBL624919,N,1,,,,,1,,BAO_0000218,
9904,178.0,Intermediate,Blood,50597,Biodistribution of compound in rat blood after 5 min of administration,CHEMBL624920,N,1,,,,,1,,BAO_0000218,
9905,178.0,Intermediate,Blood,50597,Biodistribution of compound in rat blood after 5 min of administration.,CHEMBL624921,N,1,,,,,1,,BAO_0000218,
9906,955.0,Intermediate,Brain,50597,Biodistribution of compound in rat brain after 5 min of administration,CHEMBL624922,N,1,,,,,1,,BAO_0000218,
9907,948.0,Intermediate,Heart,50597,Biodistribution of compound in rat heart after 5 min of administration,CHEMBL624923,N,1,,,,,1,,BAO_0000218,
9908,948.0,Intermediate,Heart,50597,Biodistribution of compound in rat heart after 5 min of administration.,CHEMBL624924,N,1,,,,,1,,BAO_0000218,
9909,2113.0,Intermediate,Kidney,50597,Biodistribution of compound in rat kidney after 5 min of administration,CHEMBL624925,N,1,,,,,1,,BAO_0000218,
9910,2113.0,Intermediate,Kidney,50597,Biodistribution of compound in rat kidney after 5 min of administration.,CHEMBL624926,N,1,,,,,1,,BAO_0000218,
9911,2107.0,Intermediate,Liver,50597,Biodistribution of compound in rat liver after 5 min of administration,CHEMBL624927,N,1,,,,,1,,BAO_0000218,
9912,2107.0,Intermediate,Liver,50597,Biodistribution of compound in rat liver after 5 min of administration.,CHEMBL874402,N,1,,,,,1,,BAO_0000218,
9913,2048.0,Intermediate,Lung,50597,Biodistribution of compound in rat lung after 5 min of administration,CHEMBL624928,N,1,,,,,1,,BAO_0000218,
9914,2048.0,Intermediate,Lung,50597,Biodistribution of compound in rat lung after 5 min of administration.,CHEMBL624929,N,1,,,,,1,,BAO_0000218,
9915,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of compound in rat muscle after 5 min of administration,CHEMBL624930,N,1,,,,,1,,BAO_0000218,
9916,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of compound in rat muscle after 5 min of administration.,CHEMBL624931,N,1,,,,,1,,BAO_0000218,
9917,948.0,Intermediate,Heart,50597,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624932,N,1,,,,,1,,BAO_0000218,
9918,948.0,Intermediate,Heart,50597,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624933,N,1,,,,,1,,BAO_0000218,
9919,2107.0,Intermediate,Liver,50597,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624934,N,1,,,,,1,,BAO_0000218,
9920,2107.0,Intermediate,Liver,50597,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624935,N,1,,,,,1,,BAO_0000218,
9921,,Intermediate,,50597,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624936,N,1,,,,,1,,BAO_0000218,
9922,,Intermediate,,50597,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624937,N,1,,,,,1,,BAO_0000218,
9923,2106.0,Intermediate,Spleen,50597,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624938,N,1,,,,,1,,BAO_0000218,
9924,2106.0,Intermediate,Spleen,50597,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624939,N,1,,,,,1,,BAO_0000218,
9925,,Intermediate,,50597,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL624940,N,1,,,,,1,,BAO_0000218,
9926,,Intermediate,,50597,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,CHEMBL874403,N,1,,,,,1,,BAO_0000218,
9927,,Intermediate,,50597,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,CHEMBL624941,N,1,,,,,1,,BAO_0000218,
9928,1088.0,Intermediate,Urine,50597,Dose required to lower urine osmolality to 300 mOsm/kg in rat,CHEMBL624942,N,1,,,,,1,,BAO_0000218,
9929,1088.0,Intermediate,Urine,50597,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,CHEMBL624943,N,1,,,,,1,,BAO_0000218,
9930,,Intermediate,,50597,% Bioavailability after 1 day of the drug administration in rats,CHEMBL624944,N,1,,,,,1,,BAO_0000218,
9931,,Intermediate,,50597,% Bioavailability after 4 day of the drug administration in rats,CHEMBL624945,N,1,,,,,1,,BAO_0000218,
9932,,Intermediate,,50597,Absolute bioavailability was evaluated in rat,CHEMBL624946,N,1,,,,,1,,BAO_0000218,
9933,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,CHEMBL624947,N,1,,,,,1,,BAO_0000218,
9934,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,CHEMBL624948,N,1,,,,,1,,BAO_0000218,
9935,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,CHEMBL624949,N,1,,,,,1,,BAO_0000218,
9936,2113.0,Intermediate,Kidney,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,CHEMBL622025,N,1,,,,,1,,BAO_0000218,
9937,2113.0,Intermediate,Kidney,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,CHEMBL622026,N,1,,,,,1,,BAO_0000218,
9938,2113.0,Intermediate,Kidney,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,CHEMBL622027,N,1,,,,,1,,BAO_0000218,
9939,2113.0,Intermediate,Kidney,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,CHEMBL622028,N,1,,,,,1,,BAO_0000218,
9940,2107.0,Intermediate,Liver,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,CHEMBL622029,N,1,,,,,1,,BAO_0000218,
9941,2107.0,Intermediate,Liver,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,CHEMBL622208,N,1,,,,,1,,BAO_0000218,
9942,2107.0,Intermediate,Liver,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,CHEMBL622209,N,1,,,,,1,,BAO_0000218,
9943,2107.0,Intermediate,Liver,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,CHEMBL622210,N,1,,,,,1,,BAO_0000218,
9944,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,CHEMBL622211,N,1,,,,,1,,BAO_0000218,
9945,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,CHEMBL622212,N,1,,,,,1,,BAO_0000218,
9946,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,CHEMBL622213,N,1,,,,,1,,BAO_0000218,
9947,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,CHEMBL874404,N,1,,,,,1,,BAO_0000218,
9948,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,CHEMBL620452,N,1,,,,,1,,BAO_0000218,
9949,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,CHEMBL620453,N,1,,,,,1,,BAO_0000218,
9950,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,CHEMBL620454,N,1,,,,,1,,BAO_0000218,
9951,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,CHEMBL624067,N,1,,,,,1,,BAO_0000218,
9952,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,CHEMBL624068,N,1,,,,,1,,BAO_0000218,
9953,992.0,Intermediate,Female gonad,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,CHEMBL624069,N,1,,,,,1,,BAO_0000218,
9954,992.0,Intermediate,Female gonad,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,CHEMBL624070,N,1,,,,,1,,BAO_0000218,
9955,992.0,Intermediate,Female gonad,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,CHEMBL624071,N,1,,,,,1,,BAO_0000218,
9956,995.0,Intermediate,Uterus,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,CHEMBL624072,N,1,,,,,1,,BAO_0000218,
9957,995.0,Intermediate,Uterus,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,CHEMBL624073,N,1,,,,,1,,BAO_0000218,
9958,995.0,Intermediate,Uterus,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,CHEMBL624788,N,1,,,,,1,,BAO_0000218,
9959,995.0,Intermediate,Uterus,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,CHEMBL624789,N,1,,,,,1,,BAO_0000218,
9960,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,CHEMBL624790,N,1,,,,,1,,BAO_0000218,
9961,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,CHEMBL624791,N,1,,,,,1,,BAO_0000218,
9962,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,CHEMBL624792,N,1,,,,,1,,BAO_0000218,
9963,,Intermediate,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,CHEMBL624793,N,1,,,,,1,,BAO_0000218,
9964,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,CHEMBL877491,N,1,,,,,1,,BAO_0000218,
9965,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,CHEMBL624957,N,1,,,,,1,,BAO_0000218,
9966,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,CHEMBL624958,N,1,,,,,1,,BAO_0000218,
9967,2385.0,Intermediate,Muscle tissue,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,CHEMBL624959,N,1,,,,,1,,BAO_0000218,
9968,,Intermediate,,50597,Dissociation constant was determined,CHEMBL624960,N,1,,,,,1,,BAO_0000218,
9969,,Intermediate,,50597,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",CHEMBL624961,N,1,,,,,1,,BAO_0000218,
9970,,Intermediate,,50597,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL624962,N,1,,,,,1,,BAO_0000218,
9971,,Intermediate,,50597,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",CHEMBL624963,N,1,,,,,1,,BAO_0000218,
9972,,Intermediate,,50597,Observed rate constant in 80% rat plasma at 37 degree Centigrade,CHEMBL624964,N,1,,,,,1,,BAO_0000218,
9973,,Intermediate,,50597,LogP value was evaluated in the in situ rat gut perfusion assay,CHEMBL624965,N,1,,,,,1,,BAO_0000218,
9974,,Intermediate,,50597,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,CHEMBL624966,N,1,,,,,1,,BAO_0000218,
9975,,Intermediate,,50597,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,CHEMBL624967,N,1,,,,,1,,BAO_0000218,
9976,,Intermediate,,50597,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,CHEMBL624968,N,1,,,,,1,,BAO_0000218,
9977,,Intermediate,,50597,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL624969,N,1,,,,,1,,BAO_0000218,
9978,,Expert,,50597,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,CHEMBL624970,N,1,,,,,1,,BAO_0000218,
9979,,Intermediate,,50597,Half-life was evaluated after 10 uM/kg of intra arterial administration,CHEMBL624971,N,1,,,,,1,,BAO_0000218,
9980,,Intermediate,,50597,Half-life was evaluated after 20 uM/kg of peroral administration,CHEMBL624972,N,1,,,,,1,,BAO_0000218,
9981,,Intermediate,,50597,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,CHEMBL624973,N,1,,,,,1,,BAO_0000218,
9982,1969.0,Intermediate,Plasma,50597,Half-life was evaluated in plasma of rat,CHEMBL624974,N,1,,,,,1,,BAO_0000218,
9983,,Intermediate,,50597,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,CHEMBL624975,N,1,,,,,1,,BAO_0000218,
9984,,Intermediate,,50597,Half-life was evaluated in rats at an oral dose of 30 mg/kg,CHEMBL877492,N,1,,,,,1,,BAO_0000218,
9985,,Intermediate,,50597,Half-life was measured in rat after an iv dose of 1 mg/kg,CHEMBL624976,N,1,,,,,1,,BAO_0000218,
9986,,Intermediate,,50597,Half-life period of compound in rats after peroral administration,CHEMBL624977,N,1,,,,,1,,BAO_0000218,
9987,1969.0,Intermediate,Plasma,50597,Half-life period of compound was measured in rat plasma.,CHEMBL626848,N,1,,,,,1,,BAO_0000218,
9988,1969.0,Intermediate,Plasma,50597,Half-life period of compound was measured in rat plasma; ND is not determined,CHEMBL626849,N,1,,,,,1,,BAO_0000218,
9989,1969.0,Intermediate,Plasma,50597,Half-life period of compound was measured in rat plasma; not determined,CHEMBL626850,N,1,,,,,1,,BAO_0000218,
9990,,Intermediate,,50597,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,CHEMBL626851,N,1,,,,,1,,BAO_0000218,
9991,,Intermediate,,50597,Half-life period in rat by iv administration,CHEMBL626852,N,1,,,,,1,,BAO_0000218,
9992,,Intermediate,,50597,Half-life period in rats following intravenous administration at 2 mg/kg,CHEMBL626853,N,1,,,,,1,,BAO_0000218,
9993,,Intermediate,,50597,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL626854,N,1,,,,,1,,BAO_0000218,
9994,,Intermediate,,50597,Half-life period was determined for the compound in rat,CHEMBL627486,N,1,,,,,1,,BAO_0000218,
9995,,Intermediate,,50597,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",CHEMBL627487,N,1,,,,,1,,BAO_0000218,
9996,,Intermediate,,50597,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",CHEMBL627488,N,1,,,,,1,,BAO_0000218,
9997,,Intermediate,,50597,Half-life value after IV dose at a dose of 5 mg/kg in rats.,CHEMBL627489,N,1,,,,,1,,BAO_0000218,
9998,,Intermediate,,50597,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,CHEMBL627490,N,1,,,,,1,,BAO_0000218,
9999,,Intermediate,,50597,Half-life was determined in rat after intravenous administration (0.5 mg/kg),CHEMBL873829,N,1,,,,,1,,BAO_0000218,
10000,,Intermediate,,50597,Half-life was determined in rat at a dose of 1 mpk i.v.,CHEMBL627655,N,1,,,,,1,,BAO_0000218,
10001,,Intermediate,,50597,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,CHEMBL625994,N,1,,,,,1,,BAO_0000218,
10002,,Intermediate,,50597,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,CHEMBL625995,N,1,,,,,1,,BAO_0000218,
10003,,Intermediate,,50597,Half-life in rat,CHEMBL625996,N,1,,,,,1,,BAO_0000218,
10004,1969.0,Intermediate,Plasma,50597,In vitro half life in rat plasma,CHEMBL625850,N,1,,,,,1,,BAO_0000218,
10005,1969.0,Intermediate,Plasma,50597,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",CHEMBL625851,N,1,,,,,1,,BAO_0000218,
10006,,Intermediate,,50597,In vitro half life in rat,CHEMBL625852,N,1,,,,,1,,BAO_0000218,
10007,,Intermediate,,50597,In vivo half life period after intravenous administration in rat,CHEMBL625853,N,1,,,,,1,,BAO_0000218,
10008,,Intermediate,,50597,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,CHEMBL625854,N,1,,,,,1,,BAO_0000218,
10009,,Intermediate,,50597,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,CHEMBL874450,N,1,,,,,1,,BAO_0000218,
10010,,Intermediate,,50597,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,CHEMBL625855,N,1,,,,,1,,BAO_0000218,
10011,,Intermediate,,50597,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,CHEMBL625856,N,1,,,,,1,,BAO_0000218,
10012,,Intermediate,,50597,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,CHEMBL625857,N,1,,,,,1,,BAO_0000218,
10013,,Intermediate,,50597,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,CHEMBL873831,N,1,,,,,1,,BAO_0000218,
10014,,Intermediate,,50597,Longer half-life in rat (i.v.) at 0.5 mpk,CHEMBL625858,N,1,,,,,1,,BAO_0000218,
10015,,Intermediate,,50597,Longer half-life in rat (p.o.) at 2.0 mpk,CHEMBL625859,N,1,,,,,1,,BAO_0000218,
10016,,Intermediate,,50597,Pharmacokinetic property (half life) in rat,CHEMBL625860,N,1,,,,,1,,BAO_0000218,
10017,,Intermediate,,50597,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,CHEMBL625861,N,1,,,,,1,,BAO_0000218,
10018,,Intermediate,,50597,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,CHEMBL625862,N,1,,,,,1,,BAO_0000218,
10019,,Intermediate,,50597,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,CHEMBL625863,N,1,,,,,1,,BAO_0000218,
10020,,Intermediate,,50597,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,CHEMBL625864,N,1,,,,,1,,BAO_0000218,
10021,,Intermediate,,50597,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,CHEMBL625865,N,1,,,,,1,,BAO_0000218,
10022,,Intermediate,,50597,Pharmacokinetic half time was determined intravenously in rats.,CHEMBL625866,N,1,,,,,1,,BAO_0000218,
10023,1969.0,Intermediate,Plasma,50597,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,CHEMBL625867,N,1,,,,,1,,BAO_0000218,
10024,1969.0,Intermediate,Plasma,50597,Plasma half life of hydrolysis of the compound,CHEMBL625868,N,1,,,,,1,,BAO_0000218,
10025,1969.0,Intermediate,Plasma,50597,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,CHEMBL625869,N,1,,,,,1,,BAO_0000218,
10026,1969.0,Intermediate,Plasma,50597,Plasma half life period was calculated in rat,CHEMBL874451,N,1,,,,,1,,BAO_0000218,
10027,1969.0,Intermediate,Plasma,50597,Plasma half-life in Sprague-Dawley rats,CHEMBL625870,N,1,,,,,1,,BAO_0000218,
10028,1969.0,Intermediate,Plasma,50597,Plasma half-life in Sprague-Dawley rats; Not determined,CHEMBL625871,N,1,,,,,1,,BAO_0000218,
10029,1969.0,Intermediate,Plasma,50597,Plasma half-life in rats,CHEMBL625872,N,1,,,,,1,,BAO_0000218,
10030,1969.0,Intermediate,Plasma,50597,Plasma half-life in rats; <MQL,CHEMBL625873,N,1,,,,,1,,BAO_0000218,
10031,1969.0,Intermediate,Plasma,50597,Plasma half-life period (0-8 h) was determined,CHEMBL625874,N,1,,,,,1,,BAO_0000218,
10032,1969.0,Intermediate,Plasma,50597,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,CHEMBL625875,N,1,,,,,1,,BAO_0000218,
10033,1969.0,Intermediate,Plasma,50597,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,CHEMBL625876,N,1,,,,,1,,BAO_0000218,
10034,1969.0,Intermediate,Plasma,50597,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,CHEMBL631258,N,1,,,,,1,,BAO_0000218,
10035,1969.0,Intermediate,Plasma,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,CHEMBL631259,N,1,,,,,1,,BAO_0000218,
10036,1969.0,Intermediate,Plasma,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,CHEMBL631260,N,1,,,,,1,,BAO_0000218,
10037,178.0,Intermediate,Blood,50597,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",CHEMBL631261,N,1,,,,,1,,BAO_0000218,
10038,178.0,Intermediate,Blood,50597,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",CHEMBL631262,N,1,,,,,1,,BAO_0000218,
10039,178.0,Intermediate,Blood,50597,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",CHEMBL631263,N,1,,,,,1,,BAO_0000218,
10040,,Intermediate,,50597,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",CHEMBL631264,N,1,,,,,1,,BAO_0000218,
10041,,Intermediate,,50597,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",CHEMBL631265,N,1,,,,,1,,BAO_0000218,
10042,,Intermediate,,50597,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",CHEMBL631266,N,1,,,,,1,,BAO_0000218,
10043,,Intermediate,,50597,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",CHEMBL631267,N,1,,,,,1,,BAO_0000218,
10044,,Intermediate,,50597,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",CHEMBL631268,N,1,,,,,1,,BAO_0000218,
10045,,Intermediate,,50597,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",CHEMBL631269,N,1,,,,,1,,BAO_0000218,
10046,,Intermediate,,50597,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",CHEMBL631270,N,1,,,,,1,,BAO_0000218,
10047,948.0,Intermediate,Heart,50597,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",CHEMBL631271,N,1,,,,,1,,BAO_0000218,
10048,948.0,Intermediate,Heart,50597,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",CHEMBL631272,N,1,,,,,1,,BAO_0000218,
10049,948.0,Intermediate,Heart,50597,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",CHEMBL631273,N,1,,,,,1,,BAO_0000218,
10050,948.0,Intermediate,Heart,50597,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",CHEMBL631274,N,1,,,,,1,,BAO_0000218,
10051,948.0,Intermediate,Heart,50597,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",CHEMBL631275,N,1,,,,,1,,BAO_0000218,
10052,948.0,Intermediate,Heart,50597,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",CHEMBL626984,N,1,,,,,1,,BAO_0000218,
10053,948.0,Intermediate,Heart,50597,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",CHEMBL626985,N,1,,,,,1,,BAO_0000218,
10054,2107.0,Intermediate,Liver,50597,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",CHEMBL626986,N,1,,,,,1,,BAO_0000218,
10055,2107.0,Intermediate,Liver,50597,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",CHEMBL626987,N,1,,,,,1,,BAO_0000218,
10056,2107.0,Intermediate,Liver,50597,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",CHEMBL626988,N,1,,,,,1,,BAO_0000218,
10057,2107.0,Intermediate,Liver,50597,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",CHEMBL626989,N,1,,,,,1,,BAO_0000218,
10058,2107.0,Intermediate,Liver,50597,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",CHEMBL626990,N,1,,,,,1,,BAO_0000218,
10059,2107.0,Intermediate,Liver,50597,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",CHEMBL626991,N,1,,,,,1,,BAO_0000218,
10060,2107.0,Intermediate,Liver,50597,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",CHEMBL626992,N,1,,,,,1,,BAO_0000218,
10061,2048.0,Intermediate,Lung,50597,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",CHEMBL626993,N,1,,,,,1,,BAO_0000218,
10062,2048.0,Intermediate,Lung,50597,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",CHEMBL874593,N,1,,,,,1,,BAO_0000218,
10063,2048.0,Intermediate,Lung,50597,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",CHEMBL626994,N,1,,,,,1,,BAO_0000218,
10064,2048.0,Intermediate,Lung,50597,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",CHEMBL626995,N,1,,,,,1,,BAO_0000218,
10065,2048.0,Intermediate,Lung,50597,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",CHEMBL626190,N,1,,,,,1,,BAO_0000218,
10066,2048.0,Intermediate,Lung,50597,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",CHEMBL626191,N,1,,,,,1,,BAO_0000218,
10067,2048.0,Intermediate,Lung,50597,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",CHEMBL626364,N,1,,,,,1,,BAO_0000218,
10068,2046.0,Intermediate,Thyroid gland,50597,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",CHEMBL626365,N,1,,,,,1,,BAO_0000218,
10069,2046.0,Intermediate,Thyroid gland,50597,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",CHEMBL626366,N,1,,,,,1,,BAO_0000218,
10070,2046.0,Intermediate,Thyroid gland,50597,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",CHEMBL626367,N,1,,,,,1,,BAO_0000218,
10071,2046.0,Intermediate,Thyroid gland,50597,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",CHEMBL626368,N,1,,,,,1,,BAO_0000218,
10072,2046.0,Intermediate,Thyroid gland,50597,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",CHEMBL626369,N,1,,,,,1,,BAO_0000218,
10073,2046.0,Intermediate,Thyroid gland,50597,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",CHEMBL626370,N,1,,,,,1,,BAO_0000218,
10074,,Intermediate,,50597,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",CHEMBL626371,N,1,,,,,1,,BAO_0000218,
10075,,Intermediate,,50597,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",CHEMBL626372,N,1,,,,,1,,BAO_0000218,
10076,,Intermediate,,50597,Bioavailability after a dose of 10 mg/kg p.o.,CHEMBL626373,N,1,,,,,1,,BAO_0000218,
10077,,Intermediate,,50597,Bioavailability after peroral administration (10 mg/kg) was determined in rat,CHEMBL626374,N,1,,,,,1,,BAO_0000218,
10078,,Intermediate,,50597,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,CHEMBL626375,N,1,,,,,1,,BAO_0000218,
10079,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),CHEMBL626376,N,1,,,,,1,,BAO_0000218,
10080,,Intermediate,,50597,Bioavailability in rat po was determined,CHEMBL626377,N,1,,,,,1,,BAO_0000218,
10081,,Intermediate,,50597,Bioavailability of compound at 10 mg/kg in rat after oral administration,CHEMBL626378,N,1,,,,,1,,BAO_0000218,
10082,,Intermediate,,50597,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,CHEMBL626379,N,1,,,,,1,,BAO_0000218,
10083,,Intermediate,,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),CHEMBL626380,N,1,,,,,1,,BAO_0000218,
10084,,Intermediate,,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),CHEMBL626381,N,1,,,,,1,,BAO_0000218,
10085,,Intermediate,,50597,Bioavailability in rat,CHEMBL626382,N,1,,,,,1,,BAO_0000218,
10086,,Intermediate,,50597,Bioavailability in rat (Sprague-Dawley) (female),CHEMBL626383,N,1,,,,,1,,BAO_0000218,
10087,,Intermediate,,50597,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,CHEMBL874652,N,1,,,,,1,,BAO_0000218,
10088,,Intermediate,,50597,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),CHEMBL626384,N,1,,,,,1,,BAO_0000218,
10089,,Intermediate,,50597,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,CHEMBL626385,N,1,,,,,1,,BAO_0000218,
10090,,Intermediate,,50597,Bioavailability in rat at an oral dose of 2 mg/kg,CHEMBL626386,N,1,,,,,1,,BAO_0000218,
10091,,Intermediate,,50597,Bioavailability in rat,CHEMBL626387,N,1,,,,,1,,BAO_0000218,
10092,,Intermediate,,50597,Bioavailability in rat,CHEMBL626388,N,1,,,,,1,,BAO_0000218,
10093,,Intermediate,,50597,Bioavailability in rat,CHEMBL626389,N,1,,,,,1,,BAO_0000218,
10094,,Intermediate,,50597,Bioavailability in rat,CHEMBL626390,N,1,,,,,1,,BAO_0000218,
10095,,Intermediate,,50597,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,CHEMBL626391,N,1,,,,,1,,BAO_0000218,
10096,,Intermediate,,50597,Bioavailability in rat,CHEMBL626392,N,1,,,,,1,,BAO_0000218,
10097,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL626393,N,1,,,,,1,,BAO_0000218,
10098,,Intermediate,,50597,Bioavailability was determined in rat,CHEMBL623026,N,1,,,,,1,,BAO_0000218,
10099,,Intermediate,,50597,Bioavailability,CHEMBL623027,N,1,,,,,1,,BAO_0000218,
10100,,Intermediate,,50597,Bioavailability,CHEMBL623028,N,1,,,,,1,,BAO_0000218,
10101,,Intermediate,,50597,Bioavailability in rat after 1 day dosing,CHEMBL623029,N,1,,,,,1,,BAO_0000218,
10102,,Intermediate,,50597,Bioavailability in rat after 4 day dosing,CHEMBL623030,N,1,,,,,1,,BAO_0000218,
10103,,Intermediate,,50597,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,CHEMBL623031,N,1,,,,,1,,BAO_0000218,
10104,,Intermediate,,50597,Bioavailability after IV dosing at 1 mg/kg in rat; no data,CHEMBL623032,N,1,,,,,1,,BAO_0000218,
10105,,Intermediate,,50597,Bioavailability after oral administration at a dose of 2 mg/kg in rat,CHEMBL623033,N,1,,,,,1,,BAO_0000218,
10106,,Intermediate,,50597,Bioavailability after oral administration at a dose of 4 mg/kg in rat,CHEMBL623034,N,1,,,,,1,,BAO_0000218,
10107,,Intermediate,,50597,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,CHEMBL623035,N,1,,,,,1,,BAO_0000218,
10108,,Intermediate,,50597,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,CHEMBL623036,N,1,,,,,1,,BAO_0000218,
10109,,Intermediate,,50597,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),CHEMBL623037,N,1,,,,,1,,BAO_0000218,
10110,,Intermediate,,50597,Bioavailability by intravenous administration of 3.4 mg/kg in rat,CHEMBL623038,N,1,,,,,1,,BAO_0000218,
10111,1969.0,Intermediate,Plasma,50597,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,CHEMBL874385,N,1,,,,,1,,BAO_0000218,
10112,,Intermediate,,50597,Bioavailability in rat (Fisher) (fasted),CHEMBL623039,N,1,,,,,1,,BAO_0000218,
10113,,Intermediate,,22224,Bioavailability in monkey after po administration of 10 mg/kg dose,CHEMBL623040,U,0,,,,,1,,BAO_0000218,
10114,,Intermediate,,22224,Oral bioavailability in monkey (dose 10 mg/kg),CHEMBL623041,U,0,,,,,1,,BAO_0000218,
10115,,Intermediate,,50597,Bioavailability in rat,CHEMBL623741,N,1,,,,,1,,BAO_0000218,
10116,,Intermediate,,50597,Bioavailability in rat,CHEMBL623742,N,1,,,,,1,,BAO_0000218,
10117,,Intermediate,,50597,Bioavailability in rat,CHEMBL623743,N,1,,,,,1,,BAO_0000218,
10118,,Intermediate,,50597,Bioavailability in rat,CHEMBL623744,N,1,,,,,1,,BAO_0000218,
10119,,Intermediate,,50597,Bioavailability in rat (dose 2.0 mg/kg p.o.),CHEMBL623745,N,1,,,,,1,,BAO_0000218,
10120,,Intermediate,,50597,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),CHEMBL623746,N,1,,,,,1,,BAO_0000218,
10121,,Intermediate,,50597,Oral bioavailability in rat (dose 5 mg/kg p.o.),CHEMBL623747,N,1,,,,,1,,BAO_0000218,
10122,,Intermediate,,22224,Bioavailability in rat after po administration of 30 mg/kg dose,CHEMBL623748,U,0,,,,,1,,BAO_0000218,
10123,,Intermediate,,22224,Bioavailability in rat after po administration of 30 mg/kg dose,CHEMBL623916,U,0,,,,,1,,BAO_0000218,
10124,,Intermediate,,50597,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,CHEMBL623917,N,1,,,,,1,,BAO_0000218,
10125,,Intermediate,,50597,Bioavailability in rat (dose 2 mg/kg i.v.),CHEMBL623918,N,1,,,,,1,,BAO_0000218,
10126,,Intermediate,,50597,Bioavailability in rat,CHEMBL874386,N,1,,,,,1,,BAO_0000218,
10127,1969.0,Intermediate,Plasma,50597,Bioavailability in rat; Only traces detected in rat plasma,CHEMBL623919,N,1,,,,,1,,BAO_0000218,
10128,,Intermediate,,50597,Bioavailability in rat,CHEMBL623920,N,1,,,,,1,,BAO_0000218,
10129,,Intermediate,,50597,Bioavailability upon oral administration of compound,CHEMBL623148,N,1,,,,,1,,BAO_0000218,
10130,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),CHEMBL623149,N,1,,,,,1,,BAO_0000218,
10131,,Intermediate,,50597,Bioavailability in rat,CHEMBL623150,N,1,,,,,1,,BAO_0000218,
10132,,Intermediate,,50597,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",CHEMBL623151,N,1,,,,,1,,BAO_0000218,
10133,,Intermediate,,50597,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",CHEMBL623152,N,1,,,,,1,,BAO_0000218,
10134,,Expert,,50597,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,CHEMBL623153,N,1,,,,,1,,BAO_0000218,
10135,,Expert,,50597,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,CHEMBL623154,N,1,,,,,1,,BAO_0000218,
10136,,Intermediate,,50597,In vitro and metabolic stability was determined,CHEMBL623155,N,1,,,,,1,,BAO_0000218,
10137,,Intermediate,,50597,In vitro metabolic stability in rat hepatocytes,CHEMBL623156,N,1,,,,,1,,BAO_0000218,
10138,,Intermediate,,50597,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,CHEMBL623157,N,1,,,,,1,,BAO_0000218,
10139,2107.0,Intermediate,Liver,50597,Metabolic rate for compound was observed in rat hepatocytes,CHEMBL623158,N,1,401.0,Hepatocyte,,,1,,BAO_0000218,
10140,,Intermediate,,50597,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,CHEMBL623159,N,1,,,,,1,,BAO_0000218,
10141,,Intermediate,,50597,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),CHEMBL874390,N,1,,,,,1,,BAO_0000218,
10142,,Intermediate,,50597,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),CHEMBL623160,N,1,,,,,1,,BAO_0000218,
10143,,Intermediate,,50597,Metabolism of compound in rat S9 microsomes; Trace,CHEMBL623161,N,1,,,,,1,,BAO_0000218,
10144,,Intermediate,,50597,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,CHEMBL623162,N,1,,,,,1,,BAO_0000218,
10145,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,CHEMBL623163,N,1,,,,,1,,BAO_0000218,
10146,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,CHEMBL623164,N,1,,,,,1,,BAO_0000218,
10147,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,CHEMBL623165,N,1,,,,,1,,BAO_0000218,
10148,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,CHEMBL623166,N,1,,,,,1,,BAO_0000218,
10149,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,CHEMBL624983,N,1,,,,,1,,BAO_0000218,
10150,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,CHEMBL624984,N,1,,,,,1,,BAO_0000218,
10151,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,CHEMBL624985,N,1,,,,,1,,BAO_0000218,
10152,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,CHEMBL622970,N,1,,,,,1,,BAO_0000218,
10153,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,CHEMBL622971,N,1,,,,,1,,BAO_0000218,
10154,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,CHEMBL622972,N,1,,,,,1,,BAO_0000218,
10155,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,CHEMBL622973,N,1,,,,,1,,BAO_0000218,
10156,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,CHEMBL622974,N,1,,,,,1,,BAO_0000218,
10157,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,CHEMBL622975,N,1,,,,,1,,BAO_0000218,
10158,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,CHEMBL622976,N,1,,,,,1,,BAO_0000218,
10159,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,CHEMBL622977,N,1,,,,,1,,BAO_0000218,
10160,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,CHEMBL624351,N,1,,,,,1,,BAO_0000218,
10161,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,CHEMBL624352,N,1,,,,,1,,BAO_0000218,
10162,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,CHEMBL624353,N,1,,,,,1,,BAO_0000218,
10163,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,CHEMBL622397,N,1,,,,,1,,BAO_0000218,
10164,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,CHEMBL622398,N,1,,,,,1,,BAO_0000218,
10165,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,CHEMBL622399,N,1,,,,,1,,BAO_0000218,
10166,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,CHEMBL622400,N,1,,,,,1,,BAO_0000218,
10167,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,CHEMBL628428,N,1,,,,,1,,BAO_0000218,
10168,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,CHEMBL628590,N,1,,,,,1,,BAO_0000218,
10169,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,CHEMBL628591,N,1,,,,,1,,BAO_0000218,
10170,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,CHEMBL628592,N,1,,,,,1,,BAO_0000218,
10171,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,CHEMBL628593,N,1,,,,,1,,BAO_0000218,
10172,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,CHEMBL875333,N,1,,,,,1,,BAO_0000218,
10173,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,CHEMBL628594,N,1,,,,,1,,BAO_0000218,
10174,1969.0,Intermediate,Plasma,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,CHEMBL628595,N,1,,,,,1,,BAO_0000218,
10175,1969.0,Intermediate,Plasma,50597,Stability in rat plasma was determined,CHEMBL628596,N,1,,,,,1,,BAO_0000218,
10176,1969.0,Intermediate,Plasma,50597,Stability in rat plasma was determined; ND= no data,CHEMBL628597,N,1,,,,,1,,BAO_0000218,
10177,1969.0,Intermediate,Plasma,50597,Tested for plasma half life period in rat (0-8 hr),CHEMBL628598,N,1,,,,,1,,BAO_0000218,
10178,1969.0,Intermediate,Plasma,50597,Tested for plasma half life period in rat (0-8 hr); Not determined,CHEMBL628599,N,1,,,,,1,,BAO_0000218,
10179,,Intermediate,,50597,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,CHEMBL628600,N,1,,,,,1,,BAO_0000218,
10180,,Intermediate,,50597,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,CHEMBL628601,N,1,,,,,1,,BAO_0000218,
10181,,Intermediate,,50597,Tested for the half life in rat,CHEMBL628602,N,1,,,,,1,,BAO_0000218,
10182,,Intermediate,,50597,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,CHEMBL628603,N,1,,,,,1,,BAO_0000218,
10183,,Intermediate,,50597,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,CHEMBL628604,N,1,,,,,1,,BAO_0000218,
10184,,Intermediate,,50597,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,CHEMBL628605,N,1,,,,,1,,BAO_0000218,
10185,,Intermediate,,50597,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,CHEMBL628606,N,1,,,,,1,,BAO_0000218,
10186,,Intermediate,,50597,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,CHEMBL628607,N,1,,,,,1,,BAO_0000218,
10187,,Intermediate,,50597,The biological half life the compound was measured at the dose of 100 umol/kg,CHEMBL628608,N,1,,,,,1,,BAO_0000218,
10188,,Intermediate,,50597,The biological half life the compound was measured at the dose of 30 umol/kg,CHEMBL628609,N,1,,,,,1,,BAO_0000218,
10189,1969.0,Intermediate,Plasma,50597,The compound was evaluated for plasma half life period in rat,CHEMBL628610,N,1,,,,,1,,BAO_0000218,
10190,,Intermediate,,50597,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL873819,N,1,,,,,1,,BAO_0000218,
10191,,Intermediate,,50597,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",CHEMBL628611,N,1,,,,,1,,BAO_0000218,
10192,,Intermediate,,50597,The pharmacokinetic parameter half-life period in vivo in rats,CHEMBL628612,N,1,,,,,1,,BAO_0000218,
10193,,Intermediate,,50597,"The pharmacokinetic property, Half-life was determined",CHEMBL628613,N,1,,,,,1,,BAO_0000218,
10194,,Intermediate,,50597,"The pharmacokinetic property, Half-life in rat in vivo",CHEMBL628614,N,1,,,,,1,,BAO_0000218,
10195,,Intermediate,,50597,"The pharmacokinetic property, Half-life was determined; ND denotes no data",CHEMBL628615,N,1,,,,,1,,BAO_0000218,
10196,,Intermediate,,50597,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",CHEMBL628616,N,1,,,,,1,,BAO_0000218,
10197,1969.0,Intermediate,Plasma,50597,The plasma half life period in rats,CHEMBL627924,N,1,,,,,1,,BAO_0000218,
10198,2107.0,Intermediate,Liver,50597,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,CHEMBL627925,N,1,,,,,1,,BAO_0000218,
10199,,Intermediate,,50597,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,CHEMBL627926,N,1,,,,,1,,BAO_0000218,
10200,,Intermediate,,50597,t1/2 (apparent elimination)of the compound was determined,CHEMBL627927,N,1,,,,,1,,BAO_0000218,
10201,,Intermediate,,50597,t1/2 value in rat,CHEMBL627928,N,1,,,,,1,,BAO_0000218,
10202,,Intermediate,,50597,Half life in rat,CHEMBL627539,N,1,,,,,1,,BAO_0000218,
10203,1969.0,Intermediate,Plasma,50597,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",CHEMBL876790,N,1,,,,,1,,BAO_0000218,
10204,,Intermediate,,50597,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,CHEMBL858186,N,1,,,,,1,,BAO_0000218,
10205,,Intermediate,,50597,Half-life period in fasted rats,CHEMBL627540,N,1,,,,,1,,BAO_0000218,
10206,,Intermediate,,50597,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,CHEMBL627541,N,1,,,,,1,,BAO_0000218,
10207,,Intermediate,,50597,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,CHEMBL627715,N,1,,,,,1,,BAO_0000218,
10208,,Intermediate,,50597,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,CHEMBL627716,N,1,,,,,1,,BAO_0000218,
10209,,Intermediate,,50597,Maximum time required to achieve Cmax was determined in rat,CHEMBL627717,N,1,,,,,1,,BAO_0000218,
10210,,Intermediate,,50597,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,CHEMBL627718,N,1,,,,,1,,BAO_0000218,
10211,,Intermediate,,50597,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,CHEMBL627719,N,1,,,,,1,,BAO_0000218,
10212,,Intermediate,,50597,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,CHEMBL627720,N,1,,,,,1,,BAO_0000218,
10213,,Intermediate,,50597,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,CHEMBL627721,N,1,,,,,1,,BAO_0000218,
10214,,Intermediate,,50597,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,CHEMBL627722,N,1,,,,,1,,BAO_0000218,
10215,,Intermediate,,50597,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL627723,N,1,,,,,1,,BAO_0000218,
10216,,Intermediate,,50597,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL626058,N,1,,,,,1,,BAO_0000218,
10217,,Intermediate,,50597,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL626059,N,1,,,,,1,,BAO_0000218,
10218,,Intermediate,,50597,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL626060,N,1,,,,,1,,BAO_0000218,
10219,1969.0,Intermediate,Plasma,50597,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL626061,N,1,,,,,1,,BAO_0000218,
10220,,Intermediate,,50597,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL876791,N,1,,,,,1,,BAO_0000218,
10221,,Intermediate,,50597,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,CHEMBL626062,N,1,,,,,1,,BAO_0000218,
10222,,Intermediate,,50597,Tmax at the dose of 2 mg/Kg administered perorally in rats,CHEMBL626063,N,1,,,,,1,,BAO_0000218,
10223,,Intermediate,,50597,Tmax at the dose of 5 mg/Kg administered perorally in rats,CHEMBL626064,N,1,,,,,1,,BAO_0000218,
10224,1969.0,Intermediate,Plasma,50597,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,CHEMBL626065,N,1,,,,,1,,BAO_0000218,
10225,1969.0,Intermediate,Plasma,50597,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,CHEMBL626066,N,1,,,,,1,,BAO_0000218,
10226,,Intermediate,,50597,tmax upon peroral administration of 10.0 mg/Kg dose in rat,CHEMBL626067,N,1,,,,,1,,BAO_0000218,
10227,,Intermediate,,50597,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,CHEMBL626068,N,1,,,,,1,,BAO_0000218,
10228,,Intermediate,,50597,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,CHEMBL626069,N,1,,,,,1,,BAO_0000218,
10229,,Intermediate,,50597,Percent total excretion of 3-methoxyacetaminophen glucuronide,CHEMBL626070,N,1,,,,,1,,BAO_0000218,
10230,,Intermediate,,50597,Percent total excretion of N-methoxyacetaminophen glucuronide,CHEMBL626071,N,1,,,,,1,,BAO_0000218,
10231,,Intermediate,,50597,Percent total excretion of N-methoxyacetaminophen sulfate,CHEMBL626072,N,1,,,,,1,,BAO_0000218,
10232,,Intermediate,,50597,Percent total excretion of acetaminophen,CHEMBL626073,N,1,,,,,1,,BAO_0000218,
10233,2046.0,Intermediate,Thyroid gland,50597,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",CHEMBL626741,N,1,,,,,1,,BAO_0000218,
10234,,Intermediate,,50597,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",CHEMBL626742,N,1,,,,,1,,BAO_0000218,
10235,,Intermediate,,50597,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,CHEMBL626743,N,1,,,,,1,,BAO_0000218,
10236,,Intermediate,,50597,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,CHEMBL876792,N,1,,,,,1,,BAO_0000218,
10237,,Intermediate,,50597,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,CHEMBL626744,N,1,,,,,1,,BAO_0000218,
10238,,Intermediate,,50597,Compound was tested for antidiuretic activity in rats,CHEMBL626745,N,1,,,,,1,,BAO_0000218,
10239,1969.0,Intermediate,Plasma,50597,AUC in rat after 3mg/kg oral dose,CHEMBL626746,N,1,,,,,1,,BAO_0000218,
10240,,Intermediate,,50597,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,CHEMBL626747,N,1,,,,,1,,BAO_0000218,
10241,,Intermediate,,50597,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,CHEMBL626748,N,1,,,,,1,,BAO_0000218,
10242,,Intermediate,,50597,Bioavailability administered orally at a dose of 10 mg/kg to rats,CHEMBL626749,N,1,,,,,1,,BAO_0000218,
10243,,Intermediate,,50597,Oral Bioavailability was determined,CHEMBL626750,N,1,,,,,1,,BAO_0000218,
10244,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL626751,N,1,,,,,1,,BAO_0000218,
10245,,Intermediate,,50597,Oral bioavailability in rat; Not performed.,CHEMBL626913,N,1,,,,,1,,BAO_0000218,
10246,,Intermediate,,50597,Bioavailability,CHEMBL626914,N,1,,,,,1,,BAO_0000218,
10247,,Intermediate,,50597,Bioavailability was determined; ND denotes no data,CHEMBL626915,N,1,,,,,1,,BAO_0000218,
10248,,Intermediate,,50597,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,CHEMBL626916,N,1,,,,,1,,BAO_0000218,
10249,,Intermediate,,50597,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,CHEMBL626917,N,1,,,,,1,,BAO_0000218,
10250,,Intermediate,,50597,Binding towards rat plasma protein at 10 uM,CHEMBL626918,N,1,,,,,1,,BAO_0000218,
10251,,Intermediate,,50597,Binding towards rat plasma protein at 100 uM,CHEMBL626919,N,1,,,,,1,,BAO_0000218,
10252,,Intermediate,,50597,Bioavailability in rat (dose 20 mg/kg p.o.),CHEMBL626920,N,1,,,,,1,,BAO_0000218,
10253,,Intermediate,,50597,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,CHEMBL621976,N,1,,,,,1,,BAO_0000218,
10254,,Intermediate,,50597,Bioavailability in rat after 5 mg/kg oral gavage,CHEMBL877599,N,1,,,,,1,,BAO_0000218,
10255,,Intermediate,,50597,Bioavailability in rat,CHEMBL621977,N,1,,,,,1,,BAO_0000218,
10256,,Intermediate,,50597,Bioavailability in rat (dose 1 mg/kg i.v.),CHEMBL621978,N,1,,,,,1,,BAO_0000218,
10257,,Intermediate,,50597,Bioavailability in rat (dose 3 mg/kg p.o.),CHEMBL621979,N,1,,,,,1,,BAO_0000218,
10258,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL621980,N,1,,,,,1,,BAO_0000218,
10259,,Intermediate,,50597,Bioavailability of the compound in rats after administration of 30 mg/kg,CHEMBL621981,N,1,,,,,1,,BAO_0000218,
10260,,Intermediate,,50597,Bioavailability after administration of 10 mg/kg in rats,CHEMBL621982,N,1,,,,,1,,BAO_0000218,
10261,,Intermediate,,50597,Bioavailability after administration of 2 mg/kg in rats,CHEMBL882953,N,1,,,,,1,,BAO_0000218,
10262,,Intermediate,,50597,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,CHEMBL621983,N,1,,,,,1,,BAO_0000218,
10263,,Intermediate,,50597,Bioavailability in dogs was determined; high,CHEMBL621984,N,1,,,,,1,,BAO_0000218,
10264,,Intermediate,,50597,Bioavailability in monkey after intravenous administration at 1 mpk,CHEMBL621985,N,1,,,,,1,,BAO_0000218,
10265,,Intermediate,,50597,Bioavailability in monkey after peroral administration at 10 mpk,CHEMBL621986,N,1,,,,,1,,BAO_0000218,
10266,,Intermediate,,50597,Bioavailability in rat after intravenous administration at 1 mpk,CHEMBL621987,N,1,,,,,1,,BAO_0000218,
10267,,Intermediate,,50597,Bioavailability in rat after intravenous administration at 2 mpk,CHEMBL877600,N,1,,,,,1,,BAO_0000218,
10268,,Intermediate,,50597,Bioavailability in rat after peroral administration at 30 mpk,CHEMBL621988,N,1,,,,,1,,BAO_0000218,
10269,,Intermediate,,50597,Bioavailability in rat after peroral administration at at 100 mpk,CHEMBL621989,N,1,,,,,1,,BAO_0000218,
10270,,Intermediate,,50597,Bioavailability in rats was evaluated,CHEMBL621990,N,1,,,,,1,,BAO_0000218,
10271,,Intermediate,,50597,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,CHEMBL621991,N,1,,,,,1,,BAO_0000218,
10272,,Intermediate,,50597,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,CHEMBL621992,N,1,,,,,1,,BAO_0000218,
10273,,Intermediate,,50597,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,CHEMBL621993,N,1,,,,,1,,BAO_0000218,
10274,,Intermediate,,50597,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,CHEMBL621994,N,1,,,,,1,,BAO_0000218,
10275,,Intermediate,,50597,Bioavailability in rat,CHEMBL621995,N,1,,,,,1,,BAO_0000218,
10276,,Intermediate,,50597,Bioavailability in rat,CHEMBL621996,N,1,,,,,1,,BAO_0000218,
10277,,Intermediate,,50597,Oral bioavailability in rat (dose 10 mg/kg),CHEMBL621997,N,1,,,,,1,,BAO_0000218,
10278,,Intermediate,,50597,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,CHEMBL621998,N,1,,,,,1,,BAO_0000218,
10279,,Intermediate,,50597,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,CHEMBL621999,N,1,,,,,1,,BAO_0000218,
10280,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622000,N,1,,,,,1,,BAO_0000218,
10281,,Intermediate,,50597,Bioavailability was measured in rat after oral administration; 2-4,CHEMBL622001,N,1,,,,,1,,BAO_0000218,
10282,,Intermediate,,50597,Bioavailability was measured in rat after oral administration; 3-7,CHEMBL622002,N,1,,,,,1,,BAO_0000218,
10283,,Intermediate,,50597,Bioavailability in rat (intraduodenal administration),CHEMBL622003,N,1,,,,,1,,BAO_0000218,
10284,,Intermediate,,50597,Bioavailability in rat (intraduodenal administration),CHEMBL877601,N,1,,,,,1,,BAO_0000218,
10285,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL624871,N,1,,,,,1,,BAO_0000218,
10286,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622004,N,1,,,,,1,,BAO_0000218,
10287,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),CHEMBL882954,N,1,,,,,1,,BAO_0000218,
10288,,Intermediate,,50597,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,CHEMBL622005,N,1,,,,,1,,BAO_0000218,
10289,,Intermediate,,50597,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,CHEMBL622006,N,1,,,,,1,,BAO_0000218,
10290,,Intermediate,,50597,Bioavailability was measured in rat,CHEMBL622007,N,1,,,,,1,,BAO_0000218,
10291,,Intermediate,,50597,Bioavailability was reported,CHEMBL622008,N,1,,,,,1,,BAO_0000218,
10292,,Intermediate,,50597,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),CHEMBL622009,N,1,,,,,1,,BAO_0000218,
10293,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),CHEMBL622010,N,1,,,,,1,,BAO_0000218,
10294,,Intermediate,,50597,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,CHEMBL622011,N,1,,,,,1,,BAO_0000218,
10295,,Intermediate,,50597,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),CHEMBL622012,N,1,,,,,1,,BAO_0000218,
10296,,Intermediate,,50597,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),CHEMBL622013,N,1,,,,,1,,BAO_0000218,
10297,,Intermediate,,50597,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,CHEMBL622014,N,1,,,,,1,,BAO_0000218,
10298,,Intermediate,,50597,Bioavailability was determined at 3 mg/kg po dose in rats,CHEMBL624749,N,1,,,,,1,,BAO_0000218,
10299,,Intermediate,,50597,Oral bioavailability in rat (dose 2 mg/kg),CHEMBL624750,N,1,,,,,1,,BAO_0000218,
10300,,Intermediate,,50597,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",CHEMBL624751,N,1,,,,,1,,BAO_0000218,
10301,,Intermediate,,50597,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",CHEMBL624752,N,1,,,,,1,,BAO_0000218,
10302,,Intermediate,,50597,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",CHEMBL624753,N,1,,,,,1,,BAO_0000218,
10303,,Intermediate,,50597,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,CHEMBL624754,N,1,,,,,1,,BAO_0000218,
10304,,Intermediate,,50597,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,CHEMBL624755,N,1,,,,,1,,BAO_0000218,
10305,,Intermediate,,50597,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,CHEMBL624756,N,1,,,,,1,,BAO_0000218,
10306,,Intermediate,,50597,Bioavailability in rat,CHEMBL624757,N,1,,,,,1,,BAO_0000218,
10307,,Intermediate,,50597,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,CHEMBL624758,N,1,,,,,1,,BAO_0000218,
10308,,Intermediate,,50597,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,CHEMBL622270,N,1,,,,,1,,BAO_0000218,
10309,,Intermediate,,50597,Bioavailability in rat (Sprague-Dawley),CHEMBL622271,N,1,,,,,1,,BAO_0000218,
10310,,Intermediate,,50597,Bioavailability in rat at the dose of 2 mg/kg,CHEMBL622272,N,1,,,,,1,,BAO_0000218,
10311,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622273,N,1,,,,,1,,BAO_0000218,
10312,,Intermediate,,50597,Bioavailability in rat (cannulated) (dose 2 mg/kg),CHEMBL622274,N,1,,,,,1,,BAO_0000218,
10313,,Intermediate,,50597,Bioavailability value of compound in rats was determined after peroral administration,CHEMBL622275,N,1,,,,,1,,BAO_0000218,
10314,,Intermediate,,50597,Oral bioavailability in rat (dose 20 mg/kg),CHEMBL622276,N,1,,,,,1,,BAO_0000218,
10315,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622277,N,1,,,,,1,,BAO_0000218,
10316,,Intermediate,,50597,Oral bioavailability in rat (dose 5 mg/kg),CHEMBL622278,N,1,,,,,1,,BAO_0000218,
10317,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622279,N,1,,,,,1,,BAO_0000218,
10318,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622280,N,1,,,,,1,,BAO_0000218,
10319,,Intermediate,,50597,Compound was evaluated for oral bioavailability in rats; 15-27 %,CHEMBL624083,N,1,,,,,1,,BAO_0000218,
10320,,Intermediate,,50597,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,CHEMBL624084,N,1,,,,,1,,BAO_0000218,
10321,,Intermediate,,50597,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),CHEMBL624085,N,1,,,,,1,,BAO_0000218,
10322,,Intermediate,,50597,Compound was tested for bioavailability in rats,CHEMBL624086,N,1,,,,,1,,BAO_0000218,
10323,,Intermediate,,50597,Bioavailability in rat,CHEMBL624087,N,1,,,,,1,,BAO_0000218,
10324,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL624088,N,1,,,,,1,,BAO_0000218,
10325,,Intermediate,,22224,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,CHEMBL624089,U,0,,,,,1,,BAO_0000218,
10326,,Intermediate,,22224,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),CHEMBL624090,U,0,,,,,1,,BAO_0000218,
10327,,Intermediate,,50597,Evaluated for the bioavailability in rat (in vivo),CHEMBL624091,N,1,,,,,1,,BAO_0000218,
10328,,Intermediate,,50597,F value of compound in rats was determined after peroral administration,CHEMBL624092,N,1,,,,,1,,BAO_0000218,
10329,,Intermediate,,50597,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,CHEMBL624093,N,1,,,,,1,,BAO_0000218,
10330,,Intermediate,,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,CHEMBL624094,N,1,,,,,1,,BAO_0000218,
10331,,Intermediate,,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,CHEMBL624095,N,1,,,,,1,,BAO_0000218,
10332,,Intermediate,,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,CHEMBL624096,N,1,,,,,1,,BAO_0000218,
10333,,Intermediate,,50597,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",CHEMBL624097,N,1,,,,,1,,BAO_0000218,
10334,,Intermediate,,50597,Maximum fall in carotid flow in rat,CHEMBL624098,N,1,,,,,1,,BAO_0000218,
10335,,Intermediate,,50597,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,CHEMBL874392,N,1,,,,,1,,BAO_0000218,
10336,,Intermediate,,50597,Oral bioavailability in rat (dose 5 mg/kg),CHEMBL624099,N,1,,,,,1,,BAO_0000218,
10337,,Intermediate,,50597,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,CHEMBL624100,N,1,,,,,1,,BAO_0000218,
10338,,Intermediate,,50597,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,CHEMBL624101,N,1,,,,,1,,BAO_0000218,
10339,,Intermediate,,50597,Oral bioavailability in rat (male Wistar),CHEMBL624102,N,1,,,,,1,,BAO_0000218,
10340,,Intermediate,,50597,Oral bioavailability after administration (30 mg/kg) in rat; good,CHEMBL624103,N,1,,,,,1,,BAO_0000218,
10341,,Intermediate,,50597,Oral bioavailability at the dose of 2 mg/kg in rat,CHEMBL624104,N,1,,,,,1,,BAO_0000218,
10342,,Intermediate,,50597,Oral bioavailability determined in rats,CHEMBL624105,N,1,,,,,1,,BAO_0000218,
10343,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),CHEMBL624106,N,1,,,,,1,,BAO_0000218,
10344,,Intermediate,,50597,Oral bioavailability in rat (dose single 10 mg/kg),CHEMBL624107,N,1,,,,,1,,BAO_0000218,
10345,,Intermediate,,50597,Oral bioavailability in rat (dose single 10 mg/kg),CHEMBL623943,N,1,,,,,1,,BAO_0000218,
10346,,Intermediate,,50597,Oral bioavailability in rat (dose 5 mg/kg,CHEMBL623944,N,1,,,,,1,,BAO_0000218,
10347,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,CHEMBL623945,N,1,,,,,1,,BAO_0000218,
10348,,Intermediate,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,CHEMBL623946,N,1,,,,,1,,BAO_0000218,
10349,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,CHEMBL623947,N,1,,,,,1,,BAO_0000218,
10350,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,CHEMBL623948,N,1,,,,,1,,BAO_0000218,
10351,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,CHEMBL623949,N,1,,,,,1,,BAO_0000218,
10352,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,CHEMBL623950,N,1,,,,,1,,BAO_0000218,
10353,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,CHEMBL874398,N,1,,,,,1,,BAO_0000218,
10354,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,CHEMBL623951,N,1,,,,,1,,BAO_0000218,
10355,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,CHEMBL623952,N,1,,,,,1,,BAO_0000218,
10356,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,CHEMBL623953,N,1,,,,,1,,BAO_0000218,
10357,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,CHEMBL623954,N,1,,,,,1,,BAO_0000218,
10358,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,CHEMBL623955,N,1,,,,,1,,BAO_0000218,
10359,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,CHEMBL623956,N,1,,,,,1,,BAO_0000218,
10360,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,CHEMBL627807,N,1,,,,,1,,BAO_0000218,
10361,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,CHEMBL627808,N,1,,,,,1,,BAO_0000218,
10362,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,CHEMBL627809,N,1,,,,,1,,BAO_0000218,
10363,,Intermediate,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,CHEMBL627810,N,1,,,,,1,,BAO_0000218,
10364,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",CHEMBL627811,N,1,,,,,1,,BAO_0000218,
10365,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",CHEMBL627812,N,1,,,,,1,,BAO_0000218,
10366,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",CHEMBL627813,N,1,,,,,1,,BAO_0000218,
10367,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",CHEMBL627814,N,1,,,,,1,,BAO_0000218,
10368,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",CHEMBL875336,N,1,,,,,1,,BAO_0000218,
10369,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",CHEMBL627815,N,1,,,,,1,,BAO_0000218,
10370,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",CHEMBL627816,N,1,,,,,1,,BAO_0000218,
10371,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",CHEMBL627817,N,1,,,,,1,,BAO_0000218,
10372,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",CHEMBL627818,N,1,,,,,1,,BAO_0000218,
10373,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",CHEMBL627819,N,1,,,,,1,,BAO_0000218,
10374,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",CHEMBL627820,N,1,,,,,1,,BAO_0000218,
10375,,Intermediate,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",CHEMBL627821,N,1,,,,,1,,BAO_0000218,
10376,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,CHEMBL628464,N,1,,,,,1,,BAO_0000218,
10377,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,CHEMBL626239,N,1,,,,,1,,BAO_0000218,
10378,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,CHEMBL626240,N,1,,,,,1,,BAO_0000218,
10379,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,CHEMBL626241,N,1,,,,,1,,BAO_0000218,
10380,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,CHEMBL626242,N,1,,,,,1,,BAO_0000218,
10381,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,CHEMBL626243,N,1,,,,,1,,BAO_0000218,
10382,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,CHEMBL626244,N,1,,,,,1,,BAO_0000218,
10383,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,CHEMBL626907,N,1,,,,,1,,BAO_0000218,
10384,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,CHEMBL626908,N,1,,,,,1,,BAO_0000218,
10385,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,CHEMBL626909,N,1,,,,,1,,BAO_0000218,
10386,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,CHEMBL626910,N,1,,,,,1,,BAO_0000218,
10387,,Intermediate,,50597,Percent total excretion of acetaminophen cysteine conjugate,CHEMBL875342,N,1,,,,,1,,BAO_0000218,
10388,,Intermediate,,50597,Percent total excretion of acetaminophen glucuronide,CHEMBL626911,N,1,,,,,1,,BAO_0000218,
10389,,Intermediate,,50597,Percent total excretion of acetaminophen sulfate,CHEMBL626912,N,1,,,,,1,,BAO_0000218,
10390,,Intermediate,,50597,Percent total excretion of acetaminophen-mercapturic acid,CHEMBL627065,N,1,,,,,1,,BAO_0000218,
10391,1088.0,Intermediate,Urine,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,CHEMBL627066,N,1,,,,,1,,BAO_0000218,
10392,,Intermediate,,50597,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,CHEMBL627067,N,1,,,,,1,,BAO_0000218,
10393,2385.0,Autocuration,Muscle tissue,22224,Biodistribution of compound in rat muscle after 5 min of administration,CHEMBL627068,U,0,,,,,1,,BAO_0000218,
10394,2385.0,Autocuration,Muscle tissue,22224,Biodistribution of compound in rat muscle after 5 min of administration.,CHEMBL627069,U,0,,,,,1,,BAO_0000218,
10395,,Autocuration,,22224,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),CHEMBL627070,U,0,,,,,1,,BAO_0000218,
10396,,Autocuration,,22224,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),CHEMBL627071,U,0,,,,,1,,BAO_0000218,
10397,,Autocuration,,22224,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),CHEMBL627072,U,0,,,,,1,,BAO_0000218,
10398,,Autocuration,,22224,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),CHEMBL627073,U,0,,,,,1,,BAO_0000218,
10399,,Autocuration,,22224,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),CHEMBL625387,U,0,,,,,1,,BAO_0000218,
10400,,Autocuration,,22224,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),CHEMBL625388,U,0,,,,,1,,BAO_0000218,
10401,1969.0,Autocuration,Plasma,22224,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),CHEMBL625389,U,0,,,,,1,,BAO_0000218,
10402,1969.0,Autocuration,Plasma,22224,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),CHEMBL875343,U,0,,,,,1,,BAO_0000218,
10403,,Intermediate,,50497,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),CHEMBL876795,N,1,,,,,1,,BAO_0000218,
10404,,Intermediate,,50497,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,CHEMBL626552,N,1,,,,,1,,BAO_0000218,
10405,,Intermediate,,50497,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,CHEMBL626553,N,1,,,,,1,,BAO_0000218,
10406,1969.0,Autocuration,Plasma,22224,The human biological plasma half life of the compound,CHEMBL626554,U,0,,,,,1,,BAO_0000366,
10407,1088.0,Intermediate,Urine,50597,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,CHEMBL626555,N,1,,,,,1,,BAO_0000218,
10408,,Intermediate,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,CHEMBL626556,N,1,,,,,1,,BAO_0000218,
10409,,Intermediate,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,CHEMBL626557,N,1,,,,,1,,BAO_0000218,
10410,,Intermediate,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,CHEMBL626558,N,1,,,,,1,,BAO_0000218,
10411,,Intermediate,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,CHEMBL626559,N,1,,,,,1,,BAO_0000218,
10412,,Intermediate,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,CHEMBL626560,N,1,,,,,1,,BAO_0000218,
10413,,Intermediate,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,CHEMBL876803,N,1,,,,,1,,BAO_0000218,
10414,,Intermediate,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,CHEMBL627964,N,1,,,,,1,,BAO_0000218,
10415,,Intermediate,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,CHEMBL627965,N,1,,,,,1,,BAO_0000218,
10416,,Intermediate,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,CHEMBL627966,N,1,,,,,1,,BAO_0000218,
10417,,Intermediate,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,CHEMBL627967,N,1,,,,,1,,BAO_0000218,
10418,,Intermediate,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,CHEMBL627968,N,1,,,,,1,,BAO_0000218,
10419,,Intermediate,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,CHEMBL627969,N,1,,,,,1,,BAO_0000218,
10420,,Intermediate,,50597,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,CHEMBL627970,N,1,,,,,1,,BAO_0000218,
10421,178.0,Intermediate,Blood,50597,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,CHEMBL627971,N,1,,,,,1,,BAO_0000218,
10422,178.0,Intermediate,Blood,50597,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,CHEMBL627972,N,1,,,,,1,,BAO_0000218,
10423,,Expert,,180,Dissociation constant against binding to human cyclophilin A,CHEMBL856029,D,9,,,,,1,,BAO_0000357,
10424,,Expert,,11591,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,CHEMBL627973,H,8,,,,,1,,BAO_0000019,
10425,,Autocuration,,22224,-Log C was determined by performing the electroshock minimum test,CHEMBL627974,U,0,,,,,1,,BAO_0000019,
10426,,Autocuration,,22224,-Log C was determined by performing the foot shock test,CHEMBL627975,U,0,,,,,1,,BAO_0000019,
10427,,Autocuration,,22224,-Log C was determined by performing the incl screen test,CHEMBL627976,U,0,,,,,1,,BAO_0000019,
10428,,Autocuration,,22224,-Log C was determined by performing the maximum electroshock test,CHEMBL627977,U,0,,,,,1,,BAO_0000019,
10429,,Autocuration,,22224,-Log C was determined by performing the pentylenetetrazole test,CHEMBL627978,U,0,,,,,1,,BAO_0000019,
10430,,Autocuration,,22224,Tested for experimental arotinoid inhibitory dose,CHEMBL627979,U,0,,,,,1,,BAO_0000019,
10431,,Autocuration,,22224,Negative log transformed activity,CHEMBL876804,U,0,,,,,1,,BAO_0000019,
10432,,Autocuration,,22224,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",CHEMBL627980,U,0,,,,,1,,BAO_0000019,
10433,,Intermediate,,50512,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,CHEMBL627981,N,1,,,,,1,,BAO_0000218,
10434,,Intermediate,,50512,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,CHEMBL627982,N,1,,,,,1,,BAO_0000218,
10435,,Intermediate,,50512,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,CHEMBL627983,N,1,,,,,1,,BAO_0000218,
10436,2116.0,Intermediate,Ileum,50512,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,CHEMBL627984,N,1,,,,,1,,BAO_0000218,
10437,,Autocuration,,22229,Solubility in water was determined; values expressed as -log,CHEMBL627985,U,0,,,,,1,,BAO_0000100,
10438,,Autocuration,,22224,Ratio of Kcat to that of Km was determined,CHEMBL627986,U,0,,,,,1,,BAO_0000019,
10439,,Autocuration,,22224,Observed first order rate constant,CHEMBL627987,U,0,,,,,1,,BAO_0000019,
10440,,Autocuration,,22224,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,CHEMBL627988,U,0,,,,,1,,BAO_0000019,
10441,,Intermediate,,50597,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,CHEMBL627989,N,1,,,,,1,,BAO_0000218,
10442,,Intermediate,,50597,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,CHEMBL627990,N,1,,,,,1,,BAO_0000218,
10443,,Intermediate,,50597,Oral Bioavailability after administration of 10 mg/kg in male rat,CHEMBL876805,N,1,,,,,1,,BAO_0000218,
10444,,Intermediate,,50597,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),CHEMBL627991,N,1,,,,,1,,BAO_0000218,
10445,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL627992,N,1,,,,,1,,BAO_0000218,
10446,,Intermediate,,50597,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,CHEMBL627993,N,1,,,,,1,,BAO_0000218,
10447,,Intermediate,,50597,Oral bioavailability at 1 mg/kg was determined in rat,CHEMBL622817,N,1,,,,,1,,BAO_0000218,
10448,,Intermediate,,50597,Oral bioavailability at 10 mg/kg was determined in rat,CHEMBL622818,N,1,,,,,1,,BAO_0000218,
10449,,Intermediate,,50597,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",CHEMBL622819,N,1,,,,,1,,BAO_0000218,
10450,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL872267,N,1,,,,,1,,BAO_0000218,
10451,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622820,N,1,,,,,1,,BAO_0000218,
10452,,Intermediate,,50597,Oral bioavailability after intravenous administration in rats at 24 uM/kg,CHEMBL622821,N,1,,,,,1,,BAO_0000218,
10453,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622822,N,1,,,,,1,,BAO_0000218,
10454,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622823,N,1,,,,,1,,BAO_0000218,
10455,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622824,N,1,,,,,1,,BAO_0000218,
10456,,Intermediate,,50597,Oral bioavailability in rat at a dose of 3 mg/kg,CHEMBL622825,N,1,,,,,1,,BAO_0000218,
10457,,Intermediate,,50597,Oral bioavailability in rat after oral administration at 10 mg/kg,CHEMBL622901,N,1,,,,,1,,BAO_0000218,
10458,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622902,N,1,,,,,1,,BAO_0000218,
10459,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL621844,N,1,,,,,1,,BAO_0000218,
10460,,Intermediate,,50597,Oral bioavailability in Dawley rats,CHEMBL621845,N,1,,,,,1,,BAO_0000218,
10461,,Intermediate,,50597,Oral bioavailability,CHEMBL621846,N,1,,,,,1,,BAO_0000218,
10462,,Intermediate,,50597,Oral bioavailability in rat (dose 30 mg/kg),CHEMBL621847,N,1,,,,,1,,BAO_0000218,
10463,,Intermediate,,50597,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,CHEMBL877609,N,1,,,,,1,,BAO_0000218,
10464,,Intermediate,,50597,Bioavailability in rat (dose 3 mg/kg i.v.),CHEMBL621848,N,1,,,,,1,,BAO_0000218,
10465,,Intermediate,,50597,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,CHEMBL621849,N,1,,,,,1,,BAO_0000218,
10466,,Intermediate,,50597,Oral bioavailability in rat (dose 60 mg/kg p.o.),CHEMBL622030,N,1,,,,,1,,BAO_0000218,
10467,,Intermediate,,50597,Percent oral bioavailability determined in rats,CHEMBL622031,N,1,,,,,1,,BAO_0000218,
10468,,Intermediate,,50597,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,CHEMBL622032,N,1,,,,,1,,BAO_0000218,
10469,,Intermediate,,50597,The compound was evaluated for bioavailability in rats; 32-51,CHEMBL622033,N,1,,,,,1,,BAO_0000218,
10470,,Intermediate,,50597,Bioavailability in rat (dose 20 mg/kg p.o.),CHEMBL622034,N,1,,,,,1,,BAO_0000218,
10471,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622035,N,1,,,,,1,,BAO_0000218,
10472,,Intermediate,,50597,Bioavailability percent in rat at the dose of 2 mg/kg,CHEMBL882966,N,1,,,,,1,,BAO_0000218,
10473,,Intermediate,,50597,Bioavailability was evaluated after 20 uM/kg of peroral administration,CHEMBL622036,N,1,,,,,1,,BAO_0000218,
10474,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622037,N,1,,,,,1,,BAO_0000218,
10475,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622038,N,1,,,,,1,,BAO_0000218,
10476,,Intermediate,,50597,Bioavailability in rats,CHEMBL622039,N,1,,,,,1,,BAO_0000218,
10477,178.0,Intermediate,Blood,50597,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,CHEMBL622040,N,1,,,,,1,,BAO_0000218,
10478,178.0,Intermediate,Blood,50597,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,CHEMBL622041,N,1,,,,,1,,BAO_0000218,
10479,178.0,Intermediate,Blood,50597,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,CHEMBL622042,N,1,,,,,1,,BAO_0000218,
10480,178.0,Intermediate,Blood,50597,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,CHEMBL622043,N,1,,,,,1,,BAO_0000218,
10481,178.0,Intermediate,Blood,50597,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,CHEMBL622044,N,1,,,,,1,,BAO_0000218,
10482,10000001.0,Intermediate,Bone,50597,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,CHEMBL622045,N,1,,,,,1,,BAO_0000218,
10483,10000001.0,Intermediate,Bone,50597,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,CHEMBL622046,N,1,,,,,1,,BAO_0000218,
10484,10000001.0,Intermediate,Bone,50597,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,CHEMBL622047,N,1,,,,,1,,BAO_0000218,
10485,10000001.0,Intermediate,Bone,50597,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,CHEMBL877610,N,1,,,,,1,,BAO_0000218,
10486,955.0,Intermediate,Brain,50597,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,CHEMBL622048,N,1,,,,,1,,BAO_0000218,
10487,955.0,Intermediate,Brain,50597,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,CHEMBL622049,N,1,,,,,1,,BAO_0000218,
10488,955.0,Intermediate,Brain,50597,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,CHEMBL622050,N,1,,,,,1,,BAO_0000218,
10489,955.0,Intermediate,Brain,50597,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,CHEMBL622051,N,1,,,,,1,,BAO_0000218,
10490,,Intermediate,,50597,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,CHEMBL622052,N,1,,,,,1,,BAO_0000218,
10491,,Intermediate,,50597,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,CHEMBL622053,N,1,,,,,1,,BAO_0000218,
10492,,Intermediate,,50597,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,CHEMBL622054,N,1,,,,,1,,BAO_0000218,
10493,,Intermediate,,50597,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,CHEMBL622055,N,1,,,,,1,,BAO_0000218,
10494,,Intermediate,,50597,Oral bioavailability in rats was determined; High,CHEMBL622056,N,1,,,,,1,,BAO_0000218,
10495,,Intermediate,,50597,Oral bioavailability in the rat was determined,CHEMBL622057,N,1,,,,,1,,BAO_0000218,
10496,,Intermediate,,50597,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,CHEMBL628008,N,1,,,,,1,,BAO_0000218,
10497,,Intermediate,,50597,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),CHEMBL622058,N,1,,,,,1,,BAO_0000218,
10498,,Intermediate,,50597,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL622059,N,1,,,,,1,,BAO_0000218,
10499,,Intermediate,,50597,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL622060,N,1,,,,,1,,BAO_0000218,
10500,,Intermediate,,50597,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL622061,N,1,,,,,1,,BAO_0000218,
10501,,Intermediate,,50597,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,CHEMBL622062,N,1,,,,,1,,BAO_0000218,
10502,,Intermediate,,50597,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,CHEMBL622063,N,1,,,,,1,,BAO_0000218,
10503,,Expert,,50597,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,CHEMBL877611,N,1,,,,,1,,BAO_0000218,
10504,,Intermediate,,50597,Oral bioavailability of compound in Sprague Dawley rats,CHEMBL622064,N,1,,,,,1,,BAO_0000218,
10505,,Intermediate,,50597,Oral bioavailability of compound in rat,CHEMBL622065,N,1,,,,,1,,BAO_0000218,
10506,,Intermediate,,50597,Oral bioavailability in rat (dose 2 mg/kg),CHEMBL622066,N,1,,,,,1,,BAO_0000218,
10507,,Intermediate,,50597,Oral bioavailability of compound in rat was determined,CHEMBL622067,N,1,,,,,1,,BAO_0000218,
10508,,Intermediate,,50597,Oral bioavailability of compound in rats,CHEMBL622068,N,1,,,,,1,,BAO_0000218,
10509,,Intermediate,,50597,Oral bioavailability of compound was determined in rats,CHEMBL622069,N,1,,,,,1,,BAO_0000218,
10510,,Intermediate,,50597,Oral bioavailability at a dose of 30 mg/kg in rats,CHEMBL624796,N,1,,,,,1,,BAO_0000218,
10511,,Intermediate,,50597,Oral bioavailability in rat (dose 10 mg/kg),CHEMBL624797,N,1,,,,,1,,BAO_0000218,
10512,,Intermediate,,50597,Oral bioavailability in rat (dose 10 mg/kg),CHEMBL623053,N,1,,,,,1,,BAO_0000218,
10513,,Intermediate,,50597,Oral bioavailability evaluated in rat,CHEMBL623054,N,1,,,,,1,,BAO_0000218,
10514,,Intermediate,,50597,Oral bioavailability in fasted rat,CHEMBL623055,N,1,,,,,1,,BAO_0000218,
10515,,Intermediate,,50597,Oral bioavailability in fed rat,CHEMBL623056,N,1,,,,,1,,BAO_0000218,
10516,,Intermediate,,50597,Oral bioavailability in rat (mature male) (dose 30 mg/kg),CHEMBL623057,N,1,,,,,1,,BAO_0000218,
10517,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623058,N,1,,,,,1,,BAO_0000218,
10518,,Intermediate,,50597,Oral bioavailability in rat (dose 10 mg/kg p.o.),CHEMBL623059,N,1,,,,,1,,BAO_0000218,
10519,,Intermediate,,50597,Oral bioavailability in rat after administration of 10 mg/kg po,CHEMBL623060,N,1,,,,,1,,BAO_0000218,
10520,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623061,N,1,,,,,1,,BAO_0000218,
10521,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623062,N,1,,,,,1,,BAO_0000218,
10522,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623063,N,1,,,,,1,,BAO_0000218,
10523,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623064,N,1,,,,,1,,BAO_0000218,
10524,,Intermediate,,50597,Oral bioavailability in ratrs,CHEMBL623065,N,1,,,,,1,,BAO_0000218,
10525,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623066,N,1,,,,,1,,BAO_0000218,
10526,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623067,N,1,,,,,1,,BAO_0000218,
10527,,Intermediate,,50597,Oral bioavailability in rats was determined; High,CHEMBL623068,N,1,,,,,1,,BAO_0000218,
10528,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623069,N,1,,,,,1,,BAO_0000218,
10529,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623070,N,1,,,,,1,,BAO_0000218,
10530,,Intermediate,,50597,Oral bioavailability was calculated in rat,CHEMBL623071,N,1,,,,,1,,BAO_0000218,
10531,,Intermediate,,50597,Oral bioavailability,CHEMBL623072,N,1,,,,,1,,BAO_0000218,
10532,,Intermediate,,50597,Oral bioavailability,CHEMBL623073,N,1,,,,,1,,BAO_0000218,
10533,,Intermediate,,50597,Oral bioavailability,CHEMBL623074,N,1,,,,,1,,BAO_0000218,
10534,,Intermediate,,50597,Oral bioavailability,CHEMBL623075,N,1,,,,,1,,BAO_0000218,
10535,,Intermediate,,50597,Oral bioavailability after i.v. administration,CHEMBL623076,N,1,,,,,1,,BAO_0000218,
10536,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),CHEMBL623077,N,1,,,,,1,,BAO_0000218,
10537,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley),CHEMBL623078,N,1,,,,,1,,BAO_0000218,
10538,,Intermediate,,50597,Oral bioavailability in Sprague-Dawley rats,CHEMBL623079,N,1,,,,,1,,BAO_0000218,
10539,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),CHEMBL623080,N,1,,,,,1,,BAO_0000218,
10540,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),CHEMBL623081,N,1,,,,,1,,BAO_0000218,
10541,,Intermediate,,50597,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,CHEMBL623082,N,1,,,,,1,,BAO_0000218,
10542,,Intermediate,,50597,Oral bioavailability in fasted rat,CHEMBL874400,N,1,,,,,1,,BAO_0000218,
10543,,Intermediate,,50597,Oral bioavailability in fed rat,CHEMBL623083,N,1,,,,,1,,BAO_0000218,
10544,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623084,N,1,,,,,1,,BAO_0000218,
10545,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623085,N,1,,,,,1,,BAO_0000218,
10546,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623086,N,1,,,,,1,,BAO_0000218,
10547,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623087,N,1,,,,,1,,BAO_0000218,
10548,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623088,N,1,,,,,1,,BAO_0000218,
10549,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623089,N,1,,,,,1,,BAO_0000218,
10550,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623090,N,1,,,,,1,,BAO_0000218,
10551,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623091,N,1,,,,,1,,BAO_0000218,
10552,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623092,N,1,,,,,1,,BAO_0000218,
10553,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623093,N,1,,,,,1,,BAO_0000218,
10554,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL874401,N,1,,,,,1,,BAO_0000218,
10555,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623094,N,1,,,,,1,,BAO_0000218,
10556,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL623095,N,1,,,,,1,,BAO_0000218,
10557,,Intermediate,,50597,Oral bioavailability in rat after peroral administration at 10 mg/kg,CHEMBL623096,N,1,,,,,1,,BAO_0000218,
10558,,Intermediate,,50597,Oral bioavailability in rat after peroral administration at 5 mg/kg,CHEMBL624913,N,1,,,,,1,,BAO_0000218,
10559,,Intermediate,,50597,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),CHEMBL624914,N,1,,,,,1,,BAO_0000218,
10560,,Intermediate,,50597,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,CHEMBL624915,N,1,,,,,1,,BAO_0000218,
10561,,Intermediate,,50597,Oral bioavailability in rat; Not measured,CHEMBL624916,N,1,,,,,1,,BAO_0000218,
10562,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL624917,N,1,,,,,1,,BAO_0000218,
10563,,Intermediate,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,CHEMBL625157,N,1,,,,,1,,BAO_0000218,
10564,2107.0,Intermediate,Liver,50597,In vitro metabolic potential in rat liver microsomes,CHEMBL625158,N,1,,,,,1,,BAO_0000218,
10565,,Intermediate,,50597,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",CHEMBL625159,N,1,,,,,1,,BAO_0000218,
10566,,Intermediate,,50597,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",CHEMBL625160,N,1,,,,,1,,BAO_0000218,
10567,,Intermediate,,50597,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,CHEMBL625161,N,1,,,,,1,,BAO_0000218,
10568,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL625162,N,1,,,,,1,,BAO_0000218,
10569,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL625163,N,1,,,,,1,,BAO_0000218,
10570,,Intermediate,,50597,Oral bioavailability in rats at 10 mg/kg,CHEMBL625164,N,1,,,,,1,,BAO_0000218,
10571,,Intermediate,,50597,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL625165,N,1,,,,,1,,BAO_0000218,
10572,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL625166,N,1,,,,,1,,BAO_0000218,
10573,,Intermediate,,50597,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,CHEMBL625167,N,1,,,,,1,,BAO_0000218,
10574,,Intermediate,,50597,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,CHEMBL625168,N,1,,,,,1,,BAO_0000218,
10575,,Intermediate,,50597,Plasma clearance of the compound,CHEMBL625169,N,1,,,,,1,,BAO_0000218,
10576,,Intermediate,,50597,Plasma clearance at 10 mg/kg in rat upon intravenous administration,CHEMBL626264,N,1,,,,,1,,BAO_0000218,
10577,,Intermediate,,50597,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,CHEMBL626265,N,1,,,,,1,,BAO_0000218,
10578,1969.0,Intermediate,Plasma,50597,The compound was tested for plasma clearance in rat,CHEMBL626266,N,1,,,,,1,,BAO_0000218,
10579,1969.0,Intermediate,Plasma,50597,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,CHEMBL626267,N,1,,,,,1,,BAO_0000218,
10580,,Intermediate,,50597,Plasma concentration upon oral administration of 1 mg/Kg in rats,CHEMBL626268,N,1,,,,,1,,BAO_0000218,
10581,,Intermediate,,50597,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,CHEMBL626269,N,1,,,,,1,,BAO_0000218,
10582,,Intermediate,,50597,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,CHEMBL626270,N,1,,,,,1,,BAO_0000218,
10583,,Intermediate,,50597,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,CHEMBL626271,N,1,,,,,1,,BAO_0000218,
10584,,Intermediate,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",CHEMBL626272,N,1,,,,,1,,BAO_0000218,
10585,,Intermediate,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",CHEMBL626273,N,1,,,,,1,,BAO_0000218,
10586,,Intermediate,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",CHEMBL875346,N,1,,,,,1,,BAO_0000218,
10587,,Intermediate,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",CHEMBL626274,N,1,,,,,1,,BAO_0000218,
10588,,Intermediate,,50597,Compound was tested for protein binding in rat plasma,CHEMBL626275,N,1,,,,,1,,BAO_0000218,
10589,,Intermediate,,50597,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,CHEMBL624646,N,1,,,,,1,,BAO_0000218,
10590,,Intermediate,,50597,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,CHEMBL624647,N,1,,,,,1,,BAO_0000218,
10591,2107.0,Intermediate,Liver,50597,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,CHEMBL624648,N,1,,,,,1,,BAO_0000218,
10592,,Intermediate,,50597,Area under curve ratio was determined (po/iv) in rat,CHEMBL624649,N,1,,,,,1,,BAO_0000218,
10593,,Intermediate,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,CHEMBL624650,N,1,,,,,1,,BAO_0000218,
10594,,Intermediate,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,CHEMBL624651,N,1,,,,,1,,BAO_0000218,
10595,,Intermediate,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,CHEMBL624652,N,1,,,,,1,,BAO_0000218,
10596,,Intermediate,,50597,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,CHEMBL624653,N,1,,,,,1,,BAO_0000218,
10597,,Intermediate,,50597,Ratio of AUCbrain to AUCplasma,CHEMBL624654,N,1,,,,,1,,BAO_0000218,
10598,,Intermediate,,50597,Ratio of brain to plasma,CHEMBL624655,N,1,,,,,1,,BAO_0000218,
10599,,Intermediate,,50597,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,CHEMBL624656,N,1,,,,,1,,BAO_0000218,
10600,,Intermediate,,50597,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,CHEMBL624657,N,1,,,,,1,,BAO_0000218,
10601,,Intermediate,,50597,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,CHEMBL624658,N,1,,,,,1,,BAO_0000218,
10602,,Intermediate,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,CHEMBL624659,N,1,,,,,1,,BAO_0000218,
10603,,Intermediate,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,CHEMBL624660,N,1,,,,,1,,BAO_0000218,
10604,,Intermediate,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,CHEMBL624661,N,1,,,,,1,,BAO_0000218,
10605,,Intermediate,,50597,Steady state brain :blood ratio was determined,CHEMBL624662,N,1,,,,,1,,BAO_0000218,
10606,,Intermediate,,50597,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL625199,N,1,,,,,1,,BAO_0000218,
10607,,Intermediate,,50597,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,CHEMBL625200,N,1,,,,,1,,BAO_0000218,
10608,,Intermediate,,50597,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,CHEMBL625201,N,1,,,,,1,,BAO_0000218,
10609,,Intermediate,,50597,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,CHEMBL625202,N,1,,,,,1,,BAO_0000218,
10610,,Intermediate,,50597,Percentage recovery after 3h incubation with rat hapatocytes was determined,CHEMBL625203,N,1,,,,,1,,BAO_0000218,
10611,,Intermediate,,50597,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,CHEMBL625204,N,1,,,,,1,,BAO_0000218,
10612,,Intermediate,,50597,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,CHEMBL625205,N,1,,,,,1,,BAO_0000218,
10613,,Intermediate,,50597,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,CHEMBL625206,N,1,,,,,1,,BAO_0000218,
10614,,Autocuration,,22224,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",CHEMBL625207,U,0,,,,,1,,BAO_0000019,
10615,,Autocuration,,22224,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,CHEMBL625208,U,0,,,,,1,,BAO_0000019,
10616,,Intermediate,,50587,In vivo absorption in Caco-2 cell line monolayers was determined,CHEMBL625209,N,1,495.0,Caco-2,,,1,,BAO_0000218,
10617,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625210,U,0,,,,,1,,BAO_0000100,
10618,,Intermediate,,50597,Area under curve was determine after peroral administration at 10 mpk in Rat,CHEMBL625211,N,1,,,,,1,,BAO_0000218,
10619,,Intermediate,,50797,Area under curve was determine after peroral administration at 10 mpk in Rhesus,CHEMBL625212,N,1,,,,,1,,BAO_0000218,
10620,,Intermediate,,50597,Area under curve was determine after peroral administration at 160 mpk in Rat,CHEMBL625213,N,1,,,,,1,,BAO_0000218,
10621,,Intermediate,,50597,Area under curve was determine after peroral administration at 20 mpk in Rat,CHEMBL625214,N,1,,,,,1,,BAO_0000218,
10622,,Intermediate,,50597,Area under curve was determine after peroral administration at 50 mpk in Rat,CHEMBL874542,N,1,,,,,1,,BAO_0000218,
10623,,Autocuration,,22229,Calculated partition coefficient (clogP) (AlogP),CHEMBL625215,U,0,,,,,1,,BAO_0000100,
10624,,Autocuration,,22224,Activated partial thromboplastin time measured,CHEMBL625216,U,0,,,,,1,,BAO_0000019,
10625,,Autocuration,,22224,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),CHEMBL625217,U,0,,,,,1,,BAO_0000100,
10626,,Autocuration,,22224,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),CHEMBL625218,U,0,,,,,1,,BAO_0000100,
10627,1969.0,Intermediate,Plasma,50588,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,CHEMBL622864,N,1,,,,,1,,BAO_0000218,
10628,1969.0,Intermediate,Plasma,50597,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,CHEMBL622865,N,1,,,,,1,,BAO_0000218,
10629,1969.0,Intermediate,Plasma,50597,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,CHEMBL622866,N,1,,,,,1,,BAO_0000218,
10630,1969.0,Intermediate,Plasma,50588,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,CHEMBL622867,N,1,,,,,1,,BAO_0000218,
10631,1969.0,Intermediate,Plasma,50512,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,CHEMBL876808,N,1,,,,,1,,BAO_0000218,
10632,955.0,Autocuration,Brain,22224,AUC in brain,CHEMBL627725,U,0,,,,,1,,BAO_0000019,
10633,1977.0,Autocuration,Serum,22224,AUC in serum,CHEMBL627726,U,0,,,,,1,,BAO_0000019,
10634,1969.0,Autocuration,Plasma,22224,AUC was determined,CHEMBL627727,U,0,,,,,1,,BAO_0000019,
10635,1969.0,Autocuration,Plasma,22224,AUC of the compound.,CHEMBL627728,U,0,,,,,1,,BAO_0000019,
10636,1969.0,Autocuration,Plasma,22224,AUC value (0-4 hr),CHEMBL627729,U,0,,,,,1,,BAO_0000019,
10637,1969.0,Autocuration,Plasma,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",CHEMBL627730,U,0,,,,,1,,BAO_0000019,
10638,1969.0,Autocuration,Plasma,22224,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,CHEMBL627731,U,0,,,,,1,,BAO_0000019,
10639,1969.0,Autocuration,Plasma,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",CHEMBL627732,U,0,,,,,1,,BAO_0000019,
10640,1969.0,Autocuration,Plasma,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",CHEMBL627733,U,0,,,,,1,,BAO_0000019,
10641,1969.0,Intermediate,Plasma,50597,AUC(area under curve) was determined after intravenous administration in rats,CHEMBL627734,N,1,,,,,1,,BAO_0000218,
10642,1969.0,Intermediate,Plasma,50597,AUC(area under curve) was determined after oral administration in rats,CHEMBL627735,N,1,,,,,1,,BAO_0000218,
10643,1969.0,Intermediate,Plasma,50512,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,CHEMBL627736,N,1,,,,,1,,BAO_0000218,
10644,1969.0,Intermediate,Plasma,50597,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,CHEMBL876809,N,1,,,,,1,,BAO_0000218,
10645,,Autocuration,,22224,Area Under Curve after oral dosing of 100 uM/Kg,CHEMBL627737,U,0,,,,,1,,BAO_0000019,
10646,,Autocuration,,22224,Area Under Curve after oral dosing of 30 uM/Kg,CHEMBL627738,U,0,,,,,1,,BAO_0000019,
10647,,Autocuration,,22224,Area Under Curve was measured by ploting the graph between concentration verses time,CHEMBL627739,U,0,,,,,1,,BAO_0000019,
10648,,Intermediate,,50588,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,CHEMBL626143,N,1,,,,,1,,BAO_0000218,
10649,,Autocuration,,22224,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,CHEMBL626144,U,0,,,,,1,,BAO_0000218,
10650,,Intermediate,,50592,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,CHEMBL626145,N,1,,,,,1,,BAO_0000218,
10651,,Intermediate,,50597,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,CHEMBL626146,N,1,,,,,1,,BAO_0000218,
10652,178.0,Intermediate,Blood,50597,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,CHEMBL626147,N,1,,,,,1,,BAO_0000218,
10653,,Autocuration,,22224,Area under curve (AUC) was determined,CHEMBL626148,U,0,,,,,1,,BAO_0000019,
10654,,Autocuration,,22224,Area under curve (AUC) following ip administration at 1 mg/kg,CHEMBL626149,U,0,,,,,1,,BAO_0000218,
10655,,Autocuration,,22224,Area under curve (AUC) was determined; ND is Not determined,CHEMBL626150,U,0,,,,,1,,BAO_0000019,
10656,,Intermediate,,50588,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,CHEMBL626151,N,1,,,,,1,,BAO_0000218,
10657,,Intermediate,,50588,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,CHEMBL626152,N,1,,,,,1,,BAO_0000218,
10658,,Intermediate,,50588,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,CHEMBL626153,N,1,,,,,1,,BAO_0000218,
10659,,Autocuration,,22224,Area under curve (AUR) was determined,CHEMBL626154,U,0,,,,,1,,BAO_0000019,
10660,,Autocuration,,22224,Area under curve at 1 uM/dg administered intravenously,CHEMBL626155,U,0,,,,,1,,BAO_0000019,
10661,,Autocuration,,22224,Area under curve at 10 uM/dg administered perorally,CHEMBL626156,U,0,,,,,1,,BAO_0000019,
10662,,Autocuration,,22224,Area under curve at 2 uM/dg administered intravenously,CHEMBL626157,U,0,,,,,1,,BAO_0000019,
10663,,Autocuration,,22224,Area under curve at 20 uM/dg administered perorally,CHEMBL626158,U,0,,,,,1,,BAO_0000019,
10664,,Intermediate,,50588,Area under curve at a peroral dose of 3 mg/kg in dog,CHEMBL626159,N,1,,,,,1,,BAO_0000218,
10665,,Intermediate,,50597,Area under curve at a peroral dose of 3 mg/kg in rat,CHEMBL626160,N,1,,,,,1,,BAO_0000218,
10666,,Intermediate,,50588,Area under curve at an iv dose of 1 mg/kg in dog,CHEMBL626161,N,1,,,,,1,,BAO_0000218,
10667,,Intermediate,,50597,Area under curve at an iv dose of 1 mg/kg in rat,CHEMBL626162,N,1,,,,,1,,BAO_0000218,
10668,,Autocuration,,22224,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,CHEMBL626163,U,0,,,,,1,,BAO_0000019,
10669,,Autocuration,,22224,Area under curve gives the effective duration for the angiotensin II antagonist effect.,CHEMBL626164,U,0,,,,,1,,BAO_0000019,
10670,,Intermediate,,50594,Area under curve measured as conc vs time after intravenous administration to mice.,CHEMBL626165,N,1,,,,,1,,BAO_0000218,
10671,,Intermediate,,50594,Area under curve measured as conc vs time after peroral administration to mice.,CHEMBL626166,N,1,,,,,1,,BAO_0000218,
10672,,Intermediate,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,CHEMBL626167,N,1,,,,,1,,BAO_0000218,
10673,,Intermediate,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,CHEMBL626168,N,1,,,,,1,,BAO_0000218,
10674,,Intermediate,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,CHEMBL877463,N,1,,,,,1,,BAO_0000218,
10675,,Intermediate,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,CHEMBL626169,N,1,,,,,1,,BAO_0000218,
10676,948.0,Intermediate,Heart,50597,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,CHEMBL626170,N,1,,,,,1,,BAO_0000218,
10677,948.0,Intermediate,Heart,50597,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,CHEMBL626171,N,1,,,,,1,,BAO_0000218,
10678,948.0,Intermediate,Heart,50597,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,CHEMBL626172,N,1,,,,,1,,BAO_0000218,
10679,948.0,Intermediate,Heart,50597,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,CHEMBL626173,N,1,,,,,1,,BAO_0000218,
10680,2113.0,Intermediate,Kidney,50597,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,CHEMBL626174,N,1,,,,,1,,BAO_0000218,
10681,2113.0,Intermediate,Kidney,50597,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,CHEMBL626175,N,1,,,,,1,,BAO_0000218,
10682,2113.0,Intermediate,Kidney,50597,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,CHEMBL626176,N,1,,,,,1,,BAO_0000218,
10683,2113.0,Intermediate,Kidney,50597,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,CHEMBL626177,N,1,,,,,1,,BAO_0000218,
10684,2113.0,Intermediate,Kidney,50597,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,CHEMBL622499,N,1,,,,,1,,BAO_0000218,
10685,2107.0,Intermediate,Liver,50597,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,CHEMBL622500,N,1,,,,,1,,BAO_0000218,
10686,2107.0,Intermediate,Liver,50597,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,CHEMBL622501,N,1,,,,,1,,BAO_0000218,
10687,2107.0,Intermediate,Liver,50597,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,CHEMBL622502,N,1,,,,,1,,BAO_0000218,
10688,2107.0,Intermediate,Liver,50597,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,CHEMBL622503,N,1,,,,,1,,BAO_0000218,
10689,2107.0,Intermediate,Liver,50597,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,CHEMBL877614,N,1,,,,,1,,BAO_0000218,
10690,2048.0,Intermediate,Lung,50597,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,CHEMBL624839,N,1,,,,,1,,BAO_0000218,
10691,2048.0,Intermediate,Lung,50597,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,CHEMBL624840,N,1,,,,,1,,BAO_0000218,
10692,2048.0,Intermediate,Lung,50597,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,CHEMBL624841,N,1,,,,,1,,BAO_0000218,
10693,2048.0,Intermediate,Lung,50597,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,CHEMBL624842,N,1,,,,,1,,BAO_0000218,
10694,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,CHEMBL624843,N,1,,,,,1,,BAO_0000218,
10695,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,CHEMBL624844,N,1,,,,,1,,BAO_0000218,
10696,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,CHEMBL624845,N,1,,,,,1,,BAO_0000218,
10697,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,CHEMBL621904,N,1,,,,,1,,BAO_0000218,
10698,178.0,Intermediate,Blood,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,CHEMBL621905,N,1,,,,,1,,BAO_0000218,
10699,178.0,Intermediate,Blood,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,CHEMBL874382,N,1,,,,,1,,BAO_0000218,
10700,178.0,Intermediate,Blood,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,CHEMBL621906,N,1,,,,,1,,BAO_0000218,
10701,955.0,Intermediate,Brain,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,CHEMBL621907,N,1,,,,,1,,BAO_0000218,
10702,955.0,Intermediate,Brain,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,CHEMBL622096,N,1,,,,,1,,BAO_0000218,
10703,955.0,Intermediate,Brain,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,CHEMBL622097,N,1,,,,,1,,BAO_0000218,
10704,948.0,Intermediate,Heart,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,CHEMBL622098,N,1,,,,,1,,BAO_0000218,
10705,948.0,Intermediate,Heart,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,CHEMBL622099,N,1,,,,,1,,BAO_0000218,
10706,948.0,Intermediate,Heart,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,CHEMBL622100,N,1,,,,,1,,BAO_0000218,
10707,2113.0,Intermediate,Kidney,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,CHEMBL622101,N,1,,,,,1,,BAO_0000218,
10708,2113.0,Intermediate,Kidney,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,CHEMBL622102,N,1,,,,,1,,BAO_0000218,
10709,2113.0,Intermediate,Kidney,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,CHEMBL622103,N,1,,,,,1,,BAO_0000218,
10710,2107.0,Intermediate,Liver,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,CHEMBL622104,N,1,,,,,1,,BAO_0000218,
10711,2107.0,Intermediate,Liver,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,CHEMBL622105,N,1,,,,,1,,BAO_0000218,
10712,2107.0,Intermediate,Liver,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,CHEMBL622106,N,1,,,,,1,,BAO_0000218,
10713,2048.0,Intermediate,Lung,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,CHEMBL622107,N,1,,,,,1,,BAO_0000218,
10714,2048.0,Intermediate,Lung,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,CHEMBL622108,N,1,,,,,1,,BAO_0000218,
10715,2048.0,Intermediate,Lung,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,CHEMBL622109,N,1,,,,,1,,BAO_0000218,
10716,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,CHEMBL622110,N,1,,,,,1,,BAO_0000218,
10717,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,CHEMBL622111,N,1,,,,,1,,BAO_0000218,
10718,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,CHEMBL874383,N,1,,,,,1,,BAO_0000218,
10719,14.0,Intermediate,Zone of skin,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,CHEMBL622112,N,1,,,,,1,,BAO_0000218,
10720,14.0,Intermediate,Zone of skin,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,CHEMBL622113,N,1,,,,,1,,BAO_0000218,
10721,14.0,Intermediate,Zone of skin,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,CHEMBL622114,N,1,,,,,1,,BAO_0000218,
10722,2106.0,Intermediate,Spleen,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,CHEMBL622115,N,1,,,,,1,,BAO_0000218,
10723,2106.0,Intermediate,Spleen,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,CHEMBL622116,N,1,,,,,1,,BAO_0000218,
10724,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622117,N,1,,,,,1,,BAO_0000218,
10725,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622118,N,1,,,,,1,,BAO_0000218,
10726,,Intermediate,,50597,Oral bioavailability in rats at 6 mg/kg,CHEMBL622119,N,1,,,,,1,,BAO_0000218,
10727,,Intermediate,,50597,Oral bioavailability in rat (dose 6 mg/kg),CHEMBL622120,N,1,,,,,1,,BAO_0000218,
10728,,Intermediate,,50597,Oral bioavailability in rats at 6 mg/kg dose; Not tested,CHEMBL622121,N,1,,,,,1,,BAO_0000218,
10729,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622122,N,1,,,,,1,,BAO_0000218,
10730,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622123,N,1,,,,,1,,BAO_0000218,
10731,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL622124,N,1,,,,,1,,BAO_0000218,
10732,,Intermediate,,50597,Bioavailability in rat,CHEMBL622125,N,1,,,,,1,,BAO_0000218,
10733,,Intermediate,,50597,Oral bioavailability,CHEMBL622126,N,1,,,,,1,,BAO_0000218,
10734,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),CHEMBL620455,N,1,,,,,1,,BAO_0000218,
10735,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL620456,N,1,,,,,1,,BAO_0000218,
10736,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL620457,N,1,,,,,1,,BAO_0000218,
10737,,Intermediate,,50597,Oral bioavailability was evaluated; Not tested,CHEMBL620458,N,1,,,,,1,,BAO_0000218,
10738,,Intermediate,,50597,Oral bioavailability,CHEMBL620459,N,1,,,,,1,,BAO_0000218,
10739,,Intermediate,,50597,Oral bioavailability in rat by oral dosing,CHEMBL620460,N,1,,,,,1,,BAO_0000218,
10740,,Intermediate,,50597,Oral bioavailability in rat (dose 10 mg/kg p.o.),CHEMBL620461,N,1,,,,,1,,BAO_0000218,
10741,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley),CHEMBL620462,N,1,,,,,1,,BAO_0000218,
10742,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),CHEMBL620463,N,1,,,,,1,,BAO_0000218,
10743,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),CHEMBL620464,N,1,,,,,1,,BAO_0000218,
10744,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),CHEMBL620465,N,1,,,,,1,,BAO_0000218,
10745,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),CHEMBL620466,N,1,,,,,1,,BAO_0000218,
10746,,Intermediate,,50597,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,CHEMBL620467,N,1,,,,,1,,BAO_0000218,
10747,,Intermediate,,50597,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,CHEMBL620468,N,1,,,,,1,,BAO_0000218,
10748,,Intermediate,,50597,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,CHEMBL620469,N,1,,,,,1,,BAO_0000218,
10749,,Intermediate,,50597,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,CHEMBL620470,N,1,,,,,1,,BAO_0000218,
10750,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL620471,N,1,,,,,1,,BAO_0000218,
10751,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL620472,N,1,,,,,1,,BAO_0000218,
10752,,Intermediate,,50597,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,CHEMBL620473,N,1,,,,,1,,BAO_0000218,
10753,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL620474,N,1,,,,,1,,BAO_0000218,
10754,,Intermediate,,50597,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),CHEMBL620475,N,1,,,,,1,,BAO_0000218,
10755,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL620476,N,1,,,,,1,,BAO_0000218,
10756,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL620477,N,1,,,,,1,,BAO_0000218,
10757,,Intermediate,,50597,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,CHEMBL620478,N,1,,,,,1,,BAO_0000218,
10758,,Intermediate,,50597,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,CHEMBL618768,N,1,,,,,1,,BAO_0000218,
10759,,Intermediate,,50597,Oral bioavailability in rat after oral administration at 13 mg/kg dose,CHEMBL618769,N,1,,,,,1,,BAO_0000218,
10760,,Intermediate,,50597,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,CHEMBL618770,N,1,,,,,1,,BAO_0000218,
10761,,Intermediate,,50597,Oral bioavailability (dose 20 mg/kg p.o.),CHEMBL618771,N,1,,,,,1,,BAO_0000218,
10762,,Intermediate,,50597,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,CHEMBL618772,N,1,,,,,1,,BAO_0000218,
10763,,Intermediate,,50597,Oral bioavailability in rat at 10 mg/kg of the compound,CHEMBL618773,N,1,,,,,1,,BAO_0000218,
10764,,Intermediate,,50597,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,CHEMBL875842,N,1,,,,,1,,BAO_0000218,
10765,,Intermediate,,50597,Bioavailability in rat (dose 3 mg/kg i.v.),CHEMBL618774,N,1,,,,,1,,BAO_0000218,
10766,,Intermediate,,50597,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,CHEMBL618775,N,1,,,,,1,,BAO_0000218,
10767,,Intermediate,,50597,Oral bioavailability in rat (dose 60 mg/kg p.o.),CHEMBL618776,N,1,,,,,1,,BAO_0000218,
10768,,Intermediate,,50597,Percent bioavailability (F) in rats after iv administration,CHEMBL618777,N,1,,,,,1,,BAO_0000218,
10769,,Intermediate,,50597,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,CHEMBL618778,N,1,,,,,1,,BAO_0000218,
10770,,Intermediate,,50597,Bioavailability in rat (dose 5 uM/kg p.o.),CHEMBL618779,N,1,,,,,1,,BAO_0000218,
10771,,Intermediate,,50597,Oral bioavailability,CHEMBL618780,N,1,,,,,1,,BAO_0000218,
10772,,Intermediate,,50597,Bioavailability in rat (dose 2 mg/kg p.o.),CHEMBL618781,N,1,,,,,1,,BAO_0000218,
10773,,Intermediate,,50597,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,CHEMBL618782,N,1,,,,,1,,BAO_0000218,
10774,,Intermediate,,50597,Oral bioavailability in rat (dose 20 mg/kg),CHEMBL618783,N,1,,,,,1,,BAO_0000218,
10775,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL618784,N,1,,,,,1,,BAO_0000218,
10776,,Intermediate,,50597,Percent oral bioavailability evaluated in rat,CHEMBL618785,N,1,,,,,1,,BAO_0000218,
10777,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL618786,N,1,,,,,1,,BAO_0000218,
10778,,Intermediate,,50597,Percent oral bioavailability in rat; Not determined,CHEMBL618787,N,1,,,,,1,,BAO_0000218,
10779,,Intermediate,,50597,Oral bioavailability in rat,CHEMBL618788,N,1,,,,,1,,BAO_0000218,
10780,,Intermediate,,50597,Bioavailability in rat,CHEMBL618789,N,1,,,,,1,,BAO_0000218,
10781,,Intermediate,,50597,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),CHEMBL618790,N,1,,,,,1,,BAO_0000218,
10782,,Intermediate,,50597,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),CHEMBL618791,N,1,,,,,1,,BAO_0000218,
10783,,Intermediate,,50597,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,CHEMBL875843,N,1,,,,,1,,BAO_0000218,
10784,,Intermediate,,50597,Oral bioavailability in rat (dose 20 mg/kg p.o.),CHEMBL618792,N,1,,,,,1,,BAO_0000218,
10785,,Intermediate,,50597,Cmax at a dose of 30 mg/kg in rat,CHEMBL623395,N,1,,,,,1,,BAO_0000218,
10786,,Autocuration,,22224,Cmax in monkeys at a dose of 1 mg/kg,CHEMBL623396,U,0,,,,,1,,BAO_0000218,
10787,,Intermediate,,50597,Cmax in rat,CHEMBL623397,N,1,,,,,1,,BAO_0000218,
10788,,Intermediate,,50597,Cmax in rats at a dose of 1 mg/kg,CHEMBL623398,N,1,,,,,1,,BAO_0000218,
10789,,Intermediate,,50594,Cmax was measured in mice after an oral dose of 50 mg/kg.,CHEMBL623399,N,1,,,,,1,,BAO_0000218,
10790,,Autocuration,,22224,"Cmax value at a dose of 12.7 uM/kg, po",CHEMBL623400,U,0,,,,,1,,BAO_0000218,
10791,,Autocuration,,22224,"Cmax value at a dose of 6.3 uM/kg, iv",CHEMBL623401,U,0,,,,,1,,BAO_0000218,
10792,,Autocuration,,22224,"Cmax value at a dose of 7.1 uM/kg, iv",CHEMBL623402,U,0,,,,,1,,BAO_0000218,
10793,,Autocuration,,22224,Cmax value of compound was determined after 1 hr,CHEMBL623403,U,0,,,,,1,,BAO_0000218,
10794,,Autocuration,,22224,Cmax value of the compound,CHEMBL623404,U,0,,,,,1,,BAO_0000218,
10795,,Intermediate,,50597,Cmax value administered intraintestinal in rats.,CHEMBL625997,N,1,,,,,1,,BAO_0000218,
10796,,Intermediate,,50597,Cmax value administered perorally was determined in rat; Not determined,CHEMBL625998,N,1,,,,,1,,BAO_0000218,
10797,,Autocuration,,22224,Cmax value at the dose of 2.3 mg/kg,CHEMBL625999,U,0,,,,,1,,BAO_0000218,
10798,,Autocuration,,22224,Cmax value at the dose of 5 mg/kg,CHEMBL626000,U,0,,,,,1,,BAO_0000218,
10799,,Autocuration,,22224,Cmax value in the period of 8 hr after dosing. ,CHEMBL626001,U,0,,,,,1,,BAO_0000218,
10800,,Autocuration,,22224,Cmax value at a oral dose of 20 mg/kg; Not tested,CHEMBL626002,U,0,,,,,1,,BAO_0000218,
10801,,Autocuration,,22224,Cmax value at a oral dose of 20 mg/kg,CHEMBL626003,U,0,,,,,1,,BAO_0000218,
10802,,Intermediate,,50597,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,CHEMBL626004,N,1,,,,,1,,BAO_0000218,
10803,,Intermediate,,50512,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,CHEMBL626005,N,1,,,,,1,,BAO_0000218,
10804,,Intermediate,,50597,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,CHEMBL626006,N,1,,,,,1,,BAO_0000218,
10805,1969.0,Intermediate,Plasma,50597,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,CHEMBL626007,N,1,,,,,1,,BAO_0000218,
10806,1969.0,Intermediate,Plasma,50594,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,CHEMBL626008,N,1,,,,,1,,BAO_0000218,
10807,2107.0,Intermediate,Liver,50588,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,CHEMBL626009,N,1,,,,,1,,BAO_0000218,
10808,,Intermediate,,50588,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,CHEMBL626010,N,1,,,,,1,,BAO_0000218,
10809,178.0,Intermediate,Blood,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,CHEMBL626011,N,1,,,,,1,,BAO_0000218,
10810,178.0,Intermediate,Blood,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,CHEMBL626012,N,1,,,,,1,,BAO_0000218,
10811,178.0,Intermediate,Blood,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,CHEMBL626013,N,1,,,,,1,,BAO_0000218,
10812,178.0,Intermediate,Blood,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,CHEMBL626014,N,1,,,,,1,,BAO_0000218,
10813,178.0,Intermediate,Blood,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,CHEMBL877496,N,1,,,,,1,,BAO_0000218,
10814,,Intermediate,,50588,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,CHEMBL626015,N,1,,,,,1,,BAO_0000218,
10815,,Intermediate,,50588,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,CHEMBL626016,N,1,,,,,1,,BAO_0000218,
10816,,Intermediate,,50588,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,CHEMBL626017,N,1,,,,,1,,BAO_0000218,
10817,1969.0,Intermediate,Plasma,50588,Bioavailability as maximal plasma concentration in dogs,CHEMBL626018,N,1,,,,,1,,BAO_0000218,
10818,1969.0,Intermediate,Plasma,50588,Bioavailability as maximal plasma concentration in dogs,CHEMBL626692,N,1,,,,,1,,BAO_0000218,
10819,1969.0,Intermediate,Plasma,50597,Bioavailability as maximal plasma concentration in rats,CHEMBL626693,N,1,,,,,1,,BAO_0000218,
10820,1969.0,Autocuration,Plasma,22224,Bioavailability as maximal plasma concentration in rats,CHEMBL626694,U,0,,,,,1,,BAO_0000218,
10821,178.0,Intermediate,Blood,50588,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,CHEMBL626695,N,1,,,,,1,,BAO_0000218,
10822,178.0,Intermediate,Blood,50588,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,CHEMBL626696,N,1,,,,,1,,BAO_0000218,
10823,178.0,Intermediate,Blood,50588,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,CHEMBL626697,N,1,,,,,1,,BAO_0000218,
10824,178.0,Intermediate,Blood,50588,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,CHEMBL626859,N,1,,,,,1,,BAO_0000218,
10825,178.0,Intermediate,Blood,50588,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,CHEMBL626860,N,1,,,,,1,,BAO_0000218,
10826,178.0,Intermediate,Blood,50588,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,CHEMBL626861,N,1,,,,,1,,BAO_0000218,
10827,,Intermediate,,50597,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,CHEMBL626296,N,1,,,,,1,,BAO_0000218,
10828,,Autocuration,,22224,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,CHEMBL626297,U,0,,,,,1,,BAO_0000218,
10829,1969.0,Autocuration,Plasma,22224,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,CHEMBL626298,U,0,,,,,1,,BAO_0000218,
10830,1969.0,Intermediate,Plasma,50597,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",CHEMBL626299,N,1,,,,,1,,BAO_0000218,
10831,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,CHEMBL626300,N,1,,,,,1,,BAO_0000218,
10832,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,CHEMBL626301,N,1,,,,,1,,BAO_0000218,
10833,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,CHEMBL626962,N,1,,,,,1,,BAO_0000218,
10834,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,CHEMBL626963,N,1,,,,,1,,BAO_0000218,
10835,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,CHEMBL626964,N,1,,,,,1,,BAO_0000218,
10836,1969.0,Intermediate,Plasma,100710,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,CHEMBL626965,N,1,,,,,1,,BAO_0000218,
10837,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,CHEMBL626966,N,1,,,,,1,,BAO_0000218,
10838,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,CHEMBL626967,N,1,,,,,1,,BAO_0000218,
10839,1969.0,Intermediate,Plasma,100710,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,CHEMBL626968,N,1,,,,,1,,BAO_0000218,
10840,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,CHEMBL626969,N,1,,,,,1,,BAO_0000218,
10841,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,CHEMBL627126,N,1,,,,,1,,BAO_0000218,
10842,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,CHEMBL631276,N,1,,,,,1,,BAO_0000218,
10843,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,CHEMBL631277,N,1,,,,,1,,BAO_0000218,
10844,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,CHEMBL631278,N,1,,,,,1,,BAO_0000218,
10845,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,CHEMBL874457,N,1,,,,,1,,BAO_0000218,
10846,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,CHEMBL631279,N,1,,,,,1,,BAO_0000218,
10847,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,CHEMBL631280,N,1,,,,,1,,BAO_0000218,
10848,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,CHEMBL631281,N,1,,,,,1,,BAO_0000218,
10849,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,CHEMBL631968,N,1,,,,,1,,BAO_0000218,
10850,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,CHEMBL631969,N,1,,,,,1,,BAO_0000218,
10851,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,CHEMBL631970,N,1,,,,,1,,BAO_0000218,
10852,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,CHEMBL631971,N,1,,,,,1,,BAO_0000218,
10853,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,CHEMBL631972,N,1,,,,,1,,BAO_0000218,
10854,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,CHEMBL630435,N,1,,,,,1,,BAO_0000218,
10855,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,CHEMBL630436,N,1,,,,,1,,BAO_0000218,
10856,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,CHEMBL630437,N,1,,,,,1,,BAO_0000218,
10857,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,CHEMBL630438,N,1,,,,,1,,BAO_0000218,
10858,948.0,Intermediate,Heart,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,CHEMBL630439,N,1,,,,,1,,BAO_0000218,
10859,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,CHEMBL630440,N,1,,,,,1,,BAO_0000218,
10860,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,CHEMBL630441,N,1,,,,,1,,BAO_0000218,
10861,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,CHEMBL630442,N,1,,,,,1,,BAO_0000218,
10862,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,CHEMBL625234,N,1,,,,,1,,BAO_0000218,
10863,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,CHEMBL625235,N,1,,,,,1,,BAO_0000218,
10864,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,CHEMBL625236,N,1,,,,,1,,BAO_0000218,
10865,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,CHEMBL625237,N,1,,,,,1,,BAO_0000218,
10866,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,CHEMBL626125,N,1,,,,,1,,BAO_0000218,
10867,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,CHEMBL626126,N,1,,,,,1,,BAO_0000218,
10868,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,CHEMBL626127,N,1,,,,,1,,BAO_0000218,
10869,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,CHEMBL626128,N,1,,,,,1,,BAO_0000218,
10870,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,CHEMBL626129,N,1,,,,,1,,BAO_0000218,
10871,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,CHEMBL626130,N,1,,,,,1,,BAO_0000218,
10872,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,CHEMBL626131,N,1,,,,,1,,BAO_0000218,
10873,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,CHEMBL626132,N,1,,,,,1,,BAO_0000218,
10874,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,CHEMBL626752,N,1,,,,,1,,BAO_0000218,
10875,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,CHEMBL626753,N,1,,,,,1,,BAO_0000218,
10876,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,CHEMBL626754,N,1,,,,,1,,BAO_0000218,
10877,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,CHEMBL626755,N,1,,,,,1,,BAO_0000218,
10878,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,CHEMBL626756,N,1,,,,,1,,BAO_0000218,
10879,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,CHEMBL626757,N,1,,,,,1,,BAO_0000218,
10880,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,CHEMBL626758,N,1,,,,,1,,BAO_0000218,
10881,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,CHEMBL626759,N,1,,,,,1,,BAO_0000218,
10882,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,CHEMBL626760,N,1,,,,,1,,BAO_0000218,
10883,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),CHEMBL626394,N,1,,,,,1,,BAO_0000218,
10884,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,CHEMBL626395,N,1,,,,,1,,BAO_0000218,
10885,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),CHEMBL626396,N,1,,,,,1,,BAO_0000218,
10886,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),CHEMBL626397,N,1,,,,,1,,BAO_0000218,
10887,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),CHEMBL626398,N,1,,,,,1,,BAO_0000218,
10888,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),CHEMBL626399,N,1,,,,,1,,BAO_0000218,
10889,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,CHEMBL874653,N,1,,,,,1,,BAO_0000218,
10890,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),CHEMBL626400,N,1,,,,,1,,BAO_0000218,
10891,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),CHEMBL626401,N,1,,,,,1,,BAO_0000218,
10892,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),CHEMBL626402,N,1,,,,,1,,BAO_0000218,
10893,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),CHEMBL626403,N,1,,,,,1,,BAO_0000218,
10894,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),CHEMBL626404,N,1,,,,,1,,BAO_0000218,
10895,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,CHEMBL626405,N,1,,,,,1,,BAO_0000218,
10896,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),CHEMBL625529,N,1,,,,,1,,BAO_0000218,
10897,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),CHEMBL625530,N,1,,,,,1,,BAO_0000218,
10898,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),CHEMBL625531,N,1,,,,,1,,BAO_0000218,
10899,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),CHEMBL625532,N,1,,,,,1,,BAO_0000218,
10900,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),CHEMBL625533,N,1,,,,,1,,BAO_0000218,
10901,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,CHEMBL875474,N,1,,,,,1,,BAO_0000218,
10902,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),CHEMBL625534,N,1,,,,,1,,BAO_0000218,
10903,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),CHEMBL625535,N,1,,,,,1,,BAO_0000218,
10904,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),CHEMBL625536,N,1,,,,,1,,BAO_0000218,
10905,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),CHEMBL625537,N,1,,,,,1,,BAO_0000218,
10906,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),CHEMBL625538,N,1,,,,,1,,BAO_0000218,
10907,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,CHEMBL625539,N,1,,,,,1,,BAO_0000218,
10908,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),CHEMBL625540,N,1,,,,,1,,BAO_0000218,
10909,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),CHEMBL625541,N,1,,,,,1,,BAO_0000218,
10910,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),CHEMBL625542,N,1,,,,,1,,BAO_0000218,
10911,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),CHEMBL625543,N,1,,,,,1,,BAO_0000218,
10912,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),CHEMBL625544,N,1,,,,,1,,BAO_0000218,
10913,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,CHEMBL625545,N,1,,,,,1,,BAO_0000218,
10914,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),CHEMBL625546,N,1,,,,,1,,BAO_0000218,
10915,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,CHEMBL625547,N,1,,,,,1,,BAO_0000218,
10916,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),CHEMBL625548,N,1,,,,,1,,BAO_0000218,
10917,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),CHEMBL625549,N,1,,,,,1,,BAO_0000218,
10918,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),CHEMBL625550,N,1,,,,,1,,BAO_0000218,
10919,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),CHEMBL625551,N,1,,,,,1,,BAO_0000218,
10920,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),CHEMBL875475,N,1,,,,,1,,BAO_0000218,
10921,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),CHEMBL625552,N,1,,,,,1,,BAO_0000218,
10922,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),CHEMBL625553,N,1,,,,,1,,BAO_0000218,
10923,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),CHEMBL625554,N,1,,,,,1,,BAO_0000218,
10924,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),CHEMBL625555,N,1,,,,,1,,BAO_0000218,
10925,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),CHEMBL625556,N,1,,,,,1,,BAO_0000218,
10926,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,CHEMBL624986,N,1,,,,,1,,BAO_0000218,
10927,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),CHEMBL624987,N,1,,,,,1,,BAO_0000218,
10928,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),CHEMBL624988,N,1,,,,,1,,BAO_0000218,
10929,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,CHEMBL624989,N,1,,,,,1,,BAO_0000218,
10930,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,CHEMBL624990,N,1,,,,,1,,BAO_0000218,
10931,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,CHEMBL874391,N,1,,,,,1,,BAO_0000218,
10932,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,CHEMBL624991,N,1,,,,,1,,BAO_0000218,
10933,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,CHEMBL624992,N,1,,,,,1,,BAO_0000218,
10934,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,CHEMBL624993,N,1,,,,,1,,BAO_0000218,
10935,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,CHEMBL624994,N,1,,,,,1,,BAO_0000218,
10936,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,CHEMBL624995,N,1,,,,,1,,BAO_0000218,
10937,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,CHEMBL624996,N,1,,,,,1,,BAO_0000218,
10938,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,CHEMBL624997,N,1,,,,,1,,BAO_0000218,
10939,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,CHEMBL624998,N,1,,,,,1,,BAO_0000218,
10940,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,CHEMBL624999,N,1,,,,,1,,BAO_0000218,
10941,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,CHEMBL882955,N,1,,,,,1,,BAO_0000218,
10942,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,CHEMBL625000,N,1,,,,,1,,BAO_0000218,
10943,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,CHEMBL625001,N,1,,,,,1,,BAO_0000218,
10944,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,CHEMBL625089,N,1,,,,,1,,BAO_0000218,
10945,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,CHEMBL625090,N,1,,,,,1,,BAO_0000218,
10946,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,CHEMBL625091,N,1,,,,,1,,BAO_0000218,
10947,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,CHEMBL625092,N,1,,,,,1,,BAO_0000218,
10948,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,CHEMBL625093,N,1,,,,,1,,BAO_0000218,
10949,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,CHEMBL625094,N,1,,,,,1,,BAO_0000218,
10950,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,CHEMBL625095,N,1,,,,,1,,BAO_0000218,
10951,,Intermediate,,50588,Compound was evaluated for its bioavailability in the dogs,CHEMBL625096,N,1,,,,,1,,BAO_0000218,
10952,,Intermediate,,50597,Compound was evaluated for its bioavailability in the rats,CHEMBL625097,N,1,,,,,1,,BAO_0000218,
10953,,Autocuration,,22224,Compound was evaluated for oral bioavailability,CHEMBL882956,U,0,,,,,1,,BAO_0000218,
10954,,Intermediate,,50597,Compound was evaluated for percentage of Oral bioavailability in rats,CHEMBL625098,N,1,,,,,1,,BAO_0000218,
10955,,Autocuration,,22224,Bioavailability in guinea pig,CHEMBL625099,U,0,,,,,1,,BAO_0000218,
10956,,Intermediate,,50597,Compound was evaluated for the oral bioavailability in rat,CHEMBL625100,N,1,,,,,1,,BAO_0000218,
10957,,Intermediate,,50588,Compound was evaluated for the oral bioavailability in dog,CHEMBL625101,N,1,,,,,1,,BAO_0000218,
10958,,Intermediate,,50597,Compound was evaluated for the oral bioavailability in rat,CHEMBL874396,N,1,,,,,1,,BAO_0000218,
10959,,Autocuration,,22224,Bioavailability in dog (dosed i.v.),CHEMBL625102,U,0,,,,,1,,BAO_0000218,
10960,,Intermediate,,50588,Compound was tested for in vivo bioavailability in dog,CHEMBL625103,N,1,,,,,1,,BAO_0000218,
10961,,Intermediate,,100712,Compound was tested for in vivo bioavailability in hamsters,CHEMBL625104,N,1,,,,,1,,BAO_0000218,
10962,,Autocuration,,22224,Compound was tested for in vivo bioavailability in monkey,CHEMBL625105,U,0,,,,,1,,BAO_0000218,
10963,,Intermediate,,50597,Compound was tested for in vivo bioavailability in rat,CHEMBL625106,N,1,,,,,1,,BAO_0000218,
10964,,Autocuration,,22224,Oral bioavailability in mouse,CHEMBL625107,U,0,,,,,1,,BAO_0000218,
10965,,Intermediate,,50594,Compound was tested for percent of oral bioavailability in mice; 56-74,CHEMBL625108,N,1,,,,,1,,BAO_0000218,
10966,,Autocuration,,22224,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),CHEMBL625109,U,0,,,,,1,,BAO_0000218,
10967,,Autocuration,,22224,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),CHEMBL625110,U,0,,,,,1,,BAO_0000218,
10968,,Autocuration,,22224,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),CHEMBL625111,U,0,,,,,1,,BAO_0000218,
10969,,Intermediate,,50594,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),CHEMBL625112,N,1,,,,,1,,BAO_0000218,
10970,,Intermediate,,50594,Oral bioavailability in nude mice,CHEMBL875334,N,1,,,,,1,,BAO_0000218,
10971,,Autocuration,,22224,Bioavailability in monkey (i.d. dosing),CHEMBL628617,U,0,,,,,1,,BAO_0000218,
10972,,Autocuration,,22224,Bioavailability in rat,CHEMBL628618,U,0,,,,,1,,BAO_0000218,
10973,,Autocuration,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,CHEMBL628619,U,0,,,,,1,,BAO_0000218,
10974,,Autocuration,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,CHEMBL628620,U,0,,,,,1,,BAO_0000218,
10975,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",CHEMBL628621,N,1,,,,,1,,BAO_0000218,
10976,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",CHEMBL628622,N,1,,,,,1,,BAO_0000218,
10977,,Intermediate,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",CHEMBL628623,N,1,,,,,1,,BAO_0000218,
10978,1969.0,Intermediate,Plasma,100710,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,CHEMBL628624,N,1,,,,,1,,BAO_0000218,
10979,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,CHEMBL628625,N,1,,,,,1,,BAO_0000218,
10980,1969.0,Intermediate,Plasma,100710,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,CHEMBL628626,N,1,,,,,1,,BAO_0000218,
10981,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,CHEMBL627041,N,1,,,,,1,,BAO_0000218,
10982,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,CHEMBL627042,N,1,,,,,1,,BAO_0000218,
10983,1969.0,Intermediate,Plasma,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,CHEMBL627043,N,1,,,,,1,,BAO_0000218,
10984,1969.0,Autocuration,Plasma,22224,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,CHEMBL627044,U,0,,,,,1,,BAO_0000218,
10985,1969.0,Intermediate,Plasma,50594,Cmax in mouse plasma,CHEMBL627045,N,1,,,,,1,,BAO_0000218,
10986,1969.0,Autocuration,Plasma,22224,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,CHEMBL627046,U,0,,,,,1,,BAO_0000218,
10987,1969.0,Intermediate,Plasma,50597,Maximal plasma concentration in rat,CHEMBL627047,N,1,,,,,1,,BAO_0000218,
10988,1969.0,Intermediate,Plasma,50597,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,CHEMBL627048,N,1,,,,,1,,BAO_0000218,
10989,,Intermediate,,50597,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,CHEMBL627049,N,1,,,,,1,,BAO_0000218,
10990,,Intermediate,,50597,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,CHEMBL627050,N,1,,,,,1,,BAO_0000218,
10991,,Intermediate,,50597,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,CHEMBL627051,N,1,,,,,1,,BAO_0000218,
10992,,Intermediate,,50597,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,CHEMBL627052,N,1,,,,,1,,BAO_0000218,
10993,,Intermediate,,50597,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,CHEMBL627053,N,1,,,,,1,,BAO_0000218,
10994,,Intermediate,,50597,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,CHEMBL627054,N,1,,,,,1,,BAO_0000218,
10995,,Intermediate,,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,CHEMBL627055,N,1,,,,,1,,BAO_0000218,
10996,,Intermediate,,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,CHEMBL627056,N,1,,,,,1,,BAO_0000218,
10997,,Intermediate,,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),CHEMBL627057,N,1,,,,,1,,BAO_0000218,
10998,,Intermediate,,50594,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,CHEMBL627058,N,1,,,,,1,,BAO_0000218,
10999,,Intermediate,,50594,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,CHEMBL626211,N,1,,,,,1,,BAO_0000218,
11000,,Autocuration,,22224,Maximum Concentration of the compound.,CHEMBL626212,U,0,,,,,1,,BAO_0000218,
11001,,Intermediate,,50588,Maximum Concentration was measured after iv administration into Beagle dog,CHEMBL626213,N,1,,,,,1,,BAO_0000218,
11002,,Intermediate,,50588,Maximum Concentration was measured after iv administration into Beagle dog.,CHEMBL626214,N,1,,,,,1,,BAO_0000218,
11003,,Intermediate,,50588,Maximum Concentration was measured after po administration into Beagle dog,CHEMBL626215,N,1,,,,,1,,BAO_0000218,
11004,,Intermediate,,50588,Maximum Concentration was measured after po administration into Beagle dog.,CHEMBL626216,N,1,,,,,1,,BAO_0000218,
11005,178.0,Autocuration,Blood,22224,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,CHEMBL626217,U,0,,,,,1,,BAO_0000218,
11006,178.0,Autocuration,Blood,22224,Maximum blood level reached after an iv dose of 12.2 uM/kg,CHEMBL626218,U,0,,,,,1,,BAO_0000218,
11007,178.0,Autocuration,Blood,22224,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,CHEMBL626219,U,0,,,,,1,,BAO_0000218,
11008,178.0,Autocuration,Blood,22224,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,CHEMBL626220,U,0,,,,,1,,BAO_0000218,
11009,178.0,Autocuration,Blood,22224,Maximum blood level reached after an oral dose of 5.0 mg/kg,CHEMBL626221,U,0,,,,,1,,BAO_0000218,
11010,178.0,Autocuration,Blood,22224,Maximum blood level reached at dose of 10.6 uM/kg orally,CHEMBL626222,U,0,,,,,1,,BAO_0000218,
11011,,Intermediate,,50512,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,CHEMBL626223,N,1,,,,,1,,BAO_0000218,
11012,,Intermediate,,50512,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,CHEMBL626224,N,1,,,,,1,,BAO_0000218,
11013,955.0,Intermediate,Brain,50597,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,CHEMBL626225,N,1,,,,,1,,BAO_0000218,
11014,955.0,Intermediate,Brain,50597,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,CHEMBL626226,N,1,,,,,1,,BAO_0000218,
11015,955.0,Intermediate,Brain,50597,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,CHEMBL626227,N,1,,,,,1,,BAO_0000218,
11016,955.0,Intermediate,Brain,50597,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,CHEMBL626228,N,1,,,,,1,,BAO_0000218,
11017,,Intermediate,,50597,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,CHEMBL626229,N,1,,,,,1,,BAO_0000218,
11018,,Intermediate,,50597,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,CHEMBL626921,N,1,,,,,1,,BAO_0000218,
11019,,Intermediate,,50597,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,CHEMBL876793,N,1,,,,,1,,BAO_0000218,
11020,,Intermediate,,50597,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,CHEMBL625309,N,1,,,,,1,,BAO_0000218,
11021,,Intermediate,,50278,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),CHEMBL625310,N,1,,,,,1,,BAO_0000218,
11022,,Autocuration,,22224,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,CHEMBL625311,U,0,,,,,1,,BAO_0000218,
11023,,Intermediate,,50597,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,CHEMBL625312,N,1,,,,,1,,BAO_0000218,
11024,,Autocuration,,22224,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,CHEMBL625313,U,0,,,,,1,,BAO_0000218,
11025,,Intermediate,,50594,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,CHEMBL625314,N,1,,,,,1,,BAO_0000218,
11026,,Intermediate,,50597,Maximum concentration in male rats after iv administration of 20 mg/kg,CHEMBL625315,N,1,,,,,1,,BAO_0000218,
11027,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,CHEMBL625316,N,1,,,,,1,,BAO_0000218,
11028,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,CHEMBL625317,N,1,,,,,1,,BAO_0000218,
11029,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,CHEMBL625318,N,1,,,,,1,,BAO_0000218,
11030,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,CHEMBL625319,N,1,,,,,1,,BAO_0000218,
11031,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,CHEMBL625320,N,1,,,,,1,,BAO_0000218,
11032,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,CHEMBL625321,N,1,,,,,1,,BAO_0000218,
11033,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,CHEMBL625322,N,1,,,,,1,,BAO_0000218,
11034,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,CHEMBL876801,N,1,,,,,1,,BAO_0000218,
11035,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,CHEMBL625323,N,1,,,,,1,,BAO_0000218,
11036,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,CHEMBL625324,N,1,,,,,1,,BAO_0000218,
11037,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,CHEMBL625325,N,1,,,,,1,,BAO_0000218,
11038,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,CHEMBL625326,N,1,,,,,1,,BAO_0000218,
11039,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,CHEMBL625327,N,1,,,,,1,,BAO_0000218,
11040,2107.0,Intermediate,Liver,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,CHEMBL625328,N,1,,,,,1,,BAO_0000218,
11041,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,CHEMBL625329,N,1,,,,,1,,BAO_0000218,
11042,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,CHEMBL625330,N,1,,,,,1,,BAO_0000218,
11043,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,CHEMBL627774,N,1,,,,,1,,BAO_0000218,
11044,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,CHEMBL627775,N,1,,,,,1,,BAO_0000218,
11045,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,CHEMBL627949,N,1,,,,,1,,BAO_0000218,
11046,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,CHEMBL627950,N,1,,,,,1,,BAO_0000218,
11047,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,CHEMBL627951,N,1,,,,,1,,BAO_0000218,
11048,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,CHEMBL627952,N,1,,,,,1,,BAO_0000218,
11049,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,CHEMBL627953,N,1,,,,,1,,BAO_0000218,
11050,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,CHEMBL627954,N,1,,,,,1,,BAO_0000218,
11051,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,CHEMBL627955,N,1,,,,,1,,BAO_0000218,
11052,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,CHEMBL627956,N,1,,,,,1,,BAO_0000218,
11053,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,CHEMBL876802,N,1,,,,,1,,BAO_0000218,
11054,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,CHEMBL627957,N,1,,,,,1,,BAO_0000218,
11055,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,CHEMBL627958,N,1,,,,,1,,BAO_0000218,
11056,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,CHEMBL627959,N,1,,,,,1,,BAO_0000218,
11057,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,CHEMBL627960,N,1,,,,,1,,BAO_0000218,
11058,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,CHEMBL627961,N,1,,,,,1,,BAO_0000218,
11059,2048.0,Intermediate,Lung,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,CHEMBL627962,N,1,,,,,1,,BAO_0000218,
11060,,Intermediate,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,CHEMBL627963,N,1,,,,,1,,BAO_0000218,
11061,,Intermediate,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL624759,N,1,,,,,1,,BAO_0000218,
11062,,Intermediate,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,CHEMBL624760,N,1,,,,,1,,BAO_0000218,
11063,,Intermediate,,50597,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL624761,N,1,,,,,1,,BAO_0000218,
11064,,Intermediate,,50597,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL877607,N,1,,,,,1,,BAO_0000218,
11065,2107.0,Intermediate,Liver,50597,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,CHEMBL624762,N,1,,,,,1,,BAO_0000218,
11066,2107.0,Intermediate,Liver,50597,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL624763,N,1,,,,,1,,BAO_0000218,
11067,2107.0,Intermediate,Liver,50597,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,CHEMBL624764,N,1,,,,,1,,BAO_0000218,
11068,2107.0,Intermediate,Liver,50597,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL624765,N,1,,,,,1,,BAO_0000218,
11069,2107.0,Intermediate,Liver,50597,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL624766,N,1,,,,,1,,BAO_0000218,
11070,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),CHEMBL624767,N,1,,,,,1,,BAO_0000218,
11071,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,CHEMBL624768,N,1,,,,,1,,BAO_0000218,
11072,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),CHEMBL624769,N,1,,,,,1,,BAO_0000218,
11073,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),CHEMBL624770,N,1,,,,,1,,BAO_0000218,
11074,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),CHEMBL624771,N,1,,,,,1,,BAO_0000218,
11075,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),CHEMBL624772,N,1,,,,,1,,BAO_0000218,
11076,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,CHEMBL624773,N,1,,,,,1,,BAO_0000218,
11077,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),CHEMBL624774,N,1,,,,,1,,BAO_0000218,
11078,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),CHEMBL624775,N,1,,,,,1,,BAO_0000218,
11079,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),CHEMBL624776,N,1,,,,,1,,BAO_0000218,
11080,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),CHEMBL624777,N,1,,,,,1,,BAO_0000218,
11081,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),CHEMBL624778,N,1,,,,,1,,BAO_0000218,
11082,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,CHEMBL624779,N,1,,,,,1,,BAO_0000218,
11083,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),CHEMBL624780,N,1,,,,,1,,BAO_0000218,
11084,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),CHEMBL624781,N,1,,,,,1,,BAO_0000218,
11085,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),CHEMBL877608,N,1,,,,,1,,BAO_0000218,
11086,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),CHEMBL624782,N,1,,,,,1,,BAO_0000218,
11087,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),CHEMBL624783,N,1,,,,,1,,BAO_0000218,
11088,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,CHEMBL624784,N,1,,,,,1,,BAO_0000218,
11089,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),CHEMBL624785,N,1,,,,,1,,BAO_0000218,
11090,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),CHEMBL624786,N,1,,,,,1,,BAO_0000218,
11091,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),CHEMBL624787,N,1,,,,,1,,BAO_0000218,
11092,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),CHEMBL628676,N,1,,,,,1,,BAO_0000218,
11093,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,CHEMBL621842,N,1,,,,,1,,BAO_0000218,
11094,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),CHEMBL621843,N,1,,,,,1,,BAO_0000218,
11095,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),CHEMBL623873,N,1,,,,,1,,BAO_0000218,
11096,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),CHEMBL623874,N,1,,,,,1,,BAO_0000218,
11097,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),CHEMBL623875,N,1,,,,,1,,BAO_0000218,
11098,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),CHEMBL623876,N,1,,,,,1,,BAO_0000218,
11099,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,CHEMBL623877,N,1,,,,,1,,BAO_0000218,
11100,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),CHEMBL623878,N,1,,,,,1,,BAO_0000218,
11101,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,CHEMBL623879,N,1,,,,,1,,BAO_0000218,
11102,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),CHEMBL623880,N,1,,,,,1,,BAO_0000218,
11103,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),CHEMBL623881,N,1,,,,,1,,BAO_0000218,
11104,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),CHEMBL623957,N,1,,,,,1,,BAO_0000218,
11105,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),CHEMBL623958,N,1,,,,,1,,BAO_0000218,
11106,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),CHEMBL623959,N,1,,,,,1,,BAO_0000218,
11107,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),CHEMBL623960,N,1,,,,,1,,BAO_0000218,
11108,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),CHEMBL623961,N,1,,,,,1,,BAO_0000218,
11109,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),CHEMBL623962,N,1,,,,,1,,BAO_0000218,
11110,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),CHEMBL624676,N,1,,,,,1,,BAO_0000218,
11111,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),CHEMBL624677,N,1,,,,,1,,BAO_0000218,
11112,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,CHEMBL624678,N,1,,,,,1,,BAO_0000218,
11113,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),CHEMBL624679,N,1,,,,,1,,BAO_0000218,
11114,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),CHEMBL624680,N,1,,,,,1,,BAO_0000218,
11115,,Autocuration,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,CHEMBL624849,U,0,,,,,1,,BAO_0000218,
11116,,Autocuration,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,CHEMBL624850,U,0,,,,,1,,BAO_0000218,
11117,,Autocuration,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,CHEMBL874399,U,0,,,,,1,,BAO_0000218,
11118,,Autocuration,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,CHEMBL624851,U,0,,,,,1,,BAO_0000218,
11119,,Autocuration,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,CHEMBL624852,U,0,,,,,1,,BAO_0000218,
11120,,Autocuration,,22224,Oral bioavailability in rat (dose 10 mg/kg),CHEMBL624853,U,0,,,,,1,,BAO_0000218,
11121,,Autocuration,,22224,Oral bioavailability in rat (Sprague-Dawley),CHEMBL624854,U,0,,,,,1,,BAO_0000218,
11122,,Autocuration,,22224,Oral bioavailability in rat,CHEMBL624855,U,0,,,,,1,,BAO_0000218,
11123,,Autocuration,,22224,Oral bioavailability in rats was determined in vivo,CHEMBL624856,U,0,,,,,1,,BAO_0000218,
11124,,Autocuration,,22224,Oral bioavailability in dog,CHEMBL882957,U,0,,,,,1,,BAO_0000218,
11125,,Autocuration,,22224,Oral bioavailability of compound in monkey,CHEMBL624857,U,0,,,,,1,,BAO_0000218,
11126,,Intermediate,,50597,Oral bioavailability of compound in rat,CHEMBL622202,N,1,,,,,1,,BAO_0000218,
11127,,Autocuration,,22224,Bioavailability in rat of PMEA prodrug,CHEMBL622203,U,0,,,,,1,,BAO_0000218,
11128,,Intermediate,,50597,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,CHEMBL625522,N,1,,,,,1,,BAO_0000218,
11129,,Autocuration,,22224,Serum conc at 3 hours following 25 mg/kg dose,CHEMBL622868,U,0,,,,,1,,BAO_0000218,
11130,1088.0,Autocuration,Urine,22224,Urine conc 0-5 hours following 25 mg/kg dose,CHEMBL622869,U,0,,,,,1,,BAO_0000218,
11131,1088.0,Autocuration,Urine,22224,Urine conc 0-24 hours following 25 mg/kg dose,CHEMBL622870,U,0,,,,,1,,BAO_0000218,
11132,,Autocuration,,22224,Oral bioavailability in African green monkeys; 20-25,CHEMBL622871,U,0,,,,,1,,BAO_0000218,
11133,,Intermediate,,100710,Oral bioavailability in cynomolgus monkey.,CHEMBL620560,N,1,,,,,1,,BAO_0000218,
11134,,Autocuration,,22224,Oral bioavailability in dog,CHEMBL620561,U,0,,,,,1,,BAO_0000218,
11135,,Intermediate,,50588,Oral bioavailability in dog at 10 mg/kg oral dose,CHEMBL620562,N,1,,,,,1,,BAO_0000218,
11136,,Intermediate,,100712,Oral bioavailability in hamster at 10 mg/kg oral dose,CHEMBL620563,N,1,,,,,1,,BAO_0000218,
11137,,Intermediate,,50597,Oral bioavailability in rat at 10 mg/kg oral dose,CHEMBL620564,N,1,,,,,1,,BAO_0000218,
11138,,Autocuration,,22224,Oral bioavailability in rat,CHEMBL872265,U,0,,,,,1,,BAO_0000218,
11139,,Autocuration,,22224,Oral bioavailability in rat,CHEMBL620565,U,0,,,,,1,,BAO_0000218,
11140,,Autocuration,,22224,Oral bioavailability,CHEMBL620566,U,0,,,,,1,,BAO_0000218,
11141,,Autocuration,,22224,Oral bioavailability was determined; range 49-102%,CHEMBL620567,U,0,,,,,1,,BAO_0000218,
11142,,Intermediate,,50588,Oral bioavailability was determined in dogs,CHEMBL620568,N,1,,,,,1,,BAO_0000218,
11143,,Autocuration,,22224,Oral bioavailability in rat,CHEMBL620569,U,0,,,,,1,,BAO_0000218,
11144,,Autocuration,,22224,Oral bioavailability,CHEMBL620570,U,0,,,,,1,,BAO_0000218,
11145,,Autocuration,,22224,Oral bioavailability was determined; Not orally available,CHEMBL620571,U,0,,,,,1,,BAO_0000218,
11146,,Intermediate,,50594,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),CHEMBL620572,N,1,,,,,1,,BAO_0000218,
11147,,Autocuration,,22224,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),CHEMBL620573,U,0,,,,,1,,BAO_0000218,
11148,,Autocuration,,22224,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,CHEMBL620574,U,0,,,,,1,,BAO_0000218,
11149,,Autocuration,,22224,Oral bioavailability in Rhesus monkey,CHEMBL620575,U,0,,,,,1,,BAO_0000218,
11150,,Autocuration,,22224,Oral bioavailability in dog (female mongrel),CHEMBL620576,U,0,,,,,1,,BAO_0000218,
11151,,Autocuration,,22224,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,CHEMBL875846,U,0,,,,,1,,BAO_0000218,
11152,,Autocuration,,22224,Oral bioavailability in dog,CHEMBL620577,U,0,,,,,1,,BAO_0000218,
11153,,Autocuration,,22224,Percentage Bioavailability was evaluated.,CHEMBL620578,U,0,,,,,1,,BAO_0000218,
11154,,Autocuration,,22224,Bioavailability in rat administered i.d.,CHEMBL620579,U,0,,,,,1,,BAO_0000218,
11155,,Autocuration,,22224,Bioavailability,CHEMBL621248,U,0,,,,,1,,BAO_0000218,
11156,,Autocuration,,22224,Bioavailability in dog (male Beagle) i.v. administration,CHEMBL625390,U,0,,,,,1,,BAO_0000218,
11157,,Autocuration,,22224,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",CHEMBL625391,U,0,,,,,1,,BAO_0000218,
11158,,Autocuration,,22224,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),CHEMBL872266,U,0,,,,,1,,BAO_0000218,
11159,,Autocuration,,22224,Oral bioavailability in rat (Sprague-Dawley) (male),CHEMBL625392,U,0,,,,,1,,BAO_0000218,
11160,,Intermediate,,50597,The oral bioavailability was measured on rats after oral administration,CHEMBL625393,N,1,,,,,1,,BAO_0000218,
11161,,Intermediate,,50597,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,CHEMBL625394,N,1,,,,,1,,BAO_0000218,
11162,,Intermediate,,50797,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,CHEMBL625395,N,1,,,,,1,,BAO_0000218,
11163,,Autocuration,,22224,Bioavailability in rat (dose 10 mg/kg i.d.),CHEMBL625396,U,0,,,,,1,,BAO_0000218,
11164,,Autocuration,,22224,Bioavailability in dog (male Beagle) i.v. administration,CHEMBL625397,U,0,,,,,1,,BAO_0000218,
11165,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625398,N,1,,,,,1,,BAO_0000218,
11166,178.0,Intermediate,Blood,50594,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625399,N,1,,,,,1,,BAO_0000218,
11167,2037.0,Intermediate,Cerebellum,50594,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL626074,N,1,,,,,1,,BAO_0000218,
11168,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL626075,N,1,,,,,1,,BAO_0000218,
11169,1969.0,Intermediate,Plasma,50597,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,CHEMBL626076,N,1,,,,,1,,BAO_0000218,
11170,1969.0,Intermediate,Plasma,50797,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,CHEMBL626077,N,1,,,,,1,,BAO_0000218,
11171,178.0,Intermediate,Blood,50597,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),CHEMBL626078,N,1,,,,,1,,BAO_0000218,
11172,178.0,Autocuration,Blood,22224,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),CHEMBL625846,U,0,,,,,1,,BAO_0000218,
11173,178.0,Autocuration,Blood,22224,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),CHEMBL625847,U,0,,,,,1,,BAO_0000218,
11174,,Expert,,50597,Maximum concentration observed in rats at an oral dose of 50 mg/kg,CHEMBL625848,N,1,,,,,1,,BAO_0000218,
11175,1969.0,Intermediate,Plasma,50597,Maximum concentration of compound in plasma administered orally to rats,CHEMBL625849,N,1,,,,,1,,BAO_0000218,
11176,1969.0,Intermediate,Plasma,50588,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",CHEMBL626023,N,1,,,,,1,,BAO_0000218,
11177,1969.0,Intermediate,Plasma,50588,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",CHEMBL626024,N,1,,,,,1,,BAO_0000218,
11178,1969.0,Intermediate,Plasma,50588,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",CHEMBL626025,N,1,,,,,1,,BAO_0000218,
11179,,Autocuration,,22224,Maximum concentration after 10 mg/kg by oral administration,CHEMBL626026,U,0,,,,,1,,BAO_0000218,
11180,,Autocuration,,22224,Maximum concentration at a dose of 1.5 mg/kg,CHEMBL626027,U,0,,,,,1,,BAO_0000218,
11181,,Autocuration,,22224,Maximum concentration at a dose of 2.0 mg/kg,CHEMBL626028,U,0,,,,,1,,BAO_0000218,
11182,1969.0,Intermediate,Plasma,50588,Maximum concentration in dog plasma,CHEMBL626029,N,1,,,,,1,,BAO_0000218,
11183,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,CHEMBL626030,U,0,,,,,1,,BAO_0000218,
11184,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,CHEMBL626031,U,0,,,,,1,,BAO_0000218,
11185,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,CHEMBL626032,U,0,,,,,1,,BAO_0000218,
11186,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,CHEMBL626033,U,0,,,,,1,,BAO_0000218,
11187,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,CHEMBL626034,U,0,,,,,1,,BAO_0000218,
11188,1969.0,Intermediate,Plasma,50588,Maximum concentration in plasma after oral administration in dog (25 mg/kg),CHEMBL626035,N,1,,,,,1,,BAO_0000218,
11189,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma at Tmax,CHEMBL626036,U,0,,,,,1,,BAO_0000218,
11190,1969.0,Expert,Plasma,50588,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,CHEMBL626037,N,1,,,,,1,,BAO_0000218,
11191,1969.0,Intermediate,Plasma,100712,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,CHEMBL626038,N,1,,,,,1,,BAO_0000218,
11192,1969.0,Intermediate,Plasma,50597,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,CHEMBL626039,N,1,,,,,1,,BAO_0000218,
11193,1969.0,Intermediate,Plasma,50597,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,CHEMBL626040,N,1,,,,,1,,BAO_0000218,
11194,1969.0,Intermediate,Plasma,50592,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,CHEMBL626041,N,1,,,,,1,,BAO_0000218,
11195,,Autocuration,,22224,Maximum concentration was calculated,CHEMBL626042,U,0,,,,,1,,BAO_0000218,
11196,,Autocuration,,22224,Maximum concentration was calculated.,CHEMBL626043,U,0,,,,,1,,BAO_0000218,
11197,,Autocuration,,22224,Maximum concentration at a peroral dose of 10 mg/kg,CHEMBL626044,U,0,,,,,1,,BAO_0000218,
11198,,Autocuration,,22224,Maximum concentration of the drug at 10 uM/dg administered perorally,CHEMBL626045,U,0,,,,,1,,BAO_0000218,
11199,,Autocuration,,22224,Maximum concentration of the drug at 2 uM/dg administered intravenously,CHEMBL626046,U,0,,,,,1,,BAO_0000218,
11200,1969.0,Intermediate,Plasma,50588,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",CHEMBL626047,N,1,,,,,1,,BAO_0000218,
11201,1969.0,Intermediate,Plasma,100712,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",CHEMBL626048,N,1,,,,,1,,BAO_0000218,
11202,1969.0,Intermediate,Plasma,50597,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",CHEMBL626049,N,1,,,,,1,,BAO_0000218,
11203,1969.0,Intermediate,Plasma,50597,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,CHEMBL626050,N,1,,,,,1,,BAO_0000218,
11204,1969.0,Intermediate,Plasma,50588,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,CHEMBL874541,N,1,,,,,1,,BAO_0000218,
11205,1969.0,Intermediate,Plasma,100712,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,CHEMBL622826,N,1,,,,,1,,BAO_0000218,
11206,1969.0,Intermediate,Plasma,100712,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,CHEMBL622827,N,1,,,,,1,,BAO_0000218,
11207,1969.0,Intermediate,Plasma,50597,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,CHEMBL622828,N,1,,,,,1,,BAO_0000218,
11208,1969.0,Intermediate,Plasma,50597,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,CHEMBL622829,N,1,,,,,1,,BAO_0000218,
11209,,Intermediate,,50597,Maximum concentration reached following intravenous administration in male rat,CHEMBL876806,N,1,,,,,1,,BAO_0000218,
11210,,Intermediate,,50588,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,CHEMBL622830,N,1,,,,,1,,BAO_0000218,
11211,,Intermediate,,50597,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,CHEMBL622831,N,1,,,,,1,,BAO_0000218,
11212,,Intermediate,,50588,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,CHEMBL626794,N,1,,,,,1,,BAO_0000218,
11213,,Intermediate,,50597,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,CHEMBL626795,N,1,,,,,1,,BAO_0000218,
11214,,Intermediate,,50597,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,CHEMBL626796,N,1,,,,,1,,BAO_0000218,
11215,,Intermediate,,50597,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,CHEMBL626797,N,1,,,,,1,,BAO_0000218,
11216,,Intermediate,,50597,Maximum drug concentration is determined after oral dosing in rats.,CHEMBL626798,N,1,,,,,1,,BAO_0000218,
11217,,Intermediate,,50588,Maximum observed concentration in oral (5 mg/kg) fasted dogs,CHEMBL626799,N,1,,,,,1,,BAO_0000218,
11218,,Intermediate,,50588,Maximum observed concentration in oral (5 mg/kg) fed dogs,CHEMBL626800,N,1,,,,,1,,BAO_0000218,
11219,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration,CHEMBL626801,U,0,,,,,1,,BAO_0000218,
11220,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,CHEMBL876816,N,1,,,,,1,,BAO_0000218,
11221,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,CHEMBL626802,N,1,,,,,1,,BAO_0000218,
11222,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,CHEMBL626803,N,1,,,,,1,,BAO_0000218,
11223,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration following oral administration of 30 umol/kg,CHEMBL626804,U,0,,,,,1,,BAO_0000218,
11224,1969.0,Intermediate,Plasma,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,CHEMBL626805,N,1,,,,,1,,BAO_0000218,
11225,1969.0,Intermediate,Plasma,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,CHEMBL626309,N,1,,,,,1,,BAO_0000218,
11226,1969.0,Intermediate,Plasma,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,CHEMBL626310,N,1,,,,,1,,BAO_0000218,
11227,1969.0,Intermediate,Plasma,50597,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL626311,N,1,,,,,1,,BAO_0000218,
11228,1969.0,Intermediate,Plasma,50597,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL626312,N,1,,,,,1,,BAO_0000218,
11229,995.0,Intermediate,Uterus,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL626313,N,1,,,,,1,,BAO_0000218,
11230,995.0,Intermediate,Uterus,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,CHEMBL626314,N,1,,,,,1,,BAO_0000218,
11231,995.0,Intermediate,Uterus,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,CHEMBL626315,N,1,,,,,1,,BAO_0000218,
11232,995.0,Intermediate,Uterus,50597,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL626316,N,1,,,,,1,,BAO_0000218,
11233,995.0,Intermediate,Uterus,50597,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,CHEMBL626317,N,1,,,,,1,,BAO_0000218,
11234,,Intermediate,,50597,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),CHEMBL626318,N,1,,,,,1,,BAO_0000218,
11235,,Intermediate,,50597,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),CHEMBL626319,N,1,,,,,1,,BAO_0000218,
11236,,Intermediate,,50597,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),CHEMBL626320,N,1,,,,,1,,BAO_0000218,
11237,,Intermediate,,50597,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),CHEMBL875053,N,1,,,,,1,,BAO_0000218,
11238,,Intermediate,,50597,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),CHEMBL626321,N,1,,,,,1,,BAO_0000218,
11239,,Intermediate,,50597,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),CHEMBL626322,N,1,,,,,1,,BAO_0000218,
11240,,Intermediate,,50597,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),CHEMBL626323,N,1,,,,,1,,BAO_0000218,
11241,,Intermediate,,50597,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),CHEMBL626324,N,1,,,,,1,,BAO_0000218,
11242,,Intermediate,,50597,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),CHEMBL626325,N,1,,,,,1,,BAO_0000218,
11243,,Intermediate,,50597,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),CHEMBL626326,N,1,,,,,1,,BAO_0000218,
11244,,Intermediate,,50597,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),CHEMBL626327,N,1,,,,,1,,BAO_0000218,
11245,,Intermediate,,50597,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),CHEMBL626328,N,1,,,,,1,,BAO_0000218,
11246,178.0,Intermediate,Blood,50597,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",CHEMBL626329,N,1,,,,,1,,BAO_0000218,
11247,178.0,Intermediate,Blood,50597,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",CHEMBL626330,N,1,,,,,1,,BAO_0000218,
11248,178.0,Intermediate,Blood,50597,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",CHEMBL626331,N,1,,,,,1,,BAO_0000218,
11249,178.0,Intermediate,Blood,50597,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",CHEMBL626332,N,1,,,,,1,,BAO_0000218,
11250,178.0,Intermediate,Blood,50597,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",CHEMBL626333,N,1,,,,,1,,BAO_0000218,
11251,178.0,Intermediate,Blood,50597,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",CHEMBL626334,N,1,,,,,1,,BAO_0000218,
11252,178.0,Intermediate,Blood,50597,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",CHEMBL626335,N,1,,,,,1,,BAO_0000218,
11253,178.0,Intermediate,Blood,50597,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",CHEMBL624798,N,1,,,,,1,,BAO_0000218,
11254,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",CHEMBL624799,N,1,,,,,1,,BAO_0000218,
11255,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",CHEMBL624800,N,1,,,,,1,,BAO_0000218,
11256,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",CHEMBL624801,N,1,,,,,1,,BAO_0000218,
11257,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",CHEMBL624802,N,1,,,,,1,,BAO_0000218,
11258,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",CHEMBL624803,N,1,,,,,1,,BAO_0000218,
11259,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",CHEMBL624804,N,1,,,,,1,,BAO_0000218,
11260,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",CHEMBL624805,N,1,,,,,1,,BAO_0000218,
11261,955.0,Intermediate,Brain,50597,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",CHEMBL624806,N,1,,,,,1,,BAO_0000218,
11262,,Intermediate,,50597,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",CHEMBL624807,N,1,,,,,1,,BAO_0000218,
11263,,Intermediate,,50597,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",CHEMBL624808,N,1,,,,,1,,BAO_0000218,
11264,,Intermediate,,50597,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",CHEMBL624809,N,1,,,,,1,,BAO_0000218,
11265,,Intermediate,,50597,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",CHEMBL624810,N,1,,,,,1,,BAO_0000218,
11266,,Intermediate,,50597,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",CHEMBL877618,N,1,,,,,1,,BAO_0000218,
11267,,Intermediate,,50597,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",CHEMBL624811,N,1,,,,,1,,BAO_0000218,
11268,,Intermediate,,50597,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",CHEMBL624812,N,1,,,,,1,,BAO_0000218,
11269,,Intermediate,,50597,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",CHEMBL624813,N,1,,,,,1,,BAO_0000218,
11270,,Intermediate,,50597,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",CHEMBL624814,N,1,,,,,1,,BAO_0000218,
11271,,Intermediate,,50597,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",CHEMBL624815,N,1,,,,,1,,BAO_0000218,
11272,,Intermediate,,50597,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",CHEMBL624816,N,1,,,,,1,,BAO_0000218,
11273,,Intermediate,,50597,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",CHEMBL624817,N,1,,,,,1,,BAO_0000218,
11274,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),CHEMBL624818,N,1,,,,,1,,BAO_0000218,
11275,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,CHEMBL624819,N,1,,,,,1,,BAO_0000218,
11276,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),CHEMBL624820,N,1,,,,,1,,BAO_0000218,
11277,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),CHEMBL624821,N,1,,,,,1,,BAO_0000218,
11278,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),CHEMBL624822,N,1,,,,,1,,BAO_0000218,
11279,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),CHEMBL624823,N,1,,,,,1,,BAO_0000218,
11280,,Intermediate,,50212,Observed diffusion coefficient in organic solvent for Escherichia coli,CHEMBL624824,N,1,,,,,1,,BAO_0000218,
11281,178.0,Intermediate,Blood,50597,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",CHEMBL624825,N,1,,,,,1,,BAO_0000218,
11282,178.0,Intermediate,Blood,50597,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",CHEMBL624826,N,1,,,,,1,,BAO_0000218,
11283,2081.0,Intermediate,Cardiac atrium,50597,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",CHEMBL876817,N,1,,,,,1,,BAO_0000218,
11284,2081.0,Intermediate,Cardiac atrium,50597,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",CHEMBL624827,N,1,,,,,1,,BAO_0000218,
11285,,Intermediate,,50597,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",CHEMBL624828,N,1,,,,,1,,BAO_0000218,
11286,,Intermediate,,50597,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",CHEMBL624829,N,1,,,,,1,,BAO_0000218,
11287,2107.0,Intermediate,Liver,50597,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",CHEMBL624830,N,1,,,,,1,,BAO_0000218,
11288,2107.0,Intermediate,Liver,50597,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",CHEMBL624831,N,1,,,,,1,,BAO_0000218,
11289,2081.0,Intermediate,Cardiac atrium,50597,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",CHEMBL624832,N,1,,,,,1,,BAO_0000218,
11290,2081.0,Intermediate,Cardiac atrium,50597,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",CHEMBL624833,N,1,,,,,1,,BAO_0000218,
11291,,Intermediate,,50597,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",CHEMBL624834,N,1,,,,,1,,BAO_0000218,
11292,,Intermediate,,50597,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",CHEMBL624835,N,1,,,,,1,,BAO_0000218,
11293,2106.0,Intermediate,Spleen,50597,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",CHEMBL624836,N,1,,,,,1,,BAO_0000218,
11294,2106.0,Intermediate,Spleen,50597,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",CHEMBL624837,N,1,,,,,1,,BAO_0000218,
11295,178.0,Intermediate,Blood,50597,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,CHEMBL624838,N,1,,,,,1,,BAO_0000218,
11296,178.0,Intermediate,Blood,50597,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,CHEMBL622188,N,1,,,,,1,,BAO_0000218,
11297,948.0,Intermediate,Heart,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,CHEMBL622189,N,1,,,,,1,,BAO_0000218,
11298,948.0,Intermediate,Heart,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,CHEMBL622190,N,1,,,,,1,,BAO_0000218,
11299,948.0,Intermediate,Heart,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,CHEMBL625170,N,1,,,,,1,,BAO_0000218,
11300,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,CHEMBL625171,N,1,,,,,1,,BAO_0000218,
11301,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,CHEMBL625172,N,1,,,,,1,,BAO_0000218,
11302,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,CHEMBL625173,N,1,,,,,1,,BAO_0000218,
11303,2107.0,Intermediate,Liver,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,CHEMBL625174,N,1,,,,,1,,BAO_0000218,
11304,2107.0,Intermediate,Liver,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,CHEMBL625175,N,1,,,,,1,,BAO_0000218,
11305,2107.0,Intermediate,Liver,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,CHEMBL625176,N,1,,,,,1,,BAO_0000218,
11306,2048.0,Intermediate,Lung,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,CHEMBL625177,N,1,,,,,1,,BAO_0000218,
11307,2048.0,Intermediate,Lung,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,CHEMBL625178,N,1,,,,,1,,BAO_0000218,
11308,2048.0,Intermediate,Lung,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,CHEMBL625179,N,1,,,,,1,,BAO_0000218,
11309,2048.0,Intermediate,Lung,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,CHEMBL625180,N,1,,,,,1,,BAO_0000218,
11310,,Autocuration,,22224,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",CHEMBL625181,U,0,,,,,1,,BAO_0000218,
11311,1088.0,Intermediate,Urine,50594,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,CHEMBL625182,N,1,,,,,1,,BAO_0000218,
11312,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,CHEMBL625183,N,1,,,,,1,,BAO_0000218,
11313,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,CHEMBL875848,N,1,,,,,1,,BAO_0000218,
11314,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,CHEMBL622260,N,1,,,,,1,,BAO_0000218,
11315,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,CHEMBL622261,N,1,,,,,1,,BAO_0000218,
11316,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,CHEMBL622262,N,1,,,,,1,,BAO_0000218,
11317,2113.0,Intermediate,Kidney,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,CHEMBL622263,N,1,,,,,1,,BAO_0000218,
11318,2113.0,Intermediate,Kidney,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,CHEMBL622418,N,1,,,,,1,,BAO_0000218,
11319,2107.0,Intermediate,Liver,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,CHEMBL622419,N,1,,,,,1,,BAO_0000218,
11320,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL623388,N,1,,,,,1,,BAO_0000218,
11321,2107.0,Intermediate,Liver,50594,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL623389,N,1,,,,,1,,BAO_0000218,
11322,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL623390,N,1,,,,,1,,BAO_0000218,
11323,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL623391,N,1,,,,,1,,BAO_0000218,
11324,178.0,Intermediate,Blood,50594,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL623392,N,1,,,,,1,,BAO_0000218,
11325,2037.0,Intermediate,Cerebellum,50594,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL623393,N,1,,,,,1,,BAO_0000218,
11326,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL623394,N,1,,,,,1,,BAO_0000218,
11327,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL618885,N,1,,,,,1,,BAO_0000218,
11328,2107.0,Intermediate,Liver,50594,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL618886,N,1,,,,,1,,BAO_0000218,
11329,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL618887,N,1,,,,,1,,BAO_0000218,
11330,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL619535,N,1,,,,,1,,BAO_0000218,
11331,178.0,Intermediate,Blood,50594,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL619536,N,1,,,,,1,,BAO_0000218,
11332,2037.0,Intermediate,Cerebellum,50594,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL619537,N,1,,,,,1,,BAO_0000218,
11333,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL619705,N,1,,,,,1,,BAO_0000218,
11334,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL619706,N,1,,,,,1,,BAO_0000218,
11335,2107.0,Intermediate,Liver,50594,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL619707,N,1,,,,,1,,BAO_0000218,
11336,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL619708,N,1,,,,,1,,BAO_0000218,
11337,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625219,N,1,,,,,1,,BAO_0000218,
11338,178.0,Intermediate,Blood,50594,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625220,N,1,,,,,1,,BAO_0000218,
11339,2037.0,Intermediate,Cerebellum,50594,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625221,N,1,,,,,1,,BAO_0000218,
11340,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625222,N,1,,,,,1,,BAO_0000218,
11341,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625223,N,1,,,,,1,,BAO_0000218,
11342,2107.0,Intermediate,Liver,50594,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625224,N,1,,,,,1,,BAO_0000218,
11343,,Intermediate,,50594,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),CHEMBL625225,N,1,,,,,1,,BAO_0000218,
11344,178.0,Intermediate,Blood,50597,Biodistribution in Rat blood after 24 hours of iv administration,CHEMBL625226,N,1,,,,,1,,BAO_0000218,
11345,178.0,Intermediate,Blood,50597,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,CHEMBL625227,N,1,,,,,1,,BAO_0000218,
11346,178.0,Intermediate,Blood,50597,Biodistribution in Rat blood after 30 minutes of iv administration,CHEMBL625228,N,1,,,,,1,,BAO_0000218,
11347,178.0,Intermediate,Blood,50597,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,CHEMBL875354,N,1,,,,,1,,BAO_0000218,
11348,178.0,Intermediate,Blood,50597,Biodistribution in Rat blood after 5 minutes of iv administration,CHEMBL625229,N,1,,,,,1,,BAO_0000218,
11349,178.0,Intermediate,Blood,50597,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,CHEMBL625230,N,1,,,,,1,,BAO_0000218,
11350,948.0,Intermediate,Heart,50597,Biodistribution in Rat heart after 24 hours of iv administration,CHEMBL625231,N,1,,,,,1,,BAO_0000218,
11351,948.0,Intermediate,Heart,50597,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,CHEMBL625900,N,1,,,,,1,,BAO_0000218,
11352,948.0,Intermediate,Heart,50597,Biodistribution in Rat heart after 30 minutes of iv administration,CHEMBL625901,N,1,,,,,1,,BAO_0000218,
11353,948.0,Intermediate,Heart,50597,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,CHEMBL625902,N,1,,,,,1,,BAO_0000218,
11354,948.0,Intermediate,Heart,50597,Biodistribution in Rat heart after 5 minutes of iv administration,CHEMBL625903,N,1,,,,,1,,BAO_0000218,
11355,948.0,Intermediate,Heart,50597,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,CHEMBL625904,N,1,,,,,1,,BAO_0000218,
11356,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 24 hours of iv administration,CHEMBL625905,N,1,,,,,1,,BAO_0000218,
11357,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,CHEMBL627861,N,1,,,,,1,,BAO_0000218,
11358,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 30 minutes of iv administration,CHEMBL627862,N,1,,,,,1,,BAO_0000218,
11359,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,CHEMBL627863,N,1,,,,,1,,BAO_0000218,
11360,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 30 minutes of iv administration,CHEMBL627769,N,1,,,,,1,,BAO_0000218,
11361,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,CHEMBL627770,N,1,,,,,1,,BAO_0000218,
11362,,Intermediate,,100710,Cmax in cynomolgus monkey (PO dose),CHEMBL627771,N,1,,,,,1,,BAO_0000218,
11363,,Intermediate,,50597,Cmax in rat (PO dose),CHEMBL627772,N,1,,,,,1,,BAO_0000218,
11364,,Intermediate,,50597,Cmax in rat (PO dose),CHEMBL627773,N,1,,,,,1,,BAO_0000218,
11365,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,CHEMBL621922,N,1,,,,,1,,BAO_0000218,
11366,1969.0,Intermediate,Plasma,50597,Cmax in rat plasma after oral dose (10 mg/kg),CHEMBL621923,N,1,,,,,1,,BAO_0000218,
11367,1969.0,Autocuration,Plasma,22224,Cmax in plasma after oral dose (10 mg/kg),CHEMBL621924,U,0,,,,,1,,BAO_0000218,
11368,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,CHEMBL621925,N,1,,,,,1,,BAO_0000218,
11369,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,CHEMBL621926,U,0,,,,,1,,BAO_0000218,
11370,1969.0,Intermediate,Plasma,50592,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,CHEMBL621927,N,1,,,,,1,,BAO_0000218,
11371,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,CHEMBL621928,N,1,,,,,1,,BAO_0000218,
11372,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,CHEMBL621929,N,1,,,,,1,,BAO_0000218,
11373,1969.0,Intermediate,Plasma,50594,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,CHEMBL621930,N,1,,,,,1,,BAO_0000218,
11374,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration after oral dosing in rat,CHEMBL621931,N,1,,,,,1,,BAO_0000218,
11375,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,CHEMBL621932,U,0,,,,,1,,BAO_0000218,
11376,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,CHEMBL621933,U,0,,,,,1,,BAO_0000218,
11377,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,CHEMBL621934,N,1,,,,,1,,BAO_0000218,
11378,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,CHEMBL621935,N,1,,,,,1,,BAO_0000218,
11379,1969.0,Intermediate,Plasma,50597,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,CHEMBL621936,N,1,,,,,1,,BAO_0000218,
11380,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was determined,CHEMBL621937,U,0,,,,,1,,BAO_0000218,
11381,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,CHEMBL621938,U,0,,,,,1,,BAO_0000218,
11382,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,CHEMBL621939,U,0,,,,,1,,BAO_0000218,
11383,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,CHEMBL621940,U,0,,,,,1,,BAO_0000218,
11384,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,CHEMBL621941,U,0,,,,,1,,BAO_0000218,
11385,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,CHEMBL621942,U,0,,,,,1,,BAO_0000218,
11386,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,CHEMBL626178,U,0,,,,,1,,BAO_0000218,
11387,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,CHEMBL626179,U,0,,,,,1,,BAO_0000218,
11388,1969.0,Autocuration,Plasma,22224,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,CHEMBL626180,U,0,,,,,1,,BAO_0000218,
11389,1969.0,Intermediate,Plasma,50597,Plasma Cmax in rat (PO dose),CHEMBL626181,N,1,,,,,1,,BAO_0000218,
11390,,Intermediate,,50597,Maximum serum concentration after po dose of 5.22 mg/kg in rats,CHEMBL626182,N,1,,,,,1,,BAO_0000218,
11391,,Intermediate,,50597,Maximum serum concentration after po dose of 5.46 mg/kg in rats,CHEMBL626183,N,1,,,,,1,,BAO_0000218,
11392,,Intermediate,,50597,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,CHEMBL626184,N,1,,,,,1,,BAO_0000218,
11393,,Intermediate,,50597,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,CHEMBL626185,N,1,,,,,1,,BAO_0000218,
11394,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,CHEMBL626186,N,1,,,,,1,,BAO_0000218,
11395,1969.0,Intermediate,Plasma,50588,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,CHEMBL877589,N,1,,,,,1,,BAO_0000218,
11396,,Autocuration,,22224,Maximum concentration of the drug at 1 uM/dg administered intravenously,CHEMBL626187,U,0,,,,,1,,BAO_0000218,
11397,,Autocuration,,22224,Maximum concentration of the drug at 20 uM/dg administered perorally,CHEMBL626188,U,0,,,,,1,,BAO_0000218,
11398,,Autocuration,,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,CHEMBL626189,U,0,,,,,1,,BAO_0000218,
11399,178.0,Autocuration,Blood,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,CHEMBL626855,U,0,,,,,1,,BAO_0000218,
11400,178.0,Autocuration,Blood,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,CHEMBL623781,U,0,,,,,1,,BAO_0000218,
11401,178.0,Autocuration,Blood,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,CHEMBL623782,U,0,,,,,1,,BAO_0000218,
11402,1969.0,Intermediate,Plasma,50597,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,CHEMBL623783,N,1,,,,,1,,BAO_0000218,
11403,1969.0,Intermediate,Plasma,50588,Cmax in dog plasma after 1mg/kg oral dose,CHEMBL623784,N,1,,,,,1,,BAO_0000218,
11404,1969.0,Intermediate,Plasma,50588,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,CHEMBL623785,N,1,,,,,1,,BAO_0000218,
11405,1969.0,Intermediate,Plasma,50597,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,CHEMBL623786,N,1,,,,,1,,BAO_0000218,
11406,,Intermediate,,50597,Oral maximum concentration in rat,CHEMBL623787,N,1,,,,,1,,BAO_0000218,
11407,,Intermediate,,50597,Oral maximum concentration in rat,CHEMBL623788,N,1,,,,,1,,BAO_0000218,
11408,1969.0,Intermediate,Plasma,50594,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,CHEMBL623789,N,1,,,,,1,,BAO_0000218,
11409,178.0,Intermediate,Blood,50594,Peak concentration in blood after intravenous administration to mice,CHEMBL623790,N,1,,,,,1,,BAO_0000218,
11410,178.0,Intermediate,Blood,50594,Peak concentration in blood after peroral administration to mice,CHEMBL623791,N,1,,,,,1,,BAO_0000218,
11411,1969.0,Intermediate,Plasma,50597,Peak concentration in rat plasma was determined,CHEMBL623792,N,1,,,,,1,,BAO_0000218,
11412,1969.0,Autocuration,Plasma,22224,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,CHEMBL623793,U,0,,,,,1,,BAO_0000218,
11413,1969.0,Intermediate,Plasma,50594,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,CHEMBL623794,N,1,,,,,1,,BAO_0000218,
11414,1969.0,Intermediate,Plasma,50597,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,CHEMBL623795,N,1,,,,,1,,BAO_0000218,
11415,,Intermediate,,50597,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",CHEMBL623796,N,1,,,,,1,,BAO_0000218,
11416,,Intermediate,,50597,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",CHEMBL623797,N,1,,,,,1,,BAO_0000218,
11417,,Intermediate,,50597,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",CHEMBL623798,N,1,,,,,1,,BAO_0000218,
11418,,Intermediate,,50597,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",CHEMBL623799,N,1,,,,,1,,BAO_0000218,
11419,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",CHEMBL624490,N,1,,,,,1,,BAO_0000218,
11420,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",CHEMBL624491,N,1,,,,,1,,BAO_0000218,
11421,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",CHEMBL624492,N,1,,,,,1,,BAO_0000218,
11422,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",CHEMBL624493,N,1,,,,,1,,BAO_0000218,
11423,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",CHEMBL877595,N,1,,,,,1,,BAO_0000218,
11424,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",CHEMBL624494,N,1,,,,,1,,BAO_0000218,
11425,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",CHEMBL624495,N,1,,,,,1,,BAO_0000218,
11426,160.0,Intermediate,Intestine,50597,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",CHEMBL624681,N,1,,,,,1,,BAO_0000218,
11427,,Intermediate,,50597,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",CHEMBL624682,N,1,,,,,1,,BAO_0000218,
11428,,Intermediate,,50597,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",CHEMBL624683,N,1,,,,,1,,BAO_0000218,
11429,,Intermediate,,50597,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",CHEMBL624684,N,1,,,,,1,,BAO_0000218,
11430,,Intermediate,,50597,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",CHEMBL624685,N,1,,,,,1,,BAO_0000218,
11431,,Intermediate,,50597,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",CHEMBL624686,N,1,,,,,1,,BAO_0000218,
11432,,Intermediate,,50597,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",CHEMBL624687,N,1,,,,,1,,BAO_0000218,
11433,,Intermediate,,50597,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",CHEMBL624688,N,1,,,,,1,,BAO_0000218,
11434,,Intermediate,,50597,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",CHEMBL627161,N,1,,,,,1,,BAO_0000218,
11435,,Intermediate,,50597,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",CHEMBL622127,N,1,,,,,1,,BAO_0000218,
11436,,Intermediate,,50597,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",CHEMBL622128,N,1,,,,,1,,BAO_0000218,
11437,,Intermediate,,50597,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",CHEMBL874384,N,1,,,,,1,,BAO_0000218,
11438,,Intermediate,,50597,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",CHEMBL624898,N,1,,,,,1,,BAO_0000218,
11439,,Intermediate,,50597,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",CHEMBL624899,N,1,,,,,1,,BAO_0000218,
11440,,Intermediate,,50597,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",CHEMBL624900,N,1,,,,,1,,BAO_0000218,
11441,,Intermediate,,50597,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",CHEMBL624901,N,1,,,,,1,,BAO_0000218,
11442,,Intermediate,,50597,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",CHEMBL624902,N,1,,,,,1,,BAO_0000218,
11443,,Intermediate,,50597,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",CHEMBL624903,N,1,,,,,1,,BAO_0000218,
11444,,Intermediate,,50597,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",CHEMBL624904,N,1,,,,,1,,BAO_0000218,
11445,,Intermediate,,50597,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",CHEMBL624905,N,1,,,,,1,,BAO_0000218,
11446,,Intermediate,,50597,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",CHEMBL624906,N,1,,,,,1,,BAO_0000218,
11447,,Intermediate,,50597,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",CHEMBL624907,N,1,,,,,1,,BAO_0000218,
11448,,Intermediate,,50597,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",CHEMBL624908,N,1,,,,,1,,BAO_0000218,
11449,,Intermediate,,50597,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",CHEMBL624909,N,1,,,,,1,,BAO_0000218,
11450,,Intermediate,,50597,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",CHEMBL624910,N,1,,,,,1,,BAO_0000218,
11451,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",CHEMBL624911,N,1,,,,,1,,BAO_0000218,
11452,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",CHEMBL874388,N,1,,,,,1,,BAO_0000218,
11453,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",CHEMBL624912,N,1,,,,,1,,BAO_0000218,
11454,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",CHEMBL622930,N,1,,,,,1,,BAO_0000218,
11455,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",CHEMBL623121,N,1,,,,,1,,BAO_0000218,
11456,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",CHEMBL623122,N,1,,,,,1,,BAO_0000218,
11457,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",CHEMBL623123,N,1,,,,,1,,BAO_0000218,
11458,2385.0,Intermediate,Muscle tissue,50597,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",CHEMBL623124,N,1,,,,,1,,BAO_0000218,
11459,,Intermediate,,50597,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",CHEMBL623125,N,1,,,,,1,,BAO_0000218,
11460,,Intermediate,,50597,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",CHEMBL623126,N,1,,,,,1,,BAO_0000218,
11461,,Intermediate,,50597,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",CHEMBL623127,N,1,,,,,1,,BAO_0000218,
11462,,Intermediate,,50597,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",CHEMBL623128,N,1,,,,,1,,BAO_0000218,
11463,,Intermediate,,50597,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",CHEMBL623129,N,1,,,,,1,,BAO_0000218,
11464,,Intermediate,,50597,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",CHEMBL623130,N,1,,,,,1,,BAO_0000218,
11465,,Intermediate,,50597,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",CHEMBL623131,N,1,,,,,1,,BAO_0000218,
11466,,Intermediate,,50597,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",CHEMBL623132,N,1,,,,,1,,BAO_0000218,
11467,2107.0,Intermediate,Liver,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,CHEMBL623133,N,1,,,,,1,,BAO_0000218,
11468,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,CHEMBL623134,N,1,,,,,1,,BAO_0000218,
11469,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,CHEMBL874389,N,1,,,,,1,,BAO_0000218,
11470,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,CHEMBL623135,N,1,,,,,1,,BAO_0000218,
11471,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,CHEMBL623136,N,1,,,,,1,,BAO_0000218,
11472,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,CHEMBL623137,N,1,,,,,1,,BAO_0000218,
11473,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,CHEMBL623138,N,1,,,,,1,,BAO_0000218,
11474,2113.0,Intermediate,Kidney,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,CHEMBL623139,N,1,,,,,1,,BAO_0000218,
11475,2113.0,Intermediate,Kidney,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,CHEMBL623140,N,1,,,,,1,,BAO_0000218,
11476,2107.0,Intermediate,Liver,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,CHEMBL623141,N,1,,,,,1,,BAO_0000218,
11477,2107.0,Intermediate,Liver,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,CHEMBL623142,N,1,,,,,1,,BAO_0000218,
11478,,Intermediate,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,CHEMBL623143,N,1,,,,,1,,BAO_0000218,
11479,1088.0,Intermediate,Urine,50594,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,CHEMBL623144,N,1,,,,,1,,BAO_0000218,
11480,1088.0,Intermediate,Urine,50597,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,CHEMBL623405,N,1,,,,,1,,BAO_0000218,
11481,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,CHEMBL624074,N,1,,,,,1,,BAO_0000218,
11482,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,CHEMBL624075,N,1,,,,,1,,BAO_0000218,
11483,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,CHEMBL624076,N,1,,,,,1,,BAO_0000218,
11484,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,CHEMBL624077,N,1,,,,,1,,BAO_0000218,
11485,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,CHEMBL624078,N,1,,,,,1,,BAO_0000218,
11486,2113.0,Intermediate,Kidney,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,CHEMBL624079,N,1,,,,,1,,BAO_0000218,
11487,2113.0,Intermediate,Kidney,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,CHEMBL624261,N,1,,,,,1,,BAO_0000218,
11488,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,CHEMBL624262,N,1,,,,,1,,BAO_0000218,
11489,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,CHEMBL624263,N,1,,,,,1,,BAO_0000218,
11490,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,CHEMBL624264,N,1,,,,,1,,BAO_0000218,
11491,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,CHEMBL624265,N,1,,,,,1,,BAO_0000218,
11492,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,CHEMBL624266,N,1,,,,,1,,BAO_0000218,
11493,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,CHEMBL624267,N,1,,,,,1,,BAO_0000218,
11494,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,CHEMBL624268,N,1,,,,,1,,BAO_0000218,
11495,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,CHEMBL875227,N,1,,,,,1,,BAO_0000218,
11496,2113.0,Intermediate,Kidney,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,CHEMBL624269,N,1,,,,,1,,BAO_0000218,
11497,2113.0,Intermediate,Kidney,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,CHEMBL624270,N,1,,,,,1,,BAO_0000218,
11498,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,CHEMBL624271,N,1,,,,,1,,BAO_0000218,
11499,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,CHEMBL624272,N,1,,,,,1,,BAO_0000218,
11500,,Intermediate,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,CHEMBL624273,N,1,,,,,1,,BAO_0000218,
11501,1088.0,Intermediate,Urine,50597,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,CHEMBL624274,N,1,,,,,1,,BAO_0000218,
11502,1088.0,Intermediate,Urine,50597,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,CHEMBL624275,N,1,,,,,1,,BAO_0000218,
11503,1088.0,Intermediate,Urine,50597,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,CHEMBL624276,N,1,,,,,1,,BAO_0000218,
11504,1088.0,Intermediate,Urine,50597,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,CHEMBL624277,N,1,,,,,1,,BAO_0000218,
11505,,Autocuration,,22224,% dose converted to 2-amino-5-chlorophenyl sulfate,CHEMBL624278,U,0,,,,,1,,BAO_0000019,
11506,,Autocuration,,22224,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),CHEMBL624279,U,0,,,,,1,,BAO_0000019,
11507,1988.0,Intermediate,Feces,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",CHEMBL624280,N,1,,,,,1,,BAO_0000218,
11508,1988.0,Intermediate,Feces,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",CHEMBL624281,N,1,,,,,1,,BAO_0000218,
11509,1988.0,Intermediate,Feces,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",CHEMBL622933,N,1,,,,,1,,BAO_0000218,
11510,1988.0,Intermediate,Feces,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",CHEMBL622934,N,1,,,,,1,,BAO_0000218,
11511,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,CHEMBL622935,N,1,,,,,1,,BAO_0000218,
11512,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 5 minutes of iv administration,CHEMBL622936,N,1,,,,,1,,BAO_0000218,
11513,2107.0,Intermediate,Liver,50597,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,CHEMBL875228,N,1,,,,,1,,BAO_0000218,
11514,2048.0,Intermediate,Lung,50597,Biodistribution in Rat lung after 24 hours of iv administration,CHEMBL622937,N,1,,,,,1,,BAO_0000218,
11515,2048.0,Intermediate,Lung,50597,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,CHEMBL622938,N,1,,,,,1,,BAO_0000218,
11516,2048.0,Intermediate,Lung,50597,Biodistribution in Rat lung after 30 minutes of iv administration,CHEMBL619736,N,1,,,,,1,,BAO_0000218,
11517,2048.0,Intermediate,Lung,50597,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,CHEMBL625117,N,1,,,,,1,,BAO_0000218,
11518,2048.0,Intermediate,Lung,50597,Biodistribution in Rat lung after 5 minutes of iv administration,CHEMBL625118,N,1,,,,,1,,BAO_0000218,
11519,2048.0,Intermediate,Lung,50597,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,CHEMBL625119,N,1,,,,,1,,BAO_0000218,
11520,2037.0,Intermediate,Cerebellum,50597,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",CHEMBL625120,N,1,,,,,1,,BAO_0000218,
11521,,Intermediate,,50597,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",CHEMBL625121,N,1,,,,,1,,BAO_0000218,
11522,10000006.0,Intermediate,Thalamus,50597,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",CHEMBL625122,N,1,,,,,1,,BAO_0000218,
11523,178.0,Intermediate,Blood,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL622204,N,1,,,,,1,,BAO_0000218,
11524,178.0,Intermediate,Blood,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL877503,N,1,,,,,1,,BAO_0000218,
11525,178.0,Intermediate,Blood,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL627127,N,1,,,,,1,,BAO_0000218,
11526,10000000.0,Autocuration,Hippocampus,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL627128,U,0,,,,,1,,BAO_0000218,
11527,10000000.0,Autocuration,Hippocampus,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL627129,U,0,,,,,1,,BAO_0000218,
11528,10000000.0,Autocuration,Hippocampus,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL627130,U,0,,,,,1,,BAO_0000218,
11529,955.0,Intermediate,Brain,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL627131,N,1,,,,,1,,BAO_0000218,
11530,955.0,Intermediate,Brain,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL627132,N,1,,,,,1,,BAO_0000218,
11531,955.0,Intermediate,Brain,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL627133,N,1,,,,,1,,BAO_0000218,
11532,2037.0,Intermediate,Cerebellum,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL627134,N,1,,,,,1,,BAO_0000218,
11533,2037.0,Intermediate,Cerebellum,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL627135,N,1,,,,,1,,BAO_0000218,
11534,2037.0,Intermediate,Cerebellum,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL627136,N,1,,,,,1,,BAO_0000218,
11535,,Intermediate,,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL628435,N,1,,,,,1,,BAO_0000218,
11536,,Intermediate,,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL628436,N,1,,,,,1,,BAO_0000218,
11537,,Intermediate,,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL628437,N,1,,,,,1,,BAO_0000218,
11538,948.0,Intermediate,Heart,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL628438,N,1,,,,,1,,BAO_0000218,
11539,948.0,Intermediate,Heart,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL628439,N,1,,,,,1,,BAO_0000218,
11540,948.0,Intermediate,Heart,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL628440,N,1,,,,,1,,BAO_0000218,
11541,10000000.0,Intermediate,Hippocampus,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL628441,N,1,,,,,1,,BAO_0000218,
11542,10000000.0,Intermediate,Hippocampus,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL628442,N,1,,,,,1,,BAO_0000218,
11543,10000000.0,Intermediate,Hippocampus,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL628443,N,1,,,,,1,,BAO_0000218,
11544,2113.0,Intermediate,Kidney,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL628444,N,1,,,,,1,,BAO_0000218,
11545,2113.0,Intermediate,Kidney,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL628445,N,1,,,,,1,,BAO_0000218,
11546,2113.0,Intermediate,Kidney,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL877504,N,1,,,,,1,,BAO_0000218,
11547,2107.0,Intermediate,Liver,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL628446,N,1,,,,,1,,BAO_0000218,
11548,2107.0,Intermediate,Liver,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL626874,N,1,,,,,1,,BAO_0000218,
11549,2107.0,Intermediate,Liver,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL626875,N,1,,,,,1,,BAO_0000218,
11550,2048.0,Intermediate,Lung,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL626876,N,1,,,,,1,,BAO_0000218,
11551,2048.0,Intermediate,Lung,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL626877,N,1,,,,,1,,BAO_0000218,
11552,2048.0,Intermediate,Lung,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL626878,N,1,,,,,1,,BAO_0000218,
11553,2385.0,Intermediate,Muscle tissue,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL626879,N,1,,,,,1,,BAO_0000218,
11554,1969.0,Autocuration,Plasma,22224,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,CHEMBL626880,U,0,,,,,1,,BAO_0000218,
11555,1969.0,Intermediate,Plasma,50594,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,CHEMBL626881,N,1,,,,,1,,BAO_0000218,
11556,1969.0,Intermediate,Plasma,50597,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,CHEMBL626882,N,1,,,,,1,,BAO_0000218,
11557,1969.0,Intermediate,Plasma,50588,Peak plasma concentration was measured in dogs,CHEMBL626883,N,1,,,,,1,,BAO_0000218,
11558,,Intermediate,,50597,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,CHEMBL626884,N,1,,,,,1,,BAO_0000218,
11559,,Intermediate,,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,CHEMBL626885,N,1,,,,,1,,BAO_0000218,
11560,,Intermediate,,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,CHEMBL626886,N,1,,,,,1,,BAO_0000218,
11561,,Intermediate,,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,CHEMBL626887,N,1,,,,,1,,BAO_0000218,
11562,,Intermediate,,50597,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,CHEMBL626888,N,1,,,,,1,,BAO_0000218,
11563,,Intermediate,,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,CHEMBL626889,N,1,,,,,1,,BAO_0000218,
11564,,Autocuration,,22224,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,CHEMBL626761,U,0,,,,,1,,BAO_0000218,
11565,,Intermediate,,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,CHEMBL626762,N,1,,,,,1,,BAO_0000218,
11566,,Intermediate,,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,CHEMBL626763,N,1,,,,,1,,BAO_0000218,
11567,,Intermediate,,50597,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,CHEMBL626764,N,1,,,,,1,,BAO_0000218,
11568,,Intermediate,,50597,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,CHEMBL626765,N,1,,,,,1,,BAO_0000218,
11569,,Intermediate,,50588,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,CHEMBL626766,N,1,,,,,1,,BAO_0000218,
11570,,Intermediate,,50597,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,CHEMBL626767,N,1,,,,,1,,BAO_0000218,
11571,,Intermediate,,50597,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,CHEMBL626768,N,1,,,,,1,,BAO_0000218,
11572,,Intermediate,,50588,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,CHEMBL626769,N,1,,,,,1,,BAO_0000218,
11573,,Intermediate,,50588,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,CHEMBL874463,N,1,,,,,1,,BAO_0000218,
11574,,Autocuration,,22224,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,CHEMBL626770,U,0,,,,,1,,BAO_0000218,
11575,,Autocuration,,22224,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,CHEMBL626771,U,0,,,,,1,,BAO_0000218,
11576,,Intermediate,,50597,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,CHEMBL626772,N,1,,,,,1,,BAO_0000218,
11577,,Intermediate,,100710,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,CHEMBL626773,N,1,,,,,1,,BAO_0000218,
11578,,Intermediate,,50594,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,CHEMBL626774,N,1,,,,,1,,BAO_0000218,
11579,,Intermediate,,50588,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,CHEMBL626775,N,1,,,,,1,,BAO_0000218,
11580,,Intermediate,,50588,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,CHEMBL626776,N,1,,,,,1,,BAO_0000218,
11581,,Intermediate,,50597,Maximum concentration (Cmax) in rat when administered orally,CHEMBL626777,N,1,,,,,1,,BAO_0000218,
11582,1969.0,Autocuration,Plasma,22224,Maximal concentration in monkey plasma after 25 mg/kg oral dose,CHEMBL626778,U,0,,,,,1,,BAO_0000218,
11583,,Autocuration,,22224,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",CHEMBL626779,U,0,,,,,1,,BAO_0000218,
11584,,Autocuration,,22224,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",CHEMBL626780,U,0,,,,,1,,BAO_0000218,
11585,1969.0,Autocuration,Plasma,22224,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,CHEMBL626781,U,0,,,,,1,,BAO_0000218,
11586,,Intermediate,,50597,Pharmacokinetic profile Cmax was evaluated in rats,CHEMBL632164,N,1,,,,,1,,BAO_0000218,
11587,,Intermediate,,50588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),CHEMBL632165,N,1,,,,,1,,BAO_0000218,
11588,,Intermediate,,50594,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),CHEMBL632166,N,1,,,,,1,,BAO_0000218,
11589,,Intermediate,,50588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),CHEMBL632167,N,1,,,,,1,,BAO_0000218,
11590,,Intermediate,,50594,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),CHEMBL632168,N,1,,,,,1,,BAO_0000218,
11591,1969.0,Autocuration,Plasma,22224,Cmax in rat plasma,CHEMBL632169,U,0,,,,,1,,BAO_0000218,
11592,1969.0,Intermediate,Plasma,50588,Cmax in dog plasma after 30mg/kg oral dose,CHEMBL632170,N,1,,,,,1,,BAO_0000218,
11593,1969.0,Intermediate,Plasma,50597,Cmax in rat plasma after 30mg/kg oral dose,CHEMBL632171,N,1,,,,,1,,BAO_0000218,
11594,1969.0,Intermediate,Plasma,50597,Plasma level in rats at 30 mg/kg,CHEMBL632172,N,1,,,,,1,,BAO_0000218,
11595,1969.0,Intermediate,Plasma,50594,Tested for maximum plasma concentration in mice,CHEMBL632173,N,1,,,,,1,,BAO_0000218,
11596,,Intermediate,,50597,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL632174,N,1,,,,,1,,BAO_0000218,
11597,,Intermediate,,50597,The Cmax values in female wistar rats.,CHEMBL632175,N,1,,,,,1,,BAO_0000218,
11598,1969.0,Intermediate,Plasma,50588,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,CHEMBL632176,N,1,,,,,1,,BAO_0000218,
11599,1969.0,Intermediate,Plasma,50597,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,CHEMBL632177,N,1,,,,,1,,BAO_0000218,
11600,1969.0,Intermediate,Plasma,50597,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,CHEMBL632178,N,1,,,,,1,,BAO_0000218,
11601,,Intermediate,,50597,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,CHEMBL632179,N,1,,,,,1,,BAO_0000218,
11602,178.0,Intermediate,Blood,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,CHEMBL632180,N,1,,,,,1,,BAO_0000218,
11603,178.0,Intermediate,Blood,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,CHEMBL632181,N,1,,,,,1,,BAO_0000218,
11604,178.0,Intermediate,Blood,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,CHEMBL632182,N,1,,,,,1,,BAO_0000218,
11605,178.0,Autocuration,Blood,22224,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,CHEMBL632183,U,0,,,,,1,,BAO_0000218,
11606,,Intermediate,,50588,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,CHEMBL632184,N,1,,,,,1,,BAO_0000218,
11607,,Intermediate,,50597,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,CHEMBL874470,N,1,,,,,1,,BAO_0000218,
11608,,Intermediate,,50597,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",CHEMBL631302,N,1,,,,,1,,BAO_0000218,
11609,,Intermediate,,50597,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",CHEMBL631303,N,1,,,,,1,,BAO_0000218,
11610,,Intermediate,,50597,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",CHEMBL631304,N,1,,,,,1,,BAO_0000218,
11611,,Intermediate,,50597,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",CHEMBL631305,N,1,,,,,1,,BAO_0000218,
11612,,Intermediate,,50597,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",CHEMBL631306,N,1,,,,,1,,BAO_0000218,
11613,,Intermediate,,50597,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",CHEMBL631307,N,1,,,,,1,,BAO_0000218,
11614,,Intermediate,,50597,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",CHEMBL631308,N,1,,,,,1,,BAO_0000218,
11615,,Intermediate,,50597,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",CHEMBL625557,N,1,,,,,1,,BAO_0000218,
11616,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",CHEMBL625558,N,1,,,,,1,,BAO_0000218,
11617,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",CHEMBL625559,N,1,,,,,1,,BAO_0000218,
11618,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",CHEMBL625560,N,1,,,,,1,,BAO_0000218,
11619,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",CHEMBL625561,N,1,,,,,1,,BAO_0000218,
11620,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",CHEMBL625562,N,1,,,,,1,,BAO_0000218,
11621,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",CHEMBL875320,N,1,,,,,1,,BAO_0000218,
11622,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",CHEMBL625563,N,1,,,,,1,,BAO_0000218,
11623,2106.0,Intermediate,Spleen,50597,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",CHEMBL625564,N,1,,,,,1,,BAO_0000218,
11624,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",CHEMBL625565,N,1,,,,,1,,BAO_0000218,
11625,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",CHEMBL625566,N,1,,,,,1,,BAO_0000218,
11626,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",CHEMBL625567,N,1,,,,,1,,BAO_0000218,
11627,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",CHEMBL625568,N,1,,,,,1,,BAO_0000218,
11628,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",CHEMBL628217,N,1,,,,,1,,BAO_0000218,
11629,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",CHEMBL628218,N,1,,,,,1,,BAO_0000218,
11630,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",CHEMBL628219,N,1,,,,,1,,BAO_0000218,
11631,995.0,Intermediate,Uterus,50597,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",CHEMBL628220,N,1,,,,,1,,BAO_0000218,
11632,,Autocuration,,22224,Distribution in the blood after 120 min of intravenous administration,CHEMBL628221,U,0,,,,,1,,BAO_0000019,
11633,,Autocuration,,22224,Distribution in the blood after 15 min of intravenous administration,CHEMBL628222,U,0,,,,,1,,BAO_0000019,
11634,,Autocuration,,22224,Distribution in the blood after 30 min of intravenous administration,CHEMBL628223,U,0,,,,,1,,BAO_0000019,
11635,,Autocuration,,22224,Distribution in the blood after 5 min of intravenous administration,CHEMBL628224,U,0,,,,,1,,BAO_0000019,
11636,,Autocuration,,22224,Distribution in the blood after 60 min of intravenous administration,CHEMBL628225,U,0,,,,,1,,BAO_0000019,
11637,,Autocuration,,22224,Distribution in the blood after 90 min of intravenous administration,CHEMBL628226,U,0,,,,,1,,BAO_0000019,
11638,,Autocuration,,22224,Distribution in the bone after 120 min of intravenous administration,CHEMBL628227,U,0,,,,,1,,BAO_0000019,
11639,,Autocuration,,22224,Distribution in the bone after 15 min of intravenous administration,CHEMBL875481,U,0,,,,,1,,BAO_0000019,
11640,,Autocuration,,22224,Distribution in the bone after 30 min of intravenous administration,CHEMBL628228,U,0,,,,,1,,BAO_0000019,
11641,,Autocuration,,22224,Distribution in the bone after 5 min of intravenous administration,CHEMBL628229,U,0,,,,,1,,BAO_0000019,
11642,,Autocuration,,22224,Distribution in the bone after 60 min of intravenous administration,CHEMBL628230,U,0,,,,,1,,BAO_0000019,
11643,,Autocuration,,22224,Distribution in the bone after 90 min of intravenous administration,CHEMBL628231,U,0,,,,,1,,BAO_0000019,
11644,,Autocuration,,22224,Distribution in the heart after 120 min of intravenous administration,CHEMBL628232,U,0,,,,,1,,BAO_0000019,
11645,,Autocuration,,22224,Distribution in the heart after 15 min of intravenous administration,CHEMBL628233,U,0,,,,,1,,BAO_0000019,
11646,,Autocuration,,22224,Distribution in the heart after 30 min of intravenous administration,CHEMBL628234,U,0,,,,,1,,BAO_0000019,
11647,,Autocuration,,22224,Distribution in the heart after 5 min of intravenous administration,CHEMBL628235,U,0,,,,,1,,BAO_0000019,
11648,,Autocuration,,22224,Distribution in the heart after 60 min of intravenous administration,CHEMBL628236,U,0,,,,,1,,BAO_0000019,
11649,,Autocuration,,22224,Distribution in the heart after 90 min of intravenous administration,CHEMBL628237,U,0,,,,,1,,BAO_0000019,
11650,,Autocuration,,22224,Distribution in the kidneys after 120 min of intravenous administration,CHEMBL628238,U,0,,,,,1,,BAO_0000019,
11651,,Autocuration,,22224,Distribution in the kidneys after 15 min of intravenous administration,CHEMBL628239,U,0,,,,,1,,BAO_0000019,
11652,,Autocuration,,22224,Distribution in the kidneys after 30 min of intravenous administration,CHEMBL628240,U,0,,,,,1,,BAO_0000019,
11653,,Autocuration,,22224,Distribution in the kidneys after 5 min of intravenous administration,CHEMBL628241,U,0,,,,,1,,BAO_0000019,
11654,,Autocuration,,22224,Distribution in the kidneys after 60 min of intravenous administration,CHEMBL628242,U,0,,,,,1,,BAO_0000019,
11655,,Autocuration,,22224,Distribution in the kidneys after 90 min of intravenous administration,CHEMBL875482,U,0,,,,,1,,BAO_0000019,
11656,,Autocuration,,22224,Distribution in the liver after 120 min of intravenous administration,CHEMBL628243,U,0,,,,,1,,BAO_0000019,
11657,,Autocuration,,22224,Distribution in the liver after 15 min of intravenous administration,CHEMBL628244,U,0,,,,,1,,BAO_0000019,
11658,,Autocuration,,22224,Distribution in the liver after 30 min of intravenous administration,CHEMBL628245,U,0,,,,,1,,BAO_0000019,
11659,,Autocuration,,22224,Distribution in the liver after 5 min of intravenous administration,CHEMBL628246,U,0,,,,,1,,BAO_0000019,
11660,,Autocuration,,22224,Distribution in the liver after 60 min of intravenous administration,CHEMBL628247,U,0,,,,,1,,BAO_0000019,
11661,,Autocuration,,22224,Distribution in the liver after 90 min of intravenous administration,CHEMBL628248,U,0,,,,,1,,BAO_0000019,
11662,,Autocuration,,22224,Distribution in the lung after 120 min of intravenous administration,CHEMBL628249,U,0,,,,,1,,BAO_0000019,
11663,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",CHEMBL625452,N,1,,,,,1,,BAO_0000218,
11664,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",CHEMBL625453,N,1,,,,,1,,BAO_0000218,
11665,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",CHEMBL625454,N,1,,,,,1,,BAO_0000218,
11666,,Intermediate,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",CHEMBL623844,N,1,,,,,1,,BAO_0000218,
11667,,Intermediate,,50597,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,CHEMBL623845,N,1,,,,,1,,BAO_0000218,
11668,,Intermediate,,50597,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,CHEMBL623846,N,1,,,,,1,,BAO_0000218,
11669,,Autocuration,,22224,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,CHEMBL623847,U,0,,,,,1,,BAO_0000218,
11670,,Intermediate,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,CHEMBL623848,N,1,,,,,1,,BAO_0000218,
11671,,Intermediate,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,CHEMBL623849,N,1,,,,,1,,BAO_0000218,
11672,,Intermediate,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,CHEMBL623850,N,1,,,,,1,,BAO_0000218,
11673,,Intermediate,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,CHEMBL623851,N,1,,,,,1,,BAO_0000218,
11674,,Autocuration,,22224,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,CHEMBL623852,U,0,,,,,1,,BAO_0000218,
11675,,Intermediate,,50506,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,CHEMBL624551,N,1,,,,,1,,BAO_0000218,
11676,,Intermediate,,50506,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",CHEMBL624552,N,1,,,,,1,,BAO_0000218,
11677,,Autocuration,,22224,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,CHEMBL624553,U,0,,,,,1,,BAO_0000218,
11678,,Autocuration,,22224,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,CHEMBL624554,U,0,,,,,1,,BAO_0000218,
11679,,Intermediate,,50597,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,CHEMBL624555,N,1,,,,,1,,BAO_0000218,
11680,,Intermediate,,50597,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",CHEMBL624741,N,1,,,,,1,,BAO_0000218,
11681,,Intermediate,,50588,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",CHEMBL624742,N,1,,,,,1,,BAO_0000218,
11682,,Intermediate,,100712,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",CHEMBL624743,N,1,,,,,1,,BAO_0000218,
11683,,Intermediate,,50597,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",CHEMBL877606,N,1,,,,,1,,BAO_0000218,
11684,,Autocuration,,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,CHEMBL624744,U,0,,,,,1,,BAO_0000218,
11685,178.0,Autocuration,Blood,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,CHEMBL624745,U,0,,,,,1,,BAO_0000218,
11686,178.0,Autocuration,Blood,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,CHEMBL624746,U,0,,,,,1,,BAO_0000218,
11687,178.0,Autocuration,Blood,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,CHEMBL624747,U,0,,,,,1,,BAO_0000218,
11688,,Autocuration,,22224,Oral absorption expressed as Area under curve was determined,CHEMBL624748,U,0,,,,,1,,BAO_0000019,
11689,,Intermediate,,50588,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,CHEMBL622504,N,1,,,,,1,,BAO_0000218,
11690,,Intermediate,,50588,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",CHEMBL622505,N,1,,,,,1,,BAO_0000218,
11691,,Intermediate,,100712,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",CHEMBL622506,N,1,,,,,1,,BAO_0000218,
11692,,Intermediate,,100712,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",CHEMBL622507,N,1,,,,,1,,BAO_0000218,
11693,,Intermediate,,50597,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",CHEMBL622508,N,1,,,,,1,,BAO_0000218,
11694,,Autocuration,,22224,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,CHEMBL622509,U,0,,,,,1,,BAO_0000019,
11695,,Intermediate,,50597,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,CHEMBL622510,N,1,,,,,1,,BAO_0000218,
11696,,Intermediate,,50597,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),CHEMBL622511,N,1,,,,,1,,BAO_0000218,
11697,,Intermediate,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,CHEMBL622512,N,1,,,,,1,,BAO_0000218,
11698,,Intermediate,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,CHEMBL622513,N,1,,,,,1,,BAO_0000218,
11699,,Intermediate,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,CHEMBL622514,N,1,,,,,1,,BAO_0000218,
11700,,Intermediate,,50588,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,CHEMBL622515,N,1,,,,,1,,BAO_0000218,
11701,,Intermediate,,50588,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,CHEMBL622516,N,1,,,,,1,,BAO_0000218,
11702,,Intermediate,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,CHEMBL622517,N,1,,,,,1,,BAO_0000218,
11703,,Intermediate,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,CHEMBL622518,N,1,,,,,1,,BAO_0000218,
11704,,Intermediate,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,CHEMBL622519,N,1,,,,,1,,BAO_0000218,
11705,2385.0,Intermediate,Muscle tissue,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL622520,N,1,,,,,1,,BAO_0000218,
11706,2385.0,Intermediate,Muscle tissue,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL622521,N,1,,,,,1,,BAO_0000218,
11707,14.0,Intermediate,Zone of skin,50594,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL625113,N,1,,,,,1,,BAO_0000218,
11708,14.0,Intermediate,Zone of skin,50597,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL625114,N,1,,,,,1,,BAO_0000218,
11709,14.0,Intermediate,Zone of skin,50597,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL874397,N,1,,,,,1,,BAO_0000218,
11710,2106.0,Intermediate,Spleen,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL625115,N,1,,,,,1,,BAO_0000218,
11711,2106.0,Intermediate,Spleen,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL625116,N,1,,,,,1,,BAO_0000218,
11712,2106.0,Intermediate,Spleen,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL623932,N,1,,,,,1,,BAO_0000218,
11713,2435.0,Intermediate,Striatum,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL623933,N,1,,,,,1,,BAO_0000218,
11714,2435.0,Intermediate,Striatum,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL623934,N,1,,,,,1,,BAO_0000218,
11715,2435.0,Intermediate,Striatum,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL623935,N,1,,,,,1,,BAO_0000218,
11716,2046.0,Intermediate,Thyroid gland,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,CHEMBL623936,N,1,,,,,1,,BAO_0000218,
11717,2046.0,Intermediate,Thyroid gland,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,CHEMBL623937,N,1,,,,,1,,BAO_0000218,
11718,2046.0,Intermediate,Thyroid gland,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,CHEMBL623938,N,1,,,,,1,,BAO_0000218,
11719,,Intermediate,,50594,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL623939,N,1,,,,,1,,BAO_0000218,
11720,,Intermediate,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,CHEMBL623940,N,1,,,,,1,,BAO_0000218,
11721,,Intermediate,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,CHEMBL623941,N,1,,,,,1,,BAO_0000218,
11722,,Intermediate,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL627216,N,1,,,,,1,,BAO_0000218,
11723,,Intermediate,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL623942,N,1,,,,,1,,BAO_0000218,
11724,955.0,Intermediate,Brain,50594,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL618793,N,1,,,,,1,,BAO_0000218,
11725,955.0,Intermediate,Brain,50594,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL618794,N,1,,,,,1,,BAO_0000218,
11726,955.0,Intermediate,Brain,50594,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL618795,N,1,,,,,1,,BAO_0000218,
11727,,Intermediate,,50594,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL618796,N,1,,,,,1,,BAO_0000218,
11728,,Intermediate,,50594,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL618797,N,1,,,,,1,,BAO_0000218,
11729,2113.0,Intermediate,Kidney,50594,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,CHEMBL618798,N,1,,,,,1,,BAO_0000218,
11730,2113.0,Intermediate,Kidney,50594,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL618799,N,1,,,,,1,,BAO_0000218,
11731,2113.0,Intermediate,Kidney,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,CHEMBL618800,N,1,,,,,1,,BAO_0000218,
11732,2113.0,Intermediate,Kidney,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,CHEMBL618801,N,1,,,,,1,,BAO_0000218,
11733,2113.0,Intermediate,Kidney,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL618802,N,1,,,,,1,,BAO_0000218,
11734,2113.0,Intermediate,Kidney,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL618803,N,1,,,,,1,,BAO_0000218,
11735,2107.0,Intermediate,Liver,50594,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,CHEMBL618804,N,1,,,,,1,,BAO_0000218,
11736,2107.0,Intermediate,Liver,50594,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL618805,N,1,,,,,1,,BAO_0000218,
11737,2107.0,Intermediate,Liver,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,CHEMBL618806,N,1,,,,,1,,BAO_0000218,
11738,2107.0,Intermediate,Liver,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,CHEMBL618807,N,1,,,,,1,,BAO_0000218,
11739,2107.0,Intermediate,Liver,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL618808,N,1,,,,,1,,BAO_0000218,
11740,2107.0,Intermediate,Liver,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL618809,N,1,,,,,1,,BAO_0000218,
11741,2385.0,Intermediate,Muscle tissue,50594,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL618810,N,1,,,,,1,,BAO_0000218,
11742,2385.0,Intermediate,Muscle tissue,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,CHEMBL618811,N,1,,,,,1,,BAO_0000218,
11743,2385.0,Intermediate,Muscle tissue,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,CHEMBL875844,N,1,,,,,1,,BAO_0000218,
11744,2385.0,Intermediate,Muscle tissue,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL618812,N,1,,,,,1,,BAO_0000218,
11745,2385.0,Intermediate,Muscle tissue,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL618813,N,1,,,,,1,,BAO_0000218,
11746,,Intermediate,,50594,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL618814,N,1,,,,,1,,BAO_0000218,
11747,,Intermediate,,50594,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL618815,N,1,,,,,1,,BAO_0000218,
11748,,Intermediate,,50594,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL618816,N,1,,,,,1,,BAO_0000218,
11749,,Intermediate,,50594,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL618817,N,1,,,,,1,,BAO_0000218,
11750,,Intermediate,,50594,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL620544,N,1,,,,,1,,BAO_0000218,
11751,,Intermediate,,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,CHEMBL626230,N,1,,,,,1,,BAO_0000218,
11752,,Intermediate,,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,CHEMBL626231,N,1,,,,,1,,BAO_0000218,
11753,,Intermediate,,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,CHEMBL626232,N,1,,,,,1,,BAO_0000218,
11754,1969.0,Intermediate,Plasma,50588,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,CHEMBL626233,N,1,,,,,1,,BAO_0000218,
11755,1969.0,Intermediate,Plasma,50597,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,CHEMBL626234,N,1,,,,,1,,BAO_0000218,
11756,1969.0,Intermediate,Plasma,50597,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,CHEMBL875341,N,1,,,,,1,,BAO_0000218,
11757,1969.0,Intermediate,Plasma,50587,The maximum plasma concentration (100 mg/kg) administered orally in human,CHEMBL626235,N,1,,,,,1,,BAO_0000218,
11758,1969.0,Autocuration,Plasma,22224,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,CHEMBL626236,U,0,,,,,1,,BAO_0000218,
11759,1969.0,Autocuration,Plasma,22224,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,CHEMBL626237,U,0,,,,,1,,BAO_0000218,
11760,1969.0,Intermediate,Plasma,50588,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,CHEMBL626238,N,1,,,,,1,,BAO_0000218,
11761,1969.0,Intermediate,Plasma,50587,The maximum plasma concentration (200 mg/kg) administered orally in human,CHEMBL622412,N,1,,,,,1,,BAO_0000218,
11762,1969.0,Intermediate,Plasma,50597,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,CHEMBL623114,N,1,,,,,1,,BAO_0000218,
11763,1969.0,Autocuration,Plasma,22224,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,CHEMBL623115,U,0,,,,,1,,BAO_0000218,
11764,1969.0,Autocuration,Plasma,22224,The maximum plasma concentration (25 mg/kg) administered orally in monkey,CHEMBL623116,U,0,,,,,1,,BAO_0000218,
11765,1969.0,Autocuration,Plasma,22224,The maximum plasma concentration (30 mg/kg) administered orally in dog,CHEMBL623117,U,0,,,,,1,,BAO_0000218,
11766,1969.0,Intermediate,Plasma,50587,The maximum plasma concentration (400 mg/kg) administered orally in human,CHEMBL623118,N,1,,,,,1,,BAO_0000218,
11767,1969.0,Intermediate,Plasma,50597,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,CHEMBL623119,N,1,,,,,1,,BAO_0000218,
11768,1969.0,Intermediate,Plasma,50597,The maximum plasma concentration (50 mg/kg) administered orally in rat,CHEMBL623120,N,1,,,,,1,,BAO_0000218,
11769,1969.0,Intermediate,Plasma,50587,The maximum plasma concentration (800 mg/kg) administered orally in human,CHEMBL623286,N,1,,,,,1,,BAO_0000218,
11770,1969.0,Intermediate,Plasma,50597,The maximum plasma concentration was measured on rats,CHEMBL623287,N,1,,,,,1,,BAO_0000218,
11771,1969.0,Intermediate,Plasma,50597,The maximum plasma concentration was measured on rats after oral administration,CHEMBL623288,N,1,,,,,1,,BAO_0000218,
11772,1969.0,Intermediate,Plasma,50597,Plasma drug Cmax in rat (PO dose),CHEMBL623289,N,1,,,,,1,,BAO_0000218,
11773,,Autocuration,,22224,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,CHEMBL623290,U,0,,,,,1,,BAO_0000218,
11774,1969.0,Intermediate,Plasma,50588,maximum Plasma concentration in Dog was determined after Peroral administration,CHEMBL623291,N,1,,,,,1,,BAO_0000218,
11775,1969.0,Intermediate,Plasma,50597,maximum Plasma concentration in Rats was determined after Peroral administration,CHEMBL623292,N,1,,,,,1,,BAO_0000218,
11776,1969.0,Intermediate,Plasma,50588,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,CHEMBL623293,N,1,,,,,1,,BAO_0000218,
11777,1969.0,Autocuration,Plasma,22224,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,CHEMBL623294,U,0,,,,,1,,BAO_0000218,
11778,1969.0,Intermediate,Plasma,50597,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,CHEMBL623295,N,1,,,,,1,,BAO_0000218,
11779,,Intermediate,,50594,maximum concentration was measured when administered through oral route in mice,CHEMBL623296,N,1,,,,,1,,BAO_0000218,
11780,,Intermediate,,50594,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,CHEMBL875349,N,1,,,,,1,,BAO_0000218,
11781,,Autocuration,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,CHEMBL623297,U,0,,,,,1,,BAO_0000019,
11782,,Autocuration,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,CHEMBL623298,U,0,,,,,1,,BAO_0000019,
11783,,Autocuration,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,CHEMBL623299,U,0,,,,,1,,BAO_0000019,
11784,,Intermediate,,50597,Pharmacokinetic parameter was evaluated in rats,CHEMBL623300,N,1,,,,,1,,BAO_0000218,
11785,,Intermediate,,50594,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,CHEMBL623301,N,1,,,,,1,,BAO_0000218,
11786,,Intermediate,,50594,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,CHEMBL623302,N,1,,,,,1,,BAO_0000218,
11787,,Intermediate,,50594,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,CHEMBL623303,N,1,,,,,1,,BAO_0000218,
11788,,Intermediate,,50594,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,CHEMBL623304,N,1,,,,,1,,BAO_0000218,
11789,,Intermediate,,50594,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,CHEMBL623305,N,1,,,,,1,,BAO_0000218,
11790,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,CHEMBL623306,N,1,,,,,1,,BAO_0000218,
11791,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,CHEMBL623307,N,1,,,,,1,,BAO_0000218,
11792,1969.0,Intermediate,Plasma,50597,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,CHEMBL623308,N,1,,,,,1,,BAO_0000218,
11793,1969.0,Intermediate,Plasma,50594,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,CHEMBL623309,N,1,,,,,1,,BAO_0000218,
11794,,Intermediate,,50594,Plasma Concentration after 120 min of oral administration to mice,CHEMBL623310,N,1,,,,,1,,BAO_0000218,
11795,,Intermediate,,50594,Plasma Concentration after 30 min of oral administration to mice,CHEMBL623311,N,1,,,,,1,,BAO_0000218,
11796,,Intermediate,,100710,Plasma Concentration after 60 min of oral administration to mice,CHEMBL623312,N,1,,,,,1,,BAO_0000218,
11797,,Intermediate,,50594,Plasma Concentration after 60 min of oral administration to mice; Not determined,CHEMBL875350,N,1,,,,,1,,BAO_0000218,
11798,,Intermediate,,50594,Plasma Concentration after 90 min of oral administration to mice,CHEMBL628635,N,1,,,,,1,,BAO_0000218,
11799,,Intermediate,,50597,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,CHEMBL628636,N,1,,,,,1,,BAO_0000218,
11800,,Intermediate,,50597,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,CHEMBL628637,N,1,,,,,1,,BAO_0000218,
11801,,Intermediate,,50597,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,CHEMBL628058,N,1,,,,,1,,BAO_0000218,
11802,,Intermediate,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,CHEMBL628059,N,1,,,,,1,,BAO_0000218,
11803,,Intermediate,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,CHEMBL628060,N,1,,,,,1,,BAO_0000218,
11804,,Autocuration,,22224,Distribution in the lung after 15 min of intravenous administration,CHEMBL628061,U,0,,,,,1,,BAO_0000019,
11805,,Autocuration,,22224,Distribution in the lung after 30 min of intravenous administration,CHEMBL628062,U,0,,,,,1,,BAO_0000019,
11806,,Autocuration,,22224,Distribution in the lung after 5 min of intravenous administration,CHEMBL628063,U,0,,,,,1,,BAO_0000019,
11807,,Autocuration,,22224,Distribution in the lung after 60 min of intravenous administration,CHEMBL628064,U,0,,,,,1,,BAO_0000019,
11808,,Autocuration,,22224,Distribution in the lung after 90 min of intravenous administration,CHEMBL628065,U,0,,,,,1,,BAO_0000019,
11809,2385.0,Autocuration,Muscle tissue,22224,Distribution in the muscle after 120 min of intravenous administration,CHEMBL628066,U,0,,,,,1,,BAO_0000019,
11810,2385.0,Autocuration,Muscle tissue,22224,Distribution in the muscle after 15 min of intravenous administration,CHEMBL628067,U,0,,,,,1,,BAO_0000019,
11811,2385.0,Intermediate,Muscle tissue,50594,Distribution in the muscle after 30 min of intravenous administration,CHEMBL874646,N,1,,,,,1,,BAO_0000218,
11812,2385.0,Autocuration,Muscle tissue,22224,Distribution in the muscle after 5 min of intravenous administration,CHEMBL628068,U,0,,,,,1,,BAO_0000019,
11813,2385.0,Autocuration,Muscle tissue,22224,Distribution in the muscle after 60 min of intravenous administration,CHEMBL628069,U,0,,,,,1,,BAO_0000019,
11814,2385.0,Autocuration,Muscle tissue,22224,Distribution in the muscle after 90 min of intravenous administration,CHEMBL628070,U,0,,,,,1,,BAO_0000019,
11815,2106.0,Autocuration,Spleen,22224,Distribution in the spleen after 120 min of intravenous administration,CHEMBL628071,U,0,,,,,1,,BAO_0000019,
11816,2106.0,Autocuration,Spleen,22224,Distribution in the spleen after 15 min of intravenous administration,CHEMBL628072,U,0,,,,,1,,BAO_0000019,
11817,2106.0,Autocuration,Spleen,22224,Distribution in the spleen after 30 min of intravenous administration,CHEMBL628073,U,0,,,,,1,,BAO_0000019,
11818,2106.0,Autocuration,Spleen,22224,Distribution in the spleen after 5 min of intravenous administration,CHEMBL628074,U,0,,,,,1,,BAO_0000019,
11819,2106.0,Autocuration,Spleen,22224,Distribution in the spleen after 60 min of intravenous administration,CHEMBL628075,U,0,,,,,1,,BAO_0000019,
11820,2106.0,Autocuration,Spleen,22224,Distribution in the spleen after 90 min of intravenous administration,CHEMBL628076,U,0,,,,,1,,BAO_0000019,
11821,1235.0,Intermediate,Adrenal cortex,50597,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,CHEMBL628077,N,1,,,,,1,,BAO_0000218,
11822,178.0,Intermediate,Blood,50597,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,CHEMBL628078,N,1,,,,,1,,BAO_0000218,
11823,2107.0,Intermediate,Liver,50597,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,CHEMBL628079,N,1,,,,,1,,BAO_0000218,
11824,992.0,Intermediate,Female gonad,50597,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,CHEMBL628080,N,1,,,,,1,,BAO_0000218,
11825,2046.0,Intermediate,Thyroid gland,50597,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,CHEMBL628081,N,1,,,,,1,,BAO_0000218,
11826,1235.0,Intermediate,Adrenal cortex,50597,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,CHEMBL628082,N,1,,,,,1,,BAO_0000218,
11827,178.0,Intermediate,Blood,50597,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,CHEMBL874647,N,1,,,,,1,,BAO_0000218,
11828,2107.0,Intermediate,Liver,50597,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,CHEMBL626406,N,1,,,,,1,,BAO_0000218,
11829,992.0,Intermediate,Female gonad,50597,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,CHEMBL626407,N,1,,,,,1,,BAO_0000218,
11830,2046.0,Intermediate,Thyroid gland,50597,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,CHEMBL626408,N,1,,,,,1,,BAO_0000218,
11831,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",CHEMBL626409,N,1,,,,,1,,BAO_0000218,
11832,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",CHEMBL626410,N,1,,,,,1,,BAO_0000218,
11833,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",CHEMBL626411,N,1,,,,,1,,BAO_0000218,
11834,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",CHEMBL626412,N,1,,,,,1,,BAO_0000218,
11835,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",CHEMBL626413,N,1,,,,,1,,BAO_0000218,
11836,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",CHEMBL626414,N,1,,,,,1,,BAO_0000218,
11837,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",CHEMBL626415,N,1,,,,,1,,BAO_0000218,
11838,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",CHEMBL626416,N,1,,,,,1,,BAO_0000218,
11839,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",CHEMBL627062,N,1,,,,,1,,BAO_0000218,
11840,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",CHEMBL627063,N,1,,,,,1,,BAO_0000218,
11841,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",CHEMBL627064,N,1,,,,,1,,BAO_0000218,
11842,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",CHEMBL627227,N,1,,,,,1,,BAO_0000218,
11843,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",CHEMBL627228,N,1,,,,,1,,BAO_0000218,
11844,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",CHEMBL627229,N,1,,,,,1,,BAO_0000218,
11845,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",CHEMBL625792,N,1,,,,,1,,BAO_0000218,
11846,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",CHEMBL625793,N,1,,,,,1,,BAO_0000218,
11847,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",CHEMBL625794,N,1,,,,,1,,BAO_0000218,
11848,178.0,Intermediate,Blood,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",CHEMBL625795,N,1,,,,,1,,BAO_0000218,
11849,,Intermediate,,50594,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,CHEMBL625796,N,1,,,,,1,,BAO_0000218,
11850,,Intermediate,,50588,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,CHEMBL625797,N,1,,,,,1,,BAO_0000218,
11851,,Intermediate,,50588,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,CHEMBL625798,N,1,,,,,1,,BAO_0000218,
11852,,Autocuration,,22224,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,CHEMBL875613,U,0,,,,,1,,BAO_0000218,
11853,,Autocuration,,22224,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,CHEMBL625799,U,0,,,,,1,,BAO_0000218,
11854,,Autocuration,,22224,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,CHEMBL625800,U,0,,,,,1,,BAO_0000218,
11855,,Autocuration,,22224,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,CHEMBL625801,U,0,,,,,1,,BAO_0000218,
11856,,Autocuration,,22224,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,CHEMBL625802,U,0,,,,,1,,BAO_0000218,
11857,,Autocuration,,22224,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,CHEMBL625803,U,0,,,,,1,,BAO_0000218,
11858,,Autocuration,,22224,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,CHEMBL625804,U,0,,,,,1,,BAO_0000019,
11859,,Autocuration,,22224,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,CHEMBL622530,U,0,,,,,1,,BAO_0000218,
11860,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,CHEMBL622531,N,1,,,,,1,,BAO_0000218,
11861,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),CHEMBL622532,N,1,,,,,1,,BAO_0000218,
11862,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),CHEMBL623176,N,1,,,,,1,,BAO_0000218,
11863,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),CHEMBL623177,N,1,,,,,1,,BAO_0000218,
11864,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),CHEMBL623178,N,1,,,,,1,,BAO_0000218,
11865,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,CHEMBL623179,N,1,,,,,1,,BAO_0000218,
11866,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),CHEMBL623180,N,1,,,,,1,,BAO_0000218,
11867,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),CHEMBL623181,N,1,,,,,1,,BAO_0000218,
11868,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),CHEMBL624131,N,1,,,,,1,,BAO_0000218,
11869,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),CHEMBL624132,N,1,,,,,1,,BAO_0000218,
11870,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),CHEMBL624133,N,1,,,,,1,,BAO_0000218,
11871,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,CHEMBL624846,N,1,,,,,1,,BAO_0000218,
11872,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),CHEMBL624847,N,1,,,,,1,,BAO_0000218,
11873,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),CHEMBL624848,N,1,,,,,1,,BAO_0000218,
11874,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),CHEMBL625012,N,1,,,,,1,,BAO_0000218,
11875,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),CHEMBL625013,N,1,,,,,1,,BAO_0000218,
11876,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,CHEMBL625014,N,1,,,,,1,,BAO_0000218,
11877,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),CHEMBL625015,N,1,,,,,1,,BAO_0000218,
11878,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),CHEMBL625016,N,1,,,,,1,,BAO_0000218,
11879,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,CHEMBL625017,N,1,,,,,1,,BAO_0000218,
11880,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),CHEMBL625018,N,1,,,,,1,,BAO_0000218,
11881,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),CHEMBL625019,N,1,,,,,1,,BAO_0000218,
11882,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),CHEMBL625020,N,1,,,,,1,,BAO_0000218,
11883,,Intermediate,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,CHEMBL625021,N,1,,,,,1,,BAO_0000218,
11884,,Intermediate,,50597,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,CHEMBL625022,N,1,,,,,1,,BAO_0000218,
11885,,Intermediate,,50594,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,CHEMBL625023,N,1,,,,,1,,BAO_0000218,
11886,,Intermediate,,100710,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,CHEMBL625024,N,1,,,,,1,,BAO_0000218,
11887,,Intermediate,,100710,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,CHEMBL627626,N,1,,,,,1,,BAO_0000218,
11888,955.0,Autocuration,Brain,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,CHEMBL627627,U,0,,,,,1,,BAO_0000218,
11889,1977.0,Autocuration,Serum,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,CHEMBL627628,U,0,,,,,1,,BAO_0000218,
11890,955.0,Autocuration,Brain,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,CHEMBL627629,U,0,,,,,1,,BAO_0000218,
11891,1977.0,Autocuration,Serum,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,CHEMBL627630,U,0,,,,,1,,BAO_0000218,
11892,,Autocuration,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),CHEMBL627631,U,0,,,,,1,,BAO_0000019,
11893,,Autocuration,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),CHEMBL629515,U,0,,,,,1,,BAO_0000218,
11894,2106.0,Intermediate,Spleen,50594,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL629516,N,1,,,,,1,,BAO_0000218,
11895,2106.0,Intermediate,Spleen,50594,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL629517,N,1,,,,,1,,BAO_0000218,
11896,2106.0,Intermediate,Spleen,50594,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL629518,N,1,,,,,1,,BAO_0000218,
11897,,Intermediate,,50594,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,CHEMBL877499,N,1,,,,,1,,BAO_0000218,
11898,,Intermediate,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,CHEMBL629519,N,1,,,,,1,,BAO_0000218,
11899,,Intermediate,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,CHEMBL629520,N,1,,,,,1,,BAO_0000218,
11900,,Intermediate,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,CHEMBL629521,N,1,,,,,1,,BAO_0000218,
11901,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),CHEMBL629522,N,1,,,,,1,,BAO_0000218,
11902,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),CHEMBL629523,N,1,,,,,1,,BAO_0000218,
11903,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),CHEMBL629524,N,1,,,,,1,,BAO_0000218,
11904,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),CHEMBL629525,N,1,,,,,1,,BAO_0000218,
11905,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),CHEMBL629526,N,1,,,,,1,,BAO_0000218,
11906,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),CHEMBL629527,N,1,,,,,1,,BAO_0000218,
11907,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),CHEMBL629528,N,1,,,,,1,,BAO_0000218,
11908,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),CHEMBL629529,N,1,,,,,1,,BAO_0000218,
11909,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),CHEMBL629530,N,1,,,,,1,,BAO_0000218,
11910,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),CHEMBL629531,N,1,,,,,1,,BAO_0000218,
11911,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),CHEMBL628656,N,1,,,,,1,,BAO_0000218,
11912,,Intermediate,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),CHEMBL628657,N,1,,,,,1,,BAO_0000218,
11913,,Intermediate,,50597,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL628658,N,1,,,,,1,,BAO_0000218,
11914,,Intermediate,,50597,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL628659,N,1,,,,,1,,BAO_0000218,
11915,,Intermediate,,50597,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL877500,N,1,,,,,1,,BAO_0000218,
11916,,Intermediate,,50597,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL628660,N,1,,,,,1,,BAO_0000218,
11917,,Intermediate,,50597,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL628661,N,1,,,,,1,,BAO_0000218,
11918,,Intermediate,,50597,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL628662,N,1,,,,,1,,BAO_0000218,
11919,,Intermediate,,50597,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL628663,N,1,,,,,1,,BAO_0000218,
11920,,Intermediate,,50597,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL628664,N,1,,,,,1,,BAO_0000218,
11921,178.0,Intermediate,Blood,50597,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL628665,N,1,,,,,1,,BAO_0000218,
11922,178.0,Intermediate,Blood,50597,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL628666,N,1,,,,,1,,BAO_0000218,
11923,178.0,Intermediate,Blood,50597,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL628667,N,1,,,,,1,,BAO_0000218,
11924,178.0,Intermediate,Blood,50597,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL628668,N,1,,,,,1,,BAO_0000218,
11925,178.0,Intermediate,Blood,50597,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL628669,N,1,,,,,1,,BAO_0000218,
11926,178.0,Intermediate,Blood,50597,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL628670,N,1,,,,,1,,BAO_0000218,
11927,178.0,Intermediate,Blood,50597,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL628671,N,1,,,,,1,,BAO_0000218,
11928,10000001.0,Intermediate,Bone,50597,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL628672,N,1,,,,,1,,BAO_0000218,
11929,10000001.0,Intermediate,Bone,50597,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL630300,N,1,,,,,1,,BAO_0000218,
11930,10000001.0,Intermediate,Bone,50597,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL629787,N,1,,,,,1,,BAO_0000218,
11931,10000001.0,Intermediate,Bone,50597,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL629788,N,1,,,,,1,,BAO_0000218,
11932,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL629789,N,1,,,,,1,,BAO_0000218,
11933,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL629790,N,1,,,,,1,,BAO_0000218,
11934,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL629791,N,1,,,,,1,,BAO_0000218,
11935,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL629792,N,1,,,,,1,,BAO_0000218,
11936,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL629793,N,1,,,,,1,,BAO_0000218,
11937,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL629794,N,1,,,,,1,,BAO_0000218,
11938,,Intermediate,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,CHEMBL874459,N,1,,,,,1,,BAO_0000218,
11939,,Intermediate,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,CHEMBL629795,N,1,,,,,1,,BAO_0000218,
11940,,Intermediate,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,CHEMBL629796,N,1,,,,,1,,BAO_0000218,
11941,,Intermediate,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,CHEMBL629797,N,1,,,,,1,,BAO_0000218,
11942,,Intermediate,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,CHEMBL629798,N,1,,,,,1,,BAO_0000218,
11943,2369.0,Intermediate,Adrenal gland,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL629799,N,1,,,,,1,,BAO_0000218,
11944,2369.0,Intermediate,Adrenal gland,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL629800,N,1,,,,,1,,BAO_0000218,
11945,2369.0,Intermediate,Adrenal gland,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL629801,N,1,,,,,1,,BAO_0000218,
11946,2369.0,Intermediate,Adrenal gland,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,CHEMBL629802,N,1,,,,,1,,BAO_0000218,
11947,2369.0,Intermediate,Adrenal gland,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL629803,N,1,,,,,1,,BAO_0000218,
11948,178.0,Intermediate,Blood,50597,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL629804,N,1,,,,,1,,BAO_0000218,
11949,178.0,Intermediate,Blood,50597,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL629805,N,1,,,,,1,,BAO_0000218,
11950,178.0,Intermediate,Blood,50597,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,CHEMBL629806,N,1,,,,,1,,BAO_0000218,
11951,178.0,Intermediate,Blood,50597,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL629807,N,1,,,,,1,,BAO_0000218,
11952,178.0,Intermediate,Blood,50597,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL629808,N,1,,,,,1,,BAO_0000218,
11953,955.0,Intermediate,Brain,50597,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL629809,N,1,,,,,1,,BAO_0000218,
11954,955.0,Intermediate,Brain,50597,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL629810,N,1,,,,,1,,BAO_0000218,
11955,955.0,Intermediate,Brain,50597,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,CHEMBL629811,N,1,,,,,1,,BAO_0000218,
11956,955.0,Intermediate,Brain,50597,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL629812,N,1,,,,,1,,BAO_0000218,
11957,955.0,Intermediate,Brain,50597,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,CHEMBL629813,N,1,,,,,1,,BAO_0000218,
11958,955.0,Intermediate,Brain,50597,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL874460,N,1,,,,,1,,BAO_0000218,
11959,,Intermediate,,50597,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL629814,N,1,,,,,1,,BAO_0000218,
11960,,Intermediate,,50597,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL629815,N,1,,,,,1,,BAO_0000218,
11961,,Intermediate,,50597,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL629816,N,1,,,,,1,,BAO_0000218,
11962,,Intermediate,,50597,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL629817,N,1,,,,,1,,BAO_0000218,
11963,2113.0,Intermediate,Kidney,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL626643,N,1,,,,,1,,BAO_0000218,
11964,2113.0,Intermediate,Kidney,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL626644,N,1,,,,,1,,BAO_0000218,
11965,2113.0,Intermediate,Kidney,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL626806,N,1,,,,,1,,BAO_0000218,
11966,2113.0,Intermediate,Kidney,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL626807,N,1,,,,,1,,BAO_0000218,
11967,2107.0,Intermediate,Liver,50597,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627261,N,1,,,,,1,,BAO_0000218,
11968,2107.0,Intermediate,Liver,50597,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL627262,N,1,,,,,1,,BAO_0000218,
11969,2107.0,Intermediate,Liver,50597,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL627263,N,1,,,,,1,,BAO_0000218,
11970,2107.0,Intermediate,Liver,50597,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL627264,N,1,,,,,1,,BAO_0000218,
11971,2048.0,Intermediate,Lung,50597,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627265,N,1,,,,,1,,BAO_0000218,
11972,2048.0,Intermediate,Lung,50597,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL627266,N,1,,,,,1,,BAO_0000218,
11973,2048.0,Intermediate,Lung,50597,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL627267,N,1,,,,,1,,BAO_0000218,
11974,2048.0,Intermediate,Lung,50597,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL627268,N,1,,,,,1,,BAO_0000218,
11975,2385.0,Intermediate,Muscle tissue,50597,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627269,N,1,,,,,1,,BAO_0000218,
11976,2385.0,Intermediate,Muscle tissue,50597,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL627270,N,1,,,,,1,,BAO_0000218,
11977,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",CHEMBL627271,N,1,,,,,1,,BAO_0000218,
11978,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",CHEMBL627946,N,1,,,,,1,,BAO_0000218,
11979,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",CHEMBL875472,N,1,,,,,1,,BAO_0000218,
11980,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",CHEMBL627947,N,1,,,,,1,,BAO_0000218,
11981,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",CHEMBL627948,N,1,,,,,1,,BAO_0000218,
11982,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",CHEMBL628113,N,1,,,,,1,,BAO_0000218,
11983,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",CHEMBL628114,N,1,,,,,1,,BAO_0000218,
11984,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",CHEMBL628115,N,1,,,,,1,,BAO_0000218,
11985,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",CHEMBL628116,N,1,,,,,1,,BAO_0000218,
11986,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",CHEMBL628117,N,1,,,,,1,,BAO_0000218,
11987,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",CHEMBL628118,N,1,,,,,1,,BAO_0000218,
11988,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",CHEMBL628119,N,1,,,,,1,,BAO_0000218,
11989,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",CHEMBL628120,N,1,,,,,1,,BAO_0000218,
11990,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",CHEMBL628121,N,1,,,,,1,,BAO_0000218,
11991,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",CHEMBL628122,N,1,,,,,1,,BAO_0000218,
11992,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",CHEMBL627297,N,1,,,,,1,,BAO_0000218,
11993,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",CHEMBL627298,N,1,,,,,1,,BAO_0000218,
11994,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",CHEMBL627299,N,1,,,,,1,,BAO_0000218,
11995,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",CHEMBL627300,N,1,,,,,1,,BAO_0000218,
11996,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",CHEMBL627301,N,1,,,,,1,,BAO_0000218,
11997,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",CHEMBL627302,N,1,,,,,1,,BAO_0000218,
11998,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",CHEMBL627303,N,1,,,,,1,,BAO_0000218,
11999,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",CHEMBL627304,N,1,,,,,1,,BAO_0000218,
12000,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",CHEMBL627305,N,1,,,,,1,,BAO_0000218,
12001,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",CHEMBL627306,N,1,,,,,1,,BAO_0000218,
12002,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",CHEMBL623982,N,1,,,,,1,,BAO_0000218,
12003,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",CHEMBL623983,N,1,,,,,1,,BAO_0000218,
12004,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",CHEMBL623984,N,1,,,,,1,,BAO_0000218,
12005,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",CHEMBL623985,N,1,,,,,1,,BAO_0000218,
12006,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",CHEMBL623986,N,1,,,,,1,,BAO_0000218,
12007,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",CHEMBL623987,N,1,,,,,1,,BAO_0000218,
12008,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",CHEMBL623988,N,1,,,,,1,,BAO_0000218,
12009,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",CHEMBL623989,N,1,,,,,1,,BAO_0000218,
12010,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",CHEMBL622215,N,1,,,,,1,,BAO_0000218,
12011,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",CHEMBL622216,N,1,,,,,1,,BAO_0000218,
12012,,Intermediate,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",CHEMBL877481,N,1,,,,,1,,BAO_0000218,
12013,,Autocuration,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),CHEMBL622217,U,0,,,,,1,,BAO_0000218,
12014,,Intermediate,,50594,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),CHEMBL622218,N,1,,,,,1,,BAO_0000218,
12015,,Intermediate,,50597,Pharmacokinetic profile AUC was evaluated in rats,CHEMBL622219,N,1,,,,,1,,BAO_0000218,
12016,,Autocuration,,22224,Pharmacokinetic property (Area under curve),CHEMBL622220,U,0,,,,,1,,BAO_0000019,
12017,,Intermediate,,50588,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",CHEMBL622221,N,1,,,,,1,,BAO_0000218,
12018,,Intermediate,,50594,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",CHEMBL622222,N,1,,,,,1,,BAO_0000218,
12019,,Intermediate,,50588,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",CHEMBL622223,N,1,,,,,1,,BAO_0000218,
12020,,Intermediate,,50594,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",CHEMBL622224,N,1,,,,,1,,BAO_0000218,
12021,,Autocuration,,22224,Plasma concentration (AUC) was determined,CHEMBL622225,U,0,,,,,1,,BAO_0000019,
12022,,Autocuration,,22224,Plasma concentration (AUC) was determined; Not detectable,CHEMBL622226,U,0,,,,,1,,BAO_0000019,
12023,,Intermediate,,50512,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),CHEMBL624154,N,1,,,,,1,,BAO_0000218,
12024,,Intermediate,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,CHEMBL624155,N,1,,,,,1,,BAO_0000218,
12025,,Intermediate,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,CHEMBL624156,N,1,,,,,1,,BAO_0000218,
12026,,Intermediate,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,CHEMBL624157,N,1,,,,,1,,BAO_0000218,
12027,,Intermediate,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,CHEMBL624158,N,1,,,,,1,,BAO_0000218,
12028,,Intermediate,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,CHEMBL624159,N,1,,,,,1,,BAO_0000218,
12029,,Intermediate,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,CHEMBL624160,N,1,,,,,1,,BAO_0000218,
12030,,Intermediate,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,CHEMBL624161,N,1,,,,,1,,BAO_0000218,
12031,,Intermediate,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,CHEMBL624162,N,1,,,,,1,,BAO_0000218,
12032,,Intermediate,,50588,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,CHEMBL624163,N,1,,,,,1,,BAO_0000218,
12033,,Intermediate,,50597,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL624164,N,1,,,,,1,,BAO_0000218,
12034,,Intermediate,,50597,The AUC(0-infinity) values in female wistar rats.,CHEMBL624165,N,1,,,,,1,,BAO_0000218,
12035,,Intermediate,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL624166,N,1,,,,,1,,BAO_0000218,
12036,,Intermediate,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",CHEMBL624167,N,1,,,,,1,,BAO_0000218,
12037,,Intermediate,,50597,The AUC(0-t)values in female wistar rats.,CHEMBL624168,N,1,,,,,1,,BAO_0000218,
12038,,Intermediate,,50597,The Area under the concentration time curve of compound was measured on rats,CHEMBL624169,N,1,,,,,1,,BAO_0000218,
12039,,Intermediate,,50587,The area under curve (100 mg/kg) administered orally in humans,CHEMBL624170,N,1,,,,,1,,BAO_0000218,
12040,,Autocuration,,22224,The area under curve (12.5 mg/kg) administered intravenously in marmoset,CHEMBL624171,U,0,,,,,1,,BAO_0000218,
12041,,Autocuration,,22224,The area under curve (12.5 mg/kg) administered intravenously in monkey,CHEMBL624172,U,0,,,,,1,,BAO_0000218,
12042,,Intermediate,,50588,The area under curve (15 mg/kg) administered intravenously in dog,CHEMBL624173,N,1,,,,,1,,BAO_0000218,
12043,,Intermediate,,50587,The area under curve (200 mg/kg) administered orally in humans,CHEMBL877488,N,1,,,,,1,,BAO_0000218,
12044,,Intermediate,,50597,The area under curve (25 mg/kg) administered intravenously in rat,CHEMBL624174,N,1,,,,,1,,BAO_0000218,
12045,,Autocuration,,22224,The area under curve (25 mg/kg) administered orally in marmoset,CHEMBL624175,U,0,,,,,1,,BAO_0000218,
12046,,Autocuration,,22224,The area under curve (25 mg/kg) administered orally in monkey,CHEMBL624176,U,0,,,,,1,,BAO_0000218,
12047,,Intermediate,,50588,The area under curve (30 mg/kg) administered orally in dog,CHEMBL624177,N,1,,,,,1,,BAO_0000218,
12048,,Intermediate,,50587,The area under curve (400 mg/kg) administered orally in humans,CHEMBL624178,N,1,,,,,1,,BAO_0000218,
12049,,Intermediate,,50597,The area under curve (50 mg/kg) administered orally in fasted rat,CHEMBL624179,N,1,,,,,1,,BAO_0000218,
12050,,Intermediate,,50597,The area under curve (50 mg/kg) administered orally in rat,CHEMBL627689,N,1,,,,,1,,BAO_0000218,
12051,,Intermediate,,50587,The area under curve (800 mg/kg) administered orally in humans,CHEMBL627690,N,1,,,,,1,,BAO_0000218,
12052,,Autocuration,,22224,The compound was evaluated for area under the curve,CHEMBL627691,U,0,,,,,1,,BAO_0000019,
12053,,Autocuration,,22224,The compound was evaluated for area under the curve in marmosets,CHEMBL627692,U,0,,,,,1,,BAO_0000019,
12054,,Autocuration,,22224,The compound was evaluated for area under the curve in marmosets,CHEMBL627693,U,0,,,,,1,,BAO_0000019,
12055,,Intermediate,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,CHEMBL627694,N,1,,,,,1,,BAO_0000218,
12056,,Intermediate,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,CHEMBL627695,N,1,,,,,1,,BAO_0000218,
12057,,Autocuration,,22224,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),CHEMBL627696,U,0,,,,,1,,BAO_0000218,
12058,,Intermediate,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,CHEMBL627697,N,1,,,,,1,,BAO_0000218,
12059,,Intermediate,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,CHEMBL627698,N,1,,,,,1,,BAO_0000218,
12060,,Intermediate,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,CHEMBL627699,N,1,,,,,1,,BAO_0000218,
12061,,Intermediate,,50597,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,CHEMBL627700,N,1,,,,,1,,BAO_0000218,
12062,,Intermediate,,50597,Total drug exposure is determined after oral dosing in rats.,CHEMBL627701,N,1,,,,,1,,BAO_0000218,
12063,,Autocuration,,22224,Total drug exposure (5 mg/kg) when administered intravenously,CHEMBL627702,U,0,,,,,1,,BAO_0000218,
12064,,Autocuration,,22224,Total drug exposure (5 mg/kg) when administered orally,CHEMBL627703,U,0,,,,,1,,BAO_0000218,
12065,,Autocuration,,22224,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,CHEMBL626873,U,0,,,,,1,,BAO_0000218,
12066,,Intermediate,,50597,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,CHEMBL629583,N,1,,,,,1,,BAO_0000218,
12067,,Intermediate,,50588,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,CHEMBL629584,N,1,,,,,1,,BAO_0000218,
12068,,Intermediate,,50588,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,CHEMBL629585,N,1,,,,,1,,BAO_0000218,
12069,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL629586,N,1,,,,,1,,BAO_0000218,
12070,955.0,Intermediate,Brain,50597,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL629587,N,1,,,,,1,,BAO_0000218,
12071,,Intermediate,,50597,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL629588,N,1,,,,,1,,BAO_0000218,
12072,,Intermediate,,50597,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL629589,N,1,,,,,1,,BAO_0000218,
12073,,Intermediate,,50597,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL629590,N,1,,,,,1,,BAO_0000218,
12074,,Intermediate,,50597,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL629591,N,1,,,,,1,,BAO_0000218,
12075,,Intermediate,,50597,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL629592,N,1,,,,,1,,BAO_0000218,
12076,,Intermediate,,50597,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL629593,N,1,,,,,1,,BAO_0000218,
12077,,Intermediate,,50597,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL629594,N,1,,,,,1,,BAO_0000218,
12078,948.0,Intermediate,Heart,50597,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL629595,N,1,,,,,1,,BAO_0000218,
12079,948.0,Intermediate,Heart,50597,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL630290,N,1,,,,,1,,BAO_0000218,
12080,948.0,Intermediate,Heart,50597,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL627137,N,1,,,,,1,,BAO_0000218,
12081,948.0,Intermediate,Heart,50597,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL627138,N,1,,,,,1,,BAO_0000218,
12082,948.0,Intermediate,Heart,50597,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL627139,N,1,,,,,1,,BAO_0000218,
12083,948.0,Intermediate,Heart,50597,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL627140,N,1,,,,,1,,BAO_0000218,
12084,948.0,Intermediate,Heart,50597,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL627141,N,1,,,,,1,,BAO_0000218,
12085,2113.0,Intermediate,Kidney,50597,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL627142,N,1,,,,,1,,BAO_0000218,
12086,2113.0,Intermediate,Kidney,50597,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL627143,N,1,,,,,1,,BAO_0000218,
12087,2113.0,Intermediate,Kidney,50597,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL874449,N,1,,,,,1,,BAO_0000218,
12088,2113.0,Intermediate,Kidney,50597,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL627144,N,1,,,,,1,,BAO_0000218,
12089,2113.0,Intermediate,Kidney,50597,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL627145,N,1,,,,,1,,BAO_0000218,
12090,2113.0,Intermediate,Kidney,50597,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL627146,N,1,,,,,1,,BAO_0000218,
12091,2113.0,Intermediate,Kidney,50597,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL627147,N,1,,,,,1,,BAO_0000218,
12092,2107.0,Intermediate,Liver,50597,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL627148,N,1,,,,,1,,BAO_0000218,
12093,2048.0,Intermediate,Lung,50597,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL627149,N,1,,,,,1,,BAO_0000218,
12094,2048.0,Intermediate,Lung,50597,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL632160,N,1,,,,,1,,BAO_0000218,
12095,2048.0,Intermediate,Lung,50597,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL632161,N,1,,,,,1,,BAO_0000218,
12096,2048.0,Intermediate,Lung,50597,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL632162,N,1,,,,,1,,BAO_0000218,
12097,2048.0,Intermediate,Lung,50597,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL632163,N,1,,,,,1,,BAO_0000218,
12098,2048.0,Intermediate,Lung,50597,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL874469,N,1,,,,,1,,BAO_0000218,
12099,2048.0,Intermediate,Lung,50597,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL627182,N,1,,,,,1,,BAO_0000218,
12100,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",CHEMBL627183,N,1,,,,,1,,BAO_0000218,
12101,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL627184,N,1,,,,,1,,BAO_0000218,
12102,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL627185,N,1,,,,,1,,BAO_0000218,
12103,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL627186,N,1,,,,,1,,BAO_0000218,
12104,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL627187,N,1,,,,,1,,BAO_0000218,
12105,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL627188,N,1,,,,,1,,BAO_0000218,
12106,2385.0,Intermediate,Muscle tissue,50597,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL627189,N,1,,,,,1,,BAO_0000218,
12107,,Intermediate,,50597,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL627190,N,1,,,,,1,,BAO_0000218,
12108,2107.0,Intermediate,Liver,50597,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",CHEMBL627191,N,1,,,,,1,,BAO_0000218,
12109,2107.0,Intermediate,Liver,50597,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",CHEMBL627192,N,1,,,,,1,,BAO_0000218,
12110,2107.0,Intermediate,Liver,50597,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",CHEMBL627193,N,1,,,,,1,,BAO_0000218,
12111,2385.0,Intermediate,Muscle tissue,50597,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,CHEMBL874590,N,1,,,,,1,,BAO_0000218,
12112,2385.0,Intermediate,Muscle tissue,50597,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL627194,N,1,,,,,1,,BAO_0000218,
12113,2385.0,Intermediate,Muscle tissue,50597,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL627195,N,1,,,,,1,,BAO_0000218,
12114,992.0,Intermediate,Female gonad,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627196,N,1,,,,,1,,BAO_0000218,
12115,992.0,Intermediate,Female gonad,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL627197,N,1,,,,,1,,BAO_0000218,
12116,992.0,Intermediate,Female gonad,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL627198,N,1,,,,,1,,BAO_0000218,
12117,992.0,Intermediate,Female gonad,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,CHEMBL627199,N,1,,,,,1,,BAO_0000218,
12118,992.0,Intermediate,Female gonad,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL627200,N,1,,,,,1,,BAO_0000218,
12119,1969.0,Intermediate,Plasma,50597,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627201,N,1,,,,,1,,BAO_0000218,
12120,1969.0,Intermediate,Plasma,50597,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL627202,N,1,,,,,1,,BAO_0000218,
12121,1969.0,Intermediate,Plasma,50597,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL627203,N,1,,,,,1,,BAO_0000218,
12122,1969.0,Intermediate,Plasma,50597,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL627204,N,1,,,,,1,,BAO_0000218,
12123,2106.0,Intermediate,Spleen,50597,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627205,N,1,,,,,1,,BAO_0000218,
12124,2106.0,Intermediate,Spleen,50597,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL627206,N,1,,,,,1,,BAO_0000218,
12125,2106.0,Intermediate,Spleen,50597,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL627207,N,1,,,,,1,,BAO_0000218,
12126,2106.0,Intermediate,Spleen,50597,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL627208,N,1,,,,,1,,BAO_0000218,
12127,2046.0,Intermediate,Thyroid gland,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627209,N,1,,,,,1,,BAO_0000218,
12128,2046.0,Intermediate,Thyroid gland,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL627210,N,1,,,,,1,,BAO_0000218,
12129,2046.0,Intermediate,Thyroid gland,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL627211,N,1,,,,,1,,BAO_0000218,
12130,2046.0,Intermediate,Thyroid gland,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL627212,N,1,,,,,1,,BAO_0000218,
12131,995.0,Intermediate,Uterus,50597,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,CHEMBL627213,N,1,,,,,1,,BAO_0000218,
12132,995.0,Intermediate,Uterus,50597,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,CHEMBL626599,N,1,,,,,1,,BAO_0000218,
12133,995.0,Intermediate,Uterus,50597,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,CHEMBL626600,N,1,,,,,1,,BAO_0000218,
12134,995.0,Intermediate,Uterus,50597,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,CHEMBL626601,N,1,,,,,1,,BAO_0000218,
12135,,Autocuration,,22224,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,CHEMBL627484,U,0,,,,,1,,BAO_0000019,
12136,1969.0,Intermediate,Plasma,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),CHEMBL627485,N,1,,,,,1,,BAO_0000218,
12137,1969.0,Intermediate,Plasma,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,CHEMBL628147,N,1,,,,,1,,BAO_0000218,
12138,1969.0,Intermediate,Plasma,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,CHEMBL628148,N,1,,,,,1,,BAO_0000218,
12139,1969.0,Intermediate,Plasma,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),CHEMBL628149,N,1,,,,,1,,BAO_0000218,
12140,1969.0,Intermediate,Plasma,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,CHEMBL628150,N,1,,,,,1,,BAO_0000218,
12141,1969.0,Intermediate,Plasma,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,CHEMBL628318,N,1,,,,,1,,BAO_0000218,
12142,1969.0,Intermediate,Plasma,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,CHEMBL628319,N,1,,,,,1,,BAO_0000218,
12143,,Intermediate,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",CHEMBL875609,N,1,,,,,1,,BAO_0000218,
12144,,Autocuration,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,CHEMBL628320,U,0,,,,,1,,BAO_0000019,
12145,,Autocuration,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,CHEMBL628321,U,0,,,,,1,,BAO_0000019,
12146,,Autocuration,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,CHEMBL628322,U,0,,,,,1,,BAO_0000019,
12147,,Autocuration,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,CHEMBL628323,U,0,,,,,1,,BAO_0000019,
12148,,Autocuration,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,CHEMBL628324,U,0,,,,,1,,BAO_0000019,
12149,,Autocuration,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,CHEMBL628325,U,0,,,,,1,,BAO_0000019,
12150,,Autocuration,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,CHEMBL628326,U,0,,,,,1,,BAO_0000019,
12151,1236.0,Intermediate,Adrenal medulla,50588,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",CHEMBL628327,N,1,,,,,1,,BAO_0000218,
12152,1236.0,Intermediate,Adrenal medulla,50588,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",CHEMBL628328,N,1,,,,,1,,BAO_0000218,
12153,178.0,Intermediate,Blood,50588,"Concentration of compound in blood of dog 1, after administering intravenously",CHEMBL628329,N,1,,,,,1,,BAO_0000218,
12154,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",CHEMBL628330,N,1,,,,,1,,BAO_0000218,
12155,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",CHEMBL628331,N,1,,,,,1,,BAO_0000218,
12156,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",CHEMBL628332,N,1,,,,,1,,BAO_0000218,
12157,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",CHEMBL628333,N,1,,,,,1,,BAO_0000218,
12158,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",CHEMBL628334,N,1,,,,,1,,BAO_0000218,
12159,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",CHEMBL628335,N,1,,,,,1,,BAO_0000218,
12160,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",CHEMBL628336,N,1,,,,,1,,BAO_0000218,
12161,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",CHEMBL628337,N,1,,,,,1,,BAO_0000218,
12162,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",CHEMBL628338,N,1,,,,,1,,BAO_0000218,
12163,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",CHEMBL875610,N,1,,,,,1,,BAO_0000218,
12164,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",CHEMBL628339,N,1,,,,,1,,BAO_0000218,
12165,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",CHEMBL628340,N,1,,,,,1,,BAO_0000218,
12166,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",CHEMBL628341,N,1,,,,,1,,BAO_0000218,
12167,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",CHEMBL622214,N,1,,,,,1,,BAO_0000218,
12168,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",CHEMBL623167,N,1,,,,,1,,BAO_0000218,
12169,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",CHEMBL623168,N,1,,,,,1,,BAO_0000218,
12170,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",CHEMBL623169,N,1,,,,,1,,BAO_0000218,
12171,2107.0,Intermediate,Liver,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",CHEMBL623170,N,1,,,,,1,,BAO_0000218,
12172,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",CHEMBL627224,N,1,,,,,1,,BAO_0000218,
12173,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",CHEMBL875634,N,1,,,,,1,,BAO_0000218,
12174,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",CHEMBL627225,N,1,,,,,1,,BAO_0000218,
12175,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",CHEMBL627226,N,1,,,,,1,,BAO_0000218,
12176,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",CHEMBL626083,N,1,,,,,1,,BAO_0000218,
12177,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",CHEMBL626084,N,1,,,,,1,,BAO_0000218,
12178,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",CHEMBL626085,N,1,,,,,1,,BAO_0000218,
12179,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",CHEMBL626086,N,1,,,,,1,,BAO_0000218,
12180,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",CHEMBL626087,N,1,,,,,1,,BAO_0000218,
12181,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",CHEMBL626088,N,1,,,,,1,,BAO_0000218,
12182,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",CHEMBL626089,N,1,,,,,1,,BAO_0000218,
12183,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",CHEMBL626090,N,1,,,,,1,,BAO_0000218,
12184,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",CHEMBL626091,N,1,,,,,1,,BAO_0000218,
12185,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",CHEMBL626092,N,1,,,,,1,,BAO_0000218,
12186,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",CHEMBL626093,N,1,,,,,1,,BAO_0000218,
12187,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",CHEMBL626094,N,1,,,,,1,,BAO_0000218,
12188,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",CHEMBL626095,N,1,,,,,1,,BAO_0000218,
12189,2048.0,Intermediate,Lung,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",CHEMBL626096,N,1,,,,,1,,BAO_0000218,
12190,,Autocuration,,22224,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,CHEMBL626097,U,0,,,,,1,,BAO_0000218,
12191,,Intermediate,,50597,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,CHEMBL626098,N,1,,,,,1,,BAO_0000218,
12192,1969.0,Autocuration,Plasma,22224,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,CHEMBL626099,U,0,,,,,1,,BAO_0000218,
12193,1969.0,Autocuration,Plasma,22224,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,CHEMBL626100,U,0,,,,,1,,BAO_0000218,
12194,1969.0,Intermediate,Plasma,50588,AUC 0-inf in dog,CHEMBL626101,N,1,,,,,1,,BAO_0000218,
12195,1969.0,Intermediate,Plasma,50512,AUC 0-inf in guinea pig,CHEMBL626102,N,1,,,,,1,,BAO_0000218,
12196,1969.0,Intermediate,Plasma,50588,AUC 0-t in dog,CHEMBL626103,N,1,,,,,1,,BAO_0000218,
12197,1969.0,Intermediate,Plasma,50512,AUC 0-t in guinea pig,CHEMBL628391,N,1,,,,,1,,BAO_0000218,
12198,,Intermediate,,50597,The compound was tested for brain to plasma partition in rat,CHEMBL628392,N,1,,,,,1,,BAO_0000218,
12199,,Intermediate,,50597,The compound was tested for brain to plasma partition in rat.,CHEMBL628393,N,1,,,,,1,,BAO_0000218,
12200,178.0,Autocuration,Blood,22224,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,CHEMBL628394,U,0,,,,,1,,BAO_0000019,
12201,,Intermediate,,50588,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,CHEMBL628395,N,1,,,,,1,,BAO_0000218,
12202,,Autocuration,,22224,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,CHEMBL628396,U,0,,,,,1,,BAO_0000218,
12203,,Intermediate,,50592,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,CHEMBL628397,N,1,,,,,1,,BAO_0000218,
12204,,Intermediate,,50597,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,CHEMBL628398,N,1,,,,,1,,BAO_0000218,
12205,,Intermediate,,50797,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,CHEMBL628399,N,1,,,,,1,,BAO_0000218,
12206,,Intermediate,,50588,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,CHEMBL628400,N,1,,,,,1,,BAO_0000218,
12207,,Intermediate,,50597,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,CHEMBL874907,N,1,,,,,1,,BAO_0000218,
12208,,Autocuration,,22224,Area under curve of the compound was determined,CHEMBL628401,U,0,,,,,1,,BAO_0000019,
12209,1969.0,Autocuration,Plasma,22224,AUC in monkeys at a dose of 1 mg/kg,CHEMBL628402,U,0,,,,,1,,BAO_0000218,
12210,1969.0,Intermediate,Plasma,50597,AUC in rats at a dose of 1 mg/kg,CHEMBL628403,N,1,,,,,1,,BAO_0000218,
12211,,Autocuration,,22224,Compound was evaluated for the overall absorbance loss at pH of 2,CHEMBL628404,U,0,,,,,1,,BAO_0000019,
12212,,Autocuration,,22224,Compound was evaluated for the overall absorbance loss at pH of 4,CHEMBL628405,U,0,,,,,1,,BAO_0000019,
12213,,Autocuration,,22224,Compound was evaluated for the overall absorbance loss at pH of 7,CHEMBL628406,U,0,,,,,1,,BAO_0000019,
12214,,Intermediate,,50597,Compound was evaluated for its absorption in the rats,CHEMBL628407,N,1,,,,,1,,BAO_0000218,
12215,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,CHEMBL628408,N,1,,,,,1,,BAO_0000218,
12216,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,CHEMBL629171,N,1,,,,,1,,BAO_0000218,
12217,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,CHEMBL629172,N,1,,,,,1,,BAO_0000218,
12218,1088.0,Intermediate,Urine,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,CHEMBL629173,N,1,,,,,1,,BAO_0000218,
12219,,Intermediate,,50597,In vitro percent permeability into rat ileum,CHEMBL629174,N,1,,,,,1,,BAO_0000218,
12220,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 10-17,CHEMBL629175,N,1,,,,,1,,BAO_0000218,
12221,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 10-18,CHEMBL629176,N,1,,,,,1,,BAO_0000218,
12222,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 10-19,CHEMBL629177,N,1,,,,,1,,BAO_0000218,
12223,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 12-15,CHEMBL629178,N,1,,,,,1,,BAO_0000218,
12224,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 13-19,CHEMBL631869,N,1,,,,,1,,BAO_0000218,
12225,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 14-17,CHEMBL631870,N,1,,,,,1,,BAO_0000218,
12226,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 15-18,CHEMBL631871,N,1,,,,,1,,BAO_0000218,
12227,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 2-5,CHEMBL631872,N,1,,,,,1,,BAO_0000218,
12228,2116.0,Autocuration,Ileum,22224,In vitro percent permeability into rat ileum; Range is 23-42,CHEMBL875775,U,0,,,,,1,,BAO_0000221,
12229,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 28-36,CHEMBL631873,N,1,,,,,1,,BAO_0000218,
12230,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 29-35,CHEMBL631874,N,1,,,,,1,,BAO_0000218,
12231,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 46-66,CHEMBL631875,N,1,,,,,1,,BAO_0000218,
12232,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 50-68,CHEMBL631876,N,1,,,,,1,,BAO_0000218,
12233,,Intermediate,,50597,In vitro percent permeability into rat ileum; Range is 78-81,CHEMBL631877,N,1,,,,,1,,BAO_0000218,
12234,,Intermediate,,50597,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,CHEMBL631878,N,1,,,,,1,,BAO_0000218,
12235,,Intermediate,,50597,In vitro percent permeability into rat ileum; nd indicates not detected,CHEMBL631879,N,1,,,,,1,,BAO_0000218,
12236,,Intermediate,,50597,In vitro percent permeability into rat ileum; nt indicates not detected,CHEMBL631880,N,1,,,,,1,,BAO_0000218,
12237,,Intermediate,,50597,In vitro percent permeability into rat ileum; nt indicates not tested,CHEMBL631881,N,1,,,,,1,,BAO_0000218,
12238,,Intermediate,,50597,Compound was tested for oral absorption in bile-duct cannulated rats,CHEMBL631882,N,1,,,,,1,,BAO_0000218,
12239,,Intermediate,,50597,Compound was tested for oral absorption in bile-duct cannulated rats.,CHEMBL630749,N,1,,,,,1,,BAO_0000218,
12240,,Intermediate,,50587,Oral absorption using Caco-2 cell monolayers.,CHEMBL630750,N,1,,,,,1,,BAO_0000218,
12241,,Intermediate,,50587,Percent of the drug absorbed after administration to humans was determined,CHEMBL630253,N,1,,,,,1,,BAO_0000218,
12242,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,CHEMBL630254,N,1,,,,,1,,BAO_0000218,
12243,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,CHEMBL630255,N,1,,,,,1,,BAO_0000218,
12244,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,CHEMBL630256,N,1,,,,,1,,BAO_0000218,
12245,2107.0,Intermediate,Liver,50597,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",CHEMBL875781,N,1,,,,,1,,BAO_0000218,
12246,2107.0,Intermediate,Liver,50597,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",CHEMBL630257,N,1,,,,,1,,BAO_0000218,
12247,2107.0,Intermediate,Liver,50597,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",CHEMBL630258,N,1,,,,,1,,BAO_0000218,
12248,,Intermediate,,50597,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",CHEMBL630259,N,1,,,,,1,,BAO_0000218,
12249,2435.0,Intermediate,Striatum,50597,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",CHEMBL630260,N,1,,,,,1,,BAO_0000218,
12250,2435.0,Intermediate,Striatum,50597,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",CHEMBL630261,N,1,,,,,1,,BAO_0000218,
12251,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,CHEMBL630262,N,1,,,,,1,,BAO_0000218,
12252,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,CHEMBL630263,N,1,,,,,1,,BAO_0000218,
12253,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,CHEMBL630264,N,1,,,,,1,,BAO_0000218,
12254,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,CHEMBL630265,N,1,,,,,1,,BAO_0000218,
12255,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,CHEMBL630266,N,1,,,,,1,,BAO_0000218,
12256,2113.0,Intermediate,Kidney,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,CHEMBL630267,N,1,,,,,1,,BAO_0000218,
12257,2113.0,Intermediate,Kidney,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,CHEMBL630268,N,1,,,,,1,,BAO_0000218,
12258,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,CHEMBL630269,N,1,,,,,1,,BAO_0000218,
12259,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,CHEMBL630270,N,1,,,,,1,,BAO_0000218,
12260,2048.0,Intermediate,Lung,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,CHEMBL630141,N,1,,,,,1,,BAO_0000218,
12261,2048.0,Intermediate,Lung,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,CHEMBL630142,N,1,,,,,1,,BAO_0000218,
12262,2385.0,Intermediate,Muscle tissue,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,CHEMBL630143,N,1,,,,,1,,BAO_0000218,
12263,2385.0,Intermediate,Muscle tissue,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,CHEMBL630144,N,1,,,,,1,,BAO_0000218,
12264,2367.0,Intermediate,Prostate gland,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,CHEMBL630145,N,1,,,,,1,,BAO_0000218,
12265,2367.0,Intermediate,Prostate gland,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,CHEMBL630146,N,1,,,,,1,,BAO_0000218,
12266,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,CHEMBL630147,N,1,,,,,1,,BAO_0000218,
12267,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,CHEMBL630148,N,1,,,,,1,,BAO_0000218,
12268,,Intermediate,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,CHEMBL630149,N,1,,,,,1,,BAO_0000218,
12269,2106.0,Intermediate,Spleen,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,CHEMBL630150,N,1,,,,,1,,BAO_0000218,
12270,2106.0,Intermediate,Spleen,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,CHEMBL630151,N,1,,,,,1,,BAO_0000218,
12271,2046.0,Intermediate,Thyroid gland,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,CHEMBL632031,N,1,,,,,1,,BAO_0000218,
12272,2046.0,Intermediate,Thyroid gland,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,CHEMBL632032,N,1,,,,,1,,BAO_0000218,
12273,,Intermediate,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,CHEMBL632033,N,1,,,,,1,,BAO_0000218,
12274,,Intermediate,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,CHEMBL632034,N,1,,,,,1,,BAO_0000218,
12275,2385.0,Intermediate,Muscle tissue,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,CHEMBL632035,N,1,,,,,1,,BAO_0000218,
12276,,Intermediate,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,CHEMBL632036,N,1,,,,,1,,BAO_0000218,
12277,2046.0,Intermediate,Thyroid gland,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,CHEMBL632037,N,1,,,,,1,,BAO_0000218,
12278,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,CHEMBL632038,N,1,,,,,1,,BAO_0000218,
12279,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,CHEMBL632039,N,1,,,,,1,,BAO_0000218,
12280,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,CHEMBL632040,N,1,,,,,1,,BAO_0000218,
12281,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,CHEMBL632041,N,1,,,,,1,,BAO_0000218,
12282,178.0,Intermediate,Blood,50588,"Concentration of compound in blood of dog 2, after administering intravenously",CHEMBL632042,N,1,,,,,1,,BAO_0000218,
12283,,Intermediate,,50588,"Concentration of compound in left ventricle of dog 1, after administering intravenously",CHEMBL632043,N,1,,,,,1,,BAO_0000218,
12284,,Intermediate,,50588,"Concentration of compound in left ventricle of dog 2, after administering intravenously",CHEMBL632044,N,1,,,,,1,,BAO_0000218,
12285,2107.0,Intermediate,Liver,50588,"Concentration of compound in liver of dog 1, after administering intravenously",CHEMBL632045,N,1,,,,,1,,BAO_0000218,
12286,2107.0,Intermediate,Liver,50588,"Concentration of compound in liver of dog 2, after administering intravenously",CHEMBL632046,N,1,,,,,1,,BAO_0000218,
12287,2048.0,Intermediate,Lung,50588,"Concentration of compound in lung of dog 1, after administering intravenously",CHEMBL632047,N,1,,,,,1,,BAO_0000218,
12288,2048.0,Intermediate,Lung,50588,"Concentration of compound in lung of dog 2, after administering intravenously",CHEMBL632048,N,1,,,,,1,,BAO_0000218,
12289,2385.0,Intermediate,Muscle tissue,50588,"Concentration of compound in muscle of dog 1, after administering intravenously",CHEMBL632049,N,1,,,,,1,,BAO_0000218,
12290,2385.0,Intermediate,Muscle tissue,50588,"Concentration of compound in muscle of dog 2, after administering intravenously",CHEMBL876418,N,1,,,,,1,,BAO_0000218,
12291,2106.0,Intermediate,Spleen,50588,"Concentration of compound in spleen of dog 1,after administering intravenously",CHEMBL632050,N,1,,,,,1,,BAO_0000218,
12292,2106.0,Intermediate,Spleen,50588,"Concentration of compound in spleen of dog 2, after administering intravenously",CHEMBL632051,N,1,,,,,1,,BAO_0000218,
12293,,Autocuration,,22224,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,CHEMBL632052,U,0,,,,,1,,BAO_0000218,
12294,,Autocuration,,22224,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,CHEMBL632053,U,0,,,,,1,,BAO_0000218,
12295,,Autocuration,,22224,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,CHEMBL632054,U,0,,,,,1,,BAO_0000218,
12296,,Autocuration,,22224,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,CHEMBL632055,U,0,,,,,1,,BAO_0000218,
12297,,Autocuration,,22224,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,CHEMBL631181,U,0,,,,,1,,BAO_0000218,
12298,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,CHEMBL631182,U,0,,,,,1,,BAO_0000218,
12299,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,CHEMBL631183,U,0,,,,,1,,BAO_0000218,
12300,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,CHEMBL631184,U,0,,,,,1,,BAO_0000218,
12301,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,CHEMBL629774,U,0,,,,,1,,BAO_0000218,
12302,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,CHEMBL629775,U,0,,,,,1,,BAO_0000218,
12303,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,CHEMBL876549,U,0,,,,,1,,BAO_0000218,
12304,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,CHEMBL628172,U,0,,,,,1,,BAO_0000218,
12305,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,CHEMBL628173,U,0,,,,,1,,BAO_0000218,
12306,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,CHEMBL628174,U,0,,,,,1,,BAO_0000218,
12307,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,CHEMBL628175,U,0,,,,,1,,BAO_0000218,
12308,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,CHEMBL628176,U,0,,,,,1,,BAO_0000218,
12309,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,CHEMBL628177,U,0,,,,,1,,BAO_0000218,
12310,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,CHEMBL628178,U,0,,,,,1,,BAO_0000218,
12311,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,CHEMBL628179,U,0,,,,,1,,BAO_0000218,
12312,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,CHEMBL628180,U,0,,,,,1,,BAO_0000218,
12313,,Autocuration,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,CHEMBL628181,U,0,,,,,1,,BAO_0000218,
12314,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,CHEMBL628182,U,0,,,,,1,,BAO_0000218,
12315,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,CHEMBL628183,U,0,,,,,1,,BAO_0000218,
12316,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,CHEMBL628184,U,0,,,,,1,,BAO_0000218,
12317,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,CHEMBL628185,U,0,,,,,1,,BAO_0000218,
12318,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,CHEMBL875617,U,0,,,,,1,,BAO_0000218,
12319,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,CHEMBL628186,U,0,,,,,1,,BAO_0000218,
12320,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,CHEMBL628187,U,0,,,,,1,,BAO_0000218,
12321,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,CHEMBL628188,U,0,,,,,1,,BAO_0000218,
12322,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,CHEMBL628189,U,0,,,,,1,,BAO_0000218,
12323,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,CHEMBL628190,U,0,,,,,1,,BAO_0000218,
12324,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,CHEMBL628191,U,0,,,,,1,,BAO_0000218,
12325,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,CHEMBL626513,U,0,,,,,1,,BAO_0000218,
12326,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",CHEMBL626514,N,1,,,,,1,,BAO_0000218,
12327,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",CHEMBL626515,N,1,,,,,1,,BAO_0000218,
12328,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",CHEMBL626516,N,1,,,,,1,,BAO_0000218,
12329,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",CHEMBL626517,N,1,,,,,1,,BAO_0000218,
12330,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",CHEMBL626518,N,1,,,,,1,,BAO_0000218,
12331,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",CHEMBL626519,N,1,,,,,1,,BAO_0000218,
12332,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",CHEMBL626520,N,1,,,,,1,,BAO_0000218,
12333,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",CHEMBL626521,N,1,,,,,1,,BAO_0000218,
12334,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",CHEMBL626522,N,1,,,,,1,,BAO_0000218,
12335,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",CHEMBL626523,N,1,,,,,1,,BAO_0000218,
12336,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",CHEMBL626524,N,1,,,,,1,,BAO_0000218,
12337,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",CHEMBL626688,N,1,,,,,1,,BAO_0000218,
12338,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",CHEMBL626689,N,1,,,,,1,,BAO_0000218,
12339,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",CHEMBL626690,N,1,,,,,1,,BAO_0000218,
12340,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",CHEMBL626691,N,1,,,,,1,,BAO_0000218,
12341,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",CHEMBL627319,N,1,,,,,1,,BAO_0000218,
12342,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",CHEMBL624052,N,1,,,,,1,,BAO_0000218,
12343,2046.0,Intermediate,Thyroid gland,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",CHEMBL624053,N,1,,,,,1,,BAO_0000218,
12344,,Intermediate,,50597,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL624054,N,1,,,,,1,,BAO_0000218,
12345,,Intermediate,,50597,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL624055,N,1,,,,,1,,BAO_0000218,
12346,,Intermediate,,50597,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL624056,N,1,,,,,1,,BAO_0000218,
12347,995.0,Intermediate,Uterus,50597,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL624057,N,1,,,,,1,,BAO_0000218,
12348,995.0,Intermediate,Uterus,50597,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL622281,N,1,,,,,1,,BAO_0000218,
12349,995.0,Intermediate,Uterus,50597,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL622282,N,1,,,,,1,,BAO_0000218,
12350,995.0,Intermediate,Uterus,50597,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL622283,N,1,,,,,1,,BAO_0000218,
12351,995.0,Intermediate,Uterus,50597,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL622284,N,1,,,,,1,,BAO_0000218,
12352,995.0,Intermediate,Uterus,50597,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL622285,N,1,,,,,1,,BAO_0000218,
12353,995.0,Intermediate,Uterus,50597,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,CHEMBL622286,N,1,,,,,1,,BAO_0000218,
12354,,Autocuration,,22224,Distribution coefficient (D %) between octanol and buffer of pH 7.4,CHEMBL622287,U,0,,,,,1,,BAO_0000100,
12355,,Intermediate,,50594,Partition coefficient (logD7.4),CHEMBL622288,N,1,,,,,1,,BAO_0000218,
12356,,Intermediate,,50594,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",CHEMBL622289,N,1,,,,,1,,BAO_0000218,
12357,955.0,Intermediate,Brain,50594,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",CHEMBL622290,N,1,,,,,1,,BAO_0000218,
12358,,Intermediate,,50594,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,CHEMBL622291,N,1,,,,,1,,BAO_0000218,
12359,955.0,Intermediate,Brain,50594,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,CHEMBL622292,N,1,,,,,1,,BAO_0000218,
12360,,Intermediate,,50594,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",CHEMBL622293,N,1,,,,,1,,BAO_0000218,
12361,955.0,Intermediate,Brain,50594,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",CHEMBL622294,N,1,,,,,1,,BAO_0000218,
12362,,Intermediate,,50594,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,CHEMBL622295,N,1,,,,,1,,BAO_0000218,
12363,955.0,Intermediate,Brain,50597,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,CHEMBL622296,N,1,,,,,1,,BAO_0000218,
12364,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,CHEMBL874409,N,1,,,,,1,,BAO_0000218,
12365,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,CHEMBL622297,N,1,,,,,1,,BAO_0000218,
12366,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,CHEMBL622298,N,1,,,,,1,,BAO_0000218,
12367,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,CHEMBL622299,N,1,,,,,1,,BAO_0000218,
12368,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,CHEMBL622300,N,1,,,,,1,,BAO_0000218,
12369,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,CHEMBL622301,N,1,,,,,1,,BAO_0000218,
12370,1969.0,Intermediate,Plasma,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,CHEMBL622302,N,1,,,,,1,,BAO_0000218,
12371,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,CHEMBL622303,N,1,,,,,1,,BAO_0000218,
12372,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,CHEMBL622304,N,1,,,,,1,,BAO_0000218,
12373,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,CHEMBL622305,N,1,,,,,1,,BAO_0000218,
12374,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,CHEMBL622306,N,1,,,,,1,,BAO_0000218,
12375,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,CHEMBL626864,N,1,,,,,1,,BAO_0000218,
12376,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,CHEMBL626865,N,1,,,,,1,,BAO_0000218,
12377,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,CHEMBL626866,N,1,,,,,1,,BAO_0000218,
12378,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,CHEMBL626867,N,1,,,,,1,,BAO_0000218,
12379,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,CHEMBL626868,N,1,,,,,1,,BAO_0000218,
12380,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,CHEMBL626869,N,1,,,,,1,,BAO_0000218,
12381,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,CHEMBL626870,N,1,,,,,1,,BAO_0000218,
12382,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,CHEMBL626871,N,1,,,,,1,,BAO_0000218,
12383,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,CHEMBL626872,N,1,,,,,1,,BAO_0000218,
12384,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,CHEMBL632185,N,1,,,,,1,,BAO_0000218,
12385,1969.0,Intermediate,Plasma,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,CHEMBL632186,N,1,,,,,1,,BAO_0000218,
12386,,Autocuration,,22224,Amount of acetic acid produced by the compound,CHEMBL629310,U,0,,,,,1,,BAO_0000019,
12387,,Autocuration,,22224,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,CHEMBL629311,U,0,,,,,1,,BAO_0000019,
12388,,Intermediate,,50597,Log of (Cbrain/Cblood) in rats,CHEMBL629312,N,1,,,,,1,,BAO_0000218,
12389,,Autocuration,,22224,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),CHEMBL629313,U,0,,,,,1,,BAO_0000221,
12390,,Autocuration,,22224,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),CHEMBL629314,U,0,,,,,1,,BAO_0000221,
12391,,Autocuration,,22224,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),CHEMBL629315,U,0,,,,,1,,BAO_0000221,
12392,,Autocuration,,22224,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),CHEMBL629316,U,0,,,,,1,,BAO_0000219,
12393,,Autocuration,,22224,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),CHEMBL629317,U,0,,,,,1,,BAO_0000221,
12394,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),CHEMBL629318,U,0,,,,,1,,BAO_0000019,
12395,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),CHEMBL877497,U,0,,,,,1,,BAO_0000019,
12396,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),CHEMBL629319,U,0,,,,,1,,BAO_0000019,
12397,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),CHEMBL629320,U,0,,,,,1,,BAO_0000019,
12398,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),CHEMBL629496,U,0,,,,,1,,BAO_0000019,
12399,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),CHEMBL629497,U,0,,,,,1,,BAO_0000019,
12400,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),CHEMBL629498,U,0,,,,,1,,BAO_0000019,
12401,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),CHEMBL629499,U,0,,,,,1,,BAO_0000019,
12402,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),CHEMBL629500,U,0,,,,,1,,BAO_0000019,
12403,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),CHEMBL629501,U,0,,,,,1,,BAO_0000019,
12404,,Autocuration,,22224,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),CHEMBL629502,U,0,,,,,1,,BAO_0000019,
12405,,Autocuration,,22224,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,CHEMBL629503,U,0,,,,,1,,BAO_0000218,
12406,,Intermediate,,50588,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,CHEMBL629504,N,1,,,,,1,,BAO_0000218,
12407,,Autocuration,,22224,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,CHEMBL629505,U,0,,,,,1,,BAO_0000019,
12408,,Autocuration,,22224,Compound was evaluated for total body clearance,CHEMBL629506,U,0,,,,,1,,BAO_0000019,
12409,,Autocuration,,22224,Compound was evaluated for volume of distribution at steady state,CHEMBL629507,U,0,,,,,1,,BAO_0000019,
12410,,Autocuration,,22224,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,CHEMBL877498,U,0,,,,,1,,BAO_0000019,
12411,,Autocuration,,22224,Percentage of the diamine which is monoprotonated at pH 7.4,CHEMBL629508,U,0,,,,,1,,BAO_0000019,
12412,,Autocuration,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,CHEMBL629509,U,0,,,,,1,,BAO_0000019,
12413,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,CHEMBL629510,N,1,,,,,1,,BAO_0000218,
12414,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,CHEMBL629511,N,1,,,,,1,,BAO_0000218,
12415,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,CHEMBL629512,N,1,,,,,1,,BAO_0000218,
12416,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,CHEMBL629513,N,1,,,,,1,,BAO_0000218,
12417,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,CHEMBL629514,N,1,,,,,1,,BAO_0000218,
12418,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,CHEMBL628447,N,1,,,,,1,,BAO_0000218,
12419,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,CHEMBL628448,N,1,,,,,1,,BAO_0000218,
12420,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,CHEMBL628449,N,1,,,,,1,,BAO_0000218,
12421,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,CHEMBL631119,N,1,,,,,1,,BAO_0000218,
12422,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,CHEMBL631120,N,1,,,,,1,,BAO_0000218,
12423,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,CHEMBL631121,N,1,,,,,1,,BAO_0000218,
12424,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,CHEMBL874458,N,1,,,,,1,,BAO_0000218,
12425,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,CHEMBL631122,N,1,,,,,1,,BAO_0000218,
12426,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,CHEMBL631123,N,1,,,,,1,,BAO_0000218,
12427,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,CHEMBL631124,N,1,,,,,1,,BAO_0000218,
12428,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,CHEMBL631125,N,1,,,,,1,,BAO_0000218,
12429,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,CHEMBL631290,N,1,,,,,1,,BAO_0000218,
12430,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,CHEMBL631291,N,1,,,,,1,,BAO_0000218,
12431,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,CHEMBL631292,N,1,,,,,1,,BAO_0000218,
12432,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,CHEMBL631293,N,1,,,,,1,,BAO_0000218,
12433,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,CHEMBL631294,N,1,,,,,1,,BAO_0000218,
12434,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,CHEMBL631295,N,1,,,,,1,,BAO_0000218,
12435,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,CHEMBL631296,N,1,,,,,1,,BAO_0000218,
12436,178.0,Intermediate,Blood,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,CHEMBL631297,N,1,,,,,1,,BAO_0000218,
12437,,Autocuration,,22224,Maximum biodistribution (Bmax) was determined.,CHEMBL631298,U,0,,,,,1,,BAO_0000218,
12438,,Intermediate,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,CHEMBL631299,N,1,,,,,1,,BAO_0000218,
12439,,Intermediate,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,CHEMBL631300,N,1,,,,,1,,BAO_0000218,
12440,,Intermediate,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,CHEMBL631301,N,1,,,,,1,,BAO_0000218,
12441,,Intermediate,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,CHEMBL630291,N,1,,,,,1,,BAO_0000218,
12442,,Autocuration,,22224,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,CHEMBL630292,U,0,,,,,1,,BAO_0000218,
12443,,Autocuration,,22224,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,CHEMBL630293,U,0,,,,,1,,BAO_0000218,
12444,,Autocuration,,22224,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,CHEMBL630294,U,0,,,,,1,,BAO_0000218,
12445,,Autocuration,,22224,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,CHEMBL630295,U,0,,,,,1,,BAO_0000218,
12446,,Autocuration,,22224,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,CHEMBL630296,U,0,,,,,1,,BAO_0000218,
12447,,Autocuration,,22224,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,CHEMBL626782,U,0,,,,,1,,BAO_0000218,
12448,,Autocuration,,22224,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,CHEMBL626783,U,0,,,,,1,,BAO_0000218,
12449,,Autocuration,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,CHEMBL626784,U,0,,,,,1,,BAO_0000218,
12450,,Autocuration,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,CHEMBL626785,U,0,,,,,1,,BAO_0000218,
12451,,Autocuration,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,CHEMBL626786,U,0,,,,,1,,BAO_0000218,
12452,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,CHEMBL626787,U,0,,,,,1,,BAO_0000218,
12453,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,CHEMBL626788,U,0,,,,,1,,BAO_0000218,
12454,,Autocuration,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,CHEMBL625927,U,0,,,,,1,,BAO_0000218,
12455,178.0,Intermediate,Blood,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL625928,N,1,,,,,1,,BAO_0000218,
12456,178.0,Intermediate,Blood,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,CHEMBL625929,N,1,,,,,1,,BAO_0000218,
12457,178.0,Intermediate,Blood,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,CHEMBL625930,N,1,,,,,1,,BAO_0000218,
12458,178.0,Intermediate,Blood,50597,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",CHEMBL625931,N,1,,,,,1,,BAO_0000218,
12459,178.0,Intermediate,Blood,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,CHEMBL627230,N,1,,,,,1,,BAO_0000218,
12460,178.0,Intermediate,Blood,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627231,N,1,,,,,1,,BAO_0000218,
12461,178.0,Intermediate,Blood,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,CHEMBL627232,N,1,,,,,1,,BAO_0000218,
12462,178.0,Intermediate,Blood,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,CHEMBL627233,N,1,,,,,1,,BAO_0000218,
12463,178.0,Intermediate,Blood,50597,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL875470,N,1,,,,,1,,BAO_0000218,
12464,178.0,Intermediate,Blood,50597,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627234,N,1,,,,,1,,BAO_0000218,
12465,178.0,Intermediate,Blood,50597,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627235,N,1,,,,,1,,BAO_0000218,
12466,178.0,Intermediate,Blood,50597,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627236,N,1,,,,,1,,BAO_0000218,
12467,178.0,Intermediate,Blood,50597,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627237,N,1,,,,,1,,BAO_0000218,
12468,178.0,Intermediate,Blood,50597,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627238,N,1,,,,,1,,BAO_0000218,
12469,178.0,Intermediate,Blood,50597,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627239,N,1,,,,,1,,BAO_0000218,
12470,178.0,Intermediate,Blood,50597,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627240,N,1,,,,,1,,BAO_0000218,
12471,178.0,Intermediate,Blood,50597,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627241,N,1,,,,,1,,BAO_0000218,
12472,178.0,Intermediate,Blood,50597,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627242,N,1,,,,,1,,BAO_0000218,
12473,178.0,Intermediate,Blood,50597,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,CHEMBL627243,N,1,,,,,1,,BAO_0000218,
12474,178.0,Intermediate,Blood,50597,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,CHEMBL627244,N,1,,,,,1,,BAO_0000218,
12475,178.0,Intermediate,Blood,50597,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627245,N,1,,,,,1,,BAO_0000218,
12476,178.0,Intermediate,Blood,50597,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627246,N,1,,,,,1,,BAO_0000218,
12477,178.0,Intermediate,Blood,50597,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627247,N,1,,,,,1,,BAO_0000218,
12478,178.0,Intermediate,Blood,50597,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627248,N,1,,,,,1,,BAO_0000218,
12479,178.0,Intermediate,Blood,50597,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627249,N,1,,,,,1,,BAO_0000218,
12480,178.0,Intermediate,Blood,50597,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL625569,N,1,,,,,1,,BAO_0000218,
12481,178.0,Intermediate,Blood,50597,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL625570,N,1,,,,,1,,BAO_0000218,
12482,178.0,Intermediate,Blood,50597,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL625571,N,1,,,,,1,,BAO_0000218,
12483,178.0,Intermediate,Blood,50597,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,CHEMBL625572,N,1,,,,,1,,BAO_0000218,
12484,178.0,Intermediate,Blood,50597,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,CHEMBL625573,N,1,,,,,1,,BAO_0000218,
12485,178.0,Intermediate,Blood,50597,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,CHEMBL625574,N,1,,,,,1,,BAO_0000218,
12486,178.0,Intermediate,Blood,50597,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,CHEMBL626245,N,1,,,,,1,,BAO_0000218,
12487,178.0,Intermediate,Blood,50597,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL626246,N,1,,,,,1,,BAO_0000218,
12488,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,CHEMBL626247,U,0,,,,,1,,BAO_0000218,
12489,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,CHEMBL626248,U,0,,,,,1,,BAO_0000218,
12490,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,CHEMBL626249,U,0,,,,,1,,BAO_0000218,
12491,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,CHEMBL626420,U,0,,,,,1,,BAO_0000218,
12492,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,CHEMBL626421,U,0,,,,,1,,BAO_0000218,
12493,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,CHEMBL626422,U,0,,,,,1,,BAO_0000218,
12494,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,CHEMBL626423,U,0,,,,,1,,BAO_0000218,
12495,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,CHEMBL626424,U,0,,,,,1,,BAO_0000218,
12496,,Intermediate,,50588,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,CHEMBL626425,N,1,,,,,1,,BAO_0000218,
12497,,Intermediate,,50597,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,CHEMBL875476,N,1,,,,,1,,BAO_0000218,
12498,,Intermediate,,100710,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,CHEMBL626426,N,1,,,,,1,,BAO_0000218,
12499,,Autocuration,,22224,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,CHEMBL626427,U,0,,,,,1,,BAO_0000100,
12500,,Autocuration,,22224,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,CHEMBL626428,U,0,,,,,1,,BAO_0000100,
12501,,Autocuration,,22224,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,CHEMBL626429,U,0,,,,,1,,BAO_0000019,
12502,1088.0,Autocuration,Urine,22224,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,CHEMBL625025,U,0,,,,,1,,BAO_0000019,
12503,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,CHEMBL625026,N,1,,,,,1,,BAO_0000218,
12504,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,CHEMBL625027,N,1,,,,,1,,BAO_0000218,
12505,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,CHEMBL874410,N,1,,,,,1,,BAO_0000218,
12506,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,CHEMBL625028,N,1,,,,,1,,BAO_0000218,
12507,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,CHEMBL625029,N,1,,,,,1,,BAO_0000218,
12508,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,CHEMBL625030,N,1,,,,,1,,BAO_0000218,
12509,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL625031,N,1,,,,,1,,BAO_0000218,
12510,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,CHEMBL625032,N,1,,,,,1,,BAO_0000218,
12511,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,CHEMBL625033,N,1,,,,,1,,BAO_0000218,
12512,178.0,Intermediate,Blood,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,CHEMBL625034,N,1,,,,,1,,BAO_0000218,
12513,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,CHEMBL624872,N,1,,,,,1,,BAO_0000218,
12514,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,CHEMBL624873,N,1,,,,,1,,BAO_0000218,
12515,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,CHEMBL624874,N,1,,,,,1,,BAO_0000218,
12516,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,CHEMBL624875,N,1,,,,,1,,BAO_0000218,
12517,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,CHEMBL624876,N,1,,,,,1,,BAO_0000218,
12518,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,CHEMBL624877,N,1,,,,,1,,BAO_0000218,
12519,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,CHEMBL624878,N,1,,,,,1,,BAO_0000218,
12520,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,CHEMBL624879,N,1,,,,,1,,BAO_0000218,
12521,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL624880,N,1,,,,,1,,BAO_0000218,
12522,948.0,Intermediate,Heart,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,CHEMBL624881,N,1,,,,,1,,BAO_0000218,
12523,948.0,Intermediate,Heart,50597,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",CHEMBL624882,N,1,,,,,1,,BAO_0000218,
12524,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,CHEMBL624883,N,1,,,,,1,,BAO_0000218,
12525,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,CHEMBL624884,N,1,,,,,1,,BAO_0000218,
12526,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,CHEMBL624885,N,1,,,,,1,,BAO_0000218,
12527,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,CHEMBL624886,N,1,,,,,1,,BAO_0000218,
12528,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,CHEMBL624887,N,1,,,,,1,,BAO_0000218,
12529,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,CHEMBL624888,N,1,,,,,1,,BAO_0000218,
12530,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,CHEMBL624889,N,1,,,,,1,,BAO_0000218,
12531,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,CHEMBL624890,N,1,,,,,1,,BAO_0000218,
12532,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL621964,N,1,,,,,1,,BAO_0000218,
12533,2113.0,Intermediate,Kidney,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,CHEMBL621965,N,1,,,,,1,,BAO_0000218,
12534,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,CHEMBL621966,N,1,,,,,1,,BAO_0000218,
12535,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,CHEMBL621967,N,1,,,,,1,,BAO_0000218,
12536,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,CHEMBL622164,N,1,,,,,1,,BAO_0000218,
12537,,Autocuration,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),CHEMBL623097,U,0,,,,,1,,BAO_0000019,
12538,,Autocuration,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),CHEMBL623098,U,0,,,,,1,,BAO_0000019,
12539,,Autocuration,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,CHEMBL623099,U,0,,,,,1,,BAO_0000019,
12540,,Autocuration,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,CHEMBL623100,U,0,,,,,1,,BAO_0000019,
12541,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",CHEMBL628673,N,1,,,,,1,,BAO_0000218,
12542,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",CHEMBL628674,N,1,,,,,1,,BAO_0000218,
12543,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",CHEMBL628675,N,1,,,,,1,,BAO_0000218,
12544,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",CHEMBL627644,N,1,,,,,1,,BAO_0000218,
12545,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",CHEMBL627645,N,1,,,,,1,,BAO_0000218,
12546,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",CHEMBL627646,N,1,,,,,1,,BAO_0000218,
12547,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",CHEMBL627647,N,1,,,,,1,,BAO_0000218,
12548,,Intermediate,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",CHEMBL627648,N,1,,,,,1,,BAO_0000218,
12549,,Intermediate,,50597,Free level in rat plasma,CHEMBL627649,N,1,,,,,1,,BAO_0000218,
12550,,Autocuration,,22224,Level reaching in blood plasma of rat or human was determined,CHEMBL628313,U,0,,,,,1,,BAO_0000019,
12551,,Intermediate,,50597,Log (Cbrain/Cblood) in rats,CHEMBL628314,N,1,,,,,1,,BAO_0000218,
12552,,Autocuration,,22224,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,CHEMBL628315,U,0,,,,,1,,BAO_0000019,
12553,,Autocuration,,22224,Mean percentage of compound transport through membrane; expressed as membrane transport,CHEMBL628316,U,0,,,,,1,,BAO_0000019,
12554,,Autocuration,,22224,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,CHEMBL628317,U,0,,,,,1,,BAO_0000218,
12555,,Autocuration,,22224,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,CHEMBL628473,U,0,,,,,1,,BAO_0000019,
12556,,Autocuration,,22224,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",CHEMBL628474,U,0,,,,,1,,BAO_0000019,
12557,,Autocuration,,22224,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,CHEMBL628475,U,0,,,,,1,,BAO_0000019,
12558,,Autocuration,,22224,Net water uptake by a carrier mediated transport (%cm) mechanism,CHEMBL628476,U,0,,,,,1,,BAO_0000019,
12559,,Autocuration,,22224,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,CHEMBL628477,U,0,,,,,1,,BAO_0000218,
12560,,Intermediate,,50506,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,CHEMBL628478,N,1,,,,,1,,BAO_0000218,
12561,,Intermediate,,50506,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",CHEMBL628479,N,1,,,,,1,,BAO_0000218,
12562,,Autocuration,,22224,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,CHEMBL628480,U,0,,,,,1,,BAO_0000218,
12563,,Autocuration,,22224,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",CHEMBL628481,U,0,,,,,1,,BAO_0000218,
12564,,Intermediate,,50597,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,CHEMBL628482,N,1,,,,,1,,BAO_0000218,
12565,,Intermediate,,50597,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",CHEMBL628483,N,1,,,,,1,,BAO_0000218,
12566,1969.0,Intermediate,Plasma,50597,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",CHEMBL628484,N,1,,,,,1,,BAO_0000218,
12567,1969.0,Intermediate,Plasma,50597,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",CHEMBL628485,N,1,,,,,1,,BAO_0000218,
12568,1969.0,Intermediate,Plasma,100710,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",CHEMBL628486,N,1,,,,,1,,BAO_0000218,
12569,1969.0,Intermediate,Plasma,50587,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",CHEMBL628487,N,1,,,,,1,,BAO_0000218,
12570,1969.0,Intermediate,Plasma,50597,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",CHEMBL628488,N,1,,,,,1,,BAO_0000218,
12571,1969.0,Intermediate,Plasma,50597,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",CHEMBL628489,N,1,,,,,1,,BAO_0000218,
12572,1969.0,Intermediate,Plasma,50597,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",CHEMBL628490,N,1,,,,,1,,BAO_0000218,
12573,,Intermediate,,100710,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,CHEMBL628491,N,1,,,,,1,,BAO_0000218,
12574,,Intermediate,,100710,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,CHEMBL877507,N,1,,,,,1,,BAO_0000218,
12575,,Autocuration,,22224,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,CHEMBL628492,U,0,,,,,1,,BAO_0000218,
12576,,Autocuration,,22224,% metabolized in monkey S-9 after 2 hours (10 ug/mL),CHEMBL628493,U,0,,,,,1,,BAO_0000019,
12577,,Autocuration,,22224,% metabolized in monkey S-9 after 2 hours (1 ug/ml),CHEMBL628494,U,0,,,,,1,,BAO_0000019,
12578,,Autocuration,,22224,% metabolized in monkey S-9 after 2 hours (10 ug/ml),CHEMBL628495,U,0,,,,,1,,BAO_0000019,
12579,,Intermediate,,50587,Permeability in Caco-2 assay at 10E-6,CHEMBL628496,N,1,,,,,1,,BAO_0000218,
12580,955.0,Autocuration,Brain,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,CHEMBL628497,U,0,,,,,1,,BAO_0000218,
12581,955.0,Autocuration,Brain,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,CHEMBL628498,U,0,,,,,1,,BAO_0000218,
12582,,Autocuration,,22224,Plasma protein binding was determined,CHEMBL628499,U,0,,,,,1,,BAO_0000019,
12583,,Autocuration,,22224,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,CHEMBL627656,U,0,,,,,1,,BAO_0000218,
12584,,Autocuration,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,CHEMBL627657,U,0,,,,,1,,BAO_0000218,
12585,,Autocuration,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,CHEMBL626808,U,0,,,,,1,,BAO_0000218,
12586,,Autocuration,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,CHEMBL626809,U,0,,,,,1,,BAO_0000218,
12587,,Autocuration,,22224,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,CHEMBL626810,U,0,,,,,1,,BAO_0000218,
12588,,Autocuration,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,CHEMBL626811,U,0,,,,,1,,BAO_0000218,
12589,,Autocuration,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,CHEMBL874465,U,0,,,,,1,,BAO_0000218,
12590,,Autocuration,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,CHEMBL626812,U,0,,,,,1,,BAO_0000218,
12591,,Autocuration,,22224,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,CHEMBL626813,U,0,,,,,1,,BAO_0000218,
12592,,Autocuration,,22224,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,CHEMBL626814,U,0,,,,,1,,BAO_0000218,
12593,,Autocuration,,22224,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,CHEMBL626815,U,0,,,,,1,,BAO_0000019,
12594,,Autocuration,,22224,Partition coefficient (logP),CHEMBL628566,U,0,,,,,1,,BAO_0000019,
12595,,Autocuration,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),CHEMBL628567,U,0,,,,,1,,BAO_0000100,
12596,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL628568,U,0,,,,,1,,BAO_0000100,
12597,,Intermediate,,50588,C max in dog,CHEMBL628569,N,1,,,,,1,,BAO_0000218,
12598,,Intermediate,,50512,C max in guinea pig,CHEMBL628570,N,1,,,,,1,,BAO_0000218,
12599,,Autocuration,,22224,C max value was evaluated,CHEMBL628571,U,0,,,,,1,,BAO_0000218,
12600,,Autocuration,,22224,Cmax value after oral dose of 0.1 mg//kg,CHEMBL628572,U,0,,,,,1,,BAO_0000218,
12601,,Autocuration,,22224,Cmax value after oral dose of 0.3 mg/kg,CHEMBL628573,U,0,,,,,1,,BAO_0000218,
12602,,Autocuration,,22224,Cmax value after oral dose of 1 mg/kg,CHEMBL628574,U,0,,,,,1,,BAO_0000218,
12603,,Autocuration,,22224,Cmax value after oral dose of 10 mg/kg,CHEMBL628575,U,0,,,,,1,,BAO_0000218,
12604,,Autocuration,,22224,Cmax value after oral dose of 23.4 mg/kg,CHEMBL628576,U,0,,,,,1,,BAO_0000218,
12605,,Autocuration,,22224,Cmax value after oral dose of 3 mg/kg,CHEMBL628577,U,0,,,,,1,,BAO_0000218,
12606,,Autocuration,,22224,Cmax value after oral dose of 3.87 mg/kg,CHEMBL628578,U,0,,,,,1,,BAO_0000218,
12607,,Intermediate,,50588,Cmax value in female Beagle dogs,CHEMBL874466,N,1,,,,,1,,BAO_0000218,
12608,,Intermediate,,50597,Cmax value in male rats,CHEMBL628579,N,1,,,,,1,,BAO_0000218,
12609,1969.0,Intermediate,Plasma,50597,Cmax value in rat plasma when administered 20 mg/kg perorally,CHEMBL628580,N,1,,,,,1,,BAO_0000218,
12610,1969.0,Intermediate,Plasma,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,CHEMBL628581,N,1,,,,,1,,BAO_0000218,
12611,1969.0,Intermediate,Plasma,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,CHEMBL628582,N,1,,,,,1,,BAO_0000218,
12612,,Intermediate,,50588,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,CHEMBL628583,N,1,,,,,1,,BAO_0000218,
12613,,Autocuration,,22224,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,CHEMBL625782,U,0,,,,,1,,BAO_0000218,
12614,,Intermediate,,50592,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,CHEMBL625783,N,1,,,,,1,,BAO_0000218,
12615,,Intermediate,,50597,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,CHEMBL625784,N,1,,,,,1,,BAO_0000218,
12616,1969.0,Intermediate,Plasma,50797,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,CHEMBL625785,N,1,,,,,1,,BAO_0000218,
12617,,Intermediate,,50597,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,CHEMBL625786,N,1,,,,,1,,BAO_0000218,
12618,,Autocuration,,22224,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,CHEMBL874467,U,0,,,,,1,,BAO_0000019,
12619,,Intermediate,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",CHEMBL625787,N,1,,,,,1,,BAO_0000218,
12620,,Intermediate,,50677,cytotoxicity against HIV protease enzyme.,CHEMBL625964,N,1,,,,,1,,BAO_0000218,
12621,,Intermediate,,50594,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,CHEMBL625965,N,1,,,,,1,,BAO_0000218,
12622,,Intermediate,,50594,Apparent clearance in mice after oral administration of 100 mg/kg of dose,CHEMBL625966,N,1,,,,,1,,BAO_0000218,
12623,1969.0,Intermediate,Plasma,50588,The plasma clearance in dog.,CHEMBL625967,N,1,,,,,1,,BAO_0000218,
12624,1969.0,Intermediate,Plasma,50597,The plasma clearance in rat.,CHEMBL625968,N,1,,,,,1,,BAO_0000218,
12625,1969.0,Intermediate,Plasma,50597,Clearance from plasma in male Sprague-Dawley rats,CHEMBL625969,N,1,,,,,1,,BAO_0000218,
12626,1969.0,Intermediate,Plasma,100710,Clearance from plasma in male cynomolgus monkeys,CHEMBL625970,N,1,,,,,1,,BAO_0000218,
12627,1969.0,Intermediate,Plasma,50588,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",CHEMBL625971,N,1,,,,,1,,BAO_0000218,
12628,1969.0,Intermediate,Plasma,50588,Clearance of compound in dog plasma,CHEMBL625972,N,1,,,,,1,,BAO_0000218,
12629,1969.0,Intermediate,Plasma,50587,Clearance of compound in human plasma,CHEMBL625973,N,1,,,,,1,,BAO_0000218,
12630,,Intermediate,,50588,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,CHEMBL625974,N,1,,,,,1,,BAO_0000218,
12631,,Intermediate,,50588,Clearance of compound when administered intravenously as an individual dose to a single dog.,CHEMBL625975,N,1,,,,,1,,BAO_0000218,
12632,1969.0,Intermediate,Plasma,50588,"Clearance (10 mg/kg, intravenously) in dog plasma",CHEMBL625976,N,1,,,,,1,,BAO_0000218,
12633,,Intermediate,,50588,Clearance value in dog,CHEMBL625977,N,1,,,,,1,,BAO_0000218,
12634,,Intermediate,,50512,Clearance value in guinea pig,CHEMBL625978,N,1,,,,,1,,BAO_0000218,
12635,,Intermediate,,50597,Clearance values in rats after iv administration.,CHEMBL874468,N,1,,,,,1,,BAO_0000218,
12636,1969.0,Autocuration,Plasma,22224,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,CHEMBL625421,U,0,,,,,1,,BAO_0000218,
12637,,Intermediate,,50592,In vivo clearance (5 mg/kg) was determined in rabbits,CHEMBL625422,N,1,,,,,1,,BAO_0000218,
12638,,Intermediate,,50597,Plasma Clearance rate was determined for the compound in rats,CHEMBL625423,N,1,,,,,1,,BAO_0000218,
12639,,Autocuration,,22224,Plasma Clearance rate was determined for the compound in squirrel monkeys,CHEMBL625424,U,0,,,,,1,,BAO_0000218,
12640,,Intermediate,,50597,Plasma clearance in rat,CHEMBL625425,N,1,,,,,1,,BAO_0000218,
12641,,Autocuration,,22224,Plasma clearance of the compound,CHEMBL625426,U,0,,,,,1,,BAO_0000218,
12642,,Intermediate,,50512,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,CHEMBL625427,N,1,,,,,1,,BAO_0000218,
12643,,Intermediate,,50512,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,CHEMBL625428,N,1,,,,,1,,BAO_0000218,
12644,,Autocuration,,22224,Plasma clearance was determined,CHEMBL625429,U,0,,,,,1,,BAO_0000218,
12645,,Intermediate,,50588,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,CHEMBL625430,N,1,,,,,1,,BAO_0000218,
12646,,Intermediate,,50597,Plasma clearance rate was determined for the compound in rats,CHEMBL625431,N,1,,,,,1,,BAO_0000218,
12647,,Autocuration,,22224,Plasma clearance rate was determined for the compound in squirrel monkeys,CHEMBL627307,U,0,,,,,1,,BAO_0000218,
12648,,Autocuration,,22224,Slow clearance (CL) was determined,CHEMBL627308,U,0,,,,,1,,BAO_0000218,
12649,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,CHEMBL627309,U,0,,,,,1,,BAO_0000218,
12650,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,CHEMBL627310,U,0,,,,,1,,BAO_0000218,
12651,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,CHEMBL627311,U,0,,,,,1,,BAO_0000218,
12652,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,CHEMBL627312,U,0,,,,,1,,BAO_0000218,
12653,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,CHEMBL627313,U,0,,,,,1,,BAO_0000218,
12654,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,CHEMBL627314,U,0,,,,,1,,BAO_0000218,
12655,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,CHEMBL627315,U,0,,,,,1,,BAO_0000218,
12656,,Autocuration,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,CHEMBL627316,U,0,,,,,1,,BAO_0000218,
12657,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,CHEMBL627317,U,0,,,,,1,,BAO_0000218,
12658,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,CHEMBL627318,U,0,,,,,1,,BAO_0000218,
12659,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,CHEMBL627999,U,0,,,,,1,,BAO_0000218,
12660,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,CHEMBL628000,U,0,,,,,1,,BAO_0000218,
12661,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,CHEMBL628001,U,0,,,,,1,,BAO_0000218,
12662,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,CHEMBL628002,U,0,,,,,1,,BAO_0000218,
12663,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,CHEMBL625610,U,0,,,,,1,,BAO_0000218,
12664,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,CHEMBL625611,U,0,,,,,1,,BAO_0000218,
12665,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,CHEMBL625612,U,0,,,,,1,,BAO_0000218,
12666,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,CHEMBL625613,U,0,,,,,1,,BAO_0000218,
12667,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,CHEMBL875479,U,0,,,,,1,,BAO_0000218,
12668,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,CHEMBL625614,U,0,,,,,1,,BAO_0000218,
12669,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,CHEMBL625615,U,0,,,,,1,,BAO_0000218,
12670,,Autocuration,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,CHEMBL626302,U,0,,,,,1,,BAO_0000218,
12671,178.0,Intermediate,Blood,50597,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,CHEMBL626303,N,1,,,,,1,,BAO_0000218,
12672,178.0,Intermediate,Blood,50597,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,CHEMBL627420,N,1,,,,,1,,BAO_0000218,
12673,,Intermediate,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,CHEMBL627421,N,1,,,,,1,,BAO_0000218,
12674,,Intermediate,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,CHEMBL625695,N,1,,,,,1,,BAO_0000218,
12675,,Intermediate,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,CHEMBL625696,N,1,,,,,1,,BAO_0000218,
12676,955.0,Intermediate,Brain,50594,Distribution of compound in mice brain was measured after 1 hr,CHEMBL875606,N,1,,,,,1,,BAO_0000218,
12677,955.0,Intermediate,Brain,50594,Distribution of compound in mice brain was measured after 24 hr r,CHEMBL625697,N,1,,,,,1,,BAO_0000218,
12678,955.0,Intermediate,Brain,50594,Distribution of compound in mice brain was measured after 2 hr,CHEMBL625698,N,1,,,,,1,,BAO_0000218,
12679,955.0,Intermediate,Brain,50594,Distribution of compound in mice brain was measured after 3 hr,CHEMBL625699,N,1,,,,,1,,BAO_0000218,
12680,955.0,Intermediate,Brain,50594,Distribution of compound in mice brain was measured after 6 hr,CHEMBL625700,N,1,,,,,1,,BAO_0000218,
12681,,Intermediate,,50594,Distribution of compound in mice liver was measured after 1 hr,CHEMBL625701,N,1,,,,,1,,BAO_0000218,
12682,,Intermediate,,50594,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,CHEMBL625702,N,1,,,,,1,,BAO_0000218,
12683,,Intermediate,,50594,Distribution of compound in mice liver was measured after 2 hr,CHEMBL625703,N,1,,,,,1,,BAO_0000218,
12684,,Intermediate,,50594,Distribution of compound in mice liver was measured after 3 hr,CHEMBL625704,N,1,,,,,1,,BAO_0000218,
12685,,Intermediate,,50594,Distribution of compound in mice liver was measured after 6 hr,CHEMBL625705,N,1,,,,,1,,BAO_0000218,
12686,1236.0,Intermediate,Adrenal medulla,50588,Distribution in dog adrenal medulla 30 min after administration.,CHEMBL625706,N,1,,,,,1,,BAO_0000218,
12687,1236.0,Intermediate,Adrenal medulla,50588,Distribution in dog adrenal medulla 72 hours after administration.,CHEMBL625707,N,1,,,,,1,,BAO_0000218,
12688,,Intermediate,,50588,Distribution in female dog Ovary 24 hours after administration.,CHEMBL625708,N,1,,,,,1,,BAO_0000218,
12689,,Intermediate,,50588,Distribution in female dog Ovary 72 hours after administration.,CHEMBL625709,N,1,,,,,1,,BAO_0000218,
12690,,Intermediate,,50588,Distribution in female dog adipose 24 hours after administration.,CHEMBL624180,N,1,,,,,1,,BAO_0000218,
12691,,Intermediate,,50588,Distribution in female dog adipose 72 hours after administration.,CHEMBL624181,N,1,,,,,1,,BAO_0000218,
12692,1235.0,Intermediate,Adrenal cortex,50588,Distribution in female dog adrenal cortex 72 hours after administration.,CHEMBL624182,N,1,,,,,1,,BAO_0000218,
12693,1235.0,Intermediate,Adrenal cortex,50588,Distribution in female dog adrenal cortex 72 hours after administration.,CHEMBL624183,N,1,,,,,1,,BAO_0000218,
12694,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,CHEMBL624184,N,1,,,,,1,,BAO_0000218,
12695,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,CHEMBL877489,N,1,,,,,1,,BAO_0000218,
12696,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL624185,N,1,,,,,1,,BAO_0000218,
12697,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,CHEMBL624186,N,1,,,,,1,,BAO_0000218,
12698,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,CHEMBL624187,N,1,,,,,1,,BAO_0000218,
12699,2107.0,Intermediate,Liver,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,CHEMBL624188,N,1,,,,,1,,BAO_0000218,
12700,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,CHEMBL624189,N,1,,,,,1,,BAO_0000218,
12701,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,CHEMBL624190,N,1,,,,,1,,BAO_0000218,
12702,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,CHEMBL624191,N,1,,,,,1,,BAO_0000218,
12703,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,CHEMBL624192,N,1,,,,,1,,BAO_0000218,
12704,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,CHEMBL624193,N,1,,,,,1,,BAO_0000218,
12705,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,CHEMBL624194,N,1,,,,,1,,BAO_0000218,
12706,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,CHEMBL624891,N,1,,,,,1,,BAO_0000218,
12707,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,CHEMBL624892,N,1,,,,,1,,BAO_0000218,
12708,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,CHEMBL624893,N,1,,,,,1,,BAO_0000218,
12709,2048.0,Intermediate,Lung,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL627632,N,1,,,,,1,,BAO_0000218,
12710,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,CHEMBL627633,N,1,,,,,1,,BAO_0000218,
12711,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,CHEMBL627634,N,1,,,,,1,,BAO_0000218,
12712,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,CHEMBL627635,N,1,,,,,1,,BAO_0000218,
12713,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,CHEMBL627636,N,1,,,,,1,,BAO_0000218,
12714,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,CHEMBL626816,N,1,,,,,1,,BAO_0000218,
12715,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,CHEMBL626817,N,1,,,,,1,,BAO_0000218,
12716,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,CHEMBL626818,N,1,,,,,1,,BAO_0000218,
12717,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,CHEMBL626819,N,1,,,,,1,,BAO_0000218,
12718,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,CHEMBL626820,N,1,,,,,1,,BAO_0000218,
12719,,Intermediate,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL626821,N,1,,,,,1,,BAO_0000218,
12720,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,CHEMBL626822,N,1,,,,,1,,BAO_0000218,
12721,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,CHEMBL626823,N,1,,,,,1,,BAO_0000218,
12722,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,CHEMBL626824,N,1,,,,,1,,BAO_0000218,
12723,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,CHEMBL626825,N,1,,,,,1,,BAO_0000218,
12724,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,CHEMBL626826,N,1,,,,,1,,BAO_0000218,
12725,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,CHEMBL626827,N,1,,,,,1,,BAO_0000218,
12726,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,CHEMBL626828,N,1,,,,,1,,BAO_0000218,
12727,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,CHEMBL626829,N,1,,,,,1,,BAO_0000218,
12728,2046.0,Intermediate,Thyroid gland,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL626830,N,1,,,,,1,,BAO_0000218,
12729,,Intermediate,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,CHEMBL627150,N,1,,,,,1,,BAO_0000218,
12730,,Intermediate,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL627151,N,1,,,,,1,,BAO_0000218,
12731,,Intermediate,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,CHEMBL627152,N,1,,,,,1,,BAO_0000218,
12732,,Intermediate,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,CHEMBL627153,N,1,,,,,1,,BAO_0000218,
12733,,Autocuration,,22224,Rate of acetate production by the compound was determined,CHEMBL627154,U,0,,,,,1,,BAO_0000019,
12734,,Autocuration,,22224,Rate of acetate production by the compound was determined; Not determined,CHEMBL627155,U,0,,,,,1,,BAO_0000019,
12735,,Autocuration,,22224,Rate of hydrolysis of nitrocefin by compound was evaluated in water,CHEMBL627156,U,0,,,,,1,,BAO_0000019,
12736,,Autocuration,,22224,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,CHEMBL627157,U,0,,,,,1,,BAO_0000019,
12737,,Intermediate,,50592,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,CHEMBL627158,N,1,,,,,1,,BAO_0000218,
12738,1969.0,Intermediate,Plasma,50592,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,CHEMBL627159,N,1,,,,,1,,BAO_0000218,
12739,,Intermediate,,50594,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,CHEMBL627160,N,1,,,,,1,,BAO_0000218,
12740,,Intermediate,,50597,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,CHEMBL628540,N,1,,,,,1,,BAO_0000218,
12741,1969.0,Intermediate,Plasma,50597,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,CHEMBL628541,N,1,,,,,1,,BAO_0000218,
12742,1969.0,Intermediate,Plasma,50597,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,CHEMBL628542,N,1,,,,,1,,BAO_0000218,
12743,,Autocuration,,22229,Solubility after at a pH 1.2,CHEMBL628543,U,0,,,,,1,,BAO_0000100,
12744,,Autocuration,,22229,Solubility after at pH 1.2,CHEMBL628544,U,0,,,,,1,,BAO_0000100,
12745,,Autocuration,,22229,Solubility after injection of water,CHEMBL628545,U,0,,,,,1,,BAO_0000100,
12746,,Autocuration,,22224,Statistical significance of IC 50 values; Expressed as R value,CHEMBL628546,U,0,,,,,1,,BAO_0000019,
12747,,Autocuration,,22224,Systemic availability with respect to methyldopa was determined,CHEMBL874455,U,0,,,,,1,,BAO_0000019,
12748,,Intermediate,,50597,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,CHEMBL628547,N,1,,,,,1,,BAO_0000218,
12749,1969.0,Intermediate,Plasma,50597,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,CHEMBL628548,N,1,,,,,1,,BAO_0000218,
12750,1988.0,Intermediate,Feces,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",CHEMBL628549,N,1,,,,,1,,BAO_0000218,
12751,1988.0,Intermediate,Feces,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",CHEMBL628550,N,1,,,,,1,,BAO_0000218,
12752,1988.0,Intermediate,Feces,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",CHEMBL628551,N,1,,,,,1,,BAO_0000218,
12753,1088.0,Intermediate,Urine,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",CHEMBL628552,N,1,,,,,1,,BAO_0000218,
12754,1088.0,Intermediate,Urine,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",CHEMBL628553,N,1,,,,,1,,BAO_0000218,
12755,1088.0,Intermediate,Urine,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",CHEMBL628554,N,1,,,,,1,,BAO_0000218,
12756,1088.0,Intermediate,Urine,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",CHEMBL628555,N,1,,,,,1,,BAO_0000218,
12757,1088.0,Intermediate,Urine,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",CHEMBL628556,N,1,,,,,1,,BAO_0000218,
12758,2113.0,Intermediate,Kidney,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",CHEMBL628557,N,1,,,,,1,,BAO_0000218,
12759,1988.0,Intermediate,Feces,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",CHEMBL628558,N,1,,,,,1,,BAO_0000218,
12760,1988.0,Intermediate,Feces,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",CHEMBL628559,N,1,,,,,1,,BAO_0000218,
12761,1988.0,Intermediate,Feces,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",CHEMBL628560,N,1,,,,,1,,BAO_0000218,
12762,1088.0,Intermediate,Urine,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",CHEMBL874456,N,1,,,,,1,,BAO_0000218,
12763,1988.0,Intermediate,Feces,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",CHEMBL628561,N,1,,,,,1,,BAO_0000218,
12764,1988.0,Intermediate,Feces,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",CHEMBL628562,N,1,,,,,1,,BAO_0000218,
12765,1088.0,Intermediate,Urine,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",CHEMBL628563,N,1,,,,,1,,BAO_0000218,
12766,1088.0,Intermediate,Urine,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",CHEMBL628564,N,1,,,,,1,,BAO_0000218,
12767,1088.0,Intermediate,Urine,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",CHEMBL628565,N,1,,,,,1,,BAO_0000218,
12768,1088.0,Intermediate,Urine,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",CHEMBL631248,N,1,,,,,1,,BAO_0000218,
12769,1088.0,Intermediate,Urine,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",CHEMBL631249,N,1,,,,,1,,BAO_0000218,
12770,2113.0,Intermediate,Kidney,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",CHEMBL627214,N,1,,,,,1,,BAO_0000218,
12771,1988.0,Intermediate,Feces,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",CHEMBL874591,N,1,,,,,1,,BAO_0000218,
12772,1988.0,Intermediate,Feces,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",CHEMBL627215,N,1,,,,,1,,BAO_0000218,
12773,1988.0,Intermediate,Feces,50592,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,CHEMBL625471,N,1,,,,,1,,BAO_0000218,
12774,,Intermediate,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,CHEMBL625472,N,1,,,,,1,,BAO_0000218,
12775,,Intermediate,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,CHEMBL625473,N,1,,,,,1,,BAO_0000218,
12776,,Intermediate,,50588,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,CHEMBL625474,N,1,,,,,1,,BAO_0000218,
12777,,Intermediate,,50588,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,CHEMBL625475,N,1,,,,,1,,BAO_0000218,
12778,,Intermediate,,50597,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,CHEMBL625476,N,1,,,,,1,,BAO_0000218,
12779,,Intermediate,,50597,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,CHEMBL625477,N,1,,,,,1,,BAO_0000218,
12780,,Intermediate,,50597,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,CHEMBL625478,N,1,,,,,1,,BAO_0000218,
12781,,Intermediate,esophageal tunica muscularis mucosae,50597,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,CHEMBL625479,N,1,,,,,1,,BAO_0000218,
12782,,Intermediate,esophageal tunica muscularis mucosae,50597,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,CHEMBL625480,N,1,,,,,1,,BAO_0000218,
12783,1969.0,Intermediate,Plasma,50597,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,CHEMBL625481,N,1,,,,,1,,BAO_0000218,
12784,,Intermediate,,50597,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,CHEMBL625482,N,1,,,,,1,,BAO_0000218,
12785,,Intermediate,,50597,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,CHEMBL625483,N,1,,,,,1,,BAO_0000218,
12786,,Intermediate,,50597,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,CHEMBL625484,N,1,,,,,1,,BAO_0000218,
12787,,Intermediate,,50597,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,CHEMBL625485,N,1,,,,,1,,BAO_0000218,
12788,1969.0,Intermediate,Plasma,50588,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,CHEMBL625486,N,1,,,,,1,,BAO_0000218,
12789,1969.0,Intermediate,Plasma,50597,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,CHEMBL625487,N,1,,,,,1,,BAO_0000218,
12790,1969.0,Intermediate,Plasma,50597,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,CHEMBL625488,N,1,,,,,1,,BAO_0000218,
12791,1969.0,Intermediate,Plasma,50597,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,CHEMBL625489,N,1,,,,,1,,BAO_0000218,
12792,1969.0,Intermediate,Plasma,50597,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,CHEMBL625490,N,1,,,,,1,,BAO_0000218,
12793,1969.0,Intermediate,Plasma,50588,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,CHEMBL625491,N,1,,,,,1,,BAO_0000218,
12794,1969.0,Intermediate,Plasma,50597,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,CHEMBL625492,N,1,,,,,1,,BAO_0000218,
12795,1969.0,Intermediate,Plasma,50587,plasma clearance in human,CHEMBL625493,N,1,,,,,1,,BAO_0000218,
12796,,Intermediate,,50597,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,CHEMBL625494,N,1,,,,,1,,BAO_0000218,
12797,,Intermediate,,50597,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,CHEMBL625495,N,1,,,,,1,,BAO_0000218,
12798,,Intermediate,,50597,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,CHEMBL625496,N,1,,,,,1,,BAO_0000218,
12799,,Autocuration,,22229,1-Octanol/water partition coefficient measured at 7.4,CHEMBL625497,U,0,,,,,1,,BAO_0000100,
12800,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625498,U,0,,,,,1,,BAO_0000100,
12801,,Autocuration,,22224,Partition coefficient (logP),CHEMBL625499,U,0,,,,,1,,BAO_0000019,
12802,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625500,U,0,,,,,1,,BAO_0000100,
12803,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625501,U,0,,,,,1,,BAO_0000100,
12804,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625502,U,0,,,,,1,,BAO_0000100,
12805,,Autocuration,,22229,Calculated partition coefficient (clogP) (relative to BAY K 8644),CHEMBL625503,U,0,,,,,1,,BAO_0000100,
12806,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625504,U,0,,,,,1,,BAO_0000100,
12807,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625505,U,0,,,,,1,,BAO_0000100,
12808,,Autocuration,,22229,Calculated partition coefficient of the compound,CHEMBL625506,U,0,,,,,1,,BAO_0000100,
12809,,Autocuration,,22224,Partition coefficient (logP),CHEMBL625507,U,0,,,,,1,,BAO_0000019,
12810,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625508,U,0,,,,,1,,BAO_0000100,
12811,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625509,U,0,,,,,1,,BAO_0000100,
12812,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625510,U,0,,,,,1,,BAO_0000100,
12813,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL883125,U,0,,,,,1,,BAO_0000100,
12814,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625511,U,0,,,,,1,,BAO_0000100,
12815,,Autocuration,,22224,Partition coefficient of the compound,CHEMBL874650,U,0,,,,,1,,BAO_0000019,
12816,,Autocuration,,22224,Partition coefficient of the compound,CHEMBL625512,U,0,,,,,1,,BAO_0000019,
12817,,Autocuration,,22224,Partition coefficient of compound was determined,CHEMBL625513,U,0,,,,,1,,BAO_0000019,
12818,,Autocuration,,22224,Partition coefficient was determined,CHEMBL625514,U,0,,,,,1,,BAO_0000019,
12819,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625515,U,0,,,,,1,,BAO_0000100,
12820,,Autocuration,,22229,partition coefficient of compound was determined,CHEMBL625516,U,0,,,,,1,,BAO_0000100,
12821,,Intermediate,,50588,The total body administered intravenously in dog,CHEMBL625517,N,1,,,,,1,,BAO_0000218,
12822,,Intermediate,,50597,The total body administered intravenously in rats,CHEMBL625518,N,1,,,,,1,,BAO_0000218,
12823,,Intermediate,,50594,Time taken for the administration to female NIH mice weighing 25-30 g.,CHEMBL625519,N,1,,,,,1,,BAO_0000218,
12824,,Autocuration,,22224,Time taken for the administration,CHEMBL625520,U,0,,,,,1,,BAO_0000019,
12825,,Intermediate,,50588,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,CHEMBL874651,N,1,,,,,1,,BAO_0000218,
12826,,Autocuration,,22224,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,CHEMBL625521,U,0,,,,,1,,BAO_0000218,
12827,,Intermediate,,50592,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,CHEMBL623171,N,1,,,,,1,,BAO_0000218,
12828,,Intermediate,,50597,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,CHEMBL623853,N,1,,,,,1,,BAO_0000218,
12829,,Autocuration,,22224,Plasma clearance for the compound was determined.,CHEMBL623854,U,0,,,,,1,,BAO_0000019,
12830,,Autocuration,,22224,CLog P value of the compound,CHEMBL874405,U,0,,,,,1,,BAO_0000100,
12831,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL623855,U,0,,,,,1,,BAO_0000100,
12832,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL623856,U,0,,,,,1,,BAO_0000100,
12833,,Autocuration,,22224,ClogP value of the compound; nd ='no data',CHEMBL623857,U,0,,,,,1,,BAO_0000100,
12834,,Autocuration,,22224,ClogP value of the compound; nd ='not determined',CHEMBL623858,U,0,,,,,1,,BAO_0000100,
12835,,Autocuration,,22224,CLog P was determined,CHEMBL623859,U,0,,,,,1,,BAO_0000100,
12836,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL839829,U,0,,,,,1,,BAO_0000100,
12837,,Autocuration,,22224,CLogP was calculated,CHEMBL623860,U,0,,,,,1,,BAO_0000019,
12838,,Autocuration,,22224,CLogP value was determined,CHEMBL623861,U,0,,,,,1,,BAO_0000019,
12839,,Autocuration,,22224,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,CHEMBL623862,U,0,,,,,1,,BAO_0000019,
12840,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL874406,U,0,,,,,1,,BAO_0000100,
12841,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL623863,U,0,,,,,1,,BAO_0000100,
12842,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624021,U,0,,,,,1,,BAO_0000100,
12843,1236.0,Intermediate,Adrenal medulla,50588,Distribution in female dog adrenal medulla 24 hours after administration.,CHEMBL624022,N,1,,,,,1,,BAO_0000218,
12844,1236.0,Intermediate,Adrenal medulla,50588,Distribution in female dog adrenal medulla 72 hours after administration.,CHEMBL624023,N,1,,,,,1,,BAO_0000218,
12845,,Intermediate,,50588,Distribution in female dog bile 24 hours after administration.,CHEMBL624024,N,1,,,,,1,,BAO_0000218,
12846,,Intermediate,,50588,Distribution in female dog bile 72 hr after administration.,CHEMBL624025,N,1,,,,,1,,BAO_0000218,
12847,,Intermediate,,50588,Distribution in female dog blood 24 hours after administration.,CHEMBL624026,N,1,,,,,1,,BAO_0000218,
12848,,Intermediate,,50588,Distribution in female dog blood 72 hours after administration.,CHEMBL624027,N,1,,,,,1,,BAO_0000218,
12849,,Intermediate,,50588,Distribution in female dog heart 24 hours after administration.,CHEMBL624028,N,1,,,,,1,,BAO_0000218,
12850,,Intermediate,,50588,Distribution in female dog heart 72 hours after administration.,CHEMBL624029,N,1,,,,,1,,BAO_0000218,
12851,,Intermediate,,50588,Distribution in female dog kidney 24 hours after administration.,CHEMBL624030,N,1,,,,,1,,BAO_0000218,
12852,,Intermediate,,50588,Distribution in female dog kidney 72 hours after administration.,CHEMBL624031,N,1,,,,,1,,BAO_0000218,
12853,160.0,Intermediate,Intestine,50588,Distribution in female dog large intestine 24 hours after administration.,CHEMBL624032,N,1,,,,,1,,BAO_0000218,
12854,160.0,Intermediate,Intestine,50588,Distribution in female dog large intestine 72 hours after administration.,CHEMBL874407,N,1,,,,,1,,BAO_0000218,
12855,,Intermediate,,50588,Distribution in female dog liver 24 hours after administration.,CHEMBL624033,N,1,,,,,1,,BAO_0000218,
12856,,Intermediate,,50588,Distribution in female dog liver 72 hours after administration.,CHEMBL624034,N,1,,,,,1,,BAO_0000218,
12857,,Intermediate,,50588,Distribution in female dog lung 24 hours after administration.,CHEMBL624035,N,1,,,,,1,,BAO_0000218,
12858,,Intermediate,,50588,Distribution in female dog lung 72 hours after administration.,CHEMBL624036,N,1,,,,,1,,BAO_0000218,
12859,2385.0,Intermediate,Muscle tissue,50588,Distribution in female dog muscle 24 hours after administration.,CHEMBL624037,N,1,,,,,1,,BAO_0000218,
12860,2385.0,Intermediate,Muscle tissue,50588,Distribution in female dog muscle 72 hours after administration.,CHEMBL624038,N,1,,,,,1,,BAO_0000218,
12861,,Intermediate,,50588,Distribution in female dog pancreas 24 hours after administration.,CHEMBL624039,N,1,,,,,1,,BAO_0000218,
12862,,Intermediate,,50588,Distribution in female dog pancreas 72 hours after administration.,CHEMBL624040,N,1,,,,,1,,BAO_0000218,
12863,160.0,Intermediate,Intestine,50588,Distribution in female dog small intestine 24 hours after administration.,CHEMBL624041,N,1,,,,,1,,BAO_0000218,
12864,160.0,Intermediate,Intestine,50588,Distribution in female dog small intestine 72 hours after administration.,CHEMBL624042,N,1,,,,,1,,BAO_0000218,
12865,2106.0,Intermediate,Spleen,50588,Distribution in female dog spleen 24 hours after administration.,CHEMBL624043,N,1,,,,,1,,BAO_0000218,
12866,2106.0,Intermediate,Spleen,50588,Distribution in female dog spleen 72 hours after administration.,CHEMBL624044,N,1,,,,,1,,BAO_0000218,
12867,945.0,Intermediate,Stomach,50588,Distribution in female dog stomach 24 hours after administration.,CHEMBL624045,N,1,,,,,1,,BAO_0000218,
12868,945.0,Intermediate,Stomach,50588,Distribution in female dog stomach 72 hours after administration.,CHEMBL624046,N,1,,,,,1,,BAO_0000218,
12869,2046.0,Intermediate,Thyroid gland,50588,Distribution in female dog thyroid 24 hours after administration.,CHEMBL624047,N,1,,,,,1,,BAO_0000218,
12870,2046.0,Intermediate,Thyroid gland,50588,Distribution in female dog thyroid 72 hours after administration.,CHEMBL624048,N,1,,,,,1,,BAO_0000218,
12871,1088.0,Intermediate,Urine,50588,Distribution in female dog urine 24 hours after administration.,CHEMBL874408,N,1,,,,,1,,BAO_0000218,
12872,1088.0,Intermediate,Urine,50588,Distribution in female dog urine 72 hr after administration.,CHEMBL624049,N,1,,,,,1,,BAO_0000218,
12873,1969.0,Autocuration,Plasma,22224,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,CHEMBL624050,U,0,,,,,1,,BAO_0000218,
12874,,Autocuration,,22224,Plasma concentration at 7 hr after intravenous dosing,CHEMBL624051,U,0,,,,,1,,BAO_0000019,
12875,,Intermediate,,50597,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,CHEMBL623278,N,1,,,,,1,,BAO_0000218,
12876,,Intermediate,,50597,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,CHEMBL623279,N,1,,,,,1,,BAO_0000218,
12877,,Intermediate,,50597,Plasma concentration of 3 mg/kg iv after 1 hr in rats,CHEMBL623280,N,1,,,,,1,,BAO_0000218,
12878,,Intermediate,,50597,Plasma concentration of 3 mg/kg iv after 2 hr in rats,CHEMBL623963,N,1,,,,,1,,BAO_0000218,
12879,,Intermediate,,50597,Plasma concentration of 3 mg/kg iv after 4 hr in rats,CHEMBL623964,N,1,,,,,1,,BAO_0000218,
12880,,Intermediate,,50597,Plasma concentration of 3 mg/kg iv after 6 hr in rats,CHEMBL623965,N,1,,,,,1,,BAO_0000218,
12881,,Intermediate,,50597,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,CHEMBL623966,N,1,,,,,1,,BAO_0000218,
12882,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,CHEMBL874415,N,1,,,,,1,,BAO_0000218,
12883,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,CHEMBL623967,N,1,,,,,1,,BAO_0000218,
12884,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,CHEMBL623968,N,1,,,,,1,,BAO_0000218,
12885,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,CHEMBL623969,N,1,,,,,1,,BAO_0000218,
12886,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,CHEMBL628409,N,1,,,,,1,,BAO_0000218,
12887,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,CHEMBL628410,N,1,,,,,1,,BAO_0000218,
12888,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,CHEMBL628411,N,1,,,,,1,,BAO_0000218,
12889,,Intermediate,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,CHEMBL628412,N,1,,,,,1,,BAO_0000218,
12890,,Autocuration,,22224,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,CHEMBL628413,U,0,,,,,1,,BAO_0000019,
12891,1969.0,Autocuration,Plasma,22224,The concentration in plasmat; Not determined,CHEMBL628414,U,0,,,,,1,,BAO_0000019,
12892,,Intermediate,,50597,Tissue level at 10 mg/kg/po in wistar rats in blood,CHEMBL628415,N,1,,,,,1,,BAO_0000218,
12893,,Intermediate,,50597,Tissue level at 10 mg/kg/po in wistar rats in brown fat,CHEMBL628416,N,1,,,,,1,,BAO_0000218,
12894,,Intermediate,,50597,Tissue level at 10 mg/kg/po in wistar rats in heart,CHEMBL628417,N,1,,,,,1,,BAO_0000218,
12895,2107.0,Intermediate,Liver,50597,Tissue level at 10 mg/kg/po in wistar rats in liver,CHEMBL874908,N,1,,,,,1,,BAO_0000218,
12896,,Intermediate,,50597,Tissue level at 10 mg/kg/po in wistar rats in plasma,CHEMBL628418,N,1,,,,,1,,BAO_0000218,
12897,2385.0,Intermediate,Muscle tissue,50597,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,CHEMBL628419,N,1,,,,,1,,BAO_0000218,
12898,,Intermediate,,50597,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,CHEMBL628420,N,1,,,,,1,,BAO_0000218,
12899,,Autocuration,,22224,Water solubility at 37 degree C.,CHEMBL628421,U,0,,,,,1,,BAO_0000019,
12900,,Autocuration,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,CHEMBL626726,U,0,,,,,1,,BAO_0000100,
12901,,Autocuration,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,CHEMBL626727,U,0,,,,,1,,BAO_0000100,
12902,178.0,Intermediate,Blood,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,CHEMBL626728,N,1,,,,,1,,BAO_0000218,
12903,178.0,Intermediate,Blood,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,CHEMBL626729,N,1,,,,,1,,BAO_0000218,
12904,178.0,Intermediate,Blood,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,CHEMBL626730,N,1,,,,,1,,BAO_0000218,
12905,178.0,Intermediate,Blood,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,CHEMBL626731,N,1,,,,,1,,BAO_0000218,
12906,178.0,Intermediate,Blood,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,CHEMBL626732,N,1,,,,,1,,BAO_0000218,
12907,948.0,Intermediate,Heart,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,CHEMBL626733,N,1,,,,,1,,BAO_0000218,
12908,948.0,Intermediate,Heart,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,CHEMBL626734,N,1,,,,,1,,BAO_0000218,
12909,948.0,Intermediate,Heart,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,CHEMBL626735,N,1,,,,,1,,BAO_0000218,
12910,948.0,Intermediate,Heart,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,CHEMBL874909,N,1,,,,,1,,BAO_0000218,
12911,948.0,Intermediate,Heart,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,CHEMBL626736,N,1,,,,,1,,BAO_0000218,
12912,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,CHEMBL626737,N,1,,,,,1,,BAO_0000218,
12913,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,CHEMBL630999,N,1,,,,,1,,BAO_0000218,
12914,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,CHEMBL631000,N,1,,,,,1,,BAO_0000218,
12915,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,CHEMBL631001,N,1,,,,,1,,BAO_0000218,
12916,2113.0,Intermediate,Kidney,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,CHEMBL631002,N,1,,,,,1,,BAO_0000218,
12917,2107.0,Intermediate,Liver,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,CHEMBL631003,N,1,,,,,1,,BAO_0000218,
12918,2107.0,Intermediate,Liver,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,CHEMBL631004,N,1,,,,,1,,BAO_0000218,
12919,2107.0,Intermediate,Liver,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,CHEMBL631005,N,1,,,,,1,,BAO_0000218,
12920,2107.0,Intermediate,Liver,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,CHEMBL631006,N,1,,,,,1,,BAO_0000218,
12921,2107.0,Intermediate,Liver,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,CHEMBL631007,N,1,,,,,1,,BAO_0000218,
12922,2048.0,Intermediate,Lung,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,CHEMBL631008,N,1,,,,,1,,BAO_0000218,
12923,2048.0,Intermediate,Lung,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,CHEMBL631009,N,1,,,,,1,,BAO_0000218,
12924,2048.0,Intermediate,Lung,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,CHEMBL631010,N,1,,,,,1,,BAO_0000218,
12925,2048.0,Intermediate,Lung,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,CHEMBL631011,N,1,,,,,1,,BAO_0000218,
12926,2048.0,Intermediate,Lung,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,CHEMBL631012,N,1,,,,,1,,BAO_0000218,
12927,2046.0,Intermediate,Thyroid gland,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,CHEMBL630271,N,1,,,,,1,,BAO_0000218,
12928,2046.0,Intermediate,Thyroid gland,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,CHEMBL630272,N,1,,,,,1,,BAO_0000218,
12929,2046.0,Intermediate,Thyroid gland,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,CHEMBL630273,N,1,,,,,1,,BAO_0000218,
12930,2046.0,Intermediate,Thyroid gland,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,CHEMBL630274,N,1,,,,,1,,BAO_0000218,
12931,2046.0,Intermediate,Thyroid gland,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,CHEMBL630275,N,1,,,,,1,,BAO_0000218,
12932,,Intermediate,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,CHEMBL875782,N,1,,,,,1,,BAO_0000218,
12933,,Intermediate,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,CHEMBL630276,N,1,,,,,1,,BAO_0000218,
12934,,Intermediate,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,CHEMBL630277,N,1,,,,,1,,BAO_0000218,
12935,,Intermediate,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,CHEMBL630278,N,1,,,,,1,,BAO_0000218,
12936,,Intermediate,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,CHEMBL630279,N,1,,,,,1,,BAO_0000218,
12937,,Autocuration,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,CHEMBL630280,U,0,,,,,1,,BAO_0000019,
12938,,Autocuration,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,CHEMBL630281,U,0,,,,,1,,BAO_0000019,
12939,,Intermediate,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,CHEMBL630282,N,1,,,,,1,,BAO_0000218,
12940,,Intermediate,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,CHEMBL630283,N,1,,,,,1,,BAO_0000218,
12941,,Autocuration,,22224,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),CHEMBL630284,U,0,,,,,1,,BAO_0000019,
12942,,Autocuration,,22224,Alkylating activity was determined,CHEMBL630285,U,0,,,,,1,,BAO_0000019,
12943,,Autocuration,,22224,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),CHEMBL630286,U,0,,,,Microsomes,1,,BAO_0000251,
12944,,Intermediate,,50592,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",CHEMBL630069,N,1,,,,,1,,BAO_0000218,
12945,,Intermediate,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",CHEMBL630070,N,1,,,,,1,,BAO_0000218,
12946,,Intermediate,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",CHEMBL630071,N,1,,,,,1,,BAO_0000218,
12947,,Intermediate,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",CHEMBL630072,N,1,,,,,1,,BAO_0000218,
12948,,Intermediate,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",CHEMBL875110,N,1,,,,,1,,BAO_0000218,
12949,,Intermediate,,50597,Compound was tested for antidiuretic activity in rats,CHEMBL630073,N,1,,,,,1,,BAO_0000218,
12950,,Autocuration,,22224,Compound was tested for inactivation kinetic values,CHEMBL630074,U,0,,,,,1,,BAO_0000019,
12951,,Autocuration,,22224,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,CHEMBL630075,U,0,,,,,1,,BAO_0000218,
12952,,Autocuration,,22224,Dissociation rate calculated from the first-order equation using the t1/2 value,CHEMBL630076,U,0,,,,,1,,BAO_0000019,
12953,,Autocuration,,22229,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,CHEMBL630077,U,0,,,,,1,,BAO_0000100,
12954,,Autocuration,,22229,Aqueous solubility was measured,CHEMBL630078,U,0,,,,,1,,BAO_0000100,
12955,,Autocuration,,22229,Aqueous solubility was measured at a pH 4,CHEMBL630079,U,0,,,,,1,,BAO_0000100,
12956,,Autocuration,,22229,Aqueous solubility (pH 7),CHEMBL630080,U,0,,,,,1,,BAO_0000100,
12957,,Autocuration,,22229,Aqueous solubility was measured at a pH 9,CHEMBL630081,U,0,,,,,1,,BAO_0000100,
12958,,Autocuration,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",CHEMBL630082,U,0,,,,,1,,BAO_0000019,
12959,,Autocuration,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",CHEMBL630083,U,0,,,,,1,,BAO_0000019,
12960,,Autocuration,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",CHEMBL630084,U,0,,,,,1,,BAO_0000019,
12961,,Autocuration,,22229,Aqueous solubility of the compound,CHEMBL629198,U,0,,,,,1,,BAO_0000100,
12962,,Autocuration,,22229,Aqueous solubility at 37 degree Celsius at pH 7.38,CHEMBL629199,U,0,,,,,1,,BAO_0000100,
12963,,Autocuration,,22229,Aqueous solubility in pH 7.4 phosphate buffer,CHEMBL629200,U,0,,,,,1,,BAO_0000100,
12964,,Intermediate,,50588,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,CHEMBL629201,N,1,,,,,1,,BAO_0000218,
12965,,Intermediate,,50588,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,CHEMBL629202,N,1,,,,,1,,BAO_0000218,
12966,,Intermediate,,50587,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,CHEMBL875111,N,1,,,,,1,,BAO_0000218,
12967,,Intermediate,,50587,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,CHEMBL629203,N,1,,,,,1,,BAO_0000218,
12968,,Intermediate,,50587,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,CHEMBL629204,N,1,,,,,1,,BAO_0000218,
12969,,Intermediate,,50587,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,CHEMBL629205,N,1,,,,,1,,BAO_0000218,
12970,,Intermediate,,50587,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,CHEMBL629206,N,1,,,,,1,,BAO_0000218,
12971,,Autocuration,,22224,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,CHEMBL631185,U,0,,,,,1,,BAO_0000019,
12972,,Intermediate,,50597,Compound was evaluated for the average bile flow rat in rats,CHEMBL631186,N,1,,,,,1,,BAO_0000218,
12973,,Intermediate,,50592,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",CHEMBL631187,N,1,,,,,1,,BAO_0000218,
12974,,Intermediate,,50592,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",CHEMBL631188,N,1,,,,,1,,BAO_0000218,
12975,,Autocuration,,22224,Average half life period was determined,CHEMBL876419,U,0,,,,,1,,BAO_0000019,
12976,,Autocuration,,22224,Average half life period was determined,CHEMBL631189,U,0,,,,,1,,BAO_0000019,
12977,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,CHEMBL631190,N,1,,,,,1,,BAO_0000218,
12978,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,CHEMBL631191,N,1,,,,,1,,BAO_0000218,
12979,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,CHEMBL631192,N,1,,,,,1,,BAO_0000218,
12980,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,CHEMBL632400,N,1,,,,,1,,BAO_0000218,
12981,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,CHEMBL630564,N,1,,,,,1,,BAO_0000218,
12982,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,CHEMBL630565,N,1,,,,,1,,BAO_0000218,
12983,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,CHEMBL630566,N,1,,,,,1,,BAO_0000218,
12984,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,CHEMBL631229,N,1,,,,,1,,BAO_0000218,
12985,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,CHEMBL631230,N,1,,,,,1,,BAO_0000218,
12986,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL876428,U,0,,,,,1,,BAO_0000100,
12987,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631231,U,0,,,,,1,,BAO_0000100,
12988,,Autocuration,,22229,Calculated partition coefficient (clogP) (MacLogP),CHEMBL631232,U,0,,,,,1,,BAO_0000100,
12989,,Autocuration,,22224,Hydrophilicity was determined,CHEMBL631233,U,0,,,,,1,,BAO_0000019,
12990,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631234,U,0,,,,,1,,BAO_0000100,
12991,,Autocuration,,22224,Increased absorption was determined,CHEMBL883126,U,0,,,,,1,,BAO_0000019,
12992,,Autocuration,,22224,Lipophilicity value was evaluated,CHEMBL631235,U,0,,,,,1,,BAO_0000100,
12993,,Autocuration,,22224,Log P value of the compound.,CHEMBL631236,U,0,,,,,1,,BAO_0000100,
12994,,Autocuration,,22224,Partition coefficient of compound was determined,CHEMBL631237,U,0,,,,,1,,BAO_0000019,
12995,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631238,U,0,,,,,1,,BAO_0000100,
12996,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL876429,U,0,,,,,1,,BAO_0000100,
12997,,Autocuration,,22224,Partition coefficient was measured by medchem software; Not calculated,CHEMBL631414,U,0,,,,,1,,BAO_0000019,
12998,,Autocuration,,22224,Partition coefficient was measured by octanol-water using standard shake-flask method,CHEMBL631415,U,0,,,,,1,,BAO_0000100,
12999,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631416,U,0,,,,,1,,BAO_0000100,
13000,,Autocuration,,22224,Partition coefficient (logP),CHEMBL631417,U,0,,,,,1,,BAO_0000019,
13001,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631418,U,0,,,,,1,,BAO_0000100,
13002,,Autocuration,,22229,The Octanol/Water partition coefficient CLogP,CHEMBL631419,U,0,,,,,1,,BAO_0000100,
13003,,Autocuration,,22224,The pharmacokinetic parameter C Log p was reported,CHEMBL631420,U,0,,,,,1,,BAO_0000019,
13004,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631421,U,0,,,,,1,,BAO_0000100,
13005,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631422,U,0,,,,,1,,BAO_0000100,
13006,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL631423,U,0,,,,,1,,BAO_0000100,
13007,1969.0,Intermediate,Plasma,50597,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,CHEMBL876430,N,1,,,,,1,,BAO_0000218,
13008,1969.0,Intermediate,Plasma,50597,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,CHEMBL631424,N,1,,,,,1,,BAO_0000218,
13009,1969.0,Intermediate,Plasma,50588,Compound was administered intravenously in dog to evaluate plasma clearance values,CHEMBL631425,N,1,,,,,1,,BAO_0000218,
13010,1969.0,Autocuration,Plasma,22224,Compound was administered intravenously in monkey to evaluate plasma clearance values,CHEMBL631426,U,0,,,,,1,,BAO_0000218,
13011,1969.0,Intermediate,Plasma,50594,Compound was administered intravenously in mouse to evaluate plasma clearance values,CHEMBL631427,N,1,,,,,1,,BAO_0000218,
13012,1969.0,Intermediate,Plasma,50588,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,CHEMBL631428,N,1,,,,,1,,BAO_0000218,
13013,2107.0,Intermediate,Liver,50797,Intrinsic clearance in Rhesus liver microsome,CHEMBL631429,N,1,,,,Microsomes,1,,BAO_0000218,
13014,2107.0,Intermediate,Liver,50588,Intrinsic clearance in dog liver microsome,CHEMBL631430,N,1,,,,Microsomes,1,,BAO_0000218,
13015,2107.0,Intermediate,Liver,50597,Intrinsic clearance in rat liver microsome,CHEMBL631431,N,1,,,,Microsomes,1,,BAO_0000218,
13016,1969.0,Intermediate,Plasma,50797,Low plasma clearance was calculated in rhesus monkey,CHEMBL631432,N,1,,,,,1,,BAO_0000218,
13017,,Intermediate,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,CHEMBL631433,N,1,,,,,1,,BAO_0000218,
13018,,Autocuration,,22224,Plasma clearance after intravenous dose of 0.3 mg/kg,CHEMBL631434,U,0,,,,,1,,BAO_0000218,
13019,,Autocuration,,22224,Plasma clearance after intravenous dose of 1 mg/kg,CHEMBL631435,U,0,,,,,1,,BAO_0000218,
13020,,Autocuration,,22224,Plasma clearance after intravenous dose of 3 mg/kg,CHEMBL631436,U,0,,,,,1,,BAO_0000218,
13021,,Autocuration,,22224,Plasma clearance after intravenous dose of 3.87 mg/kg,CHEMBL631437,U,0,,,,,1,,BAO_0000218,
13022,,Intermediate,,50597,Plasma clearance after peroral administration at 10 mpk in Rat,CHEMBL631438,N,1,,,,,1,,BAO_0000218,
13023,,Intermediate,,50797,Plasma clearance after peroral administration at 10 mpk in Rhesus,CHEMBL876431,N,1,,,,,1,,BAO_0000218,
13024,,Intermediate,,50588,Plasma clearance after peroral administration at 10 mpk in dog,CHEMBL631439,N,1,,,,,1,,BAO_0000218,
13025,,Intermediate,,50597,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,CHEMBL631440,N,1,,,,,1,,BAO_0000218,
13026,,Autocuration,,22224,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),CHEMBL631441,U,0,,,,,1,,BAO_0000019,
13027,,Autocuration,,22224,Critical Micellar concentration was determined,CHEMBL631442,U,0,,,,,1,,BAO_0000019,
13028,,Autocuration,,22224,Critical Micellar concentration of the compound. was determined,CHEMBL626525,U,0,,,,,1,,BAO_0000019,
13029,,Autocuration,,22224,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,CHEMBL627168,U,0,,,,,1,,BAO_0000019,
13030,,Autocuration,,22224,Critical micellar concentration was measured in water by the dye solubilization method,CHEMBL875618,U,0,,,,,1,,BAO_0000019,
13031,,Autocuration,,22224,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,CHEMBL626612,U,0,,,,,1,,BAO_0000019,
13032,,Autocuration,,22224,CMR value (relative to BAY K 8644),CHEMBL626613,U,0,,,,,1,,BAO_0000019,
13033,,Autocuration,,22224,Carbamoylating activity was determined,CHEMBL626614,U,0,,,,,1,,BAO_0000019,
13034,,Autocuration,,22224,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,CHEMBL626615,U,0,,,,,1,,BAO_0000218,
13035,,Autocuration,,22224,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,CHEMBL626616,U,0,,,,,1,,BAO_0000019,
13036,,Autocuration,,22224,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,CHEMBL626617,U,0,,,,,1,,BAO_0000019,
13037,1969.0,Intermediate,Plasma,50588,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,CHEMBL626618,N,1,,,,,1,,BAO_0000218,
13038,1969.0,Intermediate,Plasma,50597,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,CHEMBL626619,N,1,,,,,1,,BAO_0000218,
13039,,Intermediate,,50588,"Clearance rate at 0.46 mg/kg, iv, in dogs",CHEMBL626620,N,1,,,,,1,,BAO_0000218,
13040,,Intermediate,,50597,"Clearance rate at 5.5 mg/kg, iv, in rat",CHEMBL626621,N,1,,,,,1,,BAO_0000218,
13041,,Intermediate,,100710,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,CHEMBL626622,N,1,,,,,1,,BAO_0000218,
13042,,Intermediate,,100710,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,CHEMBL626623,N,1,,,,,1,,BAO_0000218,
13043,,Intermediate,,50588,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,CHEMBL626624,N,1,,,,,1,,BAO_0000218,
13044,,Intermediate,,50597,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,CHEMBL626625,N,1,,,,,1,,BAO_0000218,
13045,2107.0,Intermediate,Liver,50597,Clearance rate constant using isolated perfused rat liver (IPRL) assay,CHEMBL626626,N,1,,,,,1,,BAO_0000218,
13046,,Autocuration,,22224,Tested for the total clearance of the compound,CHEMBL626627,U,0,,,,,1,,BAO_0000218,
13047,,Intermediate,,50588,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,CHEMBL626628,N,1,,,,,1,,BAO_0000218,
13048,,Autocuration,,22224,Total body clearance was determined,CHEMBL626629,U,0,,,,,1,,BAO_0000218,
13049,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,CHEMBL626630,N,1,,,,,1,,BAO_0000218,
13050,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,CHEMBL626631,N,1,,,,,1,,BAO_0000218,
13051,,Autocuration,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,CHEMBL626632,U,0,,,,,1,,BAO_0000100,
13052,,Autocuration,,22229,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,CHEMBL626633,U,0,,,,,1,,BAO_0000100,
13053,,Autocuration,,22229,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,CHEMBL626634,U,0,,,,,1,,BAO_0000100,
13054,,Autocuration,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,CHEMBL626635,U,0,,,,,1,,BAO_0000100,
13055,,Autocuration,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,CHEMBL626636,U,0,,,,,1,,BAO_0000100,
13056,,Autocuration,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,CHEMBL626637,U,0,,,,,1,,BAO_0000100,
13057,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),CHEMBL626638,N,1,,,,,1,,BAO_0000218,
13058,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,CHEMBL626639,N,1,,,,,1,,BAO_0000218,
13059,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,CHEMBL626640,N,1,,,,,1,,BAO_0000218,
13060,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,CHEMBL626641,N,1,,,,,1,,BAO_0000218,
13061,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,CHEMBL627272,N,1,,,,,1,,BAO_0000218,
13062,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,CHEMBL627273,N,1,,,,,1,,BAO_0000218,
13063,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),CHEMBL627441,N,1,,,,,1,,BAO_0000218,
13064,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),CHEMBL628355,N,1,,,,,1,,BAO_0000218,
13065,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),CHEMBL628356,N,1,,,,,1,,BAO_0000218,
13066,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),CHEMBL628357,N,1,,,,,1,,BAO_0000218,
13067,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),CHEMBL628358,N,1,,,,,1,,BAO_0000218,
13068,,Intermediate,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),CHEMBL622307,N,1,,,,,1,,BAO_0000218,
13069,,Autocuration,,22224,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,CHEMBL622527,U,0,,,,,1,,BAO_0000019,
13070,,Autocuration,,22224,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,CHEMBL622528,U,0,,,,,1,,BAO_0000019,
13071,,Autocuration,,22224,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,CHEMBL622529,U,0,,,,,1,,BAO_0000019,
13072,,Autocuration,,22224,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,CHEMBL622992,U,0,,,,,1,,BAO_0000019,
13073,,Autocuration,,22224,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,CHEMBL622993,U,0,,,,,1,,BAO_0000019,
13074,,Autocuration,,22224,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,CHEMBL622994,U,0,,,,,1,,BAO_0000019,
13075,,Intermediate,,50597,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",CHEMBL622995,N,1,,,,,1,,BAO_0000218,
13076,,Intermediate,,50597,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",CHEMBL622996,N,1,,,,,1,,BAO_0000218,
13077,,Intermediate,,50597,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",CHEMBL622997,N,1,,,,,1,,BAO_0000218,
13078,,Intermediate,,50597,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",CHEMBL622998,N,1,,,,,1,,BAO_0000218,
13079,,Autocuration,,22224,Cp max following ip administration at 1 mg/kg,CHEMBL622999,U,0,,,,,1,,BAO_0000218,
13080,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma was reported at 0.5 hour,CHEMBL623000,U,0,,,,,1,,BAO_0000218,
13081,1969.0,Autocuration,Plasma,22224,Maximum concentration in plasma was reported at 2 hour,CHEMBL623001,U,0,,,,,1,,BAO_0000218,
13082,,Intermediate,,50594,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,CHEMBL623002,N,1,,,,,1,,BAO_0000218,
13083,,Autocuration,,22229,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),CHEMBL623003,U,0,,,,,1,,BAO_0000100,
13084,,Autocuration,,22224,Steady state concentration was evaluated,CHEMBL623004,U,0,,,,,1,,BAO_0000019,
13085,,Autocuration,,22224,Partition coefficient (logP),CHEMBL623005,U,0,,,,,1,,BAO_0000019,
13086,,Autocuration,,22224,Partition coefficient (logD7.4),CHEMBL623006,U,0,,,,,1,,BAO_0000019,
13087,2107.0,Intermediate,Liver,50597,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,CHEMBL623007,N,1,,,,,1,,BAO_0000218,
13088,10000001.0,Intermediate,Bone,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,CHEMBL623008,N,1,,,,,1,,BAO_0000218,
13089,2037.0,Intermediate,Cerebellum,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,CHEMBL876654,N,1,,,,,1,,BAO_0000218,
13090,,Intermediate,,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,CHEMBL623009,N,1,,,,,1,,BAO_0000218,
13091,,Intermediate,,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,CHEMBL623010,N,1,,,,,1,,BAO_0000218,
13092,948.0,Intermediate,Heart,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,CHEMBL623011,N,1,,,,,1,,BAO_0000218,
13093,160.0,Intermediate,Intestine,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,CHEMBL623012,N,1,,,,,1,,BAO_0000218,
13094,,Autocuration,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,CHEMBL623013,U,0,,,,,1,,BAO_0000019,
13095,,Autocuration,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,CHEMBL623014,U,0,,,,,1,,BAO_0000019,
13096,1088.0,Autocuration,Urine,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,CHEMBL623015,U,0,,,,,1,,BAO_0000019,
13097,1088.0,Autocuration,Urine,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,CHEMBL623016,U,0,,,,,1,,BAO_0000019,
13098,1088.0,Autocuration,Urine,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,CHEMBL624858,U,0,,,,,1,,BAO_0000019,
13099,,Intermediate,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,CHEMBL624859,N,1,,,,,1,,BAO_0000218,
13100,,Intermediate,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,CHEMBL624860,N,1,,,,,1,,BAO_0000218,
13101,,Intermediate,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,CHEMBL624861,N,1,,,,,1,,BAO_0000218,
13102,,Intermediate,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,CHEMBL624862,N,1,,,,,1,,BAO_0000218,
13103,,Intermediate,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,CHEMBL624863,N,1,,,,,1,,BAO_0000218,
13104,,Intermediate,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,CHEMBL876655,N,1,,,,,1,,BAO_0000218,
13105,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,CHEMBL624864,N,1,,,,,1,,BAO_0000218,
13106,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,CHEMBL624865,N,1,,,,,1,,BAO_0000218,
13107,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,CHEMBL624866,N,1,,,,,1,,BAO_0000218,
13108,,Expert,,50588,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,CHEMBL624867,N,1,,,,,1,,BAO_0000218,
13109,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,CHEMBL624868,N,1,,,,,1,,BAO_0000218,
13110,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,CHEMBL628450,N,1,,,,,1,,BAO_0000218,
13111,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,CHEMBL628451,N,1,,,,,1,,BAO_0000218,
13112,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,CHEMBL628452,N,1,,,,,1,,BAO_0000218,
13113,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,CHEMBL628453,N,1,,,,,1,,BAO_0000218,
13114,,Intermediate,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,CHEMBL628454,N,1,,,,,1,,BAO_0000218,
13115,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,CHEMBL628455,N,1,,,,,1,,BAO_0000218,
13116,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,CHEMBL628456,N,1,,,,,1,,BAO_0000218,
13117,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,CHEMBL628457,N,1,,,,,1,,BAO_0000218,
13118,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,CHEMBL877505,N,1,,,,,1,,BAO_0000218,
13119,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,CHEMBL628458,N,1,,,,,1,,BAO_0000218,
13120,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,CHEMBL628459,N,1,,,,,1,,BAO_0000218,
13121,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,CHEMBL628460,N,1,,,,,1,,BAO_0000218,
13122,,Intermediate,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,CHEMBL628461,N,1,,,,,1,,BAO_0000218,
13123,,Autocuration,,22224,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",CHEMBL628462,U,0,,,,,1,,BAO_0000218,
13124,,Intermediate,,50588,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,CHEMBL628463,N,1,,,,,1,,BAO_0000218,
13125,,Expert,,50597,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",CHEMBL625666,N,1,,,,,1,,BAO_0000218,
13126,,Autocuration,,22224,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,CHEMBL625667,U,0,,,,,1,,BAO_0000218,
13127,,Expert,,50597,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,CHEMBL625668,N,1,,,,,1,,BAO_0000218,
13128,,Intermediate,,50597,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,CHEMBL625669,N,1,,,,,1,,BAO_0000218,
13129,,Autocuration,,22224,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,CHEMBL625670,U,0,,,,,1,,BAO_0000019,
13130,,Intermediate,,50597,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,CHEMBL625671,N,1,,,,,1,,BAO_0000218,
13131,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,CHEMBL625672,N,1,,,,,1,,BAO_0000218,
13132,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,CHEMBL625673,N,1,,,,,1,,BAO_0000218,
13133,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,CHEMBL625674,N,1,,,,,1,,BAO_0000218,
13134,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,CHEMBL625675,N,1,,,,,1,,BAO_0000218,
13135,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,CHEMBL627637,N,1,,,,,1,,BAO_0000218,
13136,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,CHEMBL627638,N,1,,,,,1,,BAO_0000218,
13137,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,CHEMBL627639,N,1,,,,,1,,BAO_0000218,
13138,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,CHEMBL627640,N,1,,,,,1,,BAO_0000218,
13139,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,CHEMBL627641,N,1,,,,,1,,BAO_0000218,
13140,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,CHEMBL627642,N,1,,,,,1,,BAO_0000218,
13141,,Intermediate,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,CHEMBL877506,N,1,,,,,1,,BAO_0000218,
13142,,Intermediate,,50594,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,CHEMBL627275,N,1,,,,,1,,BAO_0000218,
13143,,Intermediate,,50506,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",CHEMBL627643,N,1,,,,,1,,BAO_0000218,
13144,,Intermediate,,50506,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",CHEMBL631246,N,1,,,,,1,,BAO_0000218,
13145,,Intermediate,,50506,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",CHEMBL631247,N,1,,,,,1,,BAO_0000218,
13146,,Intermediate,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,CHEMBL629532,N,1,,,,,1,,BAO_0000218,
13147,,Intermediate,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,CHEMBL629533,N,1,,,,,1,,BAO_0000218,
13148,,Intermediate,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,CHEMBL629534,N,1,,,,,1,,BAO_0000218,
13149,,Intermediate,,50506,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,CHEMBL629535,N,1,,,,,1,,BAO_0000218,
13150,,Autocuration,,22224,Pharmacokinetic parameter :drug bound to plasma was reported,CHEMBL625932,U,0,,,,,1,,BAO_0000019,
13151,,Autocuration,,22224,compound was evaluated for drug bound in plasma,CHEMBL625933,U,0,,,,,1,,BAO_0000019,
13152,,Intermediate,,50597,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,CHEMBL625934,N,1,,,,,1,,BAO_0000218,
13153,,Autocuration,,22224,Bioavailability,CHEMBL625935,U,0,,,,,1,,BAO_0000218,
13154,,Intermediate,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,CHEMBL625936,N,1,,,,,1,,BAO_0000218,
13155,,Intermediate,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,CHEMBL625937,N,1,,,,,1,,BAO_0000218,
13156,,Intermediate,,50588,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,CHEMBL625938,N,1,,,,,1,,BAO_0000218,
13157,1970.0,Intermediate,Bile,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,CHEMBL625939,N,1,,,,,1,,BAO_0000218,
13158,1970.0,Intermediate,Bile,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,CHEMBL625940,N,1,,,,,1,,BAO_0000218,
13159,1970.0,Intermediate,Bile,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,CHEMBL874464,N,1,,,,,1,,BAO_0000218,
13160,1970.0,Intermediate,Bile,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,CHEMBL625941,N,1,,,,,1,,BAO_0000218,
13161,1970.0,Intermediate,Bile,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,CHEMBL625942,N,1,,,,,1,,BAO_0000218,
13162,1970.0,Intermediate,Bile,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,CHEMBL625943,N,1,,,,,1,,BAO_0000218,
13163,1977.0,Intermediate,Serum,50587,In vitro protein binding in human serum at 5 ug/ml,CHEMBL625944,N,1,,,,,1,,BAO_0000218,
13164,,Autocuration,,22224,Serum protein binding ability was measured,CHEMBL625945,U,0,,,,,1,,BAO_0000019,
13165,,Autocuration,,22224,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),CHEMBL625946,U,0,,,,,1,,BAO_0000019,
13166,,Autocuration,,22224,Oral bioavailability in dog,CHEMBL625947,U,0,,,,,1,,BAO_0000218,
13167,,Intermediate,,50597,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,CHEMBL625948,N,1,,,,,1,,BAO_0000218,
13168,,Autocuration,,22224,Absolute oral bioavailability at an iv dose of 14 mg/kg,CHEMBL625949,U,0,,,,,1,,BAO_0000218,
13169,,Autocuration,,22224,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,CHEMBL625950,U,0,,,,,1,,BAO_0000218,
13170,,Autocuration,,22224,Oral bioavailability (dose 15 mg/kg i.v.),CHEMBL625951,U,0,,,,,1,,BAO_0000218,
13171,,Autocuration,,22224,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,CHEMBL625952,U,0,,,,,1,,BAO_0000218,
13172,,Autocuration,,22224,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,CHEMBL625953,U,0,,,,,1,,BAO_0000218,
13173,,Autocuration,,22224,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,CHEMBL625954,U,0,,,,,1,,BAO_0000218,
13174,,Autocuration,,22224,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,CHEMBL882959,U,0,,,,,1,,BAO_0000218,
13175,,Intermediate,,50588,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,CHEMBL625955,N,1,,,,,1,,BAO_0000218,
13176,,Autocuration,,22224,Bioavailability in ferret,CHEMBL625956,U,0,,,,,1,,BAO_0000218,
13177,,Intermediate,,100710,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,CHEMBL625957,N,1,,,,,1,,BAO_0000218,
13178,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,CHEMBL625958,N,1,,,,,1,,BAO_0000218,
13179,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,CHEMBL625959,N,1,,,,,1,,BAO_0000218,
13180,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,CHEMBL626642,N,1,,,,,1,,BAO_0000218,
13181,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,CHEMBL631330,N,1,,,,,1,,BAO_0000218,
13182,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,CHEMBL631331,N,1,,,,,1,,BAO_0000218,
13183,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,CHEMBL631332,N,1,,,,,1,,BAO_0000218,
13184,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,CHEMBL631333,N,1,,,,,1,,BAO_0000218,
13185,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,CHEMBL632018,N,1,,,,,1,,BAO_0000218,
13186,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,CHEMBL632019,N,1,,,,,1,,BAO_0000218,
13187,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,CHEMBL632020,N,1,,,,,1,,BAO_0000218,
13188,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,CHEMBL632021,N,1,,,,,1,,BAO_0000218,
13189,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,CHEMBL632022,N,1,,,,,1,,BAO_0000218,
13190,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,CHEMBL632023,N,1,,,,,1,,BAO_0000218,
13191,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,CHEMBL632024,N,1,,,,,1,,BAO_0000218,
13192,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,CHEMBL874472,N,1,,,,,1,,BAO_0000218,
13193,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,CHEMBL632025,N,1,,,,,1,,BAO_0000218,
13194,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,CHEMBL632026,N,1,,,,,1,,BAO_0000218,
13195,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,CHEMBL632027,N,1,,,,,1,,BAO_0000218,
13196,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,CHEMBL632028,N,1,,,,,1,,BAO_0000218,
13197,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,CHEMBL626430,N,1,,,,,1,,BAO_0000218,
13198,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,CHEMBL626431,N,1,,,,,1,,BAO_0000218,
13199,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,CHEMBL626432,N,1,,,,,1,,BAO_0000218,
13200,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,CHEMBL626433,N,1,,,,,1,,BAO_0000218,
13201,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,CHEMBL626434,N,1,,,,,1,,BAO_0000218,
13202,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,CHEMBL627280,N,1,,,,,1,,BAO_0000218,
13203,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,CHEMBL627281,N,1,,,,,1,,BAO_0000218,
13204,,Intermediate,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,CHEMBL627282,N,1,,,,,1,,BAO_0000218,
13205,,Autocuration,,22224,Total body clearance was measured at given dose,CHEMBL627283,U,0,,,,,1,,BAO_0000019,
13206,,Autocuration,,22224,Total body clearance was measured at given dose.,CHEMBL627284,U,0,,,,,1,,BAO_0000218,
13207,,Intermediate,,50597,Metabolic clearance from the body in rat,CHEMBL627285,N,1,,,,,1,,BAO_0000218,
13208,,Autocuration,,22224,Renal clearance from the body,CHEMBL627286,U,0,,,,,1,,BAO_0000218,
13209,,Intermediate,,50597,Renal clearance from the body in rat,CHEMBL875477,N,1,,,,,1,,BAO_0000218,
13210,,Intermediate,,50597,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,CHEMBL627287,N,1,,,,,1,,BAO_0000218,
13211,,Intermediate,,50588,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,CHEMBL627288,N,1,,,,,1,,BAO_0000218,
13212,,Intermediate,,50597,Total clearance from the body in rat,CHEMBL627289,N,1,,,,,1,,BAO_0000218,
13213,1969.0,Intermediate,Plasma,50597,Clearance into cortex from rat plasma or PBS,CHEMBL627290,N,1,,,,,1,,BAO_0000218,
13214,,Autocuration,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,CHEMBL627291,U,0,,,,,1,,BAO_0000218,
13215,,Autocuration,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,CHEMBL627292,U,0,,,,,1,,BAO_0000218,
13216,,Autocuration,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,CHEMBL627293,U,0,,,,,1,,BAO_0000218,
13217,,Autocuration,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,CHEMBL627294,U,0,,,,,1,,BAO_0000218,
13218,,Autocuration,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,CHEMBL875478,U,0,,,,,1,,BAO_0000218,
13219,,Autocuration,,22224,Clearance was determined,CHEMBL627295,U,0,,,,,1,,BAO_0000218,
13220,,Intermediate,,50594,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,CHEMBL627296,N,1,,,,,1,,BAO_0000218,
13221,,Intermediate,,50592,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,CHEMBL626119,N,1,,,,,1,,BAO_0000218,
13222,,Intermediate,,50597,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,CHEMBL626120,N,1,,,,,1,,BAO_0000218,
13223,,Intermediate,,50597,Clearance in rat after iv dose (100 ug/kg),CHEMBL626121,N,1,,,,,1,,BAO_0000218,
13224,,Autocuration,,22224,Clearance in guinea pig,CHEMBL626122,U,0,,,,,1,,BAO_0000218,
13225,,Intermediate,,50597,Compound was evaluated for clearance in rat,CHEMBL626123,N,1,,,,,1,,BAO_0000218,
13226,,Intermediate,,50588,Compound was evaluated for the clearance in dog,CHEMBL623456,N,1,,,,,1,,BAO_0000218,
13227,,Intermediate,,50597,Compound was evaluated for the clearance in rat,CHEMBL623457,N,1,,,,,1,,BAO_0000218,
13228,,Intermediate,,50597,Compound was tested in vivo for clearance after iv administration in the rat,CHEMBL623458,N,1,,,,,1,,BAO_0000218,
13229,,Autocuration,,22224,IV clearance determined at an iv dose of 14 mg/kg,CHEMBL623459,U,0,,,,,1,,BAO_0000218,
13230,,Autocuration,,22224,IV clearance determined at an iv dose of 15.2 mg/kg,CHEMBL875484,U,0,,,,,1,,BAO_0000218,
13231,,Autocuration,,22224,IV clearance determined at an iv dose of 15 mg/kg,CHEMBL623460,U,0,,,,,1,,BAO_0000218,
13232,,Autocuration,,22224,IV clearance determined at an peroral dose of 30 mg/kg.,CHEMBL623461,U,0,,,,,1,,BAO_0000218,
13233,,Autocuration,,22224,IV clearance determined at an peroral dose of 30.2 mg/kg.,CHEMBL623462,U,0,,,,,1,,BAO_0000218,
13234,,Autocuration,,22224,IV clearance determined at an peroral dose of 30.3 mg/kg.,CHEMBL627386,U,0,,,,,1,,BAO_0000218,
13235,2113.0,Intermediate,Kidney,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,CHEMBL627387,N,1,,,,,1,,BAO_0000218,
13236,2107.0,Intermediate,Liver,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,CHEMBL627388,N,1,,,,,1,,BAO_0000218,
13237,2048.0,Intermediate,Lung,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,CHEMBL627389,N,1,,,,,1,,BAO_0000218,
13238,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,CHEMBL627390,N,1,,,,,1,,BAO_0000218,
13239,1969.0,Intermediate,Plasma,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,CHEMBL627391,N,1,,,,,1,,BAO_0000218,
13240,,Intermediate,,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,CHEMBL627392,N,1,,,,,1,,BAO_0000218,
13241,2106.0,Intermediate,Spleen,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,CHEMBL627393,N,1,,,,,1,,BAO_0000218,
13242,3126.0,Intermediate,Trachea,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,CHEMBL627394,N,1,,,,,1,,BAO_0000218,
13243,10000001.0,Intermediate,Bone,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,CHEMBL627395,N,1,,,,,1,,BAO_0000218,
13244,2037.0,Intermediate,Cerebellum,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,CHEMBL875485,N,1,,,,,1,,BAO_0000218,
13245,,Intermediate,,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,CHEMBL627396,N,1,,,,,1,,BAO_0000218,
13246,,Intermediate,,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,CHEMBL627397,N,1,,,,,1,,BAO_0000218,
13247,948.0,Intermediate,Heart,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,CHEMBL627398,N,1,,,,,1,,BAO_0000218,
13248,10000001.0,Intermediate,Bone,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,CHEMBL627399,N,1,,,,,1,,BAO_0000218,
13249,2113.0,Intermediate,Kidney,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,CHEMBL627400,N,1,,,,,1,,BAO_0000218,
13250,2107.0,Intermediate,Liver,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,CHEMBL627401,N,1,,,,,1,,BAO_0000218,
13251,2048.0,Intermediate,Lung,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,CHEMBL627402,N,1,,,,,1,,BAO_0000218,
13252,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,CHEMBL627403,N,1,,,,,1,,BAO_0000218,
13253,1969.0,Intermediate,Plasma,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,CHEMBL627404,N,1,,,,,1,,BAO_0000218,
13254,,Intermediate,,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,CHEMBL623101,N,1,,,,,1,,BAO_0000218,
13255,2106.0,Intermediate,Spleen,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,CHEMBL877480,N,1,,,,,1,,BAO_0000218,
13256,3126.0,Intermediate,Trachea,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,CHEMBL623102,N,1,,,,,1,,BAO_0000218,
13257,10000001.0,Intermediate,Bone,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,CHEMBL623103,N,1,,,,,1,,BAO_0000218,
13258,2037.0,Intermediate,Cerebellum,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,CHEMBL623104,N,1,,,,,1,,BAO_0000218,
13259,,Intermediate,,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,CHEMBL623105,N,1,,,,,1,,BAO_0000218,
13260,,Intermediate,,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,CHEMBL623106,N,1,,,,,1,,BAO_0000218,
13261,948.0,Intermediate,Heart,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,CHEMBL623107,N,1,,,,,1,,BAO_0000218,
13262,160.0,Intermediate,Intestine,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,CHEMBL623108,N,1,,,,,1,,BAO_0000218,
13263,2113.0,Intermediate,Kidney,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,CHEMBL623109,N,1,,,,,1,,BAO_0000218,
13264,2107.0,Intermediate,Liver,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,CHEMBL623110,N,1,,,,,1,,BAO_0000218,
13265,2048.0,Intermediate,Lung,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,CHEMBL623111,N,1,,,,,1,,BAO_0000218,
13266,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,CHEMBL625060,N,1,,,,,1,,BAO_0000218,
13267,1969.0,Intermediate,Plasma,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,CHEMBL625061,N,1,,,,,1,,BAO_0000218,
13268,,Intermediate,,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,CHEMBL625062,N,1,,,,,1,,BAO_0000218,
13269,2106.0,Intermediate,Spleen,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,CHEMBL625063,N,1,,,,,1,,BAO_0000218,
13270,3126.0,Intermediate,Trachea,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,CHEMBL625064,N,1,,,,,1,,BAO_0000218,
13271,10000001.0,Intermediate,Bone,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,CHEMBL625065,N,1,,,,,1,,BAO_0000218,
13272,2037.0,Intermediate,Cerebellum,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,CHEMBL625066,N,1,,,,,1,,BAO_0000218,
13273,,Intermediate,,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,CHEMBL625067,N,1,,,,,1,,BAO_0000218,
13274,,Intermediate,,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,CHEMBL625068,N,1,,,,,1,,BAO_0000218,
13275,948.0,Intermediate,Heart,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,CHEMBL622159,N,1,,,,,1,,BAO_0000218,
13276,160.0,Intermediate,Intestine,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,CHEMBL622160,N,1,,,,,1,,BAO_0000218,
13277,2113.0,Intermediate,Kidney,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,CHEMBL622161,N,1,,,,,1,,BAO_0000218,
13278,2048.0,Intermediate,Lung,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,CHEMBL622162,N,1,,,,,1,,BAO_0000218,
13279,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,CHEMBL622163,N,1,,,,,1,,BAO_0000218,
13280,1969.0,Intermediate,Plasma,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,CHEMBL622313,N,1,,,,,1,,BAO_0000218,
13281,,Intermediate,,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,CHEMBL622314,N,1,,,,,1,,BAO_0000218,
13282,2106.0,Intermediate,Spleen,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,CHEMBL622315,N,1,,,,,1,,BAO_0000218,
13283,3126.0,Intermediate,Trachea,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,CHEMBL622316,N,1,,,,,1,,BAO_0000218,
13284,,Intermediate,,50212,Normal diffusion coefficient in water for Escherichia coli,CHEMBL877486,N,1,,,,,1,,BAO_0000218,
13285,,Autocuration,,22224,Average max percent decrease in RVR (renal vascular resistance) was determined,CHEMBL622317,U,0,,,,,1,,BAO_0000019,
13286,,Autocuration,,22224,Average max percent decrease in RVR (renal vascular resistance) was determined.,CHEMBL622318,U,0,,,,,1,,BAO_0000019,
13287,,Autocuration,,22224,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,CHEMBL622319,U,0,,,,,1,,BAO_0000019,
13288,,Autocuration,,22224,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,CHEMBL622320,U,0,,,,,1,,BAO_0000019,
13289,,Autocuration,,22224,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,CHEMBL622321,U,0,,,,,1,,BAO_0000019,
13290,,Autocuration,,22224,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,CHEMBL622322,U,0,,,,,1,,BAO_0000019,
13291,,Autocuration,,22224,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,CHEMBL622323,U,0,,,,,1,,BAO_0000019,
13292,,Intermediate,,50597,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,CHEMBL622324,N,1,,,,,1,,BAO_0000218,
13293,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",CHEMBL622325,N,1,,,,,1,,BAO_0000218,
13294,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",CHEMBL622326,N,1,,,,,1,,BAO_0000218,
13295,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",CHEMBL877487,N,1,,,,,1,,BAO_0000218,
13296,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",CHEMBL622327,N,1,,,,,1,,BAO_0000218,
13297,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",CHEMBL622328,N,1,,,,,1,,BAO_0000218,
13298,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",CHEMBL622329,N,1,,,,,1,,BAO_0000218,
13299,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",CHEMBL622330,N,1,,,,,1,,BAO_0000218,
13300,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",CHEMBL622331,N,1,,,,,1,,BAO_0000218,
13301,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",CHEMBL622332,N,1,,,,,1,,BAO_0000218,
13302,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",CHEMBL622333,N,1,,,,,1,,BAO_0000218,
13303,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",CHEMBL627658,U,0,,,,,1,,BAO_0000218,
13304,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",CHEMBL630428,U,0,,,,,1,,BAO_0000218,
13305,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",CHEMBL630429,U,0,,,,,1,,BAO_0000218,
13306,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",CHEMBL630430,U,0,,,,,1,,BAO_0000218,
13307,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",CHEMBL630431,U,0,,,,,1,,BAO_0000218,
13308,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",CHEMBL630432,N,1,,,,,1,,BAO_0000218,
13309,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",CHEMBL630433,N,1,,,,,1,,BAO_0000218,
13310,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",CHEMBL630434,N,1,,,,,1,,BAO_0000218,
13311,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",CHEMBL629372,N,1,,,,,1,,BAO_0000218,
13312,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",CHEMBL629553,N,1,,,,,1,,BAO_0000218,
13313,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",CHEMBL629554,N,1,,,,,1,,BAO_0000218,
13314,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",CHEMBL874447,N,1,,,,,1,,BAO_0000218,
13315,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",CHEMBL629555,N,1,,,,,1,,BAO_0000218,
13316,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",CHEMBL629556,N,1,,,,,1,,BAO_0000218,
13317,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",CHEMBL629557,N,1,,,,,1,,BAO_0000218,
13318,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",CHEMBL629558,N,1,,,,,1,,BAO_0000218,
13319,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",CHEMBL629559,N,1,,,,,1,,BAO_0000218,
13320,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",CHEMBL629560,N,1,,,,,1,,BAO_0000218,
13321,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",CHEMBL629561,N,1,,,,,1,,BAO_0000218,
13322,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",CHEMBL629562,N,1,,,,,1,,BAO_0000218,
13323,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",CHEMBL629563,N,1,,,,,1,,BAO_0000218,
13324,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",CHEMBL629564,N,1,,,,,1,,BAO_0000218,
13325,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",CHEMBL629565,N,1,,,,,1,,BAO_0000218,
13326,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",CHEMBL629566,N,1,,,,,1,,BAO_0000218,
13327,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",CHEMBL629567,N,1,,,,,1,,BAO_0000218,
13328,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",CHEMBL629568,N,1,,,,,1,,BAO_0000218,
13329,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",CHEMBL629569,N,1,,,,,1,,BAO_0000218,
13330,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",CHEMBL629570,N,1,,,,,1,,BAO_0000218,
13331,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",CHEMBL629571,U,0,,,,,1,,BAO_0000218,
13332,,Autocuration,,22224,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,CHEMBL629572,U,0,,,,,1,,BAO_0000218,
13333,,Autocuration,,22224,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,CHEMBL629573,U,0,,,,,1,,BAO_0000218,
13334,,Autocuration,,22224,Bioavailability (dose 20 mg/kg),CHEMBL629574,U,0,,,,,1,,BAO_0000218,
13335,,Autocuration,,22224,Bioavailability in dog,CHEMBL629575,U,0,,,,,1,,BAO_0000218,
13336,,Autocuration,,22224,Bioavailability in rat (Sprague-Dawley) (male),CHEMBL874448,U,0,,,,,1,,BAO_0000218,
13337,,Autocuration,,22224,Bioavailability in monkey (dose 10 mg/kg i.d.),CHEMBL629576,U,0,,,,,1,,BAO_0000218,
13338,,Autocuration,,22224,Bioavailability in rat,CHEMBL629577,U,0,,,,,1,,BAO_0000218,
13339,,Autocuration,,22224,Bioavailability in rat,CHEMBL629578,U,0,,,,,1,,BAO_0000218,
13340,,Autocuration,,22224,Bioavailability in dog (dose 3.0 mg/kg p.o.),CHEMBL629579,U,0,,,,,1,,BAO_0000218,
13341,,Autocuration,,22224,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,CHEMBL882958,U,0,,,,,1,,BAO_0000218,
13342,,Intermediate,,50505,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,CHEMBL629580,N,1,,,,,1,,BAO_0000218,
13343,,Autocuration,,22224,Bioavailability,CHEMBL629581,U,0,,,,,1,,BAO_0000218,
13344,,Autocuration,,22224,Bioavailability in squirrel monkey,CHEMBL629582,U,0,,,,,1,,BAO_0000218,
13345,,Intermediate,,50588,Bioavailability was evaluated in dog,CHEMBL628522,N,1,,,,,1,,BAO_0000218,
13346,,Intermediate,,100712,Bioavailability was evaluated in hamster,CHEMBL625432,N,1,,,,,1,,BAO_0000218,
13347,,Autocuration,,22224,Bioavailability in rat,CHEMBL625433,U,0,,,,,1,,BAO_0000218,
13348,1969.0,Intermediate,Plasma,50597,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,CHEMBL625434,N,1,,,,,1,,BAO_0000218,
13349,1969.0,Intermediate,Plasma,50597,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,CHEMBL625435,N,1,,,,,1,,BAO_0000218,
13350,,Autocuration,,22224,Bioavailability in rat (dose 10 mg/kg p.o.),CHEMBL625436,U,0,,,,,1,,BAO_0000218,
13351,,Intermediate,,100710,Bioavailability was measured in cynomolgus monkeys.,CHEMBL874588,N,1,,,,,1,,BAO_0000218,
13352,,Intermediate,,50594,Bioavailability was measured in nude mice.,CHEMBL625437,N,1,,,,,1,,BAO_0000218,
13353,,Autocuration,,22224,Bioavailability in ferret (dose 10 mg/kg i.d.),CHEMBL625438,U,0,,,,,1,,BAO_0000218,
13354,,Autocuration,,22224,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),CHEMBL625439,U,0,,,,,1,,BAO_0000218,
13355,,Autocuration,,22224,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",CHEMBL625440,U,0,,,,,1,,BAO_0000218,
13356,,Autocuration,,22224,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),CHEMBL625441,U,0,,,,,1,,BAO_0000218,
13357,,Autocuration,,22224,Bioavailability in rat (dose 10 mg/kg i.d.),CHEMBL625442,U,0,,,,,1,,BAO_0000218,
13358,,Intermediate,,50597,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",CHEMBL625443,N,1,,,,,1,,BAO_0000218,
13359,,Autocuration,,22224,Bioavailability was determined; extremely poor,CHEMBL625444,U,0,,,,,1,,BAO_0000218,
13360,,Intermediate,,50594,% bioavailability in mice after oral administration of prodrug,CHEMBL625445,N,1,,,,,1,,BAO_0000218,
13361,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,CHEMBL625446,N,1,,,,,1,,BAO_0000218,
13362,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,CHEMBL882960,N,1,,,,,1,,BAO_0000218,
13363,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,CHEMBL625447,N,1,,,,,1,,BAO_0000218,
13364,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,CHEMBL625448,N,1,,,,,1,,BAO_0000218,
13365,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,CHEMBL625449,N,1,,,,,1,,BAO_0000218,
13366,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),CHEMBL874589,N,1,,,,,1,,BAO_0000218,
13367,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,CHEMBL625450,N,1,,,,,1,,BAO_0000218,
13368,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,CHEMBL625451,N,1,,,,,1,,BAO_0000218,
13369,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,CHEMBL626584,N,1,,,,,1,,BAO_0000218,
13370,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,CHEMBL626585,N,1,,,,,1,,BAO_0000218,
13371,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,CHEMBL626586,N,1,,,,,1,,BAO_0000218,
13372,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,CHEMBL626587,N,1,,,,,1,,BAO_0000218,
13373,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,CHEMBL626588,N,1,,,,,1,,BAO_0000218,
13374,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,CHEMBL626589,N,1,,,,,1,,BAO_0000218,
13375,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,CHEMBL626590,N,1,,,,,1,,BAO_0000218,
13376,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,CHEMBL626591,N,1,,,,,1,,BAO_0000218,
13377,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,CHEMBL627181,N,1,,,,,1,,BAO_0000218,
13378,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,CHEMBL628083,N,1,,,,,1,,BAO_0000218,
13379,,Autocuration,,22224,IV clearance determined at an peroral dose of 15 mg/kg.,CHEMBL628084,U,0,,,,,1,,BAO_0000218,
13380,,Expert,,50064,Mouse oral clearance was measured against Hymenolepiasis nana.,CHEMBL628085,N,1,,,,,1,,BAO_0000218,
13381,,Expert,,50545,Mouse oral clearance was measured against Nematospiroides dubius,CHEMBL628086,N,1,,,,,1,,BAO_0000218,
13382,,Autocuration,,22224,Mouse oral clearance was measured against N. dubius; NT is Not Tested,CHEMBL628087,U,0,,,,,1,,BAO_0000218,
13383,,Intermediate,,50594,Mouse oral clearance was measured against N. nana; NT is Not Tested,CHEMBL628088,N,1,,,,,1,,BAO_0000218,
13384,,Autocuration,,22224,Mouse oral clearance was measured against N. nana; NT is Not Tested,CHEMBL628089,U,0,,,,,1,,BAO_0000218,
13385,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,CHEMBL628090,U,0,,,,,1,,BAO_0000218,
13386,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,CHEMBL628091,U,0,,,,,1,,BAO_0000218,
13387,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,CHEMBL628092,U,0,,,,,1,,BAO_0000218,
13388,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,CHEMBL628093,U,0,,,,,1,,BAO_0000218,
13389,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,CHEMBL875607,U,0,,,,,1,,BAO_0000218,
13390,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,CHEMBL625710,U,0,,,,,1,,BAO_0000218,
13391,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,CHEMBL625711,U,0,,,,,1,,BAO_0000218,
13392,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,CHEMBL625712,U,0,,,,,1,,BAO_0000218,
13393,,Autocuration,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,CHEMBL625713,U,0,,,,,1,,BAO_0000218,
13394,,Intermediate,,50588,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,CHEMBL625714,N,1,,,,,1,,BAO_0000218,
13395,,Intermediate,,50797,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,CHEMBL625715,N,1,,,,,1,,BAO_0000218,
13396,,Intermediate,,50597,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,CHEMBL625716,N,1,,,,,1,,BAO_0000218,
13397,,Intermediate,,50597,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,CHEMBL625717,N,1,,,,,1,,BAO_0000218,
13398,,Intermediate,,50597,Plasma clearance was determined for the compound in rats,CHEMBL625718,N,1,,,,,1,,BAO_0000218,
13399,,Intermediate,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,CHEMBL625719,N,1,,,,,1,,BAO_0000218,
13400,,Intermediate,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,CHEMBL625720,N,1,,,,,1,,BAO_0000218,
13401,,Intermediate,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,CHEMBL625721,N,1,,,,,1,,BAO_0000218,
13402,,Intermediate,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,CHEMBL625722,N,1,,,,,1,,BAO_0000218,
13403,,Intermediate,,50597,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,CHEMBL625723,N,1,,,,,1,,BAO_0000218,
13404,,Intermediate,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,CHEMBL625724,N,1,,,,,1,,BAO_0000218,
13405,,Intermediate,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,CHEMBL625725,N,1,,,,,1,,BAO_0000218,
13406,,Intermediate,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,CHEMBL625726,N,1,,,,,1,,BAO_0000218,
13407,,Intermediate,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,CHEMBL875608,N,1,,,,,1,,BAO_0000218,
13408,,Intermediate,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,CHEMBL625727,N,1,,,,,1,,BAO_0000218,
13409,1088.0,Autocuration,Urine,22224,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,CHEMBL625728,U,0,,,,,1,,BAO_0000218,
13410,,Autocuration,,22224,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,CHEMBL625729,U,0,,,,,1,,BAO_0000218,
13411,,Autocuration,,22224,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,CHEMBL625730,U,0,,,,,1,,BAO_0000218,
13412,1088.0,Autocuration,Urine,22224,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,CHEMBL625731,U,0,,,,,1,,BAO_0000218,
13413,1088.0,Autocuration,Urine,22224,Urinary clearance was determined in rat at 25 mg/kg os dosage,CHEMBL626417,U,0,,,,,1,,BAO_0000218,
13414,1088.0,Intermediate,Urine,50587,Urinary clearance was determined at 100 mg/kg oral dosage in human,CHEMBL626418,N,1,,,,,1,,BAO_0000218,
13415,1088.0,Intermediate,Urine,50588,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,CHEMBL626419,N,1,,,,,1,,BAO_0000218,
13416,1969.0,Intermediate,Plasma,50588,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,CHEMBL626592,N,1,,,,,1,,BAO_0000218,
13417,1969.0,Intermediate,Plasma,50597,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,CHEMBL626593,N,1,,,,,1,,BAO_0000218,
13418,,Intermediate,,50597,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,CHEMBL626594,N,1,,,,,1,,BAO_0000218,
13419,,Intermediate,,50588,Clearance rate in dogs,CHEMBL625035,N,1,,,,,1,,BAO_0000218,
13420,,Autocuration,,22224,Compound was measured for intrinsic clearance,CHEMBL625036,U,0,,,,,1,,BAO_0000019,
13421,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625037,U,0,,,,,1,,BAO_0000100,
13422,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625038,U,0,,,,,1,,BAO_0000100,
13423,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625039,U,0,,,,,1,,BAO_0000100,
13424,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625040,U,0,,,,,1,,BAO_0000100,
13425,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625041,U,0,,,,,1,,BAO_0000100,
13426,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625042,U,0,,,,,1,,BAO_0000100,
13427,,Autocuration,,22224,Partition coefficient of the compound,CHEMBL874411,U,0,,,,,1,,BAO_0000019,
13428,,Autocuration,,22224,Permeability,CHEMBL625043,U,0,,,,,1,,BAO_0000019,
13429,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625044,U,0,,,,,1,,BAO_0000100,
13430,,Autocuration,,22224,Partition coefficient (logD),CHEMBL625045,U,0,,,,,1,,BAO_0000019,
13431,,Autocuration,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),CHEMBL625046,U,0,,,,,1,,BAO_0000100,
13432,,Autocuration,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),CHEMBL625047,U,0,,,,,1,,BAO_0000100,
13433,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625048,U,0,,,,,1,,BAO_0000100,
13434,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625049,U,0,,,,,1,,BAO_0000100,
13435,,Autocuration,,22229,Calculated logarithm of partition coefficient (P) was determined,CHEMBL625050,U,0,,,,,1,,BAO_0000100,
13436,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625051,U,0,,,,,1,,BAO_0000100,
13437,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL874412,U,0,,,,,1,,BAO_0000100,
13438,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625052,U,0,,,,,1,,BAO_0000100,
13439,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL625053,U,0,,,,,1,,BAO_0000100,
13440,,Autocuration,,22224,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,CHEMBL623250,U,0,,,,,1,,BAO_0000019,
13441,,Autocuration,,22224,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,CHEMBL623251,U,0,,,,,1,,BAO_0000019,
13442,,Autocuration,,22224,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,CHEMBL623252,U,0,,,,,1,,BAO_0000019,
13443,,Autocuration,,22224,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,CHEMBL623253,U,0,,,,,1,,BAO_0000019,
13444,,Autocuration,,22224,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,CHEMBL623254,U,0,,,,,1,,BAO_0000019,
13445,,Autocuration,,22224,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,CHEMBL623255,U,0,,,,,1,,BAO_0000019,
13446,,Autocuration,,22224,Percent degradation of compound at a pH of 1 over a 18 hr period,CHEMBL626831,U,0,,,,,1,,BAO_0000019,
13447,,Autocuration,,22224,Percent degradation of compound at pH of 1 over an 18 hr period,CHEMBL877494,U,0,,,,,1,,BAO_0000019,
13448,,Autocuration,,22224,Delta Logarithm of Partition Coefficient value was determined.,CHEMBL626832,U,0,,,,,1,,BAO_0000019,
13449,,Autocuration,,22224,Delta logPoct-cyc,CHEMBL626833,U,0,,,,,1,,BAO_0000019,
13450,,Autocuration,,22224,Lipophilicity estimated on reversed phase TLC,CHEMBL626834,U,0,,,,,1,,BAO_0000100,
13451,,Autocuration,,22224,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,CHEMBL626835,U,0,,,,,1,,BAO_0000019,
13452,,Autocuration,,22224,Delta logPoct-cyc,CHEMBL626836,U,0,,,,,1,,BAO_0000019,
13453,,Autocuration,,22229,Change in logarithm of partition coefficient of the compound,CHEMBL626837,U,0,,,,,1,,BAO_0000100,
13454,,Autocuration,,22224,Delta logD (pH 6.5),CHEMBL626838,U,0,,,,,1,,BAO_0000019,
13455,,Autocuration,,22224,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",CHEMBL626839,U,0,,,,,1,,BAO_0000100,
13456,,Autocuration,,22224,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,CHEMBL626840,U,0,,,,,1,,BAO_0000019,
13457,,Autocuration,,22224,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),CHEMBL626841,U,0,,,,,1,,BAO_0000019,
13458,,Autocuration,,22224,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,CHEMBL626842,U,0,,,,,1,,BAO_0000219,
13459,,Autocuration,,22224,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,CHEMBL626843,U,0,,,,,1,,BAO_0000219,
13460,,Intermediate,,50597,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,CHEMBL626844,N,1,,,,,1,,BAO_0000218,
13461,,Intermediate,,50597,Amount of deuterium retained was reported after normal workup in rats,CHEMBL877495,N,1,,,,,1,,BAO_0000218,
13462,,Intermediate,,50597,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,CHEMBL626845,N,1,,,,,1,,BAO_0000218,
13463,,Intermediate,,50597,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,CHEMBL626846,N,1,,,,,1,,BAO_0000218,
13464,,Intermediate,,50597,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,CHEMBL626847,N,1,,,,,1,,BAO_0000218,
13465,,Intermediate,,50597,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,CHEMBL628677,N,1,,,,,1,,BAO_0000218,
13466,,Intermediate,,50597,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,CHEMBL628678,N,1,,,,,1,,BAO_0000218,
13467,,Autocuration,,22224,Compound was subjected to electrochemical oxidation,CHEMBL628679,U,0,,,,,1,,BAO_0000019,
13468,,Autocuration,,22224,Compound was subjected to photochemical oxidation,CHEMBL628680,U,0,,,,,1,,BAO_0000019,
13469,,Autocuration,,22224,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,CHEMBL628681,U,0,,,,,1,,BAO_0000019,
13470,,Autocuration,,22224,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,CHEMBL628682,U,0,,,,,1,,BAO_0000019,
13471,,Autocuration,,22224,Oxidation of compound by methemoglobin in presence of hydroperoxide,CHEMBL628683,U,0,,,,,1,,BAO_0000019,
13472,,Intermediate,,50597,Percent diffusion through fuzzy rat skin after 48 h of incubation,CHEMBL628684,N,1,,,,,1,,BAO_0000218,
13473,,Autocuration,,22229,Dissociation constant (pKa),CHEMBL877501,U,0,,,,,1,,BAO_0000100,
13474,,Autocuration,,22224,Dissociation constant value of the compound; ND means not determined.,CHEMBL628685,U,0,,,,,1,,BAO_0000100,
13475,178.0,Intermediate,Blood,50597,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,CHEMBL628686,N,1,,,,,1,,BAO_0000218,
13476,178.0,Intermediate,Blood,50597,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,CHEMBL628687,N,1,,,,,1,,BAO_0000218,
13477,,Intermediate,,50597,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,CHEMBL628688,N,1,,,,,1,,BAO_0000218,
13478,,Intermediate,,50597,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,CHEMBL628689,N,1,,,,,1,,BAO_0000218,
13479,2107.0,Intermediate,Liver,50597,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,CHEMBL628690,N,1,,,,,1,,BAO_0000218,
13480,2107.0,Intermediate,Liver,50597,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,CHEMBL629363,N,1,,,,,1,,BAO_0000218,
13481,2106.0,Intermediate,Spleen,50597,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,CHEMBL629364,N,1,,,,,1,,BAO_0000218,
13482,2106.0,Intermediate,Spleen,50597,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,CHEMBL629365,N,1,,,,,1,,BAO_0000218,
13483,,Intermediate,,50597,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,CHEMBL629366,N,1,,,,,1,,BAO_0000218,
13484,1088.0,Intermediate,Urine,50597,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,CHEMBL629367,N,1,,,,,1,,BAO_0000218,
13485,1988.0,Intermediate,Feces,50597,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,CHEMBL629368,N,1,,,,,1,,BAO_0000218,
13486,1088.0,Intermediate,Urine,50597,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,CHEMBL877502,N,1,,,,,1,,BAO_0000218,
13487,2037.0,Intermediate,Cerebellum,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,CHEMBL629369,N,1,,,,,1,,BAO_0000218,
13488,955.0,Intermediate,Brain,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,CHEMBL629370,N,1,,,,,1,,BAO_0000218,
13489,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",CHEMBL629371,U,0,,,,,1,,BAO_0000218,
13490,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",CHEMBL626276,U,0,,,,,1,,BAO_0000218,
13491,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",CHEMBL626277,U,0,,,,,1,,BAO_0000218,
13492,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",CHEMBL631250,U,0,,,,,1,,BAO_0000218,
13493,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",CHEMBL631251,N,1,,,,,1,,BAO_0000218,
13494,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",CHEMBL631252,N,1,,,,,1,,BAO_0000218,
13495,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",CHEMBL631253,N,1,,,,,1,,BAO_0000218,
13496,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",CHEMBL631254,N,1,,,,,1,,BAO_0000218,
13497,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",CHEMBL631255,N,1,,,,,1,,BAO_0000218,
13498,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",CHEMBL631256,N,1,,,,,1,,BAO_0000218,
13499,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",CHEMBL631257,N,1,,,,,1,,BAO_0000218,
13500,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",CHEMBL628009,N,1,,,,,1,,BAO_0000218,
13501,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",CHEMBL628010,N,1,,,,,1,,BAO_0000218,
13502,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",CHEMBL628011,N,1,,,,,1,,BAO_0000218,
13503,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",CHEMBL628012,N,1,,,,,1,,BAO_0000218,
13504,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",CHEMBL628013,N,1,,,,,1,,BAO_0000218,
13505,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",CHEMBL628014,N,1,,,,,1,,BAO_0000218,
13506,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",CHEMBL628015,N,1,,,,,1,,BAO_0000218,
13507,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",CHEMBL628016,N,1,,,,,1,,BAO_0000218,
13508,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",CHEMBL874461,N,1,,,,,1,,BAO_0000218,
13509,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",CHEMBL628017,N,1,,,,,1,,BAO_0000218,
13510,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",CHEMBL628018,N,1,,,,,1,,BAO_0000218,
13511,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",CHEMBL628019,N,1,,,,,1,,BAO_0000218,
13512,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",CHEMBL628020,N,1,,,,,1,,BAO_0000218,
13513,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",CHEMBL628021,N,1,,,,,1,,BAO_0000218,
13514,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",CHEMBL628022,N,1,,,,,1,,BAO_0000218,
13515,1088.0,Intermediate,Urine,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",CHEMBL628023,N,1,,,,,1,,BAO_0000218,
13516,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",CHEMBL628024,U,0,,,,,1,,BAO_0000218,
13517,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",CHEMBL628025,U,0,,,,,1,,BAO_0000218,
13518,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",CHEMBL628026,U,0,,,,,1,,BAO_0000218,
13519,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",CHEMBL628027,U,0,,,,,1,,BAO_0000218,
13520,1088.0,Autocuration,Urine,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",CHEMBL628028,U,0,,,,,1,,BAO_0000218,
13521,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",CHEMBL628029,N,1,,,,,1,,BAO_0000218,
13522,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",CHEMBL628030,N,1,,,,,1,,BAO_0000218,
13523,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",CHEMBL628031,N,1,,,,,1,,BAO_0000218,
13524,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",CHEMBL628032,N,1,,,,,1,,BAO_0000218,
13525,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",CHEMBL628033,N,1,,,,,1,,BAO_0000218,
13526,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",CHEMBL628034,N,1,,,,,1,,BAO_0000218,
13527,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",CHEMBL628035,N,1,,,,,1,,BAO_0000218,
13528,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",CHEMBL628036,N,1,,,,,1,,BAO_0000218,
13529,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",CHEMBL874462,N,1,,,,,1,,BAO_0000218,
13530,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,CHEMBL628037,N,1,,,,,1,,BAO_0000218,
13531,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,CHEMBL628123,N,1,,,,,1,,BAO_0000218,
13532,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,CHEMBL628124,N,1,,,,,1,,BAO_0000218,
13533,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,CHEMBL628125,N,1,,,,,1,,BAO_0000218,
13534,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,CHEMBL628126,N,1,,,,,1,,BAO_0000218,
13535,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),CHEMBL628127,N,1,,,,,1,,BAO_0000218,
13536,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,CHEMBL628128,N,1,,,,,1,,BAO_0000218,
13537,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,CHEMBL628129,N,1,,,,,1,,BAO_0000218,
13538,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,CHEMBL628130,N,1,,,,,1,,BAO_0000218,
13539,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,CHEMBL628131,N,1,,,,,1,,BAO_0000218,
13540,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,CHEMBL628132,N,1,,,,,1,,BAO_0000218,
13541,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,CHEMBL628133,N,1,,,,,1,,BAO_0000218,
13542,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,CHEMBL628134,N,1,,,,,1,,BAO_0000218,
13543,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,CHEMBL628135,N,1,,,,,1,,BAO_0000218,
13544,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,CHEMBL628136,N,1,,,,,1,,BAO_0000218,
13545,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,CHEMBL628137,N,1,,,,,1,,BAO_0000218,
13546,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,CHEMBL628138,N,1,,,,,1,,BAO_0000218,
13547,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,CHEMBL628139,N,1,,,,,1,,BAO_0000218,
13548,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,CHEMBL628140,N,1,,,,,1,,BAO_0000218,
13549,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,CHEMBL628141,N,1,,,,,1,,BAO_0000218,
13550,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,CHEMBL628142,N,1,,,,,1,,BAO_0000218,
13551,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,CHEMBL628143,N,1,,,,,1,,BAO_0000218,
13552,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,CHEMBL628144,N,1,,,,,1,,BAO_0000218,
13553,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,CHEMBL628145,N,1,,,,,1,,BAO_0000218,
13554,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,CHEMBL628146,N,1,,,,,1,,BAO_0000218,
13555,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,CHEMBL625355,N,1,,,,,1,,BAO_0000218,
13556,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,CHEMBL625356,N,1,,,,,1,,BAO_0000218,
13557,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,CHEMBL625357,N,1,,,,,1,,BAO_0000218,
13558,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,CHEMBL625527,N,1,,,,,1,,BAO_0000218,
13559,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),CHEMBL875473,N,1,,,,,1,,BAO_0000218,
13560,,Intermediate,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,CHEMBL625528,N,1,,,,,1,,BAO_0000218,
13561,,Intermediate,,50597,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,CHEMBL626304,N,1,,,,,1,,BAO_0000218,
13562,1637.0,Intermediate,Artery,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,CHEMBL624138,N,1,,,,,1,,BAO_0000218,
13563,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624139,U,0,,,,,1,,BAO_0000100,
13564,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624140,U,0,,,,,1,,BAO_0000100,
13565,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624141,U,0,,,,,1,,BAO_0000100,
13566,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624142,U,0,,,,,1,,BAO_0000100,
13567,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624143,U,0,,,,,1,,BAO_0000100,
13568,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624144,U,0,,,,,1,,BAO_0000100,
13569,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624145,U,0,,,,,1,,BAO_0000100,
13570,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624146,U,0,,,,,1,,BAO_0000100,
13571,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624147,U,0,,,,,1,,BAO_0000100,
13572,,Autocuration,,22229,Calculated partition coefficient (clogP) (MacLogP),CHEMBL883123,U,0,,,,,1,,BAO_0000100,
13573,,Autocuration,,22224,Partition coefficient (logP),CHEMBL624148,U,0,,,,,1,,BAO_0000019,
13574,,Autocuration,,22224,Kinetic parameter was determined,CHEMBL874416,U,0,,,,,1,,BAO_0000019,
13575,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624149,U,0,,,,,1,,BAO_0000100,
13576,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL624150,U,0,,,,,1,,BAO_0000100,
13577,,Autocuration,,22224,Lipophilicity was determined,CHEMBL624151,U,0,,,,,1,,BAO_0000100,
13578,,Autocuration,,22224,Lipophilicity was determined,CHEMBL624152,U,0,,,,,1,,BAO_0000100,
13579,,Autocuration,,22224,Lipophilicity was determined,CHEMBL622139,U,0,,,,,1,,BAO_0000100,
13580,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL622140,U,0,,,,,1,,BAO_0000100,
13581,,Autocuration,,22224,Lipophilicity was determined,CHEMBL622141,U,0,,,,,1,,BAO_0000100,
13582,,Autocuration,,22224,Lipophilicity in octanol-water,CHEMBL622142,U,0,,,,,1,,BAO_0000100,
13583,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL622143,U,0,,,,,1,,BAO_0000100,
13584,,Autocuration,,22229,Octanol-water partition coefficient was determined,CHEMBL622144,U,0,,,,,1,,BAO_0000100,
13585,,Autocuration,,22224,Partition coefficient (logP),CHEMBL877473,U,0,,,,,1,,BAO_0000019,
13586,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL622145,U,0,,,,,1,,BAO_0000100,
13587,,Autocuration,,22224,Partition coefficient was determined; ND means not determined,CHEMBL622146,U,0,,,,,1,,BAO_0000019,
13588,,Autocuration,,22229,Calculated partition coefficient (clogP),CHEMBL622147,U,0,,,,,1,,BAO_0000100,
13589,,Autocuration,,22224,Partition coefficient of the compound,CHEMBL622148,U,0,,,,,1,,BAO_0000019,
13590,,Autocuration,,22224,Permeability was determined,CHEMBL883124,U,0,,,,,1,,BAO_0000019,
13591,,Autocuration,,22229,The compound was evaluated for the partition coefficient,CHEMBL622149,U,0,,,,,1,,BAO_0000100,
13592,,Autocuration,,22224,Partition coefficient (logP),CHEMBL622150,U,0,,,,,1,,BAO_0000019,
13593,,Autocuration,,22224,The lipophilicity was reported,CHEMBL622151,U,0,,,,,1,,BAO_0000100,
13594,,Autocuration,,22229,logarithm of the octanol-water partition coefficient for the compound,CHEMBL622152,U,0,,,,,1,,BAO_0000100,
13595,,Autocuration,,22224,Clogp value was determined,CHEMBL622153,U,0,,,,,1,,BAO_0000019,
13596,,Autocuration,,22224,Clp at a dose of 1.5 mg/kg,CHEMBL877474,U,0,,,,,1,,BAO_0000218,
13597,,Autocuration,,22224,Clp at a dose of 2.0 mg/kg,CHEMBL622154,U,0,,,,,1,,BAO_0000218,
13598,1969.0,Autocuration,Plasma,22224,"Clp, plasma clearance at a dose of 10 mg/kg",CHEMBL622155,U,0,,,,,1,,BAO_0000218,
13599,1969.0,Autocuration,Plasma,22224,"Clp, plasma clearance at a dose of 50 mg/kg",CHEMBL622156,U,0,,,,,1,,BAO_0000218,
13600,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma clearance in rat,CHEMBL622157,N,1,,,,,1,,BAO_0000218,
13601,1969.0,Intermediate,Plasma,50597,Compound was tested for plasma clearance in rat; Not determined,CHEMBL622158,N,1,,,,,1,,BAO_0000218,
13602,,Intermediate,,50597,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,CHEMBL622807,N,1,,,,,1,,BAO_0000218,
13603,,Intermediate,,50797,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,CHEMBL622808,N,1,,,,,1,,BAO_0000218,
13604,,Autocuration,,22224,Plasma clearance by iv administration at a dose 0.003 ug/mL,CHEMBL622809,U,0,,,,,1,,BAO_0000218,
13605,,Autocuration,,22224,Plasma clearance determined,CHEMBL622810,U,0,,,,,1,,BAO_0000218,
13606,,Intermediate,,100712,Plasma clearance after iv administration at 3 mg/kg in hamster,CHEMBL876653,N,1,,,,,1,,BAO_0000218,
13607,,Intermediate,,100712,Plasma clearance after iv administration at 4 mg/kg in hamster,CHEMBL622811,N,1,,,,,1,,BAO_0000218,
13608,,Intermediate,,50597,Rate of clearance in rat was determined,CHEMBL622986,N,1,,,,,1,,BAO_0000218,
13609,1969.0,Intermediate,Plasma,50597,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,CHEMBL622987,N,1,,,,,1,,BAO_0000218,
13610,1969.0,Intermediate,Plasma,50597,Total plasma clearance after iv dose of 5.10 mg/kg in rats,CHEMBL622988,N,1,,,,,1,,BAO_0000218,
13611,1969.0,Intermediate,Plasma,50597,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,CHEMBL622989,N,1,,,,,1,,BAO_0000218,
13612,1969.0,Intermediate,Plasma,50597,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,CHEMBL622990,N,1,,,,,1,,BAO_0000218,
13613,1969.0,Autocuration,Plasma,22224,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,CHEMBL622991,U,0,,,,,1,,BAO_0000218,
13614,1969.0,Intermediate,Plasma,50597,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,CHEMBL622227,N,1,,,,,1,,BAO_0000218,
13615,1969.0,Intermediate,Plasma,50588,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,CHEMBL622228,N,1,,,,,1,,BAO_0000218,
13616,,Intermediate,,50597,Clpl value in rat,CHEMBL622229,N,1,,,,,1,,BAO_0000218,
13617,,Intermediate,,50512,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,CHEMBL622230,N,1,,,,,1,,BAO_0000218,
13618,,Intermediate,,50597,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,CHEMBL622231,N,1,,,,,1,,BAO_0000218,
13619,,Intermediate,,100710,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,CHEMBL622232,N,1,,,,,1,,BAO_0000218,
13620,,Autocuration,,22224,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,CHEMBL622233,U,0,,,,,1,,BAO_0000218,
13621,,Autocuration,,22224,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,CHEMBL622234,U,0,,,,,1,,BAO_0000218,
13622,,Autocuration,,22224,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,CHEMBL622235,U,0,,,,,1,,BAO_0000218,
13623,,Autocuration,,22224,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,CHEMBL622236,U,0,,,,,1,,BAO_0000218,
13624,,Autocuration,,22224,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,CHEMBL622237,U,0,,,,,1,,BAO_0000218,
13625,,Autocuration,,22224,Cmax in minutes at a po dose of 10.0(pmol/g/h).,CHEMBL877482,U,0,,,,,1,,BAO_0000218,
13626,,Autocuration,,22224,Cmax in minutes at a po dose of 20.0(pmol/g/h).,CHEMBL622238,U,0,,,,,1,,BAO_0000218,
13627,,Autocuration,,22224,Cmax in minutes at a po dose of 40.0(pmol/g/h).,CHEMBL622239,U,0,,,,,1,,BAO_0000218,
13628,178.0,Autocuration,Blood,22224,Cmax was calculated as maximum concentration reached in the blood,CHEMBL622240,U,0,,,,,1,,BAO_0000218,
13629,178.0,Autocuration,Blood,22224,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,CHEMBL622241,U,0,,,,,1,,BAO_0000218,
13630,,Intermediate,,50597,Cmax was determine after peroral administration at 10 mpk in Rat,CHEMBL631013,N,1,,,,,1,,BAO_0000218,
13631,,Intermediate,,50797,Cmax was determine after peroral administration at 10 mpk in Rhesus,CHEMBL631014,N,1,,,,,1,,BAO_0000218,
13632,,Intermediate,,50588,Cmax was determine after peroral administration at 10 mpk in dog,CHEMBL631015,N,1,,,,,1,,BAO_0000218,
13633,,Intermediate,,50597,Cmax was determine after peroral administration at 160 mpk in Rat,CHEMBL631016,N,1,,,,,1,,BAO_0000218,
13634,,Intermediate,,50597,Cmax was determine after peroral administration at 20 mpk in Rat,CHEMBL631017,N,1,,,,,1,,BAO_0000218,
13635,,Intermediate,,50597,Cmax was determine after peroral administration at 50 mpk in Rat,CHEMBL631018,N,1,,,,,1,,BAO_0000218,
13636,,Autocuration,,22224,Cmax was determined,CHEMBL631019,U,0,,,,,1,,BAO_0000218,
13637,955.0,Intermediate,Brain,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,CHEMBL875761,N,1,,,,,1,,BAO_0000218,
13638,955.0,Intermediate,Brain,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,CHEMBL631020,N,1,,,,,1,,BAO_0000218,
13639,955.0,Intermediate,Brain,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,CHEMBL631669,N,1,,,,,1,,BAO_0000218,
13640,955.0,Intermediate,Brain,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,CHEMBL631670,N,1,,,,,1,,BAO_0000218,
13641,2435.0,Intermediate,Striatum,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,CHEMBL631671,N,1,,,,,1,,BAO_0000218,
13642,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,CHEMBL631672,N,1,,,,,1,,BAO_0000218,
13643,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,CHEMBL631673,N,1,,,,,1,,BAO_0000218,
13644,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,CHEMBL631856,N,1,,,,,1,,BAO_0000218,
13645,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,CHEMBL631857,N,1,,,,,1,,BAO_0000218,
13646,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,CHEMBL631858,N,1,,,,,1,,BAO_0000218,
13647,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,CHEMBL631859,N,1,,,,,1,,BAO_0000218,
13648,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,CHEMBL631860,N,1,,,,,1,,BAO_0000218,
13649,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,CHEMBL631861,N,1,,,,,1,,BAO_0000218,
13650,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,CHEMBL631862,N,1,,,,,1,,BAO_0000218,
13651,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,CHEMBL631863,N,1,,,,,1,,BAO_0000218,
13652,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,CHEMBL631864,N,1,,,,,1,,BAO_0000218,
13653,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,CHEMBL631865,N,1,,,,,1,,BAO_0000218,
13654,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,CHEMBL631866,N,1,,,,,1,,BAO_0000218,
13655,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,CHEMBL629360,N,1,,,,,1,,BAO_0000218,
13656,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,CHEMBL629361,N,1,,,,,1,,BAO_0000218,
13657,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,CHEMBL629362,N,1,,,,,1,,BAO_0000218,
13658,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,CHEMBL630740,N,1,,,,,1,,BAO_0000218,
13659,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,CHEMBL630741,N,1,,,,,1,,BAO_0000218,
13660,178.0,Intermediate,Blood,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,CHEMBL630742,N,1,,,,,1,,BAO_0000218,
13661,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,CHEMBL630743,N,1,,,,,1,,BAO_0000218,
13662,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,CHEMBL630744,N,1,,,,,1,,BAO_0000218,
13663,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,CHEMBL630745,N,1,,,,,1,,BAO_0000218,
13664,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,CHEMBL630746,N,1,,,,,1,,BAO_0000218,
13665,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,CHEMBL630747,N,1,,,,,1,,BAO_0000218,
13666,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,CHEMBL630748,N,1,,,,,1,,BAO_0000218,
13667,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,CHEMBL632056,N,1,,,,,1,,BAO_0000218,
13668,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,CHEMBL632057,N,1,,,,,1,,BAO_0000218,
13669,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,CHEMBL632058,N,1,,,,,1,,BAO_0000218,
13670,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,CHEMBL632059,N,1,,,,,1,,BAO_0000218,
13671,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,CHEMBL632060,N,1,,,,,1,,BAO_0000218,
13672,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,CHEMBL632061,N,1,,,,,1,,BAO_0000218,
13673,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,CHEMBL629207,N,1,,,,,1,,BAO_0000218,
13674,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,CHEMBL629208,N,1,,,,,1,,BAO_0000218,
13675,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,CHEMBL629209,N,1,,,,,1,,BAO_0000218,
13676,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,CHEMBL629210,N,1,,,,,1,,BAO_0000218,
13677,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,CHEMBL629211,N,1,,,,,1,,BAO_0000218,
13678,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,CHEMBL629212,N,1,,,,,1,,BAO_0000218,
13679,,Intermediate,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,CHEMBL629213,N,1,,,,,1,,BAO_0000218,
13680,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",CHEMBL629214,N,1,,,,,1,,BAO_0000218,
13681,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",CHEMBL629215,N,1,,,,,1,,BAO_0000218,
13682,1088.0,Intermediate,Urine,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",CHEMBL635154,N,1,,,,,1,,BAO_0000218,
13683,,Intermediate,,50597,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),CHEMBL629216,N,1,,,,,1,,BAO_0000218,
13684,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,CHEMBL629217,N,1,,,,,1,,BAO_0000218,
13685,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),CHEMBL629218,N,1,,,,,1,,BAO_0000218,
13686,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),CHEMBL629219,N,1,,,,,1,,BAO_0000218,
13687,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),CHEMBL629220,N,1,,,,,1,,BAO_0000218,
13688,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),CHEMBL629221,N,1,,,,,1,,BAO_0000218,
13689,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),CHEMBL631127,N,1,,,,,1,,BAO_0000218,
13690,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,CHEMBL631128,N,1,,,,,1,,BAO_0000218,
13691,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),CHEMBL631129,N,1,,,,,1,,BAO_0000218,
13692,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),CHEMBL631130,N,1,,,,,1,,BAO_0000218,
13693,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),CHEMBL631131,N,1,,,,,1,,BAO_0000218,
13694,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),CHEMBL631132,N,1,,,,,1,,BAO_0000218,
13695,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),CHEMBL631133,N,1,,,,,1,,BAO_0000218,
13696,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,CHEMBL631134,N,1,,,,,1,,BAO_0000218,
13697,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),CHEMBL875120,N,1,,,,,1,,BAO_0000218,
13698,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),CHEMBL631135,N,1,,,,,1,,BAO_0000218,
13699,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),CHEMBL631136,N,1,,,,,1,,BAO_0000218,
13700,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),CHEMBL631137,N,1,,,,,1,,BAO_0000218,
13701,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),CHEMBL631138,N,1,,,,,1,,BAO_0000218,
13702,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,CHEMBL631139,N,1,,,,,1,,BAO_0000218,
13703,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),CHEMBL631140,N,1,,,,,1,,BAO_0000218,
13704,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),CHEMBL631141,N,1,,,,,1,,BAO_0000218,
13705,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),CHEMBL631142,N,1,,,,,1,,BAO_0000218,
13706,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),CHEMBL631143,N,1,,,,,1,,BAO_0000218,
13707,,Intermediate,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),CHEMBL631144,N,1,,,,,1,,BAO_0000218,
13708,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,CHEMBL631145,N,1,,,,,1,,BAO_0000218,
13709,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),CHEMBL631146,N,1,,,,,1,,BAO_0000218,
13710,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,CHEMBL631147,N,1,,,,,1,,BAO_0000218,
13711,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),CHEMBL631148,N,1,,,,,1,,BAO_0000218,
13712,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),CHEMBL631149,N,1,,,,,1,,BAO_0000218,
13713,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),CHEMBL631150,N,1,,,,,1,,BAO_0000218,
13714,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),CHEMBL631151,N,1,,,,,1,,BAO_0000218,
13715,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),CHEMBL631152,N,1,,,,,1,,BAO_0000218,
13716,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),CHEMBL631443,N,1,,,,,1,,BAO_0000218,
13717,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),CHEMBL631444,N,1,,,,,1,,BAO_0000218,
13718,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),CHEMBL631445,N,1,,,,,1,,BAO_0000218,
13719,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),CHEMBL631446,N,1,,,,,1,,BAO_0000218,
13720,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),CHEMBL631447,N,1,,,,,1,,BAO_0000218,
13721,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),CHEMBL631448,N,1,,,,,1,,BAO_0000218,
13722,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,CHEMBL631449,N,1,,,,,1,,BAO_0000218,
13723,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),CHEMBL631450,N,1,,,,,1,,BAO_0000218,
13724,,Intermediate,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),CHEMBL629724,N,1,,,,,1,,BAO_0000218,
13725,14.0,Intermediate,Zone of skin,50594,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL629725,N,1,,,,,1,,BAO_0000218,
13726,14.0,Intermediate,Zone of skin,50594,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL629726,N,1,,,,,1,,BAO_0000218,
13727,2106.0,Intermediate,Spleen,50594,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL629727,N,1,,,,,1,,BAO_0000218,
13728,2106.0,Intermediate,Spleen,50594,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630404,N,1,,,,,1,,BAO_0000218,
13729,2106.0,Intermediate,Spleen,50594,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630405,N,1,,,,,1,,BAO_0000218,
13730,2106.0,Intermediate,Spleen,50594,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630406,N,1,,,,,1,,BAO_0000218,
13731,945.0,Intermediate,Stomach,50594,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630407,N,1,,,,,1,,BAO_0000218,
13732,945.0,Intermediate,Stomach,50594,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630573,N,1,,,,,1,,BAO_0000218,
13733,945.0,Intermediate,Stomach,50594,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630574,N,1,,,,,1,,BAO_0000218,
13734,945.0,Intermediate,Stomach,50594,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630575,N,1,,,,,1,,BAO_0000218,
13735,,Intermediate,,50594,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630576,N,1,,,,,1,,BAO_0000218,
13736,,Intermediate,,50594,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630577,N,1,,,,,1,,BAO_0000218,
13737,,Intermediate,,50594,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630578,N,1,,,,,1,,BAO_0000218,
13738,,Intermediate,,50594,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",CHEMBL630579,N,1,,,,,1,,BAO_0000218,
13739,2113.0,Intermediate,Kidney,50594,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),CHEMBL630580,N,1,,,,,1,,BAO_0000218,
13740,2113.0,Intermediate,Kidney,50594,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,CHEMBL630581,N,1,,,,,1,,BAO_0000218,
13741,2113.0,Intermediate,Kidney,50594,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),CHEMBL630582,N,1,,,,,1,,BAO_0000218,
13742,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,CHEMBL630583,N,1,,,,,1,,BAO_0000218,
13743,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),CHEMBL630584,N,1,,,,,1,,BAO_0000218,
13744,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,CHEMBL630585,N,1,,,,,1,,BAO_0000218,
13745,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),CHEMBL630586,N,1,,,,,1,,BAO_0000218,
13746,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,CHEMBL630587,N,1,,,,,1,,BAO_0000218,
13747,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),CHEMBL630588,N,1,,,,,1,,BAO_0000218,
13748,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,CHEMBL630589,N,1,,,,,1,,BAO_0000218,
13749,,Intermediate,,50594,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),CHEMBL630590,N,1,,,,,1,,BAO_0000218,
13750,1988.0,Autocuration,Feces,22224,Removal of 238-Plutonium(IV) in feces at 24 h,CHEMBL630591,U,0,,,,,1,,BAO_0000019,
13751,1988.0,Autocuration,Feces,22224,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),CHEMBL630592,U,0,,,,,1,,BAO_0000019,
13752,,Autocuration,,22224,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,CHEMBL630593,U,0,,,,,1,,BAO_0000019,
13753,,Autocuration,,22224,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),CHEMBL630594,U,0,,,,,1,,BAO_0000019,
13754,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),CHEMBL630595,U,0,,,,,1,,BAO_0000019,
13755,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),CHEMBL630596,U,0,,,,,1,,BAO_0000019,
13756,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine after 0-24 h,CHEMBL630597,U,0,,,,,1,,BAO_0000019,
13757,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),CHEMBL630598,U,0,,,,,1,,BAO_0000019,
13758,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine after 0-4 h,CHEMBL630599,U,0,,,,,1,,BAO_0000019,
13759,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),CHEMBL630600,U,0,,,,,1,,BAO_0000019,
13760,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine after 4-24 h,CHEMBL630601,U,0,,,,,1,,BAO_0000019,
13761,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),CHEMBL630602,U,0,,,,,1,,BAO_0000019,
13762,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),CHEMBL630603,U,0,,,,,1,,BAO_0000019,
13763,1088.0,Autocuration,Urine,22224,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),CHEMBL630604,U,0,,,,,1,,BAO_0000019,
13764,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL624869,N,1,,,,,1,,BAO_0000218,
13765,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL624870,N,1,,,,,1,,BAO_0000218,
13766,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL623189,N,1,,,,,1,,BAO_0000218,
13767,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623190,N,1,,,,,1,,BAO_0000218,
13768,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623191,N,1,,,,,1,,BAO_0000218,
13769,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623192,N,1,,,,,1,,BAO_0000218,
13770,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623193,N,1,,,,,1,,BAO_0000218,
13771,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL623194,N,1,,,,,1,,BAO_0000218,
13772,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623195,N,1,,,,,1,,BAO_0000218,
13773,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623196,N,1,,,,,1,,BAO_0000218,
13774,,Intermediate,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,CHEMBL623197,N,1,,,,,1,,BAO_0000218,
13775,,Intermediate,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,CHEMBL623198,N,1,,,,,1,,BAO_0000218,
13776,,Intermediate,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,CHEMBL623199,N,1,,,,,1,,BAO_0000218,
13777,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,CHEMBL623200,N,1,,,,,1,,BAO_0000218,
13778,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,CHEMBL623201,N,1,,,,,1,,BAO_0000218,
13779,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,CHEMBL623202,N,1,,,,,1,,BAO_0000218,
13780,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,CHEMBL623203,N,1,,,,,1,,BAO_0000218,
13781,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,CHEMBL623204,N,1,,,,,1,,BAO_0000218,
13782,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,CHEMBL623205,N,1,,,,,1,,BAO_0000218,
13783,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,CHEMBL623206,N,1,,,,,1,,BAO_0000218,
13784,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,CHEMBL623207,N,1,,,,,1,,BAO_0000218,
13785,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,CHEMBL623208,N,1,,,,,1,,BAO_0000218,
13786,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,CHEMBL623209,N,1,,,,,1,,BAO_0000218,
13787,2385.0,Intermediate,Muscle tissue,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,CHEMBL623210,N,1,,,,,1,,BAO_0000218,
13788,,Intermediate,,50597,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,CHEMBL623211,N,1,,,,,1,,BAO_0000218,
13789,995.0,Intermediate,Uterus,50597,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,CHEMBL623212,N,1,,,,,1,,BAO_0000218,
13790,,Autocuration,,22224,Tested in vitro for intrinsic activity relative to quinpirole,CHEMBL623213,U,0,,,,,1,,BAO_0000019,
13791,,Autocuration,,22224,"Relative ion enhancement, determined in pulsed ultrafiltration",CHEMBL623214,U,0,,,,,1,,BAO_0000019,
13792,,Autocuration,,22224,% ionization at the pH 7.4 at 37 degree Centigrade,CHEMBL623215,U,0,,,,,1,,BAO_0000019,
13793,,Autocuration,,22224,Percentage ionization was measured,CHEMBL623216,U,0,,,,,1,,BAO_0000019,
13794,,Intermediate,,50591,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,CHEMBL623217,N,1,,,,,1,,BAO_0000218,
13795,,Autocuration,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,CHEMBL623218,U,0,,,,,1,,BAO_0000019,
13796,,Autocuration,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,CHEMBL623913,U,0,,,,,1,,BAO_0000019,
13797,,Autocuration,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,CHEMBL623914,U,0,,,,,1,,BAO_0000019,
13798,,Autocuration,,22229,Compound was evaluated for the partition coefficient in octanol/water,CHEMBL623915,U,0,,,,,1,,BAO_0000100,
13799,,Autocuration,,22229,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),CHEMBL624080,U,0,,,,,1,,BAO_0000100,
13800,,Autocuration,,22224,Equilibrium constant measured by the pulse radiolysis at pH 7,CHEMBL624081,U,0,,,,,1,,BAO_0000019,
13801,,Intermediate,,50587,In vitro hydrolytic rate constant determined in human blood,CHEMBL624082,N,1,,,,,1,,BAO_0000218,
13802,,Intermediate,,50587,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,CHEMBL625054,N,1,,,,,1,,BAO_0000218,
13803,,Autocuration,,22224,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,CHEMBL877485,U,0,,,,,1,,BAO_0000019,
13804,,Intermediate,,50594,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,CHEMBL625055,N,1,,,,,1,,BAO_0000218,
13805,,Intermediate,,50594,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,CHEMBL625056,N,1,,,,,1,,BAO_0000218,
13806,,Intermediate,,50587,In vitro oxidation of compound in presence of human plasma,CHEMBL625057,N,1,,,,,1,,BAO_0000218,
13807,,Autocuration,,22224,In vitro oxidation of compound in presence of hydrogen peroxide,CHEMBL625058,U,0,,,,,1,,BAO_0000019,
13808,,Intermediate,,50594,In vitro oxidation of compound in presence of mouse brain homogenate,CHEMBL625059,N,1,,,,,1,,BAO_0000218,
13809,,Intermediate,,50594,In vitro oxidation of compound in presence of mouse liver homogenate,CHEMBL629536,N,1,,,,,1,,BAO_0000218,
13810,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,CHEMBL629537,N,1,,,,,1,,BAO_0000218,
13811,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,CHEMBL629538,N,1,,,,,1,,BAO_0000218,
13812,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,CHEMBL629539,N,1,,,,,1,,BAO_0000218,
13813,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,CHEMBL874445,N,1,,,,,1,,BAO_0000218,
13814,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,CHEMBL629540,N,1,,,,,1,,BAO_0000218,
13815,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,CHEMBL629541,N,1,,,,,1,,BAO_0000218,
13816,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,CHEMBL629542,N,1,,,,,1,,BAO_0000218,
13817,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,CHEMBL630243,N,1,,,,,1,,BAO_0000218,
13818,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,CHEMBL630244,N,1,,,,,1,,BAO_0000218,
13819,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,CHEMBL630245,N,1,,,,,1,,BAO_0000218,
13820,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,CHEMBL630246,N,1,,,,,1,,BAO_0000218,
13821,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,CHEMBL630247,N,1,,,,,1,,BAO_0000218,
13822,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,CHEMBL630248,N,1,,,,,1,,BAO_0000218,
13823,178.0,Intermediate,Blood,50597,Biodistribution in rat blood at 240 minutes after dose administration.,CHEMBL630249,N,1,,,,,1,,BAO_0000218,
13824,178.0,Intermediate,Blood,50597,Biodistribution in rat blood at 30 minutes after dose administration.,CHEMBL630250,N,1,,,,,1,,BAO_0000218,
13825,178.0,Intermediate,Blood,50597,Biodistribution in rat blood at 360 minutes after dose administration.,CHEMBL630251,N,1,,,,,1,,BAO_0000218,
13826,178.0,Intermediate,Blood,50597,Biodistribution in rat blood at 3 hr after dose administration.,CHEMBL630252,N,1,,,,,1,,BAO_0000218,
13827,178.0,Intermediate,Blood,50597,Biodistribution in rat blood at 60 minutes after dose administration.,CHEMBL630408,N,1,,,,,1,,BAO_0000218,
13828,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 120 minutes after dose administration.,CHEMBL630409,N,1,,,,,1,,BAO_0000218,
13829,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,CHEMBL874446,N,1,,,,,1,,BAO_0000218,
13830,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 15 minutes after dose administration.,CHEMBL630410,N,1,,,,,1,,BAO_0000218,
13831,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 240 minutes after dose administration.,CHEMBL630411,N,1,,,,,1,,BAO_0000218,
13832,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 30 minutes after dose administration.,CHEMBL630412,N,1,,,,,1,,BAO_0000218,
13833,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 360 minutes after dose administration.,CHEMBL630413,N,1,,,,,1,,BAO_0000218,
13834,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 3 hr after dose administration.,CHEMBL630414,N,1,,,,,1,,BAO_0000218,
13835,2037.0,Intermediate,Cerebellum,50597,Biodistribution in rat cerebellum at 60 minutes after dose administration.,CHEMBL630415,N,1,,,,,1,,BAO_0000218,
13836,,Intermediate,,50597,Biodistribution in rat cortex at 120 minutes after dose administration.,CHEMBL630416,N,1,,,,,1,,BAO_0000218,
13837,,Intermediate,,50597,Biodistribution in rat cortex at 1440 minutes after dose administration.,CHEMBL630417,N,1,,,,,1,,BAO_0000218,
13838,,Intermediate,,50597,Biodistribution in rat cortex at 15 minutes after dose administration.,CHEMBL630418,N,1,,,,,1,,BAO_0000218,
13839,,Intermediate,,50597,Biodistribution in rat cortex at 240 minutes after dose administration.,CHEMBL630419,N,1,,,,,1,,BAO_0000218,
13840,,Intermediate,,50597,Biodistribution in rat cortex at 30 minutes after dose administration.,CHEMBL630420,N,1,,,,,1,,BAO_0000218,
13841,,Intermediate,,50597,Biodistribution in rat cortex at 360 minutes after dose administration.,CHEMBL630421,N,1,,,,,1,,BAO_0000218,
13842,,Intermediate,,50597,Biodistribution in rat cortex at 3 hr after dose administration.,CHEMBL630422,N,1,,,,,1,,BAO_0000218,
13843,,Intermediate,,50597,Biodistribution in rat cortex at 60 minutes after dose administration.,CHEMBL630423,N,1,,,,,1,,BAO_0000218,
13844,948.0,Intermediate,Heart,50597,Biodistribution in rat heart at 120 minutes after dose administration.,CHEMBL630424,N,1,,,,,1,,BAO_0000218,
13845,948.0,Intermediate,Heart,50597,Biodistribution in rat heart at 15 minutes after dose administration.,CHEMBL630425,N,1,,,,,1,,BAO_0000218,
13846,948.0,Intermediate,Heart,50597,Biodistribution in rat heart at 240 minutes after dose administration.,CHEMBL629462,N,1,,,,,1,,BAO_0000218,
13847,948.0,Intermediate,Heart,50597,Biodistribution in rat heart at 30 minutes after dose administration.,CHEMBL630426,N,1,,,,,1,,BAO_0000218,
13848,948.0,Intermediate,Heart,50597,Biodistribution in rat heart at 360 minutes after dose administration.,CHEMBL630427,N,1,,,,,1,,BAO_0000218,
13849,948.0,Intermediate,Heart,50597,Biodistribution in rat heart at 3 hr after dose administration.,CHEMBL625877,N,1,,,,,1,,BAO_0000218,
13850,948.0,Intermediate,Heart,50597,Biodistribution in rat heart at 60 minutes after dose administration.,CHEMBL625878,N,1,,,,,1,,BAO_0000218,
13851,10000000.0,Intermediate,Hippocampus,50597,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,CHEMBL625879,N,1,,,,,1,,BAO_0000218,
13852,10000000.0,Intermediate,Hippocampus,50597,Biodistribution in rat hippocampus at 240 minutes after dose administration.,CHEMBL625880,N,1,,,,,1,,BAO_0000218,
13853,10000000.0,Intermediate,Hippocampus,50597,Biodistribution in rat hippocampus at 30 minutes after dose administration.,CHEMBL625881,N,1,,,,,1,,BAO_0000218,
13854,10000000.0,Intermediate,Hippocampus,50597,Biodistribution in rat hippocampus at 360 minutes after dose administration.,CHEMBL625882,N,1,,,,,1,,BAO_0000218,
13855,10000000.0,Intermediate,Hippocampus,50597,Biodistribution in rat hippocampus at 15 minutes after dose administration.,CHEMBL625883,N,1,,,,,1,,BAO_0000218,
13856,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney at 120 minutes after dose administration.,CHEMBL625884,N,1,,,,,1,,BAO_0000218,
13857,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney at 1440 minutes after dose administration.,CHEMBL625885,N,1,,,,,1,,BAO_0000218,
13858,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney at 15 minutes after dose administration.,CHEMBL628649,N,1,,,,,1,,BAO_0000218,
13859,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney at 240 minutes after dose administration.,CHEMBL628650,N,1,,,,,1,,BAO_0000218,
13860,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney at 30 minutes after dose administration.,CHEMBL628651,N,1,,,,,1,,BAO_0000218,
13861,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney at 360 minutes after dose administration.,CHEMBL628652,N,1,,,,,1,,BAO_0000218,
13862,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney at 60 minutes after dose administration.,CHEMBL628653,N,1,,,,,1,,BAO_0000218,
13863,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver at 120 minutes after dose administration.,CHEMBL628654,N,1,,,,,1,,BAO_0000218,
13864,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver at 1440 minutes after dose administration.,CHEMBL628655,N,1,,,,,1,,BAO_0000218,
13865,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver at 15 minutes after dose administration.,CHEMBL625238,N,1,,,,,1,,BAO_0000218,
13866,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver at 240 minutes after dose administration.,CHEMBL625239,N,1,,,,,1,,BAO_0000218,
13867,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver at 30 minutes after dose administration.,CHEMBL625240,N,1,,,,,1,,BAO_0000218,
13868,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver at 360 minutes after dose administration.,CHEMBL625241,N,1,,,,,1,,BAO_0000218,
13869,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver at 60 minutes after dose administration.,CHEMBL625242,N,1,,,,,1,,BAO_0000218,
13870,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung at 120 minutes after dose administration.,CHEMBL874587,N,1,,,,,1,,BAO_0000218,
13871,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung at 1440 minutes after dose administration.,CHEMBL625405,N,1,,,,,1,,BAO_0000218,
13872,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung at 15 minutes after dose administration.,CHEMBL625406,N,1,,,,,1,,BAO_0000218,
13873,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung at 240 minutes after dose administration.,CHEMBL625407,N,1,,,,,1,,BAO_0000218,
13874,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung at 30 minutes after dose administration.,CHEMBL625408,N,1,,,,,1,,BAO_0000218,
13875,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung at 360 minutes after dose administration.,CHEMBL625409,N,1,,,,,1,,BAO_0000218,
13876,1515.0,Intermediate,Thoracic aorta,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,CHEMBL625410,N,1,,,,,1,,BAO_0000218,
13877,1515.0,Intermediate,Thoracic aorta,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,CHEMBL625411,N,1,,,,,1,,BAO_0000218,
13878,1515.0,Intermediate,Thoracic aorta,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,CHEMBL625412,N,1,,,,,1,,BAO_0000218,
13879,1515.0,Intermediate,Thoracic aorta,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,CHEMBL625413,N,1,,,,,1,,BAO_0000218,
13880,1515.0,Intermediate,Thoracic aorta,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips v,CHEMBL625414,N,1,,,,,1,,BAO_0000218,
13881,1515.0,Intermediate,Thoracic aorta,50597,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,CHEMBL625415,N,1,,,,,1,,BAO_0000218,
13882,1515.0,Intermediate,Thoracic aorta,50597,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,CHEMBL625416,N,1,,,,,1,,BAO_0000218,
13883,1088.0,Intermediate,Urine,50597,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,CHEMBL625417,N,1,,,,,1,,BAO_0000218,
13884,1988.0,Intermediate,Feces,50597,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,CHEMBL625418,N,1,,,,,1,,BAO_0000218,
13885,1088.0,Intermediate,Urine,50597,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,CHEMBL625419,N,1,,,,,1,,BAO_0000218,
13886,,Intermediate,,50597,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,CHEMBL625420,N,1,,,,,1,,BAO_0000218,
13887,,Intermediate,,50597,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,CHEMBL626996,N,1,,,,,1,,BAO_0000218,
13888,1988.0,Intermediate,Feces,50597,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",CHEMBL626997,N,1,,,,,1,,BAO_0000218,
13889,1088.0,Intermediate,Urine,50597,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",CHEMBL626998,N,1,,,,,1,,BAO_0000218,
13890,,Intermediate,,50597,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",CHEMBL626999,N,1,,,,,1,,BAO_0000218,
13891,,Intermediate,,50594,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,CHEMBL627000,N,1,,,,,1,,BAO_0000218,
13892,,Intermediate,,50594,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,CHEMBL627001,N,1,,,,,1,,BAO_0000218,
13893,,Intermediate,,50594,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,CHEMBL627002,N,1,,,,,1,,BAO_0000218,
13894,,Intermediate,,50594,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,CHEMBL627003,N,1,,,,,1,,BAO_0000218,
13895,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,CHEMBL627004,N,1,,,,,1,,BAO_0000218,
13896,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,CHEMBL627005,N,1,,,,,1,,BAO_0000218,
13897,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,CHEMBL874594,N,1,,,,,1,,BAO_0000218,
13898,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,CHEMBL627006,N,1,,,,,1,,BAO_0000218,
13899,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,CHEMBL627007,N,1,,,,,1,,BAO_0000218,
13900,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,CHEMBL627884,N,1,,,,,1,,BAO_0000218,
13901,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,CHEMBL627885,N,1,,,,,1,,BAO_0000218,
13902,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,CHEMBL627886,N,1,,,,,1,,BAO_0000218,
13903,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,CHEMBL627887,N,1,,,,,1,,BAO_0000218,
13904,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,CHEMBL627888,N,1,,,,,1,,BAO_0000218,
13905,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,CHEMBL628057,N,1,,,,,1,,BAO_0000218,
13906,1088.0,Intermediate,Urine,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,CHEMBL627405,N,1,,,,,1,,BAO_0000218,
13907,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,CHEMBL627406,N,1,,,,,1,,BAO_0000218,
13908,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,CHEMBL627407,N,1,,,,,1,,BAO_0000218,
13909,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,CHEMBL627408,N,1,,,,,1,,BAO_0000218,
13910,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,CHEMBL627409,N,1,,,,,1,,BAO_0000218,
13911,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,CHEMBL875486,N,1,,,,,1,,BAO_0000218,
13912,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,CHEMBL627410,N,1,,,,,1,,BAO_0000218,
13913,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,CHEMBL627411,N,1,,,,,1,,BAO_0000218,
13914,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,CHEMBL627412,N,1,,,,,1,,BAO_0000218,
13915,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,CHEMBL627413,N,1,,,,,1,,BAO_0000218,
13916,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,CHEMBL627414,N,1,,,,,1,,BAO_0000218,
13917,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,CHEMBL627415,N,1,,,,,1,,BAO_0000218,
13918,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,CHEMBL627416,N,1,,,,,1,,BAO_0000218,
13919,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,CHEMBL627417,N,1,,,,,1,,BAO_0000218,
13920,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,CHEMBL627418,N,1,,,,,1,,BAO_0000218,
13921,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,CHEMBL627419,N,1,,,,,1,,BAO_0000218,
13922,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,CHEMBL627320,N,1,,,,,1,,BAO_0000218,
13923,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,CHEMBL627321,N,1,,,,,1,,BAO_0000218,
13924,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627322,N,1,,,,,1,,BAO_0000218,
13925,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627323,N,1,,,,,1,,BAO_0000218,
13926,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL627491,N,1,,,,,1,,BAO_0000218,
13927,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627492,N,1,,,,,1,,BAO_0000218,
13928,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627493,N,1,,,,,1,,BAO_0000218,
13929,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627494,N,1,,,,,1,,BAO_0000218,
13930,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627495,N,1,,,,,1,,BAO_0000218,
13931,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL627496,N,1,,,,,1,,BAO_0000218,
13932,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627497,N,1,,,,,1,,BAO_0000218,
13933,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627498,N,1,,,,,1,,BAO_0000218,
13934,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627499,N,1,,,,,1,,BAO_0000218,
13935,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL627500,N,1,,,,,1,,BAO_0000218,
13936,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL627501,N,1,,,,,1,,BAO_0000218,
13937,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625616,N,1,,,,,1,,BAO_0000218,
13938,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625617,N,1,,,,,1,,BAO_0000218,
13939,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625618,N,1,,,,,1,,BAO_0000218,
13940,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625619,N,1,,,,,1,,BAO_0000218,
13941,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL625620,N,1,,,,,1,,BAO_0000218,
13942,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625621,N,1,,,,,1,,BAO_0000218,
13943,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625622,N,1,,,,,1,,BAO_0000218,
13944,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625788,N,1,,,,,1,,BAO_0000218,
13945,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625789,N,1,,,,,1,,BAO_0000218,
13946,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL625790,N,1,,,,,1,,BAO_0000218,
13947,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL625791,N,1,,,,,1,,BAO_0000218,
13948,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL622334,N,1,,,,,1,,BAO_0000218,
13949,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL622335,N,1,,,,,1,,BAO_0000218,
13950,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL622336,N,1,,,,,1,,BAO_0000218,
13951,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL622337,N,1,,,,,1,,BAO_0000218,
13952,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL622338,N,1,,,,,1,,BAO_0000218,
13953,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL622339,N,1,,,,,1,,BAO_0000218,
13954,,Intermediate,,50597,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL624153,N,1,,,,,1,,BAO_0000218,
13955,,Intermediate,,50597,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL628430,N,1,,,,,1,,BAO_0000218,
13956,,Intermediate,,50597,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL628431,N,1,,,,,1,,BAO_0000218,
13957,,Intermediate,,50597,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL628432,N,1,,,,,1,,BAO_0000218,
13958,,Intermediate,,50597,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL628433,N,1,,,,,1,,BAO_0000218,
13959,2106.0,Intermediate,Spleen,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",CHEMBL628434,N,1,,,,,1,,BAO_0000218,
13960,2106.0,Intermediate,Spleen,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",CHEMBL626789,N,1,,,,,1,,BAO_0000218,
13961,2106.0,Intermediate,Spleen,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",CHEMBL626790,N,1,,,,,1,,BAO_0000218,
13962,2106.0,Intermediate,Spleen,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",CHEMBL626791,N,1,,,,,1,,BAO_0000218,
13963,2106.0,Intermediate,Spleen,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",CHEMBL626792,N,1,,,,,1,,BAO_0000218,
13964,2106.0,Intermediate,Spleen,50597,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",CHEMBL626793,N,1,,,,,1,,BAO_0000218,
13965,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,CHEMBL627436,N,1,,,,,1,,BAO_0000218,
13966,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,CHEMBL627437,N,1,,,,,1,,BAO_0000218,
13967,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,CHEMBL627438,N,1,,,,,1,,BAO_0000218,
13968,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,CHEMBL627439,N,1,,,,,1,,BAO_0000218,
13969,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,CHEMBL627440,N,1,,,,,1,,BAO_0000218,
13970,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,CHEMBL627602,N,1,,,,,1,,BAO_0000218,
13971,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,CHEMBL627603,N,1,,,,,1,,BAO_0000218,
13972,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,CHEMBL627604,N,1,,,,,1,,BAO_0000218,
13973,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,CHEMBL627605,N,1,,,,,1,,BAO_0000218,
13974,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,CHEMBL627606,N,1,,,,,1,,BAO_0000218,
13975,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,CHEMBL627607,N,1,,,,,1,,BAO_0000218,
13976,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,CHEMBL627608,N,1,,,,,1,,BAO_0000218,
13977,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,CHEMBL627609,N,1,,,,,1,,BAO_0000218,
13978,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,CHEMBL627610,N,1,,,,,1,,BAO_0000218,
13979,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,CHEMBL627611,N,1,,,,,1,,BAO_0000218,
13980,,Intermediate,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,CHEMBL627612,N,1,,,,,1,,BAO_0000218,
13981,,Autocuration,,22229,Octanol:water partition coefficient is evaluated,CHEMBL627613,U,0,,,,,1,,BAO_0000100,
13982,,Autocuration,,22224,Partition coefficient in 1-octanol/water system,CHEMBL627614,U,0,,,,,1,,BAO_0000100,
13983,,Autocuration,,22224,Partition coefficient in 1-octanol/water system measured using radio active compounds,CHEMBL627615,U,0,,,,,1,,BAO_0000100,
13984,,Autocuration,,22224,Partition coefficient in octanol/water system was determined,CHEMBL627616,U,0,,,,,1,,BAO_0000100,
13985,,Autocuration,,22224,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,CHEMBL627617,U,0,,,,,1,,BAO_0000100,
13986,,Autocuration,,22224,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,CHEMBL627618,U,0,,,,,1,,BAO_0000019,
13987,,Autocuration,,22224,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",CHEMBL627619,U,0,,,,,1,,BAO_0000019,
13988,,Autocuration,,22224,Pseudo-first-order rate constant of the compound,CHEMBL627620,U,0,,,,,1,,BAO_0000019,
13989,,Autocuration,,22224,Pseudo-first-order rate constant with 1-min time point,CHEMBL627621,U,0,,,,,1,,BAO_0000019,
13990,,Autocuration,,22224,Pseudo-first-order rate constant without 1-min time point,CHEMBL627622,U,0,,,,,1,,BAO_0000019,
13991,,Autocuration,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,CHEMBL627623,U,0,,,,,1,,BAO_0000019,
13992,,Autocuration,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,CHEMBL627624,U,0,,,,,1,,BAO_0000019,
13993,,Autocuration,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,CHEMBL627625,U,0,,,,,1,,BAO_0000019,
13994,,Autocuration,,22224,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,CHEMBL628523,U,0,,,,,1,,BAO_0000019,
13995,,Autocuration,,22224,The alkaline hydrolysis second order rate constant(K OH) of the compound,CHEMBL628524,U,0,,,,,1,,BAO_0000019,
13996,,Autocuration,,22224,The efflux rate constant of the compound,CHEMBL628525,U,0,,,,,1,,BAO_0000019,
13997,,Autocuration,,22224,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,CHEMBL625732,U,0,,,,,1,,BAO_0000019,
13998,,Autocuration,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,CHEMBL625733,U,0,,,,,1,,BAO_0000019,
13999,,Autocuration,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,CHEMBL625734,U,0,,,,,1,,BAO_0000019,
14000,,Autocuration,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,CHEMBL625913,U,0,,,,,1,,BAO_0000019,
14001,,Autocuration,,22224,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,CHEMBL625914,U,0,,,,,1,,BAO_0000019,
14002,,Autocuration,,22224,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,CHEMBL625915,U,0,,,,,1,,BAO_0000019,
14003,,Autocuration,,22224,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,CHEMBL625916,U,0,,,,,1,,BAO_0000019,
14004,,Autocuration,,22224,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),CHEMBL625917,U,0,,,,,1,,BAO_0000019,
14005,,Autocuration,,22224,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL625918,U,0,,,,,1,,BAO_0000019,
14006,,Autocuration,,22224,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL625919,U,0,,,,,1,,BAO_0000019,
14007,,Autocuration,,22224,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL625920,U,0,,,,,1,,BAO_0000019,
14008,,Autocuration,,22224,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL874453,U,0,,,,,1,,BAO_0000019,
14009,,Autocuration,,22224,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",CHEMBL625921,U,0,,,,,1,,BAO_0000019,
14010,,Autocuration,,22224,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,CHEMBL625922,U,0,,,,,1,,BAO_0000019,
14011,,Autocuration,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL625923,U,0,,,,,1,,BAO_0000019,
14012,,Autocuration,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL625924,U,0,,,,,1,,BAO_0000019,
14013,,Autocuration,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL625925,U,0,,,,,1,,BAO_0000019,
14014,,Autocuration,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL625926,U,0,,,,,1,,BAO_0000019,
14015,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung at 60 minutes after dose administration.,CHEMBL627704,N,1,,,,,1,,BAO_0000218,
14016,,Intermediate,,50597,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,CHEMBL627705,N,1,,,,,1,,BAO_0000218,
14017,,Intermediate,,50597,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,CHEMBL627706,N,1,,,,,1,,BAO_0000218,
14018,,Intermediate,,50597,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,CHEMBL627707,N,1,,,,,1,,BAO_0000218,
14019,,Intermediate,,50597,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,CHEMBL627708,N,1,,,,,1,,BAO_0000218,
14020,,Intermediate,,50597,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,CHEMBL628361,N,1,,,,,1,,BAO_0000218,
14021,,Intermediate,,50597,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,CHEMBL628362,N,1,,,,,1,,BAO_0000218,
14022,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 120 minutes after dose administration.,CHEMBL628363,N,1,,,,,1,,BAO_0000218,
14023,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 1440 minutes after dose administration.,CHEMBL628364,N,1,,,,,1,,BAO_0000218,
14024,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 15 minutes after dose administration.,CHEMBL628365,N,1,,,,,1,,BAO_0000218,
14025,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 240 minutes after dose administration.,CHEMBL874454,N,1,,,,,1,,BAO_0000218,
14026,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 30 minutes after dose administration.,CHEMBL628531,N,1,,,,,1,,BAO_0000218,
14027,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 360 minutes after dose administration.,CHEMBL628532,N,1,,,,,1,,BAO_0000218,
14028,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 3 hr after dose administration.,CHEMBL628533,N,1,,,,,1,,BAO_0000218,
14029,2435.0,Intermediate,Striatum,50597,Biodistribution in rat striatum at 60 minutes after dose administration.,CHEMBL628534,N,1,,,,,1,,BAO_0000218,
14030,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in rat thyroid at 120 minutes after dose administration.,CHEMBL628535,N,1,,,,,1,,BAO_0000218,
14031,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in rat thyroid at 1440 minutes after dose administration.,CHEMBL628536,N,1,,,,,1,,BAO_0000218,
14032,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in rat thyroid at 15 minutes after dose administration.,CHEMBL628537,N,1,,,,,1,,BAO_0000218,
14033,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in rat thyroid at 240 minutes after dose administration.,CHEMBL628538,N,1,,,,,1,,BAO_0000218,
14034,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in rat thyroid at 30 minutes after dose administration.,CHEMBL628539,N,1,,,,,1,,BAO_0000218,
14035,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in rat thyroid at 360 minutes after dose administration.,CHEMBL630297,N,1,,,,,1,,BAO_0000218,
14036,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in rat thyroid at 60 minutes after dose administration.,CHEMBL630298,N,1,,,,,1,,BAO_0000218,
14037,955.0,Intermediate,Brain,50597,Biodistribution in rest of brain of rat 120 minutes after dose administration.,CHEMBL630299,N,1,,,,,1,,BAO_0000218,
14038,955.0,Intermediate,Brain,50597,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,CHEMBL628094,N,1,,,,,1,,BAO_0000218,
14039,955.0,Intermediate,Brain,50597,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,CHEMBL628095,N,1,,,,,1,,BAO_0000218,
14040,955.0,Intermediate,Brain,50597,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,CHEMBL874648,N,1,,,,,1,,BAO_0000218,
14041,955.0,Intermediate,Brain,50597,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,CHEMBL628096,N,1,,,,,1,,BAO_0000218,
14042,955.0,Intermediate,Brain,50597,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,CHEMBL628097,N,1,,,,,1,,BAO_0000218,
14043,955.0,Intermediate,Brain,50597,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,CHEMBL628098,N,1,,,,,1,,BAO_0000218,
14044,,Autocuration,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",CHEMBL628099,U,0,,,,,1,,BAO_0000019,
14045,,Autocuration,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",CHEMBL628100,U,0,,,,,1,,BAO_0000019,
14046,,Autocuration,,22224,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),CHEMBL628101,U,0,,,,,1,,BAO_0000019,
14047,,Autocuration,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",CHEMBL628102,U,0,,,,,1,,BAO_0000019,
14048,,Autocuration,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",CHEMBL628103,U,0,,,,,1,,BAO_0000019,
14049,,Autocuration,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",CHEMBL628104,U,0,,,,,1,,BAO_0000019,
14050,,Autocuration,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",CHEMBL628105,U,0,,,,,1,,BAO_0000019,
14051,,Autocuration,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",CHEMBL628106,U,0,,,,,1,,BAO_0000019,
14052,1088.0,Intermediate,Urine,50597,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,CHEMBL628107,N,1,,,,,1,,BAO_0000218,
14053,1088.0,Autocuration,Urine,22224,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,CHEMBL628108,U,0,,,,,1,,BAO_0000218,
14054,1088.0,Intermediate,Urine,50597,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,CHEMBL628109,N,1,,,,,1,,BAO_0000218,
14055,1088.0,Autocuration,Urine,22224,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,CHEMBL625299,U,0,,,,,1,,BAO_0000218,
14056,1088.0,Intermediate,Urine,50597,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,CHEMBL625300,N,1,,,,,1,,BAO_0000218,
14057,1088.0,Intermediate,Urine,50597,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,CHEMBL625301,N,1,,,,,1,,BAO_0000218,
14058,1088.0,Intermediate,Urine,50597,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,CHEMBL625302,N,1,,,,,1,,BAO_0000218,
14059,1088.0,Intermediate,Urine,50597,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,CHEMBL874649,N,1,,,,,1,,BAO_0000218,
14060,,Intermediate,,50597,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,CHEMBL625303,N,1,,,,,1,,BAO_0000218,
14061,,Intermediate,,50597,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,CHEMBL625463,N,1,,,,,1,,BAO_0000218,
14062,2107.0,Intermediate,Liver,50587,In vitro metabolism in human liver microsomes,CHEMBL625464,N,1,,,,,1,,BAO_0000218,
14063,,Intermediate,,50587,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,CHEMBL625465,N,1,,,,,1,,BAO_0000218,
14064,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,CHEMBL625466,N,1,,,,,1,,BAO_0000218,
14065,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,CHEMBL625467,N,1,,,,,1,,BAO_0000218,
14066,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,CHEMBL625468,N,1,,,,,1,,BAO_0000218,
14067,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,CHEMBL625469,N,1,,,,,1,,BAO_0000218,
14068,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,CHEMBL625470,N,1,,,,,1,,BAO_0000218,
14069,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,CHEMBL632418,N,1,,,,,1,,BAO_0000218,
14070,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,CHEMBL627250,N,1,,,,,1,,BAO_0000218,
14071,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,CHEMBL627251,N,1,,,,,1,,BAO_0000218,
14072,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,CHEMBL627252,N,1,,,,,1,,BAO_0000218,
14073,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,CHEMBL627253,N,1,,,,,1,,BAO_0000218,
14074,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,CHEMBL627254,N,1,,,,,1,,BAO_0000218,
14075,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,CHEMBL875471,N,1,,,,,1,,BAO_0000218,
14076,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,CHEMBL627255,N,1,,,,,1,,BAO_0000218,
14077,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,CHEMBL627256,N,1,,,,,1,,BAO_0000218,
14078,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,CHEMBL627257,N,1,,,,,1,,BAO_0000218,
14079,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,CHEMBL627258,N,1,,,,,1,,BAO_0000218,
14080,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,CHEMBL627259,N,1,,,,,1,,BAO_0000218,
14081,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,CHEMBL627260,N,1,,,,,1,,BAO_0000218,
14082,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,CHEMBL623256,N,1,,,,,1,,BAO_0000218,
14083,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,CHEMBL874413,N,1,,,,,1,,BAO_0000218,
14084,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,CHEMBL623257,N,1,,,,,1,,BAO_0000218,
14085,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,CHEMBL623258,N,1,,,,,1,,BAO_0000218,
14086,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,CHEMBL623259,N,1,,,,,1,,BAO_0000218,
14087,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,CHEMBL623260,N,1,,,,,1,,BAO_0000218,
14088,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,CHEMBL623261,N,1,,,,,1,,BAO_0000218,
14089,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,CHEMBL623262,N,1,,,,,1,,BAO_0000218,
14090,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,CHEMBL623263,N,1,,,,,1,,BAO_0000218,
14091,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,CHEMBL623264,N,1,,,,,1,,BAO_0000218,
14092,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,CHEMBL623265,N,1,,,,,1,,BAO_0000218,
14093,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,CHEMBL623266,N,1,,,,,1,,BAO_0000218,
14094,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,CHEMBL623267,N,1,,,,,1,,BAO_0000218,
14095,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,CHEMBL623268,N,1,,,,,1,,BAO_0000218,
14096,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,CHEMBL623269,N,1,,,,,1,,BAO_0000218,
14097,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,CHEMBL623270,N,1,,,,,1,,BAO_0000218,
14098,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,CHEMBL623271,N,1,,,,,1,,BAO_0000218,
14099,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,CHEMBL623272,N,1,,,,,1,,BAO_0000218,
14100,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,CHEMBL623273,N,1,,,,,1,,BAO_0000218,
14101,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,CHEMBL623274,N,1,,,,,1,,BAO_0000218,
14102,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,CHEMBL874414,N,1,,,,,1,,BAO_0000218,
14103,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,CHEMBL623275,N,1,,,,,1,,BAO_0000218,
14104,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,CHEMBL629150,N,1,,,,,1,,BAO_0000218,
14105,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,CHEMBL623276,N,1,,,,,1,,BAO_0000218,
14106,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,CHEMBL623277,N,1,,,,,1,,BAO_0000218,
14107,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,CHEMBL623112,N,1,,,,,1,,BAO_0000218,
14108,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,CHEMBL623113,N,1,,,,,1,,BAO_0000218,
14109,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,CHEMBL623800,N,1,,,,,1,,BAO_0000218,
14110,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,CHEMBL623801,N,1,,,,,1,,BAO_0000218,
14111,2106.0,Intermediate,Spleen,50597,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",CHEMBL623802,N,1,,,,,1,,BAO_0000218,
14112,995.0,Intermediate,Uterus,50597,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623803,N,1,,,,,1,,BAO_0000218,
14113,995.0,Intermediate,Uterus,50597,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623970,N,1,,,,,1,,BAO_0000218,
14114,995.0,Intermediate,Uterus,50597,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL623971,N,1,,,,,1,,BAO_0000218,
14115,178.0,Intermediate,Blood,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),CHEMBL623972,N,1,,,,,1,,BAO_0000218,
14116,178.0,Intermediate,Blood,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),CHEMBL623973,N,1,,,,,1,,BAO_0000218,
14117,178.0,Intermediate,Blood,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),CHEMBL623974,N,1,,,,,1,,BAO_0000218,
14118,178.0,Intermediate,Blood,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),CHEMBL623975,N,1,,,,,1,,BAO_0000218,
14119,955.0,Intermediate,Brain,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),CHEMBL623976,N,1,,,,,1,,BAO_0000218,
14120,955.0,Intermediate,Brain,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),CHEMBL623977,N,1,,,,,1,,BAO_0000218,
14121,955.0,Intermediate,Brain,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),CHEMBL623978,N,1,,,,,1,,BAO_0000218,
14122,955.0,Intermediate,Brain,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),CHEMBL623979,N,1,,,,,1,,BAO_0000218,
14123,,Intermediate,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),CHEMBL623980,N,1,,,,,1,,BAO_0000218,
14124,,Intermediate,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),CHEMBL623981,N,1,,,,,1,,BAO_0000218,
14125,,Intermediate,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),CHEMBL626278,N,1,,,,,1,,BAO_0000218,
14126,,Intermediate,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),CHEMBL626279,N,1,,,,,1,,BAO_0000218,
14127,,Intermediate,,50594,Biodistribution in mice bladder plus excreted urine was determined,CHEMBL626280,N,1,,,,,1,,BAO_0000218,
14128,,Intermediate,,50594,"Percentage biodistribution in mouse blood, 10 minutes post injection",CHEMBL626281,N,1,,,,,1,,BAO_0000218,
14129,,Intermediate,,50594,"Percentage biodistribution in mouse blood, 30 minutes post injection",CHEMBL626282,N,1,,,,,1,,BAO_0000218,
14130,,Intermediate,,50594,"Percentage biodistribution in mouse blood, 5 minutes post injection",CHEMBL626283,N,1,,,,,1,,BAO_0000218,
14131,,Intermediate,,50594,"Percentage biodistribution in mouse blood, 60 minutes post injection",CHEMBL626284,N,1,,,,,1,,BAO_0000218,
14132,955.0,Intermediate,Brain,50594,"Percentage biodistribution in mouse brain, 10 minutes post injection",CHEMBL626285,N,1,,,,,1,,BAO_0000218,
14133,955.0,Intermediate,Brain,50594,"Percentage biodistribution in mouse brain, 30 minutes post injection",CHEMBL626286,N,1,,,,,1,,BAO_0000218,
14134,955.0,Intermediate,Brain,50594,"Percentage biodistribution in mouse brain, 5 minutes post injection",CHEMBL626287,N,1,,,,,1,,BAO_0000218,
14135,955.0,Intermediate,Brain,50594,"Percentage biodistribution in mouse brain, 60 minutes post injection",CHEMBL626288,N,1,,,,,1,,BAO_0000218,
14136,,Intermediate,,50594,"Percentage biodistribution in mouse heart, 10 minutes post injection",CHEMBL626289,N,1,,,,,1,,BAO_0000218,
14137,,Intermediate,,50594,"Percentage biodistribution in mouse heart, 30 minutes post injection",CHEMBL626290,N,1,,,,,1,,BAO_0000218,
14138,,Intermediate,,50594,"Percentage biodistribution in mouse heart, 5 minutes post injection",CHEMBL626291,N,1,,,,,1,,BAO_0000218,
14139,,Intermediate,,50594,"Percentage biodistribution in mouse heart, 60 minutes post injection",CHEMBL839888,N,1,,,,,1,,BAO_0000218,
14140,160.0,Intermediate,Intestine,50594,"Percentage biodistribution in mouse intestine, 10 minutes post injection",CHEMBL626292,N,1,,,,,1,,BAO_0000218,
14141,160.0,Intermediate,Intestine,50594,"Percentage biodistribution in mouse intestine, 30 minutes post injection",CHEMBL626293,N,1,,,,,1,,BAO_0000218,
14142,160.0,Intermediate,Intestine,50594,"Percentage biodistribution in mouse intestine, 5 minutes post injection",CHEMBL626294,N,1,,,,,1,,BAO_0000218,
14143,160.0,Intermediate,Intestine,50594,"Percentage biodistribution in mouse intestine, 60 minutes post injection",CHEMBL626295,N,1,,,,,1,,BAO_0000218,
14144,2107.0,Intermediate,Liver,50594,"Percentage biodistribution in mouse liver, 10 minutes post injection",CHEMBL627659,N,1,,,,,1,,BAO_0000218,
14145,2107.0,Intermediate,Liver,50594,"Percentage biodistribution in mouse liver, 30 minutes of post injection",CHEMBL627660,N,1,,,,,1,,BAO_0000218,
14146,2107.0,Intermediate,Liver,50594,"Percentage biodistribution in mouse liver, 5 minutes post injection",CHEMBL627661,N,1,,,,,1,,BAO_0000218,
14147,2107.0,Intermediate,Liver,50594,Biodistribution in mice liver at 60 minutes of post injection,CHEMBL627662,N,1,,,,,1,,BAO_0000218,
14148,2048.0,Intermediate,Lung,50594,Biodistribution in mice lungs at 10 min of post injection,CHEMBL627663,N,1,,,,,1,,BAO_0000218,
14149,,Intermediate,,50594,"Percentage biodistribution in mouse lung, 30 minutes post injection",CHEMBL627664,N,1,,,,,1,,BAO_0000218,
14150,,Intermediate,,50594,"Percentage biodistribution in mousee lung, 5 minutes post injection",CHEMBL627665,N,1,,,,,1,,BAO_0000218,
14151,2048.0,Intermediate,Lung,50594,Biodistribution in mice lungs at 60 min of post injection,CHEMBL627666,N,1,,,,,1,,BAO_0000218,
14152,2106.0,Intermediate,Spleen,50594,Percentage biodistribution in mouse spleen,CHEMBL627667,N,1,,,,,1,,BAO_0000218,
14153,945.0,Intermediate,Stomach,50594,Percentage biodistribution in mouse stomach,CHEMBL627668,N,1,,,,,1,,BAO_0000218,
14154,1088.0,Intermediate,Urine,50594,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,CHEMBL627669,N,1,,,,,1,,BAO_0000218,
14155,1255.0,Autocuration,Urinary bladder,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,CHEMBL627670,U,0,,,,,1,,BAO_0000218,
14156,178.0,Autocuration,Blood,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,CHEMBL627671,U,0,,,,,1,,BAO_0000218,
14157,1474.0,Autocuration,Bone element,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,CHEMBL627672,U,0,,,,,1,,BAO_0000218,
14158,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,CHEMBL627673,U,0,,,,,1,,BAO_0000218,
14159,2113.0,Autocuration,Kidney,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,CHEMBL627674,U,0,,,,,1,,BAO_0000218,
14160,2107.0,Autocuration,Liver,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,CHEMBL627675,U,0,,,,,1,,BAO_0000218,
14161,2048.0,Autocuration,Lung,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,CHEMBL627676,U,0,,,,,1,,BAO_0000218,
14162,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,CHEMBL627677,U,0,,,,,1,,BAO_0000218,
14163,,Autocuration,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",CHEMBL627678,U,0,,,,,1,,BAO_0000019,
14164,1977.0,Intermediate,Serum,50597,Affinity for protein binding expressed as association constant in fresh rat serum,CHEMBL627679,N,1,,,,,1,,BAO_0000218,
14165,,Autocuration,,22224,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,CHEMBL627680,U,0,,,,,1,,BAO_0000019,
14166,,Autocuration,,22224,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,CHEMBL627681,U,0,,,,,1,,BAO_0000019,
14167,,Autocuration,,22224,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,CHEMBL627682,U,0,,,,,1,,BAO_0000019,
14168,,Autocuration,,22224,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,CHEMBL627683,U,0,,,,,1,,BAO_0000019,
14169,,Autocuration,,22224,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,CHEMBL627684,U,0,,,,,1,,BAO_0000019,
14170,,Autocuration,,22224,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",CHEMBL874441,U,0,,,,,1,,BAO_0000019,
14171,,Autocuration,,22224,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,CHEMBL627685,U,0,,,,,1,,BAO_0000019,
14172,,Autocuration,,22224,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",CHEMBL627686,U,0,,,,,1,,BAO_0000019,
14173,,Autocuration,,22224,Apparent rate constant Koff for inactivation of dTMP synthase.,CHEMBL627687,U,0,,,,,1,,BAO_0000019,
14174,,Autocuration,,22224,The irreversible inhibitor activity by second order rate equation.,CHEMBL627688,U,0,,,,,1,,BAO_0000019,
14175,,Intermediate,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,CHEMBL628038,N,1,,,,,1,,BAO_0000218,
14176,,Intermediate,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,CHEMBL628039,N,1,,,,,1,,BAO_0000218,
14177,,Intermediate,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,CHEMBL628040,N,1,,,,,1,,BAO_0000218,
14178,,Autocuration,,22224,Dissociation rate calculated from the first-order equation using t1/2 value,CHEMBL628041,U,0,,,,,1,,BAO_0000019,
14179,,Autocuration,,22224,The compound was tested for Binding constant against DNA,CHEMBL630226,U,0,,,,,1,,BAO_0000019,
14180,,Autocuration,,22224,First order rate constant for cyclization of the compound,CHEMBL628042,U,0,,,,,1,,BAO_0000019,
14181,,Autocuration,,22224,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,CHEMBL625232,U,0,,,,,1,,BAO_0000019,
14182,,Autocuration,,22224,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,CHEMBL625233,U,0,,,,,1,,BAO_0000019,
14183,,Autocuration,,22224,Hydrolysis rate constant was determined,CHEMBL625979,U,0,,,,,1,,BAO_0000019,
14184,,Autocuration,,22224,Observed first order rate constant,CHEMBL625980,U,0,,,,,1,,BAO_0000019,
14185,,Autocuration,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,CHEMBL625981,U,0,,,,,1,,BAO_0000019,
14186,,Autocuration,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,CHEMBL625982,U,0,,,,,1,,BAO_0000019,
14187,,Autocuration,,22224,Second-order rate constant for attack on PNPA at 25 degree Centigrade,CHEMBL625983,U,0,,,,,1,,BAO_0000019,
14188,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625984,U,0,,,,,1,,BAO_0000019,
14189,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625985,U,0,,,,,1,,BAO_0000019,
14190,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625986,U,0,,,,,1,,BAO_0000019,
14191,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625987,U,0,,,,,1,,BAO_0000019,
14192,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625988,U,0,,,,,1,,BAO_0000019,
14193,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625989,U,0,,,,,1,,BAO_0000019,
14194,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625990,U,0,,,,,1,,BAO_0000019,
14195,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625991,U,0,,,,,1,,BAO_0000019,
14196,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625992,U,0,,,,,1,,BAO_0000019,
14197,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL625993,U,0,,,,,1,,BAO_0000019,
14198,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL631973,U,0,,,,,1,,BAO_0000019,
14199,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632143,U,0,,,,,1,,BAO_0000019,
14200,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632144,U,0,,,,,1,,BAO_0000019,
14201,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632145,U,0,,,,,1,,BAO_0000019,
14202,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632146,U,0,,,,,1,,BAO_0000019,
14203,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632147,U,0,,,,,1,,BAO_0000019,
14204,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632148,U,0,,,,,1,,BAO_0000019,
14205,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632149,U,0,,,,,1,,BAO_0000019,
14206,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632150,U,0,,,,,1,,BAO_0000019,
14207,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL632151,U,0,,,,,1,,BAO_0000019,
14208,,Intermediate,,50587,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,CHEMBL632152,N,1,,,,,1,,BAO_0000218,
14209,,Intermediate,,50587,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,CHEMBL632153,N,1,,,,,1,,BAO_0000218,
14210,,Intermediate,,50587,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,CHEMBL632154,N,1,,,,,1,,BAO_0000218,
14211,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,CHEMBL632155,N,1,,,,,1,,BAO_0000218,
14212,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,CHEMBL632156,N,1,,,,,1,,BAO_0000218,
14213,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,CHEMBL632157,N,1,,,,,1,,BAO_0000218,
14214,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,CHEMBL632158,N,1,,,,,1,,BAO_0000218,
14215,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,CHEMBL632159,N,1,,,,,1,,BAO_0000218,
14216,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,CHEMBL626305,N,1,,,,,1,,BAO_0000218,
14217,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,CHEMBL626306,N,1,,,,,1,,BAO_0000218,
14218,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,CHEMBL626307,N,1,,,,,1,,BAO_0000218,
14219,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,CHEMBL626308,N,1,,,,,1,,BAO_0000218,
14220,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,CHEMBL626479,N,1,,,,,1,,BAO_0000218,
14221,,Intermediate,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,CHEMBL626480,N,1,,,,,1,,BAO_0000218,
14222,,Autocuration,,22229,Calculated partition coefficient (clogP) (MlogP),CHEMBL626481,U,0,,,,,1,,BAO_0000100,
14223,,Autocuration,,22224,Equipotent potent ratio relative to carbachol (nicotinic activity),CHEMBL626482,U,0,,,,,1,,BAO_0000019,
14224,,Intermediate,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",CHEMBL626483,N,1,,,,,1,,BAO_0000218,
14225,,Intermediate,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",CHEMBL626484,N,1,,,,,1,,BAO_0000218,
14226,,Autocuration,,22229,Solubility at pH 7.4 in micro g/mL;NA denotes available,CHEMBL626485,U,0,,,,,1,,BAO_0000100,
14227,,Autocuration,,22229,Solubility at pH 7.4 in micro g/mL;NA denotes not available,CHEMBL626486,U,0,,,,,1,,BAO_0000100,
14228,,Autocuration,,22229,Solubility at pH 7.4 in ug/mL;NA denotes not available,CHEMBL626487,U,0,,,,,1,,BAO_0000100,
14229,1969.0,Intermediate,Plasma,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,CHEMBL626488,N,1,,,,,1,,BAO_0000218,
14230,1977.0,Intermediate,Serum,50597,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,CHEMBL626489,N,1,,,,,1,,BAO_0000218,
14231,,Autocuration,,22224,Area under the MAP curve measured over 5 min; ND means Not determined,CHEMBL626490,U,0,,,,,1,,BAO_0000019,
14232,,Autocuration,,22224,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,CHEMBL626491,U,0,,,,,1,,BAO_0000100,
14233,,Autocuration,,22229,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,CHEMBL626492,U,0,,,,,1,,BAO_0000100,
14234,,Autocuration,,22224,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,CHEMBL626493,U,0,,,,,1,,BAO_0000019,
14235,,Intermediate,,50597,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,CHEMBL626494,N,1,,,,,1,,BAO_0000218,
14236,,Autocuration,,22224,Half life after oral tested,CHEMBL626495,U,0,,,,,1,,BAO_0000218,
14237,1969.0,Intermediate,Plasma,50597,Half life was determined in plasma of rat; NT indicates not tested,CHEMBL626496,N,1,,,,,1,,BAO_0000218,
14238,,Intermediate,,50597,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,CHEMBL626497,N,1,,,,,1,,BAO_0000218,
14239,,Autocuration,,22224,Oral bioavailability after oral tested,CHEMBL626498,U,0,,,,,1,,BAO_0000218,
14240,,Intermediate,,50597,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),CHEMBL626499,N,1,,,,,1,,BAO_0000218,
14241,,Intermediate,,50597,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),CHEMBL626500,N,1,,,,,1,,BAO_0000218,
14242,1969.0,Intermediate,Plasma,50597,half life was determined in plasma of rat; NT indicates not tested,CHEMBL626501,N,1,,,,,1,,BAO_0000218,
14243,1969.0,Intermediate,Plasma,50597,half life was determined in plasma of rat; NT means not tested,CHEMBL626502,N,1,,,,,1,,BAO_0000218,
14244,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,CHEMBL626503,N,1,,,,,1,,BAO_0000218,
14245,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); inactive,CHEMBL626504,N,1,,,,,1,,BAO_0000218,
14246,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,CHEMBL626505,N,1,,,,,1,,BAO_0000218,
14247,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,CHEMBL626506,N,1,,,,,1,,BAO_0000218,
14248,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,CHEMBL626507,N,1,,,,,1,,BAO_0000218,
14249,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,CHEMBL626508,N,1,,,,,1,,BAO_0000218,
14250,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,CHEMBL626509,N,1,,,,,1,,BAO_0000218,
14251,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,CHEMBL875480,N,1,,,,,1,,BAO_0000218,
14252,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,CHEMBL626510,N,1,,,,,1,,BAO_0000218,
14253,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,CHEMBL626511,N,1,,,,,1,,BAO_0000218,
14254,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,CHEMBL626512,N,1,,,,,1,,BAO_0000218,
14255,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,CHEMBL628208,N,1,,,,,1,,BAO_0000218,
14256,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,CHEMBL628209,N,1,,,,,1,,BAO_0000218,
14257,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,CHEMBL628210,N,1,,,,,1,,BAO_0000218,
14258,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,CHEMBL628211,N,1,,,,,1,,BAO_0000218,
14259,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,CHEMBL628212,N,1,,,,,1,,BAO_0000218,
14260,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,CHEMBL628213,N,1,,,,,1,,BAO_0000218,
14261,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,CHEMBL628214,N,1,,,,,1,,BAO_0000218,
14262,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,CHEMBL628215,N,1,,,,,1,,BAO_0000218,
14263,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,CHEMBL628216,N,1,,,,,1,,BAO_0000218,
14264,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,CHEMBL626595,N,1,,,,,1,,BAO_0000218,
14265,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,CHEMBL626596,N,1,,,,,1,,BAO_0000218,
14266,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,CHEMBL626597,N,1,,,,,1,,BAO_0000218,
14267,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,CHEMBL626598,N,1,,,,,1,,BAO_0000218,
14268,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,CHEMBL622242,N,1,,,,,1,,BAO_0000218,
14269,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,CHEMBL622243,N,1,,,,,1,,BAO_0000218,
14270,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,CHEMBL622244,N,1,,,,,1,,BAO_0000218,
14271,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,CHEMBL622245,N,1,,,,,1,,BAO_0000218,
14272,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,CHEMBL622246,N,1,,,,,1,,BAO_0000218,
14273,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,CHEMBL622247,N,1,,,,,1,,BAO_0000218,
14274,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,CHEMBL622248,N,1,,,,,1,,BAO_0000218,
14275,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,CHEMBL877483,N,1,,,,,1,,BAO_0000218,
14276,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,CHEMBL622249,N,1,,,,,1,,BAO_0000218,
14277,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,CHEMBL622250,N,1,,,,,1,,BAO_0000218,
14278,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,CHEMBL622251,N,1,,,,,1,,BAO_0000218,
14279,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,CHEMBL622252,N,1,,,,,1,,BAO_0000218,
14280,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,CHEMBL622253,N,1,,,,,1,,BAO_0000218,
14281,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,CHEMBL622254,N,1,,,,,1,,BAO_0000218,
14282,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,CHEMBL622255,N,1,,,,,1,,BAO_0000218,
14283,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,CHEMBL622256,N,1,,,,,1,,BAO_0000218,
14284,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,CHEMBL622257,N,1,,,,,1,,BAO_0000218,
14285,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,CHEMBL622258,N,1,,,,,1,,BAO_0000218,
14286,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,CHEMBL622259,N,1,,,,,1,,BAO_0000218,
14287,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,CHEMBL622927,N,1,,,,,1,,BAO_0000218,
14288,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,CHEMBL622928,N,1,,,,,1,,BAO_0000218,
14289,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,CHEMBL622929,N,1,,,,,1,,BAO_0000218,
14290,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,CHEMBL623182,N,1,,,,,1,,BAO_0000218,
14291,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,CHEMBL623183,N,1,,,,,1,,BAO_0000218,
14292,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,CHEMBL623184,N,1,,,,,1,,BAO_0000218,
14293,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,CHEMBL623185,N,1,,,,,1,,BAO_0000218,
14294,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,CHEMBL877484,N,1,,,,,1,,BAO_0000218,
14295,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,CHEMBL627274,N,1,,,,,1,,BAO_0000218,
14296,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,CHEMBL623186,N,1,,,,,1,,BAO_0000218,
14297,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,CHEMBL623187,N,1,,,,,1,,BAO_0000218,
14298,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,CHEMBL623188,N,1,,,,,1,,BAO_0000218,
14299,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,CHEMBL628055,N,1,,,,,1,,BAO_0000218,
14300,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,CHEMBL628056,N,1,,,,,1,,BAO_0000218,
14301,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,CHEMBL628200,N,1,,,,,1,,BAO_0000218,
14302,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,CHEMBL628201,N,1,,,,,1,,BAO_0000218,
14303,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,CHEMBL628202,N,1,,,,,1,,BAO_0000218,
14304,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,CHEMBL628203,N,1,,,,,1,,BAO_0000218,
14305,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,CHEMBL628204,N,1,,,,,1,,BAO_0000218,
14306,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,CHEMBL628205,N,1,,,,,1,,BAO_0000218,
14307,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,CHEMBL628206,N,1,,,,,1,,BAO_0000218,
14308,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),CHEMBL628207,U,0,,,,,1,,BAO_0000218,
14309,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,CHEMBL627220,U,0,,,,,1,,BAO_0000218,
14310,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,CHEMBL627221,U,0,,,,,1,,BAO_0000218,
14311,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),CHEMBL627222,U,0,,,,,1,,BAO_0000218,
14312,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,CHEMBL627223,U,0,,,,,1,,BAO_0000218,
14313,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,CHEMBL632062,U,0,,,,,1,,BAO_0000218,
14314,2106.0,Autocuration,Spleen,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,CHEMBL632063,U,0,,,,,1,,BAO_0000218,
14315,1255.0,Autocuration,Urinary bladder,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,CHEMBL632064,U,0,,,,,1,,BAO_0000218,
14316,178.0,Autocuration,Blood,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,CHEMBL632065,U,0,,,,,1,,BAO_0000218,
14317,1474.0,Autocuration,Bone element,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,CHEMBL632066,U,0,,,,,1,,BAO_0000218,
14318,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,CHEMBL632067,U,0,,,,,1,,BAO_0000218,
14319,2113.0,Autocuration,Kidney,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,CHEMBL629188,U,0,,,,,1,,BAO_0000218,
14320,2107.0,Autocuration,Liver,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,CHEMBL629189,U,0,,,,,1,,BAO_0000218,
14321,2048.0,Autocuration,Lung,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,CHEMBL629190,U,0,,,,,1,,BAO_0000218,
14322,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,CHEMBL629191,U,0,,,,,1,,BAO_0000218,
14323,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),CHEMBL629192,U,0,,,,,1,,BAO_0000218,
14324,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,CHEMBL629193,U,0,,,,,1,,BAO_0000218,
14325,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),CHEMBL629194,U,0,,,,,1,,BAO_0000218,
14326,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,CHEMBL629195,U,0,,,,,1,,BAO_0000218,
14327,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,CHEMBL629373,U,0,,,,,1,,BAO_0000218,
14328,2106.0,Autocuration,Spleen,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,CHEMBL629374,U,0,,,,,1,,BAO_0000218,
14329,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,CHEMBL629375,U,0,,,,,1,,BAO_0000218,
14330,1255.0,Autocuration,Urinary bladder,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,CHEMBL629376,U,0,,,,,1,,BAO_0000218,
14331,178.0,Autocuration,Blood,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,CHEMBL629377,U,0,,,,,1,,BAO_0000218,
14332,1474.0,Autocuration,Bone element,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,CHEMBL629378,U,0,,,,,1,,BAO_0000218,
14333,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,CHEMBL629379,U,0,,,,,1,,BAO_0000218,
14334,2113.0,Autocuration,Kidney,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,CHEMBL629151,U,0,,,,,1,,BAO_0000218,
14335,2107.0,Autocuration,Liver,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,CHEMBL629152,U,0,,,,,1,,BAO_0000218,
14336,2048.0,Autocuration,Lung,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,CHEMBL629153,U,0,,,,,1,,BAO_0000218,
14337,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,CHEMBL629154,U,0,,,,,1,,BAO_0000218,
14338,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),CHEMBL629155,U,0,,,,,1,,BAO_0000218,
14339,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,CHEMBL629156,U,0,,,,,1,,BAO_0000218,
14340,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,CHEMBL629157,U,0,,,,,1,,BAO_0000218,
14341,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),CHEMBL629158,U,0,,,,,1,,BAO_0000218,
14342,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,CHEMBL629159,U,0,,,,,1,,BAO_0000218,
14343,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,CHEMBL629160,U,0,,,,,1,,BAO_0000218,
14344,2106.0,Autocuration,Spleen,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,CHEMBL629161,U,0,,,,,1,,BAO_0000218,
14345,1255.0,Autocuration,Urinary bladder,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,CHEMBL629162,U,0,,,,,1,,BAO_0000218,
14346,178.0,Autocuration,Blood,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,CHEMBL629163,U,0,,,,,1,,BAO_0000218,
14347,1474.0,Autocuration,Bone element,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,CHEMBL629164,U,0,,,,,1,,BAO_0000218,
14348,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,CHEMBL629165,U,0,,,,,1,,BAO_0000218,
14349,2107.0,Autocuration,Liver,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,CHEMBL629166,U,0,,,,,1,,BAO_0000218,
14350,2048.0,Autocuration,Lung,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,CHEMBL629167,U,0,,,,,1,,BAO_0000218,
14351,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,CHEMBL629168,U,0,,,,,1,,BAO_0000218,
14352,,Autocuration,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,CHEMBL629169,U,0,,,,,1,,BAO_0000019,
14353,,Autocuration,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,CHEMBL629170,U,0,,,,,1,,BAO_0000019,
14354,,Autocuration,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,CHEMBL631153,U,0,,,,,1,,BAO_0000019,
14355,,Autocuration,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,CHEMBL875121,U,0,,,,,1,,BAO_0000019,
14356,,Autocuration,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,CHEMBL631154,U,0,,,,,1,,BAO_0000019,
14357,,Autocuration,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,CHEMBL631155,U,0,,,,,1,,BAO_0000019,
14358,,Autocuration,,22224,Hydrolysis rate constant was determined,CHEMBL631156,U,0,,,,,1,,BAO_0000019,
14359,,Autocuration,,22224,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",CHEMBL631157,U,0,,,,,1,,BAO_0000019,
14360,,Autocuration,,22224,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",CHEMBL631158,U,0,,,,,1,,BAO_0000019,
14361,,Autocuration,,22224,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",CHEMBL631159,U,0,,,,,1,,BAO_0000019,
14362,,Autocuration,,22224,Observed second order rate constant,CHEMBL631160,U,0,,,,,1,,BAO_0000019,
14363,,Autocuration,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,CHEMBL631161,U,0,,,,,1,,BAO_0000019,
14364,,Autocuration,,22224,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,CHEMBL631162,U,0,,,,,1,,BAO_0000019,
14365,,Autocuration,,22224,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,CHEMBL630313,U,0,,,,,1,,BAO_0000019,
14366,,Autocuration,,22224,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",CHEMBL630314,U,0,,,,,1,,BAO_0000019,
14367,,Autocuration,,22224,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",CHEMBL630315,U,0,,,,,1,,BAO_0000019,
14368,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630316,U,0,,,,,1,,BAO_0000019,
14369,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630986,U,0,,,,,1,,BAO_0000019,
14370,,Autocuration,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630987,U,0,,,,,1,,BAO_0000019,
14371,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630988,U,0,,,,,1,,BAO_0000019,
14372,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630989,U,0,,,,,1,,BAO_0000019,
14373,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630990,U,0,,,,,1,,BAO_0000019,
14374,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630991,U,0,,,,,1,,BAO_0000019,
14375,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630992,U,0,,,,,1,,BAO_0000019,
14376,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630993,U,0,,,,,1,,BAO_0000019,
14377,,Autocuration,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,CHEMBL630994,U,0,,,,,1,,BAO_0000019,
14378,,Intermediate,,50597,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,CHEMBL630995,N,1,,,,,1,,BAO_0000218,
14379,,Autocuration,,22224,Association constant for compound at 31 degree C was determined,CHEMBL629252,U,0,,,,,1,,BAO_0000019,
14380,,Autocuration,,22224,Calculated antagonist equilibrium dissociation constant of the compound,CHEMBL629253,U,0,,,,,1,,BAO_0000019,
14381,,Autocuration,,22224,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,CHEMBL629944,U,0,,,,,1,,BAO_0000019,
14382,3126.0,Intermediate,Trachea,50512,Dissociation constants vs LTE4 on guinea pig trachea,CHEMBL629945,N,1,,,,,1,,BAO_0000218,
14383,,Autocuration,,22224,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",CHEMBL629946,U,0,,,,,1,,BAO_0000019,
14384,,Autocuration,,22224,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",CHEMBL629947,U,0,,,,,1,,BAO_0000019,
14385,,Autocuration,,22224,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",CHEMBL629948,U,0,,,,,1,,BAO_0000019,
14386,,Autocuration,,22224,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",CHEMBL856024,U,0,,,,,1,,BAO_0000019,
14387,,Autocuration,,22224,Affinity constant KD value was derived from TMP,CHEMBL629949,U,0,,,,,1,,BAO_0000019,
14388,,Autocuration,,22224,Apparent dissociation (binding) rate constant was evaluated,CHEMBL629950,U,0,,,,,1,,BAO_0000019,
14389,,Autocuration,,22224,Dissociation constant (KD) of the compound,CHEMBL630127,U,0,,,,,1,,BAO_0000100,
14390,,Autocuration,,22224,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,CHEMBL630128,U,0,,,,,1,,BAO_0000100,
14391,,Autocuration,,22224,Dissociation constant from ESR titration experiments,CHEMBL630129,U,0,,,,,1,,BAO_0000100,
14392,,Autocuration,,22224,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),CHEMBL630130,U,0,,,,,1,,BAO_0000019,
14393,,Autocuration,,22224,Dissociation constant was evaluated.,CHEMBL875234,U,0,,,,,1,,BAO_0000100,
14394,,Autocuration,,22224,Dissociation constant was reported,CHEMBL630131,U,0,,,,,1,,BAO_0000100,
14395,,Intermediate,,50597,Dissociation constant was determined in rat pituitary cells.,CHEMBL630132,N,1,,,,,1,,BAO_0000218,
14396,,Autocuration,,22224,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,CHEMBL630133,U,0,,,,,1,,BAO_0000019,
14397,,Autocuration,,22224,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,CHEMBL630134,U,0,,,,,1,,BAO_0000019,
14398,,Autocuration,,22224,Equilibrium dissociation constant of the compound,CHEMBL630135,U,0,,,,,1,,BAO_0000019,
14399,,Autocuration,,22224,Equilibrium dissociation constant was determined,CHEMBL630136,U,0,,,,,1,,BAO_0000019,
14400,,Autocuration,,22224,Kinetic constant KD was evaluated,CHEMBL630137,U,0,,,,,1,,BAO_0000019,
14401,,Autocuration,,22224,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,CHEMBL630138,U,0,,,,,1,,BAO_0000019,
14402,,Autocuration,,22224,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,CHEMBL630139,U,0,,,,,1,,BAO_0000019,
14403,,Autocuration,,22224,Rate constant for hydrolysis in aqueous acetone.,CHEMBL630140,U,0,,,,,1,,BAO_0000019,
14404,,Autocuration,,22224,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,CHEMBL875235,U,0,,,,,1,,BAO_0000019,
14405,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,CHEMBL876439,N,1,,,,,1,,BAO_0000218,
14406,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,CHEMBL630605,N,1,,,,,1,,BAO_0000218,
14407,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,CHEMBL630606,N,1,,,,,1,,BAO_0000218,
14408,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,CHEMBL630607,N,1,,,,,1,,BAO_0000218,
14409,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,CHEMBL630608,N,1,,,,,1,,BAO_0000218,
14410,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,CHEMBL630609,N,1,,,,,1,,BAO_0000218,
14411,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,CHEMBL630610,N,1,,,,,1,,BAO_0000218,
14412,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,CHEMBL630611,N,1,,,,,1,,BAO_0000218,
14413,,Intermediate,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,CHEMBL629552,N,1,,,,,1,,BAO_0000218,
14414,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,CHEMBL629733,N,1,,,,,1,,BAO_0000218,
14415,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,CHEMBL629734,N,1,,,,,1,,BAO_0000218,
14416,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,CHEMBL629735,N,1,,,,,1,,BAO_0000218,
14417,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,CHEMBL629736,N,1,,,,,1,,BAO_0000218,
14418,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,CHEMBL629737,N,1,,,,,1,,BAO_0000218,
14419,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,CHEMBL629738,N,1,,,,,1,,BAO_0000218,
14420,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,CHEMBL629739,N,1,,,,,1,,BAO_0000218,
14421,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,CHEMBL629740,N,1,,,,,1,,BAO_0000218,
14422,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,CHEMBL629741,N,1,,,,,1,,BAO_0000218,
14423,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,CHEMBL629742,N,1,,,,,1,,BAO_0000218,
14424,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,CHEMBL629743,N,1,,,,,1,,BAO_0000218,
14425,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,CHEMBL629744,N,1,,,,,1,,BAO_0000218,
14426,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,CHEMBL629745,N,1,,,,,1,,BAO_0000218,
14427,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,CHEMBL629746,N,1,,,,,1,,BAO_0000218,
14428,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,CHEMBL629747,N,1,,,,,1,,BAO_0000218,
14429,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,CHEMBL629748,N,1,,,,,1,,BAO_0000218,
14430,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,CHEMBL629749,N,1,,,,,1,,BAO_0000218,
14431,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,CHEMBL629750,N,1,,,,,1,,BAO_0000218,
14432,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,CHEMBL629751,N,1,,,,,1,,BAO_0000218,
14433,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,CHEMBL629752,N,1,,,,,1,,BAO_0000218,
14434,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,CHEMBL629753,N,1,,,,,1,,BAO_0000218,
14435,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,CHEMBL629754,N,1,,,,,1,,BAO_0000218,
14436,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,CHEMBL629755,N,1,,,,,1,,BAO_0000218,
14437,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,CHEMBL629756,N,1,,,,,1,,BAO_0000218,
14438,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,CHEMBL629757,N,1,,,,,1,,BAO_0000218,
14439,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,CHEMBL629758,N,1,,,,,1,,BAO_0000218,
14440,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,CHEMBL629759,N,1,,,,,1,,BAO_0000218,
14441,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,CHEMBL629760,N,1,,,,,1,,BAO_0000218,
14442,,Intermediate,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,CHEMBL876443,N,1,,,,,1,,BAO_0000218,
14443,,Intermediate,,50588,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,CHEMBL629761,N,1,,,,,1,,BAO_0000218,
14444,,Intermediate,,50588,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,CHEMBL629762,N,1,,,,,1,,BAO_0000218,
14445,,Intermediate,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,CHEMBL629763,N,1,,,,,1,,BAO_0000218,
14446,,Intermediate,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,CHEMBL629764,N,1,,,,,1,,BAO_0000218,
14447,,Intermediate,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,CHEMBL629765,N,1,,,,,1,,BAO_0000218,
14448,,Intermediate,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,CHEMBL629766,N,1,,,,,1,,BAO_0000218,
14449,,Intermediate,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,CHEMBL629767,N,1,,,,,1,,BAO_0000218,
14450,,Intermediate,,50588,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,CHEMBL629768,N,1,,,,,1,,BAO_0000218,
14451,,Intermediate,,50594,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,CHEMBL629769,N,1,,,,,1,,BAO_0000218,
14452,,Intermediate,,50588,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,CHEMBL629770,N,1,,,,,1,,BAO_0000218,
14453,,Intermediate,,50588,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,CHEMBL629771,N,1,,,,,1,,BAO_0000218,
14454,,Intermediate,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,CHEMBL629772,N,1,,,,,1,,BAO_0000218,
14455,,Intermediate,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,CHEMBL629773,N,1,,,,,1,,BAO_0000218,
14456,,Intermediate,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,CHEMBL625455,N,1,,,,,1,,BAO_0000218,
14457,,Intermediate,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,CHEMBL625456,N,1,,,,,1,,BAO_0000218,
14458,,Intermediate,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,CHEMBL625457,N,1,,,,,1,,BAO_0000218,
14459,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,CHEMBL625458,N,1,,,,,1,,BAO_0000218,
14460,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,CHEMBL625459,N,1,,,,,1,,BAO_0000218,
14461,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,CHEMBL875483,N,1,,,,,1,,BAO_0000218,
14462,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,CHEMBL634779,N,1,,,,,1,,BAO_0000218,
14463,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,CHEMBL625460,N,1,,,,,1,,BAO_0000218,
14464,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,CHEMBL626117,N,1,,,,,1,,BAO_0000218,
14465,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,CHEMBL626118,N,1,,,,,1,,BAO_0000218,
14466,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,CHEMBL628342,N,1,,,,,1,,BAO_0000218,
14467,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,CHEMBL628343,N,1,,,,,1,,BAO_0000218,
14468,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,CHEMBL628344,N,1,,,,,1,,BAO_0000218,
14469,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,CHEMBL628345,N,1,,,,,1,,BAO_0000218,
14470,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,CHEMBL628346,N,1,,,,,1,,BAO_0000218,
14471,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,CHEMBL628347,N,1,,,,,1,,BAO_0000218,
14472,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,CHEMBL628348,N,1,,,,,1,,BAO_0000218,
14473,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,CHEMBL628349,N,1,,,,,1,,BAO_0000218,
14474,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,CHEMBL875611,N,1,,,,,1,,BAO_0000218,
14475,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,CHEMBL628350,N,1,,,,,1,,BAO_0000218,
14476,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,CHEMBL628351,N,1,,,,,1,,BAO_0000218,
14477,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,CHEMBL628352,N,1,,,,,1,,BAO_0000218,
14478,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,CHEMBL628353,N,1,,,,,1,,BAO_0000218,
14479,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,CHEMBL628354,N,1,,,,,1,,BAO_0000218,
14480,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,CHEMBL626667,N,1,,,,,1,,BAO_0000218,
14481,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,CHEMBL626668,N,1,,,,,1,,BAO_0000218,
14482,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,CHEMBL626669,N,1,,,,,1,,BAO_0000218,
14483,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,CHEMBL626670,N,1,,,,,1,,BAO_0000218,
14484,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,CHEMBL626671,N,1,,,,,1,,BAO_0000218,
14485,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,CHEMBL626672,N,1,,,,,1,,BAO_0000218,
14486,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,CHEMBL626673,N,1,,,,,1,,BAO_0000218,
14487,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,CHEMBL626674,N,1,,,,,1,,BAO_0000218,
14488,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,CHEMBL626675,N,1,,,,,1,,BAO_0000218,
14489,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,CHEMBL626676,N,1,,,,,1,,BAO_0000218,
14490,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,CHEMBL626677,N,1,,,,,1,,BAO_0000218,
14491,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,CHEMBL626678,N,1,,,,,1,,BAO_0000218,
14492,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,CHEMBL626679,N,1,,,,,1,,BAO_0000218,
14493,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,CHEMBL875612,N,1,,,,,1,,BAO_0000218,
14494,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,CHEMBL626680,N,1,,,,,1,,BAO_0000218,
14495,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,CHEMBL626681,N,1,,,,,1,,BAO_0000218,
14496,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,CHEMBL626682,N,1,,,,,1,,BAO_0000218,
14497,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,CHEMBL626683,N,1,,,,,1,,BAO_0000218,
14498,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,CHEMBL626684,N,1,,,,,1,,BAO_0000218,
14499,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,CHEMBL626685,N,1,,,,,1,,BAO_0000218,
14500,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,CHEMBL626686,N,1,,,,,1,,BAO_0000218,
14501,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,CHEMBL626687,N,1,,,,,1,,BAO_0000218,
14502,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,CHEMBL624978,N,1,,,,,1,,BAO_0000218,
14503,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,CHEMBL624979,N,1,,,,,1,,BAO_0000218,
14504,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,CHEMBL624980,N,1,,,,,1,,BAO_0000218,
14505,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,CHEMBL624981,N,1,,,,,1,,BAO_0000218,
14506,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,CHEMBL624982,N,1,,,,,1,,BAO_0000218,
14507,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),CHEMBL627564,U,0,,,,,1,,BAO_0000218,
14508,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),CHEMBL627565,U,0,,,,,1,,BAO_0000218,
14509,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,CHEMBL627566,U,0,,,,,1,,BAO_0000218,
14510,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,CHEMBL627567,U,0,,,,,1,,BAO_0000218,
14511,2106.0,Autocuration,Spleen,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,CHEMBL627568,U,0,,,,,1,,BAO_0000218,
14512,2113.0,Autocuration,Kidney,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,CHEMBL627569,U,0,,,,,1,,BAO_0000218,
14513,1255.0,Autocuration,Urinary bladder,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,CHEMBL627570,U,0,,,,,1,,BAO_0000218,
14514,178.0,Autocuration,Blood,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,CHEMBL627571,U,0,,,,,1,,BAO_0000218,
14515,1474.0,Autocuration,Bone element,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,CHEMBL627572,U,0,,,,,1,,BAO_0000218,
14516,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,CHEMBL627573,U,0,,,,,1,,BAO_0000218,
14517,2113.0,Autocuration,Kidney,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,CHEMBL627574,U,0,,,,,1,,BAO_0000218,
14518,2107.0,Autocuration,Liver,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,CHEMBL627575,U,0,,,,,1,,BAO_0000218,
14519,2048.0,Autocuration,Lung,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,CHEMBL627576,U,0,,,,,1,,BAO_0000218,
14520,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,CHEMBL627577,U,0,,,,,1,,BAO_0000218,
14521,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),CHEMBL627578,U,0,,,,,1,,BAO_0000218,
14522,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,CHEMBL627579,U,0,,,,,1,,BAO_0000218,
14523,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,CHEMBL627580,U,0,,,,,1,,BAO_0000218,
14524,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),CHEMBL627581,U,0,,,,,1,,BAO_0000218,
14525,,Autocuration,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,CHEMBL627582,U,0,,,,,1,,BAO_0000218,
14526,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,CHEMBL627583,U,0,,,,,1,,BAO_0000218,
14527,2106.0,Autocuration,Spleen,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,CHEMBL627584,U,0,,,,,1,,BAO_0000218,
14528,2367.0,Autocuration,Prostate gland,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,CHEMBL627585,U,0,,,,,1,,BAO_0000218,
14529,2385.0,Autocuration,Muscle tissue,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,CHEMBL627586,U,0,,,,,1,,BAO_0000218,
14530,,Intermediate,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,CHEMBL627587,N,1,,,,,1,,BAO_0000218,
14531,,Intermediate,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL627588,N,1,,,,,1,,BAO_0000218,
14532,,Intermediate,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,CHEMBL628250,N,1,,,,,1,,BAO_0000218,
14533,,Intermediate,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628251,N,1,,,,,1,,BAO_0000218,
14534,10000000.0,Intermediate,Hippocampus,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,CHEMBL628252,N,1,,,,,1,,BAO_0000218,
14535,10000000.0,Intermediate,Hippocampus,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628253,N,1,,,,,1,,BAO_0000218,
14536,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,CHEMBL628254,N,1,,,,,1,,BAO_0000218,
14537,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL877493,N,1,,,,,1,,BAO_0000218,
14538,,Intermediate,,50597,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628255,N,1,,,,,1,,BAO_0000218,
14539,,Intermediate,,50597,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628256,N,1,,,,,1,,BAO_0000218,
14540,10000000.0,Intermediate,Hippocampus,50597,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628257,N,1,,,,,1,,BAO_0000218,
14541,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628258,N,1,,,,,1,,BAO_0000218,
14542,,Intermediate,,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628259,N,1,,,,,1,,BAO_0000218,
14543,,Intermediate,,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL628429,N,1,,,,,1,,BAO_0000218,
14544,10000000.0,Intermediate,Hippocampus,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,CHEMBL626862,N,1,,,,,1,,BAO_0000218,
14545,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,CHEMBL626863,N,1,,,,,1,,BAO_0000218,
14546,2037.0,Intermediate,Cerebellum,50597,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,CHEMBL625886,N,1,,,,,1,,BAO_0000218,
14547,2037.0,Intermediate,Cerebellum,50597,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,CHEMBL625887,N,1,,,,,1,,BAO_0000218,
14548,,Intermediate,,50597,Biodistribution of the [11C]-radiolabeled compound in rat cortex,CHEMBL625888,N,1,,,,,1,,BAO_0000218,
14549,,Intermediate,,50597,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,CHEMBL625889,N,1,,,,,1,,BAO_0000218,
14550,10000000.0,Intermediate,Hippocampus,50597,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,CHEMBL625890,N,1,,,,,1,,BAO_0000218,
14551,10000000.0,Intermediate,Hippocampus,50597,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,CHEMBL625891,N,1,,,,,1,,BAO_0000218,
14552,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,CHEMBL625892,N,1,,,,,1,,BAO_0000218,
14553,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,CHEMBL625893,N,1,,,,,1,,BAO_0000218,
14554,2037.0,Intermediate,Cerebellum,50597,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,CHEMBL625894,N,1,,,,,1,,BAO_0000218,
14555,,Intermediate,,50597,Biodistribution of the [18F]-radiolabeled compound in rat cortex,CHEMBL625895,N,1,,,,,1,,BAO_0000218,
14556,,Autocuration,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,CHEMBL625896,U,0,,,,,1,,BAO_0000019,
14557,,Autocuration,,22224,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",CHEMBL625897,U,0,,,,,1,,BAO_0000019,
14558,,Autocuration,,22224,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",CHEMBL625898,U,0,,,,,1,,BAO_0000019,
14559,,Autocuration,,22224,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",CHEMBL625899,U,0,,,,,1,,BAO_0000019,
14560,,Autocuration,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,CHEMBL626124,U,0,,,,,1,,BAO_0000019,
14561,,Intermediate,,50212,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,CHEMBL628500,N,1,,,,,1,,BAO_0000218,
14562,,Intermediate,,50597,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",CHEMBL857856,N,1,,,,,1,,BAO_0000218,
14563,,Intermediate,,50597,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",CHEMBL628501,N,1,,,,,1,,BAO_0000218,
14564,,Autocuration,,22224,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",CHEMBL628502,U,0,,,,,1,,BAO_0000019,
14565,,Autocuration,,22224,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,CHEMBL628503,U,0,,,,,1,,BAO_0000019,
14566,,Autocuration,,22224,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,CHEMBL628504,U,0,,,,,1,,BAO_0000019,
14567,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",CHEMBL628505,U,0,,,,,1,,BAO_0000019,
14568,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",CHEMBL874452,U,0,,,,,1,,BAO_0000019,
14569,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",CHEMBL628506,U,0,,,,,1,,BAO_0000019,
14570,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",CHEMBL628507,U,0,,,,,1,,BAO_0000019,
14571,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",CHEMBL628508,U,0,,,,,1,,BAO_0000019,
14572,,Autocuration,,22224,Michaelis constant (KM) was evaluated,CHEMBL628509,U,0,,,,,1,,BAO_0000019,
14573,,Autocuration,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,CHEMBL628510,U,0,,,,,1,,BAO_0000019,
14574,,Autocuration,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase I,CHEMBL628511,U,0,,,,,1,,BAO_0000019,
14575,,Autocuration,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase II,CHEMBL628512,U,0,,,,,1,,BAO_0000019,
14576,,Autocuration,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase III,CHEMBL628513,U,0,,,,,1,,BAO_0000019,
14577,,Autocuration,,22224,Substrate concentration for half maximal velocity was reported for yeast hexokinase,CHEMBL628514,U,0,,,,,1,,BAO_0000019,
14578,,Autocuration,,22224,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,CHEMBL628515,U,0,,,,,1,,BAO_0000019,
14579,,Autocuration,,22224,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,CHEMBL628516,U,0,,,,,1,,BAO_0000019,
14580,,Autocuration,,22224,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),CHEMBL628517,U,0,,,,,1,,BAO_0000019,
14581,,Autocuration,,22224,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),CHEMBL628518,U,0,,,,,1,,BAO_0000019,
14582,,Autocuration,,22224,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,CHEMBL628519,U,0,,,,,1,,BAO_0000019,
14583,,Autocuration,,22224,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,CHEMBL628520,U,0,,,,,1,,BAO_0000019,
14584,,Autocuration,,22224,Binding constant was determined,CHEMBL628521,U,0,,,,,1,,BAO_0000019,
14585,,Autocuration,,22224,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,CHEMBL630443,U,0,,,,,1,,BAO_0000019,
14586,,Autocuration,,22224,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,CHEMBL630444,U,0,,,,,1,,BAO_0000019,
14587,,Autocuration,,22224,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,CHEMBL857732,U,0,,,,,1,,BAO_0000019,
14588,,Autocuration,,22224,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,CHEMBL630445,U,0,,,,,1,,BAO_0000100,
14589,,Autocuration,,22224,Catalytic rate constant of the compound,CHEMBL630446,U,0,,,,,1,,BAO_0000019,
14590,,Autocuration,,22224,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,CHEMBL630447,U,0,,,,,1,,BAO_0000019,
14591,,Autocuration,,22224,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),CHEMBL630448,U,0,,,,,1,,BAO_0000019,
14592,,Autocuration,,22224,Catalytic rate constant against phospholipase A2 was determined,CHEMBL630449,U,0,,,,,1,,BAO_0000019,
14593,,Autocuration,,22224,"Compound was evaluated for catalytic constant, Kcat",CHEMBL630450,U,0,,,,,1,,BAO_0000019,
14594,,Autocuration,,22224,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,CHEMBL630451,U,0,,,,,1,,BAO_0000019,
14595,,Autocuration,,22224,Kcat calculated from 0.693/T1/2,CHEMBL630452,U,0,,,,,1,,BAO_0000019,
14596,,Autocuration,,22224,Kcat was determined,CHEMBL630453,U,0,,,,,1,,BAO_0000019,
14597,,Autocuration,,22224,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,CHEMBL630454,U,0,,,,,1,,BAO_0000019,
14598,,Autocuration,,22224,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,CHEMBL630455,U,0,,,,,1,,BAO_0000019,
14599,,Autocuration,,22224,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,CHEMBL631487,U,0,,,,,1,,BAO_0000019,
14600,,Autocuration,,22224,Kcat value was determined,CHEMBL631488,U,0,,,,,1,,BAO_0000019,
14601,,Autocuration,,22224,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,CHEMBL876440,U,0,,,,,1,,BAO_0000019,
14602,,Autocuration,,22224,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,CHEMBL631489,U,0,,,,,1,,BAO_0000019,
14603,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",CHEMBL857742,U,0,,,,,1,,BAO_0000019,
14604,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",CHEMBL631490,U,0,,,,,1,,BAO_0000019,
14605,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",CHEMBL631491,U,0,,,,,1,,BAO_0000019,
14606,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",CHEMBL631492,U,0,,,,,1,,BAO_0000019,
14607,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",CHEMBL631493,U,0,,,,,1,,BAO_0000019,
14608,,Autocuration,,22224,Kinetic parameter for rate of conversion to PABA was determined,CHEMBL631494,U,0,,,,,1,,BAO_0000019,
14609,,Autocuration,,22224,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,CHEMBL631495,U,0,,,,,1,,BAO_0000019,
14610,1988.0,Intermediate,Feces,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",CHEMBL631496,N,1,,,,,1,,BAO_0000218,
14611,1088.0,Intermediate,Urine,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",CHEMBL631497,N,1,,,,,1,,BAO_0000218,
14612,1088.0,Intermediate,Urine,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",CHEMBL631498,N,1,,,,,1,,BAO_0000218,
14613,1088.0,Intermediate,Urine,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",CHEMBL629776,N,1,,,,,1,,BAO_0000218,
14614,1088.0,Intermediate,Urine,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",CHEMBL629777,N,1,,,,,1,,BAO_0000218,
14615,1088.0,Intermediate,Urine,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",CHEMBL629778,N,1,,,,,1,,BAO_0000218,
14616,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,CHEMBL630456,N,1,,,,,1,,BAO_0000218,
14617,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,CHEMBL630457,N,1,,,,,1,,BAO_0000218,
14618,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,CHEMBL630458,N,1,,,,,1,,BAO_0000218,
14619,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,CHEMBL630459,N,1,,,,,1,,BAO_0000218,
14620,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,CHEMBL630460,N,1,,,,,1,,BAO_0000218,
14621,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,CHEMBL876550,N,1,,,,,1,,BAO_0000218,
14622,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,CHEMBL630461,N,1,,,,,1,,BAO_0000218,
14623,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,CHEMBL630462,N,1,,,,,1,,BAO_0000218,
14624,,Intermediate,,50597,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,CHEMBL630463,N,1,,,,,1,,BAO_0000218,
14625,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,CHEMBL630464,N,1,,,,,1,,BAO_0000218,
14626,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,CHEMBL630465,N,1,,,,,1,,BAO_0000218,
14627,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,CHEMBL630466,N,1,,,,,1,,BAO_0000218,
14628,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,CHEMBL630467,N,1,,,,,1,,BAO_0000218,
14629,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,CHEMBL630633,N,1,,,,,1,,BAO_0000218,
14630,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,CHEMBL630634,N,1,,,,,1,,BAO_0000218,
14631,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,CHEMBL630635,N,1,,,,,1,,BAO_0000218,
14632,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,CHEMBL630636,N,1,,,,,1,,BAO_0000218,
14633,,Intermediate,,50597,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,CHEMBL630637,N,1,,,,,1,,BAO_0000218,
14634,1988.0,Intermediate,Feces,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",CHEMBL630638,N,1,,,,,1,,BAO_0000218,
14635,1988.0,Intermediate,Feces,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",CHEMBL630639,N,1,,,,,1,,BAO_0000218,
14636,1988.0,Intermediate,Feces,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",CHEMBL630640,N,1,,,,,1,,BAO_0000218,
14637,1988.0,Intermediate,Feces,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",CHEMBL876551,N,1,,,,,1,,BAO_0000218,
14638,1088.0,Intermediate,Urine,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",CHEMBL630641,N,1,,,,,1,,BAO_0000218,
14639,1088.0,Intermediate,Urine,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",CHEMBL630642,N,1,,,,,1,,BAO_0000218,
14640,1088.0,Intermediate,Urine,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",CHEMBL630643,N,1,,,,,1,,BAO_0000218,
14641,1088.0,Intermediate,Urine,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",CHEMBL630644,N,1,,,,,1,,BAO_0000218,
14642,1088.0,Intermediate,Urine,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",CHEMBL630645,N,1,,,,,1,,BAO_0000218,
14643,1988.0,Intermediate,Feces,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",CHEMBL625599,N,1,,,,,1,,BAO_0000218,
14644,1988.0,Intermediate,Feces,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",CHEMBL625600,N,1,,,,,1,,BAO_0000218,
14645,1988.0,Intermediate,Feces,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",CHEMBL625601,N,1,,,,,1,,BAO_0000218,
14646,1988.0,Intermediate,Feces,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",CHEMBL625602,N,1,,,,,1,,BAO_0000218,
14647,1088.0,Intermediate,Urine,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",CHEMBL627470,N,1,,,,,1,,BAO_0000218,
14648,1088.0,Intermediate,Urine,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",CHEMBL627471,N,1,,,,,1,,BAO_0000218,
14649,1088.0,Intermediate,Urine,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",CHEMBL627472,N,1,,,,,1,,BAO_0000218,
14650,1088.0,Intermediate,Urine,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",CHEMBL627473,N,1,,,,,1,,BAO_0000218,
14651,1088.0,Intermediate,Urine,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",CHEMBL627474,N,1,,,,,1,,BAO_0000218,
14652,178.0,Intermediate,Blood,50597,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL627475,N,1,,,,,1,,BAO_0000218,
14653,178.0,Intermediate,Blood,50597,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL627476,N,1,,,,,1,,BAO_0000218,
14654,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,CHEMBL627477,N,1,,,,,1,,BAO_0000218,
14655,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,CHEMBL627478,N,1,,,,,1,,BAO_0000218,
14656,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,CHEMBL627479,N,1,,,,,1,,BAO_0000218,
14657,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,CHEMBL627480,N,1,,,,,1,,BAO_0000218,
14658,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,CHEMBL627481,N,1,,,,,1,,BAO_0000218,
14659,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,CHEMBL627482,N,1,,,,,1,,BAO_0000218,
14660,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,CHEMBL627483,N,1,,,,,1,,BAO_0000218,
14661,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,CHEMBL875636,N,1,,,,,1,,BAO_0000218,
14662,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,CHEMBL625764,N,1,,,,,1,,BAO_0000218,
14663,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,CHEMBL625765,N,1,,,,,1,,BAO_0000218,
14664,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,CHEMBL625766,N,1,,,,,1,,BAO_0000218,
14665,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,CHEMBL625767,N,1,,,,,1,,BAO_0000218,
14666,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,CHEMBL625768,N,1,,,,,1,,BAO_0000218,
14667,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,CHEMBL625769,N,1,,,,,1,,BAO_0000218,
14668,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,CHEMBL625770,N,1,,,,,1,,BAO_0000218,
14669,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,CHEMBL625771,N,1,,,,,1,,BAO_0000218,
14670,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,CHEMBL625772,N,1,,,,,1,,BAO_0000218,
14671,1088.0,Intermediate,Urine,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,CHEMBL625773,N,1,,,,,1,,BAO_0000218,
14672,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,CHEMBL625774,N,1,,,,,1,,BAO_0000218,
14673,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,CHEMBL625775,N,1,,,,,1,,BAO_0000218,
14674,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,CHEMBL625776,N,1,,,,,1,,BAO_0000218,
14675,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,CHEMBL625777,N,1,,,,,1,,BAO_0000218,
14676,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,CHEMBL625778,N,1,,,,,1,,BAO_0000218,
14677,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,CHEMBL625779,N,1,,,,,1,,BAO_0000218,
14678,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,CHEMBL625780,N,1,,,,,1,,BAO_0000218,
14679,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,CHEMBL625781,N,1,,,,,1,,BAO_0000218,
14680,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,CHEMBL875637,N,1,,,,,1,,BAO_0000218,
14681,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,CHEMBL626473,N,1,,,,,1,,BAO_0000218,
14682,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,CHEMBL626474,N,1,,,,,1,,BAO_0000218,
14683,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,CHEMBL626475,N,1,,,,,1,,BAO_0000218,
14684,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,CHEMBL626476,N,1,,,,,1,,BAO_0000218,
14685,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,CHEMBL634397,N,1,,,,,1,,BAO_0000218,
14686,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,CHEMBL626477,N,1,,,,,1,,BAO_0000218,
14687,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,CHEMBL631069,N,1,,,,,1,,BAO_0000218,
14688,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,CHEMBL631070,N,1,,,,,1,,BAO_0000218,
14689,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,CHEMBL631071,N,1,,,,,1,,BAO_0000218,
14690,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,CHEMBL631072,N,1,,,,,1,,BAO_0000218,
14691,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,CHEMBL631073,N,1,,,,,1,,BAO_0000218,
14692,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,CHEMBL631074,N,1,,,,,1,,BAO_0000218,
14693,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,CHEMBL631075,N,1,,,,,1,,BAO_0000218,
14694,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,CHEMBL631725,N,1,,,,,1,,BAO_0000218,
14695,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,CHEMBL631726,N,1,,,,,1,,BAO_0000218,
14696,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,CHEMBL631727,N,1,,,,,1,,BAO_0000218,
14697,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,CHEMBL631728,N,1,,,,,1,,BAO_0000218,
14698,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,CHEMBL631729,N,1,,,,,1,,BAO_0000218,
14699,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,CHEMBL631730,N,1,,,,,1,,BAO_0000218,
14700,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,CHEMBL631731,N,1,,,,,1,,BAO_0000218,
14701,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,CHEMBL631910,N,1,,,,,1,,BAO_0000218,
14702,10000000.0,Intermediate,Hippocampus,50597,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,CHEMBL631911,N,1,,,,,1,,BAO_0000218,
14703,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,CHEMBL631912,N,1,,,,,1,,BAO_0000218,
14704,1898.0,Intermediate,Hypothalamus,50597,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,CHEMBL631913,N,1,,,,,1,,BAO_0000218,
14705,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631914,N,1,,,,,1,,BAO_0000218,
14706,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631915,N,1,,,,,1,,BAO_0000218,
14707,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL875778,N,1,,,,,1,,BAO_0000218,
14708,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631916,N,1,,,,,1,,BAO_0000218,
14709,178.0,Intermediate,Blood,50597,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631917,N,1,,,,,1,,BAO_0000218,
14710,178.0,Intermediate,Blood,50597,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631918,N,1,,,,,1,,BAO_0000218,
14711,178.0,Intermediate,Blood,50597,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631919,N,1,,,,,1,,BAO_0000218,
14712,178.0,Intermediate,Blood,50597,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL631920,N,1,,,,,1,,BAO_0000218,
14713,178.0,Intermediate,Blood,50597,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631921,N,1,,,,,1,,BAO_0000218,
14714,178.0,Intermediate,Blood,50597,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631922,N,1,,,,,1,,BAO_0000218,
14715,178.0,Intermediate,Blood,50597,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL631923,N,1,,,,,1,,BAO_0000218,
14716,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631924,N,1,,,,,1,,BAO_0000218,
14717,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630234,N,1,,,,,1,,BAO_0000218,
14718,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630235,N,1,,,,,1,,BAO_0000218,
14719,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630236,N,1,,,,,1,,BAO_0000218,
14720,,Intermediate,,50597,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630237,N,1,,,,,1,,BAO_0000218,
14721,,Intermediate,,50597,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630238,N,1,,,,,1,,BAO_0000218,
14722,,Intermediate,,50597,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630239,N,1,,,,,1,,BAO_0000218,
14723,,Intermediate,,50597,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630303,N,1,,,,,1,,BAO_0000218,
14724,,Intermediate,,50597,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630304,N,1,,,,,1,,BAO_0000218,
14725,,Intermediate,,50597,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630305,N,1,,,,,1,,BAO_0000218,
14726,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630306,N,1,,,,,1,,BAO_0000218,
14727,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630307,N,1,,,,,1,,BAO_0000218,
14728,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630308,N,1,,,,,1,,BAO_0000218,
14729,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630309,N,1,,,,,1,,BAO_0000218,
14730,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL629309,N,1,,,,,1,,BAO_0000218,
14731,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL629993,N,1,,,,,1,,BAO_0000218,
14732,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL629994,N,1,,,,,1,,BAO_0000218,
14733,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL629995,N,1,,,,,1,,BAO_0000218,
14734,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631993,N,1,,,,,1,,BAO_0000218,
14735,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631994,N,1,,,,,1,,BAO_0000218,
14736,2113.0,Intermediate,Kidney,50597,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631995,N,1,,,,,1,,BAO_0000218,
14737,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL631996,N,1,,,,,1,,BAO_0000218,
14738,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631997,N,1,,,,,1,,BAO_0000218,
14739,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631998,N,1,,,,,1,,BAO_0000218,
14740,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631999,N,1,,,,,1,,BAO_0000218,
14741,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL632000,N,1,,,,,1,,BAO_0000218,
14742,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL632001,N,1,,,,,1,,BAO_0000218,
14743,2107.0,Intermediate,Liver,50597,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL874424,N,1,,,,,1,,BAO_0000218,
14744,2107.0,Intermediate,Liver,50597,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL632002,N,1,,,,,1,,BAO_0000218,
14745,2107.0,Intermediate,Liver,50597,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL632003,N,1,,,,,1,,BAO_0000218,
14746,,Autocuration,,22224,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,CHEMBL632004,U,0,,,,,1,,BAO_0000019,
14747,,Autocuration,,22224,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,CHEMBL632005,U,0,,,,,1,,BAO_0000019,
14748,,Autocuration,,22224,Compound was tested for amidase rate in the presence of N62C screen enzyme,CHEMBL632006,U,0,,,,,1,,BAO_0000019,
14749,,Autocuration,,22224,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,CHEMBL632007,U,0,,,,,1,,BAO_0000019,
14750,,Autocuration,,22224,Compound was tested for amidase rate in the presence of S166C screen enzyme,CHEMBL632008,U,0,,,,,1,,BAO_0000019,
14751,,Autocuration,,22224,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,CHEMBL632009,U,0,,,,,1,,BAO_0000019,
14752,,Autocuration,,22224,Compound was tested for esterase rate in the presence of N62C screen enzyme,CHEMBL632010,U,0,,,,,1,,BAO_0000019,
14753,,Autocuration,,22224,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,CHEMBL857750,U,0,,,,,1,,BAO_0000019,
14754,,Autocuration,,22224,Compound was tested for esterase rate in the presence of S166C screen enzyme,CHEMBL632011,U,0,,,,,1,,BAO_0000019,
14755,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",CHEMBL632012,U,0,,,,,1,,BAO_0000019,
14756,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",CHEMBL632013,U,0,,,,,1,,BAO_0000019,
14757,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",CHEMBL632014,U,0,,,,,1,,BAO_0000019,
14758,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",CHEMBL629622,U,0,,,,,1,,BAO_0000019,
14759,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",CHEMBL629623,U,0,,,,,1,,BAO_0000019,
14760,,Autocuration,,22224,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",CHEMBL629624,U,0,,,,,1,,BAO_0000019,
14761,,Autocuration,,22224,Ratio of Kcat to that of Km was determined,CHEMBL629625,U,0,,,,,1,,BAO_0000019,
14762,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",CHEMBL629626,U,0,,,,,1,,BAO_0000019,
14763,,Autocuration,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",CHEMBL629627,U,0,,,,,1,,BAO_0000019,
14764,,Autocuration,,22224,"Compound was evaluated for constant, Kd",CHEMBL629628,U,0,,,,,1,,BAO_0000019,
14765,,Autocuration,,22224,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,CHEMBL629629,U,0,,,,,1,,BAO_0000019,
14766,,Autocuration,,22224,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,CHEMBL629630,U,0,,,,,1,,BAO_0000019,
14767,,Autocuration,,22224,Dissociation Constant of compound determined,CHEMBL856030,U,0,,,,,1,,BAO_0000019,
14768,,Autocuration,,22224,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,CHEMBL629631,U,0,,,,,1,,BAO_0000019,
14769,,Autocuration,,22224,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,CHEMBL629632,U,0,,,,,1,,BAO_0000019,
14770,,Autocuration,,22224,Dissociation constant of compound with Fructose was determined,CHEMBL629633,U,0,,,,,1,,BAO_0000100,
14771,,Autocuration,,22224,Dissociation constant of compound with Fructose was determined; Not determined,CHEMBL629634,U,0,,,,,1,,BAO_0000100,
14772,,Autocuration,,22224,Dissociation constant of compound with Lactulose was determined,CHEMBL629635,U,0,,,,,1,,BAO_0000100,
14773,,Autocuration,,22224,Dissociation constant of compound with Lactulose was determined; Not determined,CHEMBL629636,U,0,,,,,1,,BAO_0000100,
14774,,Autocuration,,22224,Dissociation constant of the Compound,CHEMBL629637,U,0,,,,,1,,BAO_0000100,
14775,,Autocuration,,22224,Dissociation constant by non-linear regression analysis,CHEMBL629638,U,0,,,,,1,,BAO_0000100,
14776,,Autocuration,,22224,Dissociation constant was determined,CHEMBL629639,U,0,,,,,1,,BAO_0000100,
14777,,Autocuration,,22224,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,CHEMBL629640,U,0,,,,,1,,BAO_0000100,
14778,,Autocuration,,22224,Dissociation constant was determined,CHEMBL629641,U,0,,,,,1,,BAO_0000100,
14779,,Autocuration,,22224,Dissociation constant was determined,CHEMBL631344,U,0,,,,,1,,BAO_0000100,
14780,2385.0,Intermediate,Muscle tissue,50597,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,CHEMBL631345,N,1,,,,,1,,BAO_0000218,
14781,,Autocuration,,22224,The dissociation constant determined by fluorescence displacement assay,CHEMBL631346,U,0,,,,,1,,BAO_0000019,
14782,,Autocuration,,22224,kd value surface plasmon resonance (SPR) method,CHEMBL631524,U,0,,,,,1,,BAO_0000019,
14783,2385.0,Intermediate,Muscle tissue,50597,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,CHEMBL631525,N,1,,,,,1,,BAO_0000218,
14784,,Autocuration,,22224,First dissociation constant of the binding of compound to V30M TTR,CHEMBL631526,U,0,,,,,1,,BAO_0000019,
14785,,Autocuration,,22224,Second dissociation constant of the binding of compound to V30M TTR,CHEMBL631527,U,0,,,,,1,,BAO_0000019,
14786,,Autocuration,,22224,"Compound was evaluated for equilibrium constant, Ke",CHEMBL631528,U,0,,,,,1,,BAO_0000019,
14787,1898.0,Autocuration,Hypothalamus,22224,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,CHEMBL631529,U,0,,,,,1,,BAO_0000019,
14788,1898.0,Autocuration,Hypothalamus,22224,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,CHEMBL631530,U,0,,,,,1,,BAO_0000019,
14789,,Autocuration,,22224,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,CHEMBL631531,U,0,,,,,1,,BAO_0000019,
14790,,Autocuration,,22224,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,CHEMBL631532,U,0,,,,,1,,BAO_0000019,
14791,,Autocuration,,22224,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,CHEMBL631533,U,0,,,,,1,,BAO_0000019,
14792,,Intermediate,,50594,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,CHEMBL876552,N,1,,,,,1,,BAO_0000218,
14793,,Intermediate,,50594,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,CHEMBL631534,N,1,,,,,1,,BAO_0000218,
14794,,Intermediate,,50594,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,CHEMBL631535,N,1,,,,,1,,BAO_0000218,
14795,,Intermediate,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,CHEMBL631536,N,1,,,,,1,,BAO_0000218,
14796,,Intermediate,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,CHEMBL631537,N,1,,,,,1,,BAO_0000218,
14797,,Intermediate,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,CHEMBL631538,N,1,,,,,1,,BAO_0000218,
14798,,Intermediate,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,CHEMBL631539,N,1,,,,,1,,BAO_0000218,
14799,,Intermediate,,50594,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,CHEMBL631540,N,1,,,,,1,,BAO_0000218,
14800,,Intermediate,,50597,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,CHEMBL625637,N,1,,,,,1,,BAO_0000218,
14801,,Intermediate,,50597,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,CHEMBL625638,N,1,,,,,1,,BAO_0000218,
14802,,Intermediate,,50597,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",CHEMBL625639,N,1,,,,,1,,BAO_0000218,
14803,955.0,Intermediate,Brain,50597,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625640,N,1,,,,,1,,BAO_0000218,
14804,955.0,Intermediate,Brain,50597,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625641,N,1,,,,,1,,BAO_0000218,
14805,948.0,Intermediate,Heart,50597,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625642,N,1,,,,,1,,BAO_0000218,
14806,948.0,Intermediate,Heart,50597,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625643,N,1,,,,,1,,BAO_0000218,
14807,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625644,N,1,,,,,1,,BAO_0000218,
14808,2113.0,Intermediate,Kidney,50597,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625645,N,1,,,,,1,,BAO_0000218,
14809,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625646,N,1,,,,,1,,BAO_0000218,
14810,2107.0,Intermediate,Liver,50597,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625647,N,1,,,,,1,,BAO_0000218,
14811,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625648,N,1,,,,,1,,BAO_0000218,
14812,2048.0,Intermediate,Lung,50597,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,CHEMBL625649,N,1,,,,,1,,BAO_0000218,
14813,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625650,N,1,,,,,1,,BAO_0000218,
14814,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625651,N,1,,,,,1,,BAO_0000218,
14815,14.0,Intermediate,Zone of skin,50597,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625652,N,1,,,,,1,,BAO_0000218,
14816,14.0,Intermediate,Zone of skin,50597,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625653,N,1,,,,,1,,BAO_0000218,
14817,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625654,N,1,,,,,1,,BAO_0000218,
14818,2106.0,Intermediate,Spleen,50597,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,CHEMBL625655,N,1,,,,,1,,BAO_0000218,
14819,178.0,Intermediate,Blood,50597,Biodistribution of Compound in rat blood after 15 minutes of administration,CHEMBL625656,N,1,,,,,1,,BAO_0000218,
14820,178.0,Intermediate,Blood,50597,Biodistribution of Compound in rat blood after 2 minutes of administration,CHEMBL625657,N,1,,,,,1,,BAO_0000218,
14821,955.0,Intermediate,Brain,50597,Biodistribution of Compound in rat brain after 15 minutes of administration,CHEMBL625658,N,1,,,,,1,,BAO_0000218,
14822,955.0,Intermediate,Brain,50597,Biodistribution of Compound in rat brain after 2 minutes of administration,CHEMBL625659,N,1,,,,,1,,BAO_0000218,
14823,948.0,Intermediate,Heart,50597,Biodistribution of Compound in rat heart after 15 minutes of administration,CHEMBL625660,N,1,,,,,1,,BAO_0000218,
14824,948.0,Intermediate,Heart,50597,Biodistribution of Compound in rat heart after 2 minutes of administration,CHEMBL625661,N,1,,,,,1,,BAO_0000218,
14825,2107.0,Intermediate,Liver,50597,Biodistribution of Compound in rat liver after 15 minutes of administration,CHEMBL625662,N,1,,,,,1,,BAO_0000218,
14826,2107.0,Intermediate,Liver,50597,Biodistribution of Compound in rat liver after 2 minutes of administration,CHEMBL625663,N,1,,,,,1,,BAO_0000218,
14827,2048.0,Intermediate,Lung,50597,Biodistribution of Compound in rat lung after 15 minutes of administration,CHEMBL875621,N,1,,,,,1,,BAO_0000218,
14828,2048.0,Intermediate,Lung,50597,Biodistribution of Compound in rat lung after 2 minutes of administration,CHEMBL628382,N,1,,,,,1,,BAO_0000218,
14829,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of Compound in rat muscle after 15 minutes of administration,CHEMBL628383,N,1,,,,,1,,BAO_0000218,
14830,2385.0,Intermediate,Muscle tissue,50597,Biodistribution of Compound in rat muscle after 2 minutes of administration,CHEMBL628384,N,1,,,,,1,,BAO_0000218,
14831,,Intermediate,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,CHEMBL628385,N,1,,,,,1,,BAO_0000218,
14832,,Intermediate,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,CHEMBL875753,N,1,,,,,1,,BAO_0000218,
14833,,Intermediate,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,CHEMBL628386,N,1,,,,,1,,BAO_0000218,
14834,,Intermediate,,50597,Organ distribution in rat blood 2 minutes after intravenous injection,CHEMBL628387,N,1,,,,,1,,BAO_0000218,
14835,,Intermediate,,50597,Organ distribution in rat blood 2 hr after intravenous injection,CHEMBL628388,N,1,,,,,1,,BAO_0000218,
14836,,Intermediate,,50597,Organ distribution in rat blood 30 minutes after intravenous injection,CHEMBL628389,N,1,,,,,1,,BAO_0000218,
14837,,Intermediate,,50597,Organ distribution in rat blood 30 min after intravenous injection,CHEMBL632756,N,1,,,,,1,,BAO_0000218,
14838,,Intermediate,,50597,Organ distribution in rat brain 2 minutes after intravenous injection,CHEMBL628390,N,1,,,,,1,,BAO_0000218,
14839,,Intermediate,,50597,Organ distribution in rat brain 2 hr after intravenous injection,CHEMBL631811,N,1,,,,,1,,BAO_0000218,
14840,,Intermediate,,50597,Organ distribution in rat brain 30 minutes after intravenous injection,CHEMBL631812,N,1,,,,,1,,BAO_0000218,
14841,,Intermediate,,50597,Organ distribution in rat heart 2 minutes after intravenous injection,CHEMBL631813,N,1,,,,,1,,BAO_0000218,
14842,,Intermediate,,50597,Organ distribution in rat heart 2 hr after intravenous injection,CHEMBL631814,N,1,,,,,1,,BAO_0000218,
14843,,Intermediate,,50597,Organ distribution in rat heart 30 minutes after intravenous injection,CHEMBL631815,N,1,,,,,1,,BAO_0000218,
14844,,Intermediate,,50597,Organ distribution in rat kidney 2 minutes after intravenous injection,CHEMBL631816,N,1,,,,,1,,BAO_0000218,
14845,,Intermediate,,50597,Organ distribution in rat kidney 2 hr after intravenous injection,CHEMBL875758,N,1,,,,,1,,BAO_0000218,
14846,,Intermediate,,50597,Organ distribution in rat kidney 30 minutes after intravenous injection,CHEMBL631817,N,1,,,,,1,,BAO_0000218,
14847,2107.0,Intermediate,Liver,50597,Organ distribution in rat liver 2 minutes after intravenous injection,CHEMBL631818,N,1,,,,,1,,BAO_0000218,
14848,2107.0,Intermediate,Liver,50597,Organ distribution in rat liver 2 hr after intravenous injection,CHEMBL631819,N,1,,,,,1,,BAO_0000218,
14849,2107.0,Intermediate,Liver,50597,Organ distribution in rat liver 30 minutes after intravenous injection,CHEMBL631820,N,1,,,,,1,,BAO_0000218,
14850,,Intermediate,,50597,Organ distribution in rat lung 2 minutes after intravenous injection,CHEMBL631821,N,1,,,,,1,,BAO_0000218,
14851,,Intermediate,,50597,Organ distribution in rat lung 2 hr after intravenous injection,CHEMBL631822,N,1,,,,,1,,BAO_0000218,
14852,,Intermediate,,50597,Organ distribution in rat lung 30 minutes after intravenous injection,CHEMBL631823,N,1,,,,,1,,BAO_0000218,
14853,2385.0,Intermediate,Muscle tissue,50597,Organ distribution in rat muscle 2 minutes after intravenous injection,CHEMBL631824,N,1,,,,,1,,BAO_0000218,
14854,2385.0,Intermediate,Muscle tissue,50597,Organ distribution in rat muscle 2 hr after intravenous injection,CHEMBL631825,N,1,,,,,1,,BAO_0000218,
14855,2385.0,Intermediate,Muscle tissue,50597,Organ distribution in rat muscle 30 minutes after intravenous injection,CHEMBL631826,N,1,,,,,1,,BAO_0000218,
14856,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),CHEMBL631827,N,1,,,,,1,,BAO_0000218,
14857,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),CHEMBL631828,N,1,,,,,1,,BAO_0000218,
14858,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),CHEMBL631829,N,1,,,,,1,,BAO_0000218,
14859,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,CHEMBL875759,N,1,,,,,1,,BAO_0000218,
14860,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,CHEMBL631830,N,1,,,,,1,,BAO_0000218,
14861,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,CHEMBL631831,N,1,,,,,1,,BAO_0000218,
14862,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,CHEMBL631832,N,1,,,,,1,,BAO_0000218,
14863,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,CHEMBL631833,N,1,,,,,1,,BAO_0000218,
14864,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,CHEMBL631834,N,1,,,,,1,,BAO_0000218,
14865,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,CHEMBL631835,N,1,,,,,1,,BAO_0000218,
14866,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,CHEMBL631836,N,1,,,,,1,,BAO_0000218,
14867,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,CHEMBL631837,N,1,,,,,1,,BAO_0000218,
14868,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,CHEMBL631838,N,1,,,,,1,,BAO_0000218,
14869,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,CHEMBL631839,N,1,,,,,1,,BAO_0000218,
14870,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,CHEMBL631840,N,1,,,,,1,,BAO_0000218,
14871,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,CHEMBL631841,N,1,,,,,1,,BAO_0000218,
14872,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,CHEMBL631842,N,1,,,,,1,,BAO_0000218,
14873,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,CHEMBL631843,N,1,,,,,1,,BAO_0000218,
14874,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,CHEMBL631844,N,1,,,,,1,,BAO_0000218,
14875,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,CHEMBL631845,N,1,,,,,1,,BAO_0000218,
14876,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,CHEMBL631846,N,1,,,,,1,,BAO_0000218,
14877,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,CHEMBL875760,N,1,,,,,1,,BAO_0000218,
14878,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,CHEMBL632199,N,1,,,,,1,,BAO_0000218,
14879,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,CHEMBL631847,N,1,,,,,1,,BAO_0000218,
14880,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,CHEMBL631848,N,1,,,,,1,,BAO_0000218,
14881,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,CHEMBL628707,N,1,,,,,1,,BAO_0000218,
14882,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,CHEMBL628708,N,1,,,,,1,,BAO_0000218,
14883,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,CHEMBL628709,N,1,,,,,1,,BAO_0000218,
14884,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,CHEMBL628710,N,1,,,,,1,,BAO_0000218,
14885,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,CHEMBL628711,N,1,,,,,1,,BAO_0000218,
14886,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,CHEMBL628712,N,1,,,,,1,,BAO_0000218,
14887,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,CHEMBL628713,N,1,,,,,1,,BAO_0000218,
14888,1088.0,Intermediate,Urine,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,CHEMBL628714,N,1,,,,,1,,BAO_0000218,
14889,,Intermediate,,50597,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",CHEMBL628715,N,1,,,,,1,,BAO_0000218,
14890,,Autocuration,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,CHEMBL629179,U,0,,,,,1,,BAO_0000019,
14891,,Autocuration,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,CHEMBL629180,U,0,,,,,1,,BAO_0000019,
14892,,Autocuration,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,CHEMBL875108,U,0,,,,,1,,BAO_0000019,
14893,1235.0,Autocuration,Adrenal cortex,22224,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,CHEMBL629181,U,0,,,,,1,,BAO_0000019,
14894,1235.0,Autocuration,Adrenal cortex,22224,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,CHEMBL629182,U,0,,,,,1,,BAO_0000019,
14895,,Autocuration,,22224,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,CHEMBL629183,U,0,,,,,1,,BAO_0000019,
14896,,Autocuration,,22224,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,CHEMBL629184,U,0,,,,,1,,BAO_0000019,
14897,1235.0,Autocuration,Adrenal cortex,22224,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,CHEMBL629185,U,0,,,,,1,,BAO_0000019,
14898,1235.0,Autocuration,Adrenal cortex,22224,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,CHEMBL629186,U,0,,,,,1,,BAO_0000019,
14899,,Autocuration,,22224,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,CHEMBL629187,U,0,,,,,1,,BAO_0000019,
14900,,Autocuration,,22224,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,CHEMBL629887,U,0,,,,,1,,BAO_0000019,
14901,,Autocuration,,22224,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,CHEMBL629888,U,0,,,,,1,,BAO_0000019,
14902,,Autocuration,,22224,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,CHEMBL629889,U,0,,,,,1,,BAO_0000019,
14903,1235.0,Autocuration,Adrenal cortex,22224,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,CHEMBL629890,U,0,,,,,1,,BAO_0000019,
14904,,Autocuration,,22224,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,CHEMBL629891,U,0,,,,,1,,BAO_0000019,
14905,,Autocuration,,22224,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,CHEMBL629892,U,0,,,,,1,,BAO_0000019,
14906,1235.0,Autocuration,Adrenal cortex,22224,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,CHEMBL629893,U,0,,,,,1,,BAO_0000019,
14907,,Autocuration,,22224,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,CHEMBL629894,U,0,,,,,1,,BAO_0000019,
14908,,Autocuration,,22224,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,CHEMBL629895,U,0,,,,,1,,BAO_0000019,
14909,,Autocuration,,22224,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",CHEMBL875109,U,0,,,,,1,,BAO_0000218,
14910,,Autocuration,,22224,Absolute bioavailability in male cynomolgus monkeys,CHEMBL629896,U,0,,,,,1,,BAO_0000218,
14911,,Autocuration,,22224,Absolute bioavailability in maleSprague-Dawley rats,CHEMBL629897,U,0,,,,,1,,BAO_0000218,
14912,2107.0,Intermediate,Liver,50597,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL629898,N,1,,,,,1,,BAO_0000218,
14913,2107.0,Intermediate,Liver,50597,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630057,N,1,,,,,1,,BAO_0000218,
14914,2107.0,Intermediate,Liver,50597,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630058,N,1,,,,,1,,BAO_0000218,
14915,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630059,N,1,,,,,1,,BAO_0000218,
14916,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630060,N,1,,,,,1,,BAO_0000218,
14917,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630061,N,1,,,,,1,,BAO_0000218,
14918,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630062,N,1,,,,,1,,BAO_0000218,
14919,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630063,N,1,,,,,1,,BAO_0000218,
14920,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630064,N,1,,,,,1,,BAO_0000218,
14921,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630065,N,1,,,,,1,,BAO_0000218,
14922,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630066,N,1,,,,,1,,BAO_0000218,
14923,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630067,N,1,,,,,1,,BAO_0000218,
14924,2048.0,Intermediate,Lung,50597,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630068,N,1,,,,,1,,BAO_0000218,
14925,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631113,N,1,,,,,1,,BAO_0000218,
14926,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631114,N,1,,,,,1,,BAO_0000218,
14927,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL631115,N,1,,,,,1,,BAO_0000218,
14928,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL631116,N,1,,,,,1,,BAO_0000218,
14929,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630528,N,1,,,,,1,,BAO_0000218,
14930,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630529,N,1,,,,,1,,BAO_0000218,
14931,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630530,N,1,,,,,1,,BAO_0000218,
14932,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630531,N,1,,,,,1,,BAO_0000218,
14933,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630532,N,1,,,,,1,,BAO_0000218,
14934,2385.0,Intermediate,Muscle tissue,50597,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630533,N,1,,,,,1,,BAO_0000218,
14935,178.0,Intermediate,Blood,50594,Biodistribution in normal mice blood after 120 hr,CHEMBL630534,N,1,,,,,1,,BAO_0000218,
14936,178.0,Intermediate,Blood,50594,Biodistribution in normal mice blood after 24 hr,CHEMBL630535,N,1,,,,,1,,BAO_0000218,
14937,178.0,Intermediate,Blood,50594,Biodistribution in normal mice blood after 4 hr,CHEMBL630536,N,1,,,,,1,,BAO_0000218,
14938,10000001.0,Intermediate,Bone,50594,Biodistribution in normal mice bone after 120 hr,CHEMBL630537,N,1,,,,,1,,BAO_0000218,
14939,10000001.0,Intermediate,Bone,50594,Biodistribution in normal mice bone after 24 hr,CHEMBL630538,N,1,,,,,1,,BAO_0000218,
14940,10000001.0,Intermediate,Bone,50594,Biodistribution in normal mice bone after 4 hr,CHEMBL630539,N,1,,,,,1,,BAO_0000218,
14941,948.0,Intermediate,Heart,50594,Biodistribution in normal mice heart after 120 hr,CHEMBL630540,N,1,,,,,1,,BAO_0000218,
14942,948.0,Intermediate,Heart,50594,Biodistribution in normal mice heart after 24 hr,CHEMBL630541,N,1,,,,,1,,BAO_0000218,
14943,948.0,Intermediate,Heart,50594,Biodistribution in normal mice heart after 4 hr,CHEMBL630542,N,1,,,,,1,,BAO_0000218,
14944,2113.0,Intermediate,Kidney,50594,Biodistribution in normal mice kidney after 120 hr,CHEMBL630543,N,1,,,,,1,,BAO_0000218,
14945,2113.0,Intermediate,Kidney,50594,Biodistribution in normal mice kidney after 24 hr,CHEMBL630544,N,1,,,,,1,,BAO_0000218,
14946,2113.0,Intermediate,Kidney,50594,Biodistribution in normal mice kidney after 4 hr,CHEMBL630545,N,1,,,,,1,,BAO_0000218,
14947,2107.0,Intermediate,Liver,50594,Biodistribution in normal mice liver after 120 hr,CHEMBL630546,N,1,,,,,1,,BAO_0000218,
14948,2107.0,Intermediate,Liver,50594,Biodistribution in normal mice liver after 24 hr,CHEMBL630547,N,1,,,,,1,,BAO_0000218,
14949,2107.0,Intermediate,Liver,50594,Biodistribution in normal mice liver after 4 hr,CHEMBL630548,N,1,,,,,1,,BAO_0000218,
14950,2106.0,Intermediate,Spleen,50594,Biodistribution in normal mice spleen after 120 hr,CHEMBL630549,N,1,,,,,1,,BAO_0000218,
14951,2106.0,Intermediate,Spleen,50594,Biodistribution in normal mice spleen after 24 hr,CHEMBL630550,N,1,,,,,1,,BAO_0000218,
14952,2106.0,Intermediate,Spleen,50594,Biodistribution in normal mice spleen after 4 hr,CHEMBL876426,N,1,,,,,1,,BAO_0000218,
14953,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630551,N,1,,,,,1,,BAO_0000218,
14954,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630552,N,1,,,,,1,,BAO_0000218,
14955,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630553,N,1,,,,,1,,BAO_0000218,
14956,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630554,N,1,,,,,1,,BAO_0000218,
14957,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630555,N,1,,,,,1,,BAO_0000218,
14958,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630556,N,1,,,,,1,,BAO_0000218,
14959,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630557,N,1,,,,,1,,BAO_0000218,
14960,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),CHEMBL630558,N,1,,,,,1,,BAO_0000218,
14961,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630559,N,1,,,,,1,,BAO_0000218,
14962,2106.0,Intermediate,Spleen,50597,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL630560,N,1,,,,,1,,BAO_0000218,
14963,2046.0,Intermediate,Thyroid gland,50597,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,CHEMBL876427,N,1,,,,,1,,BAO_0000218,
14964,,Intermediate,,50597,The Kel values in female wistar rats.,CHEMBL630561,N,1,,,,,1,,BAO_0000218,
14965,,Autocuration,,22224,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,CHEMBL630562,U,0,,,,,1,,BAO_0000019,
14966,,Autocuration,,22224,Hydrolysis rate constant of the compound,CHEMBL630563,U,0,,,,,1,,BAO_0000019,
14967,,Autocuration,,22229,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,CHEMBL629673,U,0,,,,,1,,BAO_0000100,
14968,,Autocuration,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",CHEMBL629674,U,0,,,,,1,,BAO_0000019,
14969,,Autocuration,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",CHEMBL629675,U,0,,,,,1,,BAO_0000019,
14970,,Autocuration,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",CHEMBL629676,U,0,,,,,1,,BAO_0000019,
14971,,Autocuration,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",CHEMBL629677,U,0,,,,,1,,BAO_0000019,
14972,,Autocuration,,22224,Apparent inactivation rate constant was evaluated,CHEMBL629678,U,0,,,,,1,,BAO_0000019,
14973,,Autocuration,,22224,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,CHEMBL629679,U,0,,,,,1,,BAO_0000019,
14974,,Autocuration,,22224,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,CHEMBL629680,U,0,,,,,1,,BAO_0000019,
14975,,Autocuration,,22224,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,CHEMBL629681,U,0,,,,,1,,BAO_0000019,
14976,,Autocuration,,22224,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,CHEMBL629682,U,0,,,,,1,,BAO_0000019,
14977,,Autocuration,,22224,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,CHEMBL629683,U,0,,,,,1,,BAO_0000019,
14978,,Autocuration,,22224,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,CHEMBL629684,U,0,,,,,1,,BAO_0000019,
14979,,Autocuration,,22224,Dissociation constant was determined,CHEMBL629685,U,0,,,,,1,,BAO_0000100,
14980,,Autocuration,,22224,Dissociation constant was determined,CHEMBL629686,U,0,,,,,1,,BAO_0000100,
14981,,Autocuration,,22224,Dissociation constant at pH 7.4,CHEMBL872932,U,0,,,,,1,,BAO_0000100,
14982,,Autocuration,,22224,Dissociation constant in presence of 1 mM dithiothreitol,CHEMBL629687,U,0,,,,,1,,BAO_0000100,
14983,,Autocuration,,22224,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,CHEMBL872931,U,0,,,,,1,,BAO_0000019,
14984,,Autocuration,,22224,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,CHEMBL628151,U,0,,,,,1,,BAO_0000019,
14985,,Autocuration,,22224,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,CHEMBL628152,U,0,,,,,1,,BAO_0000019,
14986,,Autocuration,,22224,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,CHEMBL628153,U,0,,,,,1,,BAO_0000019,
14987,,Autocuration,,22224,Kinetic constant for aromatization of androstenedione,CHEMBL628154,U,0,,,,,1,,BAO_0000019,
14988,,Autocuration,,22224,Kinetic constant for aromatization of testosterone,CHEMBL628155,U,0,,,,,1,,BAO_0000019,
14989,,Autocuration,,22224,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,CHEMBL628156,U,0,,,,,1,,BAO_0000019,
14990,,Autocuration,,22224,Local inhibition constant was determined,CHEMBL628157,U,0,,,,,1,,BAO_0000019,
14991,,Intermediate,,50347,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,CHEMBL857533,N,1,,,,,1,,BAO_0000218,
14992,,Autocuration,,22224,Dissociation constant value of the compound,CHEMBL628158,U,0,,,,,1,,BAO_0000100,
14993,964.0,Autocuration,Cornea,22224,In vitro permeability through cornea without epithelium,CHEMBL628159,U,0,,,,,1,,BAO_0000019,
14994,964.0,Autocuration,Cornea,22224,In vitro permeability through intact cornea,CHEMBL875616,U,0,,,,,1,,BAO_0000019,
14995,964.0,Intermediate,Cornea,50592,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,CHEMBL628160,N,1,,,,,1,,BAO_0000218,
14996,,Autocuration,,22224,Rate of enzyme inactivation for the compound was determined,CHEMBL628161,U,0,,,,,1,,BAO_0000019,
14997,964.0,Autocuration,Cornea,22224,In vitro permeability through cornea without epithelium,CHEMBL628162,U,0,,,,,1,,BAO_0000019,
14998,964.0,Autocuration,Cornea,22224,In vitro permeability through intact cornea,CHEMBL628163,U,0,,,,,1,,BAO_0000019,
14999,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628164,U,0,,,,,1,,BAO_0000019,
15000,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628165,U,0,,,,,1,,BAO_0000019,
15001,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628166,U,0,,,,,1,,BAO_0000019,
15002,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628167,U,0,,,,,1,,BAO_0000019,
15003,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628168,U,0,,,,,1,,BAO_0000019,
15004,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628169,U,0,,,,,1,,BAO_0000019,
15005,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628170,U,0,,,,,1,,BAO_0000019,
15006,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628171,U,0,,,,,1,,BAO_0000019,
15007,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL627434,U,0,,,,,1,,BAO_0000019,
15008,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL627435,U,0,,,,,1,,BAO_0000019,
15009,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628110,U,0,,,,,1,,BAO_0000019,
15010,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628111,U,0,,,,,1,,BAO_0000019,
15011,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628112,U,0,,,,,1,,BAO_0000019,
15012,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628260,U,0,,,,,1,,BAO_0000019,
15013,,Autocuration,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",CHEMBL628261,U,0,,,,,1,,BAO_0000019,
15014,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),CHEMBL628262,N,1,,,,,1,,BAO_0000218,
15015,,Intermediate,,50587,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,CHEMBL628263,N,1,,,,,1,,BAO_0000218,
15016,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),CHEMBL628264,N,1,,,,,1,,BAO_0000218,
15017,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),CHEMBL628265,N,1,,,,,1,,BAO_0000218,
15018,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),CHEMBL628266,N,1,,,,,1,,BAO_0000218,
15019,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),CHEMBL628267,N,1,,,,,1,,BAO_0000218,
15020,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,CHEMBL628268,N,1,,,,,1,,BAO_0000218,
15021,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),CHEMBL628269,N,1,,,,,1,,BAO_0000218,
15022,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),CHEMBL628270,N,1,,,,,1,,BAO_0000218,
15023,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),CHEMBL628271,N,1,,,,,1,,BAO_0000218,
15024,,Intermediate,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),CHEMBL628272,N,1,,,,,1,,BAO_0000218,
